| Symbol | TAK |
|---|---|
| Name | TAKEDA PHARMACEUTICAL CO LTD |
| Sector | HEALTH CARE |
| Region | Asia |
| Industry | Pharmaceutical Preparations |
| Address | 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO, M0 103-8668 |
| Telephone | 81332782111 |
| Fax | — |
| — | |
| Website | https://www.takeda.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001395064 |
| Description | Takeda Pharmaceutical is Japans largest pharmaceutical company, with revenue of JPY 3.6 trillion in fiscal 2021. The companys five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the U.S., 20% from Japan, 20% from Europe and Canada. Additional info from NASDAQ: |
2026-07-16 16:22
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies
Read more
2026-07-08 20:46
Takeda’s Annual General Shareholders Meeting: A new era, leading with purpose and possibility
Read more
2026-07-08 00:36
Takeda Completed Issuance of New Shares and Disposal of Treasury Shares under the Long-Term Incentive Plan for Company Group Employees Outside of Japan with Partial Forfeiture of Rights Granted to Allottees
Read more
2026-07-06 22:29
Director GILLIS STEVEN 🟡 adjusted position in 4.0K shares (2 derivative) of TAKEDA PHARMACEUTICAL CO LTD (TAK) Transaction Date: Jul 01, 2026 | Filing ID: 000276
Read more
2026-07-06 22:28
Director MARAGANORE JOHN 🟡 adjusted position in 4.0K shares (2 derivative) of TAKEDA PHARMACEUTICAL CO LTD (TAK) Transaction Date: Jul 01, 2026 | Filing ID: 000275
Read more
2026-07-06 22:28
Director Reed Kimberly A. 🟡 adjusted position in 4.0K shares (2 derivative) of TAKEDA PHARMACEUTICAL CO LTD (TAK) Transaction Date: Jul 01, 2026 | Filing ID: 000274
Read more
2026-07-06 22:14
Director Iijima Masami 🟡 adjusted position in 1.6K shares (2 derivative) of TAKEDA PHARMACEUTICAL CO LTD (TAK) Transaction Date: Jul 01, 2026 | Filing ID: 000270
Read more
2026-07-06 22:12
Director BROUSSARD BRUCE D 🟢 acquired 5.1K shares (1 derivative) of TAKEDA PHARMACEUTICAL CO LTD (TAK) Transaction Date: Jul 01, 2026 | Filing ID: 000268
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT00129207 | Ketoconazole Administration: How it is Affected by the Body and Broken Down and… | Phase1 | Tumors | Completed | — | — | ClinicalTrials.gov |
| NCT06856135 | Expanded Access to Vedolizumab for Children and Teenagers With Ulcerative Colit… | — | Crohn's Disease | Available | — | — | ClinicalTrials.gov |
| NCT01499693 | Magnesium Pantoprazole 20mg b.i.d. vs Magnesium Pantoprazole 40mg q.d. on Intra… | Phase3 | Gastric pH Control | Withdrawn | — | — | ClinicalTrials.gov |
| NCT01499693 | Magnesium Pantoprazole 20mg b.i.d. vs Magnesium Pantoprazole 40mg q.d. on Intra… | Phase3 | Gastric pH Control | Withdrawn | — | — | ClinicalTrials.gov |
| NCT01452698 | Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Eros… | Phase3 | Erosive Esophagitis | Completed | — | 2012-08-01 | ClinicalTrials.gov |
| NCT01433393 | Double-blind Comparative Study of TAK-875 | Phase3 | Diabetes Mellitus | Completed | — | 2012-09-01 | ClinicalTrials.gov |
| NCT04484363 | Expanded Access Program With Pevonedistat (Given With Azacitidine) for Adults W… | — | Myelodysplastic Syndromes | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT06195514 | Expanded Access to TAK-113 for Adults With Metastatic Colorectal Cancer (mCRC) | — | Colorectal Cancer | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT04535557 | An Expanded Access Protocol for Mobocertinib in Refractory Non-small Cell Lung … | — | Carcinoma, Non-Small-Cell Lung | Approved_For_Marketing | — | — | ClinicalTrials.gov |
| NCT04583007 | Expanded Access for the Prevention of Acute Attacks of 1) Hereditary Angioedema… | — | Hereditary Angioedema (HAE) | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT06955793 | Expanded Access to TAK-881 for People With Primary Immunodeficiency Diseases in… | — | Primary Immunodeficiency Diseases (PIDD) | Available | — | — | ClinicalTrials.gov |
| NCT00343720 | Study of Alimta® (Pemetrexed) Plus VELCADE® (Bortezomib) or Alimta Alone or VEL… | Phase2 | Non-Small Cell Lung Cancer | Completed | — | — | ClinicalTrials.gov |
| NCT06173024 | Post Trial Access Program of TAK-577 for Von Willebrand Disease (VWD) | — | Von Willebrand Disease (VWD) | Available | — | — | ClinicalTrials.gov |
| NCT06173024 | Post Trial Access Program of TAK-577 for Von Willebrand Disease (VWD) | — | Von Willebrand Disease (VWD) | Available | — | — | ClinicalTrials.gov |
| NCT05795361 | Post-trial Access Program of Idursulfase-IT Along With Elaprase in Children Wit… | — | Hunter Syndrome | Available | — | — | ClinicalTrials.gov |
| NCT00063791 | A Study to Assess Two Different Strategies of Combining Dexamethasone and VELCA… | — | Multiple Myeloma | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT06195514 | Expanded Access to TAK-113 for Adults With Metastatic Colorectal Cancer (mCRC) | — | Colorectal Cancer | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT05795361 | Post-trial Access Program of Idursulfase-IT Along With Elaprase in Children Wit… | — | Hunter Syndrome | Available | — | — | ClinicalTrials.gov |
| NCT00298779 | Open-Label Study to Assess the Effect of Omeprazole on the Pharmacokinetics of … | Phase1 | Tumors | Completed | — | — | ClinicalTrials.gov |
| NCT01196208 | A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients… | — | Disease, Hodgkin | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT00297921 | A Phase 2 Study of Tandutinib in Patients With Newly Diagnosed Acute Myelogenou… | Phase1 | Acute Myelogenous Leukemia | Withdrawn | — | — | ClinicalTrials.gov |
| NCT05770219 | Expanded Access Program of TAK-755 for Congenital Thrombotic Thrombocytopenic P… | — | Thrombotic Thrombocytopenic Purpura (TTP) | Approved_For_Marketing | — | — | ClinicalTrials.gov |
| NCT05770219 | Expanded Access Program of TAK-755 for Congenital Thrombotic Thrombocytopenic P… | — | Thrombotic Thrombocytopenic Purpura (TTP) | Approved_For_Marketing | — | — | ClinicalTrials.gov |
| NCT05770219 | Expanded Access Program of TAK-755 for Congenital Thrombotic Thrombocytopenic P… | — | Thrombotic Thrombocytopenic Purpura (TTP) | Approved_For_Marketing | — | — | ClinicalTrials.gov |
| NCT05795361 | Post-trial Access Program of Idursulfase-IT Along With Elaprase in Children Wit… | — | Hunter Syndrome | Available | — | — | ClinicalTrials.gov |
| NCT00257114 | Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Eff… | Phase4 | Multiple Myeloma | Completed | — | — | ClinicalTrials.gov |
| NCT01499693 | Magnesium Pantoprazole 20mg b.i.d. vs Magnesium Pantoprazole 40mg q.d. on Intra… | Phase3 | Gastric pH Control | Withdrawn | — | — | ClinicalTrials.gov |
| NCT01452698 | Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Eros… | Phase3 | Erosive Esophagitis | Completed | — | 2012-08-01 | ClinicalTrials.gov |
| NCT01433393 | Double-blind Comparative Study of TAK-875 | Phase3 | Diabetes Mellitus | Completed | — | 2012-09-01 | ClinicalTrials.gov |
| NCT01196208 | A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients… | — | Disease, Hodgkin | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT01031173 | Treatment Protocol of Replagal for Patients With Fabry Disease | — | Fabry Disease | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT00343720 | Study of Alimta® (Pemetrexed) Plus VELCADE® (Bortezomib) or Alimta Alone or VEL… | Phase2 | Non-Small Cell Lung Cancer | Completed | — | — | ClinicalTrials.gov |
| NCT00298779 | Open-Label Study to Assess the Effect of Omeprazole on the Pharmacokinetics of … | Phase1 | Tumors | Completed | — | — | ClinicalTrials.gov |
| NCT06856135 | Expanded Access to Vedolizumab for Children and Teenagers With Ulcerative Colit… | — | Crohn's Disease | Available | — | — | ClinicalTrials.gov |
| NCT00297921 | A Phase 2 Study of Tandutinib in Patients With Newly Diagnosed Acute Myelogenou… | Phase1 | Acute Myelogenous Leukemia | Withdrawn | — | — | ClinicalTrials.gov |
| NCT00257114 | Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Eff… | Phase4 | Multiple Myeloma | Completed | — | — | ClinicalTrials.gov |
| NCT00129207 | Ketoconazole Administration: How it is Affected by the Body and Broken Down and… | Phase1 | Tumors | Completed | — | — | ClinicalTrials.gov |
| NCT00241163 | TachoComb S Versus Standard Surgical Treatment in Surgical Resection of Renal T… | Phase3 | Surgical Resection of Superficial Renal Tumour | Completed | — | — | ClinicalTrials.gov |
| NCT00129207 | Ketoconazole Administration: How it is Affected by the Body and Broken Down and… | Phase1 | Tumors | Completed | — | — | ClinicalTrials.gov |
| NCT00063791 | A Study to Assess Two Different Strategies of Combining Dexamethasone and VELCA… | — | Multiple Myeloma | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT01452698 | Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Eros… | Phase3 | Erosive Esophagitis | Completed | — | 2012-08-01 | ClinicalTrials.gov |
| NCT06856135 | Expanded Access to Vedolizumab for Children and Teenagers With Ulcerative Colit… | — | Crohn's Disease | Available | — | — | ClinicalTrials.gov |
| NCT01161394 | Effect of Pioglitazone on Oxidative Load, Inflammatory End-Points and Vascular … | Phase4 | Inflammation | Completed | — | 2003-10-01 | ClinicalTrials.gov |
| NCT00343720 | Study of Alimta® (Pemetrexed) Plus VELCADE® (Bortezomib) or Alimta Alone or VEL… | Phase2 | Non-Small Cell Lung Cancer | Completed | — | — | ClinicalTrials.gov |
| NCT04484363 | Expanded Access Program With Pevonedistat (Given With Azacitidine) for Adults W… | — | Myelodysplastic Syndromes | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT06173024 | Post Trial Access Program of TAK-577 for Von Willebrand Disease (VWD) | — | Von Willebrand Disease (VWD) | Available | — | — | ClinicalTrials.gov |
| NCT00063791 | A Study to Assess Two Different Strategies of Combining Dexamethasone and VELCA… | — | Multiple Myeloma | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT01196208 | A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients… | — | Disease, Hodgkin | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT06195514 | Expanded Access to TAK-113 for Adults With Metastatic Colorectal Cancer (mCRC) | — | Colorectal Cancer | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT01031173 | Treatment Protocol of Replagal for Patients With Fabry Disease | — | Fabry Disease | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT01433393 | Double-blind Comparative Study of TAK-875 | Phase3 | Diabetes Mellitus | Completed | — | 2012-09-01 | ClinicalTrials.gov |
| NCT06955793 | Expanded Access to TAK-881 for People With Primary Immunodeficiency Diseases in… | — | Primary Immunodeficiency Diseases (PIDD) | Available | — | — | ClinicalTrials.gov |
| NCT01161394 | Effect of Pioglitazone on Oxidative Load, Inflammatory End-Points and Vascular … | Phase4 | Inflammation | Completed | — | 2003-10-01 | ClinicalTrials.gov |
| NCT00298779 | Open-Label Study to Assess the Effect of Omeprazole on the Pharmacokinetics of … | Phase1 | Tumors | Completed | — | — | ClinicalTrials.gov |
| NCT00297921 | A Phase 2 Study of Tandutinib in Patients With Newly Diagnosed Acute Myelogenou… | Phase1 | Acute Myelogenous Leukemia | Withdrawn | — | — | ClinicalTrials.gov |
| NCT01031173 | Treatment Protocol of Replagal for Patients With Fabry Disease | — | Fabry Disease | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT00257114 | Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Eff… | Phase4 | Multiple Myeloma | Completed | — | — | ClinicalTrials.gov |
| NCT01161394 | Effect of Pioglitazone on Oxidative Load, Inflammatory End-Points and Vascular … | Phase4 | Inflammation | Completed | — | 2003-10-01 | ClinicalTrials.gov |
| NCT04484363 | Expanded Access Program With Pevonedistat (Given With Azacitidine) for Adults W… | — | Myelodysplastic Syndromes | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT04535557 | An Expanded Access Protocol for Mobocertinib in Refractory Non-small Cell Lung … | — | Carcinoma, Non-Small-Cell Lung | Approved_For_Marketing | — | — | ClinicalTrials.gov |
| NCT04583007 | Expanded Access for the Prevention of Acute Attacks of 1) Hereditary Angioedema… | — | Hereditary Angioedema (HAE) | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT00241163 | TachoComb S Versus Standard Surgical Treatment in Surgical Resection of Renal T… | Phase3 | Surgical Resection of Superficial Renal Tumour | Completed | — | — | ClinicalTrials.gov |
| NCT04583007 | Expanded Access for the Prevention of Acute Attacks of 1) Hereditary Angioedema… | — | Hereditary Angioedema (HAE) | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT06955793 | Expanded Access to TAK-881 for People With Primary Immunodeficiency Diseases in… | — | Primary Immunodeficiency Diseases (PIDD) | Available | — | — | ClinicalTrials.gov |
| NCT04535557 | An Expanded Access Protocol for Mobocertinib in Refractory Non-small Cell Lung … | — | Carcinoma, Non-Small-Cell Lung | Approved_For_Marketing | — | — | ClinicalTrials.gov |
| NCT00241163 | TachoComb S Versus Standard Surgical Treatment in Surgical Resection of Renal T… | Phase3 | Surgical Resection of Superficial Renal Tumour | Completed | — | — | ClinicalTrials.gov |
| NCT07218393 | A Study About the Diagnosis and Management of Hereditary Angioedema (HAE) in Eg… | — | Hereditary Angioedema (HAE) | Not_Yet_Recruiting | 2026-12-01 | 2027-12-01 | ClinicalTrials.gov |
| NCT07218393 | A Study About the Diagnosis and Management of Hereditary Angioedema (HAE) in Eg… | — | Hereditary Angioedema (HAE) | Not_Yet_Recruiting | 2026-12-01 | 2027-12-01 | ClinicalTrials.gov |
| NCT07218393 | A Study About the Diagnosis and Management of Hereditary Angioedema (HAE) in Eg… | — | Hereditary Angioedema (HAE) | Not_Yet_Recruiting | 2026-12-01 | 2027-12-01 | ClinicalTrials.gov |
| NCT07445087 | A Study of Takhzyro in Teenagers and Adults With Hereditary Angioedema (HAE) in… | — | Hereditary Angioedema (HAE) | Not_Yet_Recruiting | 2026-10-01 | 2032-02-29 | ClinicalTrials.gov |
| NCT07445087 | A Study of Takhzyro in Teenagers and Adults With Hereditary Angioedema (HAE) in… | — | Hereditary Angioedema (HAE) | Not_Yet_Recruiting | 2026-10-01 | 2032-02-29 | ClinicalTrials.gov |
| NCT07445087 | A Study of Takhzyro in Teenagers and Adults With Hereditary Angioedema (HAE) in… | — | Hereditary Angioedema (HAE) | Not_Yet_Recruiting | 2026-10-01 | 2032-02-29 | ClinicalTrials.gov |
| NCT05669729 | A Survey to Assess Participants', Caregivers', and Nurses' Use and Understandin… | — | Gaucher Disease | Not_Yet_Recruiting | 2026-09-30 | 2027-09-30 | ClinicalTrials.gov |
| NCT05669729 | A Survey to Assess Participants', Caregivers', and Nurses' Use and Understandin… | — | Gaucher Disease | Not_Yet_Recruiting | 2026-09-30 | 2027-09-30 | ClinicalTrials.gov |
| NCT05669729 | A Survey to Assess Participants', Caregivers', and Nurses' Use and Understandin… | — | Gaucher Disease | Not_Yet_Recruiting | 2026-09-30 | 2027-09-30 | ClinicalTrials.gov |
| NCT07613359 | A Study of Mezagitamab in Adults With Late Antibody-Mediated Rejection (AMR) Af… | Phase2 | Antibody-Mediated Rejection (AMR) | Not_Yet_Recruiting | 2026-09-01 | 2029-01-15 | ClinicalTrials.gov |
| NCT07613359 | A Study of Mezagitamab in Adults With Late Antibody-Mediated Rejection (AMR) Af… | Phase2 | Antibody-Mediated Rejection (AMR) | Not_Yet_Recruiting | 2026-09-01 | 2029-01-15 | ClinicalTrials.gov |
| NCT07613359 | A Study of Mezagitamab in Adults With Late Antibody-Mediated Rejection (AMR) Af… | Phase2 | Antibody-Mediated Rejection (AMR) | Not_Yet_Recruiting | 2026-09-01 | 2029-01-15 | ClinicalTrials.gov |
| NCT07623161 | A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anem… | Phase3 | Myelofibrosis | Not_Yet_Recruiting | 2026-08-25 | 2034-03-30 | ClinicalTrials.gov |
| NCT07623161 | A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anem… | Phase3 | Myelofibrosis | Not_Yet_Recruiting | 2026-08-25 | 2034-03-30 | ClinicalTrials.gov |
| NCT07623161 | A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anem… | Phase3 | Myelofibrosis | Not_Yet_Recruiting | 2026-08-25 | 2034-03-30 | ClinicalTrials.gov |
| NCT07429942 | A Study to Learn More About the Treatment of People With Congenital Thrombotic … | — | Thrombotic Thrombocytopenic Purpura (TTP) | Not_Yet_Recruiting | 2026-07-31 | 2026-09-30 | ClinicalTrials.gov |
| NCT07429942 | A Study to Learn More About the Treatment of People With Congenital Thrombotic … | — | Thrombotic Thrombocytopenic Purpura (TTP) | Not_Yet_Recruiting | 2026-07-31 | 2026-09-30 | ClinicalTrials.gov |
| NCT07623174 | A Study of Fruquintinib in Adults With Metastatic Colorectal Cancer in Poland | — | Metastatic Colorectal Cancer | Not_Yet_Recruiting | 2026-07-31 | 2028-03-31 | ClinicalTrials.gov |
| NCT07623174 | A Study of Fruquintinib in Adults With Metastatic Colorectal Cancer in Poland | — | Metastatic Colorectal Cancer | Not_Yet_Recruiting | 2026-07-31 | 2028-03-31 | ClinicalTrials.gov |
| NCT07429942 | A Study to Learn More About the Treatment of People With Congenital Thrombotic … | — | Thrombotic Thrombocytopenic Purpura (TTP) | Not_Yet_Recruiting | 2026-07-31 | 2026-09-30 | ClinicalTrials.gov |
| NCT07623174 | A Study of Fruquintinib in Adults With Metastatic Colorectal Cancer in Poland | — | Metastatic Colorectal Cancer | Not_Yet_Recruiting | 2026-07-31 | 2028-03-31 | ClinicalTrials.gov |
| NCT07403968 | A Study of Zasocitinib (TAK-279) in Adults With Active Crohn's Disease | Phase2 | Crohn's Disease | Not_Yet_Recruiting | 2026-07-15 | 2028-03-30 | ClinicalTrials.gov |
| NCT07250815 | A Study on Infections in Adults With Ulcerative Colitis/Crohn's Disease | — | Ulcerative Colitis | Not_Yet_Recruiting | 2026-07-15 | 2026-12-15 | ClinicalTrials.gov |
| NCT07403968 | A Study of Zasocitinib (TAK-279) in Adults With Active Crohn's Disease | Phase2 | Crohn's Disease | Not_Yet_Recruiting | 2026-07-15 | 2028-03-30 | ClinicalTrials.gov |
| NCT07403968 | A Study of Zasocitinib (TAK-279) in Adults With Active Crohn's Disease | Phase2 | Crohn's Disease | Not_Yet_Recruiting | 2026-07-15 | 2028-03-30 | ClinicalTrials.gov |
| NCT07250815 | A Study on Infections in Adults With Ulcerative Colitis/Crohn's Disease | — | Ulcerative Colitis | Not_Yet_Recruiting | 2026-07-15 | 2026-12-15 | ClinicalTrials.gov |
| NCT07250815 | A Study on Infections in Adults With Ulcerative Colitis/Crohn's Disease | — | Ulcerative Colitis | Not_Yet_Recruiting | 2026-07-15 | 2026-12-15 | ClinicalTrials.gov |
| NCT07648030 | A Study of Rusfertide in Japanese Adults With Polycythemia Vera | Phase2 | Polycythemia Vera | Not_Yet_Recruiting | 2026-06-23 | 2030-05-17 | ClinicalTrials.gov |
| NCT07648030 | A Study of Rusfertide in Japanese Adults With Polycythemia Vera | Phase2 | Polycythemia Vera | Not_Yet_Recruiting | 2026-06-23 | 2030-05-17 | ClinicalTrials.gov |
| NCT07648030 | A Study of Rusfertide in Japanese Adults With Polycythemia Vera | Phase2 | Polycythemia Vera | Not_Yet_Recruiting | 2026-06-23 | 2030-05-17 | ClinicalTrials.gov |
| NCT07646678 | A Study of TAK-360 in People With Narcolepsy or Idiopathic Hypersomnia | Phase2 | Idiopathic Hypersomnia | Recruiting | 2026-06-11 | 2031-06-15 | ClinicalTrials.gov |
| NCT07646678 | A Study of TAK-360 in People With Narcolepsy or Idiopathic Hypersomnia | Phase2 | Idiopathic Hypersomnia | Recruiting | 2026-06-11 | 2031-06-15 | ClinicalTrials.gov |
| NCT07646678 | A Study of TAK-360 in People With Narcolepsy or Idiopathic Hypersomnia | Phase2 | Idiopathic Hypersomnia | Recruiting | 2026-06-11 | 2031-06-15 | ClinicalTrials.gov |
| NCT07633301 | A Study of TAK-360 in Adults With Narcolepsy Type 1 (Narcolepsy With Cataplexy) | Phase2 | Narcolepsy Type 1 | Recruiting | 2026-06-04 | 2027-11-28 | ClinicalTrials.gov |
| NCT07633301 | A Study of TAK-360 in Adults With Narcolepsy Type 1 (Narcolepsy With Cataplexy) | Phase2 | Narcolepsy Type 1 | Recruiting | 2026-06-04 | 2027-11-28 | ClinicalTrials.gov |
| NCT07633301 | A Study of TAK-360 in Adults With Narcolepsy Type 1 (Narcolepsy With Cataplexy) | Phase2 | Narcolepsy Type 1 | Recruiting | 2026-06-04 | 2027-11-28 | ClinicalTrials.gov |
| NCT04563520 | SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis | Phase3 | Hemophilia A | Recruiting | 2026-06-01 | 2027-03-01 | ClinicalTrials.gov |
| NCT04563520 | SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis | Phase3 | Hemophilia A | Recruiting | 2026-06-01 | 2027-03-01 | ClinicalTrials.gov |
| NCT04563520 | SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis | Phase3 | Hemophilia A | Recruiting | 2026-06-01 | 2027-03-01 | ClinicalTrials.gov |
| NCT07353099 | A Study in Children and, Adults With Congenital Thrombotic Thrombocytopenic Pur… | — | Thrombotic Thrombocytopenic Purpura (TTP) | Recruiting | 2026-05-26 | 2030-04-01 | ClinicalTrials.gov |
| NCT07353099 | A Study in Children and, Adults With Congenital Thrombotic Thrombocytopenic Pur… | — | Thrombotic Thrombocytopenic Purpura (TTP) | Recruiting | 2026-05-26 | 2030-04-01 | ClinicalTrials.gov |
| NCT07353099 | A Study in Children and, Adults With Congenital Thrombotic Thrombocytopenic Pur… | — | Thrombotic Thrombocytopenic Purpura (TTP) | Recruiting | 2026-05-26 | 2030-04-01 | ClinicalTrials.gov |
| NCT07422480 | A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With… | Phase3 | Myelodysplastic Syndrome | Recruiting | 2026-05-21 | 2033-10-01 | ClinicalTrials.gov |
| NCT07422480 | A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With… | Phase3 | Myelodysplastic Syndrome | Recruiting | 2026-05-21 | 2033-10-01 | ClinicalTrials.gov |
| NCT07422480 | A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With… | Phase3 | Myelodysplastic Syndrome | Recruiting | 2026-05-21 | 2033-10-01 | ClinicalTrials.gov |
| NCT07293364 | A Study to Learn About the C1-Inhibitor Function as Diagnosis for Hereditary An… | Na | Hereditary Angioedema (HAE) | Recruiting | 2026-05-12 | 2027-06-12 | ClinicalTrials.gov |
| NCT07293364 | A Study to Learn About the C1-Inhibitor Function as Diagnosis for Hereditary An… | Na | Hereditary Angioedema (HAE) | Recruiting | 2026-05-12 | 2027-06-12 | ClinicalTrials.gov |
| NCT07293364 | A Study to Learn About the C1-Inhibitor Function as Diagnosis for Hereditary An… | Na | Hereditary Angioedema (HAE) | Recruiting | 2026-05-12 | 2027-06-12 | ClinicalTrials.gov |
| NCT07436728 | A Study of TAK-505 in Adults With Solid Tumors | Phase1 | Malignant Solid Tumors | Recruiting | 2026-05-11 | 2030-08-18 | ClinicalTrials.gov |
| NCT07436728 | A Study of TAK-505 in Adults With Solid Tumors | Phase1 | Malignant Solid Tumors | Recruiting | 2026-05-11 | 2030-08-18 | ClinicalTrials.gov |
| NCT07436728 | A Study of TAK-505 in Adults With Solid Tumors | Phase1 | Malignant Solid Tumors | Recruiting | 2026-05-11 | 2030-08-18 | ClinicalTrials.gov |
| NCT07380451 | Modular Intervention for Depression Study | Na | Major Depression | Recruiting | 2026-05-01 | 2028-02-28 | ClinicalTrials.gov |
| NCT07380451 | Modular Intervention for Depression Study | Na | Major Depression | Recruiting | 2026-05-01 | 2028-02-28 | ClinicalTrials.gov |
| NCT07380451 | Modular Intervention for Depression Study | Na | Major Depression | Recruiting | 2026-05-01 | 2028-02-28 | ClinicalTrials.gov |
| NCT07263685 | A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE)… | — | Hereditary Angioedema (HAE) | Not_Yet_Recruiting | 2026-04-30 | 2026-05-31 | ClinicalTrials.gov |
| NCT07263685 | A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE)… | — | Hereditary Angioedema (HAE) | Not_Yet_Recruiting | 2026-04-30 | 2026-05-31 | ClinicalTrials.gov |
| NCT07263685 | A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE)… | — | Hereditary Angioedema (HAE) | Not_Yet_Recruiting | 2026-04-30 | 2026-05-31 | ClinicalTrials.gov |
| NCT07319845 | A Study of TAK-226 for Anemia in Japanese Patients With Lower-Risk Myelodysplas… | Phase2 | Myelodysplastic Syndromes | Recruiting | 2026-04-22 | 2033-01-10 | ClinicalTrials.gov |
| NCT07319845 | A Study of TAK-226 for Anemia in Japanese Patients With Lower-Risk Myelodysplas… | Phase2 | Myelodysplastic Syndromes | Recruiting | 2026-04-22 | 2033-01-10 | ClinicalTrials.gov |
| NCT07319845 | A Study of TAK-226 for Anemia in Japanese Patients With Lower-Risk Myelodysplas… | Phase2 | Myelodysplastic Syndromes | Recruiting | 2026-04-22 | 2033-01-10 | ClinicalTrials.gov |
| NCT07392450 | A Study of TAK-755 in Adults With Acute Ischemic Stroke | Phase2 | Acute Ischemic Stroke | Recruiting | 2026-04-07 | 2027-12-06 | ClinicalTrials.gov |
| NCT07392450 | A Study of TAK-755 in Adults With Acute Ischemic Stroke | Phase2 | Acute Ischemic Stroke | Recruiting | 2026-04-07 | 2027-12-06 | ClinicalTrials.gov |
| NCT07392450 | A Study of TAK-755 in Adults With Acute Ischemic Stroke | Phase2 | Acute Ischemic Stroke | Recruiting | 2026-04-07 | 2027-12-06 | ClinicalTrials.gov |
| NCT07224100 | Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment … | Phase2 | B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Recruiting | 2026-03-30 | 2028-07-31 | ClinicalTrials.gov |
| NCT07224100 | Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment … | Phase2 | B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Recruiting | 2026-03-30 | 2028-07-31 | ClinicalTrials.gov |
| NCT07224100 | Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment … | Phase2 | B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Recruiting | 2026-03-30 | 2028-07-31 | ClinicalTrials.gov |
| NCT07501793 | Demographic Characteristics of TAK-003 Dengue Vaccine Recipients in Vietnam | — | Dengue | Active_Not_Recruiting | 2026-03-16 | 2026-04-30 | ClinicalTrials.gov |
| NCT07501793 | Demographic Characteristics of TAK-003 Dengue Vaccine Recipients in Vietnam | — | Dengue | Active_Not_Recruiting | 2026-03-16 | 2026-04-30 | ClinicalTrials.gov |
| NCT07501793 | Demographic Characteristics of TAK-003 Dengue Vaccine Recipients in Vietnam | — | Dengue | Active_Not_Recruiting | 2026-03-16 | 2026-04-30 | ClinicalTrials.gov |
| NCT07286058 | Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis | Phase3 | Psoriatic Arthritis | Recruiting | 2026-03-11 | 2029-12-18 | ClinicalTrials.gov |
| NCT07286058 | Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis | Phase3 | Psoriatic Arthritis | Recruiting | 2026-03-11 | 2029-12-18 | ClinicalTrials.gov |
| NCT07286058 | Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis | Phase3 | Psoriatic Arthritis | Recruiting | 2026-03-11 | 2029-12-18 | ClinicalTrials.gov |
| NCT07319832 | A Study of Teduglutide in Chinese Children and Teenagers With Short Bowel Syndr… | — | Short Bowel Syndrome (SBS) | Recruiting | 2026-03-05 | 2027-09-30 | ClinicalTrials.gov |
| NCT07319832 | A Study of Teduglutide in Chinese Children and Teenagers With Short Bowel Syndr… | — | Short Bowel Syndrome (SBS) | Recruiting | 2026-03-05 | 2027-09-30 | ClinicalTrials.gov |
| NCT07319832 | A Study of Teduglutide in Chinese Children and Teenagers With Short Bowel Syndr… | — | Short Bowel Syndrome (SBS) | Recruiting | 2026-03-05 | 2027-09-30 | ClinicalTrials.gov |
| NCT07404644 | An Observational Study of Vonicog Alfa (rVWF) in Pediatric Participants With Vo… | — | Von Willebrand Disease (vWD) | Recruiting | 2026-02-19 | 2031-05-30 | ClinicalTrials.gov |
| NCT07404644 | An Observational Study of Vonicog Alfa (rVWF) in Pediatric Participants With Vo… | — | Von Willebrand Disease (vWD) | Recruiting | 2026-02-19 | 2031-05-30 | ClinicalTrials.gov |
| NCT07404644 | An Observational Study of Vonicog Alfa (rVWF) in Pediatric Participants With Vo… | — | Von Willebrand Disease (vWD) | Recruiting | 2026-02-19 | 2031-05-30 | ClinicalTrials.gov |
| NCT07624838 | Real-life Experience of Brentuximab Vedotin Plus CHP as First-line Treatment of… | — | CD30-Positive Peripheral T-Cell Lymphoma | Recruiting | 2026-02-15 | 2027-05-01 | ClinicalTrials.gov |
| NCT07624838 | Real-life Experience of Brentuximab Vedotin Plus CHP as First-line Treatment of… | — | CD30-Positive Peripheral T-Cell Lymphoma | Recruiting | 2026-02-15 | 2027-05-01 | ClinicalTrials.gov |
| NCT07624838 | Real-life Experience of Brentuximab Vedotin Plus CHP as First-line Treatment of… | — | CD30-Positive Peripheral T-Cell Lymphoma | Recruiting | 2026-02-15 | 2027-05-01 | ClinicalTrials.gov |
| NCT07251933 | A Study of Lanadelumab in Children With Hereditary Angioedema (HAE) in Multiple… | — | Hereditary Angioedema (HAE) | Recruiting | 2026-02-05 | 2026-06-30 | ClinicalTrials.gov |
| NCT07251933 | A Study of Lanadelumab in Children With Hereditary Angioedema (HAE) in Multiple… | — | Hereditary Angioedema (HAE) | Recruiting | 2026-02-05 | 2026-06-30 | ClinicalTrials.gov |
| NCT07251933 | A Study of Lanadelumab in Children With Hereditary Angioedema (HAE) in Multiple… | — | Hereditary Angioedema (HAE) | Recruiting | 2026-02-05 | 2026-06-30 | ClinicalTrials.gov |
| NCT07363720 | A Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy | Phase3 | Narcolepsy Type 1 (NT1) | Recruiting | 2026-01-29 | 2026-10-02 | ClinicalTrials.gov |
| NCT07363720 | A Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy | Phase3 | Narcolepsy Type 1 (NT1) | Recruiting | 2026-01-29 | 2026-10-02 | ClinicalTrials.gov |
| NCT07363720 | A Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy | Phase3 | Narcolepsy Type 1 (NT1) | Recruiting | 2026-01-29 | 2026-10-02 | ClinicalTrials.gov |
| NCT07244263 | A Study of Zasocitinib in Adults With Hidradenitis Suppurativa | Phase2 | Hidradenitis Suppurativa | Recruiting | 2026-01-26 | 2028-02-22 | ClinicalTrials.gov |
| NCT07244263 | A Study of Zasocitinib in Adults With Hidradenitis Suppurativa | Phase2 | Hidradenitis Suppurativa | Recruiting | 2026-01-26 | 2028-02-22 | ClinicalTrials.gov |
| NCT07244263 | A Study of Zasocitinib in Adults With Hidradenitis Suppurativa | Phase2 | Hidradenitis Suppurativa | Recruiting | 2026-01-26 | 2028-02-22 | ClinicalTrials.gov |
| NCT06579755 | A Study of Dengue Tetravalent Vaccine (TDV) in Adults (Age 45 to 60 and >60 to … | Phase3 | Dengue Fever | Recruiting | 2026-01-20 | 2027-04-14 | ClinicalTrials.gov |
| NCT06579755 | A Study of Dengue Tetravalent Vaccine (TDV) in Adults (Age 45 to 60 and >60 to … | Phase3 | Dengue Fever | Recruiting | 2026-01-20 | 2027-04-14 | ClinicalTrials.gov |
| NCT06579755 | A Study of Dengue Tetravalent Vaccine (TDV) in Adults (Age 45 to 60 and >60 to … | Phase3 | Dengue Fever | Recruiting | 2026-01-20 | 2027-04-14 | ClinicalTrials.gov |
| NCT06980480 | A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infectio… | Phase3 | Multiple Myeloma | Recruiting | 2026-01-14 | 2028-09-11 | ClinicalTrials.gov |
| NCT06980480 | A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infectio… | Phase3 | Multiple Myeloma | Recruiting | 2026-01-14 | 2028-09-11 | ClinicalTrials.gov |
| NCT06980480 | A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infectio… | Phase3 | Multiple Myeloma | Recruiting | 2026-01-14 | 2028-09-11 | ClinicalTrials.gov |
| NCT07293897 | A Database Study of Maralixibat (TAK-625) in Participants With Alagille Syndrom… | — | Alagille Syndrome (ALGS) | Recruiting | 2026-01-13 | 2031-06-30 | ClinicalTrials.gov |
| NCT07293897 | A Database Study of Maralixibat (TAK-625) in Participants With Alagille Syndrom… | — | Alagille Syndrome (ALGS) | Recruiting | 2026-01-13 | 2031-06-30 | ClinicalTrials.gov |
| NCT07293897 | A Database Study of Maralixibat (TAK-625) in Participants With Alagille Syndrom… | — | Alagille Syndrome (ALGS) | Recruiting | 2026-01-13 | 2031-06-30 | ClinicalTrials.gov |
| NCT07229911 | A Study of TAK-781 in Healthy Volunteers and in Participants With Non-Cirrhotic… | Phase1 | Healthy Volunteers | Recruiting | 2026-01-07 | 2028-04-06 | ClinicalTrials.gov |
| NCT07229911 | A Study of TAK-781 in Healthy Volunteers and in Participants With Non-Cirrhotic… | Phase1 | Healthy Volunteers | Recruiting | 2026-01-07 | 2028-04-06 | ClinicalTrials.gov |
| NCT07229911 | A Study of TAK-781 in Healthy Volunteers and in Participants With Non-Cirrhotic… | Phase1 | Healthy Volunteers | Recruiting | 2026-01-07 | 2028-04-06 | ClinicalTrials.gov |
| NCT07494058 | A Study of Home vs Hospital Treatment in People With Fabry, Gaucher or Hunter C… | — | Lysosomal Disease | Active_Not_Recruiting | 2025-12-11 | 2026-08-01 | ClinicalTrials.gov |
| NCT07494058 | A Study of Home vs Hospital Treatment in People With Fabry, Gaucher or Hunter C… | — | Lysosomal Disease | Active_Not_Recruiting | 2025-12-11 | 2026-08-01 | ClinicalTrials.gov |
| NCT07494058 | A Study of Home vs Hospital Treatment in People With Fabry, Gaucher or Hunter C… | — | Lysosomal Disease | Active_Not_Recruiting | 2025-12-11 | 2026-08-01 | ClinicalTrials.gov |
| NCT07250802 | A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis | Phase3 | Plaque Psoriasis | Recruiting | 2025-12-04 | 2033-01-24 | ClinicalTrials.gov |
| NCT07250802 | A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis | Phase3 | Plaque Psoriasis | Recruiting | 2025-12-04 | 2033-01-24 | ClinicalTrials.gov |
| NCT07250802 | A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis | Phase3 | Plaque Psoriasis | Recruiting | 2025-12-04 | 2033-01-24 | ClinicalTrials.gov |
| NCT07299097 | Epidemiology of Narcolepsy Type 1 and Type 2 in Spain | — | Narcolepsy Type 1 | Recruiting | 2025-12-02 | 2026-07-31 | ClinicalTrials.gov |
| NCT07299097 | Epidemiology of Narcolepsy Type 1 and Type 2 in Spain | — | Narcolepsy Type 1 | Recruiting | 2025-12-02 | 2026-07-31 | ClinicalTrials.gov |
| NCT07299097 | Epidemiology of Narcolepsy Type 1 and Type 2 in Spain | — | Narcolepsy Type 1 | Recruiting | 2025-12-02 | 2026-07-31 | ClinicalTrials.gov |
| NCT07217301 | A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Can… | Phase3 | IO-resistant sqNSCLC | Recruiting | 2025-11-26 | 2029-12-01 | ClinicalTrials.gov |
| NCT07217301 | A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Can… | Phase3 | IO-resistant sqNSCLC | Recruiting | 2025-11-26 | 2029-12-01 | ClinicalTrials.gov |
| NCT07217301 | A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Can… | Phase3 | IO-resistant sqNSCLC | Recruiting | 2025-11-26 | 2029-12-01 | ClinicalTrials.gov |
| NCT07205718 | A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors | Phase1 | Advanced or Metastatic Solid Tumors | Recruiting | 2025-11-19 | 2029-12-21 | ClinicalTrials.gov |
| NCT07205718 | A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors | Phase1 | Advanced or Metastatic Solid Tumors | Recruiting | 2025-11-19 | 2029-12-21 | ClinicalTrials.gov |
| NCT07205718 | A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors | Phase1 | Advanced or Metastatic Solid Tumors | Recruiting | 2025-11-19 | 2029-12-21 | ClinicalTrials.gov |
| NCT07047521 | A Study on a New Tetravalent Dengue Vaccine (TDV) Formulation in Healthy Adults | Phase3 | Dengue Fever | Active_Not_Recruiting | 2025-11-07 | 2026-12-22 | ClinicalTrials.gov |
| NCT07047521 | A Study on a New Tetravalent Dengue Vaccine (TDV) Formulation in Healthy Adults | Phase3 | Dengue Fever | Active_Not_Recruiting | 2025-11-07 | 2026-12-22 | ClinicalTrials.gov |
| NCT07047521 | A Study on a New Tetravalent Dengue Vaccine (TDV) Formulation in Healthy Adults | Phase3 | Dengue Fever | Active_Not_Recruiting | 2025-11-07 | 2026-12-22 | ClinicalTrials.gov |
| NCT06243731 | A Study of Maribavir in Adults With Kidney Failure Who Have a Cytomegalovirus (… | — | Cytomegalovirus (CMV) | Recruiting | 2025-11-03 | 2027-01-31 | ClinicalTrials.gov |
| NCT07108283 | A Study of Zasocitinib in Adults With Nonsegmental Vitiligo | Phase2 | Nonsegmental Vitiligo | Recruiting | 2025-11-03 | 2027-11-09 | ClinicalTrials.gov |
| NCT07108283 | A Study of Zasocitinib in Adults With Nonsegmental Vitiligo | Phase2 | Nonsegmental Vitiligo | Recruiting | 2025-11-03 | 2027-11-09 | ClinicalTrials.gov |
| NCT06243731 | A Study of Maribavir in Adults With Kidney Failure Who Have a Cytomegalovirus (… | — | Cytomegalovirus (CMV) | Recruiting | 2025-11-03 | 2027-01-31 | ClinicalTrials.gov |
| NCT07108283 | A Study of Zasocitinib in Adults With Nonsegmental Vitiligo | Phase2 | Nonsegmental Vitiligo | Recruiting | 2025-11-03 | 2027-11-09 | ClinicalTrials.gov |
| NCT06243731 | A Study of Maribavir in Adults With Kidney Failure Who Have a Cytomegalovirus (… | — | Cytomegalovirus (CMV) | Recruiting | 2025-11-03 | 2027-01-31 | ClinicalTrials.gov |
| NCT07187440 | A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and A… | — | Fabry Disease | Recruiting | 2025-11-01 | 2028-11-30 | ClinicalTrials.gov |
| NCT07187440 | A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and A… | — | Fabry Disease | Recruiting | 2025-11-01 | 2028-11-30 | ClinicalTrials.gov |
| NCT07187440 | A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and A… | — | Fabry Disease | Recruiting | 2025-11-01 | 2028-11-30 | ClinicalTrials.gov |
| NCT06405087 | A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcer… | Phase3 | Ulcerative Colitis | Recruiting | 2025-10-27 | 2030-08-12 | ClinicalTrials.gov |
| NCT06405087 | A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcer… | Phase3 | Ulcerative Colitis | Recruiting | 2025-10-27 | 2030-08-12 | ClinicalTrials.gov |
| NCT06405087 | A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcer… | Phase3 | Ulcerative Colitis | Recruiting | 2025-10-27 | 2030-08-12 | ClinicalTrials.gov |
| NCT07123350 | Evaluating the Shift From Intravenous to Subcutaneous Vedolizumab for Inflammat… | — | Inflammatory Bowel Disease (IBD) | Active_Not_Recruiting | 2025-10-16 | 2026-03-31 | ClinicalTrials.gov |
| NCT07123350 | Evaluating the Shift From Intravenous to Subcutaneous Vedolizumab for Inflammat… | — | Inflammatory Bowel Disease (IBD) | Active_Not_Recruiting | 2025-10-16 | 2026-03-31 | ClinicalTrials.gov |
| NCT07123350 | Evaluating the Shift From Intravenous to Subcutaneous Vedolizumab for Inflammat… | — | Inflammatory Bowel Disease (IBD) | Active_Not_Recruiting | 2025-10-16 | 2026-03-31 | ClinicalTrials.gov |
| NCT07129343 | A Study of Recombinant Von Willebrand Factor (rVWF) in Chinese Participants Wit… | Phase3 | Von Willebrand Disease (VWD) | Recruiting | 2025-10-13 | 2027-11-25 | ClinicalTrials.gov |
| NCT07129343 | A Study of Recombinant Von Willebrand Factor (rVWF) in Chinese Participants Wit… | Phase3 | Von Willebrand Disease (VWD) | Recruiting | 2025-10-13 | 2027-11-25 | ClinicalTrials.gov |
| NCT07129343 | A Study of Recombinant Von Willebrand Factor (rVWF) in Chinese Participants Wit… | Phase3 | Von Willebrand Disease (VWD) | Recruiting | 2025-10-13 | 2027-11-25 | ClinicalTrials.gov |
| NCT07204314 | A Study of Vortioxetine in Japanese Pediatric Patients With Major Depressive Di… | Phase3 | Major Depressive Disorder | Recruiting | 2025-10-01 | 2029-09-30 | ClinicalTrials.gov |
| NCT07204314 | A Study of Vortioxetine in Japanese Pediatric Patients With Major Depressive Di… | Phase3 | Major Depressive Disorder | Recruiting | 2025-10-01 | 2029-09-30 | ClinicalTrials.gov |
| NCT07204314 | A Study of Vortioxetine in Japanese Pediatric Patients With Major Depressive Di… | Phase3 | Major Depressive Disorder | Recruiting | 2025-10-01 | 2029-09-30 | ClinicalTrials.gov |
| NCT07035886 | A Study to Monitor the Fruzaqla Treatment of Adults With Metastatic Colorectal … | — | Colorectal Cancer | Recruiting | 2025-09-29 | 2031-03-01 | ClinicalTrials.gov |
| NCT07035886 | A Study to Monitor the Fruzaqla Treatment of Adults With Metastatic Colorectal … | — | Colorectal Cancer | Recruiting | 2025-09-29 | 2031-03-01 | ClinicalTrials.gov |
| NCT07035886 | A Study to Monitor the Fruzaqla Treatment of Adults With Metastatic Colorectal … | — | Colorectal Cancer | Recruiting | 2025-09-29 | 2031-03-01 | ClinicalTrials.gov |
| NCT07240168 | CurQD as Add-On Therapy in Vedolizumab-Treated Ulcerative Colitis Patients: Ret… | — | Ulcerative Colitis (UC) | Active_Not_Recruiting | 2025-09-07 | 2026-08-20 | ClinicalTrials.gov |
| NCT07240168 | CurQD as Add-On Therapy in Vedolizumab-Treated Ulcerative Colitis Patients: Ret… | — | Ulcerative Colitis (UC) | Active_Not_Recruiting | 2025-09-07 | 2026-08-20 | ClinicalTrials.gov |
| NCT07240168 | CurQD as Add-On Therapy in Vedolizumab-Treated Ulcerative Colitis Patients: Ret… | — | Ulcerative Colitis (UC) | Active_Not_Recruiting | 2025-09-07 | 2026-08-20 | ClinicalTrials.gov |
| NCT06948318 | A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thromboc… | Phase3 | Immune Thrombocytopenic Purpura (ITP) | Recruiting | 2025-08-14 | 2029-07-29 | ClinicalTrials.gov |
| NCT06948318 | A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thromboc… | Phase3 | Immune Thrombocytopenic Purpura (ITP) | Recruiting | 2025-08-14 | 2029-07-29 | ClinicalTrials.gov |
| NCT06948318 | A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thromboc… | Phase3 | Immune Thrombocytopenic Purpura (ITP) | Recruiting | 2025-08-14 | 2029-07-29 | ClinicalTrials.gov |
| NCT07111559 | Lacunar Stroke hyperAcute Clinical Utilization of Novel Approach Regimens: Rt-P… | Phase4 | Lacunar Stroke | Recruiting | 2025-08-01 | 2029-03-31 | ClinicalTrials.gov |
| NCT07111559 | Lacunar Stroke hyperAcute Clinical Utilization of Novel Approach Regimens: Rt-P… | Phase4 | Lacunar Stroke | Recruiting | 2025-08-01 | 2029-03-31 | ClinicalTrials.gov |
| NCT07111559 | Lacunar Stroke hyperAcute Clinical Utilization of Novel Approach Regimens: Rt-P… | Phase4 | Lacunar Stroke | Recruiting | 2025-08-01 | 2029-03-31 | ClinicalTrials.gov |
| NCT06550882 | A Study of OBIZUR in Adults With Acquired Hemophilia A (AHA) in South Korea | — | Acquired Hemophilia A | Recruiting | 2025-07-22 | 2026-09-30 | ClinicalTrials.gov |
| NCT06550882 | A Study of OBIZUR in Adults With Acquired Hemophilia A (AHA) in South Korea | — | Acquired Hemophilia A | Recruiting | 2025-07-22 | 2026-09-30 | ClinicalTrials.gov |
| NCT06550882 | A Study of OBIZUR in Adults With Acquired Hemophilia A (AHA) in South Korea | — | Acquired Hemophilia A | Recruiting | 2025-07-22 | 2026-09-30 | ClinicalTrials.gov |
| NCT06841705 | Early Vedolizumab as First-Line for Immune-Related Colitis Therapy Trial | Phase2 | Immune Checkpoint Inhibitor-Related Colitis | Recruiting | 2025-07-15 | 2026-12-31 | ClinicalTrials.gov |
| NCT06841705 | Early Vedolizumab as First-Line for Immune-Related Colitis Therapy Trial | Phase2 | Immune Checkpoint Inhibitor-Related Colitis | Recruiting | 2025-07-15 | 2026-12-31 | ClinicalTrials.gov |
| NCT06963827 | A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy | Phase3 | Kidney Disease | Recruiting | 2025-07-15 | 2030-01-14 | ClinicalTrials.gov |
| NCT06841705 | Early Vedolizumab as First-Line for Immune-Related Colitis Therapy Trial | Phase2 | Immune Checkpoint Inhibitor-Related Colitis | Recruiting | 2025-07-15 | 2026-12-31 | ClinicalTrials.gov |
| NCT06963827 | A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy | Phase3 | Kidney Disease | Recruiting | 2025-07-15 | 2030-01-14 | ClinicalTrials.gov |
| NCT06963827 | A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy | Phase3 | Kidney Disease | Recruiting | 2025-07-15 | 2030-01-14 | ClinicalTrials.gov |
| NCT06973291 | A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Pla… | Phase3 | Plaque Psoriasis | Active_Not_Recruiting | 2025-07-09 | 2026-07-03 | ClinicalTrials.gov |
| NCT06973291 | A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Pla… | Phase3 | Plaque Psoriasis | Active_Not_Recruiting | 2025-07-09 | 2026-07-03 | ClinicalTrials.gov |
| NCT06973291 | A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Pla… | Phase3 | Plaque Psoriasis | Active_Not_Recruiting | 2025-07-09 | 2026-07-03 | ClinicalTrials.gov |
| NCT06973304 | A Study of Teduglutide in Chinese Adults With Short Bowel Syndrome | Phase3 | Short Bowel Syndrome | Recruiting | 2025-06-26 | 2027-07-28 | ClinicalTrials.gov |
| NCT06973304 | A Study of Teduglutide in Chinese Adults With Short Bowel Syndrome | Phase3 | Short Bowel Syndrome | Recruiting | 2025-06-26 | 2027-07-28 | ClinicalTrials.gov |
| NCT06973304 | A Study of Teduglutide in Chinese Adults With Short Bowel Syndrome | Phase3 | Short Bowel Syndrome | Recruiting | 2025-06-26 | 2027-07-28 | ClinicalTrials.gov |
| NCT06665035 | A Study of 2 Doses of Tetravalent Dengue Vaccine (TDV) in Infants and Toddlers | Phase3 | Dengue Fever | Recruiting | 2025-06-16 | 2030-03-03 | ClinicalTrials.gov |
| NCT06665035 | A Study of 2 Doses of Tetravalent Dengue Vaccine (TDV) in Infants and Toddlers | Phase3 | Dengue Fever | Recruiting | 2025-06-16 | 2030-03-03 | ClinicalTrials.gov |
| NCT06665035 | A Study of 2 Doses of Tetravalent Dengue Vaccine (TDV) in Infants and Toddlers | Phase3 | Dengue Fever | Recruiting | 2025-06-16 | 2030-03-03 | ClinicalTrials.gov |
| NCT02442752 | Phase 1 Dexlansoprazole Delayed-Release Capsules for Acid-Related Disorders in … | Phase1 | Pediatric Gastroesophageal Reflux Disease | Withdrawn | 2025-06-15 | 2025-12-23 | ClinicalTrials.gov |
| NCT02442752 | Phase 1 Dexlansoprazole Delayed-Release Capsules for Acid-Related Disorders in … | Phase1 | Pediatric Gastroesophageal Reflux Disease | Withdrawn | 2025-06-15 | 2025-12-23 | ClinicalTrials.gov |
| NCT02442752 | Phase 1 Dexlansoprazole Delayed-Release Capsules for Acid-Related Disorders in … | Phase1 | Pediatric Gastroesophageal Reflux Disease | Withdrawn | 2025-06-15 | 2025-12-23 | ClinicalTrials.gov |
| NCT06377228 | A Study of TAK-007 in Adults With Refractory Lupus Nephritis (LN) or Refractory… | Phase1 | Refractory Lupus Nephritis | Withdrawn | 2025-06-13 | 2030-09-02 | ClinicalTrials.gov |
| NCT06377228 | A Study of TAK-007 in Adults With Refractory Lupus Nephritis (LN) or Refractory… | Phase1 | Refractory Lupus Nephritis | Withdrawn | 2025-06-13 | 2030-09-02 | ClinicalTrials.gov |
| NCT06377228 | A Study of TAK-007 in Adults With Refractory Lupus Nephritis (LN) or Refractory… | Phase1 | Refractory Lupus Nephritis | Withdrawn | 2025-06-13 | 2030-09-02 | ClinicalTrials.gov |
| NCT06764615 | A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Croh… | Phase2 | Crohn's Disease | Recruiting | 2025-05-28 | 2029-12-30 | ClinicalTrials.gov |
| NCT06764615 | A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Croh… | Phase2 | Crohn's Disease | Recruiting | 2025-05-28 | 2029-12-30 | ClinicalTrials.gov |
| NCT06764615 | A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Croh… | Phase2 | Crohn's Disease | Recruiting | 2025-05-28 | 2029-12-30 | ClinicalTrials.gov |
| NCT06798012 | A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradicu… | Phase2 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | Recruiting | 2025-05-14 | 2028-06-08 | ClinicalTrials.gov |
| NCT06798012 | A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradicu… | Phase2 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | Recruiting | 2025-05-14 | 2028-06-08 | ClinicalTrials.gov |
| NCT06798012 | A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradicu… | Phase2 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | Recruiting | 2025-05-14 | 2028-06-08 | ClinicalTrials.gov |
| NCT06952699 | A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2) | Phase2 | Narcolepsy Type 2 | Recruiting | 2025-05-06 | 2026-11-30 | ClinicalTrials.gov |
| NCT06747351 | A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demye… | Phase3 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | Recruiting | 2025-05-06 | 2028-06-25 | ClinicalTrials.gov |
| NCT06952699 | A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2) | Phase2 | Narcolepsy Type 2 | Recruiting | 2025-05-06 | 2026-11-30 | ClinicalTrials.gov |
| NCT06952699 | A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2) | Phase2 | Narcolepsy Type 2 | Recruiting | 2025-05-06 | 2026-11-30 | ClinicalTrials.gov |
| NCT06499285 | A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Interme… | Phase3 | Myelodysplastic Syndromes | Recruiting | 2025-05-06 | 2032-05-01 | ClinicalTrials.gov |
| NCT06747351 | A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demye… | Phase3 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | Recruiting | 2025-05-06 | 2028-06-25 | ClinicalTrials.gov |
| NCT06747351 | A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demye… | Phase3 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | Recruiting | 2025-05-06 | 2028-06-25 | ClinicalTrials.gov |
| NCT06499285 | A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Interme… | Phase3 | Myelodysplastic Syndromes | Recruiting | 2025-05-06 | 2032-05-01 | ClinicalTrials.gov |
| NCT06499285 | A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Interme… | Phase3 | Myelodysplastic Syndromes | Recruiting | 2025-05-06 | 2032-05-01 | ClinicalTrials.gov |
| NCT06750731 | Study of Efficacy and Adherence to Subcutaneous vs. Intravenous Vedolizumab in … | — | Inflammatory Bowel Disease (IBD) | Recruiting | 2025-05-05 | 2026-09-30 | ClinicalTrials.gov |
| NCT06750731 | Study of Efficacy and Adherence to Subcutaneous vs. Intravenous Vedolizumab in … | — | Inflammatory Bowel Disease (IBD) | Recruiting | 2025-05-05 | 2026-09-30 | ClinicalTrials.gov |
| NCT06750731 | Study of Efficacy and Adherence to Subcutaneous vs. Intravenous Vedolizumab in … | — | Inflammatory Bowel Disease (IBD) | Recruiting | 2025-05-05 | 2026-09-30 | ClinicalTrials.gov |
| NCT06538064 | A Study of HyQvia in Adults With Chronic Inflammatory Demyelinating Polyradicul… | — | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | Recruiting | 2025-04-29 | 2027-08-17 | ClinicalTrials.gov |
| NCT06538064 | A Study of HyQvia in Adults With Chronic Inflammatory Demyelinating Polyradicul… | — | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | Recruiting | 2025-04-29 | 2027-08-17 | ClinicalTrials.gov |
| NCT06538064 | A Study of HyQvia in Adults With Chronic Inflammatory Demyelinating Polyradicul… | — | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | Recruiting | 2025-04-29 | 2027-08-17 | ClinicalTrials.gov |
| NCT06935266 | A Study of TAK-881 With and Without Ramp-Up Dosing in Healthy Adults | Phase1 | Healthy Volunteers | Completed | 2025-04-22 | 2025-09-22 | ClinicalTrials.gov |
| NCT06935266 | A Study of TAK-881 With and Without Ramp-Up Dosing in Healthy Adults | Phase1 | Healthy Volunteers | Completed | 2025-04-22 | 2025-09-22 | ClinicalTrials.gov |
| NCT06935266 | A Study of TAK-881 With and Without Ramp-Up Dosing in Healthy Adults | Phase1 | Healthy Volunteers | Completed | 2025-04-22 | 2025-09-22 | ClinicalTrials.gov |
| NCT06581328 | A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in … | Phase4 | Ulcerative Colitis | Recruiting | 2025-03-27 | 2028-06-01 | ClinicalTrials.gov |
| NCT06581328 | A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in … | Phase4 | Ulcerative Colitis | Recruiting | 2025-03-27 | 2028-06-01 | ClinicalTrials.gov |
| NCT06581328 | A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in … | Phase4 | Ulcerative Colitis | Recruiting | 2025-03-27 | 2028-06-01 | ClinicalTrials.gov |
| NCT06895967 | A Study of TAK-881 and HyQvia in Healthy Adults | Phase1 | Healthy Volunteers | Completed | 2025-03-24 | 2025-08-08 | ClinicalTrials.gov |
| NCT06895967 | A Study of TAK-881 and HyQvia in Healthy Adults | Phase1 | Healthy Volunteers | Completed | 2025-03-24 | 2025-08-08 | ClinicalTrials.gov |
| NCT06895967 | A Study of TAK-881 and HyQvia in Healthy Adults | Phase1 | Healthy Volunteers | Completed | 2025-03-24 | 2025-08-08 | ClinicalTrials.gov |
| NCT06671496 | A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not … | Phase3 | Psoriatic Arthritis | Recruiting | 2025-03-10 | 2028-01-26 | ClinicalTrials.gov |
| NCT06671496 | A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not … | Phase3 | Psoriatic Arthritis | Recruiting | 2025-03-10 | 2028-01-26 | ClinicalTrials.gov |
| NCT06671496 | A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not … | Phase3 | Psoriatic Arthritis | Recruiting | 2025-03-10 | 2028-01-26 | ClinicalTrials.gov |
| NCT06843226 | A Study in Children and Teenagers to Learn if a TDV Dengue Vaccination Lowers t… | — | Dengue Fever | Recruiting | 2025-03-05 | 2029-12-31 | ClinicalTrials.gov |
| NCT06843226 | A Study in Children and Teenagers to Learn if a TDV Dengue Vaccination Lowers t… | — | Dengue Fever | Recruiting | 2025-03-05 | 2029-12-31 | ClinicalTrials.gov |
| NCT06843226 | A Study in Children and Teenagers to Learn if a TDV Dengue Vaccination Lowers t… | — | Dengue Fever | Recruiting | 2025-03-05 | 2029-12-31 | ClinicalTrials.gov |
| NCT06671483 | A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Bi… | Phase3 | Psoriatic Arthritis | Recruiting | 2025-03-03 | 2028-01-28 | ClinicalTrials.gov |
| NCT06671483 | A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Bi… | Phase3 | Psoriatic Arthritis | Recruiting | 2025-03-03 | 2028-01-28 | ClinicalTrials.gov |
| NCT06671483 | A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Bi… | Phase3 | Psoriatic Arthritis | Recruiting | 2025-03-03 | 2028-01-28 | ClinicalTrials.gov |
| NCT06856902 | BEhavioral and Adherence Model for Improving Quality, Health Outcomes and Cost-… | Na | Cardiovascular Diseases | Recruiting | 2025-03-01 | 2026-09-30 | ClinicalTrials.gov |
| NCT06766409 | Effect of Joint Provision of Community Group-based Counseling with Individual C… | Na | Postpartum Contraception | Not_Yet_Recruiting | 2025-03-01 | 2026-05-31 | ClinicalTrials.gov |
| NCT06856902 | BEhavioral and Adherence Model for Improving Quality, Health Outcomes and Cost-… | Na | Cardiovascular Diseases | Recruiting | 2025-03-01 | 2026-09-30 | ClinicalTrials.gov |
| NCT06766409 | Effect of Joint Provision of Community Group-based Counseling with Individual C… | Na | Postpartum Contraception | Not_Yet_Recruiting | 2025-03-01 | 2026-05-31 | ClinicalTrials.gov |
| NCT06766409 | Effect of Joint Provision of Community Group-based Counseling with Individual C… | Na | Postpartum Contraception | Not_Yet_Recruiting | 2025-03-01 | 2026-05-31 | ClinicalTrials.gov |
| NCT06856902 | BEhavioral and Adherence Model for Improving Quality, Health Outcomes and Cost-… | Na | Cardiovascular Diseases | Recruiting | 2025-03-01 | 2026-09-30 | ClinicalTrials.gov |
| NCT06588868 | Systemic Therapies in the Treatment of Cutaneous T-cell Lymphoma | — | Cutaneous T Cell Lymphoma | Recruiting | 2025-02-27 | 2026-07-01 | ClinicalTrials.gov |
| NCT06722235 | A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia | Phase3 | Immune Thrombocytopenic Purpura (ITP) | Recruiting | 2025-02-27 | 2028-03-16 | ClinicalTrials.gov |
| NCT06588868 | Systemic Therapies in the Treatment of Cutaneous T-cell Lymphoma | — | Cutaneous T Cell Lymphoma | Recruiting | 2025-02-27 | 2026-07-01 | ClinicalTrials.gov |
| NCT06722235 | A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia | Phase3 | Immune Thrombocytopenic Purpura (ITP) | Recruiting | 2025-02-27 | 2028-03-16 | ClinicalTrials.gov |
| NCT06588868 | Systemic Therapies in the Treatment of Cutaneous T-cell Lymphoma | — | Cutaneous T Cell Lymphoma | Recruiting | 2025-02-27 | 2026-07-01 | ClinicalTrials.gov |
| NCT06722235 | A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia | Phase3 | Immune Thrombocytopenic Purpura (ITP) | Recruiting | 2025-02-27 | 2028-03-16 | ClinicalTrials.gov |
| NCT06677892 | A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV) Infec… | — | Cytomegalovirus (CMV) | Recruiting | 2025-02-24 | 2026-09-01 | ClinicalTrials.gov |
| NCT06677892 | A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV) Infec… | — | Cytomegalovirus (CMV) | Recruiting | 2025-02-24 | 2026-09-01 | ClinicalTrials.gov |
| NCT06677892 | A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV) Infec… | — | Cytomegalovirus (CMV) | Recruiting | 2025-02-24 | 2026-09-01 | ClinicalTrials.gov |
| NCT06565078 | A Database Survey to Evaluate the Safety of Immune Globulin Subcutaneous (Human… | — | Primary Immunodeficiency Diseases (PID) | Recruiting | 2025-02-17 | 2030-07-31 | ClinicalTrials.gov |
| NCT06565078 | A Database Survey to Evaluate the Safety of Immune Globulin Subcutaneous (Human… | — | Primary Immunodeficiency Diseases (PID) | Recruiting | 2025-02-17 | 2030-07-31 | ClinicalTrials.gov |
| NCT06565078 | A Database Survey to Evaluate the Safety of Immune Globulin Subcutaneous (Human… | — | Primary Immunodeficiency Diseases (PID) | Recruiting | 2025-02-17 | 2030-07-31 | ClinicalTrials.gov |
| NCT06812078 | A Study of TAK-360 in Adults With Idiopathic Hypersomnia | Phase2 | Idiopathic Hypersomnia | Recruiting | 2025-02-07 | 2026-11-30 | ClinicalTrials.gov |
| NCT06812078 | A Study of TAK-360 in Adults With Idiopathic Hypersomnia | Phase2 | Idiopathic Hypersomnia | Recruiting | 2025-02-07 | 2026-11-30 | ClinicalTrials.gov |
| NCT06812078 | A Study of TAK-360 in Adults With Idiopathic Hypersomnia | Phase2 | Idiopathic Hypersomnia | Recruiting | 2025-02-07 | 2026-11-30 | ClinicalTrials.gov |
| NCT06741683 | A Study of Dengue Tetravalent Vaccine (TDV) in Healthy Participants in Japan | Phase2 | Dengue Fever | Completed | 2025-01-31 | 2025-12-17 | ClinicalTrials.gov |
| NCT06741683 | A Study of Dengue Tetravalent Vaccine (TDV) in Healthy Participants in Japan | Phase2 | Dengue Fever | Completed | 2025-01-31 | 2025-12-17 | ClinicalTrials.gov |
| NCT06741683 | A Study of Dengue Tetravalent Vaccine (TDV) in Healthy Participants in Japan | Phase2 | Dengue Fever | Completed | 2025-01-31 | 2025-12-17 | ClinicalTrials.gov |
| NCT06793943 | A Study of Interaction of Zasocitinib (TAK-279) With Other Medicines in Healthy… | Phase1 | Healthy Volunteers | Completed | 2025-01-23 | 2025-03-30 | ClinicalTrials.gov |
| NCT06793943 | A Study of Interaction of Zasocitinib (TAK-279) With Other Medicines in Healthy… | Phase1 | Healthy Volunteers | Completed | 2025-01-23 | 2025-03-30 | ClinicalTrials.gov |
| NCT06793943 | A Study of Interaction of Zasocitinib (TAK-279) With Other Medicines in Healthy… | Phase1 | Healthy Volunteers | Completed | 2025-01-23 | 2025-03-30 | ClinicalTrials.gov |
| NCT06100289 | A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Cro… | Phase3 | Ulcerative Colitis | Recruiting | 2025-01-22 | 2027-11-15 | ClinicalTrials.gov |
| NCT06100289 | A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Cro… | Phase3 | Ulcerative Colitis | Recruiting | 2025-01-22 | 2027-11-15 | ClinicalTrials.gov |
| NCT06100289 | A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Cro… | Phase3 | Ulcerative Colitis | Recruiting | 2025-01-22 | 2027-11-15 | ClinicalTrials.gov |
| NCT06562543 | A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populat… | Phase4 | Colorectal Cancer | Recruiting | 2025-01-14 | 2027-10-04 | ClinicalTrials.gov |
| NCT06562543 | A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populat… | Phase4 | Colorectal Cancer | Recruiting | 2025-01-14 | 2027-10-04 | ClinicalTrials.gov |
| NCT06562543 | A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populat… | Phase4 | Colorectal Cancer | Recruiting | 2025-01-14 | 2027-10-04 | ClinicalTrials.gov |
| NCT06227910 | A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Dis… | Phase3 | Crohn's Disease | Recruiting | 2025-01-02 | 2028-08-01 | ClinicalTrials.gov |
| NCT06227910 | A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Dis… | Phase3 | Crohn's Disease | Recruiting | 2025-01-02 | 2028-08-01 | ClinicalTrials.gov |
| NCT06227910 | A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Dis… | Phase3 | Crohn's Disease | Recruiting | 2025-01-02 | 2028-08-01 | ClinicalTrials.gov |
| NCT06439342 | A Study of Maribavir in Chinese Adults With Cytomegalovirus (CMV) Infections | Phase3 | Cytomegalovirus (CMV) | Recruiting | 2024-12-16 | 2026-12-31 | ClinicalTrials.gov |
| NCT06439342 | A Study of Maribavir in Chinese Adults With Cytomegalovirus (CMV) Infections | Phase3 | Cytomegalovirus (CMV) | Recruiting | 2024-12-16 | 2026-12-31 | ClinicalTrials.gov |
| NCT06439342 | A Study of Maribavir in Chinese Adults With Cytomegalovirus (CMV) Infections | Phase3 | Cytomegalovirus (CMV) | Recruiting | 2024-12-16 | 2026-12-31 | ClinicalTrials.gov |
| NCT06317220 | Vedolizumab for the Treatment of Collagenous Gastritis | Phase2 | Collagenous Gastritis | Active_Not_Recruiting | 2024-12-03 | 2026-10-01 | ClinicalTrials.gov |
| NCT06317220 | Vedolizumab for the Treatment of Collagenous Gastritis | Phase2 | Collagenous Gastritis | Active_Not_Recruiting | 2024-12-03 | 2026-10-01 | ClinicalTrials.gov |
| NCT06317220 | Vedolizumab for the Treatment of Collagenous Gastritis | Phase2 | Collagenous Gastritis | Active_Not_Recruiting | 2024-12-03 | 2026-10-01 | ClinicalTrials.gov |
| NCT06395792 | A Study on Dravet Syndrome (DS) and Lennox-Gastaut Syndrome (LGS) in Children, … | — | Dravet Syndrome (DS) | Withdrawn | 2024-12-01 | 2025-07-01 | ClinicalTrials.gov |
| NCT06395792 | A Study on Dravet Syndrome (DS) and Lennox-Gastaut Syndrome (LGS) in Children, … | — | Dravet Syndrome (DS) | Withdrawn | 2024-12-01 | 2025-07-01 | ClinicalTrials.gov |
| NCT06395792 | A Study on Dravet Syndrome (DS) and Lennox-Gastaut Syndrome (LGS) in Children, … | — | Dravet Syndrome (DS) | Withdrawn | 2024-12-01 | 2025-07-01 | ClinicalTrials.gov |
| NCT06443502 | A Study to Learn About the Safety of Vedolizumab and How Well it Works in Child… | Phase3 | Pouchitis | Recruiting | 2024-11-19 | 2029-12-31 | ClinicalTrials.gov |
| NCT06443502 | A Study to Learn About the Safety of Vedolizumab and How Well it Works in Child… | Phase3 | Pouchitis | Recruiting | 2024-11-19 | 2029-12-31 | ClinicalTrials.gov |
| NCT06443502 | A Study to Learn About the Safety of Vedolizumab and How Well it Works in Child… | Phase3 | Pouchitis | Recruiting | 2024-11-19 | 2029-12-31 | ClinicalTrials.gov |
| NCT06555432 | A Study of LIVTENCITY (Maribavir) in Adults With Cytomegalovirus (CMV) Infectio… | — | Cytomegalovirus (CMV) | Recruiting | 2024-11-14 | 2028-10-01 | ClinicalTrials.gov |
| NCT06555432 | A Study of LIVTENCITY (Maribavir) in Adults With Cytomegalovirus (CMV) Infectio… | — | Cytomegalovirus (CMV) | Recruiting | 2024-11-14 | 2028-10-01 | ClinicalTrials.gov |
| NCT06555432 | A Study of LIVTENCITY (Maribavir) in Adults With Cytomegalovirus (CMV) Infectio… | — | Cytomegalovirus (CMV) | Recruiting | 2024-11-14 | 2028-10-01 | ClinicalTrials.gov |
| NCT05582993 | A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (… | Phase3 | Von Willebrand Disease (VWD) | Recruiting | 2024-11-06 | 2030-04-11 | ClinicalTrials.gov |
| NCT05582993 | A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (… | Phase3 | Von Willebrand Disease (VWD) | Recruiting | 2024-11-06 | 2030-04-11 | ClinicalTrials.gov |
| NCT05582993 | A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (… | Phase3 | Von Willebrand Disease (VWD) | Recruiting | 2024-11-06 | 2030-04-11 | ClinicalTrials.gov |
| NCT06076642 | A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodefi… | Phase3 | Primary Immunodeficiency Diseases (PID) | Active_Not_Recruiting | 2024-11-04 | 2028-05-16 | ClinicalTrials.gov |
| NCT06076642 | A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodefi… | Phase3 | Primary Immunodeficiency Diseases (PID) | Active_Not_Recruiting | 2024-11-04 | 2028-05-16 | ClinicalTrials.gov |
| NCT06359782 | Complement Inhibition: Attacking the Overshooting Inflammation @Fter Subarachno… | Phase2 | Subarachnoid Hemorrhage, Aneurysmal | Recruiting | 2024-11-04 | 2027-03-01 | ClinicalTrials.gov |
| NCT06359782 | Complement Inhibition: Attacking the Overshooting Inflammation @Fter Subarachno… | Phase2 | Subarachnoid Hemorrhage, Aneurysmal | Recruiting | 2024-11-04 | 2027-03-01 | ClinicalTrials.gov |
| NCT06359782 | Complement Inhibition: Attacking the Overshooting Inflammation @Fter Subarachno… | Phase2 | Subarachnoid Hemorrhage, Aneurysmal | Recruiting | 2024-11-04 | 2027-03-01 | ClinicalTrials.gov |
| NCT06076642 | A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodefi… | Phase3 | Primary Immunodeficiency Diseases (PID) | Active_Not_Recruiting | 2024-11-04 | 2028-05-16 | ClinicalTrials.gov |
| NCT06236009 | A First-In-Human Study of TAK-004 in Healthy Adults | Phase1 | Healthy Volunteers | Completed | 2024-11-01 | 2025-10-17 | ClinicalTrials.gov |
| NCT06236009 | A First-In-Human Study of TAK-004 in Healthy Adults | Phase1 | Healthy Volunteers | Completed | 2024-11-01 | 2025-10-17 | ClinicalTrials.gov |
| NCT06236009 | A First-In-Human Study of TAK-004 in Healthy Adults | Phase1 | Healthy Volunteers | Completed | 2024-11-01 | 2025-10-17 | ClinicalTrials.gov |
| NCT06180382 | Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn… | Phase4 | Crohn's Disease | Recruiting | 2024-10-31 | 2027-01-01 | ClinicalTrials.gov |
| NCT06180382 | Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn… | Phase4 | Crohn's Disease | Recruiting | 2024-10-31 | 2027-01-01 | ClinicalTrials.gov |
| NCT06180382 | Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn… | Phase4 | Crohn's Disease | Recruiting | 2024-10-31 | 2027-01-01 | ClinicalTrials.gov |
| NCT06587464 | A Study to Explore Hereditary Angioedema (HAE) Symptoms and Treatment Patterns … | — | Hereditary Angioedema (HAE) | Completed | 2024-10-16 | 2024-12-18 | ClinicalTrials.gov |
| NCT06587464 | A Study to Explore Hereditary Angioedema (HAE) Symptoms and Treatment Patterns … | — | Hereditary Angioedema (HAE) | Completed | 2024-10-16 | 2024-12-18 | ClinicalTrials.gov |
| NCT06587464 | A Study to Explore Hereditary Angioedema (HAE) Symptoms and Treatment Patterns … | — | Hereditary Angioedema (HAE) | Completed | 2024-10-16 | 2024-12-18 | ClinicalTrials.gov |
| NCT06615921 | A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV) Infec… | — | Cytomegalovirus (CMV) | Completed | 2024-10-14 | 2025-07-04 | ClinicalTrials.gov |
| NCT06615921 | A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV) Infec… | — | Cytomegalovirus (CMV) | Completed | 2024-10-14 | 2025-07-04 | ClinicalTrials.gov |
| NCT06615921 | A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV) Infec… | — | Cytomegalovirus (CMV) | Completed | 2024-10-14 | 2025-07-04 | ClinicalTrials.gov |
| NCT06505031 | A Study of TAK-861 in People With Narcolepsy Type 1 | Phase3 | Narcolepsy Type 1 | Completed | 2024-10-08 | 2025-06-04 | ClinicalTrials.gov |
| NCT06505031 | A Study of TAK-861 in People With Narcolepsy Type 1 | Phase3 | Narcolepsy Type 1 | Completed | 2024-10-08 | 2025-06-04 | ClinicalTrials.gov |
| NCT06505031 | A Study of TAK-861 in People With Narcolepsy Type 1 | Phase3 | Narcolepsy Type 1 | Completed | 2024-10-08 | 2025-06-04 | ClinicalTrials.gov |
| NCT06568055 | A Study of Cytomegalovirus (CMV) Infection After Kidney Transplant in Adults in… | — | Cytomegalovirus (CMV) | Completed | 2024-09-30 | 2025-12-31 | ClinicalTrials.gov |
| NCT06568055 | A Study of Cytomegalovirus (CMV) Infection After Kidney Transplant in Adults in… | — | Cytomegalovirus (CMV) | Completed | 2024-09-30 | 2025-12-31 | ClinicalTrials.gov |
| NCT06568055 | A Study of Cytomegalovirus (CMV) Infection After Kidney Transplant in Adults in… | — | Cytomegalovirus (CMV) | Completed | 2024-09-30 | 2025-12-31 | ClinicalTrials.gov |
| NCT06388785 | A Study to Monitor the Adverse Events of QDENGA Vaccine in Participants in Mala… | — | Dengue Fever | Active_Not_Recruiting | 2024-09-26 | 2027-05-08 | ClinicalTrials.gov |
| NCT06388785 | A Study to Monitor the Adverse Events of QDENGA Vaccine in Participants in Mala… | — | Dengue Fever | Active_Not_Recruiting | 2024-09-26 | 2027-05-08 | ClinicalTrials.gov |
| NCT06388785 | A Study to Monitor the Adverse Events of QDENGA Vaccine in Participants in Mala… | — | Dengue Fever | Active_Not_Recruiting | 2024-09-26 | 2027-05-08 | ClinicalTrials.gov |
| NCT06512454 | A Study in Adults to Learn About Inherited Alpha-1 Antitrypsin Deficiency (AATD… | — | Alpha1-Antitrypsin Deficiency | Recruiting | 2024-09-25 | 2032-04-06 | ClinicalTrials.gov |
| NCT06512454 | A Study in Adults to Learn About Inherited Alpha-1 Antitrypsin Deficiency (AATD… | — | Alpha1-Antitrypsin Deficiency | Recruiting | 2024-09-25 | 2032-04-06 | ClinicalTrials.gov |
| NCT06512454 | A Study in Adults to Learn About Inherited Alpha-1 Antitrypsin Deficiency (AATD… | — | Alpha1-Antitrypsin Deficiency | Recruiting | 2024-09-25 | 2032-04-06 | ClinicalTrials.gov |
| NCT06590974 | A Study of Freeze-dried Human Protein C Concentrate (TAK-662) in Participants W… | — | Protein C Deficiency | Recruiting | 2024-09-06 | 2030-06-30 | ClinicalTrials.gov |
| NCT06590974 | A Study of Freeze-dried Human Protein C Concentrate (TAK-662) in Participants W… | — | Protein C Deficiency | Recruiting | 2024-09-06 | 2030-06-30 | ClinicalTrials.gov |
| NCT06590974 | A Study of Freeze-dried Human Protein C Concentrate (TAK-662) in Participants W… | — | Protein C Deficiency | Recruiting | 2024-09-06 | 2030-06-30 | ClinicalTrials.gov |
| NCT06550076 | A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis | Phase3 | Plaque Psoriasis | Active_Not_Recruiting | 2024-09-04 | 2029-08-05 | ClinicalTrials.gov |
| NCT06550076 | A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis | Phase3 | Plaque Psoriasis | Active_Not_Recruiting | 2024-09-04 | 2029-08-05 | ClinicalTrials.gov |
| NCT06586983 | Decentralization of Hepatitis B Care in Sub-Saharan Africa: a Pilot Program in … | — | Hepatitis B | Recruiting | 2024-09-04 | 2028-09-05 | ClinicalTrials.gov |
| NCT06586983 | Decentralization of Hepatitis B Care in Sub-Saharan Africa: a Pilot Program in … | — | Hepatitis B | Recruiting | 2024-09-04 | 2028-09-05 | ClinicalTrials.gov |
| NCT06550076 | A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis | Phase3 | Plaque Psoriasis | Active_Not_Recruiting | 2024-09-04 | 2029-08-05 | ClinicalTrials.gov |
| NCT06586983 | Decentralization of Hepatitis B Care in Sub-Saharan Africa: a Pilot Program in … | — | Hepatitis B | Recruiting | 2024-09-04 | 2028-09-05 | ClinicalTrials.gov |
| NCT06213974 | A Study of Maribavir in Adults and Children With Post-transplant Cytomegaloviru… | — | Cytomegalovirus (CMV) | Recruiting | 2024-09-03 | 2026-07-31 | ClinicalTrials.gov |
| NCT06213974 | A Study of Maribavir in Adults and Children With Post-transplant Cytomegaloviru… | — | Cytomegalovirus (CMV) | Recruiting | 2024-09-03 | 2026-07-31 | ClinicalTrials.gov |
| NCT06213974 | A Study of Maribavir in Adults and Children With Post-transplant Cytomegaloviru… | — | Cytomegalovirus (CMV) | Recruiting | 2024-09-03 | 2026-07-31 | ClinicalTrials.gov |
| NCT06831370 | A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in… | Phase4 | Hodgkin Lymphoma | Recruiting | 2024-08-28 | 2028-03-31 | ClinicalTrials.gov |
| NCT06577363 | A Survey of Maribavir Tablets in Participants With Cytomegalovirus Infection | — | Cytomegalovirus (CMV) | Recruiting | 2024-08-28 | 2031-08-30 | ClinicalTrials.gov |
| NCT06577363 | A Survey of Maribavir Tablets in Participants With Cytomegalovirus Infection | — | Cytomegalovirus (CMV) | Recruiting | 2024-08-28 | 2031-08-30 | ClinicalTrials.gov |
| NCT06577363 | A Survey of Maribavir Tablets in Participants With Cytomegalovirus Infection | — | Cytomegalovirus (CMV) | Recruiting | 2024-08-28 | 2031-08-30 | ClinicalTrials.gov |
| NCT06831370 | A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in… | Phase4 | Hodgkin Lymphoma | Recruiting | 2024-08-28 | 2028-03-31 | ClinicalTrials.gov |
| NCT06831370 | A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in… | Phase4 | Hodgkin Lymphoma | Recruiting | 2024-08-28 | 2028-03-31 | ClinicalTrials.gov |
| NCT06257706 | VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn… | Phase4 | Moderately to Severely Active Crohn's Disease | Recruiting | 2024-08-07 | 2029-02-06 | ClinicalTrials.gov |
| NCT06257706 | VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn… | Phase4 | Moderately to Severely Active Crohn's Disease | Recruiting | 2024-08-07 | 2029-02-06 | ClinicalTrials.gov |
| NCT06257706 | VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn… | Phase4 | Moderately to Severely Active Crohn's Disease | Recruiting | 2024-08-07 | 2029-02-06 | ClinicalTrials.gov |
| NCT06346899 | A Study of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) in Persons With HAE … | — | Hereditary Angioedema (HAE) | Completed | 2024-07-20 | 2025-07-31 | ClinicalTrials.gov |
| NCT06346899 | A Study of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) in Persons With HAE … | — | Hereditary Angioedema (HAE) | Completed | 2024-07-20 | 2025-07-31 | ClinicalTrials.gov |
| NCT06346899 | A Study of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) in Persons With HAE … | — | Hereditary Angioedema (HAE) | Completed | 2024-07-20 | 2025-07-31 | ClinicalTrials.gov |
| NCT06470828 | A Study of TAK-861 for the Treatment of Narcolepsy Type 1 | Phase3 | Narcolepsy Type 1 | Completed | 2024-07-02 | 2025-06-03 | ClinicalTrials.gov |
| NCT06470828 | A Study of TAK-861 for the Treatment of Narcolepsy Type 1 | Phase3 | Narcolepsy Type 1 | Completed | 2024-07-02 | 2025-06-03 | ClinicalTrials.gov |
| NCT06470828 | A Study of TAK-861 for the Treatment of Narcolepsy Type 1 | Phase3 | Narcolepsy Type 1 | Completed | 2024-07-02 | 2025-06-03 | ClinicalTrials.gov |
| NCT06111547 | A Study of TAK-279 in Healthy Chinese Adults | Phase1 | Healthy Volunteers | Completed | 2024-06-24 | 2024-08-04 | ClinicalTrials.gov |
| NCT06111547 | A Study of TAK-279 in Healthy Chinese Adults | Phase1 | Healthy Volunteers | Completed | 2024-06-24 | 2024-08-04 | ClinicalTrials.gov |
| NCT06111547 | A Study of TAK-279 in Healthy Chinese Adults | Phase1 | Healthy Volunteers | Completed | 2024-06-24 | 2024-08-04 | ClinicalTrials.gov |
| NCT06095128 | A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC) | Phase4 | Ulcerative Colitis | Recruiting | 2024-06-12 | 2027-07-09 | ClinicalTrials.gov |
| NCT06095128 | A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC) | Phase4 | Ulcerative Colitis | Recruiting | 2024-06-12 | 2027-07-09 | ClinicalTrials.gov |
| NCT06095128 | A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC) | Phase4 | Ulcerative Colitis | Recruiting | 2024-06-12 | 2027-07-09 | ClinicalTrials.gov |
| NCT05952804 | IVIG for Infection Prevention After CAR-T-Cell Therapy | Phase2 | Hematologic Malignancies | Recruiting | 2024-06-10 | 2028-07-31 | ClinicalTrials.gov |
| NCT07298343 | Evaluating the Efficacy and Tolerability of ZED1227 in Subjects With Non-respon… | Phase2 | Celiac Disease | Recruiting | 2024-06-10 | 2027-08-01 | ClinicalTrials.gov |
| NCT05952804 | IVIG for Infection Prevention After CAR-T-Cell Therapy | Phase2 | Hematologic Malignancies | Recruiting | 2024-06-10 | 2028-07-31 | ClinicalTrials.gov |
| NCT06461533 | A Survey of Susoctocog Alfa (Genetical Recombination) in Participants With Acqu… | — | Acquired Hemophilia A | Recruiting | 2024-06-10 | 2029-10-31 | ClinicalTrials.gov |
| NCT07298343 | Evaluating the Efficacy and Tolerability of ZED1227 in Subjects With Non-respon… | Phase2 | Celiac Disease | Recruiting | 2024-06-10 | 2027-08-01 | ClinicalTrials.gov |
| NCT07298343 | Evaluating the Efficacy and Tolerability of ZED1227 in Subjects With Non-respon… | Phase2 | Celiac Disease | Recruiting | 2024-06-10 | 2027-08-01 | ClinicalTrials.gov |
| NCT06461533 | A Survey of Susoctocog Alfa (Genetical Recombination) in Participants With Acqu… | — | Acquired Hemophilia A | Recruiting | 2024-06-10 | 2029-10-31 | ClinicalTrials.gov |
| NCT05952804 | IVIG for Infection Prevention After CAR-T-Cell Therapy | Phase2 | Hematologic Malignancies | Recruiting | 2024-06-10 | 2028-07-31 | ClinicalTrials.gov |
| NCT06461533 | A Survey of Susoctocog Alfa (Genetical Recombination) in Participants With Acqu… | — | Acquired Hemophilia A | Recruiting | 2024-06-10 | 2029-10-31 | ClinicalTrials.gov |
| NCT05718297 | Brigatinib Post Definitive Chemo-radiotherapy in Patients with ALK-fusion Non-s… | Phase2 | NSCLC, Stage III | Withdrawn | 2024-06-07 | 2024-09-30 | ClinicalTrials.gov |
| NCT05718297 | Brigatinib Post Definitive Chemo-radiotherapy in Patients with ALK-fusion Non-s… | Phase2 | NSCLC, Stage III | Withdrawn | 2024-06-07 | 2024-09-30 | ClinicalTrials.gov |
| NCT05718297 | Brigatinib Post Definitive Chemo-radiotherapy in Patients with ALK-fusion Non-s… | Phase2 | NSCLC, Stage III | Withdrawn | 2024-06-07 | 2024-09-30 | ClinicalTrials.gov |
| NCT05932407 | A Database Survey of Comparison The Risk of Haemorrhage Between Vortioxetine Ta… | — | Major Depressive Disorder | Completed | 2024-06-01 | 2024-09-09 | ClinicalTrials.gov |
| NCT05932407 | A Database Survey of Comparison The Risk of Haemorrhage Between Vortioxetine Ta… | — | Major Depressive Disorder | Completed | 2024-06-01 | 2024-09-09 | ClinicalTrials.gov |
| NCT05932407 | A Database Survey of Comparison The Risk of Haemorrhage Between Vortioxetine Ta… | — | Major Depressive Disorder | Completed | 2024-06-01 | 2024-09-09 | ClinicalTrials.gov |
| NCT06441578 | A Survey of Recombinant ADAMTS13 in Participants With Congenital Thrombotic Thr… | — | Thrombotic Thrombocytopenic Purpura (TTP) | Recruiting | 2024-05-30 | 2032-09-30 | ClinicalTrials.gov |
| NCT06441578 | A Survey of Recombinant ADAMTS13 in Participants With Congenital Thrombotic Thr… | — | Thrombotic Thrombocytopenic Purpura (TTP) | Recruiting | 2024-05-30 | 2032-09-30 | ClinicalTrials.gov |
| NCT06441578 | A Survey of Recombinant ADAMTS13 in Participants With Congenital Thrombotic Thr… | — | Thrombotic Thrombocytopenic Purpura (TTP) | Recruiting | 2024-05-30 | 2032-09-30 | ClinicalTrials.gov |
| NCT06628830 | Efficacy of a Mobile Phone App for Depression and Anxiety in College Students | Na | Depressive Symptoms | Enrolling_By_Invitation | 2024-05-23 | 2025-08-30 | ClinicalTrials.gov |
| NCT06628830 | Efficacy of a Mobile Phone App for Depression and Anxiety in College Students | Na | Depressive Symptoms | Enrolling_By_Invitation | 2024-05-23 | 2025-08-30 | ClinicalTrials.gov |
| NCT06628830 | Efficacy of a Mobile Phone App for Depression and Anxiety in College Students | Na | Depressive Symptoms | Enrolling_By_Invitation | 2024-05-23 | 2025-08-30 | ClinicalTrials.gov |
| NCT06390995 | A Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Ad… | Phase1 | Ovarian Cancer | Active_Not_Recruiting | 2024-05-20 | 2027-03-19 | ClinicalTrials.gov |
| NCT06390995 | A Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Ad… | Phase1 | Ovarian Cancer | Active_Not_Recruiting | 2024-05-20 | 2027-03-19 | ClinicalTrials.gov |
| NCT06390995 | A Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Ad… | Phase1 | Ovarian Cancer | Active_Not_Recruiting | 2024-05-20 | 2027-03-19 | ClinicalTrials.gov |
| NCT06368102 | Prophylactic Effects for Preventing Surgical Site Infection in Third Molar Surg… | Phase4 | Surgical Site Infection | Completed | 2024-05-02 | 2025-09-01 | ClinicalTrials.gov |
| NCT06368102 | Prophylactic Effects for Preventing Surgical Site Infection in Third Molar Surg… | Phase4 | Surgical Site Infection | Completed | 2024-05-02 | 2025-09-01 | ClinicalTrials.gov |
| NCT06368102 | Prophylactic Effects for Preventing Surgical Site Infection in Third Molar Surg… | Phase4 | Surgical Site Infection | Completed | 2024-05-02 | 2025-09-01 | ClinicalTrials.gov |
| NCT06258265 | A Study of TAK-279 in Healthy Adults on the Effect on ECG Measurements | Phase1 | Healthy Volunteers | Completed | 2024-04-29 | 2024-07-09 | ClinicalTrials.gov |
| NCT06258265 | A Study of TAK-279 in Healthy Adults on the Effect on ECG Measurements | Phase1 | Healthy Volunteers | Completed | 2024-04-29 | 2024-07-09 | ClinicalTrials.gov |
| NCT06258265 | A Study of TAK-279 in Healthy Adults on the Effect on ECG Measurements | Phase1 | Healthy Volunteers | Completed | 2024-04-29 | 2024-07-09 | ClinicalTrials.gov |
| NCT06422377 | A Study Evaluating Soticlestat in Participants With Dravet Syndrome or Lennox-G… | Phase3 | Dravet Syndrome (DS) | Terminated | 2024-04-25 | 2024-08-14 | ClinicalTrials.gov |
| NCT06422377 | A Study Evaluating Soticlestat in Participants With Dravet Syndrome or Lennox-G… | Phase3 | Dravet Syndrome (DS) | Terminated | 2024-04-25 | 2024-08-14 | ClinicalTrials.gov |
| NCT06422377 | A Study Evaluating Soticlestat in Participants With Dravet Syndrome or Lennox-G… | Phase3 | Dravet Syndrome (DS) | Terminated | 2024-04-25 | 2024-08-14 | ClinicalTrials.gov |
| NCT06045754 | A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustek… | Phase4 | Crohn's Disease | Recruiting | 2024-04-18 | 2027-06-28 | ClinicalTrials.gov |
| NCT05748197 | A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia | Phase1 | Acute Myeloid Leukemia | Recruiting | 2024-04-18 | 2028-04-18 | ClinicalTrials.gov |
| NCT06045754 | A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustek… | Phase4 | Crohn's Disease | Recruiting | 2024-04-18 | 2027-06-28 | ClinicalTrials.gov |
| NCT05748197 | A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia | Phase1 | Acute Myeloid Leukemia | Recruiting | 2024-04-18 | 2028-04-18 | ClinicalTrials.gov |
| NCT05748197 | A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia | Phase1 | Acute Myeloid Leukemia | Recruiting | 2024-04-18 | 2028-04-18 | ClinicalTrials.gov |
| NCT06045754 | A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustek… | Phase4 | Crohn's Disease | Recruiting | 2024-04-18 | 2027-06-28 | ClinicalTrials.gov |
| NCT05863819 | A Real World Study of Mobocertinib in Adults With Lung Cancer in China (MEANING) | — | Non-small Cell Lung Cancer (NSCLC) | Withdrawn | 2024-03-30 | 2027-02-01 | ClinicalTrials.gov |
| NCT05863819 | A Real World Study of Mobocertinib in Adults With Lung Cancer in China (MEANING) | — | Non-small Cell Lung Cancer (NSCLC) | Withdrawn | 2024-03-30 | 2027-02-01 | ClinicalTrials.gov |
| NCT05863819 | A Real World Study of Mobocertinib in Adults With Lung Cancer in China (MEANING) | — | Non-small Cell Lung Cancer (NSCLC) | Withdrawn | 2024-03-30 | 2027-02-01 | ClinicalTrials.gov |
| NCT06290050 | A Study of the Interaction of Other Drugs With TAK-279 in Healthy Adults | Phase1 | Healthy Volunteers | Completed | 2024-03-29 | 2024-05-16 | ClinicalTrials.gov |
| NCT06254950 | A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the … | Phase2 | Ulcerative Colitis | Recruiting | 2024-03-29 | 2027-08-04 | ClinicalTrials.gov |
| NCT06060067 | A Study of Dengue Vaccine in Healthy Children, Teenagers and Adults in India | Phase3 | Healthy Volunteers | Completed | 2024-03-29 | 2025-05-05 | ClinicalTrials.gov |
| NCT06254950 | A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the … | Phase2 | Ulcerative Colitis | Recruiting | 2024-03-29 | 2027-08-04 | ClinicalTrials.gov |
| NCT06290050 | A Study of the Interaction of Other Drugs With TAK-279 in Healthy Adults | Phase1 | Healthy Volunteers | Completed | 2024-03-29 | 2024-05-16 | ClinicalTrials.gov |
| NCT06254950 | A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the … | Phase2 | Ulcerative Colitis | Recruiting | 2024-03-29 | 2027-08-04 | ClinicalTrials.gov |
| NCT06060067 | A Study of Dengue Vaccine in Healthy Children, Teenagers and Adults in India | Phase3 | Healthy Volunteers | Completed | 2024-03-29 | 2025-05-05 | ClinicalTrials.gov |
| NCT06290050 | A Study of the Interaction of Other Drugs With TAK-279 in Healthy Adults | Phase1 | Healthy Volunteers | Completed | 2024-03-29 | 2024-05-16 | ClinicalTrials.gov |
| NCT06060067 | A Study of Dengue Vaccine in Healthy Children, Teenagers and Adults in India | Phase3 | Healthy Volunteers | Completed | 2024-03-29 | 2025-05-05 | ClinicalTrials.gov |
| NCT06249555 | VOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With … | — | Crohn's Disease | Recruiting | 2024-03-20 | 2026-12-01 | ClinicalTrials.gov |
| NCT06249555 | VOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With … | — | Crohn's Disease | Recruiting | 2024-03-20 | 2026-12-01 | ClinicalTrials.gov |
| NCT06249555 | VOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With … | — | Crohn's Disease | Recruiting | 2024-03-20 | 2026-12-01 | ClinicalTrials.gov |
| NCT06323356 | A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or… | Phase3 | Generalized Pustular Psoriasis | Active_Not_Recruiting | 2024-03-19 | 2026-07-22 | ClinicalTrials.gov |
| NCT06323356 | A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or… | Phase3 | Generalized Pustular Psoriasis | Active_Not_Recruiting | 2024-03-19 | 2026-07-22 | ClinicalTrials.gov |
| NCT06323356 | A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or… | Phase3 | Generalized Pustular Psoriasis | Active_Not_Recruiting | 2024-03-19 | 2026-07-22 | ClinicalTrials.gov |
| NCT06173128 | Respiratory Microbiota and Immune Response in CVID | — | CVID | Completed | 2024-03-15 | 2026-02-15 | ClinicalTrials.gov |
| NCT06173128 | Respiratory Microbiota and Immune Response in CVID | — | CVID | Completed | 2024-03-15 | 2026-02-15 | ClinicalTrials.gov |
| NCT06173128 | Respiratory Microbiota and Immune Response in CVID | — | CVID | Completed | 2024-03-15 | 2026-02-15 | ClinicalTrials.gov |
| NCT06031259 | Extension Study of Idursulfase-IT Along With Elaprase in Children and Adults Wi… | Phase2 | Hunter Syndrome | Active_Not_Recruiting | 2024-03-05 | 2029-01-01 | ClinicalTrials.gov |
| NCT06031259 | Extension Study of Idursulfase-IT Along With Elaprase in Children and Adults Wi… | Phase2 | Hunter Syndrome | Active_Not_Recruiting | 2024-03-05 | 2029-01-01 | ClinicalTrials.gov |
| NCT06233461 | A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the … | Phase2 | Crohn's Disease | Recruiting | 2024-03-05 | 2027-07-23 | ClinicalTrials.gov |
| NCT06031259 | Extension Study of Idursulfase-IT Along With Elaprase in Children and Adults Wi… | Phase2 | Hunter Syndrome | Active_Not_Recruiting | 2024-03-05 | 2029-01-01 | ClinicalTrials.gov |
| NCT06233461 | A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the … | Phase2 | Crohn's Disease | Recruiting | 2024-03-05 | 2027-07-23 | ClinicalTrials.gov |
| NCT06233461 | A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the … | Phase2 | Crohn's Disease | Recruiting | 2024-03-05 | 2027-07-23 | ClinicalTrials.gov |
| NCT06165341 | Study to Learn About the Safety of Fazirsiran and if it Can Help People With Al… | Phase3 | Alpha1-Antitrypsin Deficiency | Recruiting | 2024-03-01 | 2028-08-26 | ClinicalTrials.gov |
| NCT06165341 | Study to Learn About the Safety of Fazirsiran and if it Can Help People With Al… | Phase3 | Alpha1-Antitrypsin Deficiency | Recruiting | 2024-03-01 | 2028-08-26 | ClinicalTrials.gov |
| NCT06165341 | Study to Learn About the Safety of Fazirsiran and if it Can Help People With Al… | Phase3 | Alpha1-Antitrypsin Deficiency | Recruiting | 2024-03-01 | 2028-08-26 | ClinicalTrials.gov |
| NCT06237205 | Genome-Based Assessment of Niraparib (ZEJULA®) Efficacy in Advanced Solid Tumor… | Phase2 | Efficacy | Not_Yet_Recruiting | 2024-02-27 | 2027-06-30 | ClinicalTrials.gov |
| NCT06237205 | Genome-Based Assessment of Niraparib (ZEJULA®) Efficacy in Advanced Solid Tumor… | Phase2 | Efficacy | Not_Yet_Recruiting | 2024-02-27 | 2027-06-30 | ClinicalTrials.gov |
| NCT06237205 | Genome-Based Assessment of Niraparib (ZEJULA®) Efficacy in Advanced Solid Tumor… | Phase2 | Efficacy | Not_Yet_Recruiting | 2024-02-27 | 2027-06-30 | ClinicalTrials.gov |
| NCT05886478 | A Study in Adults With Cutaneous T-cell Lymphoma (CTCL) Retreated With Brentuxi… | — | T-Cell Lymphoma | Completed | 2024-02-08 | 2024-10-31 | ClinicalTrials.gov |
| NCT05886478 | A Study in Adults With Cutaneous T-cell Lymphoma (CTCL) Retreated With Brentuxi… | — | T-Cell Lymphoma | Completed | 2024-02-08 | 2024-10-31 | ClinicalTrials.gov |
| NCT05886478 | A Study in Adults With Cutaneous T-cell Lymphoma (CTCL) Retreated With Brentuxi… | — | T-Cell Lymphoma | Completed | 2024-02-08 | 2024-10-31 | ClinicalTrials.gov |
| NCT05737849 | A Study to Learn About the Tests Looking for a Gene Mutation in Adults With Lun… | — | Non-small Cell Lung Cancer (NSCLC) | Withdrawn | 2024-01-30 | 2024-12-30 | ClinicalTrials.gov |
| NCT05737849 | A Study to Learn About the Tests Looking for a Gene Mutation in Adults With Lun… | — | Non-small Cell Lung Cancer (NSCLC) | Withdrawn | 2024-01-30 | 2024-12-30 | ClinicalTrials.gov |
| NCT05737849 | A Study to Learn About the Tests Looking for a Gene Mutation in Adults With Lun… | — | Non-small Cell Lung Cancer (NSCLC) | Withdrawn | 2024-01-30 | 2024-12-30 | ClinicalTrials.gov |
| NCT05721950 | A Study to Learn About Brigatinib Treatment Information Available in Chinese Pa… | — | Non-small Cell Lung Cancer (NSCLC) | Active_Not_Recruiting | 2024-01-17 | 2028-12-30 | ClinicalTrials.gov |
| NCT05721950 | A Study to Learn About Brigatinib Treatment Information Available in Chinese Pa… | — | Non-small Cell Lung Cancer (NSCLC) | Active_Not_Recruiting | 2024-01-17 | 2028-12-30 | ClinicalTrials.gov |
| NCT05721950 | A Study to Learn About Brigatinib Treatment Information Available in Chinese Pa… | — | Non-small Cell Lung Cancer (NSCLC) | Active_Not_Recruiting | 2024-01-17 | 2028-12-30 | ClinicalTrials.gov |
| NCT05469802 | A Study of Purified Inactivated Zika Virus Vaccine (PIZV) in Healthy Adults | Phase2 | Healthy Volunteers | Withdrawn | 2024-01-02 | 2024-07-05 | ClinicalTrials.gov |
| NCT05469802 | A Study of Purified Inactivated Zika Virus Vaccine (PIZV) in Healthy Adults | Phase2 | Healthy Volunteers | Withdrawn | 2024-01-02 | 2024-07-05 | ClinicalTrials.gov |
| NCT05469802 | A Study of Purified Inactivated Zika Virus Vaccine (PIZV) in Healthy Adults | Phase2 | Healthy Volunteers | Withdrawn | 2024-01-02 | 2024-07-05 | ClinicalTrials.gov |
| NCT05466747 | A Study of RYMPHYSIA for Alpha1-Proteinase Inhibitor (A1PI) Therapy in Adults W… | Phase4 | Chronic Obstructive Pulmonary Disease (COPD) | Withdrawn | 2024-01-01 | 2029-05-07 | ClinicalTrials.gov |
| NCT06186986 | CD30 Imaging in Diffuse Large B-cell Lymphoma | Phase3 | Diffuse Large B-cell-lymphoma | Unknown | 2024-01-01 | 2026-01-01 | ClinicalTrials.gov |
| NCT05466747 | A Study of RYMPHYSIA for Alpha1-Proteinase Inhibitor (A1PI) Therapy in Adults W… | Phase4 | Chronic Obstructive Pulmonary Disease (COPD) | Withdrawn | 2024-01-01 | 2029-05-07 | ClinicalTrials.gov |
| NCT04845035 | Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philade… | Phase2 | Acute Lymphoblastic Leukemia | Withdrawn | 2024-01-01 | 2029-01-01 | ClinicalTrials.gov |
| NCT04845035 | Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philade… | Phase2 | Acute Lymphoblastic Leukemia | Withdrawn | 2024-01-01 | 2029-01-01 | ClinicalTrials.gov |
| NCT06186986 | CD30 Imaging in Diffuse Large B-cell Lymphoma | Phase3 | Diffuse Large B-cell-lymphoma | Unknown | 2024-01-01 | 2026-01-01 | ClinicalTrials.gov |
| NCT06186986 | CD30 Imaging in Diffuse Large B-cell Lymphoma | Phase3 | Diffuse Large B-cell-lymphoma | Unknown | 2024-01-01 | 2026-01-01 | ClinicalTrials.gov |
| NCT04845035 | Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philade… | Phase2 | Acute Lymphoblastic Leukemia | Withdrawn | 2024-01-01 | 2029-01-01 | ClinicalTrials.gov |
| NCT05466747 | A Study of RYMPHYSIA for Alpha1-Proteinase Inhibitor (A1PI) Therapy in Adults W… | Phase4 | Chronic Obstructive Pulmonary Disease (COPD) | Withdrawn | 2024-01-01 | 2029-05-07 | ClinicalTrials.gov |
| NCT06104878 | A Study in Adults With Advanced Classical Hodgkin's Lymphoma (cHL) in Brazil Tr… | — | Hodgkin Lymphoma | Withdrawn | 2023-12-31 | 2024-10-31 | ClinicalTrials.gov |
| NCT06104878 | A Study in Adults With Advanced Classical Hodgkin's Lymphoma (cHL) in Brazil Tr… | — | Hodgkin Lymphoma | Withdrawn | 2023-12-31 | 2024-10-31 | ClinicalTrials.gov |
| NCT06104878 | A Study in Adults With Advanced Classical Hodgkin's Lymphoma (cHL) in Brazil Tr… | — | Hodgkin Lymphoma | Withdrawn | 2023-12-31 | 2024-10-31 | ClinicalTrials.gov |
| NCT06150534 | At-Home Subcutaneous Immunoglobulin Replacement Therapy Using Alexa Skill | — | Primary Immunodeficiency Diseases (PID) | Completed | 2023-12-27 | 2025-02-28 | ClinicalTrials.gov |
| NCT06150534 | At-Home Subcutaneous Immunoglobulin Replacement Therapy Using Alexa Skill | — | Primary Immunodeficiency Diseases (PID) | Completed | 2023-12-27 | 2025-02-28 | ClinicalTrials.gov |
| NCT06150534 | At-Home Subcutaneous Immunoglobulin Replacement Therapy Using Alexa Skill | — | Primary Immunodeficiency Diseases (PID) | Completed | 2023-12-27 | 2025-02-28 | ClinicalTrials.gov |
| NCT06132867 | A Study to Compare the Relative Bioavailability of Brigatinib When Swallowed as… | Phase1 | Healthy Volunteers | Completed | 2023-12-20 | 2024-02-17 | ClinicalTrials.gov |
| NCT06132867 | A Study to Compare the Relative Bioavailability of Brigatinib When Swallowed as… | Phase1 | Healthy Volunteers | Completed | 2023-12-20 | 2024-02-17 | ClinicalTrials.gov |
| NCT06132867 | A Study to Compare the Relative Bioavailability of Brigatinib When Swallowed as… | Phase1 | Healthy Volunteers | Completed | 2023-12-20 | 2024-02-17 | ClinicalTrials.gov |
| NCT05341128 | A Study of Medical Records From Children With Central Precocious Puberty (CPP) … | — | Central Precocious Puberty | Completed | 2023-12-13 | 2025-08-27 | ClinicalTrials.gov |
| NCT05341128 | A Study of Medical Records From Children With Central Precocious Puberty (CPP) … | — | Central Precocious Puberty | Completed | 2023-12-13 | 2025-08-27 | ClinicalTrials.gov |
| NCT05341128 | A Study of Medical Records From Children With Central Precocious Puberty (CPP) … | — | Central Precocious Puberty | Completed | 2023-12-13 | 2025-08-27 | ClinicalTrials.gov |
| NCT05106764 | Early Detection of Fabry Disease | — | Fabry Disease | Completed | 2023-11-30 | 2025-12-16 | ClinicalTrials.gov |
| NCT05755568 | A Study to Learn About Metachromatic Leukodystrophy (MLD) in Children in Spain | — | Metachromatic Leukodystrophy (MLD) | Withdrawn | 2023-11-30 | 2024-07-01 | ClinicalTrials.gov |
| NCT05106764 | Early Detection of Fabry Disease | — | Fabry Disease | Completed | 2023-11-30 | 2025-12-16 | ClinicalTrials.gov |
| NCT05755568 | A Study to Learn About Metachromatic Leukodystrophy (MLD) in Children in Spain | — | Metachromatic Leukodystrophy (MLD) | Withdrawn | 2023-11-30 | 2024-07-01 | ClinicalTrials.gov |
| NCT05755568 | A Study to Learn About Metachromatic Leukodystrophy (MLD) in Children in Spain | — | Metachromatic Leukodystrophy (MLD) | Withdrawn | 2023-11-30 | 2024-07-01 | ClinicalTrials.gov |
| NCT05106764 | Early Detection of Fabry Disease | — | Fabry Disease | Completed | 2023-11-30 | 2025-12-16 | ClinicalTrials.gov |
| NCT05976334 | An Absorption, Distribution, Metabolism, Excretion (ADME) Study of [14C]Subasum… | Phase1 | Solid Tumors | Terminated | 2023-11-14 | 2024-07-16 | ClinicalTrials.gov |
| NCT05976334 | An Absorption, Distribution, Metabolism, Excretion (ADME) Study of [14C]Subasum… | Phase1 | Solid Tumors | Terminated | 2023-11-14 | 2024-07-16 | ClinicalTrials.gov |
| NCT05976334 | An Absorption, Distribution, Metabolism, Excretion (ADME) Study of [14C]Subasum… | Phase1 | Solid Tumors | Terminated | 2023-11-14 | 2024-07-16 | ClinicalTrials.gov |
| NCT05319353 | A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antivira… | Phase3 | Cytomegalovirus (CMV) | Recruiting | 2023-11-13 | 2027-01-18 | ClinicalTrials.gov |
| NCT05319353 | A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antivira… | Phase3 | Cytomegalovirus (CMV) | Recruiting | 2023-11-13 | 2027-01-18 | ClinicalTrials.gov |
| NCT05319353 | A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antivira… | Phase3 | Cytomegalovirus (CMV) | Recruiting | 2023-11-13 | 2027-01-18 | ClinicalTrials.gov |
| NCT06034925 | Maribavir vs. Valganciclovir for CMV Prophylaxis in High-Risk Kidney Transplant… | Phase4 | Transplant Complication | Completed | 2023-11-06 | 2025-08-30 | ClinicalTrials.gov |
| NCT04943796 | A Study to Learn About the Occurrence of ADHD in Adults With Mental Conditions … | — | Attention Deficit Hyperactivity Disorder (ADHD) | Completed | 2023-11-06 | 2025-07-28 | ClinicalTrials.gov |
| NCT04943796 | A Study to Learn About the Occurrence of ADHD in Adults With Mental Conditions … | — | Attention Deficit Hyperactivity Disorder (ADHD) | Completed | 2023-11-06 | 2025-07-28 | ClinicalTrials.gov |
| NCT06088043 | A Study About How Well TAK-279 Works and Its Safety in Participants With Modera… | Phase3 | Plaque Psoriasis | Completed | 2023-11-06 | 2025-10-22 | ClinicalTrials.gov |
| NCT06108544 | A Study About How Well TAK-279 Works and Its Safety in Participants With Modera… | Phase3 | Plaque Psoriasis | Completed | 2023-11-06 | 2025-11-07 | ClinicalTrials.gov |
| NCT06034925 | Maribavir vs. Valganciclovir for CMV Prophylaxis in High-Risk Kidney Transplant… | Phase4 | Transplant Complication | Completed | 2023-11-06 | 2025-08-30 | ClinicalTrials.gov |
| NCT04943796 | A Study to Learn About the Occurrence of ADHD in Adults With Mental Conditions … | — | Attention Deficit Hyperactivity Disorder (ADHD) | Completed | 2023-11-06 | 2025-07-28 | ClinicalTrials.gov |
| NCT06108544 | A Study About How Well TAK-279 Works and Its Safety in Participants With Modera… | Phase3 | Plaque Psoriasis | Completed | 2023-11-06 | 2025-11-07 | ClinicalTrials.gov |
| NCT06088043 | A Study About How Well TAK-279 Works and Its Safety in Participants With Modera… | Phase3 | Plaque Psoriasis | Completed | 2023-11-06 | 2025-10-22 | ClinicalTrials.gov |
| NCT06034925 | Maribavir vs. Valganciclovir for CMV Prophylaxis in High-Risk Kidney Transplant… | Phase4 | Transplant Complication | Completed | 2023-11-06 | 2025-08-30 | ClinicalTrials.gov |
| NCT06088043 | A Study About How Well TAK-279 Works and Its Safety in Participants With Modera… | Phase3 | Plaque Psoriasis | Completed | 2023-11-06 | 2025-10-22 | ClinicalTrials.gov |
| NCT06108544 | A Study About How Well TAK-279 Works and Its Safety in Participants With Modera… | Phase3 | Plaque Psoriasis | Completed | 2023-11-06 | 2025-11-07 | ClinicalTrials.gov |
| NCT05863026 | Effectiveness of iDEAL in Improving the Knowledge, Attitude, Practice, Environm… | Na | Knowledge, Attitudes, Practice | Unknown | 2023-11-01 | 2025-05-31 | ClinicalTrials.gov |
| NCT05863026 | Effectiveness of iDEAL in Improving the Knowledge, Attitude, Practice, Environm… | Na | Knowledge, Attitudes, Practice | Unknown | 2023-11-01 | 2025-05-31 | ClinicalTrials.gov |
| NCT05863026 | Effectiveness of iDEAL in Improving the Knowledge, Attitude, Practice, Environm… | Na | Knowledge, Attitudes, Practice | Unknown | 2023-11-01 | 2025-05-31 | ClinicalTrials.gov |
| NCT05982717 | A Study to Gather Information About Overall Occurrence and New Cases of Dravet … | — | Dravet Syndrome (DS) | Completed | 2023-10-26 | 2025-04-10 | ClinicalTrials.gov |
| NCT05982717 | A Study to Gather Information About Overall Occurrence and New Cases of Dravet … | — | Dravet Syndrome (DS) | Completed | 2023-10-26 | 2025-04-10 | ClinicalTrials.gov |
| NCT05982717 | A Study to Gather Information About Overall Occurrence and New Cases of Dravet … | — | Dravet Syndrome (DS) | Completed | 2023-10-26 | 2025-04-10 | ClinicalTrials.gov |
| NCT05755035 | A Study About How TAK-881 is Processed by the Body and Side Effects in People W… | Phase2 | Primary Immunodeficiency Diseases (PID) | Completed | 2023-10-24 | 2026-01-20 | ClinicalTrials.gov |
| NCT05755035 | A Study About How TAK-881 is Processed by the Body and Side Effects in People W… | Phase2 | Primary Immunodeficiency Diseases (PID) | Completed | 2023-10-24 | 2026-01-20 | ClinicalTrials.gov |
| NCT05755035 | A Study About How TAK-881 is Processed by the Body and Side Effects in People W… | Phase2 | Primary Immunodeficiency Diseases (PID) | Completed | 2023-10-24 | 2026-01-20 | ClinicalTrials.gov |
| NCT05879757 | Real-world Usage of HyQvia in Multiple Myeloma Adults With Secondary Immunodefi… | — | Multiple Myeloma | Recruiting | 2023-10-17 | 2027-02-16 | ClinicalTrials.gov |
| NCT05879757 | Real-world Usage of HyQvia in Multiple Myeloma Adults With Secondary Immunodefi… | — | Multiple Myeloma | Recruiting | 2023-10-17 | 2027-02-16 | ClinicalTrials.gov |
| NCT05879757 | Real-world Usage of HyQvia in Multiple Myeloma Adults With Secondary Immunodefi… | — | Multiple Myeloma | Recruiting | 2023-10-17 | 2027-02-16 | ClinicalTrials.gov |
| NCT05891158 | A Study About Fazirsiran in People With and Without Liver Problems | Phase1 | Hepatic Impairment | Completed | 2023-10-05 | 2025-09-03 | ClinicalTrials.gov |
| NCT05891158 | A Study About Fazirsiran in People With and Without Liver Problems | Phase1 | Hepatic Impairment | Completed | 2023-10-05 | 2025-09-03 | ClinicalTrials.gov |
| NCT05891158 | A Study About Fazirsiran in People With and Without Liver Problems | Phase1 | Hepatic Impairment | Completed | 2023-10-05 | 2025-09-03 | ClinicalTrials.gov |
| NCT05992155 | A Study of TAK-279 in Adults With or Without Kidney Problems | Phase1 | Renal Impairment | Completed | 2023-09-27 | 2024-05-28 | ClinicalTrials.gov |
| NCT05992155 | A Study of TAK-279 in Adults With or Without Kidney Problems | Phase1 | Renal Impairment | Completed | 2023-09-27 | 2024-05-28 | ClinicalTrials.gov |
| NCT05992155 | A Study of TAK-279 in Adults With or Without Kidney Problems | Phase1 | Renal Impairment | Completed | 2023-09-27 | 2024-05-28 | ClinicalTrials.gov |
| NCT05428345 | A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Co… | — | Ulcerative Colitis | Recruiting | 2023-09-25 | 2027-11-30 | ClinicalTrials.gov |
| NCT05428345 | A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Co… | — | Ulcerative Colitis | Recruiting | 2023-09-25 | 2027-11-30 | ClinicalTrials.gov |
| NCT05428345 | A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Co… | — | Ulcerative Colitis | Recruiting | 2023-09-25 | 2027-11-30 | ClinicalTrials.gov |
| NCT05371028 | A Study of Teduglutide (Revestive®) in Participants With Short Bowel Syndrome (… | — | Short Bowel Syndrome (SBS) | Completed | 2023-09-23 | 2025-02-19 | ClinicalTrials.gov |
| NCT05371028 | A Study of Teduglutide (Revestive®) in Participants With Short Bowel Syndrome (… | — | Short Bowel Syndrome (SBS) | Completed | 2023-09-23 | 2025-02-19 | ClinicalTrials.gov |
| NCT05371028 | A Study of Teduglutide (Revestive®) in Participants With Short Bowel Syndrome (… | — | Short Bowel Syndrome (SBS) | Completed | 2023-09-23 | 2025-02-19 | ClinicalTrials.gov |
| NCT05976321 | A Study of TAK-279 in Adults With or Without Liver Damage | Phase1 | Hepatic Impairment | Completed | 2023-09-22 | 2024-04-15 | ClinicalTrials.gov |
| NCT05976321 | A Study of TAK-279 in Adults With or Without Liver Damage | Phase1 | Hepatic Impairment | Completed | 2023-09-22 | 2024-04-15 | ClinicalTrials.gov |
| NCT05976321 | A Study of TAK-279 in Adults With or Without Liver Damage | Phase1 | Hepatic Impairment | Completed | 2023-09-22 | 2024-04-15 | ClinicalTrials.gov |
| NCT05995249 | A Study of the Interaction of TAK-279 With Substances That Have an Impact on Me… | Phase1 | Healthy Volunteers | Completed | 2023-08-11 | 2023-12-31 | ClinicalTrials.gov |
| NCT05995249 | A Study of the Interaction of TAK-279 With Substances That Have an Impact on Me… | Phase1 | Healthy Volunteers | Completed | 2023-08-11 | 2023-12-31 | ClinicalTrials.gov |
| NCT05995249 | A Study of the Interaction of TAK-279 With Substances That Have an Impact on Me… | Phase1 | Healthy Volunteers | Completed | 2023-08-11 | 2023-12-31 | ClinicalTrials.gov |
| NCT05899673 | An Extension Study to Learn About the Long-Term Safety of Fazirsiran and if Faz… | Phase3 | Alpha1-Antitrypsin Deficiency | Active_Not_Recruiting | 2023-08-08 | 2033-05-02 | ClinicalTrials.gov |
| NCT05899673 | An Extension Study to Learn About the Long-Term Safety of Fazirsiran and if Faz… | Phase3 | Alpha1-Antitrypsin Deficiency | Active_Not_Recruiting | 2023-08-08 | 2033-05-02 | ClinicalTrials.gov |
| NCT05899673 | An Extension Study to Learn About the Long-Term Safety of Fazirsiran and if Faz… | Phase3 | Alpha1-Antitrypsin Deficiency | Active_Not_Recruiting | 2023-08-08 | 2033-05-02 | ClinicalTrials.gov |
| NCT05970159 | Impact of Preoperative Serum Albumin Level on Postoperative Outcomes in Chinese… | — | Hepatocellular Carcinoma | Unknown | 2023-08-01 | 2025-03-01 | ClinicalTrials.gov |
| NCT05970159 | Impact of Preoperative Serum Albumin Level on Postoperative Outcomes in Chinese… | — | Hepatocellular Carcinoma | Unknown | 2023-08-01 | 2025-03-01 | ClinicalTrials.gov |
| NCT05844033 | Biomarker for Infection Risk in CLL and MM | — | Multiple Myeloma | Active_Not_Recruiting | 2023-08-01 | 2027-03-31 | ClinicalTrials.gov |
| NCT05970159 | Impact of Preoperative Serum Albumin Level on Postoperative Outcomes in Chinese… | — | Hepatocellular Carcinoma | Unknown | 2023-08-01 | 2025-03-01 | ClinicalTrials.gov |
| NCT05844033 | Biomarker for Infection Risk in CLL and MM | — | Multiple Myeloma | Active_Not_Recruiting | 2023-08-01 | 2027-03-31 | ClinicalTrials.gov |
| NCT05844033 | Biomarker for Infection Risk in CLL and MM | — | Multiple Myeloma | Active_Not_Recruiting | 2023-08-01 | 2027-03-31 | ClinicalTrials.gov |
| NCT05918822 | A Study of Maribavir Pediatric Formulation in Healthy Adult Participants | Phase1 | Healthy Volunteers | Completed | 2023-07-25 | 2023-09-01 | ClinicalTrials.gov |
| NCT05918822 | A Study of Maribavir Pediatric Formulation in Healthy Adult Participants | Phase1 | Healthy Volunteers | Completed | 2023-07-25 | 2023-09-01 | ClinicalTrials.gov |
| NCT05918822 | A Study of Maribavir Pediatric Formulation in Healthy Adult Participants | Phase1 | Healthy Volunteers | Completed | 2023-07-25 | 2023-09-01 | ClinicalTrials.gov |
| NCT05714969 | A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatmen… | Phase2 | Thrombotic Thrombocytopenic Purpura (TTP) | Completed | 2023-07-21 | 2026-04-16 | ClinicalTrials.gov |
| NCT05714969 | A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatmen… | Phase2 | Thrombotic Thrombocytopenic Purpura (TTP) | Completed | 2023-07-21 | 2026-04-16 | ClinicalTrials.gov |
| NCT05714969 | A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatmen… | Phase2 | Thrombotic Thrombocytopenic Purpura (TTP) | Completed | 2023-07-21 | 2026-04-16 | ClinicalTrials.gov |
| NCT05886491 | A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia | Phase1 | Leukemia | Terminated | 2023-07-11 | 2025-11-30 | ClinicalTrials.gov |
| NCT05886491 | A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia | Phase1 | Leukemia | Terminated | 2023-07-11 | 2025-11-30 | ClinicalTrials.gov |
| NCT05886491 | A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia | Phase1 | Leukemia | Terminated | 2023-07-11 | 2025-11-30 | ClinicalTrials.gov |
| NCT05469789 | A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE) | — | Hereditary Angioedema (HAE) | Active_Not_Recruiting | 2023-06-29 | 2026-12-31 | ClinicalTrials.gov |
| NCT05469789 | A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE) | — | Hereditary Angioedema (HAE) | Active_Not_Recruiting | 2023-06-29 | 2026-12-31 | ClinicalTrials.gov |
| NCT05469789 | A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE) | — | Hereditary Angioedema (HAE) | Active_Not_Recruiting | 2023-06-29 | 2026-12-31 | ClinicalTrials.gov |
| NCT05437211 | A Proof-of-concept Study to Reduce Treatment Burden in Haemophilia Participants… | Na | Hemophilia | Completed | 2023-06-23 | 2024-02-21 | ClinicalTrials.gov |
| NCT05437211 | A Proof-of-concept Study to Reduce Treatment Burden in Haemophilia Participants… | Na | Hemophilia | Completed | 2023-06-23 | 2024-02-21 | ClinicalTrials.gov |
| NCT05437211 | A Proof-of-concept Study to Reduce Treatment Burden in Haemophilia Participants… | Na | Hemophilia | Completed | 2023-06-23 | 2024-02-21 | ClinicalTrials.gov |
| NCT05576805 | A Study on Cytomegalovirus (CMV) Infection Outcomes Among Solid Organ Transplan… | — | Cytomegalovirus (CMV) | Completed | 2023-06-19 | 2024-03-31 | ClinicalTrials.gov |
| NCT05576805 | A Study on Cytomegalovirus (CMV) Infection Outcomes Among Solid Organ Transplan… | — | Cytomegalovirus (CMV) | Completed | 2023-06-19 | 2024-03-31 | ClinicalTrials.gov |
| NCT05576805 | A Study on Cytomegalovirus (CMV) Infection Outcomes Among Solid Organ Transplan… | — | Cytomegalovirus (CMV) | Completed | 2023-06-19 | 2024-03-31 | ClinicalTrials.gov |
| NCT05837897 | A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Di… | Phase3 | Crohn's Disease | Recruiting | 2023-06-16 | 2031-05-30 | ClinicalTrials.gov |
| NCT05837897 | A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Di… | Phase3 | Crohn's Disease | Recruiting | 2023-06-16 | 2031-05-30 | ClinicalTrials.gov |
| NCT05837897 | A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Di… | Phase3 | Crohn's Disease | Recruiting | 2023-06-16 | 2031-05-30 | ClinicalTrials.gov |
| NCT05578417 | A Study to Review the Treatment and Outcomes of Teenagers and Adults With Non-h… | — | Hereditary Angioedema (HAE) | Completed | 2023-06-15 | 2024-06-30 | ClinicalTrials.gov |
| NCT05578417 | A Study to Review the Treatment and Outcomes of Teenagers and Adults With Non-h… | — | Hereditary Angioedema (HAE) | Completed | 2023-06-15 | 2024-06-30 | ClinicalTrials.gov |
| NCT05578417 | A Study to Review the Treatment and Outcomes of Teenagers and Adults With Non-h… | — | Hereditary Angioedema (HAE) | Completed | 2023-06-15 | 2024-06-30 | ClinicalTrials.gov |
| NCT05686135 | 90Second IBD for the Improvement of Self Efficacy and Quality of Life in Inflam… | Na | IBD | Withdrawn | 2023-06-07 | 2024-04-24 | ClinicalTrials.gov |
| NCT05686135 | 90Second IBD for the Improvement of Self Efficacy and Quality of Life in Inflam… | Na | IBD | Withdrawn | 2023-06-07 | 2024-04-24 | ClinicalTrials.gov |
| NCT05686135 | 90Second IBD for the Improvement of Self Efficacy and Quality of Life in Inflam… | Na | IBD | Withdrawn | 2023-06-07 | 2024-04-24 | ClinicalTrials.gov |
| NCT05882279 | A Survey on NINLARO Risk Management Plan (RMP) Material Utilization Among Pharm… | — | Multiple Myeloma | Completed | 2023-06-01 | 2023-06-09 | ClinicalTrials.gov |
| NCT05764993 | Prevalence of Humoral Dysfunction in Pts With Frequent Exacerbations of COPD, a… | Phase2 | COPD Exacerbation Acute | Unknown | 2023-06-01 | 2025-12-30 | ClinicalTrials.gov |
| NCT05882279 | A Survey on NINLARO Risk Management Plan (RMP) Material Utilization Among Pharm… | — | Multiple Myeloma | Completed | 2023-06-01 | 2023-06-09 | ClinicalTrials.gov |
| NCT05882279 | A Survey on NINLARO Risk Management Plan (RMP) Material Utilization Among Pharm… | — | Multiple Myeloma | Completed | 2023-06-01 | 2023-06-09 | ClinicalTrials.gov |
| NCT05764993 | Prevalence of Humoral Dysfunction in Pts With Frequent Exacerbations of COPD, a… | Phase2 | COPD Exacerbation Acute | Unknown | 2023-06-01 | 2025-12-30 | ClinicalTrials.gov |
| NCT05764993 | Prevalence of Humoral Dysfunction in Pts With Frequent Exacerbations of COPD, a… | Phase2 | COPD Exacerbation Acute | Unknown | 2023-06-01 | 2025-12-30 | ClinicalTrials.gov |
| NCT05571137 | A Study on Cytomegalovirus (CMV) Infection Outcomes Among Hematopoietic Stem Ce… | — | Cytomegalovirus (CMV) | Completed | 2023-05-31 | 2024-01-31 | ClinicalTrials.gov |
| NCT05571137 | A Study on Cytomegalovirus (CMV) Infection Outcomes Among Hematopoietic Stem Ce… | — | Cytomegalovirus (CMV) | Completed | 2023-05-31 | 2024-01-31 | ClinicalTrials.gov |
| NCT05571137 | A Study on Cytomegalovirus (CMV) Infection Outcomes Among Hematopoietic Stem Ce… | — | Cytomegalovirus (CMV) | Completed | 2023-05-31 | 2024-01-31 | ClinicalTrials.gov |
| NCT05818956 | A Study of TAK-227 in Healthy Adults | Phase1 | Healthy Volunteers | Completed | 2023-05-25 | 2023-06-26 | ClinicalTrials.gov |
| NCT05818956 | A Study of TAK-227 in Healthy Adults | Phase1 | Healthy Volunteers | Completed | 2023-05-25 | 2023-06-26 | ClinicalTrials.gov |
| NCT05818956 | A Study of TAK-227 in Healthy Adults | Phase1 | Healthy Volunteers | Completed | 2023-05-25 | 2023-06-26 | ClinicalTrials.gov |
| NCT02615184 | A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive… | Phase2 | Erosive Esophagitis | Active_Not_Recruiting | 2023-05-23 | 2027-10-31 | ClinicalTrials.gov |
| NCT02615184 | A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive… | Phase2 | Erosive Esophagitis | Active_Not_Recruiting | 2023-05-23 | 2027-10-31 | ClinicalTrials.gov |
| NCT02615184 | A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive… | Phase2 | Erosive Esophagitis | Active_Not_Recruiting | 2023-05-23 | 2027-10-31 | ClinicalTrials.gov |
| NCT05735327 | A Study of Brigatinib as Preferred First Therapy for Adults With Non-Small Cell… | — | Non-small Cell Lung Cancer (NSCLC) | Active_Not_Recruiting | 2023-05-22 | 2027-04-26 | ClinicalTrials.gov |
| NCT05735327 | A Study of Brigatinib as Preferred First Therapy for Adults With Non-Small Cell… | — | Non-small Cell Lung Cancer (NSCLC) | Active_Not_Recruiting | 2023-05-22 | 2027-04-26 | ClinicalTrials.gov |
| NCT05735327 | A Study of Brigatinib as Preferred First Therapy for Adults With Non-Small Cell… | — | Non-small Cell Lung Cancer (NSCLC) | Active_Not_Recruiting | 2023-05-22 | 2027-04-26 | ClinicalTrials.gov |
| NCT05442567 | A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Dise… | Phase3 | Ulcerative Colitis | Recruiting | 2023-05-16 | 2031-08-15 | ClinicalTrials.gov |
| NCT05442567 | A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Dise… | Phase3 | Ulcerative Colitis | Recruiting | 2023-05-16 | 2031-08-15 | ClinicalTrials.gov |
| NCT05442567 | A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Dise… | Phase3 | Ulcerative Colitis | Recruiting | 2023-05-16 | 2031-08-15 | ClinicalTrials.gov |
| NCT05814016 | A Study of Danavorexton in People With Obstructive Sleep Apnea After General An… | Phase2 | Sleep Apnea | Terminated | 2023-05-11 | 2024-09-25 | ClinicalTrials.gov |
| NCT05814016 | A Study of Danavorexton in People With Obstructive Sleep Apnea After General An… | Phase2 | Sleep Apnea | Terminated | 2023-05-11 | 2024-09-25 | ClinicalTrials.gov |
| NCT05814016 | A Study of Danavorexton in People With Obstructive Sleep Apnea After General An… | Phase2 | Sleep Apnea | Terminated | 2023-05-11 | 2024-09-25 | ClinicalTrials.gov |
| NCT05626088 | A Study in Adults With Inflammatory Bowel Disease (IBD) Receiving Vedolizumab i… | — | Ulcerative Colitis | Active_Not_Recruiting | 2023-04-10 | 2026-06-30 | ClinicalTrials.gov |
| NCT05626088 | A Study in Adults With Inflammatory Bowel Disease (IBD) Receiving Vedolizumab i… | — | Ulcerative Colitis | Active_Not_Recruiting | 2023-04-10 | 2026-06-30 | ClinicalTrials.gov |
| NCT05626088 | A Study in Adults With Inflammatory Bowel Disease (IBD) Receiving Vedolizumab i… | — | Ulcerative Colitis | Active_Not_Recruiting | 2023-04-10 | 2026-06-30 | ClinicalTrials.gov |
| NCT05816382 | A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions | Phase2 | Narcolepsy Type 1 | Recruiting | 2023-04-05 | 2028-02-28 | ClinicalTrials.gov |
| NCT05816382 | A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions | Phase2 | Narcolepsy Type 1 | Recruiting | 2023-04-05 | 2028-02-28 | ClinicalTrials.gov |
| NCT05816382 | A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions | Phase2 | Narcolepsy Type 1 | Recruiting | 2023-04-05 | 2028-02-28 | ClinicalTrials.gov |
| NCT04971525 | A Study to Check How Often People Treated With Darvadstrocel for Crohn's Diseas… | — | Crohn Disease | Withdrawn | 2023-04-03 | 2027-12-31 | ClinicalTrials.gov |
| NCT04971525 | A Study to Check How Often People Treated With Darvadstrocel for Crohn's Diseas… | — | Crohn Disease | Withdrawn | 2023-04-03 | 2027-12-31 | ClinicalTrials.gov |
| NCT04971525 | A Study to Check How Often People Treated With Darvadstrocel for Crohn's Diseas… | — | Crohn Disease | Withdrawn | 2023-04-03 | 2027-12-31 | ClinicalTrials.gov |
| NCT05702814 | A Study Measuring Substances Potentially Indicating Bone Problems in Adults Wit… | — | Gaucher Disease | Completed | 2023-03-27 | 2024-05-24 | ClinicalTrials.gov |
| NCT05702814 | A Study Measuring Substances Potentially Indicating Bone Problems in Adults Wit… | — | Gaucher Disease | Completed | 2023-03-27 | 2024-05-24 | ClinicalTrials.gov |
| NCT05707351 | A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Se… | Phase3 | Hemophilia A | Completed | 2023-03-27 | 2024-09-05 | ClinicalTrials.gov |
| NCT05707351 | A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Se… | Phase3 | Hemophilia A | Completed | 2023-03-27 | 2024-09-05 | ClinicalTrials.gov |
| NCT05707351 | A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Se… | Phase3 | Hemophilia A | Completed | 2023-03-27 | 2024-09-05 | ClinicalTrials.gov |
| NCT05702814 | A Study Measuring Substances Potentially Indicating Bone Problems in Adults Wit… | — | Gaucher Disease | Completed | 2023-03-27 | 2024-05-24 | ClinicalTrials.gov |
| NCT05192863 | A Study of Vedolizumab in Adults With Crohn's Disease (CD) | — | Crohn's Disease | Completed | 2023-03-20 | 2025-10-31 | ClinicalTrials.gov |
| NCT05192863 | A Study of Vedolizumab in Adults With Crohn's Disease (CD) | — | Crohn's Disease | Completed | 2023-03-20 | 2025-10-31 | ClinicalTrials.gov |
| NCT05192863 | A Study of Vedolizumab in Adults With Crohn's Disease (CD) | — | Crohn's Disease | Completed | 2023-03-20 | 2025-10-31 | ClinicalTrials.gov |
| NCT05803200 | A Study to Describe Mothers' and Babies' Outcomes After Exposure to HyQvia Duri… | — | Exposure During Pregnancy | Completed | 2023-03-15 | 2023-04-14 | ClinicalTrials.gov |
| NCT05803200 | A Study to Describe Mothers' and Babies' Outcomes After Exposure to HyQvia Duri… | — | Exposure During Pregnancy | Completed | 2023-03-15 | 2023-04-14 | ClinicalTrials.gov |
| NCT05803200 | A Study to Describe Mothers' and Babies' Outcomes After Exposure to HyQvia Duri… | — | Exposure During Pregnancy | Completed | 2023-03-15 | 2023-04-14 | ClinicalTrials.gov |
| NCT05341115 | A Study of Leuprolide Acetate Depot in Children With Central Precocious Puberty | Phase4 | Central Precocious Puberty | Completed | 2023-03-14 | 2025-03-10 | ClinicalTrials.gov |
| NCT05341115 | A Study of Leuprolide Acetate Depot in Children With Central Precocious Puberty | Phase4 | Central Precocious Puberty | Completed | 2023-03-14 | 2025-03-10 | ClinicalTrials.gov |
| NCT05341115 | A Study of Leuprolide Acetate Depot in Children With Central Precocious Puberty | Phase4 | Central Precocious Puberty | Completed | 2023-03-14 | 2025-03-10 | ClinicalTrials.gov |
| NCT05677971 | Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People… | Phase3 | Alpha1-Antitrypsin Deficiency | Recruiting | 2023-03-06 | 2031-12-12 | ClinicalTrials.gov |
| NCT05677971 | Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People… | Phase3 | Alpha1-Antitrypsin Deficiency | Recruiting | 2023-03-06 | 2031-12-12 | ClinicalTrials.gov |
| NCT05677971 | Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People… | Phase3 | Alpha1-Antitrypsin Deficiency | Recruiting | 2023-03-06 | 2031-12-12 | ClinicalTrials.gov |
| NCT05664035 | Frequency of SPAD in Adult Patients | — | Specific Antibody Deficiency | Recruiting | 2023-03-01 | 2026-06-01 | ClinicalTrials.gov |
| NCT05664035 | Frequency of SPAD in Adult Patients | — | Specific Antibody Deficiency | Recruiting | 2023-03-01 | 2026-06-01 | ClinicalTrials.gov |
| NCT05664035 | Frequency of SPAD in Adult Patients | — | Specific Antibody Deficiency | Recruiting | 2023-03-01 | 2026-06-01 | ClinicalTrials.gov |
| NCT05506774 | A Study of People With CD30 Positive Lymphoma in China | — | Lymphoma | Completed | 2023-02-28 | 2024-07-03 | ClinicalTrials.gov |
| NCT05506774 | A Study of People With CD30 Positive Lymphoma in China | — | Lymphoma | Completed | 2023-02-28 | 2024-07-03 | ClinicalTrials.gov |
| NCT05494593 | A Study of ELAPRASE in Treatment-naïve Participants With Hunter Syndrome (Mucop… | Phase4 | Mucopolysaccharidosis (MPS) | Withdrawn | 2023-02-28 | 2025-08-29 | ClinicalTrials.gov |
| NCT05506774 | A Study of People With CD30 Positive Lymphoma in China | — | Lymphoma | Completed | 2023-02-28 | 2024-07-03 | ClinicalTrials.gov |
| NCT05494593 | A Study of ELAPRASE in Treatment-naïve Participants With Hunter Syndrome (Mucop… | Phase4 | Mucopolysaccharidosis (MPS) | Withdrawn | 2023-02-28 | 2025-08-29 | ClinicalTrials.gov |
| NCT05494593 | A Study of ELAPRASE in Treatment-naïve Participants With Hunter Syndrome (Mucop… | Phase4 | Mucopolysaccharidosis (MPS) | Withdrawn | 2023-02-28 | 2025-08-29 | ClinicalTrials.gov |
| NCT05695560 | A Survey to Describe the Experience and Unmet Needs of Persons Living With Von … | — | Von Willebrand Disease (VWD) | Completed | 2023-02-24 | 2023-11-30 | ClinicalTrials.gov |
| NCT05695560 | A Survey to Describe the Experience and Unmet Needs of Persons Living With Von … | — | Von Willebrand Disease (VWD) | Completed | 2023-02-24 | 2023-11-30 | ClinicalTrials.gov |
| NCT05695560 | A Survey to Describe the Experience and Unmet Needs of Persons Living With Von … | — | Von Willebrand Disease (VWD) | Completed | 2023-02-24 | 2023-11-30 | ClinicalTrials.gov |
| NCT05757700 | Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People Wi… | Phase1 | B-Cell Lymphoma | Active_Not_Recruiting | 2023-02-23 | 2027-02-23 | ClinicalTrials.gov |
| NCT05757700 | Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People Wi… | Phase1 | B-Cell Lymphoma | Active_Not_Recruiting | 2023-02-23 | 2027-02-23 | ClinicalTrials.gov |
| NCT05757700 | Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People Wi… | Phase1 | B-Cell Lymphoma | Active_Not_Recruiting | 2023-02-23 | 2027-02-23 | ClinicalTrials.gov |
| NCT02616302 | A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Sympto… | Phase2 | Gastroesophageal Reflux Disease (GERD) | Active_Not_Recruiting | 2023-02-20 | 2027-10-31 | ClinicalTrials.gov |
| NCT02616302 | A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Sympto… | Phase2 | Gastroesophageal Reflux Disease (GERD) | Active_Not_Recruiting | 2023-02-20 | 2027-10-31 | ClinicalTrials.gov |
| NCT02616302 | A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Sympto… | Phase2 | Gastroesophageal Reflux Disease (GERD) | Active_Not_Recruiting | 2023-02-20 | 2027-10-31 | ClinicalTrials.gov |
| NCT05673785 | A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubici… | Phase2 | Lymphoma | Active_Not_Recruiting | 2023-02-10 | 2027-12-31 | ClinicalTrials.gov |
| NCT05673785 | A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubici… | Phase2 | Lymphoma | Active_Not_Recruiting | 2023-02-10 | 2027-12-31 | ClinicalTrials.gov |
| NCT05673785 | A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubici… | Phase2 | Lymphoma | Active_Not_Recruiting | 2023-02-10 | 2027-12-31 | ClinicalTrials.gov |
| NCT06268301 | A Study to Determine the Effect Food Has on TAK-721 (Budesonide Oral Suspension… | Phase1 | Healthy Volunteers | Completed | 2023-02-06 | 2023-02-20 | ClinicalTrials.gov |
| NCT06268301 | A Study to Determine the Effect Food Has on TAK-721 (Budesonide Oral Suspension… | Phase1 | Healthy Volunteers | Completed | 2023-02-06 | 2023-02-20 | ClinicalTrials.gov |
| NCT06268301 | A Study to Determine the Effect Food Has on TAK-721 (Budesonide Oral Suspension… | Phase1 | Healthy Volunteers | Completed | 2023-02-06 | 2023-02-20 | ClinicalTrials.gov |
| NCT07052682 | A Study to Evaluate How Ontamalimab Works and Assess Its Safety and Tolerabilit… | Phase1 | Steatohepatitis | Terminated | 2023-01-18 | 2024-12-30 | ClinicalTrials.gov |
| NCT07052682 | A Study to Evaluate How Ontamalimab Works and Assess Its Safety and Tolerabilit… | Phase1 | Steatohepatitis | Terminated | 2023-01-18 | 2024-12-30 | ClinicalTrials.gov |
| NCT07052682 | A Study to Evaluate How Ontamalimab Works and Assess Its Safety and Tolerabilit… | Phase1 | Steatohepatitis | Terminated | 2023-01-18 | 2024-12-30 | ClinicalTrials.gov |
| NCT05543174 | A Study of TAK-625 for the Treatment of Alagille Syndrome (ALGS) | Phase3 | Alagille Syndrome (ALGS) | Completed | 2023-01-16 | 2025-07-25 | ClinicalTrials.gov |
| NCT05543174 | A Study of TAK-625 for the Treatment of Alagille Syndrome (ALGS) | Phase3 | Alagille Syndrome (ALGS) | Completed | 2023-01-16 | 2025-07-25 | ClinicalTrials.gov |
| NCT05543174 | A Study of TAK-625 for the Treatment of Alagille Syndrome (ALGS) | Phase3 | Alagille Syndrome (ALGS) | Completed | 2023-01-16 | 2025-07-25 | ClinicalTrials.gov |
| NCT05592119 | Effect of Stimulant Medication on Loss of Control Eating in Youth With Attentio… | — | Loss of Control Eating | Completed | 2023-01-11 | 2025-04-25 | ClinicalTrials.gov |
| NCT05592119 | Effect of Stimulant Medication on Loss of Control Eating in Youth With Attentio… | — | Loss of Control Eating | Completed | 2023-01-11 | 2025-04-25 | ClinicalTrials.gov |
| NCT05592119 | Effect of Stimulant Medication on Loss of Control Eating in Youth With Attentio… | — | Loss of Control Eating | Completed | 2023-01-11 | 2025-04-25 | ClinicalTrials.gov |
| NCT05543187 | A Study of TAK-625 for the Treatment of Progressive Familial Intrahepatic Chole… | Phase3 | Progressive Familial Intrahepatic Cholestasis (PFIC) | Completed | 2023-01-10 | 2025-07-22 | ClinicalTrials.gov |
| NCT05543187 | A Study of TAK-625 for the Treatment of Progressive Familial Intrahepatic Chole… | Phase3 | Progressive Familial Intrahepatic Cholestasis (PFIC) | Completed | 2023-01-10 | 2025-07-22 | ClinicalTrials.gov |
| NCT05543187 | A Study of TAK-625 for the Treatment of Progressive Familial Intrahepatic Chole… | Phase3 | Progressive Familial Intrahepatic Cholestasis (PFIC) | Completed | 2023-01-10 | 2025-07-22 | ClinicalTrials.gov |
| NCT05687903 | A Study of TAK-861 in Participants With Narcolepsy Type 1 | Phase2 | Narcolepsy Type 1 | Completed | 2023-01-09 | 2023-12-14 | ClinicalTrials.gov |
| NCT05687903 | A Study of TAK-861 in Participants With Narcolepsy Type 1 | Phase2 | Narcolepsy Type 1 | Completed | 2023-01-09 | 2023-12-14 | ClinicalTrials.gov |
| NCT05687916 | A Study of TAK-861 in Participants With Narcolepsy Type 2 | Phase2 | Narcolepsy Type 2 | Completed | 2023-01-09 | 2023-12-25 | ClinicalTrials.gov |
| NCT05687916 | A Study of TAK-861 in Participants With Narcolepsy Type 2 | Phase2 | Narcolepsy Type 2 | Completed | 2023-01-09 | 2023-12-25 | ClinicalTrials.gov |
| NCT05687916 | A Study of TAK-861 in Participants With Narcolepsy Type 2 | Phase2 | Narcolepsy Type 2 | Completed | 2023-01-09 | 2023-12-25 | ClinicalTrials.gov |
| NCT05687903 | A Study of TAK-861 in Participants With Narcolepsy Type 1 | Phase2 | Narcolepsy Type 1 | Completed | 2023-01-09 | 2023-12-14 | ClinicalTrials.gov |
| NCT05529992 | A Study of Velaglucerase Alfa (VPRIV) in Chinese Children, Teenagers, and Adult… | Phase3 | Gaucher Disease | Completed | 2023-01-03 | 2024-08-05 | ClinicalTrials.gov |
| NCT05529992 | A Study of Velaglucerase Alfa (VPRIV) in Chinese Children, Teenagers, and Adult… | Phase3 | Gaucher Disease | Completed | 2023-01-03 | 2024-08-05 | ClinicalTrials.gov |
| NCT05529992 | A Study of Velaglucerase Alfa (VPRIV) in Chinese Children, Teenagers, and Adult… | Phase3 | Gaucher Disease | Completed | 2023-01-03 | 2024-08-05 | ClinicalTrials.gov |
| NCT05770388 | App-based Intervention to Promote Mental Health Help-seeking Among University S… | Na | Suicidal Ideation | Completed | 2022-12-15 | 2024-07-30 | ClinicalTrials.gov |
| NCT05770388 | App-based Intervention to Promote Mental Health Help-seeking Among University S… | Na | Suicidal Ideation | Completed | 2022-12-15 | 2024-07-30 | ClinicalTrials.gov |
| NCT05770388 | App-based Intervention to Promote Mental Health Help-seeking Among University S… | Na | Suicidal Ideation | Completed | 2022-12-15 | 2024-07-30 | ClinicalTrials.gov |
| NCT05442554 | A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive C… | Phase4 | T-Cell Lymphoma | Completed | 2022-11-28 | 2024-08-09 | ClinicalTrials.gov |
| NCT05442554 | A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive C… | Phase4 | T-Cell Lymphoma | Completed | 2022-11-28 | 2024-08-09 | ClinicalTrials.gov |
| NCT05442554 | A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive C… | Phase4 | T-Cell Lymphoma | Completed | 2022-11-28 | 2024-08-09 | ClinicalTrials.gov |
| NCT05489640 | A Study in Adults With Hereditary Angioedema (HAE) Who Currently Receive Icatib… | — | Hereditary Angioedema (HAE) | Completed | 2022-11-18 | 2024-07-17 | ClinicalTrials.gov |
| NCT05489640 | A Study in Adults With Hereditary Angioedema (HAE) Who Currently Receive Icatib… | — | Hereditary Angioedema (HAE) | Completed | 2022-11-18 | 2024-07-17 | ClinicalTrials.gov |
| NCT05489640 | A Study in Adults With Hereditary Angioedema (HAE) Who Currently Receive Icatib… | — | Hereditary Angioedema (HAE) | Completed | 2022-11-18 | 2024-07-17 | ClinicalTrials.gov |
| NCT05526391 | A Study of TAK-341 in Treatment of Multiple System Atrophy | Phase2 | Multiple System Atrophy | Completed | 2022-11-16 | 2025-07-28 | ClinicalTrials.gov |
| NCT05526391 | A Study of TAK-341 in Treatment of Multiple System Atrophy | Phase2 | Multiple System Atrophy | Completed | 2022-11-16 | 2025-07-28 | ClinicalTrials.gov |
| NCT05526391 | A Study of TAK-341 in Treatment of Multiple System Atrophy | Phase2 | Multiple System Atrophy | Completed | 2022-11-16 | 2025-07-28 | ClinicalTrials.gov |
| NCT05602818 | A Study of Soticlestat in Healthy Adult Nondependent Recreational Drug Users Wi… | Phase1 | Healthy Volunteers | Completed | 2022-11-15 | 2023-07-07 | ClinicalTrials.gov |
| NCT05602818 | A Study of Soticlestat in Healthy Adult Nondependent Recreational Drug Users Wi… | Phase1 | Healthy Volunteers | Completed | 2022-11-15 | 2023-07-07 | ClinicalTrials.gov |
| NCT05602818 | A Study of Soticlestat in Healthy Adult Nondependent Recreational Drug Users Wi… | Phase1 | Healthy Volunteers | Completed | 2022-11-15 | 2023-07-07 | ClinicalTrials.gov |
| NCT06435403 | SARS-CoV-2 Specific Antibody Responses and Impact for COVID-19 Disease in Ethio… | — | SARS CoV 2 Infection | Recruiting | 2022-11-10 | 2025-02-28 | ClinicalTrials.gov |
| NCT06435403 | SARS-CoV-2 Specific Antibody Responses and Impact for COVID-19 Disease in Ethio… | — | SARS CoV 2 Infection | Recruiting | 2022-11-10 | 2025-02-28 | ClinicalTrials.gov |
| NCT06435403 | SARS-CoV-2 Specific Antibody Responses and Impact for COVID-19 Disease in Ethio… | — | SARS CoV 2 Infection | Recruiting | 2022-11-10 | 2025-02-28 | ClinicalTrials.gov |
| NCT05067868 | A Study of Replagal in Children and Adults With Fabry Disease in India | Phase4 | Fabry Disease | Recruiting | 2022-11-01 | 2026-11-30 | ClinicalTrials.gov |
| NCT05067868 | A Study of Replagal in Children and Adults With Fabry Disease in India | Phase4 | Fabry Disease | Recruiting | 2022-11-01 | 2026-11-30 | ClinicalTrials.gov |
| NCT05067868 | A Study of Replagal in Children and Adults With Fabry Disease in India | Phase4 | Fabry Disease | Recruiting | 2022-11-01 | 2026-11-30 | ClinicalTrials.gov |
| NCT05288491 | A Study of Chinese Adults With Lymphoma | — | Lymphoma | Completed | 2022-10-31 | 2024-06-20 | ClinicalTrials.gov |
| NCT05288491 | A Study of Chinese Adults With Lymphoma | — | Lymphoma | Completed | 2022-10-31 | 2024-06-20 | ClinicalTrials.gov |
| NCT05288491 | A Study of Chinese Adults With Lymphoma | — | Lymphoma | Completed | 2022-10-31 | 2024-06-20 | ClinicalTrials.gov |
| NCT05309902 | A Study of Soticlestat in Healthy Adults To Evaluate the Effect on QTc Interval | Phase1 | Healthy Volunteers | Withdrawn | 2022-10-11 | 2022-12-06 | ClinicalTrials.gov |
| NCT05309902 | A Study of Soticlestat in Healthy Adults To Evaluate the Effect on QTc Interval | Phase1 | Healthy Volunteers | Withdrawn | 2022-10-11 | 2022-12-06 | ClinicalTrials.gov |
| NCT05309902 | A Study of Soticlestat in Healthy Adults To Evaluate the Effect on QTc Interval | Phase1 | Healthy Volunteers | Withdrawn | 2022-10-11 | 2022-12-06 | ClinicalTrials.gov |
| NCT05565196 | Birth Companion Intervention in Ethiopia, Kenya and Nigeria | Na | Maternal Care Patterns | Completed | 2022-10-10 | 2024-11-18 | ClinicalTrials.gov |
| NCT05565196 | Birth Companion Intervention in Ethiopia, Kenya and Nigeria | Na | Maternal Care Patterns | Completed | 2022-10-10 | 2024-11-18 | ClinicalTrials.gov |
| NCT05565196 | Birth Companion Intervention in Ethiopia, Kenya and Nigeria | Na | Maternal Care Patterns | Completed | 2022-10-10 | 2024-11-18 | ClinicalTrials.gov |
| NCT05207423 | A Chart Review Study of Adults With Advanced NSCLC | — | Non-small Cell Lung Cancer (NSCLC) | Completed | 2022-10-03 | 2023-02-13 | ClinicalTrials.gov |
| NCT05207423 | A Chart Review Study of Adults With Advanced NSCLC | — | Non-small Cell Lung Cancer (NSCLC) | Completed | 2022-10-03 | 2023-02-13 | ClinicalTrials.gov |
| NCT05207423 | A Chart Review Study of Adults With Advanced NSCLC | — | Non-small Cell Lung Cancer (NSCLC) | Completed | 2022-10-03 | 2023-02-13 | ClinicalTrials.gov |
| NCT05073367 | A Study Reviewing Medical Records of Adults With Helicobacter Pylori Infections… | — | Helicobacter Pylori | Completed | 2022-09-21 | 2023-04-12 | ClinicalTrials.gov |
| NCT05073367 | A Study Reviewing Medical Records of Adults With Helicobacter Pylori Infections… | — | Helicobacter Pylori | Completed | 2022-09-21 | 2023-04-12 | ClinicalTrials.gov |
| NCT05073367 | A Study Reviewing Medical Records of Adults With Helicobacter Pylori Infections… | — | Helicobacter Pylori | Completed | 2022-09-21 | 2023-04-12 | ClinicalTrials.gov |
| NCT05513586 | A Study to Evaluate the Long-term Safety of TAK-771 in Japanese Primary Immunod… | Phase3 | Primary Immunodeficiency Diseases (PID) | Completed | 2022-09-13 | 2025-10-30 | ClinicalTrials.gov |
| NCT05513586 | A Study to Evaluate the Long-term Safety of TAK-771 in Japanese Primary Immunod… | Phase3 | Primary Immunodeficiency Diseases (PID) | Completed | 2022-09-13 | 2025-10-30 | ClinicalTrials.gov |
| NCT05513586 | A Study to Evaluate the Long-term Safety of TAK-771 in Japanese Primary Immunod… | Phase3 | Primary Immunodeficiency Diseases (PID) | Completed | 2022-09-13 | 2025-10-30 | ClinicalTrials.gov |
| NCT05687474 | Baby Detect : Genomic Newborn Screening | — | Congenital Adrenal Hyperplasia | Completed | 2022-09-01 | 2025-06-02 | ClinicalTrials.gov |
| NCT05687474 | Baby Detect : Genomic Newborn Screening | — | Congenital Adrenal Hyperplasia | Completed | 2022-09-01 | 2025-06-02 | ClinicalTrials.gov |
| NCT05687474 | Baby Detect : Genomic Newborn Screening | — | Congenital Adrenal Hyperplasia | Completed | 2022-09-01 | 2025-06-02 | ClinicalTrials.gov |
| NCT05156983 | A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Ne… | Phase3 | Coagulation Disorder | Recruiting | 2022-08-24 | 2028-08-30 | ClinicalTrials.gov |
| NCT05509569 | A Survey of Icatibant in Pediatric Participants With Hereditary Angioedema | — | Hereditary Angioedema (HAE) | Completed | 2022-08-24 | 2026-05-29 | ClinicalTrials.gov |
| NCT05156983 | A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Ne… | Phase3 | Coagulation Disorder | Recruiting | 2022-08-24 | 2028-08-30 | ClinicalTrials.gov |
| NCT05509569 | A Survey of Icatibant in Pediatric Participants With Hereditary Angioedema | — | Hereditary Angioedema (HAE) | Completed | 2022-08-24 | 2026-05-29 | ClinicalTrials.gov |
| NCT05509569 | A Survey of Icatibant in Pediatric Participants With Hereditary Angioedema | — | Hereditary Angioedema (HAE) | Completed | 2022-08-24 | 2026-05-29 | ClinicalTrials.gov |
| NCT05156983 | A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Ne… | Phase3 | Coagulation Disorder | Recruiting | 2022-08-24 | 2028-08-30 | ClinicalTrials.gov |
| NCT04925609 | Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other S… | Phase1 | Anaplastic Large Cell Lymphoma, ALK-Positive | Recruiting | 2022-08-18 | 2033-12-01 | ClinicalTrials.gov |
| NCT04925609 | Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other S… | Phase1 | Anaplastic Large Cell Lymphoma, ALK-Positive | Recruiting | 2022-08-18 | 2033-12-01 | ClinicalTrials.gov |
| NCT04925609 | Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other S… | Phase1 | Anaplastic Large Cell Lymphoma, ALK-Positive | Recruiting | 2022-08-18 | 2033-12-01 | ClinicalTrials.gov |
| NCT05309330 | Virtual Celiac Symptoms Study in Adults and Teenagers | — | Celiac Disease | Completed | 2022-08-16 | 2023-03-04 | ClinicalTrials.gov |
| NCT05309330 | Virtual Celiac Symptoms Study in Adults and Teenagers | — | Celiac Disease | Completed | 2022-08-16 | 2023-03-04 | ClinicalTrials.gov |
| NCT05174221 | A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Rece… | Phase1 | Kidney Disease | Completed | 2022-08-16 | 2025-12-15 | ClinicalTrials.gov |
| NCT05174221 | A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Rece… | Phase1 | Kidney Disease | Completed | 2022-08-16 | 2025-12-15 | ClinicalTrials.gov |
| NCT05309330 | Virtual Celiac Symptoms Study in Adults and Teenagers | — | Celiac Disease | Completed | 2022-08-16 | 2023-03-04 | ClinicalTrials.gov |
| NCT05174221 | A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Rece… | Phase1 | Kidney Disease | Completed | 2022-08-16 | 2025-12-15 | ClinicalTrials.gov |
| NCT05384080 | A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receivin… | — | Inflammatory Bowel Disease (IBD) | Completed | 2022-08-08 | 2025-06-13 | ClinicalTrials.gov |
| NCT05384080 | A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receivin… | — | Inflammatory Bowel Disease (IBD) | Completed | 2022-08-08 | 2025-06-13 | ClinicalTrials.gov |
| NCT05384080 | A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receivin… | — | Inflammatory Bowel Disease (IBD) | Completed | 2022-08-08 | 2025-06-13 | ClinicalTrials.gov |
| NCT05419700 | A Spanish Medical Record Review of Clinical Characteristics and Outcomes in Non… | — | Non-small Cell Lung Cancer (NSCLC) | Completed | 2022-08-05 | 2023-09-01 | ClinicalTrials.gov |
| NCT05419700 | A Spanish Medical Record Review of Clinical Characteristics and Outcomes in Non… | — | Non-small Cell Lung Cancer (NSCLC) | Completed | 2022-08-05 | 2023-09-01 | ClinicalTrials.gov |
| NCT05419700 | A Spanish Medical Record Review of Clinical Characteristics and Outcomes in Non… | — | Non-small Cell Lung Cancer (NSCLC) | Completed | 2022-08-05 | 2023-09-01 | ClinicalTrials.gov |
| NCT05481437 | A Survey of Brentuximab Vedotin in Pediatric Participants With Hodgkin Lymphoma | — | Hodgkin Lymphoma | Recruiting | 2022-08-01 | 2027-07-31 | ClinicalTrials.gov |
| NCT05481437 | A Survey of Brentuximab Vedotin in Pediatric Participants With Hodgkin Lymphoma | — | Hodgkin Lymphoma | Recruiting | 2022-08-01 | 2027-07-31 | ClinicalTrials.gov |
| NCT04892888 | Survey of the Moderna COVID-19 Vaccine in People at High-Risk of Developing Sev… | — | Coronavirus Disease (COVID-19) | Withdrawn | 2022-08-01 | 2023-04-30 | ClinicalTrials.gov |
| NCT05481437 | A Survey of Brentuximab Vedotin in Pediatric Participants With Hodgkin Lymphoma | — | Hodgkin Lymphoma | Recruiting | 2022-08-01 | 2027-07-31 | ClinicalTrials.gov |
| NCT04892888 | Survey of the Moderna COVID-19 Vaccine in People at High-Risk of Developing Sev… | — | Coronavirus Disease (COVID-19) | Withdrawn | 2022-08-01 | 2023-04-30 | ClinicalTrials.gov |
| NCT04892888 | Survey of the Moderna COVID-19 Vaccine in People at High-Risk of Developing Sev… | — | Coronavirus Disease (COVID-19) | Withdrawn | 2022-08-01 | 2023-04-30 | ClinicalTrials.gov |
| NCT05450549 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodyn… | Phase1 | Healthy Participant | Completed | 2022-07-14 | 2023-06-08 | ClinicalTrials.gov |
| NCT05450549 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodyn… | Phase1 | Healthy Participant | Completed | 2022-07-14 | 2023-06-08 | ClinicalTrials.gov |
| NCT05450549 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodyn… | Phase1 | Healthy Participant | Completed | 2022-07-14 | 2023-06-08 | ClinicalTrials.gov |
| NCT05183139 | A Multicenter In-class Transition Study of Ixazomib Combined With Pomalidomide … | Phase4 | Multiple Myeloma | Withdrawn | 2022-06-30 | 2026-12-31 | ClinicalTrials.gov |
| NCT05183139 | A Multicenter In-class Transition Study of Ixazomib Combined With Pomalidomide … | Phase4 | Multiple Myeloma | Withdrawn | 2022-06-30 | 2026-12-31 | ClinicalTrials.gov |
| NCT05353985 | A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attemp… | Phase2 | Celiac Disease | Completed | 2022-06-30 | 2024-11-06 | ClinicalTrials.gov |
| NCT05183139 | A Multicenter In-class Transition Study of Ixazomib Combined With Pomalidomide … | Phase4 | Multiple Myeloma | Withdrawn | 2022-06-30 | 2026-12-31 | ClinicalTrials.gov |
| NCT05353985 | A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attemp… | Phase2 | Celiac Disease | Completed | 2022-06-30 | 2024-11-06 | ClinicalTrials.gov |
| NCT05353985 | A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attemp… | Phase2 | Celiac Disease | Completed | 2022-06-30 | 2024-11-06 | ClinicalTrials.gov |
| NCT04530123 | Dose-Ranging Study of the Efficacy and Safety of TAK-101 for Prevention of Glut… | Phase2 | Celiac Disease | Completed | 2022-06-23 | 2026-01-08 | ClinicalTrials.gov |
| NCT04530123 | Dose-Ranging Study of the Efficacy and Safety of TAK-101 for Prevention of Glut… | Phase2 | Celiac Disease | Completed | 2022-06-23 | 2026-01-08 | ClinicalTrials.gov |
| NCT04530123 | Dose-Ranging Study of the Efficacy and Safety of TAK-101 for Prevention of Glut… | Phase2 | Celiac Disease | Completed | 2022-06-23 | 2026-01-08 | ClinicalTrials.gov |
| NCT05460325 | A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioed… | Phase3 | Hereditary Angioedema (HAE) | Completed | 2022-06-22 | 2023-11-28 | ClinicalTrials.gov |
| NCT05460325 | A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioed… | Phase3 | Hereditary Angioedema (HAE) | Completed | 2022-06-22 | 2023-11-28 | ClinicalTrials.gov |
| NCT05460325 | A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioed… | Phase3 | Hereditary Angioedema (HAE) | Completed | 2022-06-22 | 2023-11-28 | ClinicalTrials.gov |
| NCT05265078 | A Study on Estimated Risks of Certain Adverse Events in Adults With Von Willebr… | — | Von Willebrand Disease (VWD) | Completed | 2022-06-08 | 2023-04-06 | ClinicalTrials.gov |
| NCT05265078 | A Study on Estimated Risks of Certain Adverse Events in Adults With Von Willebr… | — | Von Willebrand Disease (VWD) | Completed | 2022-06-08 | 2023-04-06 | ClinicalTrials.gov |
| NCT05265078 | A Study on Estimated Risks of Certain Adverse Events in Adults With Von Willebr… | — | Von Willebrand Disease (VWD) | Completed | 2022-06-08 | 2023-04-06 | ClinicalTrials.gov |
| NCT03953170 | Pilot Study to Investigate the Effect of Teduglutide on Temporary Ileostomy Fun… | Phase3 | Ileostomy - Stoma | Withdrawn | 2022-06-02 | 2022-12-29 | ClinicalTrials.gov |
| NCT03953170 | Pilot Study to Investigate the Effect of Teduglutide on Temporary Ileostomy Fun… | Phase3 | Ileostomy - Stoma | Withdrawn | 2022-06-02 | 2022-12-29 | ClinicalTrials.gov |
| NCT03953170 | Pilot Study to Investigate the Effect of Teduglutide on Temporary Ileostomy Fun… | Phase3 | Ileostomy - Stoma | Withdrawn | 2022-06-02 | 2022-12-29 | ClinicalTrials.gov |
| NCT05316246 | Efficacy and Safety of BV With Tislelizumab for the Treatment of CD30+ Relapsed… | Phase2 | NK/T Cell Lymphoma Nos | Unknown | 2022-06-01 | 2024-12-31 | ClinicalTrials.gov |
| NCT05316246 | Efficacy and Safety of BV With Tislelizumab for the Treatment of CD30+ Relapsed… | Phase2 | NK/T Cell Lymphoma Nos | Unknown | 2022-06-01 | 2024-12-31 | ClinicalTrials.gov |
| NCT05316246 | Efficacy and Safety of BV With Tislelizumab for the Treatment of CD30+ Relapsed… | Phase2 | NK/T Cell Lymphoma Nos | Unknown | 2022-06-01 | 2024-12-31 | ClinicalTrials.gov |
| NCT05397431 | A Survey of Lanadelumab in Participants With Hereditary Angioedema | — | Hereditary Angioedema (HAE) | Active_Not_Recruiting | 2022-05-30 | 2026-06-25 | ClinicalTrials.gov |
| NCT05397431 | A Survey of Lanadelumab in Participants With Hereditary Angioedema | — | Hereditary Angioedema (HAE) | Active_Not_Recruiting | 2022-05-30 | 2026-06-25 | ClinicalTrials.gov |
| NCT05397431 | A Survey of Lanadelumab in Participants With Hereditary Angioedema | — | Hereditary Angioedema (HAE) | Active_Not_Recruiting | 2022-05-30 | 2026-06-25 | ClinicalTrials.gov |
| NCT05363358 | A Safety Study of GAMMAGARD LIQUID (GGL) in Participants With Chronic Inflammat… | — | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | Completed | 2022-05-27 | 2022-12-01 | ClinicalTrials.gov |
| NCT05363358 | A Safety Study of GAMMAGARD LIQUID (GGL) in Participants With Chronic Inflammat… | — | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | Completed | 2022-05-27 | 2022-12-01 | ClinicalTrials.gov |
| NCT05363358 | A Safety Study of GAMMAGARD LIQUID (GGL) in Participants With Chronic Inflammat… | — | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | Completed | 2022-05-27 | 2022-12-01 | ClinicalTrials.gov |
| NCT04928703 | Effects of Ketamine on ERP/EEG Measures in Healthy Volunteers | Early_Phase1 | Healthy | Completed | 2022-05-26 | 2022-12-12 | ClinicalTrials.gov |
| NCT04928703 | Effects of Ketamine on ERP/EEG Measures in Healthy Volunteers | Early_Phase1 | Healthy | Completed | 2022-05-26 | 2022-12-12 | ClinicalTrials.gov |
| NCT04928703 | Effects of Ketamine on ERP/EEG Measures in Healthy Volunteers | Early_Phase1 | Healthy | Completed | 2022-05-26 | 2022-12-12 | ClinicalTrials.gov |
| NCT05382104 | Maribavir Food-Effect Study in Healthy Adults Participants | Phase1 | Healthy Volunteers | Completed | 2022-05-25 | 2022-07-02 | ClinicalTrials.gov |
| NCT05382104 | Maribavir Food-Effect Study in Healthy Adults Participants | Phase1 | Healthy Volunteers | Completed | 2022-05-25 | 2022-07-02 | ClinicalTrials.gov |
| NCT05382104 | Maribavir Food-Effect Study in Healthy Adults Participants | Phase1 | Healthy Volunteers | Completed | 2022-05-25 | 2022-07-02 | ClinicalTrials.gov |
| NCT05113082 | Retrospective Study on Participants With Short Bowel Syndrome and Chronic Intes… | — | Short Bowel Syndrome (SBS) | Completed | 2022-05-21 | 2022-10-15 | ClinicalTrials.gov |
| NCT05113082 | Retrospective Study on Participants With Short Bowel Syndrome and Chronic Intes… | — | Short Bowel Syndrome (SBS) | Completed | 2022-05-21 | 2022-10-15 | ClinicalTrials.gov |
| NCT05113082 | Retrospective Study on Participants With Short Bowel Syndrome and Chronic Intes… | — | Short Bowel Syndrome (SBS) | Completed | 2022-05-21 | 2022-10-15 | ClinicalTrials.gov |
| NCT05414864 | Insomnia Prevalence and Treatment Impact on Systemic Hypertension | Phase4 | Insomnia | Terminated | 2022-05-01 | 2022-09-30 | ClinicalTrials.gov |
| NCT04974749 | A Study of REPLAGAL® in Treatment-naive Chinese Participants With Fabry Disease | Phase3 | Fabry Disease | Completed | 2022-05-01 | 2024-01-03 | ClinicalTrials.gov |
| NCT04974749 | A Study of REPLAGAL® in Treatment-naive Chinese Participants With Fabry Disease | Phase3 | Fabry Disease | Completed | 2022-05-01 | 2024-01-03 | ClinicalTrials.gov |
| NCT05414864 | Insomnia Prevalence and Treatment Impact on Systemic Hypertension | Phase4 | Insomnia | Terminated | 2022-05-01 | 2022-09-30 | ClinicalTrials.gov |
| NCT05414864 | Insomnia Prevalence and Treatment Impact on Systemic Hypertension | Phase4 | Insomnia | Terminated | 2022-05-01 | 2022-09-30 | ClinicalTrials.gov |
| NCT04974749 | A Study of REPLAGAL® in Treatment-naive Chinese Participants With Fabry Disease | Phase3 | Fabry Disease | Completed | 2022-05-01 | 2024-01-03 | ClinicalTrials.gov |
| NCT05058391 | A Study of Elaprase in Children and Adults With Hunter Syndrome (Mucopolysaccha… | Phase4 | Hunter Syndrome | Completed | 2022-04-21 | 2024-04-18 | ClinicalTrials.gov |
| NCT05220098 | First-in-Human Study of TAK-280 in Participants With Solid Tumors | Phase1 | Unresectable Locally Advanced or Metastatic Cancer | Terminated | 2022-04-21 | 2025-07-28 | ClinicalTrials.gov |
| NCT05058391 | A Study of Elaprase in Children and Adults With Hunter Syndrome (Mucopolysaccha… | Phase4 | Hunter Syndrome | Completed | 2022-04-21 | 2024-04-18 | ClinicalTrials.gov |
| NCT04957641 | A Study of the Burden of Illness and Treatment Patterns in Teenagers and Adults… | — | Hereditary Angioedema | Completed | 2022-04-21 | 2023-01-13 | ClinicalTrials.gov |
| NCT04957641 | A Study of the Burden of Illness and Treatment Patterns in Teenagers and Adults… | — | Hereditary Angioedema | Completed | 2022-04-21 | 2023-01-13 | ClinicalTrials.gov |
| NCT05058391 | A Study of Elaprase in Children and Adults With Hunter Syndrome (Mucopolysaccha… | Phase4 | Hunter Syndrome | Completed | 2022-04-21 | 2024-04-18 | ClinicalTrials.gov |
| NCT04957641 | A Study of the Burden of Illness and Treatment Patterns in Teenagers and Adults… | — | Hereditary Angioedema | Completed | 2022-04-21 | 2023-01-13 | ClinicalTrials.gov |
| NCT05220098 | First-in-Human Study of TAK-280 in Participants With Solid Tumors | Phase1 | Unresectable Locally Advanced or Metastatic Cancer | Terminated | 2022-04-21 | 2025-07-28 | ClinicalTrials.gov |
| NCT05220098 | First-in-Human Study of TAK-280 in Participants With Solid Tumors | Phase1 | Unresectable Locally Advanced or Metastatic Cancer | Terminated | 2022-04-21 | 2025-07-28 | ClinicalTrials.gov |
| NCT05299359 | A Single Heterologous Booster Vaccination Study of TAK-019 in Healthy Japanese … | Phase3 | Coronavirus Disease (COVID-19) | Completed | 2022-04-15 | 2023-10-18 | ClinicalTrials.gov |
| NCT05299359 | A Single Heterologous Booster Vaccination Study of TAK-019 in Healthy Japanese … | Phase3 | Coronavirus Disease (COVID-19) | Completed | 2022-04-15 | 2023-10-18 | ClinicalTrials.gov |
| NCT05299359 | A Single Heterologous Booster Vaccination Study of TAK-019 in Healthy Japanese … | Phase3 | Coronavirus Disease (COVID-19) | Completed | 2022-04-15 | 2023-10-18 | ClinicalTrials.gov |
| NCT04685616 | Brentuximab Vedotin in Early Stage Hodgkin Lymphoma | Phase3 | Hodgkin Lymphoma | Recruiting | 2022-04-14 | 2032-09-01 | ClinicalTrials.gov |
| NCT04685616 | Brentuximab Vedotin in Early Stage Hodgkin Lymphoma | Phase3 | Hodgkin Lymphoma | Recruiting | 2022-04-14 | 2032-09-01 | ClinicalTrials.gov |
| NCT05070247 | A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally … | Phase1 | Pancreatic Cancer | Terminated | 2022-04-14 | 2025-01-06 | ClinicalTrials.gov |
| NCT05070247 | A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally … | Phase1 | Pancreatic Cancer | Terminated | 2022-04-14 | 2025-01-06 | ClinicalTrials.gov |
| NCT05070247 | A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally … | Phase1 | Pancreatic Cancer | Terminated | 2022-04-14 | 2025-01-06 | ClinicalTrials.gov |
| NCT04685616 | Brentuximab Vedotin in Early Stage Hodgkin Lymphoma | Phase3 | Hodgkin Lymphoma | Recruiting | 2022-04-14 | 2032-09-01 | ClinicalTrials.gov |
| NCT05269082 | A Study to Assess the Hypersensitivity to TAK-880 Compared to Gammagard S/D in … | — | Drug Hypersensitivity | Completed | 2022-04-05 | 2022-09-19 | ClinicalTrials.gov |
| NCT05269082 | A Study to Assess the Hypersensitivity to TAK-880 Compared to Gammagard S/D in … | — | Drug Hypersensitivity | Completed | 2022-04-05 | 2022-09-19 | ClinicalTrials.gov |
| NCT05269082 | A Study to Assess the Hypersensitivity to TAK-880 Compared to Gammagard S/D in … | — | Drug Hypersensitivity | Completed | 2022-04-05 | 2022-09-19 | ClinicalTrials.gov |
| NCT05158517 | VeDOlizumab PERsistence in IBD Patients After Switching From Intravenous to Sub… | — | Inflammatory Bowel Diseases | Active_Not_Recruiting | 2022-03-20 | 2025-03-20 | ClinicalTrials.gov |
| NCT05158517 | VeDOlizumab PERsistence in IBD Patients After Switching From Intravenous to Sub… | — | Inflammatory Bowel Diseases | Active_Not_Recruiting | 2022-03-20 | 2025-03-20 | ClinicalTrials.gov |
| NCT05158517 | VeDOlizumab PERsistence in IBD Patients After Switching From Intravenous to Sub… | — | Inflammatory Bowel Diseases | Active_Not_Recruiting | 2022-03-20 | 2025-03-20 | ClinicalTrials.gov |
| NCT05147181 | A Study With Lanadelumab in Persons With Hereditary Angioedema (HAE) in Poland | — | Hereditary Angioedema (HAE) | Completed | 2022-03-11 | 2025-11-13 | ClinicalTrials.gov |
| NCT05284760 | A Study of Soticlestat Tablets in Healthy Adults | Phase1 | Healthy Volunteers | Completed | 2022-03-11 | 2022-06-02 | ClinicalTrials.gov |
| NCT05147181 | A Study With Lanadelumab in Persons With Hereditary Angioedema (HAE) in Poland | — | Hereditary Angioedema (HAE) | Completed | 2022-03-11 | 2025-11-13 | ClinicalTrials.gov |
| NCT05147181 | A Study With Lanadelumab in Persons With Hereditary Angioedema (HAE) in Poland | — | Hereditary Angioedema (HAE) | Completed | 2022-03-11 | 2025-11-13 | ClinicalTrials.gov |
| NCT05284760 | A Study of Soticlestat Tablets in Healthy Adults | Phase1 | Healthy Volunteers | Completed | 2022-03-11 | 2022-06-02 | ClinicalTrials.gov |
| NCT05284760 | A Study of Soticlestat Tablets in Healthy Adults | Phase1 | Healthy Volunteers | Completed | 2022-03-11 | 2022-06-02 | ClinicalTrials.gov |
| NCT05180890 | A Study of Danavorexton (TAK-925) in Adults With Obstructive Sleep Apnea | Phase1 | Sleep Apnea | Completed | 2022-03-10 | 2022-11-23 | ClinicalTrials.gov |
| NCT05180890 | A Study of Danavorexton (TAK-925) in Adults With Obstructive Sleep Apnea | Phase1 | Sleep Apnea | Completed | 2022-03-10 | 2022-11-23 | ClinicalTrials.gov |
| NCT05180890 | A Study of Danavorexton (TAK-925) in Adults With Obstructive Sleep Apnea | Phase1 | Sleep Apnea | Completed | 2022-03-10 | 2022-11-23 | ClinicalTrials.gov |
| NCT05100056 | A Study of Brentuximab Vedotin in Adults With Hodgkin's Lymphoma | — | Hodgkin Lymphoma | Recruiting | 2022-03-08 | 2027-01-13 | ClinicalTrials.gov |
| NCT05100056 | A Study of Brentuximab Vedotin in Adults With Hodgkin's Lymphoma | — | Hodgkin Lymphoma | Recruiting | 2022-03-08 | 2027-01-13 | ClinicalTrials.gov |
| NCT04844593 | A Study Using Artificial Intelligence to Identify Adults With Complex Perianal … | — | Crohn Disease | Completed | 2022-03-08 | 2024-04-29 | ClinicalTrials.gov |
| NCT04844593 | A Study Using Artificial Intelligence to Identify Adults With Complex Perianal … | — | Crohn Disease | Completed | 2022-03-08 | 2024-04-29 | ClinicalTrials.gov |
| NCT04844593 | A Study Using Artificial Intelligence to Identify Adults With Complex Perianal … | — | Crohn Disease | Completed | 2022-03-08 | 2024-04-29 | ClinicalTrials.gov |
| NCT05100056 | A Study of Brentuximab Vedotin in Adults With Hodgkin's Lymphoma | — | Hodgkin Lymphoma | Recruiting | 2022-03-08 | 2027-01-13 | ClinicalTrials.gov |
| NCT05163314 | A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet … | Phase3 | Dravet Syndrome (DS) | Terminated | 2022-03-04 | 2025-09-24 | ClinicalTrials.gov |
| NCT05163314 | A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet … | Phase3 | Dravet Syndrome (DS) | Terminated | 2022-03-04 | 2025-09-24 | ClinicalTrials.gov |
| NCT05163314 | A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet … | Phase3 | Dravet Syndrome (DS) | Terminated | 2022-03-04 | 2025-09-24 | ClinicalTrials.gov |
| NCT06768658 | A Study of TAK-951 in Participants With Cyclic Vomiting Syndrome (CVS) | Phase1 | Nausea and Vomitting | Terminated | 2022-03-02 | 2023-01-09 | ClinicalTrials.gov |
| NCT06768658 | A Study of TAK-951 in Participants With Cyclic Vomiting Syndrome (CVS) | Phase1 | Nausea and Vomitting | Terminated | 2022-03-02 | 2023-01-09 | ClinicalTrials.gov |
| NCT06768658 | A Study of TAK-951 in Participants With Cyclic Vomiting Syndrome (CVS) | Phase1 | Nausea and Vomitting | Terminated | 2022-03-02 | 2023-01-09 | ClinicalTrials.gov |
| NCT04838522 | A Study of Prucalopride in Breastfeeding Women With Constipation | — | Chronic Idiopathic Constipation (CIC) | Recruiting | 2022-03-02 | 2027-10-31 | ClinicalTrials.gov |
| NCT04838522 | A Study of Prucalopride in Breastfeeding Women With Constipation | — | Chronic Idiopathic Constipation (CIC) | Recruiting | 2022-03-02 | 2027-10-31 | ClinicalTrials.gov |
| NCT04838522 | A Study of Prucalopride in Breastfeeding Women With Constipation | — | Chronic Idiopathic Constipation (CIC) | Recruiting | 2022-03-02 | 2027-10-31 | ClinicalTrials.gov |
| NCT04885920 | A Study on Administration Choices of Vedolizumab and Outcomes for Adults With I… | — | Inflammatory Bowel Diseases | Completed | 2022-02-22 | 2024-03-12 | ClinicalTrials.gov |
| NCT04885920 | A Study on Administration Choices of Vedolizumab and Outcomes for Adults With I… | — | Inflammatory Bowel Diseases | Completed | 2022-02-22 | 2024-03-12 | ClinicalTrials.gov |
| NCT04885920 | A Study on Administration Choices of Vedolizumab and Outcomes for Adults With I… | — | Inflammatory Bowel Diseases | Completed | 2022-02-22 | 2024-03-12 | ClinicalTrials.gov |
| NCT04938440 | Assessment of Updated Educational Materials for Instanyl® | — | Pain | Completed | 2022-02-18 | 2023-02-06 | ClinicalTrials.gov |
| NCT04938440 | Assessment of Updated Educational Materials for Instanyl® | — | Pain | Completed | 2022-02-18 | 2023-02-06 | ClinicalTrials.gov |
| NCT04985643 | A Study of Real Life Treatment for Multiple Myeloma (MM) | — | Multiple Myeloma | Active_Not_Recruiting | 2022-02-18 | 2027-06-20 | ClinicalTrials.gov |
| NCT04938440 | Assessment of Updated Educational Materials for Instanyl® | — | Pain | Completed | 2022-02-18 | 2023-02-06 | ClinicalTrials.gov |
| NCT04985643 | A Study of Real Life Treatment for Multiple Myeloma (MM) | — | Multiple Myeloma | Active_Not_Recruiting | 2022-02-18 | 2027-06-20 | ClinicalTrials.gov |
| NCT04985643 | A Study of Real Life Treatment for Multiple Myeloma (MM) | — | Multiple Myeloma | Active_Not_Recruiting | 2022-02-18 | 2027-06-20 | ClinicalTrials.gov |
| NCT04779320 | A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn'… | Phase3 | Crohn's Disease (CD) | Recruiting | 2022-02-10 | 2026-05-22 | ClinicalTrials.gov |
| NCT04779320 | A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn'… | Phase3 | Crohn's Disease (CD) | Recruiting | 2022-02-10 | 2026-05-22 | ClinicalTrials.gov |
| NCT04779320 | A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn'… | Phase3 | Crohn's Disease (CD) | Recruiting | 2022-02-10 | 2026-05-22 | ClinicalTrials.gov |
| NCT05262023 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodyn… | Phase1 | Frontotemporal Dementia | Active_Not_Recruiting | 2022-02-01 | 2028-11-01 | ClinicalTrials.gov |
| NCT05262023 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodyn… | Phase1 | Frontotemporal Dementia | Active_Not_Recruiting | 2022-02-01 | 2028-11-01 | ClinicalTrials.gov |
| NCT05262023 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodyn… | Phase1 | Frontotemporal Dementia | Active_Not_Recruiting | 2022-02-01 | 2028-11-01 | ClinicalTrials.gov |
| NCT04883606 | A Study With Teduglutide (Revestive®) in Adults With Short Bowl Syndrome | — | Short Bowel Syndrome | Completed | 2022-01-26 | 2023-07-24 | ClinicalTrials.gov |
| NCT04883606 | A Study With Teduglutide (Revestive®) in Adults With Short Bowl Syndrome | — | Short Bowel Syndrome | Completed | 2022-01-26 | 2023-07-24 | ClinicalTrials.gov |
| NCT04883606 | A Study With Teduglutide (Revestive®) in Adults With Short Bowl Syndrome | — | Short Bowel Syndrome | Completed | 2022-01-26 | 2023-07-24 | ClinicalTrials.gov |
| NCT05150340 | A Study of TAK-771 in Japanese People With Primary Immunodeficiency Diseases (P… | Phase3 | Primary Immunodeficiency Diseases (PID) | Completed | 2022-01-24 | 2023-08-28 | ClinicalTrials.gov |
| NCT05150340 | A Study of TAK-771 in Japanese People With Primary Immunodeficiency Diseases (P… | Phase3 | Primary Immunodeficiency Diseases (PID) | Completed | 2022-01-24 | 2023-08-28 | ClinicalTrials.gov |
| NCT05150340 | A Study of TAK-771 in Japanese People With Primary Immunodeficiency Diseases (P… | Phase3 | Primary Immunodeficiency Diseases (PID) | Completed | 2022-01-24 | 2023-08-28 | ClinicalTrials.gov |
| NCT05084053 | A Study of TAK-771 in Japanese Participants With Chronic Inflammatory Demyelina… | Phase3 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | Completed | 2022-01-19 | 2026-05-29 | ClinicalTrials.gov |
| NCT05084053 | A Study of TAK-771 in Japanese Participants With Chronic Inflammatory Demyelina… | Phase3 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | Completed | 2022-01-19 | 2026-05-29 | ClinicalTrials.gov |
| NCT05084053 | A Study of TAK-771 in Japanese Participants With Chronic Inflammatory Demyelina… | Phase3 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | Completed | 2022-01-19 | 2026-05-29 | ClinicalTrials.gov |
| NCT05137717 | A Study of Maribavir in Japanese People With Cytomegalovirus (CMV) Infection | Phase3 | Cytomegalovirus (CMV) | Completed | 2022-01-18 | 2023-06-27 | ClinicalTrials.gov |
| NCT05137717 | A Study of Maribavir in Japanese People With Cytomegalovirus (CMV) Infection | Phase3 | Cytomegalovirus (CMV) | Completed | 2022-01-18 | 2023-06-27 | ClinicalTrials.gov |
| NCT05137717 | A Study of Maribavir in Japanese People With Cytomegalovirus (CMV) Infection | Phase3 | Cytomegalovirus (CMV) | Completed | 2022-01-18 | 2023-06-27 | ClinicalTrials.gov |
| NCT04985682 | A Study of ADVATE in People With Hemophilia A in India | Phase4 | Hemophilia A | Completed | 2022-01-14 | 2023-02-10 | ClinicalTrials.gov |
| NCT04985682 | A Study of ADVATE in People With Hemophilia A in India | Phase4 | Hemophilia A | Completed | 2022-01-14 | 2023-02-10 | ClinicalTrials.gov |
| NCT04985682 | A Study of ADVATE in People With Hemophilia A in India | Phase4 | Hemophilia A | Completed | 2022-01-14 | 2023-02-10 | ClinicalTrials.gov |
| NCT06610279 | A Study of TAK-951 in Healthy Adults | Phase1 | Healthy Volunteers | Terminated | 2022-01-07 | 2023-09-21 | ClinicalTrials.gov |
| NCT06610279 | A Study of TAK-951 in Healthy Adults | Phase1 | Healthy Volunteers | Terminated | 2022-01-07 | 2023-09-21 | ClinicalTrials.gov |
| NCT06610279 | A Study of TAK-951 in Healthy Adults | Phase1 | Healthy Volunteers | Terminated | 2022-01-07 | 2023-09-21 | ClinicalTrials.gov |
| NCT05153148 | A Study to Evaluate the Efficacy, Safety, and Tolerability of NDI-034858 in Par… | Phase2 | Psoriatic Arthritis | Completed | 2022-01-06 | 2023-06-02 | ClinicalTrials.gov |
| NCT05153148 | A Study to Evaluate the Efficacy, Safety, and Tolerability of NDI-034858 in Par… | Phase2 | Psoriatic Arthritis | Completed | 2022-01-06 | 2023-06-02 | ClinicalTrials.gov |
| NCT05153148 | A Study to Evaluate the Efficacy, Safety, and Tolerability of NDI-034858 in Par… | Phase2 | Psoriatic Arthritis | Completed | 2022-01-06 | 2023-06-02 | ClinicalTrials.gov |
| NCT05164666 | A Study of TAK-103 in Adult With Solid Tumors | Phase1 | Solid Tumors | Terminated | 2022-01-05 | 2025-02-22 | ClinicalTrials.gov |
| NCT05164666 | A Study of TAK-103 in Adult With Solid Tumors | Phase1 | Solid Tumors | Terminated | 2022-01-05 | 2025-02-22 | ClinicalTrials.gov |
| NCT05164666 | A Study of TAK-103 in Adult With Solid Tumors | Phase1 | Solid Tumors | Terminated | 2022-01-05 | 2025-02-22 | ClinicalTrials.gov |
| NCT05027308 | A Study of Teduglutide in Japanese Children With Short Bowel Syndrome Aged 4 Mo… | Phase3 | Short Bowel Syndrome | Completed | 2022-01-04 | 2023-09-27 | ClinicalTrials.gov |
| NCT05027308 | A Study of Teduglutide in Japanese Children With Short Bowel Syndrome Aged 4 Mo… | Phase3 | Short Bowel Syndrome | Completed | 2022-01-04 | 2023-09-27 | ClinicalTrials.gov |
| NCT05027308 | A Study of Teduglutide in Japanese Children With Short Bowel Syndrome Aged 4 Mo… | Phase3 | Short Bowel Syndrome | Completed | 2022-01-04 | 2023-09-27 | ClinicalTrials.gov |
| NCT04961840 | A Study to Assess Maternal and Fetal Outcomes After Taking Prucalopride During … | — | Constipation | Active_Not_Recruiting | 2022-01-01 | 2026-12-31 | ClinicalTrials.gov |
| NCT04961840 | A Study to Assess Maternal and Fetal Outcomes After Taking Prucalopride During … | — | Constipation | Active_Not_Recruiting | 2022-01-01 | 2026-12-31 | ClinicalTrials.gov |
| NCT05187208 | PARP Inhibitor Oral Maintenance in Low-Risk Ovarian Cancer | Phase4 | Epithelial Ovarian Cancer | Unknown | 2022-01-01 | 2025-12-01 | ClinicalTrials.gov |
| NCT04961840 | A Study to Assess Maternal and Fetal Outcomes After Taking Prucalopride During … | — | Constipation | Active_Not_Recruiting | 2022-01-01 | 2026-12-31 | ClinicalTrials.gov |
| NCT05187208 | PARP Inhibitor Oral Maintenance in Low-Risk Ovarian Cancer | Phase4 | Epithelial Ovarian Cancer | Unknown | 2022-01-01 | 2025-12-01 | ClinicalTrials.gov |
| NCT05187208 | PARP Inhibitor Oral Maintenance in Low-Risk Ovarian Cancer | Phase4 | Epithelial Ovarian Cancer | Unknown | 2022-01-01 | 2025-12-01 | ClinicalTrials.gov |
| NCT04840667 | A Study of Replagal in Treatment-naïve Adults With Fabry Disease | Phase3 | Fabry Disease | Terminated | 2021-12-28 | 2022-12-16 | ClinicalTrials.gov |
| NCT04840667 | A Study of Replagal in Treatment-naïve Adults With Fabry Disease | Phase3 | Fabry Disease | Terminated | 2021-12-28 | 2022-12-16 | ClinicalTrials.gov |
| NCT04840667 | A Study of Replagal in Treatment-naïve Adults With Fabry Disease | Phase3 | Fabry Disease | Terminated | 2021-12-28 | 2022-12-16 | ClinicalTrials.gov |
| NCT05037760 | A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelof… | Phase2 | Myelofibrosis | Recruiting | 2021-12-16 | 2030-02-28 | ClinicalTrials.gov |
| NCT06433778 | A Study on the Outcomes of Recombinant Von Willebrand Factor on Demand Treatmen… | — | Von Willebrand Disease (VWD) | Completed | 2021-12-16 | 2023-10-30 | ClinicalTrials.gov |
| NCT06433778 | A Study on the Outcomes of Recombinant Von Willebrand Factor on Demand Treatmen… | — | Von Willebrand Disease (VWD) | Completed | 2021-12-16 | 2023-10-30 | ClinicalTrials.gov |
| NCT05107960 | A Study of Azilsartan in Children From 6 to Less Than 16 Years Old With High Bl… | — | Hypertension | Completed | 2021-12-16 | 2024-08-31 | ClinicalTrials.gov |
| NCT05037760 | A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelof… | Phase2 | Myelofibrosis | Recruiting | 2021-12-16 | 2030-02-28 | ClinicalTrials.gov |
| NCT05107960 | A Study of Azilsartan in Children From 6 to Less Than 16 Years Old With High Bl… | — | Hypertension | Completed | 2021-12-16 | 2024-08-31 | ClinicalTrials.gov |
| NCT05037760 | A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelof… | Phase2 | Myelofibrosis | Recruiting | 2021-12-16 | 2030-02-28 | ClinicalTrials.gov |
| NCT05107960 | A Study of Azilsartan in Children From 6 to Less Than 16 Years Old With High Bl… | — | Hypertension | Completed | 2021-12-16 | 2024-08-31 | ClinicalTrials.gov |
| NCT06433778 | A Study on the Outcomes of Recombinant Von Willebrand Factor on Demand Treatmen… | — | Von Willebrand Disease (VWD) | Completed | 2021-12-16 | 2023-10-30 | ClinicalTrials.gov |
| NCT04888039 | Follow-up of Patients With Multiple Myeloma in the West-Occitanie Region "Livin… | — | Multiple Myeloma | Recruiting | 2021-12-15 | 2031-06-01 | ClinicalTrials.gov |
| NCT04888039 | Follow-up of Patients With Multiple Myeloma in the West-Occitanie Region "Livin… | — | Multiple Myeloma | Recruiting | 2021-12-15 | 2031-06-01 | ClinicalTrials.gov |
| NCT04888039 | Follow-up of Patients With Multiple Myeloma in the West-Occitanie Region "Livin… | — | Multiple Myeloma | Recruiting | 2021-12-15 | 2031-06-01 | ClinicalTrials.gov |
| NCT04804540 | A Study of Vedolizumab in People With Ulcerative Colitis and Crohn's Disease | Phase4 | Ulcerative Colitis | Completed | 2021-12-08 | 2024-02-02 | ClinicalTrials.gov |
| NCT04804540 | A Study of Vedolizumab in People With Ulcerative Colitis and Crohn's Disease | Phase4 | Ulcerative Colitis | Completed | 2021-12-08 | 2024-02-02 | ClinicalTrials.gov |
| NCT04804540 | A Study of Vedolizumab in People With Ulcerative Colitis and Crohn's Disease | Phase4 | Ulcerative Colitis | Completed | 2021-12-08 | 2024-02-02 | ClinicalTrials.gov |
| NCT05155488 | A Study to Improve the Awareness of Mucopolysaccharidosis Type II in Brazil | — | Mucopolysaccharidosis (MPS) | Completed | 2021-12-06 | 2022-02-15 | ClinicalTrials.gov |
| NCT05155488 | A Study to Improve the Awareness of Mucopolysaccharidosis Type II in Brazil | — | Mucopolysaccharidosis (MPS) | Completed | 2021-12-06 | 2022-02-15 | ClinicalTrials.gov |
| NCT05155488 | A Study to Improve the Awareness of Mucopolysaccharidosis Type II in Brazil | — | Mucopolysaccharidosis (MPS) | Completed | 2021-12-06 | 2022-02-15 | ClinicalTrials.gov |
| NCT04959851 | A Study on How Vedolizumab is Given and the Outcomes for Adults With Inflammato… | — | Inflammatory Bowel Diseases | Completed | 2021-12-02 | 2024-06-18 | ClinicalTrials.gov |
| NCT04959851 | A Study on How Vedolizumab is Given and the Outcomes for Adults With Inflammato… | — | Inflammatory Bowel Diseases | Completed | 2021-12-02 | 2024-06-18 | ClinicalTrials.gov |
| NCT04959851 | A Study on How Vedolizumab is Given and the Outcomes for Adults With Inflammato… | — | Inflammatory Bowel Diseases | Completed | 2021-12-02 | 2024-06-18 | ClinicalTrials.gov |
| NCT05056441 | A Study of Real-World Outcomes of People With Crohn's Disease (CD) | — | Crohn Disease | Completed | 2021-12-01 | 2022-09-30 | ClinicalTrials.gov |
| NCT05137704 | A Study on the Use of Healthcare Resources and Costs of Attention Deficit Hyper… | — | Attention Deficit Hyperactivity Disorder (ADHD) | Completed | 2021-12-01 | 2022-03-31 | ClinicalTrials.gov |
| NCT05137704 | A Study on the Use of Healthcare Resources and Costs of Attention Deficit Hyper… | — | Attention Deficit Hyperactivity Disorder (ADHD) | Completed | 2021-12-01 | 2022-03-31 | ClinicalTrials.gov |
| NCT05056441 | A Study of Real-World Outcomes of People With Crohn's Disease (CD) | — | Crohn Disease | Completed | 2021-12-01 | 2022-09-30 | ClinicalTrials.gov |
| NCT05056441 | A Study of Real-World Outcomes of People With Crohn's Disease (CD) | — | Crohn Disease | Completed | 2021-12-01 | 2022-09-30 | ClinicalTrials.gov |
| NCT05137704 | A Study on the Use of Healthcare Resources and Costs of Attention Deficit Hyper… | — | Attention Deficit Hyperactivity Disorder (ADHD) | Completed | 2021-12-01 | 2022-03-31 | ClinicalTrials.gov |
| NCT05113095 | A Survey of Darvadstrocel in People With Crohn's Disease | — | Crohn's Disease | Recruiting | 2021-11-30 | 2029-12-31 | ClinicalTrials.gov |
| NCT04876365 | A Study in Children, Teenagers and Adults With Severe Hemophilia A Who Switched… | — | Hemophilia A | Completed | 2021-11-30 | 2022-02-28 | ClinicalTrials.gov |
| NCT05113095 | A Survey of Darvadstrocel in People With Crohn's Disease | — | Crohn's Disease | Recruiting | 2021-11-30 | 2029-12-31 | ClinicalTrials.gov |
| NCT04876365 | A Study in Children, Teenagers and Adults With Severe Hemophilia A Who Switched… | — | Hemophilia A | Completed | 2021-11-30 | 2022-02-28 | ClinicalTrials.gov |
| NCT05113095 | A Survey of Darvadstrocel in People With Crohn's Disease | — | Crohn's Disease | Recruiting | 2021-11-30 | 2029-12-31 | ClinicalTrials.gov |
| NCT04876365 | A Study in Children, Teenagers and Adults With Severe Hemophilia A Who Switched… | — | Hemophilia A | Completed | 2021-11-30 | 2022-02-28 | ClinicalTrials.gov |
| NCT05137730 | A Study of Relative Bioavailability of a New Formulation Compared With the Appr… | Phase1 | Healthy Volunteers | Completed | 2021-11-29 | 2022-04-15 | ClinicalTrials.gov |
| NCT05137730 | A Study of Relative Bioavailability of a New Formulation Compared With the Appr… | Phase1 | Healthy Volunteers | Completed | 2021-11-29 | 2022-04-15 | ClinicalTrials.gov |
| NCT05137730 | A Study of Relative Bioavailability of a New Formulation Compared With the Appr… | Phase1 | Healthy Volunteers | Completed | 2021-11-29 | 2022-04-15 | ClinicalTrials.gov |
| NCT05098041 | A Study of Soticlestat and Rifampin in Healthy Adults | Phase1 | Healthy Volunteers | Completed | 2021-11-22 | 2022-03-03 | ClinicalTrials.gov |
| NCT05098041 | A Study of Soticlestat and Rifampin in Healthy Adults | Phase1 | Healthy Volunteers | Completed | 2021-11-22 | 2022-03-03 | ClinicalTrials.gov |
| NCT05098041 | A Study of Soticlestat and Rifampin in Healthy Adults | Phase1 | Healthy Volunteers | Completed | 2021-11-22 | 2022-03-03 | ClinicalTrials.gov |
| NCT04082481 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharma… | Phase1 | Healthy Volunteers | Withdrawn | 2021-11-17 | 2022-04-29 | ClinicalTrials.gov |
| NCT04082481 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharma… | Phase1 | Healthy Volunteers | Withdrawn | 2021-11-17 | 2022-04-29 | ClinicalTrials.gov |
| NCT04082481 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharma… | Phase1 | Healthy Volunteers | Withdrawn | 2021-11-17 | 2022-04-29 | ClinicalTrials.gov |
| NCT05100082 | Survey of Cabozantinib Tablets Used To Treat People With Hepatocellular Carcino… | — | Hepatocellular Cancer | Completed | 2021-11-17 | 2025-11-30 | ClinicalTrials.gov |
| NCT05100082 | Survey of Cabozantinib Tablets Used To Treat People With Hepatocellular Carcino… | — | Hepatocellular Cancer | Completed | 2021-11-17 | 2025-11-30 | ClinicalTrials.gov |
| NCT05100082 | Survey of Cabozantinib Tablets Used To Treat People With Hepatocellular Carcino… | — | Hepatocellular Cancer | Completed | 2021-11-17 | 2025-11-30 | ClinicalTrials.gov |
| NCT05020015 | A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgk… | Phase2 | Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) | Active_Not_Recruiting | 2021-11-12 | 2038-12-20 | ClinicalTrials.gov |
| NCT05020015 | A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgk… | Phase2 | Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) | Active_Not_Recruiting | 2021-11-12 | 2038-12-20 | ClinicalTrials.gov |
| NCT05020015 | A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgk… | Phase2 | Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) | Active_Not_Recruiting | 2021-11-12 | 2038-12-20 | ClinicalTrials.gov |
| NCT04938427 | A Study of Soticlestat as an Add-on Therapy in Children, Teenagers, and Adults … | Phase3 | Lennox Gastaut Syndrome (LGS) | Completed | 2021-11-08 | 2024-01-25 | ClinicalTrials.gov |
| NCT04938427 | A Study of Soticlestat as an Add-on Therapy in Children, Teenagers, and Adults … | Phase3 | Lennox Gastaut Syndrome (LGS) | Completed | 2021-11-08 | 2024-01-25 | ClinicalTrials.gov |
| NCT04938427 | A Study of Soticlestat as an Add-on Therapy in Children, Teenagers, and Adults … | Phase3 | Lennox Gastaut Syndrome (LGS) | Completed | 2021-11-08 | 2024-01-25 | ClinicalTrials.gov |
| NCT05100069 | Survey of Brigatinib Used To Treat People With Non-Small Cell Lung Cancer | — | Non-small Cell Lung Cancer (NSCLC) | Recruiting | 2021-11-01 | 2030-09-30 | ClinicalTrials.gov |
| NCT05100069 | Survey of Brigatinib Used To Treat People With Non-Small Cell Lung Cancer | — | Non-small Cell Lung Cancer (NSCLC) | Recruiting | 2021-11-01 | 2030-09-30 | ClinicalTrials.gov |
| NCT05100069 | Survey of Brigatinib Used To Treat People With Non-Small Cell Lung Cancer | — | Non-small Cell Lung Cancer (NSCLC) | Recruiting | 2021-11-01 | 2030-09-30 | ClinicalTrials.gov |
| NCT05098054 | A Study of Soticlestat in Adults With Liver Failure Compared to Those With Norm… | Phase1 | Hepatic Impairment | Completed | 2021-10-29 | 2022-06-07 | ClinicalTrials.gov |
| NCT05013190 | A Study of NINLARO® in Chinese Adults With Multiple Myeloma | — | Multiple Myeloma | Active_Not_Recruiting | 2021-10-29 | 2026-12-31 | ClinicalTrials.gov |
| NCT04998331 | A Spanish Medical Record Review of Adults With Relapsed or Refractory CD30+ Mal… | — | Hodgkin Disease | Completed | 2021-10-29 | 2023-09-07 | ClinicalTrials.gov |
| NCT04998331 | A Spanish Medical Record Review of Adults With Relapsed or Refractory CD30+ Mal… | — | Hodgkin Disease | Completed | 2021-10-29 | 2023-09-07 | ClinicalTrials.gov |
| NCT04998331 | A Spanish Medical Record Review of Adults With Relapsed or Refractory CD30+ Mal… | — | Hodgkin Disease | Completed | 2021-10-29 | 2023-09-07 | ClinicalTrials.gov |
| NCT05013190 | A Study of NINLARO® in Chinese Adults With Multiple Myeloma | — | Multiple Myeloma | Active_Not_Recruiting | 2021-10-29 | 2026-12-31 | ClinicalTrials.gov |
| NCT05013190 | A Study of NINLARO® in Chinese Adults With Multiple Myeloma | — | Multiple Myeloma | Active_Not_Recruiting | 2021-10-29 | 2026-12-31 | ClinicalTrials.gov |
| NCT05098054 | A Study of Soticlestat in Adults With Liver Failure Compared to Those With Norm… | Phase1 | Hepatic Impairment | Completed | 2021-10-29 | 2022-06-07 | ClinicalTrials.gov |
| NCT05098054 | A Study of Soticlestat in Adults With Liver Failure Compared to Those With Norm… | Phase1 | Hepatic Impairment | Completed | 2021-10-29 | 2022-06-07 | ClinicalTrials.gov |
| NCT04940624 | A Study of Soticlestat as an Add-on Therapy in Children and Young Adults With D… | Phase3 | Dravet Syndrome (DS) | Completed | 2021-10-28 | 2024-04-11 | ClinicalTrials.gov |
| NCT04940624 | A Study of Soticlestat as an Add-on Therapy in Children and Young Adults With D… | Phase3 | Dravet Syndrome (DS) | Completed | 2021-10-28 | 2024-04-11 | ClinicalTrials.gov |
| NCT04940624 | A Study of Soticlestat as an Add-on Therapy in Children and Young Adults With D… | Phase3 | Dravet Syndrome (DS) | Completed | 2021-10-28 | 2024-04-11 | ClinicalTrials.gov |
| NCT04872491 | A Study of Vedolizumab in Adults in Real-World Practice | — | Colitis, Ulcerative | Completed | 2021-10-22 | 2024-07-17 | ClinicalTrials.gov |
| NCT04872491 | A Study of Vedolizumab in Adults in Real-World Practice | — | Colitis, Ulcerative | Completed | 2021-10-22 | 2024-07-17 | ClinicalTrials.gov |
| NCT04872491 | A Study of Vedolizumab in Adults in Real-World Practice | — | Colitis, Ulcerative | Completed | 2021-10-22 | 2024-07-17 | ClinicalTrials.gov |
| NCT04779307 | A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcera… | Phase3 | Colitis, Ulcerative | Completed | 2021-10-19 | 2025-07-01 | ClinicalTrials.gov |
| NCT04779307 | A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcera… | Phase3 | Colitis, Ulcerative | Completed | 2021-10-19 | 2025-07-01 | ClinicalTrials.gov |
| NCT04779307 | A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcera… | Phase3 | Colitis, Ulcerative | Completed | 2021-10-19 | 2025-07-01 | ClinicalTrials.gov |
| NCT05064449 | A Study of Soticlestat With Itraconazole and Mefenamic Acid in Healthy Adults | Phase1 | Healthy Volunteers | Completed | 2021-10-14 | 2021-11-30 | ClinicalTrials.gov |
| NCT05064449 | A Study of Soticlestat With Itraconazole and Mefenamic Acid in Healthy Adults | Phase1 | Healthy Volunteers | Completed | 2021-10-14 | 2021-11-30 | ClinicalTrials.gov |
| NCT05064449 | A Study of Soticlestat With Itraconazole and Mefenamic Acid in Healthy Adults | Phase1 | Healthy Volunteers | Completed | 2021-10-14 | 2021-11-30 | ClinicalTrials.gov |
| NCT05059977 | A Study of TAK-881 in Healthy Adults | Phase1 | Healthy Volunteers | Completed | 2021-10-12 | 2022-04-12 | ClinicalTrials.gov |
| NCT05059977 | A Study of TAK-881 in Healthy Adults | Phase1 | Healthy Volunteers | Completed | 2021-10-12 | 2022-04-12 | ClinicalTrials.gov |
| NCT05059977 | A Study of TAK-881 in Healthy Adults | Phase1 | Healthy Volunteers | Completed | 2021-10-12 | 2022-04-12 | ClinicalTrials.gov |
| NCT05743465 | A Study to Evaluate Available Treatment Information of Ponatinib, Bosutinib, Im… | — | Leukemia | Completed | 2021-10-06 | 2022-11-30 | ClinicalTrials.gov |
| NCT05743465 | A Study to Evaluate Available Treatment Information of Ponatinib, Bosutinib, Im… | — | Leukemia | Completed | 2021-10-06 | 2022-11-30 | ClinicalTrials.gov |
| NCT05743465 | A Study to Evaluate Available Treatment Information of Ponatinib, Bosutinib, Im… | — | Leukemia | Completed | 2021-10-06 | 2022-11-30 | ClinicalTrials.gov |
| NCT04985656 | A Study of Pevonedistat Combined With Decitabine and Cedazuridine in Adults Wit… | Phase2 | Myelodysplastic Syndromes (MDS) | Withdrawn | 2021-10-01 | 2024-11-08 | ClinicalTrials.gov |
| NCT04985656 | A Study of Pevonedistat Combined With Decitabine and Cedazuridine in Adults Wit… | Phase2 | Myelodysplastic Syndromes (MDS) | Withdrawn | 2021-10-01 | 2024-11-08 | ClinicalTrials.gov |
| NCT04985656 | A Study of Pevonedistat Combined With Decitabine and Cedazuridine in Adults Wit… | Phase2 | Myelodysplastic Syndromes (MDS) | Withdrawn | 2021-10-01 | 2024-11-08 | ClinicalTrials.gov |
| NCT05025397 | A Study of Danavorexton in Anesthetized Adults | Phase1 | Healthy Volunteers | Completed | 2021-09-28 | 2022-03-08 | ClinicalTrials.gov |
| NCT05025397 | A Study of Danavorexton in Anesthetized Adults | Phase1 | Healthy Volunteers | Completed | 2021-09-28 | 2022-03-08 | ClinicalTrials.gov |
| NCT05025397 | A Study of Danavorexton in Anesthetized Adults | Phase1 | Healthy Volunteers | Completed | 2021-09-28 | 2022-03-08 | ClinicalTrials.gov |
| NCT05122806 | Analysis of Biological Characteristics of Advanced ALK-rearranged NSCLC | Na | Non-small Cell Lung Cancer | Recruiting | 2021-09-22 | 2027-06-30 | ClinicalTrials.gov |
| NCT05122806 | Analysis of Biological Characteristics of Advanced ALK-rearranged NSCLC | Na | Non-small Cell Lung Cancer | Recruiting | 2021-09-22 | 2027-06-30 | ClinicalTrials.gov |
| NCT05122806 | Analysis of Biological Characteristics of Advanced ALK-rearranged NSCLC | Na | Non-small Cell Lung Cancer | Recruiting | 2021-09-22 | 2027-06-30 | ClinicalTrials.gov |
| NCT04891718 | CIVO Intratumoural Microdosing of Anti-Cancer Therapies in Australia | Early_Phase1 | Solid Tumour | Withdrawn | 2021-09-15 | 2022-06-05 | ClinicalTrials.gov |
| NCT04861090 | A Study in Teenagers and Adults With Hereditary Angioedema (HAE) Type I or Type… | — | Hereditary Angioedema (HAE) | Completed | 2021-09-15 | 2022-06-30 | ClinicalTrials.gov |
| NCT04861090 | A Study in Teenagers and Adults With Hereditary Angioedema (HAE) Type I or Type… | — | Hereditary Angioedema (HAE) | Completed | 2021-09-15 | 2022-06-30 | ClinicalTrials.gov |
| NCT04891718 | CIVO Intratumoural Microdosing of Anti-Cancer Therapies in Australia | Early_Phase1 | Solid Tumour | Withdrawn | 2021-09-15 | 2022-06-05 | ClinicalTrials.gov |
| NCT04861090 | A Study in Teenagers and Adults With Hereditary Angioedema (HAE) Type I or Type… | — | Hereditary Angioedema (HAE) | Completed | 2021-09-15 | 2022-06-30 | ClinicalTrials.gov |
| NCT04891718 | CIVO Intratumoural Microdosing of Anti-Cancer Therapies in Australia | Early_Phase1 | Solid Tumour | Withdrawn | 2021-09-15 | 2022-06-05 | ClinicalTrials.gov |
| NCT05021562 | A Study of Niraparib in Patients With Ovarian Cancer in Clinical Practice | — | Ovarian Cancer | Completed | 2021-09-13 | 2026-03-31 | ClinicalTrials.gov |
| NCT05021562 | A Study of Niraparib in Patients With Ovarian Cancer in Clinical Practice | — | Ovarian Cancer | Completed | 2021-09-13 | 2026-03-31 | ClinicalTrials.gov |
| NCT05021562 | A Study of Niraparib in Patients With Ovarian Cancer in Clinical Practice | — | Ovarian Cancer | Completed | 2021-09-13 | 2026-03-31 | ClinicalTrials.gov |
| NCT04879849 | A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number… | Phase1 | Carcinoma, Non-Small-Cell Lung | Completed | 2021-09-09 | 2024-04-30 | ClinicalTrials.gov |
| NCT04879849 | A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number… | Phase1 | Carcinoma, Non-Small-Cell Lung | Completed | 2021-09-09 | 2024-04-30 | ClinicalTrials.gov |
| NCT04879849 | A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number… | Phase1 | Carcinoma, Non-Small-Cell Lung | Completed | 2021-09-09 | 2024-04-30 | ClinicalTrials.gov |
| NCT04989907 | A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receivin… | — | Inflammatory Bowel Diseases | Completed | 2021-09-08 | 2024-05-17 | ClinicalTrials.gov |
| NCT04989907 | A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receivin… | — | Inflammatory Bowel Diseases | Completed | 2021-09-08 | 2024-05-17 | ClinicalTrials.gov |
| NCT04989907 | A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receivin… | — | Inflammatory Bowel Diseases | Completed | 2021-09-08 | 2024-05-17 | ClinicalTrials.gov |
| NCT04984889 | A Study of TAK-662 for Japanese Patients With Congenital Protein C Deficiency | Phase1 | Congenital Protein C Deficiency | Completed | 2021-09-07 | 2024-10-31 | ClinicalTrials.gov |
| NCT04984889 | A Study of TAK-662 for Japanese Patients With Congenital Protein C Deficiency | Phase1 | Congenital Protein C Deficiency | Completed | 2021-09-07 | 2024-10-31 | ClinicalTrials.gov |
| NCT04984889 | A Study of TAK-662 for Japanese Patients With Congenital Protein C Deficiency | Phase1 | Congenital Protein C Deficiency | Completed | 2021-09-07 | 2024-10-31 | ClinicalTrials.gov |
| NCT05023382 | A Study of Teduglutide in Japanese People With Short Bowel Syndrome | — | Short Bowel Syndrome | Active_Not_Recruiting | 2021-09-01 | 2026-07-31 | ClinicalTrials.gov |
| NCT05023382 | A Study of Teduglutide in Japanese People With Short Bowel Syndrome | — | Short Bowel Syndrome | Active_Not_Recruiting | 2021-09-01 | 2026-07-31 | ClinicalTrials.gov |
| NCT05023382 | A Study of Teduglutide in Japanese People With Short Bowel Syndrome | — | Short Bowel Syndrome | Active_Not_Recruiting | 2021-09-01 | 2026-07-31 | ClinicalTrials.gov |
| NCT05030493 | An Additional Analysis of Data From the PARADIGM Exploratory Study (NCT02394834… | — | Colorectal Cancer | Active_Not_Recruiting | 2021-08-31 | 2027-07-31 | ClinicalTrials.gov |
| NCT05030493 | An Additional Analysis of Data From the PARADIGM Exploratory Study (NCT02394834… | — | Colorectal Cancer | Active_Not_Recruiting | 2021-08-31 | 2027-07-31 | ClinicalTrials.gov |
| NCT05030493 | An Additional Analysis of Data From the PARADIGM Exploratory Study (NCT02394834… | — | Colorectal Cancer | Active_Not_Recruiting | 2021-08-31 | 2027-07-31 | ClinicalTrials.gov |
| NCT04873700 | A Study of Moderate to Severe Inflammatory Bowel Disease, Including Ulcerative … | — | Inflammatory Bowel Diseases | Completed | 2021-08-30 | 2022-05-17 | ClinicalTrials.gov |
| NCT04873700 | A Study of Moderate to Severe Inflammatory Bowel Disease, Including Ulcerative … | — | Inflammatory Bowel Diseases | Completed | 2021-08-30 | 2022-05-17 | ClinicalTrials.gov |
| NCT04873700 | A Study of Moderate to Severe Inflammatory Bowel Disease, Including Ulcerative … | — | Inflammatory Bowel Diseases | Completed | 2021-08-30 | 2022-05-17 | ClinicalTrials.gov |
| NCT04953000 | A Study of Standard and Individualized Prophylactic Treatment With Advate in Me… | — | Hemophilia A | Completed | 2021-08-19 | 2023-04-04 | ClinicalTrials.gov |
| NCT04953000 | A Study of Standard and Individualized Prophylactic Treatment With Advate in Me… | — | Hemophilia A | Completed | 2021-08-19 | 2023-04-04 | ClinicalTrials.gov |
| NCT04953000 | A Study of Standard and Individualized Prophylactic Treatment With Advate in Me… | — | Hemophilia A | Completed | 2021-08-19 | 2023-04-04 | ClinicalTrials.gov |
| NCT04890262 | A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Diseas… | — | Inflammatory Bowel Diseases | Completed | 2021-08-18 | 2024-06-30 | ClinicalTrials.gov |
| NCT04890262 | A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Diseas… | — | Inflammatory Bowel Diseases | Completed | 2021-08-18 | 2024-06-30 | ClinicalTrials.gov |
| NCT04890262 | A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Diseas… | — | Inflammatory Bowel Diseases | Completed | 2021-08-18 | 2024-06-30 | ClinicalTrials.gov |
| NCT04999839 | Study of NDI-034858 in Participants With Moderate to Severe Plaque Psoriasis | Phase2 | Moderate to Severe Plaque Psoriasis | Completed | 2021-08-11 | 2022-09-12 | ClinicalTrials.gov |
| NCT04999839 | Study of NDI-034858 in Participants With Moderate to Severe Plaque Psoriasis | Phase2 | Moderate to Severe Plaque Psoriasis | Completed | 2021-08-11 | 2022-09-12 | ClinicalTrials.gov |
| NCT04999839 | Study of NDI-034858 in Participants With Moderate to Severe Plaque Psoriasis | Phase2 | Moderate to Severe Plaque Psoriasis | Completed | 2021-08-11 | 2022-09-12 | ClinicalTrials.gov |
| NCT04940611 | A Study of Surgical Interventions in Fistulizing Conditions | — | Crohns Disease | Active_Not_Recruiting | 2021-08-05 | 2026-05-02 | ClinicalTrials.gov |
| NCT04940611 | A Study of Surgical Interventions in Fistulizing Conditions | — | Crohns Disease | Active_Not_Recruiting | 2021-08-05 | 2026-05-02 | ClinicalTrials.gov |
| NCT04940611 | A Study of Surgical Interventions in Fistulizing Conditions | — | Crohns Disease | Active_Not_Recruiting | 2021-08-05 | 2026-05-02 | ClinicalTrials.gov |
| NCT04429984 | Post Marketing Surveillance (PMS) Study for Velaglucerase Alfa (VPRIV) in India | — | Gaucher Disease | Completed | 2021-07-28 | 2023-04-22 | ClinicalTrials.gov |
| NCT04955964 | A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE)… | — | Angioedemas, Hereditary | Completed | 2021-07-28 | 2023-08-07 | ClinicalTrials.gov |
| NCT04955964 | A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE)… | — | Angioedemas, Hereditary | Completed | 2021-07-28 | 2023-08-07 | ClinicalTrials.gov |
| NCT04955964 | A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE)… | — | Angioedemas, Hereditary | Completed | 2021-07-28 | 2023-08-07 | ClinicalTrials.gov |
| NCT04429984 | Post Marketing Surveillance (PMS) Study for Velaglucerase Alfa (VPRIV) in India | — | Gaucher Disease | Completed | 2021-07-28 | 2023-04-22 | ClinicalTrials.gov |
| NCT04429984 | Post Marketing Surveillance (PMS) Study for Velaglucerase Alfa (VPRIV) in India | — | Gaucher Disease | Completed | 2021-07-28 | 2023-04-22 | ClinicalTrials.gov |
| NCT06062602 | PBI-MST-01(NCT04541108) Substudy TAK-02: Intratumoral Microdosing of TAK-676 in… | Early_Phase1 | Head and Neck Squamous Cell Carcinoma | Completed | 2021-07-26 | 2022-11-15 | ClinicalTrials.gov |
| NCT04964258 | A Study of TAK-105 in Healthy Adults | Phase1 | Healthy Volunteers | Completed | 2021-07-26 | 2023-06-20 | ClinicalTrials.gov |
| NCT04964258 | A Study of TAK-105 in Healthy Adults | Phase1 | Healthy Volunteers | Completed | 2021-07-26 | 2023-06-20 | ClinicalTrials.gov |
| NCT04964258 | A Study of TAK-105 in Healthy Adults | Phase1 | Healthy Volunteers | Completed | 2021-07-26 | 2023-06-20 | ClinicalTrials.gov |
| NCT06062602 | PBI-MST-01(NCT04541108) Substudy TAK-02: Intratumoral Microdosing of TAK-676 in… | Early_Phase1 | Head and Neck Squamous Cell Carcinoma | Completed | 2021-07-26 | 2022-11-15 | ClinicalTrials.gov |
| NCT06062602 | PBI-MST-01(NCT04541108) Substudy TAK-02: Intratumoral Microdosing of TAK-676 in… | Early_Phase1 | Head and Neck Squamous Cell Carcinoma | Completed | 2021-07-26 | 2022-11-15 | ClinicalTrials.gov |
| NCT04759833 | A Study of Prucalopride For Functional Constipation in Children and Teenagers | Phase3 | Constipation | Terminated | 2021-07-13 | 2023-11-13 | ClinicalTrials.gov |
| NCT04759833 | A Study of Prucalopride For Functional Constipation in Children and Teenagers | Phase3 | Constipation | Terminated | 2021-07-13 | 2023-11-13 | ClinicalTrials.gov |
| NCT04759833 | A Study of Prucalopride For Functional Constipation in Children and Teenagers | Phase3 | Constipation | Terminated | 2021-07-13 | 2023-11-13 | ClinicalTrials.gov |
| NCT04876690 | A Study of the Quality of Life in Adults With Crohn's Disease With Complex Peri… | — | Crohn Disease | Completed | 2021-07-09 | 2022-05-27 | ClinicalTrials.gov |
| NCT04876690 | A Study of the Quality of Life in Adults With Crohn's Disease With Complex Peri… | — | Crohn Disease | Completed | 2021-07-09 | 2022-05-27 | ClinicalTrials.gov |
| NCT04876690 | A Study of the Quality of Life in Adults With Crohn's Disease With Complex Peri… | — | Crohn Disease | Completed | 2021-07-09 | 2022-05-27 | ClinicalTrials.gov |
| NCT04734665 | Niraparib and Bevacizumab Maintenance Therapy in Platinum-sensitive Recurrent O… | Phase2 | Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor | Unknown | 2021-07-05 | 2024-03-31 | ClinicalTrials.gov |
| NCT04734665 | Niraparib and Bevacizumab Maintenance Therapy in Platinum-sensitive Recurrent O… | Phase2 | Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor | Unknown | 2021-07-05 | 2024-03-31 | ClinicalTrials.gov |
| NCT04734665 | Niraparib and Bevacizumab Maintenance Therapy in Platinum-sensitive Recurrent O… | Phase2 | Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor | Unknown | 2021-07-05 | 2024-03-31 | ClinicalTrials.gov |
| NCT04943991 | Fabry Disease in High-risk Patients With Left Ventricular Hypertrophy: Prevalen… | Na | Fabry Disease | Active_Not_Recruiting | 2021-07-01 | 2024-10-01 | ClinicalTrials.gov |
| NCT04943991 | Fabry Disease in High-risk Patients With Left Ventricular Hypertrophy: Prevalen… | Na | Fabry Disease | Active_Not_Recruiting | 2021-07-01 | 2024-10-01 | ClinicalTrials.gov |
| NCT04943991 | Fabry Disease in High-risk Patients With Left Ventricular Hypertrophy: Prevalen… | Na | Fabry Disease | Active_Not_Recruiting | 2021-07-01 | 2024-10-01 | ClinicalTrials.gov |
| NCT04941898 | A Study of TAK-660 in Surgical Procedures for People With Hemophilia A. | — | Hemophilia A | Completed | 2021-06-30 | 2024-03-15 | ClinicalTrials.gov |
| NCT04941898 | A Study of TAK-660 in Surgical Procedures for People With Hemophilia A. | — | Hemophilia A | Completed | 2021-06-30 | 2024-03-15 | ClinicalTrials.gov |
| NCT04701411 | A Study of Darvadstrocel for Treating Complex Perianal Fistulas in Children and… | Phase3 | Crohn's Disease | Terminated | 2021-06-30 | 2025-05-07 | ClinicalTrials.gov |
| NCT04701411 | A Study of Darvadstrocel for Treating Complex Perianal Fistulas in Children and… | Phase3 | Crohn's Disease | Terminated | 2021-06-30 | 2025-05-07 | ClinicalTrials.gov |
| NCT04701411 | A Study of Darvadstrocel for Treating Complex Perianal Fistulas in Children and… | Phase3 | Crohn's Disease | Terminated | 2021-06-30 | 2025-05-07 | ClinicalTrials.gov |
| NCT04941898 | A Study of TAK-660 in Surgical Procedures for People With Hemophilia A. | — | Hemophilia A | Completed | 2021-06-30 | 2024-03-15 | ClinicalTrials.gov |
| NCT04809363 | A Study of CDPATH™ to Help Manage and Treat Crohn's Disease | Phase4 | Crohn's Disease | Active_Not_Recruiting | 2021-06-25 | 2026-09-12 | ClinicalTrials.gov |
| NCT04809363 | A Study of CDPATH™ to Help Manage and Treat Crohn's Disease | Phase4 | Crohn's Disease | Active_Not_Recruiting | 2021-06-25 | 2026-09-12 | ClinicalTrials.gov |
| NCT04809363 | A Study of CDPATH™ to Help Manage and Treat Crohn's Disease | Phase4 | Crohn's Disease | Active_Not_Recruiting | 2021-06-25 | 2026-09-12 | ClinicalTrials.gov |
| NCT04837222 | A Study of Brentuximab Vedotin in Adults With CD30-positive Lymphoma | — | Lymphoma | Completed | 2021-06-07 | 2026-06-26 | ClinicalTrials.gov |
| NCT04837222 | A Study of Brentuximab Vedotin in Adults With CD30-positive Lymphoma | — | Lymphoma | Completed | 2021-06-07 | 2026-06-26 | ClinicalTrials.gov |
| NCT04837222 | A Study of Brentuximab Vedotin in Adults With CD30-positive Lymphoma | — | Lymphoma | Completed | 2021-06-07 | 2026-06-26 | ClinicalTrials.gov |
| NCT04738942 | A Study of Intravenous Vedolizumab Administered Every 4 Weeks in Japanese Parti… | Phase3 | Ulcerative Colitis | Active_Not_Recruiting | 2021-06-04 | 2027-11-30 | ClinicalTrials.gov |
| NCT04738942 | A Study of Intravenous Vedolizumab Administered Every 4 Weeks in Japanese Parti… | Phase3 | Ulcerative Colitis | Active_Not_Recruiting | 2021-06-04 | 2027-11-30 | ClinicalTrials.gov |
| NCT04738942 | A Study of Intravenous Vedolizumab Administered Every 4 Weeks in Japanese Parti… | Phase3 | Ulcerative Colitis | Active_Not_Recruiting | 2021-06-04 | 2027-11-30 | ClinicalTrials.gov |
| NCT04776265 | RWE of Brentuximab Vedotin Consolidation in Patients With RR HL Who Receive Sal… | — | Hodgkin Lymphoma, Adult | Unknown | 2021-06-01 | 2024-04-01 | ClinicalTrials.gov |
| NCT04776265 | RWE of Brentuximab Vedotin Consolidation in Patients With RR HL Who Receive Sal… | — | Hodgkin Lymphoma, Adult | Unknown | 2021-06-01 | 2024-04-01 | ClinicalTrials.gov |
| NCT04776265 | RWE of Brentuximab Vedotin Consolidation in Patients With RR HL Who Receive Sal… | — | Hodgkin Lymphoma, Adult | Unknown | 2021-06-01 | 2024-04-01 | ClinicalTrials.gov |
| NCT05596422 | A Study of Vedolizumab and Biologic Agents in Participants With Inflammatory Bo… | — | Inflammatory Bowel Disease (IBD) | Completed | 2021-05-27 | 2022-12-08 | ClinicalTrials.gov |
| NCT05596422 | A Study of Vedolizumab and Biologic Agents in Participants With Inflammatory Bo… | — | Inflammatory Bowel Disease (IBD) | Completed | 2021-05-27 | 2022-12-08 | ClinicalTrials.gov |
| NCT05596422 | A Study of Vedolizumab and Biologic Agents in Participants With Inflammatory Bo… | — | Inflammatory Bowel Disease (IBD) | Completed | 2021-05-27 | 2022-12-08 | ClinicalTrials.gov |
| NCT04869280 | Post-Marketing Study of Prucalopride Safety In Pregnancy | — | Chronic Idiopathic Constipation (CIC) | Active_Not_Recruiting | 2021-05-21 | 2027-02-01 | ClinicalTrials.gov |
| NCT04869280 | Post-Marketing Study of Prucalopride Safety In Pregnancy | — | Chronic Idiopathic Constipation (CIC) | Active_Not_Recruiting | 2021-05-21 | 2027-02-01 | ClinicalTrials.gov |
| NCT04869280 | Post-Marketing Study of Prucalopride Safety In Pregnancy | — | Chronic Idiopathic Constipation (CIC) | Active_Not_Recruiting | 2021-05-21 | 2027-02-01 | ClinicalTrials.gov |
| NCT04832087 | Pediatric Teduglutide Registry | — | Short Bowel Syndrome | Completed | 2021-05-18 | 2023-08-31 | ClinicalTrials.gov |
| NCT04832087 | Pediatric Teduglutide Registry | — | Short Bowel Syndrome | Completed | 2021-05-18 | 2023-08-31 | ClinicalTrials.gov |
| NCT04832087 | Pediatric Teduglutide Registry | — | Short Bowel Syndrome | Completed | 2021-05-18 | 2023-08-31 | ClinicalTrials.gov |
| NCT04668157 | A Study of TAK-536 in Children From 2 to Less Than 6 Years Old With High Blood … | Phase3 | Hypertension | Completed | 2021-05-17 | 2023-12-28 | ClinicalTrials.gov |
| NCT04668157 | A Study of TAK-536 in Children From 2 to Less Than 6 Years Old With High Blood … | Phase3 | Hypertension | Completed | 2021-05-17 | 2023-12-28 | ClinicalTrials.gov |
| NCT04668157 | A Study of TAK-536 in Children From 2 to Less Than 6 Years Old With High Blood … | Phase3 | Hypertension | Completed | 2021-05-17 | 2023-12-28 | ClinicalTrials.gov |
| NCT04313244 | Immunogenicity and Safety of Dengue Tetravalent Vaccine (TDV) and Recombinant 9… | Phase3 | Dengue Fever | Completed | 2021-05-15 | 2022-07-19 | ClinicalTrials.gov |
| NCT04313244 | Immunogenicity and Safety of Dengue Tetravalent Vaccine (TDV) and Recombinant 9… | Phase3 | Dengue Fever | Completed | 2021-05-15 | 2022-07-19 | ClinicalTrials.gov |
| NCT04313244 | Immunogenicity and Safety of Dengue Tetravalent Vaccine (TDV) and Recombinant 9… | Phase3 | Dengue Fever | Completed | 2021-05-15 | 2022-07-19 | ClinicalTrials.gov |
| NCT04820842 | A Study of TAK-994 in Adults With Narcolepsy | Phase2 | Narcolepsy Type 1 (NT 1) | Terminated | 2021-04-30 | 2021-11-03 | ClinicalTrials.gov |
| NCT04820842 | A Study of TAK-994 in Adults With Narcolepsy | Phase2 | Narcolepsy Type 1 (NT 1) | Terminated | 2021-04-30 | 2021-11-03 | ClinicalTrials.gov |
| NCT04820842 | A Study of TAK-994 in Adults With Narcolepsy | Phase2 | Narcolepsy Type 1 (NT 1) | Terminated | 2021-04-30 | 2021-11-03 | ClinicalTrials.gov |
| NCT04842643 | An Extension Study of TAK-664 for Japanese People With Primary Immunodeficiency… | Phase3 | Primary Immunodeficiency Disease | Completed | 2021-04-27 | 2024-04-25 | ClinicalTrials.gov |
| NCT04842643 | An Extension Study of TAK-664 for Japanese People With Primary Immunodeficiency… | Phase3 | Primary Immunodeficiency Disease | Completed | 2021-04-27 | 2024-04-25 | ClinicalTrials.gov |
| NCT04842643 | An Extension Study of TAK-664 for Japanese People With Primary Immunodeficiency… | Phase3 | Primary Immunodeficiency Disease | Completed | 2021-04-27 | 2024-04-25 | ClinicalTrials.gov |
| NCT04718779 | A Study of Enzyme Replacement Therapy (VPRIV) in People With Type 1 Gaucher Dis… | Phase4 | Gaucher Disease | Completed | 2021-04-22 | 2023-02-16 | ClinicalTrials.gov |
| NCT04718779 | A Study of Enzyme Replacement Therapy (VPRIV) in People With Type 1 Gaucher Dis… | Phase4 | Gaucher Disease | Completed | 2021-04-22 | 2023-02-16 | ClinicalTrials.gov |
| NCT04718779 | A Study of Enzyme Replacement Therapy (VPRIV) in People With Type 1 Gaucher Dis… | Phase4 | Gaucher Disease | Completed | 2021-04-22 | 2023-02-16 | ClinicalTrials.gov |
| NCT04776018 | A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relap… | Phase1 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | Terminated | 2021-04-20 | 2023-11-09 | ClinicalTrials.gov |
| NCT04776018 | A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relap… | Phase1 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | Terminated | 2021-04-20 | 2023-11-09 | ClinicalTrials.gov |
| NCT04776018 | A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relap… | Phase1 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | Terminated | 2021-04-20 | 2023-11-09 | ClinicalTrials.gov |
| NCT04833049 | Study to Evaluate Absorption, Metabolism, and Excretion, of TAK-994 in 6 Health… | Phase1 | Healthy Volunteers | Completed | 2021-04-14 | 2021-06-20 | ClinicalTrials.gov |
| NCT04683003 | A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic … | Phase3 | Thrombotic Thrombocytopenic Purpura (TTP) | Active_Not_Recruiting | 2021-04-14 | 2027-03-16 | ClinicalTrials.gov |
| NCT04683003 | A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic … | Phase3 | Thrombotic Thrombocytopenic Purpura (TTP) | Active_Not_Recruiting | 2021-04-14 | 2027-03-16 | ClinicalTrials.gov |
| NCT04833049 | Study to Evaluate Absorption, Metabolism, and Excretion, of TAK-994 in 6 Health… | Phase1 | Healthy Volunteers | Completed | 2021-04-14 | 2021-06-20 | ClinicalTrials.gov |
| NCT04833049 | Study to Evaluate Absorption, Metabolism, and Excretion, of TAK-994 in 6 Health… | Phase1 | Healthy Volunteers | Completed | 2021-04-14 | 2021-06-20 | ClinicalTrials.gov |
| NCT04683003 | A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic … | Phase3 | Thrombotic Thrombocytopenic Purpura (TTP) | Active_Not_Recruiting | 2021-04-14 | 2027-03-16 | ClinicalTrials.gov |
| NCT04580407 | Study of TAK-672 in Participants With Acquired Hemophilia A | Phase2 | Acquired Hemophilia A | Completed | 2021-04-09 | 2022-11-29 | ClinicalTrials.gov |
| NCT04580407 | Study of TAK-672 in Participants With Acquired Hemophilia A | Phase2 | Acquired Hemophilia A | Completed | 2021-04-09 | 2022-11-29 | ClinicalTrials.gov |
| NCT04580407 | Study of TAK-672 in Participants With Acquired Hemophilia A | Phase2 | Acquired Hemophilia A | Completed | 2021-04-09 | 2022-11-29 | ClinicalTrials.gov |
| NCT04753437 | A Study of Vonoprazan in Adults With Helicobacter Pylori | Phase1 | Helicobacter Pylori | Completed | 2021-04-06 | 2021-11-05 | ClinicalTrials.gov |
| NCT04753437 | A Study of Vonoprazan in Adults With Helicobacter Pylori | Phase1 | Helicobacter Pylori | Completed | 2021-04-06 | 2021-11-05 | ClinicalTrials.gov |
| NCT04753437 | A Study of Vonoprazan in Adults With Helicobacter Pylori | Phase1 | Helicobacter Pylori | Completed | 2021-04-06 | 2021-11-05 | ClinicalTrials.gov |
| NCT04831502 | Bioavailability and Food Effect Study of Two Formulations of TAK-906 | Phase1 | Healthy Volunteers | Withdrawn | 2021-04-02 | 2022-02-02 | ClinicalTrials.gov |
| NCT04831502 | Bioavailability and Food Effect Study of Two Formulations of TAK-906 | Phase1 | Healthy Volunteers | Withdrawn | 2021-04-02 | 2022-02-02 | ClinicalTrials.gov |
| NCT04831502 | Bioavailability and Food Effect Study of Two Formulations of TAK-906 | Phase1 | Healthy Volunteers | Withdrawn | 2021-04-02 | 2022-02-02 | ClinicalTrials.gov |
| NCT04804813 | Survey of Cabozantinib Used To Treat People With Renal Cell Carcinoma | — | Renal Cell Carcinoma | Completed | 2021-03-29 | 2024-07-25 | ClinicalTrials.gov |
| NCT04804813 | Survey of Cabozantinib Used To Treat People With Renal Cell Carcinoma | — | Renal Cell Carcinoma | Completed | 2021-03-29 | 2024-07-25 | ClinicalTrials.gov |
| NCT04804813 | Survey of Cabozantinib Used To Treat People With Renal Cell Carcinoma | — | Renal Cell Carcinoma | Completed | 2021-03-29 | 2024-07-25 | ClinicalTrials.gov |
| NCT04840680 | A Study of Real-World Use of Ixazomib Citrate in People With Multiple Myeloma (… | — | Multiple Myeloma | Completed | 2021-03-22 | 2023-08-28 | ClinicalTrials.gov |
| NCT04840680 | A Study of Real-World Use of Ixazomib Citrate in People With Multiple Myeloma (… | — | Multiple Myeloma | Completed | 2021-03-22 | 2023-08-28 | ClinicalTrials.gov |
| NCT04840680 | A Study of Real-World Use of Ixazomib Citrate in People With Multiple Myeloma (… | — | Multiple Myeloma | Completed | 2021-03-22 | 2023-08-28 | ClinicalTrials.gov |
| NCT05001087 | A "Physician & Patient-powered" Cohort Registry (MY MYELOMA) | — | Multiple Myeloma | Recruiting | 2021-03-16 | 2027-03-31 | ClinicalTrials.gov |
| NCT05001087 | A "Physician & Patient-powered" Cohort Registry (MY MYELOMA) | — | Multiple Myeloma | Recruiting | 2021-03-16 | 2027-03-31 | ClinicalTrials.gov |
| NCT05001087 | A "Physician & Patient-powered" Cohort Registry (MY MYELOMA) | — | Multiple Myeloma | Recruiting | 2021-03-16 | 2027-03-31 | ClinicalTrials.gov |
| NCT04440488 | ARALAST NP Alpha-1 Lung Density Chronic Obstructive Pulmonary Disease-Emphysema… | Phase4 | Chronic Obstructive Pulmonary Disease | Withdrawn | 2021-03-08 | 2025-09-12 | ClinicalTrials.gov |
| NCT04440488 | ARALAST NP Alpha-1 Lung Density Chronic Obstructive Pulmonary Disease-Emphysema… | Phase4 | Chronic Obstructive Pulmonary Disease | Withdrawn | 2021-03-08 | 2025-09-12 | ClinicalTrials.gov |
| NCT04440488 | ARALAST NP Alpha-1 Lung Density Chronic Obstructive Pulmonary Disease-Emphysema… | Phase4 | Chronic Obstructive Pulmonary Disease | Withdrawn | 2021-03-08 | 2025-09-12 | ClinicalTrials.gov |
| NCT04844073 | A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastati… | Phase1 | Squamous Cell Cancer of Head and Neck (SCCHN) | Terminated | 2021-03-08 | 2025-06-17 | ClinicalTrials.gov |
| NCT04844073 | A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastati… | Phase1 | Squamous Cell Cancer of Head and Neck (SCCHN) | Terminated | 2021-03-08 | 2025-06-17 | ClinicalTrials.gov |
| NCT04844073 | A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastati… | Phase1 | Squamous Cell Cancer of Head and Neck (SCCHN) | Terminated | 2021-03-08 | 2025-06-17 | ClinicalTrials.gov |
| NCT04489160 | Complement Inhibition: Attacking the Overshooting Inflammation @Fter Traumatic … | Phase2 | Traumatic Brain Injury | Unknown | 2021-02-25 | 2024-07-01 | ClinicalTrials.gov |
| NCT04489160 | Complement Inhibition: Attacking the Overshooting Inflammation @Fter Traumatic … | Phase2 | Traumatic Brain Injury | Unknown | 2021-02-25 | 2024-07-01 | ClinicalTrials.gov |
| NCT04489160 | Complement Inhibition: Attacking the Overshooting Inflammation @Fter Traumatic … | Phase2 | Traumatic Brain Injury | Unknown | 2021-02-25 | 2024-07-01 | ClinicalTrials.gov |
| NCT04501614 | A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With … | Phase1 | Pediatric Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL) | Terminated | 2021-02-24 | 2024-07-19 | ClinicalTrials.gov |
| NCT04501614 | A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With … | Phase1 | Pediatric Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL) | Terminated | 2021-02-24 | 2024-07-19 | ClinicalTrials.gov |
| NCT04501614 | A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With … | Phase1 | Pediatric Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL) | Terminated | 2021-02-24 | 2024-07-19 | ClinicalTrials.gov |
| NCT04891224 | Use of a Digitally Enabled App With Clinical Team Interface in the Management o… | Na | Major Depressive Disorder | Completed | 2021-02-19 | 2023-01-30 | ClinicalTrials.gov |
| NCT04891224 | Use of a Digitally Enabled App With Clinical Team Interface in the Management o… | Na | Major Depressive Disorder | Completed | 2021-02-19 | 2023-01-30 | ClinicalTrials.gov |
| NCT04891224 | Use of a Digitally Enabled App With Clinical Team Interface in the Management o… | Na | Major Depressive Disorder | Completed | 2021-02-19 | 2023-01-30 | ClinicalTrials.gov |
| NCT04667338 | A Study to Collect Information of People With Narcolepsy in Spain | — | Narcolepsy | Completed | 2021-02-18 | 2022-11-04 | ClinicalTrials.gov |
| NCT04667338 | A Study to Collect Information of People With Narcolepsy in Spain | — | Narcolepsy | Completed | 2021-02-18 | 2022-11-04 | ClinicalTrials.gov |
| NCT04667338 | A Study to Collect Information of People With Narcolepsy in Spain | — | Narcolepsy | Completed | 2021-02-18 | 2022-11-04 | ClinicalTrials.gov |
| NCT04745767 | A Study of Different Forms of TAK-994 in Healthy Adults | Phase1 | Healthy Participants | Completed | 2021-02-16 | 2021-04-05 | ClinicalTrials.gov |
| NCT04745767 | A Study of Different Forms of TAK-994 in Healthy Adults | Phase1 | Healthy Participants | Completed | 2021-02-16 | 2021-04-05 | ClinicalTrials.gov |
| NCT04745767 | A Study of Different Forms of TAK-994 in Healthy Adults | Phase1 | Healthy Participants | Completed | 2021-02-16 | 2021-04-05 | ClinicalTrials.gov |
| NCT04712110 | A Study of TAK-019 in Healthy Japanese Adults (COVID-19) | Phase1 | Prevention of Infection Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) | Completed | 2021-02-12 | 2022-03-28 | ClinicalTrials.gov |
| NCT04712110 | A Study of TAK-019 in Healthy Japanese Adults (COVID-19) | Phase1 | Prevention of Infection Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) | Completed | 2021-02-12 | 2022-03-28 | ClinicalTrials.gov |
| NCT04712110 | A Study of TAK-019 in Healthy Japanese Adults (COVID-19) | Phase1 | Prevention of Infection Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) | Completed | 2021-02-12 | 2022-03-28 | ClinicalTrials.gov |
| NCT04687137 | Expanded Access Program With Lanadelumab for Japanese People With Hereditary An… | Phase3 | Hereditary Angioedema | Completed | 2021-02-10 | 2022-06-18 | ClinicalTrials.gov |
| NCT04687137 | Expanded Access Program With Lanadelumab for Japanese People With Hereditary An… | Phase3 | Hereditary Angioedema | Completed | 2021-02-10 | 2022-06-18 | ClinicalTrials.gov |
| NCT04687137 | Expanded Access Program With Lanadelumab for Japanese People With Hereditary An… | Phase3 | Hereditary Angioedema | Completed | 2021-02-10 | 2022-06-18 | ClinicalTrials.gov |
| NCT04636502 | Retrospective, Observational Chart Review Study Conducted in Poland to Document… | — | Primary Immunodeficiencies (PID) | Completed | 2021-02-08 | 2021-09-14 | ClinicalTrials.gov |
| NCT04636502 | Retrospective, Observational Chart Review Study Conducted in Poland to Document… | — | Primary Immunodeficiencies (PID) | Completed | 2021-02-08 | 2021-09-14 | ClinicalTrials.gov |
| NCT04636502 | Retrospective, Observational Chart Review Study Conducted in Poland to Document… | — | Primary Immunodeficiencies (PID) | Completed | 2021-02-08 | 2021-09-14 | ClinicalTrials.gov |
| NCT04444895 | A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute… | Phase3 | Angioedema | Completed | 2021-02-05 | 2023-05-05 | ClinicalTrials.gov |
| NCT04444895 | A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute… | Phase3 | Angioedema | Completed | 2021-02-05 | 2023-05-05 | ClinicalTrials.gov |
| NCT04444895 | A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute… | Phase3 | Angioedema | Completed | 2021-02-05 | 2023-05-05 | ClinicalTrials.gov |
| NCT04731922 | A Study of TAK-510 in Healthy Adults | Phase1 | Healthy Participants | Completed | 2021-02-03 | 2022-07-24 | ClinicalTrials.gov |
| NCT04731922 | A Study of TAK-510 in Healthy Adults | Phase1 | Healthy Participants | Completed | 2021-02-03 | 2022-07-24 | ClinicalTrials.gov |
| NCT04731922 | A Study of TAK-510 in Healthy Adults | Phase1 | Healthy Participants | Completed | 2021-02-03 | 2022-07-24 | ClinicalTrials.gov |
| NCT04102163 | Health-Related Quality of Life in Crohn's Disease Participants With Complex Per… | — | Crohn Disease | Terminated | 2021-01-26 | 2021-05-26 | ClinicalTrials.gov |
| NCT04102163 | Health-Related Quality of Life in Crohn's Disease Participants With Complex Per… | — | Crohn Disease | Terminated | 2021-01-26 | 2021-05-26 | ClinicalTrials.gov |
| NCT04102163 | Health-Related Quality of Life in Crohn's Disease Participants With Complex Per… | — | Crohn Disease | Terminated | 2021-01-26 | 2021-05-26 | ClinicalTrials.gov |
| NCT04659798 | A Study to Investigate the Relationship Between Duration of Treatment and Respo… | — | Multiple Myeloma | Completed | 2021-01-22 | 2023-09-05 | ClinicalTrials.gov |
| NCT04659798 | A Study to Investigate the Relationship Between Duration of Treatment and Respo… | — | Multiple Myeloma | Completed | 2021-01-22 | 2023-09-05 | ClinicalTrials.gov |
| NCT04659798 | A Study to Investigate the Relationship Between Duration of Treatment and Respo… | — | Multiple Myeloma | Completed | 2021-01-22 | 2023-09-05 | ClinicalTrials.gov |
| NCT04727476 | The Use of Lisdexamfetamine for Children Aged 7-13 With Attention Deficit Disor… | — | Attention Deficit Disorder | Unknown | 2021-01-19 | 2022-05-01 | ClinicalTrials.gov |
| NCT04727476 | The Use of Lisdexamfetamine for Children Aged 7-13 With Attention Deficit Disor… | — | Attention Deficit Disorder | Unknown | 2021-01-19 | 2022-05-01 | ClinicalTrials.gov |
| NCT04727476 | The Use of Lisdexamfetamine for Children Aged 7-13 With Attention Deficit Disor… | — | Attention Deficit Disorder | Unknown | 2021-01-19 | 2022-05-01 | ClinicalTrials.gov |
| NCT04654351 | A Study of Icatibant (TAK-667) in Japanese Children and Teenagers With Acute At… | Phase3 | Hereditary Angioedema | Completed | 2021-01-15 | 2021-07-27 | ClinicalTrials.gov |
| NCT04654351 | A Study of Icatibant (TAK-667) in Japanese Children and Teenagers With Acute At… | Phase3 | Hereditary Angioedema | Completed | 2021-01-15 | 2021-07-27 | ClinicalTrials.gov |
| NCT04654351 | A Study of Icatibant (TAK-667) in Japanese Children and Teenagers With Acute At… | Phase3 | Hereditary Angioedema | Completed | 2021-01-15 | 2021-07-27 | ClinicalTrials.gov |
| NCT04465396 | A Study to Evaluate the Bioavailability of Teduglutide Administered Subcutaneou… | Phase1 | Healthy Volunteers | Completed | 2021-01-13 | 2021-08-20 | ClinicalTrials.gov |
| NCT04465396 | A Study to Evaluate the Bioavailability of Teduglutide Administered Subcutaneou… | Phase1 | Healthy Volunteers | Completed | 2021-01-13 | 2021-08-20 | ClinicalTrials.gov |
| NCT04465396 | A Study to Evaluate the Bioavailability of Teduglutide Administered Subcutaneou… | Phase1 | Healthy Volunteers | Completed | 2021-01-13 | 2021-08-20 | ClinicalTrials.gov |
| NCT04721366 | A Study of Velaglucerase Alfa (VPRIV) Given as Standard Patient Care in Young C… | — | Gaucher Disease | Completed | 2021-01-08 | 2023-04-17 | ClinicalTrials.gov |
| NCT04721366 | A Study of Velaglucerase Alfa (VPRIV) Given as Standard Patient Care in Young C… | — | Gaucher Disease | Completed | 2021-01-08 | 2023-04-17 | ClinicalTrials.gov |
| NCT04721366 | A Study of Velaglucerase Alfa (VPRIV) Given as Standard Patient Care in Young C… | — | Gaucher Disease | Completed | 2021-01-08 | 2023-04-17 | ClinicalTrials.gov |
| NCT04677660 | A Study of TAK-919 in Healthy Japanese Adults (COVID-19) | Phase1 | Coronavirus Disease (COVID-19) | Completed | 2021-01-07 | 2022-02-22 | ClinicalTrials.gov |
| NCT04677660 | A Study of TAK-919 in Healthy Japanese Adults (COVID-19) | Phase1 | Coronavirus Disease (COVID-19) | Completed | 2021-01-07 | 2022-02-22 | ClinicalTrials.gov |
| NCT04677660 | A Study of TAK-919 in Healthy Japanese Adults (COVID-19) | Phase1 | Coronavirus Disease (COVID-19) | Completed | 2021-01-07 | 2022-02-22 | ClinicalTrials.gov |
| NCT04712942 | Treatment of MDS/AML Patients With an Impending Hematological Relapse With AZA … | Phase2 | Acute Myeloid Leukemia in Remission | Completed | 2021-01-01 | 2023-01-31 | ClinicalTrials.gov |
| NCT04675086 | Aralast NP With Antiviral Treatment and Standard of Care Versus Antiviral Treat… | Phase3 | Covid19 | Withdrawn | 2021-01-01 | 2021-12-01 | ClinicalTrials.gov |
| NCT04675086 | Aralast NP With Antiviral Treatment and Standard of Care Versus Antiviral Treat… | Phase3 | Covid19 | Withdrawn | 2021-01-01 | 2021-12-01 | ClinicalTrials.gov |
| NCT04712942 | Treatment of MDS/AML Patients With an Impending Hematological Relapse With AZA … | Phase2 | Acute Myeloid Leukemia in Remission | Completed | 2021-01-01 | 2023-01-31 | ClinicalTrials.gov |
| NCT04712942 | Treatment of MDS/AML Patients With an Impending Hematological Relapse With AZA … | Phase2 | Acute Myeloid Leukemia in Remission | Completed | 2021-01-01 | 2023-01-31 | ClinicalTrials.gov |
| NCT04675086 | Aralast NP With Antiviral Treatment and Standard of Care Versus Antiviral Treat… | Phase3 | Covid19 | Withdrawn | 2021-01-01 | 2021-12-01 | ClinicalTrials.gov |
| NCT04887519 | A Study of Brigatinib to Treat Adults With Anaplastic Lymphoma Kinase (ALK) Pos… | — | Carcinoma, Non-Small-Cell Lung | Completed | 2020-12-30 | 2023-03-31 | ClinicalTrials.gov |
| NCT04887519 | A Study of Brigatinib to Treat Adults With Anaplastic Lymphoma Kinase (ALK) Pos… | — | Carcinoma, Non-Small-Cell Lung | Completed | 2020-12-30 | 2023-03-31 | ClinicalTrials.gov |
| NCT04887519 | A Study of Brigatinib to Treat Adults With Anaplastic Lymphoma Kinase (ALK) Pos… | — | Carcinoma, Non-Small-Cell Lung | Completed | 2020-12-30 | 2023-03-31 | ClinicalTrials.gov |
| NCT04536298 | Vitamin D for COVID-19 Trial | Phase3 | COVID-19 | Completed | 2020-12-28 | 2024-07-01 | ClinicalTrials.gov |
| NCT04536298 | Vitamin D for COVID-19 Trial | Phase3 | COVID-19 | Completed | 2020-12-28 | 2024-07-01 | ClinicalTrials.gov |
| NCT04536298 | Vitamin D for COVID-19 Trial | Phase3 | COVID-19 | Completed | 2020-12-28 | 2024-07-01 | ClinicalTrials.gov |
| NCT04501627 | A Study on Vonoprazan in the Real-world Clinical Practice in China | — | Esophagitis Peptic | Completed | 2020-12-24 | 2023-06-27 | ClinicalTrials.gov |
| NCT04501627 | A Study on Vonoprazan in the Real-world Clinical Practice in China | — | Esophagitis Peptic | Completed | 2020-12-24 | 2023-06-27 | ClinicalTrials.gov |
| NCT04501627 | A Study on Vonoprazan in the Real-world Clinical Practice in China | — | Esophagitis Peptic | Completed | 2020-12-24 | 2023-06-27 | ClinicalTrials.gov |
| NCT04118088 | A Study of Darvadstrocel in Adults With Crohn's Disease and Complex Perianal Fi… | Phase4 | Crohn's Disease | Terminated | 2020-12-22 | 2025-02-14 | ClinicalTrials.gov |
| NCT04118088 | A Study of Darvadstrocel in Adults With Crohn's Disease and Complex Perianal Fi… | Phase4 | Crohn's Disease | Terminated | 2020-12-22 | 2025-02-14 | ClinicalTrials.gov |
| NCT04118088 | A Study of Darvadstrocel in Adults With Crohn's Disease and Complex Perianal Fi… | Phase4 | Crohn's Disease | Terminated | 2020-12-22 | 2025-02-14 | ClinicalTrials.gov |
| NCT04576208 | A Study to Evaluate the Impact of Management Strategies on Gastrointestinal-Rel… | Phase2 | Non-Small Cell Lung Cancer (NSCLC) | Withdrawn | 2020-11-30 | 2022-07-31 | ClinicalTrials.gov |
| NCT04576208 | A Study to Evaluate the Impact of Management Strategies on Gastrointestinal-Rel… | Phase2 | Non-Small Cell Lung Cancer (NSCLC) | Withdrawn | 2020-11-30 | 2022-07-31 | ClinicalTrials.gov |
| NCT04576208 | A Study to Evaluate the Impact of Management Strategies on Gastrointestinal-Rel… | Phase2 | Non-Small Cell Lung Cancer (NSCLC) | Withdrawn | 2020-11-30 | 2022-07-31 | ClinicalTrials.gov |
| NCT04830527 | EMA Baseline Screening System for Therapists Who Treat Youths With Depressive S… | Na | Depressive Symptoms | Terminated | 2020-11-24 | 2021-11-30 | ClinicalTrials.gov |
| NCT04830527 | EMA Baseline Screening System for Therapists Who Treat Youths With Depressive S… | Na | Depressive Symptoms | Terminated | 2020-11-24 | 2021-11-30 | ClinicalTrials.gov |
| NCT04830527 | EMA Baseline Screening System for Therapists Who Treat Youths With Depressive S… | Na | Depressive Symptoms | Terminated | 2020-11-24 | 2021-11-30 | ClinicalTrials.gov |
| NCT05260151 | Tau Protein and SV2a Imaging in Patients With Tau Protein-related Diseases | — | Alzheimer Disease | Unknown | 2020-11-18 | 2022-12-31 | ClinicalTrials.gov |
| NCT05260151 | Tau Protein and SV2a Imaging in Patients With Tau Protein-related Diseases | — | Alzheimer Disease | Unknown | 2020-11-18 | 2022-12-31 | ClinicalTrials.gov |
| NCT05260151 | Tau Protein and SV2a Imaging in Patients With Tau Protein-related Diseases | — | Alzheimer Disease | Unknown | 2020-11-18 | 2022-12-31 | ClinicalTrials.gov |
| NCT04278924 | A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune Thrombocyto… | Phase2 | Primary Immune Thrombocytopenia | Completed | 2020-11-09 | 2024-04-29 | ClinicalTrials.gov |
| NCT04278924 | A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune Thrombocyto… | Phase2 | Primary Immune Thrombocytopenia | Completed | 2020-11-09 | 2024-04-29 | ClinicalTrials.gov |
| NCT04278924 | A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune Thrombocyto… | Phase2 | Primary Immune Thrombocytopenia | Completed | 2020-11-09 | 2024-04-29 | ClinicalTrials.gov |
| NCT04877431 | A Study of Teduglutide (Revestive®) in Children, Teenagers and Adults With Shor… | — | Short Bowel Syndrome | Completed | 2020-11-05 | 2023-06-05 | ClinicalTrials.gov |
| NCT04877431 | A Study of Teduglutide (Revestive®) in Children, Teenagers and Adults With Shor… | — | Short Bowel Syndrome | Completed | 2020-11-05 | 2023-06-05 | ClinicalTrials.gov |
| NCT04877431 | A Study of Teduglutide (Revestive®) in Children, Teenagers and Adults With Shor… | — | Short Bowel Syndrome | Completed | 2020-11-05 | 2023-06-05 | ClinicalTrials.gov |
| NCT03880123 | Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma | Phase1 | Liposarcoma | Withdrawn | 2020-11-01 | 2020-11-24 | ClinicalTrials.gov |
| NCT03880123 | Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma | Phase1 | Liposarcoma | Withdrawn | 2020-11-01 | 2020-11-24 | ClinicalTrials.gov |
| NCT03880123 | Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma | Phase1 | Liposarcoma | Withdrawn | 2020-11-01 | 2020-11-24 | ClinicalTrials.gov |
| NCT03888534 | Intravenous Ixazomib in Pediatric Participants With Relapsed or Refractory Acut… | Phase1 | Precursor Cell Lymphoblastic Leukemia-lymphoma | Withdrawn | 2020-10-31 | 2022-08-30 | ClinicalTrials.gov |
| NCT04460105 | Lanadelumab in Participants Hospitalized With COVID-19 Pneumonia | Phase1 | COVID-19 Pneumonia | Withdrawn | 2020-10-31 | 2021-01-27 | ClinicalTrials.gov |
| NCT03888534 | Intravenous Ixazomib in Pediatric Participants With Relapsed or Refractory Acut… | Phase1 | Precursor Cell Lymphoblastic Leukemia-lymphoma | Withdrawn | 2020-10-31 | 2022-08-30 | ClinicalTrials.gov |
| NCT04460105 | Lanadelumab in Participants Hospitalized With COVID-19 Pneumonia | Phase1 | COVID-19 Pneumonia | Withdrawn | 2020-10-31 | 2021-01-27 | ClinicalTrials.gov |
| NCT04460105 | Lanadelumab in Participants Hospitalized With COVID-19 Pneumonia | Phase1 | COVID-19 Pneumonia | Withdrawn | 2020-10-31 | 2021-01-27 | ClinicalTrials.gov |
| NCT03888534 | Intravenous Ixazomib in Pediatric Participants With Relapsed or Refractory Acut… | Phase1 | Precursor Cell Lymphoblastic Leukemia-lymphoma | Withdrawn | 2020-10-31 | 2022-08-30 | ClinicalTrials.gov |
| NCT04422509 | Lanadelumab for Treatment of COVID-19 Disease | Phase1 | COVID-19 | Completed | 2020-10-30 | 2021-04-30 | ClinicalTrials.gov |
| NCT04422509 | Lanadelumab for Treatment of COVID-19 Disease | Phase1 | COVID-19 | Completed | 2020-10-30 | 2021-04-30 | ClinicalTrials.gov |
| NCT04422509 | Lanadelumab for Treatment of COVID-19 Disease | Phase1 | COVID-19 | Completed | 2020-10-30 | 2021-04-30 | ClinicalTrials.gov |
| NCT03802214 | Ulcerative Colitis - Vedolizumab- With/Without Prior Exposure to Anti-TNF（Tumor… | — | Ulcerative Colitis | Terminated | 2020-10-29 | 2020-12-11 | ClinicalTrials.gov |
| NCT03802214 | Ulcerative Colitis - Vedolizumab- With/Without Prior Exposure to Anti-TNF（Tumor… | — | Ulcerative Colitis | Terminated | 2020-10-29 | 2020-12-11 | ClinicalTrials.gov |
| NCT03802214 | Ulcerative Colitis - Vedolizumab- With/Without Prior Exposure to Anti-TNF（Tumor… | — | Ulcerative Colitis | Terminated | 2020-10-29 | 2020-12-11 | ClinicalTrials.gov |
| NCT04334317 | A Study of TAK-071 in People With Parkinson Disease | Phase2 | Parkinson Disease | Completed | 2020-10-21 | 2023-02-27 | ClinicalTrials.gov |
| NCT04334317 | A Study of TAK-071 in People With Parkinson Disease | Phase2 | Parkinson Disease | Completed | 2020-10-21 | 2023-02-27 | ClinicalTrials.gov |
| NCT04597905 | Paricipant Preferences in the Treatment of Inflammatory Bowel Disease (IBD) in … | — | Crohn Disease | Completed | 2020-10-21 | 2021-01-31 | ClinicalTrials.gov |
| NCT04009109 | Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligib… | Phase2 | Myeloma, Multiple | Active_Not_Recruiting | 2020-10-21 | 2027-06-01 | ClinicalTrials.gov |
| NCT04009109 | Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligib… | Phase2 | Myeloma, Multiple | Active_Not_Recruiting | 2020-10-21 | 2027-06-01 | ClinicalTrials.gov |
| NCT04009109 | Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligib… | Phase2 | Myeloma, Multiple | Active_Not_Recruiting | 2020-10-21 | 2027-06-01 | ClinicalTrials.gov |
| NCT04597905 | Paricipant Preferences in the Treatment of Inflammatory Bowel Disease (IBD) in … | — | Crohn Disease | Completed | 2020-10-21 | 2021-01-31 | ClinicalTrials.gov |
| NCT04334317 | A Study of TAK-071 in People With Parkinson Disease | Phase2 | Parkinson Disease | Completed | 2020-10-21 | 2023-02-27 | ClinicalTrials.gov |
| NCT04597905 | Paricipant Preferences in the Treatment of Inflammatory Bowel Disease (IBD) in … | — | Crohn Disease | Completed | 2020-10-21 | 2021-01-31 | ClinicalTrials.gov |
| NCT04557189 | A Study of TAK-951 to Stop Adults Getting Nausea and Vomiting After Planned Sur… | Phase2 | Postoperative Nausea and Vomiting (PONV) | Completed | 2020-10-20 | 2022-03-21 | ClinicalTrials.gov |
| NCT04557189 | A Study of TAK-951 to Stop Adults Getting Nausea and Vomiting After Planned Sur… | Phase2 | Postoperative Nausea and Vomiting (PONV) | Completed | 2020-10-20 | 2022-03-21 | ClinicalTrials.gov |
| NCT04557189 | A Study of TAK-951 to Stop Adults Getting Nausea and Vomiting After Planned Sur… | Phase2 | Postoperative Nausea and Vomiting (PONV) | Completed | 2020-10-20 | 2022-03-21 | ClinicalTrials.gov |
| NCT04446117 | Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Sub… | Phase3 | Metastatic Prostate Cancer | Active_Not_Recruiting | 2020-10-19 | 2026-10-16 | ClinicalTrials.gov |
| NCT04446117 | Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Sub… | Phase3 | Metastatic Prostate Cancer | Active_Not_Recruiting | 2020-10-19 | 2026-10-16 | ClinicalTrials.gov |
| NCT04446117 | Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Sub… | Phase3 | Metastatic Prostate Cancer | Active_Not_Recruiting | 2020-10-19 | 2026-10-16 | ClinicalTrials.gov |
| NCT04266795 | A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute… | Phase2 | Acute Myeloid Leukemia (AML) | Completed | 2020-10-13 | 2025-10-06 | ClinicalTrials.gov |
| NCT04266795 | A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute… | Phase2 | Acute Myeloid Leukemia (AML) | Completed | 2020-10-13 | 2025-10-06 | ClinicalTrials.gov |
| NCT04266795 | A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute… | Phase2 | Acute Myeloid Leukemia (AML) | Completed | 2020-10-13 | 2025-10-06 | ClinicalTrials.gov |
| NCT04056468 | A Study to Evaluate Pharmacokinetics (PK) and Safety of Oral Mobocertinib in Pa… | Phase1 | Hepatic Impairment | Completed | 2020-10-09 | 2022-02-26 | ClinicalTrials.gov |
| NCT04056468 | A Study to Evaluate Pharmacokinetics (PK) and Safety of Oral Mobocertinib in Pa… | Phase1 | Hepatic Impairment | Completed | 2020-10-09 | 2022-02-26 | ClinicalTrials.gov |
| NCT04056468 | A Study to Evaluate Pharmacokinetics (PK) and Safety of Oral Mobocertinib in Pa… | Phase1 | Hepatic Impairment | Completed | 2020-10-09 | 2022-02-26 | ClinicalTrials.gov |
| NCT04065555 | Intratumoral Microdosing of TAK-981 in Head and Neck Cancer | Early_Phase1 | Head and Neck Cancer | Completed | 2020-10-07 | 2022-07-20 | ClinicalTrials.gov |
| NCT04065555 | Intratumoral Microdosing of TAK-981 in Head and Neck Cancer | Early_Phase1 | Head and Neck Cancer | Completed | 2020-10-07 | 2022-07-20 | ClinicalTrials.gov |
| NCT04065555 | Intratumoral Microdosing of TAK-981 in Head and Neck Cancer | Early_Phase1 | Head and Neck Cancer | Completed | 2020-10-07 | 2022-07-20 | ClinicalTrials.gov |
| NCT04278885 | Lanadelumab in FXII-associated Cold Autoinflammatory Syndrome (FACAS) | Phase2 | Hereditary Autoinflammatory Disease | Unknown | 2020-10-05 | 2024-12-31 | ClinicalTrials.gov |
| NCT04278885 | Lanadelumab in FXII-associated Cold Autoinflammatory Syndrome (FACAS) | Phase2 | Hereditary Autoinflammatory Disease | Unknown | 2020-10-05 | 2024-12-31 | ClinicalTrials.gov |
| NCT04278885 | Lanadelumab in FXII-associated Cold Autoinflammatory Syndrome (FACAS) | Phase2 | Hereditary Autoinflammatory Disease | Unknown | 2020-10-05 | 2024-12-31 | ClinicalTrials.gov |
| NCT04567628 | Study of Relationship Between Vedolizumab Therapeutic Drug Monitoring, Biomarke… | — | Inflammatory Bowel Diseases | Completed | 2020-10-05 | 2021-09-22 | ClinicalTrials.gov |
| NCT04567628 | Study of Relationship Between Vedolizumab Therapeutic Drug Monitoring, Biomarke… | — | Inflammatory Bowel Diseases | Completed | 2020-10-05 | 2021-09-22 | ClinicalTrials.gov |
| NCT04567628 | Study of Relationship Between Vedolizumab Therapeutic Drug Monitoring, Biomarke… | — | Inflammatory Bowel Diseases | Completed | 2020-10-05 | 2021-09-22 | ClinicalTrials.gov |
| NCT04349449 | ENTYVIO in Bio-naive Patients With Moderate/Severe Crohn's Disease (CD) in Dail… | — | Crohn Disease | Withdrawn | 2020-09-30 | 2022-11-30 | ClinicalTrials.gov |
| NCT04349449 | ENTYVIO in Bio-naive Patients With Moderate/Severe Crohn's Disease (CD) in Dail… | — | Crohn Disease | Withdrawn | 2020-09-30 | 2022-11-30 | ClinicalTrials.gov |
| NCT04349449 | ENTYVIO in Bio-naive Patients With Moderate/Severe Crohn's Disease (CD) in Dail… | — | Crohn Disease | Withdrawn | 2020-09-30 | 2022-11-30 | ClinicalTrials.gov |
| NCT04464460 | A Study to Evaluate the Safety, Pharmacokinetics (PK), and Efficacy of TAK-671 … | Phase1 | Coronavirus Disease | Withdrawn | 2020-09-25 | 2020-10-30 | ClinicalTrials.gov |
| NCT04464460 | A Study to Evaluate the Safety, Pharmacokinetics (PK), and Efficacy of TAK-671 … | Phase1 | Coronavirus Disease | Withdrawn | 2020-09-25 | 2020-10-30 | ClinicalTrials.gov |
| NCT04464460 | A Study to Evaluate the Safety, Pharmacokinetics (PK), and Efficacy of TAK-671 … | Phase1 | Coronavirus Disease | Withdrawn | 2020-09-25 | 2020-10-30 | ClinicalTrials.gov |
| NCT04551079 | A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokin… | Phase1 | Healthy Volunteers | Completed | 2020-09-23 | 2020-12-31 | ClinicalTrials.gov |
| NCT04551079 | A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokin… | Phase1 | Healthy Volunteers | Completed | 2020-09-23 | 2020-12-31 | ClinicalTrials.gov |
| NCT04551079 | A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokin… | Phase1 | Healthy Volunteers | Completed | 2020-09-23 | 2020-12-31 | ClinicalTrials.gov |
| NCT04260009 | Pharmacokinetics, Safety, and Efficacy of Brigatinib Monotherapy in Pediatric a… | Phase1 | Anaplastic Lymphoma Kinase Positive (ALK +) Anaplastic Large Cell Lymphoma | Withdrawn | 2020-09-01 | 2025-09-01 | ClinicalTrials.gov |
| NCT04260009 | Pharmacokinetics, Safety, and Efficacy of Brigatinib Monotherapy in Pediatric a… | Phase1 | Anaplastic Lymphoma Kinase Positive (ALK +) Anaplastic Large Cell Lymphoma | Withdrawn | 2020-09-01 | 2025-09-01 | ClinicalTrials.gov |
| NCT04260009 | Pharmacokinetics, Safety, and Efficacy of Brigatinib Monotherapy in Pediatric a… | Phase1 | Anaplastic Lymphoma Kinase Positive (ALK +) Anaplastic Large Cell Lymphoma | Withdrawn | 2020-09-01 | 2025-09-01 | ClinicalTrials.gov |
| NCT06945146 | Genomics Study in CML Patients With Ponatinib Treatment | — | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Completed | 2020-09-01 | 2024-09-25 | ClinicalTrials.gov |
| NCT04733066 | Quality of Life in Patients With Short Bowel Syndrome Treated Without and With … | — | Short Bowel Syndrome | Unknown | 2020-09-01 | 2022-09-01 | ClinicalTrials.gov |
| NCT04733066 | Quality of Life in Patients With Short Bowel Syndrome Treated Without and With … | — | Short Bowel Syndrome | Unknown | 2020-09-01 | 2022-09-01 | ClinicalTrials.gov |
| NCT06945146 | Genomics Study in CML Patients With Ponatinib Treatment | — | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Completed | 2020-09-01 | 2024-09-25 | ClinicalTrials.gov |
| NCT06945146 | Genomics Study in CML Patients With Ponatinib Treatment | — | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Completed | 2020-09-01 | 2024-09-25 | ClinicalTrials.gov |
| NCT04733066 | Quality of Life in Patients With Short Bowel Syndrome Treated Without and With … | — | Short Bowel Syndrome | Unknown | 2020-09-01 | 2022-09-01 | ClinicalTrials.gov |
| NCT04419649 | A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Interme… | Phase2 | Myelodysplastic Syndromes | Recruiting | 2020-08-19 | 2031-10-30 | ClinicalTrials.gov |
| NCT04419649 | A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Interme… | Phase2 | Myelodysplastic Syndromes | Recruiting | 2020-08-19 | 2031-10-30 | ClinicalTrials.gov |
| NCT04419649 | A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Interme… | Phase2 | Myelodysplastic Syndromes | Recruiting | 2020-08-19 | 2031-10-30 | ClinicalTrials.gov |
| NCT04381650 | A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advance… | Phase1 | Advanced or Metastatic Solid Tumors | Completed | 2020-08-17 | 2024-10-29 | ClinicalTrials.gov |
| NCT04381650 | A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advance… | Phase1 | Advanced or Metastatic Solid Tumors | Completed | 2020-08-17 | 2024-10-29 | ClinicalTrials.gov |
| NCT04381650 | A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advance… | Phase1 | Advanced or Metastatic Solid Tumors | Completed | 2020-08-17 | 2024-10-29 | ClinicalTrials.gov |
| NCT05826756 | Project PEER: Understanding the Lung Cancer Patient ExperiEnce in the Real-Worl… | — | Lung Cancer Patients | Unknown | 2020-08-15 | 2025-12-01 | ClinicalTrials.gov |
| NCT05826756 | Project PEER: Understanding the Lung Cancer Patient ExperiEnce in the Real-Worl… | — | Lung Cancer Patients | Unknown | 2020-08-15 | 2025-12-01 | ClinicalTrials.gov |
| NCT04853160 | Drug Use Study of Febuxostat After Recent Changes in the Prescribing Information | — | Gout | Completed | 2020-08-15 | 2021-01-05 | ClinicalTrials.gov |
| NCT04853160 | Drug Use Study of Febuxostat After Recent Changes in the Prescribing Information | — | Gout | Completed | 2020-08-15 | 2021-01-05 | ClinicalTrials.gov |
| NCT04853160 | Drug Use Study of Febuxostat After Recent Changes in the Prescribing Information | — | Gout | Completed | 2020-08-15 | 2021-01-05 | ClinicalTrials.gov |
| NCT05826756 | Project PEER: Understanding the Lung Cancer Patient ExperiEnce in the Real-Worl… | — | Lung Cancer Patients | Unknown | 2020-08-15 | 2025-12-01 | ClinicalTrials.gov |
| NCT04461483 | A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Asc… | Phase1 | Healthy Volunteer | Completed | 2020-08-13 | 2020-11-14 | ClinicalTrials.gov |
| NCT04461483 | A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Asc… | Phase1 | Healthy Volunteer | Completed | 2020-08-13 | 2020-11-14 | ClinicalTrials.gov |
| NCT04461483 | A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Asc… | Phase1 | Healthy Volunteer | Completed | 2020-08-13 | 2020-11-14 | ClinicalTrials.gov |
| NCT04503603 | A Study to Determine the Safety, Tolerability, and Pharmacokinetics of Lanadelu… | Phase1 | Healthy Volunteers | Completed | 2020-08-10 | 2020-12-23 | ClinicalTrials.gov |
| NCT04503603 | A Study to Determine the Safety, Tolerability, and Pharmacokinetics of Lanadelu… | Phase1 | Healthy Volunteers | Completed | 2020-08-10 | 2020-12-23 | ClinicalTrials.gov |
| NCT04503603 | A Study to Determine the Safety, Tolerability, and Pharmacokinetics of Lanadelu… | Phase1 | Healthy Volunteers | Completed | 2020-08-10 | 2020-12-23 | ClinicalTrials.gov |
| NCT04497883 | A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single … | Phase1 | Healthy Volunteers | Completed | 2020-08-07 | 2020-11-12 | ClinicalTrials.gov |
| NCT04497883 | A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single … | Phase1 | Healthy Volunteers | Completed | 2020-08-07 | 2020-11-12 | ClinicalTrials.gov |
| NCT04497883 | A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single … | Phase1 | Healthy Volunteers | Completed | 2020-08-07 | 2020-11-12 | ClinicalTrials.gov |
| NCT03943446 | A Study of TAK-018 in Preventing the Recurrence of Crohn's Disease After Surgery | Phase2 | Crohn Disease | Terminated | 2020-08-04 | 2022-08-25 | ClinicalTrials.gov |
| NCT04449484 | Multiple Ascending Dose Study of MEDI1341 in Patients With Parkinson's Disease | Phase1 | Parkinson's Disease | Completed | 2020-08-04 | 2022-01-05 | ClinicalTrials.gov |
| NCT03943446 | A Study of TAK-018 in Preventing the Recurrence of Crohn's Disease After Surgery | Phase2 | Crohn Disease | Terminated | 2020-08-04 | 2022-08-25 | ClinicalTrials.gov |
| NCT03720041 | Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With … | Phase3 | Multiple Myeloma | Unknown | 2020-08-04 | 2024-12-01 | ClinicalTrials.gov |
| NCT03720041 | Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With … | Phase3 | Multiple Myeloma | Unknown | 2020-08-04 | 2024-12-01 | ClinicalTrials.gov |
| NCT03943446 | A Study of TAK-018 in Preventing the Recurrence of Crohn's Disease After Surgery | Phase2 | Crohn Disease | Terminated | 2020-08-04 | 2022-08-25 | ClinicalTrials.gov |
| NCT03720041 | Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With … | Phase3 | Multiple Myeloma | Unknown | 2020-08-04 | 2024-12-01 | ClinicalTrials.gov |
| NCT04449484 | Multiple Ascending Dose Study of MEDI1341 in Patients With Parkinson's Disease | Phase1 | Parkinson's Disease | Completed | 2020-08-04 | 2022-01-05 | ClinicalTrials.gov |
| NCT04449484 | Multiple Ascending Dose Study of MEDI1341 in Patients With Parkinson's Disease | Phase1 | Parkinson's Disease | Completed | 2020-08-04 | 2022-01-05 | ClinicalTrials.gov |
| NCT04445129 | Wake and Sleep State Transitions on a Portable Electroencephalogram (EEG) Devic… | — | Healthy Volunteers | Completed | 2020-08-03 | 2021-05-04 | ClinicalTrials.gov |
| NCT04445129 | Wake and Sleep State Transitions on a Portable Electroencephalogram (EEG) Devic… | — | Healthy Volunteers | Completed | 2020-08-03 | 2021-05-04 | ClinicalTrials.gov |
| NCT04445129 | Wake and Sleep State Transitions on a Portable Electroencephalogram (EEG) Devic… | — | Healthy Volunteers | Completed | 2020-08-03 | 2021-05-04 | ClinicalTrials.gov |
| NCT04362735 | Efficacy of Vedolizumab in Crohn's Disease Patients Naive to Biological Therapy | — | Crohn Disease | Unknown | 2020-08-01 | 2021-04-01 | ClinicalTrials.gov |
| NCT04362735 | Efficacy of Vedolizumab in Crohn's Disease Patients Naive to Biological Therapy | — | Crohn Disease | Unknown | 2020-08-01 | 2021-04-01 | ClinicalTrials.gov |
| NCT04362735 | Efficacy of Vedolizumab in Crohn's Disease Patients Naive to Biological Therapy | — | Crohn Disease | Unknown | 2020-08-01 | 2021-04-01 | ClinicalTrials.gov |
| NCT04135963 | A Study of People With Multiple Myeloma (MM) in Portugal (CharisMMa-Portugal) | — | Relapse and/or Refractory Multiple Myeloma | Completed | 2020-07-31 | 2022-09-30 | ClinicalTrials.gov |
| NCT04135963 | A Study of People With Multiple Myeloma (MM) in Portugal (CharisMMa-Portugal) | — | Relapse and/or Refractory Multiple Myeloma | Completed | 2020-07-31 | 2022-09-30 | ClinicalTrials.gov |
| NCT04135963 | A Study of People With Multiple Myeloma (MM) in Portugal (CharisMMa-Portugal) | — | Relapse and/or Refractory Multiple Myeloma | Completed | 2020-07-31 | 2022-09-30 | ClinicalTrials.gov |
| NCT04454918 | Study to Assess Absolute Bioavailability (ABA) of TAK-906 and to Characterize M… | Phase1 | Healthy Volunteers | Completed | 2020-07-30 | 2020-09-30 | ClinicalTrials.gov |
| NCT04454918 | Study to Assess Absolute Bioavailability (ABA) of TAK-906 and to Characterize M… | Phase1 | Healthy Volunteers | Completed | 2020-07-30 | 2020-09-30 | ClinicalTrials.gov |
| NCT04454918 | Study to Assess Absolute Bioavailability (ABA) of TAK-906 and to Characterize M… | Phase1 | Healthy Volunteers | Completed | 2020-07-30 | 2020-09-30 | ClinicalTrials.gov |
| NCT04420884 | A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembro… | Phase1 | Solid Neoplasms | Completed | 2020-07-22 | 2026-03-30 | ClinicalTrials.gov |
| NCT04420884 | A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembro… | Phase1 | Solid Neoplasms | Completed | 2020-07-22 | 2026-03-30 | ClinicalTrials.gov |
| NCT04420884 | A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembro… | Phase1 | Solid Neoplasms | Completed | 2020-07-22 | 2026-03-30 | ClinicalTrials.gov |
| NCT04405778 | A Study of TAK-102 in Adult With Previously-Treated Solid Tumors | Phase1 | Solid Tumors | Terminated | 2020-07-10 | 2025-05-09 | ClinicalTrials.gov |
| NCT04405778 | A Study of TAK-102 in Adult With Previously-Treated Solid Tumors | Phase1 | Solid Tumors | Terminated | 2020-07-10 | 2025-05-09 | ClinicalTrials.gov |
| NCT04405778 | A Study of TAK-102 in Adult With Previously-Treated Solid Tumors | Phase1 | Solid Tumors | Terminated | 2020-07-10 | 2025-05-09 | ClinicalTrials.gov |
| NCT04992442 | Study to Assess Absolute Bioavailability of TAK-935 (OV935) and to Characterize… | Phase1 | Healthy Volunteers | Completed | 2020-07-09 | 2020-08-18 | ClinicalTrials.gov |
| NCT04992442 | Study to Assess Absolute Bioavailability of TAK-935 (OV935) and to Characterize… | Phase1 | Healthy Volunteers | Completed | 2020-07-09 | 2020-08-18 | ClinicalTrials.gov |
| NCT04992442 | Study to Assess Absolute Bioavailability of TAK-935 (OV935) and to Characterize… | Phase1 | Healthy Volunteers | Completed | 2020-07-09 | 2020-08-18 | ClinicalTrials.gov |
| NCT04486950 | A Study of TAK-951 in Healthy Adults | Phase1 | Healthy Volunteer | Completed | 2020-07-07 | 2021-05-27 | ClinicalTrials.gov |
| NCT04486950 | A Study of TAK-951 in Healthy Adults | Phase1 | Healthy Volunteer | Completed | 2020-07-07 | 2021-05-27 | ClinicalTrials.gov |
| NCT04486950 | A Study of TAK-951 in Healthy Adults | Phase1 | Healthy Volunteer | Completed | 2020-07-07 | 2021-05-27 | ClinicalTrials.gov |
| NCT04464200 | 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Canc… | Phase1 | Diffuse Large B Cell Lymphoma | Active_Not_Recruiting | 2020-07-06 | 2026-07-01 | ClinicalTrials.gov |
| NCT04464200 | 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Canc… | Phase1 | Diffuse Large B Cell Lymphoma | Active_Not_Recruiting | 2020-07-06 | 2026-07-01 | ClinicalTrials.gov |
| NCT04464200 | 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Canc… | Phase1 | Diffuse Large B Cell Lymphoma | Active_Not_Recruiting | 2020-07-06 | 2026-07-01 | ClinicalTrials.gov |
| NCT04441255 | A Study to Evaluate the Effect of High-Fat Meal on TAK-788 Pharmacokinetics (PK… | Phase1 | Healthy Volunteers | Completed | 2020-07-01 | 2020-08-10 | ClinicalTrials.gov |
| NCT04441255 | A Study to Evaluate the Effect of High-Fat Meal on TAK-788 Pharmacokinetics (PK… | Phase1 | Healthy Volunteers | Completed | 2020-07-01 | 2020-08-10 | ClinicalTrials.gov |
| NCT04205175 | A Study to Evaluate the Safest Dose Range for FEIBA in Hemophilia A Patients Wi… | Phase4 | Hemophilia A With Inhibitor | Active_Not_Recruiting | 2020-07-01 | 2022-10-01 | ClinicalTrials.gov |
| NCT04441255 | A Study to Evaluate the Effect of High-Fat Meal on TAK-788 Pharmacokinetics (PK… | Phase1 | Healthy Volunteers | Completed | 2020-07-01 | 2020-08-10 | ClinicalTrials.gov |
| NCT04205175 | A Study to Evaluate the Safest Dose Range for FEIBA in Hemophilia A Patients Wi… | Phase4 | Hemophilia A With Inhibitor | Active_Not_Recruiting | 2020-07-01 | 2022-10-01 | ClinicalTrials.gov |
| NCT04205175 | A Study to Evaluate the Safest Dose Range for FEIBA in Hemophilia A Patients Wi… | Phase4 | Hemophilia A With Inhibitor | Active_Not_Recruiting | 2020-07-01 | 2022-10-01 | ClinicalTrials.gov |
| NCT06758648 | Characterizing the Retinal Microvasculature in Patients with Fabry Disease: a P… | — | Fabry Disease | Recruiting | 2020-06-25 | 2025-11-01 | ClinicalTrials.gov |
| NCT06758648 | Characterizing the Retinal Microvasculature in Patients with Fabry Disease: a P… | — | Fabry Disease | Recruiting | 2020-06-25 | 2025-11-01 | ClinicalTrials.gov |
| NCT06758648 | Characterizing the Retinal Microvasculature in Patients with Fabry Disease: a P… | — | Fabry Disease | Recruiting | 2020-06-25 | 2025-11-01 | ClinicalTrials.gov |
| NCT04374305 | Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Rela… | Phase2 | Neurofibromatosis Type 2 | Recruiting | 2020-06-20 | 2030-12-01 | ClinicalTrials.gov |
| NCT04374305 | Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Rela… | Phase2 | Neurofibromatosis Type 2 | Recruiting | 2020-06-20 | 2030-12-01 | ClinicalTrials.gov |
| NCT04374305 | Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Rela… | Phase2 | Neurofibromatosis Type 2 | Recruiting | 2020-06-20 | 2030-12-01 | ClinicalTrials.gov |
| NCT04151420 | Real Life Remote Monitoring of Mild, Moderate and Severe Infectious Complicatio… | — | Inflammatory Bowel Diseases | Completed | 2020-06-15 | 2022-02-01 | ClinicalTrials.gov |
| NCT03783416 | SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis | Phase1 | Relapsing Remitting Multiple Sclerosis | Recruiting | 2020-06-15 | 2026-07-31 | ClinicalTrials.gov |
| NCT03783416 | SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis | Phase1 | Relapsing Remitting Multiple Sclerosis | Recruiting | 2020-06-15 | 2026-07-31 | ClinicalTrials.gov |
| NCT03783416 | SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis | Phase1 | Relapsing Remitting Multiple Sclerosis | Recruiting | 2020-06-15 | 2026-07-31 | ClinicalTrials.gov |
| NCT04151420 | Real Life Remote Monitoring of Mild, Moderate and Severe Infectious Complicatio… | — | Inflammatory Bowel Diseases | Completed | 2020-06-15 | 2022-02-01 | ClinicalTrials.gov |
| NCT04151420 | Real Life Remote Monitoring of Mild, Moderate and Severe Infectious Complicatio… | — | Inflammatory Bowel Diseases | Completed | 2020-06-15 | 2022-02-01 | ClinicalTrials.gov |
| NCT04799496 | A Study of Kynteles Injection (Vedolizumab) in Adults With Moderate to Severe U… | — | Inflammatory Bowel Diseases | Completed | 2020-06-10 | 2025-06-30 | ClinicalTrials.gov |
| NCT04799496 | A Study of Kynteles Injection (Vedolizumab) in Adults With Moderate to Severe U… | — | Inflammatory Bowel Diseases | Completed | 2020-06-10 | 2025-06-30 | ClinicalTrials.gov |
| NCT04799496 | A Study of Kynteles Injection (Vedolizumab) in Adults With Moderate to Severe U… | — | Inflammatory Bowel Diseases | Completed | 2020-06-10 | 2025-06-30 | ClinicalTrials.gov |
| NCT04301011 | Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tu… | Phase1 | Solid Tumor | Terminated | 2020-06-02 | 2023-01-23 | ClinicalTrials.gov |
| NCT04301011 | Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tu… | Phase1 | Solid Tumor | Terminated | 2020-06-02 | 2023-01-23 | ClinicalTrials.gov |
| NCT04301011 | Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tu… | Phase1 | Solid Tumor | Terminated | 2020-06-02 | 2023-01-23 | ClinicalTrials.gov |
| NCT04096560 | A Study of TAK-994 in Adults With Type 1 and Type 2 Narcolepsy | Phase2 | Narcolepsy Type 1 (NT1) | Terminated | 2020-05-27 | 2021-11-05 | ClinicalTrials.gov |
| NCT04096560 | A Study of TAK-994 in Adults With Type 1 and Type 2 Narcolepsy | Phase2 | Narcolepsy Type 1 (NT1) | Terminated | 2020-05-27 | 2021-11-05 | ClinicalTrials.gov |
| NCT04096560 | A Study of TAK-994 in Adults With Type 1 and Type 2 Narcolepsy | Phase2 | Narcolepsy Type 1 (NT1) | Terminated | 2020-05-27 | 2021-11-05 | ClinicalTrials.gov |
| NCT04328662 | A Study of Ninlaro in Real World Clinical Practice in China | — | Multiple Myeloma | Completed | 2020-05-18 | 2026-02-13 | ClinicalTrials.gov |
| NCT04328662 | A Study of Ninlaro in Real World Clinical Practice in China | — | Multiple Myeloma | Completed | 2020-05-18 | 2026-02-13 | ClinicalTrials.gov |
| NCT04328662 | A Study of Ninlaro in Real World Clinical Practice in China | — | Multiple Myeloma | Completed | 2020-05-18 | 2026-02-13 | ClinicalTrials.gov |
| NCT04206605 | A Study of Lanadelumab in Teenagers and Adults to Prevent Acute Attacks of Non-… | Phase3 | Angioedema | Completed | 2020-05-04 | 2022-10-20 | ClinicalTrials.gov |
| NCT04206605 | A Study of Lanadelumab in Teenagers and Adults to Prevent Acute Attacks of Non-… | Phase3 | Angioedema | Completed | 2020-05-04 | 2022-10-20 | ClinicalTrials.gov |
| NCT04206605 | A Study of Lanadelumab in Teenagers and Adults to Prevent Acute Attacks of Non-… | Phase3 | Angioedema | Completed | 2020-05-04 | 2022-10-20 | ClinicalTrials.gov |
| NCT04198363 | A Study to Evaluate the Efficacy and Safety of Bismuth-Containing Quadruple The… | Phase3 | Helicobacter Pylori | Completed | 2020-04-30 | 2021-11-25 | ClinicalTrials.gov |
| NCT04198363 | A Study to Evaluate the Efficacy and Safety of Bismuth-Containing Quadruple The… | Phase3 | Helicobacter Pylori | Completed | 2020-04-30 | 2021-11-25 | ClinicalTrials.gov |
| NCT04198363 | A Study to Evaluate the Efficacy and Safety of Bismuth-Containing Quadruple The… | Phase3 | Helicobacter Pylori | Completed | 2020-04-30 | 2021-11-25 | ClinicalTrials.gov |
| NCT04318938 | Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping | Phase2 | NSCLC | Completed | 2020-03-30 | 2026-05-30 | ClinicalTrials.gov |
| NCT04318938 | Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping | Phase2 | NSCLC | Completed | 2020-03-30 | 2026-05-30 | ClinicalTrials.gov |
| NCT04318938 | Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping | Phase2 | NSCLC | Completed | 2020-03-30 | 2026-05-30 | ClinicalTrials.gov |
| NCT04589039 | A Study for Post-Marketing Surveillance of Niraparib in the Treatment of Adult … | — | Ovarian Neoplasms | Completed | 2020-03-16 | 2024-09-11 | ClinicalTrials.gov |
| NCT04589039 | A Study for Post-Marketing Surveillance of Niraparib in the Treatment of Adult … | — | Ovarian Neoplasms | Completed | 2020-03-16 | 2024-09-11 | ClinicalTrials.gov |
| NCT04589039 | A Study for Post-Marketing Surveillance of Niraparib in the Treatment of Adult … | — | Ovarian Neoplasms | Completed | 2020-03-16 | 2024-09-11 | ClinicalTrials.gov |
| NCT04311541 | A Study of Dexlansoprazole Modified Release (MR) in Gastroesophageal Reflux Dis… | — | Gastroesophageal Reflux Disease | Withdrawn | 2020-03-15 | 2022-01-31 | ClinicalTrials.gov |
| NCT04311541 | A Study of Dexlansoprazole Modified Release (MR) in Gastroesophageal Reflux Dis… | — | Gastroesophageal Reflux Disease | Withdrawn | 2020-03-15 | 2022-01-31 | ClinicalTrials.gov |
| NCT04311541 | A Study of Dexlansoprazole Modified Release (MR) in Gastroesophageal Reflux Dis… | — | Gastroesophageal Reflux Disease | Withdrawn | 2020-03-15 | 2022-01-31 | ClinicalTrials.gov |
| NCT04056455 | A Study of Mobocertinib Capsules in People With Severe Kidney Problems and Peop… | Phase1 | Renal Impairment | Completed | 2020-03-04 | 2022-04-20 | ClinicalTrials.gov |
| NCT04056455 | A Study of Mobocertinib Capsules in People With Severe Kidney Problems and Peop… | Phase1 | Renal Impairment | Completed | 2020-03-04 | 2022-04-20 | ClinicalTrials.gov |
| NCT04056455 | A Study of Mobocertinib Capsules in People With Severe Kidney Problems and Peop… | Phase1 | Renal Impairment | Completed | 2020-03-04 | 2022-04-20 | ClinicalTrials.gov |
| NCT04285983 | Specified Drug-Use Survey of Trelagliptin Tablets "Survey on Long-term Use in T… | — | Type 2 Diabetes Mellitus | Completed | 2020-03-01 | 2023-01-31 | ClinicalTrials.gov |
| NCT04285983 | Specified Drug-Use Survey of Trelagliptin Tablets "Survey on Long-term Use in T… | — | Type 2 Diabetes Mellitus | Completed | 2020-03-01 | 2023-01-31 | ClinicalTrials.gov |
| NCT04285983 | Specified Drug-Use Survey of Trelagliptin Tablets "Survey on Long-term Use in T… | — | Type 2 Diabetes Mellitus | Completed | 2020-03-01 | 2023-01-31 | ClinicalTrials.gov |
| NCT04005144 | Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-… | Phase1 | ALK Gene Rearrangement | Terminated | 2020-02-25 | 2022-10-01 | ClinicalTrials.gov |
| NCT04005144 | Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-… | Phase1 | ALK Gene Rearrangement | Terminated | 2020-02-25 | 2022-10-01 | ClinicalTrials.gov |
| NCT04005144 | Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-… | Phase1 | ALK Gene Rearrangement | Terminated | 2020-02-25 | 2022-10-01 | ClinicalTrials.gov |
| NCT04259138 | Determination of the Optimal Treatment Target in Ulcerative Colitis | Phase4 | Colitis, Ulcerative | Active_Not_Recruiting | 2020-02-18 | 2026-03-31 | ClinicalTrials.gov |
| NCT04259138 | Determination of the Optimal Treatment Target in Ulcerative Colitis | Phase4 | Colitis, Ulcerative | Active_Not_Recruiting | 2020-02-18 | 2026-03-31 | ClinicalTrials.gov |
| NCT04259138 | Determination of the Optimal Treatment Target in Ulcerative Colitis | Phase4 | Colitis, Ulcerative | Active_Not_Recruiting | 2020-02-18 | 2026-03-31 | ClinicalTrials.gov |
| NCT04181541 | Midlevel Versus Physician-provided Medical Abortion in the Second Trimester | Na | Induced Abortion | Completed | 2020-02-17 | 2021-03-03 | ClinicalTrials.gov |
| NCT04234672 | A Study to Assess Absolute Bioavailability (ABA) of TAK-831 and to Characterize… | Phase1 | Healthy Volunteers | Completed | 2020-02-17 | 2020-04-04 | ClinicalTrials.gov |
| NCT04234672 | A Study to Assess Absolute Bioavailability (ABA) of TAK-831 and to Characterize… | Phase1 | Healthy Volunteers | Completed | 2020-02-17 | 2020-04-04 | ClinicalTrials.gov |
| NCT04181541 | Midlevel Versus Physician-provided Medical Abortion in the Second Trimester | Na | Induced Abortion | Completed | 2020-02-17 | 2021-03-03 | ClinicalTrials.gov |
| NCT04181541 | Midlevel Versus Physician-provided Medical Abortion in the Second Trimester | Na | Induced Abortion | Completed | 2020-02-17 | 2021-03-03 | ClinicalTrials.gov |
| NCT04234672 | A Study to Assess Absolute Bioavailability (ABA) of TAK-831 and to Characterize… | Phase1 | Healthy Volunteers | Completed | 2020-02-17 | 2020-04-04 | ClinicalTrials.gov |
| NCT04213209 | Special Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Rel… | — | Peripheral T Cell Lymphoma | Completed | 2020-02-14 | 2023-12-13 | ClinicalTrials.gov |
| NCT04213209 | Special Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Rel… | — | Peripheral T Cell Lymphoma | Completed | 2020-02-14 | 2023-12-13 | ClinicalTrials.gov |
| NCT04213209 | Special Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Rel… | — | Peripheral T Cell Lymphoma | Completed | 2020-02-14 | 2023-12-13 | ClinicalTrials.gov |
| NCT04172467 | Quality Assurance of Secondary Immunodeficiencies (SID) in CLL/MM Patients | — | Secondary Immunodeficiencies (SID) | Completed | 2020-01-28 | 2020-08-03 | ClinicalTrials.gov |
| NCT04172467 | Quality Assurance of Secondary Immunodeficiencies (SID) in CLL/MM Patients | — | Secondary Immunodeficiencies (SID) | Completed | 2020-01-28 | 2020-08-03 | ClinicalTrials.gov |
| NCT04172467 | Quality Assurance of Secondary Immunodeficiencies (SID) in CLL/MM Patients | — | Secondary Immunodeficiencies (SID) | Completed | 2020-01-28 | 2020-08-03 | ClinicalTrials.gov |
| NCT04801199 | Effect of CPL-2009-0031 in the Treatment of Patients With Uncontrolled Type 2 D… | Phase3 | Uncontrolled Type 2 Diabetes Mellitus | Completed | 2020-01-26 | 2021-02-11 | ClinicalTrials.gov |
| NCT04091438 | A Study of a Single Intravenous Infusion Dose of TAK-925 in Participants With I… | Phase1 | Idiopathic Hypersomnia | Completed | 2020-01-26 | 2020-11-23 | ClinicalTrials.gov |
| NCT04091438 | A Study of a Single Intravenous Infusion Dose of TAK-925 in Participants With I… | Phase1 | Idiopathic Hypersomnia | Completed | 2020-01-26 | 2020-11-23 | ClinicalTrials.gov |
| NCT04801199 | Effect of CPL-2009-0031 in the Treatment of Patients With Uncontrolled Type 2 D… | Phase3 | Uncontrolled Type 2 Diabetes Mellitus | Completed | 2020-01-26 | 2021-02-11 | ClinicalTrials.gov |
| NCT04091438 | A Study of a Single Intravenous Infusion Dose of TAK-925 in Participants With I… | Phase1 | Idiopathic Hypersomnia | Completed | 2020-01-26 | 2020-11-23 | ClinicalTrials.gov |
| NCT04801199 | Effect of CPL-2009-0031 in the Treatment of Patients With Uncontrolled Type 2 D… | Phase3 | Uncontrolled Type 2 Diabetes Mellitus | Completed | 2020-01-26 | 2021-02-11 | ClinicalTrials.gov |
| NCT04159805 | A Study of TAK-079 in People With Generalized Myasthenia Gravis | Phase2 | Myasthenia Gravis | Completed | 2020-01-14 | 2022-07-12 | ClinicalTrials.gov |
| NCT04159805 | A Study of TAK-079 in People With Generalized Myasthenia Gravis | Phase2 | Myasthenia Gravis | Completed | 2020-01-14 | 2022-07-12 | ClinicalTrials.gov |
| NCT04159805 | A Study of TAK-079 in People With Generalized Myasthenia Gravis | Phase2 | Myasthenia Gravis | Completed | 2020-01-14 | 2022-07-12 | ClinicalTrials.gov |
| NCT04129502 | TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Smal… | Phase3 | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | Active_Not_Recruiting | 2020-01-10 | 2026-10-31 | ClinicalTrials.gov |
| NCT04129502 | TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Smal… | Phase3 | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | Active_Not_Recruiting | 2020-01-10 | 2026-10-31 | ClinicalTrials.gov |
| NCT04129502 | TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Smal… | Phase3 | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | Active_Not_Recruiting | 2020-01-10 | 2026-10-31 | ClinicalTrials.gov |
| NCT04051827 | Drug-Drug Interaction Study of TAK-788 and Midazolam in Participants With Advan… | Phase1 | Carcinoma, Non-Small-Cell Lung | Completed | 2019-12-23 | 2021-12-07 | ClinicalTrials.gov |
| NCT04051827 | Drug-Drug Interaction Study of TAK-788 and Midazolam in Participants With Advan… | Phase1 | Carcinoma, Non-Small-Cell Lung | Completed | 2019-12-23 | 2021-12-07 | ClinicalTrials.gov |
| NCT04051827 | Drug-Drug Interaction Study of TAK-788 and Midazolam in Participants With Advan… | Phase1 | Carcinoma, Non-Small-Cell Lung | Completed | 2019-12-23 | 2021-12-07 | ClinicalTrials.gov |
| NCT04202497 | A Study With [18F]MNI-1054 to Determine Lysine -Specific Demethylase 1A (LSD1) … | Phase1 | Healthy Volunteers | Terminated | 2019-12-18 | 2020-03-19 | ClinicalTrials.gov |
| NCT04202497 | A Study With [18F]MNI-1054 to Determine Lysine -Specific Demethylase 1A (LSD1) … | Phase1 | Healthy Volunteers | Terminated | 2019-12-18 | 2020-03-19 | ClinicalTrials.gov |
| NCT04202497 | A Study With [18F]MNI-1054 to Determine Lysine -Specific Demethylase 1A (LSD1) … | Phase1 | Healthy Volunteers | Terminated | 2019-12-18 | 2020-03-19 | ClinicalTrials.gov |
| NCT04180163 | Efficacy and Safety of Lanadelumab (SHP643) in Japanese Participants With Hered… | Phase3 | Hereditary Angioedema (HAE) | Completed | 2019-12-12 | 2021-08-26 | ClinicalTrials.gov |
| NCT04180163 | Efficacy and Safety of Lanadelumab (SHP643) in Japanese Participants With Hered… | Phase3 | Hereditary Angioedema (HAE) | Completed | 2019-12-12 | 2021-08-26 | ClinicalTrials.gov |
| NCT04180163 | Efficacy and Safety of Lanadelumab (SHP643) in Japanese Participants With Hered… | Phase3 | Hereditary Angioedema (HAE) | Completed | 2019-12-12 | 2021-08-26 | ClinicalTrials.gov |
| NCT04130191 | A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II | — | Hereditary Angioedema (HAE) | Completed | 2019-12-11 | 2024-09-09 | ClinicalTrials.gov |
| NCT04130191 | A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II | — | Hereditary Angioedema (HAE) | Completed | 2019-12-11 | 2024-09-09 | ClinicalTrials.gov |
| NCT04130191 | A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II | — | Hereditary Angioedema (HAE) | Completed | 2019-12-11 | 2024-09-09 | ClinicalTrials.gov |
| NCT04091425 | Study of TAK-925 in Participants With Obstructive Sleep Apnea (OSA) Who Are Exp… | Phase1 | Obstructive Sleep Apnea | Completed | 2019-11-21 | 2020-04-02 | ClinicalTrials.gov |
| NCT04091425 | Study of TAK-925 in Participants With Obstructive Sleep Apnea (OSA) Who Are Exp… | Phase1 | Obstructive Sleep Apnea | Completed | 2019-11-21 | 2020-04-02 | ClinicalTrials.gov |
| NCT04091425 | Study of TAK-925 in Participants With Obstructive Sleep Apnea (OSA) Who Are Exp… | Phase1 | Obstructive Sleep Apnea | Completed | 2019-11-21 | 2020-04-02 | ClinicalTrials.gov |
| NCT04155567 | A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of TAK-1… | Phase1 | Healthy Volunteers | Completed | 2019-11-13 | 2019-12-06 | ClinicalTrials.gov |
| NCT04155567 | A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of TAK-1… | Phase1 | Healthy Volunteers | Completed | 2019-11-13 | 2019-12-06 | ClinicalTrials.gov |
| NCT04155567 | A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of TAK-1… | Phase1 | Healthy Volunteers | Completed | 2019-11-13 | 2019-12-06 | ClinicalTrials.gov |
| NCT03999996 | Long-Term Safety and Antibody Persistence of TDV and the Impact of a Booster Do… | Phase3 | Dengue Fever | Completed | 2019-11-12 | 2024-05-25 | ClinicalTrials.gov |
| NCT03999996 | Long-Term Safety and Antibody Persistence of TDV and the Impact of a Booster Do… | Phase3 | Dengue Fever | Completed | 2019-11-12 | 2024-05-25 | ClinicalTrials.gov |
| NCT03999996 | Long-Term Safety and Antibody Persistence of TDV and the Impact of a Booster Do… | Phase3 | Dengue Fever | Completed | 2019-11-12 | 2024-05-25 | ClinicalTrials.gov |
| NCT04075825 | Long-term Follow-up Study With Darvadstrocel in the Treatment of Complex Perian… | Phase3 | Crohn's Disease | Completed | 2019-11-05 | 2024-04-02 | ClinicalTrials.gov |
| NCT04075825 | Long-term Follow-up Study With Darvadstrocel in the Treatment of Complex Perian… | Phase3 | Crohn's Disease | Completed | 2019-11-05 | 2024-04-02 | ClinicalTrials.gov |
| NCT04075825 | Long-term Follow-up Study With Darvadstrocel in the Treatment of Complex Perian… | Phase3 | Crohn's Disease | Completed | 2019-11-05 | 2024-04-02 | ClinicalTrials.gov |
| NCT03683277 | IPD in RRMM Characterized With Genomic Abnormalities of Adverse Prognostic | Phase2 | Multiple Myeloma | Terminated | 2019-11-03 | 2023-02-10 | ClinicalTrials.gov |
| NCT03683277 | IPD in RRMM Characterized With Genomic Abnormalities of Adverse Prognostic | Phase2 | Multiple Myeloma | Terminated | 2019-11-03 | 2023-02-10 | ClinicalTrials.gov |
| NCT03683277 | IPD in RRMM Characterized With Genomic Abnormalities of Adverse Prognostic | Phase2 | Multiple Myeloma | Terminated | 2019-11-03 | 2023-02-10 | ClinicalTrials.gov |
| NCT03997760 | A Study of SHP655 (rADAMTS13) in Sickle Cell Disease | Phase1 | Sickle Cell Disease | Completed | 2019-10-21 | 2022-10-26 | ClinicalTrials.gov |
| NCT03997760 | A Study of SHP655 (rADAMTS13) in Sickle Cell Disease | Phase1 | Sickle Cell Disease | Completed | 2019-10-21 | 2022-10-26 | ClinicalTrials.gov |
| NCT03997760 | A Study of SHP655 (rADAMTS13) in Sickle Cell Disease | Phase1 | Sickle Cell Disease | Completed | 2019-10-21 | 2022-10-26 | ClinicalTrials.gov |
| NCT04074330 | A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory C… | Phase1 | Lymphoma, Non-Hodgkin | Terminated | 2019-10-15 | 2023-04-26 | ClinicalTrials.gov |
| NCT04121078 | A Study to Evaluate the Effect of Single-Dose Intravenous Rifampin as a Prototy… | Phase1 | Healthy Volunteers | Completed | 2019-10-15 | 2019-11-16 | ClinicalTrials.gov |
| NCT04074330 | A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory C… | Phase1 | Lymphoma, Non-Hodgkin | Terminated | 2019-10-15 | 2023-04-26 | ClinicalTrials.gov |
| NCT04074330 | A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory C… | Phase1 | Lymphoma, Non-Hodgkin | Terminated | 2019-10-15 | 2023-04-26 | ClinicalTrials.gov |
| NCT04121078 | A Study to Evaluate the Effect of Single-Dose Intravenous Rifampin as a Prototy… | Phase1 | Healthy Volunteers | Completed | 2019-10-15 | 2019-11-16 | ClinicalTrials.gov |
| NCT04121078 | A Study to Evaluate the Effect of Single-Dose Intravenous Rifampin as a Prototy… | Phase1 | Healthy Volunteers | Completed | 2019-10-15 | 2019-11-16 | ClinicalTrials.gov |
| NCT03922308 | Study of rADAMTS-13 (SHP655) in the Treatment of Participants With Acquired Thr… | Phase2 | Acquired Thrombotic Thrombocytopenic Purpura (aTTP) | Completed | 2019-10-09 | 2021-08-05 | ClinicalTrials.gov |
| NCT03922308 | Study of rADAMTS-13 (SHP655) in the Treatment of Participants With Acquired Thr… | Phase2 | Acquired Thrombotic Thrombocytopenic Purpura (aTTP) | Completed | 2019-10-09 | 2021-08-05 | ClinicalTrials.gov |
| NCT03922308 | Study of rADAMTS-13 (SHP655) in the Treatment of Participants With Acquired Thr… | Phase2 | Acquired Thrombotic Thrombocytopenic Purpura (aTTP) | Completed | 2019-10-09 | 2021-08-05 | ClinicalTrials.gov |
| NCT04025502 | Event-Related Potential (ERP) Biomarkers in Subjects With Schizophrenia and Hea… | — | Schizophrenia | Completed | 2019-10-07 | 2021-01-31 | ClinicalTrials.gov |
| NCT04025502 | Event-Related Potential (ERP) Biomarkers in Subjects With Schizophrenia and Hea… | — | Schizophrenia | Completed | 2019-10-07 | 2021-01-31 | ClinicalTrials.gov |
| NCT04025502 | Event-Related Potential (ERP) Biomarkers in Subjects With Schizophrenia and Hea… | — | Schizophrenia | Completed | 2019-10-07 | 2021-01-31 | ClinicalTrials.gov |
| NCT03608501 | A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treat… | Phase2 | Multiple Myeloma | Withdrawn | 2019-09-30 | 2023-05-31 | ClinicalTrials.gov |
| NCT03608501 | A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treat… | Phase2 | Multiple Myeloma | Withdrawn | 2019-09-30 | 2023-05-31 | ClinicalTrials.gov |
| NCT03608501 | A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treat… | Phase2 | Multiple Myeloma | Withdrawn | 2019-09-30 | 2023-05-31 | ClinicalTrials.gov |
| NCT04090736 | Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients W… | Phase3 | Leukemia, Myeloid, Acute | Active_Not_Recruiting | 2019-09-24 | 2026-07-30 | ClinicalTrials.gov |
| NCT04090736 | Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients W… | Phase3 | Leukemia, Myeloid, Acute | Active_Not_Recruiting | 2019-09-24 | 2026-07-30 | ClinicalTrials.gov |
| NCT04090736 | Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients W… | Phase3 | Leukemia, Myeloid, Acute | Active_Not_Recruiting | 2019-09-24 | 2026-07-30 | ClinicalTrials.gov |
| NCT04079738 | Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Pr… | Phase1 | AML | Terminated | 2019-09-20 | 2022-02-23 | ClinicalTrials.gov |
| NCT04079738 | Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Pr… | Phase1 | AML | Terminated | 2019-09-20 | 2022-02-23 | ClinicalTrials.gov |
| NCT04079738 | Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Pr… | Phase1 | AML | Terminated | 2019-09-20 | 2022-02-23 | ClinicalTrials.gov |
| NCT04094181 | A Study of VPRIV in Participants With Gaucher Disease Previously Treated With O… | — | Gaucher Disease | Terminated | 2019-09-19 | 2021-11-17 | ClinicalTrials.gov |
| NCT04094181 | A Study of VPRIV in Participants With Gaucher Disease Previously Treated With O… | — | Gaucher Disease | Terminated | 2019-09-19 | 2021-11-17 | ClinicalTrials.gov |
| NCT04094181 | A Study of VPRIV in Participants With Gaucher Disease Previously Treated With O… | — | Gaucher Disease | Terminated | 2019-09-19 | 2021-11-17 | ClinicalTrials.gov |
| NCT04094961 | Ixazomib + Pomalidomide + Dexamethasone In MM | Phase1 | Multiple Myeloma | Active_Not_Recruiting | 2019-09-18 | 2027-01-01 | ClinicalTrials.gov |
| NCT04094961 | Ixazomib + Pomalidomide + Dexamethasone In MM | Phase1 | Multiple Myeloma | Active_Not_Recruiting | 2019-09-18 | 2027-01-01 | ClinicalTrials.gov |
| NCT04085172 | A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivi… | Phase4 | Attention Deficit Hyperactivity Disorder | Completed | 2019-09-18 | 2025-09-02 | ClinicalTrials.gov |
| NCT04085172 | A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivi… | Phase4 | Attention Deficit Hyperactivity Disorder | Completed | 2019-09-18 | 2025-09-02 | ClinicalTrials.gov |
| NCT04094961 | Ixazomib + Pomalidomide + Dexamethasone In MM | Phase1 | Multiple Myeloma | Active_Not_Recruiting | 2019-09-18 | 2027-01-01 | ClinicalTrials.gov |
| NCT04085172 | A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivi… | Phase4 | Attention Deficit Hyperactivity Disorder | Completed | 2019-09-18 | 2025-09-02 | ClinicalTrials.gov |
| NCT04592523 | A Study of Usage of Brigatinib in the Treatment of Adult Participants for Appro… | — | Carcinoma, Non-Small-Cell Lung | Completed | 2019-09-05 | 2026-03-12 | ClinicalTrials.gov |
| NCT04592523 | A Study of Usage of Brigatinib in the Treatment of Adult Participants for Appro… | — | Carcinoma, Non-Small-Cell Lung | Completed | 2019-09-05 | 2026-03-12 | ClinicalTrials.gov |
| NCT04592523 | A Study of Usage of Brigatinib in the Treatment of Adult Participants for Appro… | — | Carcinoma, Non-Small-Cell Lung | Completed | 2019-09-05 | 2026-03-12 | ClinicalTrials.gov |
| NCT05479721 | LITMUS Imaging Study | — | NAFLD | Active_Not_Recruiting | 2019-09-04 | 2025-10-31 | ClinicalTrials.gov |
| NCT05479721 | LITMUS Imaging Study | — | NAFLD | Active_Not_Recruiting | 2019-09-04 | 2025-10-31 | ClinicalTrials.gov |
| NCT05479721 | LITMUS Imaging Study | — | NAFLD | Active_Not_Recruiting | 2019-09-04 | 2025-10-31 | ClinicalTrials.gov |
| NCT05538390 | Assessment of Pattern of Abdominal Injury | — | Abdominal Trauma | Completed | 2019-09-01 | 2020-06-10 | ClinicalTrials.gov |
| NCT04845555 | Association Between Individual Clotting Factor Level Monitoring and the Risk of… | — | Hemophilia A | Unknown | 2019-09-01 | 2022-12-30 | ClinicalTrials.gov |
| NCT04845555 | Association Between Individual Clotting Factor Level Monitoring and the Risk of… | — | Hemophilia A | Unknown | 2019-09-01 | 2022-12-30 | ClinicalTrials.gov |
| NCT05538390 | Assessment of Pattern of Abdominal Injury | — | Abdominal Trauma | Completed | 2019-09-01 | 2020-06-10 | ClinicalTrials.gov |
| NCT03965624 | Efficacy and Safety of Ixazomib and Dexamethasone Refractory Autoimmune Cytopen… | Phase2 | Immune Thrombocytopenia | Withdrawn | 2019-09-01 | 2023-09-01 | ClinicalTrials.gov |
| NCT05538390 | Assessment of Pattern of Abdominal Injury | — | Abdominal Trauma | Completed | 2019-09-01 | 2020-06-10 | ClinicalTrials.gov |
| NCT03965624 | Efficacy and Safety of Ixazomib and Dexamethasone Refractory Autoimmune Cytopen… | Phase2 | Immune Thrombocytopenia | Withdrawn | 2019-09-01 | 2023-09-01 | ClinicalTrials.gov |
| NCT03965624 | Efficacy and Safety of Ixazomib and Dexamethasone Refractory Autoimmune Cytopen… | Phase2 | Immune Thrombocytopenia | Withdrawn | 2019-09-01 | 2023-09-01 | ClinicalTrials.gov |
| NCT04845555 | Association Between Individual Clotting Factor Level Monitoring and the Risk of… | — | Hemophilia A | Unknown | 2019-09-01 | 2022-12-30 | ClinicalTrials.gov |
| NCT03871699 | Ferric Carboximaltose on Intra-myocardial Iron Load in Patients With Heart Fail… | Phase4 | Cardiac Failure | Unknown | 2019-08-30 | 2021-02-28 | ClinicalTrials.gov |
| NCT03871699 | Ferric Carboximaltose on Intra-myocardial Iron Load in Patients With Heart Fail… | Phase4 | Cardiac Failure | Unknown | 2019-08-30 | 2021-02-28 | ClinicalTrials.gov |
| NCT03871699 | Ferric Carboximaltose on Intra-myocardial Iron Load in Patients With Heart Fail… | Phase4 | Cardiac Failure | Unknown | 2019-08-30 | 2021-02-28 | ClinicalTrials.gov |
| NCT03999567 | Validation Study: Mobile DSST on Cognition in Adults With MDD | Na | Major Depressive Episode | Completed | 2019-08-25 | 2020-02-04 | ClinicalTrials.gov |
| NCT03999567 | Validation Study: Mobile DSST on Cognition in Adults With MDD | Na | Major Depressive Episode | Completed | 2019-08-25 | 2020-02-04 | ClinicalTrials.gov |
| NCT03999567 | Validation Study: Mobile DSST on Cognition in Adults With MDD | Na | Major Depressive Episode | Completed | 2019-08-25 | 2020-02-04 | ClinicalTrials.gov |
| NCT04070326 | A Study of Lanadelumab to Prevent Hereditary Angioedema (HAE) Attacks in Childr… | Phase3 | Hereditary Angioedema | Completed | 2019-08-19 | 2021-10-30 | ClinicalTrials.gov |
| NCT04070326 | A Study of Lanadelumab to Prevent Hereditary Angioedema (HAE) Attacks in Childr… | Phase3 | Hereditary Angioedema | Completed | 2019-08-19 | 2021-10-30 | ClinicalTrials.gov |
| NCT04070326 | A Study of Lanadelumab to Prevent Hereditary Angioedema (HAE) Attacks in Childr… | Phase3 | Hereditary Angioedema | Completed | 2019-08-19 | 2021-10-30 | ClinicalTrials.gov |
| NCT03984097 | A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in … | Phase1 | Multiple Myeloma | Completed | 2019-07-29 | 2026-03-25 | ClinicalTrials.gov |
| NCT03984097 | A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in … | Phase1 | Multiple Myeloma | Completed | 2019-07-29 | 2026-03-25 | ClinicalTrials.gov |
| NCT03984097 | A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in … | Phase1 | Multiple Myeloma | Completed | 2019-07-29 | 2026-03-25 | ClinicalTrials.gov |
| NCT03521583 | Von Willebrand Disease in the Netherlands | — | Von Willebrand Disease | Unknown | 2019-07-28 | 2022-01-01 | ClinicalTrials.gov |
| NCT03521583 | Von Willebrand Disease in the Netherlands | — | Von Willebrand Disease | Unknown | 2019-07-28 | 2022-01-01 | ClinicalTrials.gov |
| NCT03521583 | Von Willebrand Disease in the Netherlands | — | Von Willebrand Disease | Unknown | 2019-07-28 | 2022-01-01 | ClinicalTrials.gov |
| NCT03838692 | Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer | Phase2 | Medullary Thyroid Cancer | Withdrawn | 2019-07-26 | 2021-06-14 | ClinicalTrials.gov |
| NCT03838692 | Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer | Phase2 | Medullary Thyroid Cancer | Withdrawn | 2019-07-26 | 2021-06-14 | ClinicalTrials.gov |
| NCT03838692 | Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer | Phase2 | Medullary Thyroid Cancer | Withdrawn | 2019-07-26 | 2021-06-14 | ClinicalTrials.gov |
| NCT03990649 | Study of TAK-935 as an Adjunctive Therapy in Adult Participants With Complex Re… | Phase2 | Complex Regional Pain Syndrome | Completed | 2019-07-23 | 2020-10-28 | ClinicalTrials.gov |
| NCT03990649 | Study of TAK-935 as an Adjunctive Therapy in Adult Participants With Complex Re… | Phase2 | Complex Regional Pain Syndrome | Completed | 2019-07-23 | 2020-10-28 | ClinicalTrials.gov |
| NCT03990649 | Study of TAK-935 as an Adjunctive Therapy in Adult Participants With Complex Re… | Phase2 | Complex Regional Pain Syndrome | Completed | 2019-07-23 | 2020-10-28 | ClinicalTrials.gov |
| NCT03814005 | A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidne… | Phase1 | Myelodysplastic Syndromes | Completed | 2019-07-10 | 2022-04-19 | ClinicalTrials.gov |
| NCT03814005 | A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidne… | Phase1 | Myelodysplastic Syndromes | Completed | 2019-07-10 | 2022-04-19 | ClinicalTrials.gov |
| NCT03814005 | A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidne… | Phase1 | Myelodysplastic Syndromes | Completed | 2019-07-10 | 2022-04-19 | ClinicalTrials.gov |
| NCT03942224 | Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethas… | Phase2 | Plasma Cell Myeloma | Active_Not_Recruiting | 2019-07-03 | 2026-07-31 | ClinicalTrials.gov |
| NCT03942224 | Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethas… | Phase2 | Plasma Cell Myeloma | Active_Not_Recruiting | 2019-07-03 | 2026-07-31 | ClinicalTrials.gov |
| NCT03942224 | Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethas… | Phase2 | Plasma Cell Myeloma | Active_Not_Recruiting | 2019-07-03 | 2026-07-31 | ClinicalTrials.gov |
| NCT03981939 | Perianal Fistula (PAF) Validation and Burden of Illness Study | — | Inflammatory Bowel Disease | Completed | 2019-07-02 | 2019-12-31 | ClinicalTrials.gov |
| NCT03981939 | Perianal Fistula (PAF) Validation and Burden of Illness Study | — | Inflammatory Bowel Disease | Completed | 2019-07-02 | 2019-12-31 | ClinicalTrials.gov |
| NCT03981939 | Perianal Fistula (PAF) Validation and Burden of Illness Study | — | Inflammatory Bowel Disease | Completed | 2019-07-02 | 2019-12-31 | ClinicalTrials.gov |
| NCT03580967 | Vortioxetine Monotherapy for Major Depressive Disorder in Type 2 Diabetes | Phase4 | Type2 Diabetes | Withdrawn | 2019-07-01 | 2021-07-01 | ClinicalTrials.gov |
| NCT04002180 | Specified Drug-Use Survey on Vedolizumab for IV Infusion 300 mg [Crohn's Diseas… | — | Crohn's Disease | Completed | 2019-07-01 | 2026-03-25 | ClinicalTrials.gov |
| NCT03580967 | Vortioxetine Monotherapy for Major Depressive Disorder in Type 2 Diabetes | Phase4 | Type2 Diabetes | Withdrawn | 2019-07-01 | 2021-07-01 | ClinicalTrials.gov |
| NCT04006080 | Investigation of the Faecal Loss of Vedolizumab and Its Role in Influencing Ser… | Phase4 | Ulcerative Colitis | Unknown | 2019-07-01 | 2020-03-01 | ClinicalTrials.gov |
| NCT04006080 | Investigation of the Faecal Loss of Vedolizumab and Its Role in Influencing Ser… | Phase4 | Ulcerative Colitis | Unknown | 2019-07-01 | 2020-03-01 | ClinicalTrials.gov |
| NCT04002180 | Specified Drug-Use Survey on Vedolizumab for IV Infusion 300 mg [Crohn's Diseas… | — | Crohn's Disease | Completed | 2019-07-01 | 2026-03-25 | ClinicalTrials.gov |
| NCT04002180 | Specified Drug-Use Survey on Vedolizumab for IV Infusion 300 mg [Crohn's Diseas… | — | Crohn's Disease | Completed | 2019-07-01 | 2026-03-25 | ClinicalTrials.gov |
| NCT04006080 | Investigation of the Faecal Loss of Vedolizumab and Its Role in Influencing Ser… | Phase4 | Ulcerative Colitis | Unknown | 2019-07-01 | 2020-03-01 | ClinicalTrials.gov |
| NCT03580967 | Vortioxetine Monotherapy for Major Depressive Disorder in Type 2 Diabetes | Phase4 | Type2 Diabetes | Withdrawn | 2019-07-01 | 2021-07-01 | ClinicalTrials.gov |
| NCT03420742 | A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrat… | Phase1 | Carcinoma, Advanced ALK+ or ROS1+Non-Small-Cell Lung, Neoplasm, Advanced ALK+ or ROS1+Solid Tumors | Completed | 2019-06-26 | 2021-04-29 | ClinicalTrials.gov |
| NCT03420742 | A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrat… | Phase1 | Carcinoma, Advanced ALK+ or ROS1+Non-Small-Cell Lung, Neoplasm, Advanced ALK+ or ROS1+Solid Tumors | Completed | 2019-06-26 | 2021-04-29 | ClinicalTrials.gov |
| NCT03420742 | A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrat… | Phase1 | Carcinoma, Advanced ALK+ or ROS1+Non-Small-Cell Lung, Neoplasm, Advanced ALK+ or ROS1+Solid Tumors | Completed | 2019-06-26 | 2021-04-29 | ClinicalTrials.gov |
| NCT03853486 | ATHN 9: Severe VWD Natural History Study | — | Von Willebrand Diseases | Active_Not_Recruiting | 2019-06-18 | 2026-07-30 | ClinicalTrials.gov |
| NCT03853486 | ATHN 9: Severe VWD Natural History Study | — | Von Willebrand Diseases | Active_Not_Recruiting | 2019-06-18 | 2026-07-30 | ClinicalTrials.gov |
| NCT03853486 | ATHN 9: Severe VWD Natural History Study | — | Von Willebrand Diseases | Active_Not_Recruiting | 2019-06-18 | 2026-07-30 | ClinicalTrials.gov |
| NCT03954080 | Trialing of ISS in Patients With CRPS | Na | CRPS I | Completed | 2019-06-13 | 2022-03-31 | ClinicalTrials.gov |
| NCT03954080 | Trialing of ISS in Patients With CRPS | Na | CRPS I | Completed | 2019-06-13 | 2022-03-31 | ClinicalTrials.gov |
| NCT03954080 | Trialing of ISS in Patients With CRPS | Na | CRPS I | Completed | 2019-06-13 | 2022-03-31 | ClinicalTrials.gov |
| NCT03942263 | A Study to Describe Treatment Patterns and Disease Control in Participants With… | — | Hodgkin Disease | Completed | 2019-05-31 | 2022-12-08 | ClinicalTrials.gov |
| NCT03942263 | A Study to Describe Treatment Patterns and Disease Control in Participants With… | — | Hodgkin Disease | Completed | 2019-05-31 | 2022-12-08 | ClinicalTrials.gov |
| NCT03942263 | A Study to Describe Treatment Patterns and Disease Control in Participants With… | — | Hodgkin Disease | Completed | 2019-05-31 | 2022-12-08 | ClinicalTrials.gov |
| NCT03918239 | A Study to Determine the Bioavailability of Lanadelumab (SHP643) Administered S… | Phase1 | Healthy Volunteers | Completed | 2019-05-14 | 2019-11-13 | ClinicalTrials.gov |
| NCT03918239 | A Study to Determine the Bioavailability of Lanadelumab (SHP643) Administered S… | Phase1 | Healthy Volunteers | Completed | 2019-05-14 | 2019-11-13 | ClinicalTrials.gov |
| NCT03918239 | A Study to Determine the Bioavailability of Lanadelumab (SHP643) Administered S… | Phase1 | Healthy Volunteers | Completed | 2019-05-14 | 2019-11-13 | ClinicalTrials.gov |
| NCT03771898 | A Study of Intrathecal SHP611 in Children With Metachromatic Leukodystrophy | Phase2 | Metachromatic Leukodystrophy (MLD) | Completed | 2019-05-13 | 2026-05-06 | ClinicalTrials.gov |
| NCT03771898 | A Study of Intrathecal SHP611 in Children With Metachromatic Leukodystrophy | Phase2 | Metachromatic Leukodystrophy (MLD) | Completed | 2019-05-13 | 2026-05-06 | ClinicalTrials.gov |
| NCT03771898 | A Study of Intrathecal SHP611 in Children With Metachromatic Leukodystrophy | Phase2 | Metachromatic Leukodystrophy (MLD) | Completed | 2019-05-13 | 2026-05-06 | ClinicalTrials.gov |
| NCT03928327 | A Study to Evaluate Drug-Drug Interaction of TAK-788 With Itraconazole and Rifa… | Phase1 | Healthy Volunteers | Completed | 2019-05-02 | 2019-08-16 | ClinicalTrials.gov |
| NCT03928327 | A Study to Evaluate Drug-Drug Interaction of TAK-788 With Itraconazole and Rifa… | Phase1 | Healthy Volunteers | Completed | 2019-05-02 | 2019-08-16 | ClinicalTrials.gov |
| NCT03928327 | A Study to Evaluate Drug-Drug Interaction of TAK-788 With Itraconazole and Rifa… | Phase1 | Healthy Volunteers | Completed | 2019-05-02 | 2019-08-16 | ClinicalTrials.gov |
| NCT03933488 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodyn… | Phase1 | Healthy Participants | Completed | 2019-05-01 | 2020-03-29 | ClinicalTrials.gov |
| NCT03933488 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodyn… | Phase1 | Healthy Participants | Completed | 2019-05-01 | 2020-03-29 | ClinicalTrials.gov |
| NCT03933488 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodyn… | Phase1 | Healthy Participants | Completed | 2019-05-01 | 2020-03-29 | ClinicalTrials.gov |
| NCT03596866 | A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung … | Phase3 | ALK+ Advanced NSCLC | Completed | 2019-04-19 | 2024-09-18 | ClinicalTrials.gov |
| NCT03596866 | A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung … | Phase3 | ALK+ Advanced NSCLC | Completed | 2019-04-19 | 2024-09-18 | ClinicalTrials.gov |
| NCT03596866 | A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung … | Phase3 | ALK+ Advanced NSCLC | Completed | 2019-04-19 | 2024-09-18 | ClinicalTrials.gov |
| NCT03889613 | Pillcam Crohn's Capsule for Monitoring of Panenteric Mucosal Healing in Crohn's… | Na | Crohn Disease | Unknown | 2019-04-03 | 2024-11-01 | ClinicalTrials.gov |
| NCT03889613 | Pillcam Crohn's Capsule for Monitoring of Panenteric Mucosal Healing in Crohn's… | Na | Crohn Disease | Unknown | 2019-04-03 | 2024-11-01 | ClinicalTrials.gov |
| NCT03889613 | Pillcam Crohn's Capsule for Monitoring of Panenteric Mucosal Healing in Crohn's… | Na | Crohn Disease | Unknown | 2019-04-03 | 2024-11-01 | ClinicalTrials.gov |
| NCT03879135 | A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Part… | Phase3 | Von Willebrand Disease (VWD) | Completed | 2019-04-01 | 2025-01-30 | ClinicalTrials.gov |
| NCT03732703 | Myeloma-Developing Regimens Using Genomics (MyDRUG) | Phase1 | Relapsed Refractory Multiple Myeloma | Completed | 2019-04-01 | 2024-12-31 | ClinicalTrials.gov |
| NCT03879135 | A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Part… | Phase3 | Von Willebrand Disease (VWD) | Completed | 2019-04-01 | 2025-01-30 | ClinicalTrials.gov |
| NCT03732703 | Myeloma-Developing Regimens Using Genomics (MyDRUG) | Phase1 | Relapsed Refractory Multiple Myeloma | Completed | 2019-04-01 | 2024-12-31 | ClinicalTrials.gov |
| NCT03732703 | Myeloma-Developing Regimens Using Genomics (MyDRUG) | Phase1 | Relapsed Refractory Multiple Myeloma | Completed | 2019-04-01 | 2024-12-31 | ClinicalTrials.gov |
| NCT03879135 | A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Part… | Phase3 | Von Willebrand Disease (VWD) | Completed | 2019-04-01 | 2025-01-30 | ClinicalTrials.gov |
| NCT03845400 | A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II… | — | Hereditary Angioedema (HAE) | Completed | 2019-03-30 | 2022-10-22 | ClinicalTrials.gov |
| NCT03845400 | A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II… | — | Hereditary Angioedema (HAE) | Completed | 2019-03-30 | 2022-10-22 | ClinicalTrials.gov |
| NCT03845400 | A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II… | — | Hereditary Angioedema (HAE) | Completed | 2019-03-30 | 2022-10-22 | ClinicalTrials.gov |
| NCT03708211 | A Study to Assess the Relative Bioavailability, Effect of Food, and Gastric Pot… | Phase1 | Neoplasms, Advanced Solid | Completed | 2019-03-28 | 2019-12-03 | ClinicalTrials.gov |
| NCT03708211 | A Study to Assess the Relative Bioavailability, Effect of Food, and Gastric Pot… | Phase1 | Neoplasms, Advanced Solid | Completed | 2019-03-28 | 2019-12-03 | ClinicalTrials.gov |
| NCT03771963 | Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) at the End of She… | Phase3 | Dengue Fever | Completed | 2019-03-28 | 2020-03-13 | ClinicalTrials.gov |
| NCT03771963 | Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) at the End of She… | Phase3 | Dengue Fever | Completed | 2019-03-28 | 2020-03-13 | ClinicalTrials.gov |
| NCT03771963 | Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) at the End of She… | Phase3 | Dengue Fever | Completed | 2019-03-28 | 2020-03-13 | ClinicalTrials.gov |
| NCT03708211 | A Study to Assess the Relative Bioavailability, Effect of Food, and Gastric Pot… | Phase1 | Neoplasms, Advanced Solid | Completed | 2019-03-28 | 2019-12-03 | ClinicalTrials.gov |
| NCT03349281 | Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/R… | Phase1 | Refractory Acute Lymphoblastic Leukemia | Completed | 2019-03-25 | 2022-10-12 | ClinicalTrials.gov |
| NCT03349281 | Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/R… | Phase1 | Refractory Acute Lymphoblastic Leukemia | Completed | 2019-03-25 | 2022-10-12 | ClinicalTrials.gov |
| NCT03349281 | Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/R… | Phase1 | Refractory Acute Lymphoblastic Leukemia | Completed | 2019-03-25 | 2022-10-12 | ClinicalTrials.gov |
| NCT04866030 | Drug Use Study With Intuniv® in Australia | — | Attention Deficit Hyperactivity Disorder (ADHD) | Completed | 2019-03-11 | 2021-08-27 | ClinicalTrials.gov |
| NCT04866030 | Drug Use Study With Intuniv® in Australia | — | Attention Deficit Hyperactivity Disorder (ADHD) | Completed | 2019-03-11 | 2021-08-27 | ClinicalTrials.gov |
| NCT04866030 | Drug Use Study With Intuniv® in Australia | — | Attention Deficit Hyperactivity Disorder (ADHD) | Completed | 2019-03-11 | 2021-08-27 | ClinicalTrials.gov |
| NCT03870555 | A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Phar… | Phase1 | Healthy Volunteers | Completed | 2019-03-08 | 2019-05-16 | ClinicalTrials.gov |
| NCT03870555 | A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Phar… | Phase1 | Healthy Volunteers | Completed | 2019-03-08 | 2019-05-16 | ClinicalTrials.gov |
| NCT03870555 | A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Phar… | Phase1 | Healthy Volunteers | Completed | 2019-03-08 | 2019-05-16 | ClinicalTrials.gov |
| NCT05567393 | A Study of TAK-951 in Healthy Adults | Phase1 | Healthy Volunteers | Completed | 2019-03-07 | 2020-11-02 | ClinicalTrials.gov |
| NCT03827655 | A Study of TAK-954 to Treat Gastrointestinal Dysfunction in Adults After Surgery | Phase2 | Postoperative Gastrointestinal Dysfunction | Completed | 2019-03-07 | 2022-05-27 | ClinicalTrials.gov |
| NCT05567393 | A Study of TAK-951 in Healthy Adults | Phase1 | Healthy Volunteers | Completed | 2019-03-07 | 2020-11-02 | ClinicalTrials.gov |
| NCT03827655 | A Study of TAK-954 to Treat Gastrointestinal Dysfunction in Adults After Surgery | Phase2 | Postoperative Gastrointestinal Dysfunction | Completed | 2019-03-07 | 2022-05-27 | ClinicalTrials.gov |
| NCT03719924 | Nal-iri/lv5-fu Versus Paclitaxel as Second Line Therapy in Patients With Metast… | Phase2 | Squamous Cell Carcinoma | Completed | 2019-03-07 | 2024-09-29 | ClinicalTrials.gov |
| NCT03719924 | Nal-iri/lv5-fu Versus Paclitaxel as Second Line Therapy in Patients With Metast… | Phase2 | Squamous Cell Carcinoma | Completed | 2019-03-07 | 2024-09-29 | ClinicalTrials.gov |
| NCT03827655 | A Study of TAK-954 to Treat Gastrointestinal Dysfunction in Adults After Surgery | Phase2 | Postoperative Gastrointestinal Dysfunction | Completed | 2019-03-07 | 2022-05-27 | ClinicalTrials.gov |
| NCT03719924 | Nal-iri/lv5-fu Versus Paclitaxel as Second Line Therapy in Patients With Metast… | Phase2 | Squamous Cell Carcinoma | Completed | 2019-03-07 | 2024-09-29 | ClinicalTrials.gov |
| NCT05567393 | A Study of TAK-951 in Healthy Adults | Phase1 | Healthy Volunteers | Completed | 2019-03-07 | 2020-11-02 | ClinicalTrials.gov |
| NCT03706456 | Phase 3 Study of Cx601 in Participants With Complex Perianal Fistulising Crohn'… | Phase3 | Complex Perianal Fistulas in Adult Participants With Crohn's Disease | Completed | 2019-03-06 | 2023-02-10 | ClinicalTrials.gov |
| NCT03706456 | Phase 3 Study of Cx601 in Participants With Complex Perianal Fistulising Crohn'… | Phase3 | Complex Perianal Fistulas in Adult Participants With Crohn's Disease | Completed | 2019-03-06 | 2023-02-10 | ClinicalTrials.gov |
| NCT03706456 | Phase 3 Study of Cx601 in Participants With Complex Perianal Fistulising Crohn'… | Phase3 | Complex Perianal Fistulas in Adult Participants With Crohn's Disease | Completed | 2019-03-06 | 2023-02-10 | ClinicalTrials.gov |
| NCT03724929 | Value of Pharmacokinetic Assays in the Prediction of Therapeutic Response in Ul… | Na | Ulcerative Colitis | Terminated | 2019-03-04 | 2022-06-28 | ClinicalTrials.gov |
| NCT03724929 | Value of Pharmacokinetic Assays in the Prediction of Therapeutic Response in Ul… | Na | Ulcerative Colitis | Terminated | 2019-03-04 | 2022-06-28 | ClinicalTrials.gov |
| NCT03724929 | Value of Pharmacokinetic Assays in the Prediction of Therapeutic Response in Ul… | Na | Ulcerative Colitis | Terminated | 2019-03-04 | 2022-06-28 | ClinicalTrials.gov |
| NCT03733691 | Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients | Phase2 | Newly Diagnosed Multiple Myeloma | Terminated | 2019-03-01 | 2023-10-19 | ClinicalTrials.gov |
| NCT03733691 | Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients | Phase2 | Newly Diagnosed Multiple Myeloma | Terminated | 2019-03-01 | 2023-10-19 | ClinicalTrials.gov |
| NCT03733691 | Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients | Phase2 | Newly Diagnosed Multiple Myeloma | Terminated | 2019-03-01 | 2023-10-19 | ClinicalTrials.gov |
| NCT03849690 | A Trial to Evaluate the Effect of the Proton Pump Inhibitor Esomeprazole on the… | Phase1 | Healthy Volunteers | Completed | 2019-02-27 | 2019-04-15 | ClinicalTrials.gov |
| NCT03849690 | A Trial to Evaluate the Effect of the Proton Pump Inhibitor Esomeprazole on the… | Phase1 | Healthy Volunteers | Completed | 2019-02-27 | 2019-04-15 | ClinicalTrials.gov |
| NCT03849690 | A Trial to Evaluate the Effect of the Proton Pump Inhibitor Esomeprazole on the… | Phase1 | Healthy Volunteers | Completed | 2019-02-27 | 2019-04-15 | ClinicalTrials.gov |
| NCT03866434 | Study to Evaluate the Effect of Omeprazole on the Pharmacokinetics of SPD422 (A… | Phase1 | Healthy Volunteers | Completed | 2019-02-26 | 2019-04-10 | ClinicalTrials.gov |
| NCT03866434 | Study to Evaluate the Effect of Omeprazole on the Pharmacokinetics of SPD422 (A… | Phase1 | Healthy Volunteers | Completed | 2019-02-26 | 2019-04-10 | ClinicalTrials.gov |
| NCT03866434 | Study to Evaluate the Effect of Omeprazole on the Pharmacokinetics of SPD422 (A… | Phase1 | Healthy Volunteers | Completed | 2019-02-26 | 2019-04-10 | ClinicalTrials.gov |
| NCT03824522 | Post Marketing Surveillance Study for ADYNOVATE in South Korea | — | Hemophilia A | Completed | 2019-02-25 | 2024-01-05 | ClinicalTrials.gov |
| NCT03824522 | Post Marketing Surveillance Study for ADYNOVATE in South Korea | — | Hemophilia A | Completed | 2019-02-25 | 2024-01-05 | ClinicalTrials.gov |
| NCT03824522 | Post Marketing Surveillance Study for ADYNOVATE in South Korea | — | Hemophilia A | Completed | 2019-02-25 | 2024-01-05 | ClinicalTrials.gov |
| NCT03710486 | A Study to Observe Vedolizumab and Anti-tumour Necrosis Factors (Anti-TNFs) Out… | — | Colitis, Ulcerative | Completed | 2019-02-19 | 2022-02-21 | ClinicalTrials.gov |
| NCT03710486 | A Study to Observe Vedolizumab and Anti-tumour Necrosis Factors (Anti-TNFs) Out… | — | Colitis, Ulcerative | Completed | 2019-02-19 | 2022-02-21 | ClinicalTrials.gov |
| NCT03710486 | A Study to Observe Vedolizumab and Anti-tumour Necrosis Factors (Anti-TNFs) Out… | — | Colitis, Ulcerative | Completed | 2019-02-19 | 2022-02-21 | ClinicalTrials.gov |
| NCT03817320 | PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refracto… | Phase1 | ALL, Childhood | Active_Not_Recruiting | 2019-02-12 | 2025-06-30 | ClinicalTrials.gov |
| NCT03817320 | PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refracto… | Phase1 | ALL, Childhood | Active_Not_Recruiting | 2019-02-12 | 2025-06-30 | ClinicalTrials.gov |
| NCT03817320 | PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refracto… | Phase1 | ALL, Childhood | Active_Not_Recruiting | 2019-02-12 | 2025-06-30 | ClinicalTrials.gov |
| NCT03792672 | A Study to Evaluate Central Nervous System (CNS) Pharmacodynamic Activity of TA… | Phase1 | Healthy Volunteers | Completed | 2019-02-11 | 2019-06-18 | ClinicalTrials.gov |
| NCT03792672 | A Study to Evaluate Central Nervous System (CNS) Pharmacodynamic Activity of TA… | Phase1 | Healthy Volunteers | Completed | 2019-02-11 | 2019-06-18 | ClinicalTrials.gov |
| NCT03792672 | A Study to Evaluate Central Nervous System (CNS) Pharmacodynamic Activity of TA… | Phase1 | Healthy Volunteers | Completed | 2019-02-11 | 2019-06-18 | ClinicalTrials.gov |
| NCT03657160 | Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease (a… | Phase3 | Hematopoietic Stem Cells | Completed | 2019-02-06 | 2022-05-09 | ClinicalTrials.gov |
| NCT03657160 | Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease (a… | Phase3 | Hematopoietic Stem Cells | Completed | 2019-02-06 | 2022-05-09 | ClinicalTrials.gov |
| NCT03657160 | Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease (a… | Phase3 | Hematopoietic Stem Cells | Completed | 2019-02-06 | 2022-05-09 | ClinicalTrials.gov |
| NCT03807778 | A Study of Mobocertinib in Japanese Adults With Non-Small Cell Lung Cancer | Phase1 | Non-Small Cell Lung Cancer | Active_Not_Recruiting | 2019-02-04 | 2026-09-30 | ClinicalTrials.gov |
| NCT03807778 | A Study of Mobocertinib in Japanese Adults With Non-Small Cell Lung Cancer | Phase1 | Non-Small Cell Lung Cancer | Active_Not_Recruiting | 2019-02-04 | 2026-09-30 | ClinicalTrials.gov |
| NCT03807778 | A Study of Mobocertinib in Japanese Adults With Non-Small Cell Lung Cancer | Phase1 | Non-Small Cell Lung Cancer | Active_Not_Recruiting | 2019-02-04 | 2026-09-30 | ClinicalTrials.gov |
| NCT03824561 | Special Drug-Use Surveillance Study on Vedolizumab for IV Infusion 300 mg [Ulce… | — | Ulcerative Colitis | Completed | 2019-02-01 | 2025-02-12 | ClinicalTrials.gov |
| NCT03824561 | Special Drug-Use Surveillance Study on Vedolizumab for IV Infusion 300 mg [Ulce… | — | Ulcerative Colitis | Completed | 2019-02-01 | 2025-02-12 | ClinicalTrials.gov |
| NCT03824561 | Special Drug-Use Surveillance Study on Vedolizumab for IV Infusion 300 mg [Ulce… | — | Ulcerative Colitis | Completed | 2019-02-01 | 2025-02-12 | ClinicalTrials.gov |
| NCT03535740 | A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive … | Phase2 | ALK-positive Advanced NSCLC | Completed | 2019-01-31 | 2024-08-21 | ClinicalTrials.gov |
| NCT02889393 | Teduglutide for Enterocutaneous Fistula (ECF) | Phase2 | Postoperative Fistula | Completed | 2019-01-31 | 2021-07-15 | ClinicalTrials.gov |
| NCT03535740 | A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive … | Phase2 | ALK-positive Advanced NSCLC | Completed | 2019-01-31 | 2024-08-21 | ClinicalTrials.gov |
| NCT03535740 | A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive … | Phase2 | ALK-positive Advanced NSCLC | Completed | 2019-01-31 | 2024-08-21 | ClinicalTrials.gov |
| NCT02889393 | Teduglutide for Enterocutaneous Fistula (ECF) | Phase2 | Postoperative Fistula | Completed | 2019-01-31 | 2021-07-15 | ClinicalTrials.gov |
| NCT02889393 | Teduglutide for Enterocutaneous Fistula (ECF) | Phase2 | Postoperative Fistula | Completed | 2019-01-31 | 2021-07-15 | ClinicalTrials.gov |
| NCT03246750 | B-MAD Chemotherapy in Newly-diagnosed Extranodal NK/ T-cell Lymphoma | Phase1 | Extranodal NK/T-cell Lymphoma | Completed | 2019-01-30 | 2024-04-10 | ClinicalTrials.gov |
| NCT03808493 | A Bioequivalence (BE) Study of TAK-438 Orally Disintegrating (OD) Tablet | Phase1 | Japanese Healthy Adult Male | Completed | 2019-01-30 | 2019-03-12 | ClinicalTrials.gov |
| NCT03246750 | B-MAD Chemotherapy in Newly-diagnosed Extranodal NK/ T-cell Lymphoma | Phase1 | Extranodal NK/T-cell Lymphoma | Completed | 2019-01-30 | 2024-04-10 | ClinicalTrials.gov |
| NCT03808493 | A Bioequivalence (BE) Study of TAK-438 Orally Disintegrating (OD) Tablet | Phase1 | Japanese Healthy Adult Male | Completed | 2019-01-30 | 2019-03-12 | ClinicalTrials.gov |
| NCT03246750 | B-MAD Chemotherapy in Newly-diagnosed Extranodal NK/ T-cell Lymphoma | Phase1 | Extranodal NK/T-cell Lymphoma | Completed | 2019-01-30 | 2024-04-10 | ClinicalTrials.gov |
| NCT03808493 | A Bioequivalence (BE) Study of TAK-438 Orally Disintegrating (OD) Tablet | Phase1 | Japanese Healthy Adult Male | Completed | 2019-01-30 | 2019-03-12 | ClinicalTrials.gov |
| NCT03748953 | Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participant… | Phase3 | Multiple Myeloma | Completed | 2019-01-24 | 2023-12-06 | ClinicalTrials.gov |
| NCT03748953 | Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participant… | Phase3 | Multiple Myeloma | Completed | 2019-01-24 | 2023-12-06 | ClinicalTrials.gov |
| NCT03748953 | Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participant… | Phase3 | Multiple Myeloma | Completed | 2019-01-24 | 2023-12-06 | ClinicalTrials.gov |
| NCT03811834 | A Study to Assess Absolute Bioavailability (ABA) of Mobocertinib (TAK-788) and … | Phase1 | Healthy Volunteers | Completed | 2019-01-22 | 2019-03-11 | ClinicalTrials.gov |
| NCT03811834 | A Study to Assess Absolute Bioavailability (ABA) of Mobocertinib (TAK-788) and … | Phase1 | Healthy Volunteers | Completed | 2019-01-22 | 2019-03-11 | ClinicalTrials.gov |
| NCT03811834 | A Study to Assess Absolute Bioavailability (ABA) of Mobocertinib (TAK-788) and … | Phase1 | Healthy Volunteers | Completed | 2019-01-22 | 2019-03-11 | ClinicalTrials.gov |
| NCT03763162 | Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, a… | Phase2 | Recurrent Plasma Cell Myeloma | Active_Not_Recruiting | 2019-01-17 | 2027-10-30 | ClinicalTrials.gov |
| NCT03763162 | Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, a… | Phase2 | Recurrent Plasma Cell Myeloma | Active_Not_Recruiting | 2019-01-17 | 2027-10-30 | ClinicalTrials.gov |
| NCT03763162 | Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, a… | Phase2 | Recurrent Plasma Cell Myeloma | Active_Not_Recruiting | 2019-01-17 | 2027-10-30 | ClinicalTrials.gov |
| NCT03801148 | A Study to Compare the Bioavailability (BA) of Dexlansoprazole Delayed-release … | Phase1 | Healthy Volunteers | Completed | 2019-01-10 | 2019-04-09 | ClinicalTrials.gov |
| NCT03801148 | A Study to Compare the Bioavailability (BA) of Dexlansoprazole Delayed-release … | Phase1 | Healthy Volunteers | Completed | 2019-01-10 | 2019-04-09 | ClinicalTrials.gov |
| NCT03801148 | A Study to Compare the Bioavailability (BA) of Dexlansoprazole Delayed-release … | Phase1 | Healthy Volunteers | Completed | 2019-01-10 | 2019-04-09 | ClinicalTrials.gov |
| NCT03408015 | Effects of Xiidra on Closed Eye Tear Film Leukocytes in Dry Eye Disease | Phase4 | Ocular Discomfort | Withdrawn | 2019-01-01 | 2019-01-30 | ClinicalTrials.gov |
| NCT03408015 | Effects of Xiidra on Closed Eye Tear Film Leukocytes in Dry Eye Disease | Phase4 | Ocular Discomfort | Withdrawn | 2019-01-01 | 2019-01-30 | ClinicalTrials.gov |
| NCT03408015 | Effects of Xiidra on Closed Eye Tear Film Leukocytes in Dry Eye Disease | Phase4 | Ocular Discomfort | Withdrawn | 2019-01-01 | 2019-01-30 | ClinicalTrials.gov |
| NCT03746015 | Immunogenicity and Safety of Tetravalent Dengue Vaccine Candidate (TDV) in Flav… | Phase2 | Dengue Fever | Completed | 2018-12-28 | 2021-03-01 | ClinicalTrials.gov |
| NCT03759587 | Japan Phase 2 Study of Niraparib (Maintenance Therapy) in Participants With Rel… | Phase2 | Ovarian Cancer | Completed | 2018-12-28 | 2022-12-28 | ClinicalTrials.gov |
| NCT03746015 | Immunogenicity and Safety of Tetravalent Dengue Vaccine Candidate (TDV) in Flav… | Phase2 | Dengue Fever | Completed | 2018-12-28 | 2021-03-01 | ClinicalTrials.gov |
| NCT03759587 | Japan Phase 2 Study of Niraparib (Maintenance Therapy) in Participants With Rel… | Phase2 | Ovarian Cancer | Completed | 2018-12-28 | 2022-12-28 | ClinicalTrials.gov |
| NCT03759587 | Japan Phase 2 Study of Niraparib (Maintenance Therapy) in Participants With Rel… | Phase2 | Ovarian Cancer | Completed | 2018-12-28 | 2022-12-28 | ClinicalTrials.gov |
| NCT03746015 | Immunogenicity and Safety of Tetravalent Dengue Vaccine Candidate (TDV) in Flav… | Phase2 | Dengue Fever | Completed | 2018-12-28 | 2021-03-01 | ClinicalTrials.gov |
| NCT03759600 | Japan Phase 2 Study of Niraparib in Participants With Advanced, Relapsed Ovaria… | Phase2 | Ovarian Cancer | Completed | 2018-12-26 | 2022-12-28 | ClinicalTrials.gov |
| NCT03759600 | Japan Phase 2 Study of Niraparib in Participants With Advanced, Relapsed Ovaria… | Phase2 | Ovarian Cancer | Completed | 2018-12-26 | 2022-12-28 | ClinicalTrials.gov |
| NCT03759600 | Japan Phase 2 Study of Niraparib in Participants With Advanced, Relapsed Ovaria… | Phase2 | Ovarian Cancer | Completed | 2018-12-26 | 2022-12-28 | ClinicalTrials.gov |
| NCT03616782 | Ixazomib Maintenance in Patients With Newly Diagnosed Mantle Cell Lymphoma(MCL) | Phase2 | Mantle Cell Lymphoma | Recruiting | 2018-12-24 | 2026-05-31 | ClinicalTrials.gov |
| NCT03616782 | Ixazomib Maintenance in Patients With Newly Diagnosed Mantle Cell Lymphoma(MCL) | Phase2 | Mantle Cell Lymphoma | Recruiting | 2018-12-24 | 2026-05-31 | ClinicalTrials.gov |
| NCT03616782 | Ixazomib Maintenance in Patients With Newly Diagnosed Mantle Cell Lymphoma(MCL) | Phase2 | Mantle Cell Lymphoma | Recruiting | 2018-12-24 | 2026-05-31 | ClinicalTrials.gov |
| NCT03666858 | A Study to Describe Pain Intensity, Pain Relief and Safety of Neosaldina in the… | — | Healthy Volunteers | Completed | 2018-12-20 | 2019-08-19 | ClinicalTrials.gov |
| NCT03666858 | A Study to Describe Pain Intensity, Pain Relief and Safety of Neosaldina in the… | — | Healthy Volunteers | Completed | 2018-12-20 | 2019-08-19 | ClinicalTrials.gov |
| NCT03666858 | A Study to Describe Pain Intensity, Pain Relief and Safety of Neosaldina in the… | — | Healthy Volunteers | Completed | 2018-12-20 | 2019-08-19 | ClinicalTrials.gov |
| NCT03488030 | A Study to Evaluate Disease Control, Treatment Patterns, Burden of Disease and … | — | Crohn Disease | Completed | 2018-12-12 | 2019-05-31 | ClinicalTrials.gov |
| NCT03488030 | A Study to Evaluate Disease Control, Treatment Patterns, Burden of Disease and … | — | Crohn Disease | Completed | 2018-12-12 | 2019-05-31 | ClinicalTrials.gov |
| NCT03488030 | A Study to Evaluate Disease Control, Treatment Patterns, Burden of Disease and … | — | Crohn Disease | Completed | 2018-12-12 | 2019-05-31 | ClinicalTrials.gov |
| NCT03746652 | Safety and Efficacy of Daratumumab in Combination With Ixazomib and Dexamethaso… | Phase2 | Multiple Myeloma | Unknown | 2018-12-01 | 2021-12-01 | ClinicalTrials.gov |
| NCT02834754 | Vedolizumab Post Op Study | Phase2 | Crohn's Disease | Withdrawn | 2018-12-01 | 2019-05-01 | ClinicalTrials.gov |
| NCT03746652 | Safety and Efficacy of Daratumumab in Combination With Ixazomib and Dexamethaso… | Phase2 | Multiple Myeloma | Unknown | 2018-12-01 | 2021-12-01 | ClinicalTrials.gov |
| NCT02834754 | Vedolizumab Post Op Study | Phase2 | Crohn's Disease | Withdrawn | 2018-12-01 | 2019-05-01 | ClinicalTrials.gov |
| NCT03746652 | Safety and Efficacy of Daratumumab in Combination With Ixazomib and Dexamethaso… | Phase2 | Multiple Myeloma | Unknown | 2018-12-01 | 2021-12-01 | ClinicalTrials.gov |
| NCT02834754 | Vedolizumab Post Op Study | Phase2 | Crohn's Disease | Withdrawn | 2018-12-01 | 2019-05-01 | ClinicalTrials.gov |
| NCT03724916 | A Study to Evaluate the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD… | Phase1 | Systemic Lupus Erythematosus | Completed | 2018-11-26 | 2021-11-04 | ClinicalTrials.gov |
| NCT03724916 | A Study to Evaluate the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD… | Phase1 | Systemic Lupus Erythematosus | Completed | 2018-11-26 | 2021-11-04 | ClinicalTrials.gov |
| NCT03724916 | A Study to Evaluate the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD… | Phase1 | Systemic Lupus Erythematosus | Completed | 2018-11-26 | 2021-11-04 | ClinicalTrials.gov |
| NCT03748979 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodyna… | Phase1 | Healthy Participants | Completed | 2018-11-21 | 2019-10-24 | ClinicalTrials.gov |
| NCT03748979 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodyna… | Phase1 | Healthy Participants | Completed | 2018-11-21 | 2019-10-24 | ClinicalTrials.gov |
| NCT03748979 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodyna… | Phase1 | Healthy Participants | Completed | 2018-11-21 | 2019-10-24 | ClinicalTrials.gov |
| NCT04057131 | FIRAZYR General Drug Use-Results Survey (Japan) | — | Hereditary Angioedema (HAE) | Completed | 2018-11-20 | 2024-07-29 | ClinicalTrials.gov |
| NCT04057131 | FIRAZYR General Drug Use-Results Survey (Japan) | — | Hereditary Angioedema (HAE) | Completed | 2018-11-20 | 2024-07-29 | ClinicalTrials.gov |
| NCT04057131 | FIRAZYR General Drug Use-Results Survey (Japan) | — | Hereditary Angioedema (HAE) | Completed | 2018-11-20 | 2024-07-29 | ClinicalTrials.gov |
| NCT05870605 | Drug Use Study With Intuniv® in European Countries | — | Attention Deficit Hyperactivity Disorder (ADHD) | Completed | 2018-11-15 | 2022-04-30 | ClinicalTrials.gov |
| NCT05870605 | Drug Use Study With Intuniv® in European Countries | — | Attention Deficit Hyperactivity Disorder (ADHD) | Completed | 2018-11-15 | 2022-04-30 | ClinicalTrials.gov |
| NCT05870605 | Drug Use Study With Intuniv® in European Countries | — | Attention Deficit Hyperactivity Disorder (ADHD) | Completed | 2018-11-15 | 2022-04-30 | ClinicalTrials.gov |
| NCT03738475 | Study of the Safety, Pharmacodynamics, Efficacy, and PK of TIMP-GLIA in Subject… | Phase2 | Celiac Disease | Completed | 2018-11-11 | 2019-07-22 | ClinicalTrials.gov |
| NCT03738475 | Study of the Safety, Pharmacodynamics, Efficacy, and PK of TIMP-GLIA in Subject… | Phase2 | Celiac Disease | Completed | 2018-11-11 | 2019-07-22 | ClinicalTrials.gov |
| NCT03738475 | Study of the Safety, Pharmacodynamics, Efficacy, and PK of TIMP-GLIA in Subject… | Phase2 | Celiac Disease | Completed | 2018-11-11 | 2019-07-22 | ClinicalTrials.gov |
| NCT04002531 | A One Visit Follow Up of Adults With Fabry Disease Who Started Long-term Enzyme… | Na | Quality of Life | Completed | 2018-11-10 | 2019-12-13 | ClinicalTrials.gov |
| NCT04002531 | A One Visit Follow Up of Adults With Fabry Disease Who Started Long-term Enzyme… | Na | Quality of Life | Completed | 2018-11-10 | 2019-12-13 | ClinicalTrials.gov |
| NCT04002531 | A One Visit Follow Up of Adults With Fabry Disease Who Started Long-term Enzyme… | Na | Quality of Life | Completed | 2018-11-10 | 2019-12-13 | ClinicalTrials.gov |
| NCT03729609 | Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Untreated C… | — | Untreated CD30-Positive Hodgkin's Lymphoma | Completed | 2018-11-01 | 2023-09-27 | ClinicalTrials.gov |
| NCT03729609 | Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Untreated C… | — | Untreated CD30-Positive Hodgkin's Lymphoma | Completed | 2018-11-01 | 2023-09-27 | ClinicalTrials.gov |
| NCT03729609 | Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Untreated C… | — | Untreated CD30-Positive Hodgkin's Lymphoma | Completed | 2018-11-01 | 2023-09-27 | ClinicalTrials.gov |
| NCT03727139 | Rasagiline Tablets Special Drug Use-Results Survey "Survey on Long-term Safety" | — | Parkinson's Disease | Completed | 2018-11-01 | 2021-10-31 | ClinicalTrials.gov |
| NCT04602052 | Comparison of Surgical Versus Medical Termination of Pregnancy Between 13-20 We… | Na | Termination of Pregnancy | Completed | 2018-11-01 | 2019-10-31 | ClinicalTrials.gov |
| NCT03431272 | Use of 5.0% Lifitegrast Ophthalmic Solution for the Treatment of Dry Eye Diseas… | Phase4 | Contact Lens Dry Eye | Withdrawn | 2018-11-01 | 2019-12-31 | ClinicalTrials.gov |
| NCT03727139 | Rasagiline Tablets Special Drug Use-Results Survey "Survey on Long-term Safety" | — | Parkinson's Disease | Completed | 2018-11-01 | 2021-10-31 | ClinicalTrials.gov |
| NCT04602052 | Comparison of Surgical Versus Medical Termination of Pregnancy Between 13-20 We… | Na | Termination of Pregnancy | Completed | 2018-11-01 | 2019-10-31 | ClinicalTrials.gov |
| NCT04602052 | Comparison of Surgical Versus Medical Termination of Pregnancy Between 13-20 We… | Na | Termination of Pregnancy | Completed | 2018-11-01 | 2019-10-31 | ClinicalTrials.gov |
| NCT03431272 | Use of 5.0% Lifitegrast Ophthalmic Solution for the Treatment of Dry Eye Diseas… | Phase4 | Contact Lens Dry Eye | Withdrawn | 2018-11-01 | 2019-12-31 | ClinicalTrials.gov |
| NCT03727139 | Rasagiline Tablets Special Drug Use-Results Survey "Survey on Long-term Safety" | — | Parkinson's Disease | Completed | 2018-11-01 | 2021-10-31 | ClinicalTrials.gov |
| NCT03431272 | Use of 5.0% Lifitegrast Ophthalmic Solution for the Treatment of Dry Eye Diseas… | Phase4 | Contact Lens Dry Eye | Withdrawn | 2018-11-01 | 2019-12-31 | ClinicalTrials.gov |
| NCT05918666 | National Register of Actionable Mutations | — | Solid Tumours in Advanced Stages | Active_Not_Recruiting | 2018-10-27 | 2026-10-27 | ClinicalTrials.gov |
| NCT05918666 | National Register of Actionable Mutations | — | Solid Tumours in Advanced Stages | Active_Not_Recruiting | 2018-10-27 | 2026-10-27 | ClinicalTrials.gov |
| NCT05918666 | National Register of Actionable Mutations | — | Solid Tumours in Advanced Stages | Active_Not_Recruiting | 2018-10-27 | 2026-10-27 | ClinicalTrials.gov |
| NCT03706469 | A Study to Evaluate the Relative Bioavailability (BA) and Effect of Food on TAK… | Phase1 | Healthy Volunteers | Completed | 2018-10-18 | 2018-12-22 | ClinicalTrials.gov |
| NCT03706469 | A Study to Evaluate the Relative Bioavailability (BA) and Effect of Food on TAK… | Phase1 | Healthy Volunteers | Completed | 2018-10-18 | 2018-12-22 | ClinicalTrials.gov |
| NCT03706469 | A Study to Evaluate the Relative Bioavailability (BA) and Effect of Food on TAK… | Phase1 | Healthy Volunteers | Completed | 2018-10-18 | 2018-12-22 | ClinicalTrials.gov |
| NCT03590652 | Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Re… | Phase2 | Relapsed/Refractory Multiple Myeloma | Terminated | 2018-10-17 | 2025-07-02 | ClinicalTrials.gov |
| NCT03590652 | Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Re… | Phase2 | Relapsed/Refractory Multiple Myeloma | Terminated | 2018-10-17 | 2025-07-02 | ClinicalTrials.gov |
| NCT03590652 | Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Re… | Phase2 | Relapsed/Refractory Multiple Myeloma | Terminated | 2018-10-17 | 2025-07-02 | ClinicalTrials.gov |
| NCT03544229 | A Study to Evaluate the Efficacy and Safety of TAK-906 in Adult Participants Wi… | Phase2 | Diabetic Gastroparesis | Completed | 2018-10-14 | 2021-07-15 | ClinicalTrials.gov |
| NCT03544229 | A Study to Evaluate the Efficacy and Safety of TAK-906 in Adult Participants Wi… | Phase2 | Diabetic Gastroparesis | Completed | 2018-10-14 | 2021-07-15 | ClinicalTrials.gov |
| NCT03544229 | A Study to Evaluate the Efficacy and Safety of TAK-906 in Adult Participants Wi… | Phase2 | Diabetic Gastroparesis | Completed | 2018-10-14 | 2021-07-15 | ClinicalTrials.gov |
| NCT03687684 | Phase 1 Study of TAK-831 in Healthy Adult Asian Subjects | Phase1 | Healthy Volunteers | Completed | 2018-10-09 | 2019-06-19 | ClinicalTrials.gov |
| NCT03687684 | Phase 1 Study of TAK-831 in Healthy Adult Asian Subjects | Phase1 | Healthy Volunteers | Completed | 2018-10-09 | 2019-06-19 | ClinicalTrials.gov |
| NCT03687684 | Phase 1 Study of TAK-831 in Healthy Adult Asian Subjects | Phase1 | Healthy Volunteers | Completed | 2018-10-09 | 2019-06-19 | ClinicalTrials.gov |
| NCT03589326 | A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia | Phase3 | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) | Active_Not_Recruiting | 2018-10-04 | 2027-07-31 | ClinicalTrials.gov |
| NCT03589326 | A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia | Phase3 | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) | Active_Not_Recruiting | 2018-10-04 | 2027-07-31 | ClinicalTrials.gov |
| NCT03589326 | A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia | Phase3 | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) | Active_Not_Recruiting | 2018-10-04 | 2027-07-31 | ClinicalTrials.gov |
| NCT03818529 | ATHN 8: Previously Untreated Patients (PUPs) Matter Study | — | Hemophilia | Completed | 2018-10-03 | 2022-12-31 | ClinicalTrials.gov |
| NCT03818529 | ATHN 8: Previously Untreated Patients (PUPs) Matter Study | — | Hemophilia | Completed | 2018-10-03 | 2022-12-31 | ClinicalTrials.gov |
| NCT03818529 | ATHN 8: Previously Untreated Patients (PUPs) Matter Study | — | Hemophilia | Completed | 2018-10-03 | 2022-12-31 | ClinicalTrials.gov |
| NCT03648372 | A Study of TAK-981 in People With Advanced Solid Tumors or Cancers in the Immun… | Phase1 | Neoplasms | Terminated | 2018-10-01 | 2023-12-14 | ClinicalTrials.gov |
| NCT03648372 | A Study of TAK-981 in People With Advanced Solid Tumors or Cancers in the Immun… | Phase1 | Neoplasms | Terminated | 2018-10-01 | 2023-12-14 | ClinicalTrials.gov |
| NCT03648372 | A Study of TAK-981 in People With Advanced Solid Tumors or Cancers in the Immun… | Phase1 | Neoplasms | Terminated | 2018-10-01 | 2023-12-14 | ClinicalTrials.gov |
| NCT03547700 | Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL) | Phase1 | Lymphoma, T-Cell, Peripheral | Active_Not_Recruiting | 2018-09-26 | 2021-07-01 | ClinicalTrials.gov |
| NCT03547700 | Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL) | Phase1 | Lymphoma, T-Cell, Peripheral | Active_Not_Recruiting | 2018-09-26 | 2021-07-01 | ClinicalTrials.gov |
| NCT03337646 | Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 W… | Phase4 | Attention Deficit Hyperactivity Disorder | Completed | 2018-09-26 | 2023-03-31 | ClinicalTrials.gov |
| NCT03547700 | Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL) | Phase1 | Lymphoma, T-Cell, Peripheral | Active_Not_Recruiting | 2018-09-26 | 2021-07-01 | ClinicalTrials.gov |
| NCT03668249 | A Study to Characterize Multidimensional Model to Predict the Course of Crohn's… | — | Inflammatory Bowel Diseases | Completed | 2018-09-26 | 2019-09-16 | ClinicalTrials.gov |
| NCT03337646 | Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 W… | Phase4 | Attention Deficit Hyperactivity Disorder | Completed | 2018-09-26 | 2023-03-31 | ClinicalTrials.gov |
| NCT03668249 | A Study to Characterize Multidimensional Model to Predict the Course of Crohn's… | — | Inflammatory Bowel Diseases | Completed | 2018-09-26 | 2019-09-16 | ClinicalTrials.gov |
| NCT03337646 | Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 W… | Phase4 | Attention Deficit Hyperactivity Disorder | Completed | 2018-09-26 | 2023-03-31 | ClinicalTrials.gov |
| NCT03364738 | Safety and Efficacy Study of rhPTH(1-84) in Subjects With Hypoparathyroidism | Phase3 | Hypoparathyroidism | Terminated | 2018-09-26 | 2020-04-14 | ClinicalTrials.gov |
| NCT03364738 | Safety and Efficacy Study of rhPTH(1-84) in Subjects With Hypoparathyroidism | Phase3 | Hypoparathyroidism | Terminated | 2018-09-26 | 2020-04-14 | ClinicalTrials.gov |
| NCT03668249 | A Study to Characterize Multidimensional Model to Predict the Course of Crohn's… | — | Inflammatory Bowel Diseases | Completed | 2018-09-26 | 2019-09-16 | ClinicalTrials.gov |
| NCT03364738 | Safety and Efficacy Study of rhPTH(1-84) in Subjects With Hypoparathyroidism | Phase3 | Hypoparathyroidism | Terminated | 2018-09-26 | 2020-04-14 | ClinicalTrials.gov |
| NCT03648489 | Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube … | Phase2 | Ovarian Cancer | Completed | 2018-09-21 | 2023-11-30 | ClinicalTrials.gov |
| NCT03648489 | Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube … | Phase2 | Ovarian Cancer | Completed | 2018-09-21 | 2023-11-30 | ClinicalTrials.gov |
| NCT03648489 | Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube … | Phase2 | Ovarian Cancer | Completed | 2018-09-21 | 2023-11-30 | ClinicalTrials.gov |
| NCT03694275 | A Multicenter, Open-label, Pilot Study of Soticlestat (TAK-935/OV935) in Partic… | Phase2 | 15q Duplication Syndrome | Completed | 2018-09-10 | 2020-07-31 | ClinicalTrials.gov |
| NCT03694275 | A Multicenter, Open-label, Pilot Study of Soticlestat (TAK-935/OV935) in Partic… | Phase2 | 15q Duplication Syndrome | Completed | 2018-09-10 | 2020-07-31 | ClinicalTrials.gov |
| NCT03694275 | A Multicenter, Open-label, Pilot Study of Soticlestat (TAK-935/OV935) in Partic… | Phase2 | 15q Duplication Syndrome | Completed | 2018-09-10 | 2020-07-31 | ClinicalTrials.gov |
| NCT03571516 | Safety, Efficacy and Pharmacokinetic Study of Teduglutide in Infants 4 to 12 Mo… | Phase3 | Short Bowel Syndrome | Completed | 2018-08-31 | 2020-09-24 | ClinicalTrials.gov |
| NCT03571516 | Safety, Efficacy and Pharmacokinetic Study of Teduglutide in Infants 4 to 12 Mo… | Phase3 | Short Bowel Syndrome | Completed | 2018-08-31 | 2020-09-24 | ClinicalTrials.gov |
| NCT03571516 | Safety, Efficacy and Pharmacokinetic Study of Teduglutide in Infants 4 to 12 Mo… | Phase3 | Short Bowel Syndrome | Completed | 2018-08-31 | 2020-09-24 | ClinicalTrials.gov |
| NCT03559517 | Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants W… | Phase3 | Crohn's Disease | Terminated | 2018-08-29 | 2020-10-08 | ClinicalTrials.gov |
| NCT03559517 | Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants W… | Phase3 | Crohn's Disease | Terminated | 2018-08-29 | 2020-10-08 | ClinicalTrials.gov |
| NCT03559517 | Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants W… | Phase3 | Crohn's Disease | Terminated | 2018-08-29 | 2020-10-08 | ClinicalTrials.gov |
| NCT03477903 | TAK-954 in Critically Ill Participants With Enteral Feeding Intolerance (EFI) | Phase2 | Critical Illness | Terminated | 2018-08-25 | 2018-08-29 | ClinicalTrials.gov |
| NCT03477903 | TAK-954 in Critically Ill Participants With Enteral Feeding Intolerance (EFI) | Phase2 | Critical Illness | Terminated | 2018-08-25 | 2018-08-29 | ClinicalTrials.gov |
| NCT03477903 | TAK-954 in Critically Ill Participants With Enteral Feeding Intolerance (EFI) | Phase2 | Critical Illness | Terminated | 2018-08-25 | 2018-08-29 | ClinicalTrials.gov |
| NCT03323151 | A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma | Phase1 | Mantle-Cell Lymphoma | Completed | 2018-08-13 | 2023-09-07 | ClinicalTrials.gov |
| NCT03486314 | A Study to Evaluate the Effects of Rifampin on Pharmacokinetics (PK) of Pevoned… | Phase1 | Advanced Solid Neoplasm | Completed | 2018-08-13 | 2021-02-28 | ClinicalTrials.gov |
| NCT03323151 | A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma | Phase1 | Mantle-Cell Lymphoma | Completed | 2018-08-13 | 2023-09-07 | ClinicalTrials.gov |
| NCT03323151 | A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma | Phase1 | Mantle-Cell Lymphoma | Completed | 2018-08-13 | 2023-09-07 | ClinicalTrials.gov |
| NCT03486314 | A Study to Evaluate the Effects of Rifampin on Pharmacokinetics (PK) of Pevoned… | Phase1 | Advanced Solid Neoplasm | Completed | 2018-08-13 | 2021-02-28 | ClinicalTrials.gov |
| NCT03486314 | A Study to Evaluate the Effects of Rifampin on Pharmacokinetics (PK) of Pevoned… | Phase1 | Advanced Solid Neoplasm | Completed | 2018-08-13 | 2021-02-28 | ClinicalTrials.gov |
| NCT03506386 | Multiple Myeloma (MM) Profile in Brazil: A Retrospective Observational Analysis | — | Multiple Myeloma | Completed | 2018-08-09 | 2020-01-27 | ClinicalTrials.gov |
| NCT03506386 | Multiple Myeloma (MM) Profile in Brazil: A Retrospective Observational Analysis | — | Multiple Myeloma | Completed | 2018-08-09 | 2020-01-27 | ClinicalTrials.gov |
| NCT03506386 | Multiple Myeloma (MM) Profile in Brazil: A Retrospective Observational Analysis | — | Multiple Myeloma | Completed | 2018-08-09 | 2020-01-27 | ClinicalTrials.gov |
| NCT03650452 | A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to E… | Phase2 | Epilepsy | Completed | 2018-08-08 | 2020-07-20 | ClinicalTrials.gov |
| NCT03576378 | BrEPEM-LH-22017 for Older Patients With Untreated Hodgkin Lymphoma (HL) | Phase1 | Hodgkin Lymphoma | Unknown | 2018-08-08 | 2024-10-30 | ClinicalTrials.gov |
| NCT03650452 | A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to E… | Phase2 | Epilepsy | Completed | 2018-08-08 | 2020-07-20 | ClinicalTrials.gov |
| NCT03576378 | BrEPEM-LH-22017 for Older Patients With Untreated Hodgkin Lymphoma (HL) | Phase1 | Hodgkin Lymphoma | Unknown | 2018-08-08 | 2024-10-30 | ClinicalTrials.gov |
| NCT03576378 | BrEPEM-LH-22017 for Older Patients With Untreated Hodgkin Lymphoma (HL) | Phase1 | Hodgkin Lymphoma | Unknown | 2018-08-08 | 2024-10-30 | ClinicalTrials.gov |
| NCT03650452 | A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to E… | Phase2 | Epilepsy | Completed | 2018-08-08 | 2020-07-20 | ClinicalTrials.gov |
| NCT03586973 | A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Hepatoce… | Phase2 | Advanced Hepatocellular Carcinoma | Completed | 2018-08-06 | 2021-06-29 | ClinicalTrials.gov |
| NCT03586973 | A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Hepatoce… | Phase2 | Advanced Hepatocellular Carcinoma | Completed | 2018-08-06 | 2021-06-29 | ClinicalTrials.gov |
| NCT03586973 | A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Hepatoce… | Phase2 | Advanced Hepatocellular Carcinoma | Completed | 2018-08-06 | 2021-06-29 | ClinicalTrials.gov |
| NCT03603847 | Prospective Study of the Prognostic Value of New Markers in Adults With ALK-pos… | — | Anaplastic Large Cell Lymphoma, ALK-Positive | Completed | 2018-08-02 | 2023-06-16 | ClinicalTrials.gov |
| NCT03603847 | Prospective Study of the Prognostic Value of New Markers in Adults With ALK-pos… | — | Anaplastic Large Cell Lymphoma, ALK-Positive | Completed | 2018-08-02 | 2023-06-16 | ClinicalTrials.gov |
| NCT03603847 | Prospective Study of the Prognostic Value of New Markers in Adults With ALK-pos… | — | Anaplastic Large Cell Lymphoma, ALK-Positive | Completed | 2018-08-02 | 2023-06-16 | ClinicalTrials.gov |
| NCT03196427 | Long-term Safety With Vedolizumab Intravenous (IV) in Pediatric Participants Wi… | Phase2 | Ulcerative Colitis | Completed | 2018-07-30 | 2025-07-17 | ClinicalTrials.gov |
| NCT03196427 | Long-term Safety With Vedolizumab Intravenous (IV) in Pediatric Participants Wi… | Phase2 | Ulcerative Colitis | Completed | 2018-07-30 | 2025-07-17 | ClinicalTrials.gov |
| NCT03196427 | Long-term Safety With Vedolizumab Intravenous (IV) in Pediatric Participants Wi… | Phase2 | Ulcerative Colitis | Completed | 2018-07-30 | 2025-07-17 | ClinicalTrials.gov |
| NCT03546894 | A Study to Determine Progression-free Survival (PFS) and Evaluate Participant E… | — | Anaplastic Lymphoma Kinase-positive | Completed | 2018-07-23 | 2023-02-13 | ClinicalTrials.gov |
| NCT03546894 | A Study to Determine Progression-free Survival (PFS) and Evaluate Participant E… | — | Anaplastic Lymphoma Kinase-positive | Completed | 2018-07-23 | 2023-02-13 | ClinicalTrials.gov |
| NCT03546894 | A Study to Determine Progression-free Survival (PFS) and Evaluate Participant E… | — | Anaplastic Lymphoma Kinase-positive | Completed | 2018-07-23 | 2023-02-13 | ClinicalTrials.gov |
| NCT03532932 | A Study to Evaluate Disease Control and Treatment Pattern in Participants With … | — | Colitis, Ulcerative | Completed | 2018-07-20 | 2021-11-08 | ClinicalTrials.gov |
| NCT03532932 | A Study to Evaluate Disease Control and Treatment Pattern in Participants With … | — | Colitis, Ulcerative | Completed | 2018-07-20 | 2021-11-08 | ClinicalTrials.gov |
| NCT03532932 | A Study to Evaluate Disease Control and Treatment Pattern in Participants With … | — | Colitis, Ulcerative | Completed | 2018-07-20 | 2021-11-08 | ClinicalTrials.gov |
| NCT03635073 | A Study of Soticlestat in Adults and Children With Rare Epilepsies | Phase2 | Epilepsy | Terminated | 2018-07-19 | 2025-07-30 | ClinicalTrials.gov |
| NCT03635073 | A Study of Soticlestat in Adults and Children With Rare Epilepsies | Phase2 | Epilepsy | Terminated | 2018-07-19 | 2025-07-30 | ClinicalTrials.gov |
| NCT03635073 | A Study of Soticlestat in Adults and Children With Rare Epilepsies | Phase2 | Epilepsy | Terminated | 2018-07-19 | 2025-07-30 | ClinicalTrials.gov |
| NCT03709576 | Pevonedistat and Azacitidine as Maintenance Therapy After Allogeneic Stem Cell … | Phase2 | Acute Myeloid Leukemia (AML) | Terminated | 2018-07-18 | 2019-07-22 | ClinicalTrials.gov |
| NCT03709576 | Pevonedistat and Azacitidine as Maintenance Therapy After Allogeneic Stem Cell … | Phase2 | Acute Myeloid Leukemia (AML) | Terminated | 2018-07-18 | 2019-07-22 | ClinicalTrials.gov |
| NCT03709576 | Pevonedistat and Azacitidine as Maintenance Therapy After Allogeneic Stem Cell … | Phase2 | Acute Myeloid Leukemia (AML) | Terminated | 2018-07-18 | 2019-07-22 | ClinicalTrials.gov |
| NCT03566823 | Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants W… | Phase3 | Crohn's Disease | Terminated | 2018-07-17 | 2020-08-18 | ClinicalTrials.gov |
| NCT03566823 | Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants W… | Phase3 | Crohn's Disease | Terminated | 2018-07-17 | 2020-08-18 | ClinicalTrials.gov |
| NCT03566823 | Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants W… | Phase3 | Crohn's Disease | Terminated | 2018-07-17 | 2020-08-18 | ClinicalTrials.gov |
| NCT03596164 | An Extension Study of Teduglutide in Japanese Participants With Short Bowel Syn… | Phase3 | Short Bowel Syndrome | Completed | 2018-07-09 | 2022-01-13 | ClinicalTrials.gov |
| NCT03596164 | An Extension Study of Teduglutide in Japanese Participants With Short Bowel Syn… | Phase3 | Short Bowel Syndrome | Completed | 2018-07-09 | 2022-01-13 | ClinicalTrials.gov |
| NCT03596164 | An Extension Study of Teduglutide in Japanese Participants With Short Bowel Syn… | Phase3 | Short Bowel Syndrome | Completed | 2018-07-09 | 2022-01-13 | ClinicalTrials.gov |
| NCT03663582 | Study of Teduglutide in Japanese Participants With Short Bowel Syndrome | Phase3 | Short Bowel Syndrome | Completed | 2018-07-06 | 2019-08-06 | ClinicalTrials.gov |
| NCT03663582 | Study of Teduglutide in Japanese Participants With Short Bowel Syndrome | Phase3 | Short Bowel Syndrome | Completed | 2018-07-06 | 2019-08-06 | ClinicalTrials.gov |
| NCT03663582 | Study of Teduglutide in Japanese Participants With Short Bowel Syndrome | Phase3 | Short Bowel Syndrome | Completed | 2018-07-06 | 2019-08-06 | ClinicalTrials.gov |
| NCT02929316 | Vedolizumab Induction May Prevent Celiac Enteritis | Phase2 | Celiac Disease | Terminated | 2018-06-25 | 2018-10-05 | ClinicalTrials.gov |
| NCT02929316 | Vedolizumab Induction May Prevent Celiac Enteritis | Phase2 | Celiac Disease | Terminated | 2018-06-25 | 2018-10-05 | ClinicalTrials.gov |
| NCT02929316 | Vedolizumab Induction May Prevent Celiac Enteritis | Phase2 | Celiac Disease | Terminated | 2018-06-25 | 2018-10-05 | ClinicalTrials.gov |
| NCT03701555 | A Study of PVP001, PVP002, and PVP003 in Healthy Adults and PVP001 and PVP002 i… | Phase1 | Digestive System Disease | Completed | 2018-06-19 | 2021-07-02 | ClinicalTrials.gov |
| NCT03701555 | A Study of PVP001, PVP002, and PVP003 in Healthy Adults and PVP001 and PVP002 i… | Phase1 | Digestive System Disease | Completed | 2018-06-19 | 2021-07-02 | ClinicalTrials.gov |
| NCT03701555 | A Study of PVP001, PVP002, and PVP003 in Healthy Adults and PVP001 and PVP002 i… | Phase1 | Digestive System Disease | Completed | 2018-06-19 | 2021-07-02 | ClinicalTrials.gov |
| NCT03376672 | Ixazomib Plus Lenalidomide Plus Dexamethasone for Newly Diagnosed Myeloma Patie… | Phase2 | Multiple Myeloma | Active_Not_Recruiting | 2018-05-31 | 2027-12-31 | ClinicalTrials.gov |
| NCT03376672 | Ixazomib Plus Lenalidomide Plus Dexamethasone for Newly Diagnosed Myeloma Patie… | Phase2 | Multiple Myeloma | Active_Not_Recruiting | 2018-05-31 | 2027-12-31 | ClinicalTrials.gov |
| NCT03376672 | Ixazomib Plus Lenalidomide Plus Dexamethasone for Newly Diagnosed Myeloma Patie… | Phase2 | Multiple Myeloma | Active_Not_Recruiting | 2018-05-31 | 2027-12-31 | ClinicalTrials.gov |
| NCT03501069 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharma… | Phase1 | Healthy Volunteers | Terminated | 2018-05-30 | 2018-12-26 | ClinicalTrials.gov |
| NCT03501069 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharma… | Phase1 | Healthy Volunteers | Terminated | 2018-05-30 | 2018-12-26 | ClinicalTrials.gov |
| NCT03501069 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharma… | Phase1 | Healthy Volunteers | Terminated | 2018-05-30 | 2018-12-26 | ClinicalTrials.gov |
| NCT03501277 | A Study to Determine the Bioequivalence of Alogliptin and Pioglitazone When Adm… | Phase1 | Healthy Volunteers | Completed | 2018-05-26 | 2018-07-11 | ClinicalTrials.gov |
| NCT03501277 | A Study to Determine the Bioequivalence of Alogliptin and Pioglitazone When Adm… | Phase1 | Healthy Volunteers | Completed | 2018-05-26 | 2018-07-11 | ClinicalTrials.gov |
| NCT03501277 | A Study to Determine the Bioequivalence of Alogliptin and Pioglitazone When Adm… | Phase1 | Healthy Volunteers | Completed | 2018-05-26 | 2018-07-11 | ClinicalTrials.gov |
| NCT03459859 | Pevonedistat and Low Dose Cytarabine in Adult Patients With AML and MDS | Phase1 | Acute Myelogenous Leukemia | Completed | 2018-05-21 | 2021-06-25 | ClinicalTrials.gov |
| NCT03459859 | Pevonedistat and Low Dose Cytarabine in Adult Patients With AML and MDS | Phase1 | Acute Myelogenous Leukemia | Completed | 2018-05-21 | 2021-06-25 | ClinicalTrials.gov |
| NCT03459859 | Pevonedistat and Low Dose Cytarabine in Adult Patients With AML and MDS | Phase1 | Acute Myelogenous Leukemia | Completed | 2018-05-21 | 2021-06-25 | ClinicalTrials.gov |
| NCT03525119 | Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Co-administered W… | Phase3 | Healthy Volunteers | Completed | 2018-05-16 | 2019-07-09 | ClinicalTrials.gov |
| NCT03525119 | Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Co-administered W… | Phase3 | Healthy Volunteers | Completed | 2018-05-16 | 2019-07-09 | ClinicalTrials.gov |
| NCT03525119 | Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Co-administered W… | Phase3 | Healthy Volunteers | Completed | 2018-05-16 | 2019-07-09 | ClinicalTrials.gov |
| NCT03522506 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmac… | Phase1 | Healthy Volunteers | Completed | 2018-05-09 | 2018-11-07 | ClinicalTrials.gov |
| NCT03522506 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmac… | Phase1 | Healthy Volunteers | Completed | 2018-05-09 | 2018-11-07 | ClinicalTrials.gov |
| NCT03522506 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmac… | Phase1 | Healthy Volunteers | Completed | 2018-05-09 | 2018-11-07 | ClinicalTrials.gov |
| NCT03745911 | Paclitaxel and TAK-228 in Urothelial Carcinoma | Phase2 | Metastatic Urothelial Cancer | Unknown | 2018-05-04 | 2020-11-01 | ClinicalTrials.gov |
| NCT03745911 | Paclitaxel and TAK-228 in Urothelial Carcinoma | Phase2 | Metastatic Urothelial Cancer | Unknown | 2018-05-04 | 2020-11-01 | ClinicalTrials.gov |
| NCT03745911 | Paclitaxel and TAK-228 in Urothelial Carcinoma | Phase2 | Metastatic Urothelial Cancer | Unknown | 2018-05-04 | 2020-11-01 | ClinicalTrials.gov |
| NCT03469349 | Actovegin 12-Week Treatment Given First Intravenously and Subsequently Orally i… | Phase3 | Peripheral Arterial Diseases | Completed | 2018-05-01 | 2019-08-28 | ClinicalTrials.gov |
| NCT03469349 | Actovegin 12-Week Treatment Given First Intravenously and Subsequently Orally i… | Phase3 | Peripheral Arterial Diseases | Completed | 2018-05-01 | 2019-08-28 | ClinicalTrials.gov |
| NCT03469349 | Actovegin 12-Week Treatment Given First Intravenously and Subsequently Orally i… | Phase3 | Peripheral Arterial Diseases | Completed | 2018-05-01 | 2019-08-28 | ClinicalTrials.gov |
| NCT03500224 | A Study to Evaluate the Mass Balance, Pharmacokinetics (PK), Metabolism and Exc… | Phase1 | Healthy Volunteers | Completed | 2018-04-30 | 2018-06-01 | ClinicalTrials.gov |
| NCT03500224 | A Study to Evaluate the Mass Balance, Pharmacokinetics (PK), Metabolism and Exc… | Phase1 | Healthy Volunteers | Completed | 2018-04-30 | 2018-06-01 | ClinicalTrials.gov |
| NCT03500224 | A Study to Evaluate the Mass Balance, Pharmacokinetics (PK), Metabolism and Exc… | Phase1 | Healthy Volunteers | Completed | 2018-04-30 | 2018-06-01 | ClinicalTrials.gov |
| NCT03409796 | Assessment of Immune Activation and Tolerance in Celiac Disease During Gluten C… | Na | Celiac Disease | Completed | 2018-04-24 | 2019-05-02 | ClinicalTrials.gov |
| NCT03409796 | Assessment of Immune Activation and Tolerance in Celiac Disease During Gluten C… | Na | Celiac Disease | Completed | 2018-04-24 | 2019-05-02 | ClinicalTrials.gov |
| NCT03409796 | Assessment of Immune Activation and Tolerance in Celiac Disease During Gluten C… | Na | Celiac Disease | Completed | 2018-04-24 | 2019-05-02 | ClinicalTrials.gov |
| NCT03336450 | Study of Midazolam Hydrochloride Oromucosal Solution (MHOS/SHP615) in Pediatric… | Phase3 | Nervous System Diseases | Completed | 2018-04-23 | 2020-10-13 | ClinicalTrials.gov |
| NCT03336450 | Study of Midazolam Hydrochloride Oromucosal Solution (MHOS/SHP615) in Pediatric… | Phase3 | Nervous System Diseases | Completed | 2018-04-23 | 2020-10-13 | ClinicalTrials.gov |
| NCT03386214 | Pevonedistat in Combination With Ruxolitinib for Treatment of Patients With Mye… | Phase1 | Myelofibroses | Terminated | 2018-04-23 | 2021-10-04 | ClinicalTrials.gov |
| NCT03449030 | A Study of TAK-164 in Participants With Advanced Gastrointestinal (GI) Cancer E… | Phase1 | Gastrointestinal Neoplasms; Esophageal, Stomach, Pancreas, Colon Neoplasms; Malignant Tumors of Digestive Organ; Advanced Gastrointestinal Malignancies | Terminated | 2018-04-23 | 2020-02-27 | ClinicalTrials.gov |
| NCT03336450 | Study of Midazolam Hydrochloride Oromucosal Solution (MHOS/SHP615) in Pediatric… | Phase3 | Nervous System Diseases | Completed | 2018-04-23 | 2020-10-13 | ClinicalTrials.gov |
| NCT03386214 | Pevonedistat in Combination With Ruxolitinib for Treatment of Patients With Mye… | Phase1 | Myelofibroses | Terminated | 2018-04-23 | 2021-10-04 | ClinicalTrials.gov |
| NCT03386214 | Pevonedistat in Combination With Ruxolitinib for Treatment of Patients With Mye… | Phase1 | Myelofibroses | Terminated | 2018-04-23 | 2021-10-04 | ClinicalTrials.gov |
| NCT03449030 | A Study of TAK-164 in Participants With Advanced Gastrointestinal (GI) Cancer E… | Phase1 | Gastrointestinal Neoplasms; Esophageal, Stomach, Pancreas, Colon Neoplasms; Malignant Tumors of Digestive Organ; Advanced Gastrointestinal Malignancies | Terminated | 2018-04-23 | 2020-02-27 | ClinicalTrials.gov |
| NCT03449030 | A Study of TAK-164 in Participants With Advanced Gastrointestinal (GI) Cancer E… | Phase1 | Gastrointestinal Neoplasms; Esophageal, Stomach, Pancreas, Colon Neoplasms; Malignant Tumors of Digestive Organ; Advanced Gastrointestinal Malignancies | Terminated | 2018-04-23 | 2020-02-27 | ClinicalTrials.gov |
| NCT03439280 | A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, an… | Phase1 | Relapsed/Refractory | Completed | 2018-04-20 | 2022-01-28 | ClinicalTrials.gov |
| NCT03439280 | A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, an… | Phase1 | Relapsed/Refractory | Completed | 2018-04-20 | 2022-01-28 | ClinicalTrials.gov |
| NCT03439280 | A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, an… | Phase1 | Relapsed/Refractory | Completed | 2018-04-20 | 2022-01-28 | ClinicalTrials.gov |
| NCT03521388 | Internet-based Program for Prevention and Early Intervention of Adolescent Depr… | Na | Depressive Symptoms | Completed | 2018-04-18 | 2019-08-31 | ClinicalTrials.gov |
| NCT03521388 | Internet-based Program for Prevention and Early Intervention of Adolescent Depr… | Na | Depressive Symptoms | Completed | 2018-04-18 | 2019-08-31 | ClinicalTrials.gov |
| NCT03521388 | Internet-based Program for Prevention and Early Intervention of Adolescent Depr… | Na | Depressive Symptoms | Completed | 2018-04-18 | 2019-08-31 | ClinicalTrials.gov |
| NCT03497429 | A Study of Niraparib as Single Agent in Participants With Advanced Solid Tumors | Phase1 | Advanced Solid Tumors | Completed | 2018-04-05 | 2020-02-10 | ClinicalTrials.gov |
| NCT03497429 | A Study of Niraparib as Single Agent in Participants With Advanced Solid Tumors | Phase1 | Advanced Solid Tumors | Completed | 2018-04-05 | 2020-02-10 | ClinicalTrials.gov |
| NCT03497429 | A Study of Niraparib as Single Agent in Participants With Advanced Solid Tumors | Phase1 | Advanced Solid Tumors | Completed | 2018-04-05 | 2020-02-10 | ClinicalTrials.gov |
| NCT03433001 | A Study in Relapsed and/or Refractory Multiple Myeloma Patients Treated With Ix… | — | Relapsed and/or Refractory Multiple Myeloma | Completed | 2018-04-02 | 2021-06-11 | ClinicalTrials.gov |
| NCT03433001 | A Study in Relapsed and/or Refractory Multiple Myeloma Patients Treated With Ix… | — | Relapsed and/or Refractory Multiple Myeloma | Completed | 2018-04-02 | 2021-06-11 | ClinicalTrials.gov |
| NCT03433001 | A Study in Relapsed and/or Refractory Multiple Myeloma Patients Treated With Ix… | — | Relapsed and/or Refractory Multiple Myeloma | Completed | 2018-04-02 | 2021-06-11 | ClinicalTrials.gov |
| NCT03482453 | A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of TAK-7… | Phase1 | Healthy Volunteers | Completed | 2018-03-28 | 2019-01-18 | ClinicalTrials.gov |
| NCT03482453 | A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of TAK-7… | Phase1 | Healthy Volunteers | Completed | 2018-03-28 | 2019-01-18 | ClinicalTrials.gov |
| NCT03482453 | A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of TAK-7… | Phase1 | Healthy Volunteers | Completed | 2018-03-28 | 2019-01-18 | ClinicalTrials.gov |
| NCT03487887 | Secondary Care - Continuous Glucose Monitoring | — | Diabetes Mellitus, Type 2 | Completed | 2018-03-19 | 2021-08-25 | ClinicalTrials.gov |
| NCT03487887 | Secondary Care - Continuous Glucose Monitoring | — | Diabetes Mellitus, Type 2 | Completed | 2018-03-19 | 2021-08-25 | ClinicalTrials.gov |
| NCT03487887 | Secondary Care - Continuous Glucose Monitoring | — | Diabetes Mellitus, Type 2 | Completed | 2018-03-19 | 2021-08-25 | ClinicalTrials.gov |
| NCT03498625 | Crohn's Disease Endoscopic REmission Definition in an Objective Way | Na | CD | Completed | 2018-03-13 | 2021-12-31 | ClinicalTrials.gov |
| NCT03327402 | Safety, Tolerability and Pharmacokinetics of SHP465 in Children Aged 4 to 5 Yea… | Phase1 | Attention Deficit Hyperactivity Disorder (ADHD) | Completed | 2018-03-13 | 2018-10-05 | ClinicalTrials.gov |
| NCT03327402 | Safety, Tolerability and Pharmacokinetics of SHP465 in Children Aged 4 to 5 Yea… | Phase1 | Attention Deficit Hyperactivity Disorder (ADHD) | Completed | 2018-03-13 | 2018-10-05 | ClinicalTrials.gov |
| NCT03439293 | A Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refracto… | Phase2 | Multiple Myeloma | Completed | 2018-03-13 | 2023-06-26 | ClinicalTrials.gov |
| NCT03439293 | A Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refracto… | Phase2 | Multiple Myeloma | Completed | 2018-03-13 | 2023-06-26 | ClinicalTrials.gov |
| NCT03487900 | Is the Endoscopic Remission Evaluation, Using the CREDO 1 Index / Score in CD P… | Na | CD | Unknown | 2018-03-13 | 2023-12-31 | ClinicalTrials.gov |
| NCT03327402 | Safety, Tolerability and Pharmacokinetics of SHP465 in Children Aged 4 to 5 Yea… | Phase1 | Attention Deficit Hyperactivity Disorder (ADHD) | Completed | 2018-03-13 | 2018-10-05 | ClinicalTrials.gov |
| NCT03487900 | Is the Endoscopic Remission Evaluation, Using the CREDO 1 Index / Score in CD P… | Na | CD | Unknown | 2018-03-13 | 2023-12-31 | ClinicalTrials.gov |
| NCT03439293 | A Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refracto… | Phase2 | Multiple Myeloma | Completed | 2018-03-13 | 2023-06-26 | ClinicalTrials.gov |
| NCT03498625 | Crohn's Disease Endoscopic REmission Definition in an Objective Way | Na | CD | Completed | 2018-03-13 | 2021-12-31 | ClinicalTrials.gov |
| NCT03498625 | Crohn's Disease Endoscopic REmission Definition in an Objective Way | Na | CD | Completed | 2018-03-13 | 2021-12-31 | ClinicalTrials.gov |
| NCT03487900 | Is the Endoscopic Remission Evaluation, Using the CREDO 1 Index / Score in CD P… | Na | CD | Unknown | 2018-03-13 | 2023-12-31 | ClinicalTrials.gov |
| NCT03961308 | A Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Inject… | Phase1 | Healthy Volunteers | Completed | 2018-03-12 | 2018-11-21 | ClinicalTrials.gov |
| NCT03230149 | Prevalence and Characteristics of Fabry Disease (FD) in Patients With Stroke or… | — | Fabry Disease | Completed | 2018-03-12 | 2021-12-24 | ClinicalTrials.gov |
| NCT03961308 | A Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Inject… | Phase1 | Healthy Volunteers | Completed | 2018-03-12 | 2018-11-21 | ClinicalTrials.gov |
| NCT03230149 | Prevalence and Characteristics of Fabry Disease (FD) in Patients With Stroke or… | — | Fabry Disease | Completed | 2018-03-12 | 2021-12-24 | ClinicalTrials.gov |
| NCT03961308 | A Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Inject… | Phase1 | Healthy Volunteers | Completed | 2018-03-12 | 2018-11-21 | ClinicalTrials.gov |
| NCT03230149 | Prevalence and Characteristics of Fabry Disease (FD) in Patients With Stroke or… | — | Fabry Disease | Completed | 2018-03-12 | 2021-12-24 | ClinicalTrials.gov |
| NCT03456960 | A Study to Evaluate the Bioequivalence (BE) and the Food Effect of TAK-438ASA T… | Phase1 | Healthy Volunteers | Completed | 2018-03-08 | 2018-10-12 | ClinicalTrials.gov |
| NCT03456960 | A Study to Evaluate the Bioequivalence (BE) and the Food Effect of TAK-438ASA T… | Phase1 | Healthy Volunteers | Completed | 2018-03-08 | 2018-10-12 | ClinicalTrials.gov |
| NCT03456960 | A Study to Evaluate the Bioequivalence (BE) and the Food Effect of TAK-438ASA T… | Phase1 | Healthy Volunteers | Completed | 2018-03-08 | 2018-10-12 | ClinicalTrials.gov |
| NCT03329209 | A Study to Determine the Pharmacokinetics (PK) of Single Intravenous (IV) Dose … | Phase1 | Colitis, Ulcerative | Completed | 2018-03-05 | 2018-09-05 | ClinicalTrials.gov |
| NCT03329209 | A Study to Determine the Pharmacokinetics (PK) of Single Intravenous (IV) Dose … | Phase1 | Colitis, Ulcerative | Completed | 2018-03-05 | 2018-09-05 | ClinicalTrials.gov |
| NCT03329209 | A Study to Determine the Pharmacokinetics (PK) of Single Intravenous (IV) Dose … | Phase1 | Colitis, Ulcerative | Completed | 2018-03-05 | 2018-09-05 | ClinicalTrials.gov |
| NCT03451019 | Different Effects of Non-calcium Phosphate Binders on Serum Calcium | Phase4 | Chronic Kidney Disease | Completed | 2018-03-01 | 2020-12-30 | ClinicalTrials.gov |
| NCT03451019 | Different Effects of Non-calcium Phosphate Binders on Serum Calcium | Phase4 | Chronic Kidney Disease | Completed | 2018-03-01 | 2020-12-30 | ClinicalTrials.gov |
| NCT03205891 | Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodg… | Phase1 | Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic | Withdrawn | 2018-03-01 | 2021-03-01 | ClinicalTrials.gov |
| NCT03205891 | Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodg… | Phase1 | Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic | Withdrawn | 2018-03-01 | 2021-03-01 | ClinicalTrials.gov |
| NCT03205891 | Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodg… | Phase1 | Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic | Withdrawn | 2018-03-01 | 2021-03-01 | ClinicalTrials.gov |
| NCT03451019 | Different Effects of Non-calcium Phosphate Binders on Serum Calcium | Phase4 | Chronic Kidney Disease | Completed | 2018-03-01 | 2020-12-30 | ClinicalTrials.gov |
| NCT03342898 | Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Administered With… | Phase3 | Dengue | Completed | 2018-02-28 | 2019-05-22 | ClinicalTrials.gov |
| NCT03342898 | Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Administered With… | Phase3 | Dengue | Completed | 2018-02-28 | 2019-05-22 | ClinicalTrials.gov |
| NCT03342898 | Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Administered With… | Phase3 | Dengue | Completed | 2018-02-28 | 2019-05-22 | ClinicalTrials.gov |
| NCT03389399 | Pulmonary Physiology and Systemic Inflammatory in EO Pulmonary Events With Brig… | — | Non-Small Cell Lung Cancer | Completed | 2018-02-22 | 2021-10-01 | ClinicalTrials.gov |
| NCT03961295 | A Pilot Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) … | Phase1 | Healthy Volunteers | Completed | 2018-02-22 | 2018-08-28 | ClinicalTrials.gov |
| NCT03961295 | A Pilot Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) … | Phase1 | Healthy Volunteers | Completed | 2018-02-22 | 2018-08-28 | ClinicalTrials.gov |
| NCT03961295 | A Pilot Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) … | Phase1 | Healthy Volunteers | Completed | 2018-02-22 | 2018-08-28 | ClinicalTrials.gov |
| NCT03389399 | Pulmonary Physiology and Systemic Inflammatory in EO Pulmonary Events With Brig… | — | Non-Small Cell Lung Cancer | Completed | 2018-02-22 | 2021-10-01 | ClinicalTrials.gov |
| NCT03389399 | Pulmonary Physiology and Systemic Inflammatory in EO Pulmonary Events With Brig… | — | Non-Small Cell Lung Cancer | Completed | 2018-02-22 | 2021-10-01 | ClinicalTrials.gov |
| NCT03948581 | A Pilot Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) … | Phase1 | Healthy Volunteers | Completed | 2018-02-21 | 2018-09-21 | ClinicalTrials.gov |
| NCT03948581 | A Pilot Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) … | Phase1 | Healthy Volunteers | Completed | 2018-02-21 | 2018-09-21 | ClinicalTrials.gov |
| NCT03948581 | A Pilot Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) … | Phase1 | Healthy Volunteers | Completed | 2018-02-21 | 2018-09-21 | ClinicalTrials.gov |
| NCT03416374 | A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Len… | Phase4 | Relapsed and/or Refractory Multiple Myeloma | Completed | 2018-02-18 | 2021-05-28 | ClinicalTrials.gov |
| NCT03416374 | A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Len… | Phase4 | Relapsed and/or Refractory Multiple Myeloma | Completed | 2018-02-18 | 2021-05-28 | ClinicalTrials.gov |
| NCT03416374 | A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Len… | Phase4 | Relapsed and/or Refractory Multiple Myeloma | Completed | 2018-02-18 | 2021-05-28 | ClinicalTrials.gov |
| NCT03437564 | A Bioequivalence Study of the Lu AA21004 20 mg and 2×10 mg Tablets | Phase1 | Healthy Adult Participants | Completed | 2018-02-16 | 2018-04-13 | ClinicalTrials.gov |
| NCT03437564 | A Bioequivalence Study of the Lu AA21004 20 mg and 2×10 mg Tablets | Phase1 | Healthy Adult Participants | Completed | 2018-02-16 | 2018-04-13 | ClinicalTrials.gov |
| NCT03437564 | A Bioequivalence Study of the Lu AA21004 20 mg and 2×10 mg Tablets | Phase1 | Healthy Adult Participants | Completed | 2018-02-16 | 2018-04-13 | ClinicalTrials.gov |
| NCT03312894 | Efficacy and Safety of TAK-653 in Treatment-Resistant Depression | Phase2 | Treatment-Resistant Depression | Withdrawn | 2018-02-15 | 2019-09-30 | ClinicalTrials.gov |
| NCT03312894 | Efficacy and Safety of TAK-653 in Treatment-Resistant Depression | Phase2 | Treatment-Resistant Depression | Withdrawn | 2018-02-15 | 2019-09-30 | ClinicalTrials.gov |
| NCT03312894 | Efficacy and Safety of TAK-653 in Treatment-Resistant Depression | Phase2 | Treatment-Resistant Depression | Withdrawn | 2018-02-15 | 2019-09-30 | ClinicalTrials.gov |
| NCT03434977 | A Phase 1 Food Effect Study of Azilsartan (TAK-536) Pediatric Formulation | Phase1 | Healthy Volunteers | Completed | 2018-02-14 | 2018-03-11 | ClinicalTrials.gov |
| NCT03434977 | A Phase 1 Food Effect Study of Azilsartan (TAK-536) Pediatric Formulation | Phase1 | Healthy Volunteers | Completed | 2018-02-14 | 2018-03-11 | ClinicalTrials.gov |
| NCT03434977 | A Phase 1 Food Effect Study of Azilsartan (TAK-536) Pediatric Formulation | Phase1 | Healthy Volunteers | Completed | 2018-02-14 | 2018-03-11 | ClinicalTrials.gov |
| NCT03378388 | A Study to Assess the Effectiveness and Safety of Treatment With Vedolizumab in… | — | Colitis, Ulcerative | Terminated | 2018-02-13 | 2019-02-15 | ClinicalTrials.gov |
| NCT03378388 | A Study to Assess the Effectiveness and Safety of Treatment With Vedolizumab in… | — | Colitis, Ulcerative | Terminated | 2018-02-13 | 2019-02-15 | ClinicalTrials.gov |
| NCT03378388 | A Study to Assess the Effectiveness and Safety of Treatment With Vedolizumab in… | — | Colitis, Ulcerative | Terminated | 2018-02-13 | 2019-02-15 | ClinicalTrials.gov |
| NCT03423173 | Lot-to-lot Consistency of 3 Lots of Tetravalent Dengue Vaccine (TDV) in Non-end… | Phase3 | Dengue Fever | Completed | 2018-02-12 | 2019-01-14 | ClinicalTrials.gov |
| NCT03423173 | Lot-to-lot Consistency of 3 Lots of Tetravalent Dengue Vaccine (TDV) in Non-end… | Phase3 | Dengue Fever | Completed | 2018-02-12 | 2019-01-14 | ClinicalTrials.gov |
| NCT03423173 | Lot-to-lot Consistency of 3 Lots of Tetravalent Dengue Vaccine (TDV) in Non-end… | Phase3 | Dengue Fever | Completed | 2018-02-12 | 2019-01-14 | ClinicalTrials.gov |
| NCT03217643 | CHP-BV Followed by Consolidation With High-dose Therapy / ASCT as Frontline Tre… | Phase2 | Enteropathy Associated T-cell Lymphoma | Completed | 2018-02-07 | 2023-05-15 | ClinicalTrials.gov |
| NCT03217643 | CHP-BV Followed by Consolidation With High-dose Therapy / ASCT as Frontline Tre… | Phase2 | Enteropathy Associated T-cell Lymphoma | Completed | 2018-02-07 | 2023-05-15 | ClinicalTrials.gov |
| NCT03217643 | CHP-BV Followed by Consolidation With High-dose Therapy / ASCT as Frontline Tre… | Phase2 | Enteropathy Associated T-cell Lymphoma | Completed | 2018-02-07 | 2023-05-15 | ClinicalTrials.gov |
| NCT03949621 | A Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Inject… | Phase1 | Healthy Volunteers | Completed | 2018-02-06 | 2018-08-13 | ClinicalTrials.gov |
| NCT03949621 | A Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Inject… | Phase1 | Healthy Volunteers | Completed | 2018-02-06 | 2018-08-13 | ClinicalTrials.gov |
| NCT03949621 | A Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Inject… | Phase1 | Healthy Volunteers | Completed | 2018-02-06 | 2018-08-13 | ClinicalTrials.gov |
| NCT03410108 | Phase 2 Study of Brigatinib in Japanese Participants With Anaplastic Lymphoma K… | Phase2 | ALK-positive Advanced NSCLC | Completed | 2018-01-29 | 2021-07-28 | ClinicalTrials.gov |
| NCT03410108 | Phase 2 Study of Brigatinib in Japanese Participants With Anaplastic Lymphoma K… | Phase2 | ALK-positive Advanced NSCLC | Completed | 2018-01-29 | 2021-07-28 | ClinicalTrials.gov |
| NCT03410108 | Phase 2 Study of Brigatinib in Japanese Participants With Anaplastic Lymphoma K… | Phase2 | ALK-positive Advanced NSCLC | Completed | 2018-01-29 | 2021-07-28 | ClinicalTrials.gov |
| NCT03324880 | A Study to Learn if Recombinant Human Parathyroid Hormone [rhPTH(1-84)] Can Imp… | Phase4 | Hypoparathyroidism | Completed | 2018-01-24 | 2022-05-19 | ClinicalTrials.gov |
| NCT03324880 | A Study to Learn if Recombinant Human Parathyroid Hormone [rhPTH(1-84)] Can Imp… | Phase4 | Hypoparathyroidism | Completed | 2018-01-24 | 2022-05-19 | ClinicalTrials.gov |
| NCT03324880 | A Study to Learn if Recombinant Human Parathyroid Hormone [rhPTH(1-84)] Can Imp… | Phase4 | Hypoparathyroidism | Completed | 2018-01-24 | 2022-05-19 | ClinicalTrials.gov |
| NCT03486990 | Study of the Safety, Tolerability and Pharmacokinetics of TIMP-GLIA in Subjects… | Phase1 | Celiac Disease | Completed | 2018-01-23 | 2019-07-22 | ClinicalTrials.gov |
| NCT03486990 | Study of the Safety, Tolerability and Pharmacokinetics of TIMP-GLIA in Subjects… | Phase1 | Celiac Disease | Completed | 2018-01-23 | 2019-07-22 | ClinicalTrials.gov |
| NCT03486990 | Study of the Safety, Tolerability and Pharmacokinetics of TIMP-GLIA in Subjects… | Phase1 | Celiac Disease | Completed | 2018-01-23 | 2019-07-22 | ClinicalTrials.gov |
| NCT03582449 | Intensive Pharmacovigilance Program for Elaprase (SHP ELA-701) | — | Hunter Syndrome | Completed | 2018-01-19 | 2020-05-10 | ClinicalTrials.gov |
| NCT03582449 | Intensive Pharmacovigilance Program for Elaprase (SHP ELA-701) | — | Hunter Syndrome | Completed | 2018-01-19 | 2020-05-10 | ClinicalTrials.gov |
| NCT03582449 | Intensive Pharmacovigilance Program for Elaprase (SHP ELA-701) | — | Hunter Syndrome | Completed | 2018-01-19 | 2020-05-10 | ClinicalTrials.gov |
| NCT03401671 | Study of Lanadelumab in Healthy Japanese and Matched Caucasian Adult Subjects | Phase1 | Healthy Volunteers | Completed | 2018-01-15 | 2018-05-30 | ClinicalTrials.gov |
| NCT03401671 | Study of Lanadelumab in Healthy Japanese and Matched Caucasian Adult Subjects | Phase1 | Healthy Volunteers | Completed | 2018-01-15 | 2018-05-30 | ClinicalTrials.gov |
| NCT03401671 | Study of Lanadelumab in Healthy Japanese and Matched Caucasian Adult Subjects | Phase1 | Healthy Volunteers | Completed | 2018-01-15 | 2018-05-30 | ClinicalTrials.gov |
| NCT03370289 | A Phase 4 Post-marketing Study of Intramuscular Injections of BLB-750 in Health… | Phase4 | Pandemic Influenza Prevention | Completed | 2018-01-12 | 2018-02-28 | ClinicalTrials.gov |
| NCT03370289 | A Phase 4 Post-marketing Study of Intramuscular Injections of BLB-750 in Health… | Phase4 | Pandemic Influenza Prevention | Completed | 2018-01-12 | 2018-02-28 | ClinicalTrials.gov |
| NCT03370289 | A Phase 4 Post-marketing Study of Intramuscular Injections of BLB-750 in Health… | Phase4 | Pandemic Influenza Prevention | Completed | 2018-01-12 | 2018-02-28 | ClinicalTrials.gov |
| NCT03359785 | A Study to Evaluate Multiple Oral Doses of Luvadaxistat in Adults With Schizoph… | Phase2 | Schizophrenia | Completed | 2018-01-10 | 2020-12-21 | ClinicalTrials.gov |
| NCT03359785 | A Study to Evaluate Multiple Oral Doses of Luvadaxistat in Adults With Schizoph… | Phase2 | Schizophrenia | Completed | 2018-01-10 | 2020-12-21 | ClinicalTrials.gov |
| NCT03359785 | A Study to Evaluate Multiple Oral Doses of Luvadaxistat in Adults With Schizoph… | Phase2 | Schizophrenia | Completed | 2018-01-10 | 2020-12-21 | ClinicalTrials.gov |
| NCT03382639 | A Study to Evaluate 3 Dose Levels of Luvadaxistat of Adults With Negative Sympt… | Phase2 | Schizophrenia | Completed | 2018-01-04 | 2021-01-12 | ClinicalTrials.gov |
| NCT03382639 | A Study to Evaluate 3 Dose Levels of Luvadaxistat of Adults With Negative Sympt… | Phase2 | Schizophrenia | Completed | 2018-01-04 | 2021-01-12 | ClinicalTrials.gov |
| NCT03382639 | A Study to Evaluate 3 Dose Levels of Luvadaxistat of Adults With Negative Sympt… | Phase2 | Schizophrenia | Completed | 2018-01-04 | 2021-01-12 | ClinicalTrials.gov |
| NCT03281577 | Effect of TAK-954 on Gastrointestinal and Colonic Transit in Diabetic or Idiopa… | Phase2 | Diabetic Gastroparesis | Completed | 2018-01-02 | 2019-07-12 | ClinicalTrials.gov |
| NCT03325894 | Safety and Tolerability Study of SHP465 in Children Aged 4 to 12 Years Diagnose… | Phase3 | Attention Deficit Hyperactivity Disorder (ADHD) | Terminated | 2018-01-02 | 2019-01-19 | ClinicalTrials.gov |
| NCT03281577 | Effect of TAK-954 on Gastrointestinal and Colonic Transit in Diabetic or Idiopa… | Phase2 | Diabetic Gastroparesis | Completed | 2018-01-02 | 2019-07-12 | ClinicalTrials.gov |
| NCT03281577 | Effect of TAK-954 on Gastrointestinal and Colonic Transit in Diabetic or Idiopa… | Phase2 | Diabetic Gastroparesis | Completed | 2018-01-02 | 2019-07-12 | ClinicalTrials.gov |
| NCT03325894 | Safety and Tolerability Study of SHP465 in Children Aged 4 to 12 Years Diagnose… | Phase3 | Attention Deficit Hyperactivity Disorder (ADHD) | Terminated | 2018-01-02 | 2019-01-19 | ClinicalTrials.gov |
| NCT03325894 | Safety and Tolerability Study of SHP465 in Children Aged 4 to 12 Years Diagnose… | Phase3 | Attention Deficit Hyperactivity Disorder (ADHD) | Terminated | 2018-01-02 | 2019-01-19 | ClinicalTrials.gov |
| NCT03319953 | A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of… | Phase2 | Stable Schizophrenia | Completed | 2017-12-21 | 2019-11-06 | ClinicalTrials.gov |
| NCT03319953 | A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of… | Phase2 | Stable Schizophrenia | Completed | 2017-12-21 | 2019-11-06 | ClinicalTrials.gov |
| NCT03319953 | A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of… | Phase2 | Stable Schizophrenia | Completed | 2017-12-21 | 2019-11-06 | ClinicalTrials.gov |
| NCT03341637 | Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) in Adolescents in… | Phase3 | Dengue | Completed | 2017-12-14 | 2019-01-26 | ClinicalTrials.gov |
| NCT03341637 | Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) in Adolescents in… | Phase3 | Dengue | Completed | 2017-12-14 | 2019-01-26 | ClinicalTrials.gov |
| NCT03341637 | Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) in Adolescents in… | Phase3 | Dengue | Completed | 2017-12-14 | 2019-01-26 | ClinicalTrials.gov |
| NCT03339219 | A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Renal Ce… | Phase2 | Advanced Renal Cell Carcinoma | Completed | 2017-12-13 | 2020-08-25 | ClinicalTrials.gov |
| NCT03339219 | A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Renal Ce… | Phase2 | Advanced Renal Cell Carcinoma | Completed | 2017-12-13 | 2020-08-25 | ClinicalTrials.gov |
| NCT03339219 | A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Renal Ce… | Phase2 | Advanced Renal Cell Carcinoma | Completed | 2017-12-13 | 2020-08-25 | ClinicalTrials.gov |
| NCT03209258 | The Third, Intensive Care Bundle With Blood Pressure Reduction in Acute Cerebra… | Na | Cerebral Hemorrhage | Completed | 2017-12-12 | 2022-11-17 | ClinicalTrials.gov |
| NCT03209258 | The Third, Intensive Care Bundle With Blood Pressure Reduction in Acute Cerebra… | Na | Cerebral Hemorrhage | Completed | 2017-12-12 | 2022-11-17 | ClinicalTrials.gov |
| NCT03209258 | The Third, Intensive Care Bundle With Blood Pressure Reduction in Acute Cerebra… | Na | Cerebral Hemorrhage | Completed | 2017-12-12 | 2022-11-17 | ClinicalTrials.gov |
| NCT03325881 | Efficacy and Safety of SHP465 at 6.25 mg in the Treatment of Attention-Deficit/… | Phase3 | Attention Deficit Hyperactivity Disorder (ADHD) | Completed | 2017-12-09 | 2018-06-07 | ClinicalTrials.gov |
| NCT03325881 | Efficacy and Safety of SHP465 at 6.25 mg in the Treatment of Attention-Deficit/… | Phase3 | Attention Deficit Hyperactivity Disorder (ADHD) | Completed | 2017-12-09 | 2018-06-07 | ClinicalTrials.gov |
| NCT03325881 | Efficacy and Safety of SHP465 at 6.25 mg in the Treatment of Attention-Deficit/… | Phase3 | Attention Deficit Hyperactivity Disorder (ADHD) | Completed | 2017-12-09 | 2018-06-07 | ClinicalTrials.gov |
| NCT03259308 | Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With M… | Phase3 | Ulcerative Colitis | Terminated | 2017-12-05 | 2020-10-06 | ClinicalTrials.gov |
| NCT03259308 | Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With M… | Phase3 | Ulcerative Colitis | Terminated | 2017-12-05 | 2020-10-06 | ClinicalTrials.gov |
| NCT03259308 | Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With M… | Phase3 | Ulcerative Colitis | Terminated | 2017-12-05 | 2020-10-06 | ClinicalTrials.gov |
| NCT02559713 | Postmarketing Vedolizumab Milk-Only Lactation Study in Lactating Women With Act… | Phase4 | Colitis, Ulcerative | Completed | 2017-11-29 | 2019-02-22 | ClinicalTrials.gov |
| NCT02559713 | Postmarketing Vedolizumab Milk-Only Lactation Study in Lactating Women With Act… | Phase4 | Colitis, Ulcerative | Completed | 2017-11-29 | 2019-02-22 | ClinicalTrials.gov |
| NCT02559713 | Postmarketing Vedolizumab Milk-Only Lactation Study in Lactating Women With Act… | Phase4 | Colitis, Ulcerative | Completed | 2017-11-29 | 2019-02-22 | ClinicalTrials.gov |
| NCT03268954 | Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Tre… | Phase3 | Myelodysplastic Syndrome | Completed | 2017-11-28 | 2024-10-14 | ClinicalTrials.gov |
| NCT03268954 | Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Tre… | Phase3 | Myelodysplastic Syndrome | Completed | 2017-11-28 | 2024-10-14 | ClinicalTrials.gov |
| NCT03268954 | Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Tre… | Phase3 | Myelodysplastic Syndrome | Completed | 2017-11-28 | 2024-10-14 | ClinicalTrials.gov |
| NCT03316976 | A Study to Evaluate the Pharmacokinetics of Dexlansoprazole 30 Milligram (mg) a… | Phase1 | Healthy Volunteers | Completed | 2017-11-22 | 2018-02-08 | ClinicalTrials.gov |
| NCT03316976 | A Study to Evaluate the Pharmacokinetics of Dexlansoprazole 30 Milligram (mg) a… | Phase1 | Healthy Volunteers | Completed | 2017-11-22 | 2018-02-08 | ClinicalTrials.gov |
| NCT03316976 | A Study to Evaluate the Pharmacokinetics of Dexlansoprazole 30 Milligram (mg) a… | Phase1 | Healthy Volunteers | Completed | 2017-11-22 | 2018-02-08 | ClinicalTrials.gov |
| NCT03296787 | A Study to Evaluate the Effect of Renal Impairment and Dialysis Treatment on th… | Phase1 | Renal Impairment | Completed | 2017-11-21 | 2019-08-09 | ClinicalTrials.gov |
| NCT03296787 | A Study to Evaluate the Effect of Renal Impairment and Dialysis Treatment on th… | Phase1 | Renal Impairment | Completed | 2017-11-21 | 2019-08-09 | ClinicalTrials.gov |
| NCT03327571 | B-CD30 + Hodgkin Lymphoma International Multi-center Retrospective Study of Tre… | — | Classical Hodgkin Lymphoma | Completed | 2017-11-21 | 2019-10-31 | ClinicalTrials.gov |
| NCT03327571 | B-CD30 + Hodgkin Lymphoma International Multi-center Retrospective Study of Tre… | — | Classical Hodgkin Lymphoma | Completed | 2017-11-21 | 2019-10-31 | ClinicalTrials.gov |
| NCT03296787 | A Study to Evaluate the Effect of Renal Impairment and Dialysis Treatment on th… | Phase1 | Renal Impairment | Completed | 2017-11-21 | 2019-08-09 | ClinicalTrials.gov |
| NCT03327571 | B-CD30 + Hodgkin Lymphoma International Multi-center Retrospective Study of Tre… | — | Classical Hodgkin Lymphoma | Completed | 2017-11-21 | 2019-10-31 | ClinicalTrials.gov |
| NCT02973087 | rVWF IN PROPHYLAXIS | Phase3 | Von Willebrand Disease | Completed | 2017-11-16 | 2020-07-06 | ClinicalTrials.gov |
| NCT02973087 | rVWF IN PROPHYLAXIS | Phase3 | Von Willebrand Disease | Completed | 2017-11-16 | 2020-07-06 | ClinicalTrials.gov |
| NCT02973087 | rVWF IN PROPHYLAXIS | Phase3 | Von Willebrand Disease | Completed | 2017-11-16 | 2020-07-06 | ClinicalTrials.gov |
| NCT03330106 | A Study to Evaluate the Effects of Pevonedistat on the Corrected QT (QTc) Inter… | Phase1 | Advanced Solid Neoplasm | Completed | 2017-11-15 | 2021-06-21 | ClinicalTrials.gov |
| NCT03330106 | A Study to Evaluate the Effects of Pevonedistat on the Corrected QT (QTc) Inter… | Phase1 | Advanced Solid Neoplasm | Completed | 2017-11-15 | 2021-06-21 | ClinicalTrials.gov |
| NCT03330106 | A Study to Evaluate the Effects of Pevonedistat on the Corrected QT (QTc) Inter… | Phase1 | Advanced Solid Neoplasm | Completed | 2017-11-15 | 2021-06-21 | ClinicalTrials.gov |
| NCT03173092 | A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethaso… | Phase4 | Multiple Myeloma | Active_Not_Recruiting | 2017-11-13 | 2026-11-30 | ClinicalTrials.gov |
| NCT03173092 | A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethaso… | Phase4 | Multiple Myeloma | Active_Not_Recruiting | 2017-11-13 | 2026-11-30 | ClinicalTrials.gov |
| NCT03343626 | Safety, Immunogenicity, and Dose Ranging Study of Inactivated Zika Virus Vaccin… | Phase1 | Virus, Zika | Completed | 2017-11-13 | 2020-11-24 | ClinicalTrials.gov |
| NCT03343626 | Safety, Immunogenicity, and Dose Ranging Study of Inactivated Zika Virus Vaccin… | Phase1 | Virus, Zika | Completed | 2017-11-13 | 2020-11-24 | ClinicalTrials.gov |
| NCT03343626 | Safety, Immunogenicity, and Dose Ranging Study of Inactivated Zika Virus Vaccin… | Phase1 | Virus, Zika | Completed | 2017-11-13 | 2020-11-24 | ClinicalTrials.gov |
| NCT03173092 | A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethaso… | Phase4 | Multiple Myeloma | Active_Not_Recruiting | 2017-11-13 | 2026-11-30 | ClinicalTrials.gov |
| NCT03277274 | A Study to Evaluate the Effect of Hepatic Impairment on the Single Dose Pharmac… | Phase1 | Hepatic Impairment | Completed | 2017-11-09 | 2018-09-10 | ClinicalTrials.gov |
| NCT03277274 | A Study to Evaluate the Effect of Hepatic Impairment on the Single Dose Pharmac… | Phase1 | Hepatic Impairment | Completed | 2017-11-09 | 2018-09-10 | ClinicalTrials.gov |
| NCT03277274 | A Study to Evaluate the Effect of Hepatic Impairment on the Single Dose Pharmac… | Phase1 | Hepatic Impairment | Completed | 2017-11-09 | 2018-09-10 | ClinicalTrials.gov |
| NCT03138655 | Vedolizumab IV in Pediatric Participants With Ulcerative Colitis (UC) or Crohn'… | Phase2 | Ulcerative Colitis | Completed | 2017-11-08 | 2020-05-26 | ClinicalTrials.gov |
| NCT03138655 | Vedolizumab IV in Pediatric Participants With Ulcerative Colitis (UC) or Crohn'… | Phase2 | Ulcerative Colitis | Completed | 2017-11-08 | 2020-05-26 | ClinicalTrials.gov |
| NCT03214588 | Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK-831 … | Phase2 | Friedreich Ataxia | Completed | 2017-11-08 | 2018-12-27 | ClinicalTrials.gov |
| NCT03214588 | Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK-831 … | Phase2 | Friedreich Ataxia | Completed | 2017-11-08 | 2018-12-27 | ClinicalTrials.gov |
| NCT03138655 | Vedolizumab IV in Pediatric Participants With Ulcerative Colitis (UC) or Crohn'… | Phase2 | Ulcerative Colitis | Completed | 2017-11-08 | 2020-05-26 | ClinicalTrials.gov |
| NCT03214588 | Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK-831 … | Phase2 | Friedreich Ataxia | Completed | 2017-11-08 | 2018-12-27 | ClinicalTrials.gov |
| NCT02932618 | A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in C… | Phase3 | Von Willebrand Disease | Completed | 2017-11-06 | 2026-04-17 | ClinicalTrials.gov |
| NCT02932618 | A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in C… | Phase3 | Von Willebrand Disease | Completed | 2017-11-06 | 2026-04-17 | ClinicalTrials.gov |
| NCT02932618 | A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in C… | Phase3 | Von Willebrand Disease | Completed | 2017-11-06 | 2026-04-17 | ClinicalTrials.gov |
| NCT03332784 | Phase 1 TAK-925 Study in Healthy Adult and Elderly Volunteers and Participants … | Phase1 | Healthy Participants and Patients With Narcolepsy | Completed | 2017-11-04 | 2018-09-04 | ClinicalTrials.gov |
| NCT03332784 | Phase 1 TAK-925 Study in Healthy Adult and Elderly Volunteers and Participants … | Phase1 | Healthy Participants and Patients With Narcolepsy | Completed | 2017-11-04 | 2018-09-04 | ClinicalTrials.gov |
| NCT03332784 | Phase 1 TAK-925 Study in Healthy Adult and Elderly Volunteers and Participants … | Phase1 | Healthy Participants and Patients With Narcolepsy | Completed | 2017-11-04 | 2018-09-04 | ClinicalTrials.gov |
| NCT03555578 | Specified Drug-Use Survey of Leuprorelin Acetate Injection Kit 11.25 mg "All-Ca… | — | Spinal and Bulbar Muscular Atrophy | Completed | 2017-11-02 | 2026-04-30 | ClinicalTrials.gov |
| NCT03555578 | Specified Drug-Use Survey of Leuprorelin Acetate Injection Kit 11.25 mg "All-Ca… | — | Spinal and Bulbar Muscular Atrophy | Completed | 2017-11-02 | 2026-04-30 | ClinicalTrials.gov |
| NCT03555578 | Specified Drug-Use Survey of Leuprorelin Acetate Injection Kit 11.25 mg "All-Ca… | — | Spinal and Bulbar Muscular Atrophy | Completed | 2017-11-02 | 2026-04-30 | ClinicalTrials.gov |
| NCT03261947 | A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Partic… | Phase2 | Metastatic Pancreatic Cancer | Completed | 2017-10-25 | 2020-08-24 | ClinicalTrials.gov |
| NCT03261947 | A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Partic… | Phase2 | Metastatic Pancreatic Cancer | Completed | 2017-10-25 | 2020-08-24 | ClinicalTrials.gov |
| NCT03261947 | A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Partic… | Phase2 | Metastatic Pancreatic Cancer | Completed | 2017-10-25 | 2020-08-24 | ClinicalTrials.gov |
| NCT02781233 | A Progressive Resistance Training Program in Patients With Haemophilia | Na | Haemophilia | Completed | 2017-10-24 | 2018-06-25 | ClinicalTrials.gov |
| NCT02781233 | A Progressive Resistance Training Program in Patients With Haemophilia | Na | Haemophilia | Completed | 2017-10-24 | 2018-06-25 | ClinicalTrials.gov |
| NCT02781233 | A Progressive Resistance Training Program in Patients With Haemophilia | Na | Haemophilia | Completed | 2017-10-24 | 2018-06-25 | ClinicalTrials.gov |
| NCT03336645 | Open-label Study of Midazolam Hydrochloride Oromucosal Solution (MHOS/SHP615) i… | Phase3 | Nervous System Diseases | Completed | 2017-10-23 | 2019-08-19 | ClinicalTrials.gov |
| NCT03336645 | Open-label Study of Midazolam Hydrochloride Oromucosal Solution (MHOS/SHP615) i… | Phase3 | Nervous System Diseases | Completed | 2017-10-23 | 2019-08-19 | ClinicalTrials.gov |
| NCT03336645 | Open-label Study of Midazolam Hydrochloride Oromucosal Solution (MHOS/SHP615) i… | Phase3 | Nervous System Diseases | Completed | 2017-10-23 | 2019-08-19 | ClinicalTrials.gov |
| NCT03272165 | Single Ascending Dose Study of MEDI1341 in Healthy Volunteers | Phase1 | Parkinson's Disease | Completed | 2017-10-17 | 2021-03-31 | ClinicalTrials.gov |
| NCT03272165 | Single Ascending Dose Study of MEDI1341 in Healthy Volunteers | Phase1 | Parkinson's Disease | Completed | 2017-10-17 | 2021-03-31 | ClinicalTrials.gov |
| NCT03272165 | Single Ascending Dose Study of MEDI1341 in Healthy Volunteers | Phase1 | Parkinson's Disease | Completed | 2017-10-17 | 2021-03-31 | ClinicalTrials.gov |
| NCT03393975 | A Study of BAX 930 in Children, Teenagers, and Adults Born With Thrombotic Thro… | Phase3 | Thrombotic Thrombocytopenic Purpura (TTP) | Completed | 2017-10-13 | 2024-05-30 | ClinicalTrials.gov |
| NCT03393975 | A Study of BAX 930 in Children, Teenagers, and Adults Born With Thrombotic Thro… | Phase3 | Thrombotic Thrombocytopenic Purpura (TTP) | Completed | 2017-10-13 | 2024-05-30 | ClinicalTrials.gov |
| NCT03393975 | A Study of BAX 930 in Children, Teenagers, and Adults Born With Thrombotic Thro… | Phase3 | Thrombotic Thrombocytopenic Purpura (TTP) | Completed | 2017-10-13 | 2024-05-30 | ClinicalTrials.gov |
| NCT03738254 | Motivating Survey Compliance: Game Play Study 1 | Na | Patient Reported Outcome Measures | Completed | 2017-10-09 | 2018-01-11 | ClinicalTrials.gov |
| NCT03738254 | Motivating Survey Compliance: Game Play Study 1 | Na | Patient Reported Outcome Measures | Completed | 2017-10-09 | 2018-01-11 | ClinicalTrials.gov |
| NCT03738254 | Motivating Survey Compliance: Game Play Study 1 | Na | Patient Reported Outcome Measures | Completed | 2017-10-09 | 2018-01-11 | ClinicalTrials.gov |
| NCT03245840 | Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adu… | Phase3 | Eosinophilic Esophagitis (EoE) | Terminated | 2017-10-05 | 2022-04-26 | ClinicalTrials.gov |
| NCT03245840 | Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adu… | Phase3 | Eosinophilic Esophagitis (EoE) | Terminated | 2017-10-05 | 2022-04-26 | ClinicalTrials.gov |
| NCT03245840 | Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adu… | Phase3 | Eosinophilic Esophagitis (EoE) | Terminated | 2017-10-05 | 2022-04-26 | ClinicalTrials.gov |
| NCT03268941 | A Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD)… | Phase2 | Diabetes Mellitus and Gastroparesis, Idiopathic Gastroparesis | Completed | 2017-09-26 | 2018-03-09 | ClinicalTrials.gov |
| NCT03268941 | A Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD)… | Phase2 | Diabetes Mellitus and Gastroparesis, Idiopathic Gastroparesis | Completed | 2017-09-26 | 2018-03-09 | ClinicalTrials.gov |
| NCT03268941 | A Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD)… | Phase2 | Diabetes Mellitus and Gastroparesis, Idiopathic Gastroparesis | Completed | 2017-09-26 | 2018-03-09 | ClinicalTrials.gov |
| NCT03213158 | Ixazomib for Desensitization | Phase2 | Kidney Diseases | Completed | 2017-09-15 | 2021-04-16 | ClinicalTrials.gov |
| NCT03213158 | Ixazomib for Desensitization | Phase2 | Kidney Diseases | Completed | 2017-09-15 | 2021-04-16 | ClinicalTrials.gov |
| NCT03213158 | Ixazomib for Desensitization | Phase2 | Kidney Diseases | Completed | 2017-09-15 | 2021-04-16 | ClinicalTrials.gov |
| NCT03260205 | Safety and Efficacy Study in Preschool Children Aged 4-5 Years With Attention-d… | Phase3 | Attention Deficit Hyperactivity Disorder (ADHD) | Completed | 2017-09-06 | 2018-10-23 | ClinicalTrials.gov |
| NCT02979522 | A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pe… | Phase1 | Hodgkin Disease | Active_Not_Recruiting | 2017-09-06 | 2029-09-24 | ClinicalTrials.gov |
| NCT03260205 | Safety and Efficacy Study in Preschool Children Aged 4-5 Years With Attention-d… | Phase3 | Attention Deficit Hyperactivity Disorder (ADHD) | Completed | 2017-09-06 | 2018-10-23 | ClinicalTrials.gov |
| NCT02979522 | A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pe… | Phase1 | Hodgkin Disease | Active_Not_Recruiting | 2017-09-06 | 2029-09-24 | ClinicalTrials.gov |
| NCT02979522 | A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pe… | Phase1 | Hodgkin Disease | Active_Not_Recruiting | 2017-09-06 | 2029-09-24 | ClinicalTrials.gov |
| NCT03260205 | Safety and Efficacy Study in Preschool Children Aged 4-5 Years With Attention-d… | Phase3 | Attention Deficit Hyperactivity Disorder (ADHD) | Completed | 2017-09-06 | 2018-10-23 | ClinicalTrials.gov |
| NCT02969876 | Pattern Separation, Brain Derived Neurotrophic Factors, and Mechanisms of Vorti… | Phase4 | Depressive Disorder | Terminated | 2017-08-24 | 2018-08-06 | ClinicalTrials.gov |
| NCT02969876 | Pattern Separation, Brain Derived Neurotrophic Factors, and Mechanisms of Vorti… | Phase4 | Depressive Disorder | Terminated | 2017-08-24 | 2018-08-06 | ClinicalTrials.gov |
| NCT02969876 | Pattern Separation, Brain Derived Neurotrophic Factors, and Mechanisms of Vorti… | Phase4 | Depressive Disorder | Terminated | 2017-08-24 | 2018-08-06 | ClinicalTrials.gov |
| NCT03268811 | A Study in Japanese Children With Short Bowel Syndrome Who Completed SHP633-302 | Phase3 | Short Bowel Syndrome | Completed | 2017-08-23 | 2021-11-02 | ClinicalTrials.gov |
| NCT03268811 | A Study in Japanese Children With Short Bowel Syndrome Who Completed SHP633-302 | Phase3 | Short Bowel Syndrome | Completed | 2017-08-23 | 2021-11-02 | ClinicalTrials.gov |
| NCT03268811 | A Study in Japanese Children With Short Bowel Syndrome Who Completed SHP633-302 | Phase3 | Short Bowel Syndrome | Completed | 2017-08-23 | 2021-11-02 | ClinicalTrials.gov |
| NCT03231709 | Treatment Preference for Weekly Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Versu… | Phase4 | Type 2 Diabetes Mellitus | Completed | 2017-08-18 | 2018-02-09 | ClinicalTrials.gov |
| NCT03231709 | Treatment Preference for Weekly Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Versu… | Phase4 | Type 2 Diabetes Mellitus | Completed | 2017-08-18 | 2018-02-09 | ClinicalTrials.gov |
| NCT03231709 | Treatment Preference for Weekly Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Versu… | Phase4 | Type 2 Diabetes Mellitus | Completed | 2017-08-18 | 2018-02-09 | ClinicalTrials.gov |
| NCT03166215 | Study of TAK-935 as an Adjunctive Therapy in Participants With Developmental an… | Phase1 | Developmental and/or Epileptic Encephalopathies | Completed | 2017-08-17 | 2018-09-19 | ClinicalTrials.gov |
| NCT03166215 | Study of TAK-935 as an Adjunctive Therapy in Participants With Developmental an… | Phase1 | Developmental and/or Epileptic Encephalopathies | Completed | 2017-08-17 | 2018-09-19 | ClinicalTrials.gov |
| NCT03535649 | A Study to Assess Clinical Effectiveness and Safety of Vedolizumab Intravenous … | — | Colitis, Ulcerative | Completed | 2017-08-17 | 2018-12-18 | ClinicalTrials.gov |
| NCT03166215 | Study of TAK-935 as an Adjunctive Therapy in Participants With Developmental an… | Phase1 | Developmental and/or Epileptic Encephalopathies | Completed | 2017-08-17 | 2018-09-19 | ClinicalTrials.gov |
| NCT03535649 | A Study to Assess Clinical Effectiveness and Safety of Vedolizumab Intravenous … | — | Colitis, Ulcerative | Completed | 2017-08-17 | 2018-12-18 | ClinicalTrials.gov |
| NCT03535649 | A Study to Assess Clinical Effectiveness and Safety of Vedolizumab Intravenous … | — | Colitis, Ulcerative | Completed | 2017-08-17 | 2018-12-18 | ClinicalTrials.gov |
| NCT03237156 | Phase 1 TAK-906 Single and Multiple Ascending Dose Study in Japanese Healthy Ma… | Phase1 | Japanese Healthy Adult Male Participants | Completed | 2017-08-07 | 2017-10-07 | ClinicalTrials.gov |
| NCT03237156 | Phase 1 TAK-906 Single and Multiple Ascending Dose Study in Japanese Healthy Ma… | Phase1 | Japanese Healthy Adult Male Participants | Completed | 2017-08-07 | 2017-10-07 | ClinicalTrials.gov |
| NCT03237156 | Phase 1 TAK-906 Single and Multiple Ascending Dose Study in Japanese Healthy Ma… | Phase1 | Japanese Healthy Adult Male Participants | Completed | 2017-08-07 | 2017-10-07 | ClinicalTrials.gov |
| NCT03221036 | Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative C… | Phase3 | Moderately to Severely Active Ulcerative Colitis | Active_Not_Recruiting | 2017-08-03 | 2028-01-30 | ClinicalTrials.gov |
| NCT03221036 | Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative C… | Phase3 | Moderately to Severely Active Ulcerative Colitis | Active_Not_Recruiting | 2017-08-03 | 2028-01-30 | ClinicalTrials.gov |
| NCT03234907 | Vedolizumab Intravenous (IV) Compared to Placebo in Chinese Participants With C… | Phase3 | Crohn's Disease | Completed | 2017-08-03 | 2020-08-14 | ClinicalTrials.gov |
| NCT03221036 | Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative C… | Phase3 | Moderately to Severely Active Ulcerative Colitis | Active_Not_Recruiting | 2017-08-03 | 2028-01-30 | ClinicalTrials.gov |
| NCT03234907 | Vedolizumab Intravenous (IV) Compared to Placebo in Chinese Participants With C… | Phase3 | Crohn's Disease | Completed | 2017-08-03 | 2020-08-14 | ClinicalTrials.gov |
| NCT03234907 | Vedolizumab Intravenous (IV) Compared to Placebo in Chinese Participants With C… | Phase3 | Crohn's Disease | Completed | 2017-08-03 | 2020-08-14 | ClinicalTrials.gov |
| NCT03116841 | Vonoprazan Study of Investigating the Effect on Sleep Disturbance Associated Wi… | Phase4 | Reflux Esophagitis | Completed | 2017-08-02 | 2017-12-20 | ClinicalTrials.gov |
| NCT03116841 | Vonoprazan Study of Investigating the Effect on Sleep Disturbance Associated Wi… | Phase4 | Reflux Esophagitis | Completed | 2017-08-02 | 2017-12-20 | ClinicalTrials.gov |
| NCT03116841 | Vonoprazan Study of Investigating the Effect on Sleep Disturbance Associated Wi… | Phase4 | Reflux Esophagitis | Completed | 2017-08-02 | 2017-12-20 | ClinicalTrials.gov |
| NCT03170882 | A Study of Ixazomib, Given With Dexamethasone in Adults With Multiple Myeloma | Phase2 | Relapsed and/or Refractory Multiple Myeloma | Completed | 2017-08-01 | 2021-11-26 | ClinicalTrials.gov |
| NCT03170882 | A Study of Ixazomib, Given With Dexamethasone in Adults With Multiple Myeloma | Phase2 | Relapsed and/or Refractory Multiple Myeloma | Completed | 2017-08-01 | 2021-11-26 | ClinicalTrials.gov |
| NCT03170882 | A Study of Ixazomib, Given With Dexamethasone in Adults With Multiple Myeloma | Phase2 | Relapsed and/or Refractory Multiple Myeloma | Completed | 2017-08-01 | 2021-11-26 | ClinicalTrials.gov |
| NCT03042325 | Safety and Efficacy of Alogliptin in Indian Participants With Type 2 Diabetes M… | Phase4 | Diabetes Mellitus, Type 2 | Withdrawn | 2017-07-30 | 2018-01-15 | ClinicalTrials.gov |
| NCT03042325 | Safety and Efficacy of Alogliptin in Indian Participants With Type 2 Diabetes M… | Phase4 | Diabetes Mellitus, Type 2 | Withdrawn | 2017-07-30 | 2018-01-15 | ClinicalTrials.gov |
| NCT03042325 | Safety and Efficacy of Alogliptin in Indian Participants With Type 2 Diabetes M… | Phase4 | Diabetes Mellitus, Type 2 | Withdrawn | 2017-07-30 | 2018-01-15 | ClinicalTrials.gov |
| NCT03188536 | Clinical and Sociodemographic Characterization of Multiple Myeloma Participants… | — | Multiple Myeloma | Completed | 2017-07-26 | 2019-01-30 | ClinicalTrials.gov |
| NCT03188536 | Clinical and Sociodemographic Characterization of Multiple Myeloma Participants… | — | Multiple Myeloma | Completed | 2017-07-26 | 2019-01-30 | ClinicalTrials.gov |
| NCT03188536 | Clinical and Sociodemographic Characterization of Multiple Myeloma Participants… | — | Multiple Myeloma | Completed | 2017-07-26 | 2019-01-30 | ClinicalTrials.gov |
| NCT03224325 | A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Mu… | Phase1 | Healthy | Completed | 2017-07-21 | 2018-09-09 | ClinicalTrials.gov |
| NCT03228433 | A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Ascending Oral… | Phase1 | Healthy Participants | Completed | 2017-07-21 | 2018-05-12 | ClinicalTrials.gov |
| NCT03224325 | A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Mu… | Phase1 | Healthy | Completed | 2017-07-21 | 2018-09-09 | ClinicalTrials.gov |
| NCT03224325 | A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Mu… | Phase1 | Healthy | Completed | 2017-07-21 | 2018-09-09 | ClinicalTrials.gov |
| NCT03228433 | A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Ascending Oral… | Phase1 | Healthy Participants | Completed | 2017-07-21 | 2018-05-12 | ClinicalTrials.gov |
| NCT03228433 | A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Ascending Oral… | Phase1 | Healthy Participants | Completed | 2017-07-21 | 2018-05-12 | ClinicalTrials.gov |
| NCT03242213 | Patient Management of Depression Through Technology: a Study of Digitally Enabl… | Na | Major Depressive Disorder | Completed | 2017-07-20 | 2019-09-09 | ClinicalTrials.gov |
| NCT03242213 | Patient Management of Depression Through Technology: a Study of Digitally Enabl… | Na | Major Depressive Disorder | Completed | 2017-07-20 | 2019-09-09 | ClinicalTrials.gov |
| NCT03242213 | Patient Management of Depression Through Technology: a Study of Digitally Enabl… | Na | Major Depressive Disorder | Completed | 2017-07-20 | 2019-09-09 | ClinicalTrials.gov |
| NCT03193853 | TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Tri… | Phase2 | Triple Negative Breast Cancer | Completed | 2017-07-18 | 2022-12-01 | ClinicalTrials.gov |
| NCT03193853 | TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Tri… | Phase2 | Triple Negative Breast Cancer | Completed | 2017-07-18 | 2022-12-01 | ClinicalTrials.gov |
| NCT03193853 | TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Tri… | Phase2 | Triple Negative Breast Cancer | Completed | 2017-07-18 | 2022-12-01 | ClinicalTrials.gov |
| NCT03154710 | Relevance of a Web-mediated Follow up in Patients Having a Lymphoma With a High… | Na | Lymphoma, T-Cell | Terminated | 2017-07-12 | 2021-03-12 | ClinicalTrials.gov |
| NCT03154710 | Relevance of a Web-mediated Follow up in Patients Having a Lymphoma With a High… | Na | Lymphoma, T-Cell | Terminated | 2017-07-12 | 2021-03-12 | ClinicalTrials.gov |
| NCT03154710 | Relevance of a Web-mediated Follow up in Patients Having a Lymphoma With a High… | Na | Lymphoma, T-Cell | Terminated | 2017-07-12 | 2021-03-12 | ClinicalTrials.gov |
| NCT02823808 | Effect of Alogliptin/Pioglitazone on the Preservation of Long-term Beta-cell Fu… | Phase4 | Diabetes | Unknown | 2017-07-01 | 2021-12-01 | ClinicalTrials.gov |
| NCT03237260 | An Open Label Single-arm Phase 4 Study of Vedolizumab in Subjects With Newly Di… | Phase4 | Ulcerative Colitis | Withdrawn | 2017-07-01 | 2019-02-01 | ClinicalTrials.gov |
| NCT03237260 | An Open Label Single-arm Phase 4 Study of Vedolizumab in Subjects With Newly Di… | Phase4 | Ulcerative Colitis | Withdrawn | 2017-07-01 | 2019-02-01 | ClinicalTrials.gov |
| NCT02823808 | Effect of Alogliptin/Pioglitazone on the Preservation of Long-term Beta-cell Fu… | Phase4 | Diabetes | Unknown | 2017-07-01 | 2021-12-01 | ClinicalTrials.gov |
| NCT02823808 | Effect of Alogliptin/Pioglitazone on the Preservation of Long-term Beta-cell Fu… | Phase4 | Diabetes | Unknown | 2017-07-01 | 2021-12-01 | ClinicalTrials.gov |
| NCT03237260 | An Open Label Single-arm Phase 4 Study of Vedolizumab in Subjects With Newly Di… | Phase4 | Ulcerative Colitis | Withdrawn | 2017-07-01 | 2019-02-01 | ClinicalTrials.gov |
| NCT03213405 | A Study to Assess Safety, Tolerability and Immunogenicity of the Live Attenuate… | Phase1 | Respiratory Syncytial Virus Infections | Completed | 2017-06-27 | 2018-06-01 | ClinicalTrials.gov |
| NCT03213405 | A Study to Assess Safety, Tolerability and Immunogenicity of the Live Attenuate… | Phase1 | Respiratory Syncytial Virus Infections | Completed | 2017-06-27 | 2018-06-01 | ClinicalTrials.gov |
| NCT03213405 | A Study to Assess Safety, Tolerability and Immunogenicity of the Live Attenuate… | Phase1 | Respiratory Syncytial Virus Infections | Completed | 2017-06-27 | 2018-06-01 | ClinicalTrials.gov |
| NCT02993926 | A Study to Assess the Safety and Efficacy of Enantone (Leuprorelin) in Central … | — | Central Precocious Puberty | Completed | 2017-06-24 | 2018-09-30 | ClinicalTrials.gov |
| NCT02993926 | A Study to Assess the Safety and Efficacy of Enantone (Leuprorelin) in Central … | — | Central Precocious Puberty | Completed | 2017-06-24 | 2018-09-30 | ClinicalTrials.gov |
| NCT02993926 | A Study to Assess the Safety and Efficacy of Enantone (Leuprorelin) in Central … | — | Central Precocious Puberty | Completed | 2017-06-24 | 2018-09-30 | ClinicalTrials.gov |
| NCT03236792 | Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagn… | Phase1 | AL Amyloidosis | Completed | 2017-06-12 | 2022-09-20 | ClinicalTrials.gov |
| NCT03236792 | Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagn… | Phase1 | AL Amyloidosis | Completed | 2017-06-12 | 2022-09-20 | ClinicalTrials.gov |
| NCT03236792 | Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagn… | Phase1 | AL Amyloidosis | Completed | 2017-06-12 | 2022-09-20 | ClinicalTrials.gov |
| NCT03092791 | IPV-102 Safety, Tolerability and Immunogenicity of TAK-195 in Healthy Infants, … | Phase1 | Poliomyelitis | Terminated | 2017-06-07 | 2018-10-18 | ClinicalTrials.gov |
| NCT03092791 | IPV-102 Safety, Tolerability and Immunogenicity of TAK-195 in Healthy Infants, … | Phase1 | Poliomyelitis | Terminated | 2017-06-07 | 2018-10-18 | ClinicalTrials.gov |
| NCT03092791 | IPV-102 Safety, Tolerability and Immunogenicity of TAK-195 in Healthy Infants, … | Phase1 | Poliomyelitis | Terminated | 2017-06-07 | 2018-10-18 | ClinicalTrials.gov |
| NCT03161405 | A Study to Evaluate the Effect of the Potent CYP3A4 Inhibitor Itraconazole on t… | Phase1 | Healthy Participants | Completed | 2017-06-05 | 2017-07-10 | ClinicalTrials.gov |
| NCT03161405 | A Study to Evaluate the Effect of the Potent CYP3A4 Inhibitor Itraconazole on t… | Phase1 | Healthy Participants | Completed | 2017-06-05 | 2017-07-10 | ClinicalTrials.gov |
| NCT03161405 | A Study to Evaluate the Effect of the Potent CYP3A4 Inhibitor Itraconazole on t… | Phase1 | Healthy Participants | Completed | 2017-06-05 | 2017-07-10 | ClinicalTrials.gov |
| NCT03173170 | A Study to Evaluate the Effect of the Potent Cytochrome P-450 3A4 (CYP3A4) Inhi… | Phase1 | Healthy Participants | Completed | 2017-05-31 | 2017-07-24 | ClinicalTrials.gov |
| NCT03173170 | A Study to Evaluate the Effect of the Potent Cytochrome P-450 3A4 (CYP3A4) Inhi… | Phase1 | Healthy Participants | Completed | 2017-05-31 | 2017-07-24 | ClinicalTrials.gov |
| NCT03173170 | A Study to Evaluate the Effect of the Potent Cytochrome P-450 3A4 (CYP3A4) Inhi… | Phase1 | Healthy Participants | Completed | 2017-05-31 | 2017-07-24 | ClinicalTrials.gov |
| NCT03169361 | NINLARO Capsules Drug Use-Results Survey (All-Case Surveillance) "Relapsed/Refr… | — | Relapsed/Refractory Multiple Myeloma | Completed | 2017-05-24 | 2022-03-08 | ClinicalTrials.gov |
| NCT03169361 | NINLARO Capsules Drug Use-Results Survey (All-Case Surveillance) "Relapsed/Refr… | — | Relapsed/Refractory Multiple Myeloma | Completed | 2017-05-24 | 2022-03-08 | ClinicalTrials.gov |
| NCT03169361 | NINLARO Capsules Drug Use-Results Survey (All-Case Surveillance) "Relapsed/Refr… | — | Relapsed/Refractory Multiple Myeloma | Completed | 2017-05-24 | 2022-03-08 | ClinicalTrials.gov |
| NCT02954159 | Vedolizumab Monotherapy Vs Combination Therapy With Tacrolimus in UC | Phase3 | Ulcerative Colitis | Terminated | 2017-05-18 | 2019-01-31 | ClinicalTrials.gov |
| NCT02954159 | Vedolizumab Monotherapy Vs Combination Therapy With Tacrolimus in UC | Phase3 | Ulcerative Colitis | Terminated | 2017-05-18 | 2019-01-31 | ClinicalTrials.gov |
| NCT02954159 | Vedolizumab Monotherapy Vs Combination Therapy With Tacrolimus in UC | Phase3 | Ulcerative Colitis | Terminated | 2017-05-18 | 2019-01-31 | ClinicalTrials.gov |
| NCT03150108 | Study of rhPTH(1-84) in Japanese Healthy Subjects Compared With Matched Caucasi… | Phase1 | Hypoparathyroidism | Completed | 2017-05-16 | 2017-06-26 | ClinicalTrials.gov |
| NCT03150108 | Study of rhPTH(1-84) in Japanese Healthy Subjects Compared With Matched Caucasi… | Phase1 | Hypoparathyroidism | Completed | 2017-05-16 | 2017-06-26 | ClinicalTrials.gov |
| NCT03150108 | Study of rhPTH(1-84) in Japanese Healthy Subjects Compared With Matched Caucasi… | Phase1 | Hypoparathyroidism | Completed | 2017-05-16 | 2017-06-26 | ClinicalTrials.gov |
| NCT03070509 | Pharmacokinetics of Lisdexamfetamine (Vyvanse®) in Post-bariatric Surgery Patie… | Phase4 | Lisdexamfetamine | Unknown | 2017-05-12 | 2019-07-01 | ClinicalTrials.gov |
| NCT03070509 | Pharmacokinetics of Lisdexamfetamine (Vyvanse®) in Post-bariatric Surgery Patie… | Phase4 | Lisdexamfetamine | Unknown | 2017-05-12 | 2019-07-01 | ClinicalTrials.gov |
| NCT03070509 | Pharmacokinetics of Lisdexamfetamine (Vyvanse®) in Post-bariatric Surgery Patie… | Phase4 | Lisdexamfetamine | Unknown | 2017-05-12 | 2019-07-01 | ClinicalTrials.gov |
| NCT03057366 | A Study of [14 C]-Pevonedistat in Participants With Advanced Solid Tumors | Phase1 | Advanced Solid Tumors, Neoplasms, Advanced Solid | Completed | 2017-05-11 | 2018-11-05 | ClinicalTrials.gov |
| NCT03057366 | A Study of [14 C]-Pevonedistat in Participants With Advanced Solid Tumors | Phase1 | Advanced Solid Tumors, Neoplasms, Advanced Solid | Completed | 2017-05-11 | 2018-11-05 | ClinicalTrials.gov |
| NCT03057366 | A Study of [14 C]-Pevonedistat in Participants With Advanced Solid Tumors | Phase1 | Advanced Solid Tumors, Neoplasms, Advanced Solid | Completed | 2017-05-11 | 2018-11-05 | ClinicalTrials.gov |
| NCT03131167 | Study of SHP639 Eye Drops in Adults With High Eye Pressure or Primary Open-angl… | Phase1 | Primary Open-angle Glaucoma (POAG) | Completed | 2017-05-10 | 2018-05-30 | ClinicalTrials.gov |
| NCT03131167 | Study of SHP639 Eye Drops in Adults With High Eye Pressure or Primary Open-angl… | Phase1 | Primary Open-angle Glaucoma (POAG) | Completed | 2017-05-10 | 2018-05-30 | ClinicalTrials.gov |
| NCT03131167 | Study of SHP639 Eye Drops in Adults With High Eye Pressure or Primary Open-angl… | Phase1 | Primary Open-angle Glaucoma (POAG) | Completed | 2017-05-10 | 2018-05-30 | ClinicalTrials.gov |
| NCT02969265 | An Efficacy and Safety Study Evaluating the Fixed-Dose Combination of Candesart… | Phase3 | Hypertension | Withdrawn | 2017-05-09 | 2018-07-26 | ClinicalTrials.gov |
| NCT02969265 | An Efficacy and Safety Study Evaluating the Fixed-Dose Combination of Candesart… | Phase3 | Hypertension | Withdrawn | 2017-05-09 | 2018-07-26 | ClinicalTrials.gov |
| NCT02669082 | The Exploratory Study to Investigate the Effect of Ramelteon for Insomnia Patie… | Phase4 | Insomnia | Completed | 2017-05-09 | 2018-01-31 | ClinicalTrials.gov |
| NCT02669082 | The Exploratory Study to Investigate the Effect of Ramelteon for Insomnia Patie… | Phase4 | Insomnia | Completed | 2017-05-09 | 2018-01-31 | ClinicalTrials.gov |
| NCT02669082 | The Exploratory Study to Investigate the Effect of Ramelteon for Insomnia Patie… | Phase4 | Insomnia | Completed | 2017-05-09 | 2018-01-31 | ClinicalTrials.gov |
| NCT02969265 | An Efficacy and Safety Study Evaluating the Fixed-Dose Combination of Candesart… | Phase3 | Hypertension | Withdrawn | 2017-05-09 | 2018-07-26 | ClinicalTrials.gov |
| NCT02993783 | A Dose-Finding Study of Vedolizumab for Treatment of Steroid-Refractory Acute I… | Phase2 | Allogeneic Hematopoietic Stem Cell Transplantation | Terminated | 2017-04-28 | 2018-05-09 | ClinicalTrials.gov |
| NCT02993783 | A Dose-Finding Study of Vedolizumab for Treatment of Steroid-Refractory Acute I… | Phase2 | Allogeneic Hematopoietic Stem Cell Transplantation | Terminated | 2017-04-28 | 2018-05-09 | ClinicalTrials.gov |
| NCT02993783 | A Dose-Finding Study of Vedolizumab for Treatment of Steroid-Refractory Acute I… | Phase2 | Allogeneic Hematopoietic Stem Cell Transplantation | Terminated | 2017-04-28 | 2018-05-09 | ClinicalTrials.gov |
| NCT03131895 | Bioequivalence Study of Dexlansoprazole Capsules From Two Manufacturing Plants | Phase1 | Healthy Volunteers | Completed | 2017-04-25 | 2017-07-31 | ClinicalTrials.gov |
| NCT03131895 | Bioequivalence Study of Dexlansoprazole Capsules From Two Manufacturing Plants | Phase1 | Healthy Volunteers | Completed | 2017-04-25 | 2017-07-31 | ClinicalTrials.gov |
| NCT03131895 | Bioequivalence Study of Dexlansoprazole Capsules From Two Manufacturing Plants | Phase1 | Healthy Volunteers | Completed | 2017-04-25 | 2017-07-31 | ClinicalTrials.gov |
| NCT02988986 | TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast Cancer | Phase2 | Estrogen Receptor Positive Breast Cancer | Completed | 2017-04-24 | 2019-03-30 | ClinicalTrials.gov |
| NCT02988986 | TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast Cancer | Phase2 | Estrogen Receptor Positive Breast Cancer | Completed | 2017-04-24 | 2019-03-30 | ClinicalTrials.gov |
| NCT02988986 | TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast Cancer | Phase2 | Estrogen Receptor Positive Breast Cancer | Completed | 2017-04-24 | 2019-03-30 | ClinicalTrials.gov |
| NCT03085836 | A Pharmacokinetic Study of TAK-438 in Healthy Adult Chinese Participants | Phase1 | Healthy Participants | Completed | 2017-04-19 | 2017-08-17 | ClinicalTrials.gov |
| NCT03085836 | A Pharmacokinetic Study of TAK-438 in Healthy Adult Chinese Participants | Phase1 | Healthy Participants | Completed | 2017-04-19 | 2017-08-17 | ClinicalTrials.gov |
| NCT03085836 | A Pharmacokinetic Study of TAK-438 in Healthy Adult Chinese Participants | Phase1 | Healthy Participants | Completed | 2017-04-19 | 2017-08-17 | ClinicalTrials.gov |
| NCT02764762 | Triple Combination Therapy in High Risk Crohn's Disease (CD) | Phase4 | Crohn Disease | Completed | 2017-04-18 | 2022-07-05 | ClinicalTrials.gov |
| NCT02764762 | Triple Combination Therapy in High Risk Crohn's Disease (CD) | Phase4 | Crohn Disease | Completed | 2017-04-18 | 2022-07-05 | ClinicalTrials.gov |
| NCT02764762 | Triple Combination Therapy in High Risk Crohn's Disease (CD) | Phase4 | Crohn Disease | Completed | 2017-04-18 | 2022-07-05 | ClinicalTrials.gov |
| NCT03050307 | Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Gastric … | Phase3 | Gastric Ulcer | Completed | 2017-04-17 | 2020-05-26 | ClinicalTrials.gov |
| NCT03050307 | Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Gastric … | Phase3 | Gastric Ulcer | Completed | 2017-04-17 | 2020-05-26 | ClinicalTrials.gov |
| NCT03050307 | Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Gastric … | Phase3 | Gastric Ulcer | Completed | 2017-04-17 | 2020-05-26 | ClinicalTrials.gov |
| NCT03313531 | Evaluation of a Standardized Protocol for Thrombin Generation Assay | — | Hemophilia A | Completed | 2017-04-15 | 2019-01-28 | ClinicalTrials.gov |
| NCT03313531 | Evaluation of a Standardized Protocol for Thrombin Generation Assay | — | Hemophilia A | Completed | 2017-04-15 | 2019-01-28 | ClinicalTrials.gov |
| NCT03313531 | Evaluation of a Standardized Protocol for Thrombin Generation Assay | — | Hemophilia A | Completed | 2017-04-15 | 2019-01-28 | ClinicalTrials.gov |
| NCT02953275 | Synergistic Effect of Vedolizumab and Pentoxifylline | Early_Phase1 | Crohn Disease | Completed | 2017-04-13 | 2019-06-13 | ClinicalTrials.gov |
| NCT02953275 | Synergistic Effect of Vedolizumab and Pentoxifylline | Early_Phase1 | Crohn Disease | Completed | 2017-04-13 | 2019-06-13 | ClinicalTrials.gov |
| NCT02953275 | Synergistic Effect of Vedolizumab and Pentoxifylline | Early_Phase1 | Crohn Disease | Completed | 2017-04-13 | 2019-06-13 | ClinicalTrials.gov |
| NCT03050359 | Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Duodenal… | Phase3 | Duodenal Ulcer | Completed | 2017-04-05 | 2019-07-19 | ClinicalTrials.gov |
| NCT03050359 | Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Duodenal… | Phase3 | Duodenal Ulcer | Completed | 2017-04-05 | 2019-07-19 | ClinicalTrials.gov |
| NCT03050359 | Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Duodenal… | Phase3 | Duodenal Ulcer | Completed | 2017-04-05 | 2019-07-19 | ClinicalTrials.gov |
| NCT03101293 | A Study to Evaluate the Effect of Food on the Pharmacokinetics of TAK-831 Table… | Phase1 | Healthy Volunteers | Completed | 2017-04-04 | 2017-05-26 | ClinicalTrials.gov |
| NCT03101293 | A Study to Evaluate the Effect of Food on the Pharmacokinetics of TAK-831 Table… | Phase1 | Healthy Volunteers | Completed | 2017-04-04 | 2017-05-26 | ClinicalTrials.gov |
| NCT03101293 | A Study to Evaluate the Effect of Food on the Pharmacokinetics of TAK-831 Table… | Phase1 | Healthy Volunteers | Completed | 2017-04-04 | 2017-05-26 | ClinicalTrials.gov |
| NCT02781844 | Study to Assess the Blood Concentrations and Actions of Recombinant Human Parat… | Phase1 | Hypoparathyroidism | Completed | 2017-04-03 | 2019-03-08 | ClinicalTrials.gov |
| NCT02948829 | Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healt… | Phase2 | Healthy Volunteers | Completed | 2017-04-03 | 2020-12-14 | ClinicalTrials.gov |
| NCT02948829 | Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healt… | Phase2 | Healthy Volunteers | Completed | 2017-04-03 | 2020-12-14 | ClinicalTrials.gov |
| NCT02781844 | Study to Assess the Blood Concentrations and Actions of Recombinant Human Parat… | Phase1 | Hypoparathyroidism | Completed | 2017-04-03 | 2019-03-08 | ClinicalTrials.gov |
| NCT02948829 | Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healt… | Phase2 | Healthy Volunteers | Completed | 2017-04-03 | 2020-12-14 | ClinicalTrials.gov |
| NCT02781844 | Study to Assess the Blood Concentrations and Actions of Recombinant Human Parat… | Phase1 | Hypoparathyroidism | Completed | 2017-04-03 | 2019-03-08 | ClinicalTrials.gov |
| NCT03029143 | Vedolizumab Intravenous (IV) Dose Optimization in Ulcerative Colitis | Phase4 | Colitis, Ulcerative | Completed | 2017-03-29 | 2020-10-16 | ClinicalTrials.gov |
| NCT03004924 | Treatment of Bacterial Conjunctivitis With SHP640 Compared to PVP-Iodine and Pl… | Phase3 | Bacterial Conjunctivitis | Completed | 2017-03-29 | 2018-10-01 | ClinicalTrials.gov |
| NCT03029143 | Vedolizumab Intravenous (IV) Dose Optimization in Ulcerative Colitis | Phase4 | Colitis, Ulcerative | Completed | 2017-03-29 | 2020-10-16 | ClinicalTrials.gov |
| NCT03029143 | Vedolizumab Intravenous (IV) Dose Optimization in Ulcerative Colitis | Phase4 | Colitis, Ulcerative | Completed | 2017-03-29 | 2020-10-16 | ClinicalTrials.gov |
| NCT03004924 | Treatment of Bacterial Conjunctivitis With SHP640 Compared to PVP-Iodine and Pl… | Phase3 | Bacterial Conjunctivitis | Completed | 2017-03-29 | 2018-10-01 | ClinicalTrials.gov |
| NCT03004924 | Treatment of Bacterial Conjunctivitis With SHP640 Compared to PVP-Iodine and Pl… | Phase3 | Bacterial Conjunctivitis | Completed | 2017-03-29 | 2018-10-01 | ClinicalTrials.gov |
| NCT03090139 | Sub-optimal Response to Anti-Tumor Necrosis Factor's in Inflammatory Bowel Dise… | — | Colitis, Ulcerative | Completed | 2017-03-28 | 2018-06-13 | ClinicalTrials.gov |
| NCT03090139 | Sub-optimal Response to Anti-Tumor Necrosis Factor's in Inflammatory Bowel Dise… | — | Colitis, Ulcerative | Completed | 2017-03-28 | 2018-06-13 | ClinicalTrials.gov |
| NCT03090139 | Sub-optimal Response to Anti-Tumor Necrosis Factor's in Inflammatory Bowel Dise… | — | Colitis, Ulcerative | Completed | 2017-03-28 | 2018-06-13 | ClinicalTrials.gov |
| NCT03083639 | A Study to Evaluate the Bioequivalence of Single Oral Dose of Esomeprazole Caps… | Phase1 | Healthy Participants | Completed | 2017-03-27 | 2017-05-13 | ClinicalTrials.gov |
| NCT03083639 | A Study to Evaluate the Bioequivalence of Single Oral Dose of Esomeprazole Caps… | Phase1 | Healthy Participants | Completed | 2017-03-27 | 2017-05-13 | ClinicalTrials.gov |
| NCT03083639 | A Study to Evaluate the Bioequivalence of Single Oral Dose of Esomeprazole Caps… | Phase1 | Healthy Participants | Completed | 2017-03-27 | 2017-05-13 | ClinicalTrials.gov |
| NCT02998541 | Treatment of Adenoviral Conjunctivitis With SHP640 Compared to Povidone-iodine … | Phase3 | Adenoviral Conjunctivitis | Terminated | 2017-03-27 | 2019-05-13 | ClinicalTrials.gov |
| NCT02998541 | Treatment of Adenoviral Conjunctivitis With SHP640 Compared to Povidone-iodine … | Phase3 | Adenoviral Conjunctivitis | Terminated | 2017-03-27 | 2019-05-13 | ClinicalTrials.gov |
| NCT02998541 | Treatment of Adenoviral Conjunctivitis With SHP640 Compared to Povidone-iodine … | Phase3 | Adenoviral Conjunctivitis | Terminated | 2017-03-27 | 2019-05-13 | ClinicalTrials.gov |
| NCT02946047 | The Effect of Ixazomib on the Latent HIV Reservoir | Phase1 | Human Immunodeficiency Virus (HIV) | Completed | 2017-03-20 | 2019-08-19 | ClinicalTrials.gov |
| NCT03562169 | The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - M… | Phase3 | Multiple Myeloma | Recruiting | 2017-03-20 | 2027-03-01 | ClinicalTrials.gov |
| NCT02946047 | The Effect of Ixazomib on the Latent HIV Reservoir | Phase1 | Human Immunodeficiency Virus (HIV) | Completed | 2017-03-20 | 2019-08-19 | ClinicalTrials.gov |
| NCT02946047 | The Effect of Ixazomib on the Latent HIV Reservoir | Phase1 | Human Immunodeficiency Virus (HIV) | Completed | 2017-03-20 | 2019-08-19 | ClinicalTrials.gov |
| NCT03562169 | The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - M… | Phase3 | Multiple Myeloma | Recruiting | 2017-03-20 | 2027-03-01 | ClinicalTrials.gov |
| NCT03562169 | The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - M… | Phase3 | Multiple Myeloma | Recruiting | 2017-03-20 | 2027-03-01 | ClinicalTrials.gov |
| NCT02926092 | Observational Natural History Study of Autosomal Dominant Retinitis Pigmentosa … | — | Retinitis Pigmentosa | Terminated | 2017-03-13 | 2017-04-13 | ClinicalTrials.gov |
| NCT02926092 | Observational Natural History Study of Autosomal Dominant Retinitis Pigmentosa … | — | Retinitis Pigmentosa | Terminated | 2017-03-13 | 2017-04-13 | ClinicalTrials.gov |
| NCT02926092 | Observational Natural History Study of Autosomal Dominant Retinitis Pigmentosa … | — | Retinitis Pigmentosa | Terminated | 2017-03-13 | 2017-04-13 | ClinicalTrials.gov |
| NCT02706626 | Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors | Phase2 | Non-Small Cell Lung Cancer | Terminated | 2017-03-09 | 2021-04-01 | ClinicalTrials.gov |
| NCT02706626 | Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors | Phase2 | Non-Small Cell Lung Cancer | Terminated | 2017-03-09 | 2021-04-01 | ClinicalTrials.gov |
| NCT02706626 | Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors | Phase2 | Non-Small Cell Lung Cancer | Terminated | 2017-03-09 | 2021-04-01 | ClinicalTrials.gov |
| NCT02942095 | Study of Ixazomib and Erlotinib in Solid Tumors | Phase1 | Solid Tumors | Completed | 2017-03-06 | 2022-12-07 | ClinicalTrials.gov |
| NCT02942095 | Study of Ixazomib and Erlotinib in Solid Tumors | Phase1 | Solid Tumors | Completed | 2017-03-06 | 2022-12-07 | ClinicalTrials.gov |
| NCT02942095 | Study of Ixazomib and Erlotinib in Solid Tumors | Phase1 | Solid Tumors | Completed | 2017-03-06 | 2022-12-07 | ClinicalTrials.gov |
| NCT02954406 | A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine… | Phase1 | Lymphoma, Non-Hodgkin | Terminated | 2017-03-05 | 2020-07-27 | ClinicalTrials.gov |
| NCT02954406 | A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine… | Phase1 | Lymphoma, Non-Hodgkin | Terminated | 2017-03-05 | 2020-07-27 | ClinicalTrials.gov |
| NCT02954406 | A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine… | Phase1 | Lymphoma, Non-Hodgkin | Terminated | 2017-03-05 | 2020-07-27 | ClinicalTrials.gov |
| NCT03067506 | Cognitive and Mood Assessment Data in Major Depressive Disorder Using Digital W… | — | Major Depressive Disorder | Completed | 2017-03-01 | 2017-07-03 | ClinicalTrials.gov |
| NCT03067506 | Cognitive and Mood Assessment Data in Major Depressive Disorder Using Digital W… | — | Major Depressive Disorder | Completed | 2017-03-01 | 2017-07-03 | ClinicalTrials.gov |
| NCT02727777 | Phase II Study of TAK228 in Relapsed Lymphoma | Phase1 | Lymphoma | Terminated | 2017-03-01 | 2018-07-10 | ClinicalTrials.gov |
| NCT02727777 | Phase II Study of TAK228 in Relapsed Lymphoma | Phase1 | Lymphoma | Terminated | 2017-03-01 | 2018-07-10 | ClinicalTrials.gov |
| NCT02727777 | Phase II Study of TAK228 in Relapsed Lymphoma | Phase1 | Lymphoma | Terminated | 2017-03-01 | 2018-07-10 | ClinicalTrials.gov |
| NCT03067506 | Cognitive and Mood Assessment Data in Major Depressive Disorder Using Digital W… | — | Major Depressive Disorder | Completed | 2017-03-01 | 2017-07-03 | ClinicalTrials.gov |
| NCT03555565 | Specified Drug-Use Survey of Alogliptin and Metformin Hydrochloride Combination… | — | Type 2 Diabetes Mellitus | Completed | 2017-02-28 | 2019-10-31 | ClinicalTrials.gov |
| NCT03555565 | Specified Drug-Use Survey of Alogliptin and Metformin Hydrochloride Combination… | — | Type 2 Diabetes Mellitus | Completed | 2017-02-28 | 2019-10-31 | ClinicalTrials.gov |
| NCT03555565 | Specified Drug-Use Survey of Alogliptin and Metformin Hydrochloride Combination… | — | Type 2 Diabetes Mellitus | Completed | 2017-02-28 | 2019-10-31 | ClinicalTrials.gov |
| NCT03079050 | An Open-Label Trial of Dexlansoprazole 60mg for the Relief of Heartburn During … | Phase4 | GERD | Completed | 2017-02-27 | 2017-07-30 | ClinicalTrials.gov |
| NCT03079050 | An Open-Label Trial of Dexlansoprazole 60mg for the Relief of Heartburn During … | Phase4 | GERD | Completed | 2017-02-27 | 2017-07-30 | ClinicalTrials.gov |
| NCT03079050 | An Open-Label Trial of Dexlansoprazole 60mg for the Relief of Heartburn During … | Phase4 | GERD | Completed | 2017-02-27 | 2017-07-30 | ClinicalTrials.gov |
| NCT03039790 | Long-Term Immunogenicity of the Norovirus GI.1/GII.4 Bivalent Virus-like Partic… | Phase2 | Healthy Volunteers | Completed | 2017-02-21 | 2021-07-22 | ClinicalTrials.gov |
| NCT03340272 | PROspective Multicenter Observational Study on Elective Pelvic Nodes Irradiatio… | — | Intermediate Risk Prostate Cancer | Unknown | 2017-02-21 | 2023-02-21 | ClinicalTrials.gov |
| NCT03039790 | Long-Term Immunogenicity of the Norovirus GI.1/GII.4 Bivalent Virus-like Partic… | Phase2 | Healthy Volunteers | Completed | 2017-02-21 | 2021-07-22 | ClinicalTrials.gov |
| NCT03039790 | Long-Term Immunogenicity of the Norovirus GI.1/GII.4 Bivalent Virus-like Partic… | Phase2 | Healthy Volunteers | Completed | 2017-02-21 | 2021-07-22 | ClinicalTrials.gov |
| NCT03340272 | PROspective Multicenter Observational Study on Elective Pelvic Nodes Irradiatio… | — | Intermediate Risk Prostate Cancer | Unknown | 2017-02-21 | 2023-02-21 | ClinicalTrials.gov |
| NCT03340272 | PROspective Multicenter Observational Study on Elective Pelvic Nodes Irradiatio… | — | Intermediate Risk Prostate Cancer | Unknown | 2017-02-21 | 2023-02-21 | ClinicalTrials.gov |
| NCT03014479 | Study of the QOL Evaluation of Trelagliptin in Patients With Type 2 Diabetes Me… | Phase4 | Type 2 Diabetes | Completed | 2017-02-18 | 2017-10-21 | ClinicalTrials.gov |
| NCT03014479 | Study of the QOL Evaluation of Trelagliptin in Patients With Type 2 Diabetes Me… | Phase4 | Type 2 Diabetes | Completed | 2017-02-18 | 2017-10-21 | ClinicalTrials.gov |
| NCT03014479 | Study of the QOL Evaluation of Trelagliptin in Patients With Type 2 Diabetes Me… | Phase4 | Type 2 Diabetes | Completed | 2017-02-18 | 2017-10-21 | ClinicalTrials.gov |
| NCT03042299 | A Phase 1, Bio-equivalence Study of TAK-536 Pediatric Formulation | Phase1 | Japanese Healthy Adult Male Participants | Completed | 2017-02-10 | 2017-03-11 | ClinicalTrials.gov |
| NCT03042299 | A Phase 1, Bio-equivalence Study of TAK-536 Pediatric Formulation | Phase1 | Japanese Healthy Adult Male Participants | Completed | 2017-02-10 | 2017-03-11 | ClinicalTrials.gov |
| NCT03042299 | A Phase 1, Bio-equivalence Study of TAK-536 Pediatric Formulation | Phase1 | Japanese Healthy Adult Male Participants | Completed | 2017-02-10 | 2017-03-11 | ClinicalTrials.gov |
| NCT02712996 | Treatment of Traumatic Brain Injury (TBI)-Related Attention Deficits in Children | Phase4 | Traumatic Brain Injury | Completed | 2017-02-06 | 2019-07-01 | ClinicalTrials.gov |
| NCT02712996 | Treatment of Traumatic Brain Injury (TBI)-Related Attention Deficits in Children | Phase4 | Traumatic Brain Injury | Completed | 2017-02-06 | 2019-07-01 | ClinicalTrials.gov |
| NCT02712996 | Treatment of Traumatic Brain Injury (TBI)-Related Attention Deficits in Children | Phase4 | Traumatic Brain Injury | Completed | 2017-02-06 | 2019-07-01 | ClinicalTrials.gov |
| NCT03035058 | Efficacy and Safety of Vedolizumab Intravenous (IV) in the Treatment of Primary… | Phase3 | Primary Sclerosing Cholangitis | Withdrawn | 2017-02-01 | 2021-01-01 | ClinicalTrials.gov |
| NCT03035058 | Efficacy and Safety of Vedolizumab Intravenous (IV) in the Treatment of Primary… | Phase3 | Primary Sclerosing Cholangitis | Withdrawn | 2017-02-01 | 2021-01-01 | ClinicalTrials.gov |
| NCT03169972 | ADYNOVATE Drug Use-Results Survey | — | Hemophilia A | Completed | 2017-02-01 | 2023-09-15 | ClinicalTrials.gov |
| NCT03169972 | ADYNOVATE Drug Use-Results Survey | — | Hemophilia A | Completed | 2017-02-01 | 2023-09-15 | ClinicalTrials.gov |
| NCT03035058 | Efficacy and Safety of Vedolizumab Intravenous (IV) in the Treatment of Primary… | Phase3 | Primary Sclerosing Cholangitis | Withdrawn | 2017-02-01 | 2021-01-01 | ClinicalTrials.gov |
| NCT03169972 | ADYNOVATE Drug Use-Results Survey | — | Hemophilia A | Completed | 2017-02-01 | 2023-09-15 | ClinicalTrials.gov |
| NCT03333447 | Retrospective and Prospective Observational Study of MRI Changes in Bone and Vi… | — | Gaucher Disease, Type 1 | Completed | 2017-01-17 | 2018-12-27 | ClinicalTrials.gov |
| NCT03333447 | Retrospective and Prospective Observational Study of MRI Changes in Bone and Vi… | — | Gaucher Disease, Type 1 | Completed | 2017-01-17 | 2018-12-27 | ClinicalTrials.gov |
| NCT03333447 | Retrospective and Prospective Observational Study of MRI Changes in Bone and Vi… | — | Gaucher Disease, Type 1 | Completed | 2017-01-17 | 2018-12-27 | ClinicalTrials.gov |
| NCT02980666 | Study in Japanese Pediatric Subjects With Short Bowel Syndrome (SBS) Who Are De… | Phase3 | Short Bowel Syndrome | Completed | 2017-01-13 | 2020-01-21 | ClinicalTrials.gov |
| NCT02980666 | Study in Japanese Pediatric Subjects With Short Bowel Syndrome (SBS) Who Are De… | Phase3 | Short Bowel Syndrome | Completed | 2017-01-13 | 2020-01-21 | ClinicalTrials.gov |
| NCT02980666 | Study in Japanese Pediatric Subjects With Short Bowel Syndrome (SBS) Who Are De… | Phase3 | Short Bowel Syndrome | Completed | 2017-01-13 | 2020-01-21 | ClinicalTrials.gov |
| NCT02878083 | Development of a Biomarker of Efficacy of Vedolizumab (EnTyvio®) in Patients Wi… | Na | ULCERATIVE COLITIS | Terminated | 2017-01-11 | 2021-01-01 | ClinicalTrials.gov |
| NCT02878083 | Development of a Biomarker of Efficacy of Vedolizumab (EnTyvio®) in Patients Wi… | Na | ULCERATIVE COLITIS | Terminated | 2017-01-11 | 2021-01-01 | ClinicalTrials.gov |
| NCT02878083 | Development of a Biomarker of Efficacy of Vedolizumab (EnTyvio®) in Patients Wi… | Na | ULCERATIVE COLITIS | Terminated | 2017-01-11 | 2021-01-01 | ClinicalTrials.gov |
| NCT02933411 | Low VW Activity in Adolescent HMB | — | Von Willebrand Factor Deficiency | Unknown | 2017-01-05 | 2025-11-01 | ClinicalTrials.gov |
| NCT02933411 | Low VW Activity in Adolescent HMB | — | Von Willebrand Factor Deficiency | Unknown | 2017-01-05 | 2025-11-01 | ClinicalTrials.gov |
| NCT02933411 | Low VW Activity in Adolescent HMB | — | Von Willebrand Factor Deficiency | Unknown | 2017-01-05 | 2025-11-01 | ClinicalTrials.gov |
| NCT02986724 | A Study to Observe the Safety and Efficacy of Vedolizumab in Biologically Naive… | — | Crohn Disease | Completed | 2017-01-04 | 2020-08-31 | ClinicalTrials.gov |
| NCT02986724 | A Study to Observe the Safety and Efficacy of Vedolizumab in Biologically Naive… | — | Crohn Disease | Completed | 2017-01-04 | 2020-08-31 | ClinicalTrials.gov |
| NCT02986724 | A Study to Observe the Safety and Efficacy of Vedolizumab in Biologically Naive… | — | Crohn Disease | Completed | 2017-01-04 | 2020-08-31 | ClinicalTrials.gov |
| NCT02727959 | Inflammatory Bowel Disease in South Eastern Norway | — | Colitis, Ulcerative | Completed | 2017-01-01 | 2019-12-31 | ClinicalTrials.gov |
| NCT02727959 | Inflammatory Bowel Disease in South Eastern Norway | — | Colitis, Ulcerative | Completed | 2017-01-01 | 2019-12-31 | ClinicalTrials.gov |
| NCT02727959 | Inflammatory Bowel Disease in South Eastern Norway | — | Colitis, Ulcerative | Completed | 2017-01-01 | 2019-12-31 | ClinicalTrials.gov |
| NCT02873689 | Efficacy and Safety of Dexlansoprazole on Heartburn Relief in Chinese Patients | Phase3 | Heartburn | Completed | 2016-12-27 | 2018-04-19 | ClinicalTrials.gov |
| NCT02839902 | Exploratory Study of the Effects of Omega-3-acid Ethyl Esters on the Lipid and … | Phase4 | Hyperlipidemia | Completed | 2016-12-27 | 2017-08-30 | ClinicalTrials.gov |
| NCT02873689 | Efficacy and Safety of Dexlansoprazole on Heartburn Relief in Chinese Patients | Phase3 | Heartburn | Completed | 2016-12-27 | 2018-04-19 | ClinicalTrials.gov |
| NCT02839902 | Exploratory Study of the Effects of Omega-3-acid Ethyl Esters on the Lipid and … | Phase4 | Hyperlipidemia | Completed | 2016-12-27 | 2017-08-30 | ClinicalTrials.gov |
| NCT02873689 | Efficacy and Safety of Dexlansoprazole on Heartburn Relief in Chinese Patients | Phase3 | Heartburn | Completed | 2016-12-27 | 2018-04-19 | ClinicalTrials.gov |
| NCT02839902 | Exploratory Study of the Effects of Omega-3-acid Ethyl Esters on the Lipid and … | Phase4 | Hyperlipidemia | Completed | 2016-12-27 | 2017-08-30 | ClinicalTrials.gov |
| NCT02931539 | Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assig… | Phase3 | Cytomegalovirus (CMV) | Completed | 2016-12-22 | 2020-08-17 | ClinicalTrials.gov |
| NCT02931539 | Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assig… | Phase3 | Cytomegalovirus (CMV) | Completed | 2016-12-22 | 2020-08-17 | ClinicalTrials.gov |
| NCT02972632 | Goal Achievement After a Change to Vortioxetine in Adults With Major Depressive… | Phase4 | Major Depressive Disorder | Completed | 2016-12-22 | 2018-02-06 | ClinicalTrials.gov |
| NCT02989649 | Non-Interventional Study of the Use of Alogliptin and Alogliptin Fixed-Dose Com… | — | Diabetes Mellitus, Type 2 | Terminated | 2016-12-22 | 2018-01-26 | ClinicalTrials.gov |
| NCT02972632 | Goal Achievement After a Change to Vortioxetine in Adults With Major Depressive… | Phase4 | Major Depressive Disorder | Completed | 2016-12-22 | 2018-02-06 | ClinicalTrials.gov |
| NCT02931539 | Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assig… | Phase3 | Cytomegalovirus (CMV) | Completed | 2016-12-22 | 2020-08-17 | ClinicalTrials.gov |
| NCT02989649 | Non-Interventional Study of the Use of Alogliptin and Alogliptin Fixed-Dose Com… | — | Diabetes Mellitus, Type 2 | Terminated | 2016-12-22 | 2018-01-26 | ClinicalTrials.gov |
| NCT02972632 | Goal Achievement After a Change to Vortioxetine in Adults With Major Depressive… | Phase4 | Major Depressive Disorder | Completed | 2016-12-22 | 2018-02-06 | ClinicalTrials.gov |
| NCT02989649 | Non-Interventional Study of the Use of Alogliptin and Alogliptin Fixed-Dose Com… | — | Diabetes Mellitus, Type 2 | Terminated | 2016-12-22 | 2018-01-26 | ClinicalTrials.gov |
| NCT02873702 | Efficacy and Safety of Dexlansoprazole in Healing and Maintaining Healing of Er… | Phase3 | Erosive Esophagitis | Terminated | 2016-12-21 | 2017-11-06 | ClinicalTrials.gov |
| NCT02873702 | Efficacy and Safety of Dexlansoprazole in Healing and Maintaining Healing of Er… | Phase3 | Erosive Esophagitis | Terminated | 2016-12-21 | 2017-11-06 | ClinicalTrials.gov |
| NCT02873702 | Efficacy and Safety of Dexlansoprazole in Healing and Maintaining Healing of Er… | Phase3 | Erosive Esophagitis | Terminated | 2016-12-21 | 2017-11-06 | ClinicalTrials.gov |
| NCT02924272 | Ixazomib Rollover Study | Phase2 | Multiple Myeloma | Completed | 2016-12-16 | 2024-07-03 | ClinicalTrials.gov |
| NCT02924272 | Ixazomib Rollover Study | Phase2 | Multiple Myeloma | Completed | 2016-12-16 | 2024-07-03 | ClinicalTrials.gov |
| NCT02924272 | Ixazomib Rollover Study | Phase2 | Multiple Myeloma | Completed | 2016-12-16 | 2024-07-03 | ClinicalTrials.gov |
| NCT02949362 | Long-term Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome … | Phase3 | Short Bowel Syndrome | Completed | 2016-12-09 | 2020-07-14 | ClinicalTrials.gov |
| NCT02949362 | Long-term Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome … | Phase3 | Short Bowel Syndrome | Completed | 2016-12-09 | 2020-07-14 | ClinicalTrials.gov |
| NCT02949362 | Long-term Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome … | Phase3 | Short Bowel Syndrome | Completed | 2016-12-09 | 2020-07-14 | ClinicalTrials.gov |
| NCT03047369 | The Myelin Disorders Biorepository Project | — | Leukodystrophy | Recruiting | 2016-12-08 | 2030-12-08 | ClinicalTrials.gov |
| NCT03047369 | The Myelin Disorders Biorepository Project | — | Leukodystrophy | Recruiting | 2016-12-08 | 2030-12-08 | ClinicalTrials.gov |
| NCT03047369 | The Myelin Disorders Biorepository Project | — | Leukodystrophy | Recruiting | 2016-12-08 | 2030-12-08 | ClinicalTrials.gov |
| NCT02959892 | A Single-Dose Positron Emission Tomography (PET) Study to Determine the Effect … | Phase1 | Healthy Volunteers | Completed | 2016-12-05 | 2017-08-23 | ClinicalTrials.gov |
| NCT02959892 | A Single-Dose Positron Emission Tomography (PET) Study to Determine the Effect … | Phase1 | Healthy Volunteers | Completed | 2016-12-05 | 2017-08-23 | ClinicalTrials.gov |
| NCT02959892 | A Single-Dose Positron Emission Tomography (PET) Study to Determine the Effect … | Phase1 | Healthy Volunteers | Completed | 2016-12-05 | 2017-08-23 | ClinicalTrials.gov |
| NCT02749721 | The Relationship Among Changes in Brain Network Activation in Adult Outpatients… | Phase4 | Major Depressive Disorder | Completed | 2016-12-01 | 2019-01-31 | ClinicalTrials.gov |
| NCT02637895 | Vortioxetine for Posttraumatic Stress Disorder | Phase4 | Post-Traumatic Stress Disorder | Completed | 2016-12-01 | 2020-02-06 | ClinicalTrials.gov |
| NCT02749721 | The Relationship Among Changes in Brain Network Activation in Adult Outpatients… | Phase4 | Major Depressive Disorder | Completed | 2016-12-01 | 2019-01-31 | ClinicalTrials.gov |
| NCT02637895 | Vortioxetine for Posttraumatic Stress Disorder | Phase4 | Post-Traumatic Stress Disorder | Completed | 2016-12-01 | 2020-02-06 | ClinicalTrials.gov |
| NCT02637895 | Vortioxetine for Posttraumatic Stress Disorder | Phase4 | Post-Traumatic Stress Disorder | Completed | 2016-12-01 | 2020-02-06 | ClinicalTrials.gov |
| NCT02749721 | The Relationship Among Changes in Brain Network Activation in Adult Outpatients… | Phase4 | Major Depressive Disorder | Completed | 2016-12-01 | 2019-01-31 | ClinicalTrials.gov |
| NCT02516423 | Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledroni… | Phase3 | Solitary Osseous Plasmacytoma | Terminated | 2016-11-29 | 2025-09-30 | ClinicalTrials.gov |
| NCT02516423 | Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledroni… | Phase3 | Solitary Osseous Plasmacytoma | Terminated | 2016-11-29 | 2025-09-30 | ClinicalTrials.gov |
| NCT02516423 | Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledroni… | Phase3 | Solitary Osseous Plasmacytoma | Terminated | 2016-11-29 | 2025-09-30 | ClinicalTrials.gov |
| NCT02918266 | TAK-071 Scopolamine-Induced Cognitive Impairment Study | Phase1 | Healthy Volunteers | Terminated | 2016-11-21 | 2017-08-08 | ClinicalTrials.gov |
| NCT02918266 | TAK-071 Scopolamine-Induced Cognitive Impairment Study | Phase1 | Healthy Volunteers | Terminated | 2016-11-21 | 2017-08-08 | ClinicalTrials.gov |
| NCT02932904 | Effect of Vortioxetine, Paroxetine, and Placebo on Sexual Functioning in Health… | Phase4 | Healthy Volunteers | Completed | 2016-11-21 | 2017-06-09 | ClinicalTrials.gov |
| NCT02932904 | Effect of Vortioxetine, Paroxetine, and Placebo on Sexual Functioning in Health… | Phase4 | Healthy Volunteers | Completed | 2016-11-21 | 2017-06-09 | ClinicalTrials.gov |
| NCT02993094 | Ixazomib (MLN9708) in Combination With Carboplatin in Pretreated Women With Adv… | Phase1 | Triple-Negative Breast Cancer | Terminated | 2016-11-21 | 2020-08-15 | ClinicalTrials.gov |
| NCT02918266 | TAK-071 Scopolamine-Induced Cognitive Impairment Study | Phase1 | Healthy Volunteers | Terminated | 2016-11-21 | 2017-08-08 | ClinicalTrials.gov |
| NCT02993094 | Ixazomib (MLN9708) in Combination With Carboplatin in Pretreated Women With Adv… | Phase1 | Triple-Negative Breast Cancer | Terminated | 2016-11-21 | 2020-08-15 | ClinicalTrials.gov |
| NCT02932904 | Effect of Vortioxetine, Paroxetine, and Placebo on Sexual Functioning in Health… | Phase4 | Healthy Volunteers | Completed | 2016-11-21 | 2017-06-09 | ClinicalTrials.gov |
| NCT02993094 | Ixazomib (MLN9708) in Combination With Carboplatin in Pretreated Women With Adv… | Phase1 | Triple-Negative Breast Cancer | Terminated | 2016-11-21 | 2020-08-15 | ClinicalTrials.gov |
| NCT02937831 | RIXUBIS Drug Use-Result Survey (Japan) | — | Hemophilia B | Completed | 2016-11-16 | 2022-05-11 | ClinicalTrials.gov |
| NCT03010631 | Comparative Pharmacokinetics and Food-Effect Bioavailability of Lubiprostone Sp… | Phase3 | Healthy Volunteers | Completed | 2016-11-16 | 2017-05-01 | ClinicalTrials.gov |
| NCT02937831 | RIXUBIS Drug Use-Result Survey (Japan) | — | Hemophilia B | Completed | 2016-11-16 | 2022-05-11 | ClinicalTrials.gov |
| NCT03010631 | Comparative Pharmacokinetics and Food-Effect Bioavailability of Lubiprostone Sp… | Phase3 | Healthy Volunteers | Completed | 2016-11-16 | 2017-05-01 | ClinicalTrials.gov |
| NCT03010631 | Comparative Pharmacokinetics and Food-Effect Bioavailability of Lubiprostone Sp… | Phase3 | Healthy Volunteers | Completed | 2016-11-16 | 2017-05-01 | ClinicalTrials.gov |
| NCT02937831 | RIXUBIS Drug Use-Result Survey (Japan) | — | Hemophilia B | Completed | 2016-11-16 | 2022-05-11 | ClinicalTrials.gov |
| NCT02954848 | Phase 3 Study of TAK-438 10 mg in the Treatment of Non-Erosive Gastroesophageal… | Phase3 | Non-erosive Gastroesophageal Reflux Disease | Completed | 2016-11-15 | 2018-02-26 | ClinicalTrials.gov |
| NCT02954848 | Phase 3 Study of TAK-438 10 mg in the Treatment of Non-Erosive Gastroesophageal… | Phase3 | Non-erosive Gastroesophageal Reflux Disease | Completed | 2016-11-15 | 2018-02-26 | ClinicalTrials.gov |
| NCT02954848 | Phase 3 Study of TAK-438 10 mg in the Treatment of Non-Erosive Gastroesophageal… | Phase3 | Non-erosive Gastroesophageal Reflux Disease | Completed | 2016-11-15 | 2018-02-26 | ClinicalTrials.gov |
| NCT02899884 | Characterisation and Epidemiology of Breakthrough Cancer Pain in Spain | — | Breakthrough Cancer Pain | Completed | 2016-11-14 | 2018-07-16 | ClinicalTrials.gov |
| NCT02899884 | Characterisation and Epidemiology of Breakthrough Cancer Pain in Spain | — | Breakthrough Cancer Pain | Completed | 2016-11-14 | 2018-07-16 | ClinicalTrials.gov |
| NCT02899884 | Characterisation and Epidemiology of Breakthrough Cancer Pain in Spain | — | Breakthrough Cancer Pain | Completed | 2016-11-14 | 2018-07-16 | ClinicalTrials.gov |
| NCT03006965 | Pharmacokinetic Characterization of the Hemophilia A Population in Spain Using … | — | Hemophilia A | Completed | 2016-11-11 | 2022-12-22 | ClinicalTrials.gov |
| NCT03006965 | Pharmacokinetic Characterization of the Hemophilia A Population in Spain Using … | — | Hemophilia A | Completed | 2016-11-11 | 2022-12-22 | ClinicalTrials.gov |
| NCT03006965 | Pharmacokinetic Characterization of the Hemophilia A Population in Spain Using … | — | Hemophilia A | Completed | 2016-11-11 | 2022-12-22 | ClinicalTrials.gov |
| NCT02939014 | Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Posit… | Phase2 | Hodgkin Disease | Completed | 2016-11-07 | 2020-02-03 | ClinicalTrials.gov |
| NCT02939014 | Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Posit… | Phase2 | Hodgkin Disease | Completed | 2016-11-07 | 2020-02-03 | ClinicalTrials.gov |
| NCT02939014 | Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Posit… | Phase2 | Hodgkin Disease | Completed | 2016-11-07 | 2020-02-03 | ClinicalTrials.gov |
| NCT02917941 | A Study of Ixazomib Plus Lenalidomide and Dexamethasone in Adult Japanese Parti… | Phase2 | Relapsed and/or Refractory Multiple Myeloma | Completed | 2016-11-01 | 2019-08-31 | ClinicalTrials.gov |
| NCT02917941 | A Study of Ixazomib Plus Lenalidomide and Dexamethasone in Adult Japanese Parti… | Phase2 | Relapsed and/or Refractory Multiple Myeloma | Completed | 2016-11-01 | 2019-08-31 | ClinicalTrials.gov |
| NCT02917941 | A Study of Ixazomib Plus Lenalidomide and Dexamethasone in Adult Japanese Parti… | Phase2 | Relapsed and/or Refractory Multiple Myeloma | Completed | 2016-11-01 | 2019-08-31 | ClinicalTrials.gov |
| NCT02760615 | Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction Study | Phase4 | Colitis, Ulcerative | Withdrawn | 2016-11-01 | 2020-08-01 | ClinicalTrials.gov |
| NCT02760615 | Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction Study | Phase4 | Colitis, Ulcerative | Withdrawn | 2016-11-01 | 2020-08-01 | ClinicalTrials.gov |
| NCT02760615 | Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction Study | Phase4 | Colitis, Ulcerative | Withdrawn | 2016-11-01 | 2020-08-01 | ClinicalTrials.gov |
| NCT02910466 | A Study of Extended Use of Recombinant Human Parathyroid Hormone (rhPTH(1-84)) … | Phase4 | Chronic Hypoparathyroidism | Completed | 2016-10-27 | 2019-12-20 | ClinicalTrials.gov |
| NCT02910466 | A Study of Extended Use of Recombinant Human Parathyroid Hormone (rhPTH(1-84)) … | Phase4 | Chronic Hypoparathyroidism | Completed | 2016-10-27 | 2019-12-20 | ClinicalTrials.gov |
| NCT02910466 | A Study of Extended Use of Recombinant Human Parathyroid Hormone (rhPTH(1-84)) … | Phase4 | Chronic Hypoparathyroidism | Completed | 2016-10-27 | 2019-12-20 | ClinicalTrials.gov |
| NCT02861118 | A Retrospective Observational Study to Assess the Impact of Co-morbidities on T… | — | Inflammatory Bowel Disease | Completed | 2016-10-26 | 2018-04-04 | ClinicalTrials.gov |
| NCT02861118 | A Retrospective Observational Study to Assess the Impact of Co-morbidities on T… | — | Inflammatory Bowel Disease | Completed | 2016-10-26 | 2018-04-04 | ClinicalTrials.gov |
| NCT02861118 | A Retrospective Observational Study to Assess the Impact of Co-morbidities on T… | — | Inflammatory Bowel Disease | Completed | 2016-10-26 | 2018-04-04 | ClinicalTrials.gov |
| NCT02856113 | Phase 3 Alogliptin Pediatric Study | Phase3 | Diabetes Mellitus, Type 2 | Completed | 2016-10-14 | 2022-02-14 | ClinicalTrials.gov |
| NCT02856113 | Phase 3 Alogliptin Pediatric Study | Phase3 | Diabetes Mellitus, Type 2 | Completed | 2016-10-14 | 2022-02-14 | ClinicalTrials.gov |
| NCT02856113 | Phase 3 Alogliptin Pediatric Study | Phase3 | Diabetes Mellitus, Type 2 | Completed | 2016-10-14 | 2022-02-14 | ClinicalTrials.gov |
| NCT02790138 | A Study to Evaluate the Efficacy and Safety of Vedolizumab in the Treatment of … | Phase4 | Pouchitis | Completed | 2016-10-12 | 2021-02-02 | ClinicalTrials.gov |
| NCT02790138 | A Study to Evaluate the Efficacy and Safety of Vedolizumab in the Treatment of … | Phase4 | Pouchitis | Completed | 2016-10-12 | 2021-02-02 | ClinicalTrials.gov |
| NCT02814565 | Cyclobenzaprine HCl Extended Release 15 mg Versus Placebo in Treatment of Cervi… | Phase3 | Neck Pain | Completed | 2016-10-12 | 2017-03-14 | ClinicalTrials.gov |
| NCT02790138 | A Study to Evaluate the Efficacy and Safety of Vedolizumab in the Treatment of … | Phase4 | Pouchitis | Completed | 2016-10-12 | 2021-02-02 | ClinicalTrials.gov |
| NCT02814565 | Cyclobenzaprine HCl Extended Release 15 mg Versus Placebo in Treatment of Cervi… | Phase3 | Neck Pain | Completed | 2016-10-12 | 2017-03-14 | ClinicalTrials.gov |
| NCT02814565 | Cyclobenzaprine HCl Extended Release 15 mg Versus Placebo in Treatment of Cervi… | Phase3 | Neck Pain | Completed | 2016-10-12 | 2017-03-14 | ClinicalTrials.gov |
| NCT02822235 | Non-interventional Study of Moderate to Severe Inflammatory Bowel Disease in Br… | — | Inflammatory Bowel Disease | Completed | 2016-10-11 | 2018-02-19 | ClinicalTrials.gov |
| NCT02822235 | Non-interventional Study of Moderate to Severe Inflammatory Bowel Disease in Br… | — | Inflammatory Bowel Disease | Completed | 2016-10-11 | 2018-02-19 | ClinicalTrials.gov |
| NCT02822235 | Non-interventional Study of Moderate to Severe Inflammatory Bowel Disease in Br… | — | Inflammatory Bowel Disease | Completed | 2016-10-11 | 2018-02-19 | ClinicalTrials.gov |
| NCT02916771 | Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smolderi… | Phase2 | Smoldering Multiple Myeloma | Completed | 2016-10-01 | 2025-01-08 | ClinicalTrials.gov |
| NCT02700022 | A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive… | Phase1 | Diffuse Large B-cell Lymphoma | Terminated | 2016-10-01 | 2017-08-18 | ClinicalTrials.gov |
| NCT02916771 | Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smolderi… | Phase2 | Smoldering Multiple Myeloma | Completed | 2016-10-01 | 2025-01-08 | ClinicalTrials.gov |
| NCT02845349 | Vortioxetine for the Treatment of Major Depression and Co-morbidities After Tra… | Phase3 | TBI | Withdrawn | 2016-10-01 | 2018-10-01 | ClinicalTrials.gov |
| NCT02916771 | Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smolderi… | Phase2 | Smoldering Multiple Myeloma | Completed | 2016-10-01 | 2025-01-08 | ClinicalTrials.gov |
| NCT02700022 | A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive… | Phase1 | Diffuse Large B-cell Lymphoma | Terminated | 2016-10-01 | 2017-08-18 | ClinicalTrials.gov |
| NCT02845349 | Vortioxetine for the Treatment of Major Depression and Co-morbidities After Tra… | Phase3 | TBI | Withdrawn | 2016-10-01 | 2018-10-01 | ClinicalTrials.gov |
| NCT02845349 | Vortioxetine for the Treatment of Major Depression and Co-morbidities After Tra… | Phase3 | TBI | Withdrawn | 2016-10-01 | 2018-10-01 | ClinicalTrials.gov |
| NCT02700022 | A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive… | Phase1 | Diffuse Large B-cell Lymphoma | Terminated | 2016-10-01 | 2017-08-18 | ClinicalTrials.gov |
| NCT02919501 | Study of the Efficacy and Safety of Initial Administration of 17 mg Vortioxetin… | Phase2 | Depressive Disorder, Major | Completed | 2016-09-27 | 2017-04-27 | ClinicalTrials.gov |
| NCT02919501 | Study of the Efficacy and Safety of Initial Administration of 17 mg Vortioxetin… | Phase2 | Depressive Disorder, Major | Completed | 2016-09-27 | 2017-04-27 | ClinicalTrials.gov |
| NCT02919501 | Study of the Efficacy and Safety of Initial Administration of 17 mg Vortioxetin… | Phase2 | Depressive Disorder, Major | Completed | 2016-09-27 | 2017-04-27 | ClinicalTrials.gov |
| NCT02756832 | An Observational Study of Alogliptin Benzoate in Participants With Diabetes Mel… | — | Diabetes Mellitus | Completed | 2016-09-20 | 2018-04-28 | ClinicalTrials.gov |
| NCT02756832 | An Observational Study of Alogliptin Benzoate in Participants With Diabetes Mel… | — | Diabetes Mellitus | Completed | 2016-09-20 | 2018-04-28 | ClinicalTrials.gov |
| NCT02756832 | An Observational Study of Alogliptin Benzoate in Participants With Diabetes Mel… | — | Diabetes Mellitus | Completed | 2016-09-20 | 2018-04-28 | ClinicalTrials.gov |
| NCT04189536 | An SMS Intervention to Improve Adherence to Stimulant Medications in Adults Wit… | Na | Attention Deficit/Hyperactivity Disorder | Unknown | 2016-09-19 | 2022-09-01 | ClinicalTrials.gov |
| NCT04189536 | An SMS Intervention to Improve Adherence to Stimulant Medications in Adults Wit… | Na | Attention Deficit/Hyperactivity Disorder | Unknown | 2016-09-19 | 2022-09-01 | ClinicalTrials.gov |
| NCT04189536 | An SMS Intervention to Improve Adherence to Stimulant Medications in Adults Wit… | Na | Attention Deficit/Hyperactivity Disorder | Unknown | 2016-09-19 | 2022-09-01 | ClinicalTrials.gov |
| NCT02716233 | A French Protocol for the Treatment of Acute Lymphoblastic Leukemia (ALL) in Ch… | Phase3 | Acute Lymphoblastic Leukemia | Active_Not_Recruiting | 2016-09-19 | 2027-03-01 | ClinicalTrials.gov |
| NCT02716233 | A French Protocol for the Treatment of Acute Lymphoblastic Leukemia (ALL) in Ch… | Phase3 | Acute Lymphoblastic Leukemia | Active_Not_Recruiting | 2016-09-19 | 2027-03-01 | ClinicalTrials.gov |
| NCT02716233 | A French Protocol for the Treatment of Acute Lymphoblastic Leukemia (ALL) in Ch… | Phase3 | Acute Lymphoblastic Leukemia | Active_Not_Recruiting | 2016-09-19 | 2027-03-01 | ClinicalTrials.gov |
| NCT02807753 | The Hemophilia Ultrasound Project | — | Hemophilia A | Terminated | 2016-09-16 | 2020-12-07 | ClinicalTrials.gov |
| NCT02807753 | The Hemophilia Ultrasound Project | — | Hemophilia A | Terminated | 2016-09-16 | 2020-12-07 | ClinicalTrials.gov |
| NCT02807753 | The Hemophilia Ultrasound Project | — | Hemophilia A | Terminated | 2016-09-16 | 2020-12-07 | ClinicalTrials.gov |
| NCT02906813 | A Study to Determine the Bioavailability and Food Effect of a Single TAK-935 Do… | Phase1 | Healthy Volunteers | Completed | 2016-09-12 | 2016-11-09 | ClinicalTrials.gov |
| NCT02906813 | A Study to Determine the Bioavailability and Food Effect of a Single TAK-935 Do… | Phase1 | Healthy Volunteers | Completed | 2016-09-12 | 2016-11-09 | ClinicalTrials.gov |
| NCT02906813 | A Study to Determine the Bioavailability and Food Effect of a Single TAK-935 Do… | Phase1 | Healthy Volunteers | Completed | 2016-09-12 | 2016-11-09 | ClinicalTrials.gov |
| NCT02771093 | An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose V… | Phase4 | Type 2 Diabetes Mellitus | Completed | 2016-09-08 | 2017-04-27 | ClinicalTrials.gov |
| NCT02771093 | An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose V… | Phase4 | Type 2 Diabetes Mellitus | Completed | 2016-09-08 | 2017-04-27 | ClinicalTrials.gov |
| NCT02865720 | Study of C1 Inhibitor (Human) for the Prevention of Angioedema Attacks and Trea… | Phase3 | Hereditary Angioedema (HAE) | Completed | 2016-09-08 | 2017-06-23 | ClinicalTrials.gov |
| NCT02865720 | Study of C1 Inhibitor (Human) for the Prevention of Angioedema Attacks and Trea… | Phase3 | Hereditary Angioedema (HAE) | Completed | 2016-09-08 | 2017-06-23 | ClinicalTrials.gov |
| NCT02865720 | Study of C1 Inhibitor (Human) for the Prevention of Angioedema Attacks and Trea… | Phase3 | Hereditary Angioedema (HAE) | Completed | 2016-09-08 | 2017-06-23 | ClinicalTrials.gov |
| NCT02771093 | An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose V… | Phase4 | Type 2 Diabetes Mellitus | Completed | 2016-09-08 | 2017-04-27 | ClinicalTrials.gov |
| NCT02892409 | TAK-438 Bismuth Drug Interaction Study | Phase1 | Helicobacter Pylori | Completed | 2016-09-05 | 2017-05-11 | ClinicalTrials.gov |
| NCT02892409 | TAK-438 Bismuth Drug Interaction Study | Phase1 | Helicobacter Pylori | Completed | 2016-09-05 | 2017-05-11 | ClinicalTrials.gov |
| NCT02892409 | TAK-438 Bismuth Drug Interaction Study | Phase1 | Helicobacter Pylori | Completed | 2016-09-05 | 2017-05-11 | ClinicalTrials.gov |
| NCT02835716 | Pre-Clinical (Alzheimers) Diagnosis PCD = Optimum Outcomes OO | — | Alzheimer Disease | Unknown | 2016-09-01 | 2020-09-01 | ClinicalTrials.gov |
| NCT03214094 | Special Drug Use Surveillance of Vonoprazan for "Prevention of Recurrence of Ga… | — | Gastric or Duodenal Ulcers | Completed | 2016-09-01 | 2019-02-28 | ClinicalTrials.gov |
| NCT02835716 | Pre-Clinical (Alzheimers) Diagnosis PCD = Optimum Outcomes OO | — | Alzheimer Disease | Unknown | 2016-09-01 | 2020-09-01 | ClinicalTrials.gov |
| NCT03013166 | THIN Database Study: Resource Use and Outcomes in Patients With Adrenal Insuffi… | — | Adrenal Insufficiency | Completed | 2016-09-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT03013166 | THIN Database Study: Resource Use and Outcomes in Patients With Adrenal Insuffi… | — | Adrenal Insufficiency | Completed | 2016-09-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT02765854 | Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Ran… | Phase2 | Recurrent Plasma Cell Myeloma | Completed | 2016-09-01 | 2023-05-23 | ClinicalTrials.gov |
| NCT03214198 | Special Drug Use Surveillance of Vonoprazan for "Prevention of Recurrence of Ga… | — | A History of Gastric or Duodenal Ulcers | Completed | 2016-09-01 | 2020-04-30 | ClinicalTrials.gov |
| NCT03214094 | Special Drug Use Surveillance of Vonoprazan for "Prevention of Recurrence of Ga… | — | Gastric or Duodenal Ulcers | Completed | 2016-09-01 | 2019-02-28 | ClinicalTrials.gov |
| NCT02812056 | Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associat… | Phase1 | Malignant Neoplasms of Digestive Organs | Withdrawn | 2016-09-01 | — | ClinicalTrials.gov |
| NCT03214094 | Special Drug Use Surveillance of Vonoprazan for "Prevention of Recurrence of Ga… | — | Gastric or Duodenal Ulcers | Completed | 2016-09-01 | 2019-02-28 | ClinicalTrials.gov |
| NCT03214198 | Special Drug Use Surveillance of Vonoprazan for "Prevention of Recurrence of Ga… | — | A History of Gastric or Duodenal Ulcers | Completed | 2016-09-01 | 2020-04-30 | ClinicalTrials.gov |
| NCT02812056 | Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associat… | Phase1 | Malignant Neoplasms of Digestive Organs | Withdrawn | 2016-09-01 | — | ClinicalTrials.gov |
| NCT02765854 | Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Ran… | Phase2 | Recurrent Plasma Cell Myeloma | Completed | 2016-09-01 | 2023-05-23 | ClinicalTrials.gov |
| NCT03013166 | THIN Database Study: Resource Use and Outcomes in Patients With Adrenal Insuffi… | — | Adrenal Insufficiency | Completed | 2016-09-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT03214198 | Special Drug Use Surveillance of Vonoprazan for "Prevention of Recurrence of Ga… | — | A History of Gastric or Duodenal Ulcers | Completed | 2016-09-01 | 2020-04-30 | ClinicalTrials.gov |
| NCT02765854 | Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Ran… | Phase2 | Recurrent Plasma Cell Myeloma | Completed | 2016-09-01 | 2023-05-23 | ClinicalTrials.gov |
| NCT02812056 | Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associat… | Phase1 | Malignant Neoplasms of Digestive Organs | Withdrawn | 2016-09-01 | — | ClinicalTrials.gov |
| NCT02835716 | Pre-Clinical (Alzheimers) Diagnosis PCD = Optimum Outcomes OO | — | Alzheimer Disease | Unknown | 2016-09-01 | 2020-09-01 | ClinicalTrials.gov |
| NCT03272711 | Remediation of Age-related Cognitive Decline: Vortioxetine and Cognitive Traini… | Phase4 | Age-related Cognitive Decline | Completed | 2016-08-31 | 2019-01-24 | ClinicalTrials.gov |
| NCT03272711 | Remediation of Age-related Cognitive Decline: Vortioxetine and Cognitive Traini… | Phase4 | Age-related Cognitive Decline | Completed | 2016-08-31 | 2019-01-24 | ClinicalTrials.gov |
| NCT03272711 | Remediation of Age-related Cognitive Decline: Vortioxetine and Cognitive Traini… | Phase4 | Age-related Cognitive Decline | Completed | 2016-08-31 | 2019-01-24 | ClinicalTrials.gov |
| NCT02791438 | A Phase 3 Long-term Study of TAK-536 in Pediatric Patients 6 to Less Than 16 Ye… | Phase3 | Pediatric Hypertension | Completed | 2016-08-18 | 2019-06-04 | ClinicalTrials.gov |
| NCT02791438 | A Phase 3 Long-term Study of TAK-536 in Pediatric Patients 6 to Less Than 16 Ye… | Phase3 | Pediatric Hypertension | Completed | 2016-08-18 | 2019-06-04 | ClinicalTrials.gov |
| NCT02791438 | A Phase 3 Long-term Study of TAK-536 in Pediatric Patients 6 to Less Than 16 Ye… | Phase3 | Pediatric Hypertension | Completed | 2016-08-18 | 2019-06-04 | ClinicalTrials.gov |
| NCT02630966 | Vedolizumab IV 300 mg in the Treatment of Fistulizing Crohn's Disease | Phase4 | Crohn's Disease | Completed | 2016-08-10 | 2018-11-14 | ClinicalTrials.gov |
| NCT02630966 | Vedolizumab IV 300 mg in the Treatment of Fistulizing Crohn's Disease | Phase4 | Crohn's Disease | Completed | 2016-08-10 | 2018-11-14 | ClinicalTrials.gov |
| NCT02630966 | Vedolizumab IV 300 mg in the Treatment of Fistulizing Crohn's Disease | Phase4 | Crohn's Disease | Completed | 2016-08-10 | 2018-11-14 | ClinicalTrials.gov |
| NCT02897830 | Ixazomib, Lenalidomide, Dexamethasone Induction and Extended Consolidation Plus… | Phase2 | Multiple Myeloma | Terminated | 2016-08-05 | 2020-08-31 | ClinicalTrials.gov |
| NCT02897830 | Ixazomib, Lenalidomide, Dexamethasone Induction and Extended Consolidation Plus… | Phase2 | Multiple Myeloma | Terminated | 2016-08-05 | 2020-08-31 | ClinicalTrials.gov |
| NCT02897830 | Ixazomib, Lenalidomide, Dexamethasone Induction and Extended Consolidation Plus… | Phase2 | Multiple Myeloma | Terminated | 2016-08-05 | 2020-08-31 | ClinicalTrials.gov |
| NCT02824432 | Exploratory Study of the Effect of Omega-3-acid Ethyl Esters (TAK-085) on Vascu… | Phase4 | Hyperlipidemia | Completed | 2016-08-04 | 2017-08-19 | ClinicalTrials.gov |
| NCT02824432 | Exploratory Study of the Effect of Omega-3-acid Ethyl Esters (TAK-085) on Vascu… | Phase4 | Hyperlipidemia | Completed | 2016-08-04 | 2017-08-19 | ClinicalTrials.gov |
| NCT02824432 | Exploratory Study of the Effect of Omega-3-acid Ethyl Esters (TAK-085) on Vascu… | Phase4 | Hyperlipidemia | Completed | 2016-08-04 | 2017-08-19 | ClinicalTrials.gov |
| NCT02743806 | Extended Access Program of Vedolizumab IV in Ulcerative Colitis and Crohn's Dis… | Phase4 | Colitis, Ulcerative | Terminated | 2016-08-01 | 2023-01-03 | ClinicalTrials.gov |
| NCT02743806 | Extended Access Program of Vedolizumab IV in Ulcerative Colitis and Crohn's Dis… | Phase4 | Colitis, Ulcerative | Terminated | 2016-08-01 | 2023-01-03 | ClinicalTrials.gov |
| NCT02743806 | Extended Access Program of Vedolizumab IV in Ulcerative Colitis and Crohn's Dis… | Phase4 | Colitis, Ulcerative | Terminated | 2016-08-01 | 2023-01-03 | ClinicalTrials.gov |
| NCT02775240 | Study of SHP620 (Maribavir) in Healthy Adults | Phase1 | Cytomegalovirus (CMV) | Completed | 2016-07-21 | 2016-09-12 | ClinicalTrials.gov |
| NCT02775240 | Study of SHP620 (Maribavir) in Healthy Adults | Phase1 | Cytomegalovirus (CMV) | Completed | 2016-07-21 | 2016-09-12 | ClinicalTrials.gov |
| NCT02775240 | Study of SHP620 (Maribavir) in Healthy Adults | Phase1 | Cytomegalovirus (CMV) | Completed | 2016-07-21 | 2016-09-12 | ClinicalTrials.gov |
| NCT02756819 | International Multicenter, Observational, Non-Interventional Prospective Study … | — | Hypertension | Completed | 2016-07-18 | 2018-05-08 | ClinicalTrials.gov |
| NCT02575339 | MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma | Phase1 | Hepatocellular Carcinoma | Terminated | 2016-07-18 | 2020-11-24 | ClinicalTrials.gov |
| NCT02575339 | MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma | Phase1 | Hepatocellular Carcinoma | Terminated | 2016-07-18 | 2020-11-24 | ClinicalTrials.gov |
| NCT02756819 | International Multicenter, Observational, Non-Interventional Prospective Study … | — | Hypertension | Completed | 2016-07-18 | 2018-05-08 | ClinicalTrials.gov |
| NCT02756819 | International Multicenter, Observational, Non-Interventional Prospective Study … | — | Hypertension | Completed | 2016-07-18 | 2018-05-08 | ClinicalTrials.gov |
| NCT02575339 | MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma | Phase1 | Hepatocellular Carcinoma | Terminated | 2016-07-18 | 2020-11-24 | ClinicalTrials.gov |
| NCT02726139 | Improved Factor VIII Inhibitor Evaluation | — | Hemophilia | Withdrawn | 2016-07-15 | 2021-01-25 | ClinicalTrials.gov |
| NCT02726139 | Improved Factor VIII Inhibitor Evaluation | — | Hemophilia | Withdrawn | 2016-07-15 | 2021-01-25 | ClinicalTrials.gov |
| NCT02726139 | Improved Factor VIII Inhibitor Evaluation | — | Hemophilia | Withdrawn | 2016-07-15 | 2021-01-25 | ClinicalTrials.gov |
| NCT02743949 | Comparison of Vonoprazan to Esomeprazole in Participants With Symptomatic GERD … | Phase2 | Gastroesophageal Reflux | Completed | 2016-07-14 | 2018-10-12 | ClinicalTrials.gov |
| NCT02743949 | Comparison of Vonoprazan to Esomeprazole in Participants With Symptomatic GERD … | Phase2 | Gastroesophageal Reflux | Completed | 2016-07-14 | 2018-10-12 | ClinicalTrials.gov |
| NCT02743949 | Comparison of Vonoprazan to Esomeprazole in Participants With Symptomatic GERD … | Phase2 | Gastroesophageal Reflux | Completed | 2016-07-14 | 2018-10-12 | ClinicalTrials.gov |
| NCT02792062 | A Food Effect Study of TAK-385 Final Formulation | Phase1 | Japanese Premenopausal Healthy Adult Women | Completed | 2016-07-04 | 2016-08-31 | ClinicalTrials.gov |
| NCT02792062 | A Food Effect Study of TAK-385 Final Formulation | Phase1 | Japanese Premenopausal Healthy Adult Women | Completed | 2016-07-04 | 2016-08-31 | ClinicalTrials.gov |
| NCT02792062 | A Food Effect Study of TAK-385 Final Formulation | Phase1 | Japanese Premenopausal Healthy Adult Women | Completed | 2016-07-04 | 2016-08-31 | ClinicalTrials.gov |
| NCT02768532 | Value of Pharmacokinetic Assays in the Prediction of Induction and Maintenance … | Phase4 | Crohn Disease | Terminated | 2016-07-01 | 2023-01-23 | ClinicalTrials.gov |
| NCT02831686 | A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexametha… | Phase1 | Multiple Myeloma | Completed | 2016-07-01 | 2020-11-19 | ClinicalTrials.gov |
| NCT02768532 | Value of Pharmacokinetic Assays in the Prediction of Induction and Maintenance … | Phase4 | Crohn Disease | Terminated | 2016-07-01 | 2023-01-23 | ClinicalTrials.gov |
| NCT02761187 | An Observational Study of Presentation, Treatment Patterns, and Outcomes in Mul… | — | Multiple Myeloma | Terminated | 2016-07-01 | 2021-09-30 | ClinicalTrials.gov |
| NCT02637466 | Vortioxetine for MDD, Cognition, and Systemic Inflammatory Biomarkers | Phase4 | Unipolar Major Depression | Withdrawn | 2016-07-01 | 2019-07-01 | ClinicalTrials.gov |
| NCT02637466 | Vortioxetine for MDD, Cognition, and Systemic Inflammatory Biomarkers | Phase4 | Unipolar Major Depression | Withdrawn | 2016-07-01 | 2019-07-01 | ClinicalTrials.gov |
| NCT02761187 | An Observational Study of Presentation, Treatment Patterns, and Outcomes in Mul… | — | Multiple Myeloma | Terminated | 2016-07-01 | 2021-09-30 | ClinicalTrials.gov |
| NCT02831686 | A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexametha… | Phase1 | Multiple Myeloma | Completed | 2016-07-01 | 2020-11-19 | ClinicalTrials.gov |
| NCT02831686 | A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexametha… | Phase1 | Multiple Myeloma | Completed | 2016-07-01 | 2020-11-19 | ClinicalTrials.gov |
| NCT02768532 | Value of Pharmacokinetic Assays in the Prediction of Induction and Maintenance … | Phase4 | Crohn Disease | Terminated | 2016-07-01 | 2023-01-23 | ClinicalTrials.gov |
| NCT02761187 | An Observational Study of Presentation, Treatment Patterns, and Outcomes in Mul… | — | Multiple Myeloma | Terminated | 2016-07-01 | 2021-09-30 | ClinicalTrials.gov |
| NCT02637466 | Vortioxetine for MDD, Cognition, and Systemic Inflammatory Biomarkers | Phase4 | Unipolar Major Depression | Withdrawn | 2016-07-01 | 2019-07-01 | ClinicalTrials.gov |
| NCT02724020 | MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adul… | Phase2 | Clear-cell Metastatic Renal Cell Carcinoma | Completed | 2016-06-30 | 2020-10-13 | ClinicalTrials.gov |
| NCT02724020 | MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adul… | Phase2 | Clear-cell Metastatic Renal Cell Carcinoma | Completed | 2016-06-30 | 2020-10-13 | ClinicalTrials.gov |
| NCT02817516 | A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of TAK-828… | Phase1 | Healthy Volunteers | Terminated | 2016-06-30 | 2016-08-22 | ClinicalTrials.gov |
| NCT02724020 | MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adul… | Phase2 | Clear-cell Metastatic Renal Cell Carcinoma | Completed | 2016-06-30 | 2020-10-13 | ClinicalTrials.gov |
| NCT02817516 | A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of TAK-828… | Phase1 | Healthy Volunteers | Terminated | 2016-06-30 | 2016-08-22 | ClinicalTrials.gov |
| NCT02817516 | A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of TAK-828… | Phase1 | Healthy Volunteers | Terminated | 2016-06-30 | 2016-08-22 | ClinicalTrials.gov |
| NCT02574286 | Study of the Effect of Velaglucerase Alfa (VPRIV®) on Bone-related Pathology in… | Phase4 | Gaucher Disease | Completed | 2016-06-29 | 2020-11-30 | ClinicalTrials.gov |
| NCT02574286 | Study of the Effect of Velaglucerase Alfa (VPRIV®) on Bone-related Pathology in… | Phase4 | Gaucher Disease | Completed | 2016-06-29 | 2020-11-30 | ClinicalTrials.gov |
| NCT02574286 | Study of the Effect of Velaglucerase Alfa (VPRIV®) on Bone-related Pathology in… | Phase4 | Gaucher Disease | Completed | 2016-06-29 | 2020-11-30 | ClinicalTrials.gov |
| NCT02723006 | Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigati… | Phase1 | Melanoma | Terminated | 2016-06-22 | 2018-05-11 | ClinicalTrials.gov |
| NCT02723006 | Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigati… | Phase1 | Melanoma | Terminated | 2016-06-22 | 2018-05-11 | ClinicalTrials.gov |
| NCT02723006 | Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigati… | Phase1 | Melanoma | Terminated | 2016-06-22 | 2018-05-11 | ClinicalTrials.gov |
| NCT02716116 | A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer | Phase1 | Carcinoma, Non-Small-Cell Lung | Active_Not_Recruiting | 2016-06-16 | 2026-10-31 | ClinicalTrials.gov |
| NCT02716116 | A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer | Phase1 | Carcinoma, Non-Small-Cell Lung | Active_Not_Recruiting | 2016-06-16 | 2026-10-31 | ClinicalTrials.gov |
| NCT02716116 | A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer | Phase1 | Carcinoma, Non-Small-Cell Lung | Active_Not_Recruiting | 2016-06-16 | 2026-10-31 | ClinicalTrials.gov |
| NCT02728895 | Dose Finding Study of Vedolizumab for GvHD in Participants Undergoing Allogenei… | Phase1 | Allogeneic Hematopoietic Stem Cell Transplantation | Completed | 2016-06-15 | 2018-07-10 | ClinicalTrials.gov |
| NCT02728895 | Dose Finding Study of Vedolizumab for GvHD in Participants Undergoing Allogenei… | Phase1 | Allogeneic Hematopoietic Stem Cell Transplantation | Completed | 2016-06-15 | 2018-07-10 | ClinicalTrials.gov |
| NCT02728895 | Dose Finding Study of Vedolizumab for GvHD in Participants Undergoing Allogenei… | Phase1 | Allogeneic Hematopoietic Stem Cell Transplantation | Completed | 2016-06-15 | 2018-07-10 | ClinicalTrials.gov |
| NCT02669121 | Efficacy and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-like Particl… | Phase2 | Healthy Volunteers | Completed | 2016-06-14 | 2018-06-16 | ClinicalTrials.gov |
| NCT02669121 | Efficacy and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-like Particl… | Phase2 | Healthy Volunteers | Completed | 2016-06-14 | 2018-06-16 | ClinicalTrials.gov |
| NCT02669121 | Efficacy and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-like Particl… | Phase2 | Healthy Volunteers | Completed | 2016-06-14 | 2018-06-16 | ClinicalTrials.gov |
| NCT02976272 | Neurotoxic Effect of Bortezomib Treatment in Patient With Myeloma Multiple | — | Multiple Myeloma | Unknown | 2016-06-07 | 2021-01-31 | ClinicalTrials.gov |
| NCT02976272 | Neurotoxic Effect of Bortezomib Treatment in Patient With Myeloma Multiple | — | Multiple Myeloma | Unknown | 2016-06-07 | 2021-01-31 | ClinicalTrials.gov |
| NCT02976272 | Neurotoxic Effect of Bortezomib Treatment in Patient With Myeloma Multiple | — | Multiple Myeloma | Unknown | 2016-06-07 | 2021-01-31 | ClinicalTrials.gov |
| NCT02528409 | Vortioxetine for Binge Eating Disorder | Phase2 | Binge Eating Disorder | Completed | 2016-06-01 | 2018-11-01 | ClinicalTrials.gov |
| NCT02528409 | Vortioxetine for Binge Eating Disorder | Phase2 | Binge Eating Disorder | Completed | 2016-06-01 | 2018-11-01 | ClinicalTrials.gov |
| NCT02528409 | Vortioxetine for Binge Eating Disorder | Phase2 | Binge Eating Disorder | Completed | 2016-06-01 | 2018-11-01 | ClinicalTrials.gov |
| NCT02741596 | Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioe… | Phase3 | Hereditary Angioedema (HAE) | Completed | 2016-05-26 | 2019-10-31 | ClinicalTrials.gov |
| NCT02741596 | Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioe… | Phase3 | Hereditary Angioedema (HAE) | Completed | 2016-05-26 | 2019-10-31 | ClinicalTrials.gov |
| NCT02741596 | Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioe… | Phase3 | Hereditary Angioedema (HAE) | Completed | 2016-05-26 | 2019-10-31 | ClinicalTrials.gov |
| NCT02339922 | Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Ho… | Phase2 | Chronic Lymphocytic Leukemia | Active_Not_Recruiting | 2016-05-19 | 2028-01-08 | ClinicalTrials.gov |
| NCT02339922 | Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Ho… | Phase2 | Chronic Lymphocytic Leukemia | Active_Not_Recruiting | 2016-05-19 | 2028-01-08 | ClinicalTrials.gov |
| NCT02339922 | Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Ho… | Phase2 | Chronic Lymphocytic Leukemia | Active_Not_Recruiting | 2016-05-19 | 2028-01-08 | ClinicalTrials.gov |
| NCT02763007 | An Extension Study of PEAK Trial | Phase4 | Diabetes Mellitus, Type 2 | Terminated | 2016-05-18 | 2019-02-28 | ClinicalTrials.gov |
| NCT02763007 | An Extension Study of PEAK Trial | Phase4 | Diabetes Mellitus, Type 2 | Terminated | 2016-05-18 | 2019-02-28 | ClinicalTrials.gov |
| NCT02709655 | Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Pa… | Phase3 | Depressive Disorder, Major | Completed | 2016-05-18 | 2022-01-21 | ClinicalTrials.gov |
| NCT02709655 | Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Pa… | Phase3 | Depressive Disorder, Major | Completed | 2016-05-18 | 2022-01-21 | ClinicalTrials.gov |
| NCT02709655 | Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Pa… | Phase3 | Depressive Disorder, Major | Completed | 2016-05-18 | 2022-01-21 | ClinicalTrials.gov |
| NCT02763007 | An Extension Study of PEAK Trial | Phase4 | Diabetes Mellitus, Type 2 | Terminated | 2016-05-18 | 2019-02-28 | ClinicalTrials.gov |
| NCT02782468 | A Study of Pevonedistat in Adult East Asian Participants | Phase1 | Leukemia, Myeloid, Acute | Completed | 2016-05-16 | 2022-01-25 | ClinicalTrials.gov |
| NCT02782468 | A Study of Pevonedistat in Adult East Asian Participants | Phase1 | Leukemia, Myeloid, Acute | Completed | 2016-05-16 | 2022-01-25 | ClinicalTrials.gov |
| NCT02782468 | A Study of Pevonedistat in Adult East Asian Participants | Phase1 | Leukemia, Myeloid, Acute | Completed | 2016-05-16 | 2022-01-25 | ClinicalTrials.gov |
| NCT02729909 | Lubiprostone for Chronic Idiopathic Constipation Treatment | Phase3 | Constipation | Completed | 2016-05-11 | 2017-06-05 | ClinicalTrials.gov |
| NCT02729909 | Lubiprostone for Chronic Idiopathic Constipation Treatment | Phase3 | Constipation | Completed | 2016-05-11 | 2017-06-05 | ClinicalTrials.gov |
| NCT02729909 | Lubiprostone for Chronic Idiopathic Constipation Treatment | Phase3 | Constipation | Completed | 2016-05-11 | 2017-06-05 | ClinicalTrials.gov |
| NCT02748694 | Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study | Phase1 | Healthy Volunteers | Completed | 2016-05-09 | 2019-09-22 | ClinicalTrials.gov |
| NCT02748694 | Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study | Phase1 | Healthy Volunteers | Completed | 2016-05-09 | 2019-09-22 | ClinicalTrials.gov |
| NCT02748694 | Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study | Phase1 | Healthy Volunteers | Completed | 2016-05-09 | 2019-09-22 | ClinicalTrials.gov |
| NCT02769065 | Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive I… | Phase1 | Alzheimer Disease | Terminated | 2016-05-05 | 2017-06-08 | ClinicalTrials.gov |
| NCT02769065 | Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive I… | Phase1 | Alzheimer Disease | Terminated | 2016-05-05 | 2017-06-08 | ClinicalTrials.gov |
| NCT02769065 | Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive I… | Phase1 | Alzheimer Disease | Terminated | 2016-05-05 | 2017-06-08 | ClinicalTrials.gov |
| NCT03555591 | Specified Drug-Use Survey of Trelagliptin Tablets "Survey on Long-term Use in P… | — | Type 2 Diabetes Mellitus | Completed | 2016-05-01 | 2021-10-31 | ClinicalTrials.gov |
| NCT02709746 | Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Pa… | Phase3 | Depressive Disorder, Major | Completed | 2016-05-01 | 2019-07-30 | ClinicalTrials.gov |
| NCT03555591 | Specified Drug-Use Survey of Trelagliptin Tablets "Survey on Long-term Use in P… | — | Type 2 Diabetes Mellitus | Completed | 2016-05-01 | 2021-10-31 | ClinicalTrials.gov |
| NCT03555591 | Specified Drug-Use Survey of Trelagliptin Tablets "Survey on Long-term Use in P… | — | Type 2 Diabetes Mellitus | Completed | 2016-05-01 | 2021-10-31 | ClinicalTrials.gov |
| NCT02709746 | Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Pa… | Phase3 | Depressive Disorder, Major | Completed | 2016-05-01 | 2019-07-30 | ClinicalTrials.gov |
| NCT02709746 | Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Pa… | Phase3 | Depressive Disorder, Major | Completed | 2016-05-01 | 2019-07-30 | ClinicalTrials.gov |
| NCT02723201 | TAK-020 Relative Bioavailability and Food Effect Study in Healthy Participants | Phase1 | Healthy | Completed | 2016-04-28 | 2016-08-24 | ClinicalTrials.gov |
| NCT02723201 | TAK-020 Relative Bioavailability and Food Effect Study in Healthy Participants | Phase1 | Healthy | Completed | 2016-04-28 | 2016-08-24 | ClinicalTrials.gov |
| NCT02723201 | TAK-020 Relative Bioavailability and Food Effect Study in Healthy Participants | Phase1 | Healthy | Completed | 2016-04-28 | 2016-08-24 | ClinicalTrials.gov |
| NCT02747927 | Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV… | Phase3 | Healthy Volunteers | Completed | 2016-04-26 | 2024-06-28 | ClinicalTrials.gov |
| NCT02747927 | Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV… | Phase3 | Healthy Volunteers | Completed | 2016-04-26 | 2024-06-28 | ClinicalTrials.gov |
| NCT02747927 | Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV… | Phase3 | Healthy Volunteers | Completed | 2016-04-26 | 2024-06-28 | ClinicalTrials.gov |
| NCT02620046 | A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerat… | Phase3 | Colitis, Ulcerative | Completed | 2016-04-15 | 2024-06-12 | ClinicalTrials.gov |
| NCT02620046 | A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerat… | Phase3 | Colitis, Ulcerative | Completed | 2016-04-15 | 2024-06-12 | ClinicalTrials.gov |
| NCT02620046 | A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerat… | Phase3 | Colitis, Ulcerative | Completed | 2016-04-15 | 2024-06-12 | ClinicalTrials.gov |
| NCT02610777 | An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Age… | Phase2 | Myelodysplastic Syndromes | Completed | 2016-04-14 | 2021-07-23 | ClinicalTrials.gov |
| NCT02695719 | Lubiprostone for Treatment of Chronic Idiopathic Constipation | Phase3 | Chronic Idiopathic Constipation | Completed | 2016-04-14 | 2017-02-24 | ClinicalTrials.gov |
| NCT02610777 | An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Age… | Phase2 | Myelodysplastic Syndromes | Completed | 2016-04-14 | 2021-07-23 | ClinicalTrials.gov |
| NCT02695719 | Lubiprostone for Treatment of Chronic Idiopathic Constipation | Phase3 | Chronic Idiopathic Constipation | Completed | 2016-04-14 | 2017-02-24 | ClinicalTrials.gov |
| NCT02695719 | Lubiprostone for Treatment of Chronic Idiopathic Constipation | Phase3 | Chronic Idiopathic Constipation | Completed | 2016-04-14 | 2017-02-24 | ClinicalTrials.gov |
| NCT02610777 | An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Age… | Phase2 | Myelodysplastic Syndromes | Completed | 2016-04-14 | 2021-07-23 | ClinicalTrials.gov |
| NCT02685007 | RollOut -Pre-Rolled TachoSil in Laparoscopic Utilisation. A Non-Interventional … | — | Laparoscopy | Completed | 2016-04-05 | 2017-08-14 | ClinicalTrials.gov |
| NCT02685007 | RollOut -Pre-Rolled TachoSil in Laparoscopic Utilisation. A Non-Interventional … | — | Laparoscopy | Completed | 2016-04-05 | 2017-08-14 | ClinicalTrials.gov |
| NCT02685007 | RollOut -Pre-Rolled TachoSil in Laparoscopic Utilisation. A Non-Interventional … | — | Laparoscopy | Completed | 2016-04-05 | 2017-08-14 | ClinicalTrials.gov |
| NCT02388971 | Proof of Mechanism Study of MLN1202 on Atherosclerotic Inflammation in Particip… | Phase2 | Atherosclerotic Cardiovascular Disease | Withdrawn | 2016-04-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT02508168 | Phase 1 Bioavailability Study of SYR-322MET | Phase1 | Healthy Volunteers | Completed | 2016-04-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT02454426 | Vortioxetine in Patients With Major Depressive Disorder and Coronary Artery Dis… | Early_Phase1 | Major Depressive Disorder | Withdrawn | 2016-04-01 | 2016-06-01 | ClinicalTrials.gov |
| NCT02508168 | Phase 1 Bioavailability Study of SYR-322MET | Phase1 | Healthy Volunteers | Completed | 2016-04-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT02324699 | Corticosteroids With Vedolizumab in Crohn's Disease | Phase4 | Crohn's Disease | Terminated | 2016-04-01 | 2018-02-08 | ClinicalTrials.gov |
| NCT02508168 | Phase 1 Bioavailability Study of SYR-322MET | Phase1 | Healthy Volunteers | Completed | 2016-04-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT02454426 | Vortioxetine in Patients With Major Depressive Disorder and Coronary Artery Dis… | Early_Phase1 | Major Depressive Disorder | Withdrawn | 2016-04-01 | 2016-06-01 | ClinicalTrials.gov |
| NCT02324699 | Corticosteroids With Vedolizumab in Crohn's Disease | Phase4 | Crohn's Disease | Terminated | 2016-04-01 | 2018-02-08 | ClinicalTrials.gov |
| NCT03209492 | Special Drug Use Surveillance of Leuplin PRO for Injection Kit 22.5 mg for "Pro… | — | Prostate Cancer | Completed | 2016-04-01 | 2017-12-01 | ClinicalTrials.gov |
| NCT02736409 | An Extension Study to Evaluate Maintenance of Efficacy and Long-term Treatment … | Phase3 | Eosinophilic Esophagitis (EoE) | Completed | 2016-04-01 | 2019-11-12 | ClinicalTrials.gov |
| NCT02725268 | A Study of Sapanisertib, Combination of Sapanisertib With MLN1117, Paclitaxel a… | Phase2 | Endometrial Neoplasms | Completed | 2016-04-01 | 2020-10-30 | ClinicalTrials.gov |
| NCT03209492 | Special Drug Use Surveillance of Leuplin PRO for Injection Kit 22.5 mg for "Pro… | — | Prostate Cancer | Completed | 2016-04-01 | 2017-12-01 | ClinicalTrials.gov |
| NCT02324699 | Corticosteroids With Vedolizumab in Crohn's Disease | Phase4 | Crohn's Disease | Terminated | 2016-04-01 | 2018-02-08 | ClinicalTrials.gov |
| NCT02388971 | Proof of Mechanism Study of MLN1202 on Atherosclerotic Inflammation in Particip… | Phase2 | Atherosclerotic Cardiovascular Disease | Withdrawn | 2016-04-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT02725268 | A Study of Sapanisertib, Combination of Sapanisertib With MLN1117, Paclitaxel a… | Phase2 | Endometrial Neoplasms | Completed | 2016-04-01 | 2020-10-30 | ClinicalTrials.gov |
| NCT02454426 | Vortioxetine in Patients With Major Depressive Disorder and Coronary Artery Dis… | Early_Phase1 | Major Depressive Disorder | Withdrawn | 2016-04-01 | 2016-06-01 | ClinicalTrials.gov |
| NCT02725268 | A Study of Sapanisertib, Combination of Sapanisertib With MLN1117, Paclitaxel a… | Phase2 | Endometrial Neoplasms | Completed | 2016-04-01 | 2020-10-30 | ClinicalTrials.gov |
| NCT02736409 | An Extension Study to Evaluate Maintenance of Efficacy and Long-term Treatment … | Phase3 | Eosinophilic Esophagitis (EoE) | Completed | 2016-04-01 | 2019-11-12 | ClinicalTrials.gov |
| NCT03209492 | Special Drug Use Surveillance of Leuplin PRO for Injection Kit 22.5 mg for "Pro… | — | Prostate Cancer | Completed | 2016-04-01 | 2017-12-01 | ClinicalTrials.gov |
| NCT02388971 | Proof of Mechanism Study of MLN1202 on Atherosclerotic Inflammation in Particip… | Phase2 | Atherosclerotic Cardiovascular Disease | Withdrawn | 2016-04-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT02736409 | An Extension Study to Evaluate Maintenance of Efficacy and Long-term Treatment … | Phase3 | Eosinophilic Esophagitis (EoE) | Completed | 2016-04-01 | 2019-11-12 | ClinicalTrials.gov |
| NCT02655224 | A Placebo-Controlled, Phase 3 Study of Relugolix (TAK-385) 40 mg in the Treatme… | Phase3 | Uterine Fibroids | Completed | 2016-03-26 | 2017-05-19 | ClinicalTrials.gov |
| NCT02655224 | A Placebo-Controlled, Phase 3 Study of Relugolix (TAK-385) 40 mg in the Treatme… | Phase3 | Uterine Fibroids | Completed | 2016-03-26 | 2017-05-19 | ClinicalTrials.gov |
| NCT02655224 | A Placebo-Controlled, Phase 3 Study of Relugolix (TAK-385) 40 mg in the Treatme… | Phase3 | Uterine Fibroids | Completed | 2016-03-26 | 2017-05-19 | ClinicalTrials.gov |
| NCT02699749 | A Study to Evaluate TAK-931 in Participants With Advanced Nonhematologic Tumors | Phase1 | Nonhematologic Neoplasms, Advanced | Completed | 2016-03-24 | 2019-12-21 | ClinicalTrials.gov |
| NCT02699749 | A Study to Evaluate TAK-931 in Participants With Advanced Nonhematologic Tumors | Phase1 | Nonhematologic Neoplasms, Advanced | Completed | 2016-03-24 | 2019-12-21 | ClinicalTrials.gov |
| NCT02699749 | A Study to Evaluate TAK-931 in Participants With Advanced Nonhematologic Tumors | Phase1 | Nonhematologic Neoplasms, Advanced | Completed | 2016-03-24 | 2019-12-21 | ClinicalTrials.gov |
| NCT02630030 | Phase 0 Analysis of Ixazomib (MLN9708) in Patients With Glioblastoma | Early_Phase1 | Glioblastoma | Completed | 2016-03-24 | 2020-09-03 | ClinicalTrials.gov |
| NCT02630030 | Phase 0 Analysis of Ixazomib (MLN9708) in Patients With Glioblastoma | Early_Phase1 | Glioblastoma | Completed | 2016-03-24 | 2020-09-03 | ClinicalTrials.gov |
| NCT02630030 | Phase 0 Analysis of Ixazomib (MLN9708) in Patients With Glioblastoma | Early_Phase1 | Glioblastoma | Completed | 2016-03-24 | 2020-09-03 | ClinicalTrials.gov |
| NCT02716987 | Study to Determine D-amino Acid Oxidase Brain Enzyme Occupancy of TAK-831 After… | Phase1 | Healthy | Completed | 2016-03-21 | 2016-08-30 | ClinicalTrials.gov |
| NCT02716987 | Study to Determine D-amino Acid Oxidase Brain Enzyme Occupancy of TAK-831 After… | Phase1 | Healthy | Completed | 2016-03-21 | 2016-08-30 | ClinicalTrials.gov |
| NCT02716987 | Study to Determine D-amino Acid Oxidase Brain Enzyme Occupancy of TAK-831 After… | Phase1 | Healthy | Completed | 2016-03-21 | 2016-08-30 | ClinicalTrials.gov |
| NCT02679508 | Vonoprazan Study in Patients With Erosive Esophagitis to Evaluate Long-term Saf… | Phase4 | Erosive Esophagitis | Completed | 2016-03-20 | 2022-03-05 | ClinicalTrials.gov |
| NCT02679508 | Vonoprazan Study in Patients With Erosive Esophagitis to Evaluate Long-term Saf… | Phase4 | Erosive Esophagitis | Completed | 2016-03-20 | 2022-03-05 | ClinicalTrials.gov |
| NCT02679508 | Vonoprazan Study in Patients With Erosive Esophagitis to Evaluate Long-term Saf… | Phase4 | Erosive Esophagitis | Completed | 2016-03-20 | 2022-03-05 | ClinicalTrials.gov |
| NCT03209518 | Special Drug Use Surveillance of Leuprorelin for Injection Kit 22.5 mg in "Prem… | — | Premenopausal Breast Cancer | Completed | 2016-03-18 | 2018-10-10 | ClinicalTrials.gov |
| NCT03209518 | Special Drug Use Surveillance of Leuprorelin for Injection Kit 22.5 mg in "Prem… | — | Premenopausal Breast Cancer | Completed | 2016-03-18 | 2018-10-10 | ClinicalTrials.gov |
| NCT03209518 | Special Drug Use Surveillance of Leuprorelin for Injection Kit 22.5 mg in "Prem… | — | Premenopausal Breast Cancer | Completed | 2016-03-18 | 2018-10-10 | ClinicalTrials.gov |
| NCT02655237 | A Phase 3 Study to Evaluate the Efficacy and Safety of Relugolix (TAK-385) 40 m… | Phase3 | Uterine Fibroids | Completed | 2016-03-05 | 2017-09-25 | ClinicalTrials.gov |
| NCT02655237 | A Phase 3 Study to Evaluate the Efficacy and Safety of Relugolix (TAK-385) 40 m… | Phase3 | Uterine Fibroids | Completed | 2016-03-05 | 2017-09-25 | ClinicalTrials.gov |
| NCT02655237 | A Phase 3 Study to Evaluate the Efficacy and Safety of Relugolix (TAK-385) 40 m… | Phase3 | Uterine Fibroids | Completed | 2016-03-05 | 2017-09-25 | ClinicalTrials.gov |
| NCT02586805 | Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Pat… | Phase3 | Hereditary Angioedema (HAE) | Completed | 2016-03-03 | 2017-04-13 | ClinicalTrials.gov |
| NCT02586805 | Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Pat… | Phase3 | Hereditary Angioedema (HAE) | Completed | 2016-03-03 | 2017-04-13 | ClinicalTrials.gov |
| NCT02586805 | Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Pat… | Phase3 | Hereditary Angioedema (HAE) | Completed | 2016-03-03 | 2017-04-13 | ClinicalTrials.gov |
| NCT02651155 | Lubiprostone for the Treatment of Chronic Idiopathic Constipation | Phase3 | Constipation | Completed | 2016-03-02 | 2017-01-11 | ClinicalTrials.gov |
| NCT02651155 | Lubiprostone for the Treatment of Chronic Idiopathic Constipation | Phase3 | Constipation | Completed | 2016-03-02 | 2017-01-11 | ClinicalTrials.gov |
| NCT02651155 | Lubiprostone for the Treatment of Chronic Idiopathic Constipation | Phase3 | Constipation | Completed | 2016-03-02 | 2017-01-11 | ClinicalTrials.gov |
| NCT02706834 | Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of TAK-828… | Phase1 | Dose Finding Study | Completed | 2016-03-01 | 2016-06-17 | ClinicalTrials.gov |
| NCT02632396 | Ixazomib & Rituximab After Stem Cell Transplant in Treating Patients With Mantl… | Phase1 | Mantle Cell Lymphoma | Unknown | 2016-03-01 | 2024-08-01 | ClinicalTrials.gov |
| NCT02632396 | Ixazomib & Rituximab After Stem Cell Transplant in Treating Patients With Mantl… | Phase1 | Mantle Cell Lymphoma | Unknown | 2016-03-01 | 2024-08-01 | ClinicalTrials.gov |
| NCT02686346 | Brentuximab Vedotin in Refractory/Relapsed Hodgkin Lymphoma Treated by ICE | Phase1 | Hodgkin Disease | Completed | 2016-03-01 | 2021-07-12 | ClinicalTrials.gov |
| NCT02632396 | Ixazomib & Rituximab After Stem Cell Transplant in Treating Patients With Mantl… | Phase1 | Mantle Cell Lymphoma | Unknown | 2016-03-01 | 2024-08-01 | ClinicalTrials.gov |
| NCT02706834 | Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of TAK-828… | Phase1 | Dose Finding Study | Completed | 2016-03-01 | 2016-06-17 | ClinicalTrials.gov |
| NCT02713061 | A Phase 2 Study of a Subcutaneous Injection of TAK-850 in Healthy Adult Partici… | Phase2 | Influenza Prevention | Withdrawn | 2016-03-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT02686346 | Brentuximab Vedotin in Refractory/Relapsed Hodgkin Lymphoma Treated by ICE | Phase1 | Hodgkin Disease | Completed | 2016-03-01 | 2021-07-12 | ClinicalTrials.gov |
| NCT03214952 | Drug Use Surveillance of Vonoprazan for "Gastric Ulcer, Duodenal Ulcer, and Ref… | — | Gastric Ulcer, Duodenal Ulcer, and Reflux Esophagitis | Completed | 2016-03-01 | 2018-10-31 | ClinicalTrials.gov |
| NCT03214081 | Special Drug Use Surveillance of Vonoprazan for "Maintenance Therapy of Reflux … | — | Reflux Esophagitis | Completed | 2016-03-01 | 2018-08-31 | ClinicalTrials.gov |
| NCT02706834 | Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of TAK-828… | Phase1 | Dose Finding Study | Completed | 2016-03-01 | 2016-06-17 | ClinicalTrials.gov |
| NCT02686346 | Brentuximab Vedotin in Refractory/Relapsed Hodgkin Lymphoma Treated by ICE | Phase1 | Hodgkin Disease | Completed | 2016-03-01 | 2021-07-12 | ClinicalTrials.gov |
| NCT02713061 | A Phase 2 Study of a Subcutaneous Injection of TAK-850 in Healthy Adult Partici… | Phase2 | Influenza Prevention | Withdrawn | 2016-03-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT03214081 | Special Drug Use Surveillance of Vonoprazan for "Maintenance Therapy of Reflux … | — | Reflux Esophagitis | Completed | 2016-03-01 | 2018-08-31 | ClinicalTrials.gov |
| NCT03214952 | Drug Use Surveillance of Vonoprazan for "Gastric Ulcer, Duodenal Ulcer, and Ref… | — | Gastric Ulcer, Duodenal Ulcer, and Reflux Esophagitis | Completed | 2016-03-01 | 2018-10-31 | ClinicalTrials.gov |
| NCT03214081 | Special Drug Use Surveillance of Vonoprazan for "Maintenance Therapy of Reflux … | — | Reflux Esophagitis | Completed | 2016-03-01 | 2018-08-31 | ClinicalTrials.gov |
| NCT02713061 | A Phase 2 Study of a Subcutaneous Injection of TAK-850 in Healthy Adult Partici… | Phase2 | Influenza Prevention | Withdrawn | 2016-03-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT03214952 | Drug Use Surveillance of Vonoprazan for "Gastric Ulcer, Duodenal Ulcer, and Ref… | — | Gastric Ulcer, Duodenal Ulcer, and Reflux Esophagitis | Completed | 2016-03-01 | 2018-10-31 | ClinicalTrials.gov |
| NCT02663687 | Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of Recom… | Phase1 | Hereditary Angioedema (HAE) | Completed | 2016-02-19 | 2016-12-05 | ClinicalTrials.gov |
| NCT02663687 | Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of Recom… | Phase1 | Hereditary Angioedema (HAE) | Completed | 2016-02-19 | 2016-12-05 | ClinicalTrials.gov |
| NCT02663687 | Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of Recom… | Phase1 | Hereditary Angioedema (HAE) | Completed | 2016-02-19 | 2016-12-05 | ClinicalTrials.gov |
| NCT02357797 | Adjunctive Vortioxetine in Schizophrenia | Phase4 | Schizophrenia | Unknown | 2016-02-01 | 2024-06-01 | ClinicalTrials.gov |
| NCT02357797 | Adjunctive Vortioxetine in Schizophrenia | Phase4 | Schizophrenia | Unknown | 2016-02-01 | 2024-06-01 | ClinicalTrials.gov |
| NCT02661490 | Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle … | Phase2 | Norovirus | Completed | 2016-02-01 | 2017-09-29 | ClinicalTrials.gov |
| NCT02697383 | Ixazomib (MLN9708) and Dexamethasone in High Risk Smoldering Multiple Myeloma: … | Phase1 | Multiple Myeloma | Completed | 2016-02-01 | 2024-05-08 | ClinicalTrials.gov |
| NCT02616315 | Efficacy of Naltrexone HCl/Bupropion HCl Extended Release Versus Placebo for Tr… | Phase4 | Weight Regain Post Bariatric Surgery | Withdrawn | 2016-02-01 | 2017-12-01 | ClinicalTrials.gov |
| NCT02616315 | Efficacy of Naltrexone HCl/Bupropion HCl Extended Release Versus Placebo for Tr… | Phase4 | Weight Regain Post Bariatric Surgery | Withdrawn | 2016-02-01 | 2017-12-01 | ClinicalTrials.gov |
| NCT02661490 | Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle … | Phase2 | Norovirus | Completed | 2016-02-01 | 2017-09-29 | ClinicalTrials.gov |
| NCT02697383 | Ixazomib (MLN9708) and Dexamethasone in High Risk Smoldering Multiple Myeloma: … | Phase1 | Multiple Myeloma | Completed | 2016-02-01 | 2024-05-08 | ClinicalTrials.gov |
| NCT02661490 | Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle … | Phase2 | Norovirus | Completed | 2016-02-01 | 2017-09-29 | ClinicalTrials.gov |
| NCT02616315 | Efficacy of Naltrexone HCl/Bupropion HCl Extended Release Versus Placebo for Tr… | Phase4 | Weight Regain Post Bariatric Surgery | Withdrawn | 2016-02-01 | 2017-12-01 | ClinicalTrials.gov |
| NCT02697383 | Ixazomib (MLN9708) and Dexamethasone in High Risk Smoldering Multiple Myeloma: … | Phase1 | Multiple Myeloma | Completed | 2016-02-01 | 2024-05-08 | ClinicalTrials.gov |
| NCT02357797 | Adjunctive Vortioxetine in Schizophrenia | Phase4 | Schizophrenia | Unknown | 2016-02-01 | 2024-06-01 | ClinicalTrials.gov |
| NCT04120506 | Long Term Impact of Rapid Intravenous Infusion of Velaglucerase Alfa (VPRIV) | Phase4 | Gaucher Disease, Type 1 | Completed | 2016-01-10 | 2022-01-01 | ClinicalTrials.gov |
| NCT04120506 | Long Term Impact of Rapid Intravenous Infusion of Velaglucerase Alfa (VPRIV) | Phase4 | Gaucher Disease, Type 1 | Completed | 2016-01-10 | 2022-01-01 | ClinicalTrials.gov |
| NCT04120506 | Long Term Impact of Rapid Intravenous Infusion of Velaglucerase Alfa (VPRIV) | Phase4 | Gaucher Disease, Type 1 | Completed | 2016-01-10 | 2022-01-01 | ClinicalTrials.gov |
| NCT02625259 | A Study to Evaluate the Relative Bioavailability, Effect of Food, and Gastric P… | Phase1 | Neoplasm, Advanced or Metastatic | Completed | 2016-01-08 | 2016-07-22 | ClinicalTrials.gov |
| NCT02625259 | A Study to Evaluate the Relative Bioavailability, Effect of Food, and Gastric P… | Phase1 | Neoplasm, Advanced or Metastatic | Completed | 2016-01-08 | 2016-07-22 | ClinicalTrials.gov |
| NCT02625259 | A Study to Evaluate the Relative Bioavailability, Effect of Food, and Gastric P… | Phase1 | Neoplasm, Advanced or Metastatic | Completed | 2016-01-08 | 2016-07-22 | ClinicalTrials.gov |
| NCT02611817 | Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in … | Phase3 | Crohn's Disease | Completed | 2016-01-04 | 2019-08-06 | ClinicalTrials.gov |
| NCT02611817 | Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in … | Phase3 | Crohn's Disease | Completed | 2016-01-04 | 2019-08-06 | ClinicalTrials.gov |
| NCT02611817 | Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in … | Phase3 | Crohn's Disease | Completed | 2016-01-04 | 2019-08-06 | ClinicalTrials.gov |
| NCT02582359 | MLN 9708 in Induction and Consolidation for Adults With AML >= 60 Years of Age | Phase1 | Acute Myeloid Leukemia | Completed | 2016-01-01 | 2022-04-01 | ClinicalTrials.gov |
| NCT02582359 | MLN 9708 in Induction and Consolidation for Adults With AML >= 60 Years of Age | Phase1 | Acute Myeloid Leukemia | Completed | 2016-01-01 | 2022-04-01 | ClinicalTrials.gov |
| NCT02582359 | MLN 9708 in Induction and Consolidation for Adults With AML >= 60 Years of Age | Phase1 | Acute Myeloid Leukemia | Completed | 2016-01-01 | 2022-04-01 | ClinicalTrials.gov |
| NCT02611830 | Efficacy and Safety of Vedolizumab Subcutaneously (SC) as Maintenance Therapy i… | Phase3 | Colitis, Ulcerative | Completed | 2015-12-18 | 2018-08-21 | ClinicalTrials.gov |
| NCT02611830 | Efficacy and Safety of Vedolizumab Subcutaneously (SC) as Maintenance Therapy i… | Phase3 | Colitis, Ulcerative | Completed | 2015-12-18 | 2018-08-21 | ClinicalTrials.gov |
| NCT02611830 | Efficacy and Safety of Vedolizumab Subcutaneously (SC) as Maintenance Therapy i… | Phase3 | Colitis, Ulcerative | Completed | 2015-12-18 | 2018-08-21 | ClinicalTrials.gov |
| NCT02549170 | A Study of HyQvia and Gammagard Liquid (Kiovig) in Adults With Chronic Inflamma… | Phase3 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy | Completed | 2015-12-15 | 2022-02-23 | ClinicalTrials.gov |
| NCT02549170 | A Study of HyQvia and Gammagard Liquid (Kiovig) in Adults With Chronic Inflamma… | Phase3 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy | Completed | 2015-12-15 | 2022-02-23 | ClinicalTrials.gov |
| NCT02549170 | A Study of HyQvia and Gammagard Liquid (Kiovig) in Adults With Chronic Inflamma… | Phase3 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy | Completed | 2015-12-15 | 2022-02-23 | ClinicalTrials.gov |
| NCT02613221 | A Phase I/II Study for the Safety and Efficacy of Panitumumab in Combination Wi… | Phase1 | Colorectal Cancer | Completed | 2015-12-07 | 2018-03-30 | ClinicalTrials.gov |
| NCT02613221 | A Phase I/II Study for the Safety and Efficacy of Panitumumab in Combination Wi… | Phase1 | Colorectal Cancer | Completed | 2015-12-07 | 2018-03-30 | ClinicalTrials.gov |
| NCT02613221 | A Phase I/II Study for the Safety and Efficacy of Panitumumab in Combination Wi… | Phase1 | Colorectal Cancer | Completed | 2015-12-07 | 2018-03-30 | ClinicalTrials.gov |
| NCT02441686 | Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib … | Phase2 | Multiple Myeloma | Completed | 2015-12-01 | 2025-10-01 | ClinicalTrials.gov |
| NCT02441686 | Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib … | Phase2 | Multiple Myeloma | Completed | 2015-12-01 | 2025-10-01 | ClinicalTrials.gov |
| NCT02560025 | Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML | Phase2 | Acute Myeloid Leukemia | Completed | 2015-12-01 | 2018-12-01 | ClinicalTrials.gov |
| NCT02614586 | Evaluation of TAK-058 and Ondansetron on P50 Auditory Gating in Participants Wi… | Phase1 | Schizophrenia | Terminated | 2015-12-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT02560025 | Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML | Phase2 | Acute Myeloid Leukemia | Completed | 2015-12-01 | 2018-12-01 | ClinicalTrials.gov |
| NCT02780011 | Alsertib (MLN8237) and Brentuximab Vedotin for Relapsed/Refractory CD30-Positiv… | Phase1 | CD30-positive Lymphoma | Withdrawn | 2015-12-01 | 2018-09-01 | ClinicalTrials.gov |
| NCT02678052 | OTIS Vedolizumab Pregnancy Exposure Registry | — | Colitis, Ulcerative | Completed | 2015-12-01 | 2022-07-31 | ClinicalTrials.gov |
| NCT02302092 | An Efficacy and Safety of Flomoxef Versus Cefepime in the Treatment of Particip… | Phase3 | Urinary Tract Infection | Terminated | 2015-12-01 | 2016-12-15 | ClinicalTrials.gov |
| NCT02622581 | Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (No… | — | Metastatic Non-small Cell Lung Cancer (NSCLC) | Recruiting | 2015-12-01 | 2027-12-01 | ClinicalTrials.gov |
| NCT02678052 | OTIS Vedolizumab Pregnancy Exposure Registry | — | Colitis, Ulcerative | Completed | 2015-12-01 | 2022-07-31 | ClinicalTrials.gov |
| NCT02622581 | Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (No… | — | Metastatic Non-small Cell Lung Cancer (NSCLC) | Recruiting | 2015-12-01 | 2027-12-01 | ClinicalTrials.gov |
| NCT02461888 | Phase II Randomised Trial of Cyclophosphamide & Dexamethasone in Combination Wi… | Phase2 | Multiple Myeloma | Completed | 2015-12-01 | 2025-01-19 | ClinicalTrials.gov |
| NCT02614586 | Evaluation of TAK-058 and Ondansetron on P50 Auditory Gating in Participants Wi… | Phase1 | Schizophrenia | Terminated | 2015-12-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT02441686 | Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib … | Phase2 | Multiple Myeloma | Completed | 2015-12-01 | 2025-10-01 | ClinicalTrials.gov |
| NCT02302092 | An Efficacy and Safety of Flomoxef Versus Cefepime in the Treatment of Particip… | Phase3 | Urinary Tract Infection | Terminated | 2015-12-01 | 2016-12-15 | ClinicalTrials.gov |
| NCT02678052 | OTIS Vedolizumab Pregnancy Exposure Registry | — | Colitis, Ulcerative | Completed | 2015-12-01 | 2022-07-31 | ClinicalTrials.gov |
| NCT02780011 | Alsertib (MLN8237) and Brentuximab Vedotin for Relapsed/Refractory CD30-Positiv… | Phase1 | CD30-positive Lymphoma | Withdrawn | 2015-12-01 | 2018-09-01 | ClinicalTrials.gov |
| NCT02560025 | Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML | Phase2 | Acute Myeloid Leukemia | Completed | 2015-12-01 | 2018-12-01 | ClinicalTrials.gov |
| NCT02622581 | Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (No… | — | Metastatic Non-small Cell Lung Cancer (NSCLC) | Recruiting | 2015-12-01 | 2027-12-01 | ClinicalTrials.gov |
| NCT02302092 | An Efficacy and Safety of Flomoxef Versus Cefepime in the Treatment of Particip… | Phase3 | Urinary Tract Infection | Terminated | 2015-12-01 | 2016-12-15 | ClinicalTrials.gov |
| NCT02461888 | Phase II Randomised Trial of Cyclophosphamide & Dexamethasone in Combination Wi… | Phase2 | Multiple Myeloma | Completed | 2015-12-01 | 2025-01-19 | ClinicalTrials.gov |
| NCT02461888 | Phase II Randomised Trial of Cyclophosphamide & Dexamethasone in Combination Wi… | Phase2 | Multiple Myeloma | Completed | 2015-12-01 | 2025-01-19 | ClinicalTrials.gov |
| NCT02614586 | Evaluation of TAK-058 and Ondansetron on P50 Auditory Gating in Participants Wi… | Phase1 | Schizophrenia | Terminated | 2015-12-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT02780011 | Alsertib (MLN8237) and Brentuximab Vedotin for Relapsed/Refractory CD30-Positiv… | Phase1 | CD30-positive Lymphoma | Withdrawn | 2015-12-01 | 2018-09-01 | ClinicalTrials.gov |
| NCT03209479 | Copaxone Subcutaneous Injection Syringe Special Drug Use-Result Investigation (… | — | Multiple Sclerosis | Completed | 2015-11-24 | 2024-03-31 | ClinicalTrials.gov |
| NCT03209479 | Copaxone Subcutaneous Injection Syringe Special Drug Use-Result Investigation (… | — | Multiple Sclerosis | Completed | 2015-11-24 | 2024-03-31 | ClinicalTrials.gov |
| NCT03209479 | Copaxone Subcutaneous Injection Syringe Special Drug Use-Result Investigation (… | — | Multiple Sclerosis | Completed | 2015-11-24 | 2024-03-31 | ClinicalTrials.gov |
| NCT02541669 | A Single- and Multiple-Dose Study of the Pharmacokinetics of TAK-491 in Healthy… | Phase1 | Healthy Volunteer | Completed | 2015-11-20 | 2017-03-17 | ClinicalTrials.gov |
| NCT02541669 | A Single- and Multiple-Dose Study of the Pharmacokinetics of TAK-491 in Healthy… | Phase1 | Healthy Volunteer | Completed | 2015-11-20 | 2017-03-17 | ClinicalTrials.gov |
| NCT02541669 | A Single- and Multiple-Dose Study of the Pharmacokinetics of TAK-491 in Healthy… | Phase1 | Healthy Volunteer | Completed | 2015-11-20 | 2017-03-17 | ClinicalTrials.gov |
| NCT02528786 | Blood Sample Collection Study for Pharmacogenomic Characterization of Participa… | Phase1 | Rheumatoid Arthritis | Completed | 2015-11-19 | 2016-04-05 | ClinicalTrials.gov |
| NCT02528786 | Blood Sample Collection Study for Pharmacogenomic Characterization of Participa… | Phase1 | Rheumatoid Arthritis | Completed | 2015-11-19 | 2016-04-05 | ClinicalTrials.gov |
| NCT02528786 | Blood Sample Collection Study for Pharmacogenomic Characterization of Participa… | Phase1 | Rheumatoid Arthritis | Completed | 2015-11-19 | 2016-04-05 | ClinicalTrials.gov |
| NCT02615691 | A Study of PEGylated Recombinant Factor VIII (BAX855) in Previously Untreated Y… | Phase3 | Hemophilia A | Completed | 2015-11-12 | 2024-10-29 | ClinicalTrials.gov |
| NCT02615691 | A Study of PEGylated Recombinant Factor VIII (BAX855) in Previously Untreated Y… | Phase3 | Hemophilia A | Completed | 2015-11-12 | 2024-10-29 | ClinicalTrials.gov |
| NCT02615691 | A Study of PEGylated Recombinant Factor VIII (BAX855) in Previously Untreated Y… | Phase3 | Hemophilia A | Completed | 2015-11-12 | 2024-10-29 | ClinicalTrials.gov |
| NCT01963650 | Natural History Study of Children With Metachromatic Leukodystrophy | — | Lipid Metabolism Disorders | Terminated | 2015-11-02 | 2016-04-08 | ClinicalTrials.gov |
| NCT01963650 | Natural History Study of Children With Metachromatic Leukodystrophy | — | Lipid Metabolism Disorders | Terminated | 2015-11-02 | 2016-04-08 | ClinicalTrials.gov |
| NCT01963650 | Natural History Study of Children With Metachromatic Leukodystrophy | — | Lipid Metabolism Disorders | Terminated | 2015-11-02 | 2016-04-08 | ClinicalTrials.gov |
| NCT02635035 | Shire SCT: Lisdexamfetamine Treatment for ADHD and SCT | Phase2 | Attention Deficit Disorder | Completed | 2015-11-01 | 2019-01-09 | ClinicalTrials.gov |
| NCT02584959 | Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administer… | Phase3 | Hereditary Angioedema (HAE) | Completed | 2015-11-01 | 2017-07-24 | ClinicalTrials.gov |
| NCT02584569 | Phase 1 TAK-915 Single-Dose Positron Emission Tomography (PET) Occupancy Study | Phase1 | Healthy Volunteers | Completed | 2015-11-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT02584959 | Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administer… | Phase3 | Hereditary Angioedema (HAE) | Completed | 2015-11-01 | 2017-07-24 | ClinicalTrials.gov |
| NCT02635035 | Shire SCT: Lisdexamfetamine Treatment for ADHD and SCT | Phase2 | Attention Deficit Disorder | Completed | 2015-11-01 | 2019-01-09 | ClinicalTrials.gov |
| NCT02635035 | Shire SCT: Lisdexamfetamine Treatment for ADHD and SCT | Phase2 | Attention Deficit Disorder | Completed | 2015-11-01 | 2019-01-09 | ClinicalTrials.gov |
| NCT02584959 | Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administer… | Phase3 | Hereditary Angioedema (HAE) | Completed | 2015-11-01 | 2017-07-24 | ClinicalTrials.gov |
| NCT02584569 | Phase 1 TAK-915 Single-Dose Positron Emission Tomography (PET) Occupancy Study | Phase1 | Healthy Volunteers | Completed | 2015-11-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT02584569 | Phase 1 TAK-915 Single-Dose Positron Emission Tomography (PET) Occupancy Study | Phase1 | Healthy Volunteers | Completed | 2015-11-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT02455622 | Long-term Evaluation on Height and Weight in Patients With MPS II Who Started T… | Phase4 | Hunter Syndrome | Completed | 2015-10-28 | 2025-07-29 | ClinicalTrials.gov |
| NCT02455622 | Long-term Evaluation on Height and Weight in Patients With MPS II Who Started T… | Phase4 | Hunter Syndrome | Completed | 2015-10-28 | 2025-07-29 | ClinicalTrials.gov |
| NCT02455622 | Long-term Evaluation on Height and Weight in Patients With MPS II Who Started T… | Phase4 | Hunter Syndrome | Completed | 2015-10-28 | 2025-07-29 | ClinicalTrials.gov |
| NCT02481310 | Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients … | Phase1 | Adult Burkitt Lymphoma | Unknown | 2015-10-28 | 2024-07-01 | ClinicalTrials.gov |
| NCT02481310 | Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients … | Phase1 | Adult Burkitt Lymphoma | Unknown | 2015-10-28 | 2024-07-01 | ClinicalTrials.gov |
| NCT02481310 | Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients … | Phase1 | Adult Burkitt Lymphoma | Unknown | 2015-10-28 | 2024-07-01 | ClinicalTrials.gov |
| NCT02578030 | Pharmacokinetic Study in Children and Adolescents Aged 6 to 17 Years Who Have B… | Phase1 | Attention Deficit Hyperactivity Disorder (ADHD) | Completed | 2015-10-24 | 2015-11-10 | ClinicalTrials.gov |
| NCT02578030 | Pharmacokinetic Study in Children and Adolescents Aged 6 to 17 Years Who Have B… | Phase1 | Attention Deficit Hyperactivity Disorder (ADHD) | Completed | 2015-10-24 | 2015-11-10 | ClinicalTrials.gov |
| NCT02578030 | Pharmacokinetic Study in Children and Adolescents Aged 6 to 17 Years Who Have B… | Phase1 | Attention Deficit Hyperactivity Disorder (ADHD) | Completed | 2015-10-24 | 2015-11-10 | ClinicalTrials.gov |
| NCT02551055 | MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational An… | Phase1 | Advanced and Metastatic Gastric or Gastroesophageal Adenocarcinoma | Terminated | 2015-10-15 | 2017-02-17 | ClinicalTrials.gov |
| NCT02551055 | MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational An… | Phase1 | Advanced and Metastatic Gastric or Gastroesophageal Adenocarcinoma | Terminated | 2015-10-15 | 2017-02-17 | ClinicalTrials.gov |
| NCT02551055 | MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational An… | Phase1 | Advanced and Metastatic Gastric or Gastroesophageal Adenocarcinoma | Terminated | 2015-10-15 | 2017-02-17 | ClinicalTrials.gov |
| NCT02530619 | Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acu… | Na | Acute Megakaryoblastic Leukemia | Unknown | 2015-10-09 | 2022-05-01 | ClinicalTrials.gov |
| NCT02530619 | Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acu… | Na | Acute Megakaryoblastic Leukemia | Unknown | 2015-10-09 | 2022-05-01 | ClinicalTrials.gov |
| NCT02530619 | Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acu… | Na | Acute Megakaryoblastic Leukemia | Unknown | 2015-10-09 | 2022-05-01 | ClinicalTrials.gov |
| NCT04980014 | A Post-Marketing Surveillance Study on NesinaAct® Tablet Use Among Type 2 Diabe… | — | Type 2 Diabetes Mellitus | Completed | 2015-10-02 | 2019-08-30 | ClinicalTrials.gov |
| NCT04980014 | A Post-Marketing Surveillance Study on NesinaAct® Tablet Use Among Type 2 Diabe… | — | Type 2 Diabetes Mellitus | Completed | 2015-10-02 | 2019-08-30 | ClinicalTrials.gov |
| NCT04980014 | A Post-Marketing Surveillance Study on NesinaAct® Tablet Use Among Type 2 Diabe… | — | Type 2 Diabetes Mellitus | Completed | 2015-10-02 | 2019-08-30 | ClinicalTrials.gov |
| NCT02542657 | Ixazomib with Pomalidomide, Clarithromycin and Dexamethasone in Treating Patien… | Phase1 | Myeloma | Active_Not_Recruiting | 2015-10-01 | 2025-12-01 | ClinicalTrials.gov |
| NCT02514824 | MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma | Phase1 | Merkel Cell Carcinoma | Completed | 2015-10-01 | 2017-06-01 | ClinicalTrials.gov |
| NCT02514824 | MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma | Phase1 | Merkel Cell Carcinoma | Completed | 2015-10-01 | 2017-06-01 | ClinicalTrials.gov |
| NCT02514824 | MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma | Phase1 | Merkel Cell Carcinoma | Completed | 2015-10-01 | 2017-06-01 | ClinicalTrials.gov |
| NCT02542657 | Ixazomib with Pomalidomide, Clarithromycin and Dexamethasone in Treating Patien… | Phase1 | Myeloma | Active_Not_Recruiting | 2015-10-01 | 2025-12-01 | ClinicalTrials.gov |
| NCT02542657 | Ixazomib with Pomalidomide, Clarithromycin and Dexamethasone in Treating Patien… | Phase1 | Myeloma | Active_Not_Recruiting | 2015-10-01 | 2025-12-01 | ClinicalTrials.gov |
| NCT02788916 | A Retrospective Study of Clinical, Phenotypic and Genetic Factors of Peripheral… | — | Lymphoma, T-Cell, Peripheral | Completed | 2015-09-25 | 2017-01-12 | ClinicalTrials.gov |
| NCT02788916 | A Retrospective Study of Clinical, Phenotypic and Genetic Factors of Peripheral… | — | Lymphoma, T-Cell, Peripheral | Completed | 2015-09-25 | 2017-01-12 | ClinicalTrials.gov |
| NCT02788916 | A Retrospective Study of Clinical, Phenotypic and Genetic Factors of Peripheral… | — | Lymphoma, T-Cell, Peripheral | Completed | 2015-09-25 | 2017-01-12 | ClinicalTrials.gov |
| NCT02566759 | A TAK-831-1001, Single and Multiple Rising Dose Study in Healthy Participants | Phase1 | Schizophrenia, Cerebellar Ataxia | Terminated | 2015-09-23 | 2016-07-12 | ClinicalTrials.gov |
| NCT02566759 | A TAK-831-1001, Single and Multiple Rising Dose Study in Healthy Participants | Phase1 | Schizophrenia, Cerebellar Ataxia | Terminated | 2015-09-23 | 2016-07-12 | ClinicalTrials.gov |
| NCT02566759 | A TAK-831-1001, Single and Multiple Rising Dose Study in Healthy Participants | Phase1 | Schizophrenia, Cerebellar Ataxia | Terminated | 2015-09-23 | 2016-07-12 | ClinicalTrials.gov |
| NCT02381288 | Effects of TAK-448 in Middle-aged and Older Men With Low Testosterone | Phase2 | Low Testosterone | Terminated | 2015-09-10 | 2016-04-08 | ClinicalTrials.gov |
| NCT02381288 | Effects of TAK-448 in Middle-aged and Older Men With Low Testosterone | Phase2 | Low Testosterone | Terminated | 2015-09-10 | 2016-04-08 | ClinicalTrials.gov |
| NCT02381288 | Effects of TAK-448 in Middle-aged and Older Men With Low Testosterone | Phase2 | Low Testosterone | Terminated | 2015-09-10 | 2016-04-08 | ClinicalTrials.gov |
| NCT02555618 | Phase 2 Study of TAK-850 in Comparison With Influenza Hemagglutinin (HA) Vaccin… | Phase2 | Influenza Infection | Completed | 2015-09-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT05556629 | A Survey to Assess Participants' and Physicians' Knowledge, Attitudes and Behav… | — | Hypoparathyroidism | Completed | 2015-09-01 | 2025-11-30 | ClinicalTrials.gov |
| NCT03219723 | Drug Use Surveillance of Takecab for "Supplement to Helicobacter Pylori Eradica… | — | Gastric/Duodenal Ulcer, Gastric MALT Lymphoma, Idiopathic Thrombocytopenic Purpura, or H. Pylori Gastritis, and Other | Completed | 2015-09-01 | 2017-04-30 | ClinicalTrials.gov |
| NCT01967251 | Efficacy, Safety and Dose-response of Udenafil in Patients With Benign Prostati… | Phase2 | Erectile Dysfunction | Withdrawn | 2015-09-01 | 2016-09-01 | ClinicalTrials.gov |
| NCT02546622 | ATHN 2: Factor Switching Study | — | Hemophilia | Completed | 2015-09-01 | 2020-06-30 | ClinicalTrials.gov |
| NCT02539134 | TAK-935 Multiple Rising Dose Study in Healthy Participants | Phase1 | Epilepsy | Completed | 2015-09-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT02499081 | UARK 2014-14: Phase II Prospective Evaluation of Bone Remodeling During Ixazomi… | Phase2 | Multiple Myeloma | Completed | 2015-09-01 | 2018-05-17 | ClinicalTrials.gov |
| NCT05556629 | A Survey to Assess Participants' and Physicians' Knowledge, Attitudes and Behav… | — | Hypoparathyroidism | Completed | 2015-09-01 | 2025-11-30 | ClinicalTrials.gov |
| NCT05556629 | A Survey to Assess Participants' and Physicians' Knowledge, Attitudes and Behav… | — | Hypoparathyroidism | Completed | 2015-09-01 | 2025-11-30 | ClinicalTrials.gov |
| NCT01967251 | Efficacy, Safety and Dose-response of Udenafil in Patients With Benign Prostati… | Phase2 | Erectile Dysfunction | Withdrawn | 2015-09-01 | 2016-09-01 | ClinicalTrials.gov |
| NCT03219723 | Drug Use Surveillance of Takecab for "Supplement to Helicobacter Pylori Eradica… | — | Gastric/Duodenal Ulcer, Gastric MALT Lymphoma, Idiopathic Thrombocytopenic Purpura, or H. Pylori Gastritis, and Other | Completed | 2015-09-01 | 2017-04-30 | ClinicalTrials.gov |
| NCT02499081 | UARK 2014-14: Phase II Prospective Evaluation of Bone Remodeling During Ixazomi… | Phase2 | Multiple Myeloma | Completed | 2015-09-01 | 2018-05-17 | ClinicalTrials.gov |
| NCT02539134 | TAK-935 Multiple Rising Dose Study in Healthy Participants | Phase1 | Epilepsy | Completed | 2015-09-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT02546622 | ATHN 2: Factor Switching Study | — | Hemophilia | Completed | 2015-09-01 | 2020-06-30 | ClinicalTrials.gov |
| NCT02555618 | Phase 2 Study of TAK-850 in Comparison With Influenza Hemagglutinin (HA) Vaccin… | Phase2 | Influenza Infection | Completed | 2015-09-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT01967251 | Efficacy, Safety and Dose-response of Udenafil in Patients With Benign Prostati… | Phase2 | Erectile Dysfunction | Withdrawn | 2015-09-01 | 2016-09-01 | ClinicalTrials.gov |
| NCT03219723 | Drug Use Surveillance of Takecab for "Supplement to Helicobacter Pylori Eradica… | — | Gastric/Duodenal Ulcer, Gastric MALT Lymphoma, Idiopathic Thrombocytopenic Purpura, or H. Pylori Gastritis, and Other | Completed | 2015-09-01 | 2017-04-30 | ClinicalTrials.gov |
| NCT02555618 | Phase 2 Study of TAK-850 in Comparison With Influenza Hemagglutinin (HA) Vaccin… | Phase2 | Influenza Infection | Completed | 2015-09-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT02546622 | ATHN 2: Factor Switching Study | — | Hemophilia | Completed | 2015-09-01 | 2020-06-30 | ClinicalTrials.gov |
| NCT02539134 | TAK-935 Multiple Rising Dose Study in Healthy Participants | Phase1 | Epilepsy | Completed | 2015-09-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT02499081 | UARK 2014-14: Phase II Prospective Evaluation of Bone Remodeling During Ixazomi… | Phase2 | Multiple Myeloma | Completed | 2015-09-01 | 2018-05-17 | ClinicalTrials.gov |
| NCT02480764 | Azilsartan Medoxomil (TAK-491) Compared to Valsartan in Chinese Participants Wi… | Phase3 | Essential Hypertension | Completed | 2015-08-27 | 2017-10-13 | ClinicalTrials.gov |
| NCT02480764 | Azilsartan Medoxomil (TAK-491) Compared to Valsartan in Chinese Participants Wi… | Phase3 | Essential Hypertension | Completed | 2015-08-27 | 2017-10-13 | ClinicalTrials.gov |
| NCT02480764 | Azilsartan Medoxomil (TAK-491) Compared to Valsartan in Chinese Participants Wi… | Phase3 | Essential Hypertension | Completed | 2015-08-27 | 2017-10-13 | ClinicalTrials.gov |
| NCT02561156 | TAK-653 Escalating Single and Multiple Dose Study in Healthy Participants | Phase1 | Depressive Disorder | Completed | 2015-08-26 | 2017-09-23 | ClinicalTrials.gov |
| NCT02561156 | TAK-653 Escalating Single and Multiple Dose Study in Healthy Participants | Phase1 | Depressive Disorder | Completed | 2015-08-26 | 2017-09-23 | ClinicalTrials.gov |
| NCT02561156 | TAK-653 Escalating Single and Multiple Dose Study in Healthy Participants | Phase1 | Depressive Disorder | Completed | 2015-08-26 | 2017-09-23 | ClinicalTrials.gov |
| NCT04909359 | Characterization of CD Responders to Vedolizumab | — | Crohn Disease | Completed | 2015-08-25 | 2020-05-18 | ClinicalTrials.gov |
| NCT04909359 | Characterization of CD Responders to Vedolizumab | — | Crohn Disease | Completed | 2015-08-25 | 2020-05-18 | ClinicalTrials.gov |
| NCT04909359 | Characterization of CD Responders to Vedolizumab | — | Crohn Disease | Completed | 2015-08-25 | 2020-05-18 | ClinicalTrials.gov |
| NCT02466386 | Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years, D… | Phase3 | Attention Deficit Hyperactivity Disorder (ADHD) | Completed | 2015-08-21 | 2020-01-03 | ClinicalTrials.gov |
| NCT02466386 | Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years, D… | Phase3 | Attention Deficit Hyperactivity Disorder (ADHD) | Completed | 2015-08-21 | 2020-01-03 | ClinicalTrials.gov |
| NCT02466386 | Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years, D… | Phase3 | Attention Deficit Hyperactivity Disorder (ADHD) | Completed | 2015-08-21 | 2020-01-03 | ClinicalTrials.gov |
| NCT03106597 | Manidipine Versus Amlodipine in Patients With Hypertension | Phase4 | Hypertension | Terminated | 2015-08-20 | 2019-08-14 | ClinicalTrials.gov |
| NCT03106597 | Manidipine Versus Amlodipine in Patients With Hypertension | Phase4 | Hypertension | Terminated | 2015-08-20 | 2019-08-14 | ClinicalTrials.gov |
| NCT03106597 | Manidipine Versus Amlodipine in Patients With Hypertension | Phase4 | Hypertension | Terminated | 2015-08-20 | 2019-08-14 | ClinicalTrials.gov |
| NCT02427958 | A Study to Assess the Safety and Efficacy of Leuprorelin in Central Precocious … | Phase4 | Central Precocious Puberty | Completed | 2015-08-07 | 2018-11-23 | ClinicalTrials.gov |
| NCT02427958 | A Study to Assess the Safety and Efficacy of Leuprorelin in Central Precocious … | Phase4 | Central Precocious Puberty | Completed | 2015-08-07 | 2018-11-23 | ClinicalTrials.gov |
| NCT02512068 | A Phase 3, Randomized, Double-blind, Parallel-group, Comparative Study and a Ph… | Phase3 | Type 2 Diabetes Mellitus | Completed | 2015-08-07 | 2018-04-24 | ClinicalTrials.gov |
| NCT02427958 | A Study to Assess the Safety and Efficacy of Leuprorelin in Central Precocious … | Phase4 | Central Precocious Puberty | Completed | 2015-08-07 | 2018-11-23 | ClinicalTrials.gov |
| NCT02512068 | A Phase 3, Randomized, Double-blind, Parallel-group, Comparative Study and a Ph… | Phase3 | Type 2 Diabetes Mellitus | Completed | 2015-08-07 | 2018-04-24 | ClinicalTrials.gov |
| NCT02512068 | A Phase 3, Randomized, Double-blind, Parallel-group, Comparative Study and a Ph… | Phase3 | Type 2 Diabetes Mellitus | Completed | 2015-08-07 | 2018-04-24 | ClinicalTrials.gov |
| NCT02451150 | A Phase 3 Pharmacokinetic Study of TAK-536 (Azilsartan) in Pediatric Patients 6… | Phase3 | Pediatric Hypertension | Completed | 2015-08-01 | 2015-09-01 | ClinicalTrials.gov |
| NCT02451150 | A Phase 3 Pharmacokinetic Study of TAK-536 (Azilsartan) in Pediatric Patients 6… | Phase3 | Pediatric Hypertension | Completed | 2015-08-01 | 2015-09-01 | ClinicalTrials.gov |
| NCT02451150 | A Phase 3 Pharmacokinetic Study of TAK-536 (Azilsartan) in Pediatric Patients 6… | Phase3 | Pediatric Hypertension | Completed | 2015-08-01 | 2015-09-01 | ClinicalTrials.gov |
| NCT02504320 | Phase 1, Febuxostat XR Relative Bioavailability Study | Phase1 | Healthy Volunteers | Completed | 2015-08-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT02520076 | Aralast NP in Islet Transplant | Phase1 | Type 1 Diabetes Mellitus | Completed | 2015-08-01 | 2019-09-30 | ClinicalTrials.gov |
| NCT02504320 | Phase 1, Febuxostat XR Relative Bioavailability Study | Phase1 | Healthy Volunteers | Completed | 2015-08-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT02520076 | Aralast NP in Islet Transplant | Phase1 | Type 1 Diabetes Mellitus | Completed | 2015-08-01 | 2019-09-30 | ClinicalTrials.gov |
| NCT02520076 | Aralast NP in Islet Transplant | Phase1 | Type 1 Diabetes Mellitus | Completed | 2015-08-01 | 2019-09-30 | ClinicalTrials.gov |
| NCT02504320 | Phase 1, Febuxostat XR Relative Bioavailability Study | Phase1 | Healthy Volunteers | Completed | 2015-08-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT02517866 | Azilsartan Medoxomil in the Treatment of Essential Hypertension and Type 2 Diab… | Phase4 | Essential Hypertension | Completed | 2015-07-13 | 2016-11-25 | ClinicalTrials.gov |
| NCT02517866 | Azilsartan Medoxomil in the Treatment of Essential Hypertension and Type 2 Diab… | Phase4 | Essential Hypertension | Completed | 2015-07-13 | 2016-11-25 | ClinicalTrials.gov |
| NCT02467270 | Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia… | Phase2 | Myeloid Leukemia, Chronic, Chronic Phase | Completed | 2015-07-13 | 2025-04-23 | ClinicalTrials.gov |
| NCT02517866 | Azilsartan Medoxomil in the Treatment of Essential Hypertension and Type 2 Diab… | Phase4 | Essential Hypertension | Completed | 2015-07-13 | 2016-11-25 | ClinicalTrials.gov |
| NCT02467270 | Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia… | Phase2 | Myeloid Leukemia, Chronic, Chronic Phase | Completed | 2015-07-13 | 2025-04-23 | ClinicalTrials.gov |
| NCT02467270 | Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia… | Phase2 | Myeloid Leukemia, Chronic, Chronic Phase | Completed | 2015-07-13 | 2025-04-23 | ClinicalTrials.gov |
| NCT02337751 | A Phase 3, Long-term, Extension Study of TVP-1012 (1 mg) in Early Parkinson's D… | Phase3 | Parkinson's Disease | Completed | 2015-07-10 | 2017-03-14 | ClinicalTrials.gov |
| NCT02337751 | A Phase 3, Long-term, Extension Study of TVP-1012 (1 mg) in Early Parkinson's D… | Phase3 | Parkinson's Disease | Completed | 2015-07-10 | 2017-03-14 | ClinicalTrials.gov |
| NCT02337751 | A Phase 3, Long-term, Extension Study of TVP-1012 (1 mg) in Early Parkinson's D… | Phase3 | Parkinson's Disease | Completed | 2015-07-10 | 2017-03-14 | ClinicalTrials.gov |
| NCT02646657 | An Open Label Phase 4 Study to Evaluate Efficacy of Early Versus Late Use of Ve… | Phase4 | Colitis, Ulcerative | Completed | 2015-07-01 | 2020-08-01 | ClinicalTrials.gov |
| NCT02244463 | A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incur… | Phase1 | Anaplastic Thyroid Cancer | Completed | 2015-07-01 | 2022-04-28 | ClinicalTrials.gov |
| NCT02535806 | Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in C… | Phase2 | Acute Lymphoblastic Leukemia | Terminated | 2015-07-01 | 2017-05-25 | ClinicalTrials.gov |
| NCT02477020 | A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Ex… | Phase2 | Schizophrenia | Completed | 2015-07-01 | 2016-07-27 | ClinicalTrials.gov |
| NCT02646683 | A Study to Evaluate Efficacy, of Early Versus Late Use of Vedolizumab in Crohn'… | Phase4 | Crohn Disease | Completed | 2015-07-01 | 2023-05-26 | ClinicalTrials.gov |
| NCT02244463 | A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incur… | Phase1 | Anaplastic Thyroid Cancer | Completed | 2015-07-01 | 2022-04-28 | ClinicalTrials.gov |
| NCT02646683 | A Study to Evaluate Efficacy, of Early Versus Late Use of Vedolizumab in Crohn'… | Phase4 | Crohn Disease | Completed | 2015-07-01 | 2023-05-26 | ClinicalTrials.gov |
| NCT02244463 | A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incur… | Phase1 | Anaplastic Thyroid Cancer | Completed | 2015-07-01 | 2022-04-28 | ClinicalTrials.gov |
| NCT02486939 | A Long Term Safety Extension Study (CHS-0214-05) | Phase3 | Rheumatoid Arthritis | Completed | 2015-07-01 | 2017-10-01 | ClinicalTrials.gov |
| NCT02646657 | An Open Label Phase 4 Study to Evaluate Efficacy of Early Versus Late Use of Ve… | Phase4 | Colitis, Ulcerative | Completed | 2015-07-01 | 2020-08-01 | ClinicalTrials.gov |
| NCT02535806 | Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in C… | Phase2 | Acute Lymphoblastic Leukemia | Terminated | 2015-07-01 | 2017-05-25 | ClinicalTrials.gov |
| NCT02477020 | A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Ex… | Phase2 | Schizophrenia | Completed | 2015-07-01 | 2016-07-27 | ClinicalTrials.gov |
| NCT02486939 | A Long Term Safety Extension Study (CHS-0214-05) | Phase3 | Rheumatoid Arthritis | Completed | 2015-07-01 | 2017-10-01 | ClinicalTrials.gov |
| NCT02497235 | A Phase 1 Positron Emission Tomography Study to Measure Cholesterol 24S-Hydroxy… | Phase1 | Epilepsy, Molecular Mechanisms of Pharmalogical Action, Protective Agents | Completed | 2015-07-01 | 2016-01-01 | ClinicalTrials.gov |
| NCT02497235 | A Phase 1 Positron Emission Tomography Study to Measure Cholesterol 24S-Hydroxy… | Phase1 | Epilepsy, Molecular Mechanisms of Pharmalogical Action, Protective Agents | Completed | 2015-07-01 | 2016-01-01 | ClinicalTrials.gov |
| NCT02486939 | A Long Term Safety Extension Study (CHS-0214-05) | Phase3 | Rheumatoid Arthritis | Completed | 2015-07-01 | 2017-10-01 | ClinicalTrials.gov |
| NCT02646657 | An Open Label Phase 4 Study to Evaluate Efficacy of Early Versus Late Use of Ve… | Phase4 | Colitis, Ulcerative | Completed | 2015-07-01 | 2020-08-01 | ClinicalTrials.gov |
| NCT02535806 | Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in C… | Phase2 | Acute Lymphoblastic Leukemia | Terminated | 2015-07-01 | 2017-05-25 | ClinicalTrials.gov |
| NCT02477020 | A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Ex… | Phase2 | Schizophrenia | Completed | 2015-07-01 | 2016-07-27 | ClinicalTrials.gov |
| NCT02646683 | A Study to Evaluate Efficacy, of Early Versus Late Use of Vedolizumab in Crohn'… | Phase4 | Crohn Disease | Completed | 2015-07-01 | 2023-05-26 | ClinicalTrials.gov |
| NCT02497235 | A Phase 1 Positron Emission Tomography Study to Measure Cholesterol 24S-Hydroxy… | Phase1 | Epilepsy, Molecular Mechanisms of Pharmalogical Action, Protective Agents | Completed | 2015-07-01 | 2016-01-01 | ClinicalTrials.gov |
| NCT02497469 | An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalim… | Phase3 | Colitis, Ulcerative | Completed | 2015-06-29 | 2019-01-18 | ClinicalTrials.gov |
| NCT02497469 | An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalim… | Phase3 | Colitis, Ulcerative | Completed | 2015-06-29 | 2019-01-18 | ClinicalTrials.gov |
| NCT02497469 | An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalim… | Phase3 | Colitis, Ulcerative | Completed | 2015-06-29 | 2019-01-18 | ClinicalTrials.gov |
| NCT02153112 | Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle … | Phase2 | Norovirus | Completed | 2015-06-23 | 2018-06-20 | ClinicalTrials.gov |
| NCT02153112 | Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle … | Phase2 | Norovirus | Completed | 2015-06-23 | 2018-06-20 | ClinicalTrials.gov |
| NCT02153112 | Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle … | Phase2 | Norovirus | Completed | 2015-06-23 | 2018-06-20 | ClinicalTrials.gov |
| NCT02466425 | Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years… | Phase3 | Attention Deficit Hyperactivity Disorder (ADHD) | Completed | 2015-06-18 | 2016-02-16 | ClinicalTrials.gov |
| NCT02466425 | Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years… | Phase3 | Attention Deficit Hyperactivity Disorder (ADHD) | Completed | 2015-06-18 | 2016-02-16 | ClinicalTrials.gov |
| NCT02466425 | Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years… | Phase3 | Attention Deficit Hyperactivity Disorder (ADHD) | Completed | 2015-06-18 | 2016-02-16 | ClinicalTrials.gov |
| NCT02234362 | Vortioxetine for Menopausal Depression | Phase4 | Depression | Completed | 2015-06-12 | 2016-09-29 | ClinicalTrials.gov |
| NCT02234362 | Vortioxetine for Menopausal Depression | Phase4 | Depression | Completed | 2015-06-12 | 2016-09-29 | ClinicalTrials.gov |
| NCT02234362 | Vortioxetine for Menopausal Depression | Phase4 | Depression | Completed | 2015-06-12 | 2016-09-29 | ClinicalTrials.gov |
| NCT02393209 | Docetaxel With or Without TAK-117 (MLN1117) in Participants With Locally Advanc… | Phase1 | Non-small Cell Lung Cancer | Terminated | 2015-06-03 | 2017-01-20 | ClinicalTrials.gov |
| NCT02425098 | Safety and Immunogenicity With Two Different Serotype 2 Potencies of Takeda's T… | Phase2 | Dengue Fever | Completed | 2015-06-03 | 2017-09-18 | ClinicalTrials.gov |
| NCT02425098 | Safety and Immunogenicity With Two Different Serotype 2 Potencies of Takeda's T… | Phase2 | Dengue Fever | Completed | 2015-06-03 | 2017-09-18 | ClinicalTrials.gov |
| NCT02425098 | Safety and Immunogenicity With Two Different Serotype 2 Potencies of Takeda's T… | Phase2 | Dengue Fever | Completed | 2015-06-03 | 2017-09-18 | ClinicalTrials.gov |
| NCT02393209 | Docetaxel With or Without TAK-117 (MLN1117) in Participants With Locally Advanc… | Phase1 | Non-small Cell Lung Cancer | Terminated | 2015-06-03 | 2017-01-20 | ClinicalTrials.gov |
| NCT02393209 | Docetaxel With or Without TAK-117 (MLN1117) in Participants With Locally Advanc… | Phase1 | Non-small Cell Lung Cancer | Terminated | 2015-06-03 | 2017-01-20 | ClinicalTrials.gov |
| NCT02480439 | A Study to Assess the Relative Bioavailability and to Assess the Effect of Food… | Phase1 | Healthy Volunteers | Completed | 2015-06-01 | 2015-09-01 | ClinicalTrials.gov |
| NCT02457247 | Calcichew D3 Preference Study in Participants Eligible for Calcium and Vitamin … | Phase4 | Calcium and Vitamin D Deficiencies | Completed | 2015-06-01 | 2015-08-01 | ClinicalTrials.gov |
| NCT02443922 | Dynamic Responsiveness of Insulin Secretory Parameters To Sitagliptin and Glime… | Na | Type 2 Diabetes | Unknown | 2015-06-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT02443922 | Dynamic Responsiveness of Insulin Secretory Parameters To Sitagliptin and Glime… | Na | Type 2 Diabetes | Unknown | 2015-06-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT02056015 | A Phase I Study of MLN6907 in Patients With Metastatic Colorectal | Phase1 | Imaging of Solid Gastrointestinal Tumors | Completed | 2015-06-01 | 2015-09-01 | ClinicalTrials.gov |
| NCT02056015 | A Phase I Study of MLN6907 in Patients With Metastatic Colorectal | Phase1 | Imaging of Solid Gastrointestinal Tumors | Completed | 2015-06-01 | 2015-09-01 | ClinicalTrials.gov |
| NCT02480439 | A Study to Assess the Relative Bioavailability and to Assess the Effect of Food… | Phase1 | Healthy Volunteers | Completed | 2015-06-01 | 2015-09-01 | ClinicalTrials.gov |
| NCT02457247 | Calcichew D3 Preference Study in Participants Eligible for Calcium and Vitamin … | Phase4 | Calcium and Vitamin D Deficiencies | Completed | 2015-06-01 | 2015-08-01 | ClinicalTrials.gov |
| NCT02480439 | A Study to Assess the Relative Bioavailability and to Assess the Effect of Food… | Phase1 | Healthy Volunteers | Completed | 2015-06-01 | 2015-09-01 | ClinicalTrials.gov |
| NCT02443922 | Dynamic Responsiveness of Insulin Secretory Parameters To Sitagliptin and Glime… | Na | Type 2 Diabetes | Unknown | 2015-06-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT02056015 | A Phase I Study of MLN6907 in Patients With Metastatic Colorectal | Phase1 | Imaging of Solid Gastrointestinal Tumors | Completed | 2015-06-01 | 2015-09-01 | ClinicalTrials.gov |
| NCT02457247 | Calcichew D3 Preference Study in Participants Eligible for Calcium and Vitamin … | Phase4 | Calcium and Vitamin D Deficiencies | Completed | 2015-06-01 | 2015-08-01 | ClinicalTrials.gov |
| NCT02394795 | Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC | Phase3 | Colorectal Cancer | Completed | 2015-05-29 | 2022-01-14 | ClinicalTrials.gov |
| NCT02394834 | An Exploratory Study of Treatment Sensitivity and Prognostic Factors in a Effic… | — | Colorectal Cancer | Active_Not_Recruiting | 2015-05-29 | 2027-09-30 | ClinicalTrials.gov |
| NCT02394795 | Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC | Phase3 | Colorectal Cancer | Completed | 2015-05-29 | 2022-01-14 | ClinicalTrials.gov |
| NCT02394834 | An Exploratory Study of Treatment Sensitivity and Prognostic Factors in a Effic… | — | Colorectal Cancer | Active_Not_Recruiting | 2015-05-29 | 2027-09-30 | ClinicalTrials.gov |
| NCT02394834 | An Exploratory Study of Treatment Sensitivity and Prognostic Factors in a Effic… | — | Colorectal Cancer | Active_Not_Recruiting | 2015-05-29 | 2027-09-30 | ClinicalTrials.gov |
| NCT02394795 | Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC | Phase3 | Colorectal Cancer | Completed | 2015-05-29 | 2022-01-14 | ClinicalTrials.gov |
| NCT02448719 | Single-Dose Phase 1 Study of TAK-792 | Phase1 | Healthy Male Adults Participants | Completed | 2015-05-27 | 2016-01-28 | ClinicalTrials.gov |
| NCT02448719 | Single-Dose Phase 1 Study of TAK-792 | Phase1 | Healthy Male Adults Participants | Completed | 2015-05-27 | 2016-01-28 | ClinicalTrials.gov |
| NCT02448719 | Single-Dose Phase 1 Study of TAK-792 | Phase1 | Healthy Male Adults Participants | Completed | 2015-05-27 | 2016-01-28 | ClinicalTrials.gov |
| NCT02410499 | Efficacy and Safety of Weekly Subcutaneous MLN1202 in Improving Diabetic Nephro… | Phase2 | Diabetic Nephropathy | Withdrawn | 2015-05-20 | 2015-11-17 | ClinicalTrials.gov |
| NCT02410499 | Efficacy and Safety of Weekly Subcutaneous MLN1202 in Improving Diabetic Nephro… | Phase2 | Diabetic Nephropathy | Withdrawn | 2015-05-20 | 2015-11-17 | ClinicalTrials.gov |
| NCT02410499 | Efficacy and Safety of Weekly Subcutaneous MLN1202 in Improving Diabetic Nephro… | Phase2 | Diabetic Nephropathy | Withdrawn | 2015-05-20 | 2015-11-17 | ClinicalTrials.gov |
| NCT02293005 | Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma | Phase2 | Lung Cancer | Completed | 2015-05-20 | 2021-07-06 | ClinicalTrials.gov |
| NCT02293005 | Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma | Phase2 | Lung Cancer | Completed | 2015-05-20 | 2021-07-06 | ClinicalTrials.gov |
| NCT02293005 | Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma | Phase2 | Lung Cancer | Completed | 2015-05-20 | 2021-07-06 | ClinicalTrials.gov |
| NCT02461160 | Phase 1, TAK-915-1001, Single-Rising Dose, Multiple-Rising Dose, Drug-Drug Inte… | Phase1 | Healthy Volunteers | Completed | 2015-05-12 | 2016-08-01 | ClinicalTrials.gov |
| NCT02461160 | Phase 1, TAK-915-1001, Single-Rising Dose, Multiple-Rising Dose, Drug-Drug Inte… | Phase1 | Healthy Volunteers | Completed | 2015-05-12 | 2016-08-01 | ClinicalTrials.gov |
| NCT02461160 | Phase 1, TAK-915-1001, Single-Rising Dose, Multiple-Rising Dose, Drug-Drug Inte… | Phase1 | Healthy Volunteers | Completed | 2015-05-12 | 2016-08-01 | ClinicalTrials.gov |
| NCT02484261 | Monitoring and Treatment of Relapsed Leukemia Following Allogeneic Hematopoieti… | Phase1 | Leukemia | Terminated | 2015-05-01 | — | ClinicalTrials.gov |
| NCT02484261 | Monitoring and Treatment of Relapsed Leukemia Following Allogeneic Hematopoieti… | Phase1 | Leukemia | Terminated | 2015-05-01 | — | ClinicalTrials.gov |
| NCT02484261 | Monitoring and Treatment of Relapsed Leukemia Following Allogeneic Hematopoieti… | Phase1 | Leukemia | Terminated | 2015-05-01 | — | ClinicalTrials.gov |
| NCT02402166 | Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschoo… | Phase2 | Attention Deficit Hyperactivity Disorder (ADHD) | Completed | 2015-04-15 | 2016-06-30 | ClinicalTrials.gov |
| NCT02402166 | Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschoo… | Phase2 | Attention Deficit Hyperactivity Disorder (ADHD) | Completed | 2015-04-15 | 2016-06-30 | ClinicalTrials.gov |
| NCT02402166 | Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschoo… | Phase2 | Attention Deficit Hyperactivity Disorder (ADHD) | Completed | 2015-04-15 | 2016-06-30 | ClinicalTrials.gov |
| NCT02412787 | Study of Long Term Safety and Clinical Outcomes of Idursulfase IT and Elaprase … | Phase2 | Hunter Syndrome | Completed | 2015-04-14 | 2024-04-18 | ClinicalTrials.gov |
| NCT02412787 | Study of Long Term Safety and Clinical Outcomes of Idursulfase IT and Elaprase … | Phase2 | Hunter Syndrome | Completed | 2015-04-14 | 2024-04-18 | ClinicalTrials.gov |
| NCT02412787 | Study of Long Term Safety and Clinical Outcomes of Idursulfase IT and Elaprase … | Phase2 | Hunter Syndrome | Completed | 2015-04-14 | 2024-04-18 | ClinicalTrials.gov |
| NCT02389816 | A Phase 3 Study of Lu AA21004 in Patients With Major Depressive Disorder | Phase3 | Major Depressive Disorder | Completed | 2015-04-10 | 2018-03-16 | ClinicalTrials.gov |
| NCT02389816 | A Phase 3 Study of Lu AA21004 in Patients With Major Depressive Disorder | Phase3 | Major Depressive Disorder | Completed | 2015-04-10 | 2018-03-16 | ClinicalTrials.gov |
| NCT02389816 | A Phase 3 Study of Lu AA21004 in Patients With Major Depressive Disorder | Phase3 | Major Depressive Disorder | Completed | 2015-04-10 | 2018-03-16 | ClinicalTrials.gov |
| NCT02312258 | A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnos… | Phase3 | Multiple Myeloma | Completed | 2015-04-09 | 2022-08-26 | ClinicalTrials.gov |
| NCT02312258 | A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnos… | Phase3 | Multiple Myeloma | Completed | 2015-04-09 | 2022-08-26 | ClinicalTrials.gov |
| NCT02312258 | A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnos… | Phase3 | Multiple Myeloma | Completed | 2015-04-09 | 2022-08-26 | ClinicalTrials.gov |
| NCT02350816 | An Extension Study to Determine Safety and Efficacy for Pediatric Patients With… | Phase2 | Sanfilippo Syndrome | Terminated | 2015-04-08 | 2019-04-12 | ClinicalTrials.gov |
| NCT02350816 | An Extension Study to Determine Safety and Efficacy for Pediatric Patients With… | Phase2 | Sanfilippo Syndrome | Terminated | 2015-04-08 | 2019-04-12 | ClinicalTrials.gov |
| NCT02350816 | An Extension Study to Determine Safety and Efficacy for Pediatric Patients With… | Phase2 | Sanfilippo Syndrome | Terminated | 2015-04-08 | 2019-04-12 | ClinicalTrials.gov |
| NCT02393378 | Namilumab vs Adalimumab in Participants With Moderate to Severe Early Rheumatoi… | Phase2 | Rheumatoid Arthritis | Terminated | 2015-04-08 | 2016-11-16 | ClinicalTrials.gov |
| NCT02393378 | Namilumab vs Adalimumab in Participants With Moderate to Severe Early Rheumatoi… | Phase2 | Rheumatoid Arthritis | Terminated | 2015-04-08 | 2016-11-16 | ClinicalTrials.gov |
| NCT02393378 | Namilumab vs Adalimumab in Participants With Moderate to Severe Early Rheumatoi… | Phase2 | Rheumatoid Arthritis | Terminated | 2015-04-08 | 2016-11-16 | ClinicalTrials.gov |
| NCT02426021 | Phase 1 Single Subcutaneous Dose Study of MLN1202 | Phase1 | Healthy Japanese and Caucasian Male Adults | Withdrawn | 2015-04-01 | 2015-11-01 | ClinicalTrials.gov |
| NCT02388737 | Efficacy and Safety of Vonoprazan Compared to Lansoprazole in the Maintenance T… | Phase3 | Erosive Esophagitis | Completed | 2015-04-01 | 2018-12-31 | ClinicalTrials.gov |
| NCT02388737 | Efficacy and Safety of Vonoprazan Compared to Lansoprazole in the Maintenance T… | Phase3 | Erosive Esophagitis | Completed | 2015-04-01 | 2018-12-31 | ClinicalTrials.gov |
| NCT02388737 | Efficacy and Safety of Vonoprazan Compared to Lansoprazole in the Maintenance T… | Phase3 | Erosive Esophagitis | Completed | 2015-04-01 | 2018-12-31 | ClinicalTrials.gov |
| NCT02430870 | TAK-648 Multiple-Rising Dose Study in Healthy Japanese Participants and Non-Jap… | Phase1 | Type 2 Diabetes Mellitus | Completed | 2015-04-01 | 2015-11-01 | ClinicalTrials.gov |
| NCT02400437 | Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Walde… | Phase2 | Waldenstrom's Macroglobulinemia | Completed | 2015-04-01 | 2019-11-01 | ClinicalTrials.gov |
| NCT02426021 | Phase 1 Single Subcutaneous Dose Study of MLN1202 | Phase1 | Healthy Japanese and Caucasian Male Adults | Withdrawn | 2015-04-01 | 2015-11-01 | ClinicalTrials.gov |
| NCT02400437 | Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Walde… | Phase2 | Waldenstrom's Macroglobulinemia | Completed | 2015-04-01 | 2019-11-01 | ClinicalTrials.gov |
| NCT02426021 | Phase 1 Single Subcutaneous Dose Study of MLN1202 | Phase1 | Healthy Japanese and Caucasian Male Adults | Withdrawn | 2015-04-01 | 2015-11-01 | ClinicalTrials.gov |
| NCT02430870 | TAK-648 Multiple-Rising Dose Study in Healthy Japanese Participants and Non-Jap… | Phase1 | Type 2 Diabetes Mellitus | Completed | 2015-04-01 | 2015-11-01 | ClinicalTrials.gov |
| NCT02430870 | TAK-648 Multiple-Rising Dose Study in Healthy Japanese Participants and Non-Jap… | Phase1 | Type 2 Diabetes Mellitus | Completed | 2015-04-01 | 2015-11-01 | ClinicalTrials.gov |
| NCT02400437 | Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Walde… | Phase2 | Waldenstrom's Macroglobulinemia | Completed | 2015-04-01 | 2019-11-01 | ClinicalTrials.gov |
| NCT02425111 | Effect of Intravenous (IV) Vedolizumab on Mucosal Healing in Crohn's Disease | Phase3 | Crohn's Disease | Completed | 2015-03-30 | 2018-02-21 | ClinicalTrials.gov |
| NCT02425111 | Effect of Intravenous (IV) Vedolizumab on Mucosal Healing in Crohn's Disease | Phase3 | Crohn's Disease | Completed | 2015-03-30 | 2018-02-21 | ClinicalTrials.gov |
| NCT02425111 | Effect of Intravenous (IV) Vedolizumab on Mucosal Healing in Crohn's Disease | Phase3 | Crohn's Disease | Completed | 2015-03-30 | 2018-02-21 | ClinicalTrials.gov |
| NCT02386839 | Long-term Safety and Efficacy Outcome Study Comparing Children Previously Enrol… | Phase2 | Retinopathy of Prematurity (ROP) | Completed | 2015-03-26 | 2021-09-28 | ClinicalTrials.gov |
| NCT02386839 | Long-term Safety and Efficacy Outcome Study Comparing Children Previously Enrol… | Phase2 | Retinopathy of Prematurity (ROP) | Completed | 2015-03-26 | 2021-09-28 | ClinicalTrials.gov |
| NCT02412722 | A Safety, Tolerability, and Pharmacokinetics Study of MLN0128 as a Single Agent… | Phase1 | Non-hematologic Malignancy | Completed | 2015-03-26 | 2018-05-31 | ClinicalTrials.gov |
| NCT02386839 | Long-term Safety and Efficacy Outcome Study Comparing Children Previously Enrol… | Phase2 | Retinopathy of Prematurity (ROP) | Completed | 2015-03-26 | 2021-09-28 | ClinicalTrials.gov |
| NCT02412722 | A Safety, Tolerability, and Pharmacokinetics Study of MLN0128 as a Single Agent… | Phase1 | Non-hematologic Malignancy | Completed | 2015-03-26 | 2018-05-31 | ClinicalTrials.gov |
| NCT02412722 | A Safety, Tolerability, and Pharmacokinetics Study of MLN0128 as a Single Agent… | Phase1 | Non-hematologic Malignancy | Completed | 2015-03-26 | 2018-05-31 | ClinicalTrials.gov |
| NCT02388724 | Efficacy and Safety of Oral Once-Daily Vonoprazan (TAK-438) in Participants Wit… | Phase3 | Erosive Esophagitis | Completed | 2015-03-24 | 2017-07-27 | ClinicalTrials.gov |
| NCT02388724 | Efficacy and Safety of Oral Once-Daily Vonoprazan (TAK-438) in Participants Wit… | Phase3 | Erosive Esophagitis | Completed | 2015-03-24 | 2017-07-27 | ClinicalTrials.gov |
| NCT02674308 | Entyvio (Vedolizumab) Long Term Safety Study | — | Ulcerative Colitis and Crohn's Disease | Completed | 2015-03-24 | 2021-07-30 | ClinicalTrials.gov |
| NCT02388724 | Efficacy and Safety of Oral Once-Daily Vonoprazan (TAK-438) in Participants Wit… | Phase3 | Erosive Esophagitis | Completed | 2015-03-24 | 2017-07-27 | ClinicalTrials.gov |
| NCT02674308 | Entyvio (Vedolizumab) Long Term Safety Study | — | Ulcerative Colitis and Crohn's Disease | Completed | 2015-03-24 | 2021-07-30 | ClinicalTrials.gov |
| NCT02674308 | Entyvio (Vedolizumab) Long Term Safety Study | — | Ulcerative Colitis and Crohn's Disease | Completed | 2015-03-24 | 2021-07-30 | ClinicalTrials.gov |
| NCT02302846 | Study of MLN9708 as Maintenance Therapy for Patients With Acute Myeloid Leukemi… | Phase2 | Leukemia | Terminated | 2015-03-20 | 2017-05-30 | ClinicalTrials.gov |
| NCT02302846 | Study of MLN9708 as Maintenance Therapy for Patients With Acute Myeloid Leukemi… | Phase2 | Leukemia | Terminated | 2015-03-20 | 2017-05-30 | ClinicalTrials.gov |
| NCT02302846 | Study of MLN9708 as Maintenance Therapy for Patients With Acute Myeloid Leukemi… | Phase2 | Leukemia | Terminated | 2015-03-20 | 2017-05-30 | ClinicalTrials.gov |
| NCT02351960 | Dexlansoprazole in Asian Participants With Gastroesophageal Reflux Disease | Phase4 | Gastroesophageal Reflux Disease | Completed | 2015-03-19 | 2016-07-13 | ClinicalTrials.gov |
| NCT02367352 | Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patient… | Phase1 | Advanced Solid Tumors | Terminated | 2015-03-19 | 2017-05-23 | ClinicalTrials.gov |
| NCT02351960 | Dexlansoprazole in Asian Participants With Gastroesophageal Reflux Disease | Phase4 | Gastroesophageal Reflux Disease | Completed | 2015-03-19 | 2016-07-13 | ClinicalTrials.gov |
| NCT02367352 | Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patient… | Phase1 | Advanced Solid Tumors | Terminated | 2015-03-19 | 2017-05-23 | ClinicalTrials.gov |
| NCT02351960 | Dexlansoprazole in Asian Participants With Gastroesophageal Reflux Disease | Phase4 | Gastroesophageal Reflux Disease | Completed | 2015-03-19 | 2016-07-13 | ClinicalTrials.gov |
| NCT02367352 | Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patient… | Phase1 | Advanced Solid Tumors | Terminated | 2015-03-19 | 2017-05-23 | ClinicalTrials.gov |
| NCT03888755 | A Study of Icatibant for Acute Attacks of Hereditary Angioedema in Japanese Par… | Phase3 | Hereditary Angioedema (HAE) | Completed | 2015-03-18 | 2016-02-12 | ClinicalTrials.gov |
| NCT02413255 | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Single… | Phase1 | Healthy Volunteers | Completed | 2015-03-18 | 2017-05-04 | ClinicalTrials.gov |
| NCT02413255 | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Single… | Phase1 | Healthy Volunteers | Completed | 2015-03-18 | 2017-05-04 | ClinicalTrials.gov |
| NCT03888755 | A Study of Icatibant for Acute Attacks of Hereditary Angioedema in Japanese Par… | Phase3 | Hereditary Angioedema (HAE) | Completed | 2015-03-18 | 2016-02-12 | ClinicalTrials.gov |
| NCT03888755 | A Study of Icatibant for Acute Attacks of Hereditary Angioedema in Japanese Par… | Phase3 | Hereditary Angioedema (HAE) | Completed | 2015-03-18 | 2016-02-12 | ClinicalTrials.gov |
| NCT02413255 | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Single… | Phase1 | Healthy Volunteers | Completed | 2015-03-18 | 2017-05-04 | ClinicalTrials.gov |
| NCT02367872 | Phase I Open-label Study to Evaluate Pharmacokinetics of TAK-272 in Participant… | Phase1 | Renal Impairment | Completed | 2015-03-01 | 2016-06-01 | ClinicalTrials.gov |
| NCT02367872 | Phase I Open-label Study to Evaluate Pharmacokinetics of TAK-272 in Participant… | Phase1 | Renal Impairment | Completed | 2015-03-01 | 2016-06-01 | ClinicalTrials.gov |
| NCT02292979 | Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Hod… | Phase2 | Hodgkin Lymphoma | Completed | 2015-03-01 | 2022-06-02 | ClinicalTrials.gov |
| NCT02372097 | A Phase 1, Bioequivalence Study of SYR-472 25mg and 50mg Tablets | Phase1 | Healthy | Completed | 2015-03-01 | 2015-04-01 | ClinicalTrials.gov |
| NCT02382640 | Effect of Antacid on Bioavailability of Febuxostat After Administration of a Fe… | Phase1 | Healthy Volunteers | Completed | 2015-03-01 | 2015-05-01 | ClinicalTrials.gov |
| NCT02396147 | Bioavailability and Effect of Food on TAK-385 Tablet Formulations in Healthy Pa… | Phase1 | Healthy Volunteers | Completed | 2015-03-01 | 2015-06-01 | ClinicalTrials.gov |
| NCT02400775 | A Study to Evaluate the Effects of Azilsartan on Coronary Artery Plaque in Esse… | Phase4 | Essential Hypertension With Stable Angina and Dyslipidemia | Withdrawn | 2015-03-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT02401464 | A Bioequivalence Study of TAK-536 Pediatric Formulation | Phase1 | Japanese Healthy Adult Males | Completed | 2015-03-01 | 2015-05-01 | ClinicalTrials.gov |
| NCT02292979 | Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Hod… | Phase2 | Hodgkin Lymphoma | Completed | 2015-03-01 | 2022-06-02 | ClinicalTrials.gov |
| NCT02367872 | Phase I Open-label Study to Evaluate Pharmacokinetics of TAK-272 in Participant… | Phase1 | Renal Impairment | Completed | 2015-03-01 | 2016-06-01 | ClinicalTrials.gov |
| NCT02372097 | A Phase 1, Bioequivalence Study of SYR-472 25mg and 50mg Tablets | Phase1 | Healthy | Completed | 2015-03-01 | 2015-04-01 | ClinicalTrials.gov |
| NCT02382640 | Effect of Antacid on Bioavailability of Febuxostat After Administration of a Fe… | Phase1 | Healthy Volunteers | Completed | 2015-03-01 | 2015-05-01 | ClinicalTrials.gov |
| NCT02396147 | Bioavailability and Effect of Food on TAK-385 Tablet Formulations in Healthy Pa… | Phase1 | Healthy Volunteers | Completed | 2015-03-01 | 2015-06-01 | ClinicalTrials.gov |
| NCT02400775 | A Study to Evaluate the Effects of Azilsartan on Coronary Artery Plaque in Esse… | Phase4 | Essential Hypertension With Stable Angina and Dyslipidemia | Withdrawn | 2015-03-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT02401464 | A Bioequivalence Study of TAK-536 Pediatric Formulation | Phase1 | Japanese Healthy Adult Males | Completed | 2015-03-01 | 2015-05-01 | ClinicalTrials.gov |
| NCT02401464 | A Bioequivalence Study of TAK-536 Pediatric Formulation | Phase1 | Japanese Healthy Adult Males | Completed | 2015-03-01 | 2015-05-01 | ClinicalTrials.gov |
| NCT02400775 | A Study to Evaluate the Effects of Azilsartan on Coronary Artery Plaque in Esse… | Phase4 | Essential Hypertension With Stable Angina and Dyslipidemia | Withdrawn | 2015-03-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT02396147 | Bioavailability and Effect of Food on TAK-385 Tablet Formulations in Healthy Pa… | Phase1 | Healthy Volunteers | Completed | 2015-03-01 | 2015-06-01 | ClinicalTrials.gov |
| NCT02382640 | Effect of Antacid on Bioavailability of Febuxostat After Administration of a Fe… | Phase1 | Healthy Volunteers | Completed | 2015-03-01 | 2015-05-01 | ClinicalTrials.gov |
| NCT02372097 | A Phase 1, Bioequivalence Study of SYR-472 25mg and 50mg Tablets | Phase1 | Healthy | Completed | 2015-03-01 | 2015-04-01 | ClinicalTrials.gov |
| NCT02292979 | Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Hod… | Phase2 | Hodgkin Lymphoma | Completed | 2015-03-01 | 2022-06-02 | ClinicalTrials.gov |
| NCT02475278 | Serologic Assay Validation, Proficiency Testing, Safety and Immunogenicity of N… | Phase2 | Norovirus | Completed | 2015-02-26 | 2015-09-09 | ClinicalTrials.gov |
| NCT02475278 | Serologic Assay Validation, Proficiency Testing, Safety and Immunogenicity of N… | Phase2 | Norovirus | Completed | 2015-02-26 | 2015-09-09 | ClinicalTrials.gov |
| NCT02475278 | Serologic Assay Validation, Proficiency Testing, Safety and Immunogenicity of N… | Phase2 | Norovirus | Completed | 2015-02-26 | 2015-09-09 | ClinicalTrials.gov |
| NCT02220608 | Phase I Study of Bortezomib With G-CSF for Stem Cell Mobilization in Patients W… | Phase1 | Multiple Myeloma | Completed | 2015-02-20 | 2016-11-30 | ClinicalTrials.gov |
| NCT02220608 | Phase I Study of Bortezomib With G-CSF for Stem Cell Mobilization in Patients W… | Phase1 | Multiple Myeloma | Completed | 2015-02-20 | 2016-11-30 | ClinicalTrials.gov |
| NCT02220608 | Phase I Study of Bortezomib With G-CSF for Stem Cell Mobilization in Patients W… | Phase1 | Multiple Myeloma | Completed | 2015-02-20 | 2016-11-30 | ClinicalTrials.gov |
| NCT02187991 | Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic o… | Phase2 | Breast Cancer | Completed | 2015-02-12 | 2024-08-01 | ClinicalTrials.gov |
| NCT02284906 | AD-4833/TOMM40_303 Extension Study of the Safety and Efficacy of Pioglitazone t… | Phase3 | Mild Cognitive Impairment Due to Alzheimer's Disease | Terminated | 2015-02-12 | 2018-05-08 | ClinicalTrials.gov |
| NCT02284906 | AD-4833/TOMM40_303 Extension Study of the Safety and Efficacy of Pioglitazone t… | Phase3 | Mild Cognitive Impairment Due to Alzheimer's Disease | Terminated | 2015-02-12 | 2018-05-08 | ClinicalTrials.gov |
| NCT02187991 | Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic o… | Phase2 | Breast Cancer | Completed | 2015-02-12 | 2024-08-01 | ClinicalTrials.gov |
| NCT02284906 | AD-4833/TOMM40_303 Extension Study of the Safety and Efficacy of Pioglitazone t… | Phase3 | Mild Cognitive Impairment Due to Alzheimer's Disease | Terminated | 2015-02-12 | 2018-05-08 | ClinicalTrials.gov |
| NCT02187991 | Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic o… | Phase2 | Breast Cancer | Completed | 2015-02-12 | 2024-08-01 | ClinicalTrials.gov |
| NCT02371980 | Vortioxetine, 5, 10, and 20 mg, Relapse Prevention Study in Adults With Major D… | Phase4 | Major Depressive Disorder | Completed | 2015-02-10 | 2019-04-25 | ClinicalTrials.gov |
| NCT02371980 | Vortioxetine, 5, 10, and 20 mg, Relapse Prevention Study in Adults With Major D… | Phase4 | Major Depressive Disorder | Completed | 2015-02-10 | 2019-04-25 | ClinicalTrials.gov |
| NCT02371980 | Vortioxetine, 5, 10, and 20 mg, Relapse Prevention Study in Adults With Major D… | Phase4 | Major Depressive Disorder | Completed | 2015-02-10 | 2019-04-25 | ClinicalTrials.gov |
| NCT02337725 | A Phase 3 Study of TVP-1012 (1 mg) in Early Parkinson's Disease Patients | Phase3 | Parkinson's Disease | Completed | 2015-02-07 | 2016-09-15 | ClinicalTrials.gov |
| NCT02337725 | A Phase 3 Study of TVP-1012 (1 mg) in Early Parkinson's Disease Patients | Phase3 | Parkinson's Disease | Completed | 2015-02-07 | 2016-09-15 | ClinicalTrials.gov |
| NCT02337725 | A Phase 3 Study of TVP-1012 (1 mg) in Early Parkinson's Disease Patients | Phase3 | Parkinson's Disease | Completed | 2015-02-07 | 2016-09-15 | ClinicalTrials.gov |
| NCT02337764 | A Long-term, Phase 3 Study of TVP-1012 (1 mg) in Levodopa Treated Parkinson's D… | Phase3 | Parkinson's Disease | Completed | 2015-02-03 | 2016-09-29 | ClinicalTrials.gov |
| NCT02337764 | A Long-term, Phase 3 Study of TVP-1012 (1 mg) in Levodopa Treated Parkinson's D… | Phase3 | Parkinson's Disease | Completed | 2015-02-03 | 2016-09-29 | ClinicalTrials.gov |
| NCT02337764 | A Long-term, Phase 3 Study of TVP-1012 (1 mg) in Levodopa Treated Parkinson's D… | Phase3 | Parkinson's Disease | Completed | 2015-02-03 | 2016-09-29 | ClinicalTrials.gov |
| NCT02367885 | Phase 1/2 Study of TAK-850 Intramuscular Injection in Healthy Pediatric Partici… | Phase1 | Influenza Infection | Completed | 2015-02-01 | 2015-05-01 | ClinicalTrials.gov |
| NCT02367885 | Phase 1/2 Study of TAK-850 Intramuscular Injection in Healthy Pediatric Partici… | Phase1 | Influenza Infection | Completed | 2015-02-01 | 2015-05-01 | ClinicalTrials.gov |
| NCT02544152 | Evaluation of the Efficacy and Safety of Lubiprostone in Adults With Mixed or U… | Phase2 | Irritable Bowel Syndrome | Terminated | 2015-02-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT02389881 | Safety, Tolerability, and Pharmacokinetics of Multiple-Dose TAK-058 in Healthy … | Phase1 | Healthy Volunteers | Completed | 2015-02-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT02369796 | A Phase 2a Pharmacodynamic Study of TAK-448 in Participants With Hypogonadotrop… | Phase2 | Hypogonadotropic Hypogonadism | Terminated | 2015-02-01 | 2015-11-01 | ClinicalTrials.gov |
| NCT02389881 | Safety, Tolerability, and Pharmacokinetics of Multiple-Dose TAK-058 in Healthy … | Phase1 | Healthy Volunteers | Completed | 2015-02-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT02940054 | RED-FLAGS Index Validation in Crohn's Disease Patients | — | Crohn's Disease | Unknown | 2015-02-01 | 2018-03-01 | ClinicalTrials.gov |
| NCT02312102 | Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic… | Phase1 | Myelodysplastic Syndrome | Completed | 2015-02-01 | 2024-10-07 | ClinicalTrials.gov |
| NCT02312102 | Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic… | Phase1 | Myelodysplastic Syndrome | Completed | 2015-02-01 | 2024-10-07 | ClinicalTrials.gov |
| NCT02940054 | RED-FLAGS Index Validation in Crohn's Disease Patients | — | Crohn's Disease | Unknown | 2015-02-01 | 2018-03-01 | ClinicalTrials.gov |
| NCT02389881 | Safety, Tolerability, and Pharmacokinetics of Multiple-Dose TAK-058 in Healthy … | Phase1 | Healthy Volunteers | Completed | 2015-02-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT02370615 | Drug-Drug Interaction Study Between TAK-272 and Itraconazole, Digoxin or Midazo… | Phase1 | Japanese Healthy Adult Males | Completed | 2015-02-01 | 2015-04-01 | ClinicalTrials.gov |
| NCT02374164 | Food Effect Study of Febuxostat XR in Healthy Participants | Phase1 | Gout | Completed | 2015-02-01 | 2015-04-01 | ClinicalTrials.gov |
| NCT02374164 | Food Effect Study of Febuxostat XR in Healthy Participants | Phase1 | Gout | Completed | 2015-02-01 | 2015-04-01 | ClinicalTrials.gov |
| NCT02940054 | RED-FLAGS Index Validation in Crohn's Disease Patients | — | Crohn's Disease | Unknown | 2015-02-01 | 2018-03-01 | ClinicalTrials.gov |
| NCT02544152 | Evaluation of the Efficacy and Safety of Lubiprostone in Adults With Mixed or U… | Phase2 | Irritable Bowel Syndrome | Terminated | 2015-02-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT02370615 | Drug-Drug Interaction Study Between TAK-272 and Itraconazole, Digoxin or Midazo… | Phase1 | Japanese Healthy Adult Males | Completed | 2015-02-01 | 2015-04-01 | ClinicalTrials.gov |
| NCT02369796 | A Phase 2a Pharmacodynamic Study of TAK-448 in Participants With Hypogonadotrop… | Phase2 | Hypogonadotropic Hypogonadism | Terminated | 2015-02-01 | 2015-11-01 | ClinicalTrials.gov |
| NCT02367885 | Phase 1/2 Study of TAK-850 Intramuscular Injection in Healthy Pediatric Partici… | Phase1 | Influenza Infection | Completed | 2015-02-01 | 2015-05-01 | ClinicalTrials.gov |
| NCT02312102 | Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic… | Phase1 | Myelodysplastic Syndrome | Completed | 2015-02-01 | 2024-10-07 | ClinicalTrials.gov |
| NCT02374164 | Food Effect Study of Febuxostat XR in Healthy Participants | Phase1 | Gout | Completed | 2015-02-01 | 2015-04-01 | ClinicalTrials.gov |
| NCT02544152 | Evaluation of the Efficacy and Safety of Lubiprostone in Adults With Mixed or U… | Phase2 | Irritable Bowel Syndrome | Terminated | 2015-02-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT02370615 | Drug-Drug Interaction Study Between TAK-272 and Itraconazole, Digoxin or Midazo… | Phase1 | Japanese Healthy Adult Males | Completed | 2015-02-01 | 2015-04-01 | ClinicalTrials.gov |
| NCT02369796 | A Phase 2a Pharmacodynamic Study of TAK-448 in Participants With Hypogonadotrop… | Phase2 | Hypogonadotropic Hypogonadism | Terminated | 2015-02-01 | 2015-11-01 | ClinicalTrials.gov |
| NCT02186509 | Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With … | Phase1 | Adult Anaplastic Astrocytoma | Completed | 2015-01-30 | 2018-12-31 | ClinicalTrials.gov |
| NCT02186509 | Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With … | Phase1 | Adult Anaplastic Astrocytoma | Completed | 2015-01-30 | 2018-12-31 | ClinicalTrials.gov |
| NCT02186509 | Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With … | Phase1 | Adult Anaplastic Astrocytoma | Completed | 2015-01-30 | 2018-12-31 | ClinicalTrials.gov |
| NCT02415712 | Specified Drug-use Survey of Fomepizole Intravenous Infusion (All-case Surveill… | — | Ethylene Glycol Poisoning, Methanol Poisoning | Completed | 2015-01-27 | 2022-06-30 | ClinicalTrials.gov |
| NCT02415712 | Specified Drug-use Survey of Fomepizole Intravenous Infusion (All-case Surveill… | — | Ethylene Glycol Poisoning, Methanol Poisoning | Completed | 2015-01-27 | 2022-06-30 | ClinicalTrials.gov |
| NCT02415712 | Specified Drug-use Survey of Fomepizole Intravenous Infusion (All-case Surveill… | — | Ethylene Glycol Poisoning, Methanol Poisoning | Completed | 2015-01-27 | 2022-06-30 | ClinicalTrials.gov |
| NCT02337738 | A Phase 2/3 Study of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's… | Phase2 | Parkinson's Disease | Completed | 2015-01-27 | 2016-09-17 | ClinicalTrials.gov |
| NCT02337738 | A Phase 2/3 Study of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's… | Phase2 | Parkinson's Disease | Completed | 2015-01-27 | 2016-09-17 | ClinicalTrials.gov |
| NCT02337738 | A Phase 2/3 Study of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's… | Phase2 | Parkinson's Disease | Completed | 2015-01-27 | 2016-09-17 | ClinicalTrials.gov |
| NCT02253316 | Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous S… | Phase2 | Multiple Myeloma | Active_Not_Recruiting | 2015-01-20 | 2026-08-31 | ClinicalTrials.gov |
| NCT02253316 | Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous S… | Phase2 | Multiple Myeloma | Active_Not_Recruiting | 2015-01-20 | 2026-08-31 | ClinicalTrials.gov |
| NCT02253316 | Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous S… | Phase2 | Multiple Myeloma | Active_Not_Recruiting | 2015-01-20 | 2026-08-31 | ClinicalTrials.gov |
| NCT02327169 | A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cet… | Phase1 | Advanced Nonhematologic Malignancies | Completed | 2015-01-14 | 2018-07-02 | ClinicalTrials.gov |
| NCT02327169 | A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cet… | Phase1 | Advanced Nonhematologic Malignancies | Completed | 2015-01-14 | 2018-07-02 | ClinicalTrials.gov |
| NCT02327169 | A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cet… | Phase1 | Advanced Nonhematologic Malignancies | Completed | 2015-01-14 | 2018-07-02 | ClinicalTrials.gov |
| NCT02338713 | Effect of Calcium 500 mg and Vitamin D3 1000 IU Chewable Tablet on Intestinal C… | Phase1 | Healthy Volunteers | Completed | 2015-01-01 | 2015-02-01 | ClinicalTrials.gov |
| NCT02338713 | Effect of Calcium 500 mg and Vitamin D3 1000 IU Chewable Tablet on Intestinal C… | Phase1 | Healthy Volunteers | Completed | 2015-01-01 | 2015-02-01 | ClinicalTrials.gov |
| NCT02348658 | A Phase 1 Food Effect Study of TAK-536TCH Final Formulation Tablet | Phase1 | Hypertension | Completed | 2015-01-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT03207789 | T-cell Brazil: Prospective Collection of Data in T-cell Lymphomas Patients | — | T-cell Lymphoma | Unknown | 2015-01-01 | 2020-12-31 | ClinicalTrials.gov |
| NCT02344498 | Treatment of Hepatitis B in Resource-limited Settings - a Pilot Program in East… | — | Hepatitis B | Active_Not_Recruiting | 2015-01-01 | 2026-12-01 | ClinicalTrials.gov |
| NCT02260869 | Efficacy of Cooled and Monopolar Radiofrequency Ablation of the Geniculate Nerv… | Na | Osteoarthritis, Knee | Terminated | 2015-01-01 | 2019-06-26 | ClinicalTrials.gov |
| NCT02348658 | A Phase 1 Food Effect Study of TAK-536TCH Final Formulation Tablet | Phase1 | Hypertension | Completed | 2015-01-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT03207789 | T-cell Brazil: Prospective Collection of Data in T-cell Lymphomas Patients | — | T-cell Lymphoma | Unknown | 2015-01-01 | 2020-12-31 | ClinicalTrials.gov |
| NCT02344498 | Treatment of Hepatitis B in Resource-limited Settings - a Pilot Program in East… | — | Hepatitis B | Active_Not_Recruiting | 2015-01-01 | 2026-12-01 | ClinicalTrials.gov |
| NCT02260869 | Efficacy of Cooled and Monopolar Radiofrequency Ablation of the Geniculate Nerv… | Na | Osteoarthritis, Knee | Terminated | 2015-01-01 | 2019-06-26 | ClinicalTrials.gov |
| NCT02338713 | Effect of Calcium 500 mg and Vitamin D3 1000 IU Chewable Tablet on Intestinal C… | Phase1 | Healthy Volunteers | Completed | 2015-01-01 | 2015-02-01 | ClinicalTrials.gov |
| NCT02348658 | A Phase 1 Food Effect Study of TAK-536TCH Final Formulation Tablet | Phase1 | Hypertension | Completed | 2015-01-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT03207789 | T-cell Brazil: Prospective Collection of Data in T-cell Lymphomas Patients | — | T-cell Lymphoma | Unknown | 2015-01-01 | 2020-12-31 | ClinicalTrials.gov |
| NCT02344498 | Treatment of Hepatitis B in Resource-limited Settings - a Pilot Program in East… | — | Hepatitis B | Active_Not_Recruiting | 2015-01-01 | 2026-12-01 | ClinicalTrials.gov |
| NCT02260869 | Efficacy of Cooled and Monopolar Radiofrequency Ablation of the Geniculate Nerv… | Na | Osteoarthritis, Knee | Terminated | 2015-01-01 | 2019-06-26 | ClinicalTrials.gov |
| NCT02324569 | A Phase 4, Randomized, Double-blind, Parallel-group, Comparative Study and a Ph… | Phase3 | Type 2 Diabetes Mellitus | Completed | 2014-12-27 | 2016-12-28 | ClinicalTrials.gov |
| NCT02324569 | A Phase 4, Randomized, Double-blind, Parallel-group, Comparative Study and a Ph… | Phase3 | Type 2 Diabetes Mellitus | Completed | 2014-12-27 | 2016-12-28 | ClinicalTrials.gov |
| NCT02324569 | A Phase 4, Randomized, Double-blind, Parallel-group, Comparative Study and a Ph… | Phase3 | Type 2 Diabetes Mellitus | Completed | 2014-12-27 | 2016-12-28 | ClinicalTrials.gov |
| NCT02340819 | Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Teduglutide in J… | Phase3 | Short Bowel Syndrome | Completed | 2014-12-18 | 2018-11-05 | ClinicalTrials.gov |
| NCT02340819 | Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Teduglutide in J… | Phase3 | Short Bowel Syndrome | Completed | 2014-12-18 | 2018-11-05 | ClinicalTrials.gov |
| NCT02340819 | Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Teduglutide in J… | Phase3 | Short Bowel Syndrome | Completed | 2014-12-18 | 2018-11-05 | ClinicalTrials.gov |
| NCT02379091 | Dose Finding Study of Namilumab in Combination With Methotrexate in Participant… | Phase2 | Rheumatoid Arthritis | Completed | 2014-12-17 | 2016-12-05 | ClinicalTrials.gov |
| NCT02379091 | Dose Finding Study of Namilumab in Combination With Methotrexate in Participant… | Phase2 | Rheumatoid Arthritis | Completed | 2014-12-17 | 2016-12-05 | ClinicalTrials.gov |
| NCT02379091 | Dose Finding Study of Namilumab in Combination With Methotrexate in Participant… | Phase2 | Rheumatoid Arthritis | Completed | 2014-12-17 | 2016-12-05 | ClinicalTrials.gov |
| NCT02093663 | Safety and Efficacy of MMX Mesalamine/Mesalazine in Pediatric Subjects With Mil… | Phase3 | Ulcerative Colitis | Completed | 2014-12-12 | 2018-11-28 | ClinicalTrials.gov |
| NCT02093663 | Safety and Efficacy of MMX Mesalamine/Mesalazine in Pediatric Subjects With Mil… | Phase3 | Ulcerative Colitis | Completed | 2014-12-12 | 2018-11-28 | ClinicalTrials.gov |
| NCT02093663 | Safety and Efficacy of MMX Mesalamine/Mesalazine in Pediatric Subjects With Mil… | Phase3 | Ulcerative Colitis | Completed | 2014-12-12 | 2018-11-28 | ClinicalTrials.gov |
| NCT02302066 | Safety and Immunogenicity of Different Schedules of Takeda's Tetravalent Dengue… | Phase2 | Dengue Fever | Completed | 2014-12-05 | 2019-02-18 | ClinicalTrials.gov |
| NCT02302066 | Safety and Immunogenicity of Different Schedules of Takeda's Tetravalent Dengue… | Phase2 | Dengue Fever | Completed | 2014-12-05 | 2019-02-18 | ClinicalTrials.gov |
| NCT02302066 | Safety and Immunogenicity of Different Schedules of Takeda's Tetravalent Dengue… | Phase2 | Dengue Fever | Completed | 2014-12-05 | 2019-02-18 | ClinicalTrials.gov |
| NCT02228772 | Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acut… | Phase1 | Acute Lymphoblastic Leukemia | Completed | 2014-12-01 | 2019-11-01 | ClinicalTrials.gov |
| NCT02228772 | Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acut… | Phase1 | Acute Lymphoblastic Leukemia | Completed | 2014-12-01 | 2019-11-01 | ClinicalTrials.gov |
| NCT02391038 | MLN0264 in Previously Treated Asian Participants With Advanced Gastrointestinal… | Phase1 | Advanced Gastrointestinal Carcinoma | Terminated | 2014-12-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT02313155 | Phase 1/2 Study of TAK-850 Subcutaneous Injection in Healthy Adults | Phase1 | Influenza Infection | Completed | 2014-12-01 | 2015-01-01 | ClinicalTrials.gov |
| NCT02313155 | Phase 1/2 Study of TAK-850 Subcutaneous Injection in Healthy Adults | Phase1 | Influenza Infection | Completed | 2014-12-01 | 2015-01-01 | ClinicalTrials.gov |
| NCT02391038 | MLN0264 in Previously Treated Asian Participants With Advanced Gastrointestinal… | Phase1 | Advanced Gastrointestinal Carcinoma | Terminated | 2014-12-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT02391038 | MLN0264 in Previously Treated Asian Participants With Advanced Gastrointestinal… | Phase1 | Advanced Gastrointestinal Carcinoma | Terminated | 2014-12-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT02228772 | Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acut… | Phase1 | Acute Lymphoblastic Leukemia | Completed | 2014-12-01 | 2019-11-01 | ClinicalTrials.gov |
| NCT02313155 | Phase 1/2 Study of TAK-850 Subcutaneous Injection in Healthy Adults | Phase1 | Influenza Infection | Completed | 2014-12-01 | 2015-01-01 | ClinicalTrials.gov |
| NCT03625895 | Agrylin Drug Use-Result Survey | — | Essential Thrombocythemia (ET) | Completed | 2014-11-25 | 2021-03-11 | ClinicalTrials.gov |
| NCT03625895 | Agrylin Drug Use-Result Survey | — | Essential Thrombocythemia (ET) | Completed | 2014-11-25 | 2021-03-11 | ClinicalTrials.gov |
| NCT03625895 | Agrylin Drug Use-Result Survey | — | Essential Thrombocythemia (ET) | Completed | 2014-11-25 | 2021-03-11 | ClinicalTrials.gov |
| NCT01927913 | Treatment of Iron Overload Requiring Chelation Therapy | Phase2 | Transfusional Iron Overload | Withdrawn | 2014-11-20 | 2015-10-30 | ClinicalTrials.gov |
| NCT01927913 | Treatment of Iron Overload Requiring Chelation Therapy | Phase2 | Transfusional Iron Overload | Withdrawn | 2014-11-20 | 2015-10-30 | ClinicalTrials.gov |
| NCT01927913 | Treatment of Iron Overload Requiring Chelation Therapy | Phase2 | Transfusional Iron Overload | Withdrawn | 2014-11-20 | 2015-10-30 | ClinicalTrials.gov |
| NCT02243436 | Brentuximab Vedotin in Pre-transplant Induction and Consolidation for Relapsed … | Phase1 | CLASSICAL HODGKIN LYMPHOMA | Completed | 2014-11-11 | 2019-01-14 | ClinicalTrials.gov |
| NCT02243436 | Brentuximab Vedotin in Pre-transplant Induction and Consolidation for Relapsed … | Phase1 | CLASSICAL HODGKIN LYMPHOMA | Completed | 2014-11-11 | 2019-01-14 | ClinicalTrials.gov |
| NCT02243436 | Brentuximab Vedotin in Pre-transplant Induction and Consolidation for Relapsed … | Phase1 | CLASSICAL HODGKIN LYMPHOMA | Completed | 2014-11-11 | 2019-01-14 | ClinicalTrials.gov |
| NCT02277691 | A Phase III Long-term Study of TAK-536TCH in Participants With Essential Hypert… | Phase3 | Essential Hypertension | Completed | 2014-11-07 | 2016-04-25 | ClinicalTrials.gov |
| NCT02277691 | A Phase III Long-term Study of TAK-536TCH in Participants With Essential Hypert… | Phase3 | Essential Hypertension | Completed | 2014-11-07 | 2016-04-25 | ClinicalTrials.gov |
| NCT02277691 | A Phase III Long-term Study of TAK-536TCH in Participants With Essential Hypert… | Phase3 | Essential Hypertension | Completed | 2014-11-07 | 2016-04-25 | ClinicalTrials.gov |
| NCT02406144 | Trial Studying Maintenance Treatment With Lenalidomide and Dexamethasone Versus… | Phase3 | Multiple Myeloma | Completed | 2014-11-01 | 2017-11-01 | ClinicalTrials.gov |
| NCT02406144 | Trial Studying Maintenance Treatment With Lenalidomide and Dexamethasone Versus… | Phase3 | Multiple Myeloma | Completed | 2014-11-01 | 2017-11-01 | ClinicalTrials.gov |
| NCT02406144 | Trial Studying Maintenance Treatment With Lenalidomide and Dexamethasone Versus… | Phase3 | Multiple Myeloma | Completed | 2014-11-01 | 2017-11-01 | ClinicalTrials.gov |
| NCT02354599 | Single-Dose Study of MT203 | Phase1 | Healthy Volunteers | Completed | 2014-11-01 | 2015-05-01 | ClinicalTrials.gov |
| NCT02322606 | A Phase 1, Single and Multiple Dose Study of TAK-137 | Phase1 | Healthy Japanese Adult Male | Withdrawn | 2014-11-01 | 2015-05-01 | ClinicalTrials.gov |
| NCT02286518 | TAK-114 Single- and Multiple-Dose Phase 1 Study | Phase1 | Clinical Pharmacology | Completed | 2014-11-01 | 2015-04-01 | ClinicalTrials.gov |
| NCT02280785 | Brentuximab Vedotin for Relapsed/Refractory CD30-positive Non-Hodgkin Lymphomas | Phase2 | Non-Hodgkin Lymphoma | Completed | 2014-11-01 | 2018-09-01 | ClinicalTrials.gov |
| NCT02178579 | Prospective Observation of Cardiac Safety With Proteasome Inhibition | — | Heart Failure | Completed | 2014-11-01 | 2019-07-15 | ClinicalTrials.gov |
| NCT02178579 | Prospective Observation of Cardiac Safety With Proteasome Inhibition | — | Heart Failure | Completed | 2014-11-01 | 2019-07-15 | ClinicalTrials.gov |
| NCT02280785 | Brentuximab Vedotin for Relapsed/Refractory CD30-positive Non-Hodgkin Lymphomas | Phase2 | Non-Hodgkin Lymphoma | Completed | 2014-11-01 | 2018-09-01 | ClinicalTrials.gov |
| NCT02286518 | TAK-114 Single- and Multiple-Dose Phase 1 Study | Phase1 | Clinical Pharmacology | Completed | 2014-11-01 | 2015-04-01 | ClinicalTrials.gov |
| NCT02322606 | A Phase 1, Single and Multiple Dose Study of TAK-137 | Phase1 | Healthy Japanese Adult Male | Withdrawn | 2014-11-01 | 2015-05-01 | ClinicalTrials.gov |
| NCT02280785 | Brentuximab Vedotin for Relapsed/Refractory CD30-positive Non-Hodgkin Lymphomas | Phase2 | Non-Hodgkin Lymphoma | Completed | 2014-11-01 | 2018-09-01 | ClinicalTrials.gov |
| NCT02286518 | TAK-114 Single- and Multiple-Dose Phase 1 Study | Phase1 | Clinical Pharmacology | Completed | 2014-11-01 | 2015-04-01 | ClinicalTrials.gov |
| NCT02178579 | Prospective Observation of Cardiac Safety With Proteasome Inhibition | — | Heart Failure | Completed | 2014-11-01 | 2019-07-15 | ClinicalTrials.gov |
| NCT02354599 | Single-Dose Study of MT203 | Phase1 | Healthy Volunteers | Completed | 2014-11-01 | 2015-05-01 | ClinicalTrials.gov |
| NCT02322606 | A Phase 1, Single and Multiple Dose Study of TAK-137 | Phase1 | Healthy Japanese Adult Male | Withdrawn | 2014-11-01 | 2015-05-01 | ClinicalTrials.gov |
| NCT02354599 | Single-Dose Study of MT203 | Phase1 | Healthy Volunteers | Completed | 2014-11-01 | 2015-05-01 | ClinicalTrials.gov |
| NCT02259010 | A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alise… | Phase1 | Advanced Solid Tumors | Completed | 2014-10-22 | 2016-10-21 | ClinicalTrials.gov |
| NCT02259010 | A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alise… | Phase1 | Advanced Solid Tumors | Completed | 2014-10-22 | 2016-10-21 | ClinicalTrials.gov |
| NCT02259010 | A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alise… | Phase1 | Advanced Solid Tumors | Completed | 2014-10-22 | 2016-10-21 | ClinicalTrials.gov |
| NCT02285166 | Specified Drug-use Survey of the Granular Capsule Formulation of Omega-3 Fatty … | — | Hyperlipidemia | Completed | 2014-10-21 | 2020-07-14 | ClinicalTrials.gov |
| NCT02285166 | Specified Drug-use Survey of the Granular Capsule Formulation of Omega-3 Fatty … | — | Hyperlipidemia | Completed | 2014-10-21 | 2020-07-14 | ClinicalTrials.gov |
| NCT02285166 | Specified Drug-use Survey of the Granular Capsule Formulation of Omega-3 Fatty … | — | Hyperlipidemia | Completed | 2014-10-21 | 2020-07-14 | ClinicalTrials.gov |
| NCT02337946 | Safety and Efficacy Study of mFOLFOX6 + Panitumumab Combination Therapy and 5-F… | Phase2 | Colorectal Carcinoma | Completed | 2014-10-16 | 2017-08-31 | ClinicalTrials.gov |
| NCT02337946 | Safety and Efficacy Study of mFOLFOX6 + Panitumumab Combination Therapy and 5-F… | Phase2 | Colorectal Carcinoma | Completed | 2014-10-16 | 2017-08-31 | ClinicalTrials.gov |
| NCT02332824 | A Phase 2 Dose-finding Study of TAK-272 in Participants With Type 2 Diabetes Me… | Phase2 | Type 2 Diabetes Mellitus and Microalbuminuria | Completed | 2014-10-16 | 2016-08-18 | ClinicalTrials.gov |
| NCT02337946 | Safety and Efficacy Study of mFOLFOX6 + Panitumumab Combination Therapy and 5-F… | Phase2 | Colorectal Carcinoma | Completed | 2014-10-16 | 2017-08-31 | ClinicalTrials.gov |
| NCT02332824 | A Phase 2 Dose-finding Study of TAK-272 in Participants With Type 2 Diabetes Me… | Phase2 | Type 2 Diabetes Mellitus and Microalbuminuria | Completed | 2014-10-16 | 2016-08-18 | ClinicalTrials.gov |
| NCT02332824 | A Phase 2 Dose-finding Study of TAK-272 in Participants With Type 2 Diabetes Me… | Phase2 | Type 2 Diabetes Mellitus and Microalbuminuria | Completed | 2014-10-16 | 2016-08-18 | ClinicalTrials.gov |
| NCT02467855 | Epidemiological Study in Thai Participants With Hypertension | — | Hypertension | Completed | 2014-10-01 | 2015-08-01 | ClinicalTrials.gov |
| NCT02467855 | Epidemiological Study in Thai Participants With Hypertension | — | Hypertension | Completed | 2014-10-01 | 2015-08-01 | ClinicalTrials.gov |
| NCT02467855 | Epidemiological Study in Thai Participants With Hypertension | — | Hypertension | Completed | 2014-10-01 | 2015-08-01 | ClinicalTrials.gov |
| NCT03625882 | Survey Study for Velaglucerase Alfa (VPRIV) in Japan | — | Gaucher Disease | Completed | 2014-09-02 | 2024-05-14 | ClinicalTrials.gov |
| NCT03625882 | Survey Study for Velaglucerase Alfa (VPRIV) in Japan | — | Gaucher Disease | Completed | 2014-09-02 | 2024-05-14 | ClinicalTrials.gov |
| NCT03625882 | Survey Study for Velaglucerase Alfa (VPRIV) in Japan | — | Gaucher Disease | Completed | 2014-09-02 | 2024-05-14 | ClinicalTrials.gov |
| NCT02206425 | Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma P… | Phase1 | Multiple Myeloma | Completed | 2014-09-01 | 2018-03-06 | ClinicalTrials.gov |
| NCT02168101 | Determining the Feasibility of MLN9708 as Maintenance After Allogeneic Stem Cel… | Phase2 | Multiple Myeloma | Completed | 2014-09-01 | 2019-02-01 | ClinicalTrials.gov |
| NCT02206425 | Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma P… | Phase1 | Multiple Myeloma | Completed | 2014-09-01 | 2018-03-06 | ClinicalTrials.gov |
| NCT02252354 | TAK-385 Phase I Absorption, Distribution, Metabolism, Excretion and Absolute Bi… | Phase1 | Healthy Volunteers | Completed | 2014-09-01 | 2014-10-01 | ClinicalTrials.gov |
| NCT02231021 | The Practical Evidence of Antidiabetic Combination Therapy in Korea | Phase4 | Type 2 Diabetes Mellitus | Completed | 2014-09-01 | 2019-01-28 | ClinicalTrials.gov |
| NCT02168101 | Determining the Feasibility of MLN9708 as Maintenance After Allogeneic Stem Cel… | Phase2 | Multiple Myeloma | Completed | 2014-09-01 | 2019-02-01 | ClinicalTrials.gov |
| NCT02246647 | Biomarkers for Intestinal Permeability in Patients With Constipation | — | Intestinal Diseases | Completed | 2014-09-01 | 2016-12-08 | ClinicalTrials.gov |
| NCT02246647 | Biomarkers for Intestinal Permeability in Patients With Constipation | — | Intestinal Diseases | Completed | 2014-09-01 | 2016-12-08 | ClinicalTrials.gov |
| NCT02246647 | Biomarkers for Intestinal Permeability in Patients With Constipation | — | Intestinal Diseases | Completed | 2014-09-01 | 2016-12-08 | ClinicalTrials.gov |
| NCT02252354 | TAK-385 Phase I Absorption, Distribution, Metabolism, Excretion and Absolute Bi… | Phase1 | Healthy Volunteers | Completed | 2014-09-01 | 2014-10-01 | ClinicalTrials.gov |
| NCT02231021 | The Practical Evidence of Antidiabetic Combination Therapy in Korea | Phase4 | Type 2 Diabetes Mellitus | Completed | 2014-09-01 | 2019-01-28 | ClinicalTrials.gov |
| NCT02252354 | TAK-385 Phase I Absorption, Distribution, Metabolism, Excretion and Absolute Bi… | Phase1 | Healthy Volunteers | Completed | 2014-09-01 | 2014-10-01 | ClinicalTrials.gov |
| NCT02231021 | The Practical Evidence of Antidiabetic Combination Therapy in Korea | Phase4 | Type 2 Diabetes Mellitus | Completed | 2014-09-01 | 2019-01-28 | ClinicalTrials.gov |
| NCT02168101 | Determining the Feasibility of MLN9708 as Maintenance After Allogeneic Stem Cel… | Phase2 | Multiple Myeloma | Completed | 2014-09-01 | 2019-02-01 | ClinicalTrials.gov |
| NCT02206425 | Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma P… | Phase1 | Multiple Myeloma | Completed | 2014-09-01 | 2018-03-06 | ClinicalTrials.gov |
| NCT02214147 | Pharmacokinetics of Alisertib in Adults With Advanced Solid Tumors or Relapsed/… | Phase1 | Advanced Solid Tumors | Completed | 2014-08-21 | 2016-07-18 | ClinicalTrials.gov |
| NCT02214147 | Pharmacokinetics of Alisertib in Adults With Advanced Solid Tumors or Relapsed/… | Phase1 | Advanced Solid Tumors | Completed | 2014-08-21 | 2016-07-18 | ClinicalTrials.gov |
| NCT02214147 | Pharmacokinetics of Alisertib in Adults With Advanced Solid Tumors or Relapsed/… | Phase1 | Advanced Solid Tumors | Completed | 2014-08-21 | 2016-07-18 | ClinicalTrials.gov |
| NCT02193087 | Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue … | Phase2 | Dengue Fever | Completed | 2014-08-06 | 2015-05-19 | ClinicalTrials.gov |
| NCT02193087 | Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue … | Phase2 | Dengue Fever | Completed | 2014-08-06 | 2015-05-19 | ClinicalTrials.gov |
| NCT02193087 | Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue … | Phase2 | Dengue Fever | Completed | 2014-08-06 | 2015-05-19 | ClinicalTrials.gov |
| NCT02202759 | A Study of MLN0264 in Participants With Cancer of the Stomach or Gastroesophage… | Phase2 | Adenocarcinoma of the Stomach | Terminated | 2014-08-04 | 2016-01-15 | ClinicalTrials.gov |
| NCT02202759 | A Study of MLN0264 in Participants With Cancer of the Stomach or Gastroesophage… | Phase2 | Adenocarcinoma of the Stomach | Terminated | 2014-08-04 | 2016-01-15 | ClinicalTrials.gov |
| NCT02202759 | A Study of MLN0264 in Participants With Cancer of the Stomach or Gastroesophage… | Phase2 | Adenocarcinoma of the Stomach | Terminated | 2014-08-04 | 2016-01-15 | ClinicalTrials.gov |
| NCT02684396 | Phase 1, TAK-648, Single-Rising Dose Study | Phase1 | Healthy Volunteers | Completed | 2014-08-01 | 2015-07-01 | ClinicalTrials.gov |
| NCT02684396 | Phase 1, TAK-648, Single-Rising Dose Study | Phase1 | Healthy Volunteers | Completed | 2014-08-01 | 2015-07-01 | ClinicalTrials.gov |
| NCT02219256 | A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of TAK… | Phase1 | Autoimmune Disease | Completed | 2014-08-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT02684396 | Phase 1, TAK-648, Single-Rising Dose Study | Phase1 | Healthy Volunteers | Completed | 2014-08-01 | 2015-07-01 | ClinicalTrials.gov |
| NCT02219256 | A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of TAK… | Phase1 | Autoimmune Disease | Completed | 2014-08-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT02219256 | A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of TAK… | Phase1 | Autoimmune Disease | Completed | 2014-08-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT02204579 | A Study to Determine the Effects of NPSP795 on the Calcium-sensing Receptor in … | Phase2 | Autosomal Dominant Hypocalcemia (ADH) | Completed | 2014-07-18 | 2015-05-04 | ClinicalTrials.gov |
| NCT02204579 | A Study to Determine the Effects of NPSP795 on the Calcium-sensing Receptor in … | Phase2 | Autosomal Dominant Hypocalcemia (ADH) | Completed | 2014-07-18 | 2015-05-04 | ClinicalTrials.gov |
| NCT02204579 | A Study to Determine the Effects of NPSP795 on the Calcium-sensing Receptor in … | Phase2 | Autosomal Dominant Hypocalcemia (ADH) | Completed | 2014-07-18 | 2015-05-04 | ClinicalTrials.gov |
| NCT02181413 | A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants … | Phase3 | Multiple Myeloma | Completed | 2014-07-16 | 2023-09-08 | ClinicalTrials.gov |
| NCT02181413 | A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants … | Phase3 | Multiple Myeloma | Completed | 2014-07-16 | 2023-09-08 | ClinicalTrials.gov |
| NCT02181413 | A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants … | Phase3 | Multiple Myeloma | Completed | 2014-07-16 | 2023-09-08 | ClinicalTrials.gov |
| NCT02169791 | Nonmyeloablative Haploidentical Transplant Followed by MLN9708 | Phase2 | Acute Leukemia | Completed | 2014-07-15 | 2020-07-28 | ClinicalTrials.gov |
| NCT02169791 | Nonmyeloablative Haploidentical Transplant Followed by MLN9708 | Phase2 | Acute Leukemia | Completed | 2014-07-15 | 2020-07-28 | ClinicalTrials.gov |
| NCT02169791 | Nonmyeloablative Haploidentical Transplant Followed by MLN9708 | Phase2 | Acute Leukemia | Completed | 2014-07-15 | 2020-07-28 | ClinicalTrials.gov |
| NCT02202785 | A Study of MLN0264 in Patients With Pancreatic Cancer | Phase2 | Pancreatic Adenocarcinoma | Terminated | 2014-07-02 | 2016-01-15 | ClinicalTrials.gov |
| NCT02202785 | A Study of MLN0264 in Patients With Pancreatic Cancer | Phase2 | Pancreatic Adenocarcinoma | Terminated | 2014-07-02 | 2016-01-15 | ClinicalTrials.gov |
| NCT02202785 | A Study of MLN0264 in Patients With Pancreatic Cancer | Phase2 | Pancreatic Adenocarcinoma | Terminated | 2014-07-02 | 2016-01-15 | ClinicalTrials.gov |
| NCT02201056 | Safety, Tolerability, and Pharmacokinetics of Escalating Single Doses of TAK-935 | Phase1 | Healthy Volunteers | Completed | 2014-07-01 | 2015-07-01 | ClinicalTrials.gov |
| NCT02201056 | Safety, Tolerability, and Pharmacokinetics of Escalating Single Doses of TAK-935 | Phase1 | Healthy Volunteers | Completed | 2014-07-01 | 2015-07-01 | ClinicalTrials.gov |
| NCT02162758 | Effect of Dexlansoprazole 60 mg QD and 60 mg BID on Recurrence of Intestinal Me… | Phase2 | Barrett's Esophagus | Terminated | 2014-07-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT02170220 | Pharmacokinetics, Safety and Tolerability of Vortioxetine in Normal Hepatic Fun… | Phase1 | Severe Hepatic Impairment | Completed | 2014-07-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT02162758 | Effect of Dexlansoprazole 60 mg QD and 60 mg BID on Recurrence of Intestinal Me… | Phase2 | Barrett's Esophagus | Terminated | 2014-07-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT02170220 | Pharmacokinetics, Safety and Tolerability of Vortioxetine in Normal Hepatic Fun… | Phase1 | Severe Hepatic Impairment | Completed | 2014-07-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT02162758 | Effect of Dexlansoprazole 60 mg QD and 60 mg BID on Recurrence of Intestinal Me… | Phase2 | Barrett's Esophagus | Terminated | 2014-07-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT02203916 | Azilsartan Medoxomil (TAK-491) Compared to Placebo in Korean Adults With Hypert… | Phase3 | Hypertension | Completed | 2014-07-01 | 2016-02-01 | ClinicalTrials.gov |
| NCT02203916 | Azilsartan Medoxomil (TAK-491) Compared to Placebo in Korean Adults With Hypert… | Phase3 | Hypertension | Completed | 2014-07-01 | 2016-02-01 | ClinicalTrials.gov |
| NCT02209506 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MLN3126 in Heal… | Phase1 | Safety | Terminated | 2014-07-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT02201056 | Safety, Tolerability, and Pharmacokinetics of Escalating Single Doses of TAK-935 | Phase1 | Healthy Volunteers | Completed | 2014-07-01 | 2015-07-01 | ClinicalTrials.gov |
| NCT02203916 | Azilsartan Medoxomil (TAK-491) Compared to Placebo in Korean Adults With Hypert… | Phase3 | Hypertension | Completed | 2014-07-01 | 2016-02-01 | ClinicalTrials.gov |
| NCT02209506 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MLN3126 in Heal… | Phase1 | Safety | Terminated | 2014-07-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT02170220 | Pharmacokinetics, Safety and Tolerability of Vortioxetine in Normal Hepatic Fun… | Phase1 | Severe Hepatic Impairment | Completed | 2014-07-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT02209506 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MLN3126 in Heal… | Phase1 | Safety | Terminated | 2014-07-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT02221284 | Alogliptin Tablets Specified Drug-use Survey "Type 2 Diabetic Patients Receivin… | — | Type 2 Diabetes Mellitus | Completed | 2014-06-30 | 2017-06-30 | ClinicalTrials.gov |
| NCT02221284 | Alogliptin Tablets Specified Drug-use Survey "Type 2 Diabetic Patients Receivin… | — | Type 2 Diabetes Mellitus | Completed | 2014-06-30 | 2017-06-30 | ClinicalTrials.gov |
| NCT02221284 | Alogliptin Tablets Specified Drug-use Survey "Type 2 Diabetic Patients Receivin… | — | Type 2 Diabetes Mellitus | Completed | 2014-06-30 | 2017-06-30 | ClinicalTrials.gov |
| NCT02042989 | MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies | Phase1 | Advanced Cancers | Completed | 2014-06-27 | 2020-01-22 | ClinicalTrials.gov |
| NCT02042989 | MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies | Phase1 | Advanced Cancers | Completed | 2014-06-27 | 2020-01-22 | ClinicalTrials.gov |
| NCT02042989 | MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies | Phase1 | Advanced Cancers | Completed | 2014-06-27 | 2020-01-22 | ClinicalTrials.gov |
| NCT02181816 | Azilsartan/Amlodipine Combination Tablets LD & HD Specified Drug-use Survey "Lo… | — | Hypertension | Completed | 2014-06-26 | 2017-01-31 | ClinicalTrials.gov |
| NCT02181816 | Azilsartan/Amlodipine Combination Tablets LD & HD Specified Drug-use Survey "Lo… | — | Hypertension | Completed | 2014-06-26 | 2017-01-31 | ClinicalTrials.gov |
| NCT02181816 | Azilsartan/Amlodipine Combination Tablets LD & HD Specified Drug-use Survey "Lo… | — | Hypertension | Completed | 2014-06-26 | 2017-01-31 | ClinicalTrials.gov |
| NCT02178969 | Short Term Observational Study in DEB Patients | — | Dystrophic Epidermolysis Bullosa | Completed | 2014-06-24 | 2015-02-23 | ClinicalTrials.gov |
| NCT02178969 | Short Term Observational Study in DEB Patients | — | Dystrophic Epidermolysis Bullosa | Completed | 2014-06-24 | 2015-02-23 | ClinicalTrials.gov |
| NCT02178969 | Short Term Observational Study in DEB Patients | — | Dystrophic Epidermolysis Bullosa | Completed | 2014-06-24 | 2015-02-23 | ClinicalTrials.gov |
| NCT01990040 | Registry for Participants With Short Bowel Syndrome | — | Short Bowel Syndrome | Active_Not_Recruiting | 2014-06-23 | 2032-06-30 | ClinicalTrials.gov |
| NCT01990040 | Registry for Participants With Short Bowel Syndrome | — | Short Bowel Syndrome | Active_Not_Recruiting | 2014-06-23 | 2032-06-30 | ClinicalTrials.gov |
| NCT01990040 | Registry for Participants With Short Bowel Syndrome | — | Short Bowel Syndrome | Active_Not_Recruiting | 2014-06-23 | 2032-06-30 | ClinicalTrials.gov |
| NCT02134210 | Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque P… | Phase3 | Plaque Psoriasis | Completed | 2014-06-16 | 2016-05-12 | ClinicalTrials.gov |
| NCT02134210 | Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque P… | Phase3 | Plaque Psoriasis | Completed | 2014-06-16 | 2016-05-12 | ClinicalTrials.gov |
| NCT02134210 | Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque P… | Phase3 | Plaque Psoriasis | Completed | 2014-06-16 | 2016-05-12 | ClinicalTrials.gov |
| NCT02176486 | Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Ixazomib … | Phase1 | Lupus Nephritis | Terminated | 2014-06-09 | 2018-01-19 | ClinicalTrials.gov |
| NCT02176486 | Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Ixazomib … | Phase1 | Lupus Nephritis | Terminated | 2014-06-09 | 2018-01-19 | ClinicalTrials.gov |
| NCT02176486 | Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Ixazomib … | Phase1 | Lupus Nephritis | Terminated | 2014-06-09 | 2018-01-19 | ClinicalTrials.gov |
| NCT02125292 | Taste Assessment Study of SHP429 in Healthy Adult Subjects | Phase1 | Healthy | Completed | 2014-06-02 | 2014-06-19 | ClinicalTrials.gov |
| NCT02125292 | Taste Assessment Study of SHP429 in Healthy Adult Subjects | Phase1 | Healthy | Completed | 2014-06-02 | 2014-06-19 | ClinicalTrials.gov |
| NCT02125292 | Taste Assessment Study of SHP429 in Healthy Adult Subjects | Phase1 | Healthy | Completed | 2014-06-02 | 2014-06-19 | ClinicalTrials.gov |
| NCT02163915 | Safety, Tolerability, and Pharmacokinetics of Multiple Rising Doses of TAK-137 … | Phase1 | Attention-Deficit/Hyperactivity Disorder | Terminated | 2014-06-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT02079805 | A Study to Explore the Effects of Azilsartan Compared to Telmisartan on Insulin… | Phase4 | Essential Hypertension Complicated by Type 2 Diabetes Mellitus | Completed | 2014-06-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT02129777 | Efficacy and Safety of Namilumab (MT203) for Plaque Psoriasis | Phase2 | Plaque Psoriasis | Completed | 2014-06-01 | 2016-02-01 | ClinicalTrials.gov |
| NCT02153099 | Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of ENV8058… | Phase1 | Dose Finding Study | Completed | 2014-06-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT02163915 | Safety, Tolerability, and Pharmacokinetics of Multiple Rising Doses of TAK-137 … | Phase1 | Attention-Deficit/Hyperactivity Disorder | Terminated | 2014-06-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT02276274 | Effect of Food on the Pharmacokinetics of Single Oral Dose Administration of a … | Phase3 | Clinical Pharmacology | Completed | 2014-06-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT02163421 | Bioavailability and Pharmacokinetics of Vedolizumab in Healthy Participants Fol… | Phase1 | Healthy | Completed | 2014-06-01 | 2015-01-01 | ClinicalTrials.gov |
| NCT02163915 | Safety, Tolerability, and Pharmacokinetics of Multiple Rising Doses of TAK-137 … | Phase1 | Attention-Deficit/Hyperactivity Disorder | Terminated | 2014-06-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT02153099 | Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of ENV8058… | Phase1 | Dose Finding Study | Completed | 2014-06-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT02054793 | Phase Ib/II Study Evaluating Orteronel (Without Prednisone) Combined With Itrac… | Phase1 | Prostate Cancer | Withdrawn | 2014-06-01 | 2016-07-01 | ClinicalTrials.gov |
| NCT02135445 | Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer | Phase2 | Prostate Cancer | Completed | 2014-06-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT02276274 | Effect of Food on the Pharmacokinetics of Single Oral Dose Administration of a … | Phase3 | Clinical Pharmacology | Completed | 2014-06-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT02129777 | Efficacy and Safety of Namilumab (MT203) for Plaque Psoriasis | Phase2 | Plaque Psoriasis | Completed | 2014-06-01 | 2016-02-01 | ClinicalTrials.gov |
| NCT02135445 | Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer | Phase2 | Prostate Cancer | Completed | 2014-06-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT02129777 | Efficacy and Safety of Namilumab (MT203) for Plaque Psoriasis | Phase2 | Plaque Psoriasis | Completed | 2014-06-01 | 2016-02-01 | ClinicalTrials.gov |
| NCT02101684 | Orteronel (TAK-700) in Metastatic or Advanced Non-resectable Granulosa Cell Ova… | Phase2 | Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors | Terminated | 2014-06-01 | 2017-01-11 | ClinicalTrials.gov |
| NCT02101684 | Orteronel (TAK-700) in Metastatic or Advanced Non-resectable Granulosa Cell Ova… | Phase2 | Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors | Terminated | 2014-06-01 | 2017-01-11 | ClinicalTrials.gov |
| NCT02153099 | Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of ENV8058… | Phase1 | Dose Finding Study | Completed | 2014-06-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT02276274 | Effect of Food on the Pharmacokinetics of Single Oral Dose Administration of a … | Phase3 | Clinical Pharmacology | Completed | 2014-06-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT02079805 | A Study to Explore the Effects of Azilsartan Compared to Telmisartan on Insulin… | Phase4 | Essential Hypertension Complicated by Type 2 Diabetes Mellitus | Completed | 2014-06-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT02054793 | Phase Ib/II Study Evaluating Orteronel (Without Prednisone) Combined With Itrac… | Phase1 | Prostate Cancer | Withdrawn | 2014-06-01 | 2016-07-01 | ClinicalTrials.gov |
| NCT02101684 | Orteronel (TAK-700) in Metastatic or Advanced Non-resectable Granulosa Cell Ova… | Phase2 | Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors | Terminated | 2014-06-01 | 2017-01-11 | ClinicalTrials.gov |
| NCT02079805 | A Study to Explore the Effects of Azilsartan Compared to Telmisartan on Insulin… | Phase4 | Essential Hypertension Complicated by Type 2 Diabetes Mellitus | Completed | 2014-06-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT02135445 | Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer | Phase2 | Prostate Cancer | Completed | 2014-06-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT02054793 | Phase Ib/II Study Evaluating Orteronel (Without Prednisone) Combined With Itrac… | Phase1 | Prostate Cancer | Withdrawn | 2014-06-01 | 2016-07-01 | ClinicalTrials.gov |
| NCT02163421 | Bioavailability and Pharmacokinetics of Vedolizumab in Healthy Participants Fol… | Phase1 | Healthy | Completed | 2014-06-01 | 2015-01-01 | ClinicalTrials.gov |
| NCT02163421 | Bioavailability and Pharmacokinetics of Vedolizumab in Healthy Participants Fol… | Phase1 | Healthy | Completed | 2014-06-01 | 2015-01-01 | ClinicalTrials.gov |
| NCT02095015 | Mucopolysaccharidosis (MPS) I, II, and VI Screening in a High-Risk Population W… | — | Mucopolysaccharidosis (MPS) | Terminated | 2014-05-21 | 2015-08-14 | ClinicalTrials.gov |
| NCT02095015 | Mucopolysaccharidosis (MPS) I, II, and VI Screening in a High-Risk Population W… | — | Mucopolysaccharidosis (MPS) | Terminated | 2014-05-21 | 2015-08-14 | ClinicalTrials.gov |
| NCT02095015 | Mucopolysaccharidosis (MPS) I, II, and VI Screening in a High-Risk Population W… | — | Mucopolysaccharidosis (MPS) | Terminated | 2014-05-21 | 2015-08-14 | ClinicalTrials.gov |
| NCT02142504 | Safety and Immunogenicity of Norovirus Bivalent Virus-Like Particle Vaccine in … | Phase2 | Norovirus Prevention | Completed | 2014-05-15 | 2016-01-06 | ClinicalTrials.gov |
| NCT02142504 | Safety and Immunogenicity of Norovirus Bivalent Virus-Like Particle Vaccine in … | Phase2 | Norovirus Prevention | Completed | 2014-05-15 | 2016-01-06 | ClinicalTrials.gov |
| NCT02142504 | Safety and Immunogenicity of Norovirus Bivalent Virus-Like Particle Vaccine in … | Phase2 | Norovirus Prevention | Completed | 2014-05-15 | 2016-01-06 | ClinicalTrials.gov |
| NCT02114229 | Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors | Phase2 | Malignant Rhabdoid Tumor | Active_Not_Recruiting | 2014-05-14 | 2027-09-01 | ClinicalTrials.gov |
| NCT02093923 | A Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability an… | Phase1 | Hereditary Angioedema (HAE) | Completed | 2014-05-14 | 2015-05-18 | ClinicalTrials.gov |
| NCT02114229 | Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors | Phase2 | Malignant Rhabdoid Tumor | Active_Not_Recruiting | 2014-05-14 | 2027-09-01 | ClinicalTrials.gov |
| NCT02093923 | A Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability an… | Phase1 | Hereditary Angioedema (HAE) | Completed | 2014-05-14 | 2015-05-18 | ClinicalTrials.gov |
| NCT02093923 | A Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability an… | Phase1 | Hereditary Angioedema (HAE) | Completed | 2014-05-14 | 2015-05-18 | ClinicalTrials.gov |
| NCT02114229 | Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors | Phase2 | Malignant Rhabdoid Tumor | Active_Not_Recruiting | 2014-05-14 | 2027-09-01 | ClinicalTrials.gov |
| NCT02038647 | Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Plac… | Phase2 | Small Cell Lung Cancer | Completed | 2014-05-12 | 2017-07-10 | ClinicalTrials.gov |
| NCT02038647 | Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Plac… | Phase2 | Small Cell Lung Cancer | Completed | 2014-05-12 | 2017-07-10 | ClinicalTrials.gov |
| NCT02038647 | Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Plac… | Phase2 | Small Cell Lung Cancer | Completed | 2014-05-12 | 2017-07-10 | ClinicalTrials.gov |
| NCT02049814 | Efficacy and Safety of Voglibose Compared With Acarbose in Participants With Ty… | Phase4 | Type 2 Diabetes Mellitus | Completed | 2014-05-09 | 2016-06-28 | ClinicalTrials.gov |
| NCT02049814 | Efficacy and Safety of Voglibose Compared With Acarbose in Participants With Ty… | Phase4 | Type 2 Diabetes Mellitus | Completed | 2014-05-09 | 2016-06-28 | ClinicalTrials.gov |
| NCT02049814 | Efficacy and Safety of Voglibose Compared With Acarbose in Participants With Ty… | Phase4 | Type 2 Diabetes Mellitus | Completed | 2014-05-09 | 2016-06-28 | ClinicalTrials.gov |
| NCT02280993 | Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Sal… | Phase1 | Hodgkin Lymphoma | Unknown | 2014-05-01 | 2020-05-01 | ClinicalTrials.gov |
| NCT02141659 | A Study of TAK-385 in Hormone Treatment-naïve Participants With Prostate Cancer | Phase1 | Hormone Treatment-naïve Participants With Prostate Cancer | Completed | 2014-05-01 | 2017-04-20 | ClinicalTrials.gov |
| NCT02141659 | A Study of TAK-385 in Hormone Treatment-naïve Participants With Prostate Cancer | Phase1 | Hormone Treatment-naïve Participants With Prostate Cancer | Completed | 2014-05-01 | 2017-04-20 | ClinicalTrials.gov |
| NCT02128490 | Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Par… | Phase2 | Gout | Completed | 2014-05-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT02128490 | Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Par… | Phase2 | Gout | Completed | 2014-05-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT02141659 | A Study of TAK-385 in Hormone Treatment-naïve Participants With Prostate Cancer | Phase1 | Hormone Treatment-naïve Participants With Prostate Cancer | Completed | 2014-05-01 | 2017-04-20 | ClinicalTrials.gov |
| NCT02128490 | Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Par… | Phase2 | Gout | Completed | 2014-05-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT02280993 | Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Sal… | Phase1 | Hodgkin Lymphoma | Unknown | 2014-05-01 | 2020-05-01 | ClinicalTrials.gov |
| NCT02280993 | Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Sal… | Phase1 | Hodgkin Lymphoma | Unknown | 2014-05-01 | 2020-05-01 | ClinicalTrials.gov |
| NCT04980040 | A Study for Post-Marketing Surveillance of Nesina® Tablet Monotherapy or Combin… | — | Type 2 Diabetes Mellitus | Completed | 2014-04-19 | 2019-08-30 | ClinicalTrials.gov |
| NCT04980040 | A Study for Post-Marketing Surveillance of Nesina® Tablet Monotherapy or Combin… | — | Type 2 Diabetes Mellitus | Completed | 2014-04-19 | 2019-08-30 | ClinicalTrials.gov |
| NCT04980040 | A Study for Post-Marketing Surveillance of Nesina® Tablet Monotherapy or Combin… | — | Type 2 Diabetes Mellitus | Completed | 2014-04-19 | 2019-08-30 | ClinicalTrials.gov |
| NCT02139592 | Brentuximab Vedotin (Recombinant) for IV Infusion - Special Drug Use Surveillan… | — | Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma | Completed | 2014-04-17 | 2017-06-30 | ClinicalTrials.gov |
| NCT02139592 | Brentuximab Vedotin (Recombinant) for IV Infusion - Special Drug Use Surveillan… | — | Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma | Completed | 2014-04-17 | 2017-06-30 | ClinicalTrials.gov |
| NCT02139592 | Brentuximab Vedotin (Recombinant) for IV Infusion - Special Drug Use Surveillan… | — | Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma | Completed | 2014-04-17 | 2017-06-30 | ClinicalTrials.gov |
| NCT02913508 | Vedolizumab Subcutaneous (SC) Versus Intravenous (IV) in Ulcerative Colitis or … | Phase2 | Ulcerative Colitis | Withdrawn | 2014-04-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT02122770 | Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharma… | Phase1 | Advanced Solid Tumors | Completed | 2014-04-01 | 2017-06-05 | ClinicalTrials.gov |
| NCT02913508 | Vedolizumab Subcutaneous (SC) Versus Intravenous (IV) in Ulcerative Colitis or … | Phase2 | Ulcerative Colitis | Withdrawn | 2014-04-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT02122770 | Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharma… | Phase1 | Advanced Solid Tumors | Completed | 2014-04-01 | 2017-06-05 | ClinicalTrials.gov |
| NCT02139046 | Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Par… | Phase3 | Gout | Completed | 2014-04-01 | 2015-11-01 | ClinicalTrials.gov |
| NCT02346344 | Outpatient Characterization of the Variability of Insulin Secretory Parameters … | — | Type 2 Diabetes | Completed | 2014-04-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT02139046 | Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Par… | Phase3 | Gout | Completed | 2014-04-01 | 2015-11-01 | ClinicalTrials.gov |
| NCT02122770 | Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharma… | Phase1 | Advanced Solid Tumors | Completed | 2014-04-01 | 2017-06-05 | ClinicalTrials.gov |
| NCT02913508 | Vedolizumab Subcutaneous (SC) Versus Intravenous (IV) in Ulcerative Colitis or … | Phase2 | Ulcerative Colitis | Withdrawn | 2014-04-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT02139046 | Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Par… | Phase3 | Gout | Completed | 2014-04-01 | 2015-11-01 | ClinicalTrials.gov |
| NCT02346344 | Outpatient Characterization of the Variability of Insulin Secretory Parameters … | — | Type 2 Diabetes | Completed | 2014-04-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT02346344 | Outpatient Characterization of the Variability of Insulin Secretory Parameters … | — | Type 2 Diabetes | Completed | 2014-04-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT02038907 | Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent VLP Vaccine | Phase2 | Healthy Volunteers | Completed | 2014-03-28 | 2015-06-19 | ClinicalTrials.gov |
| NCT02038907 | Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent VLP Vaccine | Phase2 | Healthy Volunteers | Completed | 2014-03-28 | 2015-06-19 | ClinicalTrials.gov |
| NCT02038907 | Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent VLP Vaccine | Phase2 | Healthy Volunteers | Completed | 2014-03-28 | 2015-06-19 | ClinicalTrials.gov |
| NCT02083185 | A Phase 2 Study to Evaluate the Safety and Efficacy of TAK-385, Together With a… | Phase2 | Prostate Cancer | Completed | 2014-03-26 | 2017-02-23 | ClinicalTrials.gov |
| NCT02083185 | A Phase 2 Study to Evaluate the Safety and Efficacy of TAK-385, Together With a… | Phase2 | Prostate Cancer | Completed | 2014-03-26 | 2017-02-23 | ClinicalTrials.gov |
| NCT02083185 | A Phase 2 Study to Evaluate the Safety and Efficacy of TAK-385, Together With a… | Phase2 | Prostate Cancer | Completed | 2014-03-26 | 2017-02-23 | ClinicalTrials.gov |
| NCT02052141 | Safety and Efficacy Study of CINRYZE for Prevention of Angioedema Attacks in Ch… | Phase3 | Hereditary Angioedema (HAE) | Completed | 2014-03-20 | 2017-05-04 | ClinicalTrials.gov |
| NCT02052141 | Safety and Efficacy Study of CINRYZE for Prevention of Angioedema Attacks in Ch… | Phase3 | Hereditary Angioedema (HAE) | Completed | 2014-03-20 | 2017-05-04 | ClinicalTrials.gov |
| NCT02052141 | Safety and Efficacy Study of CINRYZE for Prevention of Angioedema Attacks in Ch… | Phase3 | Hereditary Angioedema (HAE) | Completed | 2014-03-20 | 2017-05-04 | ClinicalTrials.gov |
| NCT01953783 | Mass Balance, Pharmacokinetics and Metabolism Study of IXAZOMIB | Phase1 | Advanced Solid Tumors | Completed | 2014-03-19 | 2016-02-09 | ClinicalTrials.gov |
| NCT01953783 | Mass Balance, Pharmacokinetics and Metabolism Study of IXAZOMIB | Phase1 | Advanced Solid Tumors | Completed | 2014-03-19 | 2016-02-09 | ClinicalTrials.gov |
| NCT01953783 | Mass Balance, Pharmacokinetics and Metabolism Study of IXAZOMIB | Phase1 | Advanced Solid Tumors | Completed | 2014-03-19 | 2016-02-09 | ClinicalTrials.gov |
| NCT01990534 | A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodg… | Phase4 | Hodgkin Lymphoma | Completed | 2014-03-14 | 2020-03-12 | ClinicalTrials.gov |
| NCT01990534 | A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodg… | Phase4 | Hodgkin Lymphoma | Completed | 2014-03-14 | 2020-03-12 | ClinicalTrials.gov |
| NCT01990534 | A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodg… | Phase4 | Hodgkin Lymphoma | Completed | 2014-03-14 | 2020-03-12 | ClinicalTrials.gov |
| NCT02046070 | Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclo… | Phase2 | Multiple Myeloma | Completed | 2014-03-05 | 2018-06-29 | ClinicalTrials.gov |
| NCT02046070 | Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclo… | Phase2 | Multiple Myeloma | Completed | 2014-03-05 | 2018-06-29 | ClinicalTrials.gov |
| NCT02046070 | Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclo… | Phase2 | Multiple Myeloma | Completed | 2014-03-05 | 2018-06-29 | ClinicalTrials.gov |
| NCT02100319 | Azilsaltan Tablets (Azilva Tablets) Special Drug Use Surveillance "Hypertension… | — | Hypertension | Completed | 2014-03-03 | 2016-02-29 | ClinicalTrials.gov |
| NCT02100319 | Azilsaltan Tablets (Azilva Tablets) Special Drug Use Surveillance "Hypertension… | — | Hypertension | Completed | 2014-03-03 | 2016-02-29 | ClinicalTrials.gov |
| NCT02100319 | Azilsaltan Tablets (Azilva Tablets) Special Drug Use Surveillance "Hypertension… | — | Hypertension | Completed | 2014-03-03 | 2016-02-29 | ClinicalTrials.gov |
| NCT02091531 | Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (C… | Phase2 | Metastatic Castration-Resistant Prostate Cancer | Completed | 2014-03-01 | 2018-10-01 | ClinicalTrials.gov |
| NCT02074345 | Phase III Study of Intramuscular TAK-816 in Healthy Infants | Phase3 | Healthy Volunteers | Completed | 2014-03-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT02079844 | Roflumilast Plus Antipsychotics Proof of Mechanism Study in Schizophrenia | Phase1 | Schizophrenia | Completed | 2014-03-01 | 2015-06-01 | ClinicalTrials.gov |
| NCT02079844 | Roflumilast Plus Antipsychotics Proof of Mechanism Study in Schizophrenia | Phase1 | Schizophrenia | Completed | 2014-03-01 | 2015-06-01 | ClinicalTrials.gov |
| NCT02093390 | A Phase 1 Study to Evaluate the Effects of Fluconazole and Atorvastatin on the … | Phase1 | Prostate Cancer | Completed | 2014-03-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT02091531 | Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (C… | Phase2 | Metastatic Castration-Resistant Prostate Cancer | Completed | 2014-03-01 | 2018-10-01 | ClinicalTrials.gov |
| NCT02093390 | A Phase 1 Study to Evaluate the Effects of Fluconazole and Atorvastatin on the … | Phase1 | Prostate Cancer | Completed | 2014-03-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT02026505 | Evaluation of Cardiotoxic Effects of Bortezomib | — | Multiple Myeloma | Completed | 2014-03-01 | 2019-03-01 | ClinicalTrials.gov |
| NCT02111252 | A Phase 1/2 Study of a Intramuscular Injection of TAK-850 in Healthy Adult Subj… | Phase1 | Influenza | Completed | 2014-03-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT02079844 | Roflumilast Plus Antipsychotics Proof of Mechanism Study in Schizophrenia | Phase1 | Schizophrenia | Completed | 2014-03-01 | 2015-06-01 | ClinicalTrials.gov |
| NCT02074345 | Phase III Study of Intramuscular TAK-816 in Healthy Infants | Phase3 | Healthy Volunteers | Completed | 2014-03-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT02111252 | A Phase 1/2 Study of a Intramuscular Injection of TAK-850 in Healthy Adult Subj… | Phase1 | Influenza | Completed | 2014-03-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT02091531 | Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (C… | Phase2 | Metastatic Castration-Resistant Prostate Cancer | Completed | 2014-03-01 | 2018-10-01 | ClinicalTrials.gov |
| NCT02093390 | A Phase 1 Study to Evaluate the Effects of Fluconazole and Atorvastatin on the … | Phase1 | Prostate Cancer | Completed | 2014-03-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT02111252 | A Phase 1/2 Study of a Intramuscular Injection of TAK-850 in Healthy Adult Subj… | Phase1 | Influenza | Completed | 2014-03-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT02026505 | Evaluation of Cardiotoxic Effects of Bortezomib | — | Multiple Myeloma | Completed | 2014-03-01 | 2019-03-01 | ClinicalTrials.gov |
| NCT02026505 | Evaluation of Cardiotoxic Effects of Bortezomib | — | Multiple Myeloma | Completed | 2014-03-01 | 2019-03-01 | ClinicalTrials.gov |
| NCT02074345 | Phase III Study of Intramuscular TAK-816 in Healthy Infants | Phase3 | Healthy Volunteers | Completed | 2014-03-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT01990209 | Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That E… | Phase2 | Metastatic Breast Cancer | Completed | 2014-03-01 | 2021-05-01 | ClinicalTrials.gov |
| NCT01990209 | Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That E… | Phase2 | Metastatic Breast Cancer | Completed | 2014-03-01 | 2021-05-01 | ClinicalTrials.gov |
| NCT01990209 | Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That E… | Phase2 | Metastatic Breast Cancer | Completed | 2014-03-01 | 2021-05-01 | ClinicalTrials.gov |
| NCT02065401 | Pharmacokinetics of Granule and Tablet Formulations of Deferitazole (Disodium S… | Phase1 | Healthy | Withdrawn | 2014-02-28 | 2014-03-19 | ClinicalTrials.gov |
| NCT02065401 | Pharmacokinetics of Granule and Tablet Formulations of Deferitazole (Disodium S… | Phase1 | Healthy | Withdrawn | 2014-02-28 | 2014-03-19 | ClinicalTrials.gov |
| NCT02065401 | Pharmacokinetics of Granule and Tablet Formulations of Deferitazole (Disodium S… | Phase1 | Healthy | Withdrawn | 2014-02-28 | 2014-03-19 | ClinicalTrials.gov |
| NCT02138136 | Lubiprostone for Children With Constipation | Phase3 | Constipation - Functional | Completed | 2014-02-26 | 2017-05-01 | ClinicalTrials.gov |
| NCT02138136 | Lubiprostone for Children With Constipation | Phase3 | Constipation - Functional | Completed | 2014-02-26 | 2017-05-01 | ClinicalTrials.gov |
| NCT02060526 | Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of r… | Phase2 | Sanfilippo Syndrome | Completed | 2014-02-26 | 2016-06-01 | ClinicalTrials.gov |
| NCT02060526 | Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of r… | Phase2 | Sanfilippo Syndrome | Completed | 2014-02-26 | 2016-06-01 | ClinicalTrials.gov |
| NCT02138136 | Lubiprostone for Children With Constipation | Phase3 | Constipation - Functional | Completed | 2014-02-26 | 2017-05-01 | ClinicalTrials.gov |
| NCT02060526 | Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of r… | Phase2 | Sanfilippo Syndrome | Completed | 2014-02-26 | 2016-06-01 | ClinicalTrials.gov |
| NCT02045264 | Open-label, Single-arm Study to Assess the Pharmacokinetics, Safety, and Tolera… | Phase1 | Hereditary Angioedema (HAE) | Completed | 2014-02-21 | 2014-02-27 | ClinicalTrials.gov |
| NCT02045264 | Open-label, Single-arm Study to Assess the Pharmacokinetics, Safety, and Tolera… | Phase1 | Hereditary Angioedema (HAE) | Completed | 2014-02-21 | 2014-02-27 | ClinicalTrials.gov |
| NCT02045264 | Open-label, Single-arm Study to Assess the Pharmacokinetics, Safety, and Tolera… | Phase1 | Hereditary Angioedema (HAE) | Completed | 2014-02-21 | 2014-02-27 | ClinicalTrials.gov |
| NCT02039505 | Phase III Study of MLN0002 (300 mg) in the Treatment of Ulcerative Colitis | Phase3 | Ulcerative Colitis | Completed | 2014-02-04 | 2018-06-28 | ClinicalTrials.gov |
| NCT02039505 | Phase III Study of MLN0002 (300 mg) in the Treatment of Ulcerative Colitis | Phase3 | Ulcerative Colitis | Completed | 2014-02-04 | 2018-06-28 | ClinicalTrials.gov |
| NCT02039505 | Phase III Study of MLN0002 (300 mg) in the Treatment of Ulcerative Colitis | Phase3 | Ulcerative Colitis | Completed | 2014-02-04 | 2018-06-28 | ClinicalTrials.gov |
| NCT02004275 | Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients Wi… | Phase1 | Multiple Myeloma in Relapse | Unknown | 2014-02-01 | — | ClinicalTrials.gov |
| NCT02170298 | Lisdexamfetamine's Effect In ADHD in the Brain and Cognition | Phase4 | Attention Deficit Hyperactivity Disorder | Terminated | 2014-02-01 | 2015-06-01 | ClinicalTrials.gov |
| NCT02068443 | Comparative Study to Evaluate Efficacy and Safety When Metformin Hydrochloride … | Phase3 | Type 2 Diabetes Mellitus | Completed | 2014-02-01 | 2015-02-01 | ClinicalTrials.gov |
| NCT02063854 | A Phase II/III, Double-blind, Parallel Group Comparative Study of Oral Administ… | Phase2 | Involutional Osteoporosis | Completed | 2014-02-01 | 2015-11-01 | ClinicalTrials.gov |
| NCT02068443 | Comparative Study to Evaluate Efficacy and Safety When Metformin Hydrochloride … | Phase3 | Type 2 Diabetes Mellitus | Completed | 2014-02-01 | 2015-02-01 | ClinicalTrials.gov |
| NCT02064907 | Bioavailability, Safety, and Pharmacodynamics of Dexlansoprazole Delayed-Releas… | Phase1 | Bioavailability | Completed | 2014-02-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT02068443 | Comparative Study to Evaluate Efficacy and Safety When Metformin Hydrochloride … | Phase3 | Type 2 Diabetes Mellitus | Completed | 2014-02-01 | 2015-02-01 | ClinicalTrials.gov |
| NCT02567851 | A Study of Brentuximab Vedotin in Patients With Hodgkin Lymphoma Unsuitable for… | Phase2 | Hodgkin Disease | Completed | 2014-02-01 | 2017-10-02 | ClinicalTrials.gov |
| NCT02064907 | Bioavailability, Safety, and Pharmacodynamics of Dexlansoprazole Delayed-Releas… | Phase1 | Bioavailability | Completed | 2014-02-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT02096458 | Sensory Evaluation of Dexlansoprazole Delayed-Release Orally Disintegrating Tab… | Phase1 | Gastroesophageal Reflux Disease | Completed | 2014-02-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT02063854 | A Phase II/III, Double-blind, Parallel Group Comparative Study of Oral Administ… | Phase2 | Involutional Osteoporosis | Completed | 2014-02-01 | 2015-11-01 | ClinicalTrials.gov |
| NCT02064907 | Bioavailability, Safety, and Pharmacodynamics of Dexlansoprazole Delayed-Releas… | Phase1 | Bioavailability | Completed | 2014-02-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT02113020 | A Phase I Clinical Pharmacology Study of TAK-233 in Healthy Subjects | Phase1 | Clinical Pharmacology | Completed | 2014-02-01 | 2014-09-01 | ClinicalTrials.gov |
| NCT02170298 | Lisdexamfetamine's Effect In ADHD in the Brain and Cognition | Phase4 | Attention Deficit Hyperactivity Disorder | Terminated | 2014-02-01 | 2015-06-01 | ClinicalTrials.gov |
| NCT02567851 | A Study of Brentuximab Vedotin in Patients With Hodgkin Lymphoma Unsuitable for… | Phase2 | Hodgkin Disease | Completed | 2014-02-01 | 2017-10-02 | ClinicalTrials.gov |
| NCT02096458 | Sensory Evaluation of Dexlansoprazole Delayed-Release Orally Disintegrating Tab… | Phase1 | Gastroesophageal Reflux Disease | Completed | 2014-02-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT02113020 | A Phase I Clinical Pharmacology Study of TAK-233 in Healthy Subjects | Phase1 | Clinical Pharmacology | Completed | 2014-02-01 | 2014-09-01 | ClinicalTrials.gov |
| NCT02063854 | A Phase II/III, Double-blind, Parallel Group Comparative Study of Oral Administ… | Phase2 | Involutional Osteoporosis | Completed | 2014-02-01 | 2015-11-01 | ClinicalTrials.gov |
| NCT02004275 | Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients Wi… | Phase1 | Multiple Myeloma in Relapse | Unknown | 2014-02-01 | — | ClinicalTrials.gov |
| NCT02170298 | Lisdexamfetamine's Effect In ADHD in the Brain and Cognition | Phase4 | Attention Deficit Hyperactivity Disorder | Terminated | 2014-02-01 | 2015-06-01 | ClinicalTrials.gov |
| NCT02004275 | Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients Wi… | Phase1 | Multiple Myeloma in Relapse | Unknown | 2014-02-01 | — | ClinicalTrials.gov |
| NCT02096458 | Sensory Evaluation of Dexlansoprazole Delayed-Release Orally Disintegrating Tab… | Phase1 | Gastroesophageal Reflux Disease | Completed | 2014-02-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT02113020 | A Phase I Clinical Pharmacology Study of TAK-233 in Healthy Subjects | Phase1 | Clinical Pharmacology | Completed | 2014-02-01 | 2014-09-01 | ClinicalTrials.gov |
| NCT02567851 | A Study of Brentuximab Vedotin in Patients With Hodgkin Lymphoma Unsuitable for… | Phase2 | Hodgkin Disease | Completed | 2014-02-01 | 2017-10-02 | ClinicalTrials.gov |
| NCT02045095 | A Dose Escalation Study of MLN7243 (TAK-243) in Adult Participants With Advance… | Phase1 | Advanced Malignant Solid Tumors | Terminated | 2014-01-31 | 2016-11-09 | ClinicalTrials.gov |
| NCT02045095 | A Dose Escalation Study of MLN7243 (TAK-243) in Adult Participants With Advance… | Phase1 | Advanced Malignant Solid Tumors | Terminated | 2014-01-31 | 2016-11-09 | ClinicalTrials.gov |
| NCT02045095 | A Dose Escalation Study of MLN7243 (TAK-243) in Adult Participants With Advance… | Phase1 | Advanced Malignant Solid Tumors | Terminated | 2014-01-31 | 2016-11-09 | ClinicalTrials.gov |
| NCT02038920 | Phase III Study of MLN0002 (300 mg) in Treatment of Crohn's Disease | Phase3 | Crohn's Disease | Completed | 2014-01-28 | 2019-05-21 | ClinicalTrials.gov |
| NCT02038920 | Phase III Study of MLN0002 (300 mg) in Treatment of Crohn's Disease | Phase3 | Crohn's Disease | Completed | 2014-01-28 | 2019-05-21 | ClinicalTrials.gov |
| NCT02038920 | Phase III Study of MLN0002 (300 mg) in Treatment of Crohn's Disease | Phase3 | Crohn's Disease | Completed | 2014-01-28 | 2019-05-21 | ClinicalTrials.gov |
| NCT01909934 | Study of Brentuximab Vedotin in Participants With Relapsed or Refractory System… | Phase4 | Lymphoma | Completed | 2014-01-23 | 2024-08-29 | ClinicalTrials.gov |
| NCT01909934 | Study of Brentuximab Vedotin in Participants With Relapsed or Refractory System… | Phase4 | Lymphoma | Completed | 2014-01-23 | 2024-08-29 | ClinicalTrials.gov |
| NCT01909934 | Study of Brentuximab Vedotin in Participants With Relapsed or Refractory System… | Phase4 | Lymphoma | Completed | 2014-01-23 | 2024-08-29 | ClinicalTrials.gov |
| NCT01953081 | A Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Phar… | Phase1 | Enteral Feeding Intolerance | Completed | 2014-01-01 | 2014-10-01 | ClinicalTrials.gov |
| NCT01913912 | Event Rate and Effects of Stimulants in ADHD | Phase3 | Attention Deficit Hyperactivity Disorder | Withdrawn | 2014-01-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT02037477 | Phase 3 Study to Evaluate the Acid-Inhibitory Effect of Multiple Oral Doses of … | Phase3 | Healthy Volunteers | Completed | 2014-01-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01953081 | A Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Phar… | Phase1 | Enteral Feeding Intolerance | Completed | 2014-01-01 | 2014-10-01 | ClinicalTrials.gov |
| NCT02037477 | Phase 3 Study to Evaluate the Acid-Inhibitory Effect of Multiple Oral Doses of … | Phase3 | Healthy Volunteers | Completed | 2014-01-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01913912 | Event Rate and Effects of Stimulants in ADHD | Phase3 | Attention Deficit Hyperactivity Disorder | Withdrawn | 2014-01-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT01913912 | Event Rate and Effects of Stimulants in ADHD | Phase3 | Attention Deficit Hyperactivity Disorder | Withdrawn | 2014-01-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT02037477 | Phase 3 Study to Evaluate the Acid-Inhibitory Effect of Multiple Oral Doses of … | Phase3 | Healthy Volunteers | Completed | 2014-01-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01953081 | A Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Phar… | Phase1 | Enteral Feeding Intolerance | Completed | 2014-01-01 | 2014-10-01 | ClinicalTrials.gov |
| NCT01972724 | Efficacy of Pioglitazone in Participants With Inadequately Controlled Type 2 Di… | Phase4 | Type II Diabetes Mellitus | Completed | 2013-12-16 | 2016-10-17 | ClinicalTrials.gov |
| NCT01972724 | Efficacy of Pioglitazone in Participants With Inadequately Controlled Type 2 Di… | Phase4 | Type II Diabetes Mellitus | Completed | 2013-12-16 | 2016-10-17 | ClinicalTrials.gov |
| NCT01972724 | Efficacy of Pioglitazone in Participants With Inadequately Controlled Type 2 Di… | Phase4 | Type II Diabetes Mellitus | Completed | 2013-12-16 | 2016-10-17 | ClinicalTrials.gov |
| NCT02764619 | Inhibition of Aldosterone to Reduce Myocardial Diffuse Fibrosis in Patients Wit… | Phase3 | Atrial Fibrillation | Unknown | 2013-12-01 | 2017-04-01 | ClinicalTrials.gov |
| NCT02015780 | Fasiglifam in Type 2 Diabetic Subjects With Chronic Kidney Disease Stage 4 or 5… | Phase3 | Type 2 Diabetes Mellitus | Withdrawn | 2013-12-01 | 2016-01-01 | ClinicalTrials.gov |
| NCT02015780 | Fasiglifam in Type 2 Diabetic Subjects With Chronic Kidney Disease Stage 4 or 5… | Phase3 | Type 2 Diabetes Mellitus | Withdrawn | 2013-12-01 | 2016-01-01 | ClinicalTrials.gov |
| NCT02015780 | Fasiglifam in Type 2 Diabetic Subjects With Chronic Kidney Disease Stage 4 or 5… | Phase3 | Type 2 Diabetes Mellitus | Withdrawn | 2013-12-01 | 2016-01-01 | ClinicalTrials.gov |
| NCT02764619 | Inhibition of Aldosterone to Reduce Myocardial Diffuse Fibrosis in Patients Wit… | Phase3 | Atrial Fibrillation | Unknown | 2013-12-01 | 2017-04-01 | ClinicalTrials.gov |
| NCT02764619 | Inhibition of Aldosterone to Reduce Myocardial Diffuse Fibrosis in Patients Wit… | Phase3 | Atrial Fibrillation | Unknown | 2013-12-01 | 2017-04-01 | ClinicalTrials.gov |
| NCT03752606 | Application of Tachosil During Lymphadenectomy | Phase4 | Lymphocele | Completed | 2013-11-29 | 2017-12-31 | ClinicalTrials.gov |
| NCT03752606 | Application of Tachosil During Lymphadenectomy | Phase4 | Lymphocele | Completed | 2013-11-29 | 2017-12-31 | ClinicalTrials.gov |
| NCT03752606 | Application of Tachosil During Lymphadenectomy | Phase4 | Lymphocele | Completed | 2013-11-29 | 2017-12-31 | ClinicalTrials.gov |
| NCT01989169 | Pharmacokinetic Interaction Between SSP-004184 (SPD602) and Midazolam in Health… | Phase1 | Healthy | Completed | 2013-11-26 | 2014-01-06 | ClinicalTrials.gov |
| NCT01989169 | Pharmacokinetic Interaction Between SSP-004184 (SPD602) and Midazolam in Health… | Phase1 | Healthy | Completed | 2013-11-26 | 2014-01-06 | ClinicalTrials.gov |
| NCT01989169 | Pharmacokinetic Interaction Between SSP-004184 (SPD602) and Midazolam in Health… | Phase1 | Healthy | Completed | 2013-11-26 | 2014-01-06 | ClinicalTrials.gov |
| NCT01952080 | A Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatri… | Phase3 | Short Bowel Syndrome | Completed | 2013-11-14 | 2015-01-09 | ClinicalTrials.gov |
| NCT01952080 | A Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatri… | Phase3 | Short Bowel Syndrome | Completed | 2013-11-14 | 2015-01-09 | ClinicalTrials.gov |
| NCT01952080 | A Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatri… | Phase3 | Short Bowel Syndrome | Completed | 2013-11-14 | 2015-01-09 | ClinicalTrials.gov |
| NCT01905917 | The Singapore Tele-technology Aided Rehabilitation in Stroke (STARS) Study | Na | Stroke | Completed | 2013-11-01 | 2017-09-01 | ClinicalTrials.gov |
| NCT01950364 | A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Sys… | Phase1 | Hodgkin Lymphoma | Completed | 2013-11-01 | 2015-06-01 | ClinicalTrials.gov |
| NCT02006056 | Ondissolve in the Prophylaxis/Rescue of Radiation Induced Nausea and Vomiting | Phase2 | Nausea | Completed | 2013-11-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT01905917 | The Singapore Tele-technology Aided Rehabilitation in Stroke (STARS) Study | Na | Stroke | Completed | 2013-11-01 | 2017-09-01 | ClinicalTrials.gov |
| NCT01950364 | A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Sys… | Phase1 | Hodgkin Lymphoma | Completed | 2013-11-01 | 2015-06-01 | ClinicalTrials.gov |
| NCT02006056 | Ondissolve in the Prophylaxis/Rescue of Radiation Induced Nausea and Vomiting | Phase2 | Nausea | Completed | 2013-11-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT01905917 | The Singapore Tele-technology Aided Rehabilitation in Stroke (STARS) Study | Na | Stroke | Completed | 2013-11-01 | 2017-09-01 | ClinicalTrials.gov |
| NCT01950364 | A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Sys… | Phase1 | Hodgkin Lymphoma | Completed | 2013-11-01 | 2015-06-01 | ClinicalTrials.gov |
| NCT02006056 | Ondissolve in the Prophylaxis/Rescue of Radiation Induced Nausea and Vomiting | Phase2 | Nausea | Completed | 2013-11-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT01939899 | Phase 2 Study of Oral IXAZOMIB in Adult Participants With Relapsed and/or Refra… | Phase2 | Follicular Lymphoma | Completed | 2013-10-31 | 2017-03-23 | ClinicalTrials.gov |
| NCT01939899 | Phase 2 Study of Oral IXAZOMIB in Adult Participants With Relapsed and/or Refra… | Phase2 | Follicular Lymphoma | Completed | 2013-10-31 | 2017-03-23 | ClinicalTrials.gov |
| NCT01939899 | Phase 2 Study of Oral IXAZOMIB in Adult Participants With Relapsed and/or Refra… | Phase2 | Follicular Lymphoma | Completed | 2013-10-31 | 2017-03-23 | ClinicalTrials.gov |
| NCT01866423 | Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | Phase2 | Adenocarcinoma of the Prostate | Terminated | 2013-10-25 | 2016-07-26 | ClinicalTrials.gov |
| NCT01866423 | Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | Phase2 | Adenocarcinoma of the Prostate | Terminated | 2013-10-25 | 2016-07-26 | ClinicalTrials.gov |
| NCT01866423 | Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | Phase2 | Adenocarcinoma of the Prostate | Terminated | 2013-10-25 | 2016-07-26 | ClinicalTrials.gov |
| NCT02370602 | An [^11C]T-773 Positron Emission Tomography (PET) Study to Determine Phosphodie… | Phase1 | Healthy Volunteers | Completed | 2013-10-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01993875 | Pharmacodynamic, Pharmacokinetic, and Tolerability Study of a Liquid Form of Lu… | Phase3 | Chronic Idiopathic Constipation | Completed | 2013-10-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT01982253 | Fasiglifam 25 mg BID vs 50 mg QD | Phase2 | Type 2 Diabetes Mellitus | Terminated | 2013-10-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT01993875 | Pharmacodynamic, Pharmacokinetic, and Tolerability Study of a Liquid Form of Lu… | Phase3 | Chronic Idiopathic Constipation | Completed | 2013-10-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT02370602 | An [^11C]T-773 Positron Emission Tomography (PET) Study to Determine Phosphodie… | Phase1 | Healthy Volunteers | Completed | 2013-10-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01982253 | Fasiglifam 25 mg BID vs 50 mg QD | Phase2 | Type 2 Diabetes Mellitus | Terminated | 2013-10-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT01993875 | Pharmacodynamic, Pharmacokinetic, and Tolerability Study of a Liquid Form of Lu… | Phase3 | Chronic Idiopathic Constipation | Completed | 2013-10-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT02370602 | An [^11C]T-773 Positron Emission Tomography (PET) Study to Determine Phosphodie… | Phase1 | Healthy Volunteers | Completed | 2013-10-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01982253 | Fasiglifam 25 mg BID vs 50 mg QD | Phase2 | Type 2 Diabetes Mellitus | Terminated | 2013-10-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT01830816 | Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multip… | Phase1 | Multiple Myeloma | Completed | 2013-09-16 | 2016-11-18 | ClinicalTrials.gov |
| NCT01830816 | Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multip… | Phase1 | Multiple Myeloma | Completed | 2013-09-16 | 2016-11-18 | ClinicalTrials.gov |
| NCT01830816 | Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multip… | Phase1 | Multiple Myeloma | Completed | 2013-09-16 | 2016-11-18 | ClinicalTrials.gov |
| NCT01890122 | Efficacy and Safety of Alogliptin and Metformin Fixed-Dose Combination in Parti… | Phase3 | Diabetes Mellitus | Completed | 2013-09-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT02447458 | MLN3126 Single Rising Dose Study | Phase1 | Healthy Volunteers | Terminated | 2013-09-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT02001857 | Effect of TachoSil® on Incidence of Symptomatic and Radiographic Lymphoceles Af… | Phase4 | Prostate or Bladder Cancer | Completed | 2013-09-01 | 2017-08-01 | ClinicalTrials.gov |
| NCT02447458 | MLN3126 Single Rising Dose Study | Phase1 | Healthy Volunteers | Terminated | 2013-09-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT02001857 | Effect of TachoSil® on Incidence of Symptomatic and Radiographic Lymphoceles Af… | Phase4 | Prostate or Bladder Cancer | Completed | 2013-09-01 | 2017-08-01 | ClinicalTrials.gov |
| NCT02001857 | Effect of TachoSil® on Incidence of Symptomatic and Radiographic Lymphoceles Af… | Phase4 | Prostate or Bladder Cancer | Completed | 2013-09-01 | 2017-08-01 | ClinicalTrials.gov |
| NCT01890122 | Efficacy and Safety of Alogliptin and Metformin Fixed-Dose Combination in Parti… | Phase3 | Diabetes Mellitus | Completed | 2013-09-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT01890122 | Efficacy and Safety of Alogliptin and Metformin Fixed-Dose Combination in Parti… | Phase3 | Diabetes Mellitus | Completed | 2013-09-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT02447458 | MLN3126 Single Rising Dose Study | Phase1 | Healthy Volunteers | Terminated | 2013-09-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT01905553 | The Effect of Food on the Bioavailability of a Single Dose of SSP-004184SS in H… | Phase1 | Healthy | Completed | 2013-08-27 | 2013-09-24 | ClinicalTrials.gov |
| NCT01905553 | The Effect of Food on the Bioavailability of a Single Dose of SSP-004184SS in H… | Phase1 | Healthy | Completed | 2013-08-27 | 2013-09-24 | ClinicalTrials.gov |
| NCT01905553 | The Effect of Food on the Bioavailability of a Single Dose of SSP-004184SS in H… | Phase1 | Healthy | Completed | 2013-08-27 | 2013-09-24 | ClinicalTrials.gov |
| NCT01848067 | Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone… | Phase1 | Adenocarcinoma of the Prostate | Completed | 2013-08-14 | 2016-06-23 | ClinicalTrials.gov |
| NCT01848067 | Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone… | Phase1 | Adenocarcinoma of the Prostate | Completed | 2013-08-14 | 2016-06-23 | ClinicalTrials.gov |
| NCT01639911 | Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors | Phase1 | Malignant Neoplasm of Breast | Completed | 2013-08-14 | 2016-07-28 | ClinicalTrials.gov |
| NCT01639911 | Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors | Phase1 | Malignant Neoplasm of Breast | Completed | 2013-08-14 | 2016-07-28 | ClinicalTrials.gov |
| NCT01639911 | Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors | Phase1 | Malignant Neoplasm of Breast | Completed | 2013-08-14 | 2016-07-28 | ClinicalTrials.gov |
| NCT01848067 | Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone… | Phase1 | Adenocarcinoma of the Prostate | Completed | 2013-08-14 | 2016-06-23 | ClinicalTrials.gov |
| NCT01898884 | Safety and Pharmacology Study of VP 20629 in Adults With Friedreich's Ataxia | Phase1 | Friedreich's Ataxia | Completed | 2013-08-13 | 2015-06-18 | ClinicalTrials.gov |
| NCT01898884 | Safety and Pharmacology Study of VP 20629 in Adults With Friedreich's Ataxia | Phase1 | Friedreich's Ataxia | Completed | 2013-08-13 | 2015-06-18 | ClinicalTrials.gov |
| NCT01898884 | Safety and Pharmacology Study of VP 20629 in Adults With Friedreich's Ataxia | Phase1 | Friedreich's Ataxia | Completed | 2013-08-13 | 2015-06-18 | ClinicalTrials.gov |
| NCT01924260 | Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors … | Phase1 | Acinar Cell Adenocarcinoma of the Pancreas | Completed | 2013-08-09 | 2017-02-08 | ClinicalTrials.gov |
| NCT01924260 | Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors … | Phase1 | Acinar Cell Adenocarcinoma of the Pancreas | Completed | 2013-08-09 | 2017-02-08 | ClinicalTrials.gov |
| NCT01924260 | Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors … | Phase1 | Acinar Cell Adenocarcinoma of the Pancreas | Completed | 2013-08-09 | 2017-02-08 | ClinicalTrials.gov |
| NCT01920737 | A Novel "Pediatric-Inspired" Regimen With Reduced Myelosuppressive Drugs for Ad… | Phase2 | Leukemia | Active_Not_Recruiting | 2013-08-07 | 2026-08-01 | ClinicalTrials.gov |
| NCT01891968 | Bortezomib for Low or Intermediate-1 Myelodysplastic Syndrome (MDS) With p65 Ac… | Phase2 | Leukemia | Completed | 2013-08-07 | 2017-01-18 | ClinicalTrials.gov |
| NCT01891968 | Bortezomib for Low or Intermediate-1 Myelodysplastic Syndrome (MDS) With p65 Ac… | Phase2 | Leukemia | Completed | 2013-08-07 | 2017-01-18 | ClinicalTrials.gov |
| NCT01920737 | A Novel "Pediatric-Inspired" Regimen With Reduced Myelosuppressive Drugs for Ad… | Phase2 | Leukemia | Active_Not_Recruiting | 2013-08-07 | 2026-08-01 | ClinicalTrials.gov |
| NCT01920737 | A Novel "Pediatric-Inspired" Regimen With Reduced Myelosuppressive Drugs for Ad… | Phase2 | Leukemia | Active_Not_Recruiting | 2013-08-07 | 2026-08-01 | ClinicalTrials.gov |
| NCT01891968 | Bortezomib for Low or Intermediate-1 Myelodysplastic Syndrome (MDS) With p65 Ac… | Phase2 | Leukemia | Completed | 2013-08-07 | 2017-01-18 | ClinicalTrials.gov |
| NCT01919086 | Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of … | Phase2 | Multiple Myeloma (MM) | Completed | 2013-08-06 | 2024-05-16 | ClinicalTrials.gov |
| NCT01919086 | Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of … | Phase2 | Multiple Myeloma (MM) | Completed | 2013-08-06 | 2024-05-16 | ClinicalTrials.gov |
| NCT01919086 | Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of … | Phase2 | Multiple Myeloma (MM) | Completed | 2013-08-06 | 2024-05-16 | ClinicalTrials.gov |
| NCT01905540 | A Relative Bioavailability Study of SSP-004184AQ (Magnesium Salt) and SSP-00418… | Phase1 | Healthy | Completed | 2013-08-05 | 2013-09-20 | ClinicalTrials.gov |
| NCT01905540 | A Relative Bioavailability Study of SSP-004184AQ (Magnesium Salt) and SSP-00418… | Phase1 | Healthy | Completed | 2013-08-05 | 2013-09-20 | ClinicalTrials.gov |
| NCT01905540 | A Relative Bioavailability Study of SSP-004184AQ (Magnesium Salt) and SSP-00418… | Phase1 | Healthy | Completed | 2013-08-05 | 2013-09-20 | ClinicalTrials.gov |
| NCT01892189 | Effects of TAK-063 on Preventing Ketamine-Induced Brain Activity Changes as Wel… | Phase1 | Ketamine-Induced Brain Activity Changes | Completed | 2013-08-01 | 2014-08-01 | ClinicalTrials.gov |
| NCT01931566 | Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzh… | Phase3 | Mild Cognitive Impairment Due to Alzheimer's Disease | Terminated | 2013-08-01 | 2018-09-06 | ClinicalTrials.gov |
| NCT01923337 | Irinotecan and Alisertib in Treating Patients With Advanced Solid Tumors or Col… | Phase1 | Mucinous Adenocarcinoma of the Colon | Completed | 2013-08-01 | 2016-10-17 | ClinicalTrials.gov |
| NCT01912222 | Pharmacokinetic Study of Oral IXAZOMIB in Cancer Patients With Liver Dysfunction | Phase1 | Advanced Solid Tumors | Completed | 2013-08-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT01892189 | Effects of TAK-063 on Preventing Ketamine-Induced Brain Activity Changes as Wel… | Phase1 | Ketamine-Induced Brain Activity Changes | Completed | 2013-08-01 | 2014-08-01 | ClinicalTrials.gov |
| NCT01613261 | Study of TAK-733 in Combination With Alisertib in Adult Patients With Advanced … | Phase1 | Advanced Nonhematologic Malignancies | Withdrawn | 2013-08-01 | 2015-11-01 | ClinicalTrials.gov |
| NCT01613261 | Study of TAK-733 in Combination With Alisertib in Adult Patients With Advanced … | Phase1 | Advanced Nonhematologic Malignancies | Withdrawn | 2013-08-01 | 2015-11-01 | ClinicalTrials.gov |
| NCT05561647 | A Survey to Assess Participants' and Physicians' Knowledge When Using GATTEX (K… | — | Short Bowel Syndrome (SBS) | Recruiting | 2013-08-01 | 2031-12-31 | ClinicalTrials.gov |
| NCT01613261 | Study of TAK-733 in Combination With Alisertib in Adult Patients With Advanced … | Phase1 | Advanced Nonhematologic Malignancies | Withdrawn | 2013-08-01 | 2015-11-01 | ClinicalTrials.gov |
| NCT05561647 | A Survey to Assess Participants' and Physicians' Knowledge When Using GATTEX (K… | — | Short Bowel Syndrome (SBS) | Recruiting | 2013-08-01 | 2031-12-31 | ClinicalTrials.gov |
| NCT01912222 | Pharmacokinetic Study of Oral IXAZOMIB in Cancer Patients With Liver Dysfunction | Phase1 | Advanced Solid Tumors | Completed | 2013-08-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT05561647 | A Survey to Assess Participants' and Physicians' Knowledge When Using GATTEX (K… | — | Short Bowel Syndrome (SBS) | Recruiting | 2013-08-01 | 2031-12-31 | ClinicalTrials.gov |
| NCT01923337 | Irinotecan and Alisertib in Treating Patients With Advanced Solid Tumors or Col… | Phase1 | Mucinous Adenocarcinoma of the Colon | Completed | 2013-08-01 | 2016-10-17 | ClinicalTrials.gov |
| NCT01892189 | Effects of TAK-063 on Preventing Ketamine-Induced Brain Activity Changes as Wel… | Phase1 | Ketamine-Induced Brain Activity Changes | Completed | 2013-08-01 | 2014-08-01 | ClinicalTrials.gov |
| NCT01931566 | Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzh… | Phase3 | Mild Cognitive Impairment Due to Alzheimer's Disease | Terminated | 2013-08-01 | 2018-09-06 | ClinicalTrials.gov |
| NCT01912222 | Pharmacokinetic Study of Oral IXAZOMIB in Cancer Patients With Liver Dysfunction | Phase1 | Advanced Solid Tumors | Completed | 2013-08-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT01923337 | Irinotecan and Alisertib in Treating Patients With Advanced Solid Tumors or Col… | Phase1 | Mucinous Adenocarcinoma of the Colon | Completed | 2013-08-01 | 2016-10-17 | ClinicalTrials.gov |
| NCT01931566 | Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzh… | Phase3 | Mild Cognitive Impairment Due to Alzheimer's Disease | Terminated | 2013-08-01 | 2018-09-06 | ClinicalTrials.gov |
| NCT01922440 | A Registry for Participants With Chronic Hypoparathyroidism | — | Hypoparathyroidism | Active_Not_Recruiting | 2013-07-30 | 2034-11-30 | ClinicalTrials.gov |
| NCT01922440 | A Registry for Participants With Chronic Hypoparathyroidism | — | Hypoparathyroidism | Active_Not_Recruiting | 2013-07-30 | 2034-11-30 | ClinicalTrials.gov |
| NCT01922440 | A Registry for Participants With Chronic Hypoparathyroidism | — | Hypoparathyroidism | Active_Not_Recruiting | 2013-07-30 | 2034-11-30 | ClinicalTrials.gov |
| NCT01898078 | Food Effect Study of Alisertib (MLN8237) in Participants With Advanced Solid Tu… | Phase1 | Advanced Solid Tumors | Completed | 2013-07-16 | 2017-01-24 | ClinicalTrials.gov |
| NCT01898078 | Food Effect Study of Alisertib (MLN8237) in Participants With Advanced Solid Tu… | Phase1 | Advanced Solid Tumors | Completed | 2013-07-16 | 2017-01-24 | ClinicalTrials.gov |
| NCT01898078 | Food Effect Study of Alisertib (MLN8237) in Participants With Advanced Solid Tu… | Phase1 | Advanced Solid Tumors | Completed | 2013-07-16 | 2017-01-24 | ClinicalTrials.gov |
| NCT01890785 | Bioavailability Study of SPD489 Administered With Two Different Means of Admini… | Phase1 | Healthy Volunteers | Completed | 2013-07-15 | 2013-08-22 | ClinicalTrials.gov |
| NCT01890785 | Bioavailability Study of SPD489 Administered With Two Different Means of Admini… | Phase1 | Healthy Volunteers | Completed | 2013-07-15 | 2013-08-22 | ClinicalTrials.gov |
| NCT01890785 | Bioavailability Study of SPD489 Administered With Two Different Means of Admini… | Phase1 | Healthy Volunteers | Completed | 2013-07-15 | 2013-08-22 | ClinicalTrials.gov |
| NCT01916304 | Study of Dose Adjustment From Levothyroxine to a New Levothyroxine Sodium Test … | Phase2 | Hypothyroidism | Completed | 2013-07-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT01967264 | Safety and Pharmacokinetic Profile of Udenafil in Healthy Mexican Adults | Phase1 | Erectile Dysfunction | Completed | 2013-07-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01967264 | Safety and Pharmacokinetic Profile of Udenafil in Healthy Mexican Adults | Phase1 | Erectile Dysfunction | Completed | 2013-07-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01916304 | Study of Dose Adjustment From Levothyroxine to a New Levothyroxine Sodium Test … | Phase2 | Hypothyroidism | Completed | 2013-07-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT01911091 | Identification of Novel Skeletal Muscle-derived Factors That Promote Lipid Oxid… | Na | Obesity | Active_Not_Recruiting | 2013-07-01 | 2026-12-01 | ClinicalTrials.gov |
| NCT01900522 | Safety and Tolerability of Multiple Doses of ITI-214 in Healthy Adults and in A… | Phase1 | Schizophrenia | Terminated | 2013-07-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT01911091 | Identification of Novel Skeletal Muscle-derived Factors That Promote Lipid Oxid… | Na | Obesity | Active_Not_Recruiting | 2013-07-01 | 2026-12-01 | ClinicalTrials.gov |
| NCT01900522 | Safety and Tolerability of Multiple Doses of ITI-214 in Healthy Adults and in A… | Phase1 | Schizophrenia | Terminated | 2013-07-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT01967264 | Safety and Pharmacokinetic Profile of Udenafil in Healthy Mexican Adults | Phase1 | Erectile Dysfunction | Completed | 2013-07-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01900522 | Safety and Tolerability of Multiple Doses of ITI-214 in Healthy Adults and in A… | Phase1 | Schizophrenia | Terminated | 2013-07-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT01911091 | Identification of Novel Skeletal Muscle-derived Factors That Promote Lipid Oxid… | Na | Obesity | Active_Not_Recruiting | 2013-07-01 | 2026-12-01 | ClinicalTrials.gov |
| NCT01916304 | Study of Dose Adjustment From Levothyroxine to a New Levothyroxine Sodium Test … | Phase2 | Hypothyroidism | Completed | 2013-07-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT01899053 | A Safety and Pharmacokinetic Study of TAK-228 in Combination With TAK-117 in Ad… | Phase1 | Advanced Nonhematologic Malignancies | Completed | 2013-06-28 | 2018-04-30 | ClinicalTrials.gov |
| NCT01899053 | A Safety and Pharmacokinetic Study of TAK-228 in Combination With TAK-117 in Ad… | Phase1 | Advanced Nonhematologic Malignancies | Completed | 2013-06-28 | 2018-04-30 | ClinicalTrials.gov |
| NCT01899053 | A Safety and Pharmacokinetic Study of TAK-228 in Combination With TAK-117 in Ad… | Phase1 | Advanced Nonhematologic Malignancies | Completed | 2013-06-28 | 2018-04-30 | ClinicalTrials.gov |
| NCT01844583 | Safety, Tolerability and Pharmacokinetic (PK) of Concomitant Esomeprazole and R… | Phase1 | Solid Tumors | Completed | 2013-06-25 | 2016-09-06 | ClinicalTrials.gov |
| NCT01844583 | Safety, Tolerability and Pharmacokinetic (PK) of Concomitant Esomeprazole and R… | Phase1 | Solid Tumors | Completed | 2013-06-25 | 2016-09-06 | ClinicalTrials.gov |
| NCT01844583 | Safety, Tolerability and Pharmacokinetic (PK) of Concomitant Esomeprazole and R… | Phase1 | Solid Tumors | Completed | 2013-06-25 | 2016-09-06 | ClinicalTrials.gov |
| NCT01862328 | Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Com… | Phase1 | Solid Tumors | Completed | 2013-06-10 | 2018-05-21 | ClinicalTrials.gov |
| NCT01862328 | Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Com… | Phase1 | Solid Tumors | Completed | 2013-06-10 | 2018-05-21 | ClinicalTrials.gov |
| NCT01862328 | Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Com… | Phase1 | Solid Tumors | Completed | 2013-06-10 | 2018-05-21 | ClinicalTrials.gov |
| NCT02085252 | A Study of the Effect of Enantone LP 11.25 mg (Leuprorelin) on the Histological… | Phase3 | Prostate Cancer | Completed | 2013-06-03 | 2016-11-08 | ClinicalTrials.gov |
| NCT02085252 | A Study of the Effect of Enantone LP 11.25 mg (Leuprorelin) on the Histological… | Phase3 | Prostate Cancer | Completed | 2013-06-03 | 2016-11-08 | ClinicalTrials.gov |
| NCT02085252 | A Study of the Effect of Enantone LP 11.25 mg (Leuprorelin) on the Histological… | Phase3 | Prostate Cancer | Completed | 2013-06-03 | 2016-11-08 | ClinicalTrials.gov |
| NCT01879722 | Safety, Tolerability and Pharmacokinetic Study of Multiple Rising Doses of TAK-… | Phase1 | Schizophrenia | Completed | 2013-06-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT02334982 | Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of TAK-137… | Phase1 | Dose Finding Study | Completed | 2013-06-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT01879722 | Safety, Tolerability and Pharmacokinetic Study of Multiple Rising Doses of TAK-… | Phase1 | Schizophrenia | Completed | 2013-06-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT02334982 | Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of TAK-137… | Phase1 | Dose Finding Study | Completed | 2013-06-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT01834274 | Comparison of Fasiglifam (TAK-875) With Sitagliptin When Used in Combination Wi… | Phase3 | Diabetes Mellitus, Type 2 | Terminated | 2013-06-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01861795 | Observational Study in Preterm Neonates Who Are Sufficiently Stable on Non-Inva… | — | Non-invasive Ventilatory Support | Completed | 2013-06-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT02334982 | Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of TAK-137… | Phase1 | Dose Finding Study | Completed | 2013-06-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT01879722 | Safety, Tolerability and Pharmacokinetic Study of Multiple Rising Doses of TAK-… | Phase1 | Schizophrenia | Completed | 2013-06-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT01834274 | Comparison of Fasiglifam (TAK-875) With Sitagliptin When Used in Combination Wi… | Phase3 | Diabetes Mellitus, Type 2 | Terminated | 2013-06-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01861795 | Observational Study in Preterm Neonates Who Are Sufficiently Stable on Non-Inva… | — | Non-invasive Ventilatory Support | Completed | 2013-06-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01834274 | Comparison of Fasiglifam (TAK-875) With Sitagliptin When Used in Combination Wi… | Phase3 | Diabetes Mellitus, Type 2 | Terminated | 2013-06-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01861795 | Observational Study in Preterm Neonates Who Are Sufficiently Stable on Non-Inva… | — | Non-invasive Ventilatory Support | Completed | 2013-06-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01709981 | Anti-inflammatory Effects of Colchicine in PCI | Phase4 | Coronary Artery Disease | Completed | 2013-05-30 | 2021-12-13 | ClinicalTrials.gov |
| NCT01709981 | Anti-inflammatory Effects of Colchicine in PCI | Phase4 | Coronary Artery Disease | Completed | 2013-05-30 | 2021-12-13 | ClinicalTrials.gov |
| NCT01709981 | Anti-inflammatory Effects of Colchicine in PCI | Phase4 | Coronary Artery Disease | Completed | 2013-05-30 | 2021-12-13 | ClinicalTrials.gov |
| NCT02153073 | Evaluation of the Safety and Efficacy of Long-term Use of Omega-3 Fatty Acid Et… | — | Hyperlipidemia | Completed | 2013-05-29 | 2017-05-31 | ClinicalTrials.gov |
| NCT02153073 | Evaluation of the Safety and Efficacy of Long-term Use of Omega-3 Fatty Acid Et… | — | Hyperlipidemia | Completed | 2013-05-29 | 2017-05-31 | ClinicalTrials.gov |
| NCT02153073 | Evaluation of the Safety and Efficacy of Long-term Use of Omega-3 Fatty Acid Et… | — | Hyperlipidemia | Completed | 2013-05-29 | 2017-05-31 | ClinicalTrials.gov |
| NCT02089997 | Special Drug Use Surveillance on Long-term Use of Sodium Risedronate Tablets (B… | — | Osteoporosis | Completed | 2013-05-27 | 2016-04-30 | ClinicalTrials.gov |
| NCT02089997 | Special Drug Use Surveillance on Long-term Use of Sodium Risedronate Tablets (B… | — | Osteoporosis | Completed | 2013-05-27 | 2016-04-30 | ClinicalTrials.gov |
| NCT02089997 | Special Drug Use Surveillance on Long-term Use of Sodium Risedronate Tablets (B… | — | Osteoporosis | Completed | 2013-05-27 | 2016-04-30 | ClinicalTrials.gov |
| NCT01887938 | An Efficacy and Safety Study of HGT-1110 in Participants With Metachromatic Leu… | Phase1 | Metachromatic Leukodystrophy (MLD) | Completed | 2013-05-23 | 2026-02-13 | ClinicalTrials.gov |
| NCT01887938 | An Efficacy and Safety Study of HGT-1110 in Participants With Metachromatic Leu… | Phase1 | Metachromatic Leukodystrophy (MLD) | Completed | 2013-05-23 | 2026-02-13 | ClinicalTrials.gov |
| NCT01887938 | An Efficacy and Safety Study of HGT-1110 in Participants With Metachromatic Leu… | Phase1 | Metachromatic Leukodystrophy (MLD) | Completed | 2013-05-23 | 2026-02-13 | ClinicalTrials.gov |
| NCT01812005 | Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refr… | Phase2 | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Terminated | 2013-05-21 | 2017-04-20 | ClinicalTrials.gov |
| NCT01812005 | Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refr… | Phase2 | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Terminated | 2013-05-21 | 2017-04-20 | ClinicalTrials.gov |
| NCT01812005 | Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refr… | Phase2 | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Terminated | 2013-05-21 | 2017-04-20 | ClinicalTrials.gov |
| NCT01461954 | FST-100 in the Treatment of Acute Viral Conjunctivitis | Phase2 | Acute Viral Conjunctivitis | Completed | 2013-05-17 | 2014-03-10 | ClinicalTrials.gov |
| NCT01461954 | FST-100 in the Treatment of Acute Viral Conjunctivitis | Phase2 | Acute Viral Conjunctivitis | Completed | 2013-05-17 | 2014-03-10 | ClinicalTrials.gov |
| NCT01461954 | FST-100 in the Treatment of Acute Viral Conjunctivitis | Phase2 | Acute Viral Conjunctivitis | Completed | 2013-05-17 | 2014-03-10 | ClinicalTrials.gov |
| NCT02106442 | 36-month Special Drug Use Surveillance on Frequency of Bone Fractures With Sodi… | — | Osteoporosis | Completed | 2013-05-13 | 2018-04-30 | ClinicalTrials.gov |
| NCT02106442 | 36-month Special Drug Use Surveillance on Frequency of Bone Fractures With Sodi… | — | Osteoporosis | Completed | 2013-05-13 | 2018-04-30 | ClinicalTrials.gov |
| NCT02106442 | 36-month Special Drug Use Surveillance on Frequency of Bone Fractures With Sodi… | — | Osteoporosis | Completed | 2013-05-13 | 2018-04-30 | ClinicalTrials.gov |
| NCT01824446 | AME (Absorption, Metabolism, and Excretion) of Radiolabeled SSP-004184 | Phase1 | Healthy | Completed | 2013-05-01 | 2013-05-29 | ClinicalTrials.gov |
| NCT01816048 | NaF Positron Emission Tomography/Computed Tomography (PET/CT)Imaging to Assess … | Phase2 | Prostatic Neoplasms | Terminated | 2013-05-01 | 2016-11-01 | ClinicalTrials.gov |
| NCT01824446 | AME (Absorption, Metabolism, and Excretion) of Radiolabeled SSP-004184 | Phase1 | Healthy | Completed | 2013-05-01 | 2013-05-29 | ClinicalTrials.gov |
| NCT01829464 | TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diab… | Phase3 | Diabetes | Terminated | 2013-05-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01816048 | NaF Positron Emission Tomography/Computed Tomography (PET/CT)Imaging to Assess … | Phase2 | Prostatic Neoplasms | Terminated | 2013-05-01 | 2016-11-01 | ClinicalTrials.gov |
| NCT01848210 | Efficacy and Safety of Coumarin and Troxerutin in the Symptomatic Treatment of … | Phase4 | Chronic Venous Insufficiency | Completed | 2013-05-01 | 2015-09-01 | ClinicalTrials.gov |
| NCT01829464 | TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diab… | Phase3 | Diabetes | Terminated | 2013-05-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01851200 | Brentuximab Vedotin (SGN-35) as Salvage Treatment for CD30-positive Germ Cell T… | Phase2 | Germ Cell Cancer | Completed | 2013-05-01 | 2017-09-01 | ClinicalTrials.gov |
| NCT01816048 | NaF Positron Emission Tomography/Computed Tomography (PET/CT)Imaging to Assess … | Phase2 | Prostatic Neoplasms | Terminated | 2013-05-01 | 2016-11-01 | ClinicalTrials.gov |
| NCT01824446 | AME (Absorption, Metabolism, and Excretion) of Radiolabeled SSP-004184 | Phase1 | Healthy | Completed | 2013-05-01 | 2013-05-29 | ClinicalTrials.gov |
| NCT01848210 | Efficacy and Safety of Coumarin and Troxerutin in the Symptomatic Treatment of … | Phase4 | Chronic Venous Insufficiency | Completed | 2013-05-01 | 2015-09-01 | ClinicalTrials.gov |
| NCT01829464 | TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diab… | Phase3 | Diabetes | Terminated | 2013-05-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01851200 | Brentuximab Vedotin (SGN-35) as Salvage Treatment for CD30-positive Germ Cell T… | Phase2 | Germ Cell Cancer | Completed | 2013-05-01 | 2017-09-01 | ClinicalTrials.gov |
| NCT01848210 | Efficacy and Safety of Coumarin and Troxerutin in the Symptomatic Treatment of … | Phase4 | Chronic Venous Insufficiency | Completed | 2013-05-01 | 2015-09-01 | ClinicalTrials.gov |
| NCT01763996 | The Influence of Febuxostat on Coronary Artery Endothelial Dysfunction in Parti… | Phase4 | Coronary Artery Disease | Completed | 2013-05-01 | 2015-04-01 | ClinicalTrials.gov |
| NCT01851200 | Brentuximab Vedotin (SGN-35) as Salvage Treatment for CD30-positive Germ Cell T… | Phase2 | Germ Cell Cancer | Completed | 2013-05-01 | 2017-09-01 | ClinicalTrials.gov |
| NCT01888237 | High Dose PPI Triple Therapy Versus Sequential Therapy for Helicobacter Pylori … | Phase4 | Dyspepsia | Completed | 2013-05-01 | 2014-09-01 | ClinicalTrials.gov |
| NCT01888237 | High Dose PPI Triple Therapy Versus Sequential Therapy for Helicobacter Pylori … | Phase4 | Dyspepsia | Completed | 2013-05-01 | 2014-09-01 | ClinicalTrials.gov |
| NCT01888237 | High Dose PPI Triple Therapy Versus Sequential Therapy for Helicobacter Pylori … | Phase4 | Dyspepsia | Completed | 2013-05-01 | 2014-09-01 | ClinicalTrials.gov |
| NCT01763996 | The Influence of Febuxostat on Coronary Artery Endothelial Dysfunction in Parti… | Phase4 | Coronary Artery Disease | Completed | 2013-05-01 | 2015-04-01 | ClinicalTrials.gov |
| NCT01763996 | The Influence of Febuxostat on Coronary Artery Endothelial Dysfunction in Parti… | Phase4 | Coronary Artery Disease | Completed | 2013-05-01 | 2015-04-01 | ClinicalTrials.gov |
| NCT01850524 | IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide a… | Phase3 | Multiple Myeloma | Completed | 2013-04-29 | 2022-06-24 | ClinicalTrials.gov |
| NCT01850524 | IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide a… | Phase3 | Multiple Myeloma | Completed | 2013-04-29 | 2022-06-24 | ClinicalTrials.gov |
| NCT01850524 | IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide a… | Phase3 | Multiple Myeloma | Completed | 2013-04-29 | 2022-06-24 | ClinicalTrials.gov |
| NCT01833143 | Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those … | Phase2 | Non-Small Cell Lung Cancer | Completed | 2013-04-11 | 2019-08-28 | ClinicalTrials.gov |
| NCT01833143 | Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those … | Phase2 | Non-Small Cell Lung Cancer | Completed | 2013-04-11 | 2019-08-28 | ClinicalTrials.gov |
| NCT01833143 | Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those … | Phase2 | Non-Small Cell Lung Cancer | Completed | 2013-04-11 | 2019-08-28 | ClinicalTrials.gov |
| NCT01814826 | Study of MLN4924 Plus Azacitidine in Treatment-naive Participants With Acute My… | Phase1 | Acute Myelogenous Leukemia | Completed | 2013-04-10 | 2018-04-08 | ClinicalTrials.gov |
| NCT01814826 | Study of MLN4924 Plus Azacitidine in Treatment-naive Participants With Acute My… | Phase1 | Acute Myelogenous Leukemia | Completed | 2013-04-10 | 2018-04-08 | ClinicalTrials.gov |
| NCT01814826 | Study of MLN4924 Plus Azacitidine in Treatment-naive Participants With Acute My… | Phase1 | Acute Myelogenous Leukemia | Completed | 2013-04-10 | 2018-04-08 | ClinicalTrials.gov |
| NCT01829477 | Comparison of TAK-875 to Placebo as an Add-on to Glimepiride in Patients With T… | Phase3 | Diabetes Mellitus, Type 2 | Terminated | 2013-04-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT02275598 | Brentuximab Vedotin Followed by ABVD in Patients With Previously Untreated Hodg… | Phase2 | Hodgkin Lymphoma | Unknown | 2013-04-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT01863459 | Lisdexamfetamine Dimesylate in the Treatment of Adult ADHD With Anxiety Disorde… | Phase4 | Adult Attention Deficit Hyperactivity Disorder (ADHD) With Co-occuring Anxiety and Depressive Disorders | Completed | 2013-04-01 | 2017-03-01 | ClinicalTrials.gov |
| NCT02275598 | Brentuximab Vedotin Followed by ABVD in Patients With Previously Untreated Hodg… | Phase2 | Hodgkin Lymphoma | Unknown | 2013-04-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT01751360 | SYR-472 Open-label Study | Phase3 | Diabetes Mellitus | Completed | 2013-04-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01884688 | UARK 2013-05 A Study of Autologous Expanded Natural Killer Cell Therapy for Asy… | Phase2 | Asymptomatic Multiple Myeloma | Completed | 2013-04-01 | 2016-10-01 | ClinicalTrials.gov |
| NCT01863459 | Lisdexamfetamine Dimesylate in the Treatment of Adult ADHD With Anxiety Disorde… | Phase4 | Adult Attention Deficit Hyperactivity Disorder (ADHD) With Co-occuring Anxiety and Depressive Disorders | Completed | 2013-04-01 | 2017-03-01 | ClinicalTrials.gov |
| NCT02275598 | Brentuximab Vedotin Followed by ABVD in Patients With Previously Untreated Hodg… | Phase2 | Hodgkin Lymphoma | Unknown | 2013-04-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT01884688 | UARK 2013-05 A Study of Autologous Expanded Natural Killer Cell Therapy for Asy… | Phase2 | Asymptomatic Multiple Myeloma | Completed | 2013-04-01 | 2016-10-01 | ClinicalTrials.gov |
| NCT01751360 | SYR-472 Open-label Study | Phase3 | Diabetes Mellitus | Completed | 2013-04-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01884688 | UARK 2013-05 A Study of Autologous Expanded Natural Killer Cell Therapy for Asy… | Phase2 | Asymptomatic Multiple Myeloma | Completed | 2013-04-01 | 2016-10-01 | ClinicalTrials.gov |
| NCT01829477 | Comparison of TAK-875 to Placebo as an Add-on to Glimepiride in Patients With T… | Phase3 | Diabetes Mellitus, Type 2 | Terminated | 2013-04-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT01863459 | Lisdexamfetamine Dimesylate in the Treatment of Adult ADHD With Anxiety Disorde… | Phase4 | Adult Attention Deficit Hyperactivity Disorder (ADHD) With Co-occuring Anxiety and Depressive Disorders | Completed | 2013-04-01 | 2017-03-01 | ClinicalTrials.gov |
| NCT01829477 | Comparison of TAK-875 to Placebo as an Add-on to Glimepiride in Patients With T… | Phase3 | Diabetes Mellitus, Type 2 | Terminated | 2013-04-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT01751360 | SYR-472 Open-label Study | Phase3 | Diabetes Mellitus | Completed | 2013-04-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01806545 | An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing … | Phase2 | Arteriovenous Fistula | Completed | 2013-03-26 | 2014-10-27 | ClinicalTrials.gov |
| NCT01806545 | An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing … | Phase2 | Arteriovenous Fistula | Completed | 2013-03-26 | 2014-10-27 | ClinicalTrials.gov |
| NCT01806545 | An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing … | Phase2 | Arteriovenous Fistula | Completed | 2013-03-26 | 2014-10-27 | ClinicalTrials.gov |
| NCT01771809 | Long-Term Safety Of PF-00547659 In Ulcerative Colitis | Phase2 | Ulcerative Colitis | Completed | 2013-03-18 | 2017-12-13 | ClinicalTrials.gov |
| NCT01771809 | Long-Term Safety Of PF-00547659 In Ulcerative Colitis | Phase2 | Ulcerative Colitis | Completed | 2013-03-18 | 2017-12-13 | ClinicalTrials.gov |
| NCT01771809 | Long-Term Safety Of PF-00547659 In Ulcerative Colitis | Phase2 | Ulcerative Colitis | Completed | 2013-03-18 | 2017-12-13 | ClinicalTrials.gov |
| NCT01842841 | Multicenter Extension Study of Velaglucerase Alfa in Japanese Patients With Gau… | Phase3 | Gaucher Disease | Completed | 2013-03-13 | 2014-10-08 | ClinicalTrials.gov |
| NCT01842841 | Multicenter Extension Study of Velaglucerase Alfa in Japanese Patients With Gau… | Phase3 | Gaucher Disease | Completed | 2013-03-13 | 2014-10-08 | ClinicalTrials.gov |
| NCT01842841 | Multicenter Extension Study of Velaglucerase Alfa in Japanese Patients With Gau… | Phase3 | Gaucher Disease | Completed | 2013-03-13 | 2014-10-08 | ClinicalTrials.gov |
| NCT01809691 | S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer | Phase3 | Prostate Cancer | Completed | 2013-03-08 | 2025-09-09 | ClinicalTrials.gov |
| NCT01809691 | S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer | Phase3 | Prostate Cancer | Completed | 2013-03-08 | 2025-09-09 | ClinicalTrials.gov |
| NCT01809691 | S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer | Phase3 | Prostate Cancer | Completed | 2013-03-08 | 2025-09-09 | ClinicalTrials.gov |
| NCT01786876 | Adsorption, Metabolism and Excretion (AME) of Single Dose Radiolabeled SPD557 i… | Phase1 | Healthy Volunteers | Completed | 2013-03-07 | 2013-04-12 | ClinicalTrials.gov |
| NCT01786876 | Adsorption, Metabolism and Excretion (AME) of Single Dose Radiolabeled SPD557 i… | Phase1 | Healthy Volunteers | Completed | 2013-03-07 | 2013-04-12 | ClinicalTrials.gov |
| NCT01786876 | Adsorption, Metabolism and Excretion (AME) of Single Dose Radiolabeled SPD557 i… | Phase1 | Healthy Volunteers | Completed | 2013-03-07 | 2013-04-12 | ClinicalTrials.gov |
| NCT01802957 | Health Facility Networking for Maternal Health | Na | Provider Skill | Completed | 2013-03-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT01755949 | Colchicine and CRP in Atrial Fibrillation and AF Ablation | Phase2 | Atrial Fibrillation | Completed | 2013-03-01 | 2016-12-06 | ClinicalTrials.gov |
| NCT01802957 | Health Facility Networking for Maternal Health | Na | Provider Skill | Completed | 2013-03-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT02072330 | Study to Evaluate the Efficacy and Safety of Combined Administration of TAK-536… | Phase2 | Grade I or II Essential Hypertension | Completed | 2013-03-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01755949 | Colchicine and CRP in Atrial Fibrillation and AF Ablation | Phase2 | Atrial Fibrillation | Completed | 2013-03-01 | 2016-12-06 | ClinicalTrials.gov |
| NCT01755949 | Colchicine and CRP in Atrial Fibrillation and AF Ablation | Phase2 | Atrial Fibrillation | Completed | 2013-03-01 | 2016-12-06 | ClinicalTrials.gov |
| NCT02072330 | Study to Evaluate the Efficacy and Safety of Combined Administration of TAK-536… | Phase2 | Grade I or II Essential Hypertension | Completed | 2013-03-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT02072330 | Study to Evaluate the Efficacy and Safety of Combined Administration of TAK-536… | Phase2 | Grade I or II Essential Hypertension | Completed | 2013-03-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01802957 | Health Facility Networking for Maternal Health | Na | Provider Skill | Completed | 2013-03-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT03211052 | A Study of Neoadjuvant TAK-700 and Leuprorelin Acetate Followed by Surgery Vers… | Phase2 | Prostate Cancer | Terminated | 2013-02-18 | 2015-06-02 | ClinicalTrials.gov |
| NCT03211052 | A Study of Neoadjuvant TAK-700 and Leuprorelin Acetate Followed by Surgery Vers… | Phase2 | Prostate Cancer | Terminated | 2013-02-18 | 2015-06-02 | ClinicalTrials.gov |
| NCT03211052 | A Study of Neoadjuvant TAK-700 and Leuprorelin Acetate Followed by Surgery Vers… | Phase2 | Prostate Cancer | Terminated | 2013-02-18 | 2015-06-02 | ClinicalTrials.gov |
| NCT01765426 | Phase 1b Study Investigating Safety & Immunogenicity of TDV Given Intradermally… | Phase1 | Healthy Volunteers | Completed | 2013-02-15 | 2014-06-26 | ClinicalTrials.gov |
| NCT01765426 | Phase 1b Study Investigating Safety & Immunogenicity of TDV Given Intradermally… | Phase1 | Healthy Volunteers | Completed | 2013-02-15 | 2014-06-26 | ClinicalTrials.gov |
| NCT01765426 | Phase 1b Study Investigating Safety & Immunogenicity of TDV Given Intradermally… | Phase1 | Healthy Volunteers | Completed | 2013-02-15 | 2014-06-26 | ClinicalTrials.gov |
| NCT01756157 | Subcutaneous CINRYZE With Recombinant Human Hyaluronidase for Prevention of Ang… | Phase2 | Hereditary Angioedema (HAE) | Completed | 2013-02-04 | 2013-09-13 | ClinicalTrials.gov |
| NCT01756157 | Subcutaneous CINRYZE With Recombinant Human Hyaluronidase for Prevention of Ang… | Phase2 | Hereditary Angioedema (HAE) | Completed | 2013-02-04 | 2013-09-13 | ClinicalTrials.gov |
| NCT01756157 | Subcutaneous CINRYZE With Recombinant Human Hyaluronidase for Prevention of Ang… | Phase2 | Hereditary Angioedema (HAE) | Completed | 2013-02-04 | 2013-09-13 | ClinicalTrials.gov |
| NCT01760889 | SPD489 Low Dose and High Dose Ranges When Added to Stable Doses of Antipsychoti… | Phase3 | Schizophrenia | Terminated | 2013-02-01 | 2013-04-01 | ClinicalTrials.gov |
| NCT01701934 | Impact of Roflumilast on Visceral Adiposity and Metabolic Profile in Chronic Ob… | Phase2 | Chronic Obstructive Pulmonary Disease | Terminated | 2013-02-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT01760889 | SPD489 Low Dose and High Dose Ranges When Added to Stable Doses of Antipsychoti… | Phase3 | Schizophrenia | Terminated | 2013-02-01 | 2013-04-01 | ClinicalTrials.gov |
| NCT01760993 | Long-term Safety of SPD489 When Added to Stable Doses of Antipsychotic Medicati… | Phase3 | Schizophrenia | Terminated | 2013-02-01 | 2013-04-01 | ClinicalTrials.gov |
| NCT01701934 | Impact of Roflumilast on Visceral Adiposity and Metabolic Profile in Chronic Ob… | Phase2 | Chronic Obstructive Pulmonary Disease | Terminated | 2013-02-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT01760889 | SPD489 Low Dose and High Dose Ranges When Added to Stable Doses of Antipsychoti… | Phase3 | Schizophrenia | Terminated | 2013-02-01 | 2013-04-01 | ClinicalTrials.gov |
| NCT01799278 | A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and … | Phase2 | Small Cell Prostate Cancer | Completed | 2013-02-01 | 2017-08-01 | ClinicalTrials.gov |
| NCT01799278 | A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and … | Phase2 | Small Cell Prostate Cancer | Completed | 2013-02-01 | 2017-08-01 | ClinicalTrials.gov |
| NCT01799278 | A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and … | Phase2 | Small Cell Prostate Cancer | Completed | 2013-02-01 | 2017-08-01 | ClinicalTrials.gov |
| NCT01701934 | Impact of Roflumilast on Visceral Adiposity and Metabolic Profile in Chronic Ob… | Phase2 | Chronic Obstructive Pulmonary Disease | Terminated | 2013-02-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT01760993 | Long-term Safety of SPD489 When Added to Stable Doses of Antipsychotic Medicati… | Phase3 | Schizophrenia | Terminated | 2013-02-01 | 2013-04-01 | ClinicalTrials.gov |
| NCT01760993 | Long-term Safety of SPD489 When Added to Stable Doses of Antipsychotic Medicati… | Phase3 | Schizophrenia | Terminated | 2013-02-01 | 2013-04-01 | ClinicalTrials.gov |
| NCT01777152 | ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CH… | Phase3 | Anaplastic Large-Cell Lymphoma | Completed | 2013-01-31 | 2020-10-02 | ClinicalTrials.gov |
| NCT01777152 | ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CH… | Phase3 | Anaplastic Large-Cell Lymphoma | Completed | 2013-01-31 | 2020-10-02 | ClinicalTrials.gov |
| NCT01777152 | ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CH… | Phase3 | Anaplastic Large-Cell Lymphoma | Completed | 2013-01-31 | 2020-10-02 | ClinicalTrials.gov |
| NCT01714947 | Mass Balance, Pharmacokinetics and Metabolism Study of Alisertib | Phase1 | Advanced Solid Tumors | Completed | 2013-01-24 | 2013-06-14 | ClinicalTrials.gov |
| NCT01714947 | Mass Balance, Pharmacokinetics and Metabolism Study of Alisertib | Phase1 | Advanced Solid Tumors | Completed | 2013-01-24 | 2013-06-14 | ClinicalTrials.gov |
| NCT01714947 | Mass Balance, Pharmacokinetics and Metabolism Study of Alisertib | Phase1 | Advanced Solid Tumors | Completed | 2013-01-24 | 2013-06-14 | ClinicalTrials.gov |
| NCT01728792 | Impact of SC vs IM Administration of DENVax (TDV) on Safety and Immunogenicity | Phase1 | Dengue Fever | Completed | 2013-01-22 | 2013-11-21 | ClinicalTrials.gov |
| NCT01728792 | Impact of SC vs IM Administration of DENVax (TDV) on Safety and Immunogenicity | Phase1 | Dengue Fever | Completed | 2013-01-22 | 2013-11-21 | ClinicalTrials.gov |
| NCT01728792 | Impact of SC vs IM Administration of DENVax (TDV) on Safety and Immunogenicity | Phase1 | Dengue Fever | Completed | 2013-01-22 | 2013-11-21 | ClinicalTrials.gov |
| NCT01822184 | Observational Study to Evaluate Neurodevelopmental Status in Pediatric Patients… | — | Mucopolysaccharidosis (MPS) | Completed | 2013-01-18 | 2016-10-05 | ClinicalTrials.gov |
| NCT01822184 | Observational Study to Evaluate Neurodevelopmental Status in Pediatric Patients… | — | Mucopolysaccharidosis (MPS) | Completed | 2013-01-18 | 2016-10-05 | ClinicalTrials.gov |
| NCT01822184 | Observational Study to Evaluate Neurodevelopmental Status in Pediatric Patients… | — | Mucopolysaccharidosis (MPS) | Completed | 2013-01-18 | 2016-10-05 | ClinicalTrials.gov |
| NCT01774591 | Effect of Azilsartan on Aldosterone in Postmenopausal Females | Na | Hypertension | Completed | 2013-01-01 | 2016-01-01 | ClinicalTrials.gov |
| NCT01714310 | Characterization and Sequential Pharmacotherapy of Severe Mood Dysregulation | Phase2 | Severe Mood Dysregulation | Completed | 2013-01-01 | 2016-06-01 | ClinicalTrials.gov |
| NCT01774591 | Effect of Azilsartan on Aldosterone in Postmenopausal Females | Na | Hypertension | Completed | 2013-01-01 | 2016-01-01 | ClinicalTrials.gov |
| NCT01714310 | Characterization and Sequential Pharmacotherapy of Severe Mood Dysregulation | Phase2 | Severe Mood Dysregulation | Completed | 2013-01-01 | 2016-06-01 | ClinicalTrials.gov |
| NCT01714310 | Characterization and Sequential Pharmacotherapy of Severe Mood Dysregulation | Phase2 | Severe Mood Dysregulation | Completed | 2013-01-01 | 2016-06-01 | ClinicalTrials.gov |
| NCT01774591 | Effect of Azilsartan on Aldosterone in Postmenopausal Females | Na | Hypertension | Completed | 2013-01-01 | 2016-01-01 | ClinicalTrials.gov |
| NCT02501798 | The Effects of Long-acting Methylphenidate on Academic Activity and Related Con… | Phase4 | Attention Deficit Hyperactivity Disorder | Completed | 2013-01-01 | 2016-05-01 | ClinicalTrials.gov |
| NCT02501798 | The Effects of Long-acting Methylphenidate on Academic Activity and Related Con… | Phase4 | Attention Deficit Hyperactivity Disorder | Completed | 2013-01-01 | 2016-05-01 | ClinicalTrials.gov |
| NCT02501798 | The Effects of Long-acting Methylphenidate on Academic Activity and Related Con… | Phase4 | Attention Deficit Hyperactivity Disorder | Completed | 2013-01-01 | 2016-05-01 | ClinicalTrials.gov |
| NCT01659658 | Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatmen… | Phase3 | Relapsed or Refractory Systemic Light Chain Amyloidosis | Terminated | 2012-12-26 | 2022-07-11 | ClinicalTrials.gov |
| NCT01659658 | Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatmen… | Phase3 | Relapsed or Refractory Systemic Light Chain Amyloidosis | Terminated | 2012-12-26 | 2022-07-11 | ClinicalTrials.gov |
| NCT01659658 | Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatmen… | Phase3 | Relapsed or Refractory Systemic Light Chain Amyloidosis | Terminated | 2012-12-26 | 2022-07-11 | ClinicalTrials.gov |
| NCT01736943 | Bortezomib and Doxil for the Treatment of Patients With Acute Myelogenous Leuke… | Phase2 | Acute Myelogenous Leukemia | Completed | 2012-12-19 | 2019-05-20 | ClinicalTrials.gov |
| NCT01736943 | Bortezomib and Doxil for the Treatment of Patients With Acute Myelogenous Leuke… | Phase2 | Acute Myelogenous Leukemia | Completed | 2012-12-19 | 2019-05-20 | ClinicalTrials.gov |
| NCT01736943 | Bortezomib and Doxil for the Treatment of Patients With Acute Myelogenous Leuke… | Phase2 | Acute Myelogenous Leukemia | Completed | 2012-12-19 | 2019-05-20 | ClinicalTrials.gov |
| NCT01729338 | Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma | Phase2 | Multiple Myeloma | Terminated | 2012-12-19 | 2016-12-31 | ClinicalTrials.gov |
| NCT01729338 | Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma | Phase2 | Multiple Myeloma | Terminated | 2012-12-19 | 2016-12-31 | ClinicalTrials.gov |
| NCT01729338 | Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma | Phase2 | Multiple Myeloma | Terminated | 2012-12-19 | 2016-12-31 | ClinicalTrials.gov |
| NCT01470664 | FST-100 in the Treatment of Acute Adenoviral Conjunctivitis | Phase2 | Acute Adenoviral Conjunctivitis | Completed | 2012-12-17 | 2014-05-23 | ClinicalTrials.gov |
| NCT01645930 | Phase 1 Pharmacokinetic Study of Oral Ixazomib Plus Lenalidomide and Dexamethas… | Phase1 | Multiple Myeloma | Completed | 2012-12-17 | 2017-04-11 | ClinicalTrials.gov |
| NCT01470664 | FST-100 in the Treatment of Acute Adenoviral Conjunctivitis | Phase2 | Acute Adenoviral Conjunctivitis | Completed | 2012-12-17 | 2014-05-23 | ClinicalTrials.gov |
| NCT01645930 | Phase 1 Pharmacokinetic Study of Oral Ixazomib Plus Lenalidomide and Dexamethas… | Phase1 | Multiple Myeloma | Completed | 2012-12-17 | 2017-04-11 | ClinicalTrials.gov |
| NCT01470664 | FST-100 in the Treatment of Acute Adenoviral Conjunctivitis | Phase2 | Acute Adenoviral Conjunctivitis | Completed | 2012-12-17 | 2014-05-23 | ClinicalTrials.gov |
| NCT01645930 | Phase 1 Pharmacokinetic Study of Oral Ixazomib Plus Lenalidomide and Dexamethas… | Phase1 | Multiple Myeloma | Completed | 2012-12-17 | 2017-04-11 | ClinicalTrials.gov |
| NCT01762501 | Azilsartan Circadian and Sleep Pressure | Na | Hypertension | Completed | 2012-12-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01762501 | Azilsartan Circadian and Sleep Pressure | Na | Hypertension | Completed | 2012-12-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01762501 | Azilsartan Circadian and Sleep Pressure | Na | Hypertension | Completed | 2012-12-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01718509 | SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder | Phase3 | Binge Eating Disorder | Completed | 2012-11-26 | 2013-09-20 | ClinicalTrials.gov |
| NCT01718483 | SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder | Phase3 | Binge Eating Disorder | Completed | 2012-11-26 | 2013-09-25 | ClinicalTrials.gov |
| NCT01718509 | SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder | Phase3 | Binge Eating Disorder | Completed | 2012-11-26 | 2013-09-20 | ClinicalTrials.gov |
| NCT01718483 | SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder | Phase3 | Binge Eating Disorder | Completed | 2012-11-26 | 2013-09-25 | ClinicalTrials.gov |
| NCT01718509 | SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder | Phase3 | Binge Eating Disorder | Completed | 2012-11-26 | 2013-09-20 | ClinicalTrials.gov |
| NCT01718483 | SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder | Phase3 | Binge Eating Disorder | Completed | 2012-11-26 | 2013-09-25 | ClinicalTrials.gov |
| NCT01449240 | Collection and Study of Cerebrospinal Fluid in Patients With Hunter Syndrome | — | Hunter Syndrome | Completed | 2012-11-12 | 2013-12-20 | ClinicalTrials.gov |
| NCT01449240 | Collection and Study of Cerebrospinal Fluid in Patients With Hunter Syndrome | — | Hunter Syndrome | Completed | 2012-11-12 | 2013-12-20 | ClinicalTrials.gov |
| NCT01449240 | Collection and Study of Cerebrospinal Fluid in Patients With Hunter Syndrome | — | Hunter Syndrome | Completed | 2012-11-12 | 2013-12-20 | ClinicalTrials.gov |
| NCT01732263 | Study of SSP-004184 (SPD602) in Healthy Adults and Subjects With Impaired Liver… | Phase1 | Hepatic Impairment | Completed | 2012-11-09 | 2013-04-01 | ClinicalTrials.gov |
| NCT01732263 | Study of SSP-004184 (SPD602) in Healthy Adults and Subjects With Impaired Liver… | Phase1 | Hepatic Impairment | Completed | 2012-11-09 | 2013-04-01 | ClinicalTrials.gov |
| NCT01712490 | A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymph… | Phase3 | Hodgkin Lymphoma | Completed | 2012-11-09 | 2026-02-02 | ClinicalTrials.gov |
| NCT01712490 | A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymph… | Phase3 | Hodgkin Lymphoma | Completed | 2012-11-09 | 2026-02-02 | ClinicalTrials.gov |
| NCT01712490 | A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymph… | Phase3 | Hodgkin Lymphoma | Completed | 2012-11-09 | 2026-02-02 | ClinicalTrials.gov |
| NCT01732263 | Study of SSP-004184 (SPD602) in Healthy Adults and Subjects With Impaired Liver… | Phase1 | Hepatic Impairment | Completed | 2012-11-09 | 2013-04-01 | ClinicalTrials.gov |
| NCT01732692 | Evaluation of the Efficacy, Safety and Tolerance of Experimental Morning-only M… | Phase3 | Bowel Preparation Prior to Endoscopic, Radiological and Other Examinations as Well as to Surgical Procedures Which Require Empty Bowel. | Completed | 2012-11-01 | 2013-04-01 | ClinicalTrials.gov |
| NCT01808040 | A Phase 1b Study of TAK-700 in Postmenopausal Women With Hormone-receptor Posit… | Phase1 | Post Menopausal, Hormone Receptor Positive Breast Cancer | Completed | 2012-11-01 | 2016-12-09 | ClinicalTrials.gov |
| NCT01808040 | A Phase 1b Study of TAK-700 in Postmenopausal Women With Hormone-receptor Posit… | Phase1 | Post Menopausal, Hormone Receptor Positive Breast Cancer | Completed | 2012-11-01 | 2016-12-09 | ClinicalTrials.gov |
| NCT02141113 | Efficacy and Safety Eval of Guanfacine Hydrochloride in Combination With Psycho… | Phase4 | Adult Attention-Deficit Hyperactivity Disorder | Completed | 2012-11-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT01808040 | A Phase 1b Study of TAK-700 in Postmenopausal Women With Hormone-receptor Posit… | Phase1 | Post Menopausal, Hormone Receptor Positive Breast Cancer | Completed | 2012-11-01 | 2016-12-09 | ClinicalTrials.gov |
| NCT02141113 | Efficacy and Safety Eval of Guanfacine Hydrochloride in Combination With Psycho… | Phase4 | Adult Attention-Deficit Hyperactivity Disorder | Completed | 2012-11-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT01732692 | Evaluation of the Efficacy, Safety and Tolerance of Experimental Morning-only M… | Phase3 | Bowel Preparation Prior to Endoscopic, Radiological and Other Examinations as Well as to Surgical Procedures Which Require Empty Bowel. | Completed | 2012-11-01 | 2013-04-01 | ClinicalTrials.gov |
| NCT01732692 | Evaluation of the Efficacy, Safety and Tolerance of Experimental Morning-only M… | Phase3 | Bowel Preparation Prior to Endoscopic, Radiological and Other Examinations as Well as to Surgical Procedures Which Require Empty Bowel. | Completed | 2012-11-01 | 2013-04-01 | ClinicalTrials.gov |
| NCT02141113 | Efficacy and Safety Eval of Guanfacine Hydrochloride in Combination With Psycho… | Phase4 | Adult Attention-Deficit Hyperactivity Disorder | Completed | 2012-11-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT01716455 | Study of SSP-004184 (FBS0701) in Healthy Adults and Elderly Subjects and in Sub… | Phase1 | Impaired Renal Function | Completed | 2012-10-29 | 2013-03-10 | ClinicalTrials.gov |
| NCT01716455 | Study of SSP-004184 (FBS0701) in Healthy Adults and Elderly Subjects and in Sub… | Phase1 | Impaired Renal Function | Completed | 2012-10-29 | 2013-03-10 | ClinicalTrials.gov |
| NCT01716455 | Study of SSP-004184 (FBS0701) in Healthy Adults and Elderly Subjects and in Sub… | Phase1 | Impaired Renal Function | Completed | 2012-10-29 | 2013-03-10 | ClinicalTrials.gov |
| NCT01647542 | Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 and 50mg in … | Phase3 | Type 2 Diabetes Mellitus | Terminated | 2012-10-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01647542 | Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 and 50mg in … | Phase3 | Type 2 Diabetes Mellitus | Terminated | 2012-10-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01816074 | Sequencing Treatments for Mothers With ADHD and Their At - Risk Children | Phase4 | Attention Deficit Hyperactivity Disorder | Completed | 2012-10-01 | 2017-05-01 | ClinicalTrials.gov |
| NCT01816074 | Sequencing Treatments for Mothers With ADHD and Their At - Risk Children | Phase4 | Attention Deficit Hyperactivity Disorder | Completed | 2012-10-01 | 2017-05-01 | ClinicalTrials.gov |
| NCT01466829 | Treatment With PTH After Sternotomy in Cardiac Surgery Patients | Phase3 | Disruption or Dehiscence of Closure of Sternum or Sternotomy | Completed | 2012-10-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01466829 | Treatment With PTH After Sternotomy in Cardiac Surgery Patients | Phase3 | Disruption or Dehiscence of Closure of Sternum or Sternotomy | Completed | 2012-10-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01647542 | Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 and 50mg in … | Phase3 | Type 2 Diabetes Mellitus | Terminated | 2012-10-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01466829 | Treatment With PTH After Sternotomy in Cardiac Surgery Patients | Phase3 | Disruption or Dehiscence of Closure of Sternum or Sternotomy | Completed | 2012-10-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01816074 | Sequencing Treatments for Mothers With ADHD and Their At - Risk Children | Phase4 | Attention Deficit Hyperactivity Disorder | Completed | 2012-10-01 | 2017-05-01 | ClinicalTrials.gov |
| NCT01604941 | Pharmacokinetics of SSP-004184 in the Treatment of Chronic Iron Overload Requir… | Phase2 | Iron Overload Due to Repeated Red Blood Cell Transfusions | Terminated | 2012-09-14 | 2014-04-18 | ClinicalTrials.gov |
| NCT01604941 | Pharmacokinetics of SSP-004184 in the Treatment of Chronic Iron Overload Requir… | Phase2 | Iron Overload Due to Repeated Red Blood Cell Transfusions | Terminated | 2012-09-14 | 2014-04-18 | ClinicalTrials.gov |
| NCT01604941 | Pharmacokinetics of SSP-004184 in the Treatment of Chronic Iron Overload Requir… | Phase2 | Iron Overload Due to Repeated Red Blood Cell Transfusions | Terminated | 2012-09-14 | 2014-04-18 | ClinicalTrials.gov |
| NCT01686711 | A Double-blind, Parallel Group, Comparative Study of Coadministration AD-4833 a… | Phase4 | Diabetes Mellitus | Completed | 2012-09-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01920958 | Use of Tachosil® for Lymph Sealing During Surgery | — | Lymph Node Resection | Completed | 2012-09-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01920958 | Use of Tachosil® for Lymph Sealing During Surgery | — | Lymph Node Resection | Completed | 2012-09-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01686711 | A Double-blind, Parallel Group, Comparative Study of Coadministration AD-4833 a… | Phase4 | Diabetes Mellitus | Completed | 2012-09-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01685151 | A Safety and Efficacy Study of Ramelteon Tablets for Sublingual Administration … | Phase3 | Bipolar Disorder | Withdrawn | 2012-09-01 | 2015-11-01 | ClinicalTrials.gov |
| NCT01685151 | A Safety and Efficacy Study of Ramelteon Tablets for Sublingual Administration … | Phase3 | Bipolar Disorder | Withdrawn | 2012-09-01 | 2015-11-01 | ClinicalTrials.gov |
| NCT01686711 | A Double-blind, Parallel Group, Comparative Study of Coadministration AD-4833 a… | Phase4 | Diabetes Mellitus | Completed | 2012-09-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01920958 | Use of Tachosil® for Lymph Sealing During Surgery | — | Lymph Node Resection | Completed | 2012-09-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01685151 | A Safety and Efficacy Study of Ramelteon Tablets for Sublingual Administration … | Phase3 | Bipolar Disorder | Withdrawn | 2012-09-01 | 2015-11-01 | ClinicalTrials.gov |
| NCT01666314 | Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodyn… | Phase1 | Prostate Cancer | Completed | 2012-08-20 | 2016-09-01 | ClinicalTrials.gov |
| NCT01666314 | Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodyn… | Phase1 | Prostate Cancer | Completed | 2012-08-20 | 2016-09-01 | ClinicalTrials.gov |
| NCT01666314 | Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodyn… | Phase1 | Prostate Cancer | Completed | 2012-08-20 | 2016-09-01 | ClinicalTrials.gov |
| NCT01661387 | A European Post-Authorisation Observational Study (Registry) of Patients With C… | — | Chronic Adrenal Insufficiency | Terminated | 2012-08-07 | 2020-10-31 | ClinicalTrials.gov |
| NCT01661387 | A European Post-Authorisation Observational Study (Registry) of Patients With C… | — | Chronic Adrenal Insufficiency | Terminated | 2012-08-07 | 2020-10-31 | ClinicalTrials.gov |
| NCT01661387 | A European Post-Authorisation Observational Study (Registry) of Patients With C… | — | Chronic Adrenal Insufficiency | Terminated | 2012-08-07 | 2020-10-31 | ClinicalTrials.gov |
| NCT01564537 | A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Ver… | Phase3 | Relapsed Multiple Myeloma | Completed | 2012-08-01 | 2022-02-08 | ClinicalTrials.gov |
| NCT01677182 | Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Adminis… | Phase3 | Bipolar Disorder | Terminated | 2012-08-01 | 2014-09-01 | ClinicalTrials.gov |
| NCT01677182 | Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Adminis… | Phase3 | Bipolar Disorder | Terminated | 2012-08-01 | 2014-09-01 | ClinicalTrials.gov |
| NCT01564537 | A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Ver… | Phase3 | Relapsed Multiple Myeloma | Completed | 2012-08-01 | 2022-02-08 | ClinicalTrials.gov |
| NCT01677182 | Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Adminis… | Phase3 | Bipolar Disorder | Terminated | 2012-08-01 | 2014-09-01 | ClinicalTrials.gov |
| NCT01564537 | A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Ver… | Phase3 | Relapsed Multiple Myeloma | Completed | 2012-08-01 | 2022-02-08 | ClinicalTrials.gov |
| NCT01642212 | OBS in Adolescent and Adults With EOE: A Phase II, Randomized, Double-Blind, Pl… | Phase2 | Eosinophilic Esophagitis (EoE) | Completed | 2012-07-23 | 2014-10-30 | ClinicalTrials.gov |
| NCT01642212 | OBS in Adolescent and Adults With EOE: A Phase II, Randomized, Double-Blind, Pl… | Phase2 | Eosinophilic Esophagitis (EoE) | Completed | 2012-07-23 | 2014-10-30 | ClinicalTrials.gov |
| NCT01642212 | OBS in Adolescent and Adults With EOE: A Phase II, Randomized, Double-Blind, Pl… | Phase2 | Eosinophilic Esophagitis (EoE) | Completed | 2012-07-23 | 2014-10-30 | ClinicalTrials.gov |
| NCT01611974 | Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant… | Phase2 | Cytomegalovirus (CMV) | Completed | 2012-07-17 | 2014-12-05 | ClinicalTrials.gov |
| NCT01611974 | Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant… | Phase2 | Cytomegalovirus (CMV) | Completed | 2012-07-17 | 2014-12-05 | ClinicalTrials.gov |
| NCT01611974 | Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant… | Phase2 | Cytomegalovirus (CMV) | Completed | 2012-07-17 | 2014-12-05 | ClinicalTrials.gov |
| NCT01609257 | Norovirus Bivalent-Vaccine Efficacy Study | Phase1 | Prevention From Norovirus Infection | Completed | 2012-07-16 | 2014-03-18 | ClinicalTrials.gov |
| NCT01609257 | Norovirus Bivalent-Vaccine Efficacy Study | Phase1 | Prevention From Norovirus Infection | Completed | 2012-07-16 | 2014-03-18 | ClinicalTrials.gov |
| NCT01609257 | Norovirus Bivalent-Vaccine Efficacy Study | Phase1 | Prevention From Norovirus Infection | Completed | 2012-07-16 | 2014-03-18 | ClinicalTrials.gov |
| NCT01647165 | Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone … | Phase2 | Multiple Myeloma | Withdrawn | 2012-07-11 | 2015-06-26 | ClinicalTrials.gov |
| NCT01647165 | Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone … | Phase2 | Multiple Myeloma | Withdrawn | 2012-07-11 | 2015-06-26 | ClinicalTrials.gov |
| NCT01647165 | Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone … | Phase2 | Multiple Myeloma | Withdrawn | 2012-07-11 | 2015-06-26 | ClinicalTrials.gov |
| NCT01549977 | Effect of Febuxostat Compared to Placebo on Exercise Tolerance in Participants … | Phase2 | Angina | Terminated | 2012-07-01 | 2012-11-01 | ClinicalTrials.gov |
| NCT01672229 | Bortezomib in Patients With Chronic Graft Versus Host Disease | Phase1 | Graft Versus Host Disease | Completed | 2012-07-01 | 2018-04-09 | ClinicalTrials.gov |
| NCT01549977 | Effect of Febuxostat Compared to Placebo on Exercise Tolerance in Participants … | Phase2 | Angina | Terminated | 2012-07-01 | 2012-11-01 | ClinicalTrials.gov |
| NCT02629848 | Study of Motesanib (AMG 706) in Combination With Paclitaxel and Carboplatin for… | Phase3 | Carcinoma, Non-Small-Cell Lung | Terminated | 2012-07-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT02629848 | Study of Motesanib (AMG 706) in Combination With Paclitaxel and Carboplatin for… | Phase3 | Carcinoma, Non-Small-Cell Lung | Terminated | 2012-07-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT01639222 | Human Pharmacology Trial of Calcium-vitamin D3 Tablet in Healthy Participants | Phase1 | Calcium Deficiency | Completed | 2012-07-01 | 2012-08-01 | ClinicalTrials.gov |
| NCT01642602 | Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules in Treating Sym… | Phase2 | Gastroesophageal Reflux Disease | Completed | 2012-07-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT01642602 | Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules in Treating Sym… | Phase2 | Gastroesophageal Reflux Disease | Completed | 2012-07-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT01642615 | Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules for Healing of … | Phase2 | Gastroesophageal Reflux Disease | Completed | 2012-07-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT01639222 | Human Pharmacology Trial of Calcium-vitamin D3 Tablet in Healthy Participants | Phase1 | Calcium Deficiency | Completed | 2012-07-01 | 2012-08-01 | ClinicalTrials.gov |
| NCT01630746 | A Randomized, Double-Blind, Multicenter Study to Evaluate the Acid-inhibitory a… | Phase3 | Erosive Esophagitis | Completed | 2012-07-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT01672229 | Bortezomib in Patients With Chronic Graft Versus Host Disease | Phase1 | Graft Versus Host Disease | Completed | 2012-07-01 | 2018-04-09 | ClinicalTrials.gov |
| NCT01630746 | A Randomized, Double-Blind, Multicenter Study to Evaluate the Acid-inhibitory a… | Phase3 | Erosive Esophagitis | Completed | 2012-07-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT02629848 | Study of Motesanib (AMG 706) in Combination With Paclitaxel and Carboplatin for… | Phase3 | Carcinoma, Non-Small-Cell Lung | Terminated | 2012-07-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT01549977 | Effect of Febuxostat Compared to Placebo on Exercise Tolerance in Participants … | Phase2 | Angina | Terminated | 2012-07-01 | 2012-11-01 | ClinicalTrials.gov |
| NCT01672229 | Bortezomib in Patients With Chronic Graft Versus Host Disease | Phase1 | Graft Versus Host Disease | Completed | 2012-07-01 | 2018-04-09 | ClinicalTrials.gov |
| NCT01642615 | Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules for Healing of … | Phase2 | Gastroesophageal Reflux Disease | Completed | 2012-07-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT01630746 | A Randomized, Double-Blind, Multicenter Study to Evaluate the Acid-inhibitory a… | Phase3 | Erosive Esophagitis | Completed | 2012-07-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT01642602 | Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules in Treating Sym… | Phase2 | Gastroesophageal Reflux Disease | Completed | 2012-07-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT01639222 | Human Pharmacology Trial of Calcium-vitamin D3 Tablet in Healthy Participants | Phase1 | Calcium Deficiency | Completed | 2012-07-01 | 2012-08-01 | ClinicalTrials.gov |
| NCT01642615 | Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules for Healing of … | Phase2 | Gastroesophageal Reflux Disease | Completed | 2012-07-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT02092025 | Azilsartan Tablets Special Drug Use Surveillance: Long-term Use | — | Hypertension | Completed | 2012-06-20 | 2016-01-15 | ClinicalTrials.gov |
| NCT02092025 | Azilsartan Tablets Special Drug Use Surveillance: Long-term Use | — | Hypertension | Completed | 2012-06-20 | 2016-01-15 | ClinicalTrials.gov |
| NCT02092025 | Azilsartan Tablets Special Drug Use Surveillance: Long-term Use | — | Hypertension | Completed | 2012-06-20 | 2016-01-15 | ClinicalTrials.gov |
| NCT01482962 | Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refracto… | Phase3 | Relapsed Peripheral T-Cell Lymphoma | Completed | 2012-06-11 | 2017-12-18 | ClinicalTrials.gov |
| NCT01578499 | A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Metho… | Phase3 | Primary Cutaneous Anaplastic Large Cell Lymphoma | Completed | 2012-06-11 | 2018-07-06 | ClinicalTrials.gov |
| NCT01578499 | A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Metho… | Phase3 | Primary Cutaneous Anaplastic Large Cell Lymphoma | Completed | 2012-06-11 | 2018-07-06 | ClinicalTrials.gov |
| NCT01482962 | Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refracto… | Phase3 | Relapsed Peripheral T-Cell Lymphoma | Completed | 2012-06-11 | 2017-12-18 | ClinicalTrials.gov |
| NCT01578499 | A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Metho… | Phase3 | Primary Cutaneous Anaplastic Large Cell Lymphoma | Completed | 2012-06-11 | 2018-07-06 | ClinicalTrials.gov |
| NCT01482962 | Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refracto… | Phase3 | Relapsed Peripheral T-Cell Lymphoma | Completed | 2012-06-11 | 2017-12-18 | ClinicalTrials.gov |
| NCT04272775 | A Study of MLN9708 in Japanese Participants With Relapsed and/or Refractory Mul… | Phase1 | Relapsed and/or Refractory Multiple Myeloma | Terminated | 2012-06-05 | 2019-02-15 | ClinicalTrials.gov |
| NCT04272775 | A Study of MLN9708 in Japanese Participants With Relapsed and/or Refractory Mul… | Phase1 | Relapsed and/or Refractory Multiple Myeloma | Terminated | 2012-06-05 | 2019-02-15 | ClinicalTrials.gov |
| NCT04272775 | A Study of MLN9708 in Japanese Participants With Relapsed and/or Refractory Mul… | Phase1 | Relapsed and/or Refractory Multiple Myeloma | Terminated | 2012-06-05 | 2019-02-15 | ClinicalTrials.gov |
| NCT01609582 | Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or R… | Phase3 | Type 2 Diabetes | Terminated | 2012-06-01 | 2014-05-01 | ClinicalTrials.gov |
| NCT01469819 | Lubiprostone Effect on Gastrointestinal Tract Transit Times Measured by Smartpi… | Phase2 | Chronic Idiopathic Constipation | Completed | 2012-06-01 | 2015-02-01 | ClinicalTrials.gov |
| NCT01469819 | Lubiprostone Effect on Gastrointestinal Tract Transit Times Measured by Smartpi… | Phase2 | Chronic Idiopathic Constipation | Completed | 2012-06-01 | 2015-02-01 | ClinicalTrials.gov |
| NCT01574274 | SC-PEG Asparaginase vs. Oncaspar in Pediatric Acute Lymphoblastic Leukemia (ALL… | Phase2 | Acute Lymphoblastic Leukemia | Active_Not_Recruiting | 2012-06-01 | 2027-07-01 | ClinicalTrials.gov |
| NCT01577758 | Phase 1 Study of MLN0264 in Adult Patients With Advanced Gastrointestinal Malig… | Phase1 | Advanced Gastrointestinal Malignancies | Completed | 2012-06-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT01469819 | Lubiprostone Effect on Gastrointestinal Tract Transit Times Measured by Smartpi… | Phase2 | Chronic Idiopathic Constipation | Completed | 2012-06-01 | 2015-02-01 | ClinicalTrials.gov |
| NCT01582854 | Efficacy and Safety of Actovegin in Post-stroke Cognitive Impairment (PSCI) | Phase3 | Post-Stroke Cognitive Impairment (PSCI) | Completed | 2012-06-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT01609582 | Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or R… | Phase3 | Type 2 Diabetes | Terminated | 2012-06-01 | 2014-05-01 | ClinicalTrials.gov |
| NCT01621451 | Does Early Re-administration of Aspirin/Clopidogrel Increase the Risk of Bleedi… | Phase4 | Early Gastric Cancer | Unknown | 2012-06-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT01697839 | Serum Vitamin D Levels and Peripheral Neuropathy Among Multiple Myeloma Patients | — | Multiple Myeloma | Completed | 2012-06-01 | 2015-08-01 | ClinicalTrials.gov |
| NCT01574274 | SC-PEG Asparaginase vs. Oncaspar in Pediatric Acute Lymphoblastic Leukemia (ALL… | Phase2 | Acute Lymphoblastic Leukemia | Active_Not_Recruiting | 2012-06-01 | 2027-07-01 | ClinicalTrials.gov |
| NCT01577758 | Phase 1 Study of MLN0264 in Adult Patients With Advanced Gastrointestinal Malig… | Phase1 | Advanced Gastrointestinal Malignancies | Completed | 2012-06-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT01582854 | Efficacy and Safety of Actovegin in Post-stroke Cognitive Impairment (PSCI) | Phase3 | Post-Stroke Cognitive Impairment (PSCI) | Completed | 2012-06-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT01609582 | Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or R… | Phase3 | Type 2 Diabetes | Terminated | 2012-06-01 | 2014-05-01 | ClinicalTrials.gov |
| NCT01621451 | Does Early Re-administration of Aspirin/Clopidogrel Increase the Risk of Bleedi… | Phase4 | Early Gastric Cancer | Unknown | 2012-06-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT01621451 | Does Early Re-administration of Aspirin/Clopidogrel Increase the Risk of Bleedi… | Phase4 | Early Gastric Cancer | Unknown | 2012-06-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT01697839 | Serum Vitamin D Levels and Peripheral Neuropathy Among Multiple Myeloma Patients | — | Multiple Myeloma | Completed | 2012-06-01 | 2015-08-01 | ClinicalTrials.gov |
| NCT01697839 | Serum Vitamin D Levels and Peripheral Neuropathy Among Multiple Myeloma Patients | — | Multiple Myeloma | Completed | 2012-06-01 | 2015-08-01 | ClinicalTrials.gov |
| NCT01582854 | Efficacy and Safety of Actovegin in Post-stroke Cognitive Impairment (PSCI) | Phase3 | Post-Stroke Cognitive Impairment (PSCI) | Completed | 2012-06-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT01577758 | Phase 1 Study of MLN0264 in Adult Patients With Advanced Gastrointestinal Malig… | Phase1 | Advanced Gastrointestinal Malignancies | Completed | 2012-06-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT01574274 | SC-PEG Asparaginase vs. Oncaspar in Pediatric Acute Lymphoblastic Leukemia (ALL… | Phase2 | Acute Lymphoblastic Leukemia | Active_Not_Recruiting | 2012-06-01 | 2027-07-01 | ClinicalTrials.gov |
| NCT01515865 | Clinical Efficacy of Midodrine in Symptomatic Orthostatic Hypotension | Phase4 | Symptomatic Orthostatic Hypotension | Completed | 2012-05-23 | 2013-11-11 | ClinicalTrials.gov |
| NCT01515865 | Clinical Efficacy of Midodrine in Symptomatic Orthostatic Hypotension | Phase4 | Symptomatic Orthostatic Hypotension | Completed | 2012-05-23 | 2013-11-11 | ClinicalTrials.gov |
| NCT01515865 | Clinical Efficacy of Midodrine in Symptomatic Orthostatic Hypotension | Phase4 | Symptomatic Orthostatic Hypotension | Completed | 2012-05-23 | 2013-11-11 | ClinicalTrials.gov |
| NCT01560403 | A One-Year, Open-Label Study With Teduglutide for Subjects Who Completed Study … | Phase3 | Short Bowel Syndrome | Completed | 2012-05-21 | 2013-07-23 | ClinicalTrials.gov |
| NCT01560403 | A One-Year, Open-Label Study With Teduglutide for Subjects Who Completed Study … | Phase3 | Short Bowel Syndrome | Completed | 2012-05-21 | 2013-07-23 | ClinicalTrials.gov |
| NCT01560403 | A One-Year, Open-Label Study With Teduglutide for Subjects Who Completed Study … | Phase3 | Short Bowel Syndrome | Completed | 2012-05-21 | 2013-07-23 | ClinicalTrials.gov |
| NCT01518946 | Tilt-Table Study of the Clinical Efficacy of Midodrine in Symptomatic Orthostat… | Phase4 | Orthostatic Hypotension | Completed | 2012-05-14 | 2013-06-22 | ClinicalTrials.gov |
| NCT01518946 | Tilt-Table Study of the Clinical Efficacy of Midodrine in Symptomatic Orthostat… | Phase4 | Orthostatic Hypotension | Completed | 2012-05-14 | 2013-06-22 | ClinicalTrials.gov |
| NCT01518946 | Tilt-Table Study of the Clinical Efficacy of Midodrine in Symptomatic Orthostat… | Phase4 | Orthostatic Hypotension | Completed | 2012-05-14 | 2013-06-22 | ClinicalTrials.gov |
| NCT01541423 | A European Post-Authorisation Observational Study Of Patients With Hereditary A… | — | Hereditary Angioedema (HAE) | Completed | 2012-05-11 | 2016-09-25 | ClinicalTrials.gov |
| NCT01541423 | A European Post-Authorisation Observational Study Of Patients With Hereditary A… | — | Hereditary Angioedema (HAE) | Completed | 2012-05-11 | 2016-09-25 | ClinicalTrials.gov |
| NCT01541423 | A European Post-Authorisation Observational Study Of Patients With Hereditary A… | — | Hereditary Angioedema (HAE) | Completed | 2012-05-11 | 2016-09-25 | ClinicalTrials.gov |
| NCT01387594 | Evaluate PF-00547659 On Cerebrospinal Fluid Lymphocytes In Volunteers With Croh… | Phase1 | Crohn's Disease | Completed | 2012-05-03 | 2015-11-26 | ClinicalTrials.gov |
| NCT01387594 | Evaluate PF-00547659 On Cerebrospinal Fluid Lymphocytes In Volunteers With Croh… | Phase1 | Crohn's Disease | Completed | 2012-05-03 | 2015-11-26 | ClinicalTrials.gov |
| NCT01387594 | Evaluate PF-00547659 On Cerebrospinal Fluid Lymphocytes In Volunteers With Croh… | Phase1 | Crohn's Disease | Completed | 2012-05-03 | 2015-11-26 | ClinicalTrials.gov |
| NCT01549951 | Study to Investigate the Effects of Orteronel on the QT/QTc Interval in Patient… | Phase2 | Prostate Cancer | Completed | 2012-05-01 | 2015-01-01 | ClinicalTrials.gov |
| NCT01568398 | A Unblinded Study of TAK-438 (20 mg) for Prevention of Recurrence of Gastric or… | Phase3 | Gastric Ulcer | Completed | 2012-05-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01660425 | Enhancement of Methylphenidate Treatment by Psychosocial Intervention and Suppo… | Na | Attention Deficit-/Hyperactivity Disorder | Unknown | 2012-05-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT01585792 | Double Blind Comparative Study of TAK-875 | Phase3 | Diabetic Patients | Completed | 2012-05-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT01601132 | Drug Interaction Study of Colchicine and Theophylline | Phase4 | Healthy | Completed | 2012-05-01 | 2012-07-01 | ClinicalTrials.gov |
| NCT01663207 | Characterization of the Variability Of Insulin Secretory Parameters in the Meal… | — | Type 2 Diabetes | Completed | 2012-05-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01663207 | Characterization of the Variability Of Insulin Secretory Parameters in the Meal… | — | Type 2 Diabetes | Completed | 2012-05-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01663220 | Characterization of the Variability of Insulin Secretory Parameters in the Meal… | — | Type 2 Diabetes | Completed | 2012-05-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT01632007 | Double-blind Comparative Study of SYR-472 | Phase3 | Diabetes Mellitus | Completed | 2012-05-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT01632007 | Double-blind Comparative Study of SYR-472 | Phase3 | Diabetes Mellitus | Completed | 2012-05-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT01695330 | Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV … | Phase2 | Multiple Myeloma | Terminated | 2012-05-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT01601132 | Drug Interaction Study of Colchicine and Theophylline | Phase4 | Healthy | Completed | 2012-05-01 | 2012-07-01 | ClinicalTrials.gov |
| NCT01663220 | Characterization of the Variability of Insulin Secretory Parameters in the Meal… | — | Type 2 Diabetes | Completed | 2012-05-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT01585792 | Double Blind Comparative Study of TAK-875 | Phase3 | Diabetic Patients | Completed | 2012-05-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT01660425 | Enhancement of Methylphenidate Treatment by Psychosocial Intervention and Suppo… | Na | Attention Deficit-/Hyperactivity Disorder | Unknown | 2012-05-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT01663207 | Characterization of the Variability Of Insulin Secretory Parameters in the Meal… | — | Type 2 Diabetes | Completed | 2012-05-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01663220 | Characterization of the Variability of Insulin Secretory Parameters in the Meal… | — | Type 2 Diabetes | Completed | 2012-05-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT01568398 | A Unblinded Study of TAK-438 (20 mg) for Prevention of Recurrence of Gastric or… | Phase3 | Gastric Ulcer | Completed | 2012-05-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01695330 | Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV … | Phase2 | Multiple Myeloma | Terminated | 2012-05-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT01695330 | Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV … | Phase2 | Multiple Myeloma | Terminated | 2012-05-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT01601132 | Drug Interaction Study of Colchicine and Theophylline | Phase4 | Healthy | Completed | 2012-05-01 | 2012-07-01 | ClinicalTrials.gov |
| NCT01585792 | Double Blind Comparative Study of TAK-875 | Phase3 | Diabetic Patients | Completed | 2012-05-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT01549951 | Study to Investigate the Effects of Orteronel on the QT/QTc Interval in Patient… | Phase2 | Prostate Cancer | Completed | 2012-05-01 | 2015-01-01 | ClinicalTrials.gov |
| NCT01568398 | A Unblinded Study of TAK-438 (20 mg) for Prevention of Recurrence of Gastric or… | Phase3 | Gastric Ulcer | Completed | 2012-05-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01660425 | Enhancement of Methylphenidate Treatment by Psychosocial Intervention and Suppo… | Na | Attention Deficit-/Hyperactivity Disorder | Unknown | 2012-05-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT01632007 | Double-blind Comparative Study of SYR-472 | Phase3 | Diabetes Mellitus | Completed | 2012-05-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT01549951 | Study to Investigate the Effects of Orteronel on the QT/QTc Interval in Patient… | Phase2 | Prostate Cancer | Completed | 2012-05-01 | 2015-01-01 | ClinicalTrials.gov |
| NCT01552915 | Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-def… | Phase4 | Attention-deficit/Hyperactivity Disorder | Completed | 2012-04-17 | 2014-01-22 | ClinicalTrials.gov |
| NCT01552915 | Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-def… | Phase4 | Attention-deficit/Hyperactivity Disorder | Completed | 2012-04-17 | 2014-01-22 | ClinicalTrials.gov |
| NCT01552915 | Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-def… | Phase4 | Attention-deficit/Hyperactivity Disorder | Completed | 2012-04-17 | 2014-01-22 | ClinicalTrials.gov |
| NCT01492088 | Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed o… | Phase1 | Relapsed or Refractory Hodgkin Lymphoma | Completed | 2012-04-16 | 2018-04-12 | ClinicalTrials.gov |
| NCT01492088 | Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed o… | Phase1 | Relapsed or Refractory Hodgkin Lymphoma | Completed | 2012-04-16 | 2018-04-12 | ClinicalTrials.gov |
| NCT01492088 | Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed o… | Phase1 | Relapsed or Refractory Hodgkin Lymphoma | Completed | 2012-04-16 | 2018-04-12 | ClinicalTrials.gov |
| NCT01509768 | Natural History Study of Patients With Mucopolysaccharidosis Type IIIB (MPS III… | — | Sanfilippo Syndrome Type B | Completed | 2012-04-09 | 2013-10-10 | ClinicalTrials.gov |
| NCT01509768 | Natural History Study of Patients With Mucopolysaccharidosis Type IIIB (MPS III… | — | Sanfilippo Syndrome Type B | Completed | 2012-04-09 | 2013-10-10 | ClinicalTrials.gov |
| NCT01509768 | Natural History Study of Patients With Mucopolysaccharidosis Type IIIB (MPS III… | — | Sanfilippo Syndrome Type B | Completed | 2012-04-09 | 2013-10-10 | ClinicalTrials.gov |
| NCT01552902 | Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-def… | Phase4 | Attention-deficit/Hyperactivity Disorder | Completed | 2012-04-03 | 2014-05-22 | ClinicalTrials.gov |
| NCT01552902 | Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-def… | Phase4 | Attention-deficit/Hyperactivity Disorder | Completed | 2012-04-03 | 2014-05-22 | ClinicalTrials.gov |
| NCT01552902 | Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-def… | Phase4 | Attention-deficit/Hyperactivity Disorder | Completed | 2012-04-03 | 2014-05-22 | ClinicalTrials.gov |
| NCT01549964 | Comparison of Fasiglifam (TAK-875) to Placebo and Sitagliptin in Combination Wi… | Phase3 | Glycemic Control | Terminated | 2012-04-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01568385 | A Unblinded Study of TAK-438 (20 mg) for Prevention of Recurrence of Gastric or… | Phase3 | Gastric Ulcer | Completed | 2012-04-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT01568385 | A Unblinded Study of TAK-438 (20 mg) for Prevention of Recurrence of Gastric or… | Phase3 | Gastric Ulcer | Completed | 2012-04-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT01564862 | Efficacy of Lu AA21004 on Cognitive Dysfunction in Major Depressive Disorder | Phase2 | Depressive Disorder, Major | Completed | 2012-04-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT01546649 | A Phase 3 Comparative Study of TAP-144-SR(6M) in Postoperative and Hormone Ther… | Phase3 | Premenopausal Breast Cancer | Completed | 2012-04-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT01546649 | A Phase 3 Comparative Study of TAP-144-SR(6M) in Postoperative and Hormone Ther… | Phase3 | Premenopausal Breast Cancer | Completed | 2012-04-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT01568385 | A Unblinded Study of TAK-438 (20 mg) for Prevention of Recurrence of Gastric or… | Phase3 | Gastric Ulcer | Completed | 2012-04-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT01547000 | Guanfacine in Children With Tic Disorders | Phase4 | Tourette Disorder | Completed | 2012-04-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT01549964 | Comparison of Fasiglifam (TAK-875) to Placebo and Sitagliptin in Combination Wi… | Phase3 | Glycemic Control | Terminated | 2012-04-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01546649 | A Phase 3 Comparative Study of TAP-144-SR(6M) in Postoperative and Hormone Ther… | Phase3 | Premenopausal Breast Cancer | Completed | 2012-04-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT01547000 | Guanfacine in Children With Tic Disorders | Phase4 | Tourette Disorder | Completed | 2012-04-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT01860170 | Post-Transplant Bortezomib and High Dose Cyclophosphamide as Graft-Versus-Host … | Phase1 | Hematological Malignancy | Completed | 2012-04-01 | 2018-03-01 | ClinicalTrials.gov |
| NCT01549964 | Comparison of Fasiglifam (TAK-875) to Placebo and Sitagliptin in Combination Wi… | Phase3 | Glycemic Control | Terminated | 2012-04-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01547000 | Guanfacine in Children With Tic Disorders | Phase4 | Tourette Disorder | Completed | 2012-04-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT01564862 | Efficacy of Lu AA21004 on Cognitive Dysfunction in Major Depressive Disorder | Phase2 | Depressive Disorder, Major | Completed | 2012-04-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT01564862 | Efficacy of Lu AA21004 on Cognitive Dysfunction in Major Depressive Disorder | Phase2 | Depressive Disorder, Major | Completed | 2012-04-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT01860170 | Post-Transplant Bortezomib and High Dose Cyclophosphamide as Graft-Versus-Host … | Phase1 | Hematological Malignancy | Completed | 2012-04-01 | 2018-03-01 | ClinicalTrials.gov |
| NCT01860170 | Post-Transplant Bortezomib and High Dose Cyclophosphamide as Graft-Versus-Host … | Phase1 | Hematological Malignancy | Completed | 2012-04-01 | 2018-03-01 | ClinicalTrials.gov |
| NCT01552928 | Effect of Anagrelide Hydrochloride on Any Changes in Heart Function in Healthy … | Phase1 | Healthy | Completed | 2012-03-29 | 2012-07-25 | ClinicalTrials.gov |
| NCT01552928 | Effect of Anagrelide Hydrochloride on Any Changes in Heart Function in Healthy … | Phase1 | Healthy | Completed | 2012-03-29 | 2012-07-25 | ClinicalTrials.gov |
| NCT01552928 | Effect of Anagrelide Hydrochloride on Any Changes in Heart Function in Healthy … | Phase1 | Healthy | Completed | 2012-03-29 | 2012-07-25 | ClinicalTrials.gov |
| NCT01500694 | Access to Extended Release Guanfacine HCl for Subjects Who Participated in Stud… | Phase3 | Attention Deficit Hyperactivity Disorder (ADHD) | Completed | 2012-03-20 | 2015-09-15 | ClinicalTrials.gov |
| NCT01500694 | Access to Extended Release Guanfacine HCl for Subjects Who Participated in Stud… | Phase3 | Attention Deficit Hyperactivity Disorder (ADHD) | Completed | 2012-03-20 | 2015-09-15 | ClinicalTrials.gov |
| NCT01500694 | Access to Extended Release Guanfacine HCl for Subjects Who Participated in Stud… | Phase3 | Attention Deficit Hyperactivity Disorder (ADHD) | Completed | 2012-03-20 | 2015-09-15 | ClinicalTrials.gov |
| NCT01614574 | Study of Velaglucerase Alfa Enzyme Replacement Therapy in Japanese Patients Wit… | Phase3 | Gaucher Disease | Completed | 2012-03-02 | 2013-05-25 | ClinicalTrials.gov |
| NCT01614574 | Study of Velaglucerase Alfa Enzyme Replacement Therapy in Japanese Patients Wit… | Phase3 | Gaucher Disease | Completed | 2012-03-02 | 2013-05-25 | ClinicalTrials.gov |
| NCT01614574 | Study of Velaglucerase Alfa Enzyme Replacement Therapy in Japanese Patients Wit… | Phase3 | Gaucher Disease | Completed | 2012-03-02 | 2013-05-25 | ClinicalTrials.gov |
| NCT01687374 | Parathyroid Hormone for the Treatment of Humerus Fractures | Phase4 | Shoulder Fractures | Unknown | 2012-03-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01687374 | Parathyroid Hormone for the Treatment of Humerus Fractures | Phase4 | Shoulder Fractures | Unknown | 2012-03-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01422616 | Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED) | Phase3 | Ischemic Stroke | Completed | 2012-03-01 | 2018-08-01 | ClinicalTrials.gov |
| NCT01452685 | A Long-term Extension Study of TAK-385 in the Treatment of Endometriosis | Phase2 | Endometriosis | Completed | 2012-03-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01546623 | A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previ… | Phase3 | Prostate Cancer | Completed | 2012-03-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01422616 | Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED) | Phase3 | Ischemic Stroke | Completed | 2012-03-01 | 2018-08-01 | ClinicalTrials.gov |
| NCT01456247 | Long-term Extension Study of TAK-438 for the Prevention of Recurrent Gastric or… | Phase3 | Gastric Ulcers | Completed | 2012-03-01 | 2013-10-01 | ClinicalTrials.gov |
| NCT01452685 | A Long-term Extension Study of TAK-385 in the Treatment of Endometriosis | Phase2 | Endometriosis | Completed | 2012-03-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01422616 | Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED) | Phase3 | Ischemic Stroke | Completed | 2012-03-01 | 2018-08-01 | ClinicalTrials.gov |
| NCT01456247 | Long-term Extension Study of TAK-438 for the Prevention of Recurrent Gastric or… | Phase3 | Gastric Ulcers | Completed | 2012-03-01 | 2013-10-01 | ClinicalTrials.gov |
| NCT01500135 | Comparison of Efficacy and Safety of TachoSil® Versus Surgicel® Original for th… | Phase3 | Bleeding | Completed | 2012-03-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT01500135 | Comparison of Efficacy and Safety of TachoSil® Versus Surgicel® Original for th… | Phase3 | Bleeding | Completed | 2012-03-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT01500135 | Comparison of Efficacy and Safety of TachoSil® Versus Surgicel® Original for th… | Phase3 | Bleeding | Completed | 2012-03-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT01546623 | A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previ… | Phase3 | Prostate Cancer | Completed | 2012-03-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01546623 | A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previ… | Phase3 | Prostate Cancer | Completed | 2012-03-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01687374 | Parathyroid Hormone for the Treatment of Humerus Fractures | Phase4 | Shoulder Fractures | Unknown | 2012-03-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01456247 | Long-term Extension Study of TAK-438 for the Prevention of Recurrent Gastric or… | Phase3 | Gastric Ulcers | Completed | 2012-03-01 | 2013-10-01 | ClinicalTrials.gov |
| NCT01452685 | A Long-term Extension Study of TAK-385 in the Treatment of Endometriosis | Phase2 | Endometriosis | Completed | 2012-03-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01436175 | SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability… | Phase3 | Major Depressive Disorder | Terminated | 2012-02-27 | 2014-03-27 | ClinicalTrials.gov |
| NCT01436175 | SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability… | Phase3 | Major Depressive Disorder | Terminated | 2012-02-27 | 2014-03-27 | ClinicalTrials.gov |
| NCT01472939 | Selective 5-HT4 Receptor Agonist and Proton Pump Inhibitor (PPI) in Subjects Wi… | Phase2 | Gastroesophageal Reflux Disease | Completed | 2012-02-27 | 2013-05-14 | ClinicalTrials.gov |
| NCT01472939 | Selective 5-HT4 Receptor Agonist and Proton Pump Inhibitor (PPI) in Subjects Wi… | Phase2 | Gastroesophageal Reflux Disease | Completed | 2012-02-27 | 2013-05-14 | ClinicalTrials.gov |
| NCT01472939 | Selective 5-HT4 Receptor Agonist and Proton Pump Inhibitor (PPI) in Subjects Wi… | Phase2 | Gastroesophageal Reflux Disease | Completed | 2012-02-27 | 2013-05-14 | ClinicalTrials.gov |
| NCT01436175 | SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability… | Phase3 | Major Depressive Disorder | Terminated | 2012-02-27 | 2014-03-27 | ClinicalTrials.gov |
| NCT01534260 | Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for th… | Phase1 | Acute Myeloid Leukemia | Completed | 2012-02-10 | 2017-02-13 | ClinicalTrials.gov |
| NCT01534260 | Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for th… | Phase1 | Acute Myeloid Leukemia | Completed | 2012-02-10 | 2017-02-13 | ClinicalTrials.gov |
| NCT01534260 | Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for th… | Phase1 | Acute Myeloid Leukemia | Completed | 2012-02-10 | 2017-02-13 | ClinicalTrials.gov |
| NCT01512758 | A Study of Alisertib (MLN8237) in Adult East Asian Participants With Advanced S… | Phase1 | Advanced Solid Tumors | Completed | 2012-02-06 | 2013-10-08 | ClinicalTrials.gov |
| NCT01512758 | A Study of Alisertib (MLN8237) in Adult East Asian Participants With Advanced S… | Phase1 | Advanced Solid Tumors | Completed | 2012-02-06 | 2013-10-08 | ClinicalTrials.gov |
| NCT01512758 | A Study of Alisertib (MLN8237) in Adult East Asian Participants With Advanced S… | Phase1 | Advanced Solid Tumors | Completed | 2012-02-06 | 2013-10-08 | ClinicalTrials.gov |
| NCT01510028 | Multicenter Study of HGT-1110 Administered Intrathecally in Children With Metac… | Phase1 | Metachromatic Leukodystrophy (MLD) | Completed | 2012-02-02 | 2017-01-20 | ClinicalTrials.gov |
| NCT01510028 | Multicenter Study of HGT-1110 Administered Intrathecally in Children With Metac… | Phase1 | Metachromatic Leukodystrophy (MLD) | Completed | 2012-02-02 | 2017-01-20 | ClinicalTrials.gov |
| NCT01510028 | Multicenter Study of HGT-1110 Administered Intrathecally in Children With Metac… | Phase1 | Metachromatic Leukodystrophy (MLD) | Completed | 2012-02-02 | 2017-01-20 | ClinicalTrials.gov |
| NCT01542632 | A Comparison of the Safety and Immunogenicity of Various Schedules of Dengue Va… | Phase1 | Healthy | Completed | 2012-02-01 | 2014-01-10 | ClinicalTrials.gov |
| NCT01542632 | A Comparison of the Safety and Immunogenicity of Various Schedules of Dengue Va… | Phase1 | Healthy | Completed | 2012-02-01 | 2014-01-10 | ClinicalTrials.gov |
| NCT01521962 | Study of Combination Therapy With SYR-322 | Phase3 | Diabetes Mellitus | Completed | 2012-02-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT01521962 | Study of Combination Therapy With SYR-322 | Phase3 | Diabetes Mellitus | Completed | 2012-02-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT01521962 | Study of Combination Therapy With SYR-322 | Phase3 | Diabetes Mellitus | Completed | 2012-02-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT01496469 | Effect of Febuxostat on Blood Pressure | Phase2 | Hypertension | Completed | 2012-02-01 | 2014-08-01 | ClinicalTrials.gov |
| NCT01542632 | A Comparison of the Safety and Immunogenicity of Various Schedules of Dengue Va… | Phase1 | Healthy | Completed | 2012-02-01 | 2014-01-10 | ClinicalTrials.gov |
| NCT01496469 | Effect of Febuxostat on Blood Pressure | Phase2 | Hypertension | Completed | 2012-02-01 | 2014-08-01 | ClinicalTrials.gov |
| NCT01496469 | Effect of Febuxostat on Blood Pressure | Phase2 | Hypertension | Completed | 2012-02-01 | 2014-08-01 | ClinicalTrials.gov |
| NCT01234298 | SPD489 as Adjunctive Treatment in Adults With Negative Symptoms of Schizophrenia | Phase3 | Negative Symptoms of Schizophrenia | Withdrawn | 2012-01-27 | 2014-02-24 | ClinicalTrials.gov |
| NCT01234298 | SPD489 as Adjunctive Treatment in Adults With Negative Symptoms of Schizophrenia | Phase3 | Negative Symptoms of Schizophrenia | Withdrawn | 2012-01-27 | 2014-02-24 | ClinicalTrials.gov |
| NCT01234298 | SPD489 as Adjunctive Treatment in Adults With Negative Symptoms of Schizophrenia | Phase3 | Negative Symptoms of Schizophrenia | Withdrawn | 2012-01-27 | 2014-02-24 | ClinicalTrials.gov |
| NCT01470469 | SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Sep… | Phase2 | Generalized Anxiety Disorder (GAD) | Completed | 2012-01-04 | 2013-07-15 | ClinicalTrials.gov |
| NCT01470469 | SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Sep… | Phase2 | Generalized Anxiety Disorder (GAD) | Completed | 2012-01-04 | 2013-07-15 | ClinicalTrials.gov |
| NCT01470469 | SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Sep… | Phase2 | Generalized Anxiety Disorder (GAD) | Completed | 2012-01-04 | 2013-07-15 | ClinicalTrials.gov |
| NCT01433419 | Open-label Study of TAK-875 | Phase3 | Diabetes Mellitus | Completed | 2012-01-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT01496443 | TAK-875 Glimepiride Drug-Interaction Study | Phase1 | Pharmacokinetics | Completed | 2012-01-01 | 2012-05-01 | ClinicalTrials.gov |
| NCT01496430 | Efficacy and Safety of Azilsartan Medoxomil Used in Combination With Metformin … | Phase3 | Hypertension | Terminated | 2012-01-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT01505127 | Efficacy of TAK-438, Amoxicillin and Clarithromycin in the First Line Eradicati… | Phase3 | H. Pylori Infection | Completed | 2012-01-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT01496443 | TAK-875 Glimepiride Drug-Interaction Study | Phase1 | Pharmacokinetics | Completed | 2012-01-01 | 2012-05-01 | ClinicalTrials.gov |
| NCT01505127 | Efficacy of TAK-438, Amoxicillin and Clarithromycin in the First Line Eradicati… | Phase3 | H. Pylori Infection | Completed | 2012-01-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT01505127 | Efficacy of TAK-438, Amoxicillin and Clarithromycin in the First Line Eradicati… | Phase3 | H. Pylori Infection | Completed | 2012-01-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT01481116 | Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin… | Phase3 | Diabetes Mellitus, Type 2 | Terminated | 2012-01-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01433419 | Open-label Study of TAK-875 | Phase3 | Diabetes Mellitus | Completed | 2012-01-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT01481116 | Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin… | Phase3 | Diabetes Mellitus, Type 2 | Terminated | 2012-01-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01433419 | Open-label Study of TAK-875 | Phase3 | Diabetes Mellitus | Completed | 2012-01-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT01496443 | TAK-875 Glimepiride Drug-Interaction Study | Phase1 | Pharmacokinetics | Completed | 2012-01-01 | 2012-05-01 | ClinicalTrials.gov |
| NCT01496430 | Efficacy and Safety of Azilsartan Medoxomil Used in Combination With Metformin … | Phase3 | Hypertension | Terminated | 2012-01-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT01481116 | Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin… | Phase3 | Diabetes Mellitus, Type 2 | Terminated | 2012-01-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01496430 | Efficacy and Safety of Azilsartan Medoxomil Used in Combination With Metformin … | Phase3 | Hypertension | Terminated | 2012-01-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT01504477 | Panitumumab and Bortezomib for Patients With Advanced Colorectal Cancer | Phase1 | Colorectal Cancer | Terminated | 2011-12-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT01504477 | Panitumumab and Bortezomib for Patients With Advanced Colorectal Cancer | Phase1 | Colorectal Cancer | Terminated | 2011-12-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT01474369 | Efficacy of TAK-438 Compared to Placebo in the Treatment of Non-Erosive Gastroe… | Phase3 | Non-erosive Gastroesophageal Reflux Disease | Completed | 2011-12-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT01504477 | Panitumumab and Bortezomib for Patients With Advanced Colorectal Cancer | Phase1 | Colorectal Cancer | Terminated | 2011-12-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT01467713 | Efficacy and Safety of Ramelteon Sublingual as Adjunctive Therapy for Maintenan… | Phase3 | Bipolar Disorder | Terminated | 2011-12-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT01467700 | Efficacy and Safety of Ramelteon Sublingual in Adult Patients With Acute Depres… | Phase3 | Acute Depressive Episode | Terminated | 2011-12-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT01194284 | Surveillance Study of Patients With Newly Diagnosed Osteosarcoma | — | Osteosarcoma | Terminated | 2011-12-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01435395 | Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma M… | Phase1 | Glioblastoma Multiforme | Completed | 2011-12-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT01977625 | LDX and Functional Magnetic Resonance Imaging (fMRI in Menopausal Women | Phase4 | Menopause | Completed | 2011-12-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01474369 | Efficacy of TAK-438 Compared to Placebo in the Treatment of Non-Erosive Gastroe… | Phase3 | Non-erosive Gastroesophageal Reflux Disease | Completed | 2011-12-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT01467713 | Efficacy and Safety of Ramelteon Sublingual as Adjunctive Therapy for Maintenan… | Phase3 | Bipolar Disorder | Terminated | 2011-12-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT01467700 | Efficacy and Safety of Ramelteon Sublingual in Adult Patients With Acute Depres… | Phase3 | Acute Depressive Episode | Terminated | 2011-12-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT01435395 | Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma M… | Phase1 | Glioblastoma Multiforme | Completed | 2011-12-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT01977625 | LDX and Functional Magnetic Resonance Imaging (fMRI in Menopausal Women | Phase4 | Menopause | Completed | 2011-12-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01349595 | Impact of Proteasome Inhibition on Anti-Donor HLA Antibody Production After Kid… | Phase2 | Disorder of Transplanted Kidney | Terminated | 2011-12-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT01435395 | Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma M… | Phase1 | Glioblastoma Multiforme | Completed | 2011-12-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT01349595 | Impact of Proteasome Inhibition on Anti-Donor HLA Antibody Production After Kid… | Phase2 | Disorder of Transplanted Kidney | Terminated | 2011-12-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT01474369 | Efficacy of TAK-438 Compared to Placebo in the Treatment of Non-Erosive Gastroe… | Phase3 | Non-erosive Gastroesophageal Reflux Disease | Completed | 2011-12-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT01349595 | Impact of Proteasome Inhibition on Anti-Donor HLA Antibody Production After Kid… | Phase2 | Disorder of Transplanted Kidney | Terminated | 2011-12-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT01467713 | Efficacy and Safety of Ramelteon Sublingual as Adjunctive Therapy for Maintenan… | Phase3 | Bipolar Disorder | Terminated | 2011-12-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT01467700 | Efficacy and Safety of Ramelteon Sublingual in Adult Patients With Acute Depres… | Phase3 | Acute Depressive Episode | Terminated | 2011-12-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT01194284 | Surveillance Study of Patients With Newly Diagnosed Osteosarcoma | — | Osteosarcoma | Terminated | 2011-12-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01194284 | Surveillance Study of Patients With Newly Diagnosed Osteosarcoma | — | Osteosarcoma | Terminated | 2011-12-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01977625 | LDX and Functional Magnetic Resonance Imaging (fMRI in Menopausal Women | Phase4 | Menopause | Completed | 2011-12-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01990300 | Alogliptin/Pioglitazone (Liovel) Combination Tablets Survey on Long-term Use in… | — | Type 2 Diabetes Mellitus | Completed | 2011-11-28 | 2015-03-31 | ClinicalTrials.gov |
| NCT01990300 | Alogliptin/Pioglitazone (Liovel) Combination Tablets Survey on Long-term Use in… | — | Type 2 Diabetes Mellitus | Completed | 2011-11-28 | 2015-03-31 | ClinicalTrials.gov |
| NCT01990300 | Alogliptin/Pioglitazone (Liovel) Combination Tablets Survey on Long-term Use in… | — | Type 2 Diabetes Mellitus | Completed | 2011-11-28 | 2015-03-31 | ClinicalTrials.gov |
| NCT01304277 | This Study is Designed to Evaluate PD/PK and Safety of Replagal Manufactured by… | Phase2 | Fabry Disease | Completed | 2011-11-17 | 2012-12-28 | ClinicalTrials.gov |
| NCT01304277 | This Study is Designed to Evaluate PD/PK and Safety of Replagal Manufactured by… | Phase2 | Fabry Disease | Completed | 2011-11-17 | 2012-12-28 | ClinicalTrials.gov |
| NCT01304277 | This Study is Designed to Evaluate PD/PK and Safety of Replagal Manufactured by… | Phase2 | Fabry Disease | Completed | 2011-11-17 | 2012-12-28 | ClinicalTrials.gov |
| NCT01511250 | Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric De… | Phase2 | Healthy | Completed | 2011-11-16 | 2016-04-15 | ClinicalTrials.gov |
| NCT01511250 | Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric De… | Phase2 | Healthy | Completed | 2011-11-16 | 2016-04-15 | ClinicalTrials.gov |
| NCT01511250 | Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric De… | Phase2 | Healthy | Completed | 2011-11-16 | 2016-04-15 | ClinicalTrials.gov |
| NCT01454076 | Pharmacokinetics Study of Oral IXAZOMIB in Participants With Advanced Nonhemato… | Phase1 | Nonhematologic Malignancies | Completed | 2011-11-10 | 2016-06-16 | ClinicalTrials.gov |
| NCT01454076 | Pharmacokinetics Study of Oral IXAZOMIB in Participants With Advanced Nonhemato… | Phase1 | Nonhematologic Malignancies | Completed | 2011-11-10 | 2016-06-16 | ClinicalTrials.gov |
| NCT01454076 | Pharmacokinetics Study of Oral IXAZOMIB in Participants With Advanced Nonhemato… | Phase1 | Nonhematologic Malignancies | Completed | 2011-11-10 | 2016-06-16 | ClinicalTrials.gov |
| NCT01058239 | Bortezomib Plus Rituximab for EBV+ PTLD | Phase2 | Post-transplant Lymphoproliferative Disease | Completed | 2011-11-01 | 2017-11-01 | ClinicalTrials.gov |
| NCT01497288 | A Trial to Investigate the Pharmacokinetics (PK) of Single Doses of 200 µg, 400… | Phase1 | Healthy Volunteers | Completed | 2011-11-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT01456195 | Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Dia… | Phase3 | Diabetes Mellitus, Type 2 | Completed | 2011-11-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT01456130 | Long-term Study of Alogliptin as an Add-on to Rapid-Acting Insulin Secretagogue… | Phase3 | Diabetes Mellitus | Completed | 2011-11-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT01456117 | Study to Assess the Effects of Daily Administration of Pioglitazone on Brain He… | Phase1 | Healthy | Completed | 2011-11-01 | 2012-07-01 | ClinicalTrials.gov |
| NCT01452711 | Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Gast… | Phase3 | Gastric Ulcer | Completed | 2011-11-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT01058239 | Bortezomib Plus Rituximab for EBV+ PTLD | Phase2 | Post-transplant Lymphoproliferative Disease | Completed | 2011-11-01 | 2017-11-01 | ClinicalTrials.gov |
| NCT01058239 | Bortezomib Plus Rituximab for EBV+ PTLD | Phase2 | Post-transplant Lymphoproliferative Disease | Completed | 2011-11-01 | 2017-11-01 | ClinicalTrials.gov |
| NCT01452711 | Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Gast… | Phase3 | Gastric Ulcer | Completed | 2011-11-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT01456117 | Study to Assess the Effects of Daily Administration of Pioglitazone on Brain He… | Phase1 | Healthy | Completed | 2011-11-01 | 2012-07-01 | ClinicalTrials.gov |
| NCT01456130 | Long-term Study of Alogliptin as an Add-on to Rapid-Acting Insulin Secretagogue… | Phase3 | Diabetes Mellitus | Completed | 2011-11-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT01456195 | Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Dia… | Phase3 | Diabetes Mellitus, Type 2 | Completed | 2011-11-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT01497288 | A Trial to Investigate the Pharmacokinetics (PK) of Single Doses of 200 µg, 400… | Phase1 | Healthy Volunteers | Completed | 2011-11-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT01497288 | A Trial to Investigate the Pharmacokinetics (PK) of Single Doses of 200 µg, 400… | Phase1 | Healthy Volunteers | Completed | 2011-11-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT01456195 | Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Dia… | Phase3 | Diabetes Mellitus, Type 2 | Completed | 2011-11-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT01456130 | Long-term Study of Alogliptin as an Add-on to Rapid-Acting Insulin Secretagogue… | Phase3 | Diabetes Mellitus | Completed | 2011-11-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT01456117 | Study to Assess the Effects of Daily Administration of Pioglitazone on Brain He… | Phase1 | Healthy | Completed | 2011-11-01 | 2012-07-01 | ClinicalTrials.gov |
| NCT01452711 | Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Gast… | Phase3 | Gastric Ulcer | Completed | 2011-11-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT01383928 | Study of Oral IXAZOMIB in Combination With Lenalidomide and Dexamethasone in Pa… | Phase1 | Multiple Myeloma | Completed | 2011-10-31 | 2017-11-27 | ClinicalTrials.gov |
| NCT01383928 | Study of Oral IXAZOMIB in Combination With Lenalidomide and Dexamethasone in Pa… | Phase1 | Multiple Myeloma | Completed | 2011-10-31 | 2017-11-27 | ClinicalTrials.gov |
| NCT01383928 | Study of Oral IXAZOMIB in Combination With Lenalidomide and Dexamethasone in Pa… | Phase1 | Multiple Myeloma | Completed | 2011-10-31 | 2017-11-27 | ClinicalTrials.gov |
| NCT01457339 | Assess the Safety and Pharmacokinetics of Ascending, Multiple Oral Doses of SPD… | Phase1 | Schizophrenia | Completed | 2011-10-21 | 2012-01-20 | ClinicalTrials.gov |
| NCT01457339 | Assess the Safety and Pharmacokinetics of Ascending, Multiple Oral Doses of SPD… | Phase1 | Schizophrenia | Completed | 2011-10-21 | 2012-01-20 | ClinicalTrials.gov |
| NCT01457339 | Assess the Safety and Pharmacokinetics of Ascending, Multiple Oral Doses of SPD… | Phase1 | Schizophrenia | Completed | 2011-10-21 | 2012-01-20 | ClinicalTrials.gov |
| NCT01471964 | Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotin… | Phase1 | Non-small Cell Lung Cancer Metastatic | Terminated | 2011-10-20 | 2018-04-10 | ClinicalTrials.gov |
| NCT01471964 | Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotin… | Phase1 | Non-small Cell Lung Cancer Metastatic | Terminated | 2011-10-20 | 2018-04-10 | ClinicalTrials.gov |
| NCT01471964 | Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotin… | Phase1 | Non-small Cell Lung Cancer Metastatic | Terminated | 2011-10-20 | 2018-04-10 | ClinicalTrials.gov |
| NCT01436162 | Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in th… | Phase3 | Major Depressive Disorder | Completed | 2011-10-19 | 2013-12-10 | ClinicalTrials.gov |
| NCT01436162 | Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in th… | Phase3 | Major Depressive Disorder | Completed | 2011-10-19 | 2013-12-10 | ClinicalTrials.gov |
| NCT01436162 | Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in th… | Phase3 | Major Depressive Disorder | Completed | 2011-10-19 | 2013-12-10 | ClinicalTrials.gov |
| NCT01442688 | Amoxicillin Drug Interaction Study With MMX® Mesalazine/Mesalamine | Phase1 | Healthy | Completed | 2011-10-07 | 2011-11-20 | ClinicalTrials.gov |
| NCT01442688 | Amoxicillin Drug Interaction Study With MMX® Mesalazine/Mesalamine | Phase1 | Healthy | Completed | 2011-10-07 | 2011-11-20 | ClinicalTrials.gov |
| NCT01442688 | Amoxicillin Drug Interaction Study With MMX® Mesalazine/Mesalamine | Phase1 | Healthy | Completed | 2011-10-07 | 2011-11-20 | ClinicalTrials.gov |
| NCT00998010 | Bortezomib, Temozolomide, and Regional Radiation Therapy in Treating Patients W… | Phase2 | Brain and Central Nervous System Tumors | Completed | 2011-10-03 | 2018-04-20 | ClinicalTrials.gov |
| NCT00998010 | Bortezomib, Temozolomide, and Regional Radiation Therapy in Treating Patients W… | Phase2 | Brain and Central Nervous System Tumors | Completed | 2011-10-03 | 2018-04-20 | ClinicalTrials.gov |
| NCT00998010 | Bortezomib, Temozolomide, and Regional Radiation Therapy in Treating Patients W… | Phase2 | Brain and Central Nervous System Tumors | Completed | 2011-10-03 | 2018-04-20 | ClinicalTrials.gov |
| NCT01452750 | Efficacy and Safety of TAK-438 for the Prevention of Recurrent Gastric or Duode… | Phase3 | Gastric Ulcers | Completed | 2011-10-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT01452724 | Efficacy and Safety of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatm… | Phase3 | Duodenal Ulcer | Completed | 2011-10-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT01452659 | Efficacy and Safety of TAK-385 in the Treatment of Uterine Fibroids | Phase2 | Uterine Fibroids | Completed | 2011-10-01 | 2012-09-01 | ClinicalTrials.gov |
| NCT01449370 | Dose Escalation Study of TAK-117 (MLN1117) in Subjects With Advanced Cancer | Phase1 | Metastatic Solid Tumors | Completed | 2011-10-01 | 2016-01-01 | ClinicalTrials.gov |
| NCT01449370 | Dose Escalation Study of TAK-117 (MLN1117) in Subjects With Advanced Cancer | Phase1 | Metastatic Solid Tumors | Completed | 2011-10-01 | 2016-01-01 | ClinicalTrials.gov |
| NCT01438177 | Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and R… | Phase2 | Multiple Myeloma | Terminated | 2011-10-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT01433406 | Long-term Study of TAK-875 | Phase3 | Diabetes Mellitus | Completed | 2011-10-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01459367 | Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Maintenance Treat… | Phase3 | Erosive Esophagitis | Completed | 2011-10-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT01478971 | Conversion Study From Epoetin Alfa to Monthly Peginesatide Injection in Patient… | Phase3 | Chronic Kidney Disease | Completed | 2011-10-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT01456169 | A Study to Evaluate the Effectiveness and Safety of a Fixed Dose Combination of… | Phase3 | Essential Hypertension | Completed | 2011-10-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT01397591 | Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell, … | Phase2 | Recurrent Adult Diffuse Large Cell Lymphoma | Terminated | 2011-10-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT01438177 | Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and R… | Phase2 | Multiple Myeloma | Terminated | 2011-10-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT01433406 | Long-term Study of TAK-875 | Phase3 | Diabetes Mellitus | Completed | 2011-10-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01449370 | Dose Escalation Study of TAK-117 (MLN1117) in Subjects With Advanced Cancer | Phase1 | Metastatic Solid Tumors | Completed | 2011-10-01 | 2016-01-01 | ClinicalTrials.gov |
| NCT01454973 | Characterization of the Variability of Insulin Secretory Parameters in the Meal… | — | Type 2 Diabetes | Completed | 2011-10-01 | 2012-01-01 | ClinicalTrials.gov |
| NCT01456169 | A Study to Evaluate the Effectiveness and Safety of a Fixed Dose Combination of… | Phase3 | Essential Hypertension | Completed | 2011-10-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT01454973 | Characterization of the Variability of Insulin Secretory Parameters in the Meal… | — | Type 2 Diabetes | Completed | 2011-10-01 | 2012-01-01 | ClinicalTrials.gov |
| NCT01478971 | Conversion Study From Epoetin Alfa to Monthly Peginesatide Injection in Patient… | Phase3 | Chronic Kidney Disease | Completed | 2011-10-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT01458301 | Efficacy and Safety of TAK-385 in the Treatment of Endometriosis | Phase2 | Endometriosis | Completed | 2011-10-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01438177 | Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and R… | Phase2 | Multiple Myeloma | Terminated | 2011-10-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT01459367 | Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Maintenance Treat… | Phase3 | Erosive Esophagitis | Completed | 2011-10-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT01452724 | Efficacy and Safety of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatm… | Phase3 | Duodenal Ulcer | Completed | 2011-10-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT01397591 | Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell, … | Phase2 | Recurrent Adult Diffuse Large Cell Lymphoma | Terminated | 2011-10-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT01452659 | Efficacy and Safety of TAK-385 in the Treatment of Uterine Fibroids | Phase2 | Uterine Fibroids | Completed | 2011-10-01 | 2012-09-01 | ClinicalTrials.gov |
| NCT01478971 | Conversion Study From Epoetin Alfa to Monthly Peginesatide Injection in Patient… | Phase3 | Chronic Kidney Disease | Completed | 2011-10-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT01459367 | Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Maintenance Treat… | Phase3 | Erosive Esophagitis | Completed | 2011-10-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT01458301 | Efficacy and Safety of TAK-385 in the Treatment of Endometriosis | Phase2 | Endometriosis | Completed | 2011-10-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01456169 | A Study to Evaluate the Effectiveness and Safety of a Fixed Dose Combination of… | Phase3 | Essential Hypertension | Completed | 2011-10-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT01454973 | Characterization of the Variability of Insulin Secretory Parameters in the Meal… | — | Type 2 Diabetes | Completed | 2011-10-01 | 2012-01-01 | ClinicalTrials.gov |
| NCT01458301 | Efficacy and Safety of TAK-385 in the Treatment of Endometriosis | Phase2 | Endometriosis | Completed | 2011-10-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01452763 | Efficacy and Safety of TAK-438 for the Prevention of Recurrent Gastric or Duode… | Phase3 | Gastric Ulcers | Completed | 2011-10-01 | 2013-04-01 | ClinicalTrials.gov |
| NCT01397591 | Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell, … | Phase2 | Recurrent Adult Diffuse Large Cell Lymphoma | Terminated | 2011-10-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT01452659 | Efficacy and Safety of TAK-385 in the Treatment of Uterine Fibroids | Phase2 | Uterine Fibroids | Completed | 2011-10-01 | 2012-09-01 | ClinicalTrials.gov |
| NCT01433406 | Long-term Study of TAK-875 | Phase3 | Diabetes Mellitus | Completed | 2011-10-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01452763 | Efficacy and Safety of TAK-438 for the Prevention of Recurrent Gastric or Duode… | Phase3 | Gastric Ulcers | Completed | 2011-10-01 | 2013-04-01 | ClinicalTrials.gov |
| NCT01452724 | Efficacy and Safety of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatm… | Phase3 | Duodenal Ulcer | Completed | 2011-10-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT01452750 | Efficacy and Safety of TAK-438 for the Prevention of Recurrent Gastric or Duode… | Phase3 | Gastric Ulcers | Completed | 2011-10-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT01452750 | Efficacy and Safety of TAK-438 for the Prevention of Recurrent Gastric or Duode… | Phase3 | Gastric Ulcers | Completed | 2011-10-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT01452763 | Efficacy and Safety of TAK-438 for the Prevention of Recurrent Gastric or Duode… | Phase3 | Gastric Ulcers | Completed | 2011-10-01 | 2013-04-01 | ClinicalTrials.gov |
| NCT01081132 | Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hy… | Phase3 | Attention-Deficit/Hyperactivity Disorder | Completed | 2011-09-19 | 2013-05-16 | ClinicalTrials.gov |
| NCT01081132 | Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hy… | Phase3 | Attention-Deficit/Hyperactivity Disorder | Completed | 2011-09-19 | 2013-05-16 | ClinicalTrials.gov |
| NCT01081132 | Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hy… | Phase3 | Attention-Deficit/Hyperactivity Disorder | Completed | 2011-09-19 | 2013-05-16 | ClinicalTrials.gov |
| NCT01425008 | Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Follo… | Phase1 | Melanoma | Completed | 2011-09-15 | 2018-10-16 | ClinicalTrials.gov |
| NCT01425008 | Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Follo… | Phase1 | Melanoma | Completed | 2011-09-15 | 2018-10-16 | ClinicalTrials.gov |
| NCT01425008 | Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Follo… | Phase1 | Melanoma | Completed | 2011-09-15 | 2018-10-16 | ClinicalTrials.gov |
| NCT01426763 | A Study to Evaluate the Safety and Pharmacology of Subcutaneous Administration … | Phase2 | Hereditary Angioedema | Completed | 2011-09-12 | 2011-11-28 | ClinicalTrials.gov |
| NCT01426763 | A Study to Evaluate the Safety and Pharmacology of Subcutaneous Administration … | Phase2 | Hereditary Angioedema | Completed | 2011-09-12 | 2011-11-28 | ClinicalTrials.gov |
| NCT01426763 | A Study to Evaluate the Safety and Pharmacology of Subcutaneous Administration … | Phase2 | Hereditary Angioedema | Completed | 2011-09-12 | 2011-11-28 | ClinicalTrials.gov |
| NCT01497626 | Lapatinib and Bortezomib in Patients With Advanced Malignancies | Phase1 | Advanced Solid Tumors | Terminated | 2011-09-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT01452776 | Long-Term Safety Study of TAK-438 in the Maintenance Treatment of Healed Erosiv… | Phase3 | Erosive Esophagitis | Completed | 2011-09-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT03662763 | Extended-release Guanfacine Hydrochloride in Children/Adolescents With Attentio… | Phase3 | Attention Deficit Disorder | Completed | 2011-09-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01456260 | Long-term Extension Study of TAK-438 for the Prevention of Recurrent Gastric or… | Phase3 | Gastric Ulcers | Completed | 2011-09-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01616082 | Effect of Caloric Restriction on Fat Oxidation in Obese Men and Women (Magellan… | Na | Obesity | Completed | 2011-09-01 | 2012-11-01 | ClinicalTrials.gov |
| NCT01497626 | Lapatinib and Bortezomib in Patients With Advanced Malignancies | Phase1 | Advanced Solid Tumors | Terminated | 2011-09-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT02134977 | Leuplin SR 11.25 mg Injection Kit Specified Drug-use Survey: "QOL Survey in Pre… | — | Breast Cancer | Completed | 2011-09-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT01981616 | Immune Response to Systemic and Mucosal Antigenic Challenge in the Presence of … | Phase1 | Inflammatory Bowel Disease | Completed | 2011-09-01 | 2012-07-01 | ClinicalTrials.gov |
| NCT01456260 | Long-term Extension Study of TAK-438 for the Prevention of Recurrent Gastric or… | Phase3 | Gastric Ulcers | Completed | 2011-09-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01452776 | Long-Term Safety Study of TAK-438 in the Maintenance Treatment of Healed Erosiv… | Phase3 | Erosive Esophagitis | Completed | 2011-09-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT01431807 | Long-term Study of SYR-472 | Phase3 | Diabetes Mellitus | Completed | 2011-09-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT01431807 | Long-term Study of SYR-472 | Phase3 | Diabetes Mellitus | Completed | 2011-09-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT01981616 | Immune Response to Systemic and Mucosal Antigenic Challenge in the Presence of … | Phase1 | Inflammatory Bowel Disease | Completed | 2011-09-01 | 2012-07-01 | ClinicalTrials.gov |
| NCT01452776 | Long-Term Safety Study of TAK-438 in the Maintenance Treatment of Healed Erosiv… | Phase3 | Erosive Esophagitis | Completed | 2011-09-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT01456260 | Long-term Extension Study of TAK-438 for the Prevention of Recurrent Gastric or… | Phase3 | Gastric Ulcers | Completed | 2011-09-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01981616 | Immune Response to Systemic and Mucosal Antigenic Challenge in the Presence of … | Phase1 | Inflammatory Bowel Disease | Completed | 2011-09-01 | 2012-07-01 | ClinicalTrials.gov |
| NCT02134977 | Leuplin SR 11.25 mg Injection Kit Specified Drug-use Survey: "QOL Survey in Pre… | — | Breast Cancer | Completed | 2011-09-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT01616082 | Effect of Caloric Restriction on Fat Oxidation in Obese Men and Women (Magellan… | Na | Obesity | Completed | 2011-09-01 | 2012-11-01 | ClinicalTrials.gov |
| NCT02134977 | Leuplin SR 11.25 mg Injection Kit Specified Drug-use Survey: "QOL Survey in Pre… | — | Breast Cancer | Completed | 2011-09-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT03662763 | Extended-release Guanfacine Hydrochloride in Children/Adolescents With Attentio… | Phase3 | Attention Deficit Disorder | Completed | 2011-09-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT03662763 | Extended-release Guanfacine Hydrochloride in Children/Adolescents With Attentio… | Phase3 | Attention Deficit Disorder | Completed | 2011-09-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01616082 | Effect of Caloric Restriction on Fat Oxidation in Obese Men and Women (Magellan… | Na | Obesity | Completed | 2011-09-01 | 2012-11-01 | ClinicalTrials.gov |
| NCT01431807 | Long-term Study of SYR-472 | Phase3 | Diabetes Mellitus | Completed | 2011-09-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT01497626 | Lapatinib and Bortezomib in Patients With Advanced Malignancies | Phase1 | Advanced Solid Tumors | Terminated | 2011-09-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT01421498 | Safety and Efficacy Study of SAR 1118 to Treat Dry Eye Conducted in a Controlle… | Phase3 | Keratoconjunctivitis Sicca | Completed | 2011-08-29 | 2012-04-28 | ClinicalTrials.gov |
| NCT01421498 | Safety and Efficacy Study of SAR 1118 to Treat Dry Eye Conducted in a Controlle… | Phase3 | Keratoconjunctivitis Sicca | Completed | 2011-08-29 | 2012-04-28 | ClinicalTrials.gov |
| NCT01421498 | Safety and Efficacy Study of SAR 1118 to Treat Dry Eye Conducted in a Controlle… | Phase3 | Keratoconjunctivitis Sicca | Completed | 2011-08-29 | 2012-04-28 | ClinicalTrials.gov |
| NCT01147302 | A Pilot Study to Evaluate the Use of C1 Esterase Inhibitor (Human) in Patients … | Phase2 | Graft Rejection | Completed | 2011-08-24 | 2013-06-28 | ClinicalTrials.gov |
| NCT01147302 | A Pilot Study to Evaluate the Use of C1 Esterase Inhibitor (Human) in Patients … | Phase2 | Graft Rejection | Completed | 2011-08-24 | 2013-06-28 | ClinicalTrials.gov |
| NCT01147302 | A Pilot Study to Evaluate the Use of C1 Esterase Inhibitor (Human) in Patients … | Phase2 | Graft Rejection | Completed | 2011-08-24 | 2013-06-28 | ClinicalTrials.gov |
| NCT01415349 | SSP-002358 Drug Interaction Study With Omeprazole | Phase1 | Healthy | Completed | 2011-08-11 | 2011-09-28 | ClinicalTrials.gov |
| NCT01415349 | SSP-002358 Drug Interaction Study With Omeprazole | Phase1 | Healthy | Completed | 2011-08-11 | 2011-09-28 | ClinicalTrials.gov |
| NCT01415349 | SSP-002358 Drug Interaction Study With Omeprazole | Phase1 | Healthy | Completed | 2011-08-11 | 2011-09-28 | ClinicalTrials.gov |
| NCT01298141 | A Multicenter Open-Label Treatment Protocol to Observe the Safety of Replagal (… | Phase3 | Fabry Disease | Completed | 2011-08-10 | 2017-09-25 | ClinicalTrials.gov |
| NCT01363908 | Safety, Efficacy and Pharmacokinetics of an Oral Iron Chelator Given for a Year… | Phase2 | Transfusional Iron Overload | Terminated | 2011-08-10 | 2014-05-13 | ClinicalTrials.gov |
| NCT01298141 | A Multicenter Open-Label Treatment Protocol to Observe the Safety of Replagal (… | Phase3 | Fabry Disease | Completed | 2011-08-10 | 2017-09-25 | ClinicalTrials.gov |
| NCT01298141 | A Multicenter Open-Label Treatment Protocol to Observe the Safety of Replagal (… | Phase3 | Fabry Disease | Completed | 2011-08-10 | 2017-09-25 | ClinicalTrials.gov |
| NCT01363908 | Safety, Efficacy and Pharmacokinetics of an Oral Iron Chelator Given for a Year… | Phase2 | Transfusional Iron Overload | Terminated | 2011-08-10 | 2014-05-13 | ClinicalTrials.gov |
| NCT01363908 | Safety, Efficacy and Pharmacokinetics of an Oral Iron Chelator Given for a Year… | Phase2 | Transfusional Iron Overload | Terminated | 2011-08-10 | 2014-05-13 | ClinicalTrials.gov |
| NCT01397825 | MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Trea… | Phase1 | Diffuse Large B-Cell Lymphoma | Completed | 2011-08-09 | 2016-10-05 | ClinicalTrials.gov |
| NCT01397825 | MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Trea… | Phase1 | Diffuse Large B-Cell Lymphoma | Completed | 2011-08-09 | 2016-10-05 | ClinicalTrials.gov |
| NCT01397825 | MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Trea… | Phase1 | Diffuse Large B-Cell Lymphoma | Completed | 2011-08-09 | 2016-10-05 | ClinicalTrials.gov |
| NCT01964963 | Alogliptin Tablets Special Drug Use Surveillance: Mild Type 2 Diabetes Mellitus | — | Type 2 Diabetes Mellitus | Completed | 2011-08-03 | 2017-07-31 | ClinicalTrials.gov |
| NCT01964963 | Alogliptin Tablets Special Drug Use Surveillance: Mild Type 2 Diabetes Mellitus | — | Type 2 Diabetes Mellitus | Completed | 2011-08-03 | 2017-07-31 | ClinicalTrials.gov |
| NCT01964963 | Alogliptin Tablets Special Drug Use Surveillance: Mild Type 2 Diabetes Mellitus | — | Type 2 Diabetes Mellitus | Completed | 2011-08-03 | 2017-07-31 | ClinicalTrials.gov |
| NCT01414920 | Efficacy and Safety of TAK-875 in Combination With Sitagliptin in Participants … | Phase2 | Diabetes Mellitus, Type 2 | Completed | 2011-08-01 | 2012-08-01 | ClinicalTrials.gov |
| NCT01132638 | Pantoprazole Magnesium 40 mg Versus Esomeprazole 40 mg in Patients With Erosive… | Phase3 | GERD | Completed | 2011-08-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT01429051 | A Clinical Trial With Intranasal Fentanyl in Cancer Patients With Breakthrough … | Phase3 | Break Through Pain | Completed | 2011-08-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT01415440 | Imaging the Effects of Stimulant Medication on Emotional Lability in Patients W… | Na | Attention Deficit Hyperactivity Disorder | Completed | 2011-08-01 | 2018-06-01 | ClinicalTrials.gov |
| NCT01429051 | A Clinical Trial With Intranasal Fentanyl in Cancer Patients With Breakthrough … | Phase3 | Break Through Pain | Completed | 2011-08-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT01390545 | VELVET, a Dose Range Finding Trial of Veltuzumab in Subjects With Moderate to S… | Phase2 | Rheumatoid Arthritis | Terminated | 2011-08-01 | 2012-10-01 | ClinicalTrials.gov |
| NCT01390545 | VELVET, a Dose Range Finding Trial of Veltuzumab in Subjects With Moderate to S… | Phase2 | Rheumatoid Arthritis | Terminated | 2011-08-01 | 2012-10-01 | ClinicalTrials.gov |
| NCT01414920 | Efficacy and Safety of TAK-875 in Combination With Sitagliptin in Participants … | Phase2 | Diabetes Mellitus, Type 2 | Completed | 2011-08-01 | 2012-08-01 | ClinicalTrials.gov |
| NCT01415440 | Imaging the Effects of Stimulant Medication on Emotional Lability in Patients W… | Na | Attention Deficit Hyperactivity Disorder | Completed | 2011-08-01 | 2018-06-01 | ClinicalTrials.gov |
| NCT01429051 | A Clinical Trial With Intranasal Fentanyl in Cancer Patients With Breakthrough … | Phase3 | Break Through Pain | Completed | 2011-08-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT01132638 | Pantoprazole Magnesium 40 mg Versus Esomeprazole 40 mg in Patients With Erosive… | Phase3 | GERD | Completed | 2011-08-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT01132638 | Pantoprazole Magnesium 40 mg Versus Esomeprazole 40 mg in Patients With Erosive… | Phase3 | GERD | Completed | 2011-08-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT01390545 | VELVET, a Dose Range Finding Trial of Veltuzumab in Subjects With Moderate to S… | Phase2 | Rheumatoid Arthritis | Terminated | 2011-08-01 | 2012-10-01 | ClinicalTrials.gov |
| NCT01414920 | Efficacy and Safety of TAK-875 in Combination With Sitagliptin in Participants … | Phase2 | Diabetes Mellitus, Type 2 | Completed | 2011-08-01 | 2012-08-01 | ClinicalTrials.gov |
| NCT01415440 | Imaging the Effects of Stimulant Medication on Emotional Lability in Patients W… | Na | Attention Deficit Hyperactivity Disorder | Completed | 2011-08-01 | 2018-06-01 | ClinicalTrials.gov |
| NCT01402947 | Ciprofloxacin XR Drug Interaction Study With MMX® Mesalazine/Mesalamine | Phase1 | Healthy | Completed | 2011-07-25 | 2011-08-30 | ClinicalTrials.gov |
| NCT01402947 | Ciprofloxacin XR Drug Interaction Study With MMX® Mesalazine/Mesalamine | Phase1 | Healthy | Completed | 2011-07-25 | 2011-08-30 | ClinicalTrials.gov |
| NCT01402947 | Ciprofloxacin XR Drug Interaction Study With MMX® Mesalazine/Mesalamine | Phase1 | Healthy | Completed | 2011-07-25 | 2011-08-30 | ClinicalTrials.gov |
| NCT01964976 | Alogliptin Tablets Special Drug Use Surveillance Type 2 Diabetes Mellitus: Comb… | — | Surveillance | Completed | 2011-07-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT01536457 | Reflux Disease Therapy in the Management of Childhood Asthma-data Entry and Ana… | — | Asthma | Completed | 2011-07-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT01964950 | Alogliptin Tablets Special Drug Use Surveillance Type 2 Diabetes Mellitus: Comb… | — | Surveillance | Completed | 2011-07-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT01536457 | Reflux Disease Therapy in the Management of Childhood Asthma-data Entry and Ana… | — | Asthma | Completed | 2011-07-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT01298492 | A Study To Monitor Long-Term Treatment With PF-00547659 | Phase2 | Crohn's Disease | Completed | 2011-07-01 | 2016-07-27 | ClinicalTrials.gov |
| NCT01395147 | Long-Term Extension Study of Lu AA21004 in Participants With Major Depressive D… | Phase3 | Major Depressive Disorder | Completed | 2011-07-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT01964950 | Alogliptin Tablets Special Drug Use Surveillance Type 2 Diabetes Mellitus: Comb… | — | Surveillance | Completed | 2011-07-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT01298492 | A Study To Monitor Long-Term Treatment With PF-00547659 | Phase2 | Crohn's Disease | Completed | 2011-07-01 | 2016-07-27 | ClinicalTrials.gov |
| NCT01964976 | Alogliptin Tablets Special Drug Use Surveillance Type 2 Diabetes Mellitus: Comb… | — | Surveillance | Completed | 2011-07-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT01391663 | Pharmacokinetics and Pharmacodynamics Study of Alogliptin in Healthy Korean Par… | Phase1 | Pharmacokinetics and Pharmacodynamics | Completed | 2011-07-01 | 2011-09-01 | ClinicalTrials.gov |
| NCT01419379 | This is a Multicenter, Prospective and Retrospective and Descriptive Epidemiolo… | — | COPD | Completed | 2011-07-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT01395147 | Long-Term Extension Study of Lu AA21004 in Participants With Major Depressive D… | Phase3 | Major Depressive Disorder | Completed | 2011-07-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT01391663 | Pharmacokinetics and Pharmacodynamics Study of Alogliptin in Healthy Korean Par… | Phase1 | Pharmacokinetics and Pharmacodynamics | Completed | 2011-07-01 | 2011-09-01 | ClinicalTrials.gov |
| NCT01419379 | This is a Multicenter, Prospective and Retrospective and Descriptive Epidemiolo… | — | COPD | Completed | 2011-07-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT01298492 | A Study To Monitor Long-Term Treatment With PF-00547659 | Phase2 | Crohn's Disease | Completed | 2011-07-01 | 2016-07-27 | ClinicalTrials.gov |
| NCT01419379 | This is a Multicenter, Prospective and Retrospective and Descriptive Epidemiolo… | — | COPD | Completed | 2011-07-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT01964976 | Alogliptin Tablets Special Drug Use Surveillance Type 2 Diabetes Mellitus: Comb… | — | Surveillance | Completed | 2011-07-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT01391663 | Pharmacokinetics and Pharmacodynamics Study of Alogliptin in Healthy Korean Par… | Phase1 | Pharmacokinetics and Pharmacodynamics | Completed | 2011-07-01 | 2011-09-01 | ClinicalTrials.gov |
| NCT01395147 | Long-Term Extension Study of Lu AA21004 in Participants With Major Depressive D… | Phase3 | Major Depressive Disorder | Completed | 2011-07-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT01536457 | Reflux Disease Therapy in the Management of Childhood Asthma-data Entry and Ana… | — | Asthma | Completed | 2011-07-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT01964950 | Alogliptin Tablets Special Drug Use Surveillance Type 2 Diabetes Mellitus: Comb… | — | Surveillance | Completed | 2011-07-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT01335685 | Study of Oral Ixazomib in Combination With Melphalan and Prednisone in Particip… | Phase1 | Multiple Myeloma | Completed | 2011-06-27 | 2016-12-29 | ClinicalTrials.gov |
| NCT01259726 | Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Di… | Phase2 | Clostridium Difficile Infection | Completed | 2011-06-27 | 2013-06-11 | ClinicalTrials.gov |
| NCT01259726 | Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Di… | Phase2 | Clostridium Difficile Infection | Completed | 2011-06-27 | 2013-06-11 | ClinicalTrials.gov |
| NCT01259726 | Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Di… | Phase2 | Clostridium Difficile Infection | Completed | 2011-06-27 | 2013-06-11 | ClinicalTrials.gov |
| NCT01335685 | Study of Oral Ixazomib in Combination With Melphalan and Prednisone in Particip… | Phase1 | Multiple Myeloma | Completed | 2011-06-27 | 2016-12-29 | ClinicalTrials.gov |
| NCT01335685 | Study of Oral Ixazomib in Combination With Melphalan and Prednisone in Particip… | Phase1 | Multiple Myeloma | Completed | 2011-06-27 | 2016-12-29 | ClinicalTrials.gov |
| NCT01383759 | Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation… | Na | Light Chain Deposition Disease (LCDD or MIDD) | Completed | 2011-06-24 | 2019-04-30 | ClinicalTrials.gov |
| NCT01383759 | Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation… | Na | Light Chain Deposition Disease (LCDD or MIDD) | Completed | 2011-06-24 | 2019-04-30 | ClinicalTrials.gov |
| NCT01383759 | Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation… | Na | Light Chain Deposition Disease (LCDD or MIDD) | Completed | 2011-06-24 | 2019-04-30 | ClinicalTrials.gov |
| NCT02211638 | Candesartan Cilexetil Special Drug Use Surveillance 「Challenge - Quality Contro… | — | Hypertension | Completed | 2011-06-13 | 2013-04-25 | ClinicalTrials.gov |
| NCT02211638 | Candesartan Cilexetil Special Drug Use Surveillance 「Challenge - Quality Contro… | — | Hypertension | Completed | 2011-06-13 | 2013-04-25 | ClinicalTrials.gov |
| NCT02211638 | Candesartan Cilexetil Special Drug Use Surveillance 「Challenge - Quality Contro… | — | Hypertension | Completed | 2011-06-13 | 2013-04-25 | ClinicalTrials.gov |
| NCT01364649 | Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disord… | Phase3 | Treatment Outcome | Completed | 2011-06-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01357317 | Study Comparing Effects of Lanthanum Carbonate Versus Calcium Acetate Versus Di… | Phase3 | Chronic Kidney Disease | Unknown | 2011-06-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01379846 | Study of TAK-816 in Healthy Infants | Phase3 | Immunization | Completed | 2011-06-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT01312818 | Bortezomib, Vorinostat and Dexamethasone for Relapsed/Refractory Acute Lymphobl… | Phase2 | Acute Lymphoblastic Leukemia | Terminated | 2011-06-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT02098746 | Pioglitazone/Glimepiride (Sonias) Combination Tablets Special Drug Use Surveill… | — | Type 2 Diabetes | Completed | 2011-06-01 | 2014-07-01 | ClinicalTrials.gov |
| NCT01312818 | Bortezomib, Vorinostat and Dexamethasone for Relapsed/Refractory Acute Lymphobl… | Phase2 | Acute Lymphoblastic Leukemia | Terminated | 2011-06-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT01343823 | Evaluation of Ecallantide for Treatment of Angiotensin Converting Enzyme (ACE) … | Phase2 | ACE Inhibitor Induced Angioedema | Terminated | 2011-06-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT02098746 | Pioglitazone/Glimepiride (Sonias) Combination Tablets Special Drug Use Surveill… | — | Type 2 Diabetes | Completed | 2011-06-01 | 2014-07-01 | ClinicalTrials.gov |
| NCT01357317 | Study Comparing Effects of Lanthanum Carbonate Versus Calcium Acetate Versus Di… | Phase3 | Chronic Kidney Disease | Unknown | 2011-06-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01364649 | Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disord… | Phase3 | Treatment Outcome | Completed | 2011-06-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01364649 | Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disord… | Phase3 | Treatment Outcome | Completed | 2011-06-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT02098733 | Long-term Use of Sonias Combination Tablets in Patients With Type 2 Diabetes Me… | — | Type 2 Diabetes | Completed | 2011-06-01 | 2014-05-01 | ClinicalTrials.gov |
| NCT01379846 | Study of TAK-816 in Healthy Infants | Phase3 | Immunization | Completed | 2011-06-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT01343823 | Evaluation of Ecallantide for Treatment of Angiotensin Converting Enzyme (ACE) … | Phase2 | ACE Inhibitor Induced Angioedema | Terminated | 2011-06-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT02098733 | Long-term Use of Sonias Combination Tablets in Patients With Type 2 Diabetes Me… | — | Type 2 Diabetes | Completed | 2011-06-01 | 2014-05-01 | ClinicalTrials.gov |
| NCT01379846 | Study of TAK-816 in Healthy Infants | Phase3 | Immunization | Completed | 2011-06-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT02098733 | Long-term Use of Sonias Combination Tablets in Patients With Type 2 Diabetes Me… | — | Type 2 Diabetes | Completed | 2011-06-01 | 2014-05-01 | ClinicalTrials.gov |
| NCT01343823 | Evaluation of Ecallantide for Treatment of Angiotensin Converting Enzyme (ACE) … | Phase2 | ACE Inhibitor Induced Angioedema | Terminated | 2011-06-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT01328652 | Dexlansoprazole to Treat Laryngopharyngeal Reflux and Lingual Tonsil Hypertrophy | Phase4 | Laryngopharyngeal Reflux | Unknown | 2011-06-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT01328652 | Dexlansoprazole to Treat Laryngopharyngeal Reflux and Lingual Tonsil Hypertrophy | Phase4 | Laryngopharyngeal Reflux | Unknown | 2011-06-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT02098746 | Pioglitazone/Glimepiride (Sonias) Combination Tablets Special Drug Use Surveill… | — | Type 2 Diabetes | Completed | 2011-06-01 | 2014-07-01 | ClinicalTrials.gov |
| NCT01357317 | Study Comparing Effects of Lanthanum Carbonate Versus Calcium Acetate Versus Di… | Phase3 | Chronic Kidney Disease | Unknown | 2011-06-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01328652 | Dexlansoprazole to Treat Laryngopharyngeal Reflux and Lingual Tonsil Hypertrophy | Phase4 | Laryngopharyngeal Reflux | Unknown | 2011-06-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT01312818 | Bortezomib, Vorinostat and Dexamethasone for Relapsed/Refractory Acute Lymphobl… | Phase2 | Acute Lymphoblastic Leukemia | Terminated | 2011-06-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT01363492 | Safety Study of Replagal® Therapy in Children With Fabry Disease | Phase2 | Fabry Disease | Completed | 2011-05-12 | 2013-04-17 | ClinicalTrials.gov |
| NCT01363492 | Safety Study of Replagal® Therapy in Children With Fabry Disease | Phase2 | Fabry Disease | Completed | 2011-05-12 | 2013-04-17 | ClinicalTrials.gov |
| NCT01363492 | Safety Study of Replagal® Therapy in Children With Fabry Disease | Phase2 | Fabry Disease | Completed | 2011-05-12 | 2013-04-17 | ClinicalTrials.gov |
| NCT01291173 | Forced-dose Titration of SPD489 in Adults With Binge Eating Disorder | Phase2 | Binge Eating Disorder | Completed | 2011-05-10 | 2012-01-30 | ClinicalTrials.gov |
| NCT01291173 | Forced-dose Titration of SPD489 in Adults With Binge Eating Disorder | Phase2 | Binge Eating Disorder | Completed | 2011-05-10 | 2012-01-30 | ClinicalTrials.gov |
| NCT01291173 | Forced-dose Titration of SPD489 in Adults With Binge Eating Disorder | Phase2 | Binge Eating Disorder | Completed | 2011-05-10 | 2012-01-30 | ClinicalTrials.gov |
| NCT01324024 | Attention & Memory Impairments in Menopausal Women | Phase4 | Symptomatic Menopause | Completed | 2011-05-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01355081 | Efficacy Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive D… | Phase3 | Major Depressive Disorder | Completed | 2011-05-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT01350388 | Effects of Febuxostat on Adipokines and Kidney Disease in Diabetic Chronic Kidn… | Na | Chronic Kidney Disease | Completed | 2011-05-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01324024 | Attention & Memory Impairments in Menopausal Women | Phase4 | Symptomatic Menopause | Completed | 2011-05-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01324024 | Attention & Memory Impairments in Menopausal Women | Phase4 | Symptomatic Menopause | Completed | 2011-05-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01350388 | Effects of Febuxostat on Adipokines and Kidney Disease in Diabetic Chronic Kidn… | Na | Chronic Kidney Disease | Completed | 2011-05-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01355081 | Efficacy Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive D… | Phase3 | Major Depressive Disorder | Completed | 2011-05-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT01328392 | Evaluating Treatment Response in Laryngo-Pharyngeal Reflux | Na | Laryngo-pharyngeal Reflux | Withdrawn | 2011-05-01 | 2012-04-01 | ClinicalTrials.gov |
| NCT01328392 | Evaluating Treatment Response in Laryngo-Pharyngeal Reflux | Na | Laryngo-pharyngeal Reflux | Withdrawn | 2011-05-01 | 2012-04-01 | ClinicalTrials.gov |
| NCT01328392 | Evaluating Treatment Response in Laryngo-Pharyngeal Reflux | Na | Laryngo-pharyngeal Reflux | Withdrawn | 2011-05-01 | 2012-04-01 | ClinicalTrials.gov |
| NCT01355081 | Efficacy Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive D… | Phase3 | Major Depressive Disorder | Completed | 2011-05-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT01350388 | Effects of Febuxostat on Adipokines and Kidney Disease in Diabetic Chronic Kidn… | Na | Chronic Kidney Disease | Completed | 2011-05-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01330381 | Prucalopride in Pediatric Subjects With Functional Constipation | Phase3 | Functional Constipation | Completed | 2011-04-28 | 2013-03-01 | ClinicalTrials.gov |
| NCT01330381 | Prucalopride in Pediatric Subjects With Functional Constipation | Phase3 | Functional Constipation | Completed | 2011-04-28 | 2013-03-01 | ClinicalTrials.gov |
| NCT01330381 | Prucalopride in Pediatric Subjects With Functional Constipation | Phase3 | Functional Constipation | Completed | 2011-04-28 | 2013-03-01 | ClinicalTrials.gov |
| NCT01318902 | Study of Oral Ixazomib in Adult Participants With Relapsed or Refractory Light … | Phase1 | Light-Chain Amyloidosis | Completed | 2011-04-27 | 2018-11-13 | ClinicalTrials.gov |
| NCT01318902 | Study of Oral Ixazomib in Adult Participants With Relapsed or Refractory Light … | Phase1 | Light-Chain Amyloidosis | Completed | 2011-04-27 | 2018-11-13 | ClinicalTrials.gov |
| NCT01318902 | Study of Oral Ixazomib in Adult Participants With Relapsed or Refractory Light … | Phase1 | Light-Chain Amyloidosis | Completed | 2011-04-27 | 2018-11-13 | ClinicalTrials.gov |
| NCT01231347 | QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancre… | Phase3 | Adenocarcinoma of the Pancreas | Completed | 2011-04-07 | 2012-12-12 | ClinicalTrials.gov |
| NCT01231347 | QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancre… | Phase3 | Adenocarcinoma of the Pancreas | Completed | 2011-04-07 | 2012-12-12 | ClinicalTrials.gov |
| NCT01231347 | QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancre… | Phase3 | Adenocarcinoma of the Pancreas | Completed | 2011-04-07 | 2012-12-12 | ClinicalTrials.gov |
| NCT01276509 | Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Pati… | Phase2 | Crohn's Disease | Completed | 2011-04-06 | 2015-10-09 | ClinicalTrials.gov |
| NCT01276509 | Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Pati… | Phase2 | Crohn's Disease | Completed | 2011-04-06 | 2015-10-09 | ClinicalTrials.gov |
| NCT01424228 | Evaluation of Long-term Prucalopride Treatment With Chronic Constipation in Sub… | Phase4 | Constipation | Completed | 2011-04-06 | 2012-12-19 | ClinicalTrials.gov |
| NCT01297309 | A Open-label Study Investigating the Safety and Tolerability of NPSP558, a Reco… | Phase3 | Hypoparathyroidism | Completed | 2011-04-06 | 2018-06-08 | ClinicalTrials.gov |
| NCT01276509 | Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Pati… | Phase2 | Crohn's Disease | Completed | 2011-04-06 | 2015-10-09 | ClinicalTrials.gov |
| NCT01424228 | Evaluation of Long-term Prucalopride Treatment With Chronic Constipation in Sub… | Phase4 | Constipation | Completed | 2011-04-06 | 2012-12-19 | ClinicalTrials.gov |
| NCT01424228 | Evaluation of Long-term Prucalopride Treatment With Chronic Constipation in Sub… | Phase4 | Constipation | Completed | 2011-04-06 | 2012-12-19 | ClinicalTrials.gov |
| NCT01297309 | A Open-label Study Investigating the Safety and Tolerability of NPSP558, a Reco… | Phase3 | Hypoparathyroidism | Completed | 2011-04-06 | 2018-06-08 | ClinicalTrials.gov |
| NCT01297309 | A Open-label Study Investigating the Safety and Tolerability of NPSP558, a Reco… | Phase3 | Hypoparathyroidism | Completed | 2011-04-06 | 2018-06-08 | ClinicalTrials.gov |
| NCT01349504 | Adherence to Mesalamine Profile for Patients With Inflammatory Bowel Disease | — | Ulcerative Colitis | Completed | 2011-04-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT01355627 | TASALL - TachoSil® Against Liquor Leak | Phase3 | Cerebrospinal Fluid Leaks | Completed | 2011-04-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT01355627 | TASALL - TachoSil® Against Liquor Leak | Phase3 | Cerebrospinal Fluid Leaks | Completed | 2011-04-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT01355627 | TASALL - TachoSil® Against Liquor Leak | Phase3 | Cerebrospinal Fluid Leaks | Completed | 2011-04-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT01349504 | Adherence to Mesalamine Profile for Patients With Inflammatory Bowel Disease | — | Ulcerative Colitis | Completed | 2011-04-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT01349504 | Adherence to Mesalamine Profile for Patients With Inflammatory Bowel Disease | — | Ulcerative Colitis | Completed | 2011-04-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT01355146 | Home Therapy With Replagal in Fabry Disease | — | Fabry Disease | Completed | 2011-03-15 | 2017-09-30 | ClinicalTrials.gov |
| NCT01355146 | Home Therapy With Replagal in Fabry Disease | — | Fabry Disease | Completed | 2011-03-15 | 2017-09-30 | ClinicalTrials.gov |
| NCT01355146 | Home Therapy With Replagal in Fabry Disease | — | Fabry Disease | Completed | 2011-03-15 | 2017-09-30 | ClinicalTrials.gov |
| NCT01274221 | Safety and Efficacy of SPD489 in Adolescent Subjects Aged 13-17 Years With Atte… | Phase3 | ADHD | Withdrawn | 2011-03-06 | 2011-05-04 | ClinicalTrials.gov |
| NCT01274221 | Safety and Efficacy of SPD489 in Adolescent Subjects Aged 13-17 Years With Atte… | Phase3 | ADHD | Withdrawn | 2011-03-06 | 2011-05-04 | ClinicalTrials.gov |
| NCT01274221 | Safety and Efficacy of SPD489 in Adolescent Subjects Aged 13-17 Years With Atte… | Phase3 | ADHD | Withdrawn | 2011-03-06 | 2011-05-04 | ClinicalTrials.gov |
| NCT01945242 | Alogliptin Tablets Special Drug Use Surveillance "Type 2 Diabetes Mellitus: Com… | — | Type 2 Diabetes Melitus | Completed | 2011-03-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT01945242 | Alogliptin Tablets Special Drug Use Surveillance "Type 2 Diabetes Mellitus: Com… | — | Type 2 Diabetes Melitus | Completed | 2011-03-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT01146834 | Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma | Phase3 | Multiple Myeloma | Completed | 2011-03-01 | 2019-02-04 | ClinicalTrials.gov |
| NCT01311076 | TAK-329 Glucose Clamp Study | Phase1 | Type 1 Diabetes Mellitus | Completed | 2011-03-01 | 2012-01-01 | ClinicalTrials.gov |
| NCT01317797 | A Trial to Evaluate the Safety and Tolerability of Namilumab (MT203) in Patient… | Phase1 | Rheumatoid Arthritis | Completed | 2011-03-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01311076 | TAK-329 Glucose Clamp Study | Phase1 | Type 1 Diabetes Mellitus | Completed | 2011-03-01 | 2012-01-01 | ClinicalTrials.gov |
| NCT01309828 | Long-Term Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesar… | Phase3 | Safety | Completed | 2011-03-01 | 2012-10-01 | ClinicalTrials.gov |
| NCT02153086 | Ramelteon 8 mg Tablets Specified Drug-use Survey: <Long-term Survey on Insomnia… | — | Insomnia | Completed | 2011-03-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT01299805 | Effects of Vortioxetine (Lu AA21004) on the Concentrations of Selected Neurotra… | Phase1 | Healthy | Completed | 2011-03-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT01299727 | Extension of Study HGT-SAN-055 Evaluating Administration of rhHNS in Patients W… | Phase1 | Sanfilippo Syndrome | Terminated | 2011-03-01 | 2019-04-12 | ClinicalTrials.gov |
| NCT01146834 | Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma | Phase3 | Multiple Myeloma | Completed | 2011-03-01 | 2019-02-04 | ClinicalTrials.gov |
| NCT01299727 | Extension of Study HGT-SAN-055 Evaluating Administration of rhHNS in Patients W… | Phase1 | Sanfilippo Syndrome | Terminated | 2011-03-01 | 2019-04-12 | ClinicalTrials.gov |
| NCT01299805 | Effects of Vortioxetine (Lu AA21004) on the Concentrations of Selected Neurotra… | Phase1 | Healthy | Completed | 2011-03-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT01309828 | Long-Term Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesar… | Phase3 | Safety | Completed | 2011-03-01 | 2012-10-01 | ClinicalTrials.gov |
| NCT01311076 | TAK-329 Glucose Clamp Study | Phase1 | Type 1 Diabetes Mellitus | Completed | 2011-03-01 | 2012-01-01 | ClinicalTrials.gov |
| NCT01317797 | A Trial to Evaluate the Safety and Tolerability of Namilumab (MT203) in Patient… | Phase1 | Rheumatoid Arthritis | Completed | 2011-03-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT02153086 | Ramelteon 8 mg Tablets Specified Drug-use Survey: <Long-term Survey on Insomnia… | — | Insomnia | Completed | 2011-03-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT01317797 | A Trial to Evaluate the Safety and Tolerability of Namilumab (MT203) in Patient… | Phase1 | Rheumatoid Arthritis | Completed | 2011-03-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT02153086 | Ramelteon 8 mg Tablets Specified Drug-use Survey: <Long-term Survey on Insomnia… | — | Insomnia | Completed | 2011-03-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT01146834 | Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma | Phase3 | Multiple Myeloma | Completed | 2011-03-01 | 2019-02-04 | ClinicalTrials.gov |
| NCT01299727 | Extension of Study HGT-SAN-055 Evaluating Administration of rhHNS in Patients W… | Phase1 | Sanfilippo Syndrome | Terminated | 2011-03-01 | 2019-04-12 | ClinicalTrials.gov |
| NCT01299805 | Effects of Vortioxetine (Lu AA21004) on the Concentrations of Selected Neurotra… | Phase1 | Healthy | Completed | 2011-03-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT01945242 | Alogliptin Tablets Special Drug Use Surveillance "Type 2 Diabetes Mellitus: Com… | — | Type 2 Diabetes Melitus | Completed | 2011-03-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT01309828 | Long-Term Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesar… | Phase3 | Safety | Completed | 2011-03-01 | 2012-10-01 | ClinicalTrials.gov |
| NCT01351350 | Dose Escalation Study of MLN0128 in Combination With Paclitaxel, With/Without T… | Phase1 | Advanced Solid Malignancies | Completed | 2011-02-28 | 2017-09-15 | ClinicalTrials.gov |
| NCT01351350 | Dose Escalation Study of MLN0128 in Combination With Paclitaxel, With/Without T… | Phase1 | Advanced Solid Malignancies | Completed | 2011-02-28 | 2017-09-15 | ClinicalTrials.gov |
| NCT01351350 | Dose Escalation Study of MLN0128 in Combination With Paclitaxel, With/Without T… | Phase1 | Advanced Solid Malignancies | Completed | 2011-02-28 | 2017-09-15 | ClinicalTrials.gov |
| NCT01268098 | Study of Safety and Efficacy of a rhPTH[1-84] of Fixed Doses of 25 and 50 mcg i… | Phase3 | Hypoparathyroidism | Completed | 2011-02-09 | 2011-11-11 | ClinicalTrials.gov |
| NCT01268098 | Study of Safety and Efficacy of a rhPTH[1-84] of Fixed Doses of 25 and 50 mcg i… | Phase3 | Hypoparathyroidism | Completed | 2011-02-09 | 2011-11-11 | ClinicalTrials.gov |
| NCT01268098 | Study of Safety and Efficacy of a rhPTH[1-84] of Fixed Doses of 25 and 50 mcg i… | Phase3 | Hypoparathyroidism | Completed | 2011-02-09 | 2011-11-11 | ClinicalTrials.gov |
| NCT01281917 | Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lympho… | Phase2 | Non-Hodgkins Lymphoma | Completed | 2011-02-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT01289626 | Efficacy of Lanthanum Carbonate in Calciphylaxis | Phase1 | Calciphylaxis | Completed | 2011-02-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT01289626 | Efficacy of Lanthanum Carbonate in Calciphylaxis | Phase1 | Calciphylaxis | Completed | 2011-02-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT01289626 | Efficacy of Lanthanum Carbonate in Calciphylaxis | Phase1 | Calciphylaxis | Completed | 2011-02-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT01281917 | Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lympho… | Phase2 | Non-Hodgkins Lymphoma | Completed | 2011-02-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT01309789 | A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Mul… | Phase1 | Lymphoma, Large-Cell, Anaplastic | Completed | 2011-02-01 | 2017-02-28 | ClinicalTrials.gov |
| NCT01309789 | A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Mul… | Phase1 | Lymphoma, Large-Cell, Anaplastic | Completed | 2011-02-01 | 2017-02-28 | ClinicalTrials.gov |
| NCT01309789 | A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Mul… | Phase1 | Lymphoma, Large-Cell, Anaplastic | Completed | 2011-02-01 | 2017-02-28 | ClinicalTrials.gov |
| NCT01281917 | Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lympho… | Phase2 | Non-Hodgkins Lymphoma | Completed | 2011-02-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT01244490 | Efficacy and Safety of Extended-release Guanfacine Hydrochloride in Children an… | Phase3 | Attention Deficit Hyperactivity Disorder | Completed | 2011-01-17 | 2013-05-01 | ClinicalTrials.gov |
| NCT01244490 | Efficacy and Safety of Extended-release Guanfacine Hydrochloride in Children an… | Phase3 | Attention Deficit Hyperactivity Disorder | Completed | 2011-01-17 | 2013-05-01 | ClinicalTrials.gov |
| NCT01244490 | Efficacy and Safety of Extended-release Guanfacine Hydrochloride in Children an… | Phase3 | Attention Deficit Hyperactivity Disorder | Completed | 2011-01-17 | 2013-05-01 | ClinicalTrials.gov |
| NCT01430260 | Omnaris Versus Levocetirizine Phase 4 Study | Phase4 | Allergic Rhinitis | Completed | 2011-01-01 | 2012-07-01 | ClinicalTrials.gov |
| NCT01430260 | Omnaris Versus Levocetirizine Phase 4 Study | Phase4 | Allergic Rhinitis | Completed | 2011-01-01 | 2012-07-01 | ClinicalTrials.gov |
| NCT01430260 | Omnaris Versus Levocetirizine Phase 4 Study | Phase4 | Allergic Rhinitis | Completed | 2011-01-01 | 2012-07-01 | ClinicalTrials.gov |
| NCT03291223 | Gaucher Disease Outcome Survey (GOS) | — | Gaucher Disease | Recruiting | 2010-12-29 | 2026-09-30 | ClinicalTrials.gov |
| NCT03291223 | Gaucher Disease Outcome Survey (GOS) | — | Gaucher Disease | Recruiting | 2010-12-29 | 2026-09-30 | ClinicalTrials.gov |
| NCT03291223 | Gaucher Disease Outcome Survey (GOS) | — | Gaucher Disease | Recruiting | 2010-12-29 | 2026-09-30 | ClinicalTrials.gov |
| NCT01128179 | Effects of Lanthanum Carbonate on FGF-23 in Subjects With Stage 3 CKD | Phase2 | Chronic Kidney Disease | Completed | 2010-12-06 | 2012-04-16 | ClinicalTrials.gov |
| NCT01128179 | Effects of Lanthanum Carbonate on FGF-23 in Subjects With Stage 3 CKD | Phase2 | Chronic Kidney Disease | Completed | 2010-12-06 | 2012-04-16 | ClinicalTrials.gov |
| NCT01128179 | Effects of Lanthanum Carbonate on FGF-23 in Subjects With Stage 3 CKD | Phase2 | Chronic Kidney Disease | Completed | 2010-12-06 | 2012-04-16 | ClinicalTrials.gov |
| NCT01370863 | An Explorative Trial to Evaluate the Pharmacodynamic Effect of SPD557 on Reflux… | Phase2 | Gastroesophageal Reflux Disease | Terminated | 2010-12-02 | 2012-05-29 | ClinicalTrials.gov |
| NCT01370863 | An Explorative Trial to Evaluate the Pharmacodynamic Effect of SPD557 on Reflux… | Phase2 | Gastroesophageal Reflux Disease | Terminated | 2010-12-02 | 2012-05-29 | ClinicalTrials.gov |
| NCT01370863 | An Explorative Trial to Evaluate the Pharmacodynamic Effect of SPD557 on Reflux… | Phase2 | Gastroesophageal Reflux Disease | Terminated | 2010-12-02 | 2012-05-29 | ClinicalTrials.gov |
| NCT01289119 | Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes | Phase3 | Diabetes Mellitus, Type 2 | Completed | 2010-12-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT01289119 | Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes | Phase3 | Diabetes Mellitus, Type 2 | Completed | 2010-12-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT01289119 | Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes | Phase3 | Diabetes Mellitus, Type 2 | Completed | 2010-12-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT01217957 | A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose … | Phase1 | Multiple Myeloma | Completed | 2010-11-22 | 2018-02-02 | ClinicalTrials.gov |
| NCT01217957 | A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose … | Phase1 | Multiple Myeloma | Completed | 2010-11-22 | 2018-02-02 | ClinicalTrials.gov |
| NCT01217957 | A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose … | Phase1 | Multiple Myeloma | Completed | 2010-11-22 | 2018-02-02 | ClinicalTrials.gov |
| NCT01193257 | Study Comparing Orteronel Plus Prednisone in Participants With Metastatic Castr… | Phase3 | Prostate Cancer | Completed | 2010-11-15 | 2016-02-29 | ClinicalTrials.gov |
| NCT01193257 | Study Comparing Orteronel Plus Prednisone in Participants With Metastatic Castr… | Phase3 | Prostate Cancer | Completed | 2010-11-15 | 2016-02-29 | ClinicalTrials.gov |
| NCT01193257 | Study Comparing Orteronel Plus Prednisone in Participants With Metastatic Castr… | Phase3 | Prostate Cancer | Completed | 2010-11-15 | 2016-02-29 | ClinicalTrials.gov |
| NCT01216293 | Effect of Dexlansoprazole on Bone Homeostasis | Phase1 | Homeostasis | Completed | 2010-11-01 | 2015-02-01 | ClinicalTrials.gov |
| NCT01255787 | Efficacy and Safety Study of Vortioxetine (Lu AA21004) for Treatment of Major D… | Phase2 | Depressive Disorder, Major | Completed | 2010-11-01 | 2012-04-01 | ClinicalTrials.gov |
| NCT02024945 | Efficacy, Tolerability and Impact on Quality of Life of Propiverine in Patients… | — | Overactive Bladder Syndrome | Completed | 2010-11-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT02024945 | Efficacy, Tolerability and Impact on Quality of Life of Propiverine in Patients… | — | Overactive Bladder Syndrome | Completed | 2010-11-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT01118689 | Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or … | Phase1 | Relapsed Multiple Myeloma | Completed | 2010-11-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT01132404 | Study in Men With Prostate Cancer to Assess the Safety, Pharmacokinetics and Te… | Phase1 | Prostate Cancer | Terminated | 2010-11-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT01162863 | Effects of Lubiprostone on Gastrointestinal Transit & pH in Irritable Bowel Syn… | Na | Irritable Bowel Syndrome | Completed | 2010-11-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT01132404 | Study in Men With Prostate Cancer to Assess the Safety, Pharmacokinetics and Te… | Phase1 | Prostate Cancer | Terminated | 2010-11-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT01118689 | Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or … | Phase1 | Relapsed Multiple Myeloma | Completed | 2010-11-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT01162863 | Effects of Lubiprostone on Gastrointestinal Transit & pH in Irritable Bowel Syn… | Na | Irritable Bowel Syndrome | Completed | 2010-11-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT01255787 | Efficacy and Safety Study of Vortioxetine (Lu AA21004) for Treatment of Major D… | Phase2 | Depressive Disorder, Major | Completed | 2010-11-01 | 2012-04-01 | ClinicalTrials.gov |
| NCT01118689 | Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or … | Phase1 | Relapsed Multiple Myeloma | Completed | 2010-11-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT01162863 | Effects of Lubiprostone on Gastrointestinal Transit & pH in Irritable Bowel Syn… | Na | Irritable Bowel Syndrome | Completed | 2010-11-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT01236534 | Lubiprostone in Patients With Multiple Sclerosis Associated Constipation | Phase4 | Multiple Sclerosis | Completed | 2010-11-01 | 2012-04-01 | ClinicalTrials.gov |
| NCT01224171 | Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease | Phase3 | Crohn's Disease | Completed | 2010-11-01 | 2012-04-01 | ClinicalTrials.gov |
| NCT01216293 | Effect of Dexlansoprazole on Bone Homeostasis | Phase1 | Homeostasis | Completed | 2010-11-01 | 2015-02-01 | ClinicalTrials.gov |
| NCT01236534 | Lubiprostone in Patients With Multiple Sclerosis Associated Constipation | Phase4 | Multiple Sclerosis | Completed | 2010-11-01 | 2012-04-01 | ClinicalTrials.gov |
| NCT01224756 | Efficacy of Tinoridine in Treating Pain and Inflammation in Adults | Phase4 | Pain | Completed | 2010-11-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT01236534 | Lubiprostone in Patients With Multiple Sclerosis Associated Constipation | Phase4 | Multiple Sclerosis | Completed | 2010-11-01 | 2012-04-01 | ClinicalTrials.gov |
| NCT01132404 | Study in Men With Prostate Cancer to Assess the Safety, Pharmacokinetics and Te… | Phase1 | Prostate Cancer | Terminated | 2010-11-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT01216293 | Effect of Dexlansoprazole on Bone Homeostasis | Phase1 | Homeostasis | Completed | 2010-11-01 | 2015-02-01 | ClinicalTrials.gov |
| NCT01255787 | Efficacy and Safety Study of Vortioxetine (Lu AA21004) for Treatment of Major D… | Phase2 | Depressive Disorder, Major | Completed | 2010-11-01 | 2012-04-01 | ClinicalTrials.gov |
| NCT01224171 | Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease | Phase3 | Crohn's Disease | Completed | 2010-11-01 | 2012-04-01 | ClinicalTrials.gov |
| NCT01224756 | Efficacy of Tinoridine in Treating Pain and Inflammation in Adults | Phase4 | Pain | Completed | 2010-11-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT02024945 | Efficacy, Tolerability and Impact on Quality of Life of Propiverine in Patients… | — | Overactive Bladder Syndrome | Completed | 2010-11-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT01224171 | Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease | Phase3 | Crohn's Disease | Completed | 2010-11-01 | 2012-04-01 | ClinicalTrials.gov |
| NCT01224756 | Efficacy of Tinoridine in Treating Pain and Inflammation in Adults | Phase4 | Pain | Completed | 2010-11-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT01210196 | Sophisticated Assessment of Disease Burden in Patients With Fabry Disease | — | Fabry Disease | Completed | 2010-10-31 | 2013-09-30 | ClinicalTrials.gov |
| NCT01210196 | Sophisticated Assessment of Disease Burden in Patients With Fabry Disease | — | Fabry Disease | Completed | 2010-10-31 | 2013-09-30 | ClinicalTrials.gov |
| NCT01210196 | Sophisticated Assessment of Disease Burden in Patients With Fabry Disease | — | Fabry Disease | Completed | 2010-10-31 | 2013-09-30 | ClinicalTrials.gov |
| NCT01235338 | Co-Administration of LDX (SPD489) and Venlafaxine XR (EFFEXOR XR) in Healthy Vo… | Phase1 | Healthy | Completed | 2010-10-28 | 2011-01-17 | ClinicalTrials.gov |
| NCT01235338 | Co-Administration of LDX (SPD489) and Venlafaxine XR (EFFEXOR XR) in Healthy Vo… | Phase1 | Healthy | Completed | 2010-10-28 | 2011-01-17 | ClinicalTrials.gov |
| NCT01235338 | Co-Administration of LDX (SPD489) and Venlafaxine XR (EFFEXOR XR) in Healthy Vo… | Phase1 | Healthy | Completed | 2010-10-28 | 2011-01-17 | ClinicalTrials.gov |
| NCT01467661 | Long-term Safety of SPD422 in Japanese Adults With Essential Thrombocythaemia | Phase3 | Essential Thrombocythemia (ET) | Completed | 2010-10-27 | 2015-05-01 | ClinicalTrials.gov |
| NCT01467661 | Long-term Safety of SPD422 in Japanese Adults With Essential Thrombocythaemia | Phase3 | Essential Thrombocythemia (ET) | Completed | 2010-10-27 | 2015-05-01 | ClinicalTrials.gov |
| NCT01214915 | Effect of SPD422 on Platelet Lowering and Safety in Japanese Adults With At Ris… | Phase3 | Essential Thrombocythemia (ET) | Completed | 2010-10-27 | 2012-10-24 | ClinicalTrials.gov |
| NCT01214915 | Effect of SPD422 on Platelet Lowering and Safety in Japanese Adults With At Ris… | Phase3 | Essential Thrombocythemia (ET) | Completed | 2010-10-27 | 2012-10-24 | ClinicalTrials.gov |
| NCT01214915 | Effect of SPD422 on Platelet Lowering and Safety in Japanese Adults With At Ris… | Phase3 | Essential Thrombocythemia (ET) | Completed | 2010-10-27 | 2012-10-24 | ClinicalTrials.gov |
| NCT01467661 | Long-term Safety of SPD422 in Japanese Adults With Essential Thrombocythaemia | Phase3 | Essential Thrombocythemia (ET) | Completed | 2010-10-27 | 2015-05-01 | ClinicalTrials.gov |
| NCT01186458 | Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Ho… | Phase2 | Lymphoma, Non-Hodgkin | Terminated | 2010-10-01 | 2013-10-01 | ClinicalTrials.gov |
| NCT02099708 | Long-term Use of Takepron on the Prevention of Recurrence of Gastric/Duodenal U… | — | Gastric or Duodenal Ulcers | Completed | 2010-10-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01204073 | A Study of TAK-441 in Adult Patients With Advanced Nonhematologic Malignancies | Phase1 | Advanced Nonhematologic Malignancies | Completed | 2010-10-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT01193244 | Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Nai… | Phase3 | Prostate Cancer | Completed | 2010-10-01 | 2016-04-07 | ClinicalTrials.gov |
| NCT02099708 | Long-term Use of Takepron on the Prevention of Recurrence of Gastric/Duodenal U… | — | Gastric or Duodenal Ulcers | Completed | 2010-10-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01186458 | Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Ho… | Phase2 | Lymphoma, Non-Hodgkin | Terminated | 2010-10-01 | 2013-10-01 | ClinicalTrials.gov |
| NCT01193244 | Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Nai… | Phase3 | Prostate Cancer | Completed | 2010-10-01 | 2016-04-07 | ClinicalTrials.gov |
| NCT01186458 | Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Ho… | Phase2 | Lymphoma, Non-Hodgkin | Terminated | 2010-10-01 | 2013-10-01 | ClinicalTrials.gov |
| NCT01204073 | A Study of TAK-441 in Adult Patients With Advanced Nonhematologic Malignancies | Phase1 | Advanced Nonhematologic Malignancies | Completed | 2010-10-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT02099708 | Long-term Use of Takepron on the Prevention of Recurrence of Gastric/Duodenal U… | — | Gastric or Duodenal Ulcers | Completed | 2010-10-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01472627 | Effects of Bortezomib-Based Therapy on Cellular Immunity and Response to DC/Mye… | — | Multiple Myeloma | Completed | 2010-10-01 | 2018-01-01 | ClinicalTrials.gov |
| NCT01472627 | Effects of Bortezomib-Based Therapy on Cellular Immunity and Response to DC/Mye… | — | Multiple Myeloma | Completed | 2010-10-01 | 2018-01-01 | ClinicalTrials.gov |
| NCT01472627 | Effects of Bortezomib-Based Therapy on Cellular Immunity and Response to DC/Mye… | — | Multiple Myeloma | Completed | 2010-10-01 | 2018-01-01 | ClinicalTrials.gov |
| NCT01263548 | To Evaluate the Safety and Metabolic Profile of Vyvanse for the Treatment of AD… | — | Attention Deficit/Hyperactivity Disorder | Completed | 2010-10-01 | 2012-01-01 | ClinicalTrials.gov |
| NCT01263548 | To Evaluate the Safety and Metabolic Profile of Vyvanse for the Treatment of AD… | — | Attention Deficit/Hyperactivity Disorder | Completed | 2010-10-01 | 2012-01-01 | ClinicalTrials.gov |
| NCT01193244 | Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Nai… | Phase3 | Prostate Cancer | Completed | 2010-10-01 | 2016-04-07 | ClinicalTrials.gov |
| NCT01263548 | To Evaluate the Safety and Metabolic Profile of Vyvanse for the Treatment of AD… | — | Attention Deficit/Hyperactivity Disorder | Completed | 2010-10-01 | 2012-01-01 | ClinicalTrials.gov |
| NCT01204073 | A Study of TAK-441 in Adult Patients With Advanced Nonhematologic Malignancies | Phase1 | Advanced Nonhematologic Malignancies | Completed | 2010-10-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT01198717 | Pediatric Disease Registry in Essential Thrombocythaemia (ET) | — | Essential Thrombocythemia (ET) | Completed | 2010-09-28 | 2016-03-01 | ClinicalTrials.gov |
| NCT01198717 | Pediatric Disease Registry in Essential Thrombocythaemia (ET) | — | Essential Thrombocythemia (ET) | Completed | 2010-09-28 | 2016-03-01 | ClinicalTrials.gov |
| NCT01198717 | Pediatric Disease Registry in Essential Thrombocythaemia (ET) | — | Essential Thrombocythemia (ET) | Completed | 2010-09-28 | 2016-03-01 | ClinicalTrials.gov |
| NCT01147926 | Evaluation of Prucalopride in Male Subjects With Chronic Constipation. | Phase3 | Male Subjects With Chronic Constipation | Completed | 2010-09-23 | 2013-10-25 | ClinicalTrials.gov |
| NCT01147926 | Evaluation of Prucalopride in Male Subjects With Chronic Constipation. | Phase3 | Male Subjects With Chronic Constipation | Completed | 2010-09-23 | 2013-10-25 | ClinicalTrials.gov |
| NCT01147926 | Evaluation of Prucalopride in Male Subjects With Chronic Constipation. | Phase3 | Male Subjects With Chronic Constipation | Completed | 2010-09-23 | 2013-10-25 | ClinicalTrials.gov |
| NCT01192347 | French Observational Xagrid (FOX) Study In Adult Patients With Essential Thromb… | — | Essential Thrombocythemia | Completed | 2010-09-13 | 2012-12-21 | ClinicalTrials.gov |
| NCT01192347 | French Observational Xagrid (FOX) Study In Adult Patients With Essential Thromb… | — | Essential Thrombocythemia | Completed | 2010-09-13 | 2012-12-21 | ClinicalTrials.gov |
| NCT01192347 | French Observational Xagrid (FOX) Study In Adult Patients With Essential Thromb… | — | Essential Thrombocythemia | Completed | 2010-09-13 | 2012-12-21 | ClinicalTrials.gov |
| NCT01168401 | Bivalent Norovirus Vaccine Study | Phase1 | Gastroenteritis | Completed | 2010-09-03 | 2013-01-09 | ClinicalTrials.gov |
| NCT01168401 | Bivalent Norovirus Vaccine Study | Phase1 | Gastroenteritis | Completed | 2010-09-03 | 2013-01-09 | ClinicalTrials.gov |
| NCT01168401 | Bivalent Norovirus Vaccine Study | Phase1 | Gastroenteritis | Completed | 2010-09-03 | 2013-01-09 | ClinicalTrials.gov |
| NCT01187628 | Long-term Study in Chronic Kidney Disease (Extension From Study 14817) | Phase3 | Hyperphosphatemia | Completed | 2010-09-01 | 2013-04-01 | ClinicalTrials.gov |
| NCT01179399 | Study of Orally Administered TAK-960 in Patients With Advanced Nonhematologic M… | Phase1 | Advanced Nonhematological Malignancies | Terminated | 2010-09-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT01208662 | Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatm… | Phase3 | Multiple Myeloma | Active_Not_Recruiting | 2010-09-01 | 2026-12-01 | ClinicalTrials.gov |
| NCT01187628 | Long-term Study in Chronic Kidney Disease (Extension From Study 14817) | Phase3 | Hyperphosphatemia | Completed | 2010-09-01 | 2013-04-01 | ClinicalTrials.gov |
| NCT01179399 | Study of Orally Administered TAK-960 in Patients With Advanced Nonhematologic M… | Phase1 | Advanced Nonhematological Malignancies | Terminated | 2010-09-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT01171092 | A Safety Study Looking at the Combination of Velcade and G-CSF in Patients With… | Early_Phase1 | Malignant Lymphoma, Stem Cell Type | Completed | 2010-09-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT01078961 | An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Mela… | Phase1 | Melanoma | Completed | 2010-09-01 | 2016-06-01 | ClinicalTrials.gov |
| NCT01152996 | Safety and Tolerability of Vortioxetine (LuAA21004) - Open Label Extension Study | Phase3 | Depressive Disorder, Major | Completed | 2010-09-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT01148979 | Lisdexamfetamine Dimesylate in Residual Symptoms and Cognitive Impairment in Ma… | Phase4 | Major Depressive Disorder | Completed | 2010-09-01 | 2014-10-01 | ClinicalTrials.gov |
| NCT01056601 | Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Thera… | Phase2 | Pancreatic Cancer | Terminated | 2010-09-01 | 2011-02-01 | ClinicalTrials.gov |
| NCT01078961 | An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Mela… | Phase1 | Melanoma | Completed | 2010-09-01 | 2016-06-01 | ClinicalTrials.gov |
| NCT01148979 | Lisdexamfetamine Dimesylate in Residual Symptoms and Cognitive Impairment in Ma… | Phase4 | Major Depressive Disorder | Completed | 2010-09-01 | 2014-10-01 | ClinicalTrials.gov |
| NCT01152996 | Safety and Tolerability of Vortioxetine (LuAA21004) - Open Label Extension Study | Phase3 | Depressive Disorder, Major | Completed | 2010-09-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT01078961 | An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Mela… | Phase1 | Melanoma | Completed | 2010-09-01 | 2016-06-01 | ClinicalTrials.gov |
| NCT01171092 | A Safety Study Looking at the Combination of Velcade and G-CSF in Patients With… | Early_Phase1 | Malignant Lymphoma, Stem Cell Type | Completed | 2010-09-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT01179399 | Study of Orally Administered TAK-960 in Patients With Advanced Nonhematologic M… | Phase1 | Advanced Nonhematological Malignancies | Terminated | 2010-09-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT01056601 | Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Thera… | Phase2 | Pancreatic Cancer | Terminated | 2010-09-01 | 2011-02-01 | ClinicalTrials.gov |
| NCT01208662 | Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatm… | Phase3 | Multiple Myeloma | Active_Not_Recruiting | 2010-09-01 | 2026-12-01 | ClinicalTrials.gov |
| NCT01187628 | Long-term Study in Chronic Kidney Disease (Extension From Study 14817) | Phase3 | Hyperphosphatemia | Completed | 2010-09-01 | 2013-04-01 | ClinicalTrials.gov |
| NCT01056601 | Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Thera… | Phase2 | Pancreatic Cancer | Terminated | 2010-09-01 | 2011-02-01 | ClinicalTrials.gov |
| NCT01208662 | Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatm… | Phase3 | Multiple Myeloma | Active_Not_Recruiting | 2010-09-01 | 2026-12-01 | ClinicalTrials.gov |
| NCT01148979 | Lisdexamfetamine Dimesylate in Residual Symptoms and Cognitive Impairment in Ma… | Phase4 | Major Depressive Disorder | Completed | 2010-09-01 | 2014-10-01 | ClinicalTrials.gov |
| NCT01152996 | Safety and Tolerability of Vortioxetine (LuAA21004) - Open Label Extension Study | Phase3 | Depressive Disorder, Major | Completed | 2010-09-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT01171092 | A Safety Study Looking at the Combination of Velcade and G-CSF in Patients With… | Early_Phase1 | Malignant Lymphoma, Stem Cell Type | Completed | 2010-09-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT01183234 | SPD544 High Strength Bioequivalence Study | Phase1 | ADHD | Completed | 2010-08-27 | 2010-10-22 | ClinicalTrials.gov |
| NCT01183234 | SPD544 High Strength Bioequivalence Study | Phase1 | ADHD | Completed | 2010-08-27 | 2010-10-22 | ClinicalTrials.gov |
| NCT01183234 | SPD544 High Strength Bioequivalence Study | Phase1 | ADHD | Completed | 2010-08-27 | 2010-10-22 | ClinicalTrials.gov |
| NCT01111188 | Trial of PD 0332991 Plus Bortezomib in Patients With Relapsed Mantle Cell Lymph… | Phase1 | Mantle Cell Lymphoma | Terminated | 2010-08-23 | 2019-04-12 | ClinicalTrials.gov |
| NCT01111188 | Trial of PD 0332991 Plus Bortezomib in Patients With Relapsed Mantle Cell Lymph… | Phase1 | Mantle Cell Lymphoma | Terminated | 2010-08-23 | 2019-04-12 | ClinicalTrials.gov |
| NCT01111188 | Trial of PD 0332991 Plus Bortezomib in Patients With Relapsed Mantle Cell Lymph… | Phase1 | Mantle Cell Lymphoma | Terminated | 2010-08-23 | 2019-04-12 | ClinicalTrials.gov |
| NCT01094288 | A Phase 1 Study of Alisertib Participants With Advanced Solid Tumors Including … | Phase1 | Advanced Solid Tumors | Completed | 2010-08-17 | 2017-01-04 | ClinicalTrials.gov |
| NCT01094288 | A Phase 1 Study of Alisertib Participants With Advanced Solid Tumors Including … | Phase1 | Advanced Solid Tumors | Completed | 2010-08-17 | 2017-01-04 | ClinicalTrials.gov |
| NCT01094288 | A Phase 1 Study of Alisertib Participants With Advanced Solid Tumors Including … | Phase1 | Advanced Solid Tumors | Completed | 2010-08-17 | 2017-01-04 | ClinicalTrials.gov |
| NCT01186419 | Safety and Pharmacodynamic Study of an Oral Iron Chelator Given for 6 Months to… | Phase2 | Transfusional Iron Overload | Completed | 2010-08-13 | 2013-01-08 | ClinicalTrials.gov |
| NCT01186419 | Safety and Pharmacodynamic Study of an Oral Iron Chelator Given for 6 Months to… | Phase2 | Transfusional Iron Overload | Completed | 2010-08-13 | 2013-01-08 | ClinicalTrials.gov |
| NCT01186419 | Safety and Pharmacodynamic Study of an Oral Iron Chelator Given for 6 Months to… | Phase2 | Transfusional Iron Overload | Completed | 2010-08-13 | 2013-01-08 | ClinicalTrials.gov |
| NCT02099682 | Long-term Use of Takepron Capsules on the Prevention of Recurrence of Gastric/D… | — | Gastric or Duodenal Ulcers | Completed | 2010-08-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT01174888 | Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractor… | Phase1 | Acute Myeloid Leukemia | Completed | 2010-08-01 | 2016-05-01 | ClinicalTrials.gov |
| NCT01179516 | Safety and Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Dep… | Phase3 | Depressive Disorder, Major | Completed | 2010-08-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT01506141 | An Extension Study of HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outc… | Phase1 | Hunter Syndrome | Completed | 2010-08-01 | 2024-04-30 | ClinicalTrials.gov |
| NCT01151709 | Assessment of Primary Care Providers' Knowledge and Beliefs Regarding Gout Mana… | — | Gout | Completed | 2010-08-01 | 2012-02-01 | ClinicalTrials.gov |
| NCT01151709 | Assessment of Primary Care Providers' Knowledge and Beliefs Regarding Gout Mana… | — | Gout | Completed | 2010-08-01 | 2012-02-01 | ClinicalTrials.gov |
| NCT02774902 | TAK-438_110 Drug Interaction With Cytochrome P450 3A4 (CYP3A4) Inhibitor Clarit… | Phase1 | Healthy Volunteers | Completed | 2010-08-01 | 2010-09-01 | ClinicalTrials.gov |
| NCT02774902 | TAK-438_110 Drug Interaction With Cytochrome P450 3A4 (CYP3A4) Inhibitor Clarit… | Phase1 | Healthy Volunteers | Completed | 2010-08-01 | 2010-09-01 | ClinicalTrials.gov |
| NCT01506141 | An Extension Study of HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outc… | Phase1 | Hunter Syndrome | Completed | 2010-08-01 | 2024-04-30 | ClinicalTrials.gov |
| NCT02099682 | Long-term Use of Takepron Capsules on the Prevention of Recurrence of Gastric/D… | — | Gastric or Duodenal Ulcers | Completed | 2010-08-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT02774902 | TAK-438_110 Drug Interaction With Cytochrome P450 3A4 (CYP3A4) Inhibitor Clarit… | Phase1 | Healthy Volunteers | Completed | 2010-08-01 | 2010-09-01 | ClinicalTrials.gov |
| NCT01506141 | An Extension Study of HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outc… | Phase1 | Hunter Syndrome | Completed | 2010-08-01 | 2024-04-30 | ClinicalTrials.gov |
| NCT01179516 | Safety and Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Dep… | Phase3 | Depressive Disorder, Major | Completed | 2010-08-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT01192022 | TachoSil® Versus Surgicel® Original for the Secondary Treatment of Local Bleedi… | Phase3 | Hemorrhage | Completed | 2010-08-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT01151709 | Assessment of Primary Care Providers' Knowledge and Beliefs Regarding Gout Mana… | — | Gout | Completed | 2010-08-01 | 2012-02-01 | ClinicalTrials.gov |
| NCT01174888 | Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractor… | Phase1 | Acute Myeloid Leukemia | Completed | 2010-08-01 | 2016-05-01 | ClinicalTrials.gov |
| NCT02099682 | Long-term Use of Takepron Capsules on the Prevention of Recurrence of Gastric/D… | — | Gastric or Duodenal Ulcers | Completed | 2010-08-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT01192022 | TachoSil® Versus Surgicel® Original for the Secondary Treatment of Local Bleedi… | Phase3 | Hemorrhage | Completed | 2010-08-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT01174888 | Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractor… | Phase1 | Acute Myeloid Leukemia | Completed | 2010-08-01 | 2016-05-01 | ClinicalTrials.gov |
| NCT01192022 | TachoSil® Versus Surgicel® Original for the Secondary Treatment of Local Bleedi… | Phase3 | Hemorrhage | Completed | 2010-08-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT01179516 | Safety and Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Dep… | Phase3 | Depressive Disorder, Major | Completed | 2010-08-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT01945216 | Alogliptin Tablets Special Drug Use Surveillance "Type 2 Diabetes Mellitus: Mon… | — | Type 2 Diabetes Mellitus Who Have Been Examined at a Medical Institution | Completed | 2010-07-08 | 2015-10-31 | ClinicalTrials.gov |
| NCT01945216 | Alogliptin Tablets Special Drug Use Surveillance "Type 2 Diabetes Mellitus: Mon… | — | Type 2 Diabetes Mellitus Who Have Been Examined at a Medical Institution | Completed | 2010-07-08 | 2015-10-31 | ClinicalTrials.gov |
| NCT01945216 | Alogliptin Tablets Special Drug Use Surveillance "Type 2 Diabetes Mellitus: Mon… | — | Type 2 Diabetes Mellitus Who Have Been Examined at a Medical Institution | Completed | 2010-07-08 | 2015-10-31 | ClinicalTrials.gov |
| NCT01116947 | Fosrenol for Enhancing Dietary Protein Intake in Hypoalbuminemic Dialysis Patie… | Na | End-Stage Renal Disease | Completed | 2010-07-01 | 2012-02-01 | ClinicalTrials.gov |
| NCT02024971 | Special Drug Use Surveillance of Pioglitazone/Metformin Hydrochloride Combinati… | — | Type 2 Diabetes Mellitus | Completed | 2010-07-01 | 2013-11-01 | ClinicalTrials.gov |
| NCT02058992 | Ramelteon Tablets 8mg Drug Use Surveillance: Survey on Insomnia Associated With… | — | Insomnia | Completed | 2010-07-01 | 2013-04-01 | ClinicalTrials.gov |
| NCT01163266 | Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Adults With Major Dep… | Phase3 | Depressive Disorder, Major | Completed | 2010-07-01 | 2012-01-01 | ClinicalTrials.gov |
| NCT01116947 | Fosrenol for Enhancing Dietary Protein Intake in Hypoalbuminemic Dialysis Patie… | Na | End-Stage Renal Disease | Completed | 2010-07-01 | 2012-02-01 | ClinicalTrials.gov |
| NCT02058992 | Ramelteon Tablets 8mg Drug Use Surveillance: Survey on Insomnia Associated With… | — | Insomnia | Completed | 2010-07-01 | 2013-04-01 | ClinicalTrials.gov |
| NCT02024971 | Special Drug Use Surveillance of Pioglitazone/Metformin Hydrochloride Combinati… | — | Type 2 Diabetes Mellitus | Completed | 2010-07-01 | 2013-11-01 | ClinicalTrials.gov |
| NCT01084655 | Study of TAK-700 in Combination With Docetaxel and Prednisone in Men With Metas… | Phase1 | Prostate Cancer | Completed | 2010-07-01 | 2016-03-01 | ClinicalTrials.gov |
| NCT01163266 | Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Adults With Major Dep… | Phase3 | Depressive Disorder, Major | Completed | 2010-07-01 | 2012-01-01 | ClinicalTrials.gov |
| NCT02024971 | Special Drug Use Surveillance of Pioglitazone/Metformin Hydrochloride Combinati… | — | Type 2 Diabetes Mellitus | Completed | 2010-07-01 | 2013-11-01 | ClinicalTrials.gov |
| NCT01084655 | Study of TAK-700 in Combination With Docetaxel and Prednisone in Men With Metas… | Phase1 | Prostate Cancer | Completed | 2010-07-01 | 2016-03-01 | ClinicalTrials.gov |
| NCT01116947 | Fosrenol for Enhancing Dietary Protein Intake in Hypoalbuminemic Dialysis Patie… | Na | End-Stage Renal Disease | Completed | 2010-07-01 | 2012-02-01 | ClinicalTrials.gov |
| NCT02058992 | Ramelteon Tablets 8mg Drug Use Surveillance: Survey on Insomnia Associated With… | — | Insomnia | Completed | 2010-07-01 | 2013-04-01 | ClinicalTrials.gov |
| NCT01163266 | Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Adults With Major Dep… | Phase3 | Depressive Disorder, Major | Completed | 2010-07-01 | 2012-01-01 | ClinicalTrials.gov |
| NCT01084655 | Study of TAK-700 in Combination With Docetaxel and Prednisone in Men With Metas… | Phase1 | Prostate Cancer | Completed | 2010-07-01 | 2016-03-01 | ClinicalTrials.gov |
| NCT01124149 | Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesal… | Phase4 | Ulcerative Colitis | Completed | 2010-06-29 | 2012-12-07 | ClinicalTrials.gov |
| NCT01124149 | Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesal… | Phase4 | Ulcerative Colitis | Completed | 2010-06-29 | 2012-12-07 | ClinicalTrials.gov |
| NCT01124149 | Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesal… | Phase4 | Ulcerative Colitis | Completed | 2010-06-29 | 2012-12-07 | ClinicalTrials.gov |
| NCT01106430 | Comparison of Lisdexamfetamine Dimesylate With Atomoxetine HCl in Attention-Def… | Phase3 | Attention-Deficit/Hyperactivity Disorder | Completed | 2010-06-28 | 2012-07-19 | ClinicalTrials.gov |
| NCT01106430 | Comparison of Lisdexamfetamine Dimesylate With Atomoxetine HCl in Attention-Def… | Phase3 | Attention-Deficit/Hyperactivity Disorder | Completed | 2010-06-28 | 2012-07-19 | ClinicalTrials.gov |
| NCT01106430 | Comparison of Lisdexamfetamine Dimesylate With Atomoxetine HCl in Attention-Def… | Phase3 | Attention-Deficit/Hyperactivity Disorder | Completed | 2010-06-28 | 2012-07-19 | ClinicalTrials.gov |
| NCT01096784 | IGF-1/IGFBP3 Prevention of Retinopathy of Prematurity | Phase2 | Retinopathy of Prematurity (ROP) | Completed | 2010-06-18 | 2016-03-30 | ClinicalTrials.gov |
| NCT01096784 | IGF-1/IGFBP3 Prevention of Retinopathy of Prematurity | Phase2 | Retinopathy of Prematurity (ROP) | Completed | 2010-06-18 | 2016-03-30 | ClinicalTrials.gov |
| NCT01096784 | IGF-1/IGFBP3 Prevention of Retinopathy of Prematurity | Phase2 | Retinopathy of Prematurity (ROP) | Completed | 2010-06-18 | 2016-03-30 | ClinicalTrials.gov |
| NCT02068495 | Candesartan Cilexetil/Amlodipine Besilate Combination Tablets LD, HD Special Dr… | — | Hypertension | Completed | 2010-06-15 | 2013-05-31 | ClinicalTrials.gov |
| NCT02068495 | Candesartan Cilexetil/Amlodipine Besilate Combination Tablets LD, HD Special Dr… | — | Hypertension | Completed | 2010-06-15 | 2013-05-31 | ClinicalTrials.gov |
| NCT02068495 | Candesartan Cilexetil/Amlodipine Besilate Combination Tablets LD, HD Special Dr… | — | Hypertension | Completed | 2010-06-15 | 2013-05-31 | ClinicalTrials.gov |
| NCT01095497 | A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Subcu… | Phase2 | Hereditary Angioedema | Completed | 2010-06-07 | 2010-12-16 | ClinicalTrials.gov |
| NCT01095497 | A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Subcu… | Phase2 | Hereditary Angioedema | Completed | 2010-06-07 | 2010-12-16 | ClinicalTrials.gov |
| NCT01095497 | A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Subcu… | Phase2 | Hereditary Angioedema | Completed | 2010-06-07 | 2010-12-16 | ClinicalTrials.gov |
| NCT01095510 | CINRYZE for the Treatment of Hereditary Angioedema Attacks in Children Under th… | Phase2 | Hereditary Angioedema (HAE) | Completed | 2010-06-02 | 2012-04-17 | ClinicalTrials.gov |
| NCT01095510 | CINRYZE for the Treatment of Hereditary Angioedema Attacks in Children Under th… | Phase2 | Hereditary Angioedema (HAE) | Completed | 2010-06-02 | 2012-04-17 | ClinicalTrials.gov |
| NCT01095510 | CINRYZE for the Treatment of Hereditary Angioedema Attacks in Children Under th… | Phase2 | Hereditary Angioedema (HAE) | Completed | 2010-06-02 | 2012-04-17 | ClinicalTrials.gov |
| NCT01110629 | Study in Chronic Kidney Disease (CKD) Not on Dialysis | Phase3 | Hyperphosphatemia | Completed | 2010-06-01 | 2011-11-01 | ClinicalTrials.gov |
| NCT01155778 | Safety, Tolerability, Ascending Dose and Dose Frequency Study of rhHNS Via an I… | Phase1 | Mucopolysaccharidosis (MPS) | Completed | 2010-06-01 | 2012-09-01 | ClinicalTrials.gov |
| NCT01153009 | Safety and Efficacy of Vortioxetine (Lu AA21004) in Adults With Major Depressiv… | Phase3 | Depressive Disorder, Major | Completed | 2010-06-01 | 2012-03-01 | ClinicalTrials.gov |
| NCT02089737 | Panitumumab for Intravenous Infusion 100 mg and 400 mg Special Drug Use Surveil… | — | Advanced or Recurrent Colorectal Cancer | Completed | 2010-06-01 | 2012-07-01 | ClinicalTrials.gov |
| NCT01162031 | Phase II Study of VELCADE for Relapsed or Refractory T-cell Prolymphocytic Leuk… | Phase2 | Leukemia | Withdrawn | 2010-06-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT01156051 | Effect of Guanfacine Extended-Release on Attention Deficit Hyperactivity Disord… | Phase4 | Attention-Deficit/Hyperactivity Disorder | Terminated | 2010-06-01 | 2012-02-01 | ClinicalTrials.gov |
| NCT01155778 | Safety, Tolerability, Ascending Dose and Dose Frequency Study of rhHNS Via an I… | Phase1 | Mucopolysaccharidosis (MPS) | Completed | 2010-06-01 | 2012-09-01 | ClinicalTrials.gov |
| NCT01153009 | Safety and Efficacy of Vortioxetine (Lu AA21004) in Adults With Major Depressiv… | Phase3 | Depressive Disorder, Major | Completed | 2010-06-01 | 2012-03-01 | ClinicalTrials.gov |
| NCT01162031 | Phase II Study of VELCADE for Relapsed or Refractory T-cell Prolymphocytic Leuk… | Phase2 | Leukemia | Withdrawn | 2010-06-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT01158105 | Bortezomib for the Treatment of Refractory Chronic Graft-vs-Host Disease(cGVHD) | Phase2 | Chronic Graft-versus-host Disease | Unknown | 2010-06-01 | 2017-01-01 | ClinicalTrials.gov |
| NCT02089737 | Panitumumab for Intravenous Infusion 100 mg and 400 mg Special Drug Use Surveil… | — | Advanced or Recurrent Colorectal Cancer | Completed | 2010-06-01 | 2012-07-01 | ClinicalTrials.gov |
| NCT01156051 | Effect of Guanfacine Extended-Release on Attention Deficit Hyperactivity Disord… | Phase4 | Attention-Deficit/Hyperactivity Disorder | Terminated | 2010-06-01 | 2012-02-01 | ClinicalTrials.gov |
| NCT01158105 | Bortezomib for the Treatment of Refractory Chronic Graft-vs-Host Disease(cGVHD) | Phase2 | Chronic Graft-versus-host Disease | Unknown | 2010-06-01 | 2017-01-01 | ClinicalTrials.gov |
| NCT01146002 | Language-based Learning Skills and Attention Deficit Hyperactivity Disorder (AD… | Phase4 | Attention-deficit/Hyperactivity Disorder | Completed | 2010-06-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT01156051 | Effect of Guanfacine Extended-Release on Attention Deficit Hyperactivity Disord… | Phase4 | Attention-Deficit/Hyperactivity Disorder | Terminated | 2010-06-01 | 2012-02-01 | ClinicalTrials.gov |
| NCT01155778 | Safety, Tolerability, Ascending Dose and Dose Frequency Study of rhHNS Via an I… | Phase1 | Mucopolysaccharidosis (MPS) | Completed | 2010-06-01 | 2012-09-01 | ClinicalTrials.gov |
| NCT01158105 | Bortezomib for the Treatment of Refractory Chronic Graft-vs-Host Disease(cGVHD) | Phase2 | Chronic Graft-versus-host Disease | Unknown | 2010-06-01 | 2017-01-01 | ClinicalTrials.gov |
| NCT01110629 | Study in Chronic Kidney Disease (CKD) Not on Dialysis | Phase3 | Hyperphosphatemia | Completed | 2010-06-01 | 2011-11-01 | ClinicalTrials.gov |
| NCT01153009 | Safety and Efficacy of Vortioxetine (Lu AA21004) in Adults With Major Depressiv… | Phase3 | Depressive Disorder, Major | Completed | 2010-06-01 | 2012-03-01 | ClinicalTrials.gov |
| NCT02089737 | Panitumumab for Intravenous Infusion 100 mg and 400 mg Special Drug Use Surveil… | — | Advanced or Recurrent Colorectal Cancer | Completed | 2010-06-01 | 2012-07-01 | ClinicalTrials.gov |
| NCT01110629 | Study in Chronic Kidney Disease (CKD) Not on Dialysis | Phase3 | Hyperphosphatemia | Completed | 2010-06-01 | 2011-11-01 | ClinicalTrials.gov |
| NCT01146002 | Language-based Learning Skills and Attention Deficit Hyperactivity Disorder (AD… | Phase4 | Attention-deficit/Hyperactivity Disorder | Completed | 2010-06-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT01162031 | Phase II Study of VELCADE for Relapsed or Refractory T-cell Prolymphocytic Leuk… | Phase2 | Leukemia | Withdrawn | 2010-06-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT01146002 | Language-based Learning Skills and Attention Deficit Hyperactivity Disorder (AD… | Phase4 | Attention-deficit/Hyperactivity Disorder | Completed | 2010-06-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT01101022 | Safety and Efficacy of SPD489 on Executive Function Behaviors in Adults With At… | Phase4 | ADHD Specifically With Executive Function Impairment | Completed | 2010-05-19 | 2010-11-29 | ClinicalTrials.gov |
| NCT01101022 | Safety and Efficacy of SPD489 on Executive Function Behaviors in Adults With At… | Phase4 | ADHD Specifically With Executive Function Impairment | Completed | 2010-05-19 | 2010-11-29 | ClinicalTrials.gov |
| NCT01101022 | Safety and Efficacy of SPD489 on Executive Function Behaviors in Adults With At… | Phase4 | ADHD Specifically With Executive Function Impairment | Completed | 2010-05-19 | 2010-11-29 | ClinicalTrials.gov |
| NCT01081145 | Maintenance of Efficacy of Extended-Release Guanfacine HCl in Children and Adol… | Phase3 | Attention-deficit/Hyperactivity Disorder | Completed | 2010-05-11 | 2013-06-03 | ClinicalTrials.gov |
| NCT01081145 | Maintenance of Efficacy of Extended-Release Guanfacine HCl in Children and Adol… | Phase3 | Attention-deficit/Hyperactivity Disorder | Completed | 2010-05-11 | 2013-06-03 | ClinicalTrials.gov |
| NCT01242267 | Escalating Doses of Thalidomide in Conjunction With Bortezomib and HIgh Dose Me… | Phase1 | Multiple Myeloma | Completed | 2010-05-11 | 2016-01-20 | ClinicalTrials.gov |
| NCT01081145 | Maintenance of Efficacy of Extended-Release Guanfacine HCl in Children and Adol… | Phase3 | Attention-deficit/Hyperactivity Disorder | Completed | 2010-05-11 | 2013-06-03 | ClinicalTrials.gov |
| NCT01242267 | Escalating Doses of Thalidomide in Conjunction With Bortezomib and HIgh Dose Me… | Phase1 | Multiple Myeloma | Completed | 2010-05-11 | 2016-01-20 | ClinicalTrials.gov |
| NCT01242267 | Escalating Doses of Thalidomide in Conjunction With Bortezomib and HIgh Dose Me… | Phase1 | Multiple Myeloma | Completed | 2010-05-11 | 2016-01-20 | ClinicalTrials.gov |
| NCT01056276 | Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone… | Phase2 | Multiple Myeloma | Completed | 2010-05-01 | 2017-02-01 | ClinicalTrials.gov |
| NCT01046916 | Safety and Efficacy Study of TAK-700 in Patients With Nonmetastatic Castration-… | Phase2 | Prostate Cancer | Completed | 2010-05-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT01056276 | Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone… | Phase2 | Multiple Myeloma | Completed | 2010-05-01 | 2017-02-01 | ClinicalTrials.gov |
| NCT01078376 | A Comparative Single-Dose Pharmacokinetic (PK) and Safety Study of Azilsartan M… | Phase1 | Hypertension | Terminated | 2010-05-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT01129180 | Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-C… | Phase1 | Adult Nasal Type Extranodal NK/T-cell Lymphoma | Completed | 2010-05-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT01084278 | Healthy and Renal Impairment Study of Colcrys (Colchicine, USP) | Phase4 | Pharmacokinetics | Completed | 2010-05-01 | 2011-02-01 | ClinicalTrials.gov |
| NCT01460602 | Velcade, Nipent, Rituxan (VNR) in Subjects With Relapsed Follicular, Marginal Z… | Phase1 | Follicular Lymphoma | Withdrawn | 2010-05-01 | 2014-10-01 | ClinicalTrials.gov |
| NCT01078376 | A Comparative Single-Dose Pharmacokinetic (PK) and Safety Study of Azilsartan M… | Phase1 | Hypertension | Terminated | 2010-05-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT01112982 | An Assessment of Chronic Synovial-Based Inflammation and Its Role With Serum Ur… | Phase4 | Gout | Completed | 2010-05-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT01112982 | An Assessment of Chronic Synovial-Based Inflammation and Its Role With Serum Ur… | Phase4 | Gout | Completed | 2010-05-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT01460602 | Velcade, Nipent, Rituxan (VNR) in Subjects With Relapsed Follicular, Marginal Z… | Phase1 | Follicular Lymphoma | Withdrawn | 2010-05-01 | 2014-10-01 | ClinicalTrials.gov |
| NCT01084278 | Healthy and Renal Impairment Study of Colcrys (Colchicine, USP) | Phase4 | Pharmacokinetics | Completed | 2010-05-01 | 2011-02-01 | ClinicalTrials.gov |
| NCT01078376 | A Comparative Single-Dose Pharmacokinetic (PK) and Safety Study of Azilsartan M… | Phase1 | Hypertension | Terminated | 2010-05-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT01056276 | Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone… | Phase2 | Multiple Myeloma | Completed | 2010-05-01 | 2017-02-01 | ClinicalTrials.gov |
| NCT01046916 | Safety and Efficacy Study of TAK-700 in Patients With Nonmetastatic Castration-… | Phase2 | Prostate Cancer | Completed | 2010-05-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT01129180 | Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-C… | Phase1 | Adult Nasal Type Extranodal NK/T-cell Lymphoma | Completed | 2010-05-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT01112982 | An Assessment of Chronic Synovial-Based Inflammation and Its Role With Serum Ur… | Phase4 | Gout | Completed | 2010-05-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT01046916 | Safety and Efficacy Study of TAK-700 in Patients With Nonmetastatic Castration-… | Phase2 | Prostate Cancer | Completed | 2010-05-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT01460602 | Velcade, Nipent, Rituxan (VNR) in Subjects With Relapsed Follicular, Marginal Z… | Phase1 | Follicular Lymphoma | Withdrawn | 2010-05-01 | 2014-10-01 | ClinicalTrials.gov |
| NCT01129180 | Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-C… | Phase1 | Adult Nasal Type Extranodal NK/T-cell Lymphoma | Completed | 2010-05-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT01084278 | Healthy and Renal Impairment Study of Colcrys (Colchicine, USP) | Phase4 | Pharmacokinetics | Completed | 2010-05-01 | 2011-02-01 | ClinicalTrials.gov |
| NCT01100502 | A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Res… | Phase3 | Disease, Hodgkin | Completed | 2010-04-30 | 2020-04-27 | ClinicalTrials.gov |
| NCT01100502 | A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Res… | Phase3 | Disease, Hodgkin | Completed | 2010-04-30 | 2020-04-27 | ClinicalTrials.gov |
| NCT01099215 | Study of PVS-10200 for the Treatment of Restenosis in Patients With Peripheral … | Phase1 | Peripheral Artery Disease | Completed | 2010-04-30 | 2012-10-31 | ClinicalTrials.gov |
| NCT01099215 | Study of PVS-10200 for the Treatment of Restenosis in Patients With Peripheral … | Phase1 | Peripheral Artery Disease | Completed | 2010-04-30 | 2012-10-31 | ClinicalTrials.gov |
| NCT01099215 | Study of PVS-10200 for the Treatment of Restenosis in Patients With Peripheral … | Phase1 | Peripheral Artery Disease | Completed | 2010-04-30 | 2012-10-31 | ClinicalTrials.gov |
| NCT01100502 | A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Res… | Phase3 | Disease, Hodgkin | Completed | 2010-04-30 | 2020-04-27 | ClinicalTrials.gov |
| NCT01130831 | Effect of Lanthanum Carbonate in Patients Previously Treated With Calcium-based… | — | End Stage Renal Disease | Completed | 2010-04-26 | 2012-06-12 | ClinicalTrials.gov |
| NCT01130831 | Effect of Lanthanum Carbonate in Patients Previously Treated With Calcium-based… | — | End Stage Renal Disease | Completed | 2010-04-26 | 2012-06-12 | ClinicalTrials.gov |
| NCT01130831 | Effect of Lanthanum Carbonate in Patients Previously Treated With Calcium-based… | — | End Stage Renal Disease | Completed | 2010-04-26 | 2012-06-12 | ClinicalTrials.gov |
| NCT01101035 | Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout a… | Phase3 | Cardiovascular Disease | Completed | 2010-04-23 | 2017-07-18 | ClinicalTrials.gov |
| NCT01101035 | Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout a… | Phase3 | Cardiovascular Disease | Completed | 2010-04-23 | 2017-07-18 | ClinicalTrials.gov |
| NCT01101035 | Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout a… | Phase3 | Cardiovascular Disease | Completed | 2010-04-23 | 2017-07-18 | ClinicalTrials.gov |
| NCT01091428 | Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal … | Phase2 | Ovarian Carcinoma | Completed | 2010-04-16 | 2017-07-19 | ClinicalTrials.gov |
| NCT01091428 | Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal … | Phase2 | Ovarian Carcinoma | Completed | 2010-04-16 | 2017-07-19 | ClinicalTrials.gov |
| NCT01091428 | Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal … | Phase2 | Ovarian Carcinoma | Completed | 2010-04-16 | 2017-07-19 | ClinicalTrials.gov |
| NCT01124643 | Extension Study of TKT028 Evaluating Safety and Clinical Outcomes of Replagal® … | Phase3 | Fabry Disease | Completed | 2010-04-13 | 2013-07-08 | ClinicalTrials.gov |
| NCT01124643 | Extension Study of TKT028 Evaluating Safety and Clinical Outcomes of Replagal® … | Phase3 | Fabry Disease | Completed | 2010-04-13 | 2013-07-08 | ClinicalTrials.gov |
| NCT01124643 | Extension Study of TKT028 Evaluating Safety and Clinical Outcomes of Replagal® … | Phase3 | Fabry Disease | Completed | 2010-04-13 | 2013-07-08 | ClinicalTrials.gov |
| NCT01096680 | Pharmacodynamic Profile of SPD489 in Healthy Adult Males Undergoing a Nocturnal… | Phase2 | Sleep Deprivation | Completed | 2010-04-05 | 2010-07-18 | ClinicalTrials.gov |
| NCT01096680 | Pharmacodynamic Profile of SPD489 in Healthy Adult Males Undergoing a Nocturnal… | Phase2 | Sleep Deprivation | Completed | 2010-04-05 | 2010-07-18 | ClinicalTrials.gov |
| NCT01096680 | Pharmacodynamic Profile of SPD489 in Healthy Adult Males Undergoing a Nocturnal… | Phase2 | Sleep Deprivation | Completed | 2010-04-05 | 2010-07-18 | ClinicalTrials.gov |
| NCT01082640 | Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Se… | Phase2 | Renal Impairment | Completed | 2010-04-01 | 2012-05-01 | ClinicalTrials.gov |
| NCT00934479 | Intestinal Microecology in Chronic Constipation | Phase1 | Other Constipation | Completed | 2010-04-01 | 2012-02-01 | ClinicalTrials.gov |
| NCT01125293 | Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Wa… | Phase1 | Waldenstrom's Macroglobulinemia | Terminated | 2010-04-01 | 2014-08-01 | ClinicalTrials.gov |
| NCT00934479 | Intestinal Microecology in Chronic Constipation | Phase1 | Other Constipation | Completed | 2010-04-01 | 2012-02-01 | ClinicalTrials.gov |
| NCT01096290 | Comparison of Lubiprostone and Placebo for the Relief of Constipation From Cons… | Phase4 | Constipation | Terminated | 2010-04-01 | 2012-09-01 | ClinicalTrials.gov |
| NCT01082640 | Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Se… | Phase2 | Renal Impairment | Completed | 2010-04-01 | 2012-05-01 | ClinicalTrials.gov |
| NCT01093105 | An Observational Study of Pediatric Subjects With Globoid Cell Leukodystrophy (… | — | Leukodystrophy, Globoid Cell | Withdrawn | 2010-04-01 | 2012-05-01 | ClinicalTrials.gov |
| NCT01093105 | An Observational Study of Pediatric Subjects With Globoid Cell Leukodystrophy (… | — | Leukodystrophy, Globoid Cell | Withdrawn | 2010-04-01 | 2012-05-01 | ClinicalTrials.gov |
| NCT01096290 | Comparison of Lubiprostone and Placebo for the Relief of Constipation From Cons… | Phase4 | Constipation | Terminated | 2010-04-01 | 2012-09-01 | ClinicalTrials.gov |
| NCT01125293 | Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Wa… | Phase1 | Waldenstrom's Macroglobulinemia | Terminated | 2010-04-01 | 2014-08-01 | ClinicalTrials.gov |
| NCT00934479 | Intestinal Microecology in Chronic Constipation | Phase1 | Other Constipation | Completed | 2010-04-01 | 2012-02-01 | ClinicalTrials.gov |
| NCT01082640 | Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Se… | Phase2 | Renal Impairment | Completed | 2010-04-01 | 2012-05-01 | ClinicalTrials.gov |
| NCT01096290 | Comparison of Lubiprostone and Placebo for the Relief of Constipation From Cons… | Phase4 | Constipation | Terminated | 2010-04-01 | 2012-09-01 | ClinicalTrials.gov |
| NCT01125293 | Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Wa… | Phase1 | Waldenstrom's Macroglobulinemia | Terminated | 2010-04-01 | 2014-08-01 | ClinicalTrials.gov |
| NCT01093105 | An Observational Study of Pediatric Subjects With Globoid Cell Leukodystrophy (… | — | Leukodystrophy, Globoid Cell | Withdrawn | 2010-04-01 | 2012-05-01 | ClinicalTrials.gov |
| NCT01045096 | Study to Evaluate the Pharmacokinetics and Safety of Dexlansoprazole in Pediatr… | Phase1 | Gastroesophageal Reflux | Completed | 2010-03-01 | 2011-02-01 | ClinicalTrials.gov |
| NCT01085643 | Effect of Lubiprostone on Small Bowel Contractions in Female Patients With Cons… | Na | Constipation-predominant Irritable Bowel Syndrome | Completed | 2010-03-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT02287402 | Postmarketing Clinical Study on AO-128 | Phase4 | Impaired Glucose Tolerance (IGT) | Completed | 2010-03-01 | 2012-11-01 | ClinicalTrials.gov |
| NCT01085643 | Effect of Lubiprostone on Small Bowel Contractions in Female Patients With Cons… | Na | Constipation-predominant Irritable Bowel Syndrome | Completed | 2010-03-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT01078389 | Effect of Febuxostat on Joint Damage in Hyperuricemic Subjects With Early Gout | Phase2 | Joint Damage | Completed | 2010-03-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT01029730 | Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Un… | Phase2 | Lymphoma | Completed | 2010-03-01 | 2016-07-01 | ClinicalTrials.gov |
| NCT01078389 | Effect of Febuxostat on Joint Damage in Hyperuricemic Subjects With Early Gout | Phase2 | Joint Damage | Completed | 2010-03-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT01078389 | Effect of Febuxostat on Joint Damage in Hyperuricemic Subjects With Early Gout | Phase2 | Joint Damage | Completed | 2010-03-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT01045096 | Study to Evaluate the Pharmacokinetics and Safety of Dexlansoprazole in Pediatr… | Phase1 | Gastroesophageal Reflux | Completed | 2010-03-01 | 2011-02-01 | ClinicalTrials.gov |
| NCT01085643 | Effect of Lubiprostone on Small Bowel Contractions in Female Patients With Cons… | Na | Constipation-predominant Irritable Bowel Syndrome | Completed | 2010-03-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT02287402 | Postmarketing Clinical Study on AO-128 | Phase4 | Impaired Glucose Tolerance (IGT) | Completed | 2010-03-01 | 2012-11-01 | ClinicalTrials.gov |
| NCT01045096 | Study to Evaluate the Pharmacokinetics and Safety of Dexlansoprazole in Pediatr… | Phase1 | Gastroesophageal Reflux | Completed | 2010-03-01 | 2011-02-01 | ClinicalTrials.gov |
| NCT02287402 | Postmarketing Clinical Study on AO-128 | Phase4 | Impaired Glucose Tolerance (IGT) | Completed | 2010-03-01 | 2012-11-01 | ClinicalTrials.gov |
| NCT01029730 | Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Un… | Phase2 | Lymphoma | Completed | 2010-03-01 | 2016-07-01 | ClinicalTrials.gov |
| NCT01029730 | Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Un… | Phase2 | Lymphoma | Completed | 2010-03-01 | 2016-07-01 | ClinicalTrials.gov |
| NCT01047306 | A Study of Patients With Sanfilippo Syndrome Type A (MPS IIIA) | — | Sanfilippo Syndrome Type A | Completed | 2010-02-15 | 2013-07-10 | ClinicalTrials.gov |
| NCT01047306 | A Study of Patients With Sanfilippo Syndrome Type A (MPS IIIA) | — | Sanfilippo Syndrome Type A | Completed | 2010-02-15 | 2013-07-10 | ClinicalTrials.gov |
| NCT01047306 | A Study of Patients With Sanfilippo Syndrome Type A (MPS IIIA) | — | Sanfilippo Syndrome Type A | Completed | 2010-02-15 | 2013-07-10 | ClinicalTrials.gov |
| NCT01045421 | Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib i… | Phase1 | Advanced Nonhematological Malignancies | Completed | 2010-02-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01070394 | Effectiveness and Duration of Effect of Open Treatment in Attention Deficit Hyp… | Phase4 | Attention Deficit Hyperactivity Disorder | Completed | 2010-02-01 | 2012-07-01 | ClinicalTrials.gov |
| NCT01070394 | Effectiveness and Duration of Effect of Open Treatment in Attention Deficit Hyp… | Phase4 | Attention Deficit Hyperactivity Disorder | Completed | 2010-02-01 | 2012-07-01 | ClinicalTrials.gov |
| NCT01077284 | Febuxostat Versus Allopurinol or Placebo in Patients With Hyperuricosuria and C… | Phase2 | Hyperuricosuria | Completed | 2010-02-01 | 2011-11-01 | ClinicalTrials.gov |
| NCT01052155 | Accuracy of Point of Care (POC) or In-office Urine Drug Testing (Immunoassay) i… | — | Chronic Pain | Completed | 2010-02-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT01077284 | Febuxostat Versus Allopurinol or Placebo in Patients With Hyperuricosuria and C… | Phase2 | Hyperuricosuria | Completed | 2010-02-01 | 2011-11-01 | ClinicalTrials.gov |
| NCT01070394 | Effectiveness and Duration of Effect of Open Treatment in Attention Deficit Hyp… | Phase4 | Attention Deficit Hyperactivity Disorder | Completed | 2010-02-01 | 2012-07-01 | ClinicalTrials.gov |
| NCT01052155 | Accuracy of Point of Care (POC) or In-office Urine Drug Testing (Immunoassay) i… | — | Chronic Pain | Completed | 2010-02-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT01052155 | Accuracy of Point of Care (POC) or In-office Urine Drug Testing (Immunoassay) i… | — | Chronic Pain | Completed | 2010-02-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT01059526 | Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute… | — | Hereditary Angioedema (HAE) | Completed | 2010-02-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT01077284 | Febuxostat Versus Allopurinol or Placebo in Patients With Hyperuricosuria and C… | Phase2 | Hyperuricosuria | Completed | 2010-02-01 | 2011-11-01 | ClinicalTrials.gov |
| NCT01059526 | Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute… | — | Hereditary Angioedema (HAE) | Completed | 2010-02-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT01045421 | Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib i… | Phase1 | Advanced Nonhematological Malignancies | Completed | 2010-02-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01045421 | Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib i… | Phase1 | Advanced Nonhematological Malignancies | Completed | 2010-02-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01059526 | Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute… | — | Hereditary Angioedema (HAE) | Completed | 2010-02-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT00904046 | Pathophysiology of Uric Acid Nephrolithiasis | Na | Uric Acid Kidney Stone Disease | Completed | 2010-01-15 | 2017-11-16 | ClinicalTrials.gov |
| NCT00904046 | Pathophysiology of Uric Acid Nephrolithiasis | Na | Uric Acid Kidney Stone Disease | Completed | 2010-01-15 | 2017-11-16 | ClinicalTrials.gov |
| NCT00904046 | Pathophysiology of Uric Acid Nephrolithiasis | Na | Uric Acid Kidney Stone Disease | Completed | 2010-01-15 | 2017-11-16 | ClinicalTrials.gov |
| NCT01058707 | Dose Escalation Study of MLN0128 in Participants With Advanced Malignancies | Phase1 | Advanced Solid Malignancies | Completed | 2010-01-04 | 2019-02-07 | ClinicalTrials.gov |
| NCT01058707 | Dose Escalation Study of MLN0128 in Participants With Advanced Malignancies | Phase1 | Advanced Solid Malignancies | Completed | 2010-01-04 | 2019-02-07 | ClinicalTrials.gov |
| NCT01058707 | Dose Escalation Study of MLN0128 in Participants With Advanced Malignancies | Phase1 | Advanced Solid Malignancies | Completed | 2010-01-04 | 2019-02-07 | ClinicalTrials.gov |
| NCT01921075 | Physiologic Plasticity of Intramyocardial Lipid Storage | — | Lipid Metabolism | Completed | 2010-01-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT01131559 | Adjunctive Lisdexamfetamine (LDX) in Bipolar Depression | Phase3 | Bipolar | Terminated | 2010-01-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT01093963 | Efficacy Study of Lisdexamfetamine to Treat Bipolar Depression | Phase3 | Bipolar Depression | Terminated | 2010-01-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT01090713 | Efficacy Study of Lisdexamfetamine to Treat Binge Eating Disorder | Phase3 | Binge Eating Disorder | Completed | 2010-01-01 | 2012-10-01 | ClinicalTrials.gov |
| NCT01062230 | Bone Effect of Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma | Phase2 | Multiple Myeloma | Terminated | 2010-01-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01060904 | A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy f… | Phase1 | Disease, Hodgkin | Completed | 2010-01-01 | 2012-09-01 | ClinicalTrials.gov |
| NCT01040871 | Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, … | Phase2 | Diffuse Large B-Cell Lymphoma | Completed | 2010-01-01 | 2012-08-01 | ClinicalTrials.gov |
| NCT01033071 | Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olme… | Phase3 | Essential Hypertension | Completed | 2010-01-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT01026233 | Cardiac Safety Study of Brentuximab Vedotin (SGN-35) | Phase1 | Disease, Hodgkin | Completed | 2010-01-01 | 2011-08-01 | ClinicalTrials.gov |
| NCT00920348 | The Canadian Cohort Obstructive Lung Disease | — | COPD | Unknown | 2010-01-01 | 2022-12-01 | ClinicalTrials.gov |
| NCT00920348 | The Canadian Cohort Obstructive Lung Disease | — | COPD | Unknown | 2010-01-01 | 2022-12-01 | ClinicalTrials.gov |
| NCT01026233 | Cardiac Safety Study of Brentuximab Vedotin (SGN-35) | Phase1 | Disease, Hodgkin | Completed | 2010-01-01 | 2011-08-01 | ClinicalTrials.gov |
| NCT01033071 | Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olme… | Phase3 | Essential Hypertension | Completed | 2010-01-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT01040871 | Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, … | Phase2 | Diffuse Large B-Cell Lymphoma | Completed | 2010-01-01 | 2012-08-01 | ClinicalTrials.gov |
| NCT01060904 | A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy f… | Phase1 | Disease, Hodgkin | Completed | 2010-01-01 | 2012-09-01 | ClinicalTrials.gov |
| NCT01062230 | Bone Effect of Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma | Phase2 | Multiple Myeloma | Terminated | 2010-01-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01090713 | Efficacy Study of Lisdexamfetamine to Treat Binge Eating Disorder | Phase3 | Binge Eating Disorder | Completed | 2010-01-01 | 2012-10-01 | ClinicalTrials.gov |
| NCT01093963 | Efficacy Study of Lisdexamfetamine to Treat Bipolar Depression | Phase3 | Bipolar Depression | Terminated | 2010-01-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT01131559 | Adjunctive Lisdexamfetamine (LDX) in Bipolar Depression | Phase3 | Bipolar | Terminated | 2010-01-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT01921075 | Physiologic Plasticity of Intramyocardial Lipid Storage | — | Lipid Metabolism | Completed | 2010-01-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT01921075 | Physiologic Plasticity of Intramyocardial Lipid Storage | — | Lipid Metabolism | Completed | 2010-01-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT01131559 | Adjunctive Lisdexamfetamine (LDX) in Bipolar Depression | Phase3 | Bipolar | Terminated | 2010-01-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT01093963 | Efficacy Study of Lisdexamfetamine to Treat Bipolar Depression | Phase3 | Bipolar Depression | Terminated | 2010-01-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT01090713 | Efficacy Study of Lisdexamfetamine to Treat Binge Eating Disorder | Phase3 | Binge Eating Disorder | Completed | 2010-01-01 | 2012-10-01 | ClinicalTrials.gov |
| NCT01062230 | Bone Effect of Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma | Phase2 | Multiple Myeloma | Terminated | 2010-01-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01060904 | A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy f… | Phase1 | Disease, Hodgkin | Completed | 2010-01-01 | 2012-09-01 | ClinicalTrials.gov |
| NCT01040871 | Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, … | Phase2 | Diffuse Large B-Cell Lymphoma | Completed | 2010-01-01 | 2012-08-01 | ClinicalTrials.gov |
| NCT01033071 | Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olme… | Phase3 | Essential Hypertension | Completed | 2010-01-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT01026233 | Cardiac Safety Study of Brentuximab Vedotin (SGN-35) | Phase1 | Disease, Hodgkin | Completed | 2010-01-01 | 2011-08-01 | ClinicalTrials.gov |
| NCT00920348 | The Canadian Cohort Obstructive Lung Disease | — | COPD | Unknown | 2010-01-01 | 2022-12-01 | ClinicalTrials.gov |
| NCT01007097 | Efficacy and Safety of TAK-875 in Subjects With Type 2 Diabetes Mellitus | Phase2 | Diabetes Mellitus, Type 2 | Completed | 2009-12-01 | 2010-09-01 | ClinicalTrials.gov |
| NCT01045603 | Instanyl® Non-Interventional Study | — | Breakthrough Cancer Pain | Completed | 2009-12-01 | 2012-04-01 | ClinicalTrials.gov |
| NCT01017263 | Vyvanse and Glucose Intolerance in Children With Attention Deficit Hyperactivit… | Phase4 | Attention Deficit Hyperactivity Disorder | Terminated | 2009-12-01 | 2012-08-01 | ClinicalTrials.gov |
| NCT01011530 | Dose Escalation Study of MLN4924 in Adults With Melanoma | Phase1 | Metastatic Melanoma | Completed | 2009-12-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT00942175 | A Study of the Effects of Multiple Doses of Dexlansoprazole, Lansoprazole, Omep… | Phase1 | Healthy | Completed | 2009-12-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT00942175 | A Study of the Effects of Multiple Doses of Dexlansoprazole, Lansoprazole, Omep… | Phase1 | Healthy | Completed | 2009-12-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT01040455 | Lansoprazole for Subgroups of Functional Dyspepsia | Phase4 | Functional Dyspepsia | Terminated | 2009-12-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01045603 | Instanyl® Non-Interventional Study | — | Breakthrough Cancer Pain | Completed | 2009-12-01 | 2012-04-01 | ClinicalTrials.gov |
| NCT01040455 | Lansoprazole for Subgroups of Functional Dyspepsia | Phase4 | Functional Dyspepsia | Terminated | 2009-12-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01026415 | Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35) | Phase1 | Carcinomas | Completed | 2009-12-01 | 2012-05-01 | ClinicalTrials.gov |
| NCT00942175 | A Study of the Effects of Multiple Doses of Dexlansoprazole, Lansoprazole, Omep… | Phase1 | Healthy | Completed | 2009-12-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT01007097 | Efficacy and Safety of TAK-875 in Subjects With Type 2 Diabetes Mellitus | Phase2 | Diabetes Mellitus, Type 2 | Completed | 2009-12-01 | 2010-09-01 | ClinicalTrials.gov |
| NCT00948467 | Study of TAK-733 in Adult Patients With Advanced Nonhematologic Malignancies | Phase1 | Advanced Non-hematologic Malignancies | Completed | 2009-12-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT01011530 | Dose Escalation Study of MLN4924 in Adults With Melanoma | Phase1 | Metastatic Melanoma | Completed | 2009-12-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT00948467 | Study of TAK-733 in Adult Patients With Advanced Nonhematologic Malignancies | Phase1 | Advanced Non-hematologic Malignancies | Completed | 2009-12-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT01045603 | Instanyl® Non-Interventional Study | — | Breakthrough Cancer Pain | Completed | 2009-12-01 | 2012-04-01 | ClinicalTrials.gov |
| NCT01026415 | Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35) | Phase1 | Carcinomas | Completed | 2009-12-01 | 2012-05-01 | ClinicalTrials.gov |
| NCT01017263 | Vyvanse and Glucose Intolerance in Children With Attention Deficit Hyperactivit… | Phase4 | Attention Deficit Hyperactivity Disorder | Terminated | 2009-12-01 | 2012-08-01 | ClinicalTrials.gov |
| NCT01026415 | Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35) | Phase1 | Carcinomas | Completed | 2009-12-01 | 2012-05-01 | ClinicalTrials.gov |
| NCT01007097 | Efficacy and Safety of TAK-875 in Subjects With Type 2 Diabetes Mellitus | Phase2 | Diabetes Mellitus, Type 2 | Completed | 2009-12-01 | 2010-09-01 | ClinicalTrials.gov |
| NCT00948467 | Study of TAK-733 in Adult Patients With Advanced Nonhematologic Malignancies | Phase1 | Advanced Non-hematologic Malignancies | Completed | 2009-12-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT01040455 | Lansoprazole for Subgroups of Functional Dyspepsia | Phase4 | Functional Dyspepsia | Terminated | 2009-12-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01011530 | Dose Escalation Study of MLN4924 in Adults With Melanoma | Phase1 | Metastatic Melanoma | Completed | 2009-12-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT01017263 | Vyvanse and Glucose Intolerance in Children With Attention Deficit Hyperactivit… | Phase4 | Attention Deficit Hyperactivity Disorder | Terminated | 2009-12-01 | 2012-08-01 | ClinicalTrials.gov |
| NCT01993927 | Voglibose Tablets 0.2 / OD Tablets 0.2 Special Drug Use Surveillance "Long-term… | — | Impaired Glucose Tolerance | Completed | 2009-11-18 | 2013-08-31 | ClinicalTrials.gov |
| NCT01993927 | Voglibose Tablets 0.2 / OD Tablets 0.2 Special Drug Use Surveillance "Long-term… | — | Impaired Glucose Tolerance | Completed | 2009-11-18 | 2013-08-31 | ClinicalTrials.gov |
| NCT00920647 | A Safety and Dose Ranging Study of Idursulfase (Intrathecal) Administration Via… | Phase1 | Hunter Syndrome | Completed | 2009-11-18 | 2012-10-29 | ClinicalTrials.gov |
| NCT00920647 | A Safety and Dose Ranging Study of Idursulfase (Intrathecal) Administration Via… | Phase1 | Hunter Syndrome | Completed | 2009-11-18 | 2012-10-29 | ClinicalTrials.gov |
| NCT00920647 | A Safety and Dose Ranging Study of Idursulfase (Intrathecal) Administration Via… | Phase1 | Hunter Syndrome | Completed | 2009-11-18 | 2012-10-29 | ClinicalTrials.gov |
| NCT01993927 | Voglibose Tablets 0.2 / OD Tablets 0.2 Special Drug Use Surveillance "Long-term… | — | Impaired Glucose Tolerance | Completed | 2009-11-18 | 2013-08-31 | ClinicalTrials.gov |
| NCT01350973 | Efficacy of TAK-085 in Participants With Hypertriglyceridemia | Phase3 | Hypertriglyceridemia | Completed | 2009-11-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT01350973 | Efficacy of TAK-085 in Participants With Hypertriglyceridemia | Phase3 | Hypertriglyceridemia | Completed | 2009-11-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT01350999 | Long-term Efficacy and Safety Study of TAK-085 in Participants With Hypertrigly… | Phase3 | Hypertriglyceridemia | Completed | 2009-11-01 | 2011-01-01 | ClinicalTrials.gov |
| NCT01023581 | Efficacy and Safety of Alogliptin Plus Metformin in Patients With Type 2 Diabet… | Phase3 | Diabetes Mellitus, Type 2 | Completed | 2009-11-01 | 2011-06-01 | ClinicalTrials.gov |
| NCT01023581 | Efficacy and Safety of Alogliptin Plus Metformin in Patients With Type 2 Diabet… | Phase3 | Diabetes Mellitus, Type 2 | Completed | 2009-11-01 | 2011-06-01 | ClinicalTrials.gov |
| NCT01350999 | Long-term Efficacy and Safety Study of TAK-085 in Participants With Hypertrigly… | Phase3 | Hypertriglyceridemia | Completed | 2009-11-01 | 2011-01-01 | ClinicalTrials.gov |
| NCT00914862 | Pharmacokinetic and Safety of Ramelteon Between Adolescents With Insomnia and H… | Phase1 | Insomnia | Completed | 2009-11-01 | 2011-04-01 | ClinicalTrials.gov |
| NCT01350973 | Efficacy of TAK-085 in Participants With Hypertriglyceridemia | Phase3 | Hypertriglyceridemia | Completed | 2009-11-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT01023581 | Efficacy and Safety of Alogliptin Plus Metformin in Patients With Type 2 Diabet… | Phase3 | Diabetes Mellitus, Type 2 | Completed | 2009-11-01 | 2011-06-01 | ClinicalTrials.gov |
| NCT00914862 | Pharmacokinetic and Safety of Ramelteon Between Adolescents With Insomnia and H… | Phase1 | Insomnia | Completed | 2009-11-01 | 2011-04-01 | ClinicalTrials.gov |
| NCT01350999 | Long-term Efficacy and Safety Study of TAK-085 in Participants With Hypertrigly… | Phase3 | Hypertriglyceridemia | Completed | 2009-11-01 | 2011-01-01 | ClinicalTrials.gov |
| NCT00914862 | Pharmacokinetic and Safety of Ramelteon Between Adolescents With Insomnia and H… | Phase1 | Insomnia | Completed | 2009-11-01 | 2011-04-01 | ClinicalTrials.gov |
| NCT00985725 | SPD489 in Adults With Persistent Executive Function Impairments (EFI) and Parti… | Phase2 | Major Depressive Disorder | Completed | 2009-10-29 | 2011-04-18 | ClinicalTrials.gov |
| NCT00985725 | SPD489 in Adults With Persistent Executive Function Impairments (EFI) and Parti… | Phase2 | Major Depressive Disorder | Completed | 2009-10-29 | 2011-04-18 | ClinicalTrials.gov |
| NCT00985725 | SPD489 in Adults With Persistent Executive Function Impairments (EFI) and Parti… | Phase2 | Major Depressive Disorder | Completed | 2009-10-29 | 2011-04-18 | ClinicalTrials.gov |
| NCT00932698 | Study of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (R… | Phase1 | Relapsed and Refractory Multiple Myeloma | Completed | 2009-10-12 | 2017-05-23 | ClinicalTrials.gov |
| NCT00932698 | Study of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (R… | Phase1 | Relapsed and Refractory Multiple Myeloma | Completed | 2009-10-12 | 2017-05-23 | ClinicalTrials.gov |
| NCT00932698 | Study of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (R… | Phase1 | Relapsed and Refractory Multiple Myeloma | Completed | 2009-10-12 | 2017-05-23 | ClinicalTrials.gov |
| NCT00931918 | Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previousl… | Phase2 | Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL) | Completed | 2009-10-01 | 2015-08-01 | ClinicalTrials.gov |
| NCT01012479 | Efficacy and Safety of Candesartan Cilexetil Plus Hydrochlorothiazide in Subjec… | Phase4 | Hypertension | Completed | 2009-10-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT01023620 | HIV Acquired Lipodystrophy (HAL) Classification, Measurement and Fat Response t… | Na | HIV Infections | Completed | 2009-10-01 | 2010-05-31 | ClinicalTrials.gov |
| NCT01002872 | The Effect of Lanthanum Carbonate on Fibroblast Growth Factor 23 ( FGF23) in Ch… | Na | Metabolic Bone Disease | Completed | 2009-10-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT01000064 | Treatment of Traumatic Brain Injury (TBI)-Related Attention Deficits | Phase3 | Traumatic Brain Injury | Terminated | 2009-10-01 | 2015-05-01 | ClinicalTrials.gov |
| NCT01002872 | The Effect of Lanthanum Carbonate on Fibroblast Growth Factor 23 ( FGF23) in Ch… | Na | Metabolic Bone Disease | Completed | 2009-10-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT01000064 | Treatment of Traumatic Brain Injury (TBI)-Related Attention Deficits | Phase3 | Traumatic Brain Injury | Terminated | 2009-10-01 | 2015-05-01 | ClinicalTrials.gov |
| NCT00996281 | Safety and Tolerability of Azilsartan Medoxomil Plus Chlorthalidone Compared to… | Phase3 | Essential Hypertension | Completed | 2009-10-01 | 2011-11-01 | ClinicalTrials.gov |
| NCT00634036 | Pilot Study of Pioglitazone for the Treatment of Moderate to Severe Asthma in O… | Phase2 | Asthma | Completed | 2009-10-01 | 2012-04-01 | ClinicalTrials.gov |
| NCT00996281 | Safety and Tolerability of Azilsartan Medoxomil Plus Chlorthalidone Compared to… | Phase3 | Essential Hypertension | Completed | 2009-10-01 | 2011-11-01 | ClinicalTrials.gov |
| NCT00983346 | Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients | Phase2 | Cancer | Terminated | 2009-10-01 | 2014-09-01 | ClinicalTrials.gov |
| NCT00983346 | Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients | Phase2 | Cancer | Terminated | 2009-10-01 | 2014-09-01 | ClinicalTrials.gov |
| NCT00963820 | Study Evaluating the Safety and Tolerability of Weekly Dosing of Oral IXAZOMIB … | Phase1 | Multiple Myeloma | Completed | 2009-10-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT01023620 | HIV Acquired Lipodystrophy (HAL) Classification, Measurement and Fat Response t… | Na | HIV Infections | Completed | 2009-10-01 | 2010-05-31 | ClinicalTrials.gov |
| NCT00634036 | Pilot Study of Pioglitazone for the Treatment of Moderate to Severe Asthma in O… | Phase2 | Asthma | Completed | 2009-10-01 | 2012-04-01 | ClinicalTrials.gov |
| NCT01023620 | HIV Acquired Lipodystrophy (HAL) Classification, Measurement and Fat Response t… | Na | HIV Infections | Completed | 2009-10-01 | 2010-05-31 | ClinicalTrials.gov |
| NCT00963820 | Study Evaluating the Safety and Tolerability of Weekly Dosing of Oral IXAZOMIB … | Phase1 | Multiple Myeloma | Completed | 2009-10-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT00935844 | Study of TAK-901 in Adults With Advanced Solid Tumors or Lymphoma | Phase1 | Advanced Solid Tumors | Completed | 2009-10-01 | 2011-11-01 | ClinicalTrials.gov |
| NCT00931918 | Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previousl… | Phase2 | Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL) | Completed | 2009-10-01 | 2015-08-01 | ClinicalTrials.gov |
| NCT00634036 | Pilot Study of Pioglitazone for the Treatment of Moderate to Severe Asthma in O… | Phase2 | Asthma | Completed | 2009-10-01 | 2012-04-01 | ClinicalTrials.gov |
| NCT01012479 | Efficacy and Safety of Candesartan Cilexetil Plus Hydrochlorothiazide in Subjec… | Phase4 | Hypertension | Completed | 2009-10-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT01012479 | Efficacy and Safety of Candesartan Cilexetil Plus Hydrochlorothiazide in Subjec… | Phase4 | Hypertension | Completed | 2009-10-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT01002872 | The Effect of Lanthanum Carbonate on Fibroblast Growth Factor 23 ( FGF23) in Ch… | Na | Metabolic Bone Disease | Completed | 2009-10-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT01000064 | Treatment of Traumatic Brain Injury (TBI)-Related Attention Deficits | Phase3 | Traumatic Brain Injury | Terminated | 2009-10-01 | 2015-05-01 | ClinicalTrials.gov |
| NCT00996281 | Safety and Tolerability of Azilsartan Medoxomil Plus Chlorthalidone Compared to… | Phase3 | Essential Hypertension | Completed | 2009-10-01 | 2011-11-01 | ClinicalTrials.gov |
| NCT00983346 | Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients | Phase2 | Cancer | Terminated | 2009-10-01 | 2014-09-01 | ClinicalTrials.gov |
| NCT00963820 | Study Evaluating the Safety and Tolerability of Weekly Dosing of Oral IXAZOMIB … | Phase1 | Multiple Myeloma | Completed | 2009-10-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT00935844 | Study of TAK-901 in Adults With Advanced Solid Tumors or Lymphoma | Phase1 | Advanced Solid Tumors | Completed | 2009-10-01 | 2011-11-01 | ClinicalTrials.gov |
| NCT00931918 | Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previousl… | Phase2 | Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL) | Completed | 2009-10-01 | 2015-08-01 | ClinicalTrials.gov |
| NCT00935844 | Study of TAK-901 in Adults With Advanced Solid Tumors or Lymphoma | Phase1 | Advanced Solid Tumors | Completed | 2009-10-01 | 2011-11-01 | ClinicalTrials.gov |
| NCT00962091 | Study of MLN8237 in Participants With Advanced Solid Tumors | Phase1 | Advanced Solid Tumors | Completed | 2009-09-25 | 2014-07-01 | ClinicalTrials.gov |
| NCT00997204 | EASSI - Evaluation of the Safety of Self-Administration With Icatibant | Phase3 | Hereditary Angioedema | Completed | 2009-09-25 | 2011-06-22 | ClinicalTrials.gov |
| NCT00962091 | Study of MLN8237 in Participants With Advanced Solid Tumors | Phase1 | Advanced Solid Tumors | Completed | 2009-09-25 | 2014-07-01 | ClinicalTrials.gov |
| NCT00997204 | EASSI - Evaluation of the Safety of Self-Administration With Icatibant | Phase3 | Hereditary Angioedema | Completed | 2009-09-25 | 2011-06-22 | ClinicalTrials.gov |
| NCT00997204 | EASSI - Evaluation of the Safety of Self-Administration With Icatibant | Phase3 | Hereditary Angioedema | Completed | 2009-09-25 | 2011-06-22 | ClinicalTrials.gov |
| NCT00962091 | Study of MLN8237 in Participants With Advanced Solid Tumors | Phase1 | Advanced Solid Tumors | Completed | 2009-09-25 | 2014-07-01 | ClinicalTrials.gov |
| NCT00922272 | Efficacy, Safety, and Tolerability of SPD489 in Adults With Schizophrenia and P… | Phase2 | Schizophrenia and Predominant Negative Symptoms | Completed | 2009-09-14 | 2011-01-20 | ClinicalTrials.gov |
| NCT00922272 | Efficacy, Safety, and Tolerability of SPD489 in Adults With Schizophrenia and P… | Phase2 | Schizophrenia and Predominant Negative Symptoms | Completed | 2009-09-14 | 2011-01-20 | ClinicalTrials.gov |
| NCT00922272 | Efficacy, Safety, and Tolerability of SPD489 in Adults With Schizophrenia and P… | Phase2 | Schizophrenia and Predominant Negative Symptoms | Completed | 2009-09-14 | 2011-01-20 | ClinicalTrials.gov |
| NCT00968708 | Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes an… | Phase3 | Diabetes Mellitus, Type 2 | Completed | 2009-09-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT00957268 | Pharmacokinetics, Pharmacodynamics, and Safety of Alogliptin in Children, Adole… | Phase1 | Diabetes Mellitus, Type 2 | Completed | 2009-09-01 | 2013-11-01 | ClinicalTrials.gov |
| NCT00850499 | Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fluda… | Phase2 | Follicular Lymphoma | Terminated | 2009-09-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT00957268 | Pharmacokinetics, Pharmacodynamics, and Safety of Alogliptin in Children, Adole… | Phase1 | Diabetes Mellitus, Type 2 | Completed | 2009-09-01 | 2013-11-01 | ClinicalTrials.gov |
| NCT00957268 | Pharmacokinetics, Pharmacodynamics, and Safety of Alogliptin in Children, Adole… | Phase1 | Diabetes Mellitus, Type 2 | Completed | 2009-09-01 | 2013-11-01 | ClinicalTrials.gov |
| NCT00850499 | Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fluda… | Phase2 | Follicular Lymphoma | Terminated | 2009-09-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT00998244 | Study to Evaluate the Effect of a Very Low Carbohydrate Diet on Gastroesophagea… | Na | Gastroesophageal Reflux Disease | Completed | 2009-09-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT01083316 | Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Tran… | Phase2 | Amyloidosis | Completed | 2009-09-01 | 2020-09-04 | ClinicalTrials.gov |
| NCT00994760 | Efficacy and Tolerability of Intranasal Fentanyl Spray for the Treatment of Bre… | — | Breakthrough Pain | Completed | 2009-09-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT00998244 | Study to Evaluate the Effect of a Very Low Carbohydrate Diet on Gastroesophagea… | Na | Gastroesophageal Reflux Disease | Completed | 2009-09-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT00998244 | Study to Evaluate the Effect of a Very Low Carbohydrate Diet on Gastroesophagea… | Na | Gastroesophageal Reflux Disease | Completed | 2009-09-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT00968708 | Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes an… | Phase3 | Diabetes Mellitus, Type 2 | Completed | 2009-09-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT00994760 | Efficacy and Tolerability of Intranasal Fentanyl Spray for the Treatment of Bre… | — | Breakthrough Pain | Completed | 2009-09-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT00850499 | Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fluda… | Phase2 | Follicular Lymphoma | Terminated | 2009-09-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT00994760 | Efficacy and Tolerability of Intranasal Fentanyl Spray for the Treatment of Bre… | — | Breakthrough Pain | Completed | 2009-09-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT00968708 | Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes an… | Phase3 | Diabetes Mellitus, Type 2 | Completed | 2009-09-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT01083316 | Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Tran… | Phase2 | Amyloidosis | Completed | 2009-09-01 | 2020-09-04 | ClinicalTrials.gov |
| NCT01083316 | Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Tran… | Phase2 | Amyloidosis | Completed | 2009-09-01 | 2020-09-04 | ClinicalTrials.gov |
| NCT00961675 | FST-201 in the Treatment of Acute Otitis Externa | Phase3 | Acute Otitis Externa | Completed | 2009-08-31 | 2010-06-30 | ClinicalTrials.gov |
| NCT00961675 | FST-201 in the Treatment of Acute Otitis Externa | Phase3 | Acute Otitis Externa | Completed | 2009-08-31 | 2010-06-30 | ClinicalTrials.gov |
| NCT00961675 | FST-201 in the Treatment of Acute Otitis Externa | Phase3 | Acute Otitis Externa | Completed | 2009-08-31 | 2010-06-30 | ClinicalTrials.gov |
| NCT00973284 | Norwalk Vaccine Study | Phase1 | Acute Gastroenteritis | Completed | 2009-08-04 | 2010-08-18 | ClinicalTrials.gov |
| NCT00973284 | Norwalk Vaccine Study | Phase1 | Acute Gastroenteritis | Completed | 2009-08-04 | 2010-08-18 | ClinicalTrials.gov |
| NCT00973284 | Norwalk Vaccine Study | Phase1 | Acute Gastroenteritis | Completed | 2009-08-04 | 2010-08-18 | ClinicalTrials.gov |
| NCT00926185 | A Study Evaluating the Efficacy of SAR 1118 (0.1%, 1.0%, 5.0%) Ophthalmic Solut… | Phase2 | Dry Eye | Completed | 2009-08-03 | 2010-02-18 | ClinicalTrials.gov |
| NCT00926185 | A Study Evaluating the Efficacy of SAR 1118 (0.1%, 1.0%, 5.0%) Ophthalmic Solut… | Phase2 | Dry Eye | Completed | 2009-08-03 | 2010-02-18 | ClinicalTrials.gov |
| NCT00926185 | A Study Evaluating the Efficacy of SAR 1118 (0.1%, 1.0%, 5.0%) Ophthalmic Solut… | Phase2 | Dry Eye | Completed | 2009-08-03 | 2010-02-18 | ClinicalTrials.gov |
| NCT00893464 | A Study of IXAZOMIB in Adult Patients With Lymphoma | Phase1 | Lymphoma | Completed | 2009-08-01 | 2014-10-01 | ClinicalTrials.gov |
| NCT00893464 | A Study of IXAZOMIB in Adult Patients With Lymphoma | Phase1 | Lymphoma | Completed | 2009-08-01 | 2014-10-01 | ClinicalTrials.gov |
| NCT00958256 | Study of Bortezomib in Combination With Cyclophosphamide and Rituximab | Phase2 | Mantle Cell Lymphoma | Completed | 2009-08-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT00958256 | Study of Bortezomib in Combination With Cyclophosphamide and Rituximab | Phase2 | Mantle Cell Lymphoma | Completed | 2009-08-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT00958256 | Study of Bortezomib in Combination With Cyclophosphamide and Rituximab | Phase2 | Mantle Cell Lymphoma | Completed | 2009-08-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT00893464 | A Study of IXAZOMIB in Adult Patients With Lymphoma | Phase1 | Lymphoma | Completed | 2009-08-01 | 2014-10-01 | ClinicalTrials.gov |
| NCT00945646 | FST-201 In The Treatment of Acute Fungal Otitis Externa | Phase3 | Acute Fungal Otitis Externa | Terminated | 2009-07-31 | 2010-07-31 | ClinicalTrials.gov |
| NCT00945802 | FST-201 In The Treatment of Acute Otitis Externa | Phase3 | Acute Otitis Externa | Terminated | 2009-07-31 | 2010-07-31 | ClinicalTrials.gov |
| NCT00945646 | FST-201 In The Treatment of Acute Fungal Otitis Externa | Phase3 | Acute Fungal Otitis Externa | Terminated | 2009-07-31 | 2010-07-31 | ClinicalTrials.gov |
| NCT00945802 | FST-201 In The Treatment of Acute Otitis Externa | Phase3 | Acute Otitis Externa | Terminated | 2009-07-31 | 2010-07-31 | ClinicalTrials.gov |
| NCT00945646 | FST-201 In The Treatment of Acute Fungal Otitis Externa | Phase3 | Acute Fungal Otitis Externa | Terminated | 2009-07-31 | 2010-07-31 | ClinicalTrials.gov |
| NCT00945802 | FST-201 In The Treatment of Acute Otitis Externa | Phase3 | Acute Otitis Externa | Terminated | 2009-07-31 | 2010-07-31 | ClinicalTrials.gov |
| NCT00905424 | Exploratory Study of SPD489 in Adults With Major Depressive Disorder (MDD) as A… | Phase2 | Major Depressive Disorder | Completed | 2009-07-30 | 2010-08-04 | ClinicalTrials.gov |
| NCT00905424 | Exploratory Study of SPD489 in Adults With Major Depressive Disorder (MDD) as A… | Phase2 | Major Depressive Disorder | Completed | 2009-07-30 | 2010-08-04 | ClinicalTrials.gov |
| NCT02068508 | Pioglitazone Tablets Special Drug Use Surveillance "Combined Use of Insulin Pro… | — | Type 2 Diabetes Mellitus | Completed | 2009-07-30 | 2014-06-30 | ClinicalTrials.gov |
| NCT02068508 | Pioglitazone Tablets Special Drug Use Surveillance "Combined Use of Insulin Pro… | — | Type 2 Diabetes Mellitus | Completed | 2009-07-30 | 2014-06-30 | ClinicalTrials.gov |
| NCT00905424 | Exploratory Study of SPD489 in Adults With Major Depressive Disorder (MDD) as A… | Phase2 | Major Depressive Disorder | Completed | 2009-07-30 | 2010-08-04 | ClinicalTrials.gov |
| NCT02068508 | Pioglitazone Tablets Special Drug Use Surveillance "Combined Use of Insulin Pro… | — | Type 2 Diabetes Mellitus | Completed | 2009-07-30 | 2014-06-30 | ClinicalTrials.gov |
| NCT00912093 | A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (F… | Phase3 | Hereditary Angioedema | Completed | 2009-07-16 | 2010-10-01 | ClinicalTrials.gov |
| NCT00912093 | A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (F… | Phase3 | Hereditary Angioedema | Completed | 2009-07-16 | 2010-10-01 | ClinicalTrials.gov |
| NCT00912093 | A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (F… | Phase3 | Hereditary Angioedema | Completed | 2009-07-16 | 2010-10-01 | ClinicalTrials.gov |
| NCT01034969 | Firazyr® Patient Registry (Icatibant Outcome Survey - IOS) | — | Hereditary Angioedema (HAE) | Completed | 2009-07-10 | 2024-05-31 | ClinicalTrials.gov |
| NCT01034969 | Firazyr® Patient Registry (Icatibant Outcome Survey - IOS) | — | Hereditary Angioedema (HAE) | Completed | 2009-07-10 | 2024-05-31 | ClinicalTrials.gov |
| NCT01034969 | Firazyr® Patient Registry (Icatibant Outcome Survey - IOS) | — | Hereditary Angioedema (HAE) | Completed | 2009-07-10 | 2024-05-31 | ClinicalTrials.gov |
| NCT00937794 | Screening Study to Identify Pediatric Patients With Hunter Syndrome Who Demonst… | — | Hunter Syndrome | Completed | 2009-07-02 | 2011-07-13 | ClinicalTrials.gov |
| NCT00937794 | Screening Study to Identify Pediatric Patients With Hunter Syndrome Who Demonst… | — | Hunter Syndrome | Completed | 2009-07-02 | 2011-07-13 | ClinicalTrials.gov |
| NCT00937794 | Screening Study to Identify Pediatric Patients With Hunter Syndrome Who Demonst… | — | Hunter Syndrome | Completed | 2009-07-02 | 2011-07-13 | ClinicalTrials.gov |
| NCT00947856 | A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a … | Phase2 | Disease, Hodgkin | Completed | 2009-07-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT00919152 | Economic Outcomes of Enteral and Parenteral Proton Pump Inhibitor (PPI) Use in … | — | Stress Ulcer Prophylaxis | Completed | 2009-07-01 | 2012-01-01 | ClinicalTrials.gov |
| NCT00947856 | A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a … | Phase2 | Disease, Hodgkin | Completed | 2009-07-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT00919152 | Economic Outcomes of Enteral and Parenteral Proton Pump Inhibitor (PPI) Use in … | — | Stress Ulcer Prophylaxis | Completed | 2009-07-01 | 2012-01-01 | ClinicalTrials.gov |
| NCT00919152 | Economic Outcomes of Enteral and Parenteral Proton Pump Inhibitor (PPI) Use in … | — | Stress Ulcer Prophylaxis | Completed | 2009-07-01 | 2012-01-01 | ClinicalTrials.gov |
| NCT00947856 | A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a … | Phase2 | Disease, Hodgkin | Completed | 2009-07-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT00919867 | A Drug Interaction Study of SPD503 and Vyvanse Administered Alone and In Combin… | Phase1 | Healthy | Completed | 2009-06-24 | 2009-07-30 | ClinicalTrials.gov |
| NCT00919867 | A Drug Interaction Study of SPD503 and Vyvanse Administered Alone and In Combin… | Phase1 | Healthy | Completed | 2009-06-24 | 2009-07-30 | ClinicalTrials.gov |
| NCT00919867 | A Drug Interaction Study of SPD503 and Vyvanse Administered Alone and In Combin… | Phase1 | Healthy | Completed | 2009-06-24 | 2009-07-30 | ClinicalTrials.gov |
| NCT00948922 | Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic St… | Phase2 | Multiple Myeloma | Completed | 2009-06-18 | 2019-05-14 | ClinicalTrials.gov |
| NCT00948922 | Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic St… | Phase2 | Multiple Myeloma | Completed | 2009-06-18 | 2019-05-14 | ClinicalTrials.gov |
| NCT00948922 | Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic St… | Phase2 | Multiple Myeloma | Completed | 2009-06-18 | 2019-05-14 | ClinicalTrials.gov |
| NCT00669461 | Lubiprostone as a Treatment for Constipation in Parkinson's Disease | Na | Constipation | Terminated | 2009-06-01 | 2010-09-01 | ClinicalTrials.gov |
| NCT00904852 | Safety Study of the Combination of Tandutinib With Temozolomide and Bevacizumab… | Phase1 | Glioblastoma Multiforme | Withdrawn | 2009-06-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT02525536 | A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of Tre… | Phase1 | Neoplasms, Advanced Solid | Completed | 2009-06-01 | 2014-05-01 | ClinicalTrials.gov |
| NCT00669461 | Lubiprostone as a Treatment for Constipation in Parkinson's Disease | Na | Constipation | Terminated | 2009-06-01 | 2010-09-01 | ClinicalTrials.gov |
| NCT00903968 | Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refracto… | Phase1 | Multiple Myeloma | Completed | 2009-06-01 | 2016-10-01 | ClinicalTrials.gov |
| NCT00904852 | Safety Study of the Combination of Tandutinib With Temozolomide and Bevacizumab… | Phase1 | Glioblastoma Multiforme | Withdrawn | 2009-06-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT00911066 | MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndro… | Phase1 | Acute Myelogenous Leukemia | Completed | 2009-06-01 | 2013-10-01 | ClinicalTrials.gov |
| NCT00925704 | The Pharmacokinetics of Rocaltrol When Administered Alone or in Combination Wit… | Phase1 | Healthy | Completed | 2009-06-01 | 2009-07-31 | ClinicalTrials.gov |
| NCT02525536 | A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of Tre… | Phase1 | Neoplasms, Advanced Solid | Completed | 2009-06-01 | 2014-05-01 | ClinicalTrials.gov |
| NCT02525536 | A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of Tre… | Phase1 | Neoplasms, Advanced Solid | Completed | 2009-06-01 | 2014-05-01 | ClinicalTrials.gov |
| NCT00925704 | The Pharmacokinetics of Rocaltrol When Administered Alone or in Combination Wit… | Phase1 | Healthy | Completed | 2009-06-01 | 2009-07-31 | ClinicalTrials.gov |
| NCT00903968 | Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refracto… | Phase1 | Multiple Myeloma | Completed | 2009-06-01 | 2016-10-01 | ClinicalTrials.gov |
| NCT00925704 | The Pharmacokinetics of Rocaltrol When Administered Alone or in Combination Wit… | Phase1 | Healthy | Completed | 2009-06-01 | 2009-07-31 | ClinicalTrials.gov |
| NCT00904852 | Safety Study of the Combination of Tandutinib With Temozolomide and Bevacizumab… | Phase1 | Glioblastoma Multiforme | Withdrawn | 2009-06-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT00669461 | Lubiprostone as a Treatment for Constipation in Parkinson's Disease | Na | Constipation | Terminated | 2009-06-01 | 2010-09-01 | ClinicalTrials.gov |
| NCT00911066 | MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndro… | Phase1 | Acute Myelogenous Leukemia | Completed | 2009-06-01 | 2013-10-01 | ClinicalTrials.gov |
| NCT00911066 | MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndro… | Phase1 | Acute Myelogenous Leukemia | Completed | 2009-06-01 | 2013-10-01 | ClinicalTrials.gov |
| NCT00903968 | Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refracto… | Phase1 | Multiple Myeloma | Completed | 2009-06-01 | 2016-10-01 | ClinicalTrials.gov |
| NCT00790933 | An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Co… | Phase3 | Ulcerative Colitis | Completed | 2009-05-22 | 2017-10-31 | ClinicalTrials.gov |
| NCT00790933 | An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Co… | Phase3 | Ulcerative Colitis | Completed | 2009-05-22 | 2017-10-31 | ClinicalTrials.gov |
| NCT00790933 | An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Co… | Phase3 | Ulcerative Colitis | Completed | 2009-05-22 | 2017-10-31 | ClinicalTrials.gov |
| NCT00901576 | A Drug Interaction Study of SPD503 and Concerta Administered Alone and In Combi… | Phase1 | Healthy | Completed | 2009-05-18 | 2009-07-06 | ClinicalTrials.gov |
| NCT00901576 | A Drug Interaction Study of SPD503 and Concerta Administered Alone and In Combi… | Phase1 | Healthy | Completed | 2009-05-18 | 2009-07-06 | ClinicalTrials.gov |
| NCT00901576 | A Drug Interaction Study of SPD503 and Concerta Administered Alone and In Combi… | Phase1 | Healthy | Completed | 2009-05-18 | 2009-07-06 | ClinicalTrials.gov |
| NCT00847210 | Pharmacokinetic and Safety of Dexlansoprazole in Adolescents With Gastroesophag… | Phase1 | Gastroesophageal Reflux | Completed | 2009-05-01 | 2009-09-01 | ClinicalTrials.gov |
| NCT00844831 | Effects of Lubiprostone on Small Bowel and Colonic Bacteria: A Correlation Stud… | Phase4 | Constipation | Completed | 2009-05-01 | 2011-05-01 | ClinicalTrials.gov |
| NCT00908583 | Desensitization in Kidney Transplantation | Phase4 | HLA Sensitization | Completed | 2009-05-01 | 2012-11-01 | ClinicalTrials.gov |
| NCT00990652 | Presurgery Bortezomib for Recurrent Malignant Gliomas Followed by Postop Bortez… | Phase2 | Brain and Central Nervous System Tumors | Completed | 2009-05-01 | 2012-10-01 | ClinicalTrials.gov |
| NCT00890448 | Case Control Study of Pharmacogenomic Factors Associated With Hepatocellular In… | — | Toxicity | Completed | 2009-05-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT00990652 | Presurgery Bortezomib for Recurrent Malignant Gliomas Followed by Postop Bortez… | Phase2 | Brain and Central Nervous System Tumors | Completed | 2009-05-01 | 2012-10-01 | ClinicalTrials.gov |
| NCT00890448 | Case Control Study of Pharmacogenomic Factors Associated With Hepatocellular In… | — | Toxicity | Completed | 2009-05-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT00847210 | Pharmacokinetic and Safety of Dexlansoprazole in Adolescents With Gastroesophag… | Phase1 | Gastroesophageal Reflux | Completed | 2009-05-01 | 2009-09-01 | ClinicalTrials.gov |
| NCT00847210 | Pharmacokinetic and Safety of Dexlansoprazole in Adolescents With Gastroesophag… | Phase1 | Gastroesophageal Reflux | Completed | 2009-05-01 | 2009-09-01 | ClinicalTrials.gov |
| NCT00990652 | Presurgery Bortezomib for Recurrent Malignant Gliomas Followed by Postop Bortez… | Phase2 | Brain and Central Nervous System Tumors | Completed | 2009-05-01 | 2012-10-01 | ClinicalTrials.gov |
| NCT00908583 | Desensitization in Kidney Transplantation | Phase4 | HLA Sensitization | Completed | 2009-05-01 | 2012-11-01 | ClinicalTrials.gov |
| NCT00890448 | Case Control Study of Pharmacogenomic Factors Associated With Hepatocellular In… | — | Toxicity | Completed | 2009-05-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT00844831 | Effects of Lubiprostone on Small Bowel and Colonic Bacteria: A Correlation Stud… | Phase4 | Constipation | Completed | 2009-05-01 | 2011-05-01 | ClinicalTrials.gov |
| NCT00908583 | Desensitization in Kidney Transplantation | Phase4 | HLA Sensitization | Completed | 2009-05-01 | 2012-11-01 | ClinicalTrials.gov |
| NCT00844831 | Effects of Lubiprostone on Small Bowel and Colonic Bacteria: A Correlation Stud… | Phase4 | Constipation | Completed | 2009-05-01 | 2011-05-01 | ClinicalTrials.gov |
| NCT00877487 | Safety and Efficacy of Vyvanse in Adults With Attention-Deficit/Hyperactivity D… | Phase4 | Attention-Deficit/Hyperactivity Disorder | Completed | 2009-04-30 | 2010-07-08 | ClinicalTrials.gov |
| NCT00877487 | Safety and Efficacy of Vyvanse in Adults With Attention-Deficit/Hyperactivity D… | Phase4 | Attention-Deficit/Hyperactivity Disorder | Completed | 2009-04-30 | 2010-07-08 | ClinicalTrials.gov |
| NCT00877487 | Safety and Efficacy of Vyvanse in Adults With Attention-Deficit/Hyperactivity D… | Phase4 | Attention-Deficit/Hyperactivity Disorder | Completed | 2009-04-30 | 2010-07-08 | ClinicalTrials.gov |
| NCT00882687 | Efficacy Study to Evaluate the Effectiveness of 3 Concentrations of SAR 1118 in… | Phase2 | Allergic Conjunctivitis | Completed | 2009-04-24 | 2009-05-10 | ClinicalTrials.gov |
| NCT00882687 | Efficacy Study to Evaluate the Effectiveness of 3 Concentrations of SAR 1118 in… | Phase2 | Allergic Conjunctivitis | Completed | 2009-04-24 | 2009-05-10 | ClinicalTrials.gov |
| NCT00882687 | Efficacy Study to Evaluate the Effectiveness of 3 Concentrations of SAR 1118 in… | Phase2 | Allergic Conjunctivitis | Completed | 2009-04-24 | 2009-05-10 | ClinicalTrials.gov |
| NCT00875017 | Comparing Absorption of Dietary Phosphorus When Administering FOSRENOL® or RENV… | Phase1 | Kidney Failure, Chronic | Completed | 2009-04-20 | 2009-06-16 | ClinicalTrials.gov |
| NCT00875017 | Comparing Absorption of Dietary Phosphorus When Administering FOSRENOL® or RENV… | Phase1 | Kidney Failure, Chronic | Completed | 2009-04-20 | 2009-06-16 | ClinicalTrials.gov |
| NCT00875017 | Comparing Absorption of Dietary Phosphorus When Administering FOSRENOL® or RENV… | Phase1 | Kidney Failure, Chronic | Completed | 2009-04-20 | 2009-06-16 | ClinicalTrials.gov |
| NCT02016183 | Candesartan Cilexetil / Hydrochlorothiazide Combination Tablets Special Drug Us… | — | Hypertension | Completed | 2009-04-01 | 2012-09-30 | ClinicalTrials.gov |
| NCT02016183 | Candesartan Cilexetil / Hydrochlorothiazide Combination Tablets Special Drug Us… | — | Hypertension | Completed | 2009-04-01 | 2012-09-30 | ClinicalTrials.gov |
| NCT00891618 | Acupuncture for Chemo-Induced Peripheral Neuropathy | Phase2 | Lymphoma | Completed | 2009-04-01 | 2013-04-01 | ClinicalTrials.gov |
| NCT00891618 | Acupuncture for Chemo-Induced Peripheral Neuropathy | Phase2 | Lymphoma | Completed | 2009-04-01 | 2013-04-01 | ClinicalTrials.gov |
| NCT02016183 | Candesartan Cilexetil / Hydrochlorothiazide Combination Tablets Special Drug Us… | — | Hypertension | Completed | 2009-04-01 | 2012-09-30 | ClinicalTrials.gov |
| NCT00891618 | Acupuncture for Chemo-Induced Peripheral Neuropathy | Phase2 | Lymphoma | Completed | 2009-04-01 | 2013-04-01 | ClinicalTrials.gov |
| NCT00853307 | MLN8237 for Treatment of Participants With Ovarian, Fallopian Tube, or Peritone… | Phase2 | Ovarian Carcinoma | Completed | 2009-03-23 | 2011-01-27 | ClinicalTrials.gov |
| NCT00853307 | MLN8237 for Treatment of Participants With Ovarian, Fallopian Tube, or Peritone… | Phase2 | Ovarian Carcinoma | Completed | 2009-03-23 | 2011-01-27 | ClinicalTrials.gov |
| NCT00853307 | MLN8237 for Treatment of Participants With Ovarian, Fallopian Tube, or Peritone… | Phase2 | Ovarian Carcinoma | Completed | 2009-03-23 | 2011-01-27 | ClinicalTrials.gov |
| NCT00830869 | A Phase 1 Study of IXAZOMIB in Adult Patients With Advanced Nonhematologic Mali… | Phase1 | Advanced Non-hematologic Malignancies | Completed | 2009-03-02 | 2012-04-20 | ClinicalTrials.gov |
| NCT00830869 | A Phase 1 Study of IXAZOMIB in Adult Patients With Advanced Nonhematologic Mali… | Phase1 | Advanced Non-hematologic Malignancies | Completed | 2009-03-02 | 2012-04-20 | ClinicalTrials.gov |
| NCT00830869 | A Phase 1 Study of IXAZOMIB in Adult Patients With Advanced Nonhematologic Mali… | Phase1 | Advanced Non-hematologic Malignancies | Completed | 2009-03-02 | 2012-04-20 | ClinicalTrials.gov |
| NCT00807677 | A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologi… | Phase1 | Acute Myeloid Leukemia | Completed | 2009-03-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT00835120 | Pioglitazone for the Treatment of Bipolar Disorder and Comorbid Metabolic Syndr… | Phase4 | Metabolic Syndrome | Completed | 2009-03-01 | 2013-04-01 | ClinicalTrials.gov |
| NCT00835120 | Pioglitazone for the Treatment of Bipolar Disorder and Comorbid Metabolic Syndr… | Phase4 | Metabolic Syndrome | Completed | 2009-03-01 | 2013-04-01 | ClinicalTrials.gov |
| NCT00770835 | Efficacy and Safety of Pioglitazone in Treating Subjects With Vascular Complica… | Phase4 | Diabetes Mellitus | Completed | 2009-03-01 | 2011-05-01 | ClinicalTrials.gov |
| NCT00807677 | A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologi… | Phase1 | Acute Myeloid Leukemia | Completed | 2009-03-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT00835120 | Pioglitazone for the Treatment of Bipolar Disorder and Comorbid Metabolic Syndr… | Phase4 | Metabolic Syndrome | Completed | 2009-03-01 | 2013-04-01 | ClinicalTrials.gov |
| NCT00831896 | Phase I Study of TAK-701 in Adult Patients With Advanced Nonhematological Malig… | Phase1 | Advanced Solid Tumors | Completed | 2009-03-01 | 2011-05-01 | ClinicalTrials.gov |
| NCT00846365 | Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants… | Phase3 | Essential Hypertension | Completed | 2009-03-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT00856284 | Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Met… | Phase3 | Type 2 Diabetes Mellitus | Completed | 2009-03-01 | 2012-10-01 | ClinicalTrials.gov |
| NCT00866047 | A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplas… | Phase2 | Lymphoma, Large-Cell, Anaplastic | Completed | 2009-03-01 | 2016-06-01 | ClinicalTrials.gov |
| NCT00869323 | Bortezomib and Rituximab in Treating Patients With Post-Transplant Lymphoprolif… | Phase2 | Lymphoproliferative Disorder | Terminated | 2009-03-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT00770835 | Efficacy and Safety of Pioglitazone in Treating Subjects With Vascular Complica… | Phase4 | Diabetes Mellitus | Completed | 2009-03-01 | 2011-05-01 | ClinicalTrials.gov |
| NCT00807677 | A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologi… | Phase1 | Acute Myeloid Leukemia | Completed | 2009-03-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT00831896 | Phase I Study of TAK-701 in Adult Patients With Advanced Nonhematological Malig… | Phase1 | Advanced Solid Tumors | Completed | 2009-03-01 | 2011-05-01 | ClinicalTrials.gov |
| NCT00846365 | Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants… | Phase3 | Essential Hypertension | Completed | 2009-03-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT00856284 | Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Met… | Phase3 | Type 2 Diabetes Mellitus | Completed | 2009-03-01 | 2012-10-01 | ClinicalTrials.gov |
| NCT00866047 | A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplas… | Phase2 | Lymphoma, Large-Cell, Anaplastic | Completed | 2009-03-01 | 2016-06-01 | ClinicalTrials.gov |
| NCT00869323 | Bortezomib and Rituximab in Treating Patients With Post-Transplant Lymphoprolif… | Phase2 | Lymphoproliferative Disorder | Terminated | 2009-03-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT00770835 | Efficacy and Safety of Pioglitazone in Treating Subjects With Vascular Complica… | Phase4 | Diabetes Mellitus | Completed | 2009-03-01 | 2011-05-01 | ClinicalTrials.gov |
| NCT00831896 | Phase I Study of TAK-701 in Adult Patients With Advanced Nonhematological Malig… | Phase1 | Advanced Solid Tumors | Completed | 2009-03-01 | 2011-05-01 | ClinicalTrials.gov |
| NCT00846365 | Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants… | Phase3 | Essential Hypertension | Completed | 2009-03-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT00856284 | Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Met… | Phase3 | Type 2 Diabetes Mellitus | Completed | 2009-03-01 | 2012-10-01 | ClinicalTrials.gov |
| NCT00866047 | A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplas… | Phase2 | Lymphoma, Large-Cell, Anaplastic | Completed | 2009-03-01 | 2016-06-01 | ClinicalTrials.gov |
| NCT00869323 | Bortezomib and Rituximab in Treating Patients With Post-Transplant Lymphoprolif… | Phase2 | Lymphoproliferative Disorder | Terminated | 2009-03-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT00807495 | Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma | Phase2 | Diffuse Large B-cell Lymphoma | Completed | 2009-02-10 | 2013-02-13 | ClinicalTrials.gov |
| NCT00830518 | A Phase 2 Trial of MLN8237 in Adult Participants With Acute Myelogenous Leukemi… | Phase2 | Acute Myelogenous Leukemia | Completed | 2009-02-10 | 2011-07-04 | ClinicalTrials.gov |
| NCT00830518 | A Phase 2 Trial of MLN8237 in Adult Participants With Acute Myelogenous Leukemi… | Phase2 | Acute Myelogenous Leukemia | Completed | 2009-02-10 | 2011-07-04 | ClinicalTrials.gov |
| NCT00807495 | Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma | Phase2 | Diffuse Large B-cell Lymphoma | Completed | 2009-02-10 | 2013-02-13 | ClinicalTrials.gov |
| NCT00807495 | Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma | Phase2 | Diffuse Large B-cell Lymphoma | Completed | 2009-02-10 | 2013-02-13 | ClinicalTrials.gov |
| NCT00830518 | A Phase 2 Trial of MLN8237 in Adult Participants With Acute Myelogenous Leukemi… | Phase2 | Acute Myelogenous Leukemia | Completed | 2009-02-10 | 2011-07-04 | ClinicalTrials.gov |
| NCT00847808 | Efficacy of Dexlansoprazole MR on Heartburn Control in Participants Previously … | Phase3 | Gastroesophageal Reflux | Completed | 2009-02-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT01190020 | Effect of Lubiprostone on Methanogenesis and Bowel Function in Chronic Constipa… | Phase1 | Chronic Constipation, Methanogenesis | Completed | 2009-02-01 | 2012-03-01 | ClinicalTrials.gov |
| NCT00785629 | A Double Blind Randomized Placebo Trial of Maintenance of Normal Serum Phosphor… | Na | Chronic Kidney Disease | Completed | 2009-02-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT00848926 | A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma | Phase2 | Disease, Hodgkin | Completed | 2009-02-01 | 2015-05-01 | ClinicalTrials.gov |
| NCT02003014 | Pioglitazone Tablets Special Drug Use Surveillance "Combined Use of Biguanides … | — | Type 2 Diabetes Mellitus | Completed | 2009-02-01 | 2012-01-01 | ClinicalTrials.gov |
| NCT00818883 | Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone in Participants … | Phase3 | Essential Hypertension | Completed | 2009-02-01 | 2009-11-01 | ClinicalTrials.gov |
| NCT00847808 | Efficacy of Dexlansoprazole MR on Heartburn Control in Participants Previously … | Phase3 | Gastroesophageal Reflux | Completed | 2009-02-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT00818883 | Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone in Participants … | Phase3 | Essential Hypertension | Completed | 2009-02-01 | 2009-11-01 | ClinicalTrials.gov |
| NCT00785629 | A Double Blind Randomized Placebo Trial of Maintenance of Normal Serum Phosphor… | Na | Chronic Kidney Disease | Completed | 2009-02-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT00879320 | Healthy Lifestyle in Adults With Attention Deficit Hyperactivity Disorder | — | ADHD | Completed | 2009-02-01 | 2012-05-01 | ClinicalTrials.gov |
| NCT00848926 | A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma | Phase2 | Disease, Hodgkin | Completed | 2009-02-01 | 2015-05-01 | ClinicalTrials.gov |
| NCT00847808 | Efficacy of Dexlansoprazole MR on Heartburn Control in Participants Previously … | Phase3 | Gastroesophageal Reflux | Completed | 2009-02-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT00879320 | Healthy Lifestyle in Adults With Attention Deficit Hyperactivity Disorder | — | ADHD | Completed | 2009-02-01 | 2012-05-01 | ClinicalTrials.gov |
| NCT00848926 | A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma | Phase2 | Disease, Hodgkin | Completed | 2009-02-01 | 2015-05-01 | ClinicalTrials.gov |
| NCT01190020 | Effect of Lubiprostone on Methanogenesis and Bowel Function in Chronic Constipa… | Phase1 | Chronic Constipation, Methanogenesis | Completed | 2009-02-01 | 2012-03-01 | ClinicalTrials.gov |
| NCT00785629 | A Double Blind Randomized Placebo Trial of Maintenance of Normal Serum Phosphor… | Na | Chronic Kidney Disease | Completed | 2009-02-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT01190020 | Effect of Lubiprostone on Methanogenesis and Bowel Function in Chronic Constipa… | Phase1 | Chronic Constipation, Methanogenesis | Completed | 2009-02-01 | 2012-03-01 | ClinicalTrials.gov |
| NCT02003014 | Pioglitazone Tablets Special Drug Use Surveillance "Combined Use of Biguanides … | — | Type 2 Diabetes Mellitus | Completed | 2009-02-01 | 2012-01-01 | ClinicalTrials.gov |
| NCT02003014 | Pioglitazone Tablets Special Drug Use Surveillance "Combined Use of Biguanides … | — | Type 2 Diabetes Mellitus | Completed | 2009-02-01 | 2012-01-01 | ClinicalTrials.gov |
| NCT00879320 | Healthy Lifestyle in Adults With Attention Deficit Hyperactivity Disorder | — | ADHD | Completed | 2009-02-01 | 2012-05-01 | ClinicalTrials.gov |
| NCT00818883 | Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone in Participants … | Phase3 | Essential Hypertension | Completed | 2009-02-01 | 2009-11-01 | ClinicalTrials.gov |
| NCT00880750 | Pharmacodynamic Study of Two Lanthanum Carbonate Formulations in Healthy Adults | Phase1 | End Stage Renal Disease | Completed | 2009-01-28 | 2009-06-22 | ClinicalTrials.gov |
| NCT00880750 | Pharmacodynamic Study of Two Lanthanum Carbonate Formulations in Healthy Adults | Phase1 | End Stage Renal Disease | Completed | 2009-01-28 | 2009-06-22 | ClinicalTrials.gov |
| NCT00880750 | Pharmacodynamic Study of Two Lanthanum Carbonate Formulations in Healthy Adults | Phase1 | End Stage Renal Disease | Completed | 2009-01-28 | 2009-06-22 | ClinicalTrials.gov |
| NCT00784654 | Double-blind, Placebo-controlled, Randomised Withdrawal, Extension, Safety and … | Phase3 | ADHD | Completed | 2009-01-27 | 2011-10-26 | ClinicalTrials.gov |
| NCT00784654 | Double-blind, Placebo-controlled, Randomised Withdrawal, Extension, Safety and … | Phase3 | ADHD | Completed | 2009-01-27 | 2011-10-26 | ClinicalTrials.gov |
| NCT00784654 | Double-blind, Placebo-controlled, Randomised Withdrawal, Extension, Safety and … | Phase3 | ADHD | Completed | 2009-01-27 | 2011-10-26 | ClinicalTrials.gov |
| NCT02181842 | Pioglitazone Tablets Specified Drug-use Survey <Survey on Glycemic Control in T… | — | Type 2 Diabetes Mellitus | Completed | 2009-01-26 | 2011-06-30 | ClinicalTrials.gov |
| NCT02181842 | Pioglitazone Tablets Specified Drug-use Survey <Survey on Glycemic Control in T… | — | Type 2 Diabetes Mellitus | Completed | 2009-01-26 | 2011-06-30 | ClinicalTrials.gov |
| NCT02181842 | Pioglitazone Tablets Specified Drug-use Survey <Survey on Glycemic Control in T… | — | Type 2 Diabetes Mellitus | Completed | 2009-01-26 | 2011-06-30 | ClinicalTrials.gov |
| NCT00762073 | Dose-Ranging Study of Oral Viscous Budesonide in Pediatrics With Eosinophilic E… | Phase2 | Eosinophilic Esophagitis (EoE) | Completed | 2009-01-08 | 2010-04-02 | ClinicalTrials.gov |
| NCT00762073 | Dose-Ranging Study of Oral Viscous Budesonide in Pediatrics With Eosinophilic E… | Phase2 | Eosinophilic Esophagitis (EoE) | Completed | 2009-01-08 | 2010-04-02 | ClinicalTrials.gov |
| NCT00762073 | Dose-Ranging Study of Oral Viscous Budesonide in Pediatrics With Eosinophilic E… | Phase2 | Eosinophilic Esophagitis (EoE) | Completed | 2009-01-08 | 2010-04-02 | ClinicalTrials.gov |
| NCT00783718 | Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative C… | Phase3 | Ulcerative Colitis | Completed | 2009-01-01 | 2012-03-01 | ClinicalTrials.gov |
| NCT00818649 | Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic S… | Phase2 | Leukemia | Terminated | 2009-01-01 | 2012-05-01 | ClinicalTrials.gov |
| NCT00783718 | Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative C… | Phase3 | Ulcerative Colitis | Completed | 2009-01-01 | 2012-03-01 | ClinicalTrials.gov |
| NCT00847626 | Efficacy and Safety of Azilsartan Medoxomil Combined With Chlorthalidone in Par… | Phase3 | Hypertension | Completed | 2009-01-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT00773929 | Safety Study of TAK-593 Given Orally in Subjects With Nonhematologic Advanced C… | Phase1 | Solid Tumors | Completed | 2009-01-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT00624546 | Effect of Antireflux Therapy on the Expression of Genes in Patients With GERD | — | GERD | Terminated | 2009-01-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT00624546 | Effect of Antireflux Therapy on the Expression of Genes in Patients With GERD | — | GERD | Terminated | 2009-01-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT01318135 | Long-term Safety Study of Alogliptin Used in Combination With Sulfonylurea or M… | Phase2 | Type 2 Diabetes Mellitus | Completed | 2009-01-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT00949091 | Pharmacokinetics and Pharmacodynamics of TAK-875 in Subjects With Type 2 Diabet… | Phase1 | Diabetes Mellitus, Type 2 | Completed | 2009-01-01 | 2009-07-01 | ClinicalTrials.gov |
| NCT00949091 | Pharmacokinetics and Pharmacodynamics of TAK-875 in Subjects With Type 2 Diabet… | Phase1 | Diabetes Mellitus, Type 2 | Completed | 2009-01-01 | 2009-07-01 | ClinicalTrials.gov |
| NCT00847626 | Efficacy and Safety of Azilsartan Medoxomil Combined With Chlorthalidone in Par… | Phase3 | Hypertension | Completed | 2009-01-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT00818649 | Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic S… | Phase2 | Leukemia | Terminated | 2009-01-01 | 2012-05-01 | ClinicalTrials.gov |
| NCT00773929 | Safety Study of TAK-593 Given Orally in Subjects With Nonhematologic Advanced C… | Phase1 | Solid Tumors | Completed | 2009-01-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT00847626 | Efficacy and Safety of Azilsartan Medoxomil Combined With Chlorthalidone in Par… | Phase3 | Hypertension | Completed | 2009-01-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT00624546 | Effect of Antireflux Therapy on the Expression of Genes in Patients With GERD | — | GERD | Terminated | 2009-01-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT01318135 | Long-term Safety Study of Alogliptin Used in Combination With Sulfonylurea or M… | Phase2 | Type 2 Diabetes Mellitus | Completed | 2009-01-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT00818649 | Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic S… | Phase2 | Leukemia | Terminated | 2009-01-01 | 2012-05-01 | ClinicalTrials.gov |
| NCT00949091 | Pharmacokinetics and Pharmacodynamics of TAK-875 in Subjects With Type 2 Diabet… | Phase1 | Diabetes Mellitus, Type 2 | Completed | 2009-01-01 | 2009-07-01 | ClinicalTrials.gov |
| NCT00783718 | Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative C… | Phase3 | Ulcerative Colitis | Completed | 2009-01-01 | 2012-03-01 | ClinicalTrials.gov |
| NCT00773929 | Safety Study of TAK-593 Given Orally in Subjects With Nonhematologic Advanced C… | Phase1 | Solid Tumors | Completed | 2009-01-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT01318135 | Long-term Safety Study of Alogliptin Used in Combination With Sulfonylurea or M… | Phase2 | Type 2 Diabetes Mellitus | Completed | 2009-01-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT00732615 | Use of NPSP558 in the Treatment of Hypoparathyroidism | Phase3 | Hypoparathyroidism | Completed | 2008-12-18 | 2011-09-28 | ClinicalTrials.gov |
| NCT00732615 | Use of NPSP558 in the Treatment of Hypoparathyroidism | Phase3 | Hypoparathyroidism | Completed | 2008-12-18 | 2011-09-28 | ClinicalTrials.gov |
| NCT00732615 | Use of NPSP558 in the Treatment of Hypoparathyroidism | Phase3 | Hypoparathyroidism | Completed | 2008-12-18 | 2011-09-28 | ClinicalTrials.gov |
| NCT00798720 | Vorinostat and Bortezomib as Third-line Treatment in Advanced Non-small Cell Lu… | Phase2 | Carcinoma, Non Small Cell Lung | Completed | 2008-12-01 | 2012-10-01 | ClinicalTrials.gov |
| NCT01091805 | Correlation of Oropharyngeal Pepsin and Gastroesophageal (GE) Reflux | — | Gastroesophageal Reflux Disease (GERD) | Completed | 2008-12-01 | 2013-10-01 | ClinicalTrials.gov |
| NCT00783692 | Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Dise… | Phase3 | Crohn's Disease | Completed | 2008-12-01 | 2012-05-01 | ClinicalTrials.gov |
| NCT00798720 | Vorinostat and Bortezomib as Third-line Treatment in Advanced Non-small Cell Lu… | Phase2 | Carcinoma, Non Small Cell Lung | Completed | 2008-12-01 | 2012-10-01 | ClinicalTrials.gov |
| NCT00815919 | Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft Versus Host Dis… | Phase2 | Chronic Graft Versus Host Disease | Completed | 2008-12-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT01990339 | Lansoprazole Tablets Special Drug Use Surveillance Gastroesophageal Reflux Dise… | — | Gastroesophageal Reflux Disease With Dyspepsia Symptoms | Completed | 2008-12-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT00798720 | Vorinostat and Bortezomib as Third-line Treatment in Advanced Non-small Cell Lu… | Phase2 | Carcinoma, Non Small Cell Lung | Completed | 2008-12-01 | 2012-10-01 | ClinicalTrials.gov |
| NCT01091805 | Correlation of Oropharyngeal Pepsin and Gastroesophageal (GE) Reflux | — | Gastroesophageal Reflux Disease (GERD) | Completed | 2008-12-01 | 2013-10-01 | ClinicalTrials.gov |
| NCT00783692 | Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Dise… | Phase3 | Crohn's Disease | Completed | 2008-12-01 | 2012-05-01 | ClinicalTrials.gov |
| NCT00815919 | Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft Versus Host Dis… | Phase2 | Chronic Graft Versus Host Disease | Completed | 2008-12-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT00815919 | Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft Versus Host Dis… | Phase2 | Chronic Graft Versus Host Disease | Completed | 2008-12-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT01990339 | Lansoprazole Tablets Special Drug Use Surveillance Gastroesophageal Reflux Dise… | — | Gastroesophageal Reflux Disease With Dyspepsia Symptoms | Completed | 2008-12-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT01091805 | Correlation of Oropharyngeal Pepsin and Gastroesophageal (GE) Reflux | — | Gastroesophageal Reflux Disease (GERD) | Completed | 2008-12-01 | 2013-10-01 | ClinicalTrials.gov |
| NCT00783692 | Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Dise… | Phase3 | Crohn's Disease | Completed | 2008-12-01 | 2012-05-01 | ClinicalTrials.gov |
| NCT01990339 | Lansoprazole Tablets Special Drug Use Surveillance Gastroesophageal Reflux Dise… | — | Gastroesophageal Reflux Disease With Dyspepsia Symptoms | Completed | 2008-12-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT00798967 | Study of Teduglutide Effectiveness in Parenteral Nutrition (PN)-Dependent Short… | Phase3 | Short Bowel Syndrome | Completed | 2008-11-25 | 2011-01-25 | ClinicalTrials.gov |
| NCT00798967 | Study of Teduglutide Effectiveness in Parenteral Nutrition (PN)-Dependent Short… | Phase3 | Short Bowel Syndrome | Completed | 2008-11-25 | 2011-01-25 | ClinicalTrials.gov |
| NCT00798967 | Study of Teduglutide Effectiveness in Parenteral Nutrition (PN)-Dependent Short… | Phase3 | Short Bowel Syndrome | Completed | 2008-11-25 | 2011-01-25 | ClinicalTrials.gov |
| NCT00763971 | Randomized, Double-blind Safety and Efficacy Study of Lisdexamfetamine Dimesyla… | Phase3 | ADHD | Completed | 2008-11-17 | 2011-03-16 | ClinicalTrials.gov |
| NCT00763971 | Randomized, Double-blind Safety and Efficacy Study of Lisdexamfetamine Dimesyla… | Phase3 | ADHD | Completed | 2008-11-17 | 2011-03-16 | ClinicalTrials.gov |
| NCT00763971 | Randomized, Double-blind Safety and Efficacy Study of Lisdexamfetamine Dimesyla… | Phase3 | ADHD | Completed | 2008-11-17 | 2011-03-16 | ClinicalTrials.gov |
| NCT00764868 | Vyvanse Adolescent Open-Label Safety and Efficacy Extension Study | Phase3 | ADHD | Completed | 2008-11-13 | 2010-04-22 | ClinicalTrials.gov |
| NCT00764868 | Vyvanse Adolescent Open-Label Safety and Efficacy Extension Study | Phase3 | ADHD | Completed | 2008-11-13 | 2010-04-22 | ClinicalTrials.gov |
| NCT00764868 | Vyvanse Adolescent Open-Label Safety and Efficacy Extension Study | Phase3 | ADHD | Completed | 2008-11-13 | 2010-04-22 | ClinicalTrials.gov |
| NCT00782795 | Chronic Pancreatitis. Effect of Pioglitazone on Endocrine Function, Exocrine Fu… | Phase2 | Chronic Pancreatitis | Completed | 2008-11-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT00782795 | Chronic Pancreatitis. Effect of Pioglitazone on Endocrine Function, Exocrine Fu… | Phase2 | Chronic Pancreatitis | Completed | 2008-11-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT00782795 | Chronic Pancreatitis. Effect of Pioglitazone on Endocrine Function, Exocrine Fu… | Phase2 | Chronic Pancreatitis | Completed | 2008-11-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT00756444 | A Randomized Phase 2 Pharmacokinetic Trial of Chemotherapy With or Without Pani… | Phase2 | Squamous Cell Carcinoma of Head and Neck | Completed | 2008-10-21 | 2012-03-30 | ClinicalTrials.gov |
| NCT00756444 | A Randomized Phase 2 Pharmacokinetic Trial of Chemotherapy With or Without Pani… | Phase2 | Squamous Cell Carcinoma of Head and Neck | Completed | 2008-10-21 | 2012-03-30 | ClinicalTrials.gov |
| NCT00756444 | A Randomized Phase 2 Pharmacokinetic Trial of Chemotherapy With or Without Pani… | Phase2 | Squamous Cell Carcinoma of Head and Neck | Completed | 2008-10-21 | 2012-03-30 | ClinicalTrials.gov |
| NCT00735371 | Efficacy and Safety of Lisdexamfetamine Dimesylate (LDX) in Adolescents With At… | Phase3 | Attention Deficit Hyperactivity Disorder (ADHD) | Completed | 2008-10-08 | 2009-04-06 | ClinicalTrials.gov |
| NCT00735371 | Efficacy and Safety of Lisdexamfetamine Dimesylate (LDX) in Adolescents With At… | Phase3 | Attention Deficit Hyperactivity Disorder (ADHD) | Completed | 2008-10-08 | 2009-04-06 | ClinicalTrials.gov |
| NCT00735371 | Efficacy and Safety of Lisdexamfetamine Dimesylate (LDX) in Adolescents With At… | Phase3 | Attention Deficit Hyperactivity Disorder (ADHD) | Completed | 2008-10-08 | 2009-04-06 | ClinicalTrials.gov |
| NCT00744354 | Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Pati… | Phase1 | Multiple Myeloma and Plasma Cell Neoplasm | Terminated | 2008-10-01 | 2015-04-01 | ClinicalTrials.gov |
| NCT00744354 | Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Pati… | Phase1 | Multiple Myeloma and Plasma Cell Neoplasm | Terminated | 2008-10-01 | 2015-04-01 | ClinicalTrials.gov |
| NCT00752791 | Efficacy and Safety of Peginesatide Injection for the Maintenance Treatment of … | Phase2 | Anemia | Completed | 2008-10-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT00770367 | Pioglitazone and Serum Asymmetric Dimethylarginine (ADMA) in Patients With Diab… | Phase4 | Diabetes | Completed | 2008-10-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT00793572 | Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transp… | Phase2 | Refractory Plasma Cell Myeloma | Completed | 2008-10-01 | 2016-10-01 | ClinicalTrials.gov |
| NCT00793884 | Emory Latino Diabetes Education Program | — | Diabetes | Terminated | 2008-10-01 | 2019-11-01 | ClinicalTrials.gov |
| NCT00770367 | Pioglitazone and Serum Asymmetric Dimethylarginine (ADMA) in Patients With Diab… | Phase4 | Diabetes | Completed | 2008-10-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT01303146 | Efficacy METAZYM for the Treatment Metachromatic Leukodystrophy Treated With He… | Phase2 | Metachromatic Leukodystrophy | Completed | 2008-10-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT02141711 | TAK-438 - Safety, Blood Levels & Effects of Repeated Doses | Phase1 | Erosive Esophagitis(EE) | Completed | 2008-10-01 | 2009-02-01 | ClinicalTrials.gov |
| NCT00752791 | Efficacy and Safety of Peginesatide Injection for the Maintenance Treatment of … | Phase2 | Anemia | Completed | 2008-10-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT00793572 | Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transp… | Phase2 | Refractory Plasma Cell Myeloma | Completed | 2008-10-01 | 2016-10-01 | ClinicalTrials.gov |
| NCT00744354 | Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Pati… | Phase1 | Multiple Myeloma and Plasma Cell Neoplasm | Terminated | 2008-10-01 | 2015-04-01 | ClinicalTrials.gov |
| NCT01303146 | Efficacy METAZYM for the Treatment Metachromatic Leukodystrophy Treated With He… | Phase2 | Metachromatic Leukodystrophy | Completed | 2008-10-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT00793884 | Emory Latino Diabetes Education Program | — | Diabetes | Terminated | 2008-10-01 | 2019-11-01 | ClinicalTrials.gov |
| NCT02123953 | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-438 in Healt… | Phase1 | Dose Finding Study | Completed | 2008-10-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00752791 | Efficacy and Safety of Peginesatide Injection for the Maintenance Treatment of … | Phase2 | Anemia | Completed | 2008-10-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT02141711 | TAK-438 - Safety, Blood Levels & Effects of Repeated Doses | Phase1 | Erosive Esophagitis(EE) | Completed | 2008-10-01 | 2009-02-01 | ClinicalTrials.gov |
| NCT00793572 | Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transp… | Phase2 | Refractory Plasma Cell Myeloma | Completed | 2008-10-01 | 2016-10-01 | ClinicalTrials.gov |
| NCT00793884 | Emory Latino Diabetes Education Program | — | Diabetes | Terminated | 2008-10-01 | 2019-11-01 | ClinicalTrials.gov |
| NCT02141711 | TAK-438 - Safety, Blood Levels & Effects of Repeated Doses | Phase1 | Erosive Esophagitis(EE) | Completed | 2008-10-01 | 2009-02-01 | ClinicalTrials.gov |
| NCT02123953 | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-438 in Healt… | Phase1 | Dose Finding Study | Completed | 2008-10-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT01303146 | Efficacy METAZYM for the Treatment Metachromatic Leukodystrophy Treated With He… | Phase2 | Metachromatic Leukodystrophy | Completed | 2008-10-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT00770367 | Pioglitazone and Serum Asymmetric Dimethylarginine (ADMA) in Patients With Diab… | Phase4 | Diabetes | Completed | 2008-10-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT02123953 | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-438 in Healt… | Phase1 | Dose Finding Study | Completed | 2008-10-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00746733 | Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC | Phase1 | Healthy Volunteers | Completed | 2008-09-08 | 2008-10-26 | ClinicalTrials.gov |
| NCT00746733 | Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC | Phase1 | Healthy Volunteers | Completed | 2008-09-08 | 2008-10-26 | ClinicalTrials.gov |
| NCT00746733 | Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC | Phase1 | Healthy Volunteers | Completed | 2008-09-08 | 2008-10-26 | ClinicalTrials.gov |
| NCT00734578 | Efficacy and Safety of SPD503 in Combination With Psychostimulants | Phase3 | ADHD | Completed | 2008-09-02 | 2009-12-10 | ClinicalTrials.gov |
| NCT00734578 | Efficacy and Safety of SPD503 in Combination With Psychostimulants | Phase3 | ADHD | Completed | 2008-09-02 | 2009-12-10 | ClinicalTrials.gov |
| NCT00734578 | Efficacy and Safety of SPD503 in Combination With Psychostimulants | Phase3 | ADHD | Completed | 2008-09-02 | 2009-12-10 | ClinicalTrials.gov |
| NCT00782821 | Randomized Trial of Induction Therapies in High Immunological Risk Kidney Trans… | Phase4 | Kidney Transplantation | Completed | 2008-09-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT00744627 | Efficacy and Safety of Vortioxetine (Lu AA21004) for Treatment of Generalized A… | Phase3 | Generalized Anxiety Disorder | Completed | 2008-09-01 | 2009-07-01 | ClinicalTrials.gov |
| NCT00782821 | Randomized Trial of Induction Therapies in High Immunological Risk Kidney Trans… | Phase4 | Kidney Transplantation | Completed | 2008-09-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT00750815 | Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed … | Phase1 | Multiple Myeloma | Completed | 2008-09-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT00750815 | Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed … | Phase1 | Multiple Myeloma | Completed | 2008-09-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT00752609 | Safety and Efficacy of Peginesatide Injection for the Maintenance of Anemia in … | Phase2 | Anemia | Completed | 2008-09-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT00752609 | Safety and Efficacy of Peginesatide Injection for the Maintenance of Anemia in … | Phase2 | Anemia | Completed | 2008-09-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT00750815 | Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed … | Phase1 | Multiple Myeloma | Completed | 2008-09-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT00752609 | Safety and Efficacy of Peginesatide Injection for the Maintenance of Anemia in … | Phase2 | Anemia | Completed | 2008-09-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT00753623 | Clinical Management of Neuropathic Pain With Ramelteon | Na | Neuropathic Pain | Terminated | 2008-09-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT00744627 | Efficacy and Safety of Vortioxetine (Lu AA21004) for Treatment of Generalized A… | Phase3 | Generalized Anxiety Disorder | Completed | 2008-09-01 | 2009-07-01 | ClinicalTrials.gov |
| NCT00782821 | Randomized Trial of Induction Therapies in High Immunological Risk Kidney Trans… | Phase4 | Kidney Transplantation | Completed | 2008-09-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT00652145 | Dose Escalation and Remission (DEAR) | Phase4 | Ulcerative Colitis | Completed | 2008-09-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT00652145 | Dose Escalation and Remission (DEAR) | Phase4 | Ulcerative Colitis | Completed | 2008-09-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT00715208 | Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymp… | Phase2 | Relapsed Follicular Lymphoma | Completed | 2008-09-01 | 2011-03-01 | ClinicalTrials.gov |
| NCT00715208 | Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymp… | Phase2 | Relapsed Follicular Lymphoma | Completed | 2008-09-01 | 2011-03-01 | ClinicalTrials.gov |
| NCT00652145 | Dose Escalation and Remission (DEAR) | Phase4 | Ulcerative Colitis | Completed | 2008-09-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT00744627 | Efficacy and Safety of Vortioxetine (Lu AA21004) for Treatment of Generalized A… | Phase3 | Generalized Anxiety Disorder | Completed | 2008-09-01 | 2009-07-01 | ClinicalTrials.gov |
| NCT00715208 | Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymp… | Phase2 | Relapsed Follicular Lymphoma | Completed | 2008-09-01 | 2011-03-01 | ClinicalTrials.gov |
| NCT00753623 | Clinical Management of Neuropathic Pain With Ramelteon | Na | Neuropathic Pain | Terminated | 2008-09-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT00753623 | Clinical Management of Neuropathic Pain With Ramelteon | Na | Neuropathic Pain | Terminated | 2008-09-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT01318109 | Efficacy and Safety of Alogliptin Used Combination With Metformin in Participan… | Phase2 | Type 2 Diabetes Mellitus | Completed | 2008-08-01 | 2009-04-01 | ClinicalTrials.gov |
| NCT01318083 | Efficacy and Safety of Alogliptin Used in Combination With Sulfonylurea in Part… | Phase2 | Type 2 Diabetes Mellitus | Completed | 2008-08-01 | 2009-04-01 | ClinicalTrials.gov |
| NCT00880906 | Study of the Efficiency of Esophageal Dilation on Patient With Eosinophilic Eso… | Na | Suspected Eosinophilic Esophagitis | Completed | 2008-08-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT02106455 | Sodium Risedronate Tablets - Special Drug Use Surveillance in Patients With Oss… | — | Osseous Paget's Disease | Completed | 2008-08-01 | 2017-10-24 | ClinicalTrials.gov |
| NCT00880906 | Study of the Efficiency of Esophageal Dilation on Patient With Eosinophilic Eso… | Na | Suspected Eosinophilic Esophagitis | Completed | 2008-08-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT00770640 | Efficacy of Pioglitazone and Insulin in Treating Subjects With Type 2 Diabetes … | Phase2 | Diabetes Mellitus | Completed | 2008-08-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT00735709 | Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Dis… | Phase3 | Major Depressive Disorder | Completed | 2008-08-01 | 2009-08-01 | ClinicalTrials.gov |
| NCT01318083 | Efficacy and Safety of Alogliptin Used in Combination With Sulfonylurea in Part… | Phase2 | Type 2 Diabetes Mellitus | Completed | 2008-08-01 | 2009-04-01 | ClinicalTrials.gov |
| NCT02106455 | Sodium Risedronate Tablets - Special Drug Use Surveillance in Patients With Oss… | — | Osseous Paget's Disease | Completed | 2008-08-01 | 2017-10-24 | ClinicalTrials.gov |
| NCT00770640 | Efficacy of Pioglitazone and Insulin in Treating Subjects With Type 2 Diabetes … | Phase2 | Diabetes Mellitus | Completed | 2008-08-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT02106455 | Sodium Risedronate Tablets - Special Drug Use Surveillance in Patients With Oss… | — | Osseous Paget's Disease | Completed | 2008-08-01 | 2017-10-24 | ClinicalTrials.gov |
| NCT01318109 | Efficacy and Safety of Alogliptin Used Combination With Metformin in Participan… | Phase2 | Type 2 Diabetes Mellitus | Completed | 2008-08-01 | 2009-04-01 | ClinicalTrials.gov |
| NCT00746239 | Ramelteon for Sleep Initiation Insomnia in Individuals With Panic Disorder Who … | Na | Panic Disorder | Terminated | 2008-08-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT00735709 | Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Dis… | Phase3 | Major Depressive Disorder | Completed | 2008-08-01 | 2009-08-01 | ClinicalTrials.gov |
| NCT00746239 | Ramelteon for Sleep Initiation Insomnia in Individuals With Panic Disorder Who … | Na | Panic Disorder | Terminated | 2008-08-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT01318083 | Efficacy and Safety of Alogliptin Used in Combination With Sulfonylurea in Part… | Phase2 | Type 2 Diabetes Mellitus | Completed | 2008-08-01 | 2009-04-01 | ClinicalTrials.gov |
| NCT01318109 | Efficacy and Safety of Alogliptin Used Combination With Metformin in Participan… | Phase2 | Type 2 Diabetes Mellitus | Completed | 2008-08-01 | 2009-04-01 | ClinicalTrials.gov |
| NCT00770640 | Efficacy of Pioglitazone and Insulin in Treating Subjects With Type 2 Diabetes … | Phase2 | Diabetes Mellitus | Completed | 2008-08-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT00735709 | Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Dis… | Phase3 | Major Depressive Disorder | Completed | 2008-08-01 | 2009-08-01 | ClinicalTrials.gov |
| NCT00746239 | Ramelteon for Sleep Initiation Insomnia in Individuals With Panic Disorder Who … | Na | Panic Disorder | Terminated | 2008-08-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT00880906 | Study of the Efficiency of Esophageal Dilation on Patient With Eosinophilic Eso… | Na | Suspected Eosinophilic Esophagitis | Completed | 2008-08-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT00697515 | Safety and Efficacy Workplace Environment Study of Lisdexamfetamine Dimesylate … | Phase3 | ADHD | Completed | 2008-07-18 | 2008-12-20 | ClinicalTrials.gov |
| NCT00697515 | Safety and Efficacy Workplace Environment Study of Lisdexamfetamine Dimesylate … | Phase3 | ADHD | Completed | 2008-07-18 | 2008-12-20 | ClinicalTrials.gov |
| NCT00697515 | Safety and Efficacy Workplace Environment Study of Lisdexamfetamine Dimesylate … | Phase3 | ADHD | Completed | 2008-07-18 | 2008-12-20 | ClinicalTrials.gov |
| NCT00697346 | Study of MLN8237 in Participants With Advanced Hematological Malignancies | Phase1 | B-cell Follicular Lymphoma | Completed | 2008-07-11 | 2016-10-19 | ClinicalTrials.gov |
| NCT00697346 | Study of MLN8237 in Participants With Advanced Hematological Malignancies | Phase1 | B-cell Follicular Lymphoma | Completed | 2008-07-11 | 2016-10-19 | ClinicalTrials.gov |
| NCT00697346 | Study of MLN8237 in Participants With Advanced Hematological Malignancies | Phase1 | B-cell Follicular Lymphoma | Completed | 2008-07-11 | 2016-10-19 | ClinicalTrials.gov |
| NCT00724542 | Evaluation of Intervention on Impaired Glucose Tolerance(IGT) in Patients With … | Na | Coronary Heart Disease | Unknown | 2008-07-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT00733356 | The Effects of Vyvanse(TM) on Brain Hemodynamics and Reading | Phase4 | Attention Deficit/Hyperactivity Disorder | Completed | 2008-07-01 | 2009-09-01 | ClinicalTrials.gov |
| NCT00724542 | Evaluation of Intervention on Impaired Glucose Tolerance(IGT) in Patients With … | Na | Coronary Heart Disease | Unknown | 2008-07-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT00722917 | Efficacy and Safety of TAK-379 in Adult Subjects With Type 2 Diabetes Mellitus | Phase2 | Diabetes Mellitus | Terminated | 2008-07-01 | 2009-04-01 | ClinicalTrials.gov |
| NCT00722566 | A Study of Subcutaneous and Intravenous VELCADE in Patients With Previously Tre… | Phase3 | Multiple Myeloma | Completed | 2008-07-01 | 2010-09-01 | ClinicalTrials.gov |
| NCT00722566 | A Study of Subcutaneous and Intravenous VELCADE in Patients With Previously Tre… | Phase3 | Multiple Myeloma | Completed | 2008-07-01 | 2010-09-01 | ClinicalTrials.gov |
| NCT00722917 | Efficacy and Safety of TAK-379 in Adult Subjects With Type 2 Diabetes Mellitus | Phase2 | Diabetes Mellitus | Terminated | 2008-07-01 | 2009-04-01 | ClinicalTrials.gov |
| NCT00724542 | Evaluation of Intervention on Impaired Glucose Tolerance(IGT) in Patients With … | Na | Coronary Heart Disease | Unknown | 2008-07-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT00734877 | UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low R… | Phase3 | Multiple Myeloma | Active_Not_Recruiting | 2008-07-01 | 2028-09-01 | ClinicalTrials.gov |
| NCT00733356 | The Effects of Vyvanse(TM) on Brain Hemodynamics and Reading | Phase4 | Attention Deficit/Hyperactivity Disorder | Completed | 2008-07-01 | 2009-09-01 | ClinicalTrials.gov |
| NCT00722566 | A Study of Subcutaneous and Intravenous VELCADE in Patients With Previously Tre… | Phase3 | Multiple Myeloma | Completed | 2008-07-01 | 2010-09-01 | ClinicalTrials.gov |
| NCT00722917 | Efficacy and Safety of TAK-379 in Adult Subjects With Type 2 Diabetes Mellitus | Phase2 | Diabetes Mellitus | Terminated | 2008-07-01 | 2009-04-01 | ClinicalTrials.gov |
| NCT00706004 | Short Term Safety and Efficacy of Lubiprostone in Adults With Cystic Fibrosis | Na | Constipation | Completed | 2008-07-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT00733356 | The Effects of Vyvanse(TM) on Brain Hemodynamics and Reading | Phase4 | Attention Deficit/Hyperactivity Disorder | Completed | 2008-07-01 | 2009-09-01 | ClinicalTrials.gov |
| NCT00706004 | Short Term Safety and Efficacy of Lubiprostone in Adults With Cystic Fibrosis | Na | Constipation | Completed | 2008-07-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT00734877 | UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low R… | Phase3 | Multiple Myeloma | Active_Not_Recruiting | 2008-07-01 | 2028-09-01 | ClinicalTrials.gov |
| NCT00706004 | Short Term Safety and Efficacy of Lubiprostone in Adults With Cystic Fibrosis | Na | Constipation | Completed | 2008-07-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT00734877 | UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low R… | Phase3 | Multiple Myeloma | Active_Not_Recruiting | 2008-07-01 | 2028-09-01 | ClinicalTrials.gov |
| NCT00734071 | An Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Treating Generaliz… | Phase3 | Generalized Anxiety Disorder | Completed | 2008-06-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00680043 | Safety & Efficacy of Peginesatide for Treatment of Anemia in Participants on Di… | Phase2 | Anemia | Completed | 2008-06-01 | 2009-08-01 | ClinicalTrials.gov |
| NCT00633594 | Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma | Phase1 | Mantle Cell Lymphoma | Completed | 2008-06-01 | 2016-11-01 | ClinicalTrials.gov |
| NCT00745030 | Efficacy and Tolerability of Ramelteon in Patients With Rapid Eye Movement (REM… | Na | REM Behavior Disorder | Terminated | 2008-06-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT00734071 | An Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Treating Generaliz… | Phase3 | Generalized Anxiety Disorder | Completed | 2008-06-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00731120 | Study of Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Generaliz… | Phase3 | Generalized Anxiety Disorder | Completed | 2008-06-01 | 2009-02-01 | ClinicalTrials.gov |
| NCT00730691 | Efficacy of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder | Phase3 | Generalized Anxiety Disorder | Completed | 2008-06-01 | 2009-02-01 | ClinicalTrials.gov |
| NCT00722722 | The Impact of Velcade(TM)on Antibody Secreting Cells in Sensitized Renal Allogr… | Phase2 | Kidney Transplantation | Completed | 2008-06-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT00722488 | Study of MLN4924, a Novel Inhibitor of Nedd8 Activating Enzyme, in Adult Patien… | Phase1 | Hematologic Malignancies | Completed | 2008-06-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT00707993 | Efficacy and Safety of Alogliptin Compared to Glipizide in Elderly Diabetics | Phase3 | Diabetes Mellitus | Completed | 2008-06-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT00707980 | Safety and Tolerability of Vortioxetine (Lu AA21004) in Adults With Major Depre… | Phase3 | Major Depressive Disorder | Completed | 2008-06-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT00680043 | Safety & Efficacy of Peginesatide for Treatment of Anemia in Participants on Di… | Phase2 | Anemia | Completed | 2008-06-01 | 2009-08-01 | ClinicalTrials.gov |
| NCT00633594 | Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma | Phase1 | Mantle Cell Lymphoma | Completed | 2008-06-01 | 2016-11-01 | ClinicalTrials.gov |
| NCT00745030 | Efficacy and Tolerability of Ramelteon in Patients With Rapid Eye Movement (REM… | Na | REM Behavior Disorder | Terminated | 2008-06-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT00745030 | Efficacy and Tolerability of Ramelteon in Patients With Rapid Eye Movement (REM… | Na | REM Behavior Disorder | Terminated | 2008-06-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT00731120 | Study of Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Generaliz… | Phase3 | Generalized Anxiety Disorder | Completed | 2008-06-01 | 2009-02-01 | ClinicalTrials.gov |
| NCT00730691 | Efficacy of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder | Phase3 | Generalized Anxiety Disorder | Completed | 2008-06-01 | 2009-02-01 | ClinicalTrials.gov |
| NCT00722722 | The Impact of Velcade(TM)on Antibody Secreting Cells in Sensitized Renal Allogr… | Phase2 | Kidney Transplantation | Completed | 2008-06-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT00722488 | Study of MLN4924, a Novel Inhibitor of Nedd8 Activating Enzyme, in Adult Patien… | Phase1 | Hematologic Malignancies | Completed | 2008-06-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT00707993 | Efficacy and Safety of Alogliptin Compared to Glipizide in Elderly Diabetics | Phase3 | Diabetes Mellitus | Completed | 2008-06-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT00707980 | Safety and Tolerability of Vortioxetine (Lu AA21004) in Adults With Major Depre… | Phase3 | Major Depressive Disorder | Completed | 2008-06-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT00680043 | Safety & Efficacy of Peginesatide for Treatment of Anemia in Participants on Di… | Phase2 | Anemia | Completed | 2008-06-01 | 2009-08-01 | ClinicalTrials.gov |
| NCT00734071 | An Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Treating Generaliz… | Phase3 | Generalized Anxiety Disorder | Completed | 2008-06-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00633594 | Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma | Phase1 | Mantle Cell Lymphoma | Completed | 2008-06-01 | 2016-11-01 | ClinicalTrials.gov |
| NCT00731120 | Study of Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Generaliz… | Phase3 | Generalized Anxiety Disorder | Completed | 2008-06-01 | 2009-02-01 | ClinicalTrials.gov |
| NCT00730691 | Efficacy of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder | Phase3 | Generalized Anxiety Disorder | Completed | 2008-06-01 | 2009-02-01 | ClinicalTrials.gov |
| NCT00722722 | The Impact of Velcade(TM)on Antibody Secreting Cells in Sensitized Renal Allogr… | Phase2 | Kidney Transplantation | Completed | 2008-06-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT00722488 | Study of MLN4924, a Novel Inhibitor of Nedd8 Activating Enzyme, in Adult Patien… | Phase1 | Hematologic Malignancies | Completed | 2008-06-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT00707993 | Efficacy and Safety of Alogliptin Compared to Glipizide in Elderly Diabetics | Phase3 | Diabetes Mellitus | Completed | 2008-06-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT00707980 | Safety and Tolerability of Vortioxetine (Lu AA21004) in Adults With Major Depre… | Phase3 | Major Depressive Disorder | Completed | 2008-06-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT00670423 | A Study Using Tacrolimus, Sirolimus and Bortezomib as Acute Graft Versus Host D… | Phase1 | Graft vs Host Disease | Completed | 2008-05-16 | 2013-10-16 | ClinicalTrials.gov |
| NCT00670423 | A Study Using Tacrolimus, Sirolimus and Bortezomib as Acute Graft Versus Host D… | Phase1 | Graft vs Host Disease | Completed | 2008-05-16 | 2013-10-16 | ClinicalTrials.gov |
| NCT00670423 | A Study Using Tacrolimus, Sirolimus and Bortezomib as Acute Graft Versus Host D… | Phase1 | Graft vs Host Disease | Completed | 2008-05-16 | 2013-10-16 | ClinicalTrials.gov |
| NCT00689026 | Efficacy of Lubiprostone in Combination With Standard PEG Preparation | Na | Diabetes Mellitus, Type 1 | Terminated | 2008-05-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00611325 | Phase II Avastin + Bortezomib for Patients With Recurrent Malignant Glioma | Phase2 | Glioblastoma | Completed | 2008-05-01 | 2013-10-01 | ClinicalTrials.gov |
| NCT00722137 | Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, … | Phase3 | Mantle Cell Lymphoma | Completed | 2008-05-01 | 2017-06-17 | ClinicalTrials.gov |
| NCT00611325 | Phase II Avastin + Bortezomib for Patients With Recurrent Malignant Glioma | Phase2 | Glioblastoma | Completed | 2008-05-01 | 2013-10-01 | ClinicalTrials.gov |
| NCT00708175 | Efficacy of Pioglitazone on Bone Metabolism in Postmenopausal Women With Impair… | Phase4 | Bone Metabolism | Completed | 2008-05-01 | 2011-02-01 | ClinicalTrials.gov |
| NCT00722137 | Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, … | Phase3 | Mantle Cell Lymphoma | Completed | 2008-05-01 | 2017-06-17 | ClinicalTrials.gov |
| NCT01165190 | Effect of Pioglitazone on Mitochondrial Function in Muscle and Adipose Tissue i… | — | Type II Diabetes Mellitus | Completed | 2008-05-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT01165190 | Effect of Pioglitazone on Mitochondrial Function in Muscle and Adipose Tissue i… | — | Type II Diabetes Mellitus | Completed | 2008-05-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT00656864 | Pioglitazone Incretin Study | Phase4 | Diabetes Mellitus, Type 2 | Completed | 2008-05-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT00688025 | Magnetoencephalographic (MEG) Localization of Ramelteon's Effects on Brain Func… | — | Insomnia | Completed | 2008-05-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT01318122 | Long-term Safety Study of Alogliptin Used in Combination With Thiazolidine in P… | Phase2 | Type 2 Diabetes Mellitus | Completed | 2008-05-01 | 2009-08-01 | ClinicalTrials.gov |
| NCT00722137 | Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, … | Phase3 | Mantle Cell Lymphoma | Completed | 2008-05-01 | 2017-06-17 | ClinicalTrials.gov |
| NCT00689026 | Efficacy of Lubiprostone in Combination With Standard PEG Preparation | Na | Diabetes Mellitus, Type 1 | Terminated | 2008-05-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT01318122 | Long-term Safety Study of Alogliptin Used in Combination With Thiazolidine in P… | Phase2 | Type 2 Diabetes Mellitus | Completed | 2008-05-01 | 2009-08-01 | ClinicalTrials.gov |
| NCT00708175 | Efficacy of Pioglitazone on Bone Metabolism in Postmenopausal Women With Impair… | Phase4 | Bone Metabolism | Completed | 2008-05-01 | 2011-02-01 | ClinicalTrials.gov |
| NCT00656864 | Pioglitazone Incretin Study | Phase4 | Diabetes Mellitus, Type 2 | Completed | 2008-05-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT01165190 | Effect of Pioglitazone on Mitochondrial Function in Muscle and Adipose Tissue i… | — | Type II Diabetes Mellitus | Completed | 2008-05-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT01318122 | Long-term Safety Study of Alogliptin Used in Combination With Thiazolidine in P… | Phase2 | Type 2 Diabetes Mellitus | Completed | 2008-05-01 | 2009-08-01 | ClinicalTrials.gov |
| NCT00708175 | Efficacy of Pioglitazone on Bone Metabolism in Postmenopausal Women With Impair… | Phase4 | Bone Metabolism | Completed | 2008-05-01 | 2011-02-01 | ClinicalTrials.gov |
| NCT00689026 | Efficacy of Lubiprostone in Combination With Standard PEG Preparation | Na | Diabetes Mellitus, Type 1 | Terminated | 2008-05-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00770445 | Efficacy of Pioglitazone and Metformin on Cardiovascular Risk in Subjects With … | Phase4 | Diabetes Mellitus | Completed | 2008-05-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT00688025 | Magnetoencephalographic (MEG) Localization of Ramelteon's Effects on Brain Func… | — | Insomnia | Completed | 2008-05-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00770445 | Efficacy of Pioglitazone and Metformin on Cardiovascular Risk in Subjects With … | Phase4 | Diabetes Mellitus | Completed | 2008-05-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT00611325 | Phase II Avastin + Bortezomib for Patients With Recurrent Malignant Glioma | Phase2 | Glioblastoma | Completed | 2008-05-01 | 2013-10-01 | ClinicalTrials.gov |
| NCT00688025 | Magnetoencephalographic (MEG) Localization of Ramelteon's Effects on Brain Func… | — | Insomnia | Completed | 2008-05-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00770445 | Efficacy of Pioglitazone and Metformin on Cardiovascular Risk in Subjects With … | Phase4 | Diabetes Mellitus | Completed | 2008-05-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT00656864 | Pioglitazone Incretin Study | Phase4 | Diabetes Mellitus, Type 2 | Completed | 2008-05-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT00664066 | DELFT (Dynepo Evaluation of Long-Term Follow-Up Treatment) | — | Anemia | Terminated | 2008-04-25 | 2008-07-30 | ClinicalTrials.gov |
| NCT00664066 | DELFT (Dynepo Evaluation of Long-Term Follow-Up Treatment) | — | Anemia | Terminated | 2008-04-25 | 2008-07-30 | ClinicalTrials.gov |
| NCT00664066 | DELFT (Dynepo Evaluation of Long-Term Follow-Up Treatment) | — | Anemia | Terminated | 2008-04-25 | 2008-07-30 | ClinicalTrials.gov |
| NCT00672984 | Guanfacine Immediate-release Electrocardiogram Results (QTc) Study | Phase1 | Healthy Volunteers | Completed | 2008-04-18 | 2008-08-07 | ClinicalTrials.gov |
| NCT00672984 | Guanfacine Immediate-release Electrocardiogram Results (QTc) Study | Phase1 | Healthy Volunteers | Completed | 2008-04-18 | 2008-08-07 | ClinicalTrials.gov |
| NCT00672984 | Guanfacine Immediate-release Electrocardiogram Results (QTc) Study | Phase1 | Healthy Volunteers | Completed | 2008-04-18 | 2008-08-07 | ClinicalTrials.gov |
| NCT00619125 | Proposal Evaluating Time-specific Relationships Between Variables of Pain, Stre… | — | IBS, Diarrhea Predominant | Completed | 2008-04-01 | 2009-04-01 | ClinicalTrials.gov |
| NCT00624936 | Azacytidine and Bortezomib in Treating Patients With Relapsed or Refractory Acu… | Phase1 | Leukemia | Completed | 2008-04-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT00619125 | Proposal Evaluating Time-specific Relationships Between Variables of Pain, Stre… | — | IBS, Diarrhea Predominant | Completed | 2008-04-01 | 2009-04-01 | ClinicalTrials.gov |
| NCT00662363 | Lubiprostone (Amitiza®) Vs. Standard Care in Opioid-induced Constipation After … | Na | Constipation | Completed | 2008-04-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT00672958 | Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Adults With Major … | Phase3 | Major Depressive Disorder | Completed | 2008-04-01 | 2008-11-01 | ClinicalTrials.gov |
| NCT00644696 | Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neurob… | Phase1 | Neuroblastoma | Completed | 2008-04-01 | 2012-07-01 | ClinicalTrials.gov |
| NCT01156597 | Effects of Pioglitazone on High-density Lipoprotein (HDL) Function in Persons W… | Phase3 | Type 2 Diabetes Mellitus | Completed | 2008-04-01 | 2010-09-01 | ClinicalTrials.gov |
| NCT00672620 | Efficacy and Safety of Vortioxetine (Lu AA21004) in the Treatment of Patients W… | Phase3 | Major Depressive Disorder | Completed | 2008-04-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00696436 | An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and … | Phase3 | Hypertension | Completed | 2008-04-01 | 2009-08-01 | ClinicalTrials.gov |
| NCT00677170 | Study of MLN4924 in Adult Patients With Nonhematologic Malignancies | Phase1 | Advanced Nonhematologic Malignancies | Completed | 2008-04-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT00672958 | Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Adults With Major … | Phase3 | Major Depressive Disorder | Completed | 2008-04-01 | 2008-11-01 | ClinicalTrials.gov |
| NCT00672620 | Efficacy and Safety of Vortioxetine (Lu AA21004) in the Treatment of Patients W… | Phase3 | Major Depressive Disorder | Completed | 2008-04-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00644696 | Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neurob… | Phase1 | Neuroblastoma | Completed | 2008-04-01 | 2012-07-01 | ClinicalTrials.gov |
| NCT00672620 | Efficacy and Safety of Vortioxetine (Lu AA21004) in the Treatment of Patients W… | Phase3 | Major Depressive Disorder | Completed | 2008-04-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00624936 | Azacytidine and Bortezomib in Treating Patients With Relapsed or Refractory Acu… | Phase1 | Leukemia | Completed | 2008-04-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT00569153 | Safety Study of TAK-700 in Subjects With Prostate Cancer. | Phase1 | Prostatic Neoplasms | Completed | 2008-04-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT00807222 | Effect of Vyvanse on Sleep in Children Aged 6-12 Years With Attention Deficit H… | Na | Attention Deficit Hyperactivity Disorder | Completed | 2008-04-01 | 2008-08-01 | ClinicalTrials.gov |
| NCT00671515 | Pioglitazone for the Treatment of Major Depressive Disorder Comorbid With Metab… | Phase2 | Depressive Disorder, Major | Completed | 2008-04-01 | 2011-11-01 | ClinicalTrials.gov |
| NCT00672958 | Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Adults With Major … | Phase3 | Major Depressive Disorder | Completed | 2008-04-01 | 2008-11-01 | ClinicalTrials.gov |
| NCT00569153 | Safety Study of TAK-700 in Subjects With Prostate Cancer. | Phase1 | Prostatic Neoplasms | Completed | 2008-04-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT00677170 | Study of MLN4924 in Adult Patients With Nonhematologic Malignancies | Phase1 | Advanced Nonhematologic Malignancies | Completed | 2008-04-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT00807222 | Effect of Vyvanse on Sleep in Children Aged 6-12 Years With Attention Deficit H… | Na | Attention Deficit Hyperactivity Disorder | Completed | 2008-04-01 | 2008-08-01 | ClinicalTrials.gov |
| NCT00696436 | An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and … | Phase3 | Hypertension | Completed | 2008-04-01 | 2009-08-01 | ClinicalTrials.gov |
| NCT00677170 | Study of MLN4924 in Adult Patients With Nonhematologic Malignancies | Phase1 | Advanced Nonhematologic Malignancies | Completed | 2008-04-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT00739024 | A Study of a Melatonin Receptor Agonist to Prevent Migraine | Phase2 | Migraine | Terminated | 2008-04-01 | 2010-09-01 | ClinicalTrials.gov |
| NCT00746395 | Randomized, Placebo-controlled Trial of Lubiprostone as a Preparation for Capsu… | Phase4 | Inflammatory Bowel Disease | Completed | 2008-04-01 | 2008-09-01 | ClinicalTrials.gov |
| NCT00662363 | Lubiprostone (Amitiza®) Vs. Standard Care in Opioid-induced Constipation After … | Na | Constipation | Completed | 2008-04-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT00644696 | Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neurob… | Phase1 | Neuroblastoma | Completed | 2008-04-01 | 2012-07-01 | ClinicalTrials.gov |
| NCT00619125 | Proposal Evaluating Time-specific Relationships Between Variables of Pain, Stre… | — | IBS, Diarrhea Predominant | Completed | 2008-04-01 | 2009-04-01 | ClinicalTrials.gov |
| NCT00753012 | Cardiovascular Study of Lisdexamfetamine in Healthy and Hypertensive Attention … | Phase4 | Attention Deficit Hyperactivity Disorder (ADHD) | Completed | 2008-04-01 | 2011-03-01 | ClinicalTrials.gov |
| NCT00671515 | Pioglitazone for the Treatment of Major Depressive Disorder Comorbid With Metab… | Phase2 | Depressive Disorder, Major | Completed | 2008-04-01 | 2011-11-01 | ClinicalTrials.gov |
| NCT01156597 | Effects of Pioglitazone on High-density Lipoprotein (HDL) Function in Persons W… | Phase3 | Type 2 Diabetes Mellitus | Completed | 2008-04-01 | 2010-09-01 | ClinicalTrials.gov |
| NCT00696436 | An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and … | Phase3 | Hypertension | Completed | 2008-04-01 | 2009-08-01 | ClinicalTrials.gov |
| NCT01156597 | Effects of Pioglitazone on High-density Lipoprotein (HDL) Function in Persons W… | Phase3 | Type 2 Diabetes Mellitus | Completed | 2008-04-01 | 2010-09-01 | ClinicalTrials.gov |
| NCT00671515 | Pioglitazone for the Treatment of Major Depressive Disorder Comorbid With Metab… | Phase2 | Depressive Disorder, Major | Completed | 2008-04-01 | 2011-11-01 | ClinicalTrials.gov |
| NCT00569153 | Safety Study of TAK-700 in Subjects With Prostate Cancer. | Phase1 | Prostatic Neoplasms | Completed | 2008-04-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT00739024 | A Study of a Melatonin Receptor Agonist to Prevent Migraine | Phase2 | Migraine | Terminated | 2008-04-01 | 2010-09-01 | ClinicalTrials.gov |
| NCT00753012 | Cardiovascular Study of Lisdexamfetamine in Healthy and Hypertensive Attention … | Phase4 | Attention Deficit Hyperactivity Disorder (ADHD) | Completed | 2008-04-01 | 2011-03-01 | ClinicalTrials.gov |
| NCT00746395 | Randomized, Placebo-controlled Trial of Lubiprostone as a Preparation for Capsu… | Phase4 | Inflammatory Bowel Disease | Completed | 2008-04-01 | 2008-09-01 | ClinicalTrials.gov |
| NCT00807222 | Effect of Vyvanse on Sleep in Children Aged 6-12 Years With Attention Deficit H… | Na | Attention Deficit Hyperactivity Disorder | Completed | 2008-04-01 | 2008-08-01 | ClinicalTrials.gov |
| NCT00753012 | Cardiovascular Study of Lisdexamfetamine in Healthy and Hypertensive Attention … | Phase4 | Attention Deficit Hyperactivity Disorder (ADHD) | Completed | 2008-04-01 | 2011-03-01 | ClinicalTrials.gov |
| NCT00662363 | Lubiprostone (Amitiza®) Vs. Standard Care in Opioid-induced Constipation After … | Na | Constipation | Completed | 2008-04-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT00746395 | Randomized, Placebo-controlled Trial of Lubiprostone as a Preparation for Capsu… | Phase4 | Inflammatory Bowel Disease | Completed | 2008-04-01 | 2008-09-01 | ClinicalTrials.gov |
| NCT00624936 | Azacytidine and Bortezomib in Treating Patients With Relapsed or Refractory Acu… | Phase1 | Leukemia | Completed | 2008-04-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT00739024 | A Study of a Melatonin Receptor Agonist to Prevent Migraine | Phase2 | Migraine | Terminated | 2008-04-01 | 2010-09-01 | ClinicalTrials.gov |
| NCT00635427 | An Open-Label Extension Study of GA-GCB ERT in Patients With Type 1 Gaucher Dis… | Phase3 | Gaucher Disease, Type 1 | Completed | 2008-03-13 | 2012-12-28 | ClinicalTrials.gov |
| NCT00635427 | An Open-Label Extension Study of GA-GCB ERT in Patients With Type 1 Gaucher Dis… | Phase3 | Gaucher Disease, Type 1 | Completed | 2008-03-13 | 2012-12-28 | ClinicalTrials.gov |
| NCT00635427 | An Open-Label Extension Study of GA-GCB ERT in Patients With Type 1 Gaucher Dis… | Phase3 | Gaucher Disease, Type 1 | Completed | 2008-03-13 | 2012-12-28 | ClinicalTrials.gov |
| NCT00677053 | Safety and Efficacy of TAK-442 in Subjects With Acute Coronary Syndromes | Phase2 | Acute Coronary Syndrome | Completed | 2008-03-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT00869167 | Ramelteon for Insomnia Comorbid With Asthma | Phase3 | Insomnia | Terminated | 2008-03-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT00627016 | A Study of Dexlansoprazole Modified Release Formulation to Treat Night Heartburn | Phase3 | Gastroesophageal Reflux | Completed | 2008-03-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00307268 | Evaluating Clinical Outcomes of Treatment Effectiveness for Children and Adults… | — | Attention-Deficit/Hyperactivity Disorder (ADHD) | Completed | 2008-03-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT00645801 | Amitiza® Plus GoLYTELY® (PEG) Versus Placebo Plus GoLYTELY® for Outpatient Colo… | Phase4 | Colonoscopy | Completed | 2008-03-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT03768258 | Testosterone Implants and the Incidence of Breast Cancer | — | Breast Cancer | Completed | 2008-03-01 | 2018-12-01 | ClinicalTrials.gov |
| NCT03768258 | Testosterone Implants and the Incidence of Breast Cancer | — | Breast Cancer | Completed | 2008-03-01 | 2018-12-01 | ClinicalTrials.gov |
| NCT00645801 | Amitiza® Plus GoLYTELY® (PEG) Versus Placebo Plus GoLYTELY® for Outpatient Colo… | Phase4 | Colonoscopy | Completed | 2008-03-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT00307268 | Evaluating Clinical Outcomes of Treatment Effectiveness for Children and Adults… | — | Attention-Deficit/Hyperactivity Disorder (ADHD) | Completed | 2008-03-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT00627016 | A Study of Dexlansoprazole Modified Release Formulation to Treat Night Heartburn | Phase3 | Gastroesophageal Reflux | Completed | 2008-03-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00677053 | Safety and Efficacy of TAK-442 in Subjects With Acute Coronary Syndromes | Phase2 | Acute Coronary Syndrome | Completed | 2008-03-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT00869167 | Ramelteon for Insomnia Comorbid With Asthma | Phase3 | Insomnia | Terminated | 2008-03-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT00869167 | Ramelteon for Insomnia Comorbid With Asthma | Phase3 | Insomnia | Terminated | 2008-03-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT00677053 | Safety and Efficacy of TAK-442 in Subjects With Acute Coronary Syndromes | Phase2 | Acute Coronary Syndrome | Completed | 2008-03-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT00627016 | A Study of Dexlansoprazole Modified Release Formulation to Treat Night Heartburn | Phase3 | Gastroesophageal Reflux | Completed | 2008-03-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00307268 | Evaluating Clinical Outcomes of Treatment Effectiveness for Children and Adults… | — | Attention-Deficit/Hyperactivity Disorder (ADHD) | Completed | 2008-03-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT00645801 | Amitiza® Plus GoLYTELY® (PEG) Versus Placebo Plus GoLYTELY® for Outpatient Colo… | Phase4 | Colonoscopy | Completed | 2008-03-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT03768258 | Testosterone Implants and the Incidence of Breast Cancer | — | Breast Cancer | Completed | 2008-03-01 | 2018-12-01 | ClinicalTrials.gov |
| NCT00681811 | Open-Label Extension Study of Recombinant Human Arylsulfatase A (HGT-1111) in L… | Phase2 | Late Infantile Metachromatic Leukodystrophy | Terminated | 2008-02-20 | 2010-10-22 | ClinicalTrials.gov |
| NCT00681811 | Open-Label Extension Study of Recombinant Human Arylsulfatase A (HGT-1111) in L… | Phase2 | Late Infantile Metachromatic Leukodystrophy | Terminated | 2008-02-20 | 2010-10-22 | ClinicalTrials.gov |
| NCT00681811 | Open-Label Extension Study of Recombinant Human Arylsulfatase A (HGT-1111) in L… | Phase2 | Late Infantile Metachromatic Leukodystrophy | Terminated | 2008-02-20 | 2010-10-22 | ClinicalTrials.gov |
| NCT00633477 | Efficacy and Safety of Resatorvid in Patients With Sepsis-induced Cardiovascula… | Phase3 | Sepsis | Terminated | 2008-02-01 | 2009-02-01 | ClinicalTrials.gov |
| NCT00622427 | Ramelteon for Treatment of Adult Patients With ADHD-Related Insomnia | Phase4 | ADHD With Sleep Onset Insomnia | Completed | 2008-02-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT00634179 | A Phase I/II Trial of VR-CHOP in Lymphoma Patients | Phase1 | Lymphoma, B-Cell | Completed | 2008-02-01 | 2015-11-01 | ClinicalTrials.gov |
| NCT00636792 | A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and R… | Phase2 | Follicular Lymphoma | Completed | 2008-02-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT01166789 | Lubiprostone Effects on Visceral Pain Sensitivity | Phase1 | Irritable Bowel Syndrome | Completed | 2008-02-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT01166789 | Lubiprostone Effects on Visceral Pain Sensitivity | Phase1 | Irritable Bowel Syndrome | Completed | 2008-02-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT00720148 | A Phase I Trial of Bortezomib and Sunitinib | Phase1 | Solid Tumors | Completed | 2008-02-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT00720148 | A Phase I Trial of Bortezomib and Sunitinib | Phase1 | Solid Tumors | Completed | 2008-02-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT01166802 | Development of a Questionnaire to Measure Hypervigilance for Visceral Pain | — | Irritable Bowel Syndrome | Completed | 2008-02-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT01166789 | Lubiprostone Effects on Visceral Pain Sensitivity | Phase1 | Irritable Bowel Syndrome | Completed | 2008-02-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT00636792 | A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and R… | Phase2 | Follicular Lymphoma | Completed | 2008-02-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT00634179 | A Phase I/II Trial of VR-CHOP in Lymphoma Patients | Phase1 | Lymphoma, B-Cell | Completed | 2008-02-01 | 2015-11-01 | ClinicalTrials.gov |
| NCT01166802 | Development of a Questionnaire to Measure Hypervigilance for Visceral Pain | — | Irritable Bowel Syndrome | Completed | 2008-02-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT01166802 | Development of a Questionnaire to Measure Hypervigilance for Visceral Pain | — | Irritable Bowel Syndrome | Completed | 2008-02-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT00720148 | A Phase I Trial of Bortezomib and Sunitinib | Phase1 | Solid Tumors | Completed | 2008-02-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT00622427 | Ramelteon for Treatment of Adult Patients With ADHD-Related Insomnia | Phase4 | ADHD With Sleep Onset Insomnia | Completed | 2008-02-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT00633477 | Efficacy and Safety of Resatorvid in Patients With Sepsis-induced Cardiovascula… | Phase3 | Sepsis | Terminated | 2008-02-01 | 2009-02-01 | ClinicalTrials.gov |
| NCT00636792 | A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and R… | Phase2 | Follicular Lymphoma | Completed | 2008-02-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT00634179 | A Phase I/II Trial of VR-CHOP in Lymphoma Patients | Phase1 | Lymphoma, B-Cell | Completed | 2008-02-01 | 2015-11-01 | ClinicalTrials.gov |
| NCT00633477 | Efficacy and Safety of Resatorvid in Patients With Sepsis-induced Cardiovascula… | Phase3 | Sepsis | Terminated | 2008-02-01 | 2009-02-01 | ClinicalTrials.gov |
| NCT00622427 | Ramelteon for Treatment of Adult Patients With ADHD-Related Insomnia | Phase4 | ADHD With Sleep Onset Insomnia | Completed | 2008-02-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT00553631 | Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) ERT Compared With Im… | Phase3 | Gaucher Disease, Type 1 | Completed | 2008-01-29 | 2009-05-05 | ClinicalTrials.gov |
| NCT00553631 | Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) ERT Compared With Im… | Phase3 | Gaucher Disease, Type 1 | Completed | 2008-01-29 | 2009-05-05 | ClinicalTrials.gov |
| NCT00553631 | Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) ERT Compared With Im… | Phase3 | Gaucher Disease, Type 1 | Completed | 2008-01-29 | 2009-05-05 | ClinicalTrials.gov |
| NCT00738725 | BioImage Study: A Clinical Study of Burden of Atherosclerotic Disease in an At-… | — | Plaque | Completed | 2008-01-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT00760214 | Efficacy and Safety Study of Azilsartan Medoxomil Compared to Ramipril for Trea… | Phase3 | Hypertension | Completed | 2008-01-01 | 2009-04-01 | ClinicalTrials.gov |
| NCT00679640 | Observational Usage and Efficacy Study of Candesartan in Heart Failure Treatmen… | — | Heart Failure | Completed | 2008-01-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT01418781 | CLinical Prediction Rule Score in Veterans | — | Gout | Withdrawn | 2008-01-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00595504 | Ramelteon as an Adjunct Therapy in Non-Diabetic Patients With Schizophrenia | Phase4 | Schizophrenia | Completed | 2008-01-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00629876 | A Safety and Tolerability Study of Peginesatide in Anemic Cancer Patients Recei… | Phase1 | Anemia | Terminated | 2008-01-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00631631 | Mifamurtide (L-MTP-PE) for High-Risk Osteosarcoma | — | Osteosarcoma | Completed | 2008-01-01 | 2012-10-01 | ClinicalTrials.gov |
| NCT00595504 | Ramelteon as an Adjunct Therapy in Non-Diabetic Patients With Schizophrenia | Phase4 | Schizophrenia | Completed | 2008-01-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00660530 | Chewed vs. Crushed Lanthanum Carbonate in Hemodialysis Patients | Phase2 | Hyperphosphatemia | Completed | 2008-01-01 | 2009-11-01 | ClinicalTrials.gov |
| NCT00629876 | A Safety and Tolerability Study of Peginesatide in Anemic Cancer Patients Recei… | Phase1 | Anemia | Terminated | 2008-01-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00631631 | Mifamurtide (L-MTP-PE) for High-Risk Osteosarcoma | — | Osteosarcoma | Completed | 2008-01-01 | 2012-10-01 | ClinicalTrials.gov |
| NCT00679640 | Observational Usage and Efficacy Study of Candesartan in Heart Failure Treatmen… | — | Heart Failure | Completed | 2008-01-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT00660530 | Chewed vs. Crushed Lanthanum Carbonate in Hemodialysis Patients | Phase2 | Hyperphosphatemia | Completed | 2008-01-01 | 2009-11-01 | ClinicalTrials.gov |
| NCT00775840 | Efficacy of Candesartan on Symptomatic Heart Failure in Treating Diabetic and H… | Phase3 | Heart Failure | Completed | 2008-01-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00679640 | Observational Usage and Efficacy Study of Candesartan in Heart Failure Treatmen… | — | Heart Failure | Completed | 2008-01-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT00738725 | BioImage Study: A Clinical Study of Burden of Atherosclerotic Disease in an At-… | — | Plaque | Completed | 2008-01-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT00760214 | Efficacy and Safety Study of Azilsartan Medoxomil Compared to Ramipril for Trea… | Phase3 | Hypertension | Completed | 2008-01-01 | 2009-04-01 | ClinicalTrials.gov |
| NCT01418781 | CLinical Prediction Rule Score in Veterans | — | Gout | Withdrawn | 2008-01-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00775840 | Efficacy of Candesartan on Symptomatic Heart Failure in Treating Diabetic and H… | Phase3 | Heart Failure | Completed | 2008-01-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00660530 | Chewed vs. Crushed Lanthanum Carbonate in Hemodialysis Patients | Phase2 | Hyperphosphatemia | Completed | 2008-01-01 | 2009-11-01 | ClinicalTrials.gov |
| NCT01418781 | CLinical Prediction Rule Score in Veterans | — | Gout | Withdrawn | 2008-01-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00760214 | Efficacy and Safety Study of Azilsartan Medoxomil Compared to Ramipril for Trea… | Phase3 | Hypertension | Completed | 2008-01-01 | 2009-04-01 | ClinicalTrials.gov |
| NCT00631631 | Mifamurtide (L-MTP-PE) for High-Risk Osteosarcoma | — | Osteosarcoma | Completed | 2008-01-01 | 2012-10-01 | ClinicalTrials.gov |
| NCT00629876 | A Safety and Tolerability Study of Peginesatide in Anemic Cancer Patients Recei… | Phase1 | Anemia | Terminated | 2008-01-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00775840 | Efficacy of Candesartan on Symptomatic Heart Failure in Treating Diabetic and H… | Phase3 | Heart Failure | Completed | 2008-01-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00738725 | BioImage Study: A Clinical Study of Burden of Atherosclerotic Disease in an At-… | — | Plaque | Completed | 2008-01-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT00595504 | Ramelteon as an Adjunct Therapy in Non-Diabetic Patients With Schizophrenia | Phase4 | Schizophrenia | Completed | 2008-01-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00607386 | Safety and Clinical Outcomes in Hunter Syndrome Patients 5 Years of Age and You… | Phase4 | Hunter Syndrome | Completed | 2007-12-31 | 2011-07-08 | ClinicalTrials.gov |
| NCT00607386 | Safety and Clinical Outcomes in Hunter Syndrome Patients 5 Years of Age and You… | Phase4 | Hunter Syndrome | Completed | 2007-12-31 | 2011-07-08 | ClinicalTrials.gov |
| NCT00607386 | Safety and Clinical Outcomes in Hunter Syndrome Patients 5 Years of Age and You… | Phase4 | Hunter Syndrome | Completed | 2007-12-31 | 2011-07-08 | ClinicalTrials.gov |
| NCT00585208 | Add-On Ramelteon in Bipolar I Disorder With Clinically Significant Sleep Distur… | Phase3 | Insomnia | Terminated | 2007-12-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT00595075 | Ramelteon for a Nap Prior to a Night Shift | Na | Healthy | Completed | 2007-12-01 | 2008-11-01 | ClinicalTrials.gov |
| NCT00595075 | Ramelteon for a Nap Prior to a Night Shift | Na | Healthy | Completed | 2007-12-01 | 2008-11-01 | ClinicalTrials.gov |
| NCT00591578 | Efficacy and Safety Comparison of Azilsartan Medoxomil to Valsartan in Particip… | Phase3 | Hypertension | Completed | 2007-12-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00619489 | Long Term Safety of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis a… | Phase2 | Ulcerative Colitis | Completed | 2007-12-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00585208 | Add-On Ramelteon in Bipolar I Disorder With Clinically Significant Sleep Distur… | Phase3 | Insomnia | Terminated | 2007-12-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT00619489 | Long Term Safety of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis a… | Phase2 | Ulcerative Colitis | Completed | 2007-12-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00736255 | Attention Deficit Hyperactivity Disorder (ADHD) Smoking Cessation Study | Na | Attention Deficit Hyperactivity Disorder | Completed | 2007-12-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT00591578 | Efficacy and Safety Comparison of Azilsartan Medoxomil to Valsartan in Particip… | Phase3 | Hypertension | Completed | 2007-12-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00736255 | Attention Deficit Hyperactivity Disorder (ADHD) Smoking Cessation Study | Na | Attention Deficit Hyperactivity Disorder | Completed | 2007-12-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT00595075 | Ramelteon for a Nap Prior to a Night Shift | Na | Healthy | Completed | 2007-12-01 | 2008-11-01 | ClinicalTrials.gov |
| NCT00591578 | Efficacy and Safety Comparison of Azilsartan Medoxomil to Valsartan in Particip… | Phase3 | Hypertension | Completed | 2007-12-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00585208 | Add-On Ramelteon in Bipolar I Disorder With Clinically Significant Sleep Distur… | Phase3 | Insomnia | Terminated | 2007-12-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT00619489 | Long Term Safety of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis a… | Phase2 | Ulcerative Colitis | Completed | 2007-12-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00736255 | Attention Deficit Hyperactivity Disorder (ADHD) Smoking Cessation Study | Na | Attention Deficit Hyperactivity Disorder | Completed | 2007-12-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT00552760 | Ramelteon for the Treatment of Insomnia and Mood Stability in Patients With Eut… | Phase4 | Bipolar Disorder | Completed | 2007-11-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT00598442 | Safety and Efficacy of Peginesatide for the Treatment of Anemia in Participants… | Phase3 | Chronic Renal Failure | Completed | 2007-11-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT00581360 | Phase II Trial of Doxorubicin and Bortezomib in Patients With Incurable Adenoid… | Phase2 | Adenoid Cystic Carcinoma | Completed | 2007-11-01 | 2011-06-01 | ClinicalTrials.gov |
| NCT00552760 | Ramelteon for the Treatment of Insomnia and Mood Stability in Patients With Eut… | Phase4 | Bipolar Disorder | Completed | 2007-11-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT01318070 | Efficacy and Safety of Alogliptin Used Combination With Thiazolidine in Partici… | Phase2 | Type 2 Diabetes Mellitus | Completed | 2007-11-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT00552760 | Ramelteon for the Treatment of Insomnia and Mood Stability in Patients With Eut… | Phase4 | Bipolar Disorder | Completed | 2007-11-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT01318070 | Efficacy and Safety of Alogliptin Used Combination With Thiazolidine in Partici… | Phase2 | Type 2 Diabetes Mellitus | Completed | 2007-11-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT00581360 | Phase II Trial of Doxorubicin and Bortezomib in Patients With Incurable Adenoid… | Phase2 | Adenoid Cystic Carcinoma | Completed | 2007-11-01 | 2011-06-01 | ClinicalTrials.gov |
| NCT01318070 | Efficacy and Safety of Alogliptin Used Combination With Thiazolidine in Partici… | Phase2 | Type 2 Diabetes Mellitus | Completed | 2007-11-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT00598442 | Safety and Efficacy of Peginesatide for the Treatment of Anemia in Participants… | Phase3 | Chronic Renal Failure | Completed | 2007-11-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT00598442 | Safety and Efficacy of Peginesatide for the Treatment of Anemia in Participants… | Phase3 | Chronic Renal Failure | Completed | 2007-11-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT00581360 | Phase II Trial of Doxorubicin and Bortezomib in Patients With Incurable Adenoid… | Phase2 | Adenoid Cystic Carcinoma | Completed | 2007-11-01 | 2011-06-01 | ClinicalTrials.gov |
| NCT00651664 | A Phase I Clinical and Pharmacodynamic Study of MLN8237, A Novel Aurora A Kinas… | Phase1 | Advanced Malignancies | Completed | 2007-10-22 | 2011-04-05 | ClinicalTrials.gov |
| NCT00651664 | A Phase I Clinical and Pharmacodynamic Study of MLN8237, A Novel Aurora A Kinas… | Phase1 | Advanced Malignancies | Completed | 2007-10-22 | 2011-04-05 | ClinicalTrials.gov |
| NCT00651664 | A Phase I Clinical and Pharmacodynamic Study of MLN8237, A Novel Aurora A Kinas… | Phase1 | Advanced Malignancies | Completed | 2007-10-22 | 2011-04-05 | ClinicalTrials.gov |
| NCT02002975 | Pioglitazone Special Drug Use Surveillance "Metabolic Syndrome in Patients With… | — | Type 2 Diabetes Mellitus | Completed | 2007-10-16 | 2013-06-30 | ClinicalTrials.gov |
| NCT02002975 | Pioglitazone Special Drug Use Surveillance "Metabolic Syndrome in Patients With… | — | Type 2 Diabetes Mellitus | Completed | 2007-10-16 | 2013-06-30 | ClinicalTrials.gov |
| NCT02002975 | Pioglitazone Special Drug Use Surveillance "Metabolic Syndrome in Patients With… | — | Type 2 Diabetes Mellitus | Completed | 2007-10-16 | 2013-06-30 | ClinicalTrials.gov |
| NCT00591253 | Efficacy and Safety of Azilsartan Medoxomil in African American Participants Wi… | Phase3 | Hypertension | Completed | 2007-10-01 | 2009-04-01 | ClinicalTrials.gov |
| NCT00532558 | Efficacy of Lapaquistat Acetate on Blood Cholesterol Levels in Treating Subject… | Phase3 | Hypercholesterolemia | Terminated | 2007-10-01 | 2008-05-01 | ClinicalTrials.gov |
| NCT00593736 | Efficacy of Ramelteon on Speeding Up Sleep in Subjects With Delayed Sleep Phase… | Phase2 | Sleep Disorders, Circadian Rhythm | Completed | 2007-10-01 | 2008-05-01 | ClinicalTrials.gov |
| NCT00591253 | Efficacy and Safety of Azilsartan Medoxomil in African American Participants Wi… | Phase3 | Hypertension | Completed | 2007-10-01 | 2009-04-01 | ClinicalTrials.gov |
| NCT00598273 | Safety & Efficacy of Peginesatide for the Treatment of Anemia in Participants W… | Phase3 | Chronic Renal Failure | Completed | 2007-10-01 | 2010-02-01 | ClinicalTrials.gov |
| NCT00591266 | Efficacy and Safety of Azilsartan Medoxomil, Once Daily (QD), Co-Administered W… | Phase3 | Hypertension | Completed | 2007-10-01 | 2009-04-01 | ClinicalTrials.gov |
| NCT00641732 | Efficacy and Safety of TAK-442 in Subjects Undergoing Total Knee Replacement | Phase2 | Venous Thromboembolism | Completed | 2007-10-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT00591266 | Efficacy and Safety of Azilsartan Medoxomil, Once Daily (QD), Co-Administered W… | Phase3 | Hypertension | Completed | 2007-10-01 | 2009-04-01 | ClinicalTrials.gov |
| NCT00597584 | Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Partic… | Phase3 | Chronic Renal Failure | Completed | 2007-10-01 | 2010-01-01 | ClinicalTrials.gov |
| NCT00611442 | Split Dose Golytely With Amitiza Pretreatment Versus Split Dose Golytely Plus P… | Na | Bowel Preparation for Colonoscopy | Completed | 2007-10-01 | 2008-01-01 | ClinicalTrials.gov |
| NCT00611442 | Split Dose Golytely With Amitiza Pretreatment Versus Split Dose Golytely Plus P… | Na | Bowel Preparation for Colonoscopy | Completed | 2007-10-01 | 2008-01-01 | ClinicalTrials.gov |
| NCT02141698 | Safety, Tolerability, and Pharmacokinetics of TAK-438 in Healthy Western Male S… | Phase1 | Dose Finding Study | Completed | 2007-10-01 | 2008-02-01 | ClinicalTrials.gov |
| NCT00591253 | Efficacy and Safety of Azilsartan Medoxomil in African American Participants Wi… | Phase3 | Hypertension | Completed | 2007-10-01 | 2009-04-01 | ClinicalTrials.gov |
| NCT00598273 | Safety & Efficacy of Peginesatide for the Treatment of Anemia in Participants W… | Phase3 | Chronic Renal Failure | Completed | 2007-10-01 | 2010-02-01 | ClinicalTrials.gov |
| NCT00531453 | A Study to Evaluate Two Different Regimens of VELCADE in Combination With Dexam… | Phase2 | Multiple Myeloma | Completed | 2007-10-01 | 2009-05-01 | ClinicalTrials.gov |
| NCT00591266 | Efficacy and Safety of Azilsartan Medoxomil, Once Daily (QD), Co-Administered W… | Phase3 | Hypertension | Completed | 2007-10-01 | 2009-04-01 | ClinicalTrials.gov |
| NCT00598273 | Safety & Efficacy of Peginesatide for the Treatment of Anemia in Participants W… | Phase3 | Chronic Renal Failure | Completed | 2007-10-01 | 2010-02-01 | ClinicalTrials.gov |
| NCT00532558 | Efficacy of Lapaquistat Acetate on Blood Cholesterol Levels in Treating Subject… | Phase3 | Hypercholesterolemia | Terminated | 2007-10-01 | 2008-05-01 | ClinicalTrials.gov |
| NCT00641732 | Efficacy and Safety of TAK-442 in Subjects Undergoing Total Knee Replacement | Phase2 | Venous Thromboembolism | Completed | 2007-10-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT00547534 | Pilot Study of Bortezomib, Bendamustine and Rituximab on Non-Hodgkin's Lymphoma | Phase2 | Non-Hodgkin's Lymphoma | Completed | 2007-10-01 | 2009-10-01 | ClinicalTrials.gov |
| NCT00597584 | Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Partic… | Phase3 | Chronic Renal Failure | Completed | 2007-10-01 | 2010-01-01 | ClinicalTrials.gov |
| NCT00531453 | A Study to Evaluate Two Different Regimens of VELCADE in Combination With Dexam… | Phase2 | Multiple Myeloma | Completed | 2007-10-01 | 2009-05-01 | ClinicalTrials.gov |
| NCT02141698 | Safety, Tolerability, and Pharmacokinetics of TAK-438 in Healthy Western Male S… | Phase1 | Dose Finding Study | Completed | 2007-10-01 | 2008-02-01 | ClinicalTrials.gov |
| NCT00597584 | Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Partic… | Phase3 | Chronic Renal Failure | Completed | 2007-10-01 | 2010-01-01 | ClinicalTrials.gov |
| NCT00532558 | Efficacy of Lapaquistat Acetate on Blood Cholesterol Levels in Treating Subject… | Phase3 | Hypercholesterolemia | Terminated | 2007-10-01 | 2008-05-01 | ClinicalTrials.gov |
| NCT00547534 | Pilot Study of Bortezomib, Bendamustine and Rituximab on Non-Hodgkin's Lymphoma | Phase2 | Non-Hodgkin's Lymphoma | Completed | 2007-10-01 | 2009-10-01 | ClinicalTrials.gov |
| NCT00547534 | Pilot Study of Bortezomib, Bendamustine and Rituximab on Non-Hodgkin's Lymphoma | Phase2 | Non-Hodgkin's Lymphoma | Completed | 2007-10-01 | 2009-10-01 | ClinicalTrials.gov |
| NCT00641732 | Efficacy and Safety of TAK-442 in Subjects Undergoing Total Knee Replacement | Phase2 | Venous Thromboembolism | Completed | 2007-10-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT00593736 | Efficacy of Ramelteon on Speeding Up Sleep in Subjects With Delayed Sleep Phase… | Phase2 | Sleep Disorders, Circadian Rhythm | Completed | 2007-10-01 | 2008-05-01 | ClinicalTrials.gov |
| NCT00531453 | A Study to Evaluate Two Different Regimens of VELCADE in Combination With Dexam… | Phase2 | Multiple Myeloma | Completed | 2007-10-01 | 2009-05-01 | ClinicalTrials.gov |
| NCT00611442 | Split Dose Golytely With Amitiza Pretreatment Versus Split Dose Golytely Plus P… | Na | Bowel Preparation for Colonoscopy | Completed | 2007-10-01 | 2008-01-01 | ClinicalTrials.gov |
| NCT00593736 | Efficacy of Ramelteon on Speeding Up Sleep in Subjects With Delayed Sleep Phase… | Phase2 | Sleep Disorders, Circadian Rhythm | Completed | 2007-10-01 | 2008-05-01 | ClinicalTrials.gov |
| NCT02141698 | Safety, Tolerability, and Pharmacokinetics of TAK-438 in Healthy Western Male S… | Phase1 | Dose Finding Study | Completed | 2007-10-01 | 2008-02-01 | ClinicalTrials.gov |
| NCT02123927 | Safety, Tolerability and Pharmacokinetics of TAK-438 in Healthy Male Participan… | Phase1 | Ascending Single Dose Study | Completed | 2007-09-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT01460225 | Effects of Lubiprostone on Gastric Function in Patients With Chronic Idiopathic… | Phase4 | Chronic Idiopathic Constipation | Completed | 2007-09-01 | 2011-01-01 | ClinicalTrials.gov |
| NCT01460225 | Effects of Lubiprostone on Gastric Function in Patients With Chronic Idiopathic… | Phase4 | Chronic Idiopathic Constipation | Completed | 2007-09-01 | 2011-01-01 | ClinicalTrials.gov |
| NCT01460225 | Effects of Lubiprostone on Gastric Function in Patients With Chronic Idiopathic… | Phase4 | Chronic Idiopathic Constipation | Completed | 2007-09-01 | 2011-01-01 | ClinicalTrials.gov |
| NCT00591773 | Efficacy and Safety of Azilsartan Medoxomil Co-Administered With Chlorthalidone… | Phase3 | Hypertension | Completed | 2007-09-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00597753 | Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Partic… | Phase3 | Chronic Renal Failure | Completed | 2007-09-01 | 2010-01-01 | ClinicalTrials.gov |
| NCT00608907 | An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokin… | Phase1 | Multiple Myeloma | Completed | 2007-09-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT00953043 | Lubiprostone, Colonic Motility and Sensation | Phase4 | Healthy | Completed | 2007-09-01 | 2009-07-01 | ClinicalTrials.gov |
| NCT02123927 | Safety, Tolerability and Pharmacokinetics of TAK-438 in Healthy Male Participan… | Phase1 | Ascending Single Dose Study | Completed | 2007-09-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00608907 | An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokin… | Phase1 | Multiple Myeloma | Completed | 2007-09-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT00597753 | Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Partic… | Phase3 | Chronic Renal Failure | Completed | 2007-09-01 | 2010-01-01 | ClinicalTrials.gov |
| NCT00591773 | Efficacy and Safety of Azilsartan Medoxomil Co-Administered With Chlorthalidone… | Phase3 | Hypertension | Completed | 2007-09-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00953043 | Lubiprostone, Colonic Motility and Sensation | Phase4 | Healthy | Completed | 2007-09-01 | 2009-07-01 | ClinicalTrials.gov |
| NCT02123927 | Safety, Tolerability and Pharmacokinetics of TAK-438 in Healthy Male Participan… | Phase1 | Ascending Single Dose Study | Completed | 2007-09-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00953043 | Lubiprostone, Colonic Motility and Sensation | Phase4 | Healthy | Completed | 2007-09-01 | 2009-07-01 | ClinicalTrials.gov |
| NCT00608907 | An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokin… | Phase1 | Multiple Myeloma | Completed | 2007-09-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT00597753 | Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Partic… | Phase3 | Chronic Renal Failure | Completed | 2007-09-01 | 2010-01-01 | ClinicalTrials.gov |
| NCT00591773 | Efficacy and Safety of Azilsartan Medoxomil Co-Administered With Chlorthalidone… | Phase3 | Hypertension | Completed | 2007-09-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00915343 | Once-daily Oral Modified Release Hydrocortisone in Patients With Adrenal Insuff… | Phase2 | Adrenal Insufficiency | Completed | 2007-08-21 | 2009-01-28 | ClinicalTrials.gov |
| NCT00915343 | Once-daily Oral Modified Release Hydrocortisone in Patients With Adrenal Insuff… | Phase2 | Adrenal Insufficiency | Completed | 2007-08-21 | 2009-01-28 | ClinicalTrials.gov |
| NCT00915343 | Once-daily Oral Modified Release Hydrocortisone in Patients With Adrenal Insuff… | Phase2 | Adrenal Insufficiency | Completed | 2007-08-21 | 2009-01-28 | ClinicalTrials.gov |
| NCT00760968 | Efficacy and Safety of TAK-783 in Subjects With Rheumatoid Arthritis | Phase2 | Arthritis, Rheumatoid | Completed | 2007-08-01 | 2009-02-01 | ClinicalTrials.gov |
| NCT00756002 | Safety and Efficacy Study of Ramelteon in Subjects With Chronic Insomnia | Phase3 | Sleep Initiation and Maintenance Disorders | Completed | 2007-08-01 | 2008-03-01 | ClinicalTrials.gov |
| NCT00535522 | A Safety and Pharmacokinetic Study of TAK-285 in Patients With Advanced Cancer | Phase1 | Cancer | Completed | 2007-08-01 | 2011-06-01 | ClinicalTrials.gov |
| NCT00760968 | Efficacy and Safety of TAK-783 in Subjects With Rheumatoid Arthritis | Phase2 | Arthritis, Rheumatoid | Completed | 2007-08-01 | 2009-02-01 | ClinicalTrials.gov |
| NCT00613587 | Roflumilast In-Vitro Basophil Release | — | Allergy | Completed | 2007-08-01 | 2010-01-01 | ClinicalTrials.gov |
| NCT00523367 | COPD Patients Diagnosed With GERD,COPD Exacerbations After Treatment With High … | Na | Gastroesophageal Reflux | Terminated | 2007-08-01 | 2010-10-01 | ClinicalTrials.gov |
| NCT00507442 | Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat Previously… | Phase1 | Multiple Myeloma | Completed | 2007-08-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT00535522 | A Safety and Pharmacokinetic Study of TAK-285 in Patients With Advanced Cancer | Phase1 | Cancer | Completed | 2007-08-01 | 2011-06-01 | ClinicalTrials.gov |
| NCT00756002 | Safety and Efficacy Study of Ramelteon in Subjects With Chronic Insomnia | Phase3 | Sleep Initiation and Maintenance Disorders | Completed | 2007-08-01 | 2008-03-01 | ClinicalTrials.gov |
| NCT00507442 | Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat Previously… | Phase1 | Multiple Myeloma | Completed | 2007-08-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT00613587 | Roflumilast In-Vitro Basophil Release | — | Allergy | Completed | 2007-08-01 | 2010-01-01 | ClinicalTrials.gov |
| NCT00523367 | COPD Patients Diagnosed With GERD,COPD Exacerbations After Treatment With High … | Na | Gastroesophageal Reflux | Terminated | 2007-08-01 | 2010-10-01 | ClinicalTrials.gov |
| NCT00535522 | A Safety and Pharmacokinetic Study of TAK-285 in Patients With Advanced Cancer | Phase1 | Cancer | Completed | 2007-08-01 | 2011-06-01 | ClinicalTrials.gov |
| NCT00613587 | Roflumilast In-Vitro Basophil Release | — | Allergy | Completed | 2007-08-01 | 2010-01-01 | ClinicalTrials.gov |
| NCT00523367 | COPD Patients Diagnosed With GERD,COPD Exacerbations After Treatment With High … | Na | Gastroesophageal Reflux | Terminated | 2007-08-01 | 2010-10-01 | ClinicalTrials.gov |
| NCT00756002 | Safety and Efficacy Study of Ramelteon in Subjects With Chronic Insomnia | Phase3 | Sleep Initiation and Maintenance Disorders | Completed | 2007-08-01 | 2008-03-01 | ClinicalTrials.gov |
| NCT00507442 | Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat Previously… | Phase1 | Multiple Myeloma | Completed | 2007-08-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT00760968 | Efficacy and Safety of TAK-783 in Subjects With Rheumatoid Arthritis | Phase2 | Arthritis, Rheumatoid | Completed | 2007-08-01 | 2009-02-01 | ClinicalTrials.gov |
| NCT00819468 | Pharmacokinetics (PK) of 20 mg Teduglutide in Participants With Moderately Impa… | Phase1 | Hepatic Impairment | Completed | 2007-07-26 | 2007-08-23 | ClinicalTrials.gov |
| NCT00819468 | Pharmacokinetics (PK) of 20 mg Teduglutide in Participants With Moderately Impa… | Phase1 | Hepatic Impairment | Completed | 2007-07-26 | 2007-08-23 | ClinicalTrials.gov |
| NCT00819468 | Pharmacokinetics (PK) of 20 mg Teduglutide in Participants With Moderately Impa… | Phase1 | Hepatic Impairment | Completed | 2007-07-26 | 2007-08-23 | ClinicalTrials.gov |
| NCT00478647 | Study of GA-GCB Enzyme Replacement Therapy in Type 1 Gaucher Disease Patients P… | Phase2 | Gaucher Disease | Completed | 2007-07-25 | 2009-06-26 | ClinicalTrials.gov |
| NCT00478647 | Study of GA-GCB Enzyme Replacement Therapy in Type 1 Gaucher Disease Patients P… | Phase2 | Gaucher Disease | Completed | 2007-07-25 | 2009-06-26 | ClinicalTrials.gov |
| NCT00478647 | Study of GA-GCB Enzyme Replacement Therapy in Type 1 Gaucher Disease Patients P… | Phase2 | Gaucher Disease | Completed | 2007-07-25 | 2009-06-26 | ClinicalTrials.gov |
| NCT00497796 | Maribavir Versus Oral Ganciclovir For The Prevention of Cytomegalovirus (CMV) D… | Phase3 | Cytomegalovirus Infections | Completed | 2007-07-23 | 2009-09-14 | ClinicalTrials.gov |
| NCT00497796 | Maribavir Versus Oral Ganciclovir For The Prevention of Cytomegalovirus (CMV) D… | Phase3 | Cytomegalovirus Infections | Completed | 2007-07-23 | 2009-09-14 | ClinicalTrials.gov |
| NCT00497796 | Maribavir Versus Oral Ganciclovir For The Prevention of Cytomegalovirus (CMV) D… | Phase3 | Cytomegalovirus Infections | Completed | 2007-07-23 | 2009-09-14 | ClinicalTrials.gov |
| NCT00507546 | Functional Melatonin Replacement for Sleep Disruptions in Individuals With Tetr… | Phase4 | Insomnia | Completed | 2007-07-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT00507546 | Functional Melatonin Replacement for Sleep Disruptions in Individuals With Tetr… | Phase4 | Insomnia | Completed | 2007-07-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT00532311 | Efficacy of Lapaquistat Acetate Co-Administered With Statins in Subjects With H… | Phase3 | Hypercholesterolemia | Terminated | 2007-07-01 | 2008-04-01 | ClinicalTrials.gov |
| NCT00865228 | Efficacy of Lapaquistat Acetate in Subjects With Hypercholesterolemia | Phase2 | Hypercholesterolemia | Terminated | 2007-07-01 | 2007-11-01 | ClinicalTrials.gov |
| NCT00460317 | MONET1-MOtesanib NSCLC Efficacy and Tolerability Study | Phase3 | Non-Small Cell Lung Cancer | Terminated | 2007-07-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01289132 | Efficacy and Safety of Azilsartan in Participants With Mild to Moderate Uncompl… | Phase2 | Essential Hypertension | Completed | 2007-07-01 | 2008-07-01 | ClinicalTrials.gov |
| NCT00507546 | Functional Melatonin Replacement for Sleep Disruptions in Individuals With Tetr… | Phase4 | Insomnia | Completed | 2007-07-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT01289132 | Efficacy and Safety of Azilsartan in Participants With Mild to Moderate Uncompl… | Phase2 | Essential Hypertension | Completed | 2007-07-01 | 2008-07-01 | ClinicalTrials.gov |
| NCT00532311 | Efficacy of Lapaquistat Acetate Co-Administered With Statins in Subjects With H… | Phase3 | Hypercholesterolemia | Terminated | 2007-07-01 | 2008-04-01 | ClinicalTrials.gov |
| NCT00460317 | MONET1-MOtesanib NSCLC Efficacy and Tolerability Study | Phase3 | Non-Small Cell Lung Cancer | Terminated | 2007-07-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT00655863 | Efficacy of Alogliptin and With Pioglitazone in Patients With Type 2 Diabetes. | Phase3 | Diabetes Mellitus | Completed | 2007-07-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT00865228 | Efficacy of Lapaquistat Acetate in Subjects With Hypercholesterolemia | Phase2 | Hypercholesterolemia | Terminated | 2007-07-01 | 2007-11-01 | ClinicalTrials.gov |
| NCT01289132 | Efficacy and Safety of Azilsartan in Participants With Mild to Moderate Uncompl… | Phase2 | Essential Hypertension | Completed | 2007-07-01 | 2008-07-01 | ClinicalTrials.gov |
| NCT00865228 | Efficacy of Lapaquistat Acetate in Subjects With Hypercholesterolemia | Phase2 | Hypercholesterolemia | Terminated | 2007-07-01 | 2007-11-01 | ClinicalTrials.gov |
| NCT00460317 | MONET1-MOtesanib NSCLC Efficacy and Tolerability Study | Phase3 | Non-Small Cell Lung Cancer | Terminated | 2007-07-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT00655863 | Efficacy of Alogliptin and With Pioglitazone in Patients With Type 2 Diabetes. | Phase3 | Diabetes Mellitus | Completed | 2007-07-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT00655863 | Efficacy of Alogliptin and With Pioglitazone in Patients With Type 2 Diabetes. | Phase3 | Diabetes Mellitus | Completed | 2007-07-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT00532311 | Efficacy of Lapaquistat Acetate Co-Administered With Statins in Subjects With H… | Phase3 | Hypercholesterolemia | Terminated | 2007-07-01 | 2008-04-01 | ClinicalTrials.gov |
| NCT00500149 | A Classroom Study to Assess the Time of Onset of Vyvanse (Lisdexamfetamine Dime… | Phase3 | ADHD | Completed | 2007-06-13 | 2007-12-05 | ClinicalTrials.gov |
| NCT00500149 | A Classroom Study to Assess the Time of Onset of Vyvanse (Lisdexamfetamine Dime… | Phase3 | ADHD | Completed | 2007-06-13 | 2007-12-05 | ClinicalTrials.gov |
| NCT00500149 | A Classroom Study to Assess the Time of Onset of Vyvanse (Lisdexamfetamine Dime… | Phase3 | ADHD | Completed | 2007-06-13 | 2007-12-05 | ClinicalTrials.gov |
| NCT00514813 | Dynepo Long-Term Safety Study | Phase4 | Anemia | Terminated | 2007-06-06 | 2008-07-31 | ClinicalTrials.gov |
| NCT00514813 | Dynepo Long-Term Safety Study | Phase4 | Anemia | Terminated | 2007-06-06 | 2008-07-31 | ClinicalTrials.gov |
| NCT00514813 | Dynepo Long-Term Safety Study | Phase4 | Anemia | Terminated | 2007-06-06 | 2008-07-31 | ClinicalTrials.gov |
| NCT00696241 | Efficacy and Safety of Azilsartan Medoxomil in Participants With Essential Hype… | Phase3 | Hypertension | Completed | 2007-06-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT00727857 | Efficacy and Safety of Pioglitazone and Metformin Combination Therapy in Treati… | Phase3 | Diabetes Mellitus | Completed | 2007-06-01 | 2008-08-01 | ClinicalTrials.gov |
| NCT00695955 | One-Year Safety and Tolerability Study of Azilsartan Medoxomil in Participants … | Phase3 | Hypertension | Completed | 2007-06-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT00696384 | A Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Es… | Phase3 | Hypertension | Completed | 2007-06-01 | 2009-04-01 | ClinicalTrials.gov |
| NCT00696241 | Efficacy and Safety of Azilsartan Medoxomil in Participants With Essential Hype… | Phase3 | Hypertension | Completed | 2007-06-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT00695955 | One-Year Safety and Tolerability Study of Azilsartan Medoxomil in Participants … | Phase3 | Hypertension | Completed | 2007-06-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT00507416 | Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus … | Phase3 | Multiple Myeloma | Completed | 2007-06-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT00506285 | Methylphenidate Transdermal System (MTS) in the Treatment of Adult ADHD | Phase3 | Attention Deficit Hyperactivity Disorder | Completed | 2007-06-01 | 2009-04-01 | ClinicalTrials.gov |
| NCT00696241 | Efficacy and Safety of Azilsartan Medoxomil in Participants With Essential Hype… | Phase3 | Hypertension | Completed | 2007-06-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT00695955 | One-Year Safety and Tolerability Study of Azilsartan Medoxomil in Participants … | Phase3 | Hypertension | Completed | 2007-06-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT00696384 | A Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Es… | Phase3 | Hypertension | Completed | 2007-06-01 | 2009-04-01 | ClinicalTrials.gov |
| NCT00727857 | Efficacy and Safety of Pioglitazone and Metformin Combination Therapy in Treati… | Phase3 | Diabetes Mellitus | Completed | 2007-06-01 | 2008-08-01 | ClinicalTrials.gov |
| NCT01263509 | Long-term Safety Study of Alogliptin Used in Combination With α-glucosidase Inh… | Phase2 | Type 2 Diabetes Mellitus | Completed | 2007-06-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT00506285 | Methylphenidate Transdermal System (MTS) in the Treatment of Adult ADHD | Phase3 | Attention Deficit Hyperactivity Disorder | Completed | 2007-06-01 | 2009-04-01 | ClinicalTrials.gov |
| NCT00727857 | Efficacy and Safety of Pioglitazone and Metformin Combination Therapy in Treati… | Phase3 | Diabetes Mellitus | Completed | 2007-06-01 | 2008-08-01 | ClinicalTrials.gov |
| NCT01263509 | Long-term Safety Study of Alogliptin Used in Combination With α-glucosidase Inh… | Phase2 | Type 2 Diabetes Mellitus | Completed | 2007-06-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT00507416 | Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus … | Phase3 | Multiple Myeloma | Completed | 2007-06-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT00507416 | Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus … | Phase3 | Multiple Myeloma | Completed | 2007-06-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT00506285 | Methylphenidate Transdermal System (MTS) in the Treatment of Adult ADHD | Phase3 | Attention Deficit Hyperactivity Disorder | Completed | 2007-06-01 | 2009-04-01 | ClinicalTrials.gov |
| NCT01263509 | Long-term Safety Study of Alogliptin Used in Combination With α-glucosidase Inh… | Phase2 | Type 2 Diabetes Mellitus | Completed | 2007-06-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT00696384 | A Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Es… | Phase3 | Hypertension | Completed | 2007-06-01 | 2009-04-01 | ClinicalTrials.gov |
| NCT00452478 | Conversion From Standard Phosphate Binder Therapy to Fosrenol® (Lanthanum Carbo… | Phase4 | Kidney Diseases | Terminated | 2007-05-22 | 2007-12-10 | ClinicalTrials.gov |
| NCT00452478 | Conversion From Standard Phosphate Binder Therapy to Fosrenol® (Lanthanum Carbo… | Phase4 | Kidney Diseases | Terminated | 2007-05-22 | 2007-12-10 | ClinicalTrials.gov |
| NCT00452478 | Conversion From Standard Phosphate Binder Therapy to Fosrenol® (Lanthanum Carbo… | Phase4 | Kidney Diseases | Terminated | 2007-05-22 | 2007-12-10 | ClinicalTrials.gov |
| NCT00500903 | A Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Participants With Adv… | Phase1 | Advanced Malignancies | Completed | 2007-05-15 | 2011-02-23 | ClinicalTrials.gov |
| NCT00500903 | A Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Participants With Adv… | Phase1 | Advanced Malignancies | Completed | 2007-05-15 | 2011-02-23 | ClinicalTrials.gov |
| NCT00500903 | A Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Participants With Adv… | Phase1 | Advanced Malignancies | Completed | 2007-05-15 | 2011-02-23 | ClinicalTrials.gov |
| NCT00504751 | Phase II Study of "VIPER" Chemotherapy in Rel/Ref DLBCL | Phase2 | Non-Hodgkin's Lymphoma | Completed | 2007-05-01 | 2012-02-17 | ClinicalTrials.gov |
| NCT00762359 | A Safety and Efficacy Study of Lansoprazole in Preventing Aspirin-Induced Gastr… | Phase3 | Stomach Ulcer | Terminated | 2007-05-01 | 2008-11-01 | ClinicalTrials.gov |
| NCT01300793 | Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide | Phase1 | Non-Hodgkin's Lymphoma | Terminated | 2007-05-01 | 2012-04-01 | ClinicalTrials.gov |
| NCT00483262 | Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or … | Phase1 | Multiple Myeloma | Completed | 2007-05-01 | 2012-02-01 | ClinicalTrials.gov |
| NCT00479167 | A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patient… | Phase2 | Follicular Lymphoma | Terminated | 2007-05-01 | 2008-09-01 | ClinicalTrials.gov |
| NCT01263496 | Long-term Safety Study of Alogliptin in Participants With Type 2 Diabetes in Ja… | Phase2 | Type 2 Diabetes Mellitus | Completed | 2007-05-01 | 2008-09-01 | ClinicalTrials.gov |
| NCT01177228 | Study of Vedolizumab Following Multiple Intravenous Doses in Patients With Ulce… | Phase2 | Ulcerative Colitis | Completed | 2007-05-01 | 2008-09-01 | ClinicalTrials.gov |
| NCT00471094 | Safety and Efficacy of Ilaprazole 5, 20 and 40 mg QD and Lansoprazole 30 mg QD … | Phase2 | Esophagitis | Completed | 2007-05-01 | 2007-10-01 | ClinicalTrials.gov |
| NCT00653185 | Efficacy of SYR-472 in Subjects With Type 2 Diabetes Mellitus | Phase2 | Diabetes Mellitus | Completed | 2007-05-01 | 2008-03-01 | ClinicalTrials.gov |
| NCT01177228 | Study of Vedolizumab Following Multiple Intravenous Doses in Patients With Ulce… | Phase2 | Ulcerative Colitis | Completed | 2007-05-01 | 2008-09-01 | ClinicalTrials.gov |
| NCT00446849 | Strategies in Maintenance for Patients Receiving Long-term Therapy (S.I.M.P.L.E… | Phase4 | Ulcerative Colitis | Completed | 2007-05-01 | 2009-08-17 | ClinicalTrials.gov |
| NCT00762359 | A Safety and Efficacy Study of Lansoprazole in Preventing Aspirin-Induced Gastr… | Phase3 | Stomach Ulcer | Terminated | 2007-05-01 | 2008-11-01 | ClinicalTrials.gov |
| NCT00642694 | Time to Remission of Depressive Symptoms With Combined SSRI and Ramelteon | Phase3 | Major Depressive Disorder | Terminated | 2007-05-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT00471094 | Safety and Efficacy of Ilaprazole 5, 20 and 40 mg QD and Lansoprazole 30 mg QD … | Phase2 | Esophagitis | Completed | 2007-05-01 | 2007-10-01 | ClinicalTrials.gov |
| NCT01090921 | Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multip… | Phase2 | Multiple Myeloma | Completed | 2007-05-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT01090921 | Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multip… | Phase2 | Multiple Myeloma | Completed | 2007-05-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT00762359 | A Safety and Efficacy Study of Lansoprazole in Preventing Aspirin-Induced Gastr… | Phase3 | Stomach Ulcer | Terminated | 2007-05-01 | 2008-11-01 | ClinicalTrials.gov |
| NCT01177228 | Study of Vedolizumab Following Multiple Intravenous Doses in Patients With Ulce… | Phase2 | Ulcerative Colitis | Completed | 2007-05-01 | 2008-09-01 | ClinicalTrials.gov |
| NCT00446849 | Strategies in Maintenance for Patients Receiving Long-term Therapy (S.I.M.P.L.E… | Phase4 | Ulcerative Colitis | Completed | 2007-05-01 | 2009-08-17 | ClinicalTrials.gov |
| NCT01263496 | Long-term Safety Study of Alogliptin in Participants With Type 2 Diabetes in Ja… | Phase2 | Type 2 Diabetes Mellitus | Completed | 2007-05-01 | 2008-09-01 | ClinicalTrials.gov |
| NCT01300793 | Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide | Phase1 | Non-Hodgkin's Lymphoma | Terminated | 2007-05-01 | 2012-04-01 | ClinicalTrials.gov |
| NCT01300793 | Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide | Phase1 | Non-Hodgkin's Lymphoma | Terminated | 2007-05-01 | 2012-04-01 | ClinicalTrials.gov |
| NCT01090921 | Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multip… | Phase2 | Multiple Myeloma | Completed | 2007-05-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT00642694 | Time to Remission of Depressive Symptoms With Combined SSRI and Ramelteon | Phase3 | Major Depressive Disorder | Terminated | 2007-05-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT00653185 | Efficacy of SYR-472 in Subjects With Type 2 Diabetes Mellitus | Phase2 | Diabetes Mellitus | Completed | 2007-05-01 | 2008-03-01 | ClinicalTrials.gov |
| NCT00446849 | Strategies in Maintenance for Patients Receiving Long-term Therapy (S.I.M.P.L.E… | Phase4 | Ulcerative Colitis | Completed | 2007-05-01 | 2009-08-17 | ClinicalTrials.gov |
| NCT00504751 | Phase II Study of "VIPER" Chemotherapy in Rel/Ref DLBCL | Phase2 | Non-Hodgkin's Lymphoma | Completed | 2007-05-01 | 2012-02-17 | ClinicalTrials.gov |
| NCT00642694 | Time to Remission of Depressive Symptoms With Combined SSRI and Ramelteon | Phase3 | Major Depressive Disorder | Terminated | 2007-05-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT00653185 | Efficacy of SYR-472 in Subjects With Type 2 Diabetes Mellitus | Phase2 | Diabetes Mellitus | Completed | 2007-05-01 | 2008-03-01 | ClinicalTrials.gov |
| NCT00504751 | Phase II Study of "VIPER" Chemotherapy in Rel/Ref DLBCL | Phase2 | Non-Hodgkin's Lymphoma | Completed | 2007-05-01 | 2012-02-17 | ClinicalTrials.gov |
| NCT00471094 | Safety and Efficacy of Ilaprazole 5, 20 and 40 mg QD and Lansoprazole 30 mg QD … | Phase2 | Esophagitis | Completed | 2007-05-01 | 2007-10-01 | ClinicalTrials.gov |
| NCT01263496 | Long-term Safety Study of Alogliptin in Participants With Type 2 Diabetes in Ja… | Phase2 | Type 2 Diabetes Mellitus | Completed | 2007-05-01 | 2008-09-01 | ClinicalTrials.gov |
| NCT00483262 | Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or … | Phase1 | Multiple Myeloma | Completed | 2007-05-01 | 2012-02-01 | ClinicalTrials.gov |
| NCT00479167 | A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patient… | Phase2 | Follicular Lymphoma | Terminated | 2007-05-01 | 2008-09-01 | ClinicalTrials.gov |
| NCT00479167 | A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patient… | Phase2 | Follicular Lymphoma | Terminated | 2007-05-01 | 2008-09-01 | ClinicalTrials.gov |
| NCT00483262 | Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or … | Phase1 | Multiple Myeloma | Completed | 2007-05-01 | 2012-02-01 | ClinicalTrials.gov |
| NCT00458445 | A Study of SPD465 in Young Adult Drivers With Attention-Deficit Hyperactivity D… | Phase3 | Attention Deficit Hyperactivity Disorder | Withdrawn | 2007-04-30 | 2007-06-15 | ClinicalTrials.gov |
| NCT00458445 | A Study of SPD465 in Young Adult Drivers With Attention-Deficit Hyperactivity D… | Phase3 | Attention Deficit Hyperactivity Disorder | Withdrawn | 2007-04-30 | 2007-06-15 | ClinicalTrials.gov |
| NCT00458445 | A Study of SPD465 in Young Adult Drivers With Attention-Deficit Hyperactivity D… | Phase3 | Attention Deficit Hyperactivity Disorder | Withdrawn | 2007-04-30 | 2007-06-15 | ClinicalTrials.gov |
| NCT00787254 | Efficacy and Safety of Lansoprazole on Gastric and Duodenal Ulcers in Patients … | Phase3 | Stomach Ulcer | Completed | 2007-04-01 | 2009-05-01 | ClinicalTrials.gov |
| NCT00456508 | Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Att… | Phase3 | Hereditary Angioedema (HAE) | Completed | 2007-04-01 | 2010-09-01 | ClinicalTrials.gov |
| NCT00457015 | Efficacy Study of DX-88 (Ecallantide) to Treat Acute Attacks of Hereditary Angi… | Phase3 | Hereditary Angioedema (HAE) | Completed | 2007-04-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00478569 | Adherence to PTH(1-84) Treatment (FP-002-IM) | — | Clinical Use of PTH(1-84) | Completed | 2007-04-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT00492232 | Facilitation of Zolpidem (≥10 mg) Discontinuation Through Use of Ramelteon in S… | Phase4 | Chronic Insomnia | Completed | 2007-04-01 | 2008-05-01 | ClinicalTrials.gov |
| NCT00506883 | MPC-004 for the Treatment of an Acute Gout Flare | Phase3 | Gout | Completed | 2007-04-01 | 2007-10-01 | ClinicalTrials.gov |
| NCT00770653 | Efficacy of Pioglitazone/Metformin Combination Therapy in Subjects With Type 2 … | Phase3 | Diabetes Mellitus | Completed | 2007-04-01 | 2009-05-01 | ClinicalTrials.gov |
| NCT00777114 | Phase 1 Study of Radiosensitization Using Bortezomib in Relapsed Non-Hodgkin's … | Phase1 | Non-Hodgkin's Lymphoma | Completed | 2007-04-01 | 2012-12-18 | ClinicalTrials.gov |
| NCT00780208 | Evaluating the Methylphenidate Patch to Treat Former Stimulant Users With ADHD | Na | Adult Attention Deficit Hyperactivity Disorder (ADHD) | Completed | 2007-04-01 | 2009-02-01 | ClinicalTrials.gov |
| NCT00787254 | Efficacy and Safety of Lansoprazole on Gastric and Duodenal Ulcers in Patients … | Phase3 | Stomach Ulcer | Completed | 2007-04-01 | 2009-05-01 | ClinicalTrials.gov |
| NCT00456508 | Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Att… | Phase3 | Hereditary Angioedema (HAE) | Completed | 2007-04-01 | 2010-09-01 | ClinicalTrials.gov |
| NCT00457015 | Efficacy Study of DX-88 (Ecallantide) to Treat Acute Attacks of Hereditary Angi… | Phase3 | Hereditary Angioedema (HAE) | Completed | 2007-04-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00478569 | Adherence to PTH(1-84) Treatment (FP-002-IM) | — | Clinical Use of PTH(1-84) | Completed | 2007-04-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT00492232 | Facilitation of Zolpidem (≥10 mg) Discontinuation Through Use of Ramelteon in S… | Phase4 | Chronic Insomnia | Completed | 2007-04-01 | 2008-05-01 | ClinicalTrials.gov |
| NCT00506883 | MPC-004 for the Treatment of an Acute Gout Flare | Phase3 | Gout | Completed | 2007-04-01 | 2007-10-01 | ClinicalTrials.gov |
| NCT00780208 | Evaluating the Methylphenidate Patch to Treat Former Stimulant Users With ADHD | Na | Adult Attention Deficit Hyperactivity Disorder (ADHD) | Completed | 2007-04-01 | 2009-02-01 | ClinicalTrials.gov |
| NCT00777114 | Phase 1 Study of Radiosensitization Using Bortezomib in Relapsed Non-Hodgkin's … | Phase1 | Non-Hodgkin's Lymphoma | Completed | 2007-04-01 | 2012-12-18 | ClinicalTrials.gov |
| NCT00770653 | Efficacy of Pioglitazone/Metformin Combination Therapy in Subjects With Type 2 … | Phase3 | Diabetes Mellitus | Completed | 2007-04-01 | 2009-05-01 | ClinicalTrials.gov |
| NCT00787254 | Efficacy and Safety of Lansoprazole on Gastric and Duodenal Ulcers in Patients … | Phase3 | Stomach Ulcer | Completed | 2007-04-01 | 2009-05-01 | ClinicalTrials.gov |
| NCT00780208 | Evaluating the Methylphenidate Patch to Treat Former Stimulant Users With ADHD | Na | Adult Attention Deficit Hyperactivity Disorder (ADHD) | Completed | 2007-04-01 | 2009-02-01 | ClinicalTrials.gov |
| NCT00777114 | Phase 1 Study of Radiosensitization Using Bortezomib in Relapsed Non-Hodgkin's … | Phase1 | Non-Hodgkin's Lymphoma | Completed | 2007-04-01 | 2012-12-18 | ClinicalTrials.gov |
| NCT00770653 | Efficacy of Pioglitazone/Metformin Combination Therapy in Subjects With Type 2 … | Phase3 | Diabetes Mellitus | Completed | 2007-04-01 | 2009-05-01 | ClinicalTrials.gov |
| NCT00506883 | MPC-004 for the Treatment of an Acute Gout Flare | Phase3 | Gout | Completed | 2007-04-01 | 2007-10-01 | ClinicalTrials.gov |
| NCT00492232 | Facilitation of Zolpidem (≥10 mg) Discontinuation Through Use of Ramelteon in S… | Phase4 | Chronic Insomnia | Completed | 2007-04-01 | 2008-05-01 | ClinicalTrials.gov |
| NCT00478569 | Adherence to PTH(1-84) Treatment (FP-002-IM) | — | Clinical Use of PTH(1-84) | Completed | 2007-04-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT00457015 | Efficacy Study of DX-88 (Ecallantide) to Treat Acute Attacks of Hereditary Angi… | Phase3 | Hereditary Angioedema (HAE) | Completed | 2007-04-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00456508 | Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Att… | Phase3 | Hereditary Angioedema (HAE) | Completed | 2007-04-01 | 2010-09-01 | ClinicalTrials.gov |
| NCT02158364 | Freeze-dried Live Attenuated Measles/Rubella Combined Vaccine (Schwarz FF-8 Str… | — | Measles/Rubella | Completed | 2007-03-28 | 2011-02-20 | ClinicalTrials.gov |
| NCT02158364 | Freeze-dried Live Attenuated Measles/Rubella Combined Vaccine (Schwarz FF-8 Str… | — | Measles/Rubella | Completed | 2007-03-28 | 2011-02-20 | ClinicalTrials.gov |
| NCT02158364 | Freeze-dried Live Attenuated Measles/Rubella Combined Vaccine (Schwarz FF-8 Str… | — | Measles/Rubella | Completed | 2007-03-28 | 2011-02-20 | ClinicalTrials.gov |
| NCT00557323 | Long-term Effect of Lanthanum Carbonate on Bone | — | Hyperphosphatemia | Completed | 2007-03-15 | 2010-08-31 | ClinicalTrials.gov |
| NCT00557323 | Long-term Effect of Lanthanum Carbonate on Bone | — | Hyperphosphatemia | Completed | 2007-03-15 | 2010-08-31 | ClinicalTrials.gov |
| NCT00557323 | Long-term Effect of Lanthanum Carbonate on Bone | — | Hyperphosphatemia | Completed | 2007-03-15 | 2010-08-31 | ClinicalTrials.gov |
| NCT00760344 | Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus | Phase2 | Diabetes Mellitus | Completed | 2007-03-01 | 2008-03-01 | ClinicalTrials.gov |
| NCT00770497 | Efficacy Study of Pioglitazone and Ramipril Combination Therapy in Treating Non… | Phase2 | Inflammation | Completed | 2007-03-01 | 2008-05-01 | ClinicalTrials.gov |
| NCT00770497 | Efficacy Study of Pioglitazone and Ramipril Combination Therapy in Treating Non… | Phase2 | Inflammation | Completed | 2007-03-01 | 2008-05-01 | ClinicalTrials.gov |
| NCT00449813 | The CONQUEST-Study. Evaluation of Clinical Endpoints for Treatment-induced Chan… | Phase4 | Gastroesophageal Reflux Disease | Terminated | 2007-03-01 | 2008-11-01 | ClinicalTrials.gov |
| NCT00760344 | Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus | Phase2 | Diabetes Mellitus | Completed | 2007-03-01 | 2008-03-01 | ClinicalTrials.gov |
| NCT00760344 | Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus | Phase2 | Diabetes Mellitus | Completed | 2007-03-01 | 2008-03-01 | ClinicalTrials.gov |
| NCT00449813 | The CONQUEST-Study. Evaluation of Clinical Endpoints for Treatment-induced Chan… | Phase4 | Gastroesophageal Reflux Disease | Terminated | 2007-03-01 | 2008-11-01 | ClinicalTrials.gov |
| NCT00770497 | Efficacy Study of Pioglitazone and Ramipril Combination Therapy in Treating Non… | Phase2 | Inflammation | Completed | 2007-03-01 | 2008-05-01 | ClinicalTrials.gov |
| NCT00449813 | The CONQUEST-Study. Evaluation of Clinical Endpoints for Treatment-induced Chan… | Phase4 | Gastroesophageal Reflux Disease | Terminated | 2007-03-01 | 2008-11-01 | ClinicalTrials.gov |
| NCT00430625 | A Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement… | Phase3 | Gaucher Disease, Type 1 | Completed | 2007-02-15 | 2009-04-01 | ClinicalTrials.gov |
| NCT00430625 | A Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement… | Phase3 | Gaucher Disease, Type 1 | Completed | 2007-02-15 | 2009-04-01 | ClinicalTrials.gov |
| NCT00430625 | A Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement… | Phase3 | Gaucher Disease, Type 1 | Completed | 2007-02-15 | 2009-04-01 | ClinicalTrials.gov |
| NCT00492011 | Efficacy of Ramelteon on Insomnia Symptoms Associated With Jet Lag in Healthy A… | Phase4 | Circadian Dysregulation | Completed | 2007-02-01 | 2007-08-01 | ClinicalTrials.gov |
| NCT00439361 | Velcade Plus ICE for Patients With Relapsed Classical Hodgkin Lymphoma | Phase1 | Hodgkin Lymphoma | Completed | 2007-02-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT01158911 | Uric Acid and Long-term Outcomes in Chronic Kidney Disease | — | Chronic Kidney Disease | Completed | 2007-02-01 | — | ClinicalTrials.gov |
| NCT00439361 | Velcade Plus ICE for Patients With Relapsed Classical Hodgkin Lymphoma | Phase1 | Hodgkin Lymphoma | Completed | 2007-02-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT01158911 | Uric Acid and Long-term Outcomes in Chronic Kidney Disease | — | Chronic Kidney Disease | Completed | 2007-02-01 | — | ClinicalTrials.gov |
| NCT01158911 | Uric Acid and Long-term Outcomes in Chronic Kidney Disease | — | Chronic Kidney Disease | Completed | 2007-02-01 | — | ClinicalTrials.gov |
| NCT00492011 | Efficacy of Ramelteon on Insomnia Symptoms Associated With Jet Lag in Healthy A… | Phase4 | Circadian Dysregulation | Completed | 2007-02-01 | 2007-08-01 | ClinicalTrials.gov |
| NCT00430248 | Efficacy and Safety of Oral Febuxostat in Participants With Gout | Phase3 | Gout | Completed | 2007-02-01 | 2008-03-01 | ClinicalTrials.gov |
| NCT00430248 | Efficacy and Safety of Oral Febuxostat in Participants With Gout | Phase3 | Gout | Completed | 2007-02-01 | 2008-03-01 | ClinicalTrials.gov |
| NCT00492011 | Efficacy of Ramelteon on Insomnia Symptoms Associated With Jet Lag in Healthy A… | Phase4 | Circadian Dysregulation | Completed | 2007-02-01 | 2007-08-01 | ClinicalTrials.gov |
| NCT00430248 | Efficacy and Safety of Oral Febuxostat in Participants With Gout | Phase3 | Gout | Completed | 2007-02-01 | 2008-03-01 | ClinicalTrials.gov |
| NCT00439361 | Velcade Plus ICE for Patients With Relapsed Classical Hodgkin Lymphoma | Phase1 | Hodgkin Lymphoma | Completed | 2007-02-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT00399308 | Evaluation of Safety and Activity of Celaderm in Healing Venous Leg Ulcers | Phase1 | Leg Ulcer | Completed | 2007-01-31 | 2008-04-30 | ClinicalTrials.gov |
| NCT00399308 | Evaluation of Safety and Activity of Celaderm in Healing Venous Leg Ulcers | Phase1 | Leg Ulcer | Completed | 2007-01-31 | 2008-04-30 | ClinicalTrials.gov |
| NCT00399308 | Evaluation of Safety and Activity of Celaderm in Healing Venous Leg Ulcers | Phase1 | Leg Ulcer | Completed | 2007-01-31 | 2008-04-30 | ClinicalTrials.gov |
| NCT00633139 | Long-term Metazym Treatment of Patients With Late Infantile Metachromatic Leuko… | Phase1 | Late Infantile Metachromatic Leukodystrophy | Completed | 2007-01-22 | 2008-11-25 | ClinicalTrials.gov |
| NCT00633139 | Long-term Metazym Treatment of Patients With Late Infantile Metachromatic Leuko… | Phase1 | Late Infantile Metachromatic Leukodystrophy | Completed | 2007-01-22 | 2008-11-25 | ClinicalTrials.gov |
| NCT00633139 | Long-term Metazym Treatment of Patients With Late Infantile Metachromatic Leuko… | Phase1 | Late Infantile Metachromatic Leukodystrophy | Completed | 2007-01-22 | 2008-11-25 | ClinicalTrials.gov |
| NCT00441545 | Head to Head Study Against Sevelamer Hydrochloride | Phase3 | Chronic Kidney Disease, Stage 5 | Completed | 2007-01-05 | 2008-07-31 | ClinicalTrials.gov |
| NCT00441545 | Head to Head Study Against Sevelamer Hydrochloride | Phase3 | Chronic Kidney Disease, Stage 5 | Completed | 2007-01-05 | 2008-07-31 | ClinicalTrials.gov |
| NCT00441545 | Head to Head Study Against Sevelamer Hydrochloride | Phase3 | Chronic Kidney Disease, Stage 5 | Completed | 2007-01-05 | 2008-07-31 | ClinicalTrials.gov |
| NCT02170207 | Takepron Intravenous 30 mg Specified Drug-use Survey [Acute Stress Ulcer and Ac… | — | Acute Stress Ulcer and Acute Gastric Mucosal Lesions | Completed | 2007-01-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT01263470 | Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes in Japan | Phase2 | Diabetes Mellitus, Type 2 | Completed | 2007-01-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00432276 | Efficacy of Alogliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellit… | Phase3 | Diabetes Mellitus | Completed | 2007-01-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT02170207 | Takepron Intravenous 30 mg Specified Drug-use Survey [Acute Stress Ulcer and Ac… | — | Acute Stress Ulcer and Acute Gastric Mucosal Lesions | Completed | 2007-01-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00772174 | Efficacy and Safety Study of Pioglitazone Combined With Metformin on Metabolic … | Phase3 | Diabetes Mellitus | Completed | 2007-01-01 | 2008-02-01 | ClinicalTrials.gov |
| NCT00510887 | Bortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Foll… | Phase2 | Lymphoma, Follicular | Terminated | 2007-01-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT00432276 | Efficacy of Alogliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellit… | Phase3 | Diabetes Mellitus | Completed | 2007-01-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT00510887 | Bortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Foll… | Phase2 | Lymphoma, Follicular | Terminated | 2007-01-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT01263483 | Efficacy and Safety of Alogliptin Used in Combination With α-glucosidase Inhibi… | Phase2 | Type 2 Diabetes Mellitus | Completed | 2007-01-01 | 2008-04-01 | ClinicalTrials.gov |
| NCT00458289 | Efficacy of Phosphate Binding in Healthy Volunteers: Chewed Versus Crushed Lant… | Phase1 | Hyperphosphatemia in Chronic Kidney Disease | Completed | 2007-01-01 | 2008-08-01 | ClinicalTrials.gov |
| NCT00438932 | Low Phosphate Diets in Patients With Early Stages of Chronic Kidney Disease | Na | Chronic Kidney Disease | Completed | 2007-01-01 | 2010-01-01 | ClinicalTrials.gov |
| NCT01263470 | Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes in Japan | Phase2 | Diabetes Mellitus, Type 2 | Completed | 2007-01-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT02170207 | Takepron Intravenous 30 mg Specified Drug-use Survey [Acute Stress Ulcer and Ac… | — | Acute Stress Ulcer and Acute Gastric Mucosal Lesions | Completed | 2007-01-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00458289 | Efficacy of Phosphate Binding in Healthy Volunteers: Chewed Versus Crushed Lant… | Phase1 | Hyperphosphatemia in Chronic Kidney Disease | Completed | 2007-01-01 | 2008-08-01 | ClinicalTrials.gov |
| NCT00772174 | Efficacy and Safety Study of Pioglitazone Combined With Metformin on Metabolic … | Phase3 | Diabetes Mellitus | Completed | 2007-01-01 | 2008-02-01 | ClinicalTrials.gov |
| NCT01263483 | Efficacy and Safety of Alogliptin Used in Combination With α-glucosidase Inhibi… | Phase2 | Type 2 Diabetes Mellitus | Completed | 2007-01-01 | 2008-04-01 | ClinicalTrials.gov |
| NCT00772174 | Efficacy and Safety Study of Pioglitazone Combined With Metformin on Metabolic … | Phase3 | Diabetes Mellitus | Completed | 2007-01-01 | 2008-02-01 | ClinicalTrials.gov |
| NCT01263483 | Efficacy and Safety of Alogliptin Used in Combination With α-glucosidase Inhibi… | Phase2 | Type 2 Diabetes Mellitus | Completed | 2007-01-01 | 2008-04-01 | ClinicalTrials.gov |
| NCT00510887 | Bortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Foll… | Phase2 | Lymphoma, Follicular | Terminated | 2007-01-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT01263470 | Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes in Japan | Phase2 | Diabetes Mellitus, Type 2 | Completed | 2007-01-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT02151786 | Lansoprazole Intravenous 30 mg Specified Drug-use Survey [Hemostatic Effect/Reb… | — | Gastric Ulcer, Duodenal Ulcer, Acute Stress Gastritis, and Acute Gastric Mucosal Lesions | Completed | 2007-01-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00438932 | Low Phosphate Diets in Patients With Early Stages of Chronic Kidney Disease | Na | Chronic Kidney Disease | Completed | 2007-01-01 | 2010-01-01 | ClinicalTrials.gov |
| NCT00438932 | Low Phosphate Diets in Patients With Early Stages of Chronic Kidney Disease | Na | Chronic Kidney Disease | Completed | 2007-01-01 | 2010-01-01 | ClinicalTrials.gov |
| NCT02151786 | Lansoprazole Intravenous 30 mg Specified Drug-use Survey [Hemostatic Effect/Reb… | — | Gastric Ulcer, Duodenal Ulcer, Acute Stress Gastritis, and Acute Gastric Mucosal Lesions | Completed | 2007-01-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT02151786 | Lansoprazole Intravenous 30 mg Specified Drug-use Survey [Hemostatic Effect/Reb… | — | Gastric Ulcer, Duodenal Ulcer, Acute Stress Gastritis, and Acute Gastric Mucosal Lesions | Completed | 2007-01-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00458289 | Efficacy of Phosphate Binding in Healthy Volunteers: Chewed Versus Crushed Lant… | Phase1 | Hyperphosphatemia in Chronic Kidney Disease | Completed | 2007-01-01 | 2008-08-01 | ClinicalTrials.gov |
| NCT00432276 | Efficacy of Alogliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellit… | Phase3 | Diabetes Mellitus | Completed | 2007-01-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT00411645 | Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disea… | Phase3 | Cytomegalovirus Infections | Completed | 2006-12-13 | 2009-05-23 | ClinicalTrials.gov |
| NCT00411645 | Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disea… | Phase3 | Cytomegalovirus Infections | Completed | 2006-12-13 | 2009-05-23 | ClinicalTrials.gov |
| NCT00411645 | Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disea… | Phase3 | Cytomegalovirus Infections | Completed | 2006-12-13 | 2009-05-23 | ClinicalTrials.gov |
| NCT00367835 | SPD503 (Guanfacine Hydrochloride) in ADHD Plus Oppositional Symptoms | Phase3 | ADHD | Completed | 2006-12-04 | 2008-01-04 | ClinicalTrials.gov |
| NCT00367835 | SPD503 (Guanfacine Hydrochloride) in ADHD Plus Oppositional Symptoms | Phase3 | ADHD | Completed | 2006-12-04 | 2008-01-04 | ClinicalTrials.gov |
| NCT00367835 | SPD503 (Guanfacine Hydrochloride) in ADHD Plus Oppositional Symptoms | Phase3 | ADHD | Completed | 2006-12-04 | 2008-01-04 | ClinicalTrials.gov |
| NCT00770952 | Efficacy of Pioglitazone and Glimepiride Combination Therapy in Treating Subjec… | Phase3 | Diabetes Mellitus | Completed | 2006-12-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00770952 | Efficacy of Pioglitazone and Glimepiride Combination Therapy in Treating Subjec… | Phase3 | Diabetes Mellitus | Completed | 2006-12-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00972712 | Protocol of the Combination of Bortezomib and Tipifarnib for Relapsed or Refrac… | Phase1 | Multiple Myeloma | Completed | 2006-12-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT00972712 | Protocol of the Combination of Bortezomib and Tipifarnib for Relapsed or Refrac… | Phase1 | Multiple Myeloma | Completed | 2006-12-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT00770952 | Efficacy of Pioglitazone and Glimepiride Combination Therapy in Treating Subjec… | Phase3 | Diabetes Mellitus | Completed | 2006-12-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00972712 | Protocol of the Combination of Bortezomib and Tipifarnib for Relapsed or Refrac… | Phase1 | Multiple Myeloma | Completed | 2006-12-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT00413634 | The Pharmacokinetics of Anagrelide in Elderly and Young Patients With Essential… | Phase2 | Essential Thrombocythaemia | Completed | 2006-11-13 | 2008-01-22 | ClinicalTrials.gov |
| NCT00413634 | The Pharmacokinetics of Anagrelide in Elderly and Young Patients With Essential… | Phase2 | Essential Thrombocythaemia | Completed | 2006-11-13 | 2008-01-22 | ClinicalTrials.gov |
| NCT00413634 | The Pharmacokinetics of Anagrelide in Elderly and Young Patients With Essential… | Phase2 | Essential Thrombocythaemia | Completed | 2006-11-13 | 2008-01-22 | ClinicalTrials.gov |
| NCT00402012 | "TAKE TIME" Pioglitazone Reverses Defects in Mitochondrial Biogenesis in Patien… | Phase4 | Diabetes Mellitus, Type 2 | Completed | 2006-11-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00348855 | Study to Improve Quality of Care and Patient Health in the Field of Cardiovascu… | Phase4 | High Risk Hypertensive Patients | Completed | 2006-11-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00402012 | "TAKE TIME" Pioglitazone Reverses Defects in Mitochondrial Biogenesis in Patien… | Phase4 | Diabetes Mellitus, Type 2 | Completed | 2006-11-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00395512 | Efficacy of Alogliptin With Pioglitazone (Actos®) in Subjects With Type 2 Diabe… | Phase3 | Diabetes Mellitus | Completed | 2006-11-01 | 2008-02-01 | ClinicalTrials.gov |
| NCT00402012 | "TAKE TIME" Pioglitazone Reverses Defects in Mitochondrial Biogenesis in Patien… | Phase4 | Diabetes Mellitus, Type 2 | Completed | 2006-11-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00411593 | Phase I-II for Patients With Recurrent or Refractory Non-small Cell Lung Cancer… | Phase1 | Lung Cancer | Withdrawn | 2006-11-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT00395512 | Efficacy of Alogliptin With Pioglitazone (Actos®) in Subjects With Type 2 Diabe… | Phase3 | Diabetes Mellitus | Completed | 2006-11-01 | 2008-02-01 | ClinicalTrials.gov |
| NCT00395512 | Efficacy of Alogliptin With Pioglitazone (Actos®) in Subjects With Type 2 Diabe… | Phase3 | Diabetes Mellitus | Completed | 2006-11-01 | 2008-02-01 | ClinicalTrials.gov |
| NCT00348855 | Study to Improve Quality of Care and Patient Health in the Field of Cardiovascu… | Phase4 | High Risk Hypertensive Patients | Completed | 2006-11-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00411593 | Phase I-II for Patients With Recurrent or Refractory Non-small Cell Lung Cancer… | Phase1 | Lung Cancer | Withdrawn | 2006-11-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT00348855 | Study to Improve Quality of Care and Patient Health in the Field of Cardiovascu… | Phase4 | High Risk Hypertensive Patients | Completed | 2006-11-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00763347 | Efficacy and Safety Study of SYR-619 in Treating Subjects With Type 2 Diabetes … | Phase2 | Diabetes Mellitus | Terminated | 2006-11-01 | 2007-02-01 | ClinicalTrials.gov |
| NCT00763347 | Efficacy and Safety Study of SYR-619 in Treating Subjects With Type 2 Diabetes … | Phase2 | Diabetes Mellitus | Terminated | 2006-11-01 | 2007-02-01 | ClinicalTrials.gov |
| NCT00763347 | Efficacy and Safety Study of SYR-619 in Treating Subjects With Type 2 Diabetes … | Phase2 | Diabetes Mellitus | Terminated | 2006-11-01 | 2007-02-01 | ClinicalTrials.gov |
| NCT00411593 | Phase I-II for Patients With Recurrent or Refractory Non-small Cell Lung Cancer… | Phase1 | Lung Cancer | Withdrawn | 2006-11-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT00450333 | Dynepo Infrequent Dosing Study | Phase3 | Anemia | Terminated | 2006-10-30 | 2008-07-31 | ClinicalTrials.gov |
| NCT00450333 | Dynepo Infrequent Dosing Study | Phase3 | Anemia | Terminated | 2006-10-30 | 2008-07-31 | ClinicalTrials.gov |
| NCT00450333 | Dynepo Infrequent Dosing Study | Phase3 | Anemia | Terminated | 2006-10-30 | 2008-07-31 | ClinicalTrials.gov |
| NCT00432510 | Pharmacokinetics of C1 Esterase Inhibitor in Hereditary Angioedema Subjects | Phase1 | Hereditary Angioedema | Completed | 2006-10-09 | 2007-02-28 | ClinicalTrials.gov |
| NCT00432510 | Pharmacokinetics of C1 Esterase Inhibitor in Hereditary Angioedema Subjects | Phase1 | Hereditary Angioedema | Completed | 2006-10-09 | 2007-02-28 | ClinicalTrials.gov |
| NCT00432510 | Pharmacokinetics of C1 Esterase Inhibitor in Hereditary Angioedema Subjects | Phase1 | Hereditary Angioedema | Completed | 2006-10-09 | 2007-02-28 | ClinicalTrials.gov |
| NCT00377598 | Efficacy, Safety and Tolerability Study of TAK-583 in Subjects With Postherpeti… | Phase2 | Neuralgia, Postherpetic | Completed | 2006-10-01 | 2008-02-01 | ClinicalTrials.gov |
| NCT00775814 | Efficacy of Candesartan on Reducing Blood Pressure in Insulin-Resistant, Obese … | Phase4 | Obesity | Completed | 2006-10-01 | 2008-09-01 | ClinicalTrials.gov |
| NCT00414102 | Subjective Efficacy of Ramelteon on Sleep in Adults With Chronic Insomnia. | Phase4 | Chronic Insomnia | Completed | 2006-10-01 | 2007-09-01 | ClinicalTrials.gov |
| NCT00391755 | A Double-Blind Placebo-Controlled Trial of Rozerem in Migraine Headaches | Phase4 | Migraine Headache | Terminated | 2006-10-01 | 2009-10-01 | ClinicalTrials.gov |
| NCT00414102 | Subjective Efficacy of Ramelteon on Sleep in Adults With Chronic Insomnia. | Phase4 | Chronic Insomnia | Completed | 2006-10-01 | 2007-09-01 | ClinicalTrials.gov |
| NCT00414102 | Subjective Efficacy of Ramelteon on Sleep in Adults With Chronic Insomnia. | Phase4 | Chronic Insomnia | Completed | 2006-10-01 | 2007-09-01 | ClinicalTrials.gov |
| NCT00775814 | Efficacy of Candesartan on Reducing Blood Pressure in Insulin-Resistant, Obese … | Phase4 | Obesity | Completed | 2006-10-01 | 2008-09-01 | ClinicalTrials.gov |
| NCT00775814 | Efficacy of Candesartan on Reducing Blood Pressure in Insulin-Resistant, Obese … | Phase4 | Obesity | Completed | 2006-10-01 | 2008-09-01 | ClinicalTrials.gov |
| NCT00391755 | A Double-Blind Placebo-Controlled Trial of Rozerem in Migraine Headaches | Phase4 | Migraine Headache | Terminated | 2006-10-01 | 2009-10-01 | ClinicalTrials.gov |
| NCT00377598 | Efficacy, Safety and Tolerability Study of TAK-583 in Subjects With Postherpeti… | Phase2 | Neuralgia, Postherpetic | Completed | 2006-10-01 | 2008-02-01 | ClinicalTrials.gov |
| NCT00377598 | Efficacy, Safety and Tolerability Study of TAK-583 in Subjects With Postherpeti… | Phase2 | Neuralgia, Postherpetic | Completed | 2006-10-01 | 2008-02-01 | ClinicalTrials.gov |
| NCT00391755 | A Double-Blind Placebo-Controlled Trial of Rozerem in Migraine Headaches | Phase4 | Migraine Headache | Terminated | 2006-10-01 | 2009-10-01 | ClinicalTrials.gov |
| NCT00438815 | Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Heredita… | Phase3 | Hereditary Angioedema | Completed | 2006-09-21 | 2009-03-31 | ClinicalTrials.gov |
| NCT00438815 | Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Heredita… | Phase3 | Hereditary Angioedema | Completed | 2006-09-21 | 2009-03-31 | ClinicalTrials.gov |
| NCT00438815 | Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Heredita… | Phase3 | Hereditary Angioedema | Completed | 2006-09-21 | 2009-03-31 | ClinicalTrials.gov |
| NCT00820885 | A Double-Blind Multi-Dose Tolerability and Pharmacokinetic Study of Teduglutide | Phase1 | Pharmacokinetics and Safety of Elevated Doses | Completed | 2006-09-06 | 2007-04-23 | ClinicalTrials.gov |
| NCT00820885 | A Double-Blind Multi-Dose Tolerability and Pharmacokinetic Study of Teduglutide | Phase1 | Pharmacokinetics and Safety of Elevated Doses | Completed | 2006-09-06 | 2007-04-23 | ClinicalTrials.gov |
| NCT00820885 | A Double-Blind Multi-Dose Tolerability and Pharmacokinetic Study of Teduglutide | Phase1 | Pharmacokinetics and Safety of Elevated Doses | Completed | 2006-09-06 | 2007-04-23 | ClinicalTrials.gov |
| NCT00760955 | Efficacy and Safety of TAK-583 in Subjects With Diabetic Peripheral Neuropathy | Phase2 | Diabetic Neuropathies | Completed | 2006-09-01 | 2008-02-01 | ClinicalTrials.gov |
| NCT00502320 | Ramelteon in the Treatment of Sleep and Mood in Patients With Seasonal Affectiv… | Phase4 | Seasonal Affective Disorder | Completed | 2006-09-01 | 2008-07-01 | ClinicalTrials.gov |
| NCT01124656 | Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diab… | Phase3 | Diabetes Mellitus, Type 2 | Terminated | 2006-09-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT01124656 | Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diab… | Phase3 | Diabetes Mellitus, Type 2 | Terminated | 2006-09-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT00378105 | Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With… | Phase1 | Multiple Myeloma | Active_Not_Recruiting | 2006-09-01 | 2026-12-01 | ClinicalTrials.gov |
| NCT00502320 | Ramelteon in the Treatment of Sleep and Mood in Patients With Seasonal Affectiv… | Phase4 | Seasonal Affective Disorder | Completed | 2006-09-01 | 2008-07-01 | ClinicalTrials.gov |
| NCT00502320 | Ramelteon in the Treatment of Sleep and Mood in Patients With Seasonal Affectiv… | Phase4 | Seasonal Affective Disorder | Completed | 2006-09-01 | 2008-07-01 | ClinicalTrials.gov |
| NCT00378105 | Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With… | Phase1 | Multiple Myeloma | Active_Not_Recruiting | 2006-09-01 | 2026-12-01 | ClinicalTrials.gov |
| NCT00760955 | Efficacy and Safety of TAK-583 in Subjects With Diabetic Peripheral Neuropathy | Phase2 | Diabetic Neuropathies | Completed | 2006-09-01 | 2008-02-01 | ClinicalTrials.gov |
| NCT00760955 | Efficacy and Safety of TAK-583 in Subjects With Diabetic Peripheral Neuropathy | Phase2 | Diabetic Neuropathies | Completed | 2006-09-01 | 2008-02-01 | ClinicalTrials.gov |
| NCT00378105 | Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With… | Phase1 | Multiple Myeloma | Active_Not_Recruiting | 2006-09-01 | 2026-12-01 | ClinicalTrials.gov |
| NCT01124656 | Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diab… | Phase3 | Diabetes Mellitus, Type 2 | Terminated | 2006-09-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT00422799 | Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobul… | Phase2 | Waldenstrom's Macroglobulinemia | Completed | 2006-08-30 | 2015-10-09 | ClinicalTrials.gov |
| NCT00422799 | Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobul… | Phase2 | Waldenstrom's Macroglobulinemia | Completed | 2006-08-30 | 2015-10-09 | ClinicalTrials.gov |
| NCT00422799 | Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobul… | Phase2 | Waldenstrom's Macroglobulinemia | Completed | 2006-08-30 | 2015-10-09 | ClinicalTrials.gov |
| NCT00492050 | Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia | Phase2 | Waldenstrom's Macroglobulinemia | Active_Not_Recruiting | 2006-08-02 | 2026-06-28 | ClinicalTrials.gov |
| NCT00492050 | Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia | Phase2 | Waldenstrom's Macroglobulinemia | Active_Not_Recruiting | 2006-08-02 | 2026-06-28 | ClinicalTrials.gov |
| NCT00492050 | Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia | Phase2 | Waldenstrom's Macroglobulinemia | Active_Not_Recruiting | 2006-08-02 | 2026-06-28 | ClinicalTrials.gov |
| NCT00574236 | Phase II Trial of Bortezomib and Doxorubicin in Metastatic Breast Cancer | Phase2 | Metastatic Breast Cancer | Terminated | 2006-08-01 | 2009-10-01 | ClinicalTrials.gov |
| NCT00369226 | Bortezomib Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Diseas… | Phase1 | Hematologic Malignancies | Completed | 2006-08-01 | 2011-09-01 | ClinicalTrials.gov |
| NCT00771004 | Efficacy of Pioglitazone on Myocardial Function in Patients Undergoing Coronary… | Phase2 | Oxidative Stress | Completed | 2006-08-01 | 2009-02-01 | ClinicalTrials.gov |
| NCT00336219 | Symptom Assessment in Adult Patients With Erosive GERD (Gastroesophageal Reflux… | Phase3 | GERD | Completed | 2006-08-01 | 2007-04-01 | ClinicalTrials.gov |
| NCT00574236 | Phase II Trial of Bortezomib and Doxorubicin in Metastatic Breast Cancer | Phase2 | Metastatic Breast Cancer | Terminated | 2006-08-01 | 2009-10-01 | ClinicalTrials.gov |
| NCT00574236 | Phase II Trial of Bortezomib and Doxorubicin in Metastatic Breast Cancer | Phase2 | Metastatic Breast Cancer | Terminated | 2006-08-01 | 2009-10-01 | ClinicalTrials.gov |
| NCT00337272 | Treating Chronic Insomnia in Breast Cancer Patients | Phase4 | Chronic Insomnia | Terminated | 2006-08-01 | 2009-01-01 | ClinicalTrials.gov |
| NCT00771004 | Efficacy of Pioglitazone on Myocardial Function in Patients Undergoing Coronary… | Phase2 | Oxidative Stress | Completed | 2006-08-01 | 2009-02-01 | ClinicalTrials.gov |
| NCT00413959 | VELCADE,Rituximab,Cyclophosphamide and Decadron | Phase2 | Lymphoma, Non-Hodgkin | Terminated | 2006-08-01 | 2011-01-01 | ClinicalTrials.gov |
| NCT00336219 | Symptom Assessment in Adult Patients With Erosive GERD (Gastroesophageal Reflux… | Phase3 | GERD | Completed | 2006-08-01 | 2007-04-01 | ClinicalTrials.gov |
| NCT00369226 | Bortezomib Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Diseas… | Phase1 | Hematologic Malignancies | Completed | 2006-08-01 | 2011-09-01 | ClinicalTrials.gov |
| NCT00378209 | Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients Wi… | Phase2 | Multiple Myeloma | Completed | 2006-08-01 | 2016-10-01 | ClinicalTrials.gov |
| NCT00378209 | Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients Wi… | Phase2 | Multiple Myeloma | Completed | 2006-08-01 | 2016-10-01 | ClinicalTrials.gov |
| NCT00337272 | Treating Chronic Insomnia in Breast Cancer Patients | Phase4 | Chronic Insomnia | Terminated | 2006-08-01 | 2009-01-01 | ClinicalTrials.gov |
| NCT00413959 | VELCADE,Rituximab,Cyclophosphamide and Decadron | Phase2 | Lymphoma, Non-Hodgkin | Terminated | 2006-08-01 | 2011-01-01 | ClinicalTrials.gov |
| NCT00337272 | Treating Chronic Insomnia in Breast Cancer Patients | Phase4 | Chronic Insomnia | Terminated | 2006-08-01 | 2009-01-01 | ClinicalTrials.gov |
| NCT00771004 | Efficacy of Pioglitazone on Myocardial Function in Patients Undergoing Coronary… | Phase2 | Oxidative Stress | Completed | 2006-08-01 | 2009-02-01 | ClinicalTrials.gov |
| NCT00413959 | VELCADE,Rituximab,Cyclophosphamide and Decadron | Phase2 | Lymphoma, Non-Hodgkin | Terminated | 2006-08-01 | 2011-01-01 | ClinicalTrials.gov |
| NCT00378209 | Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients Wi… | Phase2 | Multiple Myeloma | Completed | 2006-08-01 | 2016-10-01 | ClinicalTrials.gov |
| NCT00369226 | Bortezomib Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Diseas… | Phase1 | Hematologic Malignancies | Completed | 2006-08-01 | 2011-09-01 | ClinicalTrials.gov |
| NCT00336219 | Symptom Assessment in Adult Patients With Erosive GERD (Gastroesophageal Reflux… | Phase3 | GERD | Completed | 2006-08-01 | 2007-04-01 | ClinicalTrials.gov |
| NCT00365456 | Sequential Treatment of Postmenopausal Women With Primary Osteoporosis (FP-001-… | Phase3 | Osteoporosis | Completed | 2006-07-01 | 2011-08-01 | ClinicalTrials.gov |
| NCT00337285 | An Open-label Study of NRP104 in Adults With Attention Deficit Hyperactivity Di… | Phase3 | Attention Deficit Hyperactivity Disorder | Completed | 2006-07-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00337285 | An Open-label Study of NRP104 in Adults With Attention Deficit Hyperactivity Di… | Phase3 | Attention Deficit Hyperactivity Disorder | Completed | 2006-07-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00337285 | An Open-label Study of NRP104 in Adults With Attention Deficit Hyperactivity Di… | Phase3 | Attention Deficit Hyperactivity Disorder | Completed | 2006-07-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00610792 | Phase 2 Study of Twice Weekly VELCADE and CAELYX in Patients With Ovarian Cance… | Phase2 | Ovarian Cancer | Withdrawn | 2006-07-01 | — | ClinicalTrials.gov |
| NCT00366106 | Alternative Schedule of Velcade/Dexamethasone Plus Doxil for Patients With Mult… | Phase2 | Multiple Myeloma | Terminated | 2006-07-01 | 2011-03-01 | ClinicalTrials.gov |
| NCT00361621 | Ph II CHOP+Velcade in Mediastinal LBCL | Phase2 | Non-Hodgkin's Lymphoma | Terminated | 2006-07-01 | 2008-05-01 | ClinicalTrials.gov |
| NCT00885807 | A Prospective Chart Review to Validate the WFIRS (Weiss Functional Impairment R… | — | Attention-Deficit/Hyperactivity Disorder | Completed | 2006-07-01 | 2011-04-01 | ClinicalTrials.gov |
| NCT00366106 | Alternative Schedule of Velcade/Dexamethasone Plus Doxil for Patients With Mult… | Phase2 | Multiple Myeloma | Terminated | 2006-07-01 | 2011-03-01 | ClinicalTrials.gov |
| NCT01048242 | Treatment of Insomnia in Elderly Sleep Apnea Patients With Ramelteon (TAK 375) | Phase3 | Insomnia | Completed | 2006-07-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00755495 | Safety and Efficacy of Ramelteon and Doxepin in Subjects With Chronic Insomnia | Phase2 | Sleep Initiation and Maintenance Disorders | Completed | 2006-07-01 | 2007-03-01 | ClinicalTrials.gov |
| NCT01048242 | Treatment of Insomnia in Elderly Sleep Apnea Patients With Ramelteon (TAK 375) | Phase3 | Insomnia | Completed | 2006-07-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00610792 | Phase 2 Study of Twice Weekly VELCADE and CAELYX in Patients With Ovarian Cance… | Phase2 | Ovarian Cancer | Withdrawn | 2006-07-01 | — | ClinicalTrials.gov |
| NCT00361621 | Ph II CHOP+Velcade in Mediastinal LBCL | Phase2 | Non-Hodgkin's Lymphoma | Terminated | 2006-07-01 | 2008-05-01 | ClinicalTrials.gov |
| NCT00365456 | Sequential Treatment of Postmenopausal Women With Primary Osteoporosis (FP-001-… | Phase3 | Osteoporosis | Completed | 2006-07-01 | 2011-08-01 | ClinicalTrials.gov |
| NCT00365456 | Sequential Treatment of Postmenopausal Women With Primary Osteoporosis (FP-001-… | Phase3 | Osteoporosis | Completed | 2006-07-01 | 2011-08-01 | ClinicalTrials.gov |
| NCT00366106 | Alternative Schedule of Velcade/Dexamethasone Plus Doxil for Patients With Mult… | Phase2 | Multiple Myeloma | Terminated | 2006-07-01 | 2011-03-01 | ClinicalTrials.gov |
| NCT00755495 | Safety and Efficacy of Ramelteon and Doxepin in Subjects With Chronic Insomnia | Phase2 | Sleep Initiation and Maintenance Disorders | Completed | 2006-07-01 | 2007-03-01 | ClinicalTrials.gov |
| NCT00755495 | Safety and Efficacy of Ramelteon and Doxepin in Subjects With Chronic Insomnia | Phase2 | Sleep Initiation and Maintenance Disorders | Completed | 2006-07-01 | 2007-03-01 | ClinicalTrials.gov |
| NCT01048242 | Treatment of Insomnia in Elderly Sleep Apnea Patients With Ramelteon (TAK 375) | Phase3 | Insomnia | Completed | 2006-07-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00885807 | A Prospective Chart Review to Validate the WFIRS (Weiss Functional Impairment R… | — | Attention-Deficit/Hyperactivity Disorder | Completed | 2006-07-01 | 2011-04-01 | ClinicalTrials.gov |
| NCT00610792 | Phase 2 Study of Twice Weekly VELCADE and CAELYX in Patients With Ovarian Cance… | Phase2 | Ovarian Cancer | Withdrawn | 2006-07-01 | — | ClinicalTrials.gov |
| NCT00885807 | A Prospective Chart Review to Validate the WFIRS (Weiss Functional Impairment R… | — | Attention-Deficit/Hyperactivity Disorder | Completed | 2006-07-01 | 2011-04-01 | ClinicalTrials.gov |
| NCT00361621 | Ph II CHOP+Velcade in Mediastinal LBCL | Phase2 | Non-Hodgkin's Lymphoma | Terminated | 2006-07-01 | 2008-05-01 | ClinicalTrials.gov |
| NCT00462709 | Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Heredit… | Phase3 | Hereditary Angioedema | Completed | 2006-06-27 | 2009-03-31 | ClinicalTrials.gov |
| NCT00462709 | Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Heredit… | Phase3 | Hereditary Angioedema | Completed | 2006-06-27 | 2009-03-31 | ClinicalTrials.gov |
| NCT00462709 | Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Heredit… | Phase3 | Hereditary Angioedema | Completed | 2006-06-27 | 2009-03-31 | ClinicalTrials.gov |
| NCT00776074 | A Pharmacodynamic Study of Leuprorelin Gelatin-Free Formulation in Female Subje… | Phase2 | Uterine Fibroids | Completed | 2006-06-01 | 2007-07-01 | ClinicalTrials.gov |
| NCT00324974 | The Use of Lansoprazole to Treat Infants With Symptoms of Gastroesophageal Refl… | Phase3 | Gastroesophageal Reflux Disease | Completed | 2006-06-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT00321984 | Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Ga… | Phase3 | Gastroesophageal Reflux Disease | Completed | 2006-06-01 | 2006-12-01 | ClinicalTrials.gov |
| NCT00376181 | Efficacy, Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With T… | Phase3 | Type 2 Diabetes | Terminated | 2006-06-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT00325676 | Comparison of the Classical Healing Concept With the Complete Remission Concept… | Phase4 | Gastroesophageal Reflux Disease | Completed | 2006-06-01 | — | ClinicalTrials.gov |
| NCT00310037 | Bortezomib After Combination Chemotherapy, Rituximab, and an Autologous Stem Ce… | Phase2 | Mantle Cell Lymphoma | Completed | 2006-06-01 | 2022-06-01 | ClinicalTrials.gov |
| NCT00324974 | The Use of Lansoprazole to Treat Infants With Symptoms of Gastroesophageal Refl… | Phase3 | Gastroesophageal Reflux Disease | Completed | 2006-06-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT00568789 | Safety of Ramelteon in Elderly Subjects | Phase4 | Insomnia | Completed | 2006-06-01 | 2006-09-01 | ClinicalTrials.gov |
| NCT00321984 | Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Ga… | Phase3 | Gastroesophageal Reflux Disease | Completed | 2006-06-01 | 2006-12-01 | ClinicalTrials.gov |
| NCT00424840 | Phase I/II Study to Evaluate the Efficacy and Safety of a Combination Chemother… | Phase1 | Lung Cancer | Terminated | 2006-06-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT00424840 | Phase I/II Study to Evaluate the Efficacy and Safety of a Combination Chemother… | Phase1 | Lung Cancer | Terminated | 2006-06-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT02166697 | Blopress Tablets Specified Drug-use Survey "Hypertension: Survey on Patients Wi… | — | Hypertension | Completed | 2006-06-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT00310037 | Bortezomib After Combination Chemotherapy, Rituximab, and an Autologous Stem Ce… | Phase2 | Mantle Cell Lymphoma | Completed | 2006-06-01 | 2022-06-01 | ClinicalTrials.gov |
| NCT00568789 | Safety of Ramelteon in Elderly Subjects | Phase4 | Insomnia | Completed | 2006-06-01 | 2006-09-01 | ClinicalTrials.gov |
| NCT01588470 | Myocardial Dysfunction in Type 2 Diabetes Mellitus (T2DM) | Phase4 | Type 2 Diabetes | Completed | 2006-06-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT00568789 | Safety of Ramelteon in Elderly Subjects | Phase4 | Insomnia | Completed | 2006-06-01 | 2006-09-01 | ClinicalTrials.gov |
| NCT00776074 | A Pharmacodynamic Study of Leuprorelin Gelatin-Free Formulation in Female Subje… | Phase2 | Uterine Fibroids | Completed | 2006-06-01 | 2007-07-01 | ClinicalTrials.gov |
| NCT00424840 | Phase I/II Study to Evaluate the Efficacy and Safety of a Combination Chemother… | Phase1 | Lung Cancer | Terminated | 2006-06-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT00376181 | Efficacy, Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With T… | Phase3 | Type 2 Diabetes | Terminated | 2006-06-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT00321984 | Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Ga… | Phase3 | Gastroesophageal Reflux Disease | Completed | 2006-06-01 | 2006-12-01 | ClinicalTrials.gov |
| NCT00324974 | The Use of Lansoprazole to Treat Infants With Symptoms of Gastroesophageal Refl… | Phase3 | Gastroesophageal Reflux Disease | Completed | 2006-06-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT01588470 | Myocardial Dysfunction in Type 2 Diabetes Mellitus (T2DM) | Phase4 | Type 2 Diabetes | Completed | 2006-06-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT01588470 | Myocardial Dysfunction in Type 2 Diabetes Mellitus (T2DM) | Phase4 | Type 2 Diabetes | Completed | 2006-06-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT00325676 | Comparison of the Classical Healing Concept With the Complete Remission Concept… | Phase4 | Gastroesophageal Reflux Disease | Completed | 2006-06-01 | — | ClinicalTrials.gov |
| NCT00776074 | A Pharmacodynamic Study of Leuprorelin Gelatin-Free Formulation in Female Subje… | Phase2 | Uterine Fibroids | Completed | 2006-06-01 | 2007-07-01 | ClinicalTrials.gov |
| NCT02166697 | Blopress Tablets Specified Drug-use Survey "Hypertension: Survey on Patients Wi… | — | Hypertension | Completed | 2006-06-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT00376181 | Efficacy, Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With T… | Phase3 | Type 2 Diabetes | Terminated | 2006-06-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT00310037 | Bortezomib After Combination Chemotherapy, Rituximab, and an Autologous Stem Ce… | Phase2 | Mantle Cell Lymphoma | Completed | 2006-06-01 | 2022-06-01 | ClinicalTrials.gov |
| NCT00325676 | Comparison of the Classical Healing Concept With the Complete Remission Concept… | Phase4 | Gastroesophageal Reflux Disease | Completed | 2006-06-01 | — | ClinicalTrials.gov |
| NCT02166697 | Blopress Tablets Specified Drug-use Survey "Hypertension: Survey on Patients Wi… | — | Hypertension | Completed | 2006-06-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT00325286 | Open Label Study of Lithium Plus Extended-Release Carbamazepine (ERC-CBZ) for R… | Phase4 | Bipolar Disorder | Unknown | 2006-05-01 | 2008-03-01 | ClinicalTrials.gov |
| NCT00312806 | Effect of Pantoprazole on the Symptoms of Acid Reflux Disease in Adult Patients… | Phase3 | Gastroesophageal Reflux Disease (GERD) | Completed | 2006-05-01 | 2007-07-01 | ClinicalTrials.gov |
| NCT00328627 | Efficacy and Safety of Alogliptin Combined With Pioglitazone in Treating Subjec… | Phase3 | Type 2 Diabetes Mellitus | Completed | 2006-05-01 | 2008-03-01 | ClinicalTrials.gov |
| NCT00321737 | Efficacy and Safety of Dexlansoprazole MR Compared to Placebo on Maintaining He… | Phase3 | Esophagitis, Reflux | Completed | 2006-05-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT00321737 | Efficacy and Safety of Dexlansoprazole MR Compared to Placebo on Maintaining He… | Phase3 | Esophagitis, Reflux | Completed | 2006-05-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT00312806 | Effect of Pantoprazole on the Symptoms of Acid Reflux Disease in Adult Patients… | Phase3 | Gastroesophageal Reflux Disease (GERD) | Completed | 2006-05-01 | 2007-07-01 | ClinicalTrials.gov |
| NCT00328627 | Efficacy and Safety of Alogliptin Combined With Pioglitazone in Treating Subjec… | Phase3 | Type 2 Diabetes Mellitus | Completed | 2006-05-01 | 2008-03-01 | ClinicalTrials.gov |
| NCT00312806 | Effect of Pantoprazole on the Symptoms of Acid Reflux Disease in Adult Patients… | Phase3 | Gastroesophageal Reflux Disease (GERD) | Completed | 2006-05-01 | 2007-07-01 | ClinicalTrials.gov |
| NCT00362115 | Safety and Efficacy of Azilsartan Medoxomil in Participants With Mild to Modera… | Phase2 | Hypertension | Completed | 2006-05-01 | 2006-12-01 | ClinicalTrials.gov |
| NCT00362115 | Safety and Efficacy of Azilsartan Medoxomil in Participants With Mild to Modera… | Phase2 | Hypertension | Completed | 2006-05-01 | 2006-12-01 | ClinicalTrials.gov |
| NCT00362115 | Safety and Efficacy of Azilsartan Medoxomil in Participants With Mild to Modera… | Phase2 | Hypertension | Completed | 2006-05-01 | 2006-12-01 | ClinicalTrials.gov |
| NCT00328627 | Efficacy and Safety of Alogliptin Combined With Pioglitazone in Treating Subjec… | Phase3 | Type 2 Diabetes Mellitus | Completed | 2006-05-01 | 2008-03-01 | ClinicalTrials.gov |
| NCT00325286 | Open Label Study of Lithium Plus Extended-Release Carbamazepine (ERC-CBZ) for R… | Phase4 | Bipolar Disorder | Unknown | 2006-05-01 | 2008-03-01 | ClinicalTrials.gov |
| NCT00325286 | Open Label Study of Lithium Plus Extended-Release Carbamazepine (ERC-CBZ) for R… | Phase4 | Bipolar Disorder | Unknown | 2006-05-01 | 2008-03-01 | ClinicalTrials.gov |
| NCT00321737 | Efficacy and Safety of Dexlansoprazole MR Compared to Placebo on Maintaining He… | Phase3 | Esophagitis, Reflux | Completed | 2006-05-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT00567723 | Long Term Treatment of End Stage Renal Disease Patients With Lanthanum Carbonat… | — | Hyperphosphatemia | Completed | 2006-04-25 | 2016-06-07 | ClinicalTrials.gov |
| NCT00567723 | Long Term Treatment of End Stage Renal Disease Patients With Lanthanum Carbonat… | — | Hyperphosphatemia | Completed | 2006-04-25 | 2016-06-07 | ClinicalTrials.gov |
| NCT00567723 | Long Term Treatment of End Stage Renal Disease Patients With Lanthanum Carbonat… | — | Hyperphosphatemia | Completed | 2006-04-25 | 2016-06-07 | ClinicalTrials.gov |
| NCT00571493 | VELCADE®-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Non-Ho… | Phase1 | Non-hodgkin's Lymphoma | Completed | 2006-04-14 | 2014-11-01 | ClinicalTrials.gov |
| NCT00571493 | VELCADE®-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Non-Ho… | Phase1 | Non-hodgkin's Lymphoma | Completed | 2006-04-14 | 2014-11-01 | ClinicalTrials.gov |
| NCT00571493 | VELCADE®-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Non-Ho… | Phase1 | Non-hodgkin's Lymphoma | Completed | 2006-04-14 | 2014-11-01 | ClinicalTrials.gov |
| NCT00290706 | A Phase I/II Trial of VELCADE & Gemcitabine for Patients With Relapsed or Refra… | Phase1 | Lymphoma | Terminated | 2006-04-07 | 2012-09-05 | ClinicalTrials.gov |
| NCT00290706 | A Phase I/II Trial of VELCADE & Gemcitabine for Patients With Relapsed or Refra… | Phase1 | Lymphoma | Terminated | 2006-04-07 | 2012-09-05 | ClinicalTrials.gov |
| NCT00290706 | A Phase I/II Trial of VELCADE & Gemcitabine for Patients With Relapsed or Refra… | Phase1 | Lymphoma | Terminated | 2006-04-07 | 2012-09-05 | ClinicalTrials.gov |
| NCT00314795 | Efficacy and Safety of Peginesatide (AF37702) in the Treatment of Anemia in Par… | Phase2 | Anemia | Completed | 2006-04-06 | 2016-10-31 | ClinicalTrials.gov |
| NCT00314795 | Efficacy and Safety of Peginesatide (AF37702) in the Treatment of Anemia in Par… | Phase2 | Anemia | Completed | 2006-04-06 | 2016-10-31 | ClinicalTrials.gov |
| NCT00314795 | Efficacy and Safety of Peginesatide (AF37702) in the Treatment of Anemia in Par… | Phase2 | Anemia | Completed | 2006-04-06 | 2016-10-31 | ClinicalTrials.gov |
| NCT00315146 | Optimizing Body Composition for Function in Older Adults | Phase4 | Obesity | Completed | 2006-04-01 | 2007-04-01 | ClinicalTrials.gov |
| NCT00457938 | Novel Therapies for Metabolic Complications of Lipodystrophies | Na | Insulin Resistance | Completed | 2006-04-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT00117884 | Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infec… | Phase2 | Papillomavirus Infections | Terminated | 2006-04-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00315146 | Optimizing Body Composition for Function in Older Adults | Phase4 | Obesity | Completed | 2006-04-01 | 2007-04-01 | ClinicalTrials.gov |
| NCT00316992 | Safety of Ramelteon in Subjects With Chronic Obstructive Pulmonary Disease | Phase4 | Chronic Obstructive Pulmonary Disease | Completed | 2006-04-01 | 2006-11-01 | ClinicalTrials.gov |
| NCT00316992 | Safety of Ramelteon in Subjects With Chronic Obstructive Pulmonary Disease | Phase4 | Chronic Obstructive Pulmonary Disease | Completed | 2006-04-01 | 2006-11-01 | ClinicalTrials.gov |
| NCT00117884 | Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infec… | Phase2 | Papillomavirus Infections | Terminated | 2006-04-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00276614 | Bortezomib in Treating Patients With Metastatic Kidney Cancer | Phase2 | Kidney Cancer | Completed | 2006-04-01 | 2009-07-01 | ClinicalTrials.gov |
| NCT00276614 | Bortezomib in Treating Patients With Metastatic Kidney Cancer | Phase2 | Kidney Cancer | Completed | 2006-04-01 | 2009-07-01 | ClinicalTrials.gov |
| NCT00315146 | Optimizing Body Composition for Function in Older Adults | Phase4 | Obesity | Completed | 2006-04-01 | 2007-04-01 | ClinicalTrials.gov |
| NCT00457938 | Novel Therapies for Metabolic Complications of Lipodystrophies | Na | Insulin Resistance | Completed | 2006-04-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT00652158 | A Phase 1 Trial of Extended MLN8054 Dosing in Patients With Advanced Malignanci… | Phase1 | Advanced Malignancies | Terminated | 2006-04-01 | 2008-04-01 | ClinicalTrials.gov |
| NCT00652158 | A Phase 1 Trial of Extended MLN8054 Dosing in Patients With Advanced Malignanci… | Phase1 | Advanced Malignancies | Terminated | 2006-04-01 | 2008-04-01 | ClinicalTrials.gov |
| NCT00457938 | Novel Therapies for Metabolic Complications of Lipodystrophies | Na | Insulin Resistance | Completed | 2006-04-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT00286468 | Study of Alogliptin Combined With Sulfonylurea in Subjects With Type 2 Diabetes… | Phase3 | Diabetes Mellitus | Completed | 2006-04-01 | 2007-06-01 | ClinicalTrials.gov |
| NCT00117884 | Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infec… | Phase2 | Papillomavirus Infections | Terminated | 2006-04-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00286468 | Study of Alogliptin Combined With Sulfonylurea in Subjects With Type 2 Diabetes… | Phase3 | Diabetes Mellitus | Completed | 2006-04-01 | 2007-06-01 | ClinicalTrials.gov |
| NCT00652158 | A Phase 1 Trial of Extended MLN8054 Dosing in Patients With Advanced Malignanci… | Phase1 | Advanced Malignancies | Terminated | 2006-04-01 | 2008-04-01 | ClinicalTrials.gov |
| NCT00312286 | Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infec… | Phase2 | Papillomavirus Infections | Terminated | 2006-04-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00312286 | Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infec… | Phase2 | Papillomavirus Infections | Terminated | 2006-04-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00276614 | Bortezomib in Treating Patients With Metastatic Kidney Cancer | Phase2 | Kidney Cancer | Completed | 2006-04-01 | 2009-07-01 | ClinicalTrials.gov |
| NCT00316992 | Safety of Ramelteon in Subjects With Chronic Obstructive Pulmonary Disease | Phase4 | Chronic Obstructive Pulmonary Disease | Completed | 2006-04-01 | 2006-11-01 | ClinicalTrials.gov |
| NCT00286468 | Study of Alogliptin Combined With Sulfonylurea in Subjects With Type 2 Diabetes… | Phase3 | Diabetes Mellitus | Completed | 2006-04-01 | 2007-06-01 | ClinicalTrials.gov |
| NCT00312286 | Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infec… | Phase2 | Papillomavirus Infections | Terminated | 2006-04-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00325728 | Efficacy and Safety of Ramelteon in Subjects With Mild to Moderate Alzheimer's … | Phase2 | Chronic Insomnia | Completed | 2006-03-21 | 2007-08-20 | ClinicalTrials.gov |
| NCT00325728 | Efficacy and Safety of Ramelteon in Subjects With Mild to Moderate Alzheimer's … | Phase2 | Chronic Insomnia | Completed | 2006-03-21 | 2007-08-20 | ClinicalTrials.gov |
| NCT00325728 | Efficacy and Safety of Ramelteon in Subjects With Mild to Moderate Alzheimer's … | Phase2 | Chronic Insomnia | Completed | 2006-03-21 | 2007-08-20 | ClinicalTrials.gov |
| NCT00306384 | Long-term Safety of Alogliptin in Patients With Type 2 Diabetes Mellitus | Phase3 | Diabetes Mellitus | Completed | 2006-03-01 | 2011-11-01 | ClinicalTrials.gov |
| NCT00319215 | Effects of Ramelteon on Driving Ability | Phase1 | Insomnia | Completed | 2006-03-01 | 2006-07-01 | ClinicalTrials.gov |
| NCT00312845 | Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell N… | Phase3 | Non-Hodgkin's Lymphoma | Completed | 2006-03-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT00306384 | Long-term Safety of Alogliptin in Patients With Type 2 Diabetes Mellitus | Phase3 | Diabetes Mellitus | Completed | 2006-03-01 | 2011-11-01 | ClinicalTrials.gov |
| NCT00286481 | Efficacy of Lapaquistat Acetate Alone or Combined With Simvastatin in Subjects … | Phase3 | Hypercholesterolemia | Completed | 2006-03-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT00286442 | Efficacy and Safety of Alogliptin Combined With Metformin in Participants With … | Phase3 | Diabetes Mellitus | Completed | 2006-03-01 | 2007-06-01 | ClinicalTrials.gov |
| NCT00286442 | Efficacy and Safety of Alogliptin Combined With Metformin in Participants With … | Phase3 | Diabetes Mellitus | Completed | 2006-03-01 | 2007-06-01 | ClinicalTrials.gov |
| NCT00286481 | Efficacy of Lapaquistat Acetate Alone or Combined With Simvastatin in Subjects … | Phase3 | Hypercholesterolemia | Completed | 2006-03-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT00306384 | Long-term Safety of Alogliptin in Patients With Type 2 Diabetes Mellitus | Phase3 | Diabetes Mellitus | Completed | 2006-03-01 | 2011-11-01 | ClinicalTrials.gov |
| NCT00312845 | Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell N… | Phase3 | Non-Hodgkin's Lymphoma | Completed | 2006-03-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT00319215 | Effects of Ramelteon on Driving Ability | Phase1 | Insomnia | Completed | 2006-03-01 | 2006-07-01 | ClinicalTrials.gov |
| NCT00286442 | Efficacy and Safety of Alogliptin Combined With Metformin in Participants With … | Phase3 | Diabetes Mellitus | Completed | 2006-03-01 | 2007-06-01 | ClinicalTrials.gov |
| NCT00286481 | Efficacy of Lapaquistat Acetate Alone or Combined With Simvastatin in Subjects … | Phase3 | Hypercholesterolemia | Completed | 2006-03-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT00312845 | Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell N… | Phase3 | Non-Hodgkin's Lymphoma | Completed | 2006-03-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT00319215 | Effects of Ramelteon on Driving Ability | Phase1 | Insomnia | Completed | 2006-03-01 | 2006-07-01 | ClinicalTrials.gov |
| NCT00286494 | Study of Alogliptin Combined With Pioglitazone in Subjects With Type 2 Diabetes… | Phase3 | Diabetes Mellitus | Completed | 2006-02-01 | 2007-08-01 | ClinicalTrials.gov |
| NCT00286429 | Efficacy and Safety Study of Alogliptin and Insulin in the Treatment of Type 2 … | Phase3 | Diabetes Mellitus | Completed | 2006-02-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT00286455 | Efficacy and Safety of Alogliptin in Subjects With Type 2 Diabetes | Phase3 | Diabetes Mellitus | Completed | 2006-02-01 | 2007-07-01 | ClinicalTrials.gov |
| NCT02151773 | Freeze-dried Live Attenuated Measles/Rubella Combined Vaccine (Schwarz FF-8 Str… | — | Measles/Rubella | Completed | 2006-02-01 | 2009-04-01 | ClinicalTrials.gov |
| NCT00286494 | Study of Alogliptin Combined With Pioglitazone in Subjects With Type 2 Diabetes… | Phase3 | Diabetes Mellitus | Completed | 2006-02-01 | 2007-08-01 | ClinicalTrials.gov |
| NCT02151773 | Freeze-dried Live Attenuated Measles/Rubella Combined Vaccine (Schwarz FF-8 Str… | — | Measles/Rubella | Completed | 2006-02-01 | 2009-04-01 | ClinicalTrials.gov |
| NCT00286429 | Efficacy and Safety Study of Alogliptin and Insulin in the Treatment of Type 2 … | Phase3 | Diabetes Mellitus | Completed | 2006-02-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT02151773 | Freeze-dried Live Attenuated Measles/Rubella Combined Vaccine (Schwarz FF-8 Str… | — | Measles/Rubella | Completed | 2006-02-01 | 2009-04-01 | ClinicalTrials.gov |
| NCT00813527 | Effect of Lapaquistat Acetate Combined With Fenofibrate on Blood Cholesterol Le… | Phase2 | Hyperlipidemias | Completed | 2006-02-01 | 2007-01-01 | ClinicalTrials.gov |
| NCT00813527 | Effect of Lapaquistat Acetate Combined With Fenofibrate on Blood Cholesterol Le… | Phase2 | Hyperlipidemias | Completed | 2006-02-01 | 2007-01-01 | ClinicalTrials.gov |
| NCT00286455 | Efficacy and Safety of Alogliptin in Subjects With Type 2 Diabetes | Phase3 | Diabetes Mellitus | Completed | 2006-02-01 | 2007-07-01 | ClinicalTrials.gov |
| NCT00286429 | Efficacy and Safety Study of Alogliptin and Insulin in the Treatment of Type 2 … | Phase3 | Diabetes Mellitus | Completed | 2006-02-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT00813527 | Effect of Lapaquistat Acetate Combined With Fenofibrate on Blood Cholesterol Le… | Phase2 | Hyperlipidemias | Completed | 2006-02-01 | 2007-01-01 | ClinicalTrials.gov |
| NCT00286494 | Study of Alogliptin Combined With Pioglitazone in Subjects With Type 2 Diabetes… | Phase3 | Diabetes Mellitus | Completed | 2006-02-01 | 2007-08-01 | ClinicalTrials.gov |
| NCT00286455 | Efficacy and Safety of Alogliptin in Subjects With Type 2 Diabetes | Phase3 | Diabetes Mellitus | Completed | 2006-02-01 | 2007-07-01 | ClinicalTrials.gov |
| NCT00202644 | A Study of Anagrelide and Hydroxyurea in High-Risk Essential Thrombocythemia Pa… | Phase4 | Thrombocythemia, Hemorrhagic | Completed | 2006-01-13 | 2015-12-15 | ClinicalTrials.gov |
| NCT00202644 | A Study of Anagrelide and Hydroxyurea in High-Risk Essential Thrombocythemia Pa… | Phase4 | Thrombocythemia, Hemorrhagic | Completed | 2006-01-13 | 2015-12-15 | ClinicalTrials.gov |
| NCT00202644 | A Study of Anagrelide and Hydroxyurea in High-Risk Essential Thrombocythemia Pa… | Phase4 | Thrombocythemia, Hemorrhagic | Completed | 2006-01-13 | 2015-12-15 | ClinicalTrials.gov |
| NCT00234702 | Efficacy and Safety of Lanthanum Carbonate in Reducing Serum Phosphorus Levels … | Phase2 | Kidney Diseases | Completed | 2006-01-11 | 2007-06-01 | ClinicalTrials.gov |
| NCT00234702 | Efficacy and Safety of Lanthanum Carbonate in Reducing Serum Phosphorus Levels … | Phase2 | Kidney Diseases | Completed | 2006-01-11 | 2007-06-01 | ClinicalTrials.gov |
| NCT00234702 | Efficacy and Safety of Lanthanum Carbonate in Reducing Serum Phosphorus Levels … | Phase2 | Kidney Diseases | Completed | 2006-01-11 | 2007-06-01 | ClinicalTrials.gov |
| NCT00516100 | Bortezomib (Velcade) + Pemetrexed (Alimta) in Advanced NSCLC | Phase1 | Non-small Cell Lung Cancer | Unknown | 2006-01-01 | 2012-08-01 | ClinicalTrials.gov |
| NCT00410423 | Study of VELCADE® With Mitoxantrone and Etoposide for Leukemias | Phase1 | Relapsed Acute Leukemia | Completed | 2006-01-01 | 2014-09-01 | ClinicalTrials.gov |
| NCT00255151 | Comparison of Dexlansoprazole MR to Placebo on the Ability to Maintain Healing … | Phase3 | Esophagitis, Reflux | Completed | 2006-01-01 | 2006-11-01 | ClinicalTrials.gov |
| NCT00255164 | Efficacy and Safety of Dexlansoprazole MR on Maintaining Healing in Subjects Wi… | Phase3 | Esophagitis, Reflux | Completed | 2006-01-01 | 2006-11-01 | ClinicalTrials.gov |
| NCT00255190 | Safety and Quality of Life Study of Dexlansoprazole Modified Release Formulatio… | Phase3 | Gastroesophageal Reflux Disease | Completed | 2006-01-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00255190 | Safety and Quality of Life Study of Dexlansoprazole Modified Release Formulatio… | Phase3 | Gastroesophageal Reflux Disease | Completed | 2006-01-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00410423 | Study of VELCADE® With Mitoxantrone and Etoposide for Leukemias | Phase1 | Relapsed Acute Leukemia | Completed | 2006-01-01 | 2014-09-01 | ClinicalTrials.gov |
| NCT00255190 | Safety and Quality of Life Study of Dexlansoprazole Modified Release Formulatio… | Phase3 | Gastroesophageal Reflux Disease | Completed | 2006-01-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00516100 | Bortezomib (Velcade) + Pemetrexed (Alimta) in Advanced NSCLC | Phase1 | Non-small Cell Lung Cancer | Unknown | 2006-01-01 | 2012-08-01 | ClinicalTrials.gov |
| NCT00410423 | Study of VELCADE® With Mitoxantrone and Etoposide for Leukemias | Phase1 | Relapsed Acute Leukemia | Completed | 2006-01-01 | 2014-09-01 | ClinicalTrials.gov |
| NCT00255164 | Efficacy and Safety of Dexlansoprazole MR on Maintaining Healing in Subjects Wi… | Phase3 | Esophagitis, Reflux | Completed | 2006-01-01 | 2006-11-01 | ClinicalTrials.gov |
| NCT00255151 | Comparison of Dexlansoprazole MR to Placebo on the Ability to Maintain Healing … | Phase3 | Esophagitis, Reflux | Completed | 2006-01-01 | 2006-11-01 | ClinicalTrials.gov |
| NCT00255151 | Comparison of Dexlansoprazole MR to Placebo on the Ability to Maintain Healing … | Phase3 | Esophagitis, Reflux | Completed | 2006-01-01 | 2006-11-01 | ClinicalTrials.gov |
| NCT00516100 | Bortezomib (Velcade) + Pemetrexed (Alimta) in Advanced NSCLC | Phase1 | Non-small Cell Lung Cancer | Unknown | 2006-01-01 | 2012-08-01 | ClinicalTrials.gov |
| NCT00255164 | Efficacy and Safety of Dexlansoprazole MR on Maintaining Healing in Subjects Wi… | Phase3 | Esophagitis, Reflux | Completed | 2006-01-01 | 2006-11-01 | ClinicalTrials.gov |
| NCT00262080 | Efficacy and Safety Study of DX-88 to Treat Acute Attacks of Hereditary Angioed… | Phase3 | Hereditary Angioedema (HAE) | Completed | 2005-12-31 | 2007-02-28 | ClinicalTrials.gov |
| NCT00262080 | Efficacy and Safety Study of DX-88 to Treat Acute Attacks of Hereditary Angioed… | Phase3 | Hereditary Angioedema (HAE) | Completed | 2005-12-31 | 2007-02-28 | ClinicalTrials.gov |
| NCT00262080 | Efficacy and Safety Study of DX-88 to Treat Acute Attacks of Hereditary Angioed… | Phase3 | Hereditary Angioedema (HAE) | Completed | 2005-12-31 | 2007-02-28 | ClinicalTrials.gov |
| NCT00843154 | Efficacy of Candesartan on Brain Natriuretic Peptide Levels in Subjects With Ch… | Phase3 | Heart Failure | Terminated | 2005-12-01 | 2008-07-01 | ClinicalTrials.gov |
| NCT00251693 | Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosiv… | Phase3 | Esophagitis, Reflux | Completed | 2005-12-01 | 2007-01-01 | ClinicalTrials.gov |
| NCT00251719 | Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosiv… | Phase3 | Esophagitis, Reflux | Completed | 2005-12-01 | 2007-01-01 | ClinicalTrials.gov |
| NCT00251745 | Efficacy and Safety of Dexlansoprazole Modified Release Formulation to Treat He… | Phase3 | Gastroesophageal Reflux Disease | Completed | 2005-12-01 | 2006-05-01 | ClinicalTrials.gov |
| NCT00251758 | Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat He… | Phase3 | Gastroesophageal Reflux Disease | Completed | 2005-12-01 | 2006-05-01 | ClinicalTrials.gov |
| NCT02154139 | Leuprorelin Acetate SR 11.25 mg for Injection Specified Drug-use Survey "Long-t… | — | Breast Cancer | Completed | 2005-12-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00843154 | Efficacy of Candesartan on Brain Natriuretic Peptide Levels in Subjects With Ch… | Phase3 | Heart Failure | Terminated | 2005-12-01 | 2008-07-01 | ClinicalTrials.gov |
| NCT00843154 | Efficacy of Candesartan on Brain Natriuretic Peptide Levels in Subjects With Ch… | Phase3 | Heart Failure | Terminated | 2005-12-01 | 2008-07-01 | ClinicalTrials.gov |
| NCT00251693 | Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosiv… | Phase3 | Esophagitis, Reflux | Completed | 2005-12-01 | 2007-01-01 | ClinicalTrials.gov |
| NCT00251758 | Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat He… | Phase3 | Gastroesophageal Reflux Disease | Completed | 2005-12-01 | 2006-05-01 | ClinicalTrials.gov |
| NCT00251745 | Efficacy and Safety of Dexlansoprazole Modified Release Formulation to Treat He… | Phase3 | Gastroesophageal Reflux Disease | Completed | 2005-12-01 | 2006-05-01 | ClinicalTrials.gov |
| NCT02154139 | Leuprorelin Acetate SR 11.25 mg for Injection Specified Drug-use Survey "Long-t… | — | Breast Cancer | Completed | 2005-12-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00251719 | Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosiv… | Phase3 | Esophagitis, Reflux | Completed | 2005-12-01 | 2007-01-01 | ClinicalTrials.gov |
| NCT00251693 | Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosiv… | Phase3 | Esophagitis, Reflux | Completed | 2005-12-01 | 2007-01-01 | ClinicalTrials.gov |
| NCT00868127 | Safety of Lapaquistat Acetate in Subjects With Hypercholesterolemia | Phase3 | Hypercholesterolemia | Completed | 2005-12-01 | 2007-07-01 | ClinicalTrials.gov |
| NCT00868127 | Safety of Lapaquistat Acetate in Subjects With Hypercholesterolemia | Phase3 | Hypercholesterolemia | Completed | 2005-12-01 | 2007-07-01 | ClinicalTrials.gov |
| NCT02154139 | Leuprorelin Acetate SR 11.25 mg for Injection Specified Drug-use Survey "Long-t… | — | Breast Cancer | Completed | 2005-12-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00868127 | Safety of Lapaquistat Acetate in Subjects With Hypercholesterolemia | Phase3 | Hypercholesterolemia | Completed | 2005-12-01 | 2007-07-01 | ClinicalTrials.gov |
| NCT00251719 | Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosiv… | Phase3 | Esophagitis, Reflux | Completed | 2005-12-01 | 2007-01-01 | ClinicalTrials.gov |
| NCT00251745 | Efficacy and Safety of Dexlansoprazole Modified Release Formulation to Treat He… | Phase3 | Gastroesophageal Reflux Disease | Completed | 2005-12-01 | 2006-05-01 | ClinicalTrials.gov |
| NCT00251758 | Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat He… | Phase3 | Gastroesophageal Reflux Disease | Completed | 2005-12-01 | 2006-05-01 | ClinicalTrials.gov |
| NCT00249899 | Efficacy of Lapaquistat Acetate Alone or Combined With High-Dose Statin Therapy… | Phase3 | Hypercholesterolemia | Terminated | 2005-11-01 | 2007-03-01 | ClinicalTrials.gov |
| NCT00263081 | Efficacy of Lapaquistat Acetate Co-Administered With Current Lipid-Lowering Tre… | Phase3 | Hypercholesterolemia | Terminated | 2005-11-01 | 2007-03-01 | ClinicalTrials.gov |
| NCT00755508 | Efficacy and Safety of Ramelteon Combined With Gabapentin in Treating Patients … | Phase2 | Sleep Initiation and Maintenance Disorders | Completed | 2005-11-01 | 2006-09-01 | ClinicalTrials.gov |
| NCT00246909 | Determination of the Minimal Clinically Important Difference After Treatment Wi… | Phase4 | Gastroesophageal Reflux | Completed | 2005-11-01 | 2006-11-01 | ClinicalTrials.gov |
| NCT00254267 | Evaluate the Efficacy of AMG 706 to Treat Advanced Gastrointestinal Stromal Tum… | Phase2 | Advanced Gastrointestinal Stromal Tumor | Completed | 2005-11-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT00246909 | Determination of the Minimal Clinically Important Difference After Treatment Wi… | Phase4 | Gastroesophageal Reflux | Completed | 2005-11-01 | 2006-11-01 | ClinicalTrials.gov |
| NCT00249899 | Efficacy of Lapaquistat Acetate Alone or Combined With High-Dose Statin Therapy… | Phase3 | Hypercholesterolemia | Terminated | 2005-11-01 | 2007-03-01 | ClinicalTrials.gov |
| NCT00755508 | Efficacy and Safety of Ramelteon Combined With Gabapentin in Treating Patients … | Phase2 | Sleep Initiation and Maintenance Disorders | Completed | 2005-11-01 | 2006-09-01 | ClinicalTrials.gov |
| NCT00755508 | Efficacy and Safety of Ramelteon Combined With Gabapentin in Treating Patients … | Phase2 | Sleep Initiation and Maintenance Disorders | Completed | 2005-11-01 | 2006-09-01 | ClinicalTrials.gov |
| NCT00249899 | Efficacy of Lapaquistat Acetate Alone or Combined With High-Dose Statin Therapy… | Phase3 | Hypercholesterolemia | Terminated | 2005-11-01 | 2007-03-01 | ClinicalTrials.gov |
| NCT00246909 | Determination of the Minimal Clinically Important Difference After Treatment Wi… | Phase4 | Gastroesophageal Reflux | Completed | 2005-11-01 | 2006-11-01 | ClinicalTrials.gov |
| NCT00254267 | Evaluate the Efficacy of AMG 706 to Treat Advanced Gastrointestinal Stromal Tum… | Phase2 | Advanced Gastrointestinal Stromal Tumor | Completed | 2005-11-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT00254267 | Evaluate the Efficacy of AMG 706 to Treat Advanced Gastrointestinal Stromal Tum… | Phase2 | Advanced Gastrointestinal Stromal Tumor | Completed | 2005-11-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT00263081 | Efficacy of Lapaquistat Acetate Co-Administered With Current Lipid-Lowering Tre… | Phase3 | Hypercholesterolemia | Terminated | 2005-11-01 | 2007-03-01 | ClinicalTrials.gov |
| NCT00263081 | Efficacy of Lapaquistat Acetate Co-Administered With Current Lipid-Lowering Tre… | Phase3 | Hypercholesterolemia | Terminated | 2005-11-01 | 2007-03-01 | ClinicalTrials.gov |
| NCT03292887 | Hunter Outcome Survey (HOS) | — | Hunter Syndrome | Completed | 2005-10-03 | 2023-02-16 | ClinicalTrials.gov |
| NCT03292887 | Hunter Outcome Survey (HOS) | — | Hunter Syndrome | Completed | 2005-10-03 | 2023-02-16 | ClinicalTrials.gov |
| NCT03292887 | Hunter Outcome Survey (HOS) | — | Hunter Syndrome | Completed | 2005-10-03 | 2023-02-16 | ClinicalTrials.gov |
| NCT00249912 | Efficacy of Lapaquistat Acetate Alone or Combined With Rosuvastatin in Subjects… | Phase3 | Hypercholesterolemia | Completed | 2005-10-01 | 2007-04-01 | ClinicalTrials.gov |
| NCT00249912 | Efficacy of Lapaquistat Acetate Alone or Combined With Rosuvastatin in Subjects… | Phase3 | Hypercholesterolemia | Completed | 2005-10-01 | 2007-04-01 | ClinicalTrials.gov |
| NCT00268697 | Efficacy of Lapaquistat Acetate Alone and With Ezetimibe in Subjects With Prima… | Phase3 | Hypercholesterolemia | Completed | 2005-10-01 | 2007-01-01 | ClinicalTrials.gov |
| NCT00256178 | Efficacy of Lapaquistat Acetate and Simvastatin in Subjects With Primary Dyslip… | Phase3 | Hypercholesterolemia | Completed | 2005-10-01 | 2007-03-01 | ClinicalTrials.gov |
| NCT00250926 | Study of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patient… | Phase2 | Waldenstrom's Macroglobulinemia | Completed | 2005-10-01 | 2009-02-01 | ClinicalTrials.gov |
| NCT00251680 | Efficacy of Lapaquistat Acetate in Subjects Currently Treated With Lipid-Loweri… | Phase3 | Type 2 Diabetes | Completed | 2005-10-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT02167893 | Leuplin SR 11.25 mg Injection Kit Specified Drug-use Survey "Long-term Use Surv… | — | Prostate Cancer | Completed | 2005-10-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT00251680 | Efficacy of Lapaquistat Acetate in Subjects Currently Treated With Lipid-Loweri… | Phase3 | Type 2 Diabetes | Completed | 2005-10-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT00250926 | Study of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patient… | Phase2 | Waldenstrom's Macroglobulinemia | Completed | 2005-10-01 | 2009-02-01 | ClinicalTrials.gov |
| NCT00249912 | Efficacy of Lapaquistat Acetate Alone or Combined With Rosuvastatin in Subjects… | Phase3 | Hypercholesterolemia | Completed | 2005-10-01 | 2007-04-01 | ClinicalTrials.gov |
| NCT00250926 | Study of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patient… | Phase2 | Waldenstrom's Macroglobulinemia | Completed | 2005-10-01 | 2009-02-01 | ClinicalTrials.gov |
| NCT00256178 | Efficacy of Lapaquistat Acetate and Simvastatin in Subjects With Primary Dyslip… | Phase3 | Hypercholesterolemia | Completed | 2005-10-01 | 2007-03-01 | ClinicalTrials.gov |
| NCT00268697 | Efficacy of Lapaquistat Acetate Alone and With Ezetimibe in Subjects With Prima… | Phase3 | Hypercholesterolemia | Completed | 2005-10-01 | 2007-01-01 | ClinicalTrials.gov |
| NCT00268697 | Efficacy of Lapaquistat Acetate Alone and With Ezetimibe in Subjects With Prima… | Phase3 | Hypercholesterolemia | Completed | 2005-10-01 | 2007-01-01 | ClinicalTrials.gov |
| NCT00256178 | Efficacy of Lapaquistat Acetate and Simvastatin in Subjects With Primary Dyslip… | Phase3 | Hypercholesterolemia | Completed | 2005-10-01 | 2007-03-01 | ClinicalTrials.gov |
| NCT02167893 | Leuplin SR 11.25 mg Injection Kit Specified Drug-use Survey "Long-term Use Surv… | — | Prostate Cancer | Completed | 2005-10-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT00251680 | Efficacy of Lapaquistat Acetate in Subjects Currently Treated With Lipid-Loweri… | Phase3 | Type 2 Diabetes | Completed | 2005-10-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT02167893 | Leuplin SR 11.25 mg Injection Kit Specified Drug-use Survey "Long-term Use Surv… | — | Prostate Cancer | Completed | 2005-10-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT00202605 | Safety and Efficacy of SPD465 in Adults With ADHD | Phase2 | Attention Deficit Disorder With Hyperactivity | Completed | 2005-09-29 | 2006-01-06 | ClinicalTrials.gov |
| NCT00202605 | Safety and Efficacy of SPD465 in Adults With ADHD | Phase2 | Attention Deficit Disorder With Hyperactivity | Completed | 2005-09-29 | 2006-01-06 | ClinicalTrials.gov |
| NCT00202605 | Safety and Efficacy of SPD465 in Adults With ADHD | Phase2 | Attention Deficit Disorder With Hyperactivity | Completed | 2005-09-29 | 2006-01-06 | ClinicalTrials.gov |
| NCT00143663 | Effect of Lapaquistat Acetate on Blood Cholesterol Levels in Subjects With Elev… | Phase3 | Dyslipidemia | Completed | 2005-09-01 | 2006-04-01 | ClinicalTrials.gov |
| NCT00329589 | A Trial Using Velcade Plus Chemoradiation for Central Nervous System, Head and … | Phase1 | Brain Cancer | Completed | 2005-09-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT00159341 | Cigarette Smoke Nasal and Whole Blood Challenge in Patients With Chronic Obstru… | Phase1 | Lung Diseases, Obstructive | Completed | 2005-09-01 | 2006-12-01 | ClinicalTrials.gov |
| NCT00143611 | Efficacy & Safety of Resatorvid in Adults With Severe Sepsis | Phase3 | Sepsis | Completed | 2005-09-01 | 2007-02-01 | ClinicalTrials.gov |
| NCT00756041 | Safety Study of TAK-128 in Subjects With Diabetic Peripheral Neuropathy | Phase2 | Diabetic Neuropathies | Terminated | 2005-09-01 | 2006-09-01 | ClinicalTrials.gov |
| NCT01167543 | Relationship and Pathophysiology of Gastroesophageal Reflux and Dental/Periodon… | — | Gastroesophageal Reflux | Completed | 2005-09-01 | 2008-11-01 | ClinicalTrials.gov |
| NCT00159341 | Cigarette Smoke Nasal and Whole Blood Challenge in Patients With Chronic Obstru… | Phase1 | Lung Diseases, Obstructive | Completed | 2005-09-01 | 2006-12-01 | ClinicalTrials.gov |
| NCT01167543 | Relationship and Pathophysiology of Gastroesophageal Reflux and Dental/Periodon… | — | Gastroesophageal Reflux | Completed | 2005-09-01 | 2008-11-01 | ClinicalTrials.gov |
| NCT00143663 | Effect of Lapaquistat Acetate on Blood Cholesterol Levels in Subjects With Elev… | Phase3 | Dyslipidemia | Completed | 2005-09-01 | 2006-04-01 | ClinicalTrials.gov |
| NCT00756041 | Safety Study of TAK-128 in Subjects With Diabetic Peripheral Neuropathy | Phase2 | Diabetic Neuropathies | Terminated | 2005-09-01 | 2006-09-01 | ClinicalTrials.gov |
| NCT00756041 | Safety Study of TAK-128 in Subjects With Diabetic Peripheral Neuropathy | Phase2 | Diabetic Neuropathies | Terminated | 2005-09-01 | 2006-09-01 | ClinicalTrials.gov |
| NCT00143611 | Efficacy & Safety of Resatorvid in Adults With Severe Sepsis | Phase3 | Sepsis | Completed | 2005-09-01 | 2007-02-01 | ClinicalTrials.gov |
| NCT00159341 | Cigarette Smoke Nasal and Whole Blood Challenge in Patients With Chronic Obstru… | Phase1 | Lung Diseases, Obstructive | Completed | 2005-09-01 | 2006-12-01 | ClinicalTrials.gov |
| NCT00143611 | Efficacy & Safety of Resatorvid in Adults With Severe Sepsis | Phase3 | Sepsis | Completed | 2005-09-01 | 2007-02-01 | ClinicalTrials.gov |
| NCT00329589 | A Trial Using Velcade Plus Chemoradiation for Central Nervous System, Head and … | Phase1 | Brain Cancer | Completed | 2005-09-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT00143663 | Effect of Lapaquistat Acetate on Blood Cholesterol Levels in Subjects With Elev… | Phase3 | Dyslipidemia | Completed | 2005-09-01 | 2006-04-01 | ClinicalTrials.gov |
| NCT01167543 | Relationship and Pathophysiology of Gastroesophageal Reflux and Dental/Periodon… | — | Gastroesophageal Reflux | Completed | 2005-09-01 | 2008-11-01 | ClinicalTrials.gov |
| NCT00329589 | A Trial Using Velcade Plus Chemoradiation for Central Nervous System, Head and … | Phase1 | Brain Cancer | Completed | 2005-09-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT00261339 | Determination of a Questionnaire After Treatment With Pantoprazole at Full Dose… | Phase4 | Gastroesophageal Reflux | Completed | 2005-08-01 | — | ClinicalTrials.gov |
| NCT00361088 | A Combination of Zarnestra With Velcade for Patients With Relapsed Multiple Mye… | Phase1 | Multiple Myeloma | Terminated | 2005-08-01 | 2007-06-01 | ClinicalTrials.gov |
| NCT00203567 | Carbamazepine Extended-Release for the Treatment of Bipolar Depression | Phase4 | Bipolar Depression | Completed | 2005-08-01 | 2008-05-01 | ClinicalTrials.gov |
| NCT00203567 | Carbamazepine Extended-Release for the Treatment of Bipolar Depression | Phase4 | Bipolar Depression | Completed | 2005-08-01 | 2008-05-01 | ClinicalTrials.gov |
| NCT00143676 | Efficacy of Lapaquistat Acetate and Atorvastatin on Blood Cholesterol Levels in… | Phase3 | Hypercholesterolemia | Completed | 2005-08-01 | 2006-08-01 | ClinicalTrials.gov |
| NCT00283634 | A Study of Tarceva for Use in Patients With Relapsed or Refractory Metastatic N… | Phase2 | NSCLC | Terminated | 2005-08-01 | 2007-08-01 | ClinicalTrials.gov |
| NCT00283634 | A Study of Tarceva for Use in Patients With Relapsed or Refractory Metastatic N… | Phase2 | NSCLC | Terminated | 2005-08-01 | 2007-08-01 | ClinicalTrials.gov |
| NCT00715169 | Double-Blind, Randomized, Placebo-Controlled Trial of MLN1202 on C-Reactive Pro… | Phase2 | Atherosclerosis | Completed | 2005-08-01 | — | ClinicalTrials.gov |
| NCT00715169 | Double-Blind, Randomized, Placebo-Controlled Trial of MLN1202 on C-Reactive Pro… | Phase2 | Atherosclerosis | Completed | 2005-08-01 | — | ClinicalTrials.gov |
| NCT00203567 | Carbamazepine Extended-Release for the Treatment of Bipolar Depression | Phase4 | Bipolar Depression | Completed | 2005-08-01 | 2008-05-01 | ClinicalTrials.gov |
| NCT00443755 | Effect of Insulin Sensitizer Therapy on Atherothrombotic and Inflammatory Profi… | Phase2 | Type 2 Diabetes | Completed | 2005-08-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT00261339 | Determination of a Questionnaire After Treatment With Pantoprazole at Full Dose… | Phase4 | Gastroesophageal Reflux | Completed | 2005-08-01 | — | ClinicalTrials.gov |
| NCT00361088 | A Combination of Zarnestra With Velcade for Patients With Relapsed Multiple Mye… | Phase1 | Multiple Myeloma | Terminated | 2005-08-01 | 2007-06-01 | ClinicalTrials.gov |
| NCT00261339 | Determination of a Questionnaire After Treatment With Pantoprazole at Full Dose… | Phase4 | Gastroesophageal Reflux | Completed | 2005-08-01 | — | ClinicalTrials.gov |
| NCT00361088 | A Combination of Zarnestra With Velcade for Patients With Relapsed Multiple Mye… | Phase1 | Multiple Myeloma | Terminated | 2005-08-01 | 2007-06-01 | ClinicalTrials.gov |
| NCT00443755 | Effect of Insulin Sensitizer Therapy on Atherothrombotic and Inflammatory Profi… | Phase2 | Type 2 Diabetes | Completed | 2005-08-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT00443755 | Effect of Insulin Sensitizer Therapy on Atherothrombotic and Inflammatory Profi… | Phase2 | Type 2 Diabetes | Completed | 2005-08-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT00143676 | Efficacy of Lapaquistat Acetate and Atorvastatin on Blood Cholesterol Levels in… | Phase3 | Hypercholesterolemia | Completed | 2005-08-01 | 2006-08-01 | ClinicalTrials.gov |
| NCT00283634 | A Study of Tarceva for Use in Patients With Relapsed or Refractory Metastatic N… | Phase2 | NSCLC | Terminated | 2005-08-01 | 2007-08-01 | ClinicalTrials.gov |
| NCT00715169 | Double-Blind, Randomized, Placebo-Controlled Trial of MLN1202 on C-Reactive Pro… | Phase2 | Atherosclerosis | Completed | 2005-08-01 | — | ClinicalTrials.gov |
| NCT00143676 | Efficacy of Lapaquistat Acetate and Atorvastatin on Blood Cholesterol Levels in… | Phase3 | Hypercholesterolemia | Completed | 2005-08-01 | 2006-08-01 | ClinicalTrials.gov |
| NCT00181870 | Equetro for the Treatment of Mania in Children Ages 6-12 With Bipolar Disorder | Phase4 | Bipolar Disorder | Completed | 2005-07-01 | — | ClinicalTrials.gov |
| NCT00237497 | Safety and Efficacy of Ramelteon in Adults With Chronic Insomnia | Phase3 | Balance | Completed | 2005-07-01 | 2006-10-01 | ClinicalTrials.gov |
| NCT00181870 | Equetro for the Treatment of Mania in Children Ages 6-12 With Bipolar Disorder | Phase4 | Bipolar Disorder | Completed | 2005-07-01 | — | ClinicalTrials.gov |
| NCT00247390 | Long-Term Efficacy and Safety of Ramelteon in Adults With Chronic Insomnia. | Phase3 | Chronic Insomnia | Completed | 2005-07-01 | 2006-12-01 | ClinicalTrials.gov |
| NCT00181870 | Equetro for the Treatment of Mania in Children Ages 6-12 With Bipolar Disorder | Phase4 | Bipolar Disorder | Completed | 2005-07-01 | — | ClinicalTrials.gov |
| NCT00247390 | Long-Term Efficacy and Safety of Ramelteon in Adults With Chronic Insomnia. | Phase3 | Chronic Insomnia | Completed | 2005-07-01 | 2006-12-01 | ClinicalTrials.gov |
| NCT00754403 | Efficacy of Pioglitazone and Fortamet Combination Therapy in Subjects With Type… | Phase4 | Diabetes Mellitus | Completed | 2005-07-01 | 2006-10-01 | ClinicalTrials.gov |
| NCT00754403 | Efficacy of Pioglitazone and Fortamet Combination Therapy in Subjects With Type… | Phase4 | Diabetes Mellitus | Completed | 2005-07-01 | 2006-10-01 | ClinicalTrials.gov |
| NCT00247390 | Long-Term Efficacy and Safety of Ramelteon in Adults With Chronic Insomnia. | Phase3 | Chronic Insomnia | Completed | 2005-07-01 | 2006-12-01 | ClinicalTrials.gov |
| NCT00754403 | Efficacy of Pioglitazone and Fortamet Combination Therapy in Subjects With Type… | Phase4 | Diabetes Mellitus | Completed | 2005-07-01 | 2006-10-01 | ClinicalTrials.gov |
| NCT00237497 | Safety and Efficacy of Ramelteon in Adults With Chronic Insomnia | Phase3 | Balance | Completed | 2005-07-01 | 2006-10-01 | ClinicalTrials.gov |
| NCT00237497 | Safety and Efficacy of Ramelteon in Adults With Chronic Insomnia | Phase3 | Balance | Completed | 2005-07-01 | 2006-10-01 | ClinicalTrials.gov |
| NCT00770575 | Efficacy Study of Pioglitazone and Atorvastatin Combination Therapy in Treating… | Phase2 | Cardiovascular Diseases | Completed | 2005-06-01 | 2006-10-01 | ClinicalTrials.gov |
| NCT00120003 | Scandinavian Candesartan Acute Stroke Trial (SCAST) | Phase3 | Stroke | Completed | 2005-06-01 | 2010-09-01 | ClinicalTrials.gov |
| NCT00148317 | Phase II Study of Velcade, Decadron, and Doxil Followed by Cyclophosphamide in … | Phase2 | Multiple Myeloma | Completed | 2005-06-01 | 2012-11-01 | ClinicalTrials.gov |
| NCT00120003 | Scandinavian Candesartan Acute Stroke Trial (SCAST) | Phase3 | Stroke | Completed | 2005-06-01 | 2010-09-01 | ClinicalTrials.gov |
| NCT00307086 | Bortezomib Followed by High-Dose Melphalan and Bortezomib as Conditioning Regim… | Phase2 | Multiple Myeloma | Completed | 2005-06-01 | 2012-03-01 | ClinicalTrials.gov |
| NCT00479986 | Effects of Pioglitazone in Type 2 Diabetes Mellitus and Coronary Heart Disease | Phase4 | Type 2 Diabetes Mellitus | Completed | 2005-06-01 | 2006-11-01 | ClinicalTrials.gov |
| NCT00148317 | Phase II Study of Velcade, Decadron, and Doxil Followed by Cyclophosphamide in … | Phase2 | Multiple Myeloma | Completed | 2005-06-01 | 2012-11-01 | ClinicalTrials.gov |
| NCT00120003 | Scandinavian Candesartan Acute Stroke Trial (SCAST) | Phase3 | Stroke | Completed | 2005-06-01 | 2010-09-01 | ClinicalTrials.gov |
| NCT00298766 | Open-Label Phase 1/2 Study of VELCADE for Injection in Patients With Light-chai… | Phase1 | Amyloidosis | Completed | 2005-06-01 | 2009-09-01 | ClinicalTrials.gov |
| NCT00770575 | Efficacy Study of Pioglitazone and Atorvastatin Combination Therapy in Treating… | Phase2 | Cardiovascular Diseases | Completed | 2005-06-01 | 2006-10-01 | ClinicalTrials.gov |
| NCT00479986 | Effects of Pioglitazone in Type 2 Diabetes Mellitus and Coronary Heart Disease | Phase4 | Type 2 Diabetes Mellitus | Completed | 2005-06-01 | 2006-11-01 | ClinicalTrials.gov |
| NCT00148317 | Phase II Study of Velcade, Decadron, and Doxil Followed by Cyclophosphamide in … | Phase2 | Multiple Myeloma | Completed | 2005-06-01 | 2012-11-01 | ClinicalTrials.gov |
| NCT00307086 | Bortezomib Followed by High-Dose Melphalan and Bortezomib as Conditioning Regim… | Phase2 | Multiple Myeloma | Completed | 2005-06-01 | 2012-03-01 | ClinicalTrials.gov |
| NCT00770575 | Efficacy Study of Pioglitazone and Atorvastatin Combination Therapy in Treating… | Phase2 | Cardiovascular Diseases | Completed | 2005-06-01 | 2006-10-01 | ClinicalTrials.gov |
| NCT00298766 | Open-Label Phase 1/2 Study of VELCADE for Injection in Patients With Light-chai… | Phase1 | Amyloidosis | Completed | 2005-06-01 | 2009-09-01 | ClinicalTrials.gov |
| NCT00479986 | Effects of Pioglitazone in Type 2 Diabetes Mellitus and Coronary Heart Disease | Phase4 | Type 2 Diabetes Mellitus | Completed | 2005-06-01 | 2006-11-01 | ClinicalTrials.gov |
| NCT00298766 | Open-Label Phase 1/2 Study of VELCADE for Injection in Patients With Light-chai… | Phase1 | Amyloidosis | Completed | 2005-06-01 | 2009-09-01 | ClinicalTrials.gov |
| NCT00307086 | Bortezomib Followed by High-Dose Melphalan and Bortezomib as Conditioning Regim… | Phase2 | Multiple Myeloma | Completed | 2005-06-01 | 2012-03-01 | ClinicalTrials.gov |
| NCT00567502 | Safety and Pregnancy Outcomes in Thrombocythemia Patients Exposed to XAGRID® (A… | — | Thrombocythemia, Essential | Completed | 2005-05-31 | 2014-04-30 | ClinicalTrials.gov |
| NCT00567502 | Safety and Pregnancy Outcomes in Thrombocythemia Patients Exposed to XAGRID® (A… | — | Thrombocythemia, Essential | Completed | 2005-05-31 | 2014-04-30 | ClinicalTrials.gov |
| NCT00567502 | Safety and Pregnancy Outcomes in Thrombocythemia Patients Exposed to XAGRID® (A… | — | Thrombocythemia, Essential | Completed | 2005-05-31 | 2014-04-30 | ClinicalTrials.gov |
| NCT00150592 | Safety, Tolerability and Efficacy of SPD503 in Treating ADHD in Children Aged 6… | Phase2 | Attention Deficit Disorder With Hyperactivity | Completed | 2005-05-12 | 2005-10-05 | ClinicalTrials.gov |
| NCT00150592 | Safety, Tolerability and Efficacy of SPD503 in Treating ADHD in Children Aged 6… | Phase2 | Attention Deficit Disorder With Hyperactivity | Completed | 2005-05-12 | 2005-10-05 | ClinicalTrials.gov |
| NCT00150592 | Safety, Tolerability and Efficacy of SPD503 in Treating ADHD in Children Aged 6… | Phase2 | Attention Deficit Disorder With Hyperactivity | Completed | 2005-05-12 | 2005-10-05 | ClinicalTrials.gov |
| NCT00174928 | A Study to Evaluate the Effect of Lansoprazole on Hospitalized Neonates With Ga… | Phase1 | Gastroesophageal Reflux Disease | Completed | 2005-05-01 | 2005-08-01 | ClinicalTrials.gov |
| NCT00163306 | Efficacy of Pantoprazole in Patients Older Than 18 Years Who Have Symptoms of A… | Phase3 | Gastroesophageal Reflux | Completed | 2005-05-01 | — | ClinicalTrials.gov |
| NCT00174928 | A Study to Evaluate the Effect of Lansoprazole on Hospitalized Neonates With Ga… | Phase1 | Gastroesophageal Reflux Disease | Completed | 2005-05-01 | 2005-08-01 | ClinicalTrials.gov |
| NCT00380250 | Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome W… | Phase3 | Irritable Bowel Syndrome With Constipation | Completed | 2005-05-01 | 2006-07-01 | ClinicalTrials.gov |
| NCT00793650 | Combination High Dose Melphalan and Autologous Peripheral Blood Stem Cell (PBSC… | Phase1 | Cancer | Terminated | 2005-05-01 | 2011-09-01 | ClinicalTrials.gov |
| NCT01199640 | Study of the Safety and Efficacy of MLN1202 in Patients in Multiple Sclerosis | Phase2 | Multiple Sclerosis | Completed | 2005-05-01 | 2007-10-01 | ClinicalTrials.gov |
| NCT00380250 | Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome W… | Phase3 | Irritable Bowel Syndrome With Constipation | Completed | 2005-05-01 | 2006-07-01 | ClinicalTrials.gov |
| NCT01199640 | Study of the Safety and Efficacy of MLN1202 in Patients in Multiple Sclerosis | Phase2 | Multiple Sclerosis | Completed | 2005-05-01 | 2007-10-01 | ClinicalTrials.gov |
| NCT01199640 | Study of the Safety and Efficacy of MLN1202 in Patients in Multiple Sclerosis | Phase2 | Multiple Sclerosis | Completed | 2005-05-01 | 2007-10-01 | ClinicalTrials.gov |
| NCT00163306 | Efficacy of Pantoprazole in Patients Older Than 18 Years Who Have Symptoms of A… | Phase3 | Gastroesophageal Reflux | Completed | 2005-05-01 | — | ClinicalTrials.gov |
| NCT00163306 | Efficacy of Pantoprazole in Patients Older Than 18 Years Who Have Symptoms of A… | Phase3 | Gastroesophageal Reflux | Completed | 2005-05-01 | — | ClinicalTrials.gov |
| NCT00174928 | A Study to Evaluate the Effect of Lansoprazole on Hospitalized Neonates With Ga… | Phase1 | Gastroesophageal Reflux Disease | Completed | 2005-05-01 | 2005-08-01 | ClinicalTrials.gov |
| NCT00793650 | Combination High Dose Melphalan and Autologous Peripheral Blood Stem Cell (PBSC… | Phase1 | Cancer | Terminated | 2005-05-01 | 2011-09-01 | ClinicalTrials.gov |
| NCT00159211 | Abdominal Adipose Tissue Distribution in Type 2 Diabetic Patients Treated Durin… | Na | Type 2 Diabetes | Terminated | 2005-05-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT00793650 | Combination High Dose Melphalan and Autologous Peripheral Blood Stem Cell (PBSC… | Phase1 | Cancer | Terminated | 2005-05-01 | 2011-09-01 | ClinicalTrials.gov |
| NCT00159211 | Abdominal Adipose Tissue Distribution in Type 2 Diabetic Patients Treated Durin… | Na | Type 2 Diabetes | Terminated | 2005-05-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT00159211 | Abdominal Adipose Tissue Distribution in Type 2 Diabetic Patients Treated Durin… | Na | Type 2 Diabetes | Terminated | 2005-05-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT00380250 | Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome W… | Phase3 | Irritable Bowel Syndrome With Constipation | Completed | 2005-05-01 | 2006-07-01 | ClinicalTrials.gov |
| NCT00183937 | Study of Bortezomib and Docetaxel for Patients With Hormone Refractory Prostate… | Phase2 | Prostate Cancer | Terminated | 2005-04-30 | 2012-06-11 | ClinicalTrials.gov |
| NCT00183937 | Study of Bortezomib and Docetaxel for Patients With Hormone Refractory Prostate… | Phase2 | Prostate Cancer | Terminated | 2005-04-30 | 2012-06-11 | ClinicalTrials.gov |
| NCT00183937 | Study of Bortezomib and Docetaxel for Patients With Hormone Refractory Prostate… | Phase2 | Prostate Cancer | Terminated | 2005-04-30 | 2012-06-11 | ClinicalTrials.gov |
| NCT00152022 | Efficacy and Safety of SPD465 in Adults With Moderately Symptomatic ADHD. | Phase3 | Attention Deficit Disorder With Hyperactivity | Completed | 2005-04-25 | 2005-11-04 | ClinicalTrials.gov |
| NCT00152022 | Efficacy and Safety of SPD465 in Adults With Moderately Symptomatic ADHD. | Phase3 | Attention Deficit Disorder With Hyperactivity | Completed | 2005-04-25 | 2005-11-04 | ClinicalTrials.gov |
| NCT00152022 | Efficacy and Safety of SPD465 in Adults With Moderately Symptomatic ADHD. | Phase3 | Attention Deficit Disorder With Hyperactivity | Completed | 2005-04-25 | 2005-11-04 | ClinicalTrials.gov |
| NCT00151892 | Efficacy and Safety of SPD476 in Maintaining Remission in Patients With Ulcerat… | Phase3 | Ulcerative Colitis | Completed | 2005-04-08 | 2009-09-07 | ClinicalTrials.gov |
| NCT00151892 | Efficacy and Safety of SPD476 in Maintaining Remission in Patients With Ulcerat… | Phase3 | Ulcerative Colitis | Completed | 2005-04-08 | 2009-09-07 | ClinicalTrials.gov |
| NCT00151892 | Efficacy and Safety of SPD476 in Maintaining Remission in Patients With Ulcerat… | Phase3 | Ulcerative Colitis | Completed | 2005-04-08 | 2009-09-07 | ClinicalTrials.gov |
| NCT00117351 | VELCADE in Previously Treated Patients With Stage IIIB and IV Bronchioloalveola… | Phase2 | Carcinoma, Non-Small-Cell Lung | Terminated | 2005-04-01 | 2007-07-01 | ClinicalTrials.gov |
| NCT00117351 | VELCADE in Previously Treated Patients With Stage IIIB and IV Bronchioloalveola… | Phase2 | Carcinoma, Non-Small-Cell Lung | Terminated | 2005-04-01 | 2007-07-01 | ClinicalTrials.gov |
| NCT00117351 | VELCADE in Previously Treated Patients With Stage IIIB and IV Bronchioloalveola… | Phase2 | Carcinoma, Non-Small-Cell Lung | Terminated | 2005-04-01 | 2007-07-01 | ClinicalTrials.gov |
| NCT01005888 | C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioed… | Phase3 | Hereditary Angioedema | Completed | 2005-03-14 | 2007-08-22 | ClinicalTrials.gov |
| NCT01005888 | C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioed… | Phase3 | Hereditary Angioedema | Completed | 2005-03-14 | 2007-08-22 | ClinicalTrials.gov |
| NCT00289211 | C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioede… | Phase3 | Hereditary Angioedema | Completed | 2005-03-14 | 2007-04-13 | ClinicalTrials.gov |
| NCT00289211 | C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioede… | Phase3 | Hereditary Angioedema | Completed | 2005-03-14 | 2007-04-13 | ClinicalTrials.gov |
| NCT00289211 | C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioede… | Phase3 | Hereditary Angioedema | Completed | 2005-03-14 | 2007-04-13 | ClinicalTrials.gov |
| NCT01005888 | C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioed… | Phase3 | Hereditary Angioedema | Completed | 2005-03-14 | 2007-08-22 | ClinicalTrials.gov |
| NCT00152035 | Safety of SPD465 in Treating Adults With ADHD. | Phase3 | Attention Deficit Disorder With Hyperactivity | Completed | 2005-03-10 | 2006-11-07 | ClinicalTrials.gov |
| NCT00152035 | Safety of SPD465 in Treating Adults With ADHD. | Phase3 | Attention Deficit Disorder With Hyperactivity | Completed | 2005-03-10 | 2006-11-07 | ClinicalTrials.gov |
| NCT00152035 | Safety of SPD465 in Treating Adults With ADHD. | Phase3 | Attention Deficit Disorder With Hyperactivity | Completed | 2005-03-10 | 2006-11-07 | ClinicalTrials.gov |
| NCT00671190 | Safety and Efficacy of Ramelteon in Healthy Subjects | Phase2 | Sleep Disorder | Completed | 2005-03-01 | 2005-05-01 | ClinicalTrials.gov |
| NCT00106262 | Study of Velcade and Irinotecan in Advanced Cervical, Vulvar, or Vaginal Cancer | Phase2 | Cervical Cancer | Terminated | 2005-03-01 | 2007-03-01 | ClinicalTrials.gov |
| NCT00229437 | Efficacy and Safety Study of TAK-128 in Treating Subjects With Diabetic Periphe… | Phase2 | Diabetic Neuropathies | Completed | 2005-03-01 | 2006-05-01 | ClinicalTrials.gov |
| NCT00229437 | Efficacy and Safety Study of TAK-128 in Treating Subjects With Diabetic Periphe… | Phase2 | Diabetic Neuropathies | Completed | 2005-03-01 | 2006-05-01 | ClinicalTrials.gov |
| NCT00274248 | MLN518 in Combination With Standard Induction Chemo. for Treatment of Patients … | Phase1 | Acute Myelogenous Leukemia | Completed | 2005-03-01 | — | ClinicalTrials.gov |
| NCT00671190 | Safety and Efficacy of Ramelteon in Healthy Subjects | Phase2 | Sleep Disorder | Completed | 2005-03-01 | 2005-05-01 | ClinicalTrials.gov |
| NCT00755846 | Safety and Efficacy Study of Alogliptin on Glycemic Control in Subjects With Ty… | Phase2 | Diabetes Mellitus | Completed | 2005-03-01 | 2005-10-01 | ClinicalTrials.gov |
| NCT00229437 | Efficacy and Safety Study of TAK-128 in Treating Subjects With Diabetic Periphe… | Phase2 | Diabetic Neuropathies | Completed | 2005-03-01 | 2006-05-01 | ClinicalTrials.gov |
| NCT00274248 | MLN518 in Combination With Standard Induction Chemo. for Treatment of Patients … | Phase1 | Acute Myelogenous Leukemia | Completed | 2005-03-01 | — | ClinicalTrials.gov |
| NCT00106262 | Study of Velcade and Irinotecan in Advanced Cervical, Vulvar, or Vaginal Cancer | Phase2 | Cervical Cancer | Terminated | 2005-03-01 | 2007-03-01 | ClinicalTrials.gov |
| NCT00671190 | Safety and Efficacy of Ramelteon in Healthy Subjects | Phase2 | Sleep Disorder | Completed | 2005-03-01 | 2005-05-01 | ClinicalTrials.gov |
| NCT00274248 | MLN518 in Combination With Standard Induction Chemo. for Treatment of Patients … | Phase1 | Acute Myelogenous Leukemia | Completed | 2005-03-01 | — | ClinicalTrials.gov |
| NCT00755846 | Safety and Efficacy Study of Alogliptin on Glycemic Control in Subjects With Ty… | Phase2 | Diabetes Mellitus | Completed | 2005-03-01 | 2005-10-01 | ClinicalTrials.gov |
| NCT00106262 | Study of Velcade and Irinotecan in Advanced Cervical, Vulvar, or Vaginal Cancer | Phase2 | Cervical Cancer | Terminated | 2005-03-01 | 2007-03-01 | ClinicalTrials.gov |
| NCT00755846 | Safety and Efficacy Study of Alogliptin on Glycemic Control in Subjects With Ty… | Phase2 | Diabetes Mellitus | Completed | 2005-03-01 | 2005-10-01 | ClinicalTrials.gov |
| NCT00672724 | Efficacy of Ramelteon in Adults With Chronic Insomnia | Phase3 | Chronic Insomnia | Terminated | 2005-02-01 | 2005-08-01 | ClinicalTrials.gov |
| NCT00091949 | Insulin Resistance Intervention After Stroke Trial | Phase3 | Stroke | Completed | 2005-02-01 | 2015-11-01 | ClinicalTrials.gov |
| NCT00672724 | Efficacy of Ramelteon in Adults With Chronic Insomnia | Phase3 | Chronic Insomnia | Terminated | 2005-02-01 | 2005-08-01 | ClinicalTrials.gov |
| NCT00091949 | Insulin Resistance Intervention After Stroke Trial | Phase3 | Stroke | Completed | 2005-02-01 | 2015-11-01 | ClinicalTrials.gov |
| NCT00091949 | Insulin Resistance Intervention After Stroke Trial | Phase3 | Stroke | Completed | 2005-02-01 | 2015-11-01 | ClinicalTrials.gov |
| NCT00672724 | Efficacy of Ramelteon in Adults With Chronic Insomnia | Phase3 | Chronic Insomnia | Terminated | 2005-02-01 | 2005-08-01 | ClinicalTrials.gov |
| NCT00150579 | Efficacy and Safety of SPD465 in Adults With ADHD | Phase3 | Attention Deficit Disorder With Hyperactivity | Completed | 2005-01-27 | 2005-06-14 | ClinicalTrials.gov |
| NCT00150579 | Efficacy and Safety of SPD465 in Adults With ADHD | Phase3 | Attention Deficit Disorder With Hyperactivity | Completed | 2005-01-27 | 2005-06-14 | ClinicalTrials.gov |
| NCT00150579 | Efficacy and Safety of SPD465 in Adults With ADHD | Phase3 | Attention Deficit Disorder With Hyperactivity | Completed | 2005-01-27 | 2005-06-14 | ClinicalTrials.gov |
| NCT00160121 | Efficacy and Safety of Fosrenol in Treating Elevated Serum Phosphate Levels in … | Phase4 | Kidney Failure, Chronic | Completed | 2005-01-10 | 2005-12-13 | ClinicalTrials.gov |
| NCT00160121 | Efficacy and Safety of Fosrenol in Treating Elevated Serum Phosphate Levels in … | Phase4 | Kidney Failure, Chronic | Completed | 2005-01-10 | 2005-12-13 | ClinicalTrials.gov |
| NCT00172185 | Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome … | Phase3 | Short Bowel Syndrome | Completed | 2005-01-10 | 2008-01-24 | ClinicalTrials.gov |
| NCT00172120 | Open Label Extension | Phase3 | Osteoporosis | Completed | 2005-01-10 | 2006-10-27 | ClinicalTrials.gov |
| NCT00172120 | Open Label Extension | Phase3 | Osteoporosis | Completed | 2005-01-10 | 2006-10-27 | ClinicalTrials.gov |
| NCT00172185 | Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome … | Phase3 | Short Bowel Syndrome | Completed | 2005-01-10 | 2008-01-24 | ClinicalTrials.gov |
| NCT00172120 | Open Label Extension | Phase3 | Osteoporosis | Completed | 2005-01-10 | 2006-10-27 | ClinicalTrials.gov |
| NCT00160121 | Efficacy and Safety of Fosrenol in Treating Elevated Serum Phosphate Levels in … | Phase4 | Kidney Failure, Chronic | Completed | 2005-01-10 | 2005-12-13 | ClinicalTrials.gov |
| NCT00172185 | Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome … | Phase3 | Short Bowel Syndrome | Completed | 2005-01-10 | 2008-01-24 | ClinicalTrials.gov |
| NCT00151918 | Efficacy and Safety of Lanthanum Carbonate and Sevelamer Hydrochloride in Patie… | Phase3 | Kidney Failure, Chronic | Completed | 2005-01-07 | 2005-08-22 | ClinicalTrials.gov |
| NCT00151918 | Efficacy and Safety of Lanthanum Carbonate and Sevelamer Hydrochloride in Patie… | Phase3 | Kidney Failure, Chronic | Completed | 2005-01-07 | 2005-08-22 | ClinicalTrials.gov |
| NCT00151918 | Efficacy and Safety of Lanthanum Carbonate and Sevelamer Hydrochloride in Patie… | Phase3 | Kidney Failure, Chronic | Completed | 2005-01-07 | 2005-08-22 | ClinicalTrials.gov |
| NCT00220818 | A Study to Evaluate the Effect of Lansoprazole on Infants With Gastroesophageal… | Phase1 | Gastroesophageal Reflux Disease | Completed | 2005-01-01 | 2005-07-01 | ClinicalTrials.gov |
| NCT00220818 | A Study to Evaluate the Effect of Lansoprazole on Infants With Gastroesophageal… | Phase1 | Gastroesophageal Reflux Disease | Completed | 2005-01-01 | 2005-07-01 | ClinicalTrials.gov |
| NCT00220818 | A Study to Evaluate the Effect of Lansoprazole on Infants With Gastroesophageal… | Phase1 | Gastroesophageal Reflux Disease | Completed | 2005-01-01 | 2005-07-01 | ClinicalTrials.gov |
| NCT00097695 | Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema | Phase3 | Angioedema | Completed | 2004-12-28 | 2006-07-17 | ClinicalTrials.gov |
| NCT00097695 | Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema | Phase3 | Angioedema | Completed | 2004-12-28 | 2006-07-17 | ClinicalTrials.gov |
| NCT00097695 | Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema | Phase3 | Angioedema | Completed | 2004-12-28 | 2006-07-17 | ClinicalTrials.gov |
| NCT00111319 | VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Patients With Previ… | Phase3 | Multiple Myeloma | Completed | 2004-12-01 | — | ClinicalTrials.gov |
| NCT00111319 | VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Patients With Previ… | Phase3 | Multiple Myeloma | Completed | 2004-12-01 | — | ClinicalTrials.gov |
| NCT00111319 | VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Patients With Previ… | Phase3 | Multiple Myeloma | Completed | 2004-12-01 | — | ClinicalTrials.gov |
| NCT00108706 | Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST) | Phase4 | Cerebrovascular Accident | Unknown | 2004-12-01 | 2007-09-01 | ClinicalTrials.gov |
| NCT00108706 | Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST) | Phase4 | Cerebrovascular Accident | Unknown | 2004-12-01 | 2007-09-01 | ClinicalTrials.gov |
| NCT00108706 | Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST) | Phase4 | Cerebrovascular Accident | Unknown | 2004-12-01 | 2007-09-01 | ClinicalTrials.gov |
| NCT00487994 | Safety and Efficacy of Lapaquistat Acetate Taken Alone and With Atorvastatin in… | Phase3 | Dyslipidemia | Completed | 2004-11-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT00487994 | Safety and Efficacy of Lapaquistat Acetate Taken Alone and With Atorvastatin in… | Phase3 | Dyslipidemia | Completed | 2004-11-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT02678676 | An Observational Study of Patient Cohorts Who Previously Received Long-term Tre… | — | Diabetes Mellitus, Type 2 | Completed | 2004-11-01 | 2011-11-01 | ClinicalTrials.gov |
| NCT02678676 | An Observational Study of Patient Cohorts Who Previously Received Long-term Tre… | — | Diabetes Mellitus, Type 2 | Completed | 2004-11-01 | 2011-11-01 | ClinicalTrials.gov |
| NCT00762957 | Safety and Efficacy of TAK-559 in Combination With Metformin in Patients With T… | Phase3 | Diabetes Mellitus | Terminated | 2004-11-01 | 2004-12-01 | ClinicalTrials.gov |
| NCT00762684 | Efficacy and Safety Study of TAK-559 in Treating Subjects With Type 2 Diabetes … | Phase3 | Diabetes Mellitus | Terminated | 2004-11-01 | 2004-12-01 | ClinicalTrials.gov |
| NCT00762684 | Efficacy and Safety Study of TAK-559 in Treating Subjects With Type 2 Diabetes … | Phase3 | Diabetes Mellitus | Terminated | 2004-11-01 | 2004-12-01 | ClinicalTrials.gov |
| NCT00762684 | Efficacy and Safety Study of TAK-559 in Treating Subjects With Type 2 Diabetes … | Phase3 | Diabetes Mellitus | Terminated | 2004-11-01 | 2004-12-01 | ClinicalTrials.gov |
| NCT00762957 | Safety and Efficacy of TAK-559 in Combination With Metformin in Patients With T… | Phase3 | Diabetes Mellitus | Terminated | 2004-11-01 | 2004-12-01 | ClinicalTrials.gov |
| NCT02678676 | An Observational Study of Patient Cohorts Who Previously Received Long-term Tre… | — | Diabetes Mellitus, Type 2 | Completed | 2004-11-01 | 2011-11-01 | ClinicalTrials.gov |
| NCT00487994 | Safety and Efficacy of Lapaquistat Acetate Taken Alone and With Atorvastatin in… | Phase3 | Dyslipidemia | Completed | 2004-11-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT00762957 | Safety and Efficacy of TAK-559 in Combination With Metformin in Patients With T… | Phase3 | Diabetes Mellitus | Terminated | 2004-11-01 | 2004-12-01 | ClinicalTrials.gov |
| NCT00630747 | Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in … | Phase2 | Hunter Syndrome | Completed | 2004-09-13 | 2008-01-31 | ClinicalTrials.gov |
| NCT00630747 | Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in … | Phase2 | Hunter Syndrome | Completed | 2004-09-13 | 2008-01-31 | ClinicalTrials.gov |
| NCT00630747 | Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in … | Phase2 | Hunter Syndrome | Completed | 2004-09-13 | 2008-01-31 | ClinicalTrials.gov |
| NCT00391625 | Open-Label Extension Study Evaluating Long Term Safety in Patients With Type 1 … | Phase1 | Gaucher Disease | Completed | 2004-09-13 | 2008-01-31 | ClinicalTrials.gov |
| NCT00391625 | Open-Label Extension Study Evaluating Long Term Safety in Patients With Type 1 … | Phase1 | Gaucher Disease | Completed | 2004-09-13 | 2008-01-31 | ClinicalTrials.gov |
| NCT00391625 | Open-Label Extension Study Evaluating Long Term Safety in Patients With Type 1 … | Phase1 | Gaucher Disease | Completed | 2004-09-13 | 2008-01-31 | ClinicalTrials.gov |
| NCT00555880 | Study to Assess the Benefit of Midodrine in the Treatment of Patients With Neur… | Phase4 | Hypotension, Orthostatic | Completed | 2004-09-08 | 2005-03-21 | ClinicalTrials.gov |
| NCT00555880 | Study to Assess the Benefit of Midodrine in the Treatment of Patients With Neur… | Phase4 | Hypotension, Orthostatic | Completed | 2004-09-08 | 2005-03-21 | ClinicalTrials.gov |
| NCT00555880 | Study to Assess the Benefit of Midodrine in the Treatment of Patients With Neur… | Phase4 | Hypotension, Orthostatic | Completed | 2004-09-08 | 2005-03-21 | ClinicalTrials.gov |
| NCT00864643 | Efficacy and Safety of Lapaquistat Acetate Coadministered With Atorvastatin in … | Phase2 | Hypercholesterolemia | Completed | 2004-09-01 | 2005-02-01 | ClinicalTrials.gov |
| NCT00789256 | Low Dose Melphalan and Bortezomib for AML and High-Risk MDS | Na | Acute Myelogenous Leukemia | Completed | 2004-09-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00789256 | Low Dose Melphalan and Bortezomib for AML and High-Risk MDS | Na | Acute Myelogenous Leukemia | Completed | 2004-09-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00789256 | Low Dose Melphalan and Bortezomib for AML and High-Risk MDS | Na | Acute Myelogenous Leukemia | Completed | 2004-09-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT01048840 | Natural History of Gastroesophageal Reflux (GER) in Children < 12 Years of Age | — | Gastroesophageal Reflux | Completed | 2004-09-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT00864643 | Efficacy and Safety of Lapaquistat Acetate Coadministered With Atorvastatin in … | Phase2 | Hypercholesterolemia | Completed | 2004-09-01 | 2005-02-01 | ClinicalTrials.gov |
| NCT00864643 | Efficacy and Safety of Lapaquistat Acetate Coadministered With Atorvastatin in … | Phase2 | Hypercholesterolemia | Completed | 2004-09-01 | 2005-02-01 | ClinicalTrials.gov |
| NCT01048840 | Natural History of Gastroesophageal Reflux (GER) in Children < 12 Years of Age | — | Gastroesophageal Reflux | Completed | 2004-09-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT01048840 | Natural History of Gastroesophageal Reflux (GER) in Children < 12 Years of Age | — | Gastroesophageal Reflux | Completed | 2004-09-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT00151996 | Safety and Tolerability of SPD503 and Psychostimulants in Children and Adolesce… | Phase2 | Attention Deficit Disorder With Hyperactivity | Completed | 2004-08-16 | 2004-12-27 | ClinicalTrials.gov |
| NCT00151996 | Safety and Tolerability of SPD503 and Psychostimulants in Children and Adolesce… | Phase2 | Attention Deficit Disorder With Hyperactivity | Completed | 2004-08-16 | 2004-12-27 | ClinicalTrials.gov |
| NCT00151996 | Safety and Tolerability of SPD503 and Psychostimulants in Children and Adolesce… | Phase2 | Attention Deficit Disorder With Hyperactivity | Completed | 2004-08-16 | 2004-12-27 | ClinicalTrials.gov |
| NCT00759551 | Efficacy and Safety of Azilsartan in Subjects With Essential Hypertension | Phase2 | Hypertension | Completed | 2004-08-01 | 2005-06-01 | ClinicalTrials.gov |
| NCT00760864 | Safety and Efficacy of TAK-715 in Subjects With Rheumatoid Arthritis | Phase2 | Arthritis, Rheumatoid | Completed | 2004-08-01 | 2005-09-01 | ClinicalTrials.gov |
| NCT00759551 | Efficacy and Safety of Azilsartan in Subjects With Essential Hypertension | Phase2 | Hypertension | Completed | 2004-08-01 | 2005-06-01 | ClinicalTrials.gov |
| NCT00760864 | Safety and Efficacy of TAK-715 in Subjects With Rheumatoid Arthritis | Phase2 | Arthritis, Rheumatoid | Completed | 2004-08-01 | 2005-09-01 | ClinicalTrials.gov |
| NCT00759551 | Efficacy and Safety of Azilsartan in Subjects With Essential Hypertension | Phase2 | Hypertension | Completed | 2004-08-01 | 2005-06-01 | ClinicalTrials.gov |
| NCT00760864 | Safety and Efficacy of TAK-715 in Subjects With Rheumatoid Arthritis | Phase2 | Arthritis, Rheumatoid | Completed | 2004-08-01 | 2005-09-01 | ClinicalTrials.gov |
| NCT00762736 | Efficacy and Safety of Pioglitazone and Azilsartan in Treating Subjects With Ty… | Phase2 | Diabetes Mellitus | Completed | 2004-07-01 | 2005-10-01 | ClinicalTrials.gov |
| NCT00762736 | Efficacy and Safety of Pioglitazone and Azilsartan in Treating Subjects With Ty… | Phase2 | Diabetes Mellitus | Completed | 2004-07-01 | 2005-10-01 | ClinicalTrials.gov |
| NCT00182637 | Bortezomib in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Ly… | Phase2 | Lymphoma | Completed | 2004-07-01 | 2010-09-01 | ClinicalTrials.gov |
| NCT00182637 | Bortezomib in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Ly… | Phase2 | Lymphoma | Completed | 2004-07-01 | 2010-09-01 | ClinicalTrials.gov |
| NCT01637935 | Cohort Study of Pioglitazone and Bladder Cancer in Patients With Type II Diabet… | — | Diabetes | Completed | 2004-07-01 | 2014-08-01 | ClinicalTrials.gov |
| NCT00182637 | Bortezomib in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Ly… | Phase2 | Lymphoma | Completed | 2004-07-01 | 2010-09-01 | ClinicalTrials.gov |
| NCT01637935 | Cohort Study of Pioglitazone and Bladder Cancer in Patients With Type II Diabet… | — | Diabetes | Completed | 2004-07-01 | 2014-08-01 | ClinicalTrials.gov |
| NCT01637935 | Cohort Study of Pioglitazone and Bladder Cancer in Patients With Type II Diabet… | — | Diabetes | Completed | 2004-07-01 | 2014-08-01 | ClinicalTrials.gov |
| NCT00762736 | Efficacy and Safety of Pioglitazone and Azilsartan in Treating Subjects With Ty… | Phase2 | Diabetes Mellitus | Completed | 2004-07-01 | 2005-10-01 | ClinicalTrials.gov |
| NCT00928148 | The Safety and Efficacy of SPD465 in Adults With Attention Deficit Hyperactivit… | Phase2 | Attention-Deficit/Hyperactivity Disorder | Completed | 2004-06-14 | 2004-11-20 | ClinicalTrials.gov |
| NCT00928148 | The Safety and Efficacy of SPD465 in Adults With Attention Deficit Hyperactivit… | Phase2 | Attention-Deficit/Hyperactivity Disorder | Completed | 2004-06-14 | 2004-11-20 | ClinicalTrials.gov |
| NCT00928148 | The Safety and Efficacy of SPD465 in Adults With Attention Deficit Hyperactivit… | Phase2 | Attention-Deficit/Hyperactivity Disorder | Completed | 2004-06-14 | 2004-11-20 | ClinicalTrials.gov |
| NCT00084084 | Replagal Enzyme Replacement Therapy for Children With Fabry Disease | Phase2 | Fabry Disease | Completed | 2004-06-10 | 2011-06-15 | ClinicalTrials.gov |
| NCT00084084 | Replagal Enzyme Replacement Therapy for Children With Fabry Disease | Phase2 | Fabry Disease | Completed | 2004-06-10 | 2011-06-15 | ClinicalTrials.gov |
| NCT00084084 | Replagal Enzyme Replacement Therapy for Children With Fabry Disease | Phase2 | Fabry Disease | Completed | 2004-06-10 | 2011-06-15 | ClinicalTrials.gov |
| NCT00084747 | Adjuvant Bortezomib Maintenance Therapy After Autologous Peripheral Stem Cell T… | Phase1 | Multiple Myeloma and Plasma Cell Neoplasm | Completed | 2004-06-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT00084747 | Adjuvant Bortezomib Maintenance Therapy After Autologous Peripheral Stem Cell T… | Phase1 | Multiple Myeloma and Plasma Cell Neoplasm | Completed | 2004-06-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT00084747 | Adjuvant Bortezomib Maintenance Therapy After Autologous Peripheral Stem Cell T… | Phase1 | Multiple Myeloma and Plasma Cell Neoplasm | Completed | 2004-06-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT00081458 | Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome | Phase3 | Short Bowel Syndrome | Completed | 2004-05-25 | 2007-07-06 | ClinicalTrials.gov |
| NCT00081458 | Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome | Phase3 | Short Bowel Syndrome | Completed | 2004-05-25 | 2007-07-06 | ClinicalTrials.gov |
| NCT00081458 | Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome | Phase3 | Short Bowel Syndrome | Completed | 2004-05-25 | 2007-07-06 | ClinicalTrials.gov |
| NCT00151931 | Efficacy and Tolerability of Treatment With Lanthanum Carbonate in Patients Wit… | Phase3 | Kidney Failure, Chronic | Completed | 2004-05-11 | 2006-01-12 | ClinicalTrials.gov |
| NCT00151931 | Efficacy and Tolerability of Treatment With Lanthanum Carbonate in Patients Wit… | Phase3 | Kidney Failure, Chronic | Completed | 2004-05-11 | 2006-01-12 | ClinicalTrials.gov |
| NCT00151931 | Efficacy and Tolerability of Treatment With Lanthanum Carbonate in Patients Wit… | Phase3 | Kidney Failure, Chronic | Completed | 2004-05-11 | 2006-01-12 | ClinicalTrials.gov |
| NCT00200382 | Phase II Study of Therapy With PS 341 in Patients With Advanced Stage Non Small… | Phase2 | Non-small Cell Lung Cancer | Terminated | 2004-05-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT00193557 | Weekly Bortezomib (Velcade) in the Treatment of Patients With Refractory Multip… | Phase2 | Multiple Myeloma | Completed | 2004-05-01 | 2009-01-01 | ClinicalTrials.gov |
| NCT00193557 | Weekly Bortezomib (Velcade) in the Treatment of Patients With Refractory Multip… | Phase2 | Multiple Myeloma | Completed | 2004-05-01 | 2009-01-01 | ClinicalTrials.gov |
| NCT00193232 | Weekly Docetaxel and Bortezomib in the Treatment of Advanced Hormone-Refractory… | Phase2 | Prostate Cancer | Completed | 2004-05-01 | 2007-02-01 | ClinicalTrials.gov |
| NCT00085696 | VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory In… | Phase2 | B-Cell Lymphoma | Completed | 2004-05-01 | — | ClinicalTrials.gov |
| NCT00085696 | VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory In… | Phase2 | B-Cell Lymphoma | Completed | 2004-05-01 | — | ClinicalTrials.gov |
| NCT00193232 | Weekly Docetaxel and Bortezomib in the Treatment of Advanced Hormone-Refractory… | Phase2 | Prostate Cancer | Completed | 2004-05-01 | 2007-02-01 | ClinicalTrials.gov |
| NCT00193557 | Weekly Bortezomib (Velcade) in the Treatment of Patients With Refractory Multip… | Phase2 | Multiple Myeloma | Completed | 2004-05-01 | 2009-01-01 | ClinicalTrials.gov |
| NCT00193232 | Weekly Docetaxel and Bortezomib in the Treatment of Advanced Hormone-Refractory… | Phase2 | Prostate Cancer | Completed | 2004-05-01 | 2007-02-01 | ClinicalTrials.gov |
| NCT00200382 | Phase II Study of Therapy With PS 341 in Patients With Advanced Stage Non Small… | Phase2 | Non-small Cell Lung Cancer | Terminated | 2004-05-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT00200382 | Phase II Study of Therapy With PS 341 in Patients With Advanced Stage Non Small… | Phase2 | Non-small Cell Lung Cancer | Terminated | 2004-05-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT00085696 | VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory In… | Phase2 | B-Cell Lymphoma | Completed | 2004-05-01 | — | ClinicalTrials.gov |
| NCT01011751 | Treatment of Hot Flushes Caused by Leuprorelin 11.25 mg in Prostate Adenocarcin… | Phase3 | Adenocarcinoma, Prostate | Completed | 2004-04-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00388635 | Velcade-Melphalan-Prednisone in Older Untreated Multiple Myeloma Patients. | Phase1 | Multiple Myeloma | Completed | 2004-04-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT01011751 | Treatment of Hot Flushes Caused by Leuprorelin 11.25 mg in Prostate Adenocarcin… | Phase3 | Adenocarcinoma, Prostate | Completed | 2004-04-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00388635 | Velcade-Melphalan-Prednisone in Older Untreated Multiple Myeloma Patients. | Phase1 | Multiple Myeloma | Completed | 2004-04-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00388635 | Velcade-Melphalan-Prednisone in Older Untreated Multiple Myeloma Patients. | Phase1 | Multiple Myeloma | Completed | 2004-04-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT01011751 | Treatment of Hot Flushes Caused by Leuprorelin 11.25 mg in Prostate Adenocarcin… | Phase3 | Adenocarcinoma, Prostate | Completed | 2004-04-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00150618 | Safety and Efficacy of SPD503 in Treating ADHD in Children and Adolescents Aged… | Phase3 | Attention Deficit Disorder With Hyperactivity | Completed | 2004-03-30 | 2004-10-07 | ClinicalTrials.gov |
| NCT00150618 | Safety and Efficacy of SPD503 in Treating ADHD in Children and Adolescents Aged… | Phase3 | Attention Deficit Disorder With Hyperactivity | Completed | 2004-03-30 | 2004-10-07 | ClinicalTrials.gov |
| NCT00150618 | Safety and Efficacy of SPD503 in Treating ADHD in Children and Adolescents Aged… | Phase3 | Attention Deficit Disorder With Hyperactivity | Completed | 2004-03-30 | 2004-10-07 | ClinicalTrials.gov |
| NCT00308438 | Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease Who Com… | Phase2 | Crohn's Disease | Completed | 2004-03-01 | 2006-06-01 | ClinicalTrials.gov |
| NCT00161096 | On-Demand Use of Pantoprazole: Determinants for Chronic Use of Acid Suppressive… | Phase3 | Chronic Use of Acid Suppressive Medication | Unknown | 2004-03-01 | 2005-09-01 | ClinicalTrials.gov |
| NCT00080405 | Repeat-Dose Pharmacokinetics and Pharmacodynamics of Bortezomib in Patients Wit… | Phase1 | Multiple Myeloma | Completed | 2004-03-01 | — | ClinicalTrials.gov |
| NCT00080405 | Repeat-Dose Pharmacokinetics and Pharmacodynamics of Bortezomib in Patients Wit… | Phase1 | Multiple Myeloma | Completed | 2004-03-01 | — | ClinicalTrials.gov |
| NCT00080405 | Repeat-Dose Pharmacokinetics and Pharmacodynamics of Bortezomib in Patients Wit… | Phase1 | Multiple Myeloma | Completed | 2004-03-01 | — | ClinicalTrials.gov |
| NCT00161096 | On-Demand Use of Pantoprazole: Determinants for Chronic Use of Acid Suppressive… | Phase3 | Chronic Use of Acid Suppressive Medication | Unknown | 2004-03-01 | 2005-09-01 | ClinicalTrials.gov |
| NCT00308438 | Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease Who Com… | Phase2 | Crohn's Disease | Completed | 2004-03-01 | 2006-06-01 | ClinicalTrials.gov |
| NCT00161096 | On-Demand Use of Pantoprazole: Determinants for Chronic Use of Acid Suppressive… | Phase3 | Chronic Use of Acid Suppressive Medication | Unknown | 2004-03-01 | 2005-09-01 | ClinicalTrials.gov |
| NCT00308438 | Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease Who Com… | Phase2 | Crohn's Disease | Completed | 2004-03-01 | 2006-06-01 | ClinicalTrials.gov |
| NCT00557960 | ADDERALL XR (Mixed Salts of a Single-entity Amphetamine) and STRATTERA ( Atomox… | Phase3 | Attention Deficit Disorder With Hyperactivity | Completed | 2004-02-25 | 2004-10-25 | ClinicalTrials.gov |
| NCT00557960 | ADDERALL XR (Mixed Salts of a Single-entity Amphetamine) and STRATTERA ( Atomox… | Phase3 | Attention Deficit Disorder With Hyperactivity | Completed | 2004-02-25 | 2004-10-25 | ClinicalTrials.gov |
| NCT00557960 | ADDERALL XR (Mixed Salts of a Single-entity Amphetamine) and STRATTERA ( Atomox… | Phase3 | Attention Deficit Disorder With Hyperactivity | Completed | 2004-02-25 | 2004-10-25 | ClinicalTrials.gov |
| NCT00150566 | Efficacy and Safety of Lanthanum in Controlling Serum Phosphate Levels in Subje… | Phase3 | Kidney Failure, Chronic | Completed | 2004-02-09 | 2005-10-08 | ClinicalTrials.gov |
| NCT00150566 | Efficacy and Safety of Lanthanum in Controlling Serum Phosphate Levels in Subje… | Phase3 | Kidney Failure, Chronic | Completed | 2004-02-09 | 2005-10-08 | ClinicalTrials.gov |
| NCT00150566 | Efficacy and Safety of Lanthanum in Controlling Serum Phosphate Levels in Subje… | Phase3 | Kidney Failure, Chronic | Completed | 2004-02-09 | 2005-10-08 | ClinicalTrials.gov |
| NCT00581919 | Ph 2 Bortezomib, Dexamethasone, + Doxorubicin With ALCAR for Previously Treated… | Phase2 | Multiple Myeloma | Completed | 2004-02-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT00581919 | Ph 2 Bortezomib, Dexamethasone, + Doxorubicin With ALCAR for Previously Treated… | Phase2 | Multiple Myeloma | Completed | 2004-02-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT00581919 | Ph 2 Bortezomib, Dexamethasone, + Doxorubicin With ALCAR for Previously Treated… | Phase2 | Multiple Myeloma | Completed | 2004-02-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT00172172 | Calcium Supplementation in Postmenopausal Women | Phase3 | Osteoporosis | Completed | 2004-01-10 | 2005-03-11 | ClinicalTrials.gov |
| NCT00172172 | Calcium Supplementation in Postmenopausal Women | Phase3 | Osteoporosis | Completed | 2004-01-10 | 2005-03-11 | ClinicalTrials.gov |
| NCT00172172 | Calcium Supplementation in Postmenopausal Women | Phase3 | Osteoporosis | Completed | 2004-01-10 | 2005-03-11 | ClinicalTrials.gov |
| NCT00254956 | Effects Of Ciclesonide And Beclomethasone On Lens Opacification In Adult Subjec… | Phase3 | Respiratory Tract Diseases | Completed | 2004-01-01 | 2005-06-01 | ClinicalTrials.gov |
| NCT00220961 | Actos Now for Prevention of Diabetes (ACT NOW) | Phase3 | Impaired Glucose Tolerance | Completed | 2004-01-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT00151320 | Phase I/II Trial of VELCADE + CHOP-Rituximab in Untreated DLCBL or Mantle Cell … | Phase1 | Non-Hodgkin's Lymphoma | Completed | 2004-01-01 | 2013-04-24 | ClinicalTrials.gov |
| NCT00254956 | Effects Of Ciclesonide And Beclomethasone On Lens Opacification In Adult Subjec… | Phase3 | Respiratory Tract Diseases | Completed | 2004-01-01 | 2005-06-01 | ClinicalTrials.gov |
| NCT00220961 | Actos Now for Prevention of Diabetes (ACT NOW) | Phase3 | Impaired Glucose Tolerance | Completed | 2004-01-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT00220961 | Actos Now for Prevention of Diabetes (ACT NOW) | Phase3 | Impaired Glucose Tolerance | Completed | 2004-01-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT00151320 | Phase I/II Trial of VELCADE + CHOP-Rituximab in Untreated DLCBL or Mantle Cell … | Phase1 | Non-Hodgkin's Lymphoma | Completed | 2004-01-01 | 2013-04-24 | ClinicalTrials.gov |
| NCT00254956 | Effects Of Ciclesonide And Beclomethasone On Lens Opacification In Adult Subjec… | Phase3 | Respiratory Tract Diseases | Completed | 2004-01-01 | 2005-06-01 | ClinicalTrials.gov |
| NCT00151320 | Phase I/II Trial of VELCADE + CHOP-Rituximab in Untreated DLCBL or Mantle Cell … | Phase1 | Non-Hodgkin's Lymphoma | Completed | 2004-01-01 | 2013-04-24 | ClinicalTrials.gov |
| NCT00172094 | Safety and Efficacy of NPS 1776 in the Acute Treatment of Migraine Headaches | Phase2 | Migraine Headache | Completed | 2003-12-31 | 2004-07-31 | ClinicalTrials.gov |
| NCT00172094 | Safety and Efficacy of NPS 1776 in the Acute Treatment of Migraine Headaches | Phase2 | Migraine Headache | Completed | 2003-12-31 | 2004-07-31 | ClinicalTrials.gov |
| NCT00172094 | Safety and Efficacy of NPS 1776 in the Acute Treatment of Migraine Headaches | Phase2 | Migraine Headache | Completed | 2003-12-31 | 2004-07-31 | ClinicalTrials.gov |
| NCT00548574 | Efficacy and Safety of Two Doses of SPD476 (Mesalazine) 2.4g and 4.8g Once Dail… | Phase3 | Ulcerative Colitis | Completed | 2003-12-04 | 2004-10-20 | ClinicalTrials.gov |
| NCT00548574 | Efficacy and Safety of Two Doses of SPD476 (Mesalazine) 2.4g and 4.8g Once Dail… | Phase3 | Ulcerative Colitis | Completed | 2003-12-04 | 2004-10-20 | ClinicalTrials.gov |
| NCT00548574 | Efficacy and Safety of Two Doses of SPD476 (Mesalazine) 2.4g and 4.8g Once Dail… | Phase3 | Ulcerative Colitis | Completed | 2003-12-04 | 2004-10-20 | ClinicalTrials.gov |
| NCT00142129 | Bortezomib (Velcade) in Waldenstrom's Macroglobulinemia | Phase2 | Waldenstrom's Macroglobulinemia | Completed | 2003-12-01 | 2007-06-01 | ClinicalTrials.gov |
| NCT00142129 | Bortezomib (Velcade) in Waldenstrom's Macroglobulinemia | Phase2 | Waldenstrom's Macroglobulinemia | Completed | 2003-12-01 | 2007-06-01 | ClinicalTrials.gov |
| NCT00153920 | Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma | Phase2 | Multiple Myeloma | Completed | 2003-12-01 | 2008-09-01 | ClinicalTrials.gov |
| NCT00142129 | Bortezomib (Velcade) in Waldenstrom's Macroglobulinemia | Phase2 | Waldenstrom's Macroglobulinemia | Completed | 2003-12-01 | 2007-06-01 | ClinicalTrials.gov |
| NCT00153920 | Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma | Phase2 | Multiple Myeloma | Completed | 2003-12-01 | 2008-09-01 | ClinicalTrials.gov |
| NCT00153920 | Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma | Phase2 | Multiple Myeloma | Completed | 2003-12-01 | 2008-09-01 | ClinicalTrials.gov |
| NCT00072839 | Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease | Phase2 | Crohn's Disease | Completed | 2003-11-12 | 2005-07-28 | ClinicalTrials.gov |
| NCT00072839 | Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease | Phase2 | Crohn's Disease | Completed | 2003-11-12 | 2005-07-28 | ClinicalTrials.gov |
| NCT00072839 | Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease | Phase2 | Crohn's Disease | Completed | 2003-11-12 | 2005-07-28 | ClinicalTrials.gov |
| NCT00763022 | Efficacy of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus | Phase3 | Diabetes Mellitus | Completed | 2003-11-01 | 2004-12-01 | ClinicalTrials.gov |
| NCT00762190 | Study of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus | Phase3 | Diabetes Mellitus | Terminated | 2003-11-01 | 2004-12-01 | ClinicalTrials.gov |
| NCT00762112 | Safety Study of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus | Phase3 | Diabetes Mellitus | Terminated | 2003-11-01 | 2004-12-01 | ClinicalTrials.gov |
| NCT00759720 | Efficacy and Safety of TAK-559 Combined With Glyburide in Treating Subjects Wit… | Phase3 | Diabetes Mellitus | Terminated | 2003-11-01 | 2004-12-01 | ClinicalTrials.gov |
| NCT00763022 | Efficacy of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus | Phase3 | Diabetes Mellitus | Completed | 2003-11-01 | 2004-12-01 | ClinicalTrials.gov |
| NCT00672919 | Pioglitazone Study of Triglyceride Changes in Subjects With Type 2 Diabetes Aft… | Phase4 | Diabetes Mellitus | Completed | 2003-11-01 | 2004-08-01 | ClinicalTrials.gov |
| NCT00074906 | Venticute in Patients With Pneumonia or Aspiration of Gastric Contents and Intu… | Phase3 | Pneumonia | Completed | 2003-11-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00074906 | Venticute in Patients With Pneumonia or Aspiration of Gastric Contents and Intu… | Phase3 | Pneumonia | Completed | 2003-11-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00672919 | Pioglitazone Study of Triglyceride Changes in Subjects With Type 2 Diabetes Aft… | Phase4 | Diabetes Mellitus | Completed | 2003-11-01 | 2004-08-01 | ClinicalTrials.gov |
| NCT00762112 | Safety Study of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus | Phase3 | Diabetes Mellitus | Terminated | 2003-11-01 | 2004-12-01 | ClinicalTrials.gov |
| NCT00672919 | Pioglitazone Study of Triglyceride Changes in Subjects With Type 2 Diabetes Aft… | Phase4 | Diabetes Mellitus | Completed | 2003-11-01 | 2004-08-01 | ClinicalTrials.gov |
| NCT01826916 | EDEMA2: Evaluation of DX-88's Effect in Mitigating Angioedema | Phase2 | Hereditary Angioedema (HAE) | Completed | 2003-11-01 | 2006-01-01 | ClinicalTrials.gov |
| NCT00759720 | Efficacy and Safety of TAK-559 Combined With Glyburide in Treating Subjects Wit… | Phase3 | Diabetes Mellitus | Terminated | 2003-11-01 | 2004-12-01 | ClinicalTrials.gov |
| NCT00762190 | Study of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus | Phase3 | Diabetes Mellitus | Terminated | 2003-11-01 | 2004-12-01 | ClinicalTrials.gov |
| NCT00074906 | Venticute in Patients With Pneumonia or Aspiration of Gastric Contents and Intu… | Phase3 | Pneumonia | Completed | 2003-11-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00763022 | Efficacy of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus | Phase3 | Diabetes Mellitus | Completed | 2003-11-01 | 2004-12-01 | ClinicalTrials.gov |
| NCT00759720 | Efficacy and Safety of TAK-559 Combined With Glyburide in Treating Subjects Wit… | Phase3 | Diabetes Mellitus | Terminated | 2003-11-01 | 2004-12-01 | ClinicalTrials.gov |
| NCT01826916 | EDEMA2: Evaluation of DX-88's Effect in Mitigating Angioedema | Phase2 | Hereditary Angioedema (HAE) | Completed | 2003-11-01 | 2006-01-01 | ClinicalTrials.gov |
| NCT00762112 | Safety Study of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus | Phase3 | Diabetes Mellitus | Terminated | 2003-11-01 | 2004-12-01 | ClinicalTrials.gov |
| NCT01826916 | EDEMA2: Evaluation of DX-88's Effect in Mitigating Angioedema | Phase2 | Hereditary Angioedema (HAE) | Completed | 2003-11-01 | 2006-01-01 | ClinicalTrials.gov |
| NCT00762190 | Study of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus | Phase3 | Diabetes Mellitus | Terminated | 2003-11-01 | 2004-12-01 | ClinicalTrials.gov |
| NCT00225264 | Efficacy Study of Pioglitazone and Glimepiride on the Rate of Progression of At… | Phase3 | Diabetes Mellitus | Completed | 2003-10-01 | 2006-05-01 | ClinicalTrials.gov |
| NCT00070837 | MLN2704 in Subjects With Metastatic Androgen-Independent Prostate Cancer | Phase1 | Prostatic Neoplasms | Completed | 2003-10-01 | 2004-10-01 | ClinicalTrials.gov |
| NCT00225264 | Efficacy Study of Pioglitazone and Glimepiride on the Rate of Progression of At… | Phase3 | Diabetes Mellitus | Completed | 2003-10-01 | 2006-05-01 | ClinicalTrials.gov |
| NCT00070837 | MLN2704 in Subjects With Metastatic Androgen-Independent Prostate Cancer | Phase1 | Prostatic Neoplasms | Completed | 2003-10-01 | 2004-10-01 | ClinicalTrials.gov |
| NCT00225264 | Efficacy Study of Pioglitazone and Glimepiride on the Rate of Progression of At… | Phase3 | Diabetes Mellitus | Completed | 2003-10-01 | 2006-05-01 | ClinicalTrials.gov |
| NCT00242177 | Pilot Test of ACTOS in Multiple Sclerosis: Safety and Tolerability | Phase1 | Multiple Sclerosis, Relapsing-Remitting | Completed | 2003-10-01 | 2005-10-01 | ClinicalTrials.gov |
| NCT00242177 | Pilot Test of ACTOS in Multiple Sclerosis: Safety and Tolerability | Phase1 | Multiple Sclerosis, Relapsing-Remitting | Completed | 2003-10-01 | 2005-10-01 | ClinicalTrials.gov |
| NCT00242177 | Pilot Test of ACTOS in Multiple Sclerosis: Safety and Tolerability | Phase1 | Multiple Sclerosis, Relapsing-Remitting | Completed | 2003-10-01 | 2005-10-01 | ClinicalTrials.gov |
| NCT00070837 | MLN2704 in Subjects With Metastatic Androgen-Independent Prostate Cancer | Phase1 | Prostatic Neoplasms | Completed | 2003-10-01 | 2004-10-01 | ClinicalTrials.gov |
| NCT00503243 | Safety and Efficacy of SPD476 (Mesalazine) Given Twice Daily (2.4 g/Day) vs SPD… | Phase3 | Colitis, Ulcerative | Completed | 2003-09-30 | 2005-01-17 | ClinicalTrials.gov |
| NCT00503243 | Safety and Efficacy of SPD476 (Mesalazine) Given Twice Daily (2.4 g/Day) vs SPD… | Phase3 | Colitis, Ulcerative | Completed | 2003-09-30 | 2005-01-17 | ClinicalTrials.gov |
| NCT00503243 | Safety and Efficacy of SPD476 (Mesalazine) Given Twice Daily (2.4 g/Day) vs SPD… | Phase3 | Colitis, Ulcerative | Completed | 2003-09-30 | 2005-01-17 | ClinicalTrials.gov |
| NCT00069641 | Iduronate-2-sulfatase Enzyme Replacement Therapy in Mucopolysaccharidosis II (M… | Phase2 | Mucopolysaccharidosis II | Completed | 2003-09-18 | 2005-03-16 | ClinicalTrials.gov |
| NCT00069641 | Iduronate-2-sulfatase Enzyme Replacement Therapy in Mucopolysaccharidosis II (M… | Phase2 | Mucopolysaccharidosis II | Completed | 2003-09-18 | 2005-03-16 | ClinicalTrials.gov |
| NCT00069641 | Iduronate-2-sulfatase Enzyme Replacement Therapy in Mucopolysaccharidosis II (M… | Phase2 | Mucopolysaccharidosis II | Completed | 2003-09-18 | 2005-03-16 | ClinicalTrials.gov |
| NCT00737347 | Prevention of Weight Gain in Adult Patients With Type 2 Diabetes Treated With P… | Phase3 | Type 2 Diabetes | Completed | 2003-09-01 | 2008-04-01 | ClinicalTrials.gov |
| NCT00737347 | Prevention of Weight Gain in Adult Patients With Type 2 Diabetes Treated With P… | Phase3 | Type 2 Diabetes | Completed | 2003-09-01 | 2008-04-01 | ClinicalTrials.gov |
| NCT00737347 | Prevention of Weight Gain in Adult Patients With Type 2 Diabetes Treated With P… | Phase3 | Type 2 Diabetes | Completed | 2003-09-01 | 2008-04-01 | ClinicalTrials.gov |
| NCT00506727 | Analog Classroom Study Comparison of ADDERALL XR With STRATTERA in Children Age… | Phase4 | ADHD | Completed | 2003-08-05 | 2004-07-02 | ClinicalTrials.gov |
| NCT00506727 | Analog Classroom Study Comparison of ADDERALL XR With STRATTERA in Children Age… | Phase4 | ADHD | Completed | 2003-08-05 | 2004-07-02 | ClinicalTrials.gov |
| NCT00506727 | Analog Classroom Study Comparison of ADDERALL XR With STRATTERA in Children Age… | Phase4 | ADHD | Completed | 2003-08-05 | 2004-07-02 | ClinicalTrials.gov |
| NCT00672802 | Safety of Ramelteon in Subjects With Mild to Moderate Chronic Obstructive Pulmo… | Phase2 | Chronic Obstructive Pulmonary Disease | Completed | 2003-08-01 | 2004-03-01 | ClinicalTrials.gov |
| NCT00672802 | Safety of Ramelteon in Subjects With Mild to Moderate Chronic Obstructive Pulmo… | Phase2 | Chronic Obstructive Pulmonary Disease | Completed | 2003-08-01 | 2004-03-01 | ClinicalTrials.gov |
| NCT00672802 | Safety of Ramelteon in Subjects With Mild to Moderate Chronic Obstructive Pulmo… | Phase2 | Chronic Obstructive Pulmonary Disease | Completed | 2003-08-01 | 2004-03-01 | ClinicalTrials.gov |
| NCT00672061 | Safety of Ramelteon in Subjects With Mild to Moderate Obstructive Sleep Apnea | Phase2 | Sleep Apnea, Obstructive | Completed | 2003-07-01 | 2003-12-01 | ClinicalTrials.gov |
| NCT00505700 | VELCADE in Combination With Idarubicin and Cytosine Arabinoside in Patients Wit… | Phase1 | Leukemia | Completed | 2003-07-01 | — | ClinicalTrials.gov |
| NCT00225277 | Efficacy Study of Pioglitazone Compared to Glimepiride on Coronary Atherosclero… | Phase3 | Diabetes Mellitus | Completed | 2003-07-01 | 2007-10-01 | ClinicalTrials.gov |
| NCT00225277 | Efficacy Study of Pioglitazone Compared to Glimepiride on Coronary Atherosclero… | Phase3 | Diabetes Mellitus | Completed | 2003-07-01 | 2007-10-01 | ClinicalTrials.gov |
| NCT00175032 | A Comparison of Safety and Treatment in Subjects With Osteoarthritis Taking Low… | Phase3 | Osteoarthritis | Completed | 2003-07-01 | 2004-07-01 | ClinicalTrials.gov |
| NCT00672061 | Safety of Ramelteon in Subjects With Mild to Moderate Obstructive Sleep Apnea | Phase2 | Sleep Apnea, Obstructive | Completed | 2003-07-01 | 2003-12-01 | ClinicalTrials.gov |
| NCT00175032 | A Comparison of Safety and Treatment in Subjects With Osteoarthritis Taking Low… | Phase3 | Osteoarthritis | Completed | 2003-07-01 | 2004-07-01 | ClinicalTrials.gov |
| NCT00175019 | Allopurinol Versus Febuxostat in Subjects Completing the Phase 3 Trials C02-009… | Phase3 | Gout | Completed | 2003-07-01 | 2007-02-01 | ClinicalTrials.gov |
| NCT00175019 | Allopurinol Versus Febuxostat in Subjects Completing the Phase 3 Trials C02-009… | Phase3 | Gout | Completed | 2003-07-01 | 2007-02-01 | ClinicalTrials.gov |
| NCT00175019 | Allopurinol Versus Febuxostat in Subjects Completing the Phase 3 Trials C02-009… | Phase3 | Gout | Completed | 2003-07-01 | 2007-02-01 | ClinicalTrials.gov |
| NCT00505700 | VELCADE in Combination With Idarubicin and Cytosine Arabinoside in Patients Wit… | Phase1 | Leukemia | Completed | 2003-07-01 | — | ClinicalTrials.gov |
| NCT00672061 | Safety of Ramelteon in Subjects With Mild to Moderate Obstructive Sleep Apnea | Phase2 | Sleep Apnea, Obstructive | Completed | 2003-07-01 | 2003-12-01 | ClinicalTrials.gov |
| NCT00175032 | A Comparison of Safety and Treatment in Subjects With Osteoarthritis Taking Low… | Phase3 | Osteoarthritis | Completed | 2003-07-01 | 2004-07-01 | ClinicalTrials.gov |
| NCT00505700 | VELCADE in Combination With Idarubicin and Cytosine Arabinoside in Patients Wit… | Phase1 | Leukemia | Completed | 2003-07-01 | — | ClinicalTrials.gov |
| NCT00225277 | Efficacy Study of Pioglitazone Compared to Glimepiride on Coronary Atherosclero… | Phase3 | Diabetes Mellitus | Completed | 2003-07-01 | 2007-10-01 | ClinicalTrials.gov |
| NCT00063713 | VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma | Phase2 | Mantle Cell Lymphoma | Completed | 2003-06-01 | — | ClinicalTrials.gov |
| NCT00671632 | Behavioral and Subjective Efficacy of Ramelteon in Subjects With a History of P… | Phase2 | Drug Abuse | Completed | 2003-06-01 | 2003-12-01 | ClinicalTrials.gov |
| NCT00671632 | Behavioral and Subjective Efficacy of Ramelteon in Subjects With a History of P… | Phase2 | Drug Abuse | Completed | 2003-06-01 | 2003-12-01 | ClinicalTrials.gov |
| NCT00671632 | Behavioral and Subjective Efficacy of Ramelteon in Subjects With a History of P… | Phase2 | Drug Abuse | Completed | 2003-06-01 | 2003-12-01 | ClinicalTrials.gov |
| NCT00175045 | Intravenous vs Oral Lansoprazole on Gastric Acid Secretion in Subjects With Ero… | Phase2 | Esophagitis | Completed | 2003-06-01 | 2003-10-01 | ClinicalTrials.gov |
| NCT00175045 | Intravenous vs Oral Lansoprazole on Gastric Acid Secretion in Subjects With Ero… | Phase2 | Esophagitis | Completed | 2003-06-01 | 2003-10-01 | ClinicalTrials.gov |
| NCT00063713 | VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma | Phase2 | Mantle Cell Lymphoma | Completed | 2003-06-01 | — | ClinicalTrials.gov |
| NCT00175045 | Intravenous vs Oral Lansoprazole on Gastric Acid Secretion in Subjects With Ero… | Phase2 | Esophagitis | Completed | 2003-06-01 | 2003-10-01 | ClinicalTrials.gov |
| NCT00063713 | VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma | Phase2 | Mantle Cell Lymphoma | Completed | 2003-06-01 | — | ClinicalTrials.gov |
| NCT00507065 | Safety and Efficacy of ADDERALL XR in the Treatment of Adolescents Aged 13-17 W… | Phase3 | ADHD | Completed | 2003-05-28 | 2004-03-24 | ClinicalTrials.gov |
| NCT00507065 | Safety and Efficacy of ADDERALL XR in the Treatment of Adolescents Aged 13-17 W… | Phase3 | ADHD | Completed | 2003-05-28 | 2004-03-24 | ClinicalTrials.gov |
| NCT00507065 | Safety and Efficacy of ADDERALL XR in the Treatment of Adolescents Aged 13-17 W… | Phase3 | ADHD | Completed | 2003-05-28 | 2004-03-24 | ClinicalTrials.gov |
| NCT00250471 | PROTECT-TIMI 30 Trial | Phase3 | Unstable Angina | Completed | 2003-05-01 | 2004-09-01 | ClinicalTrials.gov |
| NCT00250471 | PROTECT-TIMI 30 Trial | Phase3 | Unstable Angina | Completed | 2003-05-01 | 2004-09-01 | ClinicalTrials.gov |
| NCT00250471 | PROTECT-TIMI 30 Trial | Phase3 | Unstable Angina | Completed | 2003-05-01 | 2004-09-01 | ClinicalTrials.gov |
| NCT00059618 | PS-341 Plus Carboplatin in Platinum and Taxane Resistant Recurrent Ovarian Canc… | Phase1 | Ovarian Cancer | Completed | 2003-04-01 | 2007-04-01 | ClinicalTrials.gov |
| NCT00059618 | PS-341 Plus Carboplatin in Platinum and Taxane Resistant Recurrent Ovarian Canc… | Phase1 | Ovarian Cancer | Completed | 2003-04-01 | 2007-04-01 | ClinicalTrials.gov |
| NCT00059618 | PS-341 Plus Carboplatin in Platinum and Taxane Resistant Recurrent Ovarian Canc… | Phase1 | Ovarian Cancer | Completed | 2003-04-01 | 2007-04-01 | ClinicalTrials.gov |
| NCT00059631 | Phase I Study of Weekly Intravenous PS-341 (Bortezomib) Plus Mitoxantrone | Phase1 | Prostate Cancer | Completed | 2003-03-20 | 2015-06-17 | ClinicalTrials.gov |
| NCT00059631 | Phase I Study of Weekly Intravenous PS-341 (Bortezomib) Plus Mitoxantrone | Phase1 | Prostate Cancer | Completed | 2003-03-20 | 2015-06-17 | ClinicalTrials.gov |
| NCT00059631 | Phase I Study of Weekly Intravenous PS-341 (Bortezomib) Plus Mitoxantrone | Phase1 | Prostate Cancer | Completed | 2003-03-20 | 2015-06-17 | ClinicalTrials.gov |
| NCT00204373 | Treatment of Zollinger-Ellison Syndrome With Prevacid | Phase4 | Zollinger-Ellison Syndrome | Completed | 2003-03-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT00204373 | Treatment of Zollinger-Ellison Syndrome With Prevacid | Phase4 | Zollinger-Ellison Syndrome | Completed | 2003-03-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT00816218 | Molecular Mechanisms of Type 2 Diabetes Mellitus | Phase4 | Type 2 Diabetes Mellitus | Completed | 2003-03-01 | 2008-11-01 | ClinicalTrials.gov |
| NCT00204373 | Treatment of Zollinger-Ellison Syndrome With Prevacid | Phase4 | Zollinger-Ellison Syndrome | Completed | 2003-03-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT00816218 | Molecular Mechanisms of Type 2 Diabetes Mellitus | Phase4 | Type 2 Diabetes Mellitus | Completed | 2003-03-01 | 2008-11-01 | ClinicalTrials.gov |
| NCT00816218 | Molecular Mechanisms of Type 2 Diabetes Mellitus | Phase4 | Type 2 Diabetes Mellitus | Completed | 2003-03-01 | 2008-11-01 | ClinicalTrials.gov |
| NCT00545389 | Phase II Dose-Ranging Study in Subjects With Mild to Moderate Ulcerative Coliti… | Phase2 | Colitis, Ulcerative | Completed | 2003-02-10 | 2004-10-20 | ClinicalTrials.gov |
| NCT00545389 | Phase II Dose-Ranging Study in Subjects With Mild to Moderate Ulcerative Coliti… | Phase2 | Colitis, Ulcerative | Completed | 2003-02-10 | 2004-10-20 | ClinicalTrials.gov |
| NCT00545389 | Phase II Dose-Ranging Study in Subjects With Mild to Moderate Ulcerative Coliti… | Phase2 | Colitis, Ulcerative | Completed | 2003-02-10 | 2004-10-20 | ClinicalTrials.gov |
| NCT00671086 | Efficacy of Ramelteon in Subjects With Chronic Insomnia | Phase3 | Sleep Initiation and Maintenance Disorders | Completed | 2003-02-01 | 2004-09-01 | ClinicalTrials.gov |
| NCT00174915 | Phase 3, Febuxostat, Allopurinol and Placebo-Controlled Study in Gout Subjects. | Phase3 | Gout | Completed | 2003-02-01 | 2004-04-01 | ClinicalTrials.gov |
| NCT00174915 | Phase 3, Febuxostat, Allopurinol and Placebo-Controlled Study in Gout Subjects. | Phase3 | Gout | Completed | 2003-02-01 | 2004-04-01 | ClinicalTrials.gov |
| NCT00148850 | Effect of Pioglitazone on HIV-1 Related Lipoatrophy: a Randomized, Double Blind… | Phase3 | HIV-Associated Lipodystrophy Syndrome | Terminated | 2003-02-01 | 2004-10-01 | ClinicalTrials.gov |
| NCT00671086 | Efficacy of Ramelteon in Subjects With Chronic Insomnia | Phase3 | Sleep Initiation and Maintenance Disorders | Completed | 2003-02-01 | 2004-09-01 | ClinicalTrials.gov |
| NCT00671086 | Efficacy of Ramelteon in Subjects With Chronic Insomnia | Phase3 | Sleep Initiation and Maintenance Disorders | Completed | 2003-02-01 | 2004-09-01 | ClinicalTrials.gov |
| NCT00148850 | Effect of Pioglitazone on HIV-1 Related Lipoatrophy: a Randomized, Double Blind… | Phase3 | HIV-Associated Lipodystrophy Syndrome | Terminated | 2003-02-01 | 2004-10-01 | ClinicalTrials.gov |
| NCT00148850 | Effect of Pioglitazone on HIV-1 Related Lipoatrophy: a Randomized, Double Blind… | Phase3 | HIV-Associated Lipodystrophy Syndrome | Terminated | 2003-02-01 | 2004-10-01 | ClinicalTrials.gov |
| NCT00174915 | Phase 3, Febuxostat, Allopurinol and Placebo-Controlled Study in Gout Subjects. | Phase3 | Gout | Completed | 2003-02-01 | 2004-04-01 | ClinicalTrials.gov |
| NCT00152009 | Safety and Efficacy of SPD503 in Treating Attention-Deficit/Hyperactivity Disor… | Phase3 | Attention Deficit Disorder With Hyperactivity | Completed | 2003-01-29 | 2003-08-23 | ClinicalTrials.gov |
| NCT00152009 | Safety and Efficacy of SPD503 in Treating Attention-Deficit/Hyperactivity Disor… | Phase3 | Attention Deficit Disorder With Hyperactivity | Completed | 2003-01-29 | 2003-08-23 | ClinicalTrials.gov |
| NCT00152009 | Safety and Efficacy of SPD503 in Treating Attention-Deficit/Hyperactivity Disor… | Phase3 | Attention Deficit Disorder With Hyperactivity | Completed | 2003-01-29 | 2003-08-23 | ClinicalTrials.gov |
| NCT00671125 | Study of Efficacy of Ramelteon in Adults With Chronic Insomnia | Phase3 | Chronic Insomnia | Completed | 2003-01-01 | 2003-09-01 | ClinicalTrials.gov |
| NCT00671125 | Study of Efficacy of Ramelteon in Adults With Chronic Insomnia | Phase3 | Chronic Insomnia | Completed | 2003-01-01 | 2003-09-01 | ClinicalTrials.gov |
| NCT00656994 | Long-Term Efficacy of Ramelteon on Endocrine Function in Adult Subjects With Ch… | Phase3 | Insomnia | Completed | 2003-01-01 | 2004-07-01 | ClinicalTrials.gov |
| NCT00656994 | Long-Term Efficacy of Ramelteon on Endocrine Function in Adult Subjects With Ch… | Phase3 | Insomnia | Completed | 2003-01-01 | 2004-07-01 | ClinicalTrials.gov |
| NCT00671125 | Study of Efficacy of Ramelteon in Adults With Chronic Insomnia | Phase3 | Chronic Insomnia | Completed | 2003-01-01 | 2003-09-01 | ClinicalTrials.gov |
| NCT00656994 | Long-Term Efficacy of Ramelteon on Endocrine Function in Adult Subjects With Ch… | Phase3 | Insomnia | Completed | 2003-01-01 | 2004-07-01 | ClinicalTrials.gov |
| NCT00051987 | Phase 2b Study of VELCADE Alone and VELCADE Plus Irinotecan in Patients With Re… | Phase2 | Colorectal Carcinoma | Completed | 2002-12-01 | — | ClinicalTrials.gov |
| NCT00051974 | Phase 2 Study of VELCADE Alone or VELCADE® Plus Docetaxel in Previously Treated… | Phase2 | Non-Small Cell Lung Cancer | Completed | 2002-12-01 | — | ClinicalTrials.gov |
| NCT00671567 | Ramelteon in Adults With Chronic Insomnia | Phase3 | Chronic Insomnia | Completed | 2002-12-01 | 2003-09-01 | ClinicalTrials.gov |
| NCT00671398 | Efficacy of Ramelteon on Transient Insomnia in Healthy Adults | Phase3 | Transient Insomnia | Completed | 2002-12-01 | 2003-05-01 | ClinicalTrials.gov |
| NCT00064636 | Phase I Dose Escalation Study of VELCADE Plus Docetaxel in Patients With Advanc… | Phase1 | Advanced Non-Small Cell Lung Cancer | Terminated | 2002-12-01 | — | ClinicalTrials.gov |
| NCT00671255 | Safety and Efficacy of Ramelteon in Elderly Subjects With Chronic Insomnia | Phase3 | Chronic Insomnia | Completed | 2002-12-01 | 2004-01-01 | ClinicalTrials.gov |
| NCT00064610 | Phase I/II Dose Escalation Study of VELCADE® and Docetaxel in Patients With Adv… | Phase1 | Prostatic Neoplasms | Completed | 2002-12-01 | — | ClinicalTrials.gov |
| NCT00676260 | Efficacy of Pioglitazone on Microcirculation in Type 2 Diabetes Patients Treate… | Phase2 | Diabetes Mellitus | Completed | 2002-12-01 | 2004-08-01 | ClinicalTrials.gov |
| NCT00676260 | Efficacy of Pioglitazone on Microcirculation in Type 2 Diabetes Patients Treate… | Phase2 | Diabetes Mellitus | Completed | 2002-12-01 | 2004-08-01 | ClinicalTrials.gov |
| NCT00064636 | Phase I Dose Escalation Study of VELCADE Plus Docetaxel in Patients With Advanc… | Phase1 | Advanced Non-Small Cell Lung Cancer | Terminated | 2002-12-01 | — | ClinicalTrials.gov |
| NCT00051974 | Phase 2 Study of VELCADE Alone or VELCADE® Plus Docetaxel in Previously Treated… | Phase2 | Non-Small Cell Lung Cancer | Completed | 2002-12-01 | — | ClinicalTrials.gov |
| NCT00671255 | Safety and Efficacy of Ramelteon in Elderly Subjects With Chronic Insomnia | Phase3 | Chronic Insomnia | Completed | 2002-12-01 | 2004-01-01 | ClinicalTrials.gov |
| NCT00064610 | Phase I/II Dose Escalation Study of VELCADE® and Docetaxel in Patients With Adv… | Phase1 | Prostatic Neoplasms | Completed | 2002-12-01 | — | ClinicalTrials.gov |
| NCT00676260 | Efficacy of Pioglitazone on Microcirculation in Type 2 Diabetes Patients Treate… | Phase2 | Diabetes Mellitus | Completed | 2002-12-01 | 2004-08-01 | ClinicalTrials.gov |
| NCT00671255 | Safety and Efficacy of Ramelteon in Elderly Subjects With Chronic Insomnia | Phase3 | Chronic Insomnia | Completed | 2002-12-01 | 2004-01-01 | ClinicalTrials.gov |
| NCT00064636 | Phase I Dose Escalation Study of VELCADE Plus Docetaxel in Patients With Advanc… | Phase1 | Advanced Non-Small Cell Lung Cancer | Terminated | 2002-12-01 | — | ClinicalTrials.gov |
| NCT00064610 | Phase I/II Dose Escalation Study of VELCADE® and Docetaxel in Patients With Adv… | Phase1 | Prostatic Neoplasms | Completed | 2002-12-01 | — | ClinicalTrials.gov |
| NCT00051974 | Phase 2 Study of VELCADE Alone or VELCADE® Plus Docetaxel in Previously Treated… | Phase2 | Non-Small Cell Lung Cancer | Completed | 2002-12-01 | — | ClinicalTrials.gov |
| NCT00051987 | Phase 2b Study of VELCADE Alone and VELCADE Plus Irinotecan in Patients With Re… | Phase2 | Colorectal Carcinoma | Completed | 2002-12-01 | — | ClinicalTrials.gov |
| NCT00671567 | Ramelteon in Adults With Chronic Insomnia | Phase3 | Chronic Insomnia | Completed | 2002-12-01 | 2003-09-01 | ClinicalTrials.gov |
| NCT00671398 | Efficacy of Ramelteon on Transient Insomnia in Healthy Adults | Phase3 | Transient Insomnia | Completed | 2002-12-01 | 2003-05-01 | ClinicalTrials.gov |
| NCT00051987 | Phase 2b Study of VELCADE Alone and VELCADE Plus Irinotecan in Patients With Re… | Phase2 | Colorectal Carcinoma | Completed | 2002-12-01 | — | ClinicalTrials.gov |
| NCT00671398 | Efficacy of Ramelteon on Transient Insomnia in Healthy Adults | Phase3 | Transient Insomnia | Completed | 2002-12-01 | 2003-05-01 | ClinicalTrials.gov |
| NCT00671567 | Ramelteon in Adults With Chronic Insomnia | Phase3 | Chronic Insomnia | Completed | 2002-12-01 | 2003-09-01 | ClinicalTrials.gov |
| NCT00052000 | A Trial of MLN2704 in Subjects With Metastatic Androgen Independent Prostate Ca… | Phase1 | Prostate Cancer | Completed | 2002-11-01 | — | ClinicalTrials.gov |
| NCT00052000 | A Trial of MLN2704 in Subjects With Metastatic Androgen Independent Prostate Ca… | Phase1 | Prostate Cancer | Completed | 2002-11-01 | — | ClinicalTrials.gov |
| NCT00175006 | Validation Study of Physical Measurement of Tophi | — | Gout | Completed | 2002-11-01 | 2003-01-01 | ClinicalTrials.gov |
| NCT00175006 | Validation Study of Physical Measurement of Tophi | — | Gout | Completed | 2002-11-01 | 2003-01-01 | ClinicalTrials.gov |
| NCT00175006 | Validation Study of Physical Measurement of Tophi | — | Gout | Completed | 2002-11-01 | 2003-01-01 | ClinicalTrials.gov |
| NCT00052000 | A Trial of MLN2704 in Subjects With Metastatic Androgen Independent Prostate Ca… | Phase1 | Prostate Cancer | Completed | 2002-11-01 | — | ClinicalTrials.gov |
| NCT00150540 | A Long Term Study of Lanthanum Carbonate in Patients Requiring Dialysis Who Hav… | Phase3 | Kidney Failure, Chronic | Completed | 2002-10-14 | 2005-06-29 | ClinicalTrials.gov |
| NCT00150540 | A Long Term Study of Lanthanum Carbonate in Patients Requiring Dialysis Who Hav… | Phase3 | Kidney Failure, Chronic | Completed | 2002-10-14 | 2005-06-29 | ClinicalTrials.gov |
| NCT00150540 | A Long Term Study of Lanthanum Carbonate in Patients Requiring Dialysis Who Hav… | Phase3 | Kidney Failure, Chronic | Completed | 2002-10-14 | 2005-06-29 | ClinicalTrials.gov |
| NCT00227110 | Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH) | Phase4 | Nonalcoholic Steatohepatitis | Completed | 2002-10-01 | 2006-01-01 | ClinicalTrials.gov |
| NCT00227110 | Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH) | Phase4 | Nonalcoholic Steatohepatitis | Completed | 2002-10-01 | 2006-01-01 | ClinicalTrials.gov |
| NCT00671294 | Safety and Efficacy of Ramelteon in Elderly Subjects With Chronic Insomnia. | Phase3 | Chronic Insomnia | Completed | 2002-10-01 | 2003-07-01 | ClinicalTrials.gov |
| NCT00671294 | Safety and Efficacy of Ramelteon in Elderly Subjects With Chronic Insomnia. | Phase3 | Chronic Insomnia | Completed | 2002-10-01 | 2003-07-01 | ClinicalTrials.gov |
| NCT00227110 | Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH) | Phase4 | Nonalcoholic Steatohepatitis | Completed | 2002-10-01 | 2006-01-01 | ClinicalTrials.gov |
| NCT00671294 | Safety and Efficacy of Ramelteon in Elderly Subjects With Chronic Insomnia. | Phase3 | Chronic Insomnia | Completed | 2002-10-01 | 2003-07-01 | ClinicalTrials.gov |
| NCT00046163 | A Phase IV Study in Subjects With Neurogenic Orthostatic Hypotension | Phase4 | Hypotension, Orthostatic | Terminated | 2002-09-05 | 2003-08-06 | ClinicalTrials.gov |
| NCT00046163 | A Phase IV Study in Subjects With Neurogenic Orthostatic Hypotension | Phase4 | Hypotension, Orthostatic | Terminated | 2002-09-05 | 2003-08-06 | ClinicalTrials.gov |
| NCT00046163 | A Phase IV Study in Subjects With Neurogenic Orthostatic Hypotension | Phase4 | Hypotension, Orthostatic | Terminated | 2002-09-05 | 2003-08-06 | ClinicalTrials.gov |
| NCT00050076 | Safety and Efficacy Study of Once and Twice Daily Doses of MCC-135 in Subjects … | Phase2 | Congestive Heart Failure | Completed | 2002-08-01 | 2003-08-01 | ClinicalTrials.gov |
| NCT00050076 | Safety and Efficacy Study of Once and Twice Daily Doses of MCC-135 in Subjects … | Phase2 | Congestive Heart Failure | Completed | 2002-08-01 | 2003-08-01 | ClinicalTrials.gov |
| NCT00050076 | Safety and Efficacy Study of Once and Twice Daily Doses of MCC-135 in Subjects … | Phase2 | Congestive Heart Failure | Completed | 2002-08-01 | 2003-08-01 | ClinicalTrials.gov |
| NCT00102440 | Febuxostat Versus Allopurinol Control Trial in Subjects With Gout | Phase3 | Gout | Completed | 2002-07-01 | 2004-02-01 | ClinicalTrials.gov |
| NCT00102440 | Febuxostat Versus Allopurinol Control Trial in Subjects With Gout | Phase3 | Gout | Completed | 2002-07-01 | 2004-02-01 | ClinicalTrials.gov |
| NCT00102440 | Febuxostat Versus Allopurinol Control Trial in Subjects With Gout | Phase3 | Gout | Completed | 2002-07-01 | 2004-02-01 | ClinicalTrials.gov |
| NCT00034281 | Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2 | Phase1 | Breast Neoplasm | Completed | 2002-06-01 | 2003-09-01 | ClinicalTrials.gov |
| NCT01135368 | Safety and Efficacy of Lansoprazole in Patients With Reflux Disease | Phase4 | Gastroesophageal Reflux | Completed | 2002-06-01 | 2008-09-01 | ClinicalTrials.gov |
| NCT00048230 | PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or R… | Phase3 | Multiple Myeloma | Completed | 2002-06-01 | 2004-12-01 | ClinicalTrials.gov |
| NCT00048230 | PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or R… | Phase3 | Multiple Myeloma | Completed | 2002-06-01 | 2004-12-01 | ClinicalTrials.gov |
| NCT00034281 | Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2 | Phase1 | Breast Neoplasm | Completed | 2002-06-01 | 2003-09-01 | ClinicalTrials.gov |
| NCT01135368 | Safety and Efficacy of Lansoprazole in Patients With Reflux Disease | Phase4 | Gastroesophageal Reflux | Completed | 2002-06-01 | 2008-09-01 | ClinicalTrials.gov |
| NCT00048230 | PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or R… | Phase3 | Multiple Myeloma | Completed | 2002-06-01 | 2004-12-01 | ClinicalTrials.gov |
| NCT00034281 | Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2 | Phase1 | Breast Neoplasm | Completed | 2002-06-01 | 2003-09-01 | ClinicalTrials.gov |
| NCT01135368 | Safety and Efficacy of Lansoprazole in Patients With Reflux Disease | Phase4 | Gastroesophageal Reflux | Completed | 2002-06-01 | 2008-09-01 | ClinicalTrials.gov |
| NCT00064584 | Safety and Tolerance Study of Oral Doses of CT53518 to Treat Patients With Acut… | Phase1 | Acute Myelogenous Leukemia | Completed | 2002-05-01 | 2005-07-01 | ClinicalTrials.gov |
| NCT00064584 | Safety and Tolerance Study of Oral Doses of CT53518 to Treat Patients With Acut… | Phase1 | Acute Myelogenous Leukemia | Completed | 2002-05-01 | 2005-07-01 | ClinicalTrials.gov |
| NCT00038571 | Proteasome Inhibitor PS-341 Relapsed or Refractory B Cell Lymphomas Previously … | Phase2 | Lymphoma, B-Cell | Completed | 2002-05-01 | 2005-03-01 | ClinicalTrials.gov |
| NCT00915135 | Efficacy and Safety of Ramelteon on Chronic Insomnia | Phase2 | Chronic Insomnia | Completed | 2002-05-01 | 2003-12-01 | ClinicalTrials.gov |
| NCT00038571 | Proteasome Inhibitor PS-341 Relapsed or Refractory B Cell Lymphomas Previously … | Phase2 | Lymphoma, B-Cell | Completed | 2002-05-01 | 2005-03-01 | ClinicalTrials.gov |
| NCT00064584 | Safety and Tolerance Study of Oral Doses of CT53518 to Treat Patients With Acut… | Phase1 | Acute Myelogenous Leukemia | Completed | 2002-05-01 | 2005-07-01 | ClinicalTrials.gov |
| NCT00038571 | Proteasome Inhibitor PS-341 Relapsed or Refractory B Cell Lymphomas Previously … | Phase2 | Lymphoma, B-Cell | Completed | 2002-05-01 | 2005-03-01 | ClinicalTrials.gov |
| NCT00915135 | Efficacy and Safety of Ramelteon on Chronic Insomnia | Phase2 | Chronic Insomnia | Completed | 2002-05-01 | 2003-12-01 | ClinicalTrials.gov |
| NCT00915135 | Efficacy and Safety of Ramelteon on Chronic Insomnia | Phase2 | Chronic Insomnia | Completed | 2002-05-01 | 2003-12-01 | ClinicalTrials.gov |
| NCT00063726 | A Study of PS-341 Given to Patients With Multiple Myeloma Who Experienced Progr… | Phase3 | Multiple Myeloma | Completed | 2002-04-01 | 2005-07-01 | ClinicalTrials.gov |
| NCT00063726 | A Study of PS-341 Given to Patients With Multiple Myeloma Who Experienced Progr… | Phase3 | Multiple Myeloma | Completed | 2002-04-01 | 2005-07-01 | ClinicalTrials.gov |
| NCT00063726 | A Study of PS-341 Given to Patients With Multiple Myeloma Who Experienced Progr… | Phase3 | Multiple Myeloma | Completed | 2002-04-01 | 2005-07-01 | ClinicalTrials.gov |
| NCT01799850 | The Impact of Actos Treatment of Diabetes on Glucose Transporters in Muscle | Phase4 | Diabetes Type 2 | Completed | 2002-03-01 | 2004-03-01 | ClinicalTrials.gov |
| NCT00174954 | Magnetic Resonance Imaging in Subjects With Gouty Tophi | — | Hyperuricemia | Completed | 2002-03-01 | 2003-01-01 | ClinicalTrials.gov |
| NCT01799850 | The Impact of Actos Treatment of Diabetes on Glucose Transporters in Muscle | Phase4 | Diabetes Type 2 | Completed | 2002-03-01 | 2004-03-01 | ClinicalTrials.gov |
| NCT00174954 | Magnetic Resonance Imaging in Subjects With Gouty Tophi | — | Hyperuricemia | Completed | 2002-03-01 | 2003-01-01 | ClinicalTrials.gov |
| NCT01799850 | The Impact of Actos Treatment of Diabetes on Glucose Transporters in Muscle | Phase4 | Diabetes Type 2 | Completed | 2002-03-01 | 2004-03-01 | ClinicalTrials.gov |
| NCT00174954 | Magnetic Resonance Imaging in Subjects With Gouty Tophi | — | Hyperuricemia | Completed | 2002-03-01 | 2003-01-01 | ClinicalTrials.gov |
| NCT00525317 | Does Oral Magnesium Substitution Relieve Pregnancy Induced Leg Cramps ? | Phase4 | Cramps | Completed | 2002-01-01 | 2004-09-01 | ClinicalTrials.gov |
| NCT00525317 | Does Oral Magnesium Substitution Relieve Pregnancy Induced Leg Cramps ? | Phase4 | Cramps | Completed | 2002-01-01 | 2004-09-01 | ClinicalTrials.gov |
| NCT00982202 | Pioglitazone in Alzheimer Disease | Phase2 | Alzheimer Disease | Completed | 2002-01-01 | 2005-01-01 | ClinicalTrials.gov |
| NCT00982202 | Pioglitazone in Alzheimer Disease | Phase2 | Alzheimer Disease | Completed | 2002-01-01 | 2005-01-01 | ClinicalTrials.gov |
| NCT00525317 | Does Oral Magnesium Substitution Relieve Pregnancy Induced Leg Cramps ? | Phase4 | Cramps | Completed | 2002-01-01 | 2004-09-01 | ClinicalTrials.gov |
| NCT00982202 | Pioglitazone in Alzheimer Disease | Phase2 | Alzheimer Disease | Completed | 2002-01-01 | 2005-01-01 | ClinicalTrials.gov |
| NCT00425503 | PS-341 Followed by Removal of Prostate for Those With Prostate Cancer | Phase2 | Prostate Neoplasms | Completed | 2001-12-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT00425503 | PS-341 Followed by Removal of Prostate for Those With Prostate Cancer | Phase2 | Prostate Neoplasms | Completed | 2001-12-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT00425503 | PS-341 Followed by Removal of Prostate for Those With Prostate Cancer | Phase2 | Prostate Neoplasms | Completed | 2001-12-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT00525772 | Effect of Ciclesonide on Exercise Induced Bronchoconstriction | Phase3 | Asthma | Completed | 2001-11-01 | 2007-11-01 | ClinicalTrials.gov |
| NCT00525772 | Effect of Ciclesonide on Exercise Induced Bronchoconstriction | Phase3 | Asthma | Completed | 2001-11-01 | 2007-11-01 | ClinicalTrials.gov |
| NCT00525772 | Effect of Ciclesonide on Exercise Induced Bronchoconstriction | Phase3 | Asthma | Completed | 2001-11-01 | 2007-11-01 | ClinicalTrials.gov |
| NCT00172133 | Open Label Extension Study of PREOS | Phase3 | Osteoporosis | Completed | 2001-10-16 | 2005-04-13 | ClinicalTrials.gov |
| NCT00172133 | Open Label Extension Study of PREOS | Phase3 | Osteoporosis | Completed | 2001-10-16 | 2005-04-13 | ClinicalTrials.gov |
| NCT00172133 | Open Label Extension Study of PREOS | Phase3 | Osteoporosis | Completed | 2001-10-16 | 2005-04-13 | ClinicalTrials.gov |
| NCT00252720 | DIabetic Retinopathy Candesartan Trials. | Phase3 | Type 1 Diabetes | Completed | 2001-08-01 | 2008-04-01 | ClinicalTrials.gov |
| NCT00252694 | DIabetic Retinopathy Candesartan Trials | Phase3 | Type 2 Diabetes | Completed | 2001-08-01 | 2008-04-01 | ClinicalTrials.gov |
| NCT00252720 | DIabetic Retinopathy Candesartan Trials. | Phase3 | Type 1 Diabetes | Completed | 2001-08-01 | 2008-04-01 | ClinicalTrials.gov |
| NCT00252720 | DIabetic Retinopathy Candesartan Trials. | Phase3 | Type 1 Diabetes | Completed | 2001-08-01 | 2008-04-01 | ClinicalTrials.gov |
| NCT00252694 | DIabetic Retinopathy Candesartan Trials | Phase3 | Type 2 Diabetes | Completed | 2001-08-01 | 2008-04-01 | ClinicalTrials.gov |
| NCT00252694 | DIabetic Retinopathy Candesartan Trials | Phase3 | Type 2 Diabetes | Completed | 2001-08-01 | 2008-04-01 | ClinicalTrials.gov |
| NCT00252733 | Diabetic Retinopathy Candesartan Trials | Phase3 | Type 1 Diabetes | Completed | 2001-06-01 | 2008-04-01 | ClinicalTrials.gov |
| NCT00252733 | Diabetic Retinopathy Candesartan Trials | Phase3 | Type 1 Diabetes | Completed | 2001-06-01 | 2008-04-01 | ClinicalTrials.gov |
| NCT00449553 | Observational Study to Assess Glycosylated Hemoglobin Changes After 6 Months of… | — | Diabetes Mellitus | Completed | 2001-06-01 | 2003-09-01 | ClinicalTrials.gov |
| NCT00130624 | The Winchester Falls Project | Phase3 | Accidental Falls | Completed | 2001-06-01 | 2005-02-01 | ClinicalTrials.gov |
| NCT00449553 | Observational Study to Assess Glycosylated Hemoglobin Changes After 6 Months of… | — | Diabetes Mellitus | Completed | 2001-06-01 | 2003-09-01 | ClinicalTrials.gov |
| NCT00130624 | The Winchester Falls Project | Phase3 | Accidental Falls | Completed | 2001-06-01 | 2005-02-01 | ClinicalTrials.gov |
| NCT00252733 | Diabetic Retinopathy Candesartan Trials | Phase3 | Type 1 Diabetes | Completed | 2001-06-01 | 2008-04-01 | ClinicalTrials.gov |
| NCT00130624 | The Winchester Falls Project | Phase3 | Accidental Falls | Completed | 2001-06-01 | 2005-02-01 | ClinicalTrials.gov |
| NCT00449553 | Observational Study to Assess Glycosylated Hemoglobin Changes After 6 Months of… | — | Diabetes Mellitus | Completed | 2001-06-01 | 2003-09-01 | ClinicalTrials.gov |
| NCT00174993 | Efficacy of Pioglitazone on Macrovascular Outcome in Patients With Type 2 Diabe… | Phase3 | Diabetes Mellitus | Completed | 2001-05-01 | 2005-01-01 | ClinicalTrials.gov |
| NCT00174993 | Efficacy of Pioglitazone on Macrovascular Outcome in Patients With Type 2 Diabe… | Phase3 | Diabetes Mellitus | Completed | 2001-05-01 | 2005-01-01 | ClinicalTrials.gov |
| NCT00174993 | Efficacy of Pioglitazone on Macrovascular Outcome in Patients With Type 2 Diabe… | Phase3 | Diabetes Mellitus | Completed | 2001-05-01 | 2005-01-01 | ClinicalTrials.gov |
| NCT03289065 | Fabry Outcome Survey (FOS) | — | Fabry Disease | Completed | 2001-04-01 | 2021-09-30 | ClinicalTrials.gov |
| NCT03289065 | Fabry Outcome Survey (FOS) | — | Fabry Disease | Completed | 2001-04-01 | 2021-09-30 | ClinicalTrials.gov |
| NCT03289065 | Fabry Outcome Survey (FOS) | — | Fabry Disease | Completed | 2001-04-01 | 2021-09-30 | ClinicalTrials.gov |
| NCT00521742 | Efficacy of Pioglitazone Compared to Glyburide in Treating Subjects With Type 2… | Phase3 | Diabetes Mellitus | Completed | 2001-03-01 | 2003-01-01 | ClinicalTrials.gov |
| NCT00174941 | Long-Term Safety of Febuxostat in Subjects With Gout. | Phase2 | Gout | Completed | 2001-03-01 | 2006-12-01 | ClinicalTrials.gov |
| NCT00521742 | Efficacy of Pioglitazone Compared to Glyburide in Treating Subjects With Type 2… | Phase3 | Diabetes Mellitus | Completed | 2001-03-01 | 2003-01-01 | ClinicalTrials.gov |
| NCT00174941 | Long-Term Safety of Febuxostat in Subjects With Gout. | Phase2 | Gout | Completed | 2001-03-01 | 2006-12-01 | ClinicalTrials.gov |
| NCT00521742 | Efficacy of Pioglitazone Compared to Glyburide in Treating Subjects With Type 2… | Phase3 | Diabetes Mellitus | Completed | 2001-03-01 | 2003-01-01 | ClinicalTrials.gov |
| NCT00174941 | Long-Term Safety of Febuxostat in Subjects With Gout. | Phase2 | Gout | Completed | 2001-03-01 | 2006-12-01 | ClinicalTrials.gov |
| NCT00590200 | GeneBank at the Cleveland Clinic: Molecular Determinants of Coronary Artery Dis… | — | Cardiovascular Diseases | Active_Not_Recruiting | 2001-01-01 | 2030-12-01 | ClinicalTrials.gov |
| NCT00590200 | GeneBank at the Cleveland Clinic: Molecular Determinants of Coronary Artery Dis… | — | Cardiovascular Diseases | Active_Not_Recruiting | 2001-01-01 | 2030-12-01 | ClinicalTrials.gov |
| NCT00590200 | GeneBank at the Cleveland Clinic: Molecular Determinants of Coronary Artery Dis… | — | Cardiovascular Diseases | Active_Not_Recruiting | 2001-01-01 | 2030-12-01 | ClinicalTrials.gov |
| NCT00174967 | Dose-Response, Safety and Efficacy of Febuxostat in Subjects With Gout | Phase2 | Gout | Completed | 2001-01-01 | 2001-07-01 | ClinicalTrials.gov |
| NCT00174967 | Dose-Response, Safety and Efficacy of Febuxostat in Subjects With Gout | Phase2 | Gout | Completed | 2001-01-01 | 2001-07-01 | ClinicalTrials.gov |
| NCT00174967 | Dose-Response, Safety and Efficacy of Febuxostat in Subjects With Gout | Phase2 | Gout | Completed | 2001-01-01 | 2001-07-01 | ClinicalTrials.gov |
| NCT00012259 | Troxacitabine in Treating Patients With Chronic Myelogenous Leukemia | Phase2 | Leukemia | Completed | 2000-12-11 | 2002-03-27 | ClinicalTrials.gov |
| NCT00012259 | Troxacitabine in Treating Patients With Chronic Myelogenous Leukemia | Phase2 | Leukemia | Completed | 2000-12-11 | 2002-03-27 | ClinicalTrials.gov |
| NCT00012259 | Troxacitabine in Treating Patients With Chronic Myelogenous Leukemia | Phase2 | Leukemia | Completed | 2000-12-11 | 2002-03-27 | ClinicalTrials.gov |
| NCT00270348 | Effects of Ciclesonide MDI 50mg/Day and 200mg/Day (Ex-Valve) Once-Daily on Grow… | Phase3 | Asthma | Completed | 2000-12-01 | 2004-09-01 | ClinicalTrials.gov |
| NCT00179400 | The Role of Acute Combined PPAR Alpha and Gamma Stimulation on Insulin Action i… | Phase4 | Type 2 Diabetes Mellitus | Completed | 2000-12-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT00270348 | Effects of Ciclesonide MDI 50mg/Day and 200mg/Day (Ex-Valve) Once-Daily on Grow… | Phase3 | Asthma | Completed | 2000-12-01 | 2004-09-01 | ClinicalTrials.gov |
| NCT00179400 | The Role of Acute Combined PPAR Alpha and Gamma Stimulation on Insulin Action i… | Phase4 | Type 2 Diabetes Mellitus | Completed | 2000-12-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT00270348 | Effects of Ciclesonide MDI 50mg/Day and 200mg/Day (Ex-Valve) Once-Daily on Grow… | Phase3 | Asthma | Completed | 2000-12-01 | 2004-09-01 | ClinicalTrials.gov |
| NCT00179400 | The Role of Acute Combined PPAR Alpha and Gamma Stimulation on Insulin Action i… | Phase4 | Type 2 Diabetes Mellitus | Completed | 2000-12-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT00494312 | Safety Study of Pioglitazone Compared To Glyburide on Liver Function | Phase4 | Diabetes Mellitus | Completed | 2000-10-01 | 2005-06-01 | ClinicalTrials.gov |
| NCT00261300 | Long-term Pantoprazole Trial in Patients With Symptoms of Chronic Acid Peptic C… | Phase3 | Gastroesophageal Reflux Disease (GERD) | Completed | 2000-10-01 | 2008-07-01 | ClinicalTrials.gov |
| NCT00261300 | Long-term Pantoprazole Trial in Patients With Symptoms of Chronic Acid Peptic C… | Phase3 | Gastroesophageal Reflux Disease (GERD) | Completed | 2000-10-01 | 2008-07-01 | ClinicalTrials.gov |
| NCT00494312 | Safety Study of Pioglitazone Compared To Glyburide on Liver Function | Phase4 | Diabetes Mellitus | Completed | 2000-10-01 | 2005-06-01 | ClinicalTrials.gov |
| NCT00494312 | Safety Study of Pioglitazone Compared To Glyburide on Liver Function | Phase4 | Diabetes Mellitus | Completed | 2000-10-01 | 2005-06-01 | ClinicalTrials.gov |
| NCT00261300 | Long-term Pantoprazole Trial in Patients With Symptoms of Chronic Acid Peptic C… | Phase3 | Gastroesophageal Reflux Disease (GERD) | Completed | 2000-10-01 | 2008-07-01 | ClinicalTrials.gov |
| NCT00331487 | Study to Compare Pioglitazone and Rosiglitazone in Subjects With Type 2 Diabete… | Phase3 | Diabetes Mellitus | Completed | 2000-09-01 | 2004-03-01 | ClinicalTrials.gov |
| NCT00331487 | Study to Compare Pioglitazone and Rosiglitazone in Subjects With Type 2 Diabete… | Phase3 | Diabetes Mellitus | Completed | 2000-09-01 | 2004-03-01 | ClinicalTrials.gov |
| NCT00331487 | Study to Compare Pioglitazone and Rosiglitazone in Subjects With Type 2 Diabete… | Phase3 | Diabetes Mellitus | Completed | 2000-09-01 | 2004-03-01 | ClinicalTrials.gov |
| NCT00057967 | Alemtuzumab in Treating Patients With Relapsed or Refractory Advanced Mycosis F… | Phase2 | Lymphoma | Completed | 2000-07-01 | 2010-07-26 | ClinicalTrials.gov |
| NCT00057967 | Alemtuzumab in Treating Patients With Relapsed or Refractory Advanced Mycosis F… | Phase2 | Lymphoma | Completed | 2000-07-01 | 2010-07-26 | ClinicalTrials.gov |
| NCT00057967 | Alemtuzumab in Treating Patients With Relapsed or Refractory Advanced Mycosis F… | Phase2 | Lymphoma | Completed | 2000-07-01 | 2010-07-26 | ClinicalTrials.gov |
| NCT00521820 | Safety Comparison of Pioglitazone and Glyburide in Type 2 Diabetes Subjects Wit… | Phase3 | Diabetes Mellitus | Terminated | 2000-06-01 | 2003-10-01 | ClinicalTrials.gov |
| NCT00521820 | Safety Comparison of Pioglitazone and Glyburide in Type 2 Diabetes Subjects Wit… | Phase3 | Diabetes Mellitus | Terminated | 2000-06-01 | 2003-10-01 | ClinicalTrials.gov |
| NCT00521820 | Safety Comparison of Pioglitazone and Glyburide in Type 2 Diabetes Subjects Wit… | Phase3 | Diabetes Mellitus | Terminated | 2000-06-01 | 2003-10-01 | ClinicalTrials.gov |
| NCT00172081 | TOP: Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in W… | Phase3 | Osteoporosis | Completed | 2000-04-27 | 2003-11-07 | ClinicalTrials.gov |
| NCT00172081 | TOP: Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in W… | Phase3 | Osteoporosis | Completed | 2000-04-27 | 2003-11-07 | ClinicalTrials.gov |
| NCT00172081 | TOP: Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in W… | Phase3 | Osteoporosis | Completed | 2000-04-27 | 2003-11-07 | ClinicalTrials.gov |
| NCT01122121 | Leuprorelin Associated With Radiotherapy Versus Leuprorelin Alone in T3 - T4 or… | Phase3 | Prostatic Neoplasms, Locally Advanced | Completed | 2000-03-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT01122121 | Leuprorelin Associated With Radiotherapy Versus Leuprorelin Alone in T3 - T4 or… | Phase3 | Prostatic Neoplasms, Locally Advanced | Completed | 2000-03-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT01122121 | Leuprorelin Associated With Radiotherapy Versus Leuprorelin Alone in T3 - T4 or… | Phase3 | Prostatic Neoplasms, Locally Advanced | Completed | 2000-03-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT00655135 | Phase 2 Study of the Safety and Efficacy of LDP-02 in Mildly to Moderately Acti… | Phase2 | Crohn's Disease | Completed | 2000-02-01 | — | ClinicalTrials.gov |
| NCT00655135 | Phase 2 Study of the Safety and Efficacy of LDP-02 in Mildly to Moderately Acti… | Phase2 | Crohn's Disease | Completed | 2000-02-01 | — | ClinicalTrials.gov |
| NCT00655135 | Phase 2 Study of the Safety and Efficacy of LDP-02 in Mildly to Moderately Acti… | Phase2 | Crohn's Disease | Completed | 2000-02-01 | — | ClinicalTrials.gov |
| NCT00375388 | The HOME Trial: Hyperinsulinaemia: the Outcome of Its Metabolic Effects, a Rand… | Phase3 | Type 2 Diabetes Mellitus | Completed | 1998-01-01 | 2002-10-01 | ClinicalTrials.gov |
| NCT00375388 | The HOME Trial: Hyperinsulinaemia: the Outcome of Its Metabolic Effects, a Rand… | Phase3 | Type 2 Diabetes Mellitus | Completed | 1998-01-01 | 2002-10-01 | ClinicalTrials.gov |
| NCT00375388 | The HOME Trial: Hyperinsulinaemia: the Outcome of Its Metabolic Effects, a Rand… | Phase3 | Type 2 Diabetes Mellitus | Completed | 1998-01-01 | 2002-10-01 | ClinicalTrials.gov |
| NCT00046475 | A Study for Patients With Neurogenic Orthostatic Hypotension | Phase4 | Hypotension, Orthostatic | Completed | 1997-12-01 | 1999-11-24 | ClinicalTrials.gov |
| NCT00046475 | A Study for Patients With Neurogenic Orthostatic Hypotension | Phase4 | Hypotension, Orthostatic | Completed | 1997-12-01 | 1999-11-24 | ClinicalTrials.gov |
| NCT00046475 | A Study for Patients With Neurogenic Orthostatic Hypotension | Phase4 | Hypotension, Orthostatic | Completed | 1997-12-01 | 1999-11-24 | ClinicalTrials.gov |
| NCT02958995 | Epidemiologic Study Of Diabetes And Cancer Risk | — | Diabetes Mellitus, Type 2, Cancer | Completed | 1997-01-01 | 2015-05-29 | ClinicalTrials.gov |
| NCT02958956 | Cohort Study of Pioglitazone and Cancer Incidence in Participants With Diabetes… | — | Diabetes Mellitus, Type 2, Cancer | Completed | 1997-01-01 | 2015-05-29 | ClinicalTrials.gov |
| NCT02958956 | Cohort Study of Pioglitazone and Cancer Incidence in Participants With Diabetes… | — | Diabetes Mellitus, Type 2, Cancer | Completed | 1997-01-01 | 2015-05-29 | ClinicalTrials.gov |
| NCT02958995 | Epidemiologic Study Of Diabetes And Cancer Risk | — | Diabetes Mellitus, Type 2, Cancer | Completed | 1997-01-01 | 2015-05-29 | ClinicalTrials.gov |
| NCT02958956 | Cohort Study of Pioglitazone and Cancer Incidence in Participants With Diabetes… | — | Diabetes Mellitus, Type 2, Cancer | Completed | 1997-01-01 | 2015-05-29 | ClinicalTrials.gov |
| NCT02958995 | Epidemiologic Study Of Diabetes And Cancer Risk | — | Diabetes Mellitus, Type 2, Cancer | Completed | 1997-01-01 | 2015-05-29 | ClinicalTrials.gov |
| NCT00817739 | Intermittent Hormonal Therapy With Leuprorelin and Flutamide in the Treatment o… | Phase2 | Prostatic Neoplasms | Completed | 1996-12-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00817739 | Intermittent Hormonal Therapy With Leuprorelin and Flutamide in the Treatment o… | Phase2 | Prostatic Neoplasms | Completed | 1996-12-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00817739 | Intermittent Hormonal Therapy With Leuprorelin and Flutamide in the Treatment o… | Phase2 | Prostatic Neoplasms | Completed | 1996-12-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00338117 | Safety and Efficacy of High Dose, Rapid Titration Galantamine in Patients With … | Phase3 | Alzheimer's Disease | Completed | 1995-08-01 | 1997-05-01 | ClinicalTrials.gov |
| NCT00338117 | Safety and Efficacy of High Dose, Rapid Titration Galantamine in Patients With … | Phase3 | Alzheimer's Disease | Completed | 1995-08-01 | 1997-05-01 | ClinicalTrials.gov |
| NCT00338117 | Safety and Efficacy of High Dose, Rapid Titration Galantamine in Patients With … | Phase3 | Alzheimer's Disease | Completed | 1995-08-01 | 1997-05-01 | ClinicalTrials.gov |
| NCT00172107 | A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 10… | Phase2 | Osteoporosis | Completed | 1995-05-18 | 1997-03-24 | ClinicalTrials.gov |
| NCT00172107 | A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 10… | Phase2 | Osteoporosis | Completed | 1995-05-18 | 1997-03-24 | ClinicalTrials.gov |
| NCT00172107 | A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 10… | Phase2 | Osteoporosis | Completed | 1995-05-18 | 1997-03-24 | ClinicalTrials.gov |
Total clinical trials: 6387
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Tetravalent Dengue Vaccine (TDV) | Other | Phase PHASE3 | Dengue Fever | ACTIVE_NOT_RECRUITING | NCT07047521 |
| Placebo | Other | Phase PHASE2 | Nonsegmental Vitiligo | RECRUITING | NCT07108283 |
| Zasocitinib | Other | Phase PHASE2 | Nonsegmental Vitiligo | RECRUITING | NCT07108283 |
| TAK-188 | Other | Phase PHASE1 | Advanced or Metastatic Solid Tumors | RECRUITING | NCT07205718 |
| IGI, 10% | Other | Phase PHASE3 | Multiple Myeloma | RECRUITING | NCT06980480 |
| Vedolizumab SC | Other | Phase PHASE4 | Ulcerative Colitis | RECRUITING | NCT06581328 |
| Vedolizumab IV | Other | Phase PHASE4 | Ulcerative Colitis | RECRUITING | NCT06581328 |
| Placebo | Other | Phase PHASE2 | Narcolepsy Type 2 | RECRUITING | NCT06952699 |
| TAK-360 | Other | Phase PHASE2 | Narcolepsy Type 2 | RECRUITING | NCT06952699 |
| TAK-226 | Other | Phase PHASE2 | Myelodysplastic Syndromes | RECRUITING | NCT07319845 |
| Placebo | Other | Phase PHASE3 | Narcolepsy Type 1 | COMPLETED | NCT06505031 |
| TAK-861 | Other | Phase PHASE3 | Narcolepsy Type 1 | COMPLETED | NCT06505031 |
| No Intervention | Other | Preclinical | Carcinoma, Non-Small-Cell Lung | COMPLETED | NCT04592523 |
| SC Investigational Needle Sets | Other | Preclinical | Primary Immunodeficiency Diseases (PIDD) | AVAILABLE | NCT06955793 |
| TAK-881 | Other | Preclinical | Primary Immunodeficiency Diseases (PIDD) | AVAILABLE | NCT06955793 |
| Placebo | Other | Phase PHASE3 | Kidney Disease | RECRUITING | NCT06963827 |
| Mezagitamab | Other | Phase PHASE3 | Kidney Disease | RECRUITING | NCT06963827 |
| Placebo | Other | Phase PHASE2 | Idiopathic Hypersomnia | RECRUITING | NCT07646678 |
| TAK-360 | Other | Phase PHASE2 | Idiopathic Hypersomnia | RECRUITING | NCT07646678 |
| TAK-188 | Other | Phase PHASE1 | Advanced or Metastatic Solid Tumors | RECRUITING | NCT07205718 |
| Placebo | Other | Phase PHASE2 | Idiopathic Hypersomnia | RECRUITING | NCT06812078 |
| TAK-360 | Other | Phase PHASE2 | Idiopathic Hypersomnia | RECRUITING | NCT06812078 |
| Placebo | Other | Phase PHASE2 | Narcolepsy Type 2 | RECRUITING | NCT06952699 |
| TAK-360 | Other | Phase PHASE2 | Narcolepsy Type 2 | RECRUITING | NCT06952699 |
| SHP611 | Other | Phase PHASE2 | Metachromatic Leukodystrophy (MLD) | COMPLETED | NCT03771898 |
| Control Arm | Other | Phase PHASE3 | IO-resistant sqNSCLC | RECRUITING | NCT07217301 |
| TAK-928 | Other | Phase PHASE3 | IO-resistant sqNSCLC | RECRUITING | NCT07217301 |
| No Intervention | Other | Preclinical | Thrombotic Thrombocytopenic Purpura (TTP) | NOT_YET_RECRUITING | NCT07429942 |
| Susoctocog Alfa (Genetical Recombination) | Other | Preclinical | Acquired Hemophilia A | RECRUITING | NCT06461533 |
| Placebo | Other | Phase PHASE3 | Immune Thrombocytopenic Purpura (ITP) | RECRUITING | NCT06722235 |
| Mezagitamab | Other | Phase PHASE3 | Immune Thrombocytopenic Purpura (ITP) | RECRUITING | NCT06722235 |
| Mezagitamab | Other | Phase PHASE3 | Immune Thrombocytopenic Purpura (ITP) | RECRUITING | NCT06948318 |
| Tofacitinib | Other | Phase PHASE4 | Ulcerative Colitis | RECRUITING | NCT06095128 |
| Vedolizumab | Other | Phase PHASE4 | Ulcerative Colitis | RECRUITING | NCT06095128 |
| Placebo | Other | Phase PHASE3 | Narcolepsy Type 1 (NT1) | RECRUITING | NCT07363720 |
| TAK-861 | Other | Phase PHASE3 | Narcolepsy Type 1 (NT1) | RECRUITING | NCT07363720 |
| Icatibant | Other | Preclinical | Hereditary Angioedema (HAE) | COMPLETED | NCT05509569 |
| Haematopoietic growth factor | Other | Phase PHASE3 | Hodgkin Lymphoma | RECRUITING | NCT04685616 |
| Dacarbazine | Other | Phase PHASE3 | Hodgkin Lymphoma | RECRUITING | NCT04685616 |
| Vinblastine | Other | Phase PHASE3 | Hodgkin Lymphoma | RECRUITING | NCT04685616 |
| Brentuximab vedotin | Other | Phase PHASE3 | Hodgkin Lymphoma | RECRUITING | NCT04685616 |
| Bleomycin | Other | Phase PHASE3 | Hodgkin Lymphoma | RECRUITING | NCT04685616 |
| Doxorubicin | Other | Phase PHASE3 | Hodgkin Lymphoma | RECRUITING | NCT04685616 |
| Involved site radiotherapy | Drug | Phase PHASE3 | Hodgkin Lymphoma | RECRUITING | NCT04685616 |
| Ustekinumab | Other | Phase PHASE4 | Crohn's Disease | RECRUITING | NCT06045754 |
| Adalimumab | Other | Phase PHASE4 | Crohn's Disease | RECRUITING | NCT06045754 |
| Vedolizumab | Other | Phase PHASE4 | Crohn's Disease | RECRUITING | NCT06045754 |
| TAK-280 | Other | Phase PHASE1 | Unresectable Locally Advanced or Metastatic Cancer | TERMINATED | NCT05220098 |
| TAK-103 | Other | Phase PHASE1 | Solid Tumors | TERMINATED | NCT05164666 |
| Fruquintinib | Other | Phase PHASE4 | Colorectal Cancer | RECRUITING | NCT06562543 |
| No Intervention | Other | Preclinical | Lymphoma | COMPLETED | NCT04837222 |
| Placebo | Other | Phase PHASE3 | Kidney Disease | RECRUITING | NCT06963827 |
| Mezagitamab | Other | Phase PHASE3 | Kidney Disease | RECRUITING | NCT06963827 |
| Vedolizumab (Genetical Recombination) | Other | Preclinical | Crohn's Disease | COMPLETED | NCT04002180 |
| Placebo | Other | Phase PHASE2 | Crohn's Disease | RECRUITING | NCT06233461 |
| TAK-279 | Other | Phase PHASE2 | Crohn's Disease | RECRUITING | NCT06233461 |
| Rituximab | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | ACTIVE_NOT_RECRUITING | NCT02339922 |
| Laboratory Biomarker Analysis | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | ACTIVE_NOT_RECRUITING | NCT02339922 |
| Ixazomib Citrate | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | ACTIVE_NOT_RECRUITING | NCT02339922 |
| Zasocitinib | Other | Phase PHASE2 | Crohn's Disease | NOT_YET_RECRUITING | NCT07403968 |
| No Intervention | Other | Preclinical | Lymphoma | COMPLETED | NCT04837222 |
| Placebo | Other | Phase PHASE2 | Idiopathic Hypersomnia | RECRUITING | NCT07646678 |
| TAK-360 | Other | Phase PHASE2 | Idiopathic Hypersomnia | RECRUITING | NCT07646678 |
| zoledronic acid | Other | Phase PHASE3 | Solitary Osseous Plasmacytoma | TERMINATED | NCT02516423 |
| dexamethasone | Other | Phase PHASE3 | Solitary Osseous Plasmacytoma | TERMINATED | NCT02516423 |
| lenalidomide | Other | Phase PHASE3 | Solitary Osseous Plasmacytoma | TERMINATED | NCT02516423 |
| ixazomib | Other | Phase PHASE3 | Solitary Osseous Plasmacytoma | TERMINATED | NCT02516423 |
| Placebo | Other | Phase PHASE3 | Psoriatic Arthritis | RECRUITING | NCT06671496 |
| Zasocitinib | Other | Phase PHASE3 | Psoriatic Arthritis | RECRUITING | NCT06671496 |
| Electronic Health Record Review | Other | Phase PHASE2 | Hematologic Malignancies | RECRUITING | NCT05952804 |
| Survey Administration | Other | Phase PHASE2 | Hematologic Malignancies | RECRUITING | NCT05952804 |
| Biospecimen Collection | Other | Phase PHASE2 | Hematologic Malignancies | RECRUITING | NCT05952804 |
| Saline | Other | Phase PHASE2 | Hematologic Malignancies | RECRUITING | NCT05952804 |
| Anti-CD19 CAR T Cells Preparation | Other | Phase PHASE2 | Hematologic Malignancies | RECRUITING | NCT05952804 |
| Immune Globulin Infusion (Human), 10% Solution | Other | Phase PHASE2 | Hematologic Malignancies | RECRUITING | NCT05952804 |
| Placebo | Other | Phase PHASE3 | Dengue Fever | RECRUITING | NCT06665035 |
| TDV | Other | Phase PHASE3 | Dengue Fever | RECRUITING | NCT06665035 |
| Placebo | Other | Phase PHASE3 | Psoriatic Arthritis | RECRUITING | NCT06671483 |
| Active Comparator | Other | Phase PHASE3 | Psoriatic Arthritis | RECRUITING | NCT06671483 |
| Zasocitinib | Other | Phase PHASE3 | Psoriatic Arthritis | RECRUITING | NCT06671483 |
| Placebo | Other | Phase PHASE2 | Narcolepsy Type 1 | RECRUITING | NCT07633301 |
| TAK-360 | Other | Phase PHASE2 | Narcolepsy Type 1 | RECRUITING | NCT07633301 |
| Control Arm | Other | Phase PHASE3 | IO-resistant sqNSCLC | RECRUITING | NCT07217301 |
| TAK-928 | Other | Phase PHASE3 | IO-resistant sqNSCLC | RECRUITING | NCT07217301 |
| Vedolizumab SC | Other | Phase PHASE4 | Ulcerative Colitis | RECRUITING | NCT06581328 |
| Vedolizumab IV | Other | Phase PHASE4 | Ulcerative Colitis | RECRUITING | NCT06581328 |
| Ibrutinib | Other | Phase PHASE1 | Mantle-Cell Lymphoma | COMPLETED | NCT03323151 |
| Ixazomib | Other | Phase PHASE1 | Mantle-Cell Lymphoma | COMPLETED | NCT03323151 |
| Azacitidine | Other | Phase PHASE3 | Leukemia, Myeloid, Acute | ACTIVE_NOT_RECRUITING | NCT04090736 |
| Pevonedistat | Other | Phase PHASE3 | Leukemia, Myeloid, Acute | ACTIVE_NOT_RECRUITING | NCT04090736 |
| TAK-771 | Other | Phase PHASE3 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | COMPLETED | NCT05084053 |
| Teduglutide | Other | Phase PHASE3 | Short Bowel Syndrome | RECRUITING | NCT06973304 |
| Placebo | Other | Phase PHASE3 | Kidney Disease | RECRUITING | NCT06963827 |
| Mezagitamab | Other | Phase PHASE3 | Kidney Disease | RECRUITING | NCT06963827 |
| Tyrosine kinase inhibitor | Other | Phase PHASE2 | NSCLC | COMPLETED | NCT04318938 |
| Brigatinib | Other | Phase PHASE2 | NSCLC | COMPLETED | NCT04318938 |
| No intervention | Other | Preclinical | Ulcerative Colitis | NOT_YET_RECRUITING | NCT07250815 |
| No Intervention | Other | Phase PHASE3 | Ulcerative Colitis | RECRUITING | NCT06405087 |
| Vedolizumab SC | Other | Phase PHASE3 | Ulcerative Colitis | RECRUITING | NCT06405087 |
| SOC 4F-PCC | Other | Phase PHASE3 | Coagulation Disorder | RECRUITING | NCT05156983 |
| TAK-330 | Other | Phase PHASE3 | Coagulation Disorder | RECRUITING | NCT05156983 |
| No intervention | Other | Preclinical | Hereditary Angioedema (HAE) | NOT_YET_RECRUITING | NCT07218393 |
| No intervention | Other | Preclinical | Hereditary Angioedema (HAE) | RECRUITING | NCT07251933 |
| No intervention | Other | Preclinical | Hereditary Angioedema (HAE) | NOT_YET_RECRUITING | NCT07445087 |
| No intervention | Other | Preclinical | Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07623174 |
| TAK-755 | Other | Phase PHASE2 | Thrombotic Thrombocytopenic Purpura (TTP) | COMPLETED | NCT05714969 |
| Placebo | Other | Phase PHASE2 | Narcolepsy Type 2 | RECRUITING | NCT06952699 |
| TAK-360 | Other | Phase PHASE2 | Narcolepsy Type 2 | RECRUITING | NCT06952699 |
| Vedolizumab SC | Other | Phase PHASE4 | Ulcerative Colitis | RECRUITING | NCT06581328 |
| Vedolizumab IV | Other | Phase PHASE4 | Ulcerative Colitis | RECRUITING | NCT06581328 |
| Placebo | Other | Phase PHASE3 | Plaque Psoriasis | RECRUITING | NCT07250802 |
| Zasocitinib | Other | Phase PHASE3 | Plaque Psoriasis | RECRUITING | NCT07250802 |
| Zasocitinib | Other | Phase PHASE3 | Psoriatic Arthritis | RECRUITING | NCT07286058 |
| TAK-853 | Other | Phase PHASE1 | Ovarian Cancer | ACTIVE_NOT_RECRUITING | NCT06390995 |
| Control Arm | Other | Phase PHASE3 | IO-resistant sqNSCLC | RECRUITING | NCT07217301 |
| TAK-928 | Other | Phase PHASE3 | IO-resistant sqNSCLC | RECRUITING | NCT07217301 |
| Vedolizumab | Other | Phase PHASE2 | Collagenous Gastritis | ACTIVE_NOT_RECRUITING | NCT06317220 |
| Placebo | Other | Phase PHASE2 | Narcolepsy Type 1 | RECRUITING | NCT07633301 |
| TAK-360 | Other | Phase PHASE2 | Narcolepsy Type 1 | RECRUITING | NCT07633301 |
| Rusfertide | Other | Phase PHASE2 | Polycythemia Vera | NOT_YET_RECRUITING | NCT07648030 |
| TAK-188 | Other | Phase PHASE1 | Advanced or Metastatic Solid Tumors | RECRUITING | NCT07205718 |
| No Intervention | Other | Phase PHASE3 | Ulcerative Colitis | RECRUITING | NCT06405087 |
| Vedolizumab SC | Other | Phase PHASE3 | Ulcerative Colitis | RECRUITING | NCT06405087 |
| Epoetin Alfa | Other | Phase PHASE3 | Myelodysplastic Syndrome | RECRUITING | NCT07422480 |
| Elritercept | Other | Phase PHASE3 | Myelodysplastic Syndrome | RECRUITING | NCT07422480 |
| Vedolizumab | Other | Phase PHASE3 | Ulcerative Colitis | ACTIVE_NOT_RECRUITING | NCT04738942 |
| Placebo | Other | Phase PHASE2 | Idiopathic Hypersomnia | NOT_YET_RECRUITING | NCT07646678 |
| TAK-360 | Other | Phase PHASE2 | Idiopathic Hypersomnia | NOT_YET_RECRUITING | NCT07646678 |
| Prednisone | Other | Phase PHASE2 | Lymphoma | ACTIVE_NOT_RECRUITING | NCT05673785 |
| Doxorubicin | Other | Phase PHASE2 | Lymphoma | ACTIVE_NOT_RECRUITING | NCT05673785 |
| Cyclophosphamide | Other | Phase PHASE2 | Lymphoma | ACTIVE_NOT_RECRUITING | NCT05673785 |
| Brentuximab Vedotin | Other | Phase PHASE2 | Lymphoma | ACTIVE_NOT_RECRUITING | NCT05673785 |
| Placebo | Other | Phase PHASE2 | Nonsegmental Vitiligo | RECRUITING | NCT07108283 |
| Zasocitinib | Other | Phase PHASE2 | Nonsegmental Vitiligo | RECRUITING | NCT07108283 |
| Placebo | Other | Phase PHASE3 | Kidney Disease | RECRUITING | NCT06963827 |
| Mezagitamab | Other | Phase PHASE3 | Kidney Disease | RECRUITING | NCT06963827 |
| Placebo | Other | Phase PHASE3 | Immune Thrombocytopenic Purpura (ITP) | RECRUITING | NCT06722235 |
| Mezagitamab | Other | Phase PHASE3 | Immune Thrombocytopenic Purpura (ITP) | RECRUITING | NCT06722235 |
| No Intervention | Other | Preclinical | Thrombotic Thrombocytopenic Purpura (TTP) | RECRUITING | NCT07353099 |
| SC Investigational Needle Sets | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06895967 |
| HyQvia | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06895967 |
| TAK-881 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06895967 |
| Vedolizumab SC | Other | Phase PHASE4 | Ulcerative Colitis | RECRUITING | NCT06581328 |
| Vedolizumab IV | Other | Phase PHASE4 | Ulcerative Colitis | RECRUITING | NCT06581328 |
| Placebo | Other | Phase PHASE2 | Narcolepsy Type 1 | RECRUITING | NCT07633301 |
| TAK-360 | Other | Phase PHASE2 | Narcolepsy Type 1 | RECRUITING | NCT07633301 |
| Soticlestat | Other | Phase PHASE3 | Dravet Syndrome (DS) | TERMINATED | NCT05163314 |
| Placebo | Other | Phase PHASE2 | Narcolepsy Type 1 | NOT_YET_RECRUITING | NCT07633301 |
| TAK-360 | Other | Phase PHASE2 | Narcolepsy Type 1 | NOT_YET_RECRUITING | NCT07633301 |
| Mezagitamab | Other | Phase PHASE3 | Immune Thrombocytopenic Purpura (ITP) | RECRUITING | NCT06948318 |
| DAPT | Other | Phase PHASE4 | Lacunar Stroke | RECRUITING | NCT07111559 |
| rt-PA | Other | Phase PHASE4 | Lacunar Stroke | RECRUITING | NCT07111559 |
| TAK-188 | Other | Phase PHASE1 | Advanced or Metastatic Solid Tumors | RECRUITING | NCT07205718 |
| Zasocitinib | Other | Phase PHASE2 | Crohn's Disease | NOT_YET_RECRUITING | NCT07403968 |
| Placebo | Other | Phase PHASE2 | Antibody-Mediated Rejection (AMR) | NOT_YET_RECRUITING | NCT07613359 |
| Mezagitamab | Other | Phase PHASE2 | Antibody-Mediated Rejection (AMR) | NOT_YET_RECRUITING | NCT07613359 |
| No Intervention | Other | Preclinical | Cytomegalovirus (CMV) | RECRUITING | NCT06213974 |
| Elritercept | Other | Phase PHASE3 | Myelofibrosis | NOT_YET_RECRUITING | NCT07623161 |
| Placebo | Other | Phase PHASE3 | Myelofibrosis | NOT_YET_RECRUITING | NCT07623161 |
| Brentuximab Vedotin Plus CHP | Other | Preclinical | CD30-Positive Peripheral T-Cell Lymphoma | RECRUITING | NCT07624838 |
| No intervention | Other | Preclinical | Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07623174 |
| Placebo | Other | Phase PHASE3 | Kidney Disease | RECRUITING | NCT06963827 |
| Mezagitamab | Other | Phase PHASE3 | Kidney Disease | RECRUITING | NCT06963827 |
| Placebo | Other | Phase PHASE3 | Psoriatic Arthritis | RECRUITING | NCT06671483 |
| Active Comparator | Other | Phase PHASE3 | Psoriatic Arthritis | RECRUITING | NCT06671483 |
| Zasocitinib | Other | Phase PHASE3 | Psoriatic Arthritis | RECRUITING | NCT06671483 |
| TAK-341 | Other | Phase PHASE2 | Multiple System Atrophy | COMPLETED | NCT05526391 |
| Placebo | Other | Phase PHASE2 | Multiple System Atrophy | COMPLETED | NCT05526391 |
| TAK-279 | Other | Phase PHASE3 | Plaque Psoriasis | ACTIVE_NOT_RECRUITING | NCT06550076 |
| Haematopoietic growth factor | Other | Phase PHASE3 | Hodgkin Lymphoma | RECRUITING | NCT04685616 |
| Dacarbazine | Other | Phase PHASE3 | Hodgkin Lymphoma | RECRUITING | NCT04685616 |
| Vinblastine | Other | Phase PHASE3 | Hodgkin Lymphoma | RECRUITING | NCT04685616 |
| Brentuximab vedotin | Other | Phase PHASE3 | Hodgkin Lymphoma | RECRUITING | NCT04685616 |
| Bleomycin | Other | Phase PHASE3 | Hodgkin Lymphoma | RECRUITING | NCT04685616 |
| Doxorubicin | Other | Phase PHASE3 | Hodgkin Lymphoma | RECRUITING | NCT04685616 |
| Involved site radiotherapy | Drug | Phase PHASE3 | Hodgkin Lymphoma | RECRUITING | NCT04685616 |
| Mezagitamab | Other | Phase PHASE1 | Kidney Disease | COMPLETED | NCT05174221 |
| Placebo | Other | Phase PHASE3 | Healthy Volunteers | COMPLETED | NCT06060067 |
| TDV | Other | Phase PHASE3 | Healthy Volunteers | COMPLETED | NCT06060067 |
| No Intervention | Other | Preclinical | Thrombotic Thrombocytopenic Purpura (TTP) | NOT_YET_RECRUITING | NCT07429942 |
| Vedolizumab SC | Other | Phase PHASE4 | Ulcerative Colitis | RECRUITING | NCT06581328 |
| Vedolizumab IV | Other | Phase PHASE4 | Ulcerative Colitis | RECRUITING | NCT06581328 |
| Placebo | Other | Phase PHASE2 | Antibody-Mediated Rejection (AMR) | NOT_YET_RECRUITING | NCT07613359 |
| Mezagitamab | Other | Phase PHASE2 | Antibody-Mediated Rejection (AMR) | NOT_YET_RECRUITING | NCT07613359 |
| Placebo | Other | Phase PHASE3 | Kidney Disease | RECRUITING | NCT06963827 |
| Mezagitamab | Other | Phase PHASE3 | Kidney Disease | RECRUITING | NCT06963827 |
| ADVATE | Other | Phase PHASE3 | Von Willebrand Disease (VWD) | RECRUITING | NCT05582993 |
| Vonicog Alfa | Other | Phase PHASE3 | Von Willebrand Disease (VWD) | RECRUITING | NCT05582993 |
| Placebo | Other | Phase PHASE3 | Crohn's Disease | RECRUITING | NCT06227910 |
| Upadacitinib | Other | Phase PHASE3 | Crohn's Disease | RECRUITING | NCT06227910 |
| Vedolizumab | Other | Phase PHASE3 | Crohn's Disease | RECRUITING | NCT06227910 |
| Placebo | Other | Phase PHASE2 | Narcolepsy Type 2 | RECRUITING | NCT06952699 |
| TAK-360 | Other | Phase PHASE2 | Narcolepsy Type 2 | RECRUITING | NCT06952699 |
| No Intervention | Other | Preclinical | Hodgkin Lymphoma | RECRUITING | NCT05100056 |
| Vedolizumab SC | Other | Phase PHASE4 | Ulcerative Colitis | RECRUITING | NCT06581328 |
| Vedolizumab IV | Other | Phase PHASE4 | Ulcerative Colitis | RECRUITING | NCT06581328 |
| ADVATE | Other | Phase PHASE3 | Von Willebrand Disease (VWD) | RECRUITING | NCT05582993 |
| Vonicog Alfa | Other | Phase PHASE3 | Von Willebrand Disease (VWD) | RECRUITING | NCT05582993 |
| Placebo | Other | Phase PHASE3 | Crohn's Disease | RECRUITING | NCT06227910 |
| Upadacitinib | Other | Phase PHASE3 | Crohn's Disease | RECRUITING | NCT06227910 |
| Vedolizumab | Other | Phase PHASE3 | Crohn's Disease | RECRUITING | NCT06227910 |
| Placebo | Other | Phase PHASE2 | Narcolepsy Type 2 | RECRUITING | NCT06952699 |
| TAK-360 | Other | Phase PHASE2 | Narcolepsy Type 2 | RECRUITING | NCT06952699 |
| No Intervention | Other | Preclinical | Hodgkin Lymphoma | RECRUITING | NCT05100056 |
| Vedolizumab SC | Other | Phase PHASE4 | Ulcerative Colitis | RECRUITING | NCT06581328 |
| Vedolizumab IV | Other | Phase PHASE4 | Ulcerative Colitis | RECRUITING | NCT06581328 |
| ADVATE | Other | Phase PHASE3 | Von Willebrand Disease (VWD) | RECRUITING | NCT05582993 |
| Vonicog Alfa | Other | Phase PHASE3 | Von Willebrand Disease (VWD) | RECRUITING | NCT05582993 |
| Placebo | Other | Phase PHASE3 | Crohn's Disease | RECRUITING | NCT06227910 |
| Upadacitinib | Other | Phase PHASE3 | Crohn's Disease | RECRUITING | NCT06227910 |
| Vedolizumab | Other | Phase PHASE3 | Crohn's Disease | RECRUITING | NCT06227910 |
| Placebo | Other | Phase PHASE2 | Narcolepsy Type 2 | RECRUITING | NCT06952699 |
| TAK-360 | Other | Phase PHASE2 | Narcolepsy Type 2 | RECRUITING | NCT06952699 |
| No Intervention | Other | Preclinical | Hodgkin Lymphoma | RECRUITING | NCT05100056 |
| Vedolizumab SC | Other | Phase PHASE4 | Ulcerative Colitis | RECRUITING | NCT06581328 |
| Vedolizumab IV | Other | Phase PHASE4 | Ulcerative Colitis | RECRUITING | NCT06581328 |
| ADVATE | Other | Phase PHASE3 | Von Willebrand Disease (VWD) | RECRUITING | NCT05582993 |
| Vonicog Alfa | Other | Phase PHASE3 | Von Willebrand Disease (VWD) | RECRUITING | NCT05582993 |
| Placebo | Other | Phase PHASE3 | Crohn's Disease | RECRUITING | NCT06227910 |
| Upadacitinib | Other | Phase PHASE3 | Crohn's Disease | RECRUITING | NCT06227910 |
| Vedolizumab | Other | Phase PHASE3 | Crohn's Disease | RECRUITING | NCT06227910 |
| No Intervention | Other | Preclinical | Ulcerative Colitis | ACTIVE_NOT_RECRUITING | NCT05626088 |
| Placebo | Other | Phase PHASE2 | Narcolepsy Type 2 | RECRUITING | NCT06952699 |
| TAK-360 | Other | Phase PHASE2 | Narcolepsy Type 2 | RECRUITING | NCT06952699 |
| No Intervention | Other | Preclinical | Hodgkin Lymphoma | RECRUITING | NCT05100056 |
| Vedolizumab SC | Other | Phase PHASE4 | Ulcerative Colitis | RECRUITING | NCT06581328 |
| Vedolizumab IV | Other | Phase PHASE4 | Ulcerative Colitis | RECRUITING | NCT06581328 |
| ADVATE | Other | Phase PHASE3 | Von Willebrand Disease (VWD) | RECRUITING | NCT05582993 |
| Vonicog Alfa | Other | Phase PHASE3 | Von Willebrand Disease (VWD) | RECRUITING | NCT05582993 |
| Placebo | Other | Phase PHASE3 | Crohn's Disease | RECRUITING | NCT06227910 |
| Upadacitinib | Other | Phase PHASE3 | Crohn's Disease | RECRUITING | NCT06227910 |
| Vedolizumab | Other | Phase PHASE3 | Crohn's Disease | RECRUITING | NCT06227910 |
| No Intervention | Other | Preclinical | Ulcerative Colitis | ACTIVE_NOT_RECRUITING | NCT05626088 |
| Placebo | Other | Phase PHASE2 | Narcolepsy Type 2 | RECRUITING | NCT06952699 |
| TAK-360 | Other | Phase PHASE2 | Narcolepsy Type 2 | RECRUITING | NCT06952699 |
| No Intervention | Other | Preclinical | Hodgkin Lymphoma | RECRUITING | NCT05100056 |
| Vedolizumab SC | Other | Phase PHASE4 | Ulcerative Colitis | RECRUITING | NCT06581328 |
| Vedolizumab IV | Other | Phase PHASE4 | Ulcerative Colitis | RECRUITING | NCT06581328 |
| ADVATE | Other | Phase PHASE3 | Von Willebrand Disease (VWD) | RECRUITING | NCT05582993 |
| Vonicog Alfa | Other | Phase PHASE3 | Von Willebrand Disease (VWD) | RECRUITING | NCT05582993 |
| Placebo | Other | Phase PHASE3 | Crohn's Disease | RECRUITING | NCT06227910 |
| Upadacitinib | Other | Phase PHASE3 | Crohn's Disease | RECRUITING | NCT06227910 |
| Vedolizumab | Other | Phase PHASE3 | Crohn's Disease | RECRUITING | NCT06227910 |
| No Intervention | Other | Preclinical | Ulcerative Colitis | ACTIVE_NOT_RECRUITING | NCT05626088 |
| Placebo | Other | Phase PHASE2 | Narcolepsy Type 2 | RECRUITING | NCT06952699 |
| TAK-360 | Other | Phase PHASE2 | Narcolepsy Type 2 | RECRUITING | NCT06952699 |
| No Intervention | Other | Preclinical | Hodgkin Lymphoma | RECRUITING | NCT05100056 |
| Vedolizumab SC | Other | Phase PHASE4 | Ulcerative Colitis | RECRUITING | NCT06581328 |
| Vedolizumab IV | Other | Phase PHASE4 | Ulcerative Colitis | RECRUITING | NCT06581328 |
| ADVATE | Other | Phase PHASE3 | Von Willebrand Disease (VWD) | RECRUITING | NCT05582993 |
| Vonicog Alfa | Other | Phase PHASE3 | Von Willebrand Disease (VWD) | RECRUITING | NCT05582993 |
| Placebo | Other | Phase PHASE3 | Crohn's Disease | RECRUITING | NCT06227910 |
| Upadacitinib | Other | Phase PHASE3 | Crohn's Disease | RECRUITING | NCT06227910 |
| Vedolizumab | Other | Phase PHASE3 | Crohn's Disease | RECRUITING | NCT06227910 |
| No Intervention | Other | Preclinical | Ulcerative Colitis | ACTIVE_NOT_RECRUITING | NCT05626088 |
| Placebo | Other | Phase PHASE2 | Narcolepsy Type 2 | RECRUITING | NCT06952699 |
| TAK-360 | Other | Phase PHASE2 | Narcolepsy Type 2 | RECRUITING | NCT06952699 |
| No Intervention | Other | Preclinical | Hodgkin Lymphoma | RECRUITING | NCT05100056 |
| Vedolizumab SC | Other | Phase PHASE4 | Ulcerative Colitis | RECRUITING | NCT06581328 |
| Vedolizumab IV | Other | Phase PHASE4 | Ulcerative Colitis | RECRUITING | NCT06581328 |
| No Intervention | Other | Preclinical | Ulcerative Colitis | ACTIVE_NOT_RECRUITING | NCT05626088 |
| No Intervention | Other | Preclinical | Ulcerative Colitis | ACTIVE_NOT_RECRUITING | NCT05626088 |
| No Intervention | Other | Preclinical | Ulcerative Colitis | ACTIVE_NOT_RECRUITING | NCT05626088 |
| No Intervention | Other | Preclinical | Ulcerative Colitis | ACTIVE_NOT_RECRUITING | NCT05626088 |
| No Intervention | Other | Preclinical | Ulcerative Colitis | ACTIVE_NOT_RECRUITING | NCT05626088 |
| No Intervention | Other | Preclinical | Ulcerative Colitis | ACTIVE_NOT_RECRUITING | NCT05626088 |
| Maribavir | Other | Phase PHASE3 | Cytomegalovirus (CMV) | RECRUITING | NCT05319353 |
| No Intervention | Other | Preclinical | Dengue Fever | ACTIVE_NOT_RECRUITING | NCT06388785 |
| Placebo tablets | Other | Phase PHASE3 | Major Depressive Disorder | RECRUITING | NCT07204314 |
| Vortioxetine tablets | Other | Phase PHASE3 | Major Depressive Disorder | RECRUITING | NCT07204314 |
| TT3-LITE Regimen (L-TT3) | Other | Phase PHASE3 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT00734877 |
| M-VTD-PACE | Other | Phase PHASE3 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT00734877 |
| Leuprorelin Acetate | Other | Preclinical | Spinal and Bulbar Muscular Atrophy | COMPLETED | NCT03555578 |
| TAK-188 | Other | Phase PHASE1 | Advanced or Metastatic Solid Tumors | RECRUITING | NCT07205718 |
| Placebo | Other | Phase PHASE3 | Immune Thrombocytopenic Purpura (ITP) | RECRUITING | NCT06722235 |
| Mezagitamab | Other | Phase PHASE3 | Immune Thrombocytopenic Purpura (ITP) | RECRUITING | NCT06722235 |
| Zasocitinib | Other | Phase PHASE2 | Crohn's Disease | RECRUITING | NCT06764615 |
| Placebo | Other | Phase PHASE3 | Moderately to Severely Active Ulcerative Colitis | ACTIVE_NOT_RECRUITING | NCT03221036 |
| Vedolizumab IV | Other | Phase PHASE3 | Moderately to Severely Active Ulcerative Colitis | ACTIVE_NOT_RECRUITING | NCT03221036 |
| Susoctocog Alfa (Genetical Recombination) | Other | Preclinical | Acquired Hemophilia A | RECRUITING | NCT06461533 |
| Maribavir | Other | Phase PHASE3 | Cytomegalovirus (CMV) | RECRUITING | NCT05319353 |
| No Intervention | Other | Preclinical | Dengue Fever | ACTIVE_NOT_RECRUITING | NCT06388785 |
| Placebo tablets | Other | Phase PHASE3 | Major Depressive Disorder | RECRUITING | NCT07204314 |
| Vortioxetine tablets | Other | Phase PHASE3 | Major Depressive Disorder | RECRUITING | NCT07204314 |
| TT3-LITE Regimen (L-TT3) | Other | Phase PHASE3 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT00734877 |
| M-VTD-PACE | Other | Phase PHASE3 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT00734877 |
| Leuprorelin Acetate | Other | Preclinical | Spinal and Bulbar Muscular Atrophy | COMPLETED | NCT03555578 |
| TAK-188 | Other | Phase PHASE1 | Advanced or Metastatic Solid Tumors | RECRUITING | NCT07205718 |
| Placebo | Other | Phase PHASE3 | Immune Thrombocytopenic Purpura (ITP) | RECRUITING | NCT06722235 |
| Mezagitamab | Other | Phase PHASE3 | Immune Thrombocytopenic Purpura (ITP) | RECRUITING | NCT06722235 |
| Zasocitinib | Other | Phase PHASE2 | Crohn's Disease | RECRUITING | NCT06764615 |
| Placebo | Other | Phase PHASE3 | Moderately to Severely Active Ulcerative Colitis | ACTIVE_NOT_RECRUITING | NCT03221036 |
| Vedolizumab IV | Other | Phase PHASE3 | Moderately to Severely Active Ulcerative Colitis | ACTIVE_NOT_RECRUITING | NCT03221036 |
| Susoctocog Alfa (Genetical Recombination) | Other | Preclinical | Acquired Hemophilia A | RECRUITING | NCT06461533 |
| Maribavir | Other | Phase PHASE3 | Cytomegalovirus (CMV) | RECRUITING | NCT05319353 |
| No Intervention | Other | Preclinical | Dengue Fever | ACTIVE_NOT_RECRUITING | NCT06388785 |
| Placebo tablets | Other | Phase PHASE3 | Major Depressive Disorder | RECRUITING | NCT07204314 |
| Vortioxetine tablets | Other | Phase PHASE3 | Major Depressive Disorder | RECRUITING | NCT07204314 |
| TT3-LITE Regimen (L-TT3) | Other | Phase PHASE3 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT00734877 |
| M-VTD-PACE | Other | Phase PHASE3 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT00734877 |
| Leuprorelin Acetate | Other | Preclinical | Spinal and Bulbar Muscular Atrophy | COMPLETED | NCT03555578 |
| TAK-188 | Other | Phase PHASE1 | Advanced or Metastatic Solid Tumors | RECRUITING | NCT07205718 |
| Placebo | Other | Phase PHASE3 | Immune Thrombocytopenic Purpura (ITP) | RECRUITING | NCT06722235 |
| Mezagitamab | Other | Phase PHASE3 | Immune Thrombocytopenic Purpura (ITP) | RECRUITING | NCT06722235 |
| Zasocitinib | Other | Phase PHASE2 | Crohn's Disease | RECRUITING | NCT06764615 |
| Placebo | Other | Phase PHASE3 | Moderately to Severely Active Ulcerative Colitis | ACTIVE_NOT_RECRUITING | NCT03221036 |
| Vedolizumab IV | Other | Phase PHASE3 | Moderately to Severely Active Ulcerative Colitis | ACTIVE_NOT_RECRUITING | NCT03221036 |
| Susoctocog Alfa (Genetical Recombination) | Other | Preclinical | Acquired Hemophilia A | RECRUITING | NCT06461533 |
| Maribavir | Other | Phase PHASE3 | Cytomegalovirus (CMV) | RECRUITING | NCT05319353 |
| No Intervention | Other | Preclinical | Dengue Fever | ACTIVE_NOT_RECRUITING | NCT06388785 |
| Placebo tablets | Other | Phase PHASE3 | Major Depressive Disorder | RECRUITING | NCT07204314 |
| Vortioxetine tablets | Other | Phase PHASE3 | Major Depressive Disorder | RECRUITING | NCT07204314 |
| TT3-LITE Regimen (L-TT3) | Other | Phase PHASE3 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT00734877 |
| M-VTD-PACE | Other | Phase PHASE3 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT00734877 |
| Leuprorelin Acetate | Other | Preclinical | Spinal and Bulbar Muscular Atrophy | COMPLETED | NCT03555578 |
| TAK-188 | Other | Phase PHASE1 | Advanced or Metastatic Solid Tumors | RECRUITING | NCT07205718 |
| Placebo | Other | Phase PHASE3 | Immune Thrombocytopenic Purpura (ITP) | RECRUITING | NCT06722235 |
| Mezagitamab | Other | Phase PHASE3 | Immune Thrombocytopenic Purpura (ITP) | RECRUITING | NCT06722235 |
| Zasocitinib | Other | Phase PHASE2 | Crohn's Disease | RECRUITING | NCT06764615 |
| Placebo | Other | Phase PHASE3 | Moderately to Severely Active Ulcerative Colitis | ACTIVE_NOT_RECRUITING | NCT03221036 |
| Vedolizumab IV | Other | Phase PHASE3 | Moderately to Severely Active Ulcerative Colitis | ACTIVE_NOT_RECRUITING | NCT03221036 |
| Susoctocog Alfa (Genetical Recombination) | Other | Preclinical | Acquired Hemophilia A | RECRUITING | NCT06461533 |
| Maribavir | Other | Phase PHASE3 | Cytomegalovirus (CMV) | RECRUITING | NCT05319353 |
| No Intervention | Other | Preclinical | Dengue Fever | ACTIVE_NOT_RECRUITING | NCT06388785 |
| Placebo tablets | Other | Phase PHASE3 | Major Depressive Disorder | RECRUITING | NCT07204314 |
| Vortioxetine tablets | Other | Phase PHASE3 | Major Depressive Disorder | RECRUITING | NCT07204314 |
| TT3-LITE Regimen (L-TT3) | Other | Phase PHASE3 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT00734877 |
| M-VTD-PACE | Other | Phase PHASE3 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT00734877 |
| Leuprorelin Acetate | Other | Preclinical | Spinal and Bulbar Muscular Atrophy | COMPLETED | NCT03555578 |
| TAK-188 | Other | Phase PHASE1 | Advanced or Metastatic Solid Tumors | RECRUITING | NCT07205718 |
| Placebo | Other | Phase PHASE3 | Immune Thrombocytopenic Purpura (ITP) | RECRUITING | NCT06722235 |
| Mezagitamab | Other | Phase PHASE3 | Immune Thrombocytopenic Purpura (ITP) | RECRUITING | NCT06722235 |
| Zasocitinib | Other | Phase PHASE2 | Crohn's Disease | RECRUITING | NCT06764615 |
| Placebo | Other | Phase PHASE3 | Moderately to Severely Active Ulcerative Colitis | ACTIVE_NOT_RECRUITING | NCT03221036 |
| Vedolizumab IV | Other | Phase PHASE3 | Moderately to Severely Active Ulcerative Colitis | ACTIVE_NOT_RECRUITING | NCT03221036 |
| Susoctocog Alfa (Genetical Recombination) | Other | Preclinical | Acquired Hemophilia A | RECRUITING | NCT06461533 |
| Dexlansoprazole | Other | Phase PHASE2 | Gastroesophageal Reflux Disease (GERD) | ACTIVE_NOT_RECRUITING | NCT02616302 |
| Placebo | Other | Phase PHASE3 | Kidney Disease | RECRUITING | NCT06963827 |
| Mezagitamab | Other | Phase PHASE3 | Kidney Disease | RECRUITING | NCT06963827 |
| Fruquintinib | Other | Phase PHASE4 | Colorectal Cancer | RECRUITING | NCT06562543 |
| Dexlansoprazole | Other | Phase PHASE2 | Gastroesophageal Reflux Disease (GERD) | ACTIVE_NOT_RECRUITING | NCT02616302 |
| Placebo | Other | Phase PHASE3 | Kidney Disease | RECRUITING | NCT06963827 |
| Mezagitamab | Other | Phase PHASE3 | Kidney Disease | RECRUITING | NCT06963827 |
| Fruquintinib | Other | Phase PHASE4 | Colorectal Cancer | RECRUITING | NCT06562543 |
| Dexlansoprazole | Other | Phase PHASE2 | Gastroesophageal Reflux Disease (GERD) | ACTIVE_NOT_RECRUITING | NCT02616302 |
| Placebo | Other | Phase PHASE3 | Kidney Disease | RECRUITING | NCT06963827 |
| Mezagitamab | Other | Phase PHASE3 | Kidney Disease | RECRUITING | NCT06963827 |
| Fruquintinib | Other | Phase PHASE4 | Colorectal Cancer | RECRUITING | NCT06562543 |
| Dexlansoprazole | Other | Phase PHASE2 | Gastroesophageal Reflux Disease (GERD) | ACTIVE_NOT_RECRUITING | NCT02616302 |
| Placebo | Other | Phase PHASE3 | Kidney Disease | RECRUITING | NCT06963827 |
| Mezagitamab | Other | Phase PHASE3 | Kidney Disease | RECRUITING | NCT06963827 |
| Fruquintinib | Other | Phase PHASE4 | Colorectal Cancer | RECRUITING | NCT06562543 |
| Dexlansoprazole | Other | Phase PHASE2 | Gastroesophageal Reflux Disease (GERD) | ACTIVE_NOT_RECRUITING | NCT02616302 |
| Placebo | Other | Phase PHASE3 | Kidney Disease | RECRUITING | NCT06963827 |
| Mezagitamab | Other | Phase PHASE3 | Kidney Disease | RECRUITING | NCT06963827 |
| Fruquintinib | Other | Phase PHASE4 | Colorectal Cancer | RECRUITING | NCT06562543 |
| Dexlansoprazole | Other | Phase PHASE2 | Gastroesophageal Reflux Disease (GERD) | ACTIVE_NOT_RECRUITING | NCT02616302 |
| Placebo | Other | Phase PHASE3 | Kidney Disease | RECRUITING | NCT06963827 |
| Mezagitamab | Other | Phase PHASE3 | Kidney Disease | RECRUITING | NCT06963827 |
| Fruquintinib | Other | Phase PHASE4 | Colorectal Cancer | RECRUITING | NCT06562543 |
| Dexlansoprazole | Other | Phase PHASE2 | Gastroesophageal Reflux Disease (GERD) | ACTIVE_NOT_RECRUITING | NCT02616302 |
| Placebo | Other | Phase PHASE3 | Kidney Disease | RECRUITING | NCT06963827 |
| Mezagitamab | Other | Phase PHASE3 | Kidney Disease | RECRUITING | NCT06963827 |
| Fruquintinib | Other | Phase PHASE4 | Colorectal Cancer | RECRUITING | NCT06562543 |
| Dexlansoprazole | Other | Phase PHASE2 | Gastroesophageal Reflux Disease (GERD) | ACTIVE_NOT_RECRUITING | NCT02616302 |
| Placebo | Other | Phase PHASE3 | Kidney Disease | RECRUITING | NCT06963827 |
| Mezagitamab | Other | Phase PHASE3 | Kidney Disease | RECRUITING | NCT06963827 |
| Fruquintinib | Other | Phase PHASE4 | Colorectal Cancer | RECRUITING | NCT06562543 |
| TAK-771 | Other | Phase PHASE3 | Primary Immunodeficiency Diseases (PID) | COMPLETED | NCT05513586 |
| OBIZUR | Other | Preclinical | Acquired Hemophilia A | RECRUITING | NCT06550882 |
| Dexlansoprazole | Other | Phase PHASE2 | Gastroesophageal Reflux Disease (GERD) | ACTIVE_NOT_RECRUITING | NCT02616302 |
| Placebo | Other | Phase PHASE3 | Kidney Disease | RECRUITING | NCT06963827 |
| Mezagitamab | Other | Phase PHASE3 | Kidney Disease | RECRUITING | NCT06963827 |
| Technochrom C1-INH Kit | Other | Approved | Hereditary Angioedema (HAE) | RECRUITING | NCT07293364 |
| Fruquintinib | Other | Phase PHASE4 | Colorectal Cancer | RECRUITING | NCT06562543 |
| Screening | Other | Preclinical | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT05844033 |
| TAK-771 | Other | Phase PHASE3 | Primary Immunodeficiency Diseases (PID) | COMPLETED | NCT05513586 |
| OBIZUR | Other | Preclinical | Acquired Hemophilia A | RECRUITING | NCT06550882 |
| Dexlansoprazole | Other | Phase PHASE2 | Gastroesophageal Reflux Disease (GERD) | ACTIVE_NOT_RECRUITING | NCT02616302 |
| Placebo | Other | Phase PHASE3 | Kidney Disease | RECRUITING | NCT06963827 |
| Mezagitamab | Other | Phase PHASE3 | Kidney Disease | RECRUITING | NCT06963827 |
| Technochrom C1-INH Kit | Other | Approved | Hereditary Angioedema (HAE) | RECRUITING | NCT07293364 |
| Fruquintinib | Other | Phase PHASE4 | Colorectal Cancer | RECRUITING | NCT06562543 |
| Screening | Other | Preclinical | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT05844033 |
| TAK-771 | Other | Phase PHASE3 | Primary Immunodeficiency Diseases (PID) | COMPLETED | NCT05513586 |
| OBIZUR | Other | Preclinical | Acquired Hemophilia A | RECRUITING | NCT06550882 |
| Dexlansoprazole | Other | Phase PHASE2 | Gastroesophageal Reflux Disease (GERD) | ACTIVE_NOT_RECRUITING | NCT02616302 |
| Placebo | Other | Phase PHASE3 | Kidney Disease | RECRUITING | NCT06963827 |
| Mezagitamab | Other | Phase PHASE3 | Kidney Disease | RECRUITING | NCT06963827 |
| Technochrom C1-INH Kit | Other | Approved | Hereditary Angioedema (HAE) | RECRUITING | NCT07293364 |
| Fruquintinib | Other | Phase PHASE4 | Colorectal Cancer | RECRUITING | NCT06562543 |
| Screening | Other | Preclinical | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT05844033 |
| TAK-771 | Other | Phase PHASE3 | Primary Immunodeficiency Diseases (PID) | COMPLETED | NCT05513586 |
| OBIZUR | Other | Preclinical | Acquired Hemophilia A | RECRUITING | NCT06550882 |
| Dexlansoprazole | Other | Phase PHASE2 | Gastroesophageal Reflux Disease (GERD) | ACTIVE_NOT_RECRUITING | NCT02616302 |
| Placebo | Other | Phase PHASE3 | Kidney Disease | RECRUITING | NCT06963827 |
| Mezagitamab | Other | Phase PHASE3 | Kidney Disease | RECRUITING | NCT06963827 |
| Technochrom C1-INH Kit | Other | Approved | Hereditary Angioedema (HAE) | RECRUITING | NCT07293364 |
| Fruquintinib | Other | Phase PHASE4 | Colorectal Cancer | RECRUITING | NCT06562543 |
| Screening | Other | Preclinical | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT05844033 |
| TAK-771 | Other | Phase PHASE3 | Primary Immunodeficiency Diseases (PID) | COMPLETED | NCT05513586 |
| Screening | Other | Preclinical | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT05844033 |
| OBIZUR | Other | Preclinical | Acquired Hemophilia A | RECRUITING | NCT06550882 |
| Technochrom C1-INH Kit | Other | Approved | Hereditary Angioedema (HAE) | RECRUITING | NCT07293364 |
| TAK-771 | Other | Phase PHASE3 | Primary Immunodeficiency Diseases (PID) | COMPLETED | NCT05513586 |
| Screening | Other | Preclinical | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT05844033 |
| OBIZUR | Other | Preclinical | Acquired Hemophilia A | RECRUITING | NCT06550882 |
| Technochrom C1-INH Kit | Other | Approved | Hereditary Angioedema (HAE) | RECRUITING | NCT07293364 |
| TAK-771 | Other | Phase PHASE3 | Primary Immunodeficiency Diseases (PID) | COMPLETED | NCT05513586 |
| Screening | Other | Preclinical | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT05844033 |
| OBIZUR | Other | Preclinical | Acquired Hemophilia A | RECRUITING | NCT06550882 |
| Technochrom C1-INH Kit | Other | Approved | Hereditary Angioedema (HAE) | RECRUITING | NCT07293364 |
| TAK-771 | Other | Phase PHASE3 | Primary Immunodeficiency Diseases (PID) | COMPLETED | NCT05513586 |
| Screening | Other | Preclinical | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT05844033 |
| OBIZUR | Other | Preclinical | Acquired Hemophilia A | RECRUITING | NCT06550882 |
| Technochrom C1-INH Kit | Other | Approved | Hereditary Angioedema (HAE) | RECRUITING | NCT07293364 |
| TAK-771 | Other | Phase PHASE3 | Primary Immunodeficiency Diseases (PID) | COMPLETED | NCT05513586 |
| Screening | Other | Preclinical | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT05844033 |
| OBIZUR | Other | Preclinical | Acquired Hemophilia A | RECRUITING | NCT06550882 |
| Technochrom C1-INH Kit | Other | Approved | Hereditary Angioedema (HAE) | RECRUITING | NCT07293364 |
| TAK-771 | Other | Phase PHASE3 | Primary Immunodeficiency Diseases (PID) | COMPLETED | NCT05513586 |
| Screening | Other | Preclinical | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT05844033 |
| OBIZUR | Other | Preclinical | Acquired Hemophilia A | RECRUITING | NCT06550882 |
| Technochrom C1-INH Kit | Other | Approved | Hereditary Angioedema (HAE) | RECRUITING | NCT07293364 |
| TAK-771 | Other | Phase PHASE3 | Primary Immunodeficiency Diseases (PID) | COMPLETED | NCT05513586 |
| Screening | Other | Preclinical | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT05844033 |
| OBIZUR | Other | Preclinical | Acquired Hemophilia A | RECRUITING | NCT06550882 |
| Technochrom C1-INH Kit | Other | Approved | Hereditary Angioedema (HAE) | RECRUITING | NCT07293364 |
| TAK-771 | Other | Phase PHASE3 | Primary Immunodeficiency Diseases (PID) | COMPLETED | NCT05513586 |
| Screening | Other | Preclinical | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT05844033 |
| OBIZUR | Other | Preclinical | Acquired Hemophilia A | RECRUITING | NCT06550882 |
| Technochrom C1-INH Kit | Other | Approved | Hereditary Angioedema (HAE) | RECRUITING | NCT07293364 |
| IGI, 10% | Other | Phase PHASE3 | Multiple Myeloma | RECRUITING | NCT06980480 |
| Diagnosis of SPAD using immunization with PPV23 | Other | Preclinical | Specific Antibody Deficiency | RECRUITING | NCT05664035 |
| TAK-771 | Other | Phase PHASE3 | Primary Immunodeficiency Diseases (PID) | COMPLETED | NCT05513586 |
| Screening | Other | Preclinical | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT05844033 |
| OBIZUR | Other | Preclinical | Acquired Hemophilia A | RECRUITING | NCT06550882 |
| Technochrom C1-INH Kit | Other | Approved | Hereditary Angioedema (HAE) | RECRUITING | NCT07293364 |
| IGI, 10% | Other | Phase PHASE3 | Multiple Myeloma | RECRUITING | NCT06980480 |
| Diagnosis of SPAD using immunization with PPV23 | Other | Preclinical | Specific Antibody Deficiency | RECRUITING | NCT05664035 |
| TAK-771 | Other | Phase PHASE3 | Primary Immunodeficiency Diseases (PID) | COMPLETED | NCT05513586 |
| Screening | Other | Preclinical | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT05844033 |
| OBIZUR | Other | Preclinical | Acquired Hemophilia A | RECRUITING | NCT06550882 |
| Technochrom C1-INH Kit | Other | Approved | Hereditary Angioedema (HAE) | RECRUITING | NCT07293364 |
| IGI, 10% | Other | Phase PHASE3 | Multiple Myeloma | RECRUITING | NCT06980480 |
| Diagnosis of SPAD using immunization with PPV23 | Other | Preclinical | Specific Antibody Deficiency | RECRUITING | NCT05664035 |
| TAK-771 | Other | Phase PHASE3 | Primary Immunodeficiency Diseases (PID) | COMPLETED | NCT05513586 |
| Screening | Other | Preclinical | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT05844033 |
| OBIZUR | Other | Preclinical | Acquired Hemophilia A | RECRUITING | NCT06550882 |
| Technochrom C1-INH Kit | Other | Approved | Hereditary Angioedema (HAE) | RECRUITING | NCT07293364 |
| IGI, 10% | Other | Phase PHASE3 | Multiple Myeloma | RECRUITING | NCT06980480 |
| Diagnosis of SPAD using immunization with PPV23 | Other | Preclinical | Specific Antibody Deficiency | RECRUITING | NCT05664035 |
| TAK-771 | Other | Phase PHASE3 | Primary Immunodeficiency Diseases (PID) | COMPLETED | NCT05513586 |
| Screening | Other | Preclinical | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT05844033 |
| OBIZUR | Other | Preclinical | Acquired Hemophilia A | RECRUITING | NCT06550882 |
| Technochrom C1-INH Kit | Other | Approved | Hereditary Angioedema (HAE) | RECRUITING | NCT07293364 |
| IGI, 10% | Other | Phase PHASE3 | Multiple Myeloma | RECRUITING | NCT06980480 |
| Diagnosis of SPAD using immunization with PPV23 | Other | Preclinical | Specific Antibody Deficiency | RECRUITING | NCT05664035 |
| IGI, 10% | Other | Phase PHASE3 | Multiple Myeloma | RECRUITING | NCT06980480 |
| Diagnosis of SPAD using immunization with PPV23 | Other | Preclinical | Specific Antibody Deficiency | RECRUITING | NCT05664035 |
| IGI, 10% | Other | Phase PHASE3 | Multiple Myeloma | RECRUITING | NCT06980480 |
| Diagnosis of SPAD using immunization with PPV23 | Other | Preclinical | Specific Antibody Deficiency | RECRUITING | NCT05664035 |
| IGI, 10% | Other | Phase PHASE3 | Multiple Myeloma | RECRUITING | NCT06980480 |
| Diagnosis of SPAD using immunization with PPV23 | Other | Preclinical | Specific Antibody Deficiency | RECRUITING | NCT05664035 |
| IGI, 10% | Other | Phase PHASE3 | Multiple Myeloma | RECRUITING | NCT06980480 |
| Diagnosis of SPAD using immunization with PPV23 | Other | Preclinical | Specific Antibody Deficiency | RECRUITING | NCT05664035 |
| IGI, 10% | Other | Phase PHASE3 | Multiple Myeloma | RECRUITING | NCT06980480 |
| Diagnosis of SPAD using immunization with PPV23 | Other | Preclinical | Specific Antibody Deficiency | RECRUITING | NCT05664035 |
| IGI, 10% | Other | Phase PHASE3 | Multiple Myeloma | RECRUITING | NCT06980480 |
| Diagnosis of SPAD using immunization with PPV23 | Other | Preclinical | Specific Antibody Deficiency | RECRUITING | NCT05664035 |
| IGI, 10% | Other | Phase PHASE3 | Multiple Myeloma | RECRUITING | NCT06980480 |
| Diagnosis of SPAD using immunization with PPV23 | Other | Preclinical | Specific Antibody Deficiency | RECRUITING | NCT05664035 |
| IGI, 10% | Other | Phase PHASE3 | Multiple Myeloma | RECRUITING | NCT06980480 |
| Diagnosis of SPAD using immunization with PPV23 | Other | Preclinical | Specific Antibody Deficiency | RECRUITING | NCT05664035 |
| IGI, 10% | Other | Phase PHASE3 | Multiple Myeloma | RECRUITING | NCT06980480 |
| Diagnosis of SPAD using immunization with PPV23 | Other | Preclinical | Specific Antibody Deficiency | RECRUITING | NCT05664035 |
| Bortezomib | Other | Preclinical | Multiple Myeloma | NO_LONGER_AVAILABLE | NCT00063791 |
| VELCADE TM (bortezomib) for Injection, or PS-341 | Other | Phase PHASE1 | Advanced Non-Small Cell Lung Cancer | TERMINATED | NCT00064636 |
| VELCADE TM (bortezomib) for Injection, or PS-341 | Other | Phase PHASE1 | Advanced Non-Small Cell Lung Cancer | TERMINATED | NCT00064636 |
| VELCADE TM (bortezomib) for Injection, or PS-341 | Other | Phase PHASE1 | Advanced Non-Small Cell Lung Cancer | TERMINATED | NCT00064636 |
| Multidisciplinary intervention: primary or secondary care | Other | Phase PHASE3 | Accidental Falls | COMPLETED | NCT00130624 |
| Pioglitazone | Other | Phase PHASE3 | HIV-Associated Lipodystrophy Syndrome | TERMINATED | NCT00148850 |
| Pioglitazone | Other | Phase PHASE3 | HIV-Associated Lipodystrophy Syndrome | TERMINATED | NCT00148850 |
| Percutaneous Coronary Intervention (PCI) | Other | Phase PHASE3 | Unstable Angina | COMPLETED | NCT00250471 |
| Percutaneous Coronary Intervention (PCI) | Other | Phase PHASE3 | Unstable Angina | COMPLETED | NCT00250471 |
| pantoprazole 20 mg (drug) | Drug | Phase PHASE3 | Chronic Use of Acid Suppressive Medication | UNKNOWN | NCT00161096 |
| pantoprazole 20 mg (drug) | Drug | Phase PHASE3 | Chronic Use of Acid Suppressive Medication | UNKNOWN | NCT00161096 |
| Candesartan | Other | Phase PHASE4 | Cerebrovascular Accident | UNKNOWN | NCT00108706 |
| MLN2704 (DM1 conjugated monoclonal antibody MLN591) | Other | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT00052000 |
| MLN2704 (DM1 conjugated monoclonal antibody MLN591) | Other | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT00052000 |
| Zopiclone 7.5 mg | Other | Phase PHASE1 | Insomnia | COMPLETED | NCT00319215 |
| Ramelteon 8 mg | Other | Phase PHASE1 | Insomnia | COMPLETED | NCT00319215 |
| MLN2704 (DM1 conjugated monoclonal antibody MLN591) | Other | Phase PHASE1 | Prostatic Neoplasms | COMPLETED | NCT00070837 |
| MLN2704 (DM1 conjugated monoclonal antibody MLN591) | Other | Phase PHASE1 | Prostatic Neoplasms | COMPLETED | NCT00070837 |
| pioglitazone | Other | Approved | Type 2 Diabetes | TERMINATED | NCT00159211 |
| UMULINE NPH | Other | Approved | Type 2 Diabetes | TERMINATED | NCT00159211 |
| pioglitazone | Other | Approved | Type 2 Diabetes | TERMINATED | NCT00159211 |
| UMULINE NPH | Other | Approved | Type 2 Diabetes | TERMINATED | NCT00159211 |
| Lithium Plus Extended- Release Carbamazepine | Other | Phase PHASE4 | Bipolar Disorder | UNKNOWN | NCT00325286 |
| MLN518 | Other | Phase PHASE1 | Acute Myelogenous Leukemia | COMPLETED | NCT00274248 |
| MLN518 | Other | Phase PHASE1 | Acute Myelogenous Leukemia | COMPLETED | NCT00274248 |
| MLN518 | Other | Phase PHASE1 | Acute Myelogenous Leukemia | COMPLETED | NCT00274248 |
| bortezomib | Other | Phase PHASE4 | Multiple Myeloma | COMPLETED | NCT00257114 |
| bortezomib | Other | Phase PHASE4 | Multiple Myeloma | COMPLETED | NCT00257114 |
| bortezomib | Other | Phase PHASE1 | Tumors | COMPLETED | NCT00129207 |
| VELCADE and rituximab | Other | Phase PHASE2 | B-Cell Lymphoma | COMPLETED | NCT00085696 |
| VELCADE and rituximab | Other | Phase PHASE2 | B-Cell Lymphoma | COMPLETED | NCT00085696 |
| VELCADE TM (bortezomib) for Injection | Other | Phase PHASE1 | Prostatic Neoplasms | COMPLETED | NCT00064610 |
| VELCADE TM (bortezomib) for Injection | Other | Phase PHASE1 | Prostatic Neoplasms | COMPLETED | NCT00064610 |
| VELCADE TM (bortezomib) for Injection | Other | Phase PHASE1 | Prostatic Neoplasms | COMPLETED | NCT00064610 |
| VELCADE TM (bortezomib) for Injection | Other | Phase PHASE2 | Mantle Cell Lymphoma | COMPLETED | NCT00063713 |
| VELCADE TM (bortezomib) for Injection | Other | Phase PHASE2 | Mantle Cell Lymphoma | COMPLETED | NCT00063713 |
| VELCADE TM (bortezomib) for Injection, or PS-341 | Other | Phase PHASE2 | Colorectal Carcinoma | COMPLETED | NCT00051987 |
| VELCADE TM (bortezomib) for Injection, or PS-341 | Other | Phase PHASE2 | Colorectal Carcinoma | COMPLETED | NCT00051987 |
| VELCADE™ (bortezomib) for Injection (formerly PS-341) | Other | Phase PHASE2 | Non-Small Cell Lung Cancer | COMPLETED | NCT00051974 |
| VELCADE™ (bortezomib) for Injection (formerly PS-341) | Other | Phase PHASE2 | Non-Small Cell Lung Cancer | COMPLETED | NCT00051974 |
| Bortezomib | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT00080405 |
| Bortezomib | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT00080405 |
| Placebo | Other | Phase PHASE4 | Seasonal Affective Disorder | COMPLETED | NCT00502320 |
| Ramelteon | Other | Phase PHASE4 | Seasonal Affective Disorder | COMPLETED | NCT00502320 |
| Placebo | Other | Phase PHASE4 | Seasonal Affective Disorder | COMPLETED | NCT00502320 |
| Ramelteon | Other | Phase PHASE4 | Seasonal Affective Disorder | COMPLETED | NCT00502320 |
| Placebo | Other | Phase PHASE4 | Nonalcoholic Steatohepatitis | COMPLETED | NCT00227110 |
| Pioglitazone | Other | Phase PHASE4 | Nonalcoholic Steatohepatitis | COMPLETED | NCT00227110 |
| Vedolizumab SC | Other | Phase PHASE3 | Ulcerative Colitis | RECRUITING | NCT06100289 |
| Vedolizumab IV | Other | Phase PHASE3 | Ulcerative Colitis | RECRUITING | NCT06100289 |
| Docetaxel | Other | Phase PHASE2 | Prostate Cancer | TERMINATED | NCT00183937 |
| PS 341 | Other | Phase PHASE2 | Prostate Cancer | TERMINATED | NCT00183937 |
| No intervention | Other | Preclinical | Narcolepsy Type 1 | RECRUITING | NCT07299097 |
| Antihemophilic Factor (Recombinant) | Other | Phase PHASE3 | Von Willebrand Disease | COMPLETED | NCT02932618 |
| Vonicog alfa | Other | Phase PHASE3 | Von Willebrand Disease | COMPLETED | NCT02932618 |
| Vedolizumab SC | Other | Phase PHASE3 | Ulcerative Colitis | RECRUITING | NCT06100289 |
| Vedolizumab IV | Other | Phase PHASE3 | Ulcerative Colitis | RECRUITING | NCT06100289 |
| Docetaxel | Other | Phase PHASE2 | Prostate Cancer | TERMINATED | NCT00183937 |
| PS 341 | Other | Phase PHASE2 | Prostate Cancer | TERMINATED | NCT00183937 |
| No intervention | Other | Preclinical | Narcolepsy Type 1 | RECRUITING | NCT07299097 |
| Antihemophilic Factor (Recombinant) | Other | Phase PHASE3 | Von Willebrand Disease | COMPLETED | NCT02932618 |
| Vonicog alfa | Other | Phase PHASE3 | Von Willebrand Disease | COMPLETED | NCT02932618 |
| Vedolizumab SC | Other | Phase PHASE3 | Ulcerative Colitis | RECRUITING | NCT06100289 |
| Vedolizumab IV | Other | Phase PHASE3 | Ulcerative Colitis | RECRUITING | NCT06100289 |
| Docetaxel | Other | Phase PHASE2 | Prostate Cancer | TERMINATED | NCT00183937 |
| PS 341 | Other | Phase PHASE2 | Prostate Cancer | TERMINATED | NCT00183937 |
| No intervention | Other | Preclinical | Narcolepsy Type 1 | RECRUITING | NCT07299097 |
| Antihemophilic Factor (Recombinant) | Other | Phase PHASE3 | Von Willebrand Disease | COMPLETED | NCT02932618 |
| Vonicog alfa | Other | Phase PHASE3 | Von Willebrand Disease | COMPLETED | NCT02932618 |
| Vedolizumab SC | Other | Phase PHASE3 | Ulcerative Colitis | RECRUITING | NCT06100289 |
| Vedolizumab IV | Other | Phase PHASE3 | Ulcerative Colitis | RECRUITING | NCT06100289 |
| Docetaxel | Other | Phase PHASE2 | Prostate Cancer | TERMINATED | NCT00183937 |
| PS 341 | Other | Phase PHASE2 | Prostate Cancer | TERMINATED | NCT00183937 |
| No intervention | Other | Preclinical | Narcolepsy Type 1 | RECRUITING | NCT07299097 |
| Antihemophilic Factor (Recombinant) | Other | Phase PHASE3 | Von Willebrand Disease | COMPLETED | NCT02932618 |
| Vonicog alfa | Other | Phase PHASE3 | Von Willebrand Disease | COMPLETED | NCT02932618 |
| Glimepiride | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT00770952 |
| Pioglitazone and Glimepiride | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT00770952 |
| Glimepiride | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT00770952 |
| Pioglitazone and Glimepiride | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT00770952 |
| Atorvastatin | Other | Phase PHASE2 | Cardiovascular Diseases | COMPLETED | NCT00770575 |
| Pioglitazone and atorvastatin | Other | Phase PHASE2 | Cardiovascular Diseases | COMPLETED | NCT00770575 |
| Atorvastatin | Other | Phase PHASE2 | Cardiovascular Diseases | COMPLETED | NCT00770575 |
| Pioglitazone and atorvastatin | Other | Phase PHASE2 | Cardiovascular Diseases | COMPLETED | NCT00770575 |
| Ramipril | Other | Phase PHASE2 | Inflammation | COMPLETED | NCT00770497 |
| Pioglitazone and ramipril | Other | Phase PHASE2 | Inflammation | COMPLETED | NCT00770497 |
| Pioglitazone | Other | Phase PHASE2 | Inflammation | COMPLETED | NCT00770497 |
| Ramipril | Other | Phase PHASE2 | Inflammation | COMPLETED | NCT00770497 |
| Pioglitazone and ramipril | Other | Phase PHASE2 | Inflammation | COMPLETED | NCT00770497 |
| Pioglitazone | Other | Phase PHASE2 | Inflammation | COMPLETED | NCT00770497 |
| Metformin | Other | Phase PHASE4 | Diabetes Mellitus | COMPLETED | NCT00754403 |
| Pioglitazone and metformin | Other | Phase PHASE4 | Diabetes Mellitus | COMPLETED | NCT00754403 |
| Metformin | Other | Phase PHASE4 | Diabetes Mellitus | COMPLETED | NCT00754403 |
| Pioglitazone and metformin | Other | Phase PHASE4 | Diabetes Mellitus | COMPLETED | NCT00754403 |
| Metformin and insulin | Other | Phase PHASE4 | Diabetes Mellitus | COMPLETED | NCT00770445 |
| Pioglitazone and metformin and insulin | Other | Phase PHASE4 | Diabetes Mellitus | COMPLETED | NCT00770445 |
| Pioglitazone and insulin | Other | Phase PHASE4 | Diabetes Mellitus | COMPLETED | NCT00770445 |
| Metformin and insulin | Other | Phase PHASE4 | Diabetes Mellitus | COMPLETED | NCT00770445 |
| Pioglitazone and metformin and insulin | Other | Phase PHASE4 | Diabetes Mellitus | COMPLETED | NCT00770445 |
| Pioglitazone and insulin | Other | Phase PHASE4 | Diabetes Mellitus | COMPLETED | NCT00770445 |
| Febuxostat | Other | Phase PHASE2 | Gout | COMPLETED | NCT00174941 |
| Febuxostat | Other | Phase PHASE2 | Gout | COMPLETED | NCT00174941 |
| VELCADE | Other | Phase PHASE2 | Carcinoma, Non-Small-Cell Lung | TERMINATED | NCT00117351 |
| Vedolizumab SC | Other | Phase PHASE3 | Ulcerative Colitis | RECRUITING | NCT06100289 |
| Vedolizumab IV | Other | Phase PHASE3 | Ulcerative Colitis | RECRUITING | NCT06100289 |
| Docetaxel | Other | Phase PHASE2 | Prostate Cancer | TERMINATED | NCT00183937 |
| PS 341 | Other | Phase PHASE2 | Prostate Cancer | TERMINATED | NCT00183937 |
| No intervention | Other | Preclinical | Narcolepsy Type 1 | RECRUITING | NCT07299097 |
| Antihemophilic Factor (Recombinant) | Other | Phase PHASE3 | Von Willebrand Disease | COMPLETED | NCT02932618 |
| Vonicog alfa | Other | Phase PHASE3 | Von Willebrand Disease | COMPLETED | NCT02932618 |
| TAK-505 | Other | Phase PHASE1 | Malignant Solid Tumors | RECRUITING | NCT07436728 |
| Vedolizumab SC | Other | Phase PHASE3 | Ulcerative Colitis | RECRUITING | NCT06100289 |
| Vedolizumab IV | Other | Phase PHASE3 | Ulcerative Colitis | RECRUITING | NCT06100289 |
| Docetaxel | Other | Phase PHASE2 | Prostate Cancer | TERMINATED | NCT00183937 |
| PS 341 | Other | Phase PHASE2 | Prostate Cancer | TERMINATED | NCT00183937 |
| No intervention | Other | Preclinical | Narcolepsy Type 1 | RECRUITING | NCT07299097 |
| Antihemophilic Factor (Recombinant) | Other | Phase PHASE3 | Von Willebrand Disease | COMPLETED | NCT02932618 |
| Vonicog alfa | Other | Phase PHASE3 | Von Willebrand Disease | COMPLETED | NCT02932618 |
| Mobocertinib | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT03807778 |
| TAK-505 | Other | Phase PHASE1 | Malignant Solid Tumors | RECRUITING | NCT07436728 |
| Vedolizumab SC | Other | Phase PHASE3 | Ulcerative Colitis | RECRUITING | NCT06100289 |
| Vedolizumab IV | Other | Phase PHASE3 | Ulcerative Colitis | RECRUITING | NCT06100289 |
| Docetaxel | Other | Phase PHASE2 | Prostate Cancer | TERMINATED | NCT00183937 |
| PS 341 | Other | Phase PHASE2 | Prostate Cancer | TERMINATED | NCT00183937 |
| No intervention | Other | Preclinical | Narcolepsy Type 1 | RECRUITING | NCT07299097 |
| Antihemophilic Factor (Recombinant) | Other | Phase PHASE3 | Von Willebrand Disease | COMPLETED | NCT02932618 |
| Vonicog alfa | Other | Phase PHASE3 | Von Willebrand Disease | COMPLETED | NCT02932618 |
| Mobocertinib | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT03807778 |
| TAK-505 | Other | Phase PHASE1 | Malignant Solid Tumors | RECRUITING | NCT07436728 |
| Vedolizumab SC | Other | Phase PHASE3 | Ulcerative Colitis | RECRUITING | NCT06100289 |
| Vedolizumab IV | Other | Phase PHASE3 | Ulcerative Colitis | RECRUITING | NCT06100289 |
| Docetaxel | Other | Phase PHASE2 | Prostate Cancer | TERMINATED | NCT00183937 |
| PS 341 | Other | Phase PHASE2 | Prostate Cancer | TERMINATED | NCT00183937 |
| No intervention | Other | Preclinical | Narcolepsy Type 1 | RECRUITING | NCT07299097 |
| Antihemophilic Factor (Recombinant) | Other | Phase PHASE3 | Von Willebrand Disease | COMPLETED | NCT02932618 |
| Vonicog alfa | Other | Phase PHASE3 | Von Willebrand Disease | COMPLETED | NCT02932618 |
| Mobocertinib | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT03807778 |
| Mobocertinib | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT03807778 |
| TAK-505 | Other | Phase PHASE1 | Malignant Solid Tumors | RECRUITING | NCT07436728 |
| Mobocertinib | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT03807778 |
| TAK-505 | Other | Phase PHASE1 | Malignant Solid Tumors | RECRUITING | NCT07436728 |
| Mobocertinib | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT03807778 |
| TAK-505 | Other | Phase PHASE1 | Malignant Solid Tumors | RECRUITING | NCT07436728 |
| Placebo | Other | Phase PHASE2 | Crohn's Disease | COMPLETED | NCT00655135 |
| LDP-02 | Other | Phase PHASE2 | Crohn's Disease | COMPLETED | NCT00655135 |
| Placebo | Other | Phase PHASE2 | Crohn's Disease | COMPLETED | NCT00655135 |
| LDP-02 | Other | Phase PHASE2 | Crohn's Disease | COMPLETED | NCT00655135 |
| carbamazepine ER | Other | Phase PHASE4 | Bipolar Depression | COMPLETED | NCT00203567 |
| carbamazepine ER | Other | Phase PHASE4 | Bipolar Depression | COMPLETED | NCT00203567 |
| Placebo | Other | Phase PHASE2 | Atherosclerosis | COMPLETED | NCT00715169 |
| MLN1202 | Other | Phase PHASE2 | Atherosclerosis | COMPLETED | NCT00715169 |
| Voglibose tablets | Other | Approved | Coronary Heart Disease | UNKNOWN | NCT00724542 |
| lisdexamfetamine dimesylate | Other | Approved | Attention Deficit Hyperactivity Disorder | COMPLETED | NCT00807222 |
| CT53518 | Other | Phase PHASE1 | Acute Myelogenous Leukemia | COMPLETED | NCT00064584 |
| CT53518 | Other | Phase PHASE1 | Acute Myelogenous Leukemia | COMPLETED | NCT00064584 |
| Tandutinib, bevacizumab, and temozolomide | Other | Phase PHASE1 | Glioblastoma Multiforme | WITHDRAWN | NCT00904852 |
| Tandutinib, bevacizumab, and temozolomide | Other | Phase PHASE1 | Glioblastoma Multiforme | WITHDRAWN | NCT00904852 |
| pegylated liposomal doxorubicin | Other | Phase PHASE2 | Ovarian Cancer | WITHDRAWN | NCT00610792 |
| bortezomib | Other | Phase PHASE2 | Ovarian Cancer | WITHDRAWN | NCT00610792 |
| pegylated liposomal doxorubicin | Other | Phase PHASE2 | Ovarian Cancer | WITHDRAWN | NCT00610792 |
| bortezomib | Other | Phase PHASE2 | Ovarian Cancer | WITHDRAWN | NCT00610792 |
| Placebo | Other | Phase PHASE2 | Alzheimer Disease | COMPLETED | NCT00982202 |
| pioglitazone | Other | Phase PHASE2 | Alzheimer Disease | COMPLETED | NCT00982202 |
| Placebo | Other | Phase PHASE2 | Alzheimer Disease | COMPLETED | NCT00982202 |
| pioglitazone | Other | Phase PHASE2 | Alzheimer Disease | COMPLETED | NCT00982202 |
| Placebo | Other | Phase PHASE2 | Alzheimer Disease | COMPLETED | NCT00982202 |
| pioglitazone | Other | Phase PHASE2 | Alzheimer Disease | COMPLETED | NCT00982202 |
| Placebo | Other | Phase PHASE2 | Alzheimer Disease | COMPLETED | NCT00982202 |
| pioglitazone | Other | Phase PHASE2 | Alzheimer Disease | COMPLETED | NCT00982202 |
| Placebo | Other | Phase PHASE4 | Nonalcoholic Steatohepatitis | COMPLETED | NCT00227110 |
| Pioglitazone | Other | Phase PHASE4 | Nonalcoholic Steatohepatitis | COMPLETED | NCT00227110 |
| Placebo | Other | Phase PHASE4 | Nonalcoholic Steatohepatitis | COMPLETED | NCT00227110 |
| Pioglitazone | Other | Phase PHASE4 | Nonalcoholic Steatohepatitis | COMPLETED | NCT00227110 |
| ciclesonide | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00525772 |
| ciclesonide | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00525772 |
| bortezomib | Other | Phase PHASE1 | Non-small Cell Lung Cancer | UNKNOWN | NCT00516100 |
| bortezomib | Other | Phase PHASE1 | Non-small Cell Lung Cancer | UNKNOWN | NCT00516100 |
| bortezomib | Other | Phase PHASE1 | Non-small Cell Lung Cancer | UNKNOWN | NCT00516100 |
| TAK-593 | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT00773929 |
| TAK-593 | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT00773929 |
| Placebo | Other | Phase PHASE3 | Gastroesophageal Reflux Disease | COMPLETED | NCT00251758 |
| Dexlansoprazole MR | Other | Phase PHASE3 | Gastroesophageal Reflux Disease | COMPLETED | NCT00251758 |
| Placebo | Other | Phase PHASE3 | Gastroesophageal Reflux Disease | COMPLETED | NCT00251758 |
| Dexlansoprazole MR | Other | Phase PHASE3 | Gastroesophageal Reflux Disease | COMPLETED | NCT00251758 |
| Ramelteon and Placebo (25 possible combinations total) | Other | Phase PHASE2 | Chronic Insomnia | COMPLETED | NCT00915135 |
| Placebo | Other | Phase PHASE3 | Sleep Initiation and Maintenance Disorders | COMPLETED | NCT00756002 |
| Ramelteon | Other | Phase PHASE3 | Sleep Initiation and Maintenance Disorders | COMPLETED | NCT00756002 |
| Placebo | Other | Phase PHASE3 | Sleep Initiation and Maintenance Disorders | COMPLETED | NCT00756002 |
| Ramelteon | Other | Phase PHASE3 | Sleep Initiation and Maintenance Disorders | COMPLETED | NCT00756002 |
| Ramelteon and Placebo | Other | Phase PHASE4 | Chronic Obstructive Pulmonary Disease | COMPLETED | NCT00316992 |
| Ramelteon and Placebo | Other | Phase PHASE4 | Chronic Obstructive Pulmonary Disease | COMPLETED | NCT00316992 |
| Placebo | Other | Phase PHASE3 | Chronic Insomnia | COMPLETED | NCT00247390 |
| Ramelteon | Other | Phase PHASE3 | Chronic Insomnia | COMPLETED | NCT00247390 |
| Placebo | Other | Phase PHASE3 | Chronic Insomnia | COMPLETED | NCT00247390 |
| Ramelteon | Other | Phase PHASE3 | Chronic Insomnia | COMPLETED | NCT00247390 |
| Placebo | Other | Phase PHASE3 | Chronic Insomnia | COMPLETED | NCT00247390 |
| Ramelteon | Other | Phase PHASE3 | Chronic Insomnia | COMPLETED | NCT00247390 |
| TAK-875 | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00949091 |
| TAK-875 | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00949091 |
| Standard chronic heart disease therapy | Drug | Phase PHASE3 | Heart Failure | TERMINATED | NCT00843154 |
| Candesartan and standard chronic heart disease therapy | Drug | Phase PHASE3 | Heart Failure | TERMINATED | NCT00843154 |
| Standard chronic heart disease therapy | Drug | Phase PHASE3 | Heart Failure | TERMINATED | NCT00843154 |
| Candesartan and standard chronic heart disease therapy | Drug | Phase PHASE3 | Heart Failure | TERMINATED | NCT00843154 |
| Methotrexate | Other | Phase PHASE2 | Arthritis, Rheumatoid | COMPLETED | NCT00760968 |
| TAK-783 and methotrexate | Other | Phase PHASE2 | Arthritis, Rheumatoid | COMPLETED | NCT00760968 |
| Methotrexate | Other | Phase PHASE2 | Arthritis, Rheumatoid | COMPLETED | NCT00760968 |
| TAK-783 and methotrexate | Other | Phase PHASE2 | Arthritis, Rheumatoid | COMPLETED | NCT00760968 |
| Methotrexate | Other | Phase PHASE2 | Arthritis, Rheumatoid | COMPLETED | NCT00760864 |
| TAK-715 and methotrexate | Other | Phase PHASE2 | Arthritis, Rheumatoid | COMPLETED | NCT00760864 |
| Methotrexate | Other | Phase PHASE2 | Arthritis, Rheumatoid | COMPLETED | NCT00760864 |
| TAK-715 and methotrexate | Other | Phase PHASE2 | Arthritis, Rheumatoid | COMPLETED | NCT00760864 |
| Leuprorelin (GC) | Other | Phase PHASE2 | Uterine Fibroids | COMPLETED | NCT00776074 |
| Leuprorelin (GF) | Other | Phase PHASE2 | Uterine Fibroids | COMPLETED | NCT00776074 |
| Leuprorelin (GC) | Other | Phase PHASE2 | Uterine Fibroids | COMPLETED | NCT00776074 |
| Leuprorelin (GF) | Other | Phase PHASE2 | Uterine Fibroids | COMPLETED | NCT00776074 |
| Placebo | Other | Phase PHASE3 | Heart Failure | COMPLETED | NCT00775840 |
| Candesartan | Other | Phase PHASE3 | Heart Failure | COMPLETED | NCT00775840 |
| Placebo | Other | Phase PHASE3 | Heart Failure | COMPLETED | NCT00775840 |
| Candesartan | Other | Phase PHASE3 | Heart Failure | COMPLETED | NCT00775840 |
| Placebo | Other | Phase PHASE3 | Heart Failure | COMPLETED | NCT00775840 |
| Candesartan | Other | Phase PHASE3 | Heart Failure | COMPLETED | NCT00775840 |
| Olmesartan | Other | Phase PHASE2 | Hypertension | COMPLETED | NCT00759551 |
| Placebo | Other | Phase PHASE2 | Hypertension | COMPLETED | NCT00759551 |
| Azilsartan | Other | Phase PHASE2 | Hypertension | COMPLETED | NCT00759551 |
| Olmesartan | Other | Phase PHASE2 | Hypertension | COMPLETED | NCT00759551 |
| Placebo | Other | Phase PHASE2 | Hypertension | COMPLETED | NCT00759551 |
| Azilsartan | Other | Phase PHASE2 | Hypertension | COMPLETED | NCT00759551 |
| Pioglitazone | Other | Phase PHASE3 | Type 2 Diabetes | TERMINATED | NCT00376181 |
| Pioglitazone and Azilsartan | Other | Phase PHASE3 | Type 2 Diabetes | TERMINATED | NCT00376181 |
| Pioglitazone | Other | Phase PHASE3 | Type 2 Diabetes | TERMINATED | NCT00376181 |
| Pioglitazone and Azilsartan | Other | Phase PHASE3 | Type 2 Diabetes | TERMINATED | NCT00376181 |
| Pioglitazone | Other | Phase PHASE3 | Type 2 Diabetes | TERMINATED | NCT00376181 |
| Pioglitazone and Azilsartan | Other | Phase PHASE3 | Type 2 Diabetes | TERMINATED | NCT00376181 |
| carbamazepine ER (Equetro) | Other | Phase PHASE4 | Bipolar Disorder | COMPLETED | NCT00181870 |
| Metformin | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT00772174 |
| Pioglitazone and Metformin | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT00772174 |
| Metformin | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT00772174 |
| Pioglitazone and Metformin | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT00772174 |
| Placebo | Other | Phase PHASE2 | Oxidative Stress | COMPLETED | NCT00771004 |
| Pioglitazone | Other | Phase PHASE2 | Oxidative Stress | COMPLETED | NCT00771004 |
| Placebo | Other | Phase PHASE2 | Oxidative Stress | COMPLETED | NCT00771004 |
| Pioglitazone | Other | Phase PHASE2 | Oxidative Stress | COMPLETED | NCT00771004 |
| Candesartan cilexetil and hydrochlorothiazide | Other | Phase PHASE4 | Hypertension | COMPLETED | NCT01012479 |
| Candesartan cilexetil and hydrochlorothiazide | Other | Phase PHASE4 | Hypertension | COMPLETED | NCT01012479 |
| Placebo and zolpidem | Other | Phase PHASE4 | Chronic Insomnia | COMPLETED | NCT00492232 |
| Ramelteon and zolpidem | Other | Phase PHASE4 | Chronic Insomnia | COMPLETED | NCT00492232 |
| Placebo and zolpidem | Other | Phase PHASE4 | Chronic Insomnia | COMPLETED | NCT00492232 |
| Ramelteon and zolpidem | Other | Phase PHASE4 | Chronic Insomnia | COMPLETED | NCT00492232 |
| Lansoprazole | Other | Phase PHASE2 | Esophagitis | COMPLETED | NCT00175045 |
| Lansoprazole | Other | Phase PHASE2 | Esophagitis | COMPLETED | NCT00175045 |
| Lansoprazole | Other | Phase PHASE2 | Esophagitis | COMPLETED | NCT00175045 |
| Placebo | Other | Phase PHASE3 | Gastroesophageal Reflux Disease | COMPLETED | NCT00324974 |
| Lansoprazole microgranules suspension | Other | Phase PHASE3 | Gastroesophageal Reflux Disease | COMPLETED | NCT00324974 |
| Placebo | Other | Phase PHASE3 | Gastroesophageal Reflux Disease | COMPLETED | NCT00324974 |
| Lansoprazole microgranules suspension | Other | Phase PHASE3 | Gastroesophageal Reflux Disease | COMPLETED | NCT00324974 |
| Lansoprazole | Other | Phase PHASE1 | Gastroesophageal Reflux Disease | COMPLETED | NCT00220818 |
| Lansoprazole | Other | Phase PHASE1 | Gastroesophageal Reflux Disease | COMPLETED | NCT00220818 |
| Celecoxib and aspirin | Other | Phase PHASE3 | Osteoarthritis | COMPLETED | NCT00175032 |
| Lansoprazole and naproxen and aspirin | Other | Phase PHASE3 | Osteoarthritis | COMPLETED | NCT00175032 |
| Celecoxib and aspirin | Other | Phase PHASE3 | Osteoarthritis | COMPLETED | NCT00175032 |
| Lansoprazole and naproxen and aspirin | Other | Phase PHASE3 | Osteoarthritis | COMPLETED | NCT00175032 |
| Celecoxib and aspirin | Other | Phase PHASE3 | Osteoarthritis | COMPLETED | NCT00175032 |
| Lansoprazole and naproxen and aspirin | Other | Phase PHASE3 | Osteoarthritis | COMPLETED | NCT00175032 |
| Lansoprazole | Other | Phase PHASE1 | Gastroesophageal Reflux Disease | COMPLETED | NCT00174928 |
| Lansoprazole | Other | Phase PHASE1 | Gastroesophageal Reflux Disease | COMPLETED | NCT00174928 |
| Allopurinol | Other | Phase PHASE3 | Gout | COMPLETED | NCT00175019 |
| Febuxostat | Other | Phase PHASE3 | Gout | COMPLETED | NCT00175019 |
| Allopurinol | Other | Phase PHASE3 | Gout | COMPLETED | NCT00175019 |
| Febuxostat | Other | Phase PHASE3 | Gout | COMPLETED | NCT00175019 |
| Measurement of Tophi to validate procedure | Procedure | Preclinical | Gout | COMPLETED | NCT00175006 |
| MRI | Other | Preclinical | Hyperuricemia | COMPLETED | NCT00174954 |
| MRI | Other | Preclinical | Hyperuricemia | COMPLETED | NCT00174954 |
| MRI | Other | Preclinical | Hyperuricemia | COMPLETED | NCT00174954 |
| Insulin | Other | Phase PHASE2 | Diabetes Mellitus | COMPLETED | NCT00770640 |
| Pioglitazone and insulin | Other | Phase PHASE2 | Diabetes Mellitus | COMPLETED | NCT00770640 |
| Insulin | Other | Phase PHASE2 | Diabetes Mellitus | COMPLETED | NCT00770640 |
| Pioglitazone and insulin | Other | Phase PHASE2 | Diabetes Mellitus | COMPLETED | NCT00770640 |
| MLN1202 | Other | Phase PHASE2 | Multiple Sclerosis | COMPLETED | NCT01199640 |
| MLN1202 | Other | Phase PHASE2 | Multiple Sclerosis | COMPLETED | NCT01199640 |
| Cytarabine | Other | Phase PHASE1 | Leukemia | COMPLETED | NCT00505700 |
| Idarubicin | Other | Phase PHASE1 | Leukemia | COMPLETED | NCT00505700 |
| velcade | Other | Phase PHASE1 | Leukemia | COMPLETED | NCT00505700 |
| Cytarabine | Other | Phase PHASE1 | Leukemia | COMPLETED | NCT00505700 |
| Idarubicin | Other | Phase PHASE1 | Leukemia | COMPLETED | NCT00505700 |
| velcade | Other | Phase PHASE1 | Leukemia | COMPLETED | NCT00505700 |
| Glimepiride and Metformin | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT00770653 |
| Pioglitazone and Metformin | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT00770653 |
| Glimepiride and Metformin | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT00770653 |
| Pioglitazone and Metformin | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT00770653 |
| Placebo | Other | Phase PHASE4 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00656864 |
| Pioglitazone | Other | Phase PHASE4 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00656864 |
| Placebo | Other | Phase PHASE4 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00656864 |
| Pioglitazone | Other | Phase PHASE4 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00656864 |
| Placebo | Other | Phase PHASE4 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00656864 |
| Pioglitazone | Other | Phase PHASE4 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00656864 |
| Candesartan cilexetil | Other | Phase PHASE2 | Essential Hypertension | COMPLETED | NCT01289132 |
| Azilsartan | Other | Phase PHASE2 | Essential Hypertension | COMPLETED | NCT01289132 |
| Placebo | Other | Phase PHASE2 | Essential Hypertension | COMPLETED | NCT01289132 |
| Candesartan cilexetil | Other | Phase PHASE2 | Essential Hypertension | COMPLETED | NCT01289132 |
| Azilsartan | Other | Phase PHASE2 | Essential Hypertension | COMPLETED | NCT01289132 |
| Placebo | Other | Phase PHASE2 | Essential Hypertension | COMPLETED | NCT01289132 |
| VELCADE | Other | Phase PHASE2 | Carcinoma, Non-Small-Cell Lung | TERMINATED | NCT00117351 |
| Urine Drug Testing | Drug | Preclinical | Chronic Pain | COMPLETED | NCT01052155 |
| Urine Drug Testing | Drug | Preclinical | Chronic Pain | COMPLETED | NCT01052155 |
| dexlansoprazole | Other | Phase PHASE4 | Laryngopharyngeal Reflux | UNKNOWN | NCT01328652 |
| dexlansoprazole | Other | Phase PHASE4 | Laryngopharyngeal Reflux | UNKNOWN | NCT01328652 |
| lubiprostone | Other | Approved | Constipation | COMPLETED | NCT00706004 |
| lubiprostone | Other | Approved | Constipation | COMPLETED | NCT00706004 |
| lubiprostone | Other | Approved | Constipation | COMPLETED | NCT00706004 |
| Placebo | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00696436 |
| Olmesartan | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00696436 |
| Valsartan | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00696436 |
| Azilsartan medoxomil | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00696436 |
| Azilsartan medoxomil with or without add-on hydrochlorothiazide | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00695955 |
| Azilsartan medoxomil with or without add-on chlorthalidone | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00695955 |
| Azilsartan medoxomil with or without add-on hydrochlorothiazide | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00695955 |
| Azilsartan medoxomil with or without add-on chlorthalidone | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00695955 |
| Chlorthalidone | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00591773 |
| Azilsartan medoxomil and chlorthalidone | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00591773 |
| Chlorthalidone | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00591773 |
| Azilsartan medoxomil and chlorthalidone | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00591773 |
| Chlorthalidone | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00591773 |
| Azilsartan medoxomil and chlorthalidone | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00591773 |
| Placebo | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00591253 |
| Azilsartan medoxomil | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00591253 |
| Placebo | Other | Phase PHASE2 | Hypertension | COMPLETED | NCT00362115 |
| Olmesartan | Other | Phase PHASE2 | Hypertension | COMPLETED | NCT00362115 |
| Azilsartan Medoxomil | Other | Phase PHASE2 | Hypertension | COMPLETED | NCT00362115 |
| Placebo | Other | Phase PHASE2 | Hypertension | COMPLETED | NCT00362115 |
| Olmesartan | Other | Phase PHASE2 | Hypertension | COMPLETED | NCT00362115 |
| Azilsartan Medoxomil | Other | Phase PHASE2 | Hypertension | COMPLETED | NCT00362115 |
| Placebo | Other | Phase PHASE3 | Gastroesophageal Reflux | COMPLETED | NCT00627016 |
| Dexlansoprazole | Other | Phase PHASE3 | Gastroesophageal Reflux | COMPLETED | NCT00627016 |
| Placebo | Other | Phase PHASE3 | Gastroesophageal Reflux | COMPLETED | NCT00627016 |
| Dexlansoprazole | Other | Phase PHASE3 | Gastroesophageal Reflux | COMPLETED | NCT00627016 |
| Placebo | Other | Phase PHASE3 | Gastroesophageal Reflux Disease | COMPLETED | NCT00321984 |
| Dexlansoprazole MR | Other | Phase PHASE3 | Gastroesophageal Reflux Disease | COMPLETED | NCT00321984 |
| Placebo | Other | Phase PHASE3 | Gastroesophageal Reflux Disease | COMPLETED | NCT00321984 |
| Dexlansoprazole MR | Other | Phase PHASE3 | Gastroesophageal Reflux Disease | COMPLETED | NCT00321984 |
| Placebo | Other | Phase PHASE3 | Gastroesophageal Reflux Disease | COMPLETED | NCT00251745 |
| Dexlansoprazole MR | Other | Phase PHASE3 | Gastroesophageal Reflux Disease | COMPLETED | NCT00251745 |
| Placebo | Other | Phase PHASE3 | Gastroesophageal Reflux Disease | COMPLETED | NCT00251745 |
| Dexlansoprazole MR | Other | Phase PHASE3 | Gastroesophageal Reflux Disease | COMPLETED | NCT00251745 |
| No Intervention | Other | Preclinical | Thrombotic Thrombocytopenic Purpura (TTP) | NOT_YET_RECRUITING | NCT07353099 |
| Mobocertinib | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT03807778 |
| Placebo | Other | Phase PHASE3 | Myelodysplastic Syndromes | RECRUITING | NCT06499285 |
| Elritercept | Other | Phase PHASE3 | Myelodysplastic Syndromes | RECRUITING | NCT06499285 |
| Vedolizumab SC | Other | Phase PHASE4 | Ulcerative Colitis | RECRUITING | NCT06581328 |
| Vedolizumab IV | Other | Phase PHASE4 | Ulcerative Colitis | RECRUITING | NCT06581328 |
| Placebo | Other | Phase PHASE2 | Nonsegmental Vitiligo | RECRUITING | NCT07108283 |
| Zasocitinib | Other | Phase PHASE2 | Nonsegmental Vitiligo | RECRUITING | NCT07108283 |
| Placebo | Other | Phase PHASE3 | Alpha1-Antitrypsin Deficiency | RECRUITING | NCT05677971 |
| Fazirsiran Injection | Other | Phase PHASE3 | Alpha1-Antitrypsin Deficiency | RECRUITING | NCT05677971 |
| TAK-505 | Other | Phase PHASE1 | Malignant Solid Tumors | RECRUITING | NCT07436728 |
| Placebo | Other | Phase PHASE3 | Kidney Disease | RECRUITING | NCT06963827 |
| Mezagitamab | Other | Phase PHASE3 | Kidney Disease | RECRUITING | NCT06963827 |
| Vedolizumab | Other | Phase PHASE2 | Ulcerative Colitis | COMPLETED | NCT03196427 |
| Bortezomib (Velcade) | Other | Phase PHASE2 | Waldenstrom's Macroglobulinemia | COMPLETED | NCT00142129 |
| Bortezomib (Velcade) | Other | Phase PHASE2 | Waldenstrom's Macroglobulinemia | COMPLETED | NCT00142129 |
| Glibenclamide and Metformin | Other | Phase PHASE4 | Diabetes Mellitus | COMPLETED | NCT00770835 |
| Pioglitazone and Metformin | Other | Phase PHASE4 | Diabetes Mellitus | COMPLETED | NCT00770835 |
| Glibenclamide and Metformin | Other | Phase PHASE4 | Diabetes Mellitus | COMPLETED | NCT00770835 |
| Pioglitazone and Metformin | Other | Phase PHASE4 | Diabetes Mellitus | COMPLETED | NCT00770835 |
| Amlodipine | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00591266 |
| Azilsartan Medoxomil and amlodipine | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00591266 |
| Amlodipine | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00591266 |
| Azilsartan Medoxomil and amlodipine | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00591266 |
| Metformin | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT00727857 |
| Pioglitazone | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT00727857 |
| Pioglitazone and metformin | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT00727857 |
| Placebo | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00696241 |
| Olmesartan | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00696241 |
| Azilsartan medoxomil and olmesartan | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00696241 |
| Placebo | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00696241 |
| Olmesartan | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00696241 |
| Azilsartan medoxomil and olmesartan | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00696241 |
| Febuxostat | Other | Phase PHASE2 | Gout | COMPLETED | NCT00174967 |
| Placebo | Other | Phase PHASE2 | Gout | COMPLETED | NCT00174967 |
| Febuxostat | Other | Phase PHASE2 | Gout | COMPLETED | NCT00174967 |
| Placebo | Other | Phase PHASE2 | Gout | COMPLETED | NCT00174967 |
| Ramelteon | Other | Phase PHASE4 | Chronic Insomnia | TERMINATED | NCT00337272 |
| Placebo | Other | Phase PHASE4 | Chronic Insomnia | TERMINATED | NCT00337272 |
| Ramelteon | Other | Phase PHASE4 | Chronic Insomnia | TERMINATED | NCT00337272 |
| Placebo | Other | Phase PHASE4 | Chronic Insomnia | TERMINATED | NCT00337272 |
| Ramelteon | Other | Phase PHASE4 | Chronic Insomnia | TERMINATED | NCT00337272 |
| Placebo | Other | Phase PHASE4 | Chronic Insomnia | TERMINATED | NCT00337272 |
| Placebo | Other | Phase PHASE1 | Irritable Bowel Syndrome | COMPLETED | NCT01166789 |
| Lubiprostone | Other | Phase PHASE1 | Irritable Bowel Syndrome | COMPLETED | NCT01166789 |
| Placebo | Other | Phase PHASE1 | Irritable Bowel Syndrome | COMPLETED | NCT01166789 |
| Lubiprostone | Other | Phase PHASE1 | Irritable Bowel Syndrome | COMPLETED | NCT01166789 |
| Placebo | Other | Approved | Chronic Kidney Disease | COMPLETED | NCT00438932 |
| Unrestricted Phosphorus Diet | Other | Approved | Chronic Kidney Disease | COMPLETED | NCT00438932 |
| Low Phosphorus Diet | Other | Approved | Chronic Kidney Disease | COMPLETED | NCT00438932 |
| Lanthanum Carbonate | Other | Approved | Chronic Kidney Disease | COMPLETED | NCT00438932 |
| Feed Back | Other | Phase PHASE4 | High Risk Hypertensive Patients | COMPLETED | NCT00348855 |
| Diet | Other | Phase PHASE4 | High Risk Hypertensive Patients | COMPLETED | NCT00348855 |
| Stop Smoking | Other | Phase PHASE4 | High Risk Hypertensive Patients | COMPLETED | NCT00348855 |
| Exercise | Other | Phase PHASE4 | High Risk Hypertensive Patients | COMPLETED | NCT00348855 |
| Compliance | Other | Phase PHASE4 | High Risk Hypertensive Patients | COMPLETED | NCT00348855 |
| Cardiovascular drugs strategies | Drug | Phase PHASE4 | High Risk Hypertensive Patients | COMPLETED | NCT00348855 |
| Feed Back | Other | Phase PHASE4 | High Risk Hypertensive Patients | COMPLETED | NCT00348855 |
| Diet | Other | Phase PHASE4 | High Risk Hypertensive Patients | COMPLETED | NCT00348855 |
| Stop Smoking | Other | Phase PHASE4 | High Risk Hypertensive Patients | COMPLETED | NCT00348855 |
| Exercise | Other | Phase PHASE4 | High Risk Hypertensive Patients | COMPLETED | NCT00348855 |
| Compliance | Other | Phase PHASE4 | High Risk Hypertensive Patients | COMPLETED | NCT00348855 |
| Cardiovascular drugs strategies | Drug | Phase PHASE4 | High Risk Hypertensive Patients | COMPLETED | NCT00348855 |
| Peginesatide | Other | Phase PHASE1 | Anemia | TERMINATED | NCT00629876 |
| Peginesatide | Other | Phase PHASE1 | Anemia | TERMINATED | NCT00629876 |
| TAK-701 | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT00831896 |
| TAK-701 | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT00831896 |
| TAK-901 | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT00935844 |
| TAK-901 | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT00935844 |
| TAK-285 Recommended Phase 2 Dosing Cohort | Other | Phase PHASE1 | Cancer | COMPLETED | NCT00535522 |
| TAK-285 Dose Escalation Cohorts | Other | Phase PHASE1 | Cancer | COMPLETED | NCT00535522 |
| TAK-285 Recommended Phase 2 Dosing Cohort | Other | Phase PHASE1 | Cancer | COMPLETED | NCT00535522 |
| TAK-285 Dose Escalation Cohorts | Other | Phase PHASE1 | Cancer | COMPLETED | NCT00535522 |
| Placebo | Other | Approved | Constipation-predominant Irritable Bowel Syndrome | COMPLETED | NCT01085643 |
| Lubiprostone | Other | Approved | Constipation-predominant Irritable Bowel Syndrome | COMPLETED | NCT01085643 |
| Placebo | Other | Approved | Constipation-predominant Irritable Bowel Syndrome | COMPLETED | NCT01085643 |
| Lubiprostone | Other | Approved | Constipation-predominant Irritable Bowel Syndrome | COMPLETED | NCT01085643 |
| Placebo | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00696384 |
| Azilsartan medoxomil, with or without chlorthalidone and other non-angiotensin II receptor blocker antihypertensive medications. | Drug | Phase PHASE3 | Hypertension | COMPLETED | NCT00696384 |
| Azilsartan medoxomil | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00696384 |
| Diet - very low carb or low fat | Other | Approved | Gastroesophageal Reflux Disease | COMPLETED | NCT00998244 |
| Diet - very low carb or low fat | Other | Approved | Gastroesophageal Reflux Disease | COMPLETED | NCT00998244 |
| Diet - very low carb or low fat | Other | Approved | Gastroesophageal Reflux Disease | COMPLETED | NCT00998244 |
| Placebo | Other | Phase PHASE4 | Pain | COMPLETED | NCT01224756 |
| Tinoridine HCl | Other | Phase PHASE4 | Pain | COMPLETED | NCT01224756 |
| Placebo | Other | Phase PHASE4 | Pain | COMPLETED | NCT01224756 |
| Tinoridine HCl | Other | Phase PHASE4 | Pain | COMPLETED | NCT01224756 |
| Rituximab | Other | Phase PHASE2 | Follicular Lymphoma | COMPLETED | NCT00636792 |
| Bendamustine | Other | Phase PHASE2 | Follicular Lymphoma | COMPLETED | NCT00636792 |
| VELCADE | Other | Phase PHASE2 | Follicular Lymphoma | COMPLETED | NCT00636792 |
| Rituximab | Other | Phase PHASE2 | Follicular Lymphoma | COMPLETED | NCT00636792 |
| Bendamustine | Other | Phase PHASE2 | Follicular Lymphoma | COMPLETED | NCT00636792 |
| VELCADE | Other | Phase PHASE2 | Follicular Lymphoma | COMPLETED | NCT00636792 |
| Rituximab | Other | Phase PHASE2 | Follicular Lymphoma | COMPLETED | NCT00636792 |
| Bendamustine | Other | Phase PHASE2 | Follicular Lymphoma | COMPLETED | NCT00636792 |
| VELCADE | Other | Phase PHASE2 | Follicular Lymphoma | COMPLETED | NCT00636792 |
| bortezomib | Other | Phase PHASE3 | Multiple Myeloma | COMPLETED | NCT00063726 |
| bortezomib | Other | Phase PHASE3 | Multiple Myeloma | COMPLETED | NCT00063726 |
| bortezomib | Other | Phase PHASE3 | Multiple Myeloma | COMPLETED | NCT00048230 |
| bortezomib | Other | Phase PHASE3 | Multiple Myeloma | COMPLETED | NCT00048230 |
| bortezomib | Other | Phase PHASE3 | Multiple Myeloma | COMPLETED | NCT00048230 |
| TAK-448 | Other | Phase PHASE1 | Prostate Cancer | TERMINATED | NCT01132404 |
| Leuprorelin | Other | Phase PHASE1 | Prostate Cancer | TERMINATED | NCT01132404 |
| TAK-448 | Other | Phase PHASE1 | Prostate Cancer | TERMINATED | NCT01132404 |
| Leuprorelin | Other | Phase PHASE1 | Prostate Cancer | TERMINATED | NCT01132404 |
| Dexlansoprazole MR | Other | Phase PHASE1 | Gastroesophageal Reflux | COMPLETED | NCT00847210 |
| Alogliptin and pioglitazone | Other | Phase PHASE2 | Type 2 Diabetes Mellitus | COMPLETED | NCT01318122 |
| Metformin | Other | Phase PHASE2 | Type 2 Diabetes Mellitus | COMPLETED | NCT01318109 |
| Alogliptin and metformin | Other | Phase PHASE2 | Type 2 Diabetes Mellitus | COMPLETED | NCT01318109 |
| Metformin | Other | Phase PHASE2 | Type 2 Diabetes Mellitus | COMPLETED | NCT01318109 |
| Alogliptin and metformin | Other | Phase PHASE2 | Type 2 Diabetes Mellitus | COMPLETED | NCT01318109 |
| Glimepiride | Other | Phase PHASE2 | Type 2 Diabetes Mellitus | COMPLETED | NCT01318083 |
| Alogliptin and glimepiride | Other | Phase PHASE2 | Type 2 Diabetes Mellitus | COMPLETED | NCT01318083 |
| Glimepiride | Other | Phase PHASE2 | Type 2 Diabetes Mellitus | COMPLETED | NCT01318083 |
| Alogliptin and glimepiride | Other | Phase PHASE2 | Type 2 Diabetes Mellitus | COMPLETED | NCT01318083 |
| Pioglitazone | Other | Phase PHASE2 | Type 2 Diabetes Mellitus | COMPLETED | NCT01318070 |
| Alogliptin and pioglitazone | Other | Phase PHASE2 | Type 2 Diabetes Mellitus | COMPLETED | NCT01318070 |
| Pioglitazone | Other | Phase PHASE2 | Type 2 Diabetes Mellitus | COMPLETED | NCT01318070 |
| Alogliptin and pioglitazone | Other | Phase PHASE2 | Type 2 Diabetes Mellitus | COMPLETED | NCT01318070 |
| Alogliptin and voglibose | Other | Phase PHASE2 | Type 2 Diabetes Mellitus | COMPLETED | NCT01263509 |
| Voglibose | Other | Phase PHASE2 | Type 2 Diabetes Mellitus | COMPLETED | NCT01263496 |
| Alogliptin | Other | Phase PHASE2 | Type 2 Diabetes Mellitus | COMPLETED | NCT01263496 |
| Voglibose | Other | Phase PHASE2 | Type 2 Diabetes Mellitus | COMPLETED | NCT01263496 |
| Alogliptin | Other | Phase PHASE2 | Type 2 Diabetes Mellitus | COMPLETED | NCT01263496 |
| Voglibose | Other | Phase PHASE2 | Type 2 Diabetes Mellitus | COMPLETED | NCT01263483 |
| Alogliptin and voglibose | Other | Phase PHASE2 | Type 2 Diabetes Mellitus | COMPLETED | NCT01263483 |
| Voglibose | Other | Phase PHASE2 | Type 2 Diabetes Mellitus | COMPLETED | NCT01263483 |
| Alogliptin and voglibose | Other | Phase PHASE2 | Type 2 Diabetes Mellitus | COMPLETED | NCT01263483 |
| Placebo | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01263470 |
| Voglibose | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01263470 |
| Alogliptin | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01263470 |
| Placebo | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01263470 |
| Voglibose | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01263470 |
| Alogliptin | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01263470 |
| Placebo | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01263470 |
| Voglibose | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01263470 |
| Alogliptin | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01263470 |
| Bowel preparation | Other | Phase PHASE4 | Healthy | COMPLETED | NCT00953043 |
| Placebo | Other | Phase PHASE4 | Healthy | COMPLETED | NCT00953043 |
| lubiprostone | Other | Phase PHASE4 | Healthy | COMPLETED | NCT00953043 |
| Bowel preparation | Other | Phase PHASE4 | Healthy | COMPLETED | NCT00953043 |
| Placebo | Other | Phase PHASE4 | Healthy | COMPLETED | NCT00953043 |
| lubiprostone | Other | Phase PHASE4 | Healthy | COMPLETED | NCT00953043 |
| Placebo | Other | Phase PHASE2 | Diabetic Neuropathies | COMPLETED | NCT00229437 |
| TAK-128 | Other | Phase PHASE2 | Diabetic Neuropathies | COMPLETED | NCT00229437 |
| Placebo | Other | Phase PHASE2 | Diabetic Neuropathies | COMPLETED | NCT00229437 |
| TAK-128 | Other | Phase PHASE2 | Diabetic Neuropathies | COMPLETED | NCT00229437 |
| Glimepiride | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT00225277 |
| Pioglitazone | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT00225277 |
| Glimepiride | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT00225277 |
| Pioglitazone | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT00225277 |
| Glimepiride | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT00225264 |
| Pioglitazone | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT00225264 |
| Glimepiride | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT00225264 |
| Pioglitazone | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT00225264 |
| Pantoprazole | Other | Phase PHASE4 | Gastroesophageal Reflux Disease | TERMINATED | NCT00449813 |
| Pantoprazole | Other | Phase PHASE4 | Gastroesophageal Reflux Disease | TERMINATED | NCT00449813 |
| Placebo | Other | Phase PHASE2 | Migraine | TERMINATED | NCT00739024 |
| Ramelteon | Other | Phase PHASE2 | Migraine | TERMINATED | NCT00739024 |
| Placebo | Other | Phase PHASE2 | Migraine | TERMINATED | NCT00739024 |
| Ramelteon | Other | Phase PHASE2 | Migraine | TERMINATED | NCT00739024 |
| Autologous PBSC Transplant | Other | Phase PHASE1 | Cancer | TERMINATED | NCT00793650 |
| Melphalan | Other | Phase PHASE1 | Cancer | TERMINATED | NCT00793650 |
| Bortezomib | Other | Phase PHASE1 | Cancer | TERMINATED | NCT00793650 |
| Placebo | Other | Phase PHASE4 | Schizophrenia | COMPLETED | NCT00595504 |
| Ramelteon | Other | Phase PHASE4 | Schizophrenia | COMPLETED | NCT00595504 |
| No Intervention | Other | Preclinical | Thrombotic Thrombocytopenic Purpura (TTP) | NOT_YET_RECRUITING | NCT07353099 |
| Mobocertinib | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT03807778 |
| Placebo | Other | Phase PHASE3 | Myelodysplastic Syndromes | RECRUITING | NCT06499285 |
| Elritercept | Other | Phase PHASE3 | Myelodysplastic Syndromes | RECRUITING | NCT06499285 |
| Vedolizumab SC | Other | Phase PHASE4 | Ulcerative Colitis | RECRUITING | NCT06581328 |
| Vedolizumab IV | Other | Phase PHASE4 | Ulcerative Colitis | RECRUITING | NCT06581328 |
| Placebo | Other | Phase PHASE2 | Nonsegmental Vitiligo | RECRUITING | NCT07108283 |
| Zasocitinib | Other | Phase PHASE2 | Nonsegmental Vitiligo | RECRUITING | NCT07108283 |
| Placebo | Other | Phase PHASE3 | Alpha1-Antitrypsin Deficiency | RECRUITING | NCT05677971 |
| Fazirsiran Injection | Other | Phase PHASE3 | Alpha1-Antitrypsin Deficiency | RECRUITING | NCT05677971 |
| TAK-505 | Other | Phase PHASE1 | Malignant Solid Tumors | RECRUITING | NCT07436728 |
| Placebo | Other | Phase PHASE3 | Kidney Disease | RECRUITING | NCT06963827 |
| Mezagitamab | Other | Phase PHASE3 | Kidney Disease | RECRUITING | NCT06963827 |
| Vedolizumab | Other | Phase PHASE2 | Ulcerative Colitis | COMPLETED | NCT03196427 |
| Glyburide | Other | Phase PHASE3 | Diabetes Mellitus | TERMINATED | NCT00759720 |
| TAK-559 and glyburide | Other | Phase PHASE3 | Diabetes Mellitus | TERMINATED | NCT00759720 |
| Glyburide | Other | Phase PHASE3 | Diabetes Mellitus | TERMINATED | NCT00759720 |
| TAK-559 and glyburide | Other | Phase PHASE3 | Diabetes Mellitus | TERMINATED | NCT00759720 |
| Valsartan | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00591578 |
| Azilsartan Medoxomil | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00591578 |
| Valsartan | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00591578 |
| Azilsartan Medoxomil | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00591578 |
| Lansoprazole | Other | Phase PHASE2 | Esophagitis | COMPLETED | NCT00471094 |
| Ilaprazole | Other | Phase PHASE2 | Esophagitis | COMPLETED | NCT00471094 |
| Lansoprazole | Other | Phase PHASE2 | Esophagitis | COMPLETED | NCT00471094 |
| Ilaprazole | Other | Phase PHASE2 | Esophagitis | COMPLETED | NCT00471094 |
| Lansoprazole | Other | Phase PHASE2 | Esophagitis | COMPLETED | NCT00471094 |
| Ilaprazole | Other | Phase PHASE2 | Esophagitis | COMPLETED | NCT00471094 |
| Allopurinol | Other | Phase PHASE3 | Gout | COMPLETED | NCT00430248 |
| Febuxostat | Other | Phase PHASE3 | Gout | COMPLETED | NCT00430248 |
| Allopurinol | Other | Phase PHASE3 | Gout | COMPLETED | NCT00430248 |
| Febuxostat | Other | Phase PHASE3 | Gout | COMPLETED | NCT00430248 |
| Placebo | Other | Phase PHASE2 | Neuralgia, Postherpetic | COMPLETED | NCT00377598 |
| TAK-583 | Other | Phase PHASE2 | Neuralgia, Postherpetic | COMPLETED | NCT00377598 |
| Placebo | Other | Phase PHASE3 | Balance | COMPLETED | NCT00237497 |
| Zopiclone | Other | Phase PHASE3 | Balance | COMPLETED | NCT00237497 |
| Ramelteon | Other | Phase PHASE3 | Balance | COMPLETED | NCT00237497 |
| Placebo | Other | Phase PHASE3 | Balance | COMPLETED | NCT00237497 |
| Zopiclone | Other | Phase PHASE3 | Balance | COMPLETED | NCT00237497 |
| Ramelteon | Other | Phase PHASE3 | Balance | COMPLETED | NCT00237497 |
| Placebo | Other | Phase PHASE3 | Gout | COMPLETED | NCT00174915 |
| Allopurinol | Other | Phase PHASE3 | Gout | COMPLETED | NCT00174915 |
| Febuxostat | Other | Phase PHASE3 | Gout | COMPLETED | NCT00174915 |
| Placebo | Other | Phase PHASE3 | Gout | COMPLETED | NCT00174915 |
| Allopurinol | Other | Phase PHASE3 | Gout | COMPLETED | NCT00174915 |
| Febuxostat | Other | Phase PHASE3 | Gout | COMPLETED | NCT00174915 |
| Placebo | Other | Phase PHASE3 | Sepsis | COMPLETED | NCT00143611 |
| Resatorvid | Other | Phase PHASE3 | Sepsis | COMPLETED | NCT00143611 |
| Allopurinol | Other | Phase PHASE3 | Gout | COMPLETED | NCT00102440 |
| Febuxostat | Other | Phase PHASE3 | Gout | COMPLETED | NCT00102440 |
| Placebo | Other | Phase PHASE2 | Congestive Heart Failure | COMPLETED | NCT00050076 |
| MCC-135 | Other | Phase PHASE2 | Congestive Heart Failure | COMPLETED | NCT00050076 |
| Placebo | Other | Phase PHASE2 | Congestive Heart Failure | COMPLETED | NCT00050076 |
| MCC-135 | Other | Phase PHASE2 | Congestive Heart Failure | COMPLETED | NCT00050076 |
| Placebo | Other | Phase PHASE2 | Congestive Heart Failure | COMPLETED | NCT00050076 |
| MCC-135 | Other | Phase PHASE2 | Congestive Heart Failure | COMPLETED | NCT00050076 |
| TAK-165 | Other | Phase PHASE1 | Breast Neoplasm | COMPLETED | NCT00034281 |
| TAK-165 | Other | Phase PHASE1 | Breast Neoplasm | COMPLETED | NCT00034281 |
| Clopidogrel and Esomeprazole | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00942175 |
| Clopidogrel and Omeprazole | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00942175 |
| Clopidogrel and Dexlansoprazole | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00942175 |
| Clopidogrel and Lansoprazole | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00942175 |
| Clopidogrel | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00942175 |
| Clopidogrel and Esomeprazole | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00942175 |
| Clopidogrel and Omeprazole | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00942175 |
| Clopidogrel and Dexlansoprazole | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00942175 |
| Clopidogrel and Lansoprazole | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00942175 |
| Clopidogrel | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00942175 |
| Dexlansoprazole MR QD | Other | Phase PHASE3 | Gastroesophageal Reflux | COMPLETED | NCT00847808 |
| Gefarnate | Other | Phase PHASE3 | Stomach Ulcer | COMPLETED | NCT00787254 |
| Lansoprazole | Other | Phase PHASE3 | Stomach Ulcer | COMPLETED | NCT00787254 |
| Gefarnate | Other | Phase PHASE3 | Stomach Ulcer | COMPLETED | NCT00787254 |
| Lansoprazole | Other | Phase PHASE3 | Stomach Ulcer | COMPLETED | NCT00787254 |
| Gefarnate | Other | Phase PHASE3 | Stomach Ulcer | TERMINATED | NCT00762359 |
| Lansoprazole | Other | Phase PHASE3 | Stomach Ulcer | TERMINATED | NCT00762359 |
| Gefarnate | Other | Phase PHASE3 | Stomach Ulcer | TERMINATED | NCT00762359 |
| Lansoprazole | Other | Phase PHASE3 | Stomach Ulcer | TERMINATED | NCT00762359 |
| Placebo | Other | Phase PHASE2 | Diabetes Mellitus | COMPLETED | NCT00755846 |
| Alogliptin | Other | Phase PHASE2 | Diabetes Mellitus | COMPLETED | NCT00755846 |
| Placebo | Other | Phase PHASE2 | Diabetes Mellitus | COMPLETED | NCT00755846 |
| Alogliptin | Other | Phase PHASE2 | Diabetes Mellitus | COMPLETED | NCT00755846 |
| Placebo | Other | Phase PHASE4 | Bone Metabolism | COMPLETED | NCT00708175 |
| Pioglitazone | Other | Phase PHASE4 | Bone Metabolism | COMPLETED | NCT00708175 |
| Placebo | Other | Phase PHASE4 | Bone Metabolism | COMPLETED | NCT00708175 |
| Pioglitazone | Other | Phase PHASE4 | Bone Metabolism | COMPLETED | NCT00708175 |
| Placebo | Other | Phase PHASE3 | Esophagitis, Reflux | COMPLETED | NCT00321737 |
| Dexlansoprazole MR | Other | Phase PHASE3 | Esophagitis, Reflux | COMPLETED | NCT00321737 |
| Placebo | Other | Phase PHASE3 | Esophagitis, Reflux | COMPLETED | NCT00321737 |
| Dexlansoprazole MR | Other | Phase PHASE3 | Esophagitis, Reflux | COMPLETED | NCT00321737 |
| Pioglitazone | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT00286494 |
| Alogliptin and pioglitazone | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT00286494 |
| Pioglitazone | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT00286494 |
| Alogliptin and pioglitazone | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT00286494 |
| Glyburide | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT00286468 |
| Alogliptin and glyburide | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT00286468 |
| Glyburide | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT00286468 |
| Alogliptin and glyburide | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT00286468 |
| Placebo | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT00286455 |
| Alogliptin | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT00286455 |
| Placebo | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT00286455 |
| Alogliptin | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT00286455 |
| Metformin | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT00286442 |
| Alogliptin and metformin | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT00286442 |
| Metformin | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT00286442 |
| Alogliptin and metformin | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT00286442 |
| Insulin | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT00286429 |
| Alogliptin and insulin | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT00286429 |
| Insulin | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT00286429 |
| Alogliptin and insulin | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT00286429 |
| Placebo | Other | Phase PHASE3 | Esophagitis, Reflux | COMPLETED | NCT00255164 |
| Dexlansoprazole MR | Other | Phase PHASE3 | Esophagitis, Reflux | COMPLETED | NCT00255164 |
| Placebo | Other | Phase PHASE3 | Esophagitis, Reflux | COMPLETED | NCT00255164 |
| Dexlansoprazole MR | Other | Phase PHASE3 | Esophagitis, Reflux | COMPLETED | NCT00255164 |
| Placebo | Other | Phase PHASE3 | Esophagitis, Reflux | COMPLETED | NCT00255164 |
| Dexlansoprazole MR | Other | Phase PHASE3 | Esophagitis, Reflux | COMPLETED | NCT00255164 |
| Placebo | Other | Phase PHASE3 | Esophagitis, Reflux | COMPLETED | NCT00255151 |
| Dexlansoprazole MR | Other | Phase PHASE3 | Esophagitis, Reflux | COMPLETED | NCT00255151 |
| Placebo | Other | Phase PHASE3 | Esophagitis, Reflux | COMPLETED | NCT00255151 |
| Dexlansoprazole MR | Other | Phase PHASE3 | Esophagitis, Reflux | COMPLETED | NCT00255151 |
| Lansoprazole | Other | Phase PHASE3 | Esophagitis, Reflux | COMPLETED | NCT00251719 |
| Dexlansoprazole MR | Other | Phase PHASE3 | Esophagitis, Reflux | COMPLETED | NCT00251719 |
| Lansoprazole | Other | Phase PHASE3 | Esophagitis, Reflux | COMPLETED | NCT00251693 |
| Dexlansoprazole MR | Other | Phase PHASE3 | Esophagitis, Reflux | COMPLETED | NCT00251693 |
| Olmesartan medoxomil and hydrochlorothiazide | Other | Phase PHASE3 | Essential Hypertension | COMPLETED | NCT01033071 |
| Azilsartan medoxomil and chlorthalidone | Other | Phase PHASE3 | Essential Hypertension | COMPLETED | NCT01033071 |
| Azilsartan medoxomil | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00847626 |
| Chlorthalidone | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00847626 |
| Azilsartan medoxomil and chlorthalidone | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00847626 |
| Azilsartan medoxomil and hydrochlorothiazide | Other | Phase PHASE3 | Essential Hypertension | COMPLETED | NCT00818883 |
| Azilsartan medoxomil and chlorthalidone | Other | Phase PHASE3 | Essential Hypertension | COMPLETED | NCT00818883 |
| Azilsartan medoxomil and hydrochlorothiazide | Other | Phase PHASE3 | Essential Hypertension | COMPLETED | NCT00818883 |
| Azilsartan medoxomil and chlorthalidone | Other | Phase PHASE3 | Essential Hypertension | COMPLETED | NCT00818883 |
| Bortezomib | Other | Phase PHASE1 | Lung Cancer | WITHDRAWN | NCT00411593 |
| Bevacizumab | Other | Phase PHASE1 | Lung Cancer | WITHDRAWN | NCT00411593 |
| Bortezomib | Other | Phase PHASE1 | Lung Cancer | WITHDRAWN | NCT00411593 |
| Bevacizumab | Other | Phase PHASE1 | Lung Cancer | WITHDRAWN | NCT00411593 |
| ramelteon | Other | Phase PHASE4 | Migraine Headache | TERMINATED | NCT00391755 |
| ramelteon | Other | Phase PHASE4 | Migraine Headache | TERMINATED | NCT00391755 |
| ramelteon | Other | Phase PHASE4 | Migraine Headache | TERMINATED | NCT00391755 |
| Placebo | Other | Phase PHASE1 | Type 1 Diabetes Mellitus | COMPLETED | NCT01311076 |
| Insulin | Other | Phase PHASE1 | Type 1 Diabetes Mellitus | COMPLETED | NCT01311076 |
| TAK-329 | Other | Phase PHASE1 | Type 1 Diabetes Mellitus | COMPLETED | NCT01311076 |
| Placebo | Other | Phase PHASE1 | Type 1 Diabetes Mellitus | COMPLETED | NCT01311076 |
| Insulin | Other | Phase PHASE1 | Type 1 Diabetes Mellitus | COMPLETED | NCT01311076 |
| TAK-329 | Other | Phase PHASE1 | Type 1 Diabetes Mellitus | COMPLETED | NCT01311076 |
| Metformin | Other | Phase PHASE3 | Diabetes Mellitus | TERMINATED | NCT00762957 |
| TAK-559 and metformin | Other | Phase PHASE3 | Diabetes Mellitus | TERMINATED | NCT00762957 |
| Metformin | Other | Phase PHASE3 | Diabetes Mellitus | TERMINATED | NCT00762957 |
| TAK-559 and metformin | Other | Phase PHASE3 | Diabetes Mellitus | TERMINATED | NCT00762957 |
| Pioglitazone | Other | Phase PHASE2 | Diabetes Mellitus | COMPLETED | NCT00762736 |
| Pioglitazone and azilsartan | Other | Phase PHASE2 | Diabetes Mellitus | COMPLETED | NCT00762736 |
| TAK-128 | Other | Phase PHASE2 | Diabetic Neuropathies | TERMINATED | NCT00756041 |
| TAK-128 | Other | Phase PHASE2 | Diabetic Neuropathies | TERMINATED | NCT00756041 |
| Placebo | Other | Phase PHASE2 | Sleep Initiation and Maintenance Disorders | COMPLETED | NCT00755508 |
| Gabapentin | Other | Phase PHASE2 | Sleep Initiation and Maintenance Disorders | COMPLETED | NCT00755508 |
| Ramelteon | Other | Phase PHASE2 | Sleep Initiation and Maintenance Disorders | COMPLETED | NCT00755508 |
| Ramelteon and gabapentin | Other | Phase PHASE2 | Sleep Initiation and Maintenance Disorders | COMPLETED | NCT00755508 |
| Placebo | Other | Phase PHASE2 | Sleep Initiation and Maintenance Disorders | COMPLETED | NCT00755495 |
| Doxepin | Other | Phase PHASE2 | Sleep Initiation and Maintenance Disorders | COMPLETED | NCT00755495 |
| Ramelteon | Other | Phase PHASE2 | Sleep Initiation and Maintenance Disorders | COMPLETED | NCT00755495 |
| Ramelteon and doxepin | Other | Phase PHASE2 | Sleep Initiation and Maintenance Disorders | COMPLETED | NCT00755495 |
| Placebo | Other | Phase PHASE2 | Sleep Initiation and Maintenance Disorders | COMPLETED | NCT00755495 |
| Doxepin | Other | Phase PHASE2 | Sleep Initiation and Maintenance Disorders | COMPLETED | NCT00755495 |
| Ramelteon | Other | Phase PHASE2 | Sleep Initiation and Maintenance Disorders | COMPLETED | NCT00755495 |
| Ramelteon and doxepin | Other | Phase PHASE2 | Sleep Initiation and Maintenance Disorders | COMPLETED | NCT00755495 |
| Placebo | Other | Phase PHASE2 | Diabetes Mellitus | COMPLETED | NCT00676260 |
| Pioglitazone | Other | Phase PHASE2 | Diabetes Mellitus | COMPLETED | NCT00676260 |
| Placebo | Other | Phase PHASE2 | Diabetes Mellitus | COMPLETED | NCT00676260 |
| Pioglitazone | Other | Phase PHASE2 | Diabetes Mellitus | COMPLETED | NCT00676260 |
| Pioglitazone | Other | Phase PHASE4 | Diabetes Mellitus | COMPLETED | NCT00672919 |
| Pioglitazone | Other | Phase PHASE4 | Diabetes Mellitus | COMPLETED | NCT00672919 |
| Ramelteon and Placebo | Other | Phase PHASE2 | Chronic Obstructive Pulmonary Disease | COMPLETED | NCT00672802 |
| Ramelteon and Placebo | Other | Phase PHASE2 | Chronic Obstructive Pulmonary Disease | COMPLETED | NCT00672802 |
| Placebo | Other | Phase PHASE3 | Chronic Insomnia | TERMINATED | NCT00672724 |
| Ramelteon | Other | Phase PHASE3 | Chronic Insomnia | TERMINATED | NCT00672724 |
| Placebo | Other | Phase PHASE3 | Chronic Insomnia | TERMINATED | NCT00672724 |
| Ramelteon | Other | Phase PHASE3 | Chronic Insomnia | TERMINATED | NCT00672724 |
| Ramelteon or Placebo | Other | Phase PHASE2 | Sleep Apnea, Obstructive | COMPLETED | NCT00672061 |
| Ramelteon or Placebo | Other | Phase PHASE2 | Sleep Apnea, Obstructive | COMPLETED | NCT00672061 |
| Ramelteon, triazolam, and placebo (56 possible combinations total) | Other | Phase PHASE2 | Drug Abuse | COMPLETED | NCT00671632 |
| Placebo | Other | Phase PHASE3 | Transient Insomnia | COMPLETED | NCT00671398 |
| Ramelteon | Other | Phase PHASE3 | Transient Insomnia | COMPLETED | NCT00671398 |
| Placebo | Other | Phase PHASE3 | Transient Insomnia | COMPLETED | NCT00671398 |
| Ramelteon | Other | Phase PHASE3 | Transient Insomnia | COMPLETED | NCT00671398 |
| Ramelteon and Placebo (9 possible combinations total) | Other | Phase PHASE3 | Chronic Insomnia | COMPLETED | NCT00671294 |
| Ramelteon and Placebo (9 possible combinations total) | Other | Phase PHASE3 | Chronic Insomnia | COMPLETED | NCT00671294 |
| Placebo | Other | Phase PHASE3 | Chronic Insomnia | COMPLETED | NCT00671255 |
| Ramelteon | Other | Phase PHASE3 | Chronic Insomnia | COMPLETED | NCT00671255 |
| Placebo | Other | Phase PHASE2 | Sleep Disorder | COMPLETED | NCT00671190 |
| Ramelteon | Other | Phase PHASE2 | Sleep Disorder | COMPLETED | NCT00671190 |
| Placebo | Other | Phase PHASE2 | Sleep Disorder | COMPLETED | NCT00671190 |
| Ramelteon | Other | Phase PHASE2 | Sleep Disorder | COMPLETED | NCT00671190 |
| Ramelteon | Other | Phase PHASE3 | Sleep Initiation and Maintenance Disorders | COMPLETED | NCT00671086 |
| Ramelteon | Other | Phase PHASE3 | Sleep Initiation and Maintenance Disorders | COMPLETED | NCT00671086 |
| Placebo | Other | Phase PHASE3 | Insomnia | COMPLETED | NCT00656994 |
| Ramelteon | Other | Phase PHASE3 | Insomnia | COMPLETED | NCT00656994 |
| Placebo | Other | Phase PHASE3 | Insomnia | COMPLETED | NCT00656994 |
| Ramelteon | Other | Phase PHASE3 | Insomnia | COMPLETED | NCT00656994 |
| Placebo | Other | Phase PHASE2 | Sleep Disorders, Circadian Rhythm | COMPLETED | NCT00593736 |
| Ramelteon | Other | Phase PHASE2 | Sleep Disorders, Circadian Rhythm | COMPLETED | NCT00593736 |
| Placebo | Other | Phase PHASE2 | Sleep Disorders, Circadian Rhythm | COMPLETED | NCT00593736 |
| Ramelteon | Other | Phase PHASE2 | Sleep Disorders, Circadian Rhythm | COMPLETED | NCT00593736 |
| Ramelteon, zolpidem and placebo | Other | Phase PHASE4 | Insomnia | COMPLETED | NCT00568789 |
| Glyburide | Other | Phase PHASE3 | Diabetes Mellitus | TERMINATED | NCT00521820 |
| Pioglitazone | Other | Phase PHASE3 | Diabetes Mellitus | TERMINATED | NCT00521820 |
| Glyburide | Other | Phase PHASE3 | Diabetes Mellitus | TERMINATED | NCT00521820 |
| Pioglitazone | Other | Phase PHASE3 | Diabetes Mellitus | TERMINATED | NCT00521820 |
| Glyburide | Other | Phase PHASE3 | Diabetes Mellitus | TERMINATED | NCT00521820 |
| Pioglitazone | Other | Phase PHASE3 | Diabetes Mellitus | TERMINATED | NCT00521820 |
| Glyburide | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT00521742 |
| Pioglitazone | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT00521742 |
| Glyburide | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT00521742 |
| Pioglitazone | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT00521742 |
| Glyburide | Other | Phase PHASE4 | Diabetes Mellitus | COMPLETED | NCT00494312 |
| Pioglitazone | Other | Phase PHASE4 | Diabetes Mellitus | COMPLETED | NCT00494312 |
| Glyburide | Other | Phase PHASE4 | Diabetes Mellitus | COMPLETED | NCT00494312 |
| Pioglitazone | Other | Phase PHASE4 | Diabetes Mellitus | COMPLETED | NCT00494312 |
| Placebo | Other | Phase PHASE4 | Circadian Dysregulation | COMPLETED | NCT00492011 |
| Ramelteon | Other | Phase PHASE4 | Circadian Dysregulation | COMPLETED | NCT00492011 |
| Placebo | Other | Phase PHASE4 | Circadian Dysregulation | COMPLETED | NCT00492011 |
| Ramelteon | Other | Phase PHASE4 | Circadian Dysregulation | COMPLETED | NCT00492011 |
| Olmesartan medoxomil-hydrochlorothiazide | Other | Phase PHASE3 | Essential Hypertension | COMPLETED | NCT00846365 |
| Azilsartan medoxomil and chlorthalidone | Other | Phase PHASE3 | Essential Hypertension | COMPLETED | NCT00846365 |
| Ramelteon | Other | Phase PHASE1 | Insomnia | COMPLETED | NCT00914862 |
| Ramelteon | Other | Phase PHASE1 | Insomnia | COMPLETED | NCT00914862 |
| Dexlansoprazole | Other | Phase PHASE1 | Gastroesophageal Reflux | COMPLETED | NCT01045096 |
| Dexlansoprazole | Other | Phase PHASE1 | Gastroesophageal Reflux | COMPLETED | NCT01045096 |
| doxorubicin HCl liposome | Other | Phase PHASE2 | Multiple Myeloma | TERMINATED | NCT00366106 |
| dexamethasone | Other | Phase PHASE2 | Multiple Myeloma | TERMINATED | NCT00366106 |
| bortezomib | Other | Phase PHASE2 | Multiple Myeloma | TERMINATED | NCT00366106 |
| Pantoprazole | Other | Phase PHASE3 | GERD | COMPLETED | NCT00336219 |
| Pantoprazole | Other | Phase PHASE4 | Gastroesophageal Reflux Disease | COMPLETED | NCT00325676 |
| Pantoprazole | Other | Phase PHASE4 | Gastroesophageal Reflux Disease | COMPLETED | NCT00325676 |
| Pantoprazole | Other | Phase PHASE3 | Gastroesophageal Reflux Disease (GERD) | COMPLETED | NCT00312806 |
| Pantoprazole | Other | Phase PHASE3 | Gastroesophageal Reflux Disease (GERD) | COMPLETED | NCT00312806 |
| Pantoprazole | Other | Phase PHASE4 | Gastroesophageal Reflux | COMPLETED | NCT00261339 |
| Pantoprazole | Other | Phase PHASE4 | Gastroesophageal Reflux | COMPLETED | NCT00261339 |
| Pantoprazole | Other | Phase PHASE4 | Gastroesophageal Reflux | COMPLETED | NCT00261339 |
| Pantoprazole | Other | Phase PHASE3 | Gastroesophageal Reflux Disease (GERD) | COMPLETED | NCT00261300 |
| Pantoprazole | Other | Phase PHASE3 | Gastroesophageal Reflux Disease (GERD) | COMPLETED | NCT00261300 |
| Pantoprazole | Other | Phase PHASE3 | Gastroesophageal Reflux Disease (GERD) | COMPLETED | NCT00261300 |
| Pantoprazole | Other | Phase PHASE4 | Gastroesophageal Reflux | COMPLETED | NCT00246909 |
| Pantoprazole | Other | Phase PHASE4 | Gastroesophageal Reflux | COMPLETED | NCT00246909 |
| Pantoprazole | Other | Phase PHASE4 | Gastroesophageal Reflux | COMPLETED | NCT00246909 |
| Pantoprazole | Other | Phase PHASE3 | Gastroesophageal Reflux | COMPLETED | NCT00163306 |
| Venticute | Other | Phase PHASE3 | Pneumonia | COMPLETED | NCT00074906 |
| Venticute | Other | Phase PHASE3 | Pneumonia | COMPLETED | NCT00074906 |
| Pioglitazone-Azilsartan | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | TERMINATED | NCT01124656 |
| Pioglitazone-Azilsartan | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | TERMINATED | NCT01124656 |
| Alogliptin | Other | Phase PHASE2 | Diabetes Mellitus | TERMINATED | NCT00763347 |
| Placebo | Other | Phase PHASE2 | Diabetes Mellitus | TERMINATED | NCT00763347 |
| SYR-619 | Other | Phase PHASE2 | Diabetes Mellitus | TERMINATED | NCT00763347 |
| Pharmacogenomic whole blood sampling | Other | Preclinical | Toxicity | COMPLETED | NCT00890448 |
| Pharmacogenomic whole blood sampling | Other | Preclinical | Toxicity | COMPLETED | NCT00890448 |
| Lapaquistat acetate and additional lipid-lowering therapy | Drug | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00868127 |
| Lapaquistat acetate | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00868127 |
| Lapaquistat acetate and additional lipid-lowering therapy | Drug | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00868127 |
| Lapaquistat acetate | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00868127 |
| Lapaquistat acetate and additional lipid-lowering therapy | Drug | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00868127 |
| Lapaquistat acetate | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00868127 |
| Placebo | Other | Phase PHASE2 | Hypercholesterolemia | TERMINATED | NCT00865228 |
| Lapaquistat acetate | Other | Phase PHASE2 | Hypercholesterolemia | TERMINATED | NCT00865228 |
| Placebo | Other | Phase PHASE2 | Hypercholesterolemia | TERMINATED | NCT00865228 |
| Lapaquistat acetate | Other | Phase PHASE2 | Hypercholesterolemia | TERMINATED | NCT00865228 |
| Atorvastatin | Other | Phase PHASE2 | Hypercholesterolemia | COMPLETED | NCT00864643 |
| Lapaquistat acetate and atorvastatin | Other | Phase PHASE2 | Hypercholesterolemia | COMPLETED | NCT00864643 |
| Fenofibrate | Other | Phase PHASE2 | Hyperlipidemias | COMPLETED | NCT00813527 |
| Lapaquistat acetate and fenofibrate | Other | Phase PHASE2 | Hyperlipidemias | COMPLETED | NCT00813527 |
| Fenofibrate | Other | Phase PHASE2 | Hyperlipidemias | COMPLETED | NCT00813527 |
| Lapaquistat acetate and fenofibrate | Other | Phase PHASE2 | Hyperlipidemias | COMPLETED | NCT00813527 |
| Fenofibrate | Other | Phase PHASE2 | Hyperlipidemias | COMPLETED | NCT00813527 |
| Lapaquistat acetate and fenofibrate | Other | Phase PHASE2 | Hyperlipidemias | COMPLETED | NCT00813527 |
| Placebo | Other | Phase PHASE3 | Hypercholesterolemia | TERMINATED | NCT00532558 |
| Lapaquistat acetate | Other | Phase PHASE3 | Hypercholesterolemia | TERMINATED | NCT00532558 |
| Placebo | Other | Phase PHASE3 | Hypercholesterolemia | TERMINATED | NCT00532558 |
| Lapaquistat acetate | Other | Phase PHASE3 | Hypercholesterolemia | TERMINATED | NCT00532558 |
| Atorvastatin | Other | Phase PHASE3 | Dyslipidemia | COMPLETED | NCT00487994 |
| Lapaquistat acetate and atorvastatin | Other | Phase PHASE3 | Dyslipidemia | COMPLETED | NCT00487994 |
| Lapaquistat acetate | Other | Phase PHASE3 | Dyslipidemia | COMPLETED | NCT00487994 |
| Atorvastatin | Other | Phase PHASE3 | Dyslipidemia | COMPLETED | NCT00487994 |
| Lapaquistat acetate and atorvastatin | Other | Phase PHASE3 | Dyslipidemia | COMPLETED | NCT00487994 |
| Lapaquistat acetate | Other | Phase PHASE3 | Dyslipidemia | COMPLETED | NCT00487994 |
| Simvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00286481 |
| Lapaquistat acetate and simvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00286481 |
| Simvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00286481 |
| Lapaquistat acetate and simvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00286481 |
| Simvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00286481 |
| Lapaquistat acetate and simvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00286481 |
| Ezetimibe | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00268697 |
| Lapaquistat acetate and ezetimibe | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00268697 |
| Lapaquistat acetate | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00268697 |
| Ezetimibe | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00268697 |
| Lapaquistat acetate and ezetimibe | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00268697 |
| Lapaquistat acetate | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00268697 |
| Ezetimibe | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00268697 |
| Lapaquistat acetate and ezetimibe | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00268697 |
| Lapaquistat acetate | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00268697 |
| Current lipid-lowering treatment | Drug | Phase PHASE3 | Hypercholesterolemia | TERMINATED | NCT00263081 |
| Lapaquistat acetate and current lipid-lowering treatment | Drug | Phase PHASE3 | Hypercholesterolemia | TERMINATED | NCT00263081 |
| Current lipid-lowering treatment | Drug | Phase PHASE3 | Hypercholesterolemia | TERMINATED | NCT00263081 |
| Lapaquistat acetate and current lipid-lowering treatment | Drug | Phase PHASE3 | Hypercholesterolemia | TERMINATED | NCT00263081 |
| Current lipid-lowering treatment | Drug | Phase PHASE3 | Hypercholesterolemia | TERMINATED | NCT00263081 |
| Lapaquistat acetate and current lipid-lowering treatment | Drug | Phase PHASE3 | Hypercholesterolemia | TERMINATED | NCT00263081 |
| Simvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00256178 |
| Lapaquistat acetate and simvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00256178 |
| Simvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00256178 |
| Lapaquistat acetate and simvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00256178 |
| Lipid-lowering therapy | Drug | Phase PHASE3 | Type 2 Diabetes | COMPLETED | NCT00251680 |
| Lapaquistat acetate and lipid-lowering therapy | Drug | Phase PHASE3 | Type 2 Diabetes | COMPLETED | NCT00251680 |
| Rosuvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00249912 |
| Lapaquistat acetate and rosuvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00249912 |
| Rosuvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00249912 |
| Lapaquistat acetate and rosuvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00249912 |
| Rosuvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00249912 |
| Lapaquistat acetate and rosuvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00249912 |
| Stable statin therapy | Drug | Phase PHASE3 | Hypercholesterolemia | TERMINATED | NCT00249899 |
| Lapaquistat acetate and stable statin therapy | Drug | Phase PHASE3 | Hypercholesterolemia | TERMINATED | NCT00249899 |
| Stable statin therapy | Drug | Phase PHASE3 | Hypercholesterolemia | TERMINATED | NCT00249899 |
| Lapaquistat acetate and stable statin therapy | Drug | Phase PHASE3 | Hypercholesterolemia | TERMINATED | NCT00249899 |
| Atorvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00143676 |
| Lapaquistat acetate and atorvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00143676 |
| Atorvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00143676 |
| Lapaquistat acetate and atorvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00143676 |
| Atorvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00143676 |
| Lapaquistat acetate and atorvastatin | Other | Phase PHASE3 | Hypercholesterolemia | COMPLETED | NCT00143676 |
| Placebo | Other | Phase PHASE3 | Dyslipidemia | COMPLETED | NCT00143663 |
| Lapaquistat Acetate | Other | Phase PHASE3 | Dyslipidemia | COMPLETED | NCT00143663 |
| Placebo | Other | Phase PHASE3 | Dyslipidemia | COMPLETED | NCT00143663 |
| Lapaquistat Acetate | Other | Phase PHASE3 | Dyslipidemia | COMPLETED | NCT00143663 |
| Pioglitazone | Other | Phase PHASE4 | Type 2 Diabetes Mellitus | COMPLETED | NCT00816218 |
| Pioglitazone | Other | Phase PHASE4 | Type 2 Diabetes Mellitus | COMPLETED | NCT00816218 |
| lisdexamfetamine dimesylate | Other | Preclinical | Attention Deficit/Hyperactivity Disorder | COMPLETED | NCT01263548 |
| Phosphorus binder | Other | Phase PHASE3 | Chronic Kidney Disease | UNKNOWN | NCT01357317 |
| Diet counseling | Other | Phase PHASE3 | Chronic Kidney Disease | UNKNOWN | NCT01357317 |
| Magnesium Esomeprazole | Other | Phase PHASE3 | GERD | COMPLETED | NCT01132638 |
| Magnesium Pantoprazole | Other | Phase PHASE3 | GERD | COMPLETED | NCT01132638 |
| Epoetin Alfa | Other | Phase PHASE2 | Anemia | COMPLETED | NCT00680043 |
| peginesatide | Other | Phase PHASE2 | Anemia | COMPLETED | NCT00680043 |
| Epoetin Alfa | Other | Phase PHASE2 | Anemia | COMPLETED | NCT00680043 |
| peginesatide | Other | Phase PHASE2 | Anemia | COMPLETED | NCT00680043 |
| Mesna | Other | Phase PHASE1 | Hodgkin Lymphoma | COMPLETED | NCT00439361 |
| Ifosfamide | Other | Phase PHASE1 | Hodgkin Lymphoma | COMPLETED | NCT00439361 |
| Etoposide | Other | Phase PHASE1 | Hodgkin Lymphoma | COMPLETED | NCT00439361 |
| Carboplatin | Other | Phase PHASE1 | Hodgkin Lymphoma | COMPLETED | NCT00439361 |
| Bortezomib | Other | Phase PHASE1 | Hodgkin Lymphoma | COMPLETED | NCT00439361 |
| Mesna | Other | Phase PHASE1 | Hodgkin Lymphoma | COMPLETED | NCT00439361 |
| Ifosfamide | Other | Phase PHASE1 | Hodgkin Lymphoma | COMPLETED | NCT00439361 |
| Etoposide | Other | Phase PHASE1 | Hodgkin Lymphoma | COMPLETED | NCT00439361 |
| Carboplatin | Other | Phase PHASE1 | Hodgkin Lymphoma | COMPLETED | NCT00439361 |
| Bortezomib | Other | Phase PHASE1 | Hodgkin Lymphoma | COMPLETED | NCT00439361 |
| Mesna | Other | Phase PHASE1 | Hodgkin Lymphoma | COMPLETED | NCT00439361 |
| Ifosfamide | Other | Phase PHASE1 | Hodgkin Lymphoma | COMPLETED | NCT00439361 |
| Etoposide | Other | Phase PHASE1 | Hodgkin Lymphoma | COMPLETED | NCT00439361 |
| Carboplatin | Other | Phase PHASE1 | Hodgkin Lymphoma | COMPLETED | NCT00439361 |
| Bortezomib | Other | Phase PHASE1 | Hodgkin Lymphoma | COMPLETED | NCT00439361 |
| Peginesatide | Other | Phase PHASE2 | Anemia | COMPLETED | NCT00752609 |
| Peginesatide | Other | Phase PHASE2 | Anemia | COMPLETED | NCT00752609 |
| Carboplatin | Other | Phase PHASE1 | Ovarian Cancer | COMPLETED | NCT00059618 |
| PS-341 (Bortezomib) | Other | Phase PHASE1 | Ovarian Cancer | COMPLETED | NCT00059618 |
| Carboplatin | Other | Phase PHASE1 | Ovarian Cancer | COMPLETED | NCT00059618 |
| PS-341 (Bortezomib) | Other | Phase PHASE1 | Ovarian Cancer | COMPLETED | NCT00059618 |
| Fibrinogen (human) + thrombin (human) (TachoSil) | Other | Phase PHASE3 | Surgical Resection of Superficial Renal Tumour | COMPLETED | NCT00241163 |
| Fibrinogen (human) + thrombin (human) (TachoSil) | Other | Phase PHASE3 | Surgical Resection of Superficial Renal Tumour | COMPLETED | NCT00241163 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01456117 |
| Pioglitazone | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01456117 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01456117 |
| Pioglitazone | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01456117 |
| Hydrochlorothiazide (HCT) | Other | Phase PHASE4 | Obesity | COMPLETED | NCT00775814 |
| Candesartan and Hydrochlorothiazide | Other | Phase PHASE4 | Obesity | COMPLETED | NCT00775814 |
| Hydrochlorothiazide (HCT) | Other | Phase PHASE4 | Obesity | COMPLETED | NCT00775814 |
| Candesartan and Hydrochlorothiazide | Other | Phase PHASE4 | Obesity | COMPLETED | NCT00775814 |
| Peginesatide | Other | Phase PHASE2 | Anemia | COMPLETED | NCT00752791 |
| Peginesatide | Other | Phase PHASE2 | Anemia | COMPLETED | NCT00752791 |
| Alogliptin and metformin | Other | Phase PHASE2 | Type 2 Diabetes Mellitus | COMPLETED | NCT01318135 |
| Alogliptin and glimepiride | Other | Phase PHASE2 | Type 2 Diabetes Mellitus | COMPLETED | NCT01318135 |
| Alogliptin and metformin | Other | Phase PHASE2 | Type 2 Diabetes Mellitus | COMPLETED | NCT01318135 |
| Alogliptin and glimepiride | Other | Phase PHASE2 | Type 2 Diabetes Mellitus | COMPLETED | NCT01318135 |
| Risedronate | Other | Phase PHASE3 | Osteoporosis | COMPLETED | NCT00365456 |
| Parathyroid Hormone (PTH) | Other | Phase PHASE3 | Osteoporosis | COMPLETED | NCT00365456 |
| Risedronate | Other | Phase PHASE3 | Osteoporosis | COMPLETED | NCT00365456 |
| Parathyroid Hormone (PTH) | Other | Phase PHASE3 | Osteoporosis | COMPLETED | NCT00365456 |
| Vyvanse (lisdexamfetamine dimesylate), NRP104 | Other | Phase PHASE3 | Attention Deficit Hyperactivity Disorder | COMPLETED | NCT00337285 |
| Lansoprazole | Other | Phase PHASE4 | Gastroesophageal Reflux | COMPLETED | NCT01135368 |
| Lansoprazole | Other | Phase PHASE4 | Gastroesophageal Reflux | COMPLETED | NCT01135368 |
| Ciclesonide & Levocetirizine | Other | Phase PHASE4 | Allergic Rhinitis | COMPLETED | NCT01430260 |
| Levocetirizine | Other | Phase PHASE4 | Allergic Rhinitis | COMPLETED | NCT01430260 |
| Ciclesonide | Other | Phase PHASE4 | Allergic Rhinitis | COMPLETED | NCT01430260 |
| Ciclesonide & Levocetirizine | Other | Phase PHASE4 | Allergic Rhinitis | COMPLETED | NCT01430260 |
| Levocetirizine | Other | Phase PHASE4 | Allergic Rhinitis | COMPLETED | NCT01430260 |
| Ciclesonide | Other | Phase PHASE4 | Allergic Rhinitis | COMPLETED | NCT01430260 |
| Ciclesonide & Levocetirizine | Other | Phase PHASE4 | Allergic Rhinitis | COMPLETED | NCT01430260 |
| Levocetirizine | Other | Phase PHASE4 | Allergic Rhinitis | COMPLETED | NCT01430260 |
| Ciclesonide | Other | Phase PHASE4 | Allergic Rhinitis | COMPLETED | NCT01430260 |
| TAK-875 and Glimepiride | Other | Phase PHASE1 | Pharmacokinetics | COMPLETED | NCT01496443 |
| Placebo | Other | Phase PHASE4 | Schizophrenia | COMPLETED | NCT00595504 |
| Ramelteon | Other | Phase PHASE4 | Schizophrenia | COMPLETED | NCT00595504 |
| Placebo | Other | Phase PHASE3 | Gastric pH Control | WITHDRAWN | NCT01499693 |
| Magnesium Pantoprazole 40 mg | Other | Phase PHASE3 | Gastric pH Control | WITHDRAWN | NCT01499693 |
| Magnesium Pantoprazole 20 mg | Other | Phase PHASE3 | Gastric pH Control | WITHDRAWN | NCT01499693 |
| Placebo | Other | Phase PHASE3 | Gastric pH Control | WITHDRAWN | NCT01499693 |
| Magnesium Pantoprazole 40 mg | Other | Phase PHASE3 | Gastric pH Control | WITHDRAWN | NCT01499693 |
| Magnesium Pantoprazole 20 mg | Other | Phase PHASE3 | Gastric pH Control | WITHDRAWN | NCT01499693 |
| Placebo | Other | Phase PHASE4 | Shoulder Fractures | UNKNOWN | NCT01687374 |
| 1-84 parathyroid hormone | Other | Phase PHASE4 | Shoulder Fractures | UNKNOWN | NCT01687374 |
| Placebo | Other | Phase PHASE4 | Shoulder Fractures | UNKNOWN | NCT01687374 |
| 1-84 parathyroid hormone | Other | Phase PHASE4 | Shoulder Fractures | UNKNOWN | NCT01687374 |
| Placebo | Other | Phase PHASE4 | Shoulder Fractures | UNKNOWN | NCT01687374 |
| 1-84 parathyroid hormone | Other | Phase PHASE4 | Shoulder Fractures | UNKNOWN | NCT01687374 |
| Lisdexamfetamine | Other | Phase PHASE4 | Attention Deficit Hyperactivity Disorder (ADHD) | COMPLETED | NCT00753012 |
| Lisdexamfetamine | Other | Phase PHASE4 | Attention Deficit Hyperactivity Disorder (ADHD) | COMPLETED | NCT00753012 |
| Velcade (bortezomib), rituximab, ifosfamide, carboplatin, etoposide | Other | Phase PHASE1 | Non-Hodgkin's Lymphoma | TERMINATED | NCT01300793 |
| Velcade (bortezomib), rituximab, ifosfamide, carboplatin, etoposide | Other | Phase PHASE1 | Non-Hodgkin's Lymphoma | TERMINATED | NCT01300793 |
| Instanyl (Intranasal Fentanyl) | Other | Preclinical | Breakthrough Pain | COMPLETED | NCT00994760 |
| Instanyl (Intranasal Fentanyl) | Other | Preclinical | Breakthrough Pain | COMPLETED | NCT00994760 |
| Instanyl (Intranasal Fentanyl) | Other | Preclinical | Breakthrough Pain | COMPLETED | NCT00994760 |
| INFS (Intranasal Fentanyl Spray) | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01497288 |
| INFS (Intranasal Fentanyl Spray) | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01497288 |
| INFS (Intranasal Fentanyl Spray) | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01497288 |
| Colchicine | Other | Phase PHASE4 | Pharmacokinetics | COMPLETED | NCT01084278 |
| placebo | Other | Approved | Healthy | COMPLETED | NCT00595075 |
| Ramelteon | Other | Approved | Healthy | COMPLETED | NCT00595075 |
| Lansoprazole (Prevacid) | Other | Phase PHASE4 | Zollinger-Ellison Syndrome | COMPLETED | NCT00204373 |
| Lansoprazole (Prevacid) | Other | Phase PHASE4 | Zollinger-Ellison Syndrome | COMPLETED | NCT00204373 |
| Lansoprazole (Prevacid) | Other | Phase PHASE4 | Zollinger-Ellison Syndrome | COMPLETED | NCT00204373 |
| Lansoprazole (Prevacid) | Other | Phase PHASE4 | Zollinger-Ellison Syndrome | COMPLETED | NCT00204373 |
| placebo | Other | Approved | Bowel Preparation for Colonoscopy | COMPLETED | NCT00611442 |
| lubiprostone | Other | Approved | Bowel Preparation for Colonoscopy | COMPLETED | NCT00611442 |
| placebo | Other | Approved | Bowel Preparation for Colonoscopy | COMPLETED | NCT00611442 |
| lubiprostone | Other | Approved | Bowel Preparation for Colonoscopy | COMPLETED | NCT00611442 |
| placebo | Other | Approved | Bowel Preparation for Colonoscopy | COMPLETED | NCT00611442 |
| lubiprostone | Other | Approved | Bowel Preparation for Colonoscopy | COMPLETED | NCT00611442 |
| Placebo Control | Other | Phase PHASE3 | Gout | COMPLETED | NCT00506883 |
| Low Dose Colchicine (1.8mg total dose) | Other | Phase PHASE3 | Gout | COMPLETED | NCT00506883 |
| High Dose Colchicine (4.8 mg total dose) | Other | Phase PHASE3 | Gout | COMPLETED | NCT00506883 |
| Placebo Control | Other | Phase PHASE3 | Gout | COMPLETED | NCT00506883 |
| Low Dose Colchicine (1.8mg total dose) | Other | Phase PHASE3 | Gout | COMPLETED | NCT00506883 |
| High Dose Colchicine (4.8 mg total dose) | Other | Phase PHASE3 | Gout | COMPLETED | NCT00506883 |
| Placebo | Other | Phase PHASE3 | Bipolar Disorder | WITHDRAWN | NCT01685151 |
| Ramelteon SL (Dose 2) | Other | Phase PHASE3 | Bipolar Disorder | WITHDRAWN | NCT01685151 |
| Ramelteon SL (Dose 1) | Other | Phase PHASE3 | Bipolar Disorder | WITHDRAWN | NCT01685151 |
| Placebo | Other | Phase PHASE3 | Bipolar Disorder | WITHDRAWN | NCT01685151 |
| Ramelteon SL (Dose 2) | Other | Phase PHASE3 | Bipolar Disorder | WITHDRAWN | NCT01685151 |
| Ramelteon SL (Dose 1) | Other | Phase PHASE3 | Bipolar Disorder | WITHDRAWN | NCT01685151 |
| Darbepoetin alfa | Other | Phase PHASE3 | Chronic Renal Failure | COMPLETED | NCT00598442 |
| peginesatide | Other | Phase PHASE3 | Chronic Renal Failure | COMPLETED | NCT00598442 |
| Darbepoetin alfa | Other | Phase PHASE3 | Chronic Renal Failure | COMPLETED | NCT00598442 |
| peginesatide | Other | Phase PHASE3 | Chronic Renal Failure | COMPLETED | NCT00598442 |
| Darbepoetin alfa | Other | Phase PHASE3 | Chronic Renal Failure | COMPLETED | NCT00598442 |
| peginesatide | Other | Phase PHASE3 | Chronic Renal Failure | COMPLETED | NCT00598442 |
| Darbepoetin alfa | Other | Phase PHASE3 | Chronic Renal Failure | COMPLETED | NCT00598273 |
| peginesatide | Other | Phase PHASE3 | Chronic Renal Failure | COMPLETED | NCT00598273 |
| Darbepoetin alfa | Other | Phase PHASE3 | Chronic Renal Failure | COMPLETED | NCT00598273 |
| peginesatide | Other | Phase PHASE3 | Chronic Renal Failure | COMPLETED | NCT00598273 |
| Darbepoetin alfa | Other | Phase PHASE3 | Chronic Renal Failure | COMPLETED | NCT00598273 |
| peginesatide | Other | Phase PHASE3 | Chronic Renal Failure | COMPLETED | NCT00598273 |
| placebo | Other | Phase PHASE4 | Diabetes Type 2 | COMPLETED | NCT01799850 |
| Pioglitazone | Other | Phase PHASE4 | Diabetes Type 2 | COMPLETED | NCT01799850 |
| placebo | Other | Phase PHASE4 | Diabetes Type 2 | COMPLETED | NCT01799850 |
| Pioglitazone | Other | Phase PHASE4 | Diabetes Type 2 | COMPLETED | NCT01799850 |
| placebo | Other | Phase PHASE4 | Diabetes Type 2 | COMPLETED | NCT01799850 |
| Pioglitazone | Other | Phase PHASE4 | Diabetes Type 2 | COMPLETED | NCT01799850 |
| Senna | Other | Approved | Constipation | COMPLETED | NCT00662363 |
| Lubiprostone | Other | Approved | Constipation | COMPLETED | NCT00662363 |
| Senna | Other | Approved | Constipation | COMPLETED | NCT00662363 |
| Lubiprostone | Other | Approved | Constipation | COMPLETED | NCT00662363 |
| TAK-875 | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT01433419 |
| Alogliptin | Other | Phase PHASE1 | Pharmacokinetics and Pharmacodynamics | COMPLETED | NCT01391663 |
| Alogliptin | Other | Phase PHASE1 | Pharmacokinetics and Pharmacodynamics | COMPLETED | NCT01391663 |
| Placebo | Other | Phase PHASE3 | Non-erosive Gastroesophageal Reflux Disease | COMPLETED | NCT01474369 |
| TAK-438 | Other | Phase PHASE3 | Non-erosive Gastroesophageal Reflux Disease | COMPLETED | NCT01474369 |
| Placebo | Other | Phase PHASE3 | Non-erosive Gastroesophageal Reflux Disease | COMPLETED | NCT01474369 |
| TAK-438 | Other | Phase PHASE3 | Non-erosive Gastroesophageal Reflux Disease | COMPLETED | NCT01474369 |
| Placebo | Other | Phase PHASE3 | Non-erosive Gastroesophageal Reflux Disease | COMPLETED | NCT01474369 |
| TAK-438 | Other | Phase PHASE3 | Non-erosive Gastroesophageal Reflux Disease | COMPLETED | NCT01474369 |
| MLN4924 | Other | Phase PHASE1 | Advanced Nonhematologic Malignancies | COMPLETED | NCT00677170 |
| Clarithromycin | Other | Phase PHASE3 | H. Pylori Infection | COMPLETED | NCT01505127 |
| Amoxicillin | Other | Phase PHASE3 | H. Pylori Infection | COMPLETED | NCT01505127 |
| Lansoprazole | Other | Phase PHASE3 | H. Pylori Infection | COMPLETED | NCT01505127 |
| TAK-438 | Other | Phase PHASE3 | H. Pylori Infection | COMPLETED | NCT01505127 |
| TAK-438 | Other | Phase PHASE3 | Erosive Esophagitis | COMPLETED | NCT01452776 |
| TAK-875 | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT01433406 |
| TAK-875 | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT01433406 |
| PS-341 (bortezomib) | Other | Phase PHASE2 | Prostate Neoplasms | COMPLETED | NCT00425503 |
| Lansoprazole | Other | Phase PHASE3 | Gastric Ulcers | COMPLETED | NCT01456260 |
| Placebo | Other | Phase PHASE3 | Gastric Ulcers | COMPLETED | NCT01456260 |
| TAK-438 | Other | Phase PHASE3 | Gastric Ulcers | COMPLETED | NCT01456260 |
| Lansoprazole | Other | Phase PHASE3 | Gastric Ulcers | COMPLETED | NCT01456260 |
| Placebo | Other | Phase PHASE3 | Gastric Ulcers | COMPLETED | NCT01456260 |
| TAK-438 | Other | Phase PHASE3 | Gastric Ulcers | COMPLETED | NCT01456260 |
| Lansoprazole | Other | Phase PHASE3 | Gastric Ulcers | COMPLETED | NCT01456260 |
| Placebo | Other | Phase PHASE3 | Gastric Ulcers | COMPLETED | NCT01456260 |
| TAK-438 | Other | Phase PHASE3 | Gastric Ulcers | COMPLETED | NCT01456260 |
| Lansoprazole | Other | Phase PHASE3 | Gastric Ulcers | COMPLETED | NCT01456247 |
| Placebo | Other | Phase PHASE3 | Gastric Ulcers | COMPLETED | NCT01456247 |
| TAK-438 | Other | Phase PHASE3 | Gastric Ulcers | COMPLETED | NCT01456247 |
| Lansoprazole | Other | Phase PHASE3 | Gastric Ulcers | COMPLETED | NCT01456247 |
| Placebo | Other | Phase PHASE3 | Gastric Ulcers | COMPLETED | NCT01456247 |
| TAK-438 | Other | Phase PHASE3 | Gastric Ulcers | COMPLETED | NCT01456247 |
| Leuprorelin acetate | Other | Phase PHASE2 | Endometriosis | COMPLETED | NCT01452685 |
| TAK-385 | Other | Phase PHASE2 | Endometriosis | COMPLETED | NCT01452685 |
| Placebo | Other | Phase PHASE2 | Endometriosis | COMPLETED | NCT01452685 |
| Leuprorelin acetate | Other | Phase PHASE2 | Endometriosis | COMPLETED | NCT01452685 |
| TAK-385 | Other | Phase PHASE2 | Endometriosis | COMPLETED | NCT01452685 |
| Placebo | Other | Phase PHASE2 | Endometriosis | COMPLETED | NCT01452685 |
| Leuprorelin acetate | Other | Preclinical | Prostate Cancer | COMPLETED | NCT02167893 |
| Leuprorelin acetate | Other | Preclinical | Prostate Cancer | COMPLETED | NCT02167893 |
| pioglitazone | Other | Phase PHASE4 | Type 2 Diabetes | COMPLETED | NCT01588470 |
| TAK-536 | Other | Phase PHASE1 | Japanese Healthy Adult Male Participants | COMPLETED | NCT03042299 |
| Placebo | Other | Phase PHASE3 | Myelodysplastic Syndromes | RECRUITING | NCT06499285 |
| Elritercept | Other | Phase PHASE3 | Myelodysplastic Syndromes | RECRUITING | NCT06499285 |
| Placebo | Other | Phase PHASE3 | Alpha1-Antitrypsin Deficiency | RECRUITING | NCT05677971 |
| Fazirsiran Injection | Other | Phase PHASE3 | Alpha1-Antitrypsin Deficiency | RECRUITING | NCT05677971 |
| Vedolizumab | Other | Phase PHASE2 | Ulcerative Colitis | COMPLETED | NCT03196427 |
| No Intervention | Other | Preclinical | Thrombotic Thrombocytopenic Purpura (TTP) | NOT_YET_RECRUITING | NCT07353099 |
| Vedolizumab SC | Other | Phase PHASE4 | Ulcerative Colitis | RECRUITING | NCT06581328 |
| Vedolizumab IV | Other | Phase PHASE4 | Ulcerative Colitis | RECRUITING | NCT06581328 |
| Placebo | Other | Phase PHASE2 | Nonsegmental Vitiligo | RECRUITING | NCT07108283 |
| Zasocitinib | Other | Phase PHASE2 | Nonsegmental Vitiligo | RECRUITING | NCT07108283 |
| Placebo | Other | Phase PHASE3 | Kidney Disease | RECRUITING | NCT06963827 |
| Mezagitamab | Other | Phase PHASE3 | Kidney Disease | RECRUITING | NCT06963827 |
| Placebo | Other | Phase PHASE3 | Myelodysplastic Syndromes | RECRUITING | NCT06499285 |
| Elritercept | Other | Phase PHASE3 | Myelodysplastic Syndromes | RECRUITING | NCT06499285 |
| Placebo | Other | Phase PHASE3 | Alpha1-Antitrypsin Deficiency | RECRUITING | NCT05677971 |
| Fazirsiran Injection | Other | Phase PHASE3 | Alpha1-Antitrypsin Deficiency | RECRUITING | NCT05677971 |
| Vedolizumab | Other | Phase PHASE2 | Ulcerative Colitis | COMPLETED | NCT03196427 |
| No Intervention | Other | Preclinical | Thrombotic Thrombocytopenic Purpura (TTP) | NOT_YET_RECRUITING | NCT07353099 |
| Vedolizumab SC | Other | Phase PHASE4 | Ulcerative Colitis | RECRUITING | NCT06581328 |
| Vedolizumab IV | Other | Phase PHASE4 | Ulcerative Colitis | RECRUITING | NCT06581328 |
| Placebo | Other | Phase PHASE2 | Nonsegmental Vitiligo | RECRUITING | NCT07108283 |
| Zasocitinib | Other | Phase PHASE2 | Nonsegmental Vitiligo | RECRUITING | NCT07108283 |
| Placebo | Other | Phase PHASE3 | Kidney Disease | RECRUITING | NCT06963827 |
| Mezagitamab | Other | Phase PHASE3 | Kidney Disease | RECRUITING | NCT06963827 |
| Lansoprazole | Other | Phase PHASE3 | Erosive Esophagitis | COMPLETED | NCT01452698 |
| Placebo | Other | Phase PHASE3 | Erosive Esophagitis | COMPLETED | NCT01452698 |
| TAK-438 | Other | Phase PHASE3 | Erosive Esophagitis | COMPLETED | NCT01452698 |
| Lansoprazole | Other | Phase PHASE3 | Erosive Esophagitis | COMPLETED | NCT01452698 |
| Placebo | Other | Phase PHASE3 | Erosive Esophagitis | COMPLETED | NCT01452698 |
| TAK-438 | Other | Phase PHASE3 | Erosive Esophagitis | COMPLETED | NCT01452698 |
| Placebo | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT01433393 |
| TAK-875 | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT01433393 |
| Placebo | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT01433393 |
| TAK-875 | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT01433393 |
| Placebo | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT01433393 |
| TAK-875 | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT01433393 |
| Olmesartan medoxomil and hydrochlorothiazide | Other | Phase PHASE3 | Essential Hypertension | COMPLETED | NCT00996281 |
| Azilsartan medoxomil and chlorthalidone | Other | Phase PHASE3 | Essential Hypertension | COMPLETED | NCT00996281 |
| Placebo | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT00763022 |
| TAK-559 | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT00763022 |
| Placebo | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT00763022 |
| TAK-559 | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT00763022 |
| Placebo | Other | Phase PHASE3 | Diabetes Mellitus | TERMINATED | NCT00762684 |
| TAK-559 | Other | Phase PHASE3 | Diabetes Mellitus | TERMINATED | NCT00762684 |
| Placebo | Other | Phase PHASE3 | Diabetes Mellitus | TERMINATED | NCT00762684 |
| TAK-559 | Other | Phase PHASE3 | Diabetes Mellitus | TERMINATED | NCT00762684 |
| Insulin | Other | Phase PHASE3 | Diabetes Mellitus | TERMINATED | NCT00762190 |
| TAK-559 and insulin | Other | Phase PHASE3 | Diabetes Mellitus | TERMINATED | NCT00762190 |
| TAK-559 | Other | Phase PHASE3 | Diabetes Mellitus | TERMINATED | NCT00762112 |
| TAK-559 | Other | Phase PHASE3 | Diabetes Mellitus | TERMINATED | NCT00762112 |
| Placebo | Other | Phase PHASE3 | Chronic Insomnia | COMPLETED | NCT00671125 |
| Ramelteon | Other | Phase PHASE3 | Chronic Insomnia | COMPLETED | NCT00671125 |
| Ramipril | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00760214 |
| Azilsartan medoxomil | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00760214 |
| Ramipril | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00760214 |
| Azilsartan medoxomil | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00760214 |
| Placebo | Other | Phase PHASE3 | Chronic Insomnia | COMPLETED | NCT00671567 |
| Ramelteon | Other | Phase PHASE3 | Chronic Insomnia | COMPLETED | NCT00671567 |
| Placebo | Other | Phase PHASE3 | Chronic Insomnia | COMPLETED | NCT00671567 |
| Ramelteon | Other | Phase PHASE3 | Chronic Insomnia | COMPLETED | NCT00671567 |
| aspirin and/or clopidogrel | Other | Phase PHASE4 | Early Gastric Cancer | UNKNOWN | NCT01621451 |
| Radiation therapy | Drug | Phase PHASE2 | Non-Hodgkin's Lymphoma | TERMINATED | NCT00361621 |
| Prednisone | Other | Phase PHASE2 | Non-Hodgkin's Lymphoma | TERMINATED | NCT00361621 |
| Vincristine | Other | Phase PHASE2 | Non-Hodgkin's Lymphoma | TERMINATED | NCT00361621 |
| Doxorubicin | Other | Phase PHASE2 | Non-Hodgkin's Lymphoma | TERMINATED | NCT00361621 |
| Cyclophosphamide | Other | Phase PHASE2 | Non-Hodgkin's Lymphoma | TERMINATED | NCT00361621 |
| Rituximab | Other | Phase PHASE2 | Non-Hodgkin's Lymphoma | TERMINATED | NCT00361621 |
| bortezomib | Other | Phase PHASE2 | Non-Hodgkin's Lymphoma | TERMINATED | NCT00361621 |
| Radiation therapy | Drug | Phase PHASE2 | Non-Hodgkin's Lymphoma | TERMINATED | NCT00361621 |
| Prednisone | Other | Phase PHASE2 | Non-Hodgkin's Lymphoma | TERMINATED | NCT00361621 |
| Vincristine | Other | Phase PHASE2 | Non-Hodgkin's Lymphoma | TERMINATED | NCT00361621 |
| Doxorubicin | Other | Phase PHASE2 | Non-Hodgkin's Lymphoma | TERMINATED | NCT00361621 |
| Cyclophosphamide | Other | Phase PHASE2 | Non-Hodgkin's Lymphoma | TERMINATED | NCT00361621 |
| Rituximab | Other | Phase PHASE2 | Non-Hodgkin's Lymphoma | TERMINATED | NCT00361621 |
| bortezomib | Other | Phase PHASE2 | Non-Hodgkin's Lymphoma | TERMINATED | NCT00361621 |
| Placebo | Other | Phase PHASE3 | Sepsis | TERMINATED | NCT00633477 |
| Resatorvid | Other | Phase PHASE3 | Sepsis | TERMINATED | NCT00633477 |
| Placebo | Other | Phase PHASE3 | Sepsis | TERMINATED | NCT00633477 |
| Resatorvid | Other | Phase PHASE3 | Sepsis | TERMINATED | NCT00633477 |
| 24 hour pH testing | Other | Approved | Gastroesophageal Reflux | TERMINATED | NCT00523367 |
| 24 hour pH testing | Other | Approved | Gastroesophageal Reflux | TERMINATED | NCT00523367 |
| 24 hour pH testing | Other | Approved | Gastroesophageal Reflux | TERMINATED | NCT00523367 |
| Placebo | Other | Phase PHASE2 | Uterine Fibroids | COMPLETED | NCT01452659 |
| TAK-385 | Other | Phase PHASE2 | Uterine Fibroids | COMPLETED | NCT01452659 |
| Epoetin Alfa | Other | Phase PHASE3 | Chronic Renal Failure | COMPLETED | NCT00597753 |
| peginesatide | Other | Phase PHASE3 | Chronic Renal Failure | COMPLETED | NCT00597753 |
| Placebo | Other | Phase PHASE2 | Hyperuricosuria | COMPLETED | NCT01077284 |
| Allopurinol | Other | Phase PHASE2 | Hyperuricosuria | COMPLETED | NCT01077284 |
| Febuxostat | Other | Phase PHASE2 | Hyperuricosuria | COMPLETED | NCT01077284 |
| ActHIB+ DPT-TAKEDA | Other | Phase PHASE3 | Immunization | COMPLETED | NCT01379846 |
| TAK-816+ DPT-TAKEDA | Other | Phase PHASE3 | Immunization | COMPLETED | NCT01379846 |
| ActHIB+ DPT-TAKEDA | Other | Phase PHASE3 | Immunization | COMPLETED | NCT01379846 |
| TAK-816+ DPT-TAKEDA | Other | Phase PHASE3 | Immunization | COMPLETED | NCT01379846 |
| Epoetin alfa or Epoetin beta | Other | Phase PHASE3 | Chronic Renal Failure | COMPLETED | NCT00597584 |
| peginesatide | Other | Phase PHASE3 | Chronic Renal Failure | COMPLETED | NCT00597584 |
| Epoetin alfa or Epoetin beta | Other | Phase PHASE3 | Chronic Renal Failure | COMPLETED | NCT00597584 |
| peginesatide | Other | Phase PHASE3 | Chronic Renal Failure | COMPLETED | NCT00597584 |
| Pioglitazone | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01289119 |
| Metformin | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01289119 |
| Placebo to alogliptin | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01289119 |
| Alogliptin | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01289119 |
| Pioglitazone | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01289119 |
| Metformin | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01289119 |
| Placebo to alogliptin | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01289119 |
| Alogliptin | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01289119 |
| Alogliptin | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT00306384 |
| Alogliptin | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT00306384 |
| Metformin Placebo | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01023581 |
| Alogliptin Placebo | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01023581 |
| Metformin | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01023581 |
| Alogliptin | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01023581 |
| Metformin Placebo | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01023581 |
| Alogliptin Placebo | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01023581 |
| Metformin | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01023581 |
| Alogliptin | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01023581 |
| Placebo | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT00395512 |
| Pioglitazone | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT00395512 |
| Alogliptin | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT00395512 |
| Placebo | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT00432276 |
| Metformin | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT00432276 |
| Pioglitazone | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT00432276 |
| Alogliptin | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT00432276 |
| Placebo | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT00432276 |
| Metformin | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT00432276 |
| Pioglitazone | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT00432276 |
| Alogliptin | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT00432276 |
| Pioglitazone placebo | Other | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT00328627 |
| Pioglitazone | Other | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT00328627 |
| Alogliptin placebo | Other | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT00328627 |
| Alogliptin | Other | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT00328627 |
| Placebo | Other | Phase PHASE3 | Diabetic Patients | COMPLETED | NCT01585792 |
| Glimepiride | Other | Phase PHASE3 | Diabetic Patients | COMPLETED | NCT01585792 |
| TAK-875 | Other | Phase PHASE3 | Diabetic Patients | COMPLETED | NCT01585792 |
| Placebo | Other | Phase PHASE3 | Diabetic Patients | COMPLETED | NCT01585792 |
| Glimepiride | Other | Phase PHASE3 | Diabetic Patients | COMPLETED | NCT01585792 |
| TAK-875 | Other | Phase PHASE3 | Diabetic Patients | COMPLETED | NCT01585792 |
| prednisone | Other | Phase PHASE2 | Relapsed Follicular Lymphoma | COMPLETED | NCT00715208 |
| VELCADE | Other | Phase PHASE2 | Relapsed Follicular Lymphoma | COMPLETED | NCT00715208 |
| doxorubicin | Other | Phase PHASE2 | Relapsed Follicular Lymphoma | COMPLETED | NCT00715208 |
| cyclophosphamide | Other | Phase PHASE2 | Relapsed Follicular Lymphoma | COMPLETED | NCT00715208 |
| rituximab | Other | Phase PHASE2 | Relapsed Follicular Lymphoma | COMPLETED | NCT00715208 |
| prednisone | Other | Phase PHASE2 | Relapsed Follicular Lymphoma | COMPLETED | NCT00715208 |
| VELCADE | Other | Phase PHASE2 | Relapsed Follicular Lymphoma | COMPLETED | NCT00715208 |
| doxorubicin | Other | Phase PHASE2 | Relapsed Follicular Lymphoma | COMPLETED | NCT00715208 |
| cyclophosphamide | Other | Phase PHASE2 | Relapsed Follicular Lymphoma | COMPLETED | NCT00715208 |
| rituximab | Other | Phase PHASE2 | Relapsed Follicular Lymphoma | COMPLETED | NCT00715208 |
| prednisone | Other | Phase PHASE2 | Relapsed Follicular Lymphoma | COMPLETED | NCT00715208 |
| VELCADE | Other | Phase PHASE2 | Relapsed Follicular Lymphoma | COMPLETED | NCT00715208 |
| doxorubicin | Other | Phase PHASE2 | Relapsed Follicular Lymphoma | COMPLETED | NCT00715208 |
| cyclophosphamide | Other | Phase PHASE2 | Relapsed Follicular Lymphoma | COMPLETED | NCT00715208 |
| rituximab | Other | Phase PHASE2 | Relapsed Follicular Lymphoma | COMPLETED | NCT00715208 |
| Placebo | Other | Phase PHASE3 | Insomnia | TERMINATED | NCT00585208 |
| Ramelteon | Other | Phase PHASE3 | Insomnia | TERMINATED | NCT00585208 |
| Placebo | Other | Phase PHASE3 | Insomnia | TERMINATED | NCT00585208 |
| Ramelteon | Other | Phase PHASE3 | Insomnia | TERMINATED | NCT00585208 |
| Glipizide | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT00707993 |
| Alogliptin | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT00707993 |
| Glipizide | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT00707993 |
| Alogliptin | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT00707993 |
| Placebo | Other | Phase PHASE4 | ADHD With Sleep Onset Insomnia | COMPLETED | NCT00622427 |
| Ramelteon | Other | Phase PHASE4 | ADHD With Sleep Onset Insomnia | COMPLETED | NCT00622427 |
| Placebo | Other | Phase PHASE4 | ADHD With Sleep Onset Insomnia | COMPLETED | NCT00622427 |
| Ramelteon | Other | Phase PHASE4 | ADHD With Sleep Onset Insomnia | COMPLETED | NCT00622427 |
| Placebo | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT00655863 |
| Alogliptin | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT00655863 |
| Alogliptin and Pioglitazone | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT00655863 |
| colchicine | Other | Phase PHASE4 | Healthy | COMPLETED | NCT01601132 |
| theophylline | Other | Phase PHASE4 | Healthy | COMPLETED | NCT01601132 |
| colchicine | Other | Phase PHASE4 | Healthy | COMPLETED | NCT01601132 |
| theophylline | Other | Phase PHASE4 | Healthy | COMPLETED | NCT01601132 |
| Lansoprazole | Other | Phase PHASE3 | Gastric Ulcer | COMPLETED | NCT01452711 |
| Placebo | Other | Phase PHASE3 | Gastric Ulcer | COMPLETED | NCT01452711 |
| TAK-438 | Other | Phase PHASE3 | Gastric Ulcer | COMPLETED | NCT01452711 |
| Lansoprazole | Other | Phase PHASE3 | Gastric Ulcer | COMPLETED | NCT01452711 |
| Placebo | Other | Phase PHASE3 | Gastric Ulcer | COMPLETED | NCT01452711 |
| TAK-438 | Other | Phase PHASE3 | Gastric Ulcer | COMPLETED | NCT01452711 |
| TAK-441 | Other | Phase PHASE1 | Advanced Nonhematologic Malignancies | COMPLETED | NCT01204073 |
| TAK-441 | Other | Phase PHASE1 | Advanced Nonhematologic Malignancies | COMPLETED | NCT01204073 |
| TAK-733 | Other | Phase PHASE1 | Advanced Non-hematologic Malignancies | COMPLETED | NCT00948467 |
| TAK-733 | Other | Phase PHASE1 | Advanced Non-hematologic Malignancies | COMPLETED | NCT00948467 |
| TAK-901 | Other | Phase PHASE1 | Acute Myeloid Leukemia | COMPLETED | NCT00807677 |
| TAK-901 | Other | Phase PHASE1 | Acute Myeloid Leukemia | COMPLETED | NCT00807677 |
| MLN4924 | Other | Phase PHASE1 | Metastatic Melanoma | COMPLETED | NCT01011530 |
| MLN4924 | Other | Phase PHASE1 | Metastatic Melanoma | COMPLETED | NCT01011530 |
| Lubiprostone | Other | Phase PHASE1 | Other Constipation | COMPLETED | NCT00934479 |
| Lubiprostone | Other | Phase PHASE1 | Other Constipation | COMPLETED | NCT00934479 |
| Lubiprostone | Other | Phase PHASE1 | Other Constipation | COMPLETED | NCT00934479 |
| blood stem cell transplantation | Other | Phase PHASE1 | Hematologic Malignancies | COMPLETED | NCT00369226 |
| Methotrexate | Other | Phase PHASE1 | Hematologic Malignancies | COMPLETED | NCT00369226 |
| Tacrolimus | Other | Phase PHASE1 | Hematologic Malignancies | COMPLETED | NCT00369226 |
| Bortezomib (Velcade) | Other | Phase PHASE1 | Hematologic Malignancies | COMPLETED | NCT00369226 |
| blood stem cell transplantation | Other | Phase PHASE1 | Hematologic Malignancies | COMPLETED | NCT00369226 |
| Methotrexate | Other | Phase PHASE1 | Hematologic Malignancies | COMPLETED | NCT00369226 |
| Tacrolimus | Other | Phase PHASE1 | Hematologic Malignancies | COMPLETED | NCT00369226 |
| Bortezomib (Velcade) | Other | Phase PHASE1 | Hematologic Malignancies | COMPLETED | NCT00369226 |
| blood stem cell transplantation | Other | Phase PHASE1 | Hematologic Malignancies | COMPLETED | NCT00369226 |
| Methotrexate | Other | Phase PHASE1 | Hematologic Malignancies | COMPLETED | NCT00369226 |
| Tacrolimus | Other | Phase PHASE1 | Hematologic Malignancies | COMPLETED | NCT00369226 |
| Bortezomib (Velcade) | Other | Phase PHASE1 | Hematologic Malignancies | COMPLETED | NCT00369226 |
| MLN0128 | Other | Phase PHASE1 | Relapsed Multiple Myeloma | COMPLETED | NCT01118689 |
| MLN0128 | Other | Phase PHASE1 | Relapsed Multiple Myeloma | COMPLETED | NCT01118689 |
| Magnetic resonance spectroscopy | Other | Preclinical | Lipid Metabolism | COMPLETED | NCT01921075 |
| normal dietary behavior | Other | Preclinical | Lipid Metabolism | COMPLETED | NCT01921075 |
| Magnetic resonance spectroscopy | Other | Preclinical | Lipid Metabolism | COMPLETED | NCT01921075 |
| normal dietary behavior | Other | Preclinical | Lipid Metabolism | COMPLETED | NCT01921075 |
| Magnetic resonance spectroscopy | Other | Preclinical | Lipid Metabolism | COMPLETED | NCT01921075 |
| normal dietary behavior | Other | Preclinical | Lipid Metabolism | COMPLETED | NCT01921075 |
| Lansoprazole | Other | Phase PHASE3 | Duodenal Ulcer | COMPLETED | NCT01452724 |
| Placebo | Other | Phase PHASE3 | Duodenal Ulcer | COMPLETED | NCT01452724 |
| TAK-438 | Other | Phase PHASE3 | Duodenal Ulcer | COMPLETED | NCT01452724 |
| Lansoprazole | Other | Phase PHASE3 | Erosive Esophagitis | COMPLETED | NCT01459367 |
| TAK-438 | Other | Phase PHASE3 | Erosive Esophagitis | COMPLETED | NCT01459367 |
| Lansoprazole | Other | Phase PHASE3 | Erosive Esophagitis | COMPLETED | NCT01459367 |
| TAK-438 | Other | Phase PHASE3 | Erosive Esophagitis | COMPLETED | NCT01459367 |
| MLN8054 | Other | Phase PHASE1 | Advanced Malignancies | TERMINATED | NCT00652158 |
| MLN8054 | Other | Phase PHASE1 | Advanced Malignancies | TERMINATED | NCT00652158 |
| MLN8054 | Other | Phase PHASE1 | Advanced Malignancies | TERMINATED | NCT00652158 |
| Placebo | Other | Phase PHASE2 | Renal Impairment | COMPLETED | NCT01082640 |
| Febuxostat | Other | Phase PHASE2 | Renal Impairment | COMPLETED | NCT01082640 |
| Placebo | Other | Phase PHASE2 | Renal Impairment | COMPLETED | NCT01082640 |
| Febuxostat | Other | Phase PHASE2 | Renal Impairment | COMPLETED | NCT01082640 |
| Low calcium meals | Other | Phase PHASE1 | Calcium Deficiency | COMPLETED | NCT01639222 |
| Calcium 500 mg and Vitamin D3 800 IU | Other | Phase PHASE1 | Calcium Deficiency | COMPLETED | NCT01639222 |
| Low calcium meals | Other | Phase PHASE1 | Calcium Deficiency | COMPLETED | NCT01639222 |
| Calcium 500 mg and Vitamin D3 800 IU | Other | Phase PHASE1 | Calcium Deficiency | COMPLETED | NCT01639222 |
| Placebo | Other | Phase PHASE1 | Erectile Dysfunction | COMPLETED | NCT01967264 |
| Udenafil | Other | Phase PHASE1 | Erectile Dysfunction | COMPLETED | NCT01967264 |
| Placebo | Other | Phase PHASE1 | Erectile Dysfunction | COMPLETED | NCT01967264 |
| Udenafil | Other | Phase PHASE1 | Erectile Dysfunction | COMPLETED | NCT01967264 |
| Placebo | Other | Phase PHASE2 | Type 2 Diabetes | COMPLETED | NCT00443755 |
| pioglitazone | Other | Phase PHASE2 | Type 2 Diabetes | COMPLETED | NCT00443755 |
| metformin | Other | Phase PHASE2 | Type 2 Diabetes | COMPLETED | NCT00443755 |
| Placebo | Other | Phase PHASE2 | Type 2 Diabetes | COMPLETED | NCT00443755 |
| pioglitazone | Other | Phase PHASE2 | Type 2 Diabetes | COMPLETED | NCT00443755 |
| metformin | Other | Phase PHASE2 | Type 2 Diabetes | COMPLETED | NCT00443755 |
| Placebo | Other | Phase PHASE2 | Type 2 Diabetes | COMPLETED | NCT00443755 |
| pioglitazone | Other | Phase PHASE2 | Type 2 Diabetes | COMPLETED | NCT00443755 |
| metformin | Other | Phase PHASE2 | Type 2 Diabetes | COMPLETED | NCT00443755 |
| TAK-733 and alisertib | Other | Phase PHASE1 | Advanced Nonhematologic Malignancies | WITHDRAWN | NCT01613261 |
| TAK-438 | Other | Phase PHASE3 | Erosive Esophagitis | COMPLETED | NCT01452776 |
| TAK-438 | Other | Phase PHASE3 | Erosive Esophagitis | COMPLETED | NCT01452776 |
| Lu AA21004 | Other | Phase PHASE3 | Major Depressive Disorder | COMPLETED | NCT01395147 |
| Lu AA21004 | Other | Phase PHASE3 | Major Depressive Disorder | COMPLETED | NCT01395147 |
| tandutinib | Other | Phase PHASE1 | Acute Myelogenous Leukemia | WITHDRAWN | NCT00297921 |
| tandutinib | Other | Phase PHASE1 | Acute Myelogenous Leukemia | WITHDRAWN | NCT00297921 |
| Insulin | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT01521962 |
| Alogliptin | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT01521962 |
| Insulin | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT01521962 |
| Alogliptin | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT01521962 |
| Insulin | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT01521962 |
| Alogliptin | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT01521962 |
| MLN4924 | Other | Phase PHASE1 | Hematologic Malignancies | COMPLETED | NCT00722488 |
| MLN4924 | Other | Phase PHASE1 | Hematologic Malignancies | COMPLETED | NCT00722488 |
| MLN4924 | Other | Phase PHASE1 | Hematologic Malignancies | COMPLETED | NCT00722488 |
| R11577 | Other | Phase PHASE1 | Multiple Myeloma | TERMINATED | NCT00361088 |
| PS-341 | Other | Phase PHASE1 | Multiple Myeloma | TERMINATED | NCT00361088 |
| Correlative studies | Other | Phase PHASE1 | Adult Nasal Type Extranodal NK/T-cell Lymphoma | COMPLETED | NCT01129180 |
| bortezomib | Other | Phase PHASE1 | Adult Nasal Type Extranodal NK/T-cell Lymphoma | COMPLETED | NCT01129180 |
| azacitidine | Other | Phase PHASE1 | Adult Nasal Type Extranodal NK/T-cell Lymphoma | COMPLETED | NCT01129180 |
| Correlative studies | Other | Phase PHASE1 | Adult Nasal Type Extranodal NK/T-cell Lymphoma | COMPLETED | NCT01129180 |
| bortezomib | Other | Phase PHASE1 | Adult Nasal Type Extranodal NK/T-cell Lymphoma | COMPLETED | NCT01129180 |
| azacitidine | Other | Phase PHASE1 | Adult Nasal Type Extranodal NK/T-cell Lymphoma | COMPLETED | NCT01129180 |
| Glipizide | Other | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT00856284 |
| Metformin | Other | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT00856284 |
| Alogliptin | Other | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT00856284 |
| Glipizide | Other | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT00856284 |
| Metformin | Other | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT00856284 |
| Alogliptin | Other | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT00856284 |
| Azacitidine | Other | Phase PHASE1 | Acute Myelogenous Leukemia | COMPLETED | NCT00911066 |
| MLN4924 | Other | Phase PHASE1 | Acute Myelogenous Leukemia | COMPLETED | NCT00911066 |
| Azacitidine | Other | Phase PHASE1 | Acute Myelogenous Leukemia | COMPLETED | NCT00911066 |
| MLN4924 | Other | Phase PHASE1 | Acute Myelogenous Leukemia | COMPLETED | NCT00911066 |
| Olmesartan medoxomil and hydrochlorothiazide | Other | Phase PHASE3 | Safety | COMPLETED | NCT01309828 |
| Azilsartan medoxomil and chlorthalidone | Other | Phase PHASE3 | Safety | COMPLETED | NCT01309828 |
| Olmesartan medoxomil and hydrochlorothiazide | Other | Phase PHASE3 | Safety | COMPLETED | NCT01309828 |
| Azilsartan medoxomil and chlorthalidone | Other | Phase PHASE3 | Safety | COMPLETED | NCT01309828 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01299805 |
| Vortioxetine | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01299805 |
| "Nycoplus Magnesium" (120 mg x 3 daily for 2 weeks) | Other | Phase PHASE4 | Cramps | COMPLETED | NCT00525317 |
| "Nycoplus Magnesium" (120 mg x 3 daily for 2 weeks) | Other | Phase PHASE4 | Cramps | COMPLETED | NCT00525317 |
| Placebo | Other | Phase PHASE2 | Depressive Disorder, Major | COMPLETED | NCT01255787 |
| Vortioxetine | Other | Phase PHASE2 | Depressive Disorder, Major | COMPLETED | NCT01255787 |
| Placebo | Other | Phase PHASE2 | Depressive Disorder, Major | COMPLETED | NCT01255787 |
| Vortioxetine | Other | Phase PHASE2 | Depressive Disorder, Major | COMPLETED | NCT01255787 |
| Placebo | Other | Phase PHASE3 | Depressive Disorder, Major | COMPLETED | NCT01179516 |
| Vortioxetine | Other | Phase PHASE3 | Depressive Disorder, Major | COMPLETED | NCT01179516 |
| Placebo | Other | Phase PHASE3 | Depressive Disorder, Major | COMPLETED | NCT01163266 |
| Vortioxetine | Other | Phase PHASE3 | Depressive Disorder, Major | COMPLETED | NCT01163266 |
| Placebo | Other | Phase PHASE3 | Depressive Disorder, Major | COMPLETED | NCT01163266 |
| Vortioxetine | Other | Phase PHASE3 | Depressive Disorder, Major | COMPLETED | NCT01163266 |
| Placebo | Other | Phase PHASE3 | Depressive Disorder, Major | COMPLETED | NCT01153009 |
| Duloxetine | Other | Phase PHASE3 | Depressive Disorder, Major | COMPLETED | NCT01153009 |
| Vortioxetine | Other | Phase PHASE3 | Depressive Disorder, Major | COMPLETED | NCT01153009 |
| Placebo | Other | Phase PHASE3 | Depressive Disorder, Major | COMPLETED | NCT01153009 |
| Duloxetine | Other | Phase PHASE3 | Depressive Disorder, Major | COMPLETED | NCT01153009 |
| Vortioxetine | Other | Phase PHASE3 | Depressive Disorder, Major | COMPLETED | NCT01153009 |
| Placebo | Other | Phase PHASE2 | Angina | TERMINATED | NCT01549977 |
| Febuxostat | Other | Phase PHASE2 | Angina | TERMINATED | NCT01549977 |
| Placebo | Other | Phase PHASE2 | Angina | TERMINATED | NCT01549977 |
| Febuxostat | Other | Phase PHASE2 | Angina | TERMINATED | NCT01549977 |
| Propiverine | Other | Preclinical | Overactive Bladder Syndrome | COMPLETED | NCT02024945 |
| Propiverine | Other | Preclinical | Overactive Bladder Syndrome | COMPLETED | NCT02024945 |
| Lansoprazole | Other | Phase PHASE3 | Gastric Ulcers | COMPLETED | NCT01452763 |
| Placebo | Other | Phase PHASE3 | Gastric Ulcers | COMPLETED | NCT01452763 |
| TAK-438 | Other | Phase PHASE3 | Gastric Ulcers | COMPLETED | NCT01452763 |
| Bortezomib; Pegylated Liposomal Doxorubicin; Dexamethasone (VDD) | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT00750815 |
| Cyclophosphamide | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT00750815 |
| Bortezomib; Pegylated Liposomal Doxorubicin; Dexamethasone (VDD) | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT00750815 |
| Cyclophosphamide | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT00750815 |
| Antihyperglycemic therapy | Drug | Phase PHASE3 | Type 2 Diabetes Mellitus | WITHDRAWN | NCT02015780 |
| Placebo | Other | Phase PHASE3 | Type 2 Diabetes Mellitus | WITHDRAWN | NCT02015780 |
| Fasiglifam | Other | Phase PHASE3 | Type 2 Diabetes Mellitus | WITHDRAWN | NCT02015780 |
| Lansoprazole | Other | Phase PHASE3 | Gastric Ulcers | COMPLETED | NCT01452750 |
| Placebo | Other | Phase PHASE3 | Gastric Ulcers | COMPLETED | NCT01452750 |
| TAK-438 | Other | Phase PHASE3 | Gastric Ulcers | COMPLETED | NCT01452750 |
| Lansoprazole | Other | Phase PHASE3 | Gastric Ulcers | COMPLETED | NCT01452750 |
| Placebo | Other | Phase PHASE3 | Gastric Ulcers | COMPLETED | NCT01452750 |
| TAK-438 | Other | Phase PHASE3 | Gastric Ulcers | COMPLETED | NCT01452750 |
| TAK-438 | Other | Phase PHASE3 | Erosive Esophagitis | COMPLETED | NCT01630746 |
| TAK-438 | Other | Phase PHASE3 | Erosive Esophagitis | COMPLETED | NCT01630746 |
| TAK-438 | Other | Phase PHASE3 | Erosive Esophagitis | COMPLETED | NCT01630746 |
| TAK-438 | Other | Phase PHASE3 | Gastric Ulcer | COMPLETED | NCT01568398 |
| TAK-438 | Other | Phase PHASE3 | Gastric Ulcer | COMPLETED | NCT01568398 |
| TAK-438 | Other | Phase PHASE3 | Gastric Ulcer | COMPLETED | NCT01568398 |
| TAK-438 | Other | Phase PHASE3 | Gastric Ulcer | COMPLETED | NCT01568385 |
| TAK-438 | Other | Phase PHASE3 | Gastric Ulcer | COMPLETED | NCT01568385 |
| TAK-438 | Other | Phase PHASE3 | Gastric Ulcer | COMPLETED | NCT01568385 |
| Lis-dexamphetamine | Other | Phase PHASE4 | Attention Deficit Hyperactivity Disorder | TERMINATED | NCT01017263 |
| Lis-dexamphetamine | Other | Phase PHASE4 | Attention Deficit Hyperactivity Disorder | TERMINATED | NCT01017263 |
| Leuprorelin acetate | Other | Phase PHASE2 | Endometriosis | COMPLETED | NCT01458301 |
| TAK-385 | Other | Phase PHASE2 | Endometriosis | COMPLETED | NCT01458301 |
| Placebo | Other | Phase PHASE2 | Endometriosis | COMPLETED | NCT01458301 |
| Leuprorelin acetate | Other | Phase PHASE2 | Endometriosis | COMPLETED | NCT01458301 |
| TAK-385 | Other | Phase PHASE2 | Endometriosis | COMPLETED | NCT01458301 |
| Placebo | Other | Phase PHASE2 | Endometriosis | COMPLETED | NCT01458301 |
| Hydrochlorothiazide | Other | Phase PHASE2 | Grade I or II Essential Hypertension | COMPLETED | NCT02072330 |
| TAK-536CCB + Hydrochlorothiazide | Other | Phase PHASE2 | Grade I or II Essential Hypertension | COMPLETED | NCT02072330 |
| TAK-536CCB | Other | Phase PHASE2 | Grade I or II Essential Hypertension | COMPLETED | NCT02072330 |
| Hydrochlorothiazide | Other | Phase PHASE2 | Grade I or II Essential Hypertension | COMPLETED | NCT02072330 |
| TAK-536CCB + Hydrochlorothiazide | Other | Phase PHASE2 | Grade I or II Essential Hypertension | COMPLETED | NCT02072330 |
| TAK-536CCB | Other | Phase PHASE2 | Grade I or II Essential Hypertension | COMPLETED | NCT02072330 |
| TAK-960 | Other | Phase PHASE1 | Advanced Nonhematological Malignancies | TERMINATED | NCT01179399 |
| TAK-960 | Other | Phase PHASE1 | Advanced Nonhematological Malignancies | TERMINATED | NCT01179399 |
| Placebo control | Other | Phase PHASE3 | Bipolar | TERMINATED | NCT01131559 |
| Lisdexamfetamine | Other | Phase PHASE3 | Bipolar | TERMINATED | NCT01131559 |
| Placebo control | Other | Phase PHASE3 | Bipolar | TERMINATED | NCT01131559 |
| Lisdexamfetamine | Other | Phase PHASE3 | Bipolar | TERMINATED | NCT01131559 |
| Bortezomib | Other | Phase PHASE2 | Glioblastoma | COMPLETED | NCT00611325 |
| Avastin | Other | Phase PHASE2 | Glioblastoma | COMPLETED | NCT00611325 |
| Bortezomib | Other | Phase PHASE2 | Glioblastoma | COMPLETED | NCT00611325 |
| Avastin | Other | Phase PHASE2 | Glioblastoma | COMPLETED | NCT00611325 |
| Enhancement with psychosocial intervention | Other | Approved | Attention Deficit-/Hyperactivity Disorder | UNKNOWN | NCT01660425 |
| Placebo | Other | Phase PHASE3 | Break Through Pain | COMPLETED | NCT01429051 |
| Intranasal Fentanyl Spray (INFS) | Other | Phase PHASE3 | Break Through Pain | COMPLETED | NCT01429051 |
| Placebo | Other | Phase PHASE3 | Break Through Pain | COMPLETED | NCT01429051 |
| Intranasal Fentanyl Spray (INFS) | Other | Phase PHASE3 | Break Through Pain | COMPLETED | NCT01429051 |
| Guanfacine (sustained release) | Other | Phase PHASE4 | Attention-deficit/Hyperactivity Disorder | COMPLETED | NCT01146002 |
| Placebo | Other | Phase PHASE4 | Bipolar Disorder | COMPLETED | NCT00552760 |
| Ramelteon | Other | Phase PHASE4 | Bipolar Disorder | COMPLETED | NCT00552760 |
| Placebo | Other | Phase PHASE4 | Bipolar Disorder | COMPLETED | NCT00552760 |
| Ramelteon | Other | Phase PHASE4 | Bipolar Disorder | COMPLETED | NCT00552760 |
| placebo | Other | Phase PHASE4 | Functional Dyspepsia | TERMINATED | NCT01040455 |
| Lansoprazole | Other | Phase PHASE4 | Functional Dyspepsia | TERMINATED | NCT01040455 |
| placebo | Other | Phase PHASE4 | Functional Dyspepsia | TERMINATED | NCT01040455 |
| Lansoprazole | Other | Phase PHASE4 | Functional Dyspepsia | TERMINATED | NCT01040455 |
| placebo | Other | Phase PHASE4 | Functional Dyspepsia | TERMINATED | NCT01040455 |
| Lansoprazole | Other | Phase PHASE4 | Functional Dyspepsia | TERMINATED | NCT01040455 |
| Rapid-acting insulin secretagogue | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT01456130 |
| Alogliptin | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT01456130 |
| PS-341 (bortezomib) | Other | Phase PHASE2 | Prostate Neoplasms | COMPLETED | NCT00425503 |
| Azilsartan medoxomil - chlorthalidone | Other | Phase PHASE3 | Essential Hypertension | COMPLETED | NCT01456169 |
| Azilsartan medoxomil/placebo | Other | Phase PHASE3 | Essential Hypertension | COMPLETED | NCT01456169 |
| TAK-438 Placebo | Other | Phase PHASE1 | Dose Finding Study | COMPLETED | NCT02123953 |
| TAK-438 | Other | Phase PHASE1 | Dose Finding Study | COMPLETED | NCT02123953 |
| TAK-438 Placebo | Other | Phase PHASE1 | Dose Finding Study | COMPLETED | NCT02123953 |
| TAK-438 | Other | Phase PHASE1 | Dose Finding Study | COMPLETED | NCT02123953 |
| Placebo | Other | Phase PHASE1 | Ascending Single Dose Study | COMPLETED | NCT02123927 |
| TAK-438 | Other | Phase PHASE1 | Ascending Single Dose Study | COMPLETED | NCT02123927 |
| Placebo | Other | Phase PHASE1 | Ascending Single Dose Study | COMPLETED | NCT02123927 |
| TAK-438 | Other | Phase PHASE1 | Ascending Single Dose Study | COMPLETED | NCT02123927 |
| Thalidomide | Other | Phase PHASE3 | Multiple Myeloma | COMPLETED | NCT00507416 |
| Prednisone | Other | Phase PHASE3 | Multiple Myeloma | COMPLETED | NCT00507416 |
| Melphalan | Other | Phase PHASE3 | Multiple Myeloma | COMPLETED | NCT00507416 |
| Dexamethasone | Other | Phase PHASE3 | Multiple Myeloma | COMPLETED | NCT00507416 |
| Bortezomib | Other | Phase PHASE3 | Multiple Myeloma | COMPLETED | NCT00507416 |
| Thalidomide | Other | Phase PHASE3 | Multiple Myeloma | COMPLETED | NCT00507416 |
| Prednisone | Other | Phase PHASE3 | Multiple Myeloma | COMPLETED | NCT00507416 |
| Melphalan | Other | Phase PHASE3 | Multiple Myeloma | COMPLETED | NCT00507416 |
| Dexamethasone | Other | Phase PHASE3 | Multiple Myeloma | COMPLETED | NCT00507416 |
| Bortezomib | Other | Phase PHASE3 | Multiple Myeloma | COMPLETED | NCT00507416 |
| Placebo | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00968708 |
| Alogliptin | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00968708 |
| Placebo | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00968708 |
| Alogliptin | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00968708 |
| Dexamethasone | Other | Phase PHASE2 | Lymphoma, Follicular | TERMINATED | NCT00510887 |
| Mitoxantrone | Other | Phase PHASE2 | Lymphoma, Follicular | TERMINATED | NCT00510887 |
| Fludarabine | Other | Phase PHASE2 | Lymphoma, Follicular | TERMINATED | NCT00510887 |
| Rituximab | Other | Phase PHASE2 | Lymphoma, Follicular | TERMINATED | NCT00510887 |
| Bortezomib | Other | Phase PHASE2 | Lymphoma, Follicular | TERMINATED | NCT00510887 |
| Dexamethasone | Other | Phase PHASE2 | Lymphoma, Follicular | TERMINATED | NCT00510887 |
| Mitoxantrone | Other | Phase PHASE2 | Lymphoma, Follicular | TERMINATED | NCT00510887 |
| Fludarabine | Other | Phase PHASE2 | Lymphoma, Follicular | TERMINATED | NCT00510887 |
| Rituximab | Other | Phase PHASE2 | Lymphoma, Follicular | TERMINATED | NCT00510887 |
| Bortezomib | Other | Phase PHASE2 | Lymphoma, Follicular | TERMINATED | NCT00510887 |
| Dexamethasone | Other | Phase PHASE2 | Lymphoma, Follicular | TERMINATED | NCT00510887 |
| Mitoxantrone | Other | Phase PHASE2 | Lymphoma, Follicular | TERMINATED | NCT00510887 |
| Fludarabine | Other | Phase PHASE2 | Lymphoma, Follicular | TERMINATED | NCT00510887 |
| Rituximab | Other | Phase PHASE2 | Lymphoma, Follicular | TERMINATED | NCT00510887 |
| Bortezomib | Other | Phase PHASE2 | Lymphoma, Follicular | TERMINATED | NCT00510887 |
| Mifamurtide (L-MTP-PE) | Other | Preclinical | Osteosarcoma | COMPLETED | NCT00631631 |
| Mifamurtide (L-MTP-PE) | Other | Preclinical | Osteosarcoma | COMPLETED | NCT00631631 |
| MOVIPREP | Other | Phase PHASE3 | Bowel Preparation Prior to Endoscopic, Radiological and Other Examinations as Well as to Surgical Procedures Which Require Empty Bowel. | COMPLETED | NCT01732692 |
| MOVIPREP | Other | Phase PHASE3 | Bowel Preparation Prior to Endoscopic, Radiological and Other Examinations as Well as to Surgical Procedures Which Require Empty Bowel. | COMPLETED | NCT01732692 |
| TAK-438 Placebo | Other | Phase PHASE1 | Erosive Esophagitis(EE) | COMPLETED | NCT02141711 |
| TAK-438 | Other | Phase PHASE1 | Erosive Esophagitis(EE) | COMPLETED | NCT02141711 |
| TAK-438 Placebo | Other | Phase PHASE1 | Erosive Esophagitis(EE) | COMPLETED | NCT02141711 |
| TAK-438 | Other | Phase PHASE1 | Erosive Esophagitis(EE) | COMPLETED | NCT02141711 |
| Esomeprazole | Other | Phase PHASE1 | Dose Finding Study | COMPLETED | NCT02141698 |
| TAK-438 Placebo | Other | Phase PHASE1 | Dose Finding Study | COMPLETED | NCT02141698 |
| TAK-438 | Other | Phase PHASE1 | Dose Finding Study | COMPLETED | NCT02141698 |
| Esomeprazole | Other | Phase PHASE1 | Dose Finding Study | COMPLETED | NCT02141698 |
| TAK-438 Placebo | Other | Phase PHASE1 | Dose Finding Study | COMPLETED | NCT02141698 |
| TAK-438 | Other | Phase PHASE1 | Dose Finding Study | COMPLETED | NCT02141698 |
| Lanthanum for calciphylaxis | Other | Phase PHASE1 | Calciphylaxis | COMPLETED | NCT01289626 |
| lanthanum carbonate | Other | Phase PHASE1 | Calciphylaxis | COMPLETED | NCT01289626 |
| Placebo | Other | Phase PHASE4 | Insomnia | COMPLETED | NCT00507546 |
| Ramelteon | Other | Phase PHASE4 | Insomnia | COMPLETED | NCT00507546 |
| Placebo | Other | Phase PHASE4 | Insomnia | COMPLETED | NCT00507546 |
| Ramelteon | Other | Phase PHASE4 | Insomnia | COMPLETED | NCT00507546 |
| Placebo | Other | Phase PHASE4 | Insomnia | COMPLETED | NCT00507546 |
| Ramelteon | Other | Phase PHASE4 | Insomnia | COMPLETED | NCT00507546 |
| Vortioxetine | Other | Phase PHASE3 | Depressive Disorder, Major | COMPLETED | NCT01152996 |
| Vortioxetine | Other | Phase PHASE3 | Depressive Disorder, Major | COMPLETED | NCT01152996 |
| Parathyroid Hormone (PTH) (1-84) | Other | Preclinical | Clinical Use of PTH(1-84) | COMPLETED | NCT00478569 |
| Parathyroid Hormone (PTH) (1-84) | Other | Preclinical | Clinical Use of PTH(1-84) | COMPLETED | NCT00478569 |
| Placebo | Other | Phase PHASE3 | Disruption or Dehiscence of Closure of Sternum or Sternotomy | COMPLETED | NCT01466829 |
| Parathyroid hormone | Other | Phase PHASE3 | Disruption or Dehiscence of Closure of Sternum or Sternotomy | COMPLETED | NCT01466829 |
| Placebo | Other | Phase PHASE3 | Disruption or Dehiscence of Closure of Sternum or Sternotomy | COMPLETED | NCT01466829 |
| Parathyroid hormone | Other | Phase PHASE3 | Disruption or Dehiscence of Closure of Sternum or Sternotomy | COMPLETED | NCT01466829 |
| Placebo | Other | Phase PHASE3 | Disruption or Dehiscence of Closure of Sternum or Sternotomy | COMPLETED | NCT01466829 |
| Parathyroid hormone | Other | Phase PHASE3 | Disruption or Dehiscence of Closure of Sternum or Sternotomy | COMPLETED | NCT01466829 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | COMPLETED | NCT01177228 |
| Vedolizumab | Other | Phase PHASE2 | Ulcerative Colitis | COMPLETED | NCT01177228 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | COMPLETED | NCT01177228 |
| Vedolizumab | Other | Phase PHASE2 | Ulcerative Colitis | COMPLETED | NCT01177228 |
| Placebo | Other | Phase PHASE3 | Ulcerative Colitis | COMPLETED | NCT00783718 |
| vedolizumab | Other | Phase PHASE3 | Ulcerative Colitis | COMPLETED | NCT00783718 |
| Placebo | Other | Phase PHASE3 | Ulcerative Colitis | COMPLETED | NCT00783718 |
| vedolizumab | Other | Phase PHASE3 | Ulcerative Colitis | COMPLETED | NCT00783718 |
| vedolizumab | Other | Phase PHASE2 | Ulcerative Colitis | COMPLETED | NCT00619489 |
| vedolizumab | Other | Phase PHASE2 | Ulcerative Colitis | COMPLETED | NCT00619489 |
| Oral cholera vaccine | Other | Phase PHASE1 | Inflammatory Bowel Disease | COMPLETED | NCT01981616 |
| Hepatitis B vaccine | Other | Phase PHASE1 | Inflammatory Bowel Disease | COMPLETED | NCT01981616 |
| Placebo | Other | Phase PHASE1 | Inflammatory Bowel Disease | COMPLETED | NCT01981616 |
| Vedolizumab | Other | Phase PHASE1 | Inflammatory Bowel Disease | COMPLETED | NCT01981616 |
| Oral cholera vaccine | Other | Phase PHASE1 | Inflammatory Bowel Disease | COMPLETED | NCT01981616 |
| Hepatitis B vaccine | Other | Phase PHASE1 | Inflammatory Bowel Disease | COMPLETED | NCT01981616 |
| Placebo | Other | Phase PHASE1 | Inflammatory Bowel Disease | COMPLETED | NCT01981616 |
| Vedolizumab | Other | Phase PHASE1 | Inflammatory Bowel Disease | COMPLETED | NCT01981616 |
| Placebo | Other | Phase PHASE3 | Crohn's Disease | COMPLETED | NCT01224171 |
| vedolizumab | Other | Phase PHASE3 | Crohn's Disease | COMPLETED | NCT01224171 |
| Placebo | Other | Phase PHASE3 | Crohn's Disease | COMPLETED | NCT00783692 |
| vedolizumab | Other | Phase PHASE3 | Crohn's Disease | COMPLETED | NCT00783692 |
| Placebo | Other | Phase PHASE3 | Crohn's Disease | COMPLETED | NCT00783692 |
| vedolizumab | Other | Phase PHASE3 | Crohn's Disease | COMPLETED | NCT00783692 |
| Orteronel | Other | Phase PHASE1 | Prostate Cancer | WITHDRAWN | NCT02054793 |
| Itraconazole | Other | Phase PHASE1 | Prostate Cancer | WITHDRAWN | NCT02054793 |
| Current Practice | Other | Phase PHASE3 | Cerebrospinal Fluid Leaks | COMPLETED | NCT01355627 |
| TachoSil® | Other | Phase PHASE3 | Cerebrospinal Fluid Leaks | COMPLETED | NCT01355627 |
| Azilsartan medoxomil (TAK-491) | Other | Phase PHASE1 | Hypertension | TERMINATED | NCT01078376 |
| Bortezomib | Other | Phase PHASE2 | Recurrent Adult Diffuse Large Cell Lymphoma | TERMINATED | NCT01397591 |
| Ofatumumab | Other | Phase PHASE2 | Recurrent Adult Diffuse Large Cell Lymphoma | TERMINATED | NCT01397591 |
| Bortezomib | Other | Phase PHASE2 | Recurrent Adult Diffuse Large Cell Lymphoma | TERMINATED | NCT01397591 |
| Ofatumumab | Other | Phase PHASE2 | Recurrent Adult Diffuse Large Cell Lymphoma | TERMINATED | NCT01397591 |
| Bortezomib | Other | Phase PHASE2 | Recurrent Adult Diffuse Large Cell Lymphoma | TERMINATED | NCT01397591 |
| Ofatumumab | Other | Phase PHASE2 | Recurrent Adult Diffuse Large Cell Lymphoma | TERMINATED | NCT01397591 |
| Dexlansoprazole | Other | Phase PHASE2 | Gastroesophageal Reflux Disease | COMPLETED | NCT01642602 |
| Dexlansoprazole | Other | Phase PHASE2 | Gastroesophageal Reflux Disease | COMPLETED | NCT01642602 |
| Dexlansoprazole | Other | Phase PHASE2 | Gastroesophageal Reflux Disease | COMPLETED | NCT01642602 |
| Placebo comparator | Other | Phase PHASE4 | Attention-Deficit/Hyperactivity Disorder | TERMINATED | NCT01156051 |
| Guanfacine extended-release tablets | Other | Phase PHASE4 | Attention-Deficit/Hyperactivity Disorder | TERMINATED | NCT01156051 |
| Placebo comparator | Other | Phase PHASE4 | Attention-Deficit/Hyperactivity Disorder | TERMINATED | NCT01156051 |
| Guanfacine extended-release tablets | Other | Phase PHASE4 | Attention-Deficit/Hyperactivity Disorder | TERMINATED | NCT01156051 |
| Preterm Neonates | Other | Preclinical | Non-invasive Ventilatory Support | COMPLETED | NCT01861795 |
| Preterm Neonates | Other | Preclinical | Non-invasive Ventilatory Support | COMPLETED | NCT01861795 |
| Sunitinib and Bortezomib | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT00720148 |
| Sunitinib and Bortezomib | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT00720148 |
| Placebo for Febuxostat | Other | Phase PHASE2 | Joint Damage | COMPLETED | NCT01078389 |
| Febuxostat | Other | Phase PHASE2 | Joint Damage | COMPLETED | NCT01078389 |
| Placebo for Febuxostat | Other | Phase PHASE2 | Joint Damage | COMPLETED | NCT01078389 |
| Febuxostat | Other | Phase PHASE2 | Joint Damage | COMPLETED | NCT01078389 |
| Placebo | Other | Phase PHASE3 | Treatment Outcome | COMPLETED | NCT01364649 |
| Escitalopram | Other | Phase PHASE3 | Treatment Outcome | COMPLETED | NCT01364649 |
| Vortioxetine | Other | Phase PHASE3 | Treatment Outcome | COMPLETED | NCT01364649 |
| Placebo | Other | Phase PHASE3 | Treatment Outcome | COMPLETED | NCT01364649 |
| Escitalopram | Other | Phase PHASE3 | Treatment Outcome | COMPLETED | NCT01364649 |
| Vortioxetine | Other | Phase PHASE3 | Treatment Outcome | COMPLETED | NCT01364649 |
| Polyethylene glycol with electrolytes | Other | Approved | Diabetes Mellitus, Type 1 | TERMINATED | NCT00689026 |
| Lubiprostone | Other | Approved | Diabetes Mellitus, Type 1 | TERMINATED | NCT00689026 |
| Polyethylene glycol with electrolytes | Other | Approved | Diabetes Mellitus, Type 1 | TERMINATED | NCT00689026 |
| Lubiprostone | Other | Approved | Diabetes Mellitus, Type 1 | TERMINATED | NCT00689026 |
| Polyethylene glycol with electrolytes | Other | Approved | Diabetes Mellitus, Type 1 | TERMINATED | NCT00689026 |
| Lubiprostone | Other | Approved | Diabetes Mellitus, Type 1 | TERMINATED | NCT00689026 |
| Polyethylene glycol with electrolytes | Other | Approved | Diabetes Mellitus, Type 1 | TERMINATED | NCT00689026 |
| Lubiprostone | Other | Approved | Diabetes Mellitus, Type 1 | TERMINATED | NCT00689026 |
| Placebo | Other | Phase PHASE1 | Clinical Pharmacology | COMPLETED | NCT02113020 |
| TAK-233 | Other | Phase PHASE1 | Clinical Pharmacology | COMPLETED | NCT02113020 |
| Placebo | Other | Phase PHASE1 | Clinical Pharmacology | COMPLETED | NCT02113020 |
| TAK-233 | Other | Phase PHASE1 | Clinical Pharmacology | COMPLETED | NCT02113020 |
| ABVD | Other | Phase PHASE2 | Hodgkin Lymphoma | UNKNOWN | NCT02275598 |
| Brentuximab vedotin | Other | Phase PHASE2 | Hodgkin Lymphoma | UNKNOWN | NCT02275598 |
| ABVD | Other | Phase PHASE2 | Hodgkin Lymphoma | UNKNOWN | NCT02275598 |
| Brentuximab vedotin | Other | Phase PHASE2 | Hodgkin Lymphoma | UNKNOWN | NCT02275598 |
| bleomycin | Other | Phase PHASE1 | Disease, Hodgkin | COMPLETED | NCT01060904 |
| dacarbazine | Other | Phase PHASE1 | Disease, Hodgkin | COMPLETED | NCT01060904 |
| vinblastine | Other | Phase PHASE1 | Disease, Hodgkin | COMPLETED | NCT01060904 |
| doxorubicin | Other | Phase PHASE1 | Disease, Hodgkin | COMPLETED | NCT01060904 |
| brentuximab vedotin | Other | Phase PHASE1 | Disease, Hodgkin | COMPLETED | NCT01060904 |
| bleomycin | Other | Phase PHASE1 | Disease, Hodgkin | COMPLETED | NCT01060904 |
| dacarbazine | Other | Phase PHASE1 | Disease, Hodgkin | COMPLETED | NCT01060904 |
| vinblastine | Other | Phase PHASE1 | Disease, Hodgkin | COMPLETED | NCT01060904 |
| doxorubicin | Other | Phase PHASE1 | Disease, Hodgkin | COMPLETED | NCT01060904 |
| brentuximab vedotin | Other | Phase PHASE1 | Disease, Hodgkin | COMPLETED | NCT01060904 |
| ketoconazole | Other | Phase PHASE1 | Carcinomas | COMPLETED | NCT01026415 |
| midazolam | Other | Phase PHASE1 | Carcinomas | COMPLETED | NCT01026415 |
| rifampin | Other | Phase PHASE1 | Carcinomas | COMPLETED | NCT01026415 |
| brentuximab vedotin | Other | Phase PHASE1 | Carcinomas | COMPLETED | NCT01026415 |
| ketoconazole | Other | Phase PHASE1 | Carcinomas | COMPLETED | NCT01026415 |
| midazolam | Other | Phase PHASE1 | Carcinomas | COMPLETED | NCT01026415 |
| rifampin | Other | Phase PHASE1 | Carcinomas | COMPLETED | NCT01026415 |
| brentuximab vedotin | Other | Phase PHASE1 | Carcinomas | COMPLETED | NCT01026415 |
| ITI-214 Dose H | Other | Phase PHASE1 | Schizophrenia | TERMINATED | NCT01900522 |
| ITI-214 Dose G | Other | Phase PHASE1 | Schizophrenia | TERMINATED | NCT01900522 |
| ITI-214 Dose F | Other | Phase PHASE1 | Schizophrenia | TERMINATED | NCT01900522 |
| ITI-214 Dose E | Other | Phase PHASE1 | Schizophrenia | TERMINATED | NCT01900522 |
| Placebo | Other | Phase PHASE1 | Schizophrenia | TERMINATED | NCT01900522 |
| ITI-214 Dose D (Elderly) | Other | Phase PHASE1 | Schizophrenia | TERMINATED | NCT01900522 |
| ITI-214 Dose C | Other | Phase PHASE1 | Schizophrenia | TERMINATED | NCT01900522 |
| ITI-214 Dose B | Other | Phase PHASE1 | Schizophrenia | TERMINATED | NCT01900522 |
| ITI-214 Dose A | Other | Phase PHASE1 | Schizophrenia | TERMINATED | NCT01900522 |
| ITI-214 Dose H | Other | Phase PHASE1 | Schizophrenia | TERMINATED | NCT01900522 |
| ITI-214 Dose G | Other | Phase PHASE1 | Schizophrenia | TERMINATED | NCT01900522 |
| ITI-214 Dose F | Other | Phase PHASE1 | Schizophrenia | TERMINATED | NCT01900522 |
| ITI-214 Dose E | Other | Phase PHASE1 | Schizophrenia | TERMINATED | NCT01900522 |
| Placebo | Other | Phase PHASE1 | Schizophrenia | TERMINATED | NCT01900522 |
| ITI-214 Dose D (Elderly) | Other | Phase PHASE1 | Schizophrenia | TERMINATED | NCT01900522 |
| ITI-214 Dose C | Other | Phase PHASE1 | Schizophrenia | TERMINATED | NCT01900522 |
| ITI-214 Dose B | Other | Phase PHASE1 | Schizophrenia | TERMINATED | NCT01900522 |
| ITI-214 Dose A | Other | Phase PHASE1 | Schizophrenia | TERMINATED | NCT01900522 |
| placebo | Other | Phase PHASE4 | Type 2 Diabetes Mellitus | COMPLETED | NCT00479986 |
| pioglitazone | Other | Phase PHASE4 | Type 2 Diabetes Mellitus | COMPLETED | NCT00479986 |
| Bortezomib (Velcade) | Other | Phase PHASE2 | Multiple Myeloma | TERMINATED | NCT01062230 |
| Bortezomib (Velcade) | Other | Phase PHASE2 | Multiple Myeloma | TERMINATED | NCT01062230 |
| Bortezomib (Velcade) | Other | Phase PHASE2 | Multiple Myeloma | TERMINATED | NCT01062230 |
| sequence of drug use | Drug | Phase PHASE4 | Dyspepsia | COMPLETED | NCT01888237 |
| Double dose of PPI | Other | Phase PHASE4 | Dyspepsia | COMPLETED | NCT01888237 |
| sequence of drug use | Drug | Phase PHASE4 | Dyspepsia | COMPLETED | NCT01888237 |
| Double dose of PPI | Other | Phase PHASE4 | Dyspepsia | COMPLETED | NCT01888237 |
| TAK-850 | Other | Phase PHASE1 | Influenza | COMPLETED | NCT02111252 |
| No Intervention | Other | Preclinical | Hypertension | COMPLETED | NCT02467855 |
| No Intervention | Other | Preclinical | Hypertension | COMPLETED | NCT02467855 |
| TAK-137 5mg tablet, TAK-137 placebo tablet | Other | Phase PHASE1 | Healthy Japanese Adult Male | WITHDRAWN | NCT02322606 |
| TAK-137 5 mg tablet, TAK-137 placebo tablet or TAK-137 0.5 mg tablet, TAK-137 placebo tablet | Other | Phase PHASE1 | Healthy Japanese Adult Male | WITHDRAWN | NCT02322606 |
| TAK-137 5 mg tablet, TAK-137 placebo tablet | Other | Phase PHASE1 | Healthy Japanese Adult Male | WITHDRAWN | NCT02322606 |
| TAK-137 5mg tablet, TAK-137 placebo tablet | Other | Phase PHASE1 | Healthy Japanese Adult Male | WITHDRAWN | NCT02322606 |
| TAK-137 5 mg tablet, TAK-137 placebo tablet or TAK-137 0.5 mg tablet, TAK-137 placebo tablet | Other | Phase PHASE1 | Healthy Japanese Adult Male | WITHDRAWN | NCT02322606 |
| TAK-137 5 mg tablet, TAK-137 placebo tablet | Other | Phase PHASE1 | Healthy Japanese Adult Male | WITHDRAWN | NCT02322606 |
| Placebo | Other | Phase PHASE1 | Dose Finding Study | COMPLETED | NCT02153099 |
| TAK-058 (ENV8058) | Other | Phase PHASE1 | Dose Finding Study | COMPLETED | NCT02153099 |
| Placebo | Other | Phase PHASE1 | Dose Finding Study | COMPLETED | NCT02153099 |
| TAK-058 (ENV8058) | Other | Phase PHASE1 | Dose Finding Study | COMPLETED | NCT02153099 |
| TAK-850 0.25 mL injection | Other | Phase PHASE1 | Influenza Infection | COMPLETED | NCT02367885 |
| TAK-850 0.5 mL injection | Other | Phase PHASE1 | Influenza Infection | COMPLETED | NCT02367885 |
| TAK-850 0.25 mL injection | Other | Phase PHASE1 | Influenza Infection | COMPLETED | NCT02367885 |
| TAK-850 0.5 mL injection | Other | Phase PHASE1 | Influenza Infection | COMPLETED | NCT02367885 |
| IXAZOMIB | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT01912222 |
| IXAZOMIB | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT01912222 |
| Lansoprazole | Other | Preclinical | Gastric or Duodenal Ulcers | COMPLETED | NCT02099682 |
| Pioglitazone | Other | Phase PHASE4 | Metabolic Syndrome | COMPLETED | NCT00835120 |
| Pioglitazone | Other | Phase PHASE4 | Metabolic Syndrome | COMPLETED | NCT00835120 |
| Pioglitazone | Other | Phase PHASE4 | Metabolic Syndrome | COMPLETED | NCT00835120 |
| Placebo | Other | Phase PHASE2 | Plaque Psoriasis | COMPLETED | NCT02129777 |
| Namilumab | Other | Phase PHASE2 | Plaque Psoriasis | COMPLETED | NCT02129777 |
| mesna, cisplatin, etoposide, rituximab | Other | Phase PHASE2 | Non-Hodgkin's Lymphoma | COMPLETED | NCT00504751 |
| bortezomib, dexamethasone, ifosfamide | Other | Phase PHASE2 | Non-Hodgkin's Lymphoma | COMPLETED | NCT00504751 |
| mesna, cisplatin, etoposide, rituximab | Other | Phase PHASE2 | Non-Hodgkin's Lymphoma | COMPLETED | NCT00504751 |
| bortezomib, dexamethasone, ifosfamide | Other | Phase PHASE2 | Non-Hodgkin's Lymphoma | COMPLETED | NCT00504751 |
| Degarelix | Other | Phase PHASE2 | Prostate Cancer | COMPLETED | NCT02135445 |
| TAK-385 | Other | Phase PHASE2 | Prostate Cancer | COMPLETED | NCT02135445 |
| Telmisartan | Other | Phase PHASE4 | Essential Hypertension Complicated by Type 2 Diabetes Mellitus | COMPLETED | NCT02079805 |
| Azilsartan | Other | Phase PHASE4 | Essential Hypertension Complicated by Type 2 Diabetes Mellitus | COMPLETED | NCT02079805 |
| placebo | Other | Phase PHASE4 | Adult Attention Deficit Hyperactivity Disorder (ADHD) With Co-occuring Anxiety and Depressive Disorders | COMPLETED | NCT01863459 |
| Lisdexamfetamine Dimesylate | Other | Phase PHASE4 | Adult Attention Deficit Hyperactivity Disorder (ADHD) With Co-occuring Anxiety and Depressive Disorders | COMPLETED | NCT01863459 |
| pioglitazone | Other | Phase PHASE4 | Type 2 Diabetes | COMPLETED | NCT01588470 |
| pioglitazone | Other | Phase PHASE4 | Type 2 Diabetes | COMPLETED | NCT01588470 |
| NoV GI.1/GII.4 Bivalent VLP Vaccine | Other | Phase PHASE2 | Norovirus | COMPLETED | NCT02475278 |
| NoV GI.1/GII.4 Bivalent VLP Vaccine | Other | Phase PHASE2 | Norovirus | COMPLETED | NCT02475278 |
| Orteronel 300mg BID | Other | Phase PHASE2 | Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors | TERMINATED | NCT02101684 |
| Orteronel 300mg BID | Other | Phase PHASE2 | Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors | TERMINATED | NCT02101684 |
| Ramelteon and Escitalopram | Other | Approved | Panic Disorder | TERMINATED | NCT00746239 |
| Placebo and Escitalopram | Other | Approved | Panic Disorder | TERMINATED | NCT00746239 |
| Ramelteon and Escitalopram | Other | Approved | Panic Disorder | TERMINATED | NCT00746239 |
| Placebo and Escitalopram | Other | Approved | Panic Disorder | TERMINATED | NCT00746239 |
| laboratory biomarker analysis | Other | Phase PHASE2 | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | TERMINATED | NCT01812005 |
| rituximab | Other | Phase PHASE2 | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | TERMINATED | NCT01812005 |
| alisertib | Other | Phase PHASE2 | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | TERMINATED | NCT01812005 |
| laboratory biomarker analysis | Other | Phase PHASE2 | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | TERMINATED | NCT01812005 |
| rituximab | Other | Phase PHASE2 | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | TERMINATED | NCT01812005 |
| alisertib | Other | Phase PHASE2 | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | TERMINATED | NCT01812005 |
| laboratory biomarker analysis | Other | Phase PHASE2 | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | TERMINATED | NCT01812005 |
| rituximab | Other | Phase PHASE2 | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | TERMINATED | NCT01812005 |
| alisertib | Other | Phase PHASE2 | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | TERMINATED | NCT01812005 |
| PS-341 (Velcade-drug) | Drug | Phase PHASE2 | Non-small Cell Lung Cancer | TERMINATED | NCT00200382 |
| PS-341 (Velcade-drug) | Drug | Phase PHASE2 | Non-small Cell Lung Cancer | TERMINATED | NCT00200382 |
| Placebo then Pioglitazone | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT00770367 |
| Pioglitazone then Placebo | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT00770367 |
| Placebo then Pioglitazone | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT00770367 |
| Pioglitazone then Placebo | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT00770367 |
| Folic/folinic acid | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT02379091 |
| Methotrexate | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT02379091 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT02379091 |
| Namilumab | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT02379091 |
| Lifitegrast | Other | Phase PHASE4 | Contact Lens Dry Eye | WITHDRAWN | NCT03431272 |
| Candesartan cilexetil / hydrochlorothiazide | Other | Preclinical | Hypertension | COMPLETED | NCT02016183 |
| Candesartan cilexetil / hydrochlorothiazide | Other | Preclinical | Hypertension | COMPLETED | NCT02016183 |
| TAK-536 | Other | Phase PHASE1 | Japanese Healthy Adult Male Participants | COMPLETED | NCT03042299 |
| Orteronel Placebo | Other | Phase PHASE3 | Prostate Cancer | COMPLETED | NCT01193257 |
| Prednisone | Other | Phase PHASE3 | Prostate Cancer | COMPLETED | NCT01193257 |
| Orteronel | Other | Phase PHASE3 | Prostate Cancer | COMPLETED | NCT01193257 |
| Azilsartan | Other | Preclinical | Hypertension | COMPLETED | NCT02092025 |
| Azilsartan | Other | Preclinical | Hypertension | COMPLETED | NCT02092025 |
| Pioglitazone | Other | Preclinical | Type 2 Diabetes Mellitus | COMPLETED | NCT02002975 |
| TAK-438 | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT03085836 |
| Not treated with omega-3-acid ethyl esters | Other | Phase PHASE4 | Hyperlipidemia | COMPLETED | NCT02839902 |
| TAK-085 | Other | Phase PHASE4 | Hyperlipidemia | COMPLETED | NCT02839902 |
| Not treated with omega-3-acid ethyl esters | Other | Phase PHASE4 | Hyperlipidemia | COMPLETED | NCT02839902 |
| TAK-085 | Other | Phase PHASE4 | Hyperlipidemia | COMPLETED | NCT02839902 |
| Not treated with omega-3-acid ethyl esters | Other | Phase PHASE4 | Hyperlipidemia | COMPLETED | NCT02839902 |
| TAK-085 | Other | Phase PHASE4 | Hyperlipidemia | COMPLETED | NCT02839902 |
| Valsartan Placebo | Other | Phase PHASE3 | Essential Hypertension | COMPLETED | NCT02480764 |
| Azilsartan medoxomil Placebo | Other | Phase PHASE3 | Essential Hypertension | COMPLETED | NCT02480764 |
| Valsartan | Other | Phase PHASE3 | Essential Hypertension | COMPLETED | NCT02480764 |
| Azilsartan medoxomil | Other | Phase PHASE3 | Essential Hypertension | COMPLETED | NCT02480764 |
| Valsartan Placebo | Other | Phase PHASE3 | Essential Hypertension | COMPLETED | NCT02480764 |
| Azilsartan medoxomil Placebo | Other | Phase PHASE3 | Essential Hypertension | COMPLETED | NCT02480764 |
| Valsartan | Other | Phase PHASE3 | Essential Hypertension | COMPLETED | NCT02480764 |
| Azilsartan medoxomil | Other | Phase PHASE3 | Essential Hypertension | COMPLETED | NCT02480764 |
| Azilsartan | Other | Preclinical | Hypertension | COMPLETED | NCT02100319 |
| Azilsartan | Other | Preclinical | Hypertension | COMPLETED | NCT02100319 |
| Placebo | Other | Phase PHASE2 | Norovirus | COMPLETED | NCT02153112 |
| GI.1/GII.4 (50/150) | Other | Phase PHASE2 | Norovirus | COMPLETED | NCT02153112 |
| GI.1/GII.4 (50/50) | Other | Phase PHASE2 | Norovirus | COMPLETED | NCT02153112 |
| GI.1/GII.4 (15/50) | Other | Phase PHASE2 | Norovirus | COMPLETED | NCT02153112 |
| GI.1/GII.4 (15/15) | Other | Phase PHASE2 | Norovirus | COMPLETED | NCT02153112 |
| Placebo | Other | Phase PHASE1 | Lupus Nephritis | TERMINATED | NCT02176486 |
| Ixazomib | Other | Phase PHASE1 | Lupus Nephritis | TERMINATED | NCT02176486 |
| Placebo | Other | Phase PHASE1 | Lupus Nephritis | TERMINATED | NCT02176486 |
| Ixazomib | Other | Phase PHASE1 | Lupus Nephritis | TERMINATED | NCT02176486 |
| Lifitegrast | Other | Phase PHASE4 | Ocular Discomfort | WITHDRAWN | NCT03408015 |
| Lifitegrast | Other | Phase PHASE4 | Ocular Discomfort | WITHDRAWN | NCT03408015 |
| Alisertib | Other | Phase PHASE1 | B-cell Follicular Lymphoma | COMPLETED | NCT00697346 |
| Alisertib | Other | Phase PHASE1 | B-cell Follicular Lymphoma | COMPLETED | NCT00697346 |
| TAK-536 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03434977 |
| TAK-536 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03434977 |
| Placebo | Other | Phase PHASE3 | Mild Cognitive Impairment Due to Alzheimer's Disease | TERMINATED | NCT02284906 |
| Pioglitazone | Other | Phase PHASE3 | Mild Cognitive Impairment Due to Alzheimer's Disease | TERMINATED | NCT02284906 |
| Placebo | Other | Phase PHASE2 | Dengue Fever | COMPLETED | NCT02193087 |
| TDV IDT Lyophilized | Other | Phase PHASE2 | Dengue Fever | COMPLETED | NCT02193087 |
| TDV Liquid Formulation 2 | Other | Phase PHASE2 | Dengue Fever | COMPLETED | NCT02193087 |
| TDV Liquid Formulation 1 | Other | Phase PHASE2 | Dengue Fever | COMPLETED | NCT02193087 |
| Placebo | Other | Phase PHASE2 | Dengue Fever | COMPLETED | NCT02193087 |
| TDV IDT Lyophilized | Other | Phase PHASE2 | Dengue Fever | COMPLETED | NCT02193087 |
| TDV Liquid Formulation 2 | Other | Phase PHASE2 | Dengue Fever | COMPLETED | NCT02193087 |
| TDV Liquid Formulation 1 | Other | Phase PHASE2 | Dengue Fever | COMPLETED | NCT02193087 |
| Omega-3 fatty acid ethyl esters | Other | Preclinical | Hyperlipidemia | COMPLETED | NCT02153073 |
| Omega-3 fatty acid ethyl esters | Other | Preclinical | Hyperlipidemia | COMPLETED | NCT02153073 |
| Omega-3 fatty acid ethyl esters | Other | Preclinical | Hyperlipidemia | COMPLETED | NCT02153073 |
| Ramelteon | Other | Phase PHASE4 | Insomnia | COMPLETED | NCT02669082 |
| trastuzumab | Other | Phase PHASE1 | Advanced Solid Malignancies | COMPLETED | NCT01351350 |
| paclitaxel | Other | Phase PHASE1 | Advanced Solid Malignancies | COMPLETED | NCT01351350 |
| MLN0128 | Other | Phase PHASE1 | Advanced Solid Malignancies | COMPLETED | NCT01351350 |
| trastuzumab | Other | Phase PHASE1 | Advanced Solid Malignancies | COMPLETED | NCT01351350 |
| paclitaxel | Other | Phase PHASE1 | Advanced Solid Malignancies | COMPLETED | NCT01351350 |
| MLN0128 | Other | Phase PHASE1 | Advanced Solid Malignancies | COMPLETED | NCT01351350 |
| trastuzumab | Other | Phase PHASE1 | Advanced Solid Malignancies | COMPLETED | NCT01351350 |
| paclitaxel | Other | Phase PHASE1 | Advanced Solid Malignancies | COMPLETED | NCT01351350 |
| MLN0128 | Other | Phase PHASE1 | Advanced Solid Malignancies | COMPLETED | NCT01351350 |
| Allogeneic Stem Cell Transplant | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT00948922 |
| Fludarabine | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT00948922 |
| Autologous Stem Cell Transplant | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT00948922 |
| Melphalan | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT00948922 |
| Bortezomib | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT00948922 |
| TAK-954 | Other | Phase PHASE1 | Hepatic Impairment | COMPLETED | NCT03277274 |
| TAK-954 | Other | Phase PHASE1 | Hepatic Impairment | COMPLETED | NCT03277274 |
| Observation | Other | Approved | HIV Infections | COMPLETED | NCT01023620 |
| Pioglitazone | Other | Approved | HIV Infections | COMPLETED | NCT01023620 |
| Observation | Other | Approved | HIV Infections | COMPLETED | NCT01023620 |
| Pioglitazone | Other | Approved | HIV Infections | COMPLETED | NCT01023620 |
| Observation | Other | Approved | HIV Infections | COMPLETED | NCT01023620 |
| Pioglitazone | Other | Approved | HIV Infections | COMPLETED | NCT01023620 |
| TAK-117 | Other | Phase PHASE1 | Advanced Nonhematologic Malignancies | COMPLETED | NCT01899053 |
| TAK-228 | Other | Phase PHASE1 | Advanced Nonhematologic Malignancies | COMPLETED | NCT01899053 |
| TAK-117 | Other | Phase PHASE1 | Advanced Nonhematologic Malignancies | COMPLETED | NCT01899053 |
| TAK-228 | Other | Phase PHASE1 | Advanced Nonhematologic Malignancies | COMPLETED | NCT01899053 |
| Leuprorelin acetate | Other | Preclinical | Premenopausal Breast Cancer | COMPLETED | NCT03209518 |
| Paclitaxel | Other | Phase PHASE1 | Advanced Solid Tumors, Neoplasms, Advanced Solid | COMPLETED | NCT03057366 |
| Carboplatin | Other | Phase PHASE1 | Advanced Solid Tumors, Neoplasms, Advanced Solid | COMPLETED | NCT03057366 |
| Docetaxel | Other | Phase PHASE1 | Advanced Solid Tumors, Neoplasms, Advanced Solid | COMPLETED | NCT03057366 |
| [14C]-Pevonedistat | Other | Phase PHASE1 | Advanced Solid Tumors, Neoplasms, Advanced Solid | COMPLETED | NCT03057366 |
| Pevonedistat | Other | Phase PHASE1 | Advanced Solid Tumors, Neoplasms, Advanced Solid | COMPLETED | NCT03057366 |
| Alogliptin | Other | Preclinical | Type 2 Diabetes Mellitus Who Have Been Examined at a Medical Institution | COMPLETED | NCT01945216 |
| Alogliptin | Other | Preclinical | Type 2 Diabetes Mellitus Who Have Been Examined at a Medical Institution | COMPLETED | NCT01945216 |
| No Intervention | Other | Preclinical | Inflammatory Bowel Disease | COMPLETED | NCT02822235 |
| No Intervention | Other | Preclinical | Inflammatory Bowel Disease | COMPLETED | NCT02822235 |
| Bismuth-Containing Quadruple Therapy | Drug | Phase PHASE3 | Duodenal Ulcer | COMPLETED | NCT03050359 |
| Lansoprazole Placebo | Other | Phase PHASE3 | Duodenal Ulcer | COMPLETED | NCT03050359 |
| TAK-438 Placebo | Other | Phase PHASE3 | Duodenal Ulcer | COMPLETED | NCT03050359 |
| Lansoprazole | Other | Phase PHASE3 | Duodenal Ulcer | COMPLETED | NCT03050359 |
| TAK-438 | Other | Phase PHASE3 | Duodenal Ulcer | COMPLETED | NCT03050359 |
| TAK-994 Placebo | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT03933488 |
| TAK-994 | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT03933488 |
| MLN2480 | Other | Phase PHASE1 | Melanoma | COMPLETED | NCT01425008 |
| Rifampin | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03928327 |
| Itraconazole | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03928327 |
| TAK-788 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03928327 |
| Rifampin | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03928327 |
| Itraconazole | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03928327 |
| TAK-788 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03928327 |
| ARALAST NP | Other | Phase PHASE4 | Chronic Obstructive Pulmonary Disease | WITHDRAWN | NCT04440488 |
| ARALAST NP | Other | Phase PHASE4 | Chronic Obstructive Pulmonary Disease | WITHDRAWN | NCT04440488 |
| Placebo | Other | Phase PHASE3 | Dengue | COMPLETED | NCT03342898 |
| TDV | Other | Phase PHASE3 | Dengue | COMPLETED | NCT03342898 |
| YF-17D | Other | Phase PHASE3 | Dengue | COMPLETED | NCT03342898 |
| Placebo | Other | Phase PHASE3 | Dengue | COMPLETED | NCT03342898 |
| TDV | Other | Phase PHASE3 | Dengue | COMPLETED | NCT03342898 |
| YF-17D | Other | Phase PHASE3 | Dengue | COMPLETED | NCT03342898 |
| Placebo | Other | Phase PHASE3 | Dengue Fever | COMPLETED | NCT03423173 |
| TAK-003 | Other | Phase PHASE3 | Dengue Fever | COMPLETED | NCT03423173 |
| Vedolizumab | Other | Phase PHASE4 | Colitis, Ulcerative | WITHDRAWN | NCT02760615 |
| Midazolam | Other | Phase PHASE4 | Colitis, Ulcerative | WITHDRAWN | NCT02760615 |
| Dextromethorphan | Other | Phase PHASE4 | Colitis, Ulcerative | WITHDRAWN | NCT02760615 |
| Omeprazole | Other | Phase PHASE4 | Colitis, Ulcerative | WITHDRAWN | NCT02760615 |
| Losartan | Other | Phase PHASE4 | Colitis, Ulcerative | WITHDRAWN | NCT02760615 |
| Caffeine | Other | Phase PHASE4 | Colitis, Ulcerative | WITHDRAWN | NCT02760615 |
| Vedolizumab | Other | Phase PHASE4 | Colitis, Ulcerative | WITHDRAWN | NCT02760615 |
| Midazolam | Other | Phase PHASE4 | Colitis, Ulcerative | WITHDRAWN | NCT02760615 |
| Dextromethorphan | Other | Phase PHASE4 | Colitis, Ulcerative | WITHDRAWN | NCT02760615 |
| Omeprazole | Other | Phase PHASE4 | Colitis, Ulcerative | WITHDRAWN | NCT02760615 |
| Losartan | Other | Phase PHASE4 | Colitis, Ulcerative | WITHDRAWN | NCT02760615 |
| Caffeine | Other | Phase PHASE4 | Colitis, Ulcerative | WITHDRAWN | NCT02760615 |
| Placebo | Other | Phase PHASE3 | Peripheral Arterial Diseases | COMPLETED | NCT03469349 |
| Actovegin | Other | Phase PHASE3 | Peripheral Arterial Diseases | COMPLETED | NCT03469349 |
| Dexamethasone | Other | Phase PHASE2 | Multiple Myeloma | TERMINATED | NCT02897830 |
| Lenalidomide | Other | Phase PHASE2 | Multiple Myeloma | TERMINATED | NCT02897830 |
| Ixazomib | Other | Phase PHASE2 | Multiple Myeloma | TERMINATED | NCT02897830 |
| Hydrocortisone, oral tablet, 10 mg | Other | Phase PHASE2 | Adrenal Insufficiency | COMPLETED | NCT00915343 |
| hydrocortisone (modified release), oral tablet 20 and 5 mg | Other | Phase PHASE2 | Adrenal Insufficiency | COMPLETED | NCT00915343 |
| Placebo | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT03748979 |
| TAK-925 | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT03748979 |
| Placebo | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT03748979 |
| TAK-925 | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT03748979 |
| Vedolizumab | Other | Phase PHASE4 | Colitis, Ulcerative | COMPLETED | NCT02559713 |
| 89Zr-TAK-164 | Other | Phase PHASE1 | Gastrointestinal Neoplasms; Esophageal, Stomach, Pancreas, Colon Neoplasms; Malignant Tumors of Digestive Organ; Advanced Gastrointestinal Malignancies | TERMINATED | NCT03449030 |
| TAK-164 | Other | Phase PHASE1 | Gastrointestinal Neoplasms; Esophageal, Stomach, Pancreas, Colon Neoplasms; Malignant Tumors of Digestive Organ; Advanced Gastrointestinal Malignancies | TERMINATED | NCT03449030 |
| 89Zr-TAK-164 | Other | Phase PHASE1 | Gastrointestinal Neoplasms; Esophageal, Stomach, Pancreas, Colon Neoplasms; Malignant Tumors of Digestive Organ; Advanced Gastrointestinal Malignancies | TERMINATED | NCT03449030 |
| TAK-164 | Other | Phase PHASE1 | Gastrointestinal Neoplasms; Esophageal, Stomach, Pancreas, Colon Neoplasms; Malignant Tumors of Digestive Organ; Advanced Gastrointestinal Malignancies | TERMINATED | NCT03449030 |
| 89Zr-TAK-164 | Other | Phase PHASE1 | Gastrointestinal Neoplasms; Esophageal, Stomach, Pancreas, Colon Neoplasms; Malignant Tumors of Digestive Organ; Advanced Gastrointestinal Malignancies | TERMINATED | NCT03449030 |
| TAK-164 | Other | Phase PHASE1 | Gastrointestinal Neoplasms; Esophageal, Stomach, Pancreas, Colon Neoplasms; Malignant Tumors of Digestive Organ; Advanced Gastrointestinal Malignancies | TERMINATED | NCT03449030 |
| Leuprorelin | Other | Phase PHASE4 | Central Precocious Puberty | COMPLETED | NCT02427958 |
| Placebo | Other | Phase PHASE3 | Myelodysplastic Syndromes | RECRUITING | NCT06499285 |
| Elritercept | Other | Phase PHASE3 | Myelodysplastic Syndromes | RECRUITING | NCT06499285 |
| Placebo | Other | Phase PHASE3 | Alpha1-Antitrypsin Deficiency | RECRUITING | NCT05677971 |
| Fazirsiran Injection | Other | Phase PHASE3 | Alpha1-Antitrypsin Deficiency | RECRUITING | NCT05677971 |
| Vedolizumab | Other | Phase PHASE2 | Ulcerative Colitis | COMPLETED | NCT03196427 |
| No Intervention | Other | Preclinical | Thrombotic Thrombocytopenic Purpura (TTP) | NOT_YET_RECRUITING | NCT07353099 |
| Vedolizumab SC | Other | Phase PHASE4 | Ulcerative Colitis | RECRUITING | NCT06581328 |
| Vedolizumab IV | Other | Phase PHASE4 | Ulcerative Colitis | RECRUITING | NCT06581328 |
| Placebo | Other | Phase PHASE2 | Nonsegmental Vitiligo | RECRUITING | NCT07108283 |
| Zasocitinib | Other | Phase PHASE2 | Nonsegmental Vitiligo | RECRUITING | NCT07108283 |
| Placebo | Other | Phase PHASE3 | Kidney Disease | RECRUITING | NCT06963827 |
| Mezagitamab | Other | Phase PHASE3 | Kidney Disease | RECRUITING | NCT06963827 |
| Placebo | Other | Phase PHASE2 | Chronic Obstructive Pulmonary Disease | TERMINATED | NCT01701934 |
| Roflumilast | Other | Phase PHASE2 | Chronic Obstructive Pulmonary Disease | TERMINATED | NCT01701934 |
| Placebo | Other | Phase PHASE2 | Chronic Obstructive Pulmonary Disease | TERMINATED | NCT01701934 |
| Roflumilast | Other | Phase PHASE2 | Chronic Obstructive Pulmonary Disease | TERMINATED | NCT01701934 |
| Placebo | Other | Phase PHASE3 | Major Depressive Disorder | COMPLETED | NCT01355081 |
| Vortioxetine | Other | Phase PHASE3 | Major Depressive Disorder | COMPLETED | NCT01355081 |
| Placebo | Other | Phase PHASE3 | Major Depressive Disorder | COMPLETED | NCT01355081 |
| Vortioxetine | Other | Phase PHASE3 | Major Depressive Disorder | COMPLETED | NCT01355081 |
| pioglitazone | Other | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT01156597 |
| pioglitazone | Other | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT01156597 |
| pioglitazone | Other | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT01156597 |
| brentuximab vedotin | Other | Phase PHASE1 | Disease, Hodgkin | COMPLETED | NCT01026233 |
| brentuximab vedotin | Other | Phase PHASE1 | Disease, Hodgkin | COMPLETED | NCT01026233 |
| placebo patch | Other | Phase PHASE3 | Attention Deficit Hyperactivity Disorder | COMPLETED | NCT00506285 |
| Methylphenidate Transdermal System (MTS) | Other | Phase PHASE3 | Attention Deficit Hyperactivity Disorder | COMPLETED | NCT00506285 |
| Emergency Drills | Other | Approved | Provider Skill | COMPLETED | NCT01802957 |
| Facility Checklists | Other | Approved | Provider Skill | COMPLETED | NCT01802957 |
| Strengthening the referral network | Other | Approved | Provider Skill | COMPLETED | NCT01802957 |
| Midwives exchange program | Other | Approved | Provider Skill | COMPLETED | NCT01802957 |
| Team-Based Supportive supervision | Other | Approved | Provider Skill | COMPLETED | NCT01802957 |
| Post Basic Emergency Obstetric Training Mentorship | Other | Approved | Provider Skill | COMPLETED | NCT01802957 |
| Hospital-health center networking system | Other | Approved | Provider Skill | COMPLETED | NCT01802957 |
| Training of health workers in Basic Obstetric Emergency Care | Other | Approved | Provider Skill | COMPLETED | NCT01802957 |
| Emergency Drills | Other | Approved | Provider Skill | COMPLETED | NCT01802957 |
| Facility Checklists | Other | Approved | Provider Skill | COMPLETED | NCT01802957 |
| Strengthening the referral network | Other | Approved | Provider Skill | COMPLETED | NCT01802957 |
| Midwives exchange program | Other | Approved | Provider Skill | COMPLETED | NCT01802957 |
| Team-Based Supportive supervision | Other | Approved | Provider Skill | COMPLETED | NCT01802957 |
| Post Basic Emergency Obstetric Training Mentorship | Other | Approved | Provider Skill | COMPLETED | NCT01802957 |
| Hospital-health center networking system | Other | Approved | Provider Skill | COMPLETED | NCT01802957 |
| Training of health workers in Basic Obstetric Emergency Care | Other | Approved | Provider Skill | COMPLETED | NCT01802957 |
| Emergency Drills | Other | Approved | Provider Skill | COMPLETED | NCT01802957 |
| Facility Checklists | Other | Approved | Provider Skill | COMPLETED | NCT01802957 |
| Strengthening the referral network | Other | Approved | Provider Skill | COMPLETED | NCT01802957 |
| Midwives exchange program | Other | Approved | Provider Skill | COMPLETED | NCT01802957 |
| Team-Based Supportive supervision | Other | Approved | Provider Skill | COMPLETED | NCT01802957 |
| Post Basic Emergency Obstetric Training Mentorship | Other | Approved | Provider Skill | COMPLETED | NCT01802957 |
| Hospital-health center networking system | Other | Approved | Provider Skill | COMPLETED | NCT01802957 |
| Training of health workers in Basic Obstetric Emergency Care | Other | Approved | Provider Skill | COMPLETED | NCT01802957 |
| Alogliptin | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00957268 |
| Alogliptin | Other | Phase PHASE1 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00957268 |
| Placebo | Other | Phase PHASE2 | Depressive Disorder, Major | COMPLETED | NCT01564862 |
| Duloxetine | Other | Phase PHASE2 | Depressive Disorder, Major | COMPLETED | NCT01564862 |
| vortioxetine (Lu AA21004) | Other | Phase PHASE2 | Depressive Disorder, Major | COMPLETED | NCT01564862 |
| Placebo | Other | Phase PHASE2 | Depressive Disorder, Major | COMPLETED | NCT01564862 |
| Duloxetine | Other | Phase PHASE2 | Depressive Disorder, Major | COMPLETED | NCT01564862 |
| vortioxetine (Lu AA21004) | Other | Phase PHASE2 | Depressive Disorder, Major | COMPLETED | NCT01564862 |
| Placebo | Other | Phase PHASE1 | Dose Finding Study | COMPLETED | NCT02334982 |
| TAK-137 | Other | Phase PHASE1 | Dose Finding Study | COMPLETED | NCT02334982 |
| Placebo | Other | Phase PHASE1 | Dose Finding Study | COMPLETED | NCT02334982 |
| TAK-137 | Other | Phase PHASE1 | Dose Finding Study | COMPLETED | NCT02334982 |
| Dexlansoprazole | Other | Phase PHASE1 | Gastroesophageal Reflux Disease | COMPLETED | NCT02096458 |
| Dexlansoprazole | Other | Phase PHASE1 | Gastroesophageal Reflux Disease | COMPLETED | NCT02096458 |
| Bortezomib and Tipifarnib | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT00972712 |
| [^11C]T-773 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02370602 |
| TAK-063 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02370602 |
| [^11C]T-773 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02370602 |
| TAK-063 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02370602 |
| placebo | Other | Phase PHASE4 | Type 2 Diabetes Mellitus | COMPLETED | NCT00479986 |
| pioglitazone | Other | Phase PHASE4 | Type 2 Diabetes Mellitus | COMPLETED | NCT00479986 |
| AO-128 | Other | Phase PHASE4 | Impaired Glucose Tolerance (IGT) | COMPLETED | NCT02287402 |
| AO-128 | Other | Phase PHASE4 | Impaired Glucose Tolerance (IGT) | COMPLETED | NCT02287402 |
| AO-128 | Other | Phase PHASE4 | Impaired Glucose Tolerance (IGT) | COMPLETED | NCT02287402 |
| G-CSF | Other | Phase PHASE2 | Mantle Cell Lymphoma | COMPLETED | NCT00958256 |
| Mesna | Other | Phase PHASE2 | Mantle Cell Lymphoma | COMPLETED | NCT00958256 |
| Cyclophosphamide | Other | Phase PHASE2 | Mantle Cell Lymphoma | COMPLETED | NCT00958256 |
| Rituximab | Other | Phase PHASE2 | Mantle Cell Lymphoma | COMPLETED | NCT00958256 |
| Bortezomib | Other | Phase PHASE2 | Mantle Cell Lymphoma | COMPLETED | NCT00958256 |
| G-CSF | Other | Phase PHASE2 | Mantle Cell Lymphoma | COMPLETED | NCT00958256 |
| Mesna | Other | Phase PHASE2 | Mantle Cell Lymphoma | COMPLETED | NCT00958256 |
| Cyclophosphamide | Other | Phase PHASE2 | Mantle Cell Lymphoma | COMPLETED | NCT00958256 |
| Rituximab | Other | Phase PHASE2 | Mantle Cell Lymphoma | COMPLETED | NCT00958256 |
| Bortezomib | Other | Phase PHASE2 | Mantle Cell Lymphoma | COMPLETED | NCT00958256 |
| Dexlansoprazole Delayed Release Capsules | Other | Phase PHASE1 | Bioavailability | COMPLETED | NCT02064907 |
| Dexlansoprazole Delayed Release Orally Disintegrating Tablets | Other | Phase PHASE1 | Bioavailability | COMPLETED | NCT02064907 |
| Dexlansoprazole Delayed Release Capsules | Other | Phase PHASE1 | Bioavailability | COMPLETED | NCT02064907 |
| Dexlansoprazole Delayed Release Orally Disintegrating Tablets | Other | Phase PHASE1 | Bioavailability | COMPLETED | NCT02064907 |
| mesalamine | Other | Phase PHASE4 | Ulcerative Colitis | COMPLETED | NCT00652145 |
| Azilsartan medoxomil | Other | Phase PHASE3 | Hypertension | TERMINATED | NCT01496430 |
| Placebo | Other | Phase PHASE3 | Hypertension | TERMINATED | NCT01496430 |
| Azilsartan medoxomil | Other | Phase PHASE3 | Hypertension | TERMINATED | NCT01496430 |
| Placebo | Other | Phase PHASE3 | Hypertension | TERMINATED | NCT01496430 |
| Placebo | Other | Phase PHASE2 | Gastroesophageal Reflux Disease | COMPLETED | NCT01642615 |
| Dexlansoprazole | Other | Phase PHASE2 | Gastroesophageal Reflux Disease | COMPLETED | NCT01642615 |
| Placebo | Other | Phase PHASE2 | Gastroesophageal Reflux Disease | COMPLETED | NCT01642615 |
| Dexlansoprazole | Other | Phase PHASE2 | Gastroesophageal Reflux Disease | COMPLETED | NCT01642615 |
| Levothyroxine sodium new formulation | Other | Phase PHASE2 | Hypothyroidism | COMPLETED | NCT01916304 |
| Levothyroxine sodium new formulation | Other | Phase PHASE2 | Hypothyroidism | COMPLETED | NCT01916304 |
| TAP-144-SR(3M) | Other | Phase PHASE3 | Prostate Cancer | COMPLETED | NCT01546623 |
| TAP-144-SR(6M) | Other | Phase PHASE3 | Prostate Cancer | COMPLETED | NCT01546623 |
| TAP-144-SR(3M) | Other | Phase PHASE3 | Prostate Cancer | COMPLETED | NCT01546623 |
| TAP-144-SR(6M) | Other | Phase PHASE3 | Prostate Cancer | COMPLETED | NCT01546623 |
| Prednisone | Other | Phase PHASE2 | Chronic Graft Versus Host Disease | COMPLETED | NCT00815919 |
| bortezomib | Other | Phase PHASE2 | Chronic Graft Versus Host Disease | COMPLETED | NCT00815919 |
| Prednisone | Other | Phase PHASE2 | Chronic Graft Versus Host Disease | COMPLETED | NCT00815919 |
| bortezomib | Other | Phase PHASE2 | Chronic Graft Versus Host Disease | COMPLETED | NCT00815919 |
| Prednisone | Other | Phase PHASE2 | Chronic Graft Versus Host Disease | COMPLETED | NCT00815919 |
| bortezomib | Other | Phase PHASE2 | Chronic Graft Versus Host Disease | COMPLETED | NCT00815919 |
| TAK-850 | Other | Phase PHASE1 | Influenza | COMPLETED | NCT02111252 |
| Flutamide | Other | Phase PHASE3 | Prostatic Neoplasms, Locally Advanced | COMPLETED | NCT01122121 |
| Radiotherapy | Drug | Phase PHASE3 | Prostatic Neoplasms, Locally Advanced | COMPLETED | NCT01122121 |
| Leuprorelin SR | Other | Phase PHASE3 | Prostatic Neoplasms, Locally Advanced | COMPLETED | NCT01122121 |
| Flutamide | Other | Phase PHASE3 | Prostatic Neoplasms, Locally Advanced | COMPLETED | NCT01122121 |
| Radiotherapy | Drug | Phase PHASE3 | Prostatic Neoplasms, Locally Advanced | COMPLETED | NCT01122121 |
| Leuprorelin SR | Other | Phase PHASE3 | Prostatic Neoplasms, Locally Advanced | COMPLETED | NCT01122121 |
| Flutamide | Other | Phase PHASE2 | Prostatic Neoplasms | COMPLETED | NCT00817739 |
| Leuprorelin | Other | Phase PHASE2 | Prostatic Neoplasms | COMPLETED | NCT00817739 |
| Flutamide | Other | Phase PHASE2 | Prostatic Neoplasms | COMPLETED | NCT00817739 |
| Leuprorelin | Other | Phase PHASE2 | Prostatic Neoplasms | COMPLETED | NCT00817739 |
| Flutamide | Other | Phase PHASE2 | Prostatic Neoplasms | COMPLETED | NCT00817739 |
| Leuprorelin | Other | Phase PHASE2 | Prostatic Neoplasms | COMPLETED | NCT00817739 |
| Placebo | Other | Phase PHASE3 | Adenocarcinoma, Prostate | COMPLETED | NCT01011751 |
| Flutamide | Other | Phase PHASE3 | Adenocarcinoma, Prostate | COMPLETED | NCT01011751 |
| Leuprorelin | Other | Phase PHASE3 | Adenocarcinoma, Prostate | COMPLETED | NCT01011751 |
| Venlafaxine | Other | Phase PHASE3 | Adenocarcinoma, Prostate | COMPLETED | NCT01011751 |
| Medroxyprogesterone acetate | Other | Phase PHASE3 | Adenocarcinoma, Prostate | COMPLETED | NCT01011751 |
| Cyproterone acetate | Other | Phase PHASE3 | Adenocarcinoma, Prostate | COMPLETED | NCT01011751 |
| Placebo | Other | Phase PHASE3 | Adenocarcinoma, Prostate | COMPLETED | NCT01011751 |
| Flutamide | Other | Phase PHASE3 | Adenocarcinoma, Prostate | COMPLETED | NCT01011751 |
| Leuprorelin | Other | Phase PHASE3 | Adenocarcinoma, Prostate | COMPLETED | NCT01011751 |
| Venlafaxine | Other | Phase PHASE3 | Adenocarcinoma, Prostate | COMPLETED | NCT01011751 |
| Medroxyprogesterone acetate | Other | Phase PHASE3 | Adenocarcinoma, Prostate | COMPLETED | NCT01011751 |
| Cyproterone acetate | Other | Phase PHASE3 | Adenocarcinoma, Prostate | COMPLETED | NCT01011751 |
| MLN3126 Placebo | Other | Phase PHASE1 | Healthy Volunteers | TERMINATED | NCT02447458 |
| MLN3126 | Other | Phase PHASE1 | Healthy Volunteers | TERMINATED | NCT02447458 |
| MLN3126 Placebo | Other | Phase PHASE1 | Healthy Volunteers | TERMINATED | NCT02447458 |
| MLN3126 | Other | Phase PHASE1 | Healthy Volunteers | TERMINATED | NCT02447458 |
| rituximab | Other | Phase PHASE2 | Non-Hodgkin's Lymphoma | COMPLETED | NCT00547534 |
| bendamustine | Other | Phase PHASE2 | Non-Hodgkin's Lymphoma | COMPLETED | NCT00547534 |
| bortezomib | Other | Phase PHASE2 | Non-Hodgkin's Lymphoma | COMPLETED | NCT00547534 |
| rituximab | Other | Phase PHASE2 | Non-Hodgkin's Lymphoma | COMPLETED | NCT00547534 |
| bendamustine | Other | Phase PHASE2 | Non-Hodgkin's Lymphoma | COMPLETED | NCT00547534 |
| bortezomib | Other | Phase PHASE2 | Non-Hodgkin's Lymphoma | COMPLETED | NCT00547534 |
| Placebo | Other | Phase PHASE1 | Rheumatoid Arthritis | COMPLETED | NCT01317797 |
| namilumab (MT203) | Other | Phase PHASE1 | Rheumatoid Arthritis | COMPLETED | NCT01317797 |
| Placebo | Other | Phase PHASE1 | Rheumatoid Arthritis | COMPLETED | NCT01317797 |
| namilumab (MT203) | Other | Phase PHASE1 | Rheumatoid Arthritis | COMPLETED | NCT01317797 |
| Placebo | Other | Phase PHASE2 | Hypertension | COMPLETED | NCT01496469 |
| Febuxostat | Other | Phase PHASE2 | Hypertension | COMPLETED | NCT01496469 |
| Placebo | Other | Phase PHASE3 | Bipolar Depression | TERMINATED | NCT01093963 |
| Lisdexamfetamine | Other | Phase PHASE3 | Bipolar Depression | TERMINATED | NCT01093963 |
| Trebananib 30 mg/kg | Other | Phase PHASE1 | Neoplasms, Advanced Solid | COMPLETED | NCT02525536 |
| Trebananib 10 mg/kg | Other | Phase PHASE1 | Neoplasms, Advanced Solid | COMPLETED | NCT02525536 |
| Trebananib 3 mg/kg | Other | Phase PHASE1 | Neoplasms, Advanced Solid | COMPLETED | NCT02525536 |
| Trebananib 30 mg/kg | Other | Phase PHASE1 | Neoplasms, Advanced Solid | COMPLETED | NCT02525536 |
| Trebananib 10 mg/kg | Other | Phase PHASE1 | Neoplasms, Advanced Solid | COMPLETED | NCT02525536 |
| Trebananib 3 mg/kg | Other | Phase PHASE1 | Neoplasms, Advanced Solid | COMPLETED | NCT02525536 |
| Metformin | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | TERMINATED | NCT01834274 |
| Sitagliptin Placebo | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | TERMINATED | NCT01834274 |
| Sitagliptin | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | TERMINATED | NCT01834274 |
| Fasiglifam (TAK-875) Placebo | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | TERMINATED | NCT01834274 |
| Fasiglifam (TAK-875) | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | TERMINATED | NCT01834274 |
| Metformin | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | TERMINATED | NCT01834274 |
| Sitagliptin Placebo | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | TERMINATED | NCT01834274 |
| Sitagliptin | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | TERMINATED | NCT01834274 |
| Fasiglifam (TAK-875) Placebo | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | TERMINATED | NCT01834274 |
| Fasiglifam (TAK-875) | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | TERMINATED | NCT01834274 |
| TAK-875 Placebo | Other | Phase PHASE3 | Type 2 Diabetes | TERMINATED | NCT01609582 |
| TAK-875 | Other | Phase PHASE3 | Type 2 Diabetes | TERMINATED | NCT01609582 |
| TAK-875 Placebo | Other | Phase PHASE3 | Type 2 Diabetes | TERMINATED | NCT01609582 |
| TAK-875 | Other | Phase PHASE3 | Type 2 Diabetes | TERMINATED | NCT01609582 |
| Antireflux surgery | Procedure | Preclinical | GERD | TERMINATED | NCT00624546 |
| Prevacid Solutabs | Other | Preclinical | GERD | TERMINATED | NCT00624546 |
| Antireflux surgery | Procedure | Preclinical | GERD | TERMINATED | NCT00624546 |
| Prevacid Solutabs | Other | Preclinical | GERD | TERMINATED | NCT00624546 |
| Antireflux surgery | Procedure | Preclinical | GERD | TERMINATED | NCT00624546 |
| Prevacid Solutabs | Other | Preclinical | GERD | TERMINATED | NCT00624546 |
| Bortezomib | Other | Phase PHASE2 | Disorder of Transplanted Kidney | TERMINATED | NCT01349595 |
| TAK-875 Placebo | Other | Phase PHASE3 | Type 2 Diabetes Mellitus | TERMINATED | NCT01647542 |
| TAK-875 | Other | Phase PHASE3 | Type 2 Diabetes Mellitus | TERMINATED | NCT01647542 |
| TAK-875 Placebo | Other | Phase PHASE3 | Type 2 Diabetes Mellitus | TERMINATED | NCT01647542 |
| TAK-875 | Other | Phase PHASE3 | Type 2 Diabetes Mellitus | TERMINATED | NCT01647542 |
| IXAZOMIB | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT00893464 |
| IXAZOMIB | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT00893464 |
| Surgicel® Original | Other | Phase PHASE3 | Hemorrhage | COMPLETED | NCT01192022 |
| TachoSil® | Other | Phase PHASE3 | Hemorrhage | COMPLETED | NCT01192022 |
| Surgicel® Original | Other | Phase PHASE3 | Hemorrhage | COMPLETED | NCT01192022 |
| TachoSil® | Other | Phase PHASE3 | Hemorrhage | COMPLETED | NCT01192022 |
| TAP-144-SR(3M) | Other | Phase PHASE3 | Premenopausal Breast Cancer | COMPLETED | NCT01546649 |
| TAP-144-SR(6M) | Other | Phase PHASE3 | Premenopausal Breast Cancer | COMPLETED | NCT01546649 |
| TAP-144-SR(3M) | Other | Phase PHASE3 | Premenopausal Breast Cancer | COMPLETED | NCT01546649 |
| TAP-144-SR(6M) | Other | Phase PHASE3 | Premenopausal Breast Cancer | COMPLETED | NCT01546649 |
| Placebo | Other | Phase PHASE2 | Atherosclerotic Cardiovascular Disease | WITHDRAWN | NCT02388971 |
| MLN1202 | Other | Phase PHASE2 | Atherosclerotic Cardiovascular Disease | WITHDRAWN | NCT02388971 |
| Placebo | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT01236534 |
| Lubiprostone | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT01236534 |
| Placebo | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT01236534 |
| Lubiprostone | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT01236534 |
| Carboplatin | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | TERMINATED | NCT02629848 |
| Paclitaxel | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | TERMINATED | NCT02629848 |
| Placebo | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | TERMINATED | NCT02629848 |
| Motesanib | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | TERMINATED | NCT02629848 |
| Carboplatin | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | TERMINATED | NCT02629848 |
| Paclitaxel | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | TERMINATED | NCT02629848 |
| Placebo | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | TERMINATED | NCT02629848 |
| Motesanib | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | TERMINATED | NCT02629848 |
| Pioglitazone | Other | Phase PHASE4 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00402012 |
| Pioglitazone | Other | Phase PHASE4 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00402012 |
| Pioglitazone | Other | Phase PHASE4 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00402012 |
| Amlodipine | Other | Approved | Hypertension | COMPLETED | NCT01762501 |
| Azilsartan | Other | Approved | Hypertension | COMPLETED | NCT01762501 |
| Amlodipine | Other | Approved | Hypertension | COMPLETED | NCT01762501 |
| Azilsartan | Other | Approved | Hypertension | COMPLETED | NCT01762501 |
| Amlodipine | Other | Approved | Hypertension | COMPLETED | NCT01762501 |
| Azilsartan | Other | Approved | Hypertension | COMPLETED | NCT01762501 |
| Vortioxetine | Other | Phase PHASE1 | Severe Hepatic Impairment | COMPLETED | NCT02170220 |
| Bortezomib | Other | Phase PHASE2 | Chronic Graft-versus-host Disease | UNKNOWN | NCT01158105 |
| Bortezomib | Other | Phase PHASE2 | Chronic Graft-versus-host Disease | UNKNOWN | NCT01158105 |
| Intramuscular injection of TAK-850 | Other | Phase PHASE1 | Influenza Infection | COMPLETED | NCT02313155 |
| Subcutaneous injection of TAK-850 | Other | Phase PHASE1 | Influenza Infection | COMPLETED | NCT02313155 |
| Intramuscular injection of TAK-850 | Other | Phase PHASE1 | Influenza Infection | COMPLETED | NCT02313155 |
| Subcutaneous injection of TAK-850 | Other | Phase PHASE1 | Influenza Infection | COMPLETED | NCT02313155 |
| Leuprorelin acetate | Other | Preclinical | Breast Cancer | COMPLETED | NCT02154139 |
| Leuprorelin acetate | Other | Preclinical | Breast Cancer | COMPLETED | NCT02154139 |
| Leuprorelin acetate | Other | Preclinical | Breast Cancer | COMPLETED | NCT02154139 |
| Placebo | Other | Phase PHASE3 | Post-Stroke Cognitive Impairment (PSCI) | COMPLETED | NCT01582854 |
| Actovegin | Other | Phase PHASE3 | Post-Stroke Cognitive Impairment (PSCI) | COMPLETED | NCT01582854 |
| Placebo | Other | Phase PHASE3 | Post-Stroke Cognitive Impairment (PSCI) | COMPLETED | NCT01582854 |
| Actovegin | Other | Phase PHASE3 | Post-Stroke Cognitive Impairment (PSCI) | COMPLETED | NCT01582854 |
| Lansoprazole | Other | Preclinical | Gastric Ulcer, Duodenal Ulcer, Acute Stress Gastritis, and Acute Gastric Mucosal Lesions | COMPLETED | NCT02151786 |
| Lansoprazole | Other | Preclinical | Gastric Ulcer, Duodenal Ulcer, Acute Stress Gastritis, and Acute Gastric Mucosal Lesions | COMPLETED | NCT02151786 |
| Placebo | Other | Phase PHASE2 | Erectile Dysfunction | WITHDRAWN | NCT01967251 |
| Udenafil | Other | Phase PHASE2 | Erectile Dysfunction | WITHDRAWN | NCT01967251 |
| Lansoprazole | Other | Preclinical | Acute Stress Ulcer and Acute Gastric Mucosal Lesions | COMPLETED | NCT02170207 |
| Lansoprazole | Other | Preclinical | Acute Stress Ulcer and Acute Gastric Mucosal Lesions | COMPLETED | NCT02170207 |
| Placebo | Other | Phase PHASE3 | Bipolar Disorder | TERMINATED | NCT01677182 |
| Ramelteon | Other | Phase PHASE3 | Bipolar Disorder | TERMINATED | NCT01677182 |
| Placebo | Other | Phase PHASE3 | Bipolar Disorder | TERMINATED | NCT01677182 |
| Ramelteon | Other | Phase PHASE3 | Bipolar Disorder | TERMINATED | NCT01677182 |
| Methylprednisolone | Other | Phase PHASE4 | HLA Sensitization | COMPLETED | NCT00908583 |
| Rituximab | Other | Phase PHASE4 | HLA Sensitization | COMPLETED | NCT00908583 |
| Bortezomib | Other | Phase PHASE4 | HLA Sensitization | COMPLETED | NCT00908583 |
| plasmapheresis | Other | Phase PHASE4 | HLA Sensitization | COMPLETED | NCT00908583 |
| Methylprednisolone | Other | Phase PHASE4 | HLA Sensitization | COMPLETED | NCT00908583 |
| Rituximab | Other | Phase PHASE4 | HLA Sensitization | COMPLETED | NCT00908583 |
| Bortezomib | Other | Phase PHASE4 | HLA Sensitization | COMPLETED | NCT00908583 |
| plasmapheresis | Other | Phase PHASE4 | HLA Sensitization | COMPLETED | NCT00908583 |
| TAK-875 and Sitagliptin | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01414920 |
| Sitagliptin | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01414920 |
| TAK-875 | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01414920 |
| Placebo | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01414920 |
| TAK-875 and Sitagliptin | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01414920 |
| Sitagliptin | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01414920 |
| TAK-875 | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01414920 |
| Placebo | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01414920 |
| TAK-700 | Other | Phase PHASE2 | Prostate Cancer | COMPLETED | NCT01046916 |
| TAK-700 | Other | Phase PHASE1 | Prostatic Neoplasms | COMPLETED | NCT00569153 |
| Fasiglifam | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01456195 |
| Placebo | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01456195 |
| Azilsartan | Other | Phase PHASE3 | Pediatric Hypertension | COMPLETED | NCT02451150 |
| Azilsartan | Other | Phase PHASE3 | Pediatric Hypertension | COMPLETED | NCT02451150 |
| Naltrexone HCl/Bupropion HCl | Other | Phase PHASE4 | Weight Regain Post Bariatric Surgery | WITHDRAWN | NCT02616315 |
| Naltrexone HCl/Bupropion HCl Placebo | Other | Phase PHASE4 | Weight Regain Post Bariatric Surgery | WITHDRAWN | NCT02616315 |
| Naltrexone HCl/Bupropion HCl | Other | Phase PHASE4 | Weight Regain Post Bariatric Surgery | WITHDRAWN | NCT02616315 |
| Naltrexone HCl/Bupropion HCl Placebo | Other | Phase PHASE4 | Weight Regain Post Bariatric Surgery | WITHDRAWN | NCT02616315 |
| Rituximab | Other | Phase PHASE2 | Waldenstrom's Macroglobulinemia | COMPLETED | NCT00250926 |
| Dexamethasone | Other | Phase PHASE2 | Waldenstrom's Macroglobulinemia | COMPLETED | NCT00250926 |
| Bortezomib | Other | Phase PHASE2 | Waldenstrom's Macroglobulinemia | COMPLETED | NCT00250926 |
| Rituximab | Other | Phase PHASE2 | Waldenstrom's Macroglobulinemia | COMPLETED | NCT00250926 |
| Dexamethasone | Other | Phase PHASE2 | Waldenstrom's Macroglobulinemia | COMPLETED | NCT00250926 |
| Bortezomib | Other | Phase PHASE2 | Waldenstrom's Macroglobulinemia | COMPLETED | NCT00250926 |
| Febuxostat placebo | Other | Phase PHASE4 | Coronary Artery Disease | COMPLETED | NCT01763996 |
| Febuxostat | Other | Phase PHASE4 | Coronary Artery Disease | COMPLETED | NCT01763996 |
| Febuxostat placebo | Other | Phase PHASE4 | Coronary Artery Disease | COMPLETED | NCT01763996 |
| Febuxostat | Other | Phase PHASE4 | Coronary Artery Disease | COMPLETED | NCT01763996 |
| Veltuzumab | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT01390545 |
| Veltuzumab | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT01390545 |
| Placebo | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01007097 |
| Glimepiride | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01007097 |
| TAK-875 | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01007097 |
| Placebo | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01007097 |
| Glimepiride | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01007097 |
| TAK-875 | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01007097 |
| Placebo | Other | Phase PHASE2 | Acute Coronary Syndrome | COMPLETED | NCT00677053 |
| TAK-442 | Other | Phase PHASE2 | Acute Coronary Syndrome | COMPLETED | NCT00677053 |
| Placebo | Other | Phase PHASE2 | Acute Coronary Syndrome | COMPLETED | NCT00677053 |
| TAK-442 | Other | Phase PHASE2 | Acute Coronary Syndrome | COMPLETED | NCT00677053 |
| Enoxaparin | Other | Phase PHASE2 | Venous Thromboembolism | COMPLETED | NCT00641732 |
| TAK-442 | Other | Phase PHASE2 | Venous Thromboembolism | COMPLETED | NCT00641732 |
| Pioglitazone/glimepiride | Other | Preclinical | Type 2 Diabetes | COMPLETED | NCT02098733 |
| Pioglitazone/glimepiride | Other | Preclinical | Type 2 Diabetes | COMPLETED | NCT02098733 |
| TAK-536TCH | Other | Phase PHASE1 | Hypertension | COMPLETED | NCT02348658 |
| TAK-536TCH | Other | Phase PHASE1 | Hypertension | COMPLETED | NCT02348658 |
| TAK-816 | Other | Phase PHASE3 | Healthy Volunteers | COMPLETED | NCT02074345 |
| TAK-816 | Other | Phase PHASE3 | Healthy Volunteers | COMPLETED | NCT02074345 |
| Febuxostat XR | Other | Phase PHASE1 | Gout | COMPLETED | NCT02374164 |
| Febuxostat XR | Other | Phase PHASE1 | Gout | COMPLETED | NCT02374164 |
| Maalox Advance Regular Strength liquid | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02382640 |
| Febuxostat XR | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02382640 |
| Maalox Advance Regular Strength liquid | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02382640 |
| Febuxostat XR | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02382640 |
| Bortezomib | Other | Phase PHASE2 | Kidney Transplantation | COMPLETED | NCT00722722 |
| Bortezomib | Other | Phase PHASE2 | Kidney Transplantation | COMPLETED | NCT00722722 |
| Bortezomib | Other | Phase PHASE2 | Kidney Transplantation | COMPLETED | NCT00722722 |
| Brentuximab vedotin and rifampicin | Other | Phase PHASE1 | Hodgkin Lymphoma | COMPLETED | NCT01950364 |
| brentuximab vedotin | Other | Phase PHASE1 | Hodgkin Lymphoma | COMPLETED | NCT01950364 |
| Brentuximab vedotin and rifampicin | Other | Phase PHASE1 | Hodgkin Lymphoma | COMPLETED | NCT01950364 |
| brentuximab vedotin | Other | Phase PHASE1 | Hodgkin Lymphoma | COMPLETED | NCT01950364 |
| Placebo | Other | Phase PHASE4 | Attention Deficit Hyperactivity Disorder | COMPLETED | NCT02501798 |
| Methylphenidate | Other | Phase PHASE4 | Attention Deficit Hyperactivity Disorder | COMPLETED | NCT02501798 |
| Placebo | Other | Phase PHASE3 | Bipolar Disorder | TERMINATED | NCT01467713 |
| Ramelteon SL | Other | Phase PHASE3 | Bipolar Disorder | TERMINATED | NCT01467713 |
| Placebo | Other | Phase PHASE3 | Acute Depressive Episode | TERMINATED | NCT01467700 |
| Ramelteon SL | Other | Phase PHASE3 | Acute Depressive Episode | TERMINATED | NCT01467700 |
| Placebo | Other | Phase PHASE3 | Acute Depressive Episode | TERMINATED | NCT01467700 |
| Ramelteon SL | Other | Phase PHASE3 | Acute Depressive Episode | TERMINATED | NCT01467700 |
| Clarithromycin | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02774902 |
| TAK-438 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02774902 |
| Clarithromycin | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02774902 |
| TAK-438 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02774902 |
| Placebo | Other | Phase PHASE3 | Atrial Fibrillation | UNKNOWN | NCT02764619 |
| Spironolactone | Other | Phase PHASE3 | Atrial Fibrillation | UNKNOWN | NCT02764619 |
| Placebo | Other | Phase PHASE3 | Atrial Fibrillation | UNKNOWN | NCT02764619 |
| Spironolactone | Other | Phase PHASE3 | Atrial Fibrillation | UNKNOWN | NCT02764619 |
| Midazolam | Other | Phase PHASE1 | Japanese Healthy Adult Males | COMPLETED | NCT02370615 |
| Itraconazole | Other | Phase PHASE1 | Japanese Healthy Adult Males | COMPLETED | NCT02370615 |
| Digoxin | Other | Phase PHASE1 | Japanese Healthy Adult Males | COMPLETED | NCT02370615 |
| TAK-272 | Other | Phase PHASE1 | Japanese Healthy Adult Males | COMPLETED | NCT02370615 |
| Midazolam | Other | Phase PHASE1 | Japanese Healthy Adult Males | COMPLETED | NCT02370615 |
| Itraconazole | Other | Phase PHASE1 | Japanese Healthy Adult Males | COMPLETED | NCT02370615 |
| Digoxin | Other | Phase PHASE1 | Japanese Healthy Adult Males | COMPLETED | NCT02370615 |
| TAK-272 | Other | Phase PHASE1 | Japanese Healthy Adult Males | COMPLETED | NCT02370615 |
| Azilsartan | Other | Phase PHASE4 | Essential Hypertension With Stable Angina and Dyslipidemia | WITHDRAWN | NCT02400775 |
| Azilsartan | Other | Phase PHASE4 | Essential Hypertension With Stable Angina and Dyslipidemia | WITHDRAWN | NCT02400775 |
| Glimepiride | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | TERMINATED | NCT01829477 |
| TAK-875 Placebo | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | TERMINATED | NCT01829477 |
| TAK-875 | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | TERMINATED | NCT01829477 |
| Glimepiride | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | TERMINATED | NCT01829477 |
| TAK-875 Placebo | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | TERMINATED | NCT01829477 |
| TAK-875 | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | TERMINATED | NCT01829477 |
| TAK-875 | Other | Phase PHASE3 | Diabetes | TERMINATED | NCT01829464 |
| Placebo | Other | Phase PHASE3 | Diabetes | TERMINATED | NCT01829464 |
| TAK-875 | Other | Phase PHASE3 | Diabetes | TERMINATED | NCT01829464 |
| Placebo | Other | Phase PHASE3 | Diabetes | TERMINATED | NCT01829464 |
| TAK-875 | Other | Phase PHASE3 | Diabetes | TERMINATED | NCT01829464 |
| Placebo | Other | Phase PHASE3 | Diabetes | TERMINATED | NCT01829464 |
| Orteronel+Prednisone | Other | Phase PHASE2 | Prostate Cancer | COMPLETED | NCT01549951 |
| Orteronel+Prednisone | Other | Phase PHASE2 | Prostate Cancer | COMPLETED | NCT01549951 |
| Glimepiride | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | TERMINATED | NCT01481116 |
| TAK-875 | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | TERMINATED | NCT01481116 |
| Glimepiride | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | TERMINATED | NCT01481116 |
| TAK-875 | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | TERMINATED | NCT01481116 |
| Placebo | Other | Phase PHASE3 | Glycemic Control | TERMINATED | NCT01549964 |
| Sitagliptin | Other | Phase PHASE3 | Glycemic Control | TERMINATED | NCT01549964 |
| Fasiglifam (TAK-875) | Other | Phase PHASE3 | Glycemic Control | TERMINATED | NCT01549964 |
| Placebo | Other | Phase PHASE3 | Glycemic Control | TERMINATED | NCT01549964 |
| Sitagliptin | Other | Phase PHASE3 | Glycemic Control | TERMINATED | NCT01549964 |
| Fasiglifam (TAK-875) | Other | Phase PHASE3 | Glycemic Control | TERMINATED | NCT01549964 |
| Atorvastatin | Other | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT02093390 |
| Fluconazole | Other | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT02093390 |
| TAK-385 | Other | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT02093390 |
| Atorvastatin | Other | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT02093390 |
| Fluconazole | Other | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT02093390 |
| TAK-385 | Other | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT02093390 |
| MT203 300 mg or matching placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02354599 |
| MT203 150mg or matching Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02354599 |
| MT203 80 mg or matching Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02354599 |
| MT203 300 mg or matching placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02354599 |
| MT203 150mg or matching Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02354599 |
| MT203 80 mg or matching Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02354599 |
| Placebo | Other | Phase PHASE2 | Diabetic Neuropathies | COMPLETED | NCT00760955 |
| TAK-583 | Other | Phase PHASE2 | Diabetic Neuropathies | COMPLETED | NCT00760955 |
| Placebo | Other | Phase PHASE2 | Diabetic Neuropathies | COMPLETED | NCT00760955 |
| TAK-583 | Other | Phase PHASE2 | Diabetic Neuropathies | COMPLETED | NCT00760955 |
| Sitagliptin | Other | Phase PHASE2 | Diabetes Mellitus | COMPLETED | NCT00760344 |
| Placebo | Other | Phase PHASE2 | Diabetes Mellitus | COMPLETED | NCT00760344 |
| SYR-472 | Other | Phase PHASE2 | Diabetes Mellitus | COMPLETED | NCT00760344 |
| Sitagliptin | Other | Phase PHASE2 | Diabetes Mellitus | COMPLETED | NCT00760344 |
| Placebo | Other | Phase PHASE2 | Diabetes Mellitus | COMPLETED | NCT00760344 |
| SYR-472 | Other | Phase PHASE2 | Diabetes Mellitus | COMPLETED | NCT00760344 |
| Placebo | Other | Phase PHASE2 | Diabetes Mellitus | TERMINATED | NCT00722917 |
| Pioglitazone | Other | Phase PHASE2 | Diabetes Mellitus | TERMINATED | NCT00722917 |
| TAK-379 | Other | Phase PHASE2 | Diabetes Mellitus | TERMINATED | NCT00722917 |
| Placebo | Other | Phase PHASE2 | Diabetes Mellitus | TERMINATED | NCT00722917 |
| Pioglitazone | Other | Phase PHASE2 | Diabetes Mellitus | TERMINATED | NCT00722917 |
| TAK-379 | Other | Phase PHASE2 | Diabetes Mellitus | TERMINATED | NCT00722917 |
| Placebo | Other | Phase PHASE2 | Diabetes Mellitus | COMPLETED | NCT00653185 |
| SYR-472 | Other | Phase PHASE2 | Diabetes Mellitus | COMPLETED | NCT00653185 |
| Placebo | Other | Phase PHASE2 | Diabetes Mellitus | COMPLETED | NCT00653185 |
| SYR-472 | Other | Phase PHASE2 | Diabetes Mellitus | COMPLETED | NCT00653185 |
| Stable statin therapy | Drug | Phase PHASE3 | Hypercholesterolemia | TERMINATED | NCT00532311 |
| Lapaquistat acetate and stable statin therapy | Drug | Phase PHASE3 | Hypercholesterolemia | TERMINATED | NCT00532311 |
| Stable statin therapy | Drug | Phase PHASE3 | Hypercholesterolemia | TERMINATED | NCT00532311 |
| Lapaquistat acetate and stable statin therapy | Drug | Phase PHASE3 | Hypercholesterolemia | TERMINATED | NCT00532311 |
| Placebo | Other | Phase PHASE4 | Chronic Insomnia | COMPLETED | NCT00414102 |
| Ramelteon | Other | Phase PHASE4 | Chronic Insomnia | COMPLETED | NCT00414102 |
| Placebo | Other | Phase PHASE4 | Chronic Insomnia | COMPLETED | NCT00414102 |
| Ramelteon | Other | Phase PHASE4 | Chronic Insomnia | COMPLETED | NCT00414102 |
| TAK-536 Ganule Formulation | Other | Phase PHASE1 | Japanese Healthy Adult Males | COMPLETED | NCT02401464 |
| TAK-536 Dry Syrup Formulation | Other | Phase PHASE1 | Japanese Healthy Adult Males | COMPLETED | NCT02401464 |
| TAK-536 Tablet | Other | Phase PHASE1 | Japanese Healthy Adult Males | COMPLETED | NCT02401464 |
| TAK-536 Ganule Formulation | Other | Phase PHASE1 | Japanese Healthy Adult Males | COMPLETED | NCT02401464 |
| TAK-536 Dry Syrup Formulation | Other | Phase PHASE1 | Japanese Healthy Adult Males | COMPLETED | NCT02401464 |
| TAK-536 Tablet | Other | Phase PHASE1 | Japanese Healthy Adult Males | COMPLETED | NCT02401464 |
| No Intervention | Other | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT02678676 |
| No Intervention | Other | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT02678676 |
| No Intervention | Other | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT02678676 |
| TAK-137 Placebo | Other | Phase PHASE1 | Attention-Deficit/Hyperactivity Disorder | TERMINATED | NCT02163915 |
| TAK-137 | Other | Phase PHASE1 | Attention-Deficit/Hyperactivity Disorder | TERMINATED | NCT02163915 |
| TAK-137 Placebo | Other | Phase PHASE1 | Attention-Deficit/Hyperactivity Disorder | TERMINATED | NCT02163915 |
| TAK-137 | Other | Phase PHASE1 | Attention-Deficit/Hyperactivity Disorder | TERMINATED | NCT02163915 |
| Bortezomib | Other | Phase PHASE2 | Cancer | TERMINATED | NCT00983346 |
| Bortezomib | Other | Phase PHASE2 | Cancer | TERMINATED | NCT00983346 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02201056 |
| TAK-935 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02201056 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02201056 |
| TAK-935 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02201056 |
| TAK-648 Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02684396 |
| TAK-648 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02684396 |
| Ramelteon | Other | Preclinical | Insomnia | COMPLETED | NCT02058992 |
| Ramelteon | Other | Preclinical | Insomnia | COMPLETED | NCT02058992 |
| Placebo control | Other | Phase PHASE3 | Binge Eating Disorder | COMPLETED | NCT01090713 |
| lisdexamfetamine | Other | Phase PHASE3 | Binge Eating Disorder | COMPLETED | NCT01090713 |
| TAK-915 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02584569 |
| TAK-915 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02584569 |
| TAK-385 T4 Formulation C | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02396147 |
| TAK-385 T4 Formulation B | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02396147 |
| TAK-385 T2 Formulation | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02396147 |
| TAK-385 T4 Formulation C | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02396147 |
| TAK-385 T4 Formulation B | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02396147 |
| TAK-385 T2 Formulation | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02396147 |
| TAK-114 matched placebo | Other | Phase PHASE1 | Clinical Pharmacology | COMPLETED | NCT02286518 |
| TAK-114 10 mg capsule | Other | Phase PHASE1 | Clinical Pharmacology | COMPLETED | NCT02286518 |
| TAK-114 matched placebo | Other | Phase PHASE1 | Clinical Pharmacology | COMPLETED | NCT02286518 |
| TAK-114 10 mg capsule | Other | Phase PHASE1 | Clinical Pharmacology | COMPLETED | NCT02286518 |
| MLN3126 Matched Placebo | Other | Phase PHASE1 | Safety | TERMINATED | NCT02209506 |
| MLN3126 | Other | Phase PHASE1 | Safety | TERMINATED | NCT02209506 |
| MLN3126 Matched Placebo | Other | Phase PHASE1 | Safety | TERMINATED | NCT02209506 |
| MLN3126 | Other | Phase PHASE1 | Safety | TERMINATED | NCT02209506 |
| Dexlansoprazole MR | Other | Phase PHASE3 | Gastroesophageal Reflux Disease | COMPLETED | NCT00255190 |
| Placebo | Other | Phase PHASE3 | Impaired Glucose Tolerance | COMPLETED | NCT00220961 |
| Pioglitazone | Other | Phase PHASE3 | Impaired Glucose Tolerance | COMPLETED | NCT00220961 |
| Placebo | Other | Phase PHASE3 | Impaired Glucose Tolerance | COMPLETED | NCT00220961 |
| Pioglitazone | Other | Phase PHASE3 | Impaired Glucose Tolerance | COMPLETED | NCT00220961 |
| Placebo | Other | Phase PHASE3 | Impaired Glucose Tolerance | COMPLETED | NCT00220961 |
| Pioglitazone | Other | Phase PHASE3 | Impaired Glucose Tolerance | COMPLETED | NCT00220961 |
| MLN8237 (Alisertib) | Other | Phase PHASE1 | Advanced Nonhematological Malignancies | COMPLETED | NCT01045421 |
| MLN8237 (Alisertib) | Other | Phase PHASE1 | Advanced Nonhematological Malignancies | COMPLETED | NCT01045421 |
| MLN8237 (Alisertib) | Other | Phase PHASE1 | Advanced Nonhematological Malignancies | COMPLETED | NCT01045421 |
| 851B | Other | Phase PHASE2 | Papillomavirus Infections | TERMINATED | NCT00117884 |
| 851B | Other | Phase PHASE2 | Papillomavirus Infections | TERMINATED | NCT00117884 |
| TAK-850 | Other | Phase PHASE2 | Influenza Prevention | WITHDRAWN | NCT02713061 |
| TAK-850 | Other | Phase PHASE2 | Influenza Prevention | WITHDRAWN | NCT02713061 |
| Vortioxetine | Other | Phase EARLY_PHASE1 | Major Depressive Disorder | WITHDRAWN | NCT02454426 |
| Vortioxetine | Other | Phase EARLY_PHASE1 | Major Depressive Disorder | WITHDRAWN | NCT02454426 |
| TAK-648 Oral Solution | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02480439 |
| TAK-648 Tablet | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02480439 |
| TAK-648 Oral Solution | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02480439 |
| TAK-648 Tablet | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02480439 |
| Placebo | Other | Phase PHASE1 | Type 2 Diabetes Mellitus | COMPLETED | NCT02430870 |
| TAK-648 | Other | Phase PHASE1 | Type 2 Diabetes Mellitus | COMPLETED | NCT02430870 |
| Placebo | Other | Phase PHASE3 | TBI | WITHDRAWN | NCT02845349 |
| Vortioxetine | Other | Phase PHASE3 | TBI | WITHDRAWN | NCT02845349 |
| Placebo | Other | Phase PHASE3 | TBI | WITHDRAWN | NCT02845349 |
| Vortioxetine | Other | Phase PHASE3 | TBI | WITHDRAWN | NCT02845349 |
| MLN0264 | Other | Phase PHASE1 | Advanced Gastrointestinal Malignancies | COMPLETED | NCT01577758 |
| MLN0264 | Other | Phase PHASE1 | Advanced Gastrointestinal Malignancies | COMPLETED | NCT01577758 |
| ustekinumab | Other | Preclinical | Alzheimer Disease | UNKNOWN | NCT02835716 |
| roflumilast | Other | Preclinical | Alzheimer Disease | UNKNOWN | NCT02835716 |
| ustekinumab | Other | Preclinical | Alzheimer Disease | UNKNOWN | NCT02835716 |
| roflumilast | Other | Preclinical | Alzheimer Disease | UNKNOWN | NCT02835716 |
| Peginesatide | Other | Phase PHASE3 | Chronic Kidney Disease | COMPLETED | NCT01478971 |
| Epoetin | Other | Phase PHASE3 | Chronic Kidney Disease | COMPLETED | NCT01478971 |
| Peginesatide | Other | Phase PHASE3 | Chronic Kidney Disease | COMPLETED | NCT01478971 |
| Epoetin | Other | Phase PHASE3 | Chronic Kidney Disease | COMPLETED | NCT01478971 |
| Eicosapentaenoic acid-ethyl (EPA) | Other | Phase PHASE3 | Hypertriglyceridemia | COMPLETED | NCT01350999 |
| omega-3-acid ethyl esters 90 (TAK-085) | Other | Phase PHASE3 | Hypertriglyceridemia | COMPLETED | NCT01350999 |
| Eicosapentaenoic acid-ethyl (EPA) | Other | Phase PHASE3 | Hypertriglyceridemia | COMPLETED | NCT01350999 |
| omega-3-acid ethyl esters 90 (TAK-085) | Other | Phase PHASE3 | Hypertriglyceridemia | COMPLETED | NCT01350999 |
| Eicosapentaenoic acid-ethyl (EPA-E) | Other | Phase PHASE3 | Hypertriglyceridemia | COMPLETED | NCT01350973 |
| Omega-3-acid ethyl esters 90 (TAK-085) | Other | Phase PHASE3 | Hypertriglyceridemia | COMPLETED | NCT01350973 |
| Eicosapentaenoic acid-ethyl (EPA-E) | Other | Phase PHASE3 | Hypertriglyceridemia | COMPLETED | NCT01350973 |
| Omega-3-acid ethyl esters 90 (TAK-085) | Other | Phase PHASE3 | Hypertriglyceridemia | COMPLETED | NCT01350973 |
| Vedolizumab subcutaneous injection | Other | Phase PHASE2 | Ulcerative Colitis | WITHDRAWN | NCT02913508 |
| Vedolizumab intravenous injection | Other | Phase PHASE2 | Ulcerative Colitis | WITHDRAWN | NCT02913508 |
| Vedolizumab subcutaneous injection | Other | Phase PHASE2 | Ulcerative Colitis | WITHDRAWN | NCT02913508 |
| Vedolizumab intravenous injection | Other | Phase PHASE2 | Ulcerative Colitis | WITHDRAWN | NCT02913508 |
| 851B | Other | Phase PHASE2 | Papillomavirus Infections | TERMINATED | NCT00312286 |
| Lansoprazole | Other | Preclinical | Gastroesophageal Reflux Disease With Dyspepsia Symptoms | COMPLETED | NCT01990339 |
| Alogliptin | Other | Preclinical | Type 2 Diabetes Melitus | COMPLETED | NCT01945242 |
| Alogliptin | Other | Preclinical | Type 2 Diabetes Melitus | COMPLETED | NCT01945242 |
| candesartan cilexetil | Other | Preclinical | Hypertension | COMPLETED | NCT02166697 |
| candesartan cilexetil | Other | Preclinical | Hypertension | COMPLETED | NCT02166697 |
| candesartan cilexetil | Other | Preclinical | Hypertension | COMPLETED | NCT02166697 |
| Vortioxetine | Other | Phase PHASE4 | Unipolar Major Depression | WITHDRAWN | NCT02637466 |
| Vortioxetine | Other | Phase PHASE4 | Unipolar Major Depression | WITHDRAWN | NCT02637466 |
| Second generation antipsychotic | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT02079844 |
| Placebo | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT02079844 |
| Roflumilast | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT02079844 |
| Second generation antipsychotic | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT02079844 |
| Placebo | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT02079844 |
| Roflumilast | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT02079844 |
| Placebo | Other | Approved | Chronic Kidney Disease | COMPLETED | NCT01350388 |
| Febuxostat | Other | Approved | Chronic Kidney Disease | COMPLETED | NCT01350388 |
| Placebo | Other | Approved | Chronic Kidney Disease | COMPLETED | NCT01350388 |
| Febuxostat | Other | Approved | Chronic Kidney Disease | COMPLETED | NCT01350388 |
| Placebo | Other | Approved | Chronic Kidney Disease | COMPLETED | NCT01350388 |
| Febuxostat | Other | Approved | Chronic Kidney Disease | COMPLETED | NCT01350388 |
| SYR-322MET | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02508168 |
| Metformin Hydrochloride | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02508168 |
| Alogliptin | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02508168 |
| SYR-322MET | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02508168 |
| Metformin Hydrochloride | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02508168 |
| Alogliptin | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02508168 |
| Placebo to fasiglifam | Other | Phase PHASE2 | Type 2 Diabetes Mellitus | TERMINATED | NCT01982253 |
| Fasiglifam | Other | Phase PHASE2 | Type 2 Diabetes Mellitus | TERMINATED | NCT01982253 |
| Placebo to fasiglifam | Other | Phase PHASE2 | Type 2 Diabetes Mellitus | TERMINATED | NCT01982253 |
| Fasiglifam | Other | Phase PHASE2 | Type 2 Diabetes Mellitus | TERMINATED | NCT01982253 |
| Ramelteon | Other | Preclinical | Insomnia | COMPLETED | NCT02153086 |
| Rabeprazole sodium | Other | Phase PHASE3 | Healthy Volunteers | COMPLETED | NCT02037477 |
| Esomeprazole | Other | Phase PHASE3 | Healthy Volunteers | COMPLETED | NCT02037477 |
| Vonoprazan | Other | Phase PHASE3 | Healthy Volunteers | COMPLETED | NCT02037477 |
| Rabeprazole sodium | Other | Phase PHASE3 | Healthy Volunteers | COMPLETED | NCT02037477 |
| Esomeprazole | Other | Phase PHASE3 | Healthy Volunteers | COMPLETED | NCT02037477 |
| Vonoprazan | Other | Phase PHASE3 | Healthy Volunteers | COMPLETED | NCT02037477 |
| Leuprorelin Acetate | Other | Preclinical | Breast Cancer | COMPLETED | NCT02134977 |
| Leuprorelin Acetate | Other | Preclinical | Breast Cancer | COMPLETED | NCT02134977 |
| Pioglitazone/glimepiride | Other | Preclinical | Type 2 Diabetes | COMPLETED | NCT02098746 |
| Pioglitazone/glimepiride | Other | Preclinical | Type 2 Diabetes | COMPLETED | NCT02098746 |
| Red-flags questionnaire | Other | Preclinical | Crohn's Disease | UNKNOWN | NCT02940054 |
| Red-flags questionnaire | Other | Preclinical | Crohn's Disease | UNKNOWN | NCT02940054 |
| Kalcipos-D | Other | Phase PHASE4 | Calcium and Vitamin D Deficiencies | COMPLETED | NCT02457247 |
| Adcal-D3 | Other | Phase PHASE4 | Calcium and Vitamin D Deficiencies | COMPLETED | NCT02457247 |
| Calcichew D3 | Other | Phase PHASE4 | Calcium and Vitamin D Deficiencies | COMPLETED | NCT02457247 |
| Kalcipos-D | Other | Phase PHASE4 | Calcium and Vitamin D Deficiencies | COMPLETED | NCT02457247 |
| Adcal-D3 | Other | Phase PHASE4 | Calcium and Vitamin D Deficiencies | COMPLETED | NCT02457247 |
| Calcichew D3 | Other | Phase PHASE4 | Calcium and Vitamin D Deficiencies | COMPLETED | NCT02457247 |
| MLN1202 Placebo | Other | Phase PHASE1 | Healthy Japanese and Caucasian Male Adults | WITHDRAWN | NCT02426021 |
| MLN1202 | Other | Phase PHASE1 | Healthy Japanese and Caucasian Male Adults | WITHDRAWN | NCT02426021 |
| [14C]-TAK-385 Solution for Intravenous Infusion | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02252354 |
| TAK-385 Tablets | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02252354 |
| [14C]-TAK-385 Oral Solution | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02252354 |
| [14C]-TAK-385 Solution for Intravenous Infusion | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02252354 |
| TAK-385 Tablets | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02252354 |
| [14C]-TAK-385 Oral Solution | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02252354 |
| Lansoprazole | Other | Preclinical | Gastric or Duodenal Ulcers | COMPLETED | NCT02099708 |
| Lansoprazole | Other | Preclinical | Gastric or Duodenal Ulcers | COMPLETED | NCT02099708 |
| Prednisone | Other | Phase PHASE1 | Lymphoma, B-Cell | COMPLETED | NCT00634179 |
| Vincristine | Other | Phase PHASE1 | Lymphoma, B-Cell | COMPLETED | NCT00634179 |
| Cyclophosphamide | Other | Phase PHASE1 | Lymphoma, B-Cell | COMPLETED | NCT00634179 |
| Doxorubicin | Other | Phase PHASE1 | Lymphoma, B-Cell | COMPLETED | NCT00634179 |
| Rituximab | Other | Phase PHASE1 | Lymphoma, B-Cell | COMPLETED | NCT00634179 |
| Bortezomib | Other | Phase PHASE1 | Lymphoma, B-Cell | COMPLETED | NCT00634179 |
| Prednisone | Other | Phase PHASE1 | Lymphoma, B-Cell | COMPLETED | NCT00634179 |
| Vincristine | Other | Phase PHASE1 | Lymphoma, B-Cell | COMPLETED | NCT00634179 |
| Cyclophosphamide | Other | Phase PHASE1 | Lymphoma, B-Cell | COMPLETED | NCT00634179 |
| Doxorubicin | Other | Phase PHASE1 | Lymphoma, B-Cell | COMPLETED | NCT00634179 |
| Rituximab | Other | Phase PHASE1 | Lymphoma, B-Cell | COMPLETED | NCT00634179 |
| Bortezomib | Other | Phase PHASE1 | Lymphoma, B-Cell | COMPLETED | NCT00634179 |
| TAK-063 Placebo | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT01879722 |
| TAK-063 | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT01879722 |
| Acupuncture | Other | Phase PHASE2 | Lymphoma | COMPLETED | NCT00891618 |
| Lansoprazole | Other | Phase PHASE3 | Gout | COMPLETED | NCT02139046 |
| Naproxen | Other | Phase PHASE3 | Gout | COMPLETED | NCT02139046 |
| Colchicine | Other | Phase PHASE3 | Gout | COMPLETED | NCT02139046 |
| Febuxostat placebo | Other | Phase PHASE3 | Gout | COMPLETED | NCT02139046 |
| Febuxostat XR | Other | Phase PHASE3 | Gout | COMPLETED | NCT02139046 |
| Febuxostat IR | Other | Phase PHASE3 | Gout | COMPLETED | NCT02139046 |
| Lansoprazole | Other | Phase PHASE2 | Gout | COMPLETED | NCT02128490 |
| Naproxen | Other | Phase PHASE2 | Gout | COMPLETED | NCT02128490 |
| Colchicine | Other | Phase PHASE2 | Gout | COMPLETED | NCT02128490 |
| Febuxostat placebo | Other | Phase PHASE2 | Gout | COMPLETED | NCT02128490 |
| Febuxostat XR | Other | Phase PHASE2 | Gout | COMPLETED | NCT02128490 |
| Febuxostat IR | Other | Phase PHASE2 | Gout | COMPLETED | NCT02128490 |
| Lansoprazole | Other | Phase PHASE2 | Gout | COMPLETED | NCT02128490 |
| Naproxen | Other | Phase PHASE2 | Gout | COMPLETED | NCT02128490 |
| Colchicine | Other | Phase PHASE2 | Gout | COMPLETED | NCT02128490 |
| Febuxostat placebo | Other | Phase PHASE2 | Gout | COMPLETED | NCT02128490 |
| Febuxostat XR | Other | Phase PHASE2 | Gout | COMPLETED | NCT02128490 |
| Febuxostat IR | Other | Phase PHASE2 | Gout | COMPLETED | NCT02128490 |
| Lansoprazole | Other | Preclinical | Gastric or Duodenal Ulcers | COMPLETED | NCT02099682 |
| Lansoprazole | Other | Preclinical | Gastric or Duodenal Ulcers | COMPLETED | NCT02099682 |
| doxorubicin and bortezomib | Other | Phase PHASE2 | Adenoid Cystic Carcinoma | COMPLETED | NCT00581360 |
| doxorubicin and bortezomib | Other | Phase PHASE2 | Adenoid Cystic Carcinoma | COMPLETED | NCT00581360 |
| Pioglitazone | Other | Preclinical | Type 2 Diabetes Mellitus | COMPLETED | NCT02003014 |
| Pioglitazone | Other | Preclinical | Type 2 Diabetes Mellitus | COMPLETED | NCT02003014 |
| Pioglitazone | Other | Preclinical | Type 2 Diabetes Mellitus | COMPLETED | NCT02003014 |
| Placebo | Other | Phase PHASE4 | Chronic Venous Insufficiency | COMPLETED | NCT01848210 |
| Coumarin/troxerutin | Other | Phase PHASE4 | Chronic Venous Insufficiency | COMPLETED | NCT01848210 |
| Placebo | Other | Phase PHASE4 | Chronic Venous Insufficiency | COMPLETED | NCT01848210 |
| Coumarin/troxerutin | Other | Phase PHASE4 | Chronic Venous Insufficiency | COMPLETED | NCT01848210 |
| Pioglitazone/metformin hydrochloride | Other | Preclinical | Type 2 Diabetes Mellitus | COMPLETED | NCT02024971 |
| Pioglitazone/metformin hydrochloride | Other | Preclinical | Type 2 Diabetes Mellitus | COMPLETED | NCT02024971 |
| Pioglitazone/metformin hydrochloride | Other | Preclinical | Type 2 Diabetes Mellitus | COMPLETED | NCT02024971 |
| Alogliptin and Metformin FDC Placebo | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT01890122 |
| Metformin Placebo | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT01890122 |
| Alogliptin Placebo | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT01890122 |
| Alogliptin and Metformin Fixed-Dose Combination (FDC) | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT01890122 |
| Metformin HCl | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT01890122 |
| Alogliptin | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT01890122 |
| Alogliptin and Metformin FDC Placebo | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT01890122 |
| Metformin Placebo | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT01890122 |
| Alogliptin Placebo | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT01890122 |
| Alogliptin and Metformin Fixed-Dose Combination (FDC) | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT01890122 |
| Metformin HCl | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT01890122 |
| Alogliptin | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT01890122 |
| Azilsartan medoxomil placebo | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT02203916 |
| Azilsartan medoxomil | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT02203916 |
| TachoSil® | Other | Preclinical | Lymph Node Resection | COMPLETED | NCT01920958 |
| TachoSil® | Other | Preclinical | Lymph Node Resection | COMPLETED | NCT01920958 |
| Influenza HA vaccine | Other | Phase PHASE2 | Influenza Infection | COMPLETED | NCT02555618 |
| TAK-850 | Other | Phase PHASE2 | Influenza Infection | COMPLETED | NCT02555618 |
| Influenza HA vaccine | Other | Phase PHASE2 | Influenza Infection | COMPLETED | NCT02555618 |
| TAK-850 | Other | Phase PHASE2 | Influenza Infection | COMPLETED | NCT02555618 |
| Lubiprostone | Other | Approved | Constipation | TERMINATED | NCT00669461 |
| Lubiprostone | Other | Approved | Constipation | TERMINATED | NCT00669461 |
| [68Ga]MLN6907 | Other | Phase PHASE1 | Imaging of Solid Gastrointestinal Tumors | COMPLETED | NCT02056015 |
| [68Ga]MLN6907 | Other | Phase PHASE1 | Imaging of Solid Gastrointestinal Tumors | COMPLETED | NCT02056015 |
| [68Ga]MLN6907 | Other | Phase PHASE1 | Imaging of Solid Gastrointestinal Tumors | COMPLETED | NCT02056015 |
| bortezomib and G-CSF | Other | Phase EARLY_PHASE1 | Malignant Lymphoma, Stem Cell Type | COMPLETED | NCT01171092 |
| bortezomib and G-CSF | Other | Phase EARLY_PHASE1 | Malignant Lymphoma, Stem Cell Type | COMPLETED | NCT01171092 |
| Prednisone | Other | Phase PHASE2 | Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL) | COMPLETED | NCT00931918 |
| Vincristine | Other | Phase PHASE2 | Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL) | COMPLETED | NCT00931918 |
| Doxorubicin | Other | Phase PHASE2 | Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL) | COMPLETED | NCT00931918 |
| Cyclophosphamide | Other | Phase PHASE2 | Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL) | COMPLETED | NCT00931918 |
| Rituximab | Other | Phase PHASE2 | Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL) | COMPLETED | NCT00931918 |
| Bortezomib | Other | Phase PHASE2 | Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL) | COMPLETED | NCT00931918 |
| Prednisone | Other | Phase PHASE2 | Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL) | COMPLETED | NCT00931918 |
| Vincristine | Other | Phase PHASE2 | Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL) | COMPLETED | NCT00931918 |
| Doxorubicin | Other | Phase PHASE2 | Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL) | COMPLETED | NCT00931918 |
| Cyclophosphamide | Other | Phase PHASE2 | Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL) | COMPLETED | NCT00931918 |
| Rituximab | Other | Phase PHASE2 | Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL) | COMPLETED | NCT00931918 |
| Bortezomib | Other | Phase PHASE2 | Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL) | COMPLETED | NCT00931918 |
| TAK-063 Placebo | Other | Phase PHASE1 | Ketamine-Induced Brain Activity Changes | COMPLETED | NCT01892189 |
| TAK-063 | Other | Phase PHASE1 | Ketamine-Induced Brain Activity Changes | COMPLETED | NCT01892189 |
| Ketamine | Other | Phase PHASE1 | Ketamine-Induced Brain Activity Changes | COMPLETED | NCT01892189 |
| TAK-063 Placebo | Other | Phase PHASE1 | Ketamine-Induced Brain Activity Changes | COMPLETED | NCT01892189 |
| TAK-063 | Other | Phase PHASE1 | Ketamine-Induced Brain Activity Changes | COMPLETED | NCT01892189 |
| Ketamine | Other | Phase PHASE1 | Ketamine-Induced Brain Activity Changes | COMPLETED | NCT01892189 |
| Febuxostat XR 80 mg Capsule F4 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02504320 |
| Febuxostat XR 80 mg Capsule F3 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02504320 |
| Febuxostat XR 80 mg Capsule F2 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02504320 |
| Febuxostat XR 80 mg Capsule F1 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02504320 |
| Febuxostat XR 80 mg Capsule F4 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02504320 |
| Febuxostat XR 80 mg Capsule F3 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02504320 |
| Febuxostat XR 80 mg Capsule F2 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02504320 |
| Febuxostat XR 80 mg Capsule F1 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02504320 |
| Mifamurtide | Other | Preclinical | Osteosarcoma | TERMINATED | NCT01194284 |
| Pioglitazone | Other | Phase PHASE4 | Metabolic Syndrome | COMPLETED | NCT00835120 |
| Pioglitazone | Other | Phase PHASE2 | Depressive Disorder, Major | COMPLETED | NCT00671515 |
| Pioglitazone | Other | Phase PHASE2 | Depressive Disorder, Major | COMPLETED | NCT00671515 |
| Pioglitazone | Other | Phase PHASE2 | Depressive Disorder, Major | COMPLETED | NCT00671515 |
| Smartpill wireless motility capsule | Other | Approved | Irritable Bowel Syndrome | COMPLETED | NCT01162863 |
| Placebo | Other | Approved | Irritable Bowel Syndrome | COMPLETED | NCT01162863 |
| Lubiprostone | Other | Approved | Irritable Bowel Syndrome | COMPLETED | NCT01162863 |
| Smartpill wireless motility capsule | Other | Approved | Irritable Bowel Syndrome | COMPLETED | NCT01162863 |
| Placebo | Other | Approved | Irritable Bowel Syndrome | COMPLETED | NCT01162863 |
| Lubiprostone | Other | Approved | Irritable Bowel Syndrome | COMPLETED | NCT01162863 |
| Smartpill wireless motility capsule | Other | Approved | Irritable Bowel Syndrome | COMPLETED | NCT01162863 |
| Placebo | Other | Approved | Irritable Bowel Syndrome | COMPLETED | NCT01162863 |
| Lubiprostone | Other | Approved | Irritable Bowel Syndrome | COMPLETED | NCT01162863 |
| Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain) | Other | Preclinical | Measles/Rubella | COMPLETED | NCT02151773 |
| Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain) | Other | Preclinical | Measles/Rubella | COMPLETED | NCT02151773 |
| Vedolizumab IV | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02163421 |
| Vedolizumab SC | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02163421 |
| brentuximab vedotin | Other | Phase PHASE2 | Disease, Hodgkin | COMPLETED | NCT00947856 |
| Surgicel® Original | Other | Phase PHASE3 | Bleeding | COMPLETED | NCT01500135 |
| TachoSil® | Other | Phase PHASE3 | Bleeding | COMPLETED | NCT01500135 |
| Surgicel® Original | Other | Phase PHASE3 | Bleeding | COMPLETED | NCT01500135 |
| TachoSil® | Other | Phase PHASE3 | Bleeding | COMPLETED | NCT01500135 |
| TAK-058 Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02389881 |
| TAK-058 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02389881 |
| TAK-058 Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02389881 |
| TAK-058 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02389881 |
| NE-58095 DR Placebo | Other | Phase PHASE2 | Involutional Osteoporosis | COMPLETED | NCT02063854 |
| NE-58095 DR | Other | Phase PHASE2 | Involutional Osteoporosis | COMPLETED | NCT02063854 |
| NE-58095 IR Placebo | Other | Phase PHASE2 | Involutional Osteoporosis | COMPLETED | NCT02063854 |
| NE-58095 IR | Other | Phase PHASE2 | Involutional Osteoporosis | COMPLETED | NCT02063854 |
| NE-58095 DR Placebo | Other | Phase PHASE2 | Involutional Osteoporosis | COMPLETED | NCT02063854 |
| NE-58095 DR | Other | Phase PHASE2 | Involutional Osteoporosis | COMPLETED | NCT02063854 |
| NE-58095 IR Placebo | Other | Phase PHASE2 | Involutional Osteoporosis | COMPLETED | NCT02063854 |
| NE-58095 IR | Other | Phase PHASE2 | Involutional Osteoporosis | COMPLETED | NCT02063854 |
| PBSCT | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT00307086 |
| Melphalan | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT00307086 |
| Bortezomib | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT00307086 |
| PBSCT | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT00307086 |
| Melphalan | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT00307086 |
| Bortezomib | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT00307086 |
| Placebo | Other | Phase PHASE3 | Primary Sclerosing Cholangitis | WITHDRAWN | NCT03035058 |
| Vedolizumab | Other | Phase PHASE3 | Primary Sclerosing Cholangitis | WITHDRAWN | NCT03035058 |
| Placebo | Other | Phase PHASE3 | Primary Sclerosing Cholangitis | WITHDRAWN | NCT03035058 |
| Vedolizumab | Other | Phase PHASE3 | Primary Sclerosing Cholangitis | WITHDRAWN | NCT03035058 |
| TAK-117 | Other | Phase PHASE1 | Metastatic Solid Tumors | COMPLETED | NCT01449370 |
| TAK-117 | Other | Phase PHASE1 | Metastatic Solid Tumors | COMPLETED | NCT01449370 |
| TAK-117 | Other | Phase PHASE1 | Metastatic Solid Tumors | COMPLETED | NCT01449370 |
| brentuximab vedotin | Other | Phase PHASE2 | Disease, Hodgkin | COMPLETED | NCT00848926 |
| brentuximab vedotin | Other | Phase PHASE2 | Disease, Hodgkin | COMPLETED | NCT00848926 |
| No Intervention | Other | Preclinical | Lymphoma, T-Cell, Peripheral | COMPLETED | NCT02788916 |
| No Intervention | Other | Preclinical | Lymphoma, T-Cell, Peripheral | COMPLETED | NCT02788916 |
| brentuximab vedotin | Other | Phase PHASE2 | Lymphoma, Large-Cell, Anaplastic | COMPLETED | NCT00866047 |
| brentuximab vedotin | Other | Phase PHASE2 | Lymphoma, Large-Cell, Anaplastic | COMPLETED | NCT00866047 |
| TAK-228 | Other | Phase PHASE1 | Malignant Neoplasms of Digestive Organs | WITHDRAWN | NCT02812056 |
| Alisertib | Other | Phase PHASE1 | Malignant Neoplasms of Digestive Organs | WITHDRAWN | NCT02812056 |
| MLN0264 | Other | Phase PHASE1 | Advanced Gastrointestinal Carcinoma | TERMINATED | NCT02391038 |
| MLN0264 | Other | Phase PHASE1 | Advanced Gastrointestinal Carcinoma | TERMINATED | NCT02391038 |
| MLN0264 | Other | Phase PHASE1 | Advanced Gastrointestinal Carcinoma | TERMINATED | NCT02391038 |
| MLN0264 | Other | Phase PHASE1 | Advanced Gastrointestinal Carcinoma | TERMINATED | NCT02391038 |
| TAK-448 | Other | Phase PHASE2 | Hypogonadotropic Hypogonadism | TERMINATED | NCT02369796 |
| TAK-448 | Other | Phase PHASE2 | Hypogonadotropic Hypogonadism | TERMINATED | NCT02369796 |
| Panitumumab | Other | Preclinical | Advanced or Recurrent Colorectal Cancer | COMPLETED | NCT02089737 |
| Panitumumab | Other | Preclinical | Advanced or Recurrent Colorectal Cancer | COMPLETED | NCT02089737 |
| [18F]MNI-792 (tracer) | Other | Phase PHASE1 | Epilepsy, Molecular Mechanisms of Pharmalogical Action, Protective Agents | COMPLETED | NCT02497235 |
| TAK-935 | Other | Phase PHASE1 | Epilepsy, Molecular Mechanisms of Pharmalogical Action, Protective Agents | COMPLETED | NCT02497235 |
| [18F]MNI-792 (tracer) | Other | Phase PHASE1 | Epilepsy, Molecular Mechanisms of Pharmalogical Action, Protective Agents | COMPLETED | NCT02497235 |
| TAK-935 | Other | Phase PHASE1 | Epilepsy, Molecular Mechanisms of Pharmalogical Action, Protective Agents | COMPLETED | NCT02497235 |
| ENK Cell Infusion | Other | Phase PHASE2 | Asymptomatic Multiple Myeloma | COMPLETED | NCT01884688 |
| ENK Cell Infusion | Other | Phase PHASE2 | Asymptomatic Multiple Myeloma | COMPLETED | NCT01884688 |
| Ondansetron Placebo | Other | Phase PHASE1 | Schizophrenia | TERMINATED | NCT02614586 |
| TAK-058 Placebo | Other | Phase PHASE1 | Schizophrenia | TERMINATED | NCT02614586 |
| Ondansetron | Other | Phase PHASE1 | Schizophrenia | TERMINATED | NCT02614586 |
| TAK-058 | Other | Phase PHASE1 | Schizophrenia | TERMINATED | NCT02614586 |
| Ondansetron Placebo | Other | Phase PHASE1 | Schizophrenia | TERMINATED | NCT02614586 |
| TAK-058 Placebo | Other | Phase PHASE1 | Schizophrenia | TERMINATED | NCT02614586 |
| Ondansetron | Other | Phase PHASE1 | Schizophrenia | TERMINATED | NCT02614586 |
| TAK-058 | Other | Phase PHASE1 | Schizophrenia | TERMINATED | NCT02614586 |
| Placebo to TAK-079 | Other | Phase PHASE1 | Autoimmune Disease | COMPLETED | NCT02219256 |
| TAK-079 | Other | Phase PHASE1 | Autoimmune Disease | COMPLETED | NCT02219256 |
| Dexlansoprazole Placebo | Other | Phase PHASE2 | Barrett's Esophagus | TERMINATED | NCT02162758 |
| Dexlansoprazole | Other | Phase PHASE2 | Barrett's Esophagus | TERMINATED | NCT02162758 |
| Dexlansoprazole Placebo | Other | Phase PHASE2 | Barrett's Esophagus | TERMINATED | NCT02162758 |
| Dexlansoprazole | Other | Phase PHASE2 | Barrett's Esophagus | TERMINATED | NCT02162758 |
| MLN0264 | Other | Phase PHASE2 | Pancreatic Adenocarcinoma | TERMINATED | NCT02202785 |
| MLN0264 | Other | Phase PHASE2 | Adenocarcinoma of the Stomach | TERMINATED | NCT02202759 |
| MLN0264 | Other | Phase PHASE2 | Adenocarcinoma of the Stomach | TERMINATED | NCT02202759 |
| Placebo | Other | Approved | Neuropathic Pain | TERMINATED | NCT00753623 |
| Ramelteon | Other | Approved | Neuropathic Pain | TERMINATED | NCT00753623 |
| Placebo | Other | Approved | Neuropathic Pain | TERMINATED | NCT00753623 |
| Ramelteon | Other | Approved | Neuropathic Pain | TERMINATED | NCT00753623 |
| Placebo | Other | Approved | Neuropathic Pain | TERMINATED | NCT00753623 |
| Ramelteon | Other | Approved | Neuropathic Pain | TERMINATED | NCT00753623 |
| TAK-448 Placebo | Other | Phase PHASE2 | Low Testosterone | TERMINATED | NCT02381288 |
| TAK-448 | Other | Phase PHASE2 | Low Testosterone | TERMINATED | NCT02381288 |
| Prednisone | Other | Phase PHASE3 | Prostate Cancer | COMPLETED | NCT01193244 |
| Placebo | Other | Phase PHASE3 | Prostate Cancer | COMPLETED | NCT01193244 |
| Orteronel | Other | Phase PHASE3 | Prostate Cancer | COMPLETED | NCT01193244 |
| Prednisone | Other | Phase PHASE3 | Prostate Cancer | COMPLETED | NCT01193244 |
| Placebo | Other | Phase PHASE3 | Prostate Cancer | COMPLETED | NCT01193244 |
| Orteronel | Other | Phase PHASE3 | Prostate Cancer | COMPLETED | NCT01193244 |
| Placebo | Other | Phase PHASE3 | Traumatic Brain Injury | TERMINATED | NCT01000064 |
| fMRI | Other | Phase PHASE3 | Traumatic Brain Injury | TERMINATED | NCT01000064 |
| Vyvanse | Other | Phase PHASE3 | Traumatic Brain Injury | TERMINATED | NCT01000064 |
| Placebo | Other | Phase PHASE4 | Major Depressive Disorder | COMPLETED | NCT01148979 |
| Lisdexamfetamine Dimesylate (Vyvanse) | Other | Phase PHASE4 | Major Depressive Disorder | COMPLETED | NCT01148979 |
| Revlimid | Other | Phase PHASE2 | Multiple Myeloma | TERMINATED | NCT01729338 |
| Cyclophosphamide | Other | Phase PHASE2 | Multiple Myeloma | TERMINATED | NCT01729338 |
| Velcade | Other | Phase PHASE2 | Multiple Myeloma | TERMINATED | NCT01729338 |
| TCV-116CCB Placebo | Other | Phase PHASE3 | Hypertension | WITHDRAWN | NCT02969265 |
| Amlodipine Placebo | Other | Phase PHASE3 | Hypertension | WITHDRAWN | NCT02969265 |
| TCV-116CCB | Other | Phase PHASE3 | Hypertension | WITHDRAWN | NCT02969265 |
| Amlodipine | Other | Phase PHASE3 | Hypertension | WITHDRAWN | NCT02969265 |
| TCV-116CCB Placebo | Other | Phase PHASE3 | Hypertension | WITHDRAWN | NCT02969265 |
| Amlodipine Placebo | Other | Phase PHASE3 | Hypertension | WITHDRAWN | NCT02969265 |
| TCV-116CCB | Other | Phase PHASE3 | Hypertension | WITHDRAWN | NCT02969265 |
| Amlodipine | Other | Phase PHASE3 | Hypertension | WITHDRAWN | NCT02969265 |
| Lubiprostone | Other | Phase PHASE2 | Chronic Idiopathic Constipation | COMPLETED | NCT01469819 |
| Lubiprostone | Other | Phase PHASE2 | Chronic Idiopathic Constipation | COMPLETED | NCT01469819 |
| Lubiprostone | Other | Phase PHASE2 | Chronic Idiopathic Constipation | COMPLETED | NCT01469819 |
| Noncarbonated Water | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02338713 |
| Calcichew D3 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02338713 |
| palm pilot recording responses to questionnaires | Other | Preclinical | IBS, Diarrhea Predominant | COMPLETED | NCT00619125 |
| palm pilot recording responses to questionnaires | Other | Preclinical | IBS, Diarrhea Predominant | COMPLETED | NCT00619125 |
| palm pilot recording responses to questionnaires | Other | Preclinical | IBS, Diarrhea Predominant | COMPLETED | NCT00619125 |
| vortioxetine | Other | Phase PHASE4 | Depression | COMPLETED | NCT02234362 |
| vortioxetine | Other | Phase PHASE4 | Depression | COMPLETED | NCT02234362 |
| vortioxetine | Other | Phase PHASE4 | Depression | COMPLETED | NCT02234362 |
| Placebo | Other | Phase PHASE4 | Symptomatic Menopause | COMPLETED | NCT01324024 |
| Lisdexamfetamine | Other | Phase PHASE4 | Symptomatic Menopause | COMPLETED | NCT01324024 |
| vincristine | Other | Phase PHASE1 | Lymphoma, Large-Cell, Anaplastic | COMPLETED | NCT01309789 |
| doxorubicin | Other | Phase PHASE1 | Lymphoma, Large-Cell, Anaplastic | COMPLETED | NCT01309789 |
| prednisone | Other | Phase PHASE1 | Lymphoma, Large-Cell, Anaplastic | COMPLETED | NCT01309789 |
| cyclophosphamide | Other | Phase PHASE1 | Lymphoma, Large-Cell, Anaplastic | COMPLETED | NCT01309789 |
| brentuximab vedotin | Other | Phase PHASE1 | Lymphoma, Large-Cell, Anaplastic | COMPLETED | NCT01309789 |
| vincristine | Other | Phase PHASE1 | Lymphoma, Large-Cell, Anaplastic | COMPLETED | NCT01309789 |
| doxorubicin | Other | Phase PHASE1 | Lymphoma, Large-Cell, Anaplastic | COMPLETED | NCT01309789 |
| prednisone | Other | Phase PHASE1 | Lymphoma, Large-Cell, Anaplastic | COMPLETED | NCT01309789 |
| cyclophosphamide | Other | Phase PHASE1 | Lymphoma, Large-Cell, Anaplastic | COMPLETED | NCT01309789 |
| brentuximab vedotin | Other | Phase PHASE1 | Lymphoma, Large-Cell, Anaplastic | COMPLETED | NCT01309789 |
| Dexlansoprazole | Other | Approved | Laryngo-pharyngeal Reflux | WITHDRAWN | NCT01328392 |
| Dexlansoprazole | Other | Approved | Laryngo-pharyngeal Reflux | WITHDRAWN | NCT01328392 |
| Dexlansoprazole | Other | Approved | Laryngo-pharyngeal Reflux | WITHDRAWN | NCT01328392 |
| Dexlansoprazole | Other | Approved | Laryngo-pharyngeal Reflux | WITHDRAWN | NCT01328392 |
| Irinotecan and Bortezomib | Other | Phase PHASE1 | Neuroblastoma | COMPLETED | NCT00644696 |
| Irinotecan and Bortezomib | Other | Phase PHASE1 | Neuroblastoma | COMPLETED | NCT00644696 |
| prostatectomy | Other | Phase PHASE2 | Prostate Cancer | TERMINATED | NCT03211052 |
| TAK-700 and LHRH agonist | Other | Phase PHASE2 | Prostate Cancer | TERMINATED | NCT03211052 |
| prostatectomy | Other | Phase PHASE2 | Prostate Cancer | TERMINATED | NCT03211052 |
| TAK-700 and LHRH agonist | Other | Phase PHASE2 | Prostate Cancer | TERMINATED | NCT03211052 |
| prostatectomy | Other | Phase PHASE2 | Prostate Cancer | TERMINATED | NCT03211052 |
| TAK-700 and LHRH agonist | Other | Phase PHASE2 | Prostate Cancer | TERMINATED | NCT03211052 |
| Placebo | Other | Phase PHASE1 | Epilepsy | COMPLETED | NCT02539134 |
| TAK-935 | Other | Phase PHASE1 | Epilepsy | COMPLETED | NCT02539134 |
| Placebo | Other | Phase PHASE1 | Epilepsy | COMPLETED | NCT02539134 |
| TAK-935 | Other | Phase PHASE1 | Epilepsy | COMPLETED | NCT02539134 |
| filgrastim | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT00148317 |
| cyclophoshamide | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT00148317 |
| liposomal doxorubicin | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT00148317 |
| dexamethasone | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT00148317 |
| Bortezomib | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT00148317 |
| filgrastim | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT00148317 |
| cyclophoshamide | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT00148317 |
| liposomal doxorubicin | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT00148317 |
| dexamethasone | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT00148317 |
| Bortezomib | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT00148317 |
| filgrastim | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT00148317 |
| cyclophoshamide | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT00148317 |
| liposomal doxorubicin | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT00148317 |
| dexamethasone | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT00148317 |
| Bortezomib | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT00148317 |
| placebo | Other | Phase PHASE2 | Asthma | COMPLETED | NCT00634036 |
| pioglitazone | Other | Phase PHASE2 | Asthma | COMPLETED | NCT00634036 |
| placebo | Other | Phase PHASE2 | Asthma | COMPLETED | NCT00634036 |
| pioglitazone | Other | Phase PHASE2 | Asthma | COMPLETED | NCT00634036 |
| AMARYL-M TAB. 2/500mg | Other | Phase PHASE4 | Diabetes | UNKNOWN | NCT02823808 |
| NESINA ACT TAB. 25/15mg | Other | Phase PHASE4 | Diabetes | UNKNOWN | NCT02823808 |
| Lubiprostone | Other | Phase PHASE4 | Constipation | COMPLETED | NCT00844831 |
| Lubiprostone | Other | Phase PHASE4 | Constipation | COMPLETED | NCT00844831 |
| HCTZ 12.5 mg tablet | Other | Phase PHASE3 | Essential Hypertension | COMPLETED | NCT02277691 |
| TAK-536CCB tablet | Other | Phase PHASE3 | Essential Hypertension | COMPLETED | NCT02277691 |
| TAK-536TCH tablet | Other | Phase PHASE3 | Essential Hypertension | COMPLETED | NCT02277691 |
| HCTZ 12.5 mg tablet | Other | Phase PHASE3 | Essential Hypertension | COMPLETED | NCT02277691 |
| TAK-536CCB tablet | Other | Phase PHASE3 | Essential Hypertension | COMPLETED | NCT02277691 |
| TAK-536TCH tablet | Other | Phase PHASE3 | Essential Hypertension | COMPLETED | NCT02277691 |
| HCTZ 12.5 mg tablet | Other | Phase PHASE3 | Essential Hypertension | COMPLETED | NCT02277691 |
| TAK-536CCB tablet | Other | Phase PHASE3 | Essential Hypertension | COMPLETED | NCT02277691 |
| TAK-536TCH tablet | Other | Phase PHASE3 | Essential Hypertension | COMPLETED | NCT02277691 |
| Norovirus Bivalent VLP Vaccine | Other | Phase PHASE2 | Healthy Volunteers | COMPLETED | NCT02038907 |
| Hepatitis A Vaccine | Other | Phase PHASE2 | Healthy Volunteers | COMPLETED | NCT02038907 |
| Norovirus Bivalent VLP Vaccine | Other | Phase PHASE2 | Healthy Volunteers | COMPLETED | NCT02038907 |
| Hepatitis A Vaccine | Other | Phase PHASE2 | Healthy Volunteers | COMPLETED | NCT02038907 |
| Norwalk virus | Other | Phase PHASE1 | Acute Gastroenteritis | COMPLETED | NCT00973284 |
| mannitol and sucrose | Other | Phase PHASE1 | Acute Gastroenteritis | COMPLETED | NCT00973284 |
| Norwalk VLP vaccine | Other | Phase PHASE1 | Acute Gastroenteritis | COMPLETED | NCT00973284 |
| Norwalk virus | Other | Phase PHASE1 | Acute Gastroenteritis | COMPLETED | NCT00973284 |
| mannitol and sucrose | Other | Phase PHASE1 | Acute Gastroenteritis | COMPLETED | NCT00973284 |
| Norwalk VLP vaccine | Other | Phase PHASE1 | Acute Gastroenteritis | COMPLETED | NCT00973284 |
| Placebo | Other | Phase PHASE2 | Chronic Insomnia | COMPLETED | NCT00325728 |
| Ramelteon | Other | Phase PHASE2 | Chronic Insomnia | COMPLETED | NCT00325728 |
| Placebo | Other | Phase PHASE2 | Chronic Insomnia | COMPLETED | NCT00325728 |
| Ramelteon | Other | Phase PHASE2 | Chronic Insomnia | COMPLETED | NCT00325728 |
| Placebo | Other | Phase PHASE2 | Chronic Insomnia | COMPLETED | NCT00325728 |
| Ramelteon | Other | Phase PHASE2 | Chronic Insomnia | COMPLETED | NCT00325728 |
| Placebo (Saline) | Other | Phase PHASE2 | Norovirus Prevention | COMPLETED | NCT02142504 |
| Norovirus Bivalent VLP Vaccine | Other | Phase PHASE2 | Norovirus Prevention | COMPLETED | NCT02142504 |
| Placebo (Saline) | Other | Phase PHASE2 | Norovirus Prevention | COMPLETED | NCT02142504 |
| Norovirus Bivalent VLP Vaccine | Other | Phase PHASE2 | Norovirus Prevention | COMPLETED | NCT02142504 |
| Velcade | Other | Phase PHASE1 | Leukemia | COMPLETED | NCT00624936 |
| Vidaza | Other | Phase PHASE1 | Leukemia | COMPLETED | NCT00624936 |
| Velcade | Other | Phase PHASE1 | Leukemia | COMPLETED | NCT00624936 |
| Vidaza | Other | Phase PHASE1 | Leukemia | COMPLETED | NCT00624936 |
| Velcade | Other | Phase PHASE1 | Leukemia | COMPLETED | NCT00624936 |
| Vidaza | Other | Phase PHASE1 | Leukemia | COMPLETED | NCT00624936 |
| 1 TachoSil hemostatic sponge (9,5 cm x 4,8 cm) placed on each side on the external iliac artery. | Other | Phase PHASE4 | Prostate or Bladder Cancer | COMPLETED | NCT02001857 |
| 1 TachoSil hemostatic sponge (9,5 cm x 4,8 cm) placed on each side on the external iliac artery. | Other | Phase PHASE4 | Prostate or Bladder Cancer | COMPLETED | NCT02001857 |
| laboratory biomarker analysis | Other | Phase PHASE2 | Adenocarcinoma of the Prostate | TERMINATED | NCT01866423 |
| orteronel | Other | Phase PHASE2 | Adenocarcinoma of the Prostate | TERMINATED | NCT01866423 |
| laboratory biomarker analysis | Other | Phase PHASE2 | Adenocarcinoma of the Prostate | TERMINATED | NCT01866423 |
| orteronel | Other | Phase PHASE2 | Adenocarcinoma of the Prostate | TERMINATED | NCT01866423 |
| Tele-rehabilitation | Other | Approved | Stroke | COMPLETED | NCT01905917 |
| Tele-rehabilitation | Other | Approved | Stroke | COMPLETED | NCT01905917 |
| Dexlansoprazole 60 MG | Other | Phase PHASE4 | GERD | COMPLETED | NCT03079050 |
| Dexlansoprazole 60 MG | Other | Phase PHASE4 | GERD | COMPLETED | NCT03079050 |
| MLN1202 | Other | Phase PHASE2 | Diabetic Nephropathy | WITHDRAWN | NCT02410499 |
| MLN1202 Placebo | Other | Phase PHASE2 | Diabetic Nephropathy | WITHDRAWN | NCT02410499 |
| MLN1202 | Other | Phase PHASE2 | Diabetic Nephropathy | WITHDRAWN | NCT02410499 |
| MLN1202 Placebo | Other | Phase PHASE2 | Diabetic Nephropathy | WITHDRAWN | NCT02410499 |
| Placebo | Other | Phase PHASE2 | Schizophrenia | COMPLETED | NCT02477020 |
| TAK-063 20 mg | Other | Phase PHASE2 | Schizophrenia | COMPLETED | NCT02477020 |
| Placebo | Other | Phase PHASE2 | Schizophrenia | COMPLETED | NCT02477020 |
| TAK-063 20 mg | Other | Phase PHASE2 | Schizophrenia | COMPLETED | NCT02477020 |
| Dexlansoprazole | Other | Phase PHASE4 | Gastroesophageal Reflux Disease | COMPLETED | NCT02351960 |
| Dexlansoprazole | Other | Phase PHASE4 | Gastroesophageal Reflux Disease | COMPLETED | NCT02351960 |
| Alogliptin | Other | Phase PHASE4 | Diabetes Mellitus, Type 2 | WITHDRAWN | NCT03042325 |
| Cefepime | Other | Phase PHASE3 | Urinary Tract Infection | TERMINATED | NCT02302092 |
| Flomoxef | Other | Phase PHASE3 | Urinary Tract Infection | TERMINATED | NCT02302092 |
| Clarithromycin | Other | Phase PHASE1 | Nonhematologic Malignancies | COMPLETED | NCT01454076 |
| Rifampin | Other | Phase PHASE1 | Nonhematologic Malignancies | COMPLETED | NCT01454076 |
| Ketoconazole | Other | Phase PHASE1 | Nonhematologic Malignancies | COMPLETED | NCT01454076 |
| Ixazomib 4 mg Capsule B | Other | Phase PHASE1 | Nonhematologic Malignancies | COMPLETED | NCT01454076 |
| Ixazomib 4 mg Capsule A | Other | Phase PHASE1 | Nonhematologic Malignancies | COMPLETED | NCT01454076 |
| Ixazomib 2.5 mg | Other | Phase PHASE1 | Nonhematologic Malignancies | COMPLETED | NCT01454076 |
| TAK-272 | Other | Phase PHASE1 | Renal Impairment | COMPLETED | NCT02367872 |
| TAK-272 | Other | Phase PHASE1 | Renal Impairment | COMPLETED | NCT02367872 |
| Steroid and Proton Pump Inhibitor Therapy | Drug | Approved | Suspected Eosinophilic Esophagitis | COMPLETED | NCT00880906 |
| Esophageal dilation | Other | Approved | Suspected Eosinophilic Esophagitis | COMPLETED | NCT00880906 |
| Steroid and Proton Pump Inhibitor Therapy | Drug | Approved | Suspected Eosinophilic Esophagitis | COMPLETED | NCT00880906 |
| Esophageal dilation | Other | Approved | Suspected Eosinophilic Esophagitis | COMPLETED | NCT00880906 |
| Placebo | Other | Approved | Hypertension | COMPLETED | NCT01774591 |
| Azilsartan medoximil | Other | Approved | Hypertension | COMPLETED | NCT01774591 |
| Placebo | Other | Approved | Hypertension | COMPLETED | NCT01774591 |
| Azilsartan medoximil | Other | Approved | Hypertension | COMPLETED | NCT01774591 |
| Alisertib | Other | Phase PHASE1 | Diffuse Large B-cell Lymphoma | TERMINATED | NCT02700022 |
| Alisertib | Other | Phase PHASE1 | Diffuse Large B-cell Lymphoma | TERMINATED | NCT02700022 |
| bortezomib | Other | Phase PHASE2 | Lymphoproliferative Disorder | TERMINATED | NCT00869323 |
| rituximab | Other | Phase PHASE2 | Lymphoproliferative Disorder | TERMINATED | NCT00869323 |
| bortezomib | Other | Phase PHASE2 | Lymphoproliferative Disorder | TERMINATED | NCT00869323 |
| rituximab | Other | Phase PHASE2 | Lymphoproliferative Disorder | TERMINATED | NCT00869323 |
| bortezomib | Other | Phase PHASE2 | Lymphoproliferative Disorder | TERMINATED | NCT00869323 |
| rituximab | Other | Phase PHASE2 | Lymphoproliferative Disorder | TERMINATED | NCT00869323 |
| TAK-385 40 mg | Other | Phase PHASE1 | Japanese Premenopausal Healthy Adult Women | COMPLETED | NCT02792062 |
| TAK-385 40 mg | Other | Phase PHASE1 | Japanese Premenopausal Healthy Adult Women | COMPLETED | NCT02792062 |
| Imatinib mesylate | Other | Phase PHASE2 | Acute Lymphoblastic Leukemia | TERMINATED | NCT01312818 |
| Methotrexate | Other | Phase PHASE2 | Acute Lymphoblastic Leukemia | TERMINATED | NCT01312818 |
| Dexamethasone | Other | Phase PHASE2 | Acute Lymphoblastic Leukemia | TERMINATED | NCT01312818 |
| Vorinostat | Other | Phase PHASE2 | Acute Lymphoblastic Leukemia | TERMINATED | NCT01312818 |
| Bortezomib | Other | Phase PHASE2 | Acute Lymphoblastic Leukemia | TERMINATED | NCT01312818 |
| No Intervention | Other | Phase PHASE1 | Rheumatoid Arthritis | COMPLETED | NCT02528786 |
| Lansoprazole | Other | Phase PHASE1 | Neoplasm, Advanced or Metastatic | COMPLETED | NCT02625259 |
| TAK-117 | Other | Phase PHASE1 | Neoplasm, Advanced or Metastatic | COMPLETED | NCT02625259 |
| Lansoprazole | Other | Phase PHASE1 | Neoplasm, Advanced or Metastatic | COMPLETED | NCT02625259 |
| TAK-117 | Other | Phase PHASE1 | Neoplasm, Advanced or Metastatic | COMPLETED | NCT02625259 |
| G-CSF | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT02220608 |
| Bortezomib | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT02220608 |
| G-CSF | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT02220608 |
| Bortezomib | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT02220608 |
| Ixazomib citrate | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT00963820 |
| Ixazomib citrate | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT00963820 |
| Ixazomib citrate | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT00963820 |
| Blood draws | Other | Preclinical | Multiple Myeloma | COMPLETED | NCT01472627 |
| Blood draws | Other | Preclinical | Multiple Myeloma | COMPLETED | NCT01472627 |
| Placebo | Other | Phase PHASE2 | Chronic Pancreatitis | COMPLETED | NCT00782795 |
| Pioglitazone | Other | Phase PHASE2 | Chronic Pancreatitis | COMPLETED | NCT00782795 |
| Placebo | Other | Phase PHASE2 | Chronic Pancreatitis | COMPLETED | NCT00782795 |
| Pioglitazone | Other | Phase PHASE2 | Chronic Pancreatitis | COMPLETED | NCT00782795 |
| Placebo | Other | Phase PHASE2 | Chronic Pancreatitis | COMPLETED | NCT00782795 |
| Pioglitazone | Other | Phase PHASE2 | Chronic Pancreatitis | COMPLETED | NCT00782795 |
| Glucose Monitor | Other | Phase PHASE1 | Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic | WITHDRAWN | NCT03205891 |
| TAK228 | Other | Phase PHASE1 | Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic | WITHDRAWN | NCT03205891 |
| Brentuximab Vedotin | Other | Phase PHASE1 | Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic | WITHDRAWN | NCT03205891 |
| Glucose Monitor | Other | Phase PHASE1 | Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic | WITHDRAWN | NCT03205891 |
| TAK228 | Other | Phase PHASE1 | Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic | WITHDRAWN | NCT03205891 |
| Brentuximab Vedotin | Other | Phase PHASE1 | Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic | WITHDRAWN | NCT03205891 |
| MLN8237 | Other | Phase PHASE2 | Small Cell Prostate Cancer | COMPLETED | NCT01799278 |
| Prednisone | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT01335685 |
| Melphalan | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT01335685 |
| Ixazomib | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT01335685 |
| Prednisone | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT01335685 |
| Melphalan | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT01335685 |
| Ixazomib | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT01335685 |
| TAK-117 | Other | Phase PHASE1 | Non-small Cell Lung Cancer | TERMINATED | NCT02393209 |
| Docetaxel | Other | Phase PHASE1 | Non-small Cell Lung Cancer | TERMINATED | NCT02393209 |
| TAK-117 | Other | Phase PHASE1 | Non-small Cell Lung Cancer | TERMINATED | NCT02393209 |
| Docetaxel | Other | Phase PHASE1 | Non-small Cell Lung Cancer | TERMINATED | NCT02393209 |
| Brentuximab Vedotin | Other | Phase PHASE2 | Germ Cell Cancer | COMPLETED | NCT01851200 |
| Brentuximab Vedotin | Other | Phase PHASE2 | Germ Cell Cancer | COMPLETED | NCT01851200 |
| Vyvanse | Other | Phase PHASE4 | Attention Deficit/Hyperactivity Disorder | COMPLETED | NCT00733356 |
| rituximab | Other | Phase PHASE2 | Post-transplant Lymphoproliferative Disease | COMPLETED | NCT01058239 |
| bortezomib | Other | Phase PHASE2 | Post-transplant Lymphoproliferative Disease | COMPLETED | NCT01058239 |
| Placebo | Other | Phase PHASE2 | Treatment-Resistant Depression | WITHDRAWN | NCT03312894 |
| TAK-653 | Other | Phase PHASE2 | Treatment-Resistant Depression | WITHDRAWN | NCT03312894 |
| Placebo | Other | Phase PHASE2 | Treatment-Resistant Depression | WITHDRAWN | NCT03312894 |
| TAK-653 | Other | Phase PHASE2 | Treatment-Resistant Depression | WITHDRAWN | NCT03312894 |
| Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain) | Other | Preclinical | Measles/Rubella | COMPLETED | NCT02158364 |
| Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain) | Other | Preclinical | Measles/Rubella | COMPLETED | NCT02158364 |
| fluoxetine | Other | Phase PHASE2 | Severe Mood Dysregulation | COMPLETED | NCT01714310 |
| Placebo | Other | Phase PHASE2 | Severe Mood Dysregulation | COMPLETED | NCT01714310 |
| lisdexamfetamine | Other | Phase PHASE2 | Severe Mood Dysregulation | COMPLETED | NCT01714310 |
| No Intervention | Other | Preclinical | Diabetes Mellitus, Type 2, Cancer | COMPLETED | NCT02958995 |
| No Intervention | Other | Preclinical | Diabetes Mellitus, Type 2, Cancer | COMPLETED | NCT02958995 |
| Pioglitazone | Other | Preclinical | Diabetes Mellitus, Type 2, Cancer | COMPLETED | NCT02958956 |
| Pioglitazone | Other | Preclinical | Diabetes | COMPLETED | NCT01637935 |
| Pioglitazone | Other | Preclinical | Diabetes | COMPLETED | NCT01637935 |
| Pioglitazone | Other | Preclinical | Diabetes | COMPLETED | NCT01637935 |
| Autologous Peripheral Blood Stem Cell Transplantation | Other | Phase PHASE1 | Hodgkin Lymphoma | UNKNOWN | NCT02280993 |
| Brentuximab Vedotin | Other | Phase PHASE1 | Hodgkin Lymphoma | UNKNOWN | NCT02280993 |
| DHAP | Other | Phase PHASE1 | Hodgkin Lymphoma | UNKNOWN | NCT02280993 |
| Autologous Peripheral Blood Stem Cell Transplantation | Other | Phase PHASE1 | Hodgkin Lymphoma | UNKNOWN | NCT02280993 |
| Brentuximab Vedotin | Other | Phase PHASE1 | Hodgkin Lymphoma | UNKNOWN | NCT02280993 |
| DHAP | Other | Phase PHASE1 | Hodgkin Lymphoma | UNKNOWN | NCT02280993 |
| Dexamethasone | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT01217957 |
| Lenalidomide | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT01217957 |
| Ixazomib | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT01217957 |
| Dexamethasone | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT01217957 |
| Lenalidomide | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT01217957 |
| Ixazomib | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT01217957 |
| Prednisone | Other | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT01666314 |
| Orteronel Placebo | Other | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT01666314 |
| Orteronel | Other | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT01666314 |
| Prednisone | Other | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT01666314 |
| Orteronel Placebo | Other | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT01666314 |
| Orteronel | Other | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT01666314 |
| Vincristine | Other | Phase PHASE1 | Diffuse Large B-Cell Lymphoma | COMPLETED | NCT01397825 |
| Rituximab | Other | Phase PHASE1 | Diffuse Large B-Cell Lymphoma | COMPLETED | NCT01397825 |
| Alisertib (MLN8237) | Other | Phase PHASE1 | Diffuse Large B-Cell Lymphoma | COMPLETED | NCT01397825 |
| Vincristine | Other | Phase PHASE1 | Diffuse Large B-Cell Lymphoma | COMPLETED | NCT01397825 |
| Rituximab | Other | Phase PHASE1 | Diffuse Large B-Cell Lymphoma | COMPLETED | NCT01397825 |
| Alisertib (MLN8237) | Other | Phase PHASE1 | Diffuse Large B-Cell Lymphoma | COMPLETED | NCT01397825 |
| Vincristine | Other | Phase PHASE1 | Diffuse Large B-Cell Lymphoma | COMPLETED | NCT01397825 |
| Rituximab | Other | Phase PHASE1 | Diffuse Large B-Cell Lymphoma | COMPLETED | NCT01397825 |
| Alisertib (MLN8237) | Other | Phase PHASE1 | Diffuse Large B-Cell Lymphoma | COMPLETED | NCT01397825 |
| Alisertib | Other | Phase PHASE2 | Diffuse Large B-cell Lymphoma | COMPLETED | NCT00807495 |
| Alisertib | Other | Phase PHASE2 | Diffuse Large B-cell Lymphoma | COMPLETED | NCT00807495 |
| LDX Treatment | Drug | Phase PHASE4 | Attention Deficit Hyperactivity Disorder | COMPLETED | NCT01070394 |
| TAK-020 Solid Formulation | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02723201 |
| TAK-020 IRT | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02723201 |
| TAK-020 SDT | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02723201 |
| TAK-020 CCT | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02723201 |
| TAK-020 Captisol Oral Solution | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02723201 |
| TAK-020 Solid Formulation | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02723201 |
| TAK-020 IRT | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02723201 |
| TAK-020 SDT | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02723201 |
| TAK-020 CCT | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02723201 |
| TAK-020 Captisol Oral Solution | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02723201 |
| Bortezomib | Other | Phase PHASE2 | Leukemia | COMPLETED | NCT01891968 |
| Bortezomib | Other | Phase PHASE2 | Leukemia | COMPLETED | NCT01891968 |
| Leuprorelin | Other | Phase PHASE2 | Prostate Cancer | COMPLETED | NCT02083185 |
| Relugolix | Other | Phase PHASE2 | Prostate Cancer | COMPLETED | NCT02083185 |
| Brentuximab Vedotin | Other | Phase PHASE2 | Hodgkin Disease | COMPLETED | NCT02567851 |
| Alisertib | Other | Phase PHASE2 | Acute Myelogenous Leukemia | COMPLETED | NCT00830518 |
| Alisertib | Other | Phase PHASE2 | Acute Myelogenous Leukemia | COMPLETED | NCT00830518 |
| Docetaxel | Other | Phase PHASE2 | Prostate Cancer | COMPLETED | NCT00183937 |
| PS 341 | Other | Phase PHASE2 | Prostate Cancer | COMPLETED | NCT00183937 |
| MLN8237 and Erlotinib | Other | Phase PHASE1 | Non-small Cell Lung Cancer Metastatic | TERMINATED | NCT01471964 |
| MLN8237 and Erlotinib | Other | Phase PHASE1 | Non-small Cell Lung Cancer Metastatic | TERMINATED | NCT01471964 |
| Velcade | Other | Phase PHASE2 | Leukemia | WITHDRAWN | NCT01162031 |
| Velcade | Other | Phase PHASE2 | Leukemia | WITHDRAWN | NCT01162031 |
| Velcade | Other | Phase PHASE2 | Leukemia | WITHDRAWN | NCT01162031 |
| Ramelteon and Escitalopram | Other | Approved | Panic Disorder | TERMINATED | NCT00746239 |
| Placebo and Escitalopram | Other | Approved | Panic Disorder | TERMINATED | NCT00746239 |
| Ramelteon and Escitalopram | Other | Approved | Panic Disorder | TERMINATED | NCT00746239 |
| Placebo and Escitalopram | Other | Approved | Panic Disorder | TERMINATED | NCT00746239 |
| Paclitaxel | Other | Phase PHASE2 | Ovarian Carcinoma | COMPLETED | NCT01091428 |
| Alisertib | Other | Phase PHASE2 | Ovarian Carcinoma | COMPLETED | NCT01091428 |
| Paclitaxel | Other | Phase PHASE2 | Ovarian Carcinoma | COMPLETED | NCT01091428 |
| Alisertib | Other | Phase PHASE2 | Ovarian Carcinoma | COMPLETED | NCT01091428 |
| Allopurinol | Other | Phase PHASE3 | Cardiovascular Disease | COMPLETED | NCT01101035 |
| Febuxostat | Other | Phase PHASE3 | Cardiovascular Disease | COMPLETED | NCT01101035 |
| Allopurinol | Other | Phase PHASE3 | Cardiovascular Disease | COMPLETED | NCT01101035 |
| Febuxostat | Other | Phase PHASE3 | Cardiovascular Disease | COMPLETED | NCT01101035 |
| Daytrana (methylphenidate patch) | Other | Approved | Adult Attention Deficit Hyperactivity Disorder (ADHD) | COMPLETED | NCT00780208 |
| ITD consolidation and ixazomib maintenance vs. No further therapy | Drug | Phase PHASE3 | Multiple Myeloma | RECRUITING | NCT03562169 |
| Augmented autologous stem cell transplant (ASCT-aug) | Other | Phase PHASE3 | Multiple Myeloma | RECRUITING | NCT03562169 |
| Conventional autologous stem cell transplant (ASCT-con) | Other | Phase PHASE3 | Multiple Myeloma | RECRUITING | NCT03562169 |
| Ixazomib, thalidomide, & dexamethasone (ITD) re-induction | Other | Phase PHASE3 | Multiple Myeloma | RECRUITING | NCT03562169 |
| ITD consolidation and ixazomib maintenance vs. No further therapy | Drug | Phase PHASE3 | Multiple Myeloma | RECRUITING | NCT03562169 |
| Augmented autologous stem cell transplant (ASCT-aug) | Other | Phase PHASE3 | Multiple Myeloma | RECRUITING | NCT03562169 |
| Conventional autologous stem cell transplant (ASCT-con) | Other | Phase PHASE3 | Multiple Myeloma | RECRUITING | NCT03562169 |
| Ixazomib, thalidomide, & dexamethasone (ITD) re-induction | Other | Phase PHASE3 | Multiple Myeloma | RECRUITING | NCT03562169 |
| Bortezomib, CHOP, Rituximab | Other | Phase PHASE1 | Non-Hodgkin's Lymphoma | COMPLETED | NCT00151320 |
| Bortezomib, CHOP, Rituximab | Other | Phase PHASE1 | Non-Hodgkin's Lymphoma | COMPLETED | NCT00151320 |
| Bortezomib, CHOP, Rituximab | Other | Phase PHASE1 | Non-Hodgkin's Lymphoma | COMPLETED | NCT00151320 |
| Anti-TNF Therapy | Drug | Preclinical | Colitis, Ulcerative | COMPLETED | NCT03090139 |
| Anti-TNF Therapy | Drug | Preclinical | Colitis, Ulcerative | COMPLETED | NCT03090139 |
| lubiprostone | Other | Phase PHASE4 | Chronic Idiopathic Constipation | COMPLETED | NCT01460225 |
| lubiprostone | Other | Phase PHASE4 | Chronic Idiopathic Constipation | COMPLETED | NCT01460225 |
| lubiprostone | Other | Phase PHASE4 | Chronic Idiopathic Constipation | COMPLETED | NCT01460225 |
| lubiprostone | Other | Phase PHASE4 | Chronic Idiopathic Constipation | COMPLETED | NCT01460225 |
| Candesartan cilexetil/Amlodipine besilate | Other | Preclinical | Hypertension | COMPLETED | NCT02068495 |
| Candesartan cilexetil/Amlodipine besilate | Other | Preclinical | Hypertension | COMPLETED | NCT02068495 |
| Alsertib | Other | Phase PHASE1 | CD30-positive Lymphoma | WITHDRAWN | NCT02780011 |
| Brentuximab Vedotin | Other | Phase PHASE1 | CD30-positive Lymphoma | WITHDRAWN | NCT02780011 |
| Alsertib | Other | Phase PHASE1 | CD30-positive Lymphoma | WITHDRAWN | NCT02780011 |
| Brentuximab Vedotin | Other | Phase PHASE1 | CD30-positive Lymphoma | WITHDRAWN | NCT02780011 |
| Placebo | Other | Phase PHASE4 | Menopause | COMPLETED | NCT01977625 |
| Lisdexamfetamine | Other | Phase PHASE4 | Menopause | COMPLETED | NCT01977625 |
| Romidepsin | Other | Phase PHASE3 | Relapsed Peripheral T-Cell Lymphoma | COMPLETED | NCT01482962 |
| Gemcitabine | Other | Phase PHASE3 | Relapsed Peripheral T-Cell Lymphoma | COMPLETED | NCT01482962 |
| Pralatrexate | Other | Phase PHASE3 | Relapsed Peripheral T-Cell Lymphoma | COMPLETED | NCT01482962 |
| Alisertib | Other | Phase PHASE3 | Relapsed Peripheral T-Cell Lymphoma | COMPLETED | NCT01482962 |
| Placebo | Other | Phase PHASE3 | Constipation | COMPLETED | NCT02651155 |
| Lubiprostone | Other | Phase PHASE3 | Constipation | COMPLETED | NCT02651155 |
| Placebo | Other | Phase PHASE3 | Constipation | COMPLETED | NCT02651155 |
| Lubiprostone | Other | Phase PHASE3 | Constipation | COMPLETED | NCT02651155 |
| Candesartan cilexetil Placebo | Other | Phase PHASE2 | Type 2 Diabetes Mellitus and Microalbuminuria | COMPLETED | NCT02332824 |
| Candesartan cilexetil | Other | Phase PHASE2 | Type 2 Diabetes Mellitus and Microalbuminuria | COMPLETED | NCT02332824 |
| TAK-272 Placebo | Other | Phase PHASE2 | Type 2 Diabetes Mellitus and Microalbuminuria | COMPLETED | NCT02332824 |
| TAK-272 | Other | Phase PHASE2 | Type 2 Diabetes Mellitus and Microalbuminuria | COMPLETED | NCT02332824 |
| Candesartan cilexetil Placebo | Other | Phase PHASE2 | Type 2 Diabetes Mellitus and Microalbuminuria | COMPLETED | NCT02332824 |
| Candesartan cilexetil | Other | Phase PHASE2 | Type 2 Diabetes Mellitus and Microalbuminuria | COMPLETED | NCT02332824 |
| TAK-272 Placebo | Other | Phase PHASE2 | Type 2 Diabetes Mellitus and Microalbuminuria | COMPLETED | NCT02332824 |
| TAK-272 | Other | Phase PHASE2 | Type 2 Diabetes Mellitus and Microalbuminuria | COMPLETED | NCT02332824 |
| bortezomib, tositumomab | Other | Phase PHASE1 | Non-Hodgkin's Lymphoma | COMPLETED | NCT00777114 |
| bortezomib, tositumomab | Other | Phase PHASE1 | Non-Hodgkin's Lymphoma | COMPLETED | NCT00777114 |
| bortezomib, tositumomab | Other | Phase PHASE1 | Non-Hodgkin's Lymphoma | COMPLETED | NCT00777114 |
| Ondansetron | Other | Phase PHASE2 | Nausea | COMPLETED | NCT02006056 |
| Ondansetron | Other | Phase PHASE2 | Nausea | COMPLETED | NCT02006056 |
| Ondansetron | Other | Phase PHASE2 | Nausea | COMPLETED | NCT02006056 |
| Bortezomib | Other | Phase PHASE1 | Graft vs Host Disease | COMPLETED | NCT00670423 |
| Sirolimus | Other | Phase PHASE1 | Graft vs Host Disease | COMPLETED | NCT00670423 |
| Tacrolimus | Other | Phase PHASE1 | Graft vs Host Disease | COMPLETED | NCT00670423 |
| Bortezomib | Other | Phase PHASE1 | Graft vs Host Disease | COMPLETED | NCT00670423 |
| Sirolimus | Other | Phase PHASE1 | Graft vs Host Disease | COMPLETED | NCT00670423 |
| Tacrolimus | Other | Phase PHASE1 | Graft vs Host Disease | COMPLETED | NCT00670423 |
| sorafenib, vorinostat and bortezomib | Other | Phase PHASE1 | Acute Myeloid Leukemia | COMPLETED | NCT01534260 |
| sorafenib, vorinostat and bortezomib | Other | Phase PHASE1 | Acute Myeloid Leukemia | COMPLETED | NCT01534260 |
| Lisdexamfetamine | Other | Phase PHASE4 | Lisdexamfetamine | UNKNOWN | NCT03070509 |
| Lisdexamfetamine | Other | Phase PHASE4 | Lisdexamfetamine | UNKNOWN | NCT03070509 |
| Placebo | Other | Phase PHASE4 | Obesity | COMPLETED | NCT00315146 |
| Hypocaloric diet | Other | Phase PHASE4 | Obesity | COMPLETED | NCT00315146 |
| Resistance exercise training to maximize muscle power | Other | Phase PHASE4 | Obesity | COMPLETED | NCT00315146 |
| Pioglitazone | Other | Phase PHASE4 | Obesity | COMPLETED | NCT00315146 |
| Placebo | Other | Phase PHASE4 | Obesity | COMPLETED | NCT00315146 |
| Hypocaloric diet | Other | Phase PHASE4 | Obesity | COMPLETED | NCT00315146 |
| Resistance exercise training to maximize muscle power | Other | Phase PHASE4 | Obesity | COMPLETED | NCT00315146 |
| Pioglitazone | Other | Phase PHASE4 | Obesity | COMPLETED | NCT00315146 |
| Placebo | Other | Phase PHASE4 | Obesity | COMPLETED | NCT00315146 |
| Hypocaloric diet | Other | Phase PHASE4 | Obesity | COMPLETED | NCT00315146 |
| Resistance exercise training to maximize muscle power | Other | Phase PHASE4 | Obesity | COMPLETED | NCT00315146 |
| Pioglitazone | Other | Phase PHASE4 | Obesity | COMPLETED | NCT00315146 |
| Brentuximab vedotin | Other | Phase PHASE2 | Non-Hodgkin Lymphoma | COMPLETED | NCT02280785 |
| Brentuximab vedotin | Other | Phase PHASE2 | Non-Hodgkin Lymphoma | COMPLETED | NCT02280785 |
| Placebo oral capsule | Other | Phase PHASE3 | Attention Deficit Disorder | COMPLETED | NCT03662763 |
| Extended-release Guanfacine Hydrochloride (SPD503) | Other | Phase PHASE3 | Attention Deficit Disorder | COMPLETED | NCT03662763 |
| Sulfonylurea | Other | Phase PHASE4 | Type II Diabetes Mellitus | COMPLETED | NCT01972724 |
| Metformin | Other | Phase PHASE4 | Type II Diabetes Mellitus | COMPLETED | NCT01972724 |
| Pioglitazone | Other | Phase PHASE4 | Type II Diabetes Mellitus | COMPLETED | NCT01972724 |
| Sulfonylurea | Other | Phase PHASE4 | Type II Diabetes Mellitus | COMPLETED | NCT01972724 |
| Metformin | Other | Phase PHASE4 | Type II Diabetes Mellitus | COMPLETED | NCT01972724 |
| Pioglitazone | Other | Phase PHASE4 | Type II Diabetes Mellitus | COMPLETED | NCT01972724 |
| Placebo | Other | Phase PHASE4 | Healthy Volunteers | COMPLETED | NCT02932904 |
| Paroxetine | Other | Phase PHASE4 | Healthy Volunteers | COMPLETED | NCT02932904 |
| Vortioxetine | Other | Phase PHASE4 | Healthy Volunteers | COMPLETED | NCT02932904 |
| Placebo | Other | Phase PHASE4 | Healthy Volunteers | COMPLETED | NCT02932904 |
| Paroxetine | Other | Phase PHASE4 | Healthy Volunteers | COMPLETED | NCT02932904 |
| Vortioxetine | Other | Phase PHASE4 | Healthy Volunteers | COMPLETED | NCT02932904 |
| Vedolizumab | Other | Phase PHASE3 | Crohn's Disease | COMPLETED | NCT02425111 |
| Vedolizumab | Other | Phase PHASE3 | Crohn's Disease | COMPLETED | NCT02425111 |
| Folic/folinic acid | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT02379091 |
| Methotrexate | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT02379091 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT02379091 |
| Namilumab | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT02379091 |
| Folic/folinic acid | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT02379091 |
| Methotrexate | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT02379091 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT02379091 |
| Namilumab | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT02379091 |
| TAK-935 Oral Solution | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02906813 |
| TAK-935 Tablets | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02906813 |
| TAK-935 Oral Solution | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02906813 |
| TAK-935 Tablets | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02906813 |
| Decadron | Other | Phase PHASE2 | Lymphoma, Non-Hodgkin | TERMINATED | NCT00413959 |
| Cyclophosphamide | Other | Phase PHASE2 | Lymphoma, Non-Hodgkin | TERMINATED | NCT00413959 |
| Rituximab | Other | Phase PHASE2 | Lymphoma, Non-Hodgkin | TERMINATED | NCT00413959 |
| VELCADE® | Other | Phase PHASE2 | Lymphoma, Non-Hodgkin | TERMINATED | NCT00413959 |
| Decadron | Other | Phase PHASE2 | Lymphoma, Non-Hodgkin | TERMINATED | NCT00413959 |
| Cyclophosphamide | Other | Phase PHASE2 | Lymphoma, Non-Hodgkin | TERMINATED | NCT00413959 |
| Rituximab | Other | Phase PHASE2 | Lymphoma, Non-Hodgkin | TERMINATED | NCT00413959 |
| VELCADE® | Other | Phase PHASE2 | Lymphoma, Non-Hodgkin | TERMINATED | NCT00413959 |
| Ixazomib | Other | Phase PHASE2 | Leukemia | TERMINATED | NCT02302846 |
| Ixazomib | Other | Phase PHASE2 | Leukemia | TERMINATED | NCT02302846 |
| Ixazomib | Other | Phase PHASE2 | Leukemia | TERMINATED | NCT02302846 |
| Behavior Parent Training | Other | Phase PHASE4 | Attention Deficit Hyperactivity Disorder | COMPLETED | NCT01816074 |
| Vyvanse (lisdexamphetamine) | Other | Phase PHASE4 | Attention Deficit Hyperactivity Disorder | COMPLETED | NCT01816074 |
| Vedolizumab | Other | Phase PHASE2 | Celiac Disease | TERMINATED | NCT02929316 |
| Vedolizumab | Other | Phase PHASE2 | Celiac Disease | TERMINATED | NCT02929316 |
| Diet | Other | Approved | Insulin Resistance | COMPLETED | NCT00457938 |
| low-fat diet ( Still recruiting ) | Other | Approved | Insulin Resistance | COMPLETED | NCT00457938 |
| Diet | Other | Approved | Insulin Resistance | COMPLETED | NCT00457938 |
| low-fat diet ( Still recruiting ) | Other | Approved | Insulin Resistance | COMPLETED | NCT00457938 |
| Normal daily activities | Other | Approved | Haemophilia | COMPLETED | NCT02781233 |
| Progressive resistance training | Other | Approved | Haemophilia | COMPLETED | NCT02781233 |
| Placebo | Other | Phase PHASE1 | Dose Finding Study | COMPLETED | NCT02706834 |
| TAK-828 | Other | Phase PHASE1 | Dose Finding Study | COMPLETED | NCT02706834 |
| Placebo | Other | Phase PHASE1 | Dose Finding Study | COMPLETED | NCT02706834 |
| TAK-828 | Other | Phase PHASE1 | Dose Finding Study | COMPLETED | NCT02706834 |
| Sodium Risedronate | Other | Preclinical | Osteoporosis | COMPLETED | NCT02089997 |
| Sodium Risedronate | Other | Preclinical | Osteoporosis | COMPLETED | NCT02089997 |
| Melphalan and bortezomib | Other | Approved | Acute Myelogenous Leukemia | COMPLETED | NCT00789256 |
| Bortezomib | Other | Approved | Acute Myelogenous Leukemia | COMPLETED | NCT00789256 |
| Melphalan | Other | Approved | Acute Myelogenous Leukemia | COMPLETED | NCT00789256 |
| Melphalan and bortezomib | Other | Approved | Acute Myelogenous Leukemia | COMPLETED | NCT00789256 |
| Bortezomib | Other | Approved | Acute Myelogenous Leukemia | COMPLETED | NCT00789256 |
| Melphalan | Other | Approved | Acute Myelogenous Leukemia | COMPLETED | NCT00789256 |
| Melphalan and bortezomib | Other | Approved | Acute Myelogenous Leukemia | COMPLETED | NCT00789256 |
| Bortezomib | Other | Approved | Acute Myelogenous Leukemia | COMPLETED | NCT00789256 |
| Melphalan | Other | Approved | Acute Myelogenous Leukemia | COMPLETED | NCT00789256 |
| alisertib | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT01714947 |
| [^14C]-alisertib | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT01714947 |
| alisertib | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT01714947 |
| [^14C]-alisertib | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT01714947 |
| alisertib | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT01714947 |
| [^14C]-alisertib | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT01714947 |
| PS341 (Bortezomib) | Other | Phase PHASE2 | Lymphoma, B-Cell | COMPLETED | NCT00038571 |
| PS341 (Bortezomib) | Other | Phase PHASE2 | Lymphoma, B-Cell | COMPLETED | NCT00038571 |
| Candesartan Cilexetil | Other | Preclinical | Hypertension | COMPLETED | NCT02211638 |
| Candesartan Cilexetil | Other | Preclinical | Hypertension | COMPLETED | NCT02211638 |
| Candesartan Cilexetil | Other | Preclinical | Hypertension | COMPLETED | NCT02211638 |
| Dexamethasone | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT01645930 |
| Lenalidomide | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT01645930 |
| Ixazomib | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT01645930 |
| Dexamethasone | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT01645930 |
| Lenalidomide | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT01645930 |
| Ixazomib | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT01645930 |
| Alisertib | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT02214147 |
| Alisertib | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT02214147 |
| Bortezomib (PS-341) | Other | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT00059631 |
| Mitoxantrone (Novantrone) | Other | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT00059631 |
| Bortezomib (PS-341) | Other | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT00059631 |
| Mitoxantrone (Novantrone) | Other | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT00059631 |
| Paclitaxel and TAK-228 | Other | Phase PHASE2 | Metastatic Urothelial Cancer | UNKNOWN | NCT03745911 |
| Paclitaxel and TAK-228 | Other | Phase PHASE2 | Metastatic Urothelial Cancer | UNKNOWN | NCT03745911 |
| Paclitaxel and TAK-228 | Other | Phase PHASE2 | Metastatic Urothelial Cancer | UNKNOWN | NCT03745911 |
| TAK-385 | Other | Phase PHASE1 | Hormone Treatment-naïve Participants With Prostate Cancer | COMPLETED | NCT02141659 |
| TAK-385 | Other | Phase PHASE1 | Hormone Treatment-naïve Participants With Prostate Cancer | COMPLETED | NCT02141659 |
| Daratumumab, Ixazomib, Dexamethasone | Other | Phase PHASE2 | Multiple Myeloma | UNKNOWN | NCT03746652 |
| Saline | Other | Phase PHASE1 | Gastroenteritis | COMPLETED | NCT01168401 |
| NoV GI.1/GII.4 Bivalent VLP Vaccine | Other | Phase PHASE1 | Gastroenteritis | COMPLETED | NCT01168401 |
| Saline | Other | Phase PHASE1 | Gastroenteritis | COMPLETED | NCT01168401 |
| NoV GI.1/GII.4 Bivalent VLP Vaccine | Other | Phase PHASE1 | Gastroenteritis | COMPLETED | NCT01168401 |
| TACHOSIL GROUP | Other | Phase PHASE4 | Lymphocele | COMPLETED | NCT03752606 |
| Placebo | Other | Approved | Attention Deficit Hyperactivity Disorder | COMPLETED | NCT00736255 |
| Lis-dexamphetamine (Vyvanse) | Other | Approved | Attention Deficit Hyperactivity Disorder | COMPLETED | NCT00736255 |
| Transdermal Nicotine Patch | Other | Approved | Attention Deficit Hyperactivity Disorder | COMPLETED | NCT00736255 |
| Voglibose | Other | Preclinical | Impaired Glucose Tolerance | COMPLETED | NCT01993927 |
| Voglibose | Other | Preclinical | Impaired Glucose Tolerance | COMPLETED | NCT01993927 |
| Voglibose | Other | Preclinical | Impaired Glucose Tolerance | COMPLETED | NCT01993927 |
| Paclitaxel | Other | Phase PHASE2 | Small Cell Lung Cancer | COMPLETED | NCT02038647 |
| Placebo | Other | Phase PHASE2 | Small Cell Lung Cancer | COMPLETED | NCT02038647 |
| Alisertib | Other | Phase PHASE2 | Small Cell Lung Cancer | COMPLETED | NCT02038647 |
| Lubiprostone | Other | Phase PHASE3 | Chronic Idiopathic Constipation | COMPLETED | NCT02695719 |
| Placebo | Other | Phase PHASE3 | Chronic Idiopathic Constipation | COMPLETED | NCT02695719 |
| TAK-438 | Other | Phase PHASE1 | Helicobacter Pylori | COMPLETED | NCT02892409 |
| Lansoprazole | Other | Phase PHASE1 | Helicobacter Pylori | COMPLETED | NCT02892409 |
| Tripotassium bismuth dicitrate | Other | Phase PHASE1 | Helicobacter Pylori | COMPLETED | NCT02892409 |
| Amoxicillin | Other | Phase PHASE1 | Helicobacter Pylori | COMPLETED | NCT02892409 |
| Clarithromycin | Other | Phase PHASE1 | Helicobacter Pylori | COMPLETED | NCT02892409 |
| TAK-438 | Other | Phase PHASE1 | Helicobacter Pylori | COMPLETED | NCT02892409 |
| Lansoprazole | Other | Phase PHASE1 | Helicobacter Pylori | COMPLETED | NCT02892409 |
| Tripotassium bismuth dicitrate | Other | Phase PHASE1 | Helicobacter Pylori | COMPLETED | NCT02892409 |
| Amoxicillin | Other | Phase PHASE1 | Helicobacter Pylori | COMPLETED | NCT02892409 |
| Clarithromycin | Other | Phase PHASE1 | Helicobacter Pylori | COMPLETED | NCT02892409 |
| alisertib | Other | Phase PHASE1 | Mucinous Adenocarcinoma of the Colon | COMPLETED | NCT01923337 |
| irinotecan hydrochloride | Other | Phase PHASE1 | Mucinous Adenocarcinoma of the Colon | COMPLETED | NCT01923337 |
| TAK-020 Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02413255 |
| TAK-020 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02413255 |
| TAK-020 Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02413255 |
| TAK-020 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02413255 |
| Paclitaxel | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT02122770 |
| Carboplatin | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT02122770 |
| Docetaxel | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT02122770 |
| Itraconazole | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT02122770 |
| Fluconazole | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT02122770 |
| MLN4924 | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT02122770 |
| Paclitaxel | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT02122770 |
| Carboplatin | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT02122770 |
| Docetaxel | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT02122770 |
| Itraconazole | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT02122770 |
| Fluconazole | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT02122770 |
| MLN4924 | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT02122770 |
| Saline Comparator | Other | Phase PHASE1 | Prevention From Norovirus Infection | COMPLETED | NCT01609257 |
| Norovirus Bivalent Vaccine | Other | Phase PHASE1 | Prevention From Norovirus Infection | COMPLETED | NCT01609257 |
| Saline Comparator | Other | Phase PHASE1 | Prevention From Norovirus Infection | COMPLETED | NCT01609257 |
| Norovirus Bivalent Vaccine | Other | Phase PHASE1 | Prevention From Norovirus Infection | COMPLETED | NCT01609257 |
| No intervention | Other | Preclinical | Major Depressive Disorder | COMPLETED | NCT03067506 |
| No intervention | Other | Preclinical | Major Depressive Disorder | COMPLETED | NCT03067506 |
| Itraconazole | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT03161405 |
| TAK-906 Maleate | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT03161405 |
| Itraconazole | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT03161405 |
| TAK-906 Maleate | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT03161405 |
| Itraconazole | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT03173170 |
| TAK-954 | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT03173170 |
| Itraconazole | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT03173170 |
| TAK-954 | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT03173170 |
| Azilsartan | Other | Preclinical | Hypertension | COMPLETED | NCT02092025 |
| Lubiprostone Control | Other | Phase PHASE1 | Chronic Constipation, Methanogenesis | COMPLETED | NCT01190020 |
| Lubiprostone | Other | Phase PHASE1 | Chronic Constipation, Methanogenesis | COMPLETED | NCT01190020 |
| Lubiprostone Control | Other | Phase PHASE1 | Chronic Constipation, Methanogenesis | COMPLETED | NCT01190020 |
| Lubiprostone | Other | Phase PHASE1 | Chronic Constipation, Methanogenesis | COMPLETED | NCT01190020 |
| Lubiprostone Control | Other | Phase PHASE1 | Chronic Constipation, Methanogenesis | COMPLETED | NCT01190020 |
| Lubiprostone | Other | Phase PHASE1 | Chronic Constipation, Methanogenesis | COMPLETED | NCT01190020 |
| Lubiprostone Control | Other | Phase PHASE1 | Chronic Constipation, Methanogenesis | COMPLETED | NCT01190020 |
| Lubiprostone | Other | Phase PHASE1 | Chronic Constipation, Methanogenesis | COMPLETED | NCT01190020 |
| Pioglitazone | Other | Preclinical | Type 2 Diabetes Mellitus | COMPLETED | NCT02181842 |
| Pioglitazone | Other | Preclinical | Type 2 Diabetes Mellitus | COMPLETED | NCT02181842 |
| Pioglitazone | Other | Preclinical | Type 2 Diabetes Mellitus | COMPLETED | NCT02181842 |
| Treatment with recombinant coagulation factor | Drug | Preclinical | Hemophilia A | COMPLETED | NCT03313531 |
| Thrombin Generation Assay | Other | Preclinical | Hemophilia A | COMPLETED | NCT03313531 |
| Treatment with recombinant coagulation factor | Drug | Preclinical | Hemophilia A | COMPLETED | NCT03313531 |
| Thrombin Generation Assay | Other | Preclinical | Hemophilia A | COMPLETED | NCT03313531 |
| Taxotere | Other | Phase PHASE1 | Lung Cancer | TERMINATED | NCT00424840 |
| Bevacizumab | Other | Phase PHASE1 | Lung Cancer | TERMINATED | NCT00424840 |
| Carboplatin AUC 6 | Other | Phase PHASE1 | Lung Cancer | TERMINATED | NCT00424840 |
| Bortezomib 1.8 mg/m2 | Other | Phase PHASE1 | Lung Cancer | TERMINATED | NCT00424840 |
| Bortezomib 1.6 mg/m2 | Other | Phase PHASE1 | Lung Cancer | TERMINATED | NCT00424840 |
| Bortezomib 1.3 mg/m2 | Other | Phase PHASE1 | Lung Cancer | TERMINATED | NCT00424840 |
| Taxotere | Other | Phase PHASE1 | Lung Cancer | TERMINATED | NCT00424840 |
| Bevacizumab | Other | Phase PHASE1 | Lung Cancer | TERMINATED | NCT00424840 |
| Carboplatin AUC 6 | Other | Phase PHASE1 | Lung Cancer | TERMINATED | NCT00424840 |
| Bortezomib 1.8 mg/m2 | Other | Phase PHASE1 | Lung Cancer | TERMINATED | NCT00424840 |
| Bortezomib 1.6 mg/m2 | Other | Phase PHASE1 | Lung Cancer | TERMINATED | NCT00424840 |
| Bortezomib 1.3 mg/m2 | Other | Phase PHASE1 | Lung Cancer | TERMINATED | NCT00424840 |
| Taxotere | Other | Phase PHASE1 | Lung Cancer | TERMINATED | NCT00424840 |
| Bevacizumab | Other | Phase PHASE1 | Lung Cancer | TERMINATED | NCT00424840 |
| Carboplatin AUC 6 | Other | Phase PHASE1 | Lung Cancer | TERMINATED | NCT00424840 |
| Bortezomib 1.8 mg/m2 | Other | Phase PHASE1 | Lung Cancer | TERMINATED | NCT00424840 |
| Bortezomib 1.6 mg/m2 | Other | Phase PHASE1 | Lung Cancer | TERMINATED | NCT00424840 |
| Bortezomib 1.3 mg/m2 | Other | Phase PHASE1 | Lung Cancer | TERMINATED | NCT00424840 |
| Folic Acid | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT02393378 |
| Methotrexate | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT02393378 |
| Adalimumab | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT02393378 |
| Namilumab | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT02393378 |
| Folic Acid | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT02393378 |
| Methotrexate | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT02393378 |
| Adalimumab | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT02393378 |
| Namilumab | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT02393378 |
| alogliptin + pioglitazone | Other | Phase PHASE4 | Type 2 Diabetes Mellitus | COMPLETED | NCT02231021 |
| Pioglitazone | Other | Phase PHASE4 | Type 2 Diabetes Mellitus | COMPLETED | NCT02231021 |
| alogliptin | Other | Phase PHASE4 | Type 2 Diabetes Mellitus | COMPLETED | NCT02231021 |
| TAK-915 tablet | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02461160 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02461160 |
| Midazolam | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02461160 |
| TAK-915 suspension | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02461160 |
| TAK-915 tablet | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02461160 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02461160 |
| Midazolam | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02461160 |
| TAK-915 suspension | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02461160 |
| Docetaxel | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT01094288 |
| Alisertib | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT01094288 |
| Docetaxel | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT01094288 |
| Alisertib | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT01094288 |
| Electronic Survey | Other | Approved | Patient Reported Outcome Measures | COMPLETED | NCT03738254 |
| Paper Survey | Other | Approved | Patient Reported Outcome Measures | COMPLETED | NCT03738254 |
| The Guardians: A smartphone game | Other | Approved | Patient Reported Outcome Measures | COMPLETED | NCT03738254 |
| Placebo | Other | Phase PHASE3 | Erosive Esophagitis | TERMINATED | NCT02873702 |
| Lansoprazole | Other | Phase PHASE3 | Erosive Esophagitis | TERMINATED | NCT02873702 |
| Dexlansoprazole | Other | Phase PHASE3 | Erosive Esophagitis | TERMINATED | NCT02873702 |
| Placebo | Other | Phase PHASE3 | Erosive Esophagitis | TERMINATED | NCT02873702 |
| Lansoprazole | Other | Phase PHASE3 | Erosive Esophagitis | TERMINATED | NCT02873702 |
| Dexlansoprazole | Other | Phase PHASE3 | Erosive Esophagitis | TERMINATED | NCT02873702 |
| Azilsartan Medoxomil | Other | Phase PHASE4 | Essential Hypertension | COMPLETED | NCT02517866 |
| Azilsartan Medoxomil | Other | Phase PHASE4 | Essential Hypertension | COMPLETED | NCT02517866 |
| Pioglitazone | Other | Preclinical | Type 2 Diabetes Mellitus | COMPLETED | NCT02068508 |
| Pioglitazone | Other | Preclinical | Type 2 Diabetes Mellitus | COMPLETED | NCT02068508 |
| Pioglitazone | Other | Preclinical | Type 2 Diabetes Mellitus | COMPLETED | NCT02068508 |
| Alisertib | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT00962091 |
| Alisertib | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT00962091 |
| Acarbose | Other | Phase PHASE4 | Type 2 Diabetes Mellitus | COMPLETED | NCT02049814 |
| Voglibose | Other | Phase PHASE4 | Type 2 Diabetes Mellitus | COMPLETED | NCT02049814 |
| Metformin | Other | Phase PHASE4 | Type 2 Diabetes Mellitus | COMPLETED | NCT02049814 |
| Acarbose | Other | Phase PHASE4 | Type 2 Diabetes Mellitus | COMPLETED | NCT02049814 |
| Voglibose | Other | Phase PHASE4 | Type 2 Diabetes Mellitus | COMPLETED | NCT02049814 |
| Metformin | Other | Phase PHASE4 | Type 2 Diabetes Mellitus | COMPLETED | NCT02049814 |
| Bortezomib | Other | Preclinical | Multiple Myeloma | COMPLETED | NCT02026505 |
| Bortezomib | Other | Preclinical | Multiple Myeloma | COMPLETED | NCT02026505 |
| MLN7243 | Other | Phase PHASE1 | Advanced Malignant Solid Tumors | TERMINATED | NCT02045095 |
| MLN7243 | Other | Phase PHASE1 | Advanced Malignant Solid Tumors | TERMINATED | NCT02045095 |
| Alisertib | Other | Phase PHASE1 | Advanced Malignancies | COMPLETED | NCT00500903 |
| Peginesatide | Other | Phase PHASE2 | Anemia | COMPLETED | NCT00314795 |
| Peginesatide | Other | Phase PHASE2 | Anemia | COMPLETED | NCT00314795 |
| Alisertib | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT01512758 |
| Alisertib | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT01512758 |
| alisertib | Other | Phase PHASE1 | Advanced Malignancies | COMPLETED | NCT00651664 |
| alisertib | Other | Phase PHASE1 | Advanced Malignancies | COMPLETED | NCT00651664 |
| TAK-792 1250 mg placebo | Other | Phase PHASE1 | Healthy Male Adults Participants | COMPLETED | NCT02448719 |
| TAK-792 1250 mg | Other | Phase PHASE1 | Healthy Male Adults Participants | COMPLETED | NCT02448719 |
| TAK-792 750 mg placebo | Other | Phase PHASE1 | Healthy Male Adults Participants | COMPLETED | NCT02448719 |
| TAK-792 750 mg | Other | Phase PHASE1 | Healthy Male Adults Participants | COMPLETED | NCT02448719 |
| TAK-792 500 mg placebo | Other | Phase PHASE1 | Healthy Male Adults Participants | COMPLETED | NCT02448719 |
| TAK-792 500 mg | Other | Phase PHASE1 | Healthy Male Adults Participants | COMPLETED | NCT02448719 |
| TAK-792 250 mg placebo | Other | Phase PHASE1 | Healthy Male Adults Participants | COMPLETED | NCT02448719 |
| TAK-792 250 mg | Other | Phase PHASE1 | Healthy Male Adults Participants | COMPLETED | NCT02448719 |
| TAK-792 100 mg placebo | Other | Phase PHASE1 | Healthy Male Adults Participants | COMPLETED | NCT02448719 |
| TAK-792 100 mg | Other | Phase PHASE1 | Healthy Male Adults Participants | COMPLETED | NCT02448719 |
| TAK-792 30 mg placebo | Other | Phase PHASE1 | Healthy Male Adults Participants | COMPLETED | NCT02448719 |
| TAK-792 30 mg | Other | Phase PHASE1 | Healthy Male Adults Participants | COMPLETED | NCT02448719 |
| TAK-792 1250 mg placebo | Other | Phase PHASE1 | Healthy Male Adults Participants | COMPLETED | NCT02448719 |
| TAK-792 1250 mg | Other | Phase PHASE1 | Healthy Male Adults Participants | COMPLETED | NCT02448719 |
| TAK-792 750 mg placebo | Other | Phase PHASE1 | Healthy Male Adults Participants | COMPLETED | NCT02448719 |
| TAK-792 750 mg | Other | Phase PHASE1 | Healthy Male Adults Participants | COMPLETED | NCT02448719 |
| TAK-792 500 mg placebo | Other | Phase PHASE1 | Healthy Male Adults Participants | COMPLETED | NCT02448719 |
| TAK-792 500 mg | Other | Phase PHASE1 | Healthy Male Adults Participants | COMPLETED | NCT02448719 |
| TAK-792 250 mg placebo | Other | Phase PHASE1 | Healthy Male Adults Participants | COMPLETED | NCT02448719 |
| TAK-792 250 mg | Other | Phase PHASE1 | Healthy Male Adults Participants | COMPLETED | NCT02448719 |
| TAK-792 100 mg placebo | Other | Phase PHASE1 | Healthy Male Adults Participants | COMPLETED | NCT02448719 |
| TAK-792 100 mg | Other | Phase PHASE1 | Healthy Male Adults Participants | COMPLETED | NCT02448719 |
| TAK-792 30 mg placebo | Other | Phase PHASE1 | Healthy Male Adults Participants | COMPLETED | NCT02448719 |
| TAK-792 30 mg | Other | Phase PHASE1 | Healthy Male Adults Participants | COMPLETED | NCT02448719 |
| Dexamethasone | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT01383928 |
| Lenalidomide | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT01383928 |
| Ixazomib | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT01383928 |
| Metronidazole | Other | Preclinical | Gastric/Duodenal Ulcer, Gastric MALT Lymphoma, Idiopathic Thrombocytopenic Purpura, or H. Pylori Gastritis, and Other | COMPLETED | NCT03219723 |
| Clarithromycin | Other | Preclinical | Gastric/Duodenal Ulcer, Gastric MALT Lymphoma, Idiopathic Thrombocytopenic Purpura, or H. Pylori Gastritis, and Other | COMPLETED | NCT03219723 |
| Amoxicillin hydrate | Other | Preclinical | Gastric/Duodenal Ulcer, Gastric MALT Lymphoma, Idiopathic Thrombocytopenic Purpura, or H. Pylori Gastritis, and Other | COMPLETED | NCT03219723 |
| Vonoprazan | Other | Preclinical | Gastric/Duodenal Ulcer, Gastric MALT Lymphoma, Idiopathic Thrombocytopenic Purpura, or H. Pylori Gastritis, and Other | COMPLETED | NCT03219723 |
| Metronidazole | Other | Preclinical | Gastric/Duodenal Ulcer, Gastric MALT Lymphoma, Idiopathic Thrombocytopenic Purpura, or H. Pylori Gastritis, and Other | COMPLETED | NCT03219723 |
| Clarithromycin | Other | Preclinical | Gastric/Duodenal Ulcer, Gastric MALT Lymphoma, Idiopathic Thrombocytopenic Purpura, or H. Pylori Gastritis, and Other | COMPLETED | NCT03219723 |
| Amoxicillin hydrate | Other | Preclinical | Gastric/Duodenal Ulcer, Gastric MALT Lymphoma, Idiopathic Thrombocytopenic Purpura, or H. Pylori Gastritis, and Other | COMPLETED | NCT03219723 |
| Vonoprazan | Other | Preclinical | Gastric/Duodenal Ulcer, Gastric MALT Lymphoma, Idiopathic Thrombocytopenic Purpura, or H. Pylori Gastritis, and Other | COMPLETED | NCT03219723 |
| Metronidazole | Other | Preclinical | Gastric/Duodenal Ulcer, Gastric MALT Lymphoma, Idiopathic Thrombocytopenic Purpura, or H. Pylori Gastritis, and Other | COMPLETED | NCT03219723 |
| Clarithromycin | Other | Preclinical | Gastric/Duodenal Ulcer, Gastric MALT Lymphoma, Idiopathic Thrombocytopenic Purpura, or H. Pylori Gastritis, and Other | COMPLETED | NCT03219723 |
| Amoxicillin hydrate | Other | Preclinical | Gastric/Duodenal Ulcer, Gastric MALT Lymphoma, Idiopathic Thrombocytopenic Purpura, or H. Pylori Gastritis, and Other | COMPLETED | NCT03219723 |
| Vonoprazan | Other | Preclinical | Gastric/Duodenal Ulcer, Gastric MALT Lymphoma, Idiopathic Thrombocytopenic Purpura, or H. Pylori Gastritis, and Other | COMPLETED | NCT03219723 |
| Leuprorelin Placebo | Other | Phase PHASE3 | Uterine Fibroids | COMPLETED | NCT02655237 |
| Leuprorelin | Other | Phase PHASE3 | Uterine Fibroids | COMPLETED | NCT02655237 |
| Relugolix Placebo | Other | Phase PHASE3 | Uterine Fibroids | COMPLETED | NCT02655237 |
| Relugolix | Other | Phase PHASE3 | Uterine Fibroids | COMPLETED | NCT02655237 |
| Leuprorelin Placebo | Other | Phase PHASE3 | Uterine Fibroids | COMPLETED | NCT02655237 |
| Leuprorelin | Other | Phase PHASE3 | Uterine Fibroids | COMPLETED | NCT02655237 |
| Relugolix Placebo | Other | Phase PHASE3 | Uterine Fibroids | COMPLETED | NCT02655237 |
| Relugolix | Other | Phase PHASE3 | Uterine Fibroids | COMPLETED | NCT02655237 |
| Leuprorelin Placebo | Other | Phase PHASE3 | Uterine Fibroids | COMPLETED | NCT02655237 |
| Leuprorelin | Other | Phase PHASE3 | Uterine Fibroids | COMPLETED | NCT02655237 |
| Relugolix Placebo | Other | Phase PHASE3 | Uterine Fibroids | COMPLETED | NCT02655237 |
| Relugolix | Other | Phase PHASE3 | Uterine Fibroids | COMPLETED | NCT02655237 |
| Relugolix placebo | Other | Phase PHASE3 | Uterine Fibroids | COMPLETED | NCT02655224 |
| Relugolix | Other | Phase PHASE3 | Uterine Fibroids | COMPLETED | NCT02655224 |
| Relugolix placebo | Other | Phase PHASE3 | Uterine Fibroids | COMPLETED | NCT02655224 |
| Relugolix | Other | Phase PHASE3 | Uterine Fibroids | COMPLETED | NCT02655224 |
| Relugolix placebo | Other | Phase PHASE3 | Uterine Fibroids | COMPLETED | NCT02655224 |
| Relugolix | Other | Phase PHASE3 | Uterine Fibroids | COMPLETED | NCT02655224 |
| Rifampin | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT01844583 |
| Esomeprazole | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT01844583 |
| Alisertib | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT01844583 |
| Rifampin | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT01844583 |
| Esomeprazole | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT01844583 |
| Alisertib | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT01844583 |
| Rifampin | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT01844583 |
| Esomeprazole | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT01844583 |
| Alisertib | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT01844583 |
| Vonoprazan | Other | Phase PHASE4 | Reflux Esophagitis | COMPLETED | NCT03116841 |
| Vonoprazan | Other | Phase PHASE4 | Reflux Esophagitis | COMPLETED | NCT03116841 |
| Placebo | Other | Phase PHASE3 | Constipation | COMPLETED | NCT02729909 |
| Lubiprostone | Other | Phase PHASE3 | Constipation | COMPLETED | NCT02729909 |
| Placebo | Other | Phase PHASE3 | Constipation | COMPLETED | NCT02729909 |
| Lubiprostone | Other | Phase PHASE3 | Constipation | COMPLETED | NCT02729909 |
| Placebo | Other | Phase PHASE2 | Norovirus | COMPLETED | NCT02153112 |
| GI.1/GII.4 (50/150) | Other | Phase PHASE2 | Norovirus | COMPLETED | NCT02153112 |
| GI.1/GII.4 (50/50) | Other | Phase PHASE2 | Norovirus | COMPLETED | NCT02153112 |
| GI.1/GII.4 (15/50) | Other | Phase PHASE2 | Norovirus | COMPLETED | NCT02153112 |
| GI.1/GII.4 (15/15) | Other | Phase PHASE2 | Norovirus | COMPLETED | NCT02153112 |
| Placebo | Other | Phase PHASE3 | Neck Pain | COMPLETED | NCT02814565 |
| Cyclobenzaprine HCl | Other | Phase PHASE3 | Neck Pain | COMPLETED | NCT02814565 |
| Placebo | Other | Phase PHASE3 | Neck Pain | COMPLETED | NCT02814565 |
| Cyclobenzaprine HCl | Other | Phase PHASE3 | Neck Pain | COMPLETED | NCT02814565 |
| Leuprorelin acetate | Other | Preclinical | Prostate Cancer | COMPLETED | NCT03209492 |
| Alogliptin FDC With Metformin | Other | Preclinical | Diabetes Mellitus, Type 2 | TERMINATED | NCT02989649 |
| Alogliptin FDC With Pioglitazone | Other | Preclinical | Diabetes Mellitus, Type 2 | TERMINATED | NCT02989649 |
| Alogliptin | Other | Preclinical | Diabetes Mellitus, Type 2 | TERMINATED | NCT02989649 |
| Alogliptin FDC With Metformin | Other | Preclinical | Diabetes Mellitus, Type 2 | TERMINATED | NCT02989649 |
| Alogliptin FDC With Pioglitazone | Other | Preclinical | Diabetes Mellitus, Type 2 | TERMINATED | NCT02989649 |
| Alogliptin | Other | Preclinical | Diabetes Mellitus, Type 2 | TERMINATED | NCT02989649 |
| Ara C | Other | Phase PHASE1 | CLASSICAL HODGKIN LYMPHOMA | COMPLETED | NCT02243436 |
| Cisplatin | Other | Phase PHASE1 | CLASSICAL HODGKIN LYMPHOMA | COMPLETED | NCT02243436 |
| Soludomerin | Other | Phase PHASE1 | CLASSICAL HODGKIN LYMPHOMA | COMPLETED | NCT02243436 |
| Etoposide | Other | Phase PHASE1 | CLASSICAL HODGKIN LYMPHOMA | COMPLETED | NCT02243436 |
| Brentuximab Vedotin | Other | Phase PHASE1 | CLASSICAL HODGKIN LYMPHOMA | COMPLETED | NCT02243436 |
| Ara C | Other | Phase PHASE1 | CLASSICAL HODGKIN LYMPHOMA | COMPLETED | NCT02243436 |
| Cisplatin | Other | Phase PHASE1 | CLASSICAL HODGKIN LYMPHOMA | COMPLETED | NCT02243436 |
| Soludomerin | Other | Phase PHASE1 | CLASSICAL HODGKIN LYMPHOMA | COMPLETED | NCT02243436 |
| Etoposide | Other | Phase PHASE1 | CLASSICAL HODGKIN LYMPHOMA | COMPLETED | NCT02243436 |
| Brentuximab Vedotin | Other | Phase PHASE1 | CLASSICAL HODGKIN LYMPHOMA | COMPLETED | NCT02243436 |
| Ara C | Other | Phase PHASE1 | CLASSICAL HODGKIN LYMPHOMA | COMPLETED | NCT02243436 |
| Cisplatin | Other | Phase PHASE1 | CLASSICAL HODGKIN LYMPHOMA | COMPLETED | NCT02243436 |
| Soludomerin | Other | Phase PHASE1 | CLASSICAL HODGKIN LYMPHOMA | COMPLETED | NCT02243436 |
| Etoposide | Other | Phase PHASE1 | CLASSICAL HODGKIN LYMPHOMA | COMPLETED | NCT02243436 |
| Brentuximab Vedotin | Other | Phase PHASE1 | CLASSICAL HODGKIN LYMPHOMA | COMPLETED | NCT02243436 |
| Vedolizumab placebo | Other | Phase PHASE3 | Ulcerative Colitis | COMPLETED | NCT02039505 |
| Vedolizumab | Other | Phase PHASE3 | Ulcerative Colitis | COMPLETED | NCT02039505 |
| Vedolizumab placebo | Other | Phase PHASE3 | Ulcerative Colitis | COMPLETED | NCT02039505 |
| Vedolizumab | Other | Phase PHASE3 | Ulcerative Colitis | COMPLETED | NCT02039505 |
| Vedolizumab | Other | Phase PHASE4 | Crohn's Disease | TERMINATED | NCT02324699 |
| Placebo | Other | Phase PHASE4 | Crohn's Disease | TERMINATED | NCT02324699 |
| Prednisone | Other | Phase PHASE4 | Crohn's Disease | TERMINATED | NCT02324699 |
| Vedolizumab | Other | Phase PHASE4 | Crohn's Disease | TERMINATED | NCT02324699 |
| Placebo | Other | Phase PHASE4 | Crohn's Disease | TERMINATED | NCT02324699 |
| Prednisone | Other | Phase PHASE4 | Crohn's Disease | TERMINATED | NCT02324699 |
| TAK-085 | Other | Phase PHASE4 | Hyperlipidemia | COMPLETED | NCT02824432 |
| TAK-085 | Other | Phase PHASE4 | Hyperlipidemia | COMPLETED | NCT02824432 |
| Matching placebo | Other | Phase PHASE2 | Atrial Fibrillation | COMPLETED | NCT01755949 |
| Colchicine, 0.6 mg PO BID | Other | Phase PHASE2 | Atrial Fibrillation | COMPLETED | NCT01755949 |
| Matching placebo | Other | Phase PHASE2 | Atrial Fibrillation | COMPLETED | NCT01755949 |
| Colchicine, 0.6 mg PO BID | Other | Phase PHASE2 | Atrial Fibrillation | COMPLETED | NCT01755949 |
| Matching placebo | Other | Phase PHASE2 | Atrial Fibrillation | COMPLETED | NCT01755949 |
| Colchicine, 0.6 mg PO BID | Other | Phase PHASE2 | Atrial Fibrillation | COMPLETED | NCT01755949 |
| Dexlansoprazole | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03316976 |
| Dexlansoprazole | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03316976 |
| Vedolizumab | Other | Phase PHASE2 | Allogeneic Hematopoietic Stem Cell Transplantation | TERMINATED | NCT02993783 |
| Lansoprazole Placebo | Other | Phase PHASE3 | Erosive Esophagitis | COMPLETED | NCT02388724 |
| Vonoprazan Placebo | Other | Phase PHASE3 | Erosive Esophagitis | COMPLETED | NCT02388724 |
| Lansoprazole | Other | Phase PHASE3 | Erosive Esophagitis | COMPLETED | NCT02388724 |
| Vonoprazan | Other | Phase PHASE3 | Erosive Esophagitis | COMPLETED | NCT02388724 |
| Azilsartan/Amlodipine | Other | Preclinical | Hypertension | COMPLETED | NCT02181816 |
| Azilsartan/Amlodipine | Other | Preclinical | Hypertension | COMPLETED | NCT02181816 |
| Azilsartan/Amlodipine | Other | Preclinical | Hypertension | COMPLETED | NCT02181816 |
| Sodium risedronate | Other | Preclinical | Osseous Paget's Disease | COMPLETED | NCT02106455 |
| Sodium risedronate | Other | Preclinical | Osseous Paget's Disease | COMPLETED | NCT02106455 |
| Sodium risedronate | Other | Preclinical | Osseous Paget's Disease | COMPLETED | NCT02106455 |
| pioglitazone | Other | Phase PHASE4 | Diabetes Mellitus, Type 2 | TERMINATED | NCT02763007 |
| alogliptin | Other | Phase PHASE4 | Diabetes Mellitus, Type 2 | TERMINATED | NCT02763007 |
| alogliptin+pioglitazone | Other | Phase PHASE4 | Diabetes Mellitus, Type 2 | TERMINATED | NCT02763007 |
| Donepezil Placebo | Other | Phase PHASE1 | Alzheimer Disease | TERMINATED | NCT02769065 |
| TAK-071 Placebo | Other | Phase PHASE1 | Alzheimer Disease | TERMINATED | NCT02769065 |
| Donepezil | Other | Phase PHASE1 | Alzheimer Disease | TERMINATED | NCT02769065 |
| TAK-071 | Other | Phase PHASE1 | Alzheimer Disease | TERMINATED | NCT02769065 |
| Donepezil Placebo | Other | Phase PHASE1 | Alzheimer Disease | TERMINATED | NCT02769065 |
| TAK-071 Placebo | Other | Phase PHASE1 | Alzheimer Disease | TERMINATED | NCT02769065 |
| Donepezil | Other | Phase PHASE1 | Alzheimer Disease | TERMINATED | NCT02769065 |
| TAK-071 | Other | Phase PHASE1 | Alzheimer Disease | TERMINATED | NCT02769065 |
| Ixazomib | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT01830816 |
| Ixazomib | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT01830816 |
| bortezomib | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT00153920 |
| bortezomib | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT00153920 |
| 60 mg dexlansoprazole capsules manufactured at TPC | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03131895 |
| 60 mg dexlansoprazole capsules manufactured at TOB | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03131895 |
| 30 mg dexlansoprazole capsules manufactured at TPC | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03131895 |
| 30 mg dexlansoprazole capsules manufactured at TOB | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03131895 |
| Esomeprazole Tablet | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT03083639 |
| Esomeprazole Capsule | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT03083639 |
| Esomeprazole Tablet | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT03083639 |
| Esomeprazole Capsule | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT03083639 |
| Donepezil Placebo | Other | Phase PHASE1 | Healthy Volunteers | TERMINATED | NCT02918266 |
| TAK-071 Placebo | Other | Phase PHASE1 | Healthy Volunteers | TERMINATED | NCT02918266 |
| Scopolamine Placebo | Other | Phase PHASE1 | Healthy Volunteers | TERMINATED | NCT02918266 |
| Donepezil | Other | Phase PHASE1 | Healthy Volunteers | TERMINATED | NCT02918266 |
| TAK-071 | Other | Phase PHASE1 | Healthy Volunteers | TERMINATED | NCT02918266 |
| Scopolamine | Other | Phase PHASE1 | Healthy Volunteers | TERMINATED | NCT02918266 |
| Donepezil Placebo | Other | Phase PHASE1 | Healthy Volunteers | TERMINATED | NCT02918266 |
| TAK-071 Placebo | Other | Phase PHASE1 | Healthy Volunteers | TERMINATED | NCT02918266 |
| Scopolamine Placebo | Other | Phase PHASE1 | Healthy Volunteers | TERMINATED | NCT02918266 |
| Donepezil | Other | Phase PHASE1 | Healthy Volunteers | TERMINATED | NCT02918266 |
| TAK-071 | Other | Phase PHASE1 | Healthy Volunteers | TERMINATED | NCT02918266 |
| Scopolamine | Other | Phase PHASE1 | Healthy Volunteers | TERMINATED | NCT02918266 |
| Alisertib | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT01898078 |
| Alisertib | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT01898078 |
| Paclitaxel | Other | Phase PHASE1 | Advanced Solid Tumors | TERMINATED | NCT02367352 |
| Alisertib | Other | Phase PHASE1 | Advanced Solid Tumors | TERMINATED | NCT02367352 |
| Paclitaxel | Other | Phase PHASE1 | Advanced Solid Tumors | TERMINATED | NCT02367352 |
| Alisertib | Other | Phase PHASE1 | Advanced Solid Tumors | TERMINATED | NCT02367352 |
| Paclitaxel | Other | Phase PHASE1 | Advanced Solid Tumors | TERMINATED | NCT02367352 |
| Alisertib | Other | Phase PHASE1 | Advanced Solid Tumors | TERMINATED | NCT02367352 |
| Vortioxetine | Other | Phase PHASE1 | Healthy Adult Participants | COMPLETED | NCT03437564 |
| Vortioxetine | Other | Phase PHASE1 | Healthy Adult Participants | COMPLETED | NCT03437564 |
| bortezomib | Other | Phase PHASE1 | Mantle Cell Lymphoma | TERMINATED | NCT01111188 |
| PD 0332991 | Other | Phase PHASE1 | Mantle Cell Lymphoma | TERMINATED | NCT01111188 |
| Bicalutamide | Other | Phase PHASE3 | Prostate Cancer | COMPLETED | NCT02085252 |
| Leuprorelin | Other | Phase PHASE3 | Prostate Cancer | COMPLETED | NCT02085252 |
| bortezomib | Other | Preclinical | Multiple Myeloma | UNKNOWN | NCT02976272 |
| bortezomib | Other | Preclinical | Multiple Myeloma | UNKNOWN | NCT02976272 |
| Placebo | Other | Phase PHASE3 | Heartburn | COMPLETED | NCT02873689 |
| Dexlansoprazole | Other | Phase PHASE3 | Heartburn | COMPLETED | NCT02873689 |
| Placebo | Other | Phase PHASE3 | Heartburn | COMPLETED | NCT02873689 |
| Dexlansoprazole | Other | Phase PHASE3 | Heartburn | COMPLETED | NCT02873689 |
| Placebo | Other | Phase PHASE3 | Heartburn | COMPLETED | NCT02873689 |
| Dexlansoprazole | Other | Phase PHASE3 | Heartburn | COMPLETED | NCT02873689 |
| Vedolizumab | Other | Phase PHASE4 | Ulcerative Colitis | UNKNOWN | NCT04006080 |
| Vedolizumab | Other | Phase PHASE4 | Ulcerative Colitis | UNKNOWN | NCT04006080 |
| Vedolizumab | Other | Phase PHASE4 | Ulcerative Colitis | WITHDRAWN | NCT03237260 |
| Alogliptin Benzoate | Other | Preclinical | Diabetes Mellitus | COMPLETED | NCT02756832 |
| Alogliptin Benzoate | Other | Preclinical | Diabetes Mellitus | COMPLETED | NCT02756832 |
| Vortioxetine | Other | Phase PHASE4 | Major Depressive Disorder | COMPLETED | NCT02972632 |
| Vortioxetine | Other | Phase PHASE4 | Major Depressive Disorder | COMPLETED | NCT02972632 |
| placebo | Other | Phase EARLY_PHASE1 | Crohn Disease | COMPLETED | NCT02953275 |
| Pentoxifylline | Other | Phase EARLY_PHASE1 | Crohn Disease | COMPLETED | NCT02953275 |
| vedolizumab | Other | Phase EARLY_PHASE1 | Crohn Disease | COMPLETED | NCT02953275 |
| placebo | Other | Phase EARLY_PHASE1 | Crohn Disease | COMPLETED | NCT02953275 |
| Pentoxifylline | Other | Phase EARLY_PHASE1 | Crohn Disease | COMPLETED | NCT02953275 |
| vedolizumab | Other | Phase EARLY_PHASE1 | Crohn Disease | COMPLETED | NCT02953275 |
| placebo | Other | Phase EARLY_PHASE1 | Crohn Disease | COMPLETED | NCT02953275 |
| Pentoxifylline | Other | Phase EARLY_PHASE1 | Crohn Disease | COMPLETED | NCT02953275 |
| vedolizumab | Other | Phase EARLY_PHASE1 | Crohn Disease | COMPLETED | NCT02953275 |
| Ferric carboxymaltose | Other | Phase PHASE4 | Cardiac Failure | UNKNOWN | NCT03871699 |
| Ferric carboxymaltose | Other | Phase PHASE4 | Cardiac Failure | UNKNOWN | NCT03871699 |
| Ferric carboxymaltose | Other | Phase PHASE4 | Cardiac Failure | UNKNOWN | NCT03871699 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | TERMINATED | NCT02817516 |
| TAK-828 | Other | Phase PHASE1 | Healthy Volunteers | TERMINATED | NCT02817516 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | TERMINATED | NCT02817516 |
| TAK-828 | Other | Phase PHASE1 | Healthy Volunteers | TERMINATED | NCT02817516 |
| Dexamethasone | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT02046070 |
| Ixazomib | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT02046070 |
| Cyclophosphamide | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT02046070 |
| Dexamethasone | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT02046070 |
| Ixazomib | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT02046070 |
| Cyclophosphamide | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT02046070 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01765426 |
| TDV | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01765426 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01765426 |
| TDV | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01765426 |
| TDV | Other | Phase PHASE1 | Dengue Fever | COMPLETED | NCT01728792 |
| New Formulation Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01542632 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01542632 |
| TDV New Formulation | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01542632 |
| Takeda's Tetravalent Dengue Vaccine Candidate (TDV) | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01542632 |
| New Formulation Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01542632 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01542632 |
| TDV New Formulation | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01542632 |
| Takeda's Tetravalent Dengue Vaccine Candidate (TDV) | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01542632 |
| New Formulation Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01542632 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01542632 |
| TDV New Formulation | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01542632 |
| Takeda's Tetravalent Dengue Vaccine Candidate (TDV) | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01542632 |
| Pazopanib | Other | Phase PHASE1 | Malignant Neoplasm of Breast | COMPLETED | NCT01639911 |
| Alisertib | Other | Phase PHASE1 | Malignant Neoplasm of Breast | COMPLETED | NCT01639911 |
| Pazopanib | Other | Phase PHASE1 | Malignant Neoplasm of Breast | COMPLETED | NCT01639911 |
| Alisertib | Other | Phase PHASE1 | Malignant Neoplasm of Breast | COMPLETED | NCT01639911 |
| ACTOS (Pioglitazone) | Other | Phase PHASE1 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT00242177 |
| ACTOS (Pioglitazone) | Other | Phase PHASE1 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT00242177 |
| ACTOS (Pioglitazone) | Other | Phase PHASE1 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT00242177 |
| Placebo | Other | Phase PHASE3 | Major Depressive Disorder | TERMINATED | NCT00642694 |
| Ramelteon | Other | Phase PHASE3 | Major Depressive Disorder | TERMINATED | NCT00642694 |
| Escitalopram | Other | Phase PHASE3 | Major Depressive Disorder | TERMINATED | NCT00642694 |
| Placebo | Other | Phase PHASE3 | Major Depressive Disorder | TERMINATED | NCT00642694 |
| Ramelteon | Other | Phase PHASE3 | Major Depressive Disorder | TERMINATED | NCT00642694 |
| Escitalopram | Other | Phase PHASE3 | Major Depressive Disorder | TERMINATED | NCT00642694 |
| Placebo | Other | Phase PHASE3 | Major Depressive Disorder | TERMINATED | NCT00642694 |
| Ramelteon | Other | Phase PHASE3 | Major Depressive Disorder | TERMINATED | NCT00642694 |
| Escitalopram | Other | Phase PHASE3 | Major Depressive Disorder | TERMINATED | NCT00642694 |
| [14C]-TAK-954 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03500224 |
| [14C]-TAK-954 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03500224 |
| BLB-750 Vaccine (Qinghai RG strain) | Other | Phase PHASE4 | Pandemic Influenza Prevention | COMPLETED | NCT03370289 |
| BLB-750 Vaccine (Qinghai RG strain) | Other | Phase PHASE4 | Pandemic Influenza Prevention | COMPLETED | NCT03370289 |
| Sodium risedronate | Other | Preclinical | Osteoporosis | COMPLETED | NCT02106442 |
| Prednisone | Other | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT01084655 |
| Docetaxel | Other | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT01084655 |
| TAK-700 | Other | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT01084655 |
| Prednisone | Other | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT01084655 |
| Docetaxel | Other | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT01084655 |
| TAK-700 | Other | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT01084655 |
| Panitumumab + TAS-102 | Other | Phase PHASE1 | Colorectal Cancer | COMPLETED | NCT02613221 |
| Panitumumab + TAS-102 | Other | Phase PHASE1 | Colorectal Cancer | COMPLETED | NCT02613221 |
| TAK-438 10 mg | Other | Phase PHASE3 | Non-erosive Gastroesophageal Reflux Disease | COMPLETED | NCT02954848 |
| Placebo | Other | Phase PHASE3 | Non-erosive Gastroesophageal Reflux Disease | COMPLETED | NCT02954848 |
| TAK-438 10 mg | Other | Phase PHASE3 | Non-erosive Gastroesophageal Reflux Disease | COMPLETED | NCT02954848 |
| Placebo | Other | Phase PHASE3 | Non-erosive Gastroesophageal Reflux Disease | COMPLETED | NCT02954848 |
| TAK-438 10 mg | Other | Phase PHASE3 | Non-erosive Gastroesophageal Reflux Disease | COMPLETED | NCT02954848 |
| Placebo | Other | Phase PHASE3 | Non-erosive Gastroesophageal Reflux Disease | COMPLETED | NCT02954848 |
| Colchicine | Other | Phase PHASE4 | Gout | COMPLETED | NCT01112982 |
| Febuxostat | Other | Phase PHASE4 | Gout | COMPLETED | NCT01112982 |
| Magnetic Resonance Imaging | Other | Phase PHASE4 | Gout | COMPLETED | NCT01112982 |
| Colchicine | Other | Phase PHASE4 | Gout | COMPLETED | NCT01112982 |
| Febuxostat | Other | Phase PHASE4 | Gout | COMPLETED | NCT01112982 |
| Magnetic Resonance Imaging | Other | Phase PHASE4 | Gout | COMPLETED | NCT01112982 |
| Ixazomib | Other | Phase PHASE1 | Relapsed and Refractory Multiple Myeloma | COMPLETED | NCT00932698 |
| Ixazomib | Other | Phase PHASE1 | Relapsed and Refractory Multiple Myeloma | COMPLETED | NCT00932698 |
| Ixazomib | Other | Phase PHASE1 | Relapsed and Refractory Multiple Myeloma | COMPLETED | NCT00932698 |
| SYR-322-4833 BL | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03501277 |
| Pioglitazone | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03501277 |
| Alogliptin | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03501277 |
| SYR-322-4833 BL | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03501277 |
| Pioglitazone | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03501277 |
| Alogliptin | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03501277 |
| Pegaspargase | Other | Phase PHASE2 | Acute Lymphoblastic Leukemia | TERMINATED | NCT02535806 |
| Vincristine | Other | Phase PHASE2 | Acute Lymphoblastic Leukemia | TERMINATED | NCT02535806 |
| Mitoxantrone | Other | Phase PHASE2 | Acute Lymphoblastic Leukemia | TERMINATED | NCT02535806 |
| Dexamethasone | Other | Phase PHASE2 | Acute Lymphoblastic Leukemia | TERMINATED | NCT02535806 |
| Methotrexate / Hydrocortisone / Cytarabine | Other | Phase PHASE2 | Acute Lymphoblastic Leukemia | TERMINATED | NCT02535806 |
| Methotrexate | Other | Phase PHASE2 | Acute Lymphoblastic Leukemia | TERMINATED | NCT02535806 |
| Velcade | Other | Phase PHASE2 | Acute Lymphoblastic Leukemia | TERMINATED | NCT02535806 |
| Pegaspargase | Other | Phase PHASE2 | Acute Lymphoblastic Leukemia | TERMINATED | NCT02535806 |
| Vincristine | Other | Phase PHASE2 | Acute Lymphoblastic Leukemia | TERMINATED | NCT02535806 |
| Mitoxantrone | Other | Phase PHASE2 | Acute Lymphoblastic Leukemia | TERMINATED | NCT02535806 |
| Dexamethasone | Other | Phase PHASE2 | Acute Lymphoblastic Leukemia | TERMINATED | NCT02535806 |
| Methotrexate / Hydrocortisone / Cytarabine | Other | Phase PHASE2 | Acute Lymphoblastic Leukemia | TERMINATED | NCT02535806 |
| Methotrexate | Other | Phase PHASE2 | Acute Lymphoblastic Leukemia | TERMINATED | NCT02535806 |
| Velcade | Other | Phase PHASE2 | Acute Lymphoblastic Leukemia | TERMINATED | NCT02535806 |
| No Intervention | Other | Preclinical | Inflammatory Bowel Disease | COMPLETED | NCT02861118 |
| No Intervention | Other | Preclinical | Inflammatory Bowel Disease | COMPLETED | NCT02861118 |
| Placebo | Other | Phase PHASE3 | Dengue | COMPLETED | NCT03341637 |
| Tetravalent Dengue Vaccine (TDV) | Other | Phase PHASE3 | Dengue | COMPLETED | NCT03341637 |
| Placebo | Other | Phase PHASE3 | Dengue | COMPLETED | NCT03341637 |
| Tetravalent Dengue Vaccine (TDV) | Other | Phase PHASE3 | Dengue | COMPLETED | NCT03341637 |
| Flexible sigmoidoscopy | Other | Preclinical | Intestinal Diseases | COMPLETED | NCT02246647 |
| Esophagogastroduodenoscopy | Other | Preclinical | Intestinal Diseases | COMPLETED | NCT02246647 |
| Permeability measurement | Other | Preclinical | Intestinal Diseases | COMPLETED | NCT02246647 |
| Flexible sigmoidoscopy | Other | Preclinical | Intestinal Diseases | COMPLETED | NCT02246647 |
| Esophagogastroduodenoscopy | Other | Preclinical | Intestinal Diseases | COMPLETED | NCT02246647 |
| Permeability measurement | Other | Preclinical | Intestinal Diseases | COMPLETED | NCT02246647 |
| Flexible sigmoidoscopy | Other | Preclinical | Intestinal Diseases | COMPLETED | NCT02246647 |
| Esophagogastroduodenoscopy | Other | Preclinical | Intestinal Diseases | COMPLETED | NCT02246647 |
| Permeability measurement | Other | Preclinical | Intestinal Diseases | COMPLETED | NCT02246647 |
| Flexible sigmoidoscopy | Other | Preclinical | Intestinal Diseases | COMPLETED | NCT02246647 |
| Esophagogastroduodenoscopy | Other | Preclinical | Intestinal Diseases | COMPLETED | NCT02246647 |
| Permeability measurement | Other | Preclinical | Intestinal Diseases | COMPLETED | NCT02246647 |
| Vedolizumab | Other | Phase PHASE1 | Allogeneic Hematopoietic Stem Cell Transplantation | COMPLETED | NCT02728895 |
| Takeda's High-Dose Tetravalent Dengue Vaccine Candidate (HD-TDV) | Other | Phase PHASE2 | Dengue Fever | COMPLETED | NCT02425098 |
| Takeda's Tetravalent Dengue Vaccine Candidate (TDV) | Other | Phase PHASE2 | Dengue Fever | COMPLETED | NCT02425098 |
| Takeda's High-Dose Tetravalent Dengue Vaccine Candidate (HD-TDV) | Other | Phase PHASE2 | Dengue Fever | COMPLETED | NCT02425098 |
| Takeda's Tetravalent Dengue Vaccine Candidate (TDV) | Other | Phase PHASE2 | Dengue Fever | COMPLETED | NCT02425098 |
| Vedolizumab | Other | Phase PHASE1 | Colitis, Ulcerative | COMPLETED | NCT03329209 |
| Vedolizumab | Other | Phase PHASE1 | Colitis, Ulcerative | COMPLETED | NCT03329209 |
| TAK-418 Placebo | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT03228433 |
| TAK-418 | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT03228433 |
| TAK-418 Placebo | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT03228433 |
| TAK-418 | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT03228433 |
| IXAZOMIB | Other | Phase PHASE1 | Advanced Non-hematologic Malignancies | COMPLETED | NCT00830869 |
| IXAZOMIB | Other | Phase PHASE1 | Advanced Non-hematologic Malignancies | COMPLETED | NCT00830869 |
| oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab | Other | Phase PHASE2 | Colorectal Carcinoma | COMPLETED | NCT02337946 |
| oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab | Other | Phase PHASE2 | Colorectal Carcinoma | COMPLETED | NCT02337946 |
| oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab | Other | Phase PHASE2 | Colorectal Carcinoma | COMPLETED | NCT02337946 |
| Pioglitazone placebo | Other | Phase PHASE3 | Mild Cognitive Impairment Due to Alzheimer's Disease | TERMINATED | NCT01931566 |
| Pioglitazone | Other | Phase PHASE3 | Mild Cognitive Impairment Due to Alzheimer's Disease | TERMINATED | NCT01931566 |
| Pioglitazone placebo | Other | Phase PHASE3 | Mild Cognitive Impairment Due to Alzheimer's Disease | TERMINATED | NCT01931566 |
| Pioglitazone | Other | Phase PHASE3 | Mild Cognitive Impairment Due to Alzheimer's Disease | TERMINATED | NCT01931566 |
| Allogeneic Stem Cell Transplant | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT00948922 |
| Fludarabine | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT00948922 |
| Autologous Stem Cell Transplant | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT00948922 |
| Melphalan | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT00948922 |
| Bortezomib | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT00948922 |
| Allogeneic Stem Cell Transplant | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT00948922 |
| Fludarabine | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT00948922 |
| Autologous Stem Cell Transplant | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT00948922 |
| Melphalan | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT00948922 |
| Bortezomib | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT00948922 |
| Docetaxel | Other | Phase PHASE1 | Advanced and Metastatic Gastric or Gastroesophageal Adenocarcinoma | TERMINATED | NCT02551055 |
| Paclitaxel | Other | Phase PHASE1 | Advanced and Metastatic Gastric or Gastroesophageal Adenocarcinoma | TERMINATED | NCT02551055 |
| Alisertib | Other | Phase PHASE1 | Advanced and Metastatic Gastric or Gastroesophageal Adenocarcinoma | TERMINATED | NCT02551055 |
| TAK-659 | Other | Phase PHASE1 | Advanced and Metastatic Gastric or Gastroesophageal Adenocarcinoma | TERMINATED | NCT02551055 |
| MLN1117 | Other | Phase PHASE1 | Advanced and Metastatic Gastric or Gastroesophageal Adenocarcinoma | TERMINATED | NCT02551055 |
| Docetaxel | Other | Phase PHASE1 | Advanced and Metastatic Gastric or Gastroesophageal Adenocarcinoma | TERMINATED | NCT02551055 |
| Paclitaxel | Other | Phase PHASE1 | Advanced and Metastatic Gastric or Gastroesophageal Adenocarcinoma | TERMINATED | NCT02551055 |
| Alisertib | Other | Phase PHASE1 | Advanced and Metastatic Gastric or Gastroesophageal Adenocarcinoma | TERMINATED | NCT02551055 |
| TAK-659 | Other | Phase PHASE1 | Advanced and Metastatic Gastric or Gastroesophageal Adenocarcinoma | TERMINATED | NCT02551055 |
| MLN1117 | Other | Phase PHASE1 | Advanced and Metastatic Gastric or Gastroesophageal Adenocarcinoma | TERMINATED | NCT02551055 |
| Itraconazole | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT02259010 |
| Alisertib | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT02259010 |
| Itraconazole | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT02259010 |
| Alisertib | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT02259010 |
| Itraconazole | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT02259010 |
| Alisertib | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT02259010 |
| Normal Saline | Other | Phase PHASE2 | Critical Illness | TERMINATED | NCT03477903 |
| Metoclopramide | Other | Phase PHASE2 | Critical Illness | TERMINATED | NCT03477903 |
| TAK-954 | Other | Phase PHASE2 | Critical Illness | TERMINATED | NCT03477903 |
| Normal Saline | Other | Phase PHASE2 | Critical Illness | TERMINATED | NCT03477903 |
| Metoclopramide | Other | Phase PHASE2 | Critical Illness | TERMINATED | NCT03477903 |
| TAK-954 | Other | Phase PHASE2 | Critical Illness | TERMINATED | NCT03477903 |
| Control | Other | Approved | Depressive Symptoms | COMPLETED | NCT03521388 |
| Take care of your mood (CUIDA TU ANIMO in Spanish) | Other | Approved | Depressive Symptoms | COMPLETED | NCT03521388 |
| Control | Other | Approved | Depressive Symptoms | COMPLETED | NCT03521388 |
| Take care of your mood (CUIDA TU ANIMO in Spanish) | Other | Approved | Depressive Symptoms | COMPLETED | NCT03521388 |
| Vortioxetine | Other | Phase PHASE4 | Depressive Disorder | TERMINATED | NCT02969876 |
| Vortioxetine | Other | Phase PHASE4 | Depressive Disorder | TERMINATED | NCT02969876 |
| Ninlaro | Other | Phase PHASE2 | Immune Thrombocytopenia | WITHDRAWN | NCT03965624 |
| Ninlaro | Other | Phase PHASE2 | Immune Thrombocytopenia | WITHDRAWN | NCT03965624 |
| Ninlaro | Other | Phase PHASE2 | Immune Thrombocytopenia | WITHDRAWN | NCT03965624 |
| IXAZOMIB | Other | Phase PHASE2 | Follicular Lymphoma | COMPLETED | NCT01939899 |
| IXAZOMIB | Other | Phase PHASE2 | Follicular Lymphoma | COMPLETED | NCT01939899 |
| TAK-117 | Other | Phase PHASE1 | Advanced Nonhematologic Malignancies | COMPLETED | NCT01899053 |
| TAK-228 | Other | Phase PHASE1 | Advanced Nonhematologic Malignancies | COMPLETED | NCT01899053 |
| Leuprorelin acetate | Other | Preclinical | Premenopausal Breast Cancer | COMPLETED | NCT03209518 |
| Leuprorelin acetate | Other | Preclinical | Premenopausal Breast Cancer | COMPLETED | NCT03209518 |
| Alogliptin | Other | Preclinical | Type 2 Diabetes Mellitus | COMPLETED | NCT02221284 |
| Alogliptin | Other | Preclinical | Type 2 Diabetes Mellitus | COMPLETED | NCT02221284 |
| Vedolizumab SC | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03961295 |
| Vedolizumab SC | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03949621 |
| Vedolizumab SC | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03949621 |
| Vedolizumab SC | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03961308 |
| Vedolizumab SC | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03961308 |
| Placebo | Other | Phase PHASE3 | Irritable Bowel Syndrome With Constipation | COMPLETED | NCT00380250 |
| Lubiprostone | Other | Phase PHASE3 | Irritable Bowel Syndrome With Constipation | COMPLETED | NCT00380250 |
| Placebo | Other | Phase PHASE3 | Irritable Bowel Syndrome With Constipation | COMPLETED | NCT00380250 |
| Lubiprostone | Other | Phase PHASE3 | Irritable Bowel Syndrome With Constipation | COMPLETED | NCT00380250 |
| TAK700 | Other | Phase PHASE1 | Post Menopausal, Hormone Receptor Positive Breast Cancer | COMPLETED | NCT01808040 |
| Aspirin | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03456960 |
| TAK-438 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03456960 |
| TAK-438ASA | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03456960 |
| Aspirin | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03456960 |
| TAK-438 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03456960 |
| TAK-438ASA | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03456960 |
| Placebo | Other | Phase PHASE4 | Crohn's Disease | COMPLETED | NCT02630966 |
| Vedolizumab | Other | Phase PHASE4 | Crohn's Disease | COMPLETED | NCT02630966 |
| Azilsartan Medoxomil | Other | Preclinical | Hypertension | COMPLETED | NCT02756819 |
| Azilsartan Medoxomil | Other | Preclinical | Hypertension | COMPLETED | NCT02756819 |
| Azilsartan Medoxomil | Other | Preclinical | Hypertension | COMPLETED | NCT02756819 |
| MLN0128 | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT02091531 |
| MLN0128 | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT02091531 |
| MLN0128 | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT02091531 |
| Alogliptin | Other | Preclinical | Type 2 Diabetes Mellitus | COMPLETED | NCT01964963 |
| Alogliptin | Other | Preclinical | Type 2 Diabetes Mellitus | COMPLETED | NCT01964963 |
| No Intervention | Other | Preclinical | Breakthrough Cancer Pain | COMPLETED | NCT02899884 |
| No Intervention | Other | Preclinical | Breakthrough Cancer Pain | COMPLETED | NCT02899884 |
| Methotrexate | Other | Phase PHASE1 | Acute Lymphoblastic Leukemia | COMPLETED | NCT02228772 |
| Cyclophosphamide | Other | Phase PHASE1 | Acute Lymphoblastic Leukemia | COMPLETED | NCT02228772 |
| Mercaptopurine | Other | Phase PHASE1 | Acute Lymphoblastic Leukemia | COMPLETED | NCT02228772 |
| Doxorubicin | Other | Phase PHASE1 | Acute Lymphoblastic Leukemia | COMPLETED | NCT02228772 |
| Cytarabine | Other | Phase PHASE1 | Acute Lymphoblastic Leukemia | COMPLETED | NCT02228772 |
| Vincristine | Other | Phase PHASE1 | Acute Lymphoblastic Leukemia | COMPLETED | NCT02228772 |
| MLN 9708 | Other | Phase PHASE1 | Acute Lymphoblastic Leukemia | COMPLETED | NCT02228772 |
| Methotrexate | Other | Phase PHASE1 | Acute Lymphoblastic Leukemia | COMPLETED | NCT02228772 |
| Cyclophosphamide | Other | Phase PHASE1 | Acute Lymphoblastic Leukemia | COMPLETED | NCT02228772 |
| Mercaptopurine | Other | Phase PHASE1 | Acute Lymphoblastic Leukemia | COMPLETED | NCT02228772 |
| Doxorubicin | Other | Phase PHASE1 | Acute Lymphoblastic Leukemia | COMPLETED | NCT02228772 |
| Cytarabine | Other | Phase PHASE1 | Acute Lymphoblastic Leukemia | COMPLETED | NCT02228772 |
| Vincristine | Other | Phase PHASE1 | Acute Lymphoblastic Leukemia | COMPLETED | NCT02228772 |
| MLN 9708 | Other | Phase PHASE1 | Acute Lymphoblastic Leukemia | COMPLETED | NCT02228772 |
| Vedolizumab placebo | Other | Phase PHASE3 | Crohn's Disease | COMPLETED | NCT02038920 |
| Vedolizumab | Other | Phase PHASE3 | Crohn's Disease | COMPLETED | NCT02038920 |
| Vedolizumab placebo | Other | Phase PHASE3 | Crohn's Disease | COMPLETED | NCT02038920 |
| Vedolizumab | Other | Phase PHASE3 | Crohn's Disease | COMPLETED | NCT02038920 |
| Computed Tomography | Other | Phase PHASE2 | Prostatic Neoplasms | TERMINATED | NCT01816048 |
| Positron Emission Tomography | Other | Phase PHASE2 | Prostatic Neoplasms | TERMINATED | NCT01816048 |
| Fluorine F 18 Sodium Fluoride | Other | Phase PHASE2 | Prostatic Neoplasms | TERMINATED | NCT01816048 |
| TAK-700 | Other | Phase PHASE2 | Prostatic Neoplasms | TERMINATED | NCT01816048 |
| Computed Tomography | Other | Phase PHASE2 | Prostatic Neoplasms | TERMINATED | NCT01816048 |
| Positron Emission Tomography | Other | Phase PHASE2 | Prostatic Neoplasms | TERMINATED | NCT01816048 |
| Fluorine F 18 Sodium Fluoride | Other | Phase PHASE2 | Prostatic Neoplasms | TERMINATED | NCT01816048 |
| TAK-700 | Other | Phase PHASE2 | Prostatic Neoplasms | TERMINATED | NCT01816048 |
| Vonoprazan | Other | Preclinical | Gastric Ulcer, Duodenal Ulcer, and Reflux Esophagitis | COMPLETED | NCT03214952 |
| Vonoprazan | Other | Preclinical | Gastric Ulcer, Duodenal Ulcer, and Reflux Esophagitis | COMPLETED | NCT03214952 |
| Dexamethasone | Other | Phase PHASE2 | Multiple Myeloma | WITHDRAWN | NCT01647165 |
| Lenalidomide | Other | Phase PHASE2 | Multiple Myeloma | WITHDRAWN | NCT01647165 |
| Bortezomib | Other | Phase PHASE2 | Multiple Myeloma | WITHDRAWN | NCT01647165 |
| Placebo | Other | Phase PHASE3 | Chronic Idiopathic Constipation | COMPLETED | NCT01993875 |
| Lubiprostone | Other | Phase PHASE3 | Chronic Idiopathic Constipation | COMPLETED | NCT01993875 |
| Placebo | Other | Phase PHASE3 | Chronic Idiopathic Constipation | COMPLETED | NCT01993875 |
| Lubiprostone | Other | Phase PHASE3 | Chronic Idiopathic Constipation | COMPLETED | NCT01993875 |
| Placebo | Other | Phase PHASE3 | Chronic Idiopathic Constipation | COMPLETED | NCT01993875 |
| Lubiprostone | Other | Phase PHASE3 | Chronic Idiopathic Constipation | COMPLETED | NCT01993875 |
| Temsirolimus | Other | Phase PHASE2 | Non-Hodgkins Lymphoma | COMPLETED | NCT01281917 |
| Velcade | Other | Phase PHASE2 | Non-Hodgkins Lymphoma | COMPLETED | NCT01281917 |
| bortezomib | Other | Phase PHASE2 | Carcinoma, Non Small Cell Lung | COMPLETED | NCT00798720 |
| vorinostat | Other | Phase PHASE2 | Carcinoma, Non Small Cell Lung | COMPLETED | NCT00798720 |
| bortezomib | Other | Phase PHASE2 | Carcinoma, Non Small Cell Lung | COMPLETED | NCT00798720 |
| vorinostat | Other | Phase PHASE2 | Carcinoma, Non Small Cell Lung | COMPLETED | NCT00798720 |
| bortezomib | Other | Phase PHASE2 | Carcinoma, Non Small Cell Lung | COMPLETED | NCT00798720 |
| vorinostat | Other | Phase PHASE2 | Carcinoma, Non Small Cell Lung | COMPLETED | NCT00798720 |
| Bort, Dex, and Dox with ALCAR | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT00581919 |
| Bort, Dex, and Dox with ALCAR | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT00581919 |
| PS-341, doxorubicin | Other | Phase PHASE2 | Metastatic Breast Cancer | TERMINATED | NCT00574236 |
| PS-341, doxorubicin | Other | Phase PHASE2 | Metastatic Breast Cancer | TERMINATED | NCT00574236 |
| Lanthanum carbonate (chewed vs. crushed) | Other | Phase PHASE1 | Hyperphosphatemia in Chronic Kidney Disease | COMPLETED | NCT00458289 |
| Lisdexamfetamine | Other | Phase PHASE4 | Attention Deficit Hyperactivity Disorder | TERMINATED | NCT02170298 |
| Lisdexamfetamine | Other | Phase PHASE4 | Attention Deficit Hyperactivity Disorder | TERMINATED | NCT02170298 |
| Placebo | Other | Phase PHASE2 | Irritable Bowel Syndrome | TERMINATED | NCT02544152 |
| Lubiprostone | Other | Phase PHASE2 | Irritable Bowel Syndrome | TERMINATED | NCT02544152 |
| Placebo | Other | Phase PHASE2 | Irritable Bowel Syndrome | TERMINATED | NCT02544152 |
| Lubiprostone | Other | Phase PHASE2 | Irritable Bowel Syndrome | TERMINATED | NCT02544152 |
| Placebo | Other | Phase PHASE2 | Irritable Bowel Syndrome | TERMINATED | NCT02544152 |
| Lubiprostone | Other | Phase PHASE2 | Irritable Bowel Syndrome | TERMINATED | NCT02544152 |
| Plerixafor | Other | Phase PHASE3 | Multiple Myeloma | COMPLETED | NCT01146834 |
| G-CSF | Other | Phase PHASE3 | Multiple Myeloma | COMPLETED | NCT01146834 |
| cyclophosphamide | Other | Phase PHASE3 | Multiple Myeloma | COMPLETED | NCT01146834 |
| bortezomib (Velcade) | Other | Phase PHASE3 | Multiple Myeloma | COMPLETED | NCT01146834 |
| Plerixafor | Other | Phase PHASE3 | Multiple Myeloma | COMPLETED | NCT01146834 |
| G-CSF | Other | Phase PHASE3 | Multiple Myeloma | COMPLETED | NCT01146834 |
| cyclophosphamide | Other | Phase PHASE3 | Multiple Myeloma | COMPLETED | NCT01146834 |
| bortezomib (Velcade) | Other | Phase PHASE3 | Multiple Myeloma | COMPLETED | NCT01146834 |
| Dexamethasone | Other | Phase PHASE2 | Multiple Myeloma | WITHDRAWN | NCT03608501 |
| Thalidomide | Other | Phase PHASE2 | Multiple Myeloma | WITHDRAWN | NCT03608501 |
| Ixazomib | Other | Phase PHASE2 | Multiple Myeloma | WITHDRAWN | NCT03608501 |
| Dexamethasone | Other | Phase PHASE2 | Multiple Myeloma | WITHDRAWN | NCT03608501 |
| Thalidomide | Other | Phase PHASE2 | Multiple Myeloma | WITHDRAWN | NCT03608501 |
| Ixazomib | Other | Phase PHASE2 | Multiple Myeloma | WITHDRAWN | NCT03608501 |
| Dexamethasone | Other | Phase PHASE2 | Multiple Myeloma | WITHDRAWN | NCT03608501 |
| Thalidomide | Other | Phase PHASE2 | Multiple Myeloma | WITHDRAWN | NCT03608501 |
| Ixazomib | Other | Phase PHASE2 | Multiple Myeloma | WITHDRAWN | NCT03608501 |
| Cognitive training program | Other | Phase PHASE4 | Age-related Cognitive Decline | COMPLETED | NCT03272711 |
| Vortioxetine 10 mg | Other | Phase PHASE4 | Age-related Cognitive Decline | COMPLETED | NCT03272711 |
| Lubiprostone | Other | Phase PHASE3 | Constipation - Functional | COMPLETED | NCT02138136 |
| Lubiprostone | Other | Phase PHASE3 | Constipation - Functional | COMPLETED | NCT02138136 |
| Total-Body Irradiation | Other | Phase PHASE2 | Refractory Plasma Cell Myeloma | COMPLETED | NCT00793572 |
| Syngeneic Bone Marrow Transplantation | Other | Phase PHASE2 | Refractory Plasma Cell Myeloma | COMPLETED | NCT00793572 |
| Peripheral Blood Stem Cell Transplantation | Other | Phase PHASE2 | Refractory Plasma Cell Myeloma | COMPLETED | NCT00793572 |
| Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation | Other | Phase PHASE2 | Refractory Plasma Cell Myeloma | COMPLETED | NCT00793572 |
| Mycophenolate Mofetil | Other | Phase PHASE2 | Refractory Plasma Cell Myeloma | COMPLETED | NCT00793572 |
| Melphalan | Other | Phase PHASE2 | Refractory Plasma Cell Myeloma | COMPLETED | NCT00793572 |
| Laboratory Biomarker Analysis | Other | Phase PHASE2 | Refractory Plasma Cell Myeloma | COMPLETED | NCT00793572 |
| Fludarabine Phosphate | Other | Phase PHASE2 | Refractory Plasma Cell Myeloma | COMPLETED | NCT00793572 |
| Cyclosporine | Other | Phase PHASE2 | Refractory Plasma Cell Myeloma | COMPLETED | NCT00793572 |
| Bortezomib | Other | Phase PHASE2 | Refractory Plasma Cell Myeloma | COMPLETED | NCT00793572 |
| Autologous Hematopoietic Stem Cell Transplantation | Other | Phase PHASE2 | Refractory Plasma Cell Myeloma | COMPLETED | NCT00793572 |
| Total-Body Irradiation | Other | Phase PHASE2 | Refractory Plasma Cell Myeloma | COMPLETED | NCT00793572 |
| Syngeneic Bone Marrow Transplantation | Other | Phase PHASE2 | Refractory Plasma Cell Myeloma | COMPLETED | NCT00793572 |
| Peripheral Blood Stem Cell Transplantation | Other | Phase PHASE2 | Refractory Plasma Cell Myeloma | COMPLETED | NCT00793572 |
| Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation | Other | Phase PHASE2 | Refractory Plasma Cell Myeloma | COMPLETED | NCT00793572 |
| Mycophenolate Mofetil | Other | Phase PHASE2 | Refractory Plasma Cell Myeloma | COMPLETED | NCT00793572 |
| Melphalan | Other | Phase PHASE2 | Refractory Plasma Cell Myeloma | COMPLETED | NCT00793572 |
| Laboratory Biomarker Analysis | Other | Phase PHASE2 | Refractory Plasma Cell Myeloma | COMPLETED | NCT00793572 |
| Fludarabine Phosphate | Other | Phase PHASE2 | Refractory Plasma Cell Myeloma | COMPLETED | NCT00793572 |
| Cyclosporine | Other | Phase PHASE2 | Refractory Plasma Cell Myeloma | COMPLETED | NCT00793572 |
| Bortezomib | Other | Phase PHASE2 | Refractory Plasma Cell Myeloma | COMPLETED | NCT00793572 |
| Autologous Hematopoietic Stem Cell Transplantation | Other | Phase PHASE2 | Refractory Plasma Cell Myeloma | COMPLETED | NCT00793572 |
| Total-Body Irradiation | Other | Phase PHASE2 | Refractory Plasma Cell Myeloma | COMPLETED | NCT00793572 |
| Syngeneic Bone Marrow Transplantation | Other | Phase PHASE2 | Refractory Plasma Cell Myeloma | COMPLETED | NCT00793572 |
| Peripheral Blood Stem Cell Transplantation | Other | Phase PHASE2 | Refractory Plasma Cell Myeloma | COMPLETED | NCT00793572 |
| Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation | Other | Phase PHASE2 | Refractory Plasma Cell Myeloma | COMPLETED | NCT00793572 |
| Mycophenolate Mofetil | Other | Phase PHASE2 | Refractory Plasma Cell Myeloma | COMPLETED | NCT00793572 |
| Melphalan | Other | Phase PHASE2 | Refractory Plasma Cell Myeloma | COMPLETED | NCT00793572 |
| Laboratory Biomarker Analysis | Other | Phase PHASE2 | Refractory Plasma Cell Myeloma | COMPLETED | NCT00793572 |
| Fludarabine Phosphate | Other | Phase PHASE2 | Refractory Plasma Cell Myeloma | COMPLETED | NCT00793572 |
| Cyclosporine | Other | Phase PHASE2 | Refractory Plasma Cell Myeloma | COMPLETED | NCT00793572 |
| Bortezomib | Other | Phase PHASE2 | Refractory Plasma Cell Myeloma | COMPLETED | NCT00793572 |
| Autologous Hematopoietic Stem Cell Transplantation | Other | Phase PHASE2 | Refractory Plasma Cell Myeloma | COMPLETED | NCT00793572 |
| Vedolizumab placebo | Other | Phase PHASE3 | Colitis, Ulcerative | COMPLETED | NCT02497469 |
| Adalimumab | Other | Phase PHASE3 | Colitis, Ulcerative | COMPLETED | NCT02497469 |
| Adalimumab placebo | Other | Phase PHASE3 | Colitis, Ulcerative | COMPLETED | NCT02497469 |
| Vedolizumab | Other | Phase PHASE3 | Colitis, Ulcerative | COMPLETED | NCT02497469 |
| Vedolizumab placebo | Other | Phase PHASE3 | Colitis, Ulcerative | COMPLETED | NCT02497469 |
| Adalimumab | Other | Phase PHASE3 | Colitis, Ulcerative | COMPLETED | NCT02497469 |
| Adalimumab placebo | Other | Phase PHASE3 | Colitis, Ulcerative | COMPLETED | NCT02497469 |
| Vedolizumab | Other | Phase PHASE3 | Colitis, Ulcerative | COMPLETED | NCT02497469 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03482453 |
| TAK-788 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03482453 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03482453 |
| TAK-788 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03482453 |
| sIPV Placebo | Other | Phase PHASE1 | Poliomyelitis | TERMINATED | NCT03092791 |
| Reference IPV | Other | Phase PHASE1 | Poliomyelitis | TERMINATED | NCT03092791 |
| Sabin-Based Inactivated Poliomyelitis Vaccine (sIPV) | Other | Phase PHASE1 | Poliomyelitis | TERMINATED | NCT03092791 |
| TAK-491 placebo | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT02541669 |
| TAK-491 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT02541669 |
| TAK-491 placebo | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT02541669 |
| TAK-491 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT02541669 |
| Placebo | Other | Phase PHASE3 | Pediatric Hypertension | COMPLETED | NCT02791438 |
| Azilsartan | Other | Phase PHASE3 | Pediatric Hypertension | COMPLETED | NCT02791438 |
| Placebo | Other | Phase PHASE3 | Pediatric Hypertension | COMPLETED | NCT02791438 |
| Azilsartan | Other | Phase PHASE3 | Pediatric Hypertension | COMPLETED | NCT02791438 |
| Esomeprazole Placebo | Other | Phase PHASE2 | Gastroesophageal Reflux | COMPLETED | NCT02743949 |
| Esomeprazole | Other | Phase PHASE2 | Gastroesophageal Reflux | COMPLETED | NCT02743949 |
| Vonoprazan | Other | Phase PHASE2 | Gastroesophageal Reflux | COMPLETED | NCT02743949 |
| Esomeprazole Placebo | Other | Phase PHASE2 | Gastroesophageal Reflux | COMPLETED | NCT02743949 |
| Esomeprazole | Other | Phase PHASE2 | Gastroesophageal Reflux | COMPLETED | NCT02743949 |
| Vonoprazan | Other | Phase PHASE2 | Gastroesophageal Reflux | COMPLETED | NCT02743949 |
| Lansoprazole Placebo | Other | Phase PHASE3 | Erosive Esophagitis | COMPLETED | NCT02388737 |
| Vonoprazan Placebo | Other | Phase PHASE3 | Erosive Esophagitis | COMPLETED | NCT02388737 |
| Lansoprazole | Other | Phase PHASE3 | Erosive Esophagitis | COMPLETED | NCT02388737 |
| Vonoprazan | Other | Phase PHASE3 | Erosive Esophagitis | COMPLETED | NCT02388737 |
| Lansoprazole Placebo | Other | Phase PHASE3 | Erosive Esophagitis | COMPLETED | NCT02388737 |
| Vonoprazan Placebo | Other | Phase PHASE3 | Erosive Esophagitis | COMPLETED | NCT02388737 |
| Lansoprazole | Other | Phase PHASE3 | Erosive Esophagitis | COMPLETED | NCT02388737 |
| Vonoprazan | Other | Phase PHASE3 | Erosive Esophagitis | COMPLETED | NCT02388737 |
| TDV Placebo | Other | Phase PHASE2 | Dengue Fever | COMPLETED | NCT02302066 |
| Takeda's Tetravalent Dengue Vaccine Candidate (TDV) | Other | Phase PHASE2 | Dengue Fever | COMPLETED | NCT02302066 |
| TDV Placebo | Other | Phase PHASE2 | Dengue Fever | COMPLETED | NCT02302066 |
| Takeda's Tetravalent Dengue Vaccine Candidate (TDV) | Other | Phase PHASE2 | Dengue Fever | COMPLETED | NCT02302066 |
| Chloroquine | Other | Phase PHASE2 | Multiple Myeloma | TERMINATED | NCT01438177 |
| Cyclophosphamide | Other | Phase PHASE2 | Multiple Myeloma | TERMINATED | NCT01438177 |
| Velcade | Other | Phase PHASE2 | Multiple Myeloma | TERMINATED | NCT01438177 |
| Chloroquine | Other | Phase PHASE2 | Multiple Myeloma | TERMINATED | NCT01438177 |
| Cyclophosphamide | Other | Phase PHASE2 | Multiple Myeloma | TERMINATED | NCT01438177 |
| Velcade | Other | Phase PHASE2 | Multiple Myeloma | TERMINATED | NCT01438177 |
| Irinotecan | Other | Phase PHASE1 | Advanced Nonhematologic Malignancies | COMPLETED | NCT02327169 |
| Cetuximab | Other | Phase PHASE1 | Advanced Nonhematologic Malignancies | COMPLETED | NCT02327169 |
| Paclitaxel | Other | Phase PHASE1 | Advanced Nonhematologic Malignancies | COMPLETED | NCT02327169 |
| Alisertib | Other | Phase PHASE1 | Advanced Nonhematologic Malignancies | COMPLETED | NCT02327169 |
| MLN0128 | Other | Phase PHASE1 | Advanced Nonhematologic Malignancies | COMPLETED | NCT02327169 |
| MLN2480 | Other | Phase PHASE1 | Advanced Nonhematologic Malignancies | COMPLETED | NCT02327169 |
| Irinotecan | Other | Phase PHASE1 | Advanced Nonhematologic Malignancies | COMPLETED | NCT02327169 |
| Cetuximab | Other | Phase PHASE1 | Advanced Nonhematologic Malignancies | COMPLETED | NCT02327169 |
| Paclitaxel | Other | Phase PHASE1 | Advanced Nonhematologic Malignancies | COMPLETED | NCT02327169 |
| Alisertib | Other | Phase PHASE1 | Advanced Nonhematologic Malignancies | COMPLETED | NCT02327169 |
| MLN0128 | Other | Phase PHASE1 | Advanced Nonhematologic Malignancies | COMPLETED | NCT02327169 |
| MLN2480 | Other | Phase PHASE1 | Advanced Nonhematologic Malignancies | COMPLETED | NCT02327169 |
| Paclitaxel | Other | Phase PHASE1 | Non-hematologic Malignancy | COMPLETED | NCT02412722 |
| Sapanisertib | Other | Phase PHASE1 | Non-hematologic Malignancy | COMPLETED | NCT02412722 |
| Paclitaxel | Other | Phase PHASE1 | Non-hematologic Malignancy | COMPLETED | NCT02412722 |
| Sapanisertib | Other | Phase PHASE1 | Non-hematologic Malignancy | COMPLETED | NCT02412722 |
| Paclitaxel | Other | Phase PHASE1 | Non-hematologic Malignancy | COMPLETED | NCT02412722 |
| Sapanisertib | Other | Phase PHASE1 | Non-hematologic Malignancy | COMPLETED | NCT02412722 |
| Paclitaxel | Other | Phase PHASE1 | Non-hematologic Malignancy | COMPLETED | NCT02412722 |
| Sapanisertib | Other | Phase PHASE1 | Non-hematologic Malignancy | COMPLETED | NCT02412722 |
| Azacitidine | Other | Phase PHASE1 | Acute Myelogenous Leukemia | COMPLETED | NCT01814826 |
| MLN4924 | Other | Phase PHASE1 | Acute Myelogenous Leukemia | COMPLETED | NCT01814826 |
| Azacitidine | Other | Phase PHASE1 | Acute Myelogenous Leukemia | COMPLETED | NCT01814826 |
| MLN4924 | Other | Phase PHASE1 | Acute Myelogenous Leukemia | COMPLETED | NCT01814826 |
| Brigatinib AAF | Other | Phase PHASE1 | Anaplastic Lymphoma Kinase Positive (ALK +) Anaplastic Large Cell Lymphoma | WITHDRAWN | NCT04260009 |
| Brigatinib | Other | Phase PHASE1 | Anaplastic Lymphoma Kinase Positive (ALK +) Anaplastic Large Cell Lymphoma | WITHDRAWN | NCT04260009 |
| Brigatinib AAF | Other | Phase PHASE1 | Anaplastic Lymphoma Kinase Positive (ALK +) Anaplastic Large Cell Lymphoma | WITHDRAWN | NCT04260009 |
| Brigatinib | Other | Phase PHASE1 | Anaplastic Lymphoma Kinase Positive (ALK +) Anaplastic Large Cell Lymphoma | WITHDRAWN | NCT04260009 |
| Cohort 2: Lubiprostone Sprinkle Formulation, Fasted | Other | Phase PHASE3 | Healthy Volunteers | COMPLETED | NCT03010631 |
| Cohort 2: Lubiprostone Sprinkle Formulation, Fed | Other | Phase PHASE3 | Healthy Volunteers | COMPLETED | NCT03010631 |
| Cohort 1: Lubiprostone Sprinkle Formulation, Fasted | Other | Phase PHASE3 | Healthy Volunteers | COMPLETED | NCT03010631 |
| Cohort 1: Lubiprostone Capsule, Fasted | Other | Phase PHASE3 | Healthy Volunteers | COMPLETED | NCT03010631 |
| Cohort 2: Lubiprostone Sprinkle Formulation, Fasted | Other | Phase PHASE3 | Healthy Volunteers | COMPLETED | NCT03010631 |
| Cohort 2: Lubiprostone Sprinkle Formulation, Fed | Other | Phase PHASE3 | Healthy Volunteers | COMPLETED | NCT03010631 |
| Cohort 1: Lubiprostone Sprinkle Formulation, Fasted | Other | Phase PHASE3 | Healthy Volunteers | COMPLETED | NCT03010631 |
| Cohort 1: Lubiprostone Capsule, Fasted | Other | Phase PHASE3 | Healthy Volunteers | COMPLETED | NCT03010631 |
| Vonoprazan | Other | Preclinical | Gastric or Duodenal Ulcers | COMPLETED | NCT03214094 |
| Blood Sugar Testing | Other | Phase PHASE1 | Lymphoma | TERMINATED | NCT02727777 |
| TAK228 | Other | Phase PHASE1 | Lymphoma | TERMINATED | NCT02727777 |
| Blood Sugar Testing | Other | Phase PHASE1 | Lymphoma | TERMINATED | NCT02727777 |
| TAK228 | Other | Phase PHASE1 | Lymphoma | TERMINATED | NCT02727777 |
| Panitumumab and bortezomib | Other | Phase PHASE1 | Colorectal Cancer | TERMINATED | NCT01504477 |
| Panitumumab and bortezomib | Other | Phase PHASE1 | Colorectal Cancer | TERMINATED | NCT01504477 |
| Dexamethasone | Other | Phase PHASE1 | Relapsed and/or Refractory Multiple Myeloma | TERMINATED | NCT04272775 |
| Lenalidomide | Other | Phase PHASE1 | Relapsed and/or Refractory Multiple Myeloma | TERMINATED | NCT04272775 |
| Ixazomib | Other | Phase PHASE1 | Relapsed and/or Refractory Multiple Myeloma | TERMINATED | NCT04272775 |
| Dexamethasone | Other | Phase PHASE1 | Relapsed and/or Refractory Multiple Myeloma | TERMINATED | NCT04272775 |
| Lenalidomide | Other | Phase PHASE1 | Relapsed and/or Refractory Multiple Myeloma | TERMINATED | NCT04272775 |
| Ixazomib | Other | Phase PHASE1 | Relapsed and/or Refractory Multiple Myeloma | TERMINATED | NCT04272775 |
| 60 mg dexlansoprazole capsules manufactured at TPC | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03801148 |
| 60 mg dexlansoprazole capsules manufactured at TOB | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03801148 |
| 30 mg dexlansoprazole capsules manufactured at TPC | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03801148 |
| 30 mg dexlansoprazole capsules manufactured at TOB | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03801148 |
| 60 mg dexlansoprazole capsules manufactured at TPC | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03801148 |
| 60 mg dexlansoprazole capsules manufactured at TOB | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03801148 |
| 30 mg dexlansoprazole capsules manufactured at TPC | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03801148 |
| 30 mg dexlansoprazole capsules manufactured at TOB | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03801148 |
| Tachosil | Other | Preclinical | Laparoscopy | COMPLETED | NCT02685007 |
| Tachosil | Other | Preclinical | Laparoscopy | COMPLETED | NCT02685007 |
| Dexamethasone | Other | Phase PHASE1 | Light-Chain Amyloidosis | COMPLETED | NCT01318902 |
| Ixazomib | Other | Phase PHASE1 | Light-Chain Amyloidosis | COMPLETED | NCT01318902 |
| MLN0128 | Other | Phase PHASE1 | Advanced Solid Malignancies | COMPLETED | NCT01058707 |
| MLN0128 | Other | Phase PHASE1 | Advanced Solid Malignancies | COMPLETED | NCT01058707 |
| TAK-438 | Other | Phase PHASE1 | Japanese Healthy Adult Male | COMPLETED | NCT03808493 |
| TAK-438 OD | Other | Phase PHASE1 | Japanese Healthy Adult Male | COMPLETED | NCT03808493 |
| TAK-438 | Other | Phase PHASE1 | Japanese Healthy Adult Male | COMPLETED | NCT03808493 |
| TAK-438 OD | Other | Phase PHASE1 | Japanese Healthy Adult Male | COMPLETED | NCT03808493 |
| Bortezomib/Dexamethasone (BD), Followed By Autologous STC & Maintenance Bortezomib/Dexamethasone | Other | Approved | Light Chain Deposition Disease (LCDD or MIDD) | COMPLETED | NCT01383759 |
| Bortezomib/Dexamethasone (BD), Followed By Autologous STC & Maintenance Bortezomib/Dexamethasone | Other | Approved | Light Chain Deposition Disease (LCDD or MIDD) | COMPLETED | NCT01383759 |
| Dexlansoprazole | Other | Phase PHASE1 | Pediatric Gastroesophageal Reflux Disease | WITHDRAWN | NCT02442752 |
| Dexlansoprazole | Other | Phase PHASE1 | Pediatric Gastroesophageal Reflux Disease | WITHDRAWN | NCT02442752 |
| Placebo | Other | Phase PHASE1 | Obstructive Sleep Apnea | COMPLETED | NCT04091425 |
| TAK-925 | Other | Phase PHASE1 | Obstructive Sleep Apnea | COMPLETED | NCT04091425 |
| Vedolizumab | Other | Preclinical | Crohn Disease | UNKNOWN | NCT04362735 |
| Vedolizumab | Other | Preclinical | Crohn Disease | UNKNOWN | NCT04362735 |
| placebo | Other | Phase PHASE3 | Stroke | COMPLETED | NCT00091949 |
| pioglitazone | Other | Phase PHASE3 | Stroke | COMPLETED | NCT00091949 |
| placebo | Other | Phase PHASE3 | Stroke | COMPLETED | NCT00091949 |
| pioglitazone | Other | Phase PHASE3 | Stroke | COMPLETED | NCT00091949 |
| placebo | Other | Phase PHASE3 | Stroke | COMPLETED | NCT00091949 |
| pioglitazone | Other | Phase PHASE3 | Stroke | COMPLETED | NCT00091949 |
| placebo | Other | Phase PHASE3 | Stroke | COMPLETED | NCT00091949 |
| pioglitazone | Other | Phase PHASE3 | Stroke | COMPLETED | NCT00091949 |
| Daunorubicin | Other | Phase PHASE2 | Acute Myeloid Leukemia | COMPLETED | NCT02560025 |
| Idarubicin | Other | Phase PHASE2 | Acute Myeloid Leukemia | COMPLETED | NCT02560025 |
| Cytarabine | Other | Phase PHASE2 | Acute Myeloid Leukemia | COMPLETED | NCT02560025 |
| Alisertib | Other | Phase PHASE2 | Acute Myeloid Leukemia | COMPLETED | NCT02560025 |
| Daunorubicin | Other | Phase PHASE2 | Acute Myeloid Leukemia | COMPLETED | NCT02560025 |
| Idarubicin | Other | Phase PHASE2 | Acute Myeloid Leukemia | COMPLETED | NCT02560025 |
| Cytarabine | Other | Phase PHASE2 | Acute Myeloid Leukemia | COMPLETED | NCT02560025 |
| Alisertib | Other | Phase PHASE2 | Acute Myeloid Leukemia | COMPLETED | NCT02560025 |
| placebo | Other | Phase PHASE2 | Crohn's Disease | WITHDRAWN | NCT02834754 |
| Vedolizumab | Other | Phase PHASE2 | Crohn's Disease | WITHDRAWN | NCT02834754 |
| placebo | Other | Phase PHASE2 | Crohn's Disease | WITHDRAWN | NCT02834754 |
| Vedolizumab | Other | Phase PHASE2 | Crohn's Disease | WITHDRAWN | NCT02834754 |
| 0.9% sodium chloride (saline) | Other | Phase PHASE2 | Norovirus | COMPLETED | NCT02661490 |
| Norovirus GI.1/GII.4 Bivalent VLP Vaccine | Other | Phase PHASE2 | Norovirus | COMPLETED | NCT02661490 |
| 0.9% sodium chloride (saline) | Other | Phase PHASE2 | Norovirus | COMPLETED | NCT02661490 |
| Norovirus GI.1/GII.4 Bivalent VLP Vaccine | Other | Phase PHASE2 | Norovirus | COMPLETED | NCT02661490 |
| 0.9% sodium chloride (saline) | Other | Phase PHASE2 | Norovirus | COMPLETED | NCT02661490 |
| Norovirus GI.1/GII.4 Bivalent VLP Vaccine | Other | Phase PHASE2 | Norovirus | COMPLETED | NCT02661490 |
| Bortezomib | Other | Phase PHASE1 | Graft Versus Host Disease | COMPLETED | NCT01672229 |
| Bortezomib | Other | Phase PHASE1 | Graft Versus Host Disease | COMPLETED | NCT01672229 |
| Bortezomib | Other | Phase PHASE1 | Graft Versus Host Disease | COMPLETED | NCT01672229 |
| TIMP-GLIA | Other | Phase PHASE1 | Celiac Disease | COMPLETED | NCT03486990 |
| TIMP-GLIA | Other | Phase PHASE1 | Celiac Disease | COMPLETED | NCT03486990 |
| Bismuth-Containing Quadruple Therapy | Drug | Phase PHASE3 | Duodenal Ulcer | COMPLETED | NCT03050359 |
| Lansoprazole Placebo | Other | Phase PHASE3 | Duodenal Ulcer | COMPLETED | NCT03050359 |
| TAK-438 Placebo | Other | Phase PHASE3 | Duodenal Ulcer | COMPLETED | NCT03050359 |
| Lansoprazole | Other | Phase PHASE3 | Duodenal Ulcer | COMPLETED | NCT03050359 |
| TAK-438 | Other | Phase PHASE3 | Duodenal Ulcer | COMPLETED | NCT03050359 |
| TAK-418 Matching Placebo | Other | Phase PHASE1 | Healthy Volunteers | TERMINATED | NCT03501069 |
| TAK-418 | Other | Phase PHASE1 | Healthy Volunteers | TERMINATED | NCT03501069 |
| Carboplatin | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT01862328 |
| Docetaxel | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT01862328 |
| Gemcitabine | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT01862328 |
| Paclitaxel | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT01862328 |
| MLN4924 | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT01862328 |
| Carboplatin | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT01862328 |
| Docetaxel | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT01862328 |
| Gemcitabine | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT01862328 |
| Paclitaxel | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT01862328 |
| MLN4924 | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT01862328 |
| TAK-994 Placebo | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT03933488 |
| TAK-994 | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT03933488 |
| TAK-954 Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03870555 |
| TAK-954 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03870555 |
| TAK-954 Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03870555 |
| TAK-954 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03870555 |
| Placebo | Other | Phase PHASE4 | Traumatic Brain Injury | COMPLETED | NCT02712996 |
| Lisdexamfetamine | Other | Phase PHASE4 | Traumatic Brain Injury | COMPLETED | NCT02712996 |
| Brentuximab vedotin (recombinant) | Other | Preclinical | Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma | COMPLETED | NCT02139592 |
| Brentuximab vedotin (recombinant) | Other | Preclinical | Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma | COMPLETED | NCT02139592 |
| SHP615 | Other | Phase PHASE3 | Nervous System Diseases | COMPLETED | NCT03336645 |
| SHP615 | Other | Phase PHASE3 | Nervous System Diseases | COMPLETED | NCT03336645 |
| bortezomib | Other | Phase PHASE2 | Lymphoma | COMPLETED | NCT00182637 |
| bortezomib | Other | Phase PHASE2 | Lymphoma | COMPLETED | NCT00182637 |
| Vial Adapter for Device | Device | Phase PHASE3 | Short Bowel Syndrome | COMPLETED | NCT03663582 |
| Needle | Other | Phase PHASE3 | Short Bowel Syndrome | COMPLETED | NCT03663582 |
| Syringe | Other | Phase PHASE3 | Short Bowel Syndrome | COMPLETED | NCT03663582 |
| Teduglutide | Other | Phase PHASE3 | Short Bowel Syndrome | COMPLETED | NCT03663582 |
| Acyclovir | Other | Phase PHASE2 | Non-Small Cell Lung Cancer | COMPLETED | NCT01833143 |
| Bortezomib | Other | Phase PHASE2 | Non-Small Cell Lung Cancer | COMPLETED | NCT01833143 |
| Acyclovir | Other | Phase PHASE2 | Non-Small Cell Lung Cancer | COMPLETED | NCT01833143 |
| Bortezomib | Other | Phase PHASE2 | Non-Small Cell Lung Cancer | COMPLETED | NCT01833143 |
| MLN2480 | Other | Phase PHASE1 | Melanoma | COMPLETED | NCT01425008 |
| MLN2480 | Other | Phase PHASE1 | Melanoma | COMPLETED | NCT01425008 |
| Placebo | Other | Phase PHASE2 | Celiac Disease | COMPLETED | NCT03738475 |
| TIMP-GLIA | Other | Phase PHASE2 | Celiac Disease | COMPLETED | NCT03738475 |
| bortezomib | Other | Phase PHASE1 | Multiple Myeloma and Plasma Cell Neoplasm | COMPLETED | NCT00084747 |
| bortezomib | Other | Phase PHASE1 | Multiple Myeloma and Plasma Cell Neoplasm | COMPLETED | NCT00084747 |
| TAK-954 | Other | Phase PHASE1 | Renal Impairment | COMPLETED | NCT03296787 |
| TAK-954 | Other | Phase PHASE1 | Renal Impairment | COMPLETED | NCT03296787 |
| IXAZOMIB | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT01953783 |
| IXAZOMIB | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT01953783 |
| bortezomib + temozolomide+ radiation therapy | Drug | Phase PHASE2 | Brain and Central Nervous System Tumors | COMPLETED | NCT00998010 |
| bortezomib + temozolomide+ radiation therapy | Drug | Phase PHASE2 | Brain and Central Nervous System Tumors | COMPLETED | NCT00998010 |
| MTD of Velcade, Nipent and Rituxan established in Part 1 | Other | Phase PHASE1 | Follicular Lymphoma | WITHDRAWN | NCT01460602 |
| MTD of Velcade, Nipent and Rituxan established in Part 1 | Other | Phase PHASE1 | Follicular Lymphoma | WITHDRAWN | NCT01460602 |
| bortezomib | Other | Phase PHASE2 | Kidney Cancer | COMPLETED | NCT00276614 |
| bortezomib | Other | Phase PHASE2 | Kidney Cancer | COMPLETED | NCT00276614 |
| Rituximab | Other | Phase PHASE2 | Waldenstrom's Macroglobulinemia | COMPLETED | NCT02400437 |
| Dexamethasone | Other | Phase PHASE2 | Waldenstrom's Macroglobulinemia | COMPLETED | NCT02400437 |
| Ixazomib | Other | Phase PHASE2 | Waldenstrom's Macroglobulinemia | COMPLETED | NCT02400437 |
| Rituximab | Other | Phase PHASE2 | Waldenstrom's Macroglobulinemia | COMPLETED | NCT02400437 |
| Dexamethasone | Other | Phase PHASE2 | Waldenstrom's Macroglobulinemia | COMPLETED | NCT02400437 |
| Ixazomib | Other | Phase PHASE2 | Waldenstrom's Macroglobulinemia | COMPLETED | NCT02400437 |
| Rituximab | Other | Phase PHASE2 | Waldenstrom's Macroglobulinemia | COMPLETED | NCT02400437 |
| Dexamethasone | Other | Phase PHASE2 | Waldenstrom's Macroglobulinemia | COMPLETED | NCT02400437 |
| Ixazomib | Other | Phase PHASE2 | Waldenstrom's Macroglobulinemia | COMPLETED | NCT02400437 |
| Placebo | Other | Phase PHASE3 | Ulcerative Colitis | TERMINATED | NCT02954159 |
| Vedolizumab | Other | Phase PHASE3 | Ulcerative Colitis | TERMINATED | NCT02954159 |
| Tacrolimus | Other | Phase PHASE3 | Ulcerative Colitis | TERMINATED | NCT02954159 |
| Placebo | Other | Phase PHASE3 | Ulcerative Colitis | TERMINATED | NCT02954159 |
| Vedolizumab | Other | Phase PHASE3 | Ulcerative Colitis | TERMINATED | NCT02954159 |
| Tacrolimus | Other | Phase PHASE3 | Ulcerative Colitis | TERMINATED | NCT02954159 |
| Amlodipine 10mg | Other | Phase PHASE4 | Hypertension | TERMINATED | NCT03106597 |
| Manidipine 20mg | Other | Phase PHASE4 | Hypertension | TERMINATED | NCT03106597 |
| Amlodipine 10mg | Other | Phase PHASE4 | Hypertension | TERMINATED | NCT03106597 |
| Manidipine 20mg | Other | Phase PHASE4 | Hypertension | TERMINATED | NCT03106597 |
| Amlodipine 10mg | Other | Phase PHASE4 | Hypertension | TERMINATED | NCT03106597 |
| Manidipine 20mg | Other | Phase PHASE4 | Hypertension | TERMINATED | NCT03106597 |
| brentuximab vedotin | Other | Preclinical | Disease, Hodgkin | NO_LONGER_AVAILABLE | NCT01196208 |
| brentuximab vedotin | Other | Preclinical | Disease, Hodgkin | NO_LONGER_AVAILABLE | NCT01196208 |
| Ixazomib | Other | Phase PHASE1 | Precursor Cell Lymphoblastic Leukemia-lymphoma | WITHDRAWN | NCT03888534 |
| Ixazomib | Other | Phase PHASE1 | Precursor Cell Lymphoblastic Leukemia-lymphoma | WITHDRAWN | NCT03888534 |
| TAK-671 Placebo | Other | Phase PHASE1 | Coronavirus Disease | WITHDRAWN | NCT04464460 |
| TAK-671 | Other | Phase PHASE1 | Coronavirus Disease | WITHDRAWN | NCT04464460 |
| TAK-671 Placebo | Other | Phase PHASE1 | Coronavirus Disease | WITHDRAWN | NCT04464460 |
| TAK-671 | Other | Phase PHASE1 | Coronavirus Disease | WITHDRAWN | NCT04464460 |
| Vedolizumab 300 mg | Other | Phase PHASE4 | Colitis, Ulcerative | COMPLETED | NCT02646657 |
| Vedolizumab 300 mg | Other | Phase PHASE4 | Colitis, Ulcerative | COMPLETED | NCT02646657 |
| Placebo | Other | Phase PHASE1 | COVID-19 Pneumonia | WITHDRAWN | NCT04460105 |
| Lanadelumab | Other | Phase PHASE1 | COVID-19 Pneumonia | WITHDRAWN | NCT04460105 |
| Placebo | Other | Phase PHASE1 | COVID-19 Pneumonia | WITHDRAWN | NCT04460105 |
| Lanadelumab | Other | Phase PHASE1 | COVID-19 Pneumonia | WITHDRAWN | NCT04460105 |
| No Intervention | Other | Preclinical | Multiple Myeloma | COMPLETED | NCT03188536 |
| No Intervention | Other | Preclinical | Multiple Myeloma | COMPLETED | NCT03188536 |
| Placebo | Other | Phase PHASE3 | Dengue Fever | COMPLETED | NCT03423173 |
| TAK-003 | Other | Phase PHASE3 | Dengue Fever | COMPLETED | NCT03423173 |
| Dilation and evacuation | Other | Approved | Termination of Pregnancy | COMPLETED | NCT04602052 |
| Dilation and evacuation | Other | Approved | Termination of Pregnancy | COMPLETED | NCT04602052 |
| Rituximab | Other | Phase PHASE2 | Waldenstrom's Macroglobulinemia | COMPLETED | NCT00422799 |
| Bortezomib | Other | Phase PHASE2 | Waldenstrom's Macroglobulinemia | COMPLETED | NCT00422799 |
| Rituximab | Other | Phase PHASE2 | Waldenstrom's Macroglobulinemia | COMPLETED | NCT00422799 |
| Bortezomib | Other | Phase PHASE2 | Waldenstrom's Macroglobulinemia | COMPLETED | NCT00422799 |
| Rituximab | Other | Phase PHASE2 | Waldenstrom's Macroglobulinemia | COMPLETED | NCT00422799 |
| Bortezomib | Other | Phase PHASE2 | Waldenstrom's Macroglobulinemia | COMPLETED | NCT00422799 |
| Placebo | Other | Phase PHASE3 | Peripheral Arterial Diseases | COMPLETED | NCT03469349 |
| Actovegin | Other | Phase PHASE3 | Peripheral Arterial Diseases | COMPLETED | NCT03469349 |
| Lanthanum carbonate crushed powder | Other | Phase PHASE2 | Hyperphosphatemia | COMPLETED | NCT00660530 |
| Lanthanum Carbonate Chewable Product | Other | Phase PHASE2 | Hyperphosphatemia | COMPLETED | NCT00660530 |
| Phentermine | Other | Approved | Obesity | COMPLETED | NCT01616082 |
| Low Calorie Diet (LCD) | Other | Approved | Obesity | COMPLETED | NCT01616082 |
| Phentermine | Other | Approved | Obesity | COMPLETED | NCT01616082 |
| Low Calorie Diet (LCD) | Other | Approved | Obesity | COMPLETED | NCT01616082 |
| Matched placebo | Other | Phase PHASE4 | Constipation | TERMINATED | NCT01096290 |
| lubiprostone | Other | Phase PHASE4 | Constipation | TERMINATED | NCT01096290 |
| Placebo | Other | Phase PHASE2 | Binge Eating Disorder | COMPLETED | NCT02528409 |
| Vortioxetine | Other | Phase PHASE2 | Binge Eating Disorder | COMPLETED | NCT02528409 |
| Placebo | Other | Phase PHASE2 | Binge Eating Disorder | COMPLETED | NCT02528409 |
| Vortioxetine | Other | Phase PHASE2 | Binge Eating Disorder | COMPLETED | NCT02528409 |
| Carboplatin | Other | Phase PHASE1 | Triple-Negative Breast Cancer | TERMINATED | NCT02993094 |
| Ixazomib | Other | Phase PHASE1 | Triple-Negative Breast Cancer | TERMINATED | NCT02993094 |
| Carboplatin | Other | Phase PHASE1 | Triple-Negative Breast Cancer | TERMINATED | NCT02993094 |
| Ixazomib | Other | Phase PHASE1 | Triple-Negative Breast Cancer | TERMINATED | NCT02993094 |
| SHP643 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03918239 |
| Rifampin | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04121078 |
| TAK-906 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04121078 |
| Rifampin | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04121078 |
| TAK-906 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04121078 |
| Conventional BCG full dose | Other | Phase PHASE1 | Respiratory Syncytial Virus Infections | COMPLETED | NCT03213405 |
| rBCG-N-hRSV full dose | Other | Phase PHASE1 | Respiratory Syncytial Virus Infections | COMPLETED | NCT03213405 |
| rBCG-N-hRSV 1/10 | Other | Phase PHASE1 | Respiratory Syncytial Virus Infections | COMPLETED | NCT03213405 |
| rBCG-N-hRSV 1/100 | Other | Phase PHASE1 | Respiratory Syncytial Virus Infections | COMPLETED | NCT03213405 |
| Conventional BCG full dose | Other | Phase PHASE1 | Respiratory Syncytial Virus Infections | COMPLETED | NCT03213405 |
| rBCG-N-hRSV full dose | Other | Phase PHASE1 | Respiratory Syncytial Virus Infections | COMPLETED | NCT03213405 |
| rBCG-N-hRSV 1/10 | Other | Phase PHASE1 | Respiratory Syncytial Virus Infections | COMPLETED | NCT03213405 |
| rBCG-N-hRSV 1/100 | Other | Phase PHASE1 | Respiratory Syncytial Virus Infections | COMPLETED | NCT03213405 |
| Azacitidine | Other | Phase PHASE2 | Acute Myeloid Leukemia (AML) | TERMINATED | NCT03709576 |
| transplant | Other | Phase PHASE2 | Acute Myeloid Leukemia (AML) | TERMINATED | NCT03709576 |
| Pevonedistat | Other | Phase PHASE2 | Acute Myeloid Leukemia (AML) | TERMINATED | NCT03709576 |
| Azacitidine | Other | Phase PHASE2 | Acute Myeloid Leukemia (AML) | TERMINATED | NCT03709576 |
| transplant | Other | Phase PHASE2 | Acute Myeloid Leukemia (AML) | TERMINATED | NCT03709576 |
| Pevonedistat | Other | Phase PHASE2 | Acute Myeloid Leukemia (AML) | TERMINATED | NCT03709576 |
| Antidiarrheal prophylaxis | Other | Phase PHASE2 | Non-Small Cell Lung Cancer (NSCLC) | WITHDRAWN | NCT04576208 |
| TAK-788 | Other | Phase PHASE2 | Non-Small Cell Lung Cancer (NSCLC) | WITHDRAWN | NCT04576208 |
| Antidiarrheal prophylaxis | Other | Phase PHASE2 | Non-Small Cell Lung Cancer (NSCLC) | WITHDRAWN | NCT04576208 |
| TAK-788 | Other | Phase PHASE2 | Non-Small Cell Lung Cancer (NSCLC) | WITHDRAWN | NCT04576208 |
| Antidiarrheal prophylaxis | Other | Phase PHASE2 | Non-Small Cell Lung Cancer (NSCLC) | WITHDRAWN | NCT04576208 |
| TAK-788 | Other | Phase PHASE2 | Non-Small Cell Lung Cancer (NSCLC) | WITHDRAWN | NCT04576208 |
| Antiviral Agents | Other | Phase PHASE3 | Covid19 | WITHDRAWN | NCT04675086 |
| alpha1-proteinase inhibitor | Other | Phase PHASE3 | Covid19 | WITHDRAWN | NCT04675086 |
| Antiviral Agents | Other | Phase PHASE3 | Covid19 | WITHDRAWN | NCT04675086 |
| alpha1-proteinase inhibitor | Other | Phase PHASE3 | Covid19 | WITHDRAWN | NCT04675086 |
| Antiviral Agents | Other | Phase PHASE3 | Covid19 | WITHDRAWN | NCT04675086 |
| alpha1-proteinase inhibitor | Other | Phase PHASE3 | Covid19 | WITHDRAWN | NCT04675086 |
| Antiviral Agents | Other | Phase PHASE3 | Covid19 | WITHDRAWN | NCT04675086 |
| alpha1-proteinase inhibitor | Other | Phase PHASE3 | Covid19 | WITHDRAWN | NCT04675086 |
| Vedolizumab | Other | Preclinical | Ulcerative Colitis | TERMINATED | NCT03802214 |
| Vedolizumab | Other | Preclinical | Ulcerative Colitis | TERMINATED | NCT03802214 |
| Vedolizumab | Other | Preclinical | Ulcerative Colitis | TERMINATED | NCT03802214 |
| Vedolizumab | Other | Phase PHASE2 | Ulcerative Colitis | COMPLETED | NCT03138655 |
| Vedolizumab | Other | Phase PHASE2 | Ulcerative Colitis | COMPLETED | NCT03138655 |
| Esomeprazole | Other | Phase PHASE1 | Neoplasms, Advanced Solid | COMPLETED | NCT03708211 |
| TAK-931 Tablet | Other | Phase PHASE1 | Neoplasms, Advanced Solid | COMPLETED | NCT03708211 |
| TAK-931 PIC | Other | Phase PHASE1 | Neoplasms, Advanced Solid | COMPLETED | NCT03708211 |
| Esomeprazole | Other | Phase PHASE1 | Neoplasms, Advanced Solid | COMPLETED | NCT03708211 |
| TAK-931 Tablet | Other | Phase PHASE1 | Neoplasms, Advanced Solid | COMPLETED | NCT03708211 |
| TAK-931 PIC | Other | Phase PHASE1 | Neoplasms, Advanced Solid | COMPLETED | NCT03708211 |
| MLN0128 | Other | Phase PHASE1 | Merkel Cell Carcinoma | COMPLETED | NCT02514824 |
| MLN0128 | Other | Phase PHASE1 | Merkel Cell Carcinoma | COMPLETED | NCT02514824 |
| Bexarotene | Other | Phase PHASE3 | Primary Cutaneous Anaplastic Large Cell Lymphoma | COMPLETED | NCT01578499 |
| Methotrexate | Other | Phase PHASE3 | Primary Cutaneous Anaplastic Large Cell Lymphoma | COMPLETED | NCT01578499 |
| Brentuximab Vedotin | Other | Phase PHASE3 | Primary Cutaneous Anaplastic Large Cell Lymphoma | COMPLETED | NCT01578499 |
| TAK-906 Maleate Placebo | Other | Phase PHASE2 | Diabetes Mellitus and Gastroparesis, Idiopathic Gastroparesis | COMPLETED | NCT03268941 |
| Metaclopramide | Other | Phase PHASE2 | Diabetes Mellitus and Gastroparesis, Idiopathic Gastroparesis | COMPLETED | NCT03268941 |
| TAK-906 Maleate | Other | Phase PHASE2 | Diabetes Mellitus and Gastroparesis, Idiopathic Gastroparesis | COMPLETED | NCT03268941 |
| TAK-906 Maleate Placebo | Other | Phase PHASE2 | Diabetes Mellitus and Gastroparesis, Idiopathic Gastroparesis | COMPLETED | NCT03268941 |
| Metaclopramide | Other | Phase PHASE2 | Diabetes Mellitus and Gastroparesis, Idiopathic Gastroparesis | COMPLETED | NCT03268941 |
| TAK-906 Maleate | Other | Phase PHASE2 | Diabetes Mellitus and Gastroparesis, Idiopathic Gastroparesis | COMPLETED | NCT03268941 |
| Placebo | Other | Phase PHASE4 | Major Depressive Disorder | COMPLETED | NCT02371980 |
| Vortioxetine | Other | Phase PHASE4 | Major Depressive Disorder | COMPLETED | NCT02371980 |
| Placebo | Other | Phase PHASE4 | Major Depressive Disorder | COMPLETED | NCT02371980 |
| Vortioxetine | Other | Phase PHASE4 | Major Depressive Disorder | COMPLETED | NCT02371980 |
| Placebo | Other | Phase PHASE2 | Diabetic Gastroparesis | COMPLETED | NCT03281577 |
| TAK-954 | Other | Phase PHASE2 | Diabetic Gastroparesis | COMPLETED | NCT03281577 |
| Placebo | Other | Phase PHASE2 | Diabetic Gastroparesis | COMPLETED | NCT03281577 |
| TAK-954 | Other | Phase PHASE2 | Diabetic Gastroparesis | COMPLETED | NCT03281577 |
| Placebo | Other | Phase PHASE1 | Developmental and/or Epileptic Encephalopathies | COMPLETED | NCT03166215 |
| TAK-935 | Other | Phase PHASE1 | Developmental and/or Epileptic Encephalopathies | COMPLETED | NCT03166215 |
| Placebo | Other | Phase PHASE1 | Developmental and/or Epileptic Encephalopathies | COMPLETED | NCT03166215 |
| TAK-935 | Other | Phase PHASE1 | Developmental and/or Epileptic Encephalopathies | COMPLETED | NCT03166215 |
| Vedolizumab | Other | Phase PHASE4 | Colitis, Ulcerative | COMPLETED | NCT02559713 |
| TAK-906 Placebo | Other | Phase PHASE1 | Japanese Healthy Adult Male Participants | COMPLETED | NCT03237156 |
| TAK-906 | Other | Phase PHASE1 | Japanese Healthy Adult Male Participants | COMPLETED | NCT03237156 |
| TAK-906 Placebo | Other | Phase PHASE1 | Japanese Healthy Adult Male Participants | COMPLETED | NCT03237156 |
| TAK-906 | Other | Phase PHASE1 | Japanese Healthy Adult Male Participants | COMPLETED | NCT03237156 |
| Dexamethasone | Other | Phase PHASE2 | Relapsed and/or Refractory Multiple Myeloma | COMPLETED | NCT02917941 |
| Lenalidomide | Other | Phase PHASE2 | Relapsed and/or Refractory Multiple Myeloma | COMPLETED | NCT02917941 |
| Ixazomib | Other | Phase PHASE2 | Relapsed and/or Refractory Multiple Myeloma | COMPLETED | NCT02917941 |
| Dexamethasone | Other | Phase PHASE2 | Relapsed and/or Refractory Multiple Myeloma | COMPLETED | NCT02917941 |
| Lenalidomide | Other | Phase PHASE2 | Relapsed and/or Refractory Multiple Myeloma | COMPLETED | NCT02917941 |
| Ixazomib | Other | Phase PHASE2 | Relapsed and/or Refractory Multiple Myeloma | COMPLETED | NCT02917941 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04551079 |
| TAK-994 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04551079 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04551079 |
| TAK-994 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04551079 |
| Ixazomib | Other | Phase PHASE1 | Lymphoma, T-Cell, Peripheral | ACTIVE_NOT_RECRUITING | NCT03547700 |
| Romidepsin | Other | Phase PHASE1 | Lymphoma, T-Cell, Peripheral | ACTIVE_NOT_RECRUITING | NCT03547700 |
| Ixazomib | Other | Phase PHASE1 | Lymphoma, T-Cell, Peripheral | ACTIVE_NOT_RECRUITING | NCT03547700 |
| Romidepsin | Other | Phase PHASE1 | Lymphoma, T-Cell, Peripheral | ACTIVE_NOT_RECRUITING | NCT03547700 |
| Ankle and Knee Magnetic Resonance Imaging | Other | Preclinical | Hemophilia A | TERMINATED | NCT02807753 |
| Ankle and Knee Ultrasound Joint Assessment | Other | Preclinical | Hemophilia A | TERMINATED | NCT02807753 |
| Teduglutide | Other | Preclinical | Short Bowel Syndrome | UNKNOWN | NCT04733066 |
| Teduglutide | Other | Preclinical | Short Bowel Syndrome | UNKNOWN | NCT04733066 |
| No Intervention | Other | Preclinical | Multiple Myeloma | COMPLETED | NCT03506386 |
| No Intervention | Other | Preclinical | Multiple Myeloma | COMPLETED | NCT03506386 |
| Vortioxetine | Other | Phase PHASE4 | Post-Traumatic Stress Disorder | COMPLETED | NCT02637895 |
| Placebo | Other | Phase PHASE4 | Post-Traumatic Stress Disorder | COMPLETED | NCT02637895 |
| Vortioxetine | Other | Phase PHASE4 | Post-Traumatic Stress Disorder | COMPLETED | NCT02637895 |
| Placebo | Other | Phase PHASE4 | Post-Traumatic Stress Disorder | COMPLETED | NCT02637895 |
| Placebo | Other | Phase PHASE2 | Epilepsy | COMPLETED | NCT03650452 |
| TAK-935 | Other | Phase PHASE2 | Epilepsy | COMPLETED | NCT03650452 |
| TAK-931 | Other | Phase PHASE1 | Nonhematologic Neoplasms, Advanced | COMPLETED | NCT02699749 |
| TAK-931 | Other | Phase PHASE1 | Nonhematologic Neoplasms, Advanced | COMPLETED | NCT02699749 |
| Brentuximab Vedotin | Other | Phase PHASE2 | Hodgkin Disease | COMPLETED | NCT02939014 |
| Doxil | Other | Phase PHASE2 | Acute Myelogenous Leukemia | COMPLETED | NCT01736943 |
| Bortezomib | Other | Phase PHASE2 | Acute Myelogenous Leukemia | COMPLETED | NCT01736943 |
| Doxil | Other | Phase PHASE2 | Acute Myelogenous Leukemia | COMPLETED | NCT01736943 |
| Bortezomib | Other | Phase PHASE2 | Acute Myelogenous Leukemia | COMPLETED | NCT01736943 |
| SPD489 | Other | Phase PHASE3 | Attention Deficit Hyperactivity Disorder (ADHD) | COMPLETED | NCT02466386 |
| Observation | Other | Preclinical | Retinitis Pigmentosa | TERMINATED | NCT02926092 |
| Observation | Other | Preclinical | Retinitis Pigmentosa | TERMINATED | NCT02926092 |
| Vortioxetine | Other | Phase PHASE3 | Major Depressive Disorder | COMPLETED | NCT02389816 |
| Placebo | Other | Phase PHASE3 | Major Depressive Disorder | COMPLETED | NCT02389816 |
| Modafinil Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03522506 |
| Modafinil | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03522506 |
| TAK-925 Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03522506 |
| TAK-925 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03522506 |
| Modafinil Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03522506 |
| Modafinil | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03522506 |
| TAK-925 Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03522506 |
| TAK-925 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03522506 |
| Ixazomib | Other | Phase EARLY_PHASE1 | Glioblastoma | COMPLETED | NCT02630030 |
| Ixazomib | Other | Phase EARLY_PHASE1 | Glioblastoma | COMPLETED | NCT02630030 |
| SHP465 25mg | Other | Phase PHASE1 | Attention Deficit Hyperactivity Disorder (ADHD) | COMPLETED | NCT02578030 |
| SHP465 12.5mg | Other | Phase PHASE1 | Attention Deficit Hyperactivity Disorder (ADHD) | COMPLETED | NCT02578030 |
| Placebo | Other | Phase PHASE3 | Hereditary Angioedema (HAE) | COMPLETED | NCT02586805 |
| DX-2930 - 150mg/4wk | Other | Phase PHASE3 | Hereditary Angioedema (HAE) | COMPLETED | NCT02586805 |
| DX-2930 - 300mg/4wk | Other | Phase PHASE3 | Hereditary Angioedema (HAE) | COMPLETED | NCT02586805 |
| DX-2930 - 300mg/2wk | Other | Phase PHASE3 | Hereditary Angioedema (HAE) | COMPLETED | NCT02586805 |
| Dextromethorphan | Other | Phase PHASE1 | Cytomegalovirus (CMV) | COMPLETED | NCT02775240 |
| Maribavir | Other | Phase PHASE1 | Cytomegalovirus (CMV) | COMPLETED | NCT02775240 |
| Digoxin | Other | Phase PHASE1 | Cytomegalovirus (CMV) | COMPLETED | NCT02775240 |
| SHP623 | Other | Phase PHASE1 | Hereditary Angioedema (HAE) | COMPLETED | NCT02663687 |
| Placebo | Other | Phase PHASE1 | Hereditary Angioedema (HAE) | COMPLETED | NCT02663687 |
| Recombinant human C1 esterase inhibitor | Other | Phase PHASE1 | Hereditary Angioedema (HAE) | COMPLETED | NCT02663687 |
| Placebo | Other | Phase PHASE3 | Attention Deficit Hyperactivity Disorder (ADHD) | COMPLETED | NCT02466425 |
| SHP465 | Other | Phase PHASE3 | Attention Deficit Hyperactivity Disorder (ADHD) | COMPLETED | NCT02466425 |
| Placebo | Other | Phase PHASE3 | Attention Deficit Hyperactivity Disorder (ADHD) | COMPLETED | NCT02466425 |
| SHP465 | Other | Phase PHASE3 | Attention Deficit Hyperactivity Disorder (ADHD) | COMPLETED | NCT02466425 |
| Participating Site's standard practice | Other | Phase PHASE2 | Arteriovenous Fistula | COMPLETED | NCT01806545 |
| SRM003 | Other | Phase PHASE2 | Arteriovenous Fistula | COMPLETED | NCT01806545 |
| Placebo | Other | Phase PHASE3 | Binge Eating Disorder | COMPLETED | NCT01718483 |
| SPD489 (Lisdexamfetamine dimesylate) | Other | Phase PHASE3 | Binge Eating Disorder | COMPLETED | NCT01718483 |
| Placebo | Other | Phase PHASE2 | Eosinophilic Esophagitis (EoE) | COMPLETED | NCT01642212 |
| Oral Budesonide Suspension (MB-9) | Other | Phase PHASE2 | Eosinophilic Esophagitis (EoE) | COMPLETED | NCT01642212 |
| Placebo | Other | Phase PHASE4 | Attention-deficit/Hyperactivity Disorder | COMPLETED | NCT01552915 |
| Methylphenidate Hydrochloride | Other | Phase PHASE4 | Attention-deficit/Hyperactivity Disorder | COMPLETED | NCT01552915 |
| Lisdexamfetamine dimesylate | Other | Phase PHASE4 | Attention-deficit/Hyperactivity Disorder | COMPLETED | NCT01552915 |
| Placebo | Other | Phase PHASE4 | Orthostatic Hypotension | COMPLETED | NCT01518946 |
| Midodrine HCl | Other | Phase PHASE4 | Orthostatic Hypotension | COMPLETED | NCT01518946 |
| Placebo | Other | Phase PHASE4 | Orthostatic Hypotension | COMPLETED | NCT01518946 |
| Midodrine HCl | Other | Phase PHASE4 | Orthostatic Hypotension | COMPLETED | NCT01518946 |
| agalsidase alfa | Other | Phase PHASE3 | Fabry Disease | COMPLETED | NCT01298141 |
| Placebo | Other | Phase PHASE3 | Bacterial Conjunctivitis | COMPLETED | NCT03004924 |
| PVP-I 0.6% | Other | Phase PHASE3 | Bacterial Conjunctivitis | COMPLETED | NCT03004924 |
| SHP640 | Other | Phase PHASE3 | Bacterial Conjunctivitis | COMPLETED | NCT03004924 |
| Placebo | Other | Phase PHASE3 | ADHD | COMPLETED | NCT00367835 |
| SPD503 (Guanfacine hydrochloride) | Other | Phase PHASE3 | ADHD | COMPLETED | NCT00367835 |
| Placebo | Other | Phase PHASE3 | ADHD | COMPLETED | NCT00367835 |
| SPD503 (Guanfacine hydrochloride) | Other | Phase PHASE3 | ADHD | COMPLETED | NCT00367835 |
| Asacol | Other | Phase PHASE3 | Ulcerative Colitis | COMPLETED | NCT00151892 |
| SPD476 | Other | Phase PHASE3 | Ulcerative Colitis | COMPLETED | NCT00151892 |
| Niraparib-Bevacizumab | Other | Phase PHASE2 | Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor | UNKNOWN | NCT04734665 |
| Niraparib-Bevacizumab | Other | Phase PHASE2 | Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor | UNKNOWN | NCT04734665 |
| regular care | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT04422509 |
| lanadelumab | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT04422509 |
| regular care | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT04422509 |
| lanadelumab | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT04422509 |
| [18F]MNI-1054 (radiotracer) | Other | Phase PHASE1 | Healthy Volunteers | TERMINATED | NCT04202497 |
| TAK-418 | Other | Phase PHASE1 | Healthy Volunteers | TERMINATED | NCT04202497 |
| [18F]MNI-1054 (radiotracer) | Other | Phase PHASE1 | Healthy Volunteers | TERMINATED | NCT04202497 |
| TAK-418 | Other | Phase PHASE1 | Healthy Volunteers | TERMINATED | NCT04202497 |
| Provider type: Midlevel Providers | Other | Approved | Induced Abortion | COMPLETED | NCT04181541 |
| Provider type: Physicians | Other | Approved | Induced Abortion | COMPLETED | NCT04181541 |
| Feiba | Other | Phase PHASE4 | Hemophilia A With Inhibitor | ACTIVE_NOT_RECRUITING | NCT04205175 |
| Feiba | Other | Phase PHASE4 | Hemophilia A With Inhibitor | ACTIVE_NOT_RECRUITING | NCT04205175 |
| Leuprorelin | Other | Phase PHASE4 | Central Precocious Puberty | COMPLETED | NCT02427958 |
| Pen injector | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04465396 |
| Syringe Injection | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04465396 |
| Teduglutide | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04465396 |
| No Intervention | Other | Preclinical | Carcinoma, Non-Small-Cell Lung | COMPLETED | NCT04887519 |
| Rectosigmoidoscopy | Other | Approved | Ulcerative Colitis | TERMINATED | NCT03724929 |
| Blood sample | Other | Approved | Ulcerative Colitis | TERMINATED | NCT03724929 |
| Rectosigmoidoscopy | Other | Approved | Ulcerative Colitis | TERMINATED | NCT03724929 |
| Blood sample | Other | Approved | Ulcerative Colitis | TERMINATED | NCT03724929 |
| Methotrexate | Other | Phase PHASE4 | Crohn Disease | COMPLETED | NCT02764762 |
| Adalimumab | Other | Phase PHASE4 | Crohn Disease | COMPLETED | NCT02764762 |
| Vedolizumab | Other | Phase PHASE4 | Crohn Disease | COMPLETED | NCT02764762 |
| Ixazomib | Other | Phase PHASE3 | Multiple Myeloma | COMPLETED | NCT02312258 |
| Placebo | Other | Phase PHASE3 | Multiple Myeloma | COMPLETED | NCT02312258 |
| Ixazomib | Other | Phase PHASE3 | Multiple Myeloma | COMPLETED | NCT02312258 |
| Placebo | Other | Phase PHASE3 | Multiple Myeloma | COMPLETED | NCT02312258 |
| Ixazomib | Other | Phase PHASE3 | Multiple Myeloma | COMPLETED | NCT02312258 |
| Placebo | Other | Phase PHASE3 | Multiple Myeloma | COMPLETED | NCT02312258 |
| SYR-322-MET | Other | Phase PHASE3 | Clinical Pharmacology | COMPLETED | NCT02276274 |
| SYR-322-MET | Other | Phase PHASE3 | Clinical Pharmacology | COMPLETED | NCT02276274 |
| Placebo | Other | Phase PHASE3 | Myelodysplastic Syndromes | RECRUITING | NCT06499285 |
| Elritercept | Other | Phase PHASE3 | Myelodysplastic Syndromes | RECRUITING | NCT06499285 |
| Placebo | Other | Phase PHASE3 | Alpha1-Antitrypsin Deficiency | RECRUITING | NCT05677971 |
| Fazirsiran Injection | Other | Phase PHASE3 | Alpha1-Antitrypsin Deficiency | RECRUITING | NCT05677971 |
| Vedolizumab | Other | Phase PHASE2 | Ulcerative Colitis | COMPLETED | NCT03196427 |
| No Intervention | Other | Preclinical | Thrombotic Thrombocytopenic Purpura (TTP) | NOT_YET_RECRUITING | NCT07353099 |
| Vedolizumab SC | Other | Phase PHASE4 | Ulcerative Colitis | RECRUITING | NCT06581328 |
| Vedolizumab IV | Other | Phase PHASE4 | Ulcerative Colitis | RECRUITING | NCT06581328 |
| Placebo | Other | Phase PHASE2 | Nonsegmental Vitiligo | RECRUITING | NCT07108283 |
| Zasocitinib | Other | Phase PHASE2 | Nonsegmental Vitiligo | RECRUITING | NCT07108283 |
| Placebo | Other | Phase PHASE3 | Kidney Disease | RECRUITING | NCT06963827 |
| Mezagitamab | Other | Phase PHASE3 | Kidney Disease | RECRUITING | NCT06963827 |
| Psychotherapy as Usual (TAU) | Drug | Approved | Major Depression | RECRUITING | NCT07380451 |
| Modular Intervention for Depression Therapy (MIND Therapy) | Drug | Approved | Major Depression | RECRUITING | NCT07380451 |
| Psychotherapy as Usual (TAU) | Drug | Approved | Major Depression | RECRUITING | NCT07380451 |
| Modular Intervention for Depression Therapy (MIND Therapy) | Drug | Approved | Major Depression | RECRUITING | NCT07380451 |
| Vedolizumab | Other | Phase PHASE4 | Colitis, Ulcerative | TERMINATED | NCT02743806 |
| Ibrutinib | Other | Phase PHASE1 | Mantle-Cell Lymphoma | COMPLETED | NCT03323151 |
| Ixazomib | Other | Phase PHASE1 | Mantle-Cell Lymphoma | COMPLETED | NCT03323151 |
| Methotrexate and Cytarabine | Other | Phase PHASE2 | Acute Lymphoblastic Leukemia | WITHDRAWN | NCT04845035 |
| Berlin-Frankfurt-Münster Chemotherapy | Drug | Phase PHASE2 | Acute Lymphoblastic Leukemia | WITHDRAWN | NCT04845035 |
| Ponatinib | Other | Phase PHASE2 | Acute Lymphoblastic Leukemia | WITHDRAWN | NCT04845035 |
| Dasatinib | Other | Phase PHASE2 | Acute Lymphoblastic Leukemia | WITHDRAWN | NCT04845035 |
| Brigatinib | Other | Phase PHASE2 | ALK-positive Advanced NSCLC | COMPLETED | NCT03410108 |
| Brigatinib | Other | Phase PHASE2 | ALK-positive Advanced NSCLC | COMPLETED | NCT03410108 |
| Placebo | Other | Phase PHASE3 | Constipation | TERMINATED | NCT04759833 |
| Prucalopride | Other | Phase PHASE3 | Constipation | TERMINATED | NCT04759833 |
| Placebo | Other | Phase PHASE3 | Constipation | TERMINATED | NCT04759833 |
| Prucalopride | Other | Phase PHASE3 | Constipation | TERMINATED | NCT04759833 |
| TAK-279 | Other | Phase PHASE1 | Renal Impairment | COMPLETED | NCT05992155 |
| TAK-279 | Other | Phase PHASE1 | Renal Impairment | COMPLETED | NCT05992155 |
| Psychotherapy as Usual (TAU) | Drug | Approved | Major Depression | RECRUITING | NCT07380451 |
| Modular Intervention for Depression Therapy (MIND Therapy) | Drug | Approved | Major Depression | RECRUITING | NCT07380451 |
| Placebo | Other | Phase PHASE1 | Healthy Participants and Patients With Narcolepsy | COMPLETED | NCT03332784 |
| TAK-925 | Other | Phase PHASE1 | Healthy Participants and Patients With Narcolepsy | COMPLETED | NCT03332784 |
| Brentuximab Vedotin | Other | Phase PHASE4 | Hodgkin Lymphoma | COMPLETED | NCT01990534 |
| Brentuximab Vedotin | Other | Phase PHASE4 | Hodgkin Lymphoma | COMPLETED | NCT01990534 |
| No intervention | Other | Preclinical | Inflammatory Bowel Disease | COMPLETED | NCT03981939 |
| No intervention | Other | Preclinical | Inflammatory Bowel Disease | COMPLETED | NCT03981939 |
| No intervention | Other | Preclinical | Inflammatory Bowel Disease | COMPLETED | NCT03981939 |
| TAK-994 | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT04745767 |
| Placebo | Other | Phase PHASE3 | Ulcerative Colitis | TERMINATED | NCT03259308 |
| Ontamalimab | Other | Phase PHASE3 | Ulcerative Colitis | TERMINATED | NCT03259308 |
| Placebo | Other | Phase PHASE3 | Crohn's Disease | TERMINATED | NCT03559517 |
| Ontamalimab | Other | Phase PHASE3 | Crohn's Disease | TERMINATED | NCT03559517 |
| Accelerometry | Other | Preclinical | Healthy Volunteers | COMPLETED | NCT04445129 |
| Portable ECG Device | Device | Preclinical | Healthy Volunteers | COMPLETED | NCT04445129 |
| Portable EEG Device | Device | Preclinical | Healthy Volunteers | COMPLETED | NCT04445129 |
| Accelerometry | Other | Preclinical | Healthy Volunteers | COMPLETED | NCT04445129 |
| Portable ECG Device | Device | Preclinical | Healthy Volunteers | COMPLETED | NCT04445129 |
| Portable EEG Device | Device | Preclinical | Healthy Volunteers | COMPLETED | NCT04445129 |
| Needle | Other | Phase PHASE3 | Short Bowel Syndrome | COMPLETED | NCT03571516 |
| Syringe | Other | Phase PHASE3 | Short Bowel Syndrome | COMPLETED | NCT03571516 |
| Standard Medical Therapy | Drug | Phase PHASE3 | Short Bowel Syndrome | COMPLETED | NCT03571516 |
| Teduglutide | Other | Phase PHASE3 | Short Bowel Syndrome | COMPLETED | NCT03571516 |
| Placebo | Other | Phase PHASE3 | Crohn's Disease | TERMINATED | NCT03566823 |
| Ontamalimab | Other | Phase PHASE3 | Crohn's Disease | TERMINATED | NCT03566823 |
| placebo | Other | Phase PHASE3 | Disease, Hodgkin | COMPLETED | NCT01100502 |
| brentuximab vedotin | Other | Phase PHASE3 | Disease, Hodgkin | COMPLETED | NCT01100502 |
| Teduglutide | Other | Phase PHASE1 | Hepatic Impairment | COMPLETED | NCT00819468 |
| Teduglutide (ALX-0600) | Other | Phase PHASE2 | Crohn's Disease | COMPLETED | NCT00308438 |
| ALX1-11 | Other | Phase PHASE3 | Osteoporosis | COMPLETED | NCT00172081 |
| placebo | Other | Phase PHASE3 | Osteoporosis | COMPLETED | NCT00172081 |
| ALX1-11 (drug) | Drug | Phase PHASE3 | Osteoporosis | COMPLETED | NCT00172133 |
| ALX1-11 | Other | Phase PHASE3 | Osteoporosis | COMPLETED | NCT00172120 |
| ALX1-11 | Other | Phase PHASE2 | Osteoporosis | COMPLETED | NCT00172107 |
| ALX1-11 75mcg | Other | Phase PHASE2 | Osteoporosis | COMPLETED | NCT00172107 |
| placebo | Other | Phase PHASE2 | Osteoporosis | COMPLETED | NCT00172107 |
| ALX1-11 50 mcg | Other | Phase PHASE2 | Osteoporosis | COMPLETED | NCT00172107 |
| DX-88 (ecallantide) | Other | Phase PHASE2 | Hereditary Angioedema (HAE) | COMPLETED | NCT01826916 |
| agalsidase alfa | Other | Preclinical | Fabry Disease | NO_LONGER_AVAILABLE | NCT01031173 |
| 100mcg rhPTH(1-84) | Other | Phase PHASE1 | Hypoparathyroidism | COMPLETED | NCT02781844 |
| 50mcg rhPTH(1-84) | Other | Phase PHASE1 | Hypoparathyroidism | COMPLETED | NCT02781844 |
| 25mcg rhPTH(1-84) | Other | Phase PHASE1 | Hypoparathyroidism | COMPLETED | NCT02781844 |
| 100mcg rhPTH(1-84) | Other | Phase PHASE1 | Hypoparathyroidism | COMPLETED | NCT02781844 |
| 50mcg rhPTH(1-84) | Other | Phase PHASE1 | Hypoparathyroidism | COMPLETED | NCT02781844 |
| 25mcg rhPTH(1-84) | Other | Phase PHASE1 | Hypoparathyroidism | COMPLETED | NCT02781844 |
| NPSP558 | Other | Phase PHASE3 | Hypoparathyroidism | COMPLETED | NCT01297309 |
| tedguglutide | Other | Phase PHASE1 | Pharmacokinetics and Safety of Elevated Doses | COMPLETED | NCT00820885 |
| teduglutide | Other | Phase PHASE1 | Pharmacokinetics and Safety of Elevated Doses | COMPLETED | NCT00820885 |
| Atomoxetine hydrochloride | Other | Phase PHASE3 | Attention Deficit Disorder With Hyperactivity | COMPLETED | NCT00557960 |
| Mixed salts of a single-entity amphetamine | Other | Phase PHASE3 | Attention Deficit Disorder With Hyperactivity | COMPLETED | NCT00557960 |
| Lanthanum carbonate | Other | Phase PHASE4 | Kidney Diseases | TERMINATED | NCT00452478 |
| Lanthanum carbonate | Other | Phase PHASE4 | Kidney Diseases | TERMINATED | NCT00452478 |
| placebo | Other | Phase PHASE3 | Osteoporosis | COMPLETED | NCT00172172 |
| PTH/placebo | Other | Phase PHASE3 | Osteoporosis | COMPLETED | NCT00172172 |
| PTH/Calcium | Other | Phase PHASE3 | Osteoporosis | COMPLETED | NCT00172172 |
| teduglutide 0.1 mg dose | Other | Phase PHASE2 | Crohn's Disease | COMPLETED | NCT00072839 |
| Teduglutide 0.05 dose | Other | Phase PHASE2 | Crohn's Disease | COMPLETED | NCT00072839 |
| teduglutide 0.2 mg | Other | Phase PHASE2 | Crohn's Disease | COMPLETED | NCT00072839 |
| teduglutide 0.05 | Other | Phase PHASE2 | Crohn's Disease | COMPLETED | NCT00072839 |
| placebo | Other | Phase PHASE2 | Crohn's Disease | COMPLETED | NCT00072839 |
| ALX-0600 | Other | Phase PHASE2 | Crohn's Disease | COMPLETED | NCT00072839 |
| Placebo | Other | Phase PHASE1 | Hereditary Angioedema (HAE) | COMPLETED | NCT02093923 |
| DX-2930 | Other | Phase PHASE1 | Hereditary Angioedema (HAE) | COMPLETED | NCT02093923 |
| ciprofloxacin 0.3%, dexamethasone 0.1% | Other | Phase PHASE3 | Acute Otitis Externa | TERMINATED | NCT00945802 |
| FST-201 (dexamethasone 0.1%) Otic Suspension | Other | Phase PHASE3 | Acute Otitis Externa | TERMINATED | NCT00945802 |
| Vehicle | Other | Phase PHASE3 | Acute Fungal Otitis Externa | TERMINATED | NCT00945646 |
| FST-201 (dexamethasone 0.1%) Otic Suspension | Other | Phase PHASE3 | Acute Fungal Otitis Externa | TERMINATED | NCT00945646 |
| Placebo | Other | Phase PHASE3 | Attention Deficit Hyperactivity Disorder (ADHD) | COMPLETED | NCT03325881 |
| SHP465 | Other | Phase PHASE3 | Attention Deficit Hyperactivity Disorder (ADHD) | COMPLETED | NCT03325881 |
| CINRYZE 1000 U | Other | Phase PHASE3 | Hereditary Angioedema (HAE) | COMPLETED | NCT02865720 |
| CINRYZE 500 U | Other | Phase PHASE3 | Hereditary Angioedema (HAE) | COMPLETED | NCT02865720 |
| Deferitazole (magnesium hydroxide salt) | Other | Phase PHASE1 | Healthy | WITHDRAWN | NCT02065401 |
| Deferitazole (disodium salt, tablet) | Other | Phase PHASE1 | Healthy | WITHDRAWN | NCT02065401 |
| Deferitazole (disodium salt, granule) | Other | Phase PHASE1 | Healthy | WITHDRAWN | NCT02065401 |
| Deferitazole (magnesium hydroxide salt) | Other | Phase PHASE1 | Healthy | WITHDRAWN | NCT02065401 |
| Deferitazole (disodium salt, tablet) | Other | Phase PHASE1 | Healthy | WITHDRAWN | NCT02065401 |
| Deferitazole (disodium salt, granule) | Other | Phase PHASE1 | Healthy | WITHDRAWN | NCT02065401 |
| Deferasirox | Other | Phase PHASE2 | Transfusional Iron Overload | WITHDRAWN | NCT01927913 |
| SPD602 | Other | Phase PHASE2 | Transfusional Iron Overload | WITHDRAWN | NCT01927913 |
| Placebo | Other | Phase PHASE1 | Friedreich's Ataxia | COMPLETED | NCT01898884 |
| VP 20629 | Other | Phase PHASE1 | Friedreich's Ataxia | COMPLETED | NCT01898884 |
| Maribavir | Other | Phase PHASE2 | Cytomegalovirus (CMV) | COMPLETED | NCT01611974 |
| Maribavir | Other | Phase PHASE2 | Cytomegalovirus (CMV) | COMPLETED | NCT01611974 |
| Hydroxyurea | Other | Phase PHASE4 | Thrombocythemia, Hemorrhagic | COMPLETED | NCT00202644 |
| Anagrelide | Other | Phase PHASE4 | Thrombocythemia, Hemorrhagic | COMPLETED | NCT00202644 |
| teduglutide 0.10 mg/kg/d | Other | Phase PHASE3 | Short Bowel Syndrome | COMPLETED | NCT00172185 |
| teduglutide 0.05 mg/kg/d | Other | Phase PHASE3 | Short Bowel Syndrome | COMPLETED | NCT00172185 |
| Icatibant | Other | Phase PHASE3 | Hereditary Angioedema (HAE) | COMPLETED | NCT03888755 |
| Icatibant | Other | Phase PHASE3 | Hereditary Angioedema (HAE) | COMPLETED | NCT03888755 |
| Lanadelumab | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03401671 |
| SHP465 | Other | Phase PHASE3 | Attention Deficit Hyperactivity Disorder (ADHD) | TERMINATED | NCT03325894 |
| Corticosteroid medication | Drug | Preclinical | Adrenal Insufficiency | COMPLETED | NCT03013166 |
| Mesalamine | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02125292 |
| CINRYZE 1000 | Other | Phase PHASE3 | Hereditary Angioedema (HAE) | COMPLETED | NCT02052141 |
| CINRYZE 500 | Other | Phase PHASE3 | Hereditary Angioedema (HAE) | COMPLETED | NCT02052141 |
| Icatibant (30 mg) | Other | Phase PHASE1 | Hereditary Angioedema (HAE) | COMPLETED | NCT02045264 |
| Lisdexamfetamine Dimesylate | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01890785 |
| 225mg SHP647 (PF-00547659) | Other | Phase PHASE2 | Ulcerative Colitis | COMPLETED | NCT01771809 |
| 75mg SHP647 (PF-00547659) | Other | Phase PHASE2 | Ulcerative Colitis | COMPLETED | NCT01771809 |
| CINRYZE with rHuPH20 | Other | Phase PHASE2 | Hereditary Angioedema (HAE) | COMPLETED | NCT01756157 |
| Placebo | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT01457339 |
| SPD489 (Lisdexamfetamine dimesylate) | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT01457339 |
| lumbar puncture | Other | Phase PHASE1 | Crohn's Disease | COMPLETED | NCT01387594 |
| lumbar puncture | Other | Phase PHASE1 | Crohn's Disease | COMPLETED | NCT01387594 |
| PF-00547659 | Other | Phase PHASE2 | Crohn's Disease | COMPLETED | NCT01298492 |
| PF-00547659 SC injection | Other | Phase PHASE2 | Crohn's Disease | COMPLETED | NCT01276509 |
| Placebo | Other | Phase PHASE3 | ADHD | WITHDRAWN | NCT01274221 |
| SPD489 | Other | Phase PHASE3 | ADHD | WITHDRAWN | NCT01274221 |
| Placebo | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | WITHDRAWN | NCT01234298 |
| SPD489 High-Dose | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | WITHDRAWN | NCT01234298 |
| SPD489 Low-Dose | Other | Phase PHASE3 | Negative Symptoms of Schizophrenia | WITHDRAWN | NCT01234298 |
| MRI | Other | Preclinical | Fabry Disease | COMPLETED | NCT01210196 |
| CINRYZE | Other | Phase PHASE2 | Hereditary Angioedema (HAE) | COMPLETED | NCT01095510 |
| Placebo | Other | Phase PHASE2 | Attention-Deficit/Hyperactivity Disorder | COMPLETED | NCT00928148 |
| Immediate Release Amphetamine Salt | Other | Phase PHASE2 | Attention-Deficit/Hyperactivity Disorder | COMPLETED | NCT00928148 |
| SPD465 | Other | Phase PHASE2 | Attention-Deficit/Hyperactivity Disorder | COMPLETED | NCT00928148 |
| placebo | Other | Phase PHASE3 | Short Bowel Syndrome | COMPLETED | NCT00798967 |
| teduglutide | Other | Phase PHASE3 | Short Bowel Syndrome | COMPLETED | NCT00798967 |
| NPSP558 | Other | Phase PHASE3 | Hypoparathyroidism | COMPLETED | NCT00732615 |
| Placebo | Other | Phase PHASE3 | Hypoparathyroidism | COMPLETED | NCT00732615 |
| C1 esterase inhibitor [human] (C1INH-nf) | Other | Phase PHASE1 | Hereditary Angioedema | COMPLETED | NCT00432510 |
| NPS 1776 (400 mg) | Other | Phase PHASE2 | Migraine Headache | COMPLETED | NCT00172094 |
| PLACEBO | Other | Phase PHASE2 | Migraine Headache | COMPLETED | NCT00172094 |
| NPS 1776 (800 mg) | Other | Phase PHASE2 | Migraine Headache | COMPLETED | NCT00172094 |
| Tetravalent Dengue Vaccine (TDV) | Other | Phase PHASE3 | Dengue Fever | COMPLETED | NCT03771963 |
| SHP465 | Other | Phase PHASE1 | Attention Deficit Hyperactivity Disorder (ADHD) | COMPLETED | NCT03327402 |
| SPD489 | Other | Phase PHASE3 | Attention Deficit Hyperactivity Disorder (ADHD) | COMPLETED | NCT03260205 |
| SPD489 (Lisdexamfetamine dimesylate) | Other | Phase PHASE3 | Attention Deficit Hyperactivity Disorder (ADHD) | COMPLETED | NCT03260205 |
| Placebo | Other | Phase PHASE3 | Attention Deficit Hyperactivity Disorder (ADHD) | COMPLETED | NCT03260205 |
| rhPTH(1-84) | Other | Phase PHASE1 | Hypoparathyroidism | COMPLETED | NCT03150108 |
| Placebo Comparator (n=24) | Other | Phase PHASE1 | Primary Open-angle Glaucoma (POAG) | COMPLETED | NCT03131167 |
| SHP639 (n=60) | Other | Phase PHASE1 | Primary Open-angle Glaucoma (POAG) | COMPLETED | NCT03131167 |
| DX-2930 | Other | Phase PHASE3 | Hereditary Angioedema (HAE) | COMPLETED | NCT02741596 |
| DX-2930 | Other | Phase PHASE3 | Hereditary Angioedema (HAE) | COMPLETED | NCT02741596 |
| Placebo | Other | Phase PHASE3 | Hereditary Angioedema (HAE) | COMPLETED | NCT02584959 |
| C1 esterase inhibitor [human] liquid | Other | Phase PHASE3 | Hereditary Angioedema (HAE) | COMPLETED | NCT02584959 |
| SPD489 | Other | Phase PHASE2 | Attention Deficit Hyperactivity Disorder (ADHD) | COMPLETED | NCT02402166 |
| Recombinant human heparan N-sulfatase [rhHNS] | Other | Phase PHASE2 | Sanfilippo Syndrome | COMPLETED | NCT02060526 |
| Replagal | Other | Phase PHASE3 | Fabry Disease | COMPLETED | NCT01124643 |
| ecallantide | Other | Preclinical | Hereditary Angioedema (HAE) | COMPLETED | NCT01059526 |
| Matching placebo | Other | Phase PHASE2 | Major Depressive Disorder | COMPLETED | NCT00985725 |
| SPD489 (Lisdexamfetamine dimesylate) | Other | Phase PHASE2 | Major Depressive Disorder | COMPLETED | NCT00985725 |
| HGT-1111 | Other | Phase PHASE2 | Late Infantile Metachromatic Leukodystrophy | TERMINATED | NCT00681811 |
| Idursulfase | Other | Phase PHASE4 | Hunter Syndrome | COMPLETED | NCT00607386 |
| imiglucerase | Other | Phase PHASE3 | Gaucher Disease, Type 1 | COMPLETED | NCT00553631 |
| velaglucerase alfa | Other | Phase PHASE3 | Gaucher Disease, Type 1 | COMPLETED | NCT00553631 |
| Placebo | Other | Phase PHASE3 | ADHD | COMPLETED | NCT00507065 |
| Mixed salts of a single-entity amphetamine (ADDERALL XR) | Other | Phase PHASE3 | ADHD | COMPLETED | NCT00507065 |
| Atomoxetine hydrochloride | Other | Phase PHASE4 | ADHD | COMPLETED | NCT00506727 |
| Mixed amphetamine salts (ADDERALL XR) | Other | Phase PHASE4 | ADHD | COMPLETED | NCT00506727 |
| C1 esterase inhibitor [human] (C1INH-nf) | Other | Phase PHASE3 | Hereditary Angioedema | COMPLETED | NCT00462709 |
| Phosphate Buffer Saline (PBS), pH 7.0 | Other | Phase PHASE3 | Hereditary Angioedema (HAE) | COMPLETED | NCT00457015 |
| ecallantide | Other | Phase PHASE3 | Hereditary Angioedema (HAE) | COMPLETED | NCT00457015 |
| Phosphate Buffer Saline (PBS), pH 7.0 | Other | Phase PHASE3 | Hereditary Angioedema (HAE) | COMPLETED | NCT00457015 |
| ecallantide | Other | Phase PHASE3 | Hereditary Angioedema (HAE) | COMPLETED | NCT00457015 |
| ecallantide | Other | Phase PHASE3 | Hereditary Angioedema (HAE) | COMPLETED | NCT00456508 |
| ecallantide | Other | Phase PHASE3 | Hereditary Angioedema (HAE) | COMPLETED | NCT00456508 |
| C1 esterase inhibitor [human] (C1INH-nf) | Other | Phase PHASE3 | Hereditary Angioedema | COMPLETED | NCT00438815 |
| Placebo | Other | Phase PHASE2 | Kidney Diseases | COMPLETED | NCT00234702 |
| Lanthanum carbonate | Other | Phase PHASE2 | Kidney Diseases | COMPLETED | NCT00234702 |
| Lanthanum carbonate | Other | Phase PHASE3 | Kidney Failure, Chronic | COMPLETED | NCT00151931 |
| Lanthanum carbonate | Other | Phase PHASE3 | Kidney Failure, Chronic | COMPLETED | NCT00151931 |
| Lanthanum carbonate | Other | Phase PHASE3 | Kidney Failure, Chronic | COMPLETED | NCT00150566 |
| Teduglutide | Other | Phase PHASE3 | Short Bowel Syndrome | COMPLETED | NCT02340819 |
| MMX Mesalamine/Mesalazine (High Dose) | Other | Phase PHASE3 | Ulcerative Colitis | COMPLETED | NCT02093663 |
| MMX Mesalamine/Mesalazine (Low Dose) | Other | Phase PHASE3 | Ulcerative Colitis | COMPLETED | NCT02093663 |
| teduglutide | Other | Phase PHASE3 | Short Bowel Syndrome | COMPLETED | NCT01952080 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01552928 |
| Moxifloxacin | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01552928 |
| Anagrelide 2.5 mg | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01552928 |
| Anagrelide 0.5 mg | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01552928 |
| Placebo | Other | Phase PHASE4 | Symptomatic Orthostatic Hypotension | COMPLETED | NCT01515865 |
| Midodrine HCl | Other | Phase PHASE4 | Symptomatic Orthostatic Hypotension | COMPLETED | NCT01515865 |
| Placebo | Other | Phase PHASE4 | Symptomatic Orthostatic Hypotension | COMPLETED | NCT01515865 |
| Midodrine HCl | Other | Phase PHASE4 | Symptomatic Orthostatic Hypotension | COMPLETED | NCT01515865 |
| Placebo + PPI | Other | Phase PHASE2 | Gastroesophageal Reflux Disease | COMPLETED | NCT01472939 |
| SSP-002358 (2.0 mg) + PPI | Other | Phase PHASE2 | Gastroesophageal Reflux Disease | COMPLETED | NCT01472939 |
| SSP-002358 (0.5 mg) + PPI | Other | Phase PHASE2 | Gastroesophageal Reflux Disease | COMPLETED | NCT01472939 |
| SSP-002358 (0.1 mg) + PPI | Other | Phase PHASE2 | Gastroesophageal Reflux Disease | COMPLETED | NCT01472939 |
| Placebo + PPI | Other | Phase PHASE2 | Gastroesophageal Reflux Disease | COMPLETED | NCT01472939 |
| SSP-002358 (2.0 mg) + PPI | Other | Phase PHASE2 | Gastroesophageal Reflux Disease | COMPLETED | NCT01472939 |
| SSP-002358 (0.5 mg) + PPI | Other | Phase PHASE2 | Gastroesophageal Reflux Disease | COMPLETED | NCT01472939 |
| SSP-002358 (0.1 mg) + PPI | Other | Phase PHASE2 | Gastroesophageal Reflux Disease | COMPLETED | NCT01472939 |
| SPD422 (anagrelide hydrochloride) | Other | Phase PHASE3 | Essential Thrombocythemia (ET) | COMPLETED | NCT01467661 |
| No treatment | Drug | Preclinical | Hunter Syndrome | COMPLETED | NCT01449240 |
| Amoxicillin + MMX mesalazine/mesalamine | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01442688 |
| Amoxicillin + MMX placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01442688 |
| Amoxicillin + MMX mesalazine/mesalamine | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01442688 |
| Amoxicillin + MMX placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01442688 |
| Antidepressant + Placebo | Other | Phase PHASE3 | Major Depressive Disorder | COMPLETED | NCT01436162 |
| Antidepressant + SPD489 (Lisdexamfetamine dimesylate ) | Other | Phase PHASE3 | Major Depressive Disorder | COMPLETED | NCT01436162 |
| MMX Mesalazine/mesalamine + Ciprofloxacin XR | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01402947 |
| Ciprofloxacin XR + MMX Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01402947 |
| MMX Mesalazine/mesalamine + Ciprofloxacin XR | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01402947 |
| Ciprofloxacin XR + MMX Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01402947 |
| Replagal (agalsidase alfa) | Other | Phase PHASE2 | Fabry Disease | COMPLETED | NCT01363492 |
| Anagrelide Hydrochloride | Other | Phase PHASE3 | Essential Thrombocythemia (ET) | COMPLETED | NCT01214915 |
| Anagrelide Hydrochloride | Other | Phase PHASE3 | Essential Thrombocythemia (ET) | COMPLETED | NCT01214915 |
| Methylphenidate hydrochloride | Other | Phase PHASE1 | ADHD | COMPLETED | NCT01183234 |
| SPD544 | Other | Phase PHASE1 | ADHD | COMPLETED | NCT01183234 |
| Placebo | Other | Phase PHASE2 | Chronic Kidney Disease | COMPLETED | NCT01128179 |
| Lanthanum carbonate | Other | Phase PHASE2 | Chronic Kidney Disease | COMPLETED | NCT01128179 |
| MMX mesalamine/ mesalazine | Other | Phase PHASE4 | Ulcerative Colitis | COMPLETED | NCT01124149 |
| MMX mesalamine/ mesalazine | Other | Phase PHASE4 | Ulcerative Colitis | COMPLETED | NCT01124149 |
| Placebo | Other | Phase PHASE4 | ADHD Specifically With Executive Function Impairment | COMPLETED | NCT01101022 |
| SPD489 | Other | Phase PHASE4 | ADHD Specifically With Executive Function Impairment | COMPLETED | NCT01101022 |
| Placebo | Other | Phase PHASE4 | ADHD Specifically With Executive Function Impairment | COMPLETED | NCT01101022 |
| SPD489 | Other | Phase PHASE4 | ADHD Specifically With Executive Function Impairment | COMPLETED | NCT01101022 |
| Placebo | Other | Phase PHASE4 | ADHD Specifically With Executive Function Impairment | COMPLETED | NCT01101022 |
| SPD489 | Other | Phase PHASE4 | ADHD Specifically With Executive Function Impairment | COMPLETED | NCT01101022 |
| Placebo matching SPD489 (lisdexamfetamine dimesylate) | Other | Phase PHASE2 | Schizophrenia and Predominant Negative Symptoms | COMPLETED | NCT00922272 |
| SPD489 (lisdexamfetamine dimesylate) | Other | Phase PHASE2 | Schizophrenia and Predominant Negative Symptoms | COMPLETED | NCT00922272 |
| Placebo | Other | Phase PHASE3 | ADHD | COMPLETED | NCT00784654 |
| Lisdexamfetamine dimesylate (LDX) | Other | Phase PHASE3 | ADHD | COMPLETED | NCT00784654 |
| Placebo | Other | Phase PHASE3 | ADHD | COMPLETED | NCT00784654 |
| Lisdexamfetamine dimesylate (LDX) | Other | Phase PHASE3 | ADHD | COMPLETED | NCT00784654 |
| Placebo | Other | Phase PHASE3 | ADHD | COMPLETED | NCT00697515 |
| LDX | Other | Phase PHASE3 | ADHD | COMPLETED | NCT00697515 |
| Placebo | Other | Phase PHASE3 | Angioedema | COMPLETED | NCT00097695 |
| Icatibant | Other | Phase PHASE3 | Angioedema | COMPLETED | NCT00097695 |
| Teduglutide 0.1 mg/kg/d | Other | Phase PHASE3 | Short Bowel Syndrome | COMPLETED | NCT00081458 |
| Teduglutide 0.05 mg/kg/d | Other | Phase PHASE3 | Short Bowel Syndrome | COMPLETED | NCT00081458 |
| Placebo | Other | Phase PHASE3 | Short Bowel Syndrome | COMPLETED | NCT00081458 |
| NoV GI.1/GII.4 Bivalent VLP Vaccine | Other | Phase PHASE2 | Healthy Volunteers | COMPLETED | NCT02669121 |
| NoV Placebo-matching Saline | Other | Phase PHASE2 | Healthy Volunteers | COMPLETED | NCT02669121 |
| Radiolabeled SPD557 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01786876 |
| SSP-004184 | Other | Phase PHASE1 | Impaired Renal Function | COMPLETED | NCT01716455 |
| Teduglutide | Other | Phase PHASE3 | Short Bowel Syndrome | COMPLETED | NCT01560403 |
| Placebo | Other | Phase PHASE4 | Attention-deficit/Hyperactivity Disorder | COMPLETED | NCT01552902 |
| Methylphenidate Hydrochloride | Other | Phase PHASE4 | Attention-deficit/Hyperactivity Disorder | COMPLETED | NCT01552902 |
| Lisdexamfetamine dimesylate | Other | Phase PHASE4 | Attention-deficit/Hyperactivity Disorder | COMPLETED | NCT01552902 |
| Placebo | Other | Phase PHASE2 | Generalized Anxiety Disorder (GAD) | COMPLETED | NCT01470469 |
| SPD503 (extended-release Guanfacine hydrochloride) | Other | Phase PHASE2 | Generalized Anxiety Disorder (GAD) | COMPLETED | NCT01470469 |
| SSP-002358 + omeprazole | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01415349 |
| SSP-002358 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01415349 |
| placebo | Other | Phase PHASE2 | Gastroesophageal Reflux Disease | TERMINATED | NCT01370863 |
| SPD557 | Other | Phase PHASE2 | Gastroesophageal Reflux Disease | TERMINATED | NCT01370863 |
| PEG 4000 | Other | Phase PHASE3 | Functional Constipation | COMPLETED | NCT01330381 |
| Placebo | Other | Phase PHASE3 | Functional Constipation | COMPLETED | NCT01330381 |
| prucalopride | Other | Phase PHASE3 | Functional Constipation | COMPLETED | NCT01330381 |
| PEG 4000 | Other | Phase PHASE3 | Functional Constipation | COMPLETED | NCT01330381 |
| Placebo | Other | Phase PHASE3 | Functional Constipation | COMPLETED | NCT01330381 |
| prucalopride | Other | Phase PHASE3 | Functional Constipation | COMPLETED | NCT01330381 |
| Placebo | Other | Phase PHASE2 | Binge Eating Disorder | COMPLETED | NCT01291173 |
| lisdexamfetamine dimesylate (SPD489) | Other | Phase PHASE2 | Binge Eating Disorder | COMPLETED | NCT01291173 |
| Placebo | Other | Phase PHASE2 | Clostridium Difficile Infection | COMPLETED | NCT01259726 |
| VP20621 | Other | Phase PHASE2 | Clostridium Difficile Infection | COMPLETED | NCT01259726 |
| SPD602 (FBS0701, SSP-004184) | Other | Phase PHASE2 | Transfusional Iron Overload | COMPLETED | NCT01186419 |
| Prucalopride | Other | Phase PHASE3 | Male Subjects With Chronic Constipation | COMPLETED | NCT01147926 |
| Placebo | Other | Phase PHASE3 | Male Subjects With Chronic Constipation | COMPLETED | NCT01147926 |
| Prucalopride | Other | Phase PHASE3 | Male Subjects With Chronic Constipation | COMPLETED | NCT01147926 |
| Placebo | Other | Phase PHASE3 | Male Subjects With Chronic Constipation | COMPLETED | NCT01147926 |
| VPRIV® | Other | Phase PHASE3 | Gaucher Disease, Type 1 | COMPLETED | NCT00635427 |
| Idursulfase | Other | Phase PHASE2 | Hunter Syndrome | COMPLETED | NCT00630747 |
| GA-GCB (velaglucerase alfa) | Other | Phase PHASE2 | Gaucher Disease | COMPLETED | NCT00478647 |
| GA-GCB (velaglucerase alfa) | Other | Phase PHASE2 | Gaucher Disease | COMPLETED | NCT00478647 |
| Placebo | Other | Phase PHASE3 | Attention Deficit Disorder With Hyperactivity | COMPLETED | NCT00152009 |
| SPD503 (4 mg) | Other | Phase PHASE3 | Attention Deficit Disorder With Hyperactivity | COMPLETED | NCT00152009 |
| SPD503 (3 mg) | Other | Phase PHASE3 | Attention Deficit Disorder With Hyperactivity | COMPLETED | NCT00152009 |
| SPD503 (Guanfacine hydrochloride) (2 mg) | Other | Phase PHASE3 | Attention Deficit Disorder With Hyperactivity | COMPLETED | NCT00152009 |
| Amphetamine + SPD503 | Other | Phase PHASE2 | Attention Deficit Disorder With Hyperactivity | COMPLETED | NCT00151996 |
| Methylphenidate + SPD503 (Guanfacine hydrochloride) | Other | Phase PHASE2 | Attention Deficit Disorder With Hyperactivity | COMPLETED | NCT00151996 |
| Placebo | Other | Phase PHASE3 | Attention Deficit Disorder With Hyperactivity | COMPLETED | NCT00150618 |
| SPD503 (4 mg) | Other | Phase PHASE3 | Attention Deficit Disorder With Hyperactivity | COMPLETED | NCT00150618 |
| SPD503 (3 mg) | Other | Phase PHASE3 | Attention Deficit Disorder With Hyperactivity | COMPLETED | NCT00150618 |
| SPD503 (2 mg) | Other | Phase PHASE3 | Attention Deficit Disorder With Hyperactivity | COMPLETED | NCT00150618 |
| SPD503 (1 mg) | Other | Phase PHASE3 | Attention Deficit Disorder With Hyperactivity | COMPLETED | NCT00150618 |
| Placebo | Other | Phase PHASE2 | Attention Deficit Disorder With Hyperactivity | COMPLETED | NCT00150592 |
| SPD503 (Guanfacine HCl) | Other | Phase PHASE2 | Attention Deficit Disorder With Hyperactivity | COMPLETED | NCT00150592 |
| Placebo | Other | Phase PHASE2 | Attention Deficit Disorder With Hyperactivity | COMPLETED | NCT00150592 |
| SPD503 (Guanfacine HCl) | Other | Phase PHASE2 | Attention Deficit Disorder With Hyperactivity | COMPLETED | NCT00150592 |
| Placebo | Other | Phase PHASE2 | Mucopolysaccharidosis II | COMPLETED | NCT00069641 |
| iduronate-2-sulfatase enzyme replacement therapy | Drug | Phase PHASE2 | Mucopolysaccharidosis II | COMPLETED | NCT00069641 |
| Iduronate-2-sulfatase enzyme replacement therapy | Drug | Phase PHASE2 | Mucopolysaccharidosis II | COMPLETED | NCT00069641 |
| troxacitabine | Other | Phase PHASE2 | Leukemia | COMPLETED | NCT00012259 |
| Ixazomib | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT02499081 |
| Ixazomib | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT02499081 |
| HGT-1410 | Other | Phase PHASE2 | Sanfilippo Syndrome | TERMINATED | NCT02350816 |
| prucalopride | Other | Phase PHASE4 | Constipation | COMPLETED | NCT01424228 |
| placebo | Other | Phase PHASE4 | Constipation | COMPLETED | NCT01424228 |
| Placebo | Other | Phase PHASE3 | Keratoconjunctivitis Sicca | COMPLETED | NCT01421498 |
| Lifitegrast | Other | Phase PHASE3 | Keratoconjunctivitis Sicca | COMPLETED | NCT01421498 |
| placebo match for 10 mg ecallantide arm | Other | Phase PHASE2 | ACE Inhibitor Induced Angioedema | TERMINATED | NCT01343823 |
| placebo match for 30 mg ecallantide arm | Other | Phase PHASE2 | ACE Inhibitor Induced Angioedema | TERMINATED | NCT01343823 |
| placebo | Other | Phase PHASE2 | ACE Inhibitor Induced Angioedema | TERMINATED | NCT01343823 |
| ecallantide 10 mg | Other | Phase PHASE2 | ACE Inhibitor Induced Angioedema | TERMINATED | NCT01343823 |
| ecallantide 30 mg | Other | Phase PHASE2 | ACE Inhibitor Induced Angioedema | TERMINATED | NCT01343823 |
| ecallantide 60 mg | Other | Phase PHASE2 | ACE Inhibitor Induced Angioedema | TERMINATED | NCT01343823 |
| NPSP558 | Other | Phase PHASE3 | Hypoparathyroidism | COMPLETED | NCT01268098 |
| C1 Esterase Inhibitor (Human) | Other | Phase PHASE2 | Graft Rejection | COMPLETED | NCT01147302 |
| Placebo | Other | Phase PHASE2 | Graft Rejection | COMPLETED | NCT01147302 |
| Atomoxetine Hydrochloride | Other | Phase PHASE3 | Attention-Deficit/Hyperactivity Disorder | COMPLETED | NCT01106430 |
| Lisdexamfetamine Dimesylate | Other | Phase PHASE3 | Attention-Deficit/Hyperactivity Disorder | COMPLETED | NCT01106430 |
| Atomoxetine Hydrochloride | Other | Phase PHASE3 | Attention-Deficit/Hyperactivity Disorder | COMPLETED | NCT01106430 |
| Lisdexamfetamine Dimesylate | Other | Phase PHASE3 | Attention-Deficit/Hyperactivity Disorder | COMPLETED | NCT01106430 |
| assessment | Other | Preclinical | Sanfilippo Syndrome Type A | COMPLETED | NCT01047306 |
| assessment | Other | Preclinical | Sanfilippo Syndrome Type A | COMPLETED | NCT01047306 |
| Placebo (saline) | Other | Phase PHASE3 | Hereditary Angioedema | COMPLETED | NCT01005888 |
| C1 esterase inhibitor [human] (C1INH-nf) | Other | Phase PHASE3 | Hereditary Angioedema | COMPLETED | NCT01005888 |
| Icatibant | Other | Phase PHASE3 | Hereditary Angioedema | COMPLETED | NCT00997204 |
| Icatibant | Other | Phase PHASE3 | Hereditary Angioedema | COMPLETED | NCT00997204 |
| Placebo | Other | Phase PHASE3 | Hereditary Angioedema | COMPLETED | NCT00912093 |
| Icatibant | Other | Phase PHASE3 | Hereditary Angioedema | COMPLETED | NCT00912093 |
| Placebo | Other | Phase PHASE2 | Allergic Conjunctivitis | COMPLETED | NCT00882687 |
| Lifitegrast | Other | Phase PHASE2 | Allergic Conjunctivitis | COMPLETED | NCT00882687 |
| Placebo | Other | Phase PHASE2 | Allergic Conjunctivitis | COMPLETED | NCT00882687 |
| Lifitegrast | Other | Phase PHASE2 | Allergic Conjunctivitis | COMPLETED | NCT00882687 |
| Lanthanum carbonate Chewable Tablets (Fosrenol) | Other | Phase PHASE1 | End Stage Renal Disease | COMPLETED | NCT00880750 |
| Lanthanum carbonate Granule Formulation | Other | Phase PHASE1 | End Stage Renal Disease | COMPLETED | NCT00880750 |
| placebo | Other | Phase PHASE2 | Eosinophilic Esophagitis (EoE) | COMPLETED | NCT00762073 |
| budesonide | Other | Phase PHASE2 | Eosinophilic Esophagitis (EoE) | COMPLETED | NCT00762073 |
| placebo | Other | Phase PHASE2 | Eosinophilic Esophagitis (EoE) | COMPLETED | NCT00762073 |
| budesonide | Other | Phase PHASE2 | Eosinophilic Esophagitis (EoE) | COMPLETED | NCT00762073 |
| Mesalazine | Other | Phase PHASE3 | Ulcerative Colitis | COMPLETED | NCT00548574 |
| SPD476 is a polymeric matrix formulation that displays both delayed- and extended-release of mesalazine | Other | Phase PHASE3 | Ulcerative Colitis | COMPLETED | NCT00548574 |
| SPD476 is a polymeric matrix formulation that displays both delayed- and extended-release of mesalazine | Other | Phase PHASE2 | Colitis, Ulcerative | COMPLETED | NCT00545389 |
| SPD476 is a polymeric matrix formulation that displays both delayed- and extended-release of mesalazine | Other | Phase PHASE2 | Colitis, Ulcerative | COMPLETED | NCT00545389 |
| Delayed and extended release mesalazine | Other | Phase PHASE3 | Colitis, Ulcerative | COMPLETED | NCT00503243 |
| Delayed and extended release mesalazine | Other | Phase PHASE3 | Colitis, Ulcerative | COMPLETED | NCT00503243 |
| ganciclovir | Other | Phase PHASE3 | Cytomegalovirus Infections | COMPLETED | NCT00497796 |
| maribavir | Other | Phase PHASE3 | Cytomegalovirus Infections | COMPLETED | NCT00497796 |
| Sevelamer hydrochloride | Other | Phase PHASE3 | Chronic Kidney Disease, Stage 5 | COMPLETED | NCT00441545 |
| Fosrenol (Lanthanum Carbonate) | Other | Phase PHASE3 | Chronic Kidney Disease, Stage 5 | COMPLETED | NCT00441545 |
| placebo | Other | Phase PHASE3 | Cytomegalovirus Infections | COMPLETED | NCT00411645 |
| maribavir | Other | Phase PHASE3 | Cytomegalovirus Infections | COMPLETED | NCT00411645 |
| placebo | Other | Phase PHASE3 | Cytomegalovirus Infections | COMPLETED | NCT00411645 |
| maribavir | Other | Phase PHASE3 | Cytomegalovirus Infections | COMPLETED | NCT00411645 |
| Control (compression bandaging) | Other | Phase PHASE1 | Leg Ulcer | COMPLETED | NCT00399308 |
| Celaderm (Frozen Cultured Epidermal Allograft) | Other | Phase PHASE1 | Leg Ulcer | COMPLETED | NCT00399308 |
| Placebo (saline) | Other | Phase PHASE3 | Hereditary Angioedema | COMPLETED | NCT00289211 |
| C1 esterase inhibitor [human] (C1INH-nf) | Other | Phase PHASE3 | Hereditary Angioedema | COMPLETED | NCT00289211 |
| Phosphate Buffer Saline (PBS), | Other | Phase PHASE3 | Hereditary Angioedema (HAE) | COMPLETED | NCT00262080 |
| ecallantide | Other | Phase PHASE3 | Hereditary Angioedema (HAE) | COMPLETED | NCT00262080 |
| Midodrine Hydrochloride | Other | Phase PHASE4 | Hypotension, Orthostatic | COMPLETED | NCT00046475 |
| Midodrine Hydrochloride | Other | Phase PHASE4 | Hypotension, Orthostatic | COMPLETED | NCT00046475 |
| Placebo | Other | Phase PHASE3 | Adenoviral Conjunctivitis | TERMINATED | NCT02998541 |
| PVP-I 0.6% | Other | Phase PHASE3 | Adenoviral Conjunctivitis | TERMINATED | NCT02998541 |
| SHP640 | Other | Phase PHASE3 | Adenoviral Conjunctivitis | TERMINATED | NCT02998541 |
| velaglucerase alfa | Other | Phase PHASE3 | Gaucher Disease | COMPLETED | NCT01842841 |
| Recombinant human arylsulfatase A | Other | Phase PHASE1 | Metachromatic Leukodystrophy (MLD) | COMPLETED | NCT01510028 |
| SPD489 (Lisdexamfetamine dimesylate) + Antidepressant | Other | Phase PHASE3 | Major Depressive Disorder | TERMINATED | NCT01436175 |
| SPD602 | Other | Phase PHASE2 | Transfusional Iron Overload | TERMINATED | NCT01363908 |
| rhHNS-90 mg | Other | Phase PHASE1 | Sanfilippo Syndrome | TERMINATED | NCT01299727 |
| rhHNS-45 mg | Other | Phase PHASE1 | Sanfilippo Syndrome | TERMINATED | NCT01299727 |
| rhHNS-10 mg | Other | Phase PHASE1 | Sanfilippo Syndrome | TERMINATED | NCT01299727 |
| Venlafaxine XR + LDX | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01235338 |
| LDX + Venlafaxine XR | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01235338 |
| Venlafaxine XR + LDX | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01235338 |
| LDX + Venlafaxine XR | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01235338 |
| Recombinant human heparan N-sulfatase (rhHNS) | Other | Phase PHASE1 | Mucopolysaccharidosis (MPS) | COMPLETED | NCT01155778 |
| rhIGF-I/rhIGFBP-3 | Other | Phase PHASE2 | Retinopathy of Prematurity (ROP) | COMPLETED | NCT01096784 |
| Placebo | Other | Phase PHASE2 | Sleep Deprivation | COMPLETED | NCT01096680 |
| Armodafinil | Other | Phase PHASE2 | Sleep Deprivation | COMPLETED | NCT01096680 |
| SPD489 70 mg | Other | Phase PHASE2 | Sleep Deprivation | COMPLETED | NCT01096680 |
| SPD489 50 mg | Other | Phase PHASE2 | Sleep Deprivation | COMPLETED | NCT01096680 |
| SPD489 20 mg | Other | Phase PHASE2 | Sleep Deprivation | COMPLETED | NCT01096680 |
| Placebo | Other | Phase PHASE2 | Sleep Deprivation | COMPLETED | NCT01096680 |
| Armodafinil | Other | Phase PHASE2 | Sleep Deprivation | COMPLETED | NCT01096680 |
| SPD489 70 mg | Other | Phase PHASE2 | Sleep Deprivation | COMPLETED | NCT01096680 |
| SPD489 50 mg | Other | Phase PHASE2 | Sleep Deprivation | COMPLETED | NCT01096680 |
| SPD489 20 mg | Other | Phase PHASE2 | Sleep Deprivation | COMPLETED | NCT01096680 |
| Placebo | Other | Phase PHASE3 | Attention-deficit/Hyperactivity Disorder | COMPLETED | NCT01081145 |
| Extended-release Guanfacine Hydrochloride | Other | Phase PHASE3 | Attention-deficit/Hyperactivity Disorder | COMPLETED | NCT01081145 |
| Ciprodex (Ciprofloxacin 0.3%; dexamethasone 0.1% ) | Other | Phase PHASE3 | Acute Otitis Externa | COMPLETED | NCT00961675 |
| FST201 (dexamethasone 0.1% with povidone-iodine 1%) | Other | Phase PHASE3 | Acute Otitis Externa | COMPLETED | NCT00961675 |
| Visual and auditory assessments | Other | Preclinical | Hunter Syndrome | COMPLETED | NCT00937794 |
| Neurobehavioral testing | Other | Preclinical | Hunter Syndrome | COMPLETED | NCT00937794 |
| SPD503 and VYVANSE | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00919867 |
| VYVANSE | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00919867 |
| SPD503 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00919867 |
| Antidepressant + placebo | Other | Phase PHASE2 | Major Depressive Disorder | COMPLETED | NCT00905424 |
| Antidepressant + SPD489 (lisdexamfetamine dimesylate) | Other | Phase PHASE2 | Major Depressive Disorder | COMPLETED | NCT00905424 |
| Antidepressant + placebo | Other | Phase PHASE2 | Major Depressive Disorder | COMPLETED | NCT00905424 |
| Antidepressant + SPD489 (lisdexamfetamine dimesylate) | Other | Phase PHASE2 | Major Depressive Disorder | COMPLETED | NCT00905424 |
| SPD503 + Concerta | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00901576 |
| Concerta | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00901576 |
| SPD503 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00901576 |
| SPD503 + Concerta | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00901576 |
| Concerta | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00901576 |
| SPD503 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00901576 |
| Lisdexamfetamine Dimesylate (LDX) | Other | Phase PHASE3 | ADHD | COMPLETED | NCT00764868 |
| Placebo | Other | Phase PHASE3 | ADHD | COMPLETED | NCT00763971 |
| Methylphenidate Hydrochloride | Other | Phase PHASE3 | ADHD | COMPLETED | NCT00763971 |
| Lisdexamfetamine Dimesylate (LDX) | Other | Phase PHASE3 | ADHD | COMPLETED | NCT00763971 |
| Adderall XR (mixed salts amphetamine) | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT00746733 |
| Lisdexamfetamine Dimesylate | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT00746733 |
| Adderall XR (mixed salts amphetamine) | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT00746733 |
| Lisdexamfetamine Dimesylate | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT00746733 |
| Placebo | Other | Phase PHASE3 | Attention Deficit Hyperactivity Disorder (ADHD) | COMPLETED | NCT00735371 |
| LDX 70 mg | Other | Phase PHASE3 | Attention Deficit Hyperactivity Disorder (ADHD) | COMPLETED | NCT00735371 |
| LDX 50 mg | Other | Phase PHASE3 | Attention Deficit Hyperactivity Disorder (ADHD) | COMPLETED | NCT00735371 |
| LDX 30 mg | Other | Phase PHASE3 | Attention Deficit Hyperactivity Disorder (ADHD) | COMPLETED | NCT00735371 |
| Placebo | Other | Phase PHASE3 | ADHD | COMPLETED | NCT00734578 |
| SPD503-PM | Other | Phase PHASE3 | ADHD | COMPLETED | NCT00734578 |
| SPD503-AM | Other | Phase PHASE3 | ADHD | COMPLETED | NCT00734578 |
| Placebo | Other | Phase PHASE3 | ADHD | COMPLETED | NCT00734578 |
| SPD503-PM | Other | Phase PHASE3 | ADHD | COMPLETED | NCT00734578 |
| SPD503-AM | Other | Phase PHASE3 | ADHD | COMPLETED | NCT00734578 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT00672984 |
| moxifloxacin | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT00672984 |
| immediate release guanfacine hydrochloride | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT00672984 |
| Recombinant human Arylsulfatase A (rhASA) | Other | Phase PHASE1 | Late Infantile Metachromatic Leukodystrophy | COMPLETED | NCT00633139 |
| Recombinant human Arylsulfatase A (rhASA) | Other | Phase PHASE1 | Late Infantile Metachromatic Leukodystrophy | COMPLETED | NCT00633139 |
| Placebo | Other | Phase PHASE4 | Hypotension, Orthostatic | COMPLETED | NCT00555880 |
| Midodrine hydrochloride | Other | Phase PHASE4 | Hypotension, Orthostatic | COMPLETED | NCT00555880 |
| Placebo | Other | Phase PHASE3 | ADHD | COMPLETED | NCT00500149 |
| Vyvanse (lisdexamfetamine dimesylate) | Other | Phase PHASE3 | ADHD | COMPLETED | NCT00500149 |
| Placebo | Other | Phase PHASE3 | ADHD | COMPLETED | NCT00500149 |
| Vyvanse (lisdexamfetamine dimesylate) | Other | Phase PHASE3 | ADHD | COMPLETED | NCT00500149 |
| Dynepo | Other | Phase PHASE3 | Anemia | TERMINATED | NCT00450333 |
| Dynepo (Epoetin delta) | Other | Phase PHASE3 | Anemia | TERMINATED | NCT00450333 |
| MMX Mesalamine | Other | Phase PHASE4 | Ulcerative Colitis | COMPLETED | NCT00446849 |
| Omeprazole | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03866434 |
| SPD422 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03866434 |
| Esomeprazole | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03849690 |
| TAK-906 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03849690 |
| Esomeprazole | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03849690 |
| TAK-906 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03849690 |
| R2: Lenalidomide + ixazomib maintenance | Other | Phase PHASE3 | Multiple Myeloma | UNKNOWN | NCT03720041 |
| R2: Lenalidomide plus placebo maintenance | Other | Phase PHASE3 | Multiple Myeloma | UNKNOWN | NCT03720041 |
| R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - adaptive arm | Drug | Phase PHASE3 | Multiple Myeloma | UNKNOWN | NCT03720041 |
| R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - reactive arm | Drug | Phase PHASE3 | Multiple Myeloma | UNKNOWN | NCT03720041 |
| R2: Lenalidomide + ixazomib maintenance | Other | Phase PHASE3 | Multiple Myeloma | UNKNOWN | NCT03720041 |
| R2: Lenalidomide plus placebo maintenance | Other | Phase PHASE3 | Multiple Myeloma | UNKNOWN | NCT03720041 |
| R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - adaptive arm | Drug | Phase PHASE3 | Multiple Myeloma | UNKNOWN | NCT03720041 |
| R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - reactive arm | Drug | Phase PHASE3 | Multiple Myeloma | UNKNOWN | NCT03720041 |
| R2: Lenalidomide + ixazomib maintenance | Other | Phase PHASE3 | Multiple Myeloma | UNKNOWN | NCT03720041 |
| R2: Lenalidomide plus placebo maintenance | Other | Phase PHASE3 | Multiple Myeloma | UNKNOWN | NCT03720041 |
| R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - adaptive arm | Drug | Phase PHASE3 | Multiple Myeloma | UNKNOWN | NCT03720041 |
| R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - reactive arm | Drug | Phase PHASE3 | Multiple Myeloma | UNKNOWN | NCT03720041 |
| Sevelamer carbonate + Calcitriol | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00925704 |
| Lanthanum carbonate + Calcitriol | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00925704 |
| Calcitriol | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00925704 |
| Sevelamer | Other | Phase PHASE1 | Kidney Failure, Chronic | COMPLETED | NCT00875017 |
| Lanthanum Carbonate | Other | Phase PHASE1 | Kidney Failure, Chronic | COMPLETED | NCT00875017 |
| Sevelamer | Other | Phase PHASE1 | Kidney Failure, Chronic | COMPLETED | NCT00875017 |
| Lanthanum Carbonate | Other | Phase PHASE1 | Kidney Failure, Chronic | COMPLETED | NCT00875017 |
| Extended-release Guanfacine HCl (Intuniv, SPD503) | Other | Phase PHASE3 | Attention Deficit Hyperactivity Disorder (ADHD) | COMPLETED | NCT01500694 |
| Bismuth-Containing Quadruple Therapy | Drug | Phase PHASE3 | Gastric Ulcer | COMPLETED | NCT03050307 |
| Lansoprazole Placebo | Other | Phase PHASE3 | Gastric Ulcer | COMPLETED | NCT03050307 |
| TAK-438 Placebo | Other | Phase PHASE3 | Gastric Ulcer | COMPLETED | NCT03050307 |
| Lansoprazole | Other | Phase PHASE3 | Gastric Ulcer | COMPLETED | NCT03050307 |
| TAK-438 | Other | Phase PHASE3 | Gastric Ulcer | COMPLETED | NCT03050307 |
| MRI | Other | Preclinical | Gaucher Disease, Type 1 | COMPLETED | NCT03333447 |
| MRI | Other | Preclinical | Gaucher Disease, Type 1 | COMPLETED | NCT03333447 |
| MRI | Other | Preclinical | Gaucher Disease, Type 1 | COMPLETED | NCT03333447 |
| SPD489 | Other | Phase PHASE3 | Schizophrenia | TERMINATED | NCT01760993 |
| Placebo | Other | Phase PHASE3 | Schizophrenia | TERMINATED | NCT01760889 |
| SPD489 high dose range (120mg, 140mg and 160mg) | Other | Phase PHASE3 | Schizophrenia | TERMINATED | NCT01760889 |
| SPD489 low dose range (40mg, 80mg, and 100mg) | Other | Phase PHASE3 | Schizophrenia | TERMINATED | NCT01760889 |
| Placebo | Other | Phase PHASE4 | Attention-Deficit/Hyperactivity Disorder | COMPLETED | NCT00877487 |
| SPD489 (Lisdexamfetamine dimesylate) | Other | Phase PHASE4 | Attention-Deficit/Hyperactivity Disorder | COMPLETED | NCT00877487 |
| GA-GCB | Other | Phase PHASE1 | Gaucher Disease | COMPLETED | NCT00391625 |
| Lanthanum carbonate | Other | Phase PHASE3 | Kidney Failure, Chronic | COMPLETED | NCT00150540 |
| Lanthanum carbonate | Other | Phase PHASE3 | Kidney Failure, Chronic | COMPLETED | NCT00150540 |
| SSP-004184SS | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01989169 |
| Midazolam | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01989169 |
| SSP-004184SS | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01905553 |
| SSP-004184SS | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01905553 |
| Radiolabeled SPD602 (FBS0701, SSP-004184) | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01824446 |
| FST-100 Vehicle | Other | Phase PHASE2 | Acute Viral Conjunctivitis | COMPLETED | NCT01461954 |
| FST-100 | Other | Phase PHASE2 | Acute Viral Conjunctivitis | COMPLETED | NCT01461954 |
| Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d,I-amphetamine aspartate monohydrate | Other | Phase PHASE2 | Attention Deficit Disorder With Hyperactivity | COMPLETED | NCT00202605 |
| Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d,I-amphetamine aspartate monohydrate | Other | Phase PHASE2 | Attention Deficit Disorder With Hyperactivity | COMPLETED | NCT00202605 |
| FST-100 Vehicle | Other | Phase PHASE2 | Acute Adenoviral Conjunctivitis | COMPLETED | NCT01470664 |
| FST-100 (Component #1) | Other | Phase PHASE2 | Acute Adenoviral Conjunctivitis | COMPLETED | NCT01470664 |
| FST-100 | Other | Phase PHASE2 | Acute Adenoviral Conjunctivitis | COMPLETED | NCT01470664 |
| DYNEPO (epoetin delta) | Other | Preclinical | Anemia | TERMINATED | NCT00664066 |
| velaglucerase alfa | Other | Phase PHASE3 | Gaucher Disease | COMPLETED | NCT01614574 |
| Lanthanum carbonate | Other | Preclinical | End Stage Renal Disease | COMPLETED | NCT01130831 |
| PVS-10200 | Other | Phase PHASE1 | Peripheral Artery Disease | COMPLETED | NCT01099215 |
| Placebo | Other | Phase PHASE3 | Attention-Deficit/Hyperactivity Disorder | COMPLETED | NCT01081132 |
| Extended-release Guanfacine Hydrochloride | Other | Phase PHASE3 | Attention-Deficit/Hyperactivity Disorder | COMPLETED | NCT01081132 |
| Placebo | Other | Phase PHASE3 | Attention-Deficit/Hyperactivity Disorder | COMPLETED | NCT01081132 |
| Extended-release Guanfacine Hydrochloride | Other | Phase PHASE3 | Attention-Deficit/Hyperactivity Disorder | COMPLETED | NCT01081132 |
| Idursulfase IT (30 mg) | Other | Phase PHASE1 | Hunter Syndrome | COMPLETED | NCT00920647 |
| Idursulfase IT (10 mg) | Other | Phase PHASE1 | Hunter Syndrome | COMPLETED | NCT00920647 |
| Idursulfase IT (1 mg) | Other | Phase PHASE1 | Hunter Syndrome | COMPLETED | NCT00920647 |
| Control | Other | Phase PHASE1 | Hunter Syndrome | COMPLETED | NCT00920647 |
| [14C]TAK-994 Oral Suspension | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04833049 |
| [14C]TAK-994 Intravenous Infusion | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04833049 |
| TAK-994 Oral Tablet | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04833049 |
| [14C]TAK-994 Oral Suspension | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04833049 |
| [14C]TAK-994 Intravenous Infusion | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04833049 |
| TAK-994 Oral Tablet | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04833049 |
| SPD602 | Other | Phase PHASE2 | Iron Overload Due to Repeated Red Blood Cell Transfusions | TERMINATED | NCT01604941 |
| VPRIV ®, | Other | Phase PHASE3 | Gaucher Disease, Type 1 | COMPLETED | NCT00430625 |
| anagrelide hydrochloride | Other | Phase PHASE2 | Essential Thrombocythaemia | COMPLETED | NCT00413634 |
| midodrine hydrochloride (ProAmatine®) | Other | Phase PHASE4 | Hypotension, Orthostatic | TERMINATED | NCT00046163 |
| Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate | Other | Phase PHASE3 | Attention Deficit Disorder With Hyperactivity | COMPLETED | NCT00150579 |
| Placebo Comparator | Other | Phase PHASE3 | Attention Deficit Hyperactivity Disorder | COMPLETED | NCT01244490 |
| Atomoxetine Hydrochloride | Other | Phase PHASE3 | Attention Deficit Hyperactivity Disorder | COMPLETED | NCT01244490 |
| Extended-release Guanfacine Hydrochloride | Other | Phase PHASE3 | Attention Deficit Hyperactivity Disorder | COMPLETED | NCT01244490 |
| Lanthanum carbonate | Other | Phase PHASE4 | Kidney Failure, Chronic | COMPLETED | NCT00160121 |
| Placebo | Other | Phase PHASE3 | Attention Deficit Hyperactivity Disorder | WITHDRAWN | NCT00458445 |
| SPD465 | Other | Phase PHASE3 | Attention Deficit Hyperactivity Disorder | WITHDRAWN | NCT00458445 |
| Lanthanum carbonate | Other | Phase PHASE3 | Kidney Failure, Chronic | COMPLETED | NCT00151918 |
| CINRYZE | Other | Phase PHASE2 | Hereditary Angioedema | COMPLETED | NCT01095497 |
| Lanthanum carbonate | Other | Preclinical | Hyperphosphatemia | COMPLETED | NCT00557323 |
| Lanthanum carbonate | Other | Preclinical | Hyperphosphatemia | COMPLETED | NCT00557323 |
| Dynepo | Other | Phase PHASE4 | Anemia | TERMINATED | NCT00514813 |
| Dynepo | Other | Phase PHASE4 | Anemia | TERMINATED | NCT00514813 |
| Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulphate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate. | Other | Phase PHASE3 | Attention Deficit Disorder With Hyperactivity | COMPLETED | NCT00152022 |
| Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulphate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate. | Other | Phase PHASE3 | Attention Deficit Disorder With Hyperactivity | COMPLETED | NCT00152022 |
| Placebo | Other | Phase PHASE2 | Complex Regional Pain Syndrome | COMPLETED | NCT03990649 |
| Soticlestat | Other | Phase PHASE2 | Complex Regional Pain Syndrome | COMPLETED | NCT03990649 |
| Placebo | Other | Phase PHASE3 | Binge Eating Disorder | COMPLETED | NCT01718509 |
| SPD489 (Lisdexamfetamine dimesylate) | Other | Phase PHASE3 | Binge Eating Disorder | COMPLETED | NCT01718509 |
| SSP-004184SS | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01905540 |
| SSP-004184AQ | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01905540 |
| SSP-004184 | Other | Phase PHASE1 | Hepatic Impairment | COMPLETED | NCT01732263 |
| agalsidase alfa | Other | Phase PHASE2 | Fabry Disease | COMPLETED | NCT01304277 |
| Lanthanum Carbonate | Other | Phase PHASE4 | Chronic Kidney Disease | COMPLETED | NCT03451019 |
| Sevelamer Hydrochloride | Other | Phase PHASE4 | Chronic Kidney Disease | COMPLETED | NCT03451019 |
| Lanthanum Carbonate | Other | Phase PHASE4 | Chronic Kidney Disease | COMPLETED | NCT03451019 |
| Sevelamer Hydrochloride | Other | Phase PHASE4 | Chronic Kidney Disease | COMPLETED | NCT03451019 |
| rhPTH(1-84) | Other | Phase PHASE4 | Chronic Hypoparathyroidism | COMPLETED | NCT02910466 |
| rhPTH(1-84) | Other | Phase PHASE4 | Chronic Hypoparathyroidism | COMPLETED | NCT02910466 |
| Agalsidase alfa | Other | Phase PHASE2 | Fabry Disease | COMPLETED | NCT00084084 |
| NPSP795 | Other | Phase PHASE2 | Autosomal Dominant Hypocalcemia (ADH) | COMPLETED | NCT02204579 |
| Placebo | Other | Phase PHASE2 | Dry Eye | COMPLETED | NCT00926185 |
| Lifitegrast | Other | Phase PHASE2 | Dry Eye | COMPLETED | NCT00926185 |
| Lisdexamfetamine | Other | Preclinical | Attention Deficit Disorder | UNKNOWN | NCT04727476 |
| Lisdexamfetamine | Other | Preclinical | Attention Deficit Disorder | UNKNOWN | NCT04727476 |
| Lisdexamfetamine | Other | Preclinical | Attention Deficit Disorder | UNKNOWN | NCT04727476 |
| extended-release guanfacine (Intuniv) | Other | Phase PHASE4 | Tourette Disorder | COMPLETED | NCT01547000 |
| placebo | Other | Phase PHASE4 | Tourette Disorder | COMPLETED | NCT01547000 |
| Sitagliptin 100mg | Other | Phase PHASE3 | Uncontrolled Type 2 Diabetes Mellitus | COMPLETED | NCT04801199 |
| CPL-2009-0031 140 mg | Other | Phase PHASE3 | Uncontrolled Type 2 Diabetes Mellitus | COMPLETED | NCT04801199 |
| Sitagliptin 100mg | Other | Phase PHASE3 | Uncontrolled Type 2 Diabetes Mellitus | COMPLETED | NCT04801199 |
| CPL-2009-0031 140 mg | Other | Phase PHASE3 | Uncontrolled Type 2 Diabetes Mellitus | COMPLETED | NCT04801199 |
| Sitagliptin 100mg | Other | Phase PHASE3 | Uncontrolled Type 2 Diabetes Mellitus | COMPLETED | NCT04801199 |
| CPL-2009-0031 140 mg | Other | Phase PHASE3 | Uncontrolled Type 2 Diabetes Mellitus | COMPLETED | NCT04801199 |
| zoledronic acid | Other | Phase PHASE3 | Solitary Osseous Plasmacytoma | UNKNOWN | NCT02516423 |
| dexamethasone | Other | Phase PHASE3 | Solitary Osseous Plasmacytoma | UNKNOWN | NCT02516423 |
| lenalidomide | Other | Phase PHASE3 | Solitary Osseous Plasmacytoma | UNKNOWN | NCT02516423 |
| ixazomib | Other | Phase PHASE3 | Solitary Osseous Plasmacytoma | UNKNOWN | NCT02516423 |
| zoledronic acid | Other | Phase PHASE3 | Solitary Osseous Plasmacytoma | UNKNOWN | NCT02516423 |
| dexamethasone | Other | Phase PHASE3 | Solitary Osseous Plasmacytoma | UNKNOWN | NCT02516423 |
| lenalidomide | Other | Phase PHASE3 | Solitary Osseous Plasmacytoma | UNKNOWN | NCT02516423 |
| ixazomib | Other | Phase PHASE3 | Solitary Osseous Plasmacytoma | UNKNOWN | NCT02516423 |
| zoledronic acid | Other | Phase PHASE3 | Solitary Osseous Plasmacytoma | UNKNOWN | NCT02516423 |
| dexamethasone | Other | Phase PHASE3 | Solitary Osseous Plasmacytoma | UNKNOWN | NCT02516423 |
| lenalidomide | Other | Phase PHASE3 | Solitary Osseous Plasmacytoma | UNKNOWN | NCT02516423 |
| ixazomib | Other | Phase PHASE3 | Solitary Osseous Plasmacytoma | UNKNOWN | NCT02516423 |
| Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate. | Other | Phase PHASE3 | Attention Deficit Disorder With Hyperactivity | COMPLETED | NCT00152035 |
| MLN9708 | Other | Phase PHASE2 | Acute Leukemia | COMPLETED | NCT02169791 |
| MLN9708 | Other | Phase PHASE2 | Acute Leukemia | COMPLETED | NCT02169791 |
| TAK-788 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04441255 |
| TAK-788 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04441255 |
| Testosterone Implant | Other | Preclinical | Breast Cancer | COMPLETED | NCT03768258 |
| Testosterone Implant | Other | Preclinical | Breast Cancer | COMPLETED | NCT03768258 |
| Placebo | Other | Phase PHASE2 | Traumatic Brain Injury | UNKNOWN | NCT04489160 |
| C1 Inhibitor, Human | Other | Phase PHASE2 | Traumatic Brain Injury | UNKNOWN | NCT04489160 |
| Placebo | Other | Phase PHASE2 | Traumatic Brain Injury | UNKNOWN | NCT04489160 |
| C1 Inhibitor, Human | Other | Phase PHASE2 | Traumatic Brain Injury | UNKNOWN | NCT04489160 |
| MHOS/SHP615 | Other | Phase PHASE3 | Nervous System Diseases | COMPLETED | NCT03336450 |
| SHP615 | Other | Phase PHASE3 | Nervous System Diseases | COMPLETED | NCT03336450 |
| MHOS/SHP615 | Other | Phase PHASE3 | Nervous System Diseases | COMPLETED | NCT03336450 |
| SHP615 | Other | Phase PHASE3 | Nervous System Diseases | COMPLETED | NCT03336450 |
| Provider type: Midlevel Providers | Other | Approved | Induced Abortion | COMPLETED | NCT04181541 |
| Provider type: Physicians | Other | Approved | Induced Abortion | COMPLETED | NCT04181541 |
| Cabozantinib | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma | COMPLETED | NCT03339219 |
| TAK-931 | Other | Phase PHASE2 | Metastatic Pancreatic Cancer | COMPLETED | NCT03261947 |
| TAK-931 | Other | Phase PHASE2 | Metastatic Pancreatic Cancer | COMPLETED | NCT03261947 |
| Tamoxifen | Other | Phase PHASE2 | Estrogen Receptor Positive Breast Cancer | COMPLETED | NCT02988986 |
| TAK-228 | Other | Phase PHASE2 | Estrogen Receptor Positive Breast Cancer | COMPLETED | NCT02988986 |
| Tamoxifen | Other | Phase PHASE2 | Estrogen Receptor Positive Breast Cancer | COMPLETED | NCT02988986 |
| TAK-228 | Other | Phase PHASE2 | Estrogen Receptor Positive Breast Cancer | COMPLETED | NCT02988986 |
| Cedazuridine | Other | Phase PHASE2 | Myelodysplastic Syndromes (MDS) | WITHDRAWN | NCT04985656 |
| Decitabine | Other | Phase PHASE2 | Myelodysplastic Syndromes (MDS) | WITHDRAWN | NCT04985656 |
| Pevonedistat | Other | Phase PHASE2 | Myelodysplastic Syndromes (MDS) | WITHDRAWN | NCT04985656 |
| Cedazuridine | Other | Phase PHASE2 | Myelodysplastic Syndromes (MDS) | WITHDRAWN | NCT04985656 |
| Decitabine | Other | Phase PHASE2 | Myelodysplastic Syndromes (MDS) | WITHDRAWN | NCT04985656 |
| Pevonedistat | Other | Phase PHASE2 | Myelodysplastic Syndromes (MDS) | WITHDRAWN | NCT04985656 |
| [14C]TAK-935 Oral Solution | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04992442 |
| [14C]TAK-935 IV Infusion | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04992442 |
| TAK-935 Oral Tablet | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04992442 |
| vortioxetine | Other | Phase PHASE4 | Major Depressive Disorder | COMPLETED | NCT02749721 |
| vortioxetine | Other | Phase PHASE4 | Major Depressive Disorder | COMPLETED | NCT02749721 |
| vortioxetine | Other | Phase PHASE4 | Major Depressive Disorder | COMPLETED | NCT02749721 |
| Standard of Care | Other | Phase PHASE2 | Postoperative Fistula | COMPLETED | NCT02889393 |
| Teduglutide | Other | Phase PHASE2 | Postoperative Fistula | COMPLETED | NCT02889393 |
| Standard of Care | Other | Phase PHASE2 | Postoperative Fistula | COMPLETED | NCT02889393 |
| Teduglutide | Other | Phase PHASE2 | Postoperative Fistula | COMPLETED | NCT02889393 |
| Ponatinib | Other | Phase PHASE2 | Medullary Thyroid Cancer | WITHDRAWN | NCT03838692 |
| Cidofovir | Other | Phase PHASE3 | Cytomegalovirus (CMV) | COMPLETED | NCT02931539 |
| Foscarnet | Other | Phase PHASE3 | Cytomegalovirus (CMV) | COMPLETED | NCT02931539 |
| Valganciclovir | Other | Phase PHASE3 | Cytomegalovirus (CMV) | COMPLETED | NCT02931539 |
| Ganciclovir | Other | Phase PHASE3 | Cytomegalovirus (CMV) | COMPLETED | NCT02931539 |
| Maribavir | Other | Phase PHASE3 | Cytomegalovirus (CMV) | COMPLETED | NCT02931539 |
| Niraparib | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT03497429 |
| Niraparib | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT03497429 |
| Placebo | Other | Phase PHASE2 | Attention Deficit Disorder | COMPLETED | NCT02635035 |
| Lisdexamfetamine | Other | Phase PHASE2 | Attention Deficit Disorder | COMPLETED | NCT02635035 |
| MLN1117 | Other | Phase PHASE2 | Clear-cell Metastatic Renal Cell Carcinoma | COMPLETED | NCT02724020 |
| MLN0128 | Other | Phase PHASE2 | Clear-cell Metastatic Renal Cell Carcinoma | COMPLETED | NCT02724020 |
| Everolimus | Other | Phase PHASE2 | Clear-cell Metastatic Renal Cell Carcinoma | COMPLETED | NCT02724020 |
| MLN1117 | Other | Phase PHASE2 | Clear-cell Metastatic Renal Cell Carcinoma | COMPLETED | NCT02724020 |
| MLN0128 | Other | Phase PHASE2 | Clear-cell Metastatic Renal Cell Carcinoma | COMPLETED | NCT02724020 |
| Everolimus | Other | Phase PHASE2 | Clear-cell Metastatic Renal Cell Carcinoma | COMPLETED | NCT02724020 |
| MLN1117 | Other | Phase PHASE2 | Endometrial Neoplasms | COMPLETED | NCT02725268 |
| Sapanisertib | Other | Phase PHASE2 | Endometrial Neoplasms | COMPLETED | NCT02725268 |
| Paclitaxel | Other | Phase PHASE2 | Endometrial Neoplasms | COMPLETED | NCT02725268 |
| MLN1117 | Other | Phase PHASE2 | Endometrial Neoplasms | COMPLETED | NCT02725268 |
| Sapanisertib | Other | Phase PHASE2 | Endometrial Neoplasms | COMPLETED | NCT02725268 |
| Paclitaxel | Other | Phase PHASE2 | Endometrial Neoplasms | COMPLETED | NCT02725268 |
| TAK-988 Placebo | Other | Phase PHASE1 | Healthy Volunteers | WITHDRAWN | NCT04082481 |
| TAK-988 | Other | Phase PHASE1 | Healthy Volunteers | WITHDRAWN | NCT04082481 |
| cyclophosphamide | Other | Phase PHASE3 | Anaplastic Large-Cell Lymphoma | COMPLETED | NCT01777152 |
| vincristine | Other | Phase PHASE3 | Anaplastic Large-Cell Lymphoma | COMPLETED | NCT01777152 |
| prednisone | Other | Phase PHASE3 | Anaplastic Large-Cell Lymphoma | COMPLETED | NCT01777152 |
| doxorubicin | Other | Phase PHASE3 | Anaplastic Large-Cell Lymphoma | COMPLETED | NCT01777152 |
| brentuximab vedotin | Other | Phase PHASE3 | Anaplastic Large-Cell Lymphoma | COMPLETED | NCT01777152 |
| cyclophosphamide | Other | Phase PHASE3 | Anaplastic Large-Cell Lymphoma | COMPLETED | NCT01777152 |
| vincristine | Other | Phase PHASE3 | Anaplastic Large-Cell Lymphoma | COMPLETED | NCT01777152 |
| prednisone | Other | Phase PHASE3 | Anaplastic Large-Cell Lymphoma | COMPLETED | NCT01777152 |
| doxorubicin | Other | Phase PHASE3 | Anaplastic Large-Cell Lymphoma | COMPLETED | NCT01777152 |
| brentuximab vedotin | Other | Phase PHASE3 | Anaplastic Large-Cell Lymphoma | COMPLETED | NCT01777152 |
| pupil size measurements (by using eye tracking) | Other | Phase PHASE3 | Attention Deficit Hyperactivity Disorder | WITHDRAWN | NCT01913912 |
| EEG | Other | Phase PHASE3 | Attention Deficit Hyperactivity Disorder | WITHDRAWN | NCT01913912 |
| computer task (Go/No-Go task) | Other | Phase PHASE3 | Attention Deficit Hyperactivity Disorder | WITHDRAWN | NCT01913912 |
| sugar pill | Other | Phase PHASE3 | Attention Deficit Hyperactivity Disorder | WITHDRAWN | NCT01913912 |
| LDX. | Other | Phase PHASE3 | Attention Deficit Hyperactivity Disorder | WITHDRAWN | NCT01913912 |
| Ifosfamide | Other | Phase PHASE1 | Hodgkin Disease | COMPLETED | NCT02686346 |
| Carboplatine | Other | Phase PHASE1 | Hodgkin Disease | COMPLETED | NCT02686346 |
| Etoposide | Other | Phase PHASE1 | Hodgkin Disease | COMPLETED | NCT02686346 |
| Brentuximab Vedotin | Other | Phase PHASE1 | Hodgkin Disease | COMPLETED | NCT02686346 |
| Ifosfamide | Other | Phase PHASE1 | Hodgkin Disease | COMPLETED | NCT02686346 |
| Carboplatine | Other | Phase PHASE1 | Hodgkin Disease | COMPLETED | NCT02686346 |
| Etoposide | Other | Phase PHASE1 | Hodgkin Disease | COMPLETED | NCT02686346 |
| Brentuximab Vedotin | Other | Phase PHASE1 | Hodgkin Disease | COMPLETED | NCT02686346 |
| Cytarabine | Other | Phase PHASE1 | Acute Myelogenous Leukemia | COMPLETED | NCT03459859 |
| Pevonedistat | Other | Phase PHASE1 | Acute Myelogenous Leukemia | COMPLETED | NCT03459859 |
| Skin biopsy | Other | Phase PHASE1 | Myelofibroses | TERMINATED | NCT03386214 |
| Peripheral blood draw | Other | Phase PHASE1 | Myelofibroses | TERMINATED | NCT03386214 |
| Ruxolitinib | Other | Phase PHASE1 | Myelofibroses | TERMINATED | NCT03386214 |
| Pevonedistat | Other | Phase PHASE1 | Myelofibroses | TERMINATED | NCT03386214 |
| Skin biopsy | Other | Phase PHASE1 | Myelofibroses | TERMINATED | NCT03386214 |
| Peripheral blood draw | Other | Phase PHASE1 | Myelofibroses | TERMINATED | NCT03386214 |
| Ruxolitinib | Other | Phase PHASE1 | Myelofibroses | TERMINATED | NCT03386214 |
| Pevonedistat | Other | Phase PHASE1 | Myelofibroses | TERMINATED | NCT03386214 |
| Ixazomib 4 MG | Other | Phase PHASE1 | Human Immunodeficiency Virus (HIV) | COMPLETED | NCT02946047 |
| Ixazomib 3 MG | Other | Phase PHASE1 | Human Immunodeficiency Virus (HIV) | COMPLETED | NCT02946047 |
| Ixazomib 2 MG | Other | Phase PHASE1 | Human Immunodeficiency Virus (HIV) | COMPLETED | NCT02946047 |
| Ixazomib 1 MG | Other | Phase PHASE1 | Human Immunodeficiency Virus (HIV) | COMPLETED | NCT02946047 |
| Ixazomib 4 MG | Other | Phase PHASE1 | Human Immunodeficiency Virus (HIV) | COMPLETED | NCT02946047 |
| Ixazomib 3 MG | Other | Phase PHASE1 | Human Immunodeficiency Virus (HIV) | COMPLETED | NCT02946047 |
| Ixazomib 2 MG | Other | Phase PHASE1 | Human Immunodeficiency Virus (HIV) | COMPLETED | NCT02946047 |
| Ixazomib 1 MG | Other | Phase PHASE1 | Human Immunodeficiency Virus (HIV) | COMPLETED | NCT02946047 |
| non-interventional retrospective epidemiological observational study | Other | Preclinical | Secondary Immunodeficiencies (SID) | COMPLETED | NCT04172467 |
| non-interventional retrospective epidemiological observational study | Other | Preclinical | Secondary Immunodeficiencies (SID) | COMPLETED | NCT04172467 |
| non-interventional retrospective epidemiological observational study | Other | Preclinical | Secondary Immunodeficiencies (SID) | COMPLETED | NCT04172467 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT04461483 |
| TAK-935 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT04461483 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT04461483 |
| TAK-935 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT04461483 |
| SMS Intervention | Other | Approved | Attention Deficit/Hyperactivity Disorder | UNKNOWN | NCT04189536 |
| Niraparib | Other | Phase PHASE4 | Epithelial Ovarian Cancer | NOT_YET_RECRUITING | NCT05187208 |
| Niraparib | Other | Phase PHASE4 | Epithelial Ovarian Cancer | UNKNOWN | NCT05187208 |
| placebo | Other | Phase PHASE4 | Inflammation | COMPLETED | NCT01161394 |
| pioglitazone 30mg | Other | Phase PHASE4 | Inflammation | COMPLETED | NCT01161394 |
| Pioglitazone 15mg | Other | Phase PHASE4 | Inflammation | COMPLETED | NCT01161394 |
| placebo | Other | Phase PHASE4 | Inflammation | COMPLETED | NCT01161394 |
| pioglitazone 30mg | Other | Phase PHASE4 | Inflammation | COMPLETED | NCT01161394 |
| Pioglitazone 15mg | Other | Phase PHASE4 | Inflammation | COMPLETED | NCT01161394 |
| Vitamin D | Other | Phase PHASE4 | Gaucher Disease | COMPLETED | NCT02574286 |
| Velaglucerase alfa | Other | Phase PHASE4 | Gaucher Disease | COMPLETED | NCT02574286 |
| Vitamin D | Other | Phase PHASE4 | Gaucher Disease | COMPLETED | NCT02574286 |
| Velaglucerase alfa | Other | Phase PHASE4 | Gaucher Disease | COMPLETED | NCT02574286 |
| Teduglutide | Other | Phase PHASE3 | Short Bowel Syndrome | COMPLETED | NCT02980666 |
| PIZV | Other | Phase PHASE1 | Virus, Zika | COMPLETED | NCT03343626 |
| Placebo | Other | Phase PHASE1 | Virus, Zika | COMPLETED | NCT03343626 |
| PIZV | Other | Phase PHASE1 | Virus, Zika | COMPLETED | NCT03343626 |
| Placebo | Other | Phase PHASE1 | Virus, Zika | COMPLETED | NCT03343626 |
| Ibrutinib | Other | Phase PHASE1 | Lymphoma, Non-Hodgkin | TERMINATED | NCT02954406 |
| Lenalidomide | Other | Phase PHASE1 | Lymphoma, Non-Hodgkin | TERMINATED | NCT02954406 |
| Gemcitabine | Other | Phase PHASE1 | Lymphoma, Non-Hodgkin | TERMINATED | NCT02954406 |
| Rituximab | Other | Phase PHASE1 | Lymphoma, Non-Hodgkin | TERMINATED | NCT02954406 |
| Bendamustine | Other | Phase PHASE1 | Lymphoma, Non-Hodgkin | TERMINATED | NCT02954406 |
| TAK-659 | Other | Phase PHASE1 | Lymphoma, Non-Hodgkin | TERMINATED | NCT02954406 |
| Ibrutinib | Other | Phase PHASE1 | Lymphoma, Non-Hodgkin | TERMINATED | NCT02954406 |
| Lenalidomide | Other | Phase PHASE1 | Lymphoma, Non-Hodgkin | TERMINATED | NCT02954406 |
| Gemcitabine | Other | Phase PHASE1 | Lymphoma, Non-Hodgkin | TERMINATED | NCT02954406 |
| Rituximab | Other | Phase PHASE1 | Lymphoma, Non-Hodgkin | TERMINATED | NCT02954406 |
| Bendamustine | Other | Phase PHASE1 | Lymphoma, Non-Hodgkin | TERMINATED | NCT02954406 |
| TAK-659 | Other | Phase PHASE1 | Lymphoma, Non-Hodgkin | TERMINATED | NCT02954406 |
| Standard antihyperlipidemic therapy other than administration of omega-3 fatty acid ethyl esters (Lotriga). | Drug | Preclinical | Hyperlipidemia | COMPLETED | NCT02285166 |
| Omega-3 fatty acid ethyl esters | Other | Preclinical | Hyperlipidemia | COMPLETED | NCT02285166 |
| Standard antihyperlipidemic therapy other than administration of omega-3 fatty acid ethyl esters (Lotriga). | Drug | Preclinical | Hyperlipidemia | COMPLETED | NCT02285166 |
| Omega-3 fatty acid ethyl esters | Other | Preclinical | Hyperlipidemia | COMPLETED | NCT02285166 |
| Vedolizumab | Other | Phase PHASE4 | Pouchitis | COMPLETED | NCT02790138 |
| Ciprofloxacin | Other | Phase PHASE4 | Pouchitis | COMPLETED | NCT02790138 |
| Vedolizumab Placebo | Other | Phase PHASE4 | Pouchitis | COMPLETED | NCT02790138 |
| Vedolizumab | Other | Phase PHASE4 | Pouchitis | COMPLETED | NCT02790138 |
| Ciprofloxacin | Other | Phase PHASE4 | Pouchitis | COMPLETED | NCT02790138 |
| Vedolizumab Placebo | Other | Phase PHASE4 | Pouchitis | COMPLETED | NCT02790138 |
| TVP-1012 1mg | Other | Phase PHASE3 | Parkinson's Disease | COMPLETED | NCT02337764 |
| TVP-1012 1mg | Other | Phase PHASE3 | Parkinson's Disease | COMPLETED | NCT02337764 |
| TVP-1012 1mg | Other | Phase PHASE3 | Parkinson's Disease | COMPLETED | NCT02337751 |
| TVP-1012 1mg | Other | Phase PHASE3 | Parkinson's Disease | COMPLETED | NCT02337751 |
| Placebo | Other | Phase PHASE2 | Parkinson's Disease | COMPLETED | NCT02337738 |
| TVP-1012 0.5mg | Other | Phase PHASE2 | Parkinson's Disease | COMPLETED | NCT02337738 |
| TVP-1012 1mg | Other | Phase PHASE2 | Parkinson's Disease | COMPLETED | NCT02337738 |
| Placebo | Other | Phase PHASE2 | Parkinson's Disease | COMPLETED | NCT02337738 |
| TVP-1012 0.5mg | Other | Phase PHASE2 | Parkinson's Disease | COMPLETED | NCT02337738 |
| TVP-1012 1mg | Other | Phase PHASE2 | Parkinson's Disease | COMPLETED | NCT02337738 |
| Placebo | Other | Phase PHASE3 | Parkinson's Disease | COMPLETED | NCT02337725 |
| TVP-1012 | Other | Phase PHASE3 | Parkinson's Disease | COMPLETED | NCT02337725 |
| Placebo | Other | Phase PHASE3 | Parkinson's Disease | COMPLETED | NCT02337725 |
| TVP-1012 | Other | Phase PHASE3 | Parkinson's Disease | COMPLETED | NCT02337725 |
| NesinaAct® Tablet | Other | Preclinical | Type 2 Diabetes Mellitus | COMPLETED | NCT04980014 |
| NesinaAct® Tablet | Other | Preclinical | Type 2 Diabetes Mellitus | COMPLETED | NCT04980014 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04503603 |
| Lanadelumab | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04503603 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04503603 |
| Lanadelumab | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04503603 |
| [14C]-TAK-906 Oral Solution | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04454918 |
| [14C]-TAK-906 Intravenous Infusion | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04454918 |
| TAK-906 Oral Capsule | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04454918 |
| [14C]-TAK-906 Oral Solution | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04454918 |
| [14C]-TAK-906 Intravenous Infusion | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04454918 |
| TAK-906 Oral Capsule | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04454918 |
| GnRH agonist | Other | Preclinical | Central Precocious Puberty | COMPLETED | NCT02993926 |
| Enantone | Other | Preclinical | Central Precocious Puberty | COMPLETED | NCT02993926 |
| GnRH agonist | Other | Preclinical | Central Precocious Puberty | COMPLETED | NCT02993926 |
| Enantone | Other | Preclinical | Central Precocious Puberty | COMPLETED | NCT02993926 |
| TAK-906 | Other | Phase PHASE1 | Healthy Volunteers | WITHDRAWN | NCT04831502 |
| TAK-906 | Other | Phase PHASE1 | Healthy Volunteers | WITHDRAWN | NCT04831502 |
| TAK-667 | Other | Phase PHASE3 | Hereditary Angioedema | COMPLETED | NCT04654351 |
| TAK-667 | Other | Phase PHASE3 | Hereditary Angioedema | COMPLETED | NCT04654351 |
| Alogliptin Benzoate | Other | Preclinical | Type 2 Diabetes Mellitus | COMPLETED | NCT04980040 |
| Alogliptin Benzoate | Other | Preclinical | Type 2 Diabetes Mellitus | COMPLETED | NCT04980040 |
| Intraspinal-optimal stim therapy | Drug | Approved | CRPS I | COMPLETED | NCT03954080 |
| Intraspinal-optimal stim therapy | Drug | Approved | CRPS I | COMPLETED | NCT03954080 |
| Brentuximab Vedotin in Combination with Tislelizumab | Other | Phase PHASE2 | NK/T Cell Lymphoma Nos | UNKNOWN | NCT05316246 |
| Brentuximab Vedotin in Combination with Tislelizumab | Other | Phase PHASE2 | NK/T Cell Lymphoma Nos | UNKNOWN | NCT05316246 |
| Alisertib | Other | Phase PHASE2 | Ovarian Carcinoma | COMPLETED | NCT00853307 |
| Alisertib | Other | Phase PHASE2 | Ovarian Carcinoma | COMPLETED | NCT00853307 |
| Alisertib | Other | Phase PHASE2 | Ovarian Carcinoma | COMPLETED | NCT00853307 |
| Complete Bleeding Symptom ISTH Bleeding Assessment Tool | Other | Preclinical | Von Willebrand Factor Deficiency | UNKNOWN | NCT02933411 |
| Pictorial Blood Assessment Chart (PBAC) score | Other | Preclinical | Von Willebrand Factor Deficiency | UNKNOWN | NCT02933411 |
| Medical Record Data Abstraction | Other | Preclinical | Von Willebrand Factor Deficiency | UNKNOWN | NCT02933411 |
| Genetic Analysis | Other | Preclinical | Von Willebrand Factor Deficiency | UNKNOWN | NCT02933411 |
| Paclitaxel | Other | Phase PHASE1 | Advanced Solid Neoplasm | COMPLETED | NCT03486314 |
| Carboplatin | Other | Phase PHASE1 | Advanced Solid Neoplasm | COMPLETED | NCT03486314 |
| Docetaxel | Other | Phase PHASE1 | Advanced Solid Neoplasm | COMPLETED | NCT03486314 |
| Rifampin | Other | Phase PHASE1 | Advanced Solid Neoplasm | COMPLETED | NCT03486314 |
| Pevonedistat | Other | Phase PHASE1 | Advanced Solid Neoplasm | COMPLETED | NCT03486314 |
| Paclitaxel | Other | Phase PHASE1 | Advanced Solid Neoplasm | COMPLETED | NCT03486314 |
| Carboplatin | Other | Phase PHASE1 | Advanced Solid Neoplasm | COMPLETED | NCT03486314 |
| Docetaxel | Other | Phase PHASE1 | Advanced Solid Neoplasm | COMPLETED | NCT03486314 |
| Rifampin | Other | Phase PHASE1 | Advanced Solid Neoplasm | COMPLETED | NCT03486314 |
| Pevonedistat | Other | Phase PHASE1 | Advanced Solid Neoplasm | COMPLETED | NCT03486314 |
| Pain Management Radiofrequency Kit | Other | Approved | Osteoarthritis, Knee | TERMINATED | NCT02260869 |
| Genicular nerve radiofrequency ablation | Other | Approved | Osteoarthritis, Knee | TERMINATED | NCT02260869 |
| Pain Management Radiofrequency Kit | Other | Approved | Osteoarthritis, Knee | TERMINATED | NCT02260869 |
| Genicular nerve radiofrequency ablation | Other | Approved | Osteoarthritis, Knee | TERMINATED | NCT02260869 |
| Dexamethasone | Other | Phase PHASE4 | Multiple Myeloma | WITHDRAWN | NCT05183139 |
| Lenalidomide | Other | Phase PHASE4 | Multiple Myeloma | WITHDRAWN | NCT05183139 |
| Pomalidomide | Other | Phase PHASE4 | Multiple Myeloma | WITHDRAWN | NCT05183139 |
| Ixazomib | Other | Phase PHASE4 | Multiple Myeloma | WITHDRAWN | NCT05183139 |
| Dexamethasone | Other | Phase PHASE4 | Multiple Myeloma | WITHDRAWN | NCT05183139 |
| Lenalidomide | Other | Phase PHASE4 | Multiple Myeloma | WITHDRAWN | NCT05183139 |
| Pomalidomide | Other | Phase PHASE4 | Multiple Myeloma | WITHDRAWN | NCT05183139 |
| Ixazomib | Other | Phase PHASE4 | Multiple Myeloma | WITHDRAWN | NCT05183139 |
| No Intervention | Other | Preclinical | Mucopolysaccharidosis (MPS) | COMPLETED | NCT05155488 |
| No Intervention | Other | Preclinical | Mucopolysaccharidosis (MPS) | COMPLETED | NCT05155488 |
| Sevoflurane | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05025397 |
| Propofol | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05025397 |
| Danavorexton Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05025397 |
| Danavorexton | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05025397 |
| Sevoflurane | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05025397 |
| Propofol | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05025397 |
| Danavorexton Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05025397 |
| Danavorexton | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05025397 |
| Observation of the association between clotting factor level and risk of bleeding whilst physical activity | Other | Preclinical | Hemophilia A | UNKNOWN | NCT04845555 |
| rhIGF-1/rhIGFBP-3 | Other | Phase PHASE2 | Retinopathy of Prematurity (ROP) | COMPLETED | NCT02386839 |
| PDF Reports for therapists | Other | Approved | Depressive Symptoms | TERMINATED | NCT04830527 |
| EMA prompting for patients | Other | Approved | Depressive Symptoms | TERMINATED | NCT04830527 |
| PDF Reports for therapists | Other | Approved | Depressive Symptoms | TERMINATED | NCT04830527 |
| EMA prompting for patients | Other | Approved | Depressive Symptoms | TERMINATED | NCT04830527 |
| Gluten | Other | Approved | Celiac Disease | COMPLETED | NCT03409796 |
| Gluten | Other | Approved | Celiac Disease | COMPLETED | NCT03409796 |
| Teduglutide | Other | Phase PHASE3 | Short Bowel Syndrome | COMPLETED | NCT03268811 |
| Teduglutide | Other | Phase PHASE3 | Short Bowel Syndrome | COMPLETED | NCT03268811 |
| Teduglutide | Other | Phase PHASE3 | Short Bowel Syndrome | COMPLETED | NCT03268811 |
| Alpha-1 Antitrypsin | Other | Phase PHASE1 | Type 1 Diabetes Mellitus | COMPLETED | NCT02520076 |
| Vedolizumab | Other | Phase PHASE3 | Ulcerative Colitis | COMPLETED | NCT00790933 |
| Placebo SC | Other | Phase PHASE3 | Colitis, Ulcerative | COMPLETED | NCT02611830 |
| Vedolizumab 108 mg SC | Other | Phase PHASE3 | Colitis, Ulcerative | COMPLETED | NCT02611830 |
| Placebo IV | Other | Phase PHASE3 | Colitis, Ulcerative | COMPLETED | NCT02611830 |
| Vedolizumab 300 mg IV | Other | Phase PHASE3 | Colitis, Ulcerative | COMPLETED | NCT02611830 |
| Vedolizumab IV 300 mg | Other | Phase PHASE3 | Crohn's Disease | COMPLETED | NCT02611817 |
| Placebo | Other | Phase PHASE3 | Crohn's Disease | COMPLETED | NCT02611817 |
| Vedolizumab SC 108 mg | Other | Phase PHASE3 | Crohn's Disease | COMPLETED | NCT02611817 |
| Vedolizumab IV 300 mg | Other | Phase PHASE3 | Crohn's Disease | COMPLETED | NCT02611817 |
| Placebo | Other | Phase PHASE3 | Crohn's Disease | COMPLETED | NCT02611817 |
| Vedolizumab SC 108 mg | Other | Phase PHASE3 | Crohn's Disease | COMPLETED | NCT02611817 |
| Placebo | Other | Phase PHASE4 | Coronary Artery Disease | COMPLETED | NCT01709981 |
| Colchicine | Other | Phase PHASE4 | Coronary Artery Disease | COMPLETED | NCT01709981 |
| Placebo | Other | Phase PHASE4 | Coronary Artery Disease | COMPLETED | NCT01709981 |
| Colchicine | Other | Phase PHASE4 | Coronary Artery Disease | COMPLETED | NCT01709981 |
| Lanadelumab | Other | Phase PHASE3 | Hereditary Angioedema | COMPLETED | NCT04070326 |
| Soticlestat | Other | Phase PHASE2 | 15q Duplication Syndrome | COMPLETED | NCT03694275 |
| Soticlestat | Other | Phase PHASE2 | 15q Duplication Syndrome | COMPLETED | NCT03694275 |
| Ixazomib Oral Capsule | Other | Phase PHASE2 | Kidney Diseases | COMPLETED | NCT03213158 |
| Ixazomib Oral Capsule | Other | Phase PHASE2 | Kidney Diseases | COMPLETED | NCT03213158 |
| Remote monitoring tool (infections questionnaire) validation | Other | Preclinical | Inflammatory Bowel Diseases | COMPLETED | NCT04151420 |
| MVC-101 + Nivolumab | Other | Phase EARLY_PHASE1 | Solid Tumour | WITHDRAWN | NCT04891718 |
| Nivolumab | Other | Phase EARLY_PHASE1 | Solid Tumour | WITHDRAWN | NCT04891718 |
| MVC-101 | Other | Phase EARLY_PHASE1 | Solid Tumour | WITHDRAWN | NCT04891718 |
| Vorinostat | Other | Phase PHASE1 | Advanced Cancers | COMPLETED | NCT02042989 |
| MLN9708 | Other | Phase PHASE1 | Advanced Cancers | COMPLETED | NCT02042989 |
| Vorinostat | Other | Phase PHASE1 | Advanced Cancers | COMPLETED | NCT02042989 |
| MLN9708 | Other | Phase PHASE1 | Advanced Cancers | COMPLETED | NCT02042989 |
| No intervention | Other | Preclinical | Attention Deficit Hyperactivity Disorder (ADHD) | COMPLETED | NCT05137704 |
| No intervention | Other | Preclinical | Attention Deficit Hyperactivity Disorder (ADHD) | COMPLETED | NCT05137704 |
| Sorafenib | Other | Phase PHASE1 | Hepatocellular Carcinoma | TERMINATED | NCT02575339 |
| MLN0128 (RP2D) | Other | Phase PHASE1 | Hepatocellular Carcinoma | TERMINATED | NCT02575339 |
| MLN0128 | Other | Phase PHASE1 | Hepatocellular Carcinoma | TERMINATED | NCT02575339 |
| Sorafenib | Other | Phase PHASE1 | Hepatocellular Carcinoma | TERMINATED | NCT02575339 |
| MLN0128 (RP2D) | Other | Phase PHASE1 | Hepatocellular Carcinoma | TERMINATED | NCT02575339 |
| MLN0128 | Other | Phase PHASE1 | Hepatocellular Carcinoma | TERMINATED | NCT02575339 |
| COVID-19 Vaccine | Other | Preclinical | Coronavirus Disease (COVID-19) | WITHDRAWN | NCT04892888 |
| COVID-19 Vaccine | Other | Preclinical | Coronavirus Disease (COVID-19) | WITHDRAWN | NCT04892888 |
| COVID-19 Vaccine | Other | Preclinical | Coronavirus Disease (COVID-19) | WITHDRAWN | NCT04892888 |
| TAK-981 + Avelumab | Other | Phase EARLY_PHASE1 | Head and Neck Cancer | COMPLETED | NCT04065555 |
| TAK-981 + Cetuximab | Other | Phase EARLY_PHASE1 | Head and Neck Cancer | COMPLETED | NCT04065555 |
| Avelumab | Other | Phase EARLY_PHASE1 | Head and Neck Cancer | COMPLETED | NCT04065555 |
| Cetuximab | Other | Phase EARLY_PHASE1 | Head and Neck Cancer | COMPLETED | NCT04065555 |
| TAK-981 | Other | Phase EARLY_PHASE1 | Head and Neck Cancer | COMPLETED | NCT04065555 |
| Vedolizumab SC | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03948581 |
| Vedolizumab SC | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03948581 |
| gemcitabine | Other | Phase PHASE1 | Acinar Cell Adenocarcinoma of the Pancreas | COMPLETED | NCT01924260 |
| alisertib | Other | Phase PHASE1 | Acinar Cell Adenocarcinoma of the Pancreas | COMPLETED | NCT01924260 |
| Placebo | Other | Approved | Attention Deficit Hyperactivity Disorder | COMPLETED | NCT01415440 |
| Lisdexamfetamine | Other | Approved | Attention Deficit Hyperactivity Disorder | COMPLETED | NCT01415440 |
| HAV Vaccine Placebo | Other | Phase PHASE3 | Healthy Volunteers | COMPLETED | NCT03525119 |
| TDV Placebo | Other | Phase PHASE3 | Healthy Volunteers | COMPLETED | NCT03525119 |
| HAV Vaccine | Other | Phase PHASE3 | Healthy Volunteers | COMPLETED | NCT03525119 |
| TDV | Other | Phase PHASE3 | Healthy Volunteers | COMPLETED | NCT03525119 |
| HAV Vaccine Placebo | Other | Phase PHASE3 | Healthy Volunteers | COMPLETED | NCT03525119 |
| TDV Placebo | Other | Phase PHASE3 | Healthy Volunteers | COMPLETED | NCT03525119 |
| HAV Vaccine | Other | Phase PHASE3 | Healthy Volunteers | COMPLETED | NCT03525119 |
| TDV | Other | Phase PHASE3 | Healthy Volunteers | COMPLETED | NCT03525119 |
| Brentuximab Vedotin | Other | Phase PHASE2 | Hodgkin Lymphoma | COMPLETED | NCT02292979 |
| Dacarbazine | Other | Phase PHASE2 | Hodgkin Lymphoma | COMPLETED | NCT02292979 |
| Vinblastine | Other | Phase PHASE2 | Hodgkin Lymphoma | COMPLETED | NCT02292979 |
| Bleomycin | Other | Phase PHASE2 | Hodgkin Lymphoma | COMPLETED | NCT02292979 |
| Doxorubicin | Other | Phase PHASE2 | Hodgkin Lymphoma | COMPLETED | NCT02292979 |
| Brentuximab Vedotin | Other | Phase PHASE2 | Hodgkin Lymphoma | COMPLETED | NCT02292979 |
| Dacarbazine | Other | Phase PHASE2 | Hodgkin Lymphoma | COMPLETED | NCT02292979 |
| Vinblastine | Other | Phase PHASE2 | Hodgkin Lymphoma | COMPLETED | NCT02292979 |
| Bleomycin | Other | Phase PHASE2 | Hodgkin Lymphoma | COMPLETED | NCT02292979 |
| Doxorubicin | Other | Phase PHASE2 | Hodgkin Lymphoma | COMPLETED | NCT02292979 |
| Daunorubicin | Other | Phase PHASE1 | Acute Myeloid Leukemia | COMPLETED | NCT02582359 |
| Cytarabine | Other | Phase PHASE1 | Acute Myeloid Leukemia | COMPLETED | NCT02582359 |
| MLN9708 | Other | Phase PHASE1 | Acute Myeloid Leukemia | COMPLETED | NCT02582359 |
| Daunorubicin | Other | Phase PHASE1 | Acute Myeloid Leukemia | COMPLETED | NCT02582359 |
| Cytarabine | Other | Phase PHASE1 | Acute Myeloid Leukemia | COMPLETED | NCT02582359 |
| MLN9708 | Other | Phase PHASE1 | Acute Myeloid Leukemia | COMPLETED | NCT02582359 |
| Measurements of the alpha-GAL enzyme activity | Other | Preclinical | Fabry Disease | COMPLETED | NCT03230149 |
| Measurements of the alpha-GAL enzyme activity | Other | Preclinical | Fabry Disease | COMPLETED | NCT03230149 |
| Measurements of the alpha-GAL enzyme activity | Other | Preclinical | Fabry Disease | COMPLETED | NCT03230149 |
| continuous glucose monitoring (CGM) iPro™2 Medtronic | Other | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT03487887 |
| continuous glucose monitoring (CGM) iPro™2 Medtronic | Other | Preclinical | Diabetes Mellitus, Type 2 | COMPLETED | NCT03487887 |
| Pevonedistat | Other | Phase PHASE2 | Myelodysplastic Syndromes | COMPLETED | NCT02610777 |
| Azacitidine | Other | Phase PHASE2 | Myelodysplastic Syndromes | COMPLETED | NCT02610777 |
| Pevonedistat | Other | Phase PHASE2 | Myelodysplastic Syndromes | COMPLETED | NCT02610777 |
| Azacitidine | Other | Phase PHASE2 | Myelodysplastic Syndromes | COMPLETED | NCT02610777 |
| Pevonedistat | Other | Phase PHASE2 | Myelodysplastic Syndromes | COMPLETED | NCT02610777 |
| Azacitidine | Other | Phase PHASE2 | Myelodysplastic Syndromes | COMPLETED | NCT02610777 |
| No intervention | Other | Preclinical | Drug Hypersensitivity | COMPLETED | NCT05269082 |
| No intervention | Other | Preclinical | Drug Hypersensitivity | COMPLETED | NCT05269082 |
| No intervention | Other | Preclinical | Drug Hypersensitivity | COMPLETED | NCT05269082 |
| Dexamethasone | Other | Phase PHASE4 | Relapsed and/or Refractory Multiple Myeloma | COMPLETED | NCT03416374 |
| Lenalidomide | Other | Phase PHASE4 | Relapsed and/or Refractory Multiple Myeloma | COMPLETED | NCT03416374 |
| Carfilzomib | Other | Phase PHASE4 | Relapsed and/or Refractory Multiple Myeloma | COMPLETED | NCT03416374 |
| Bortezomib | Other | Phase PHASE4 | Relapsed and/or Refractory Multiple Myeloma | COMPLETED | NCT03416374 |
| Ixazomib | Other | Phase PHASE4 | Relapsed and/or Refractory Multiple Myeloma | COMPLETED | NCT03416374 |
| Dexamethasone | Other | Phase PHASE4 | Relapsed and/or Refractory Multiple Myeloma | COMPLETED | NCT03416374 |
| Lenalidomide | Other | Phase PHASE4 | Relapsed and/or Refractory Multiple Myeloma | COMPLETED | NCT03416374 |
| Carfilzomib | Other | Phase PHASE4 | Relapsed and/or Refractory Multiple Myeloma | COMPLETED | NCT03416374 |
| Bortezomib | Other | Phase PHASE4 | Relapsed and/or Refractory Multiple Myeloma | COMPLETED | NCT03416374 |
| Ixazomib | Other | Phase PHASE4 | Relapsed and/or Refractory Multiple Myeloma | COMPLETED | NCT03416374 |
| Dexamethasone | Other | Phase PHASE1 | AL Amyloidosis | COMPLETED | NCT03236792 |
| Cyclophosphamide | Other | Phase PHASE1 | AL Amyloidosis | COMPLETED | NCT03236792 |
| Ixazomib | Other | Phase PHASE1 | AL Amyloidosis | COMPLETED | NCT03236792 |
| Dexamethasone | Other | Phase PHASE1 | AL Amyloidosis | COMPLETED | NCT03236792 |
| Cyclophosphamide | Other | Phase PHASE1 | AL Amyloidosis | COMPLETED | NCT03236792 |
| Ixazomib | Other | Phase PHASE1 | AL Amyloidosis | COMPLETED | NCT03236792 |
| Dexamethasone | Other | Phase PHASE1 | AL Amyloidosis | COMPLETED | NCT03236792 |
| Cyclophosphamide | Other | Phase PHASE1 | AL Amyloidosis | COMPLETED | NCT03236792 |
| Ixazomib | Other | Phase PHASE1 | AL Amyloidosis | COMPLETED | NCT03236792 |
| Mobocertinib 160 mg | Other | Preclinical | Carcinoma, Non-Small-Cell Lung | APPROVED_FOR_MARKETING | NCT04535557 |
| Mobocertinib 160 mg | Other | Preclinical | Carcinoma, Non-Small-Cell Lung | APPROVED_FOR_MARKETING | NCT04535557 |
| Mobocertinib 160 mg | Other | Preclinical | Carcinoma, Non-Small-Cell Lung | APPROVED_FOR_MARKETING | NCT04535557 |
| Azacitidine | Other | Preclinical | Myelodysplastic Syndromes | NO_LONGER_AVAILABLE | NCT04484363 |
| Pevonedistat | Other | Preclinical | Myelodysplastic Syndromes | NO_LONGER_AVAILABLE | NCT04484363 |
| Azacitidine | Other | Preclinical | Myelodysplastic Syndromes | NO_LONGER_AVAILABLE | NCT04484363 |
| Pevonedistat | Other | Preclinical | Myelodysplastic Syndromes | NO_LONGER_AVAILABLE | NCT04484363 |
| Lanadelumab | Other | Phase PHASE3 | Hereditary Angioedema (HAE) | COMPLETED | NCT04180163 |
| Alisertib | Other | Phase PHASE2 | Lung Cancer | COMPLETED | NCT02293005 |
| Alisertib | Other | Phase PHASE2 | Lung Cancer | COMPLETED | NCT02293005 |
| Alisertib | Other | Phase PHASE2 | Lung Cancer | COMPLETED | NCT02293005 |
| rhPTH(1-84) | Other | Phase PHASE3 | Hypoparathyroidism | TERMINATED | NCT03364738 |
| Brigatinib | Other | Phase PHASE1 | ALK Gene Rearrangement | TERMINATED | NCT04005144 |
| Binimetinib | Other | Phase PHASE1 | ALK Gene Rearrangement | TERMINATED | NCT04005144 |
| Brigatinib | Other | Phase PHASE1 | ALK Gene Rearrangement | TERMINATED | NCT04005144 |
| Binimetinib | Other | Phase PHASE1 | ALK Gene Rearrangement | TERMINATED | NCT04005144 |
| Placebo | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT02856113 |
| Alogliptin Benzoate | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT02856113 |
| Placebo | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT02856113 |
| Alogliptin Benzoate | Other | Phase PHASE3 | Diabetes Mellitus, Type 2 | COMPLETED | NCT02856113 |
| Hydrocortisone | Other | Phase PHASE1 | Refractory Acute Lymphoblastic Leukemia | COMPLETED | NCT03349281 |
| Methotrexate | Other | Phase PHASE1 | Refractory Acute Lymphoblastic Leukemia | COMPLETED | NCT03349281 |
| Cytarabine | Other | Phase PHASE1 | Refractory Acute Lymphoblastic Leukemia | COMPLETED | NCT03349281 |
| Doxorubicin | Other | Phase PHASE1 | Refractory Acute Lymphoblastic Leukemia | COMPLETED | NCT03349281 |
| PEG-asparaginase | Other | Phase PHASE1 | Refractory Acute Lymphoblastic Leukemia | COMPLETED | NCT03349281 |
| Dexamethasone | Other | Phase PHASE1 | Refractory Acute Lymphoblastic Leukemia | COMPLETED | NCT03349281 |
| Vincristine | Other | Phase PHASE1 | Refractory Acute Lymphoblastic Leukemia | COMPLETED | NCT03349281 |
| Pevonedistat | Other | Phase PHASE1 | Refractory Acute Lymphoblastic Leukemia | COMPLETED | NCT03349281 |
| VPRIV | Other | Phase PHASE4 | Gaucher Disease, Type 1 | COMPLETED | NCT04120506 |
| NoV Vaccine | Other | Phase PHASE2 | Healthy Volunteers | COMPLETED | NCT03039790 |
| NoV Vaccine | Other | Phase PHASE2 | Healthy Volunteers | COMPLETED | NCT03039790 |
| Moxifloxacin | Other | Phase PHASE1 | Healthy Volunteers | WITHDRAWN | NCT05309902 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | WITHDRAWN | NCT05309902 |
| Soticlestat | Other | Phase PHASE1 | Healthy Volunteers | WITHDRAWN | NCT05309902 |
| Placebo | Other | Phase PHASE2 | Diabetic Gastroparesis | COMPLETED | NCT03544229 |
| TAK-906 Maleate | Other | Phase PHASE2 | Diabetic Gastroparesis | COMPLETED | NCT03544229 |
| Placebo | Other | Phase PHASE2 | Diabetic Gastroparesis | COMPLETED | NCT03544229 |
| TAK-906 Maleate | Other | Phase PHASE2 | Diabetic Gastroparesis | COMPLETED | NCT03544229 |
| Vortioxetine | Other | Phase PHASE4 | Type2 Diabetes | WITHDRAWN | NCT03580967 |
| Standard of Care | Other | Phase PHASE2 | Acquired Thrombotic Thrombocytopenic Purpura (aTTP) | COMPLETED | NCT03922308 |
| SHP655 | Other | Phase PHASE2 | Acquired Thrombotic Thrombocytopenic Purpura (aTTP) | COMPLETED | NCT03922308 |
| Placebo | Other | Phase PHASE2 | Acquired Thrombotic Thrombocytopenic Purpura (aTTP) | COMPLETED | NCT03922308 |
| Placebo | Other | Phase PHASE1 | Sleep Apnea | COMPLETED | NCT05180890 |
| Danavorexton | Other | Phase PHASE1 | Sleep Apnea | COMPLETED | NCT05180890 |
| Placebo | Other | Phase PHASE1 | Sleep Apnea | COMPLETED | NCT05180890 |
| Danavorexton | Other | Phase PHASE1 | Sleep Apnea | COMPLETED | NCT05180890 |
| Dexamethasone | Other | Phase PHASE2 | Relapsed and/or Refractory Multiple Myeloma | COMPLETED | NCT03170882 |
| Pomalidomide | Other | Phase PHASE2 | Relapsed and/or Refractory Multiple Myeloma | COMPLETED | NCT03170882 |
| Ixazomib | Other | Phase PHASE2 | Relapsed and/or Refractory Multiple Myeloma | COMPLETED | NCT03170882 |
| Diagnosis of SPAD using immunization with PPV23 | Other | Preclinical | Specific Antibody Deficiency | NOT_YET_RECRUITING | NCT05664035 |
| Diagnosis of SPAD using immunization with PPV23 | Other | Preclinical | Specific Antibody Deficiency | NOT_YET_RECRUITING | NCT05664035 |
| sleep hygiene | Other | Phase PHASE4 | Insomnia | TERMINATED | NCT05414864 |
| Ramelteon (RozeremR) | Other | Phase PHASE4 | Insomnia | TERMINATED | NCT05414864 |
| sleep hygiene | Other | Phase PHASE4 | Insomnia | TERMINATED | NCT05414864 |
| Ramelteon (RozeremR) | Other | Phase PHASE4 | Insomnia | TERMINATED | NCT05414864 |
| brigatinib | Other | Phase PHASE2 | Non-Small Cell Lung Cancer | TERMINATED | NCT02706626 |
| Brigatinib | Other | Phase PHASE1 | Carcinoma, Advanced ALK+ or ROS1+Non-Small-Cell Lung, Neoplasm, Advanced ALK+ or ROS1+Solid Tumors | COMPLETED | NCT03420742 |
| Midazolam | Other | Phase PHASE1 | Carcinoma, Advanced ALK+ or ROS1+Non-Small-Cell Lung, Neoplasm, Advanced ALK+ or ROS1+Solid Tumors | COMPLETED | NCT03420742 |
| Brigatinib | Other | Phase PHASE1 | Carcinoma, Advanced ALK+ or ROS1+Non-Small-Cell Lung, Neoplasm, Advanced ALK+ or ROS1+Solid Tumors | COMPLETED | NCT03420742 |
| Midazolam | Other | Phase PHASE1 | Carcinoma, Advanced ALK+ or ROS1+Non-Small-Cell Lung, Neoplasm, Advanced ALK+ or ROS1+Solid Tumors | COMPLETED | NCT03420742 |
| ADALIMUMAB | Other | Approved | ULCERATIVE COLITIS | TERMINATED | NCT02878083 |
| VEDOLIZUMAB | Other | Approved | ULCERATIVE COLITIS | TERMINATED | NCT02878083 |
| Placebo | Other | Phase PHASE3 | Ileostomy - Stoma | WITHDRAWN | NCT03953170 |
| Teduglutide | Other | Phase PHASE3 | Ileostomy - Stoma | WITHDRAWN | NCT03953170 |
| Dexamethasone | Other | Phase PHASE1 | Relapsed/Refractory | COMPLETED | NCT03439280 |
| Pomalidomide | Other | Phase PHASE1 | Relapsed/Refractory | COMPLETED | NCT03439280 |
| Mezagitamab | Other | Phase PHASE1 | Relapsed/Refractory | COMPLETED | NCT03439280 |
| Dexamethasone | Other | Phase PHASE1 | Relapsed/Refractory | COMPLETED | NCT03439280 |
| Pomalidomide | Other | Phase PHASE1 | Relapsed/Refractory | COMPLETED | NCT03439280 |
| Mezagitamab | Other | Phase PHASE1 | Relapsed/Refractory | COMPLETED | NCT03439280 |
| Placebo | Other | Phase PHASE3 | Crohn's Disease | COMPLETED | NCT03234907 |
| Vedolizumab IV | Other | Phase PHASE3 | Crohn's Disease | COMPLETED | NCT03234907 |
| Placebo | Other | Phase PHASE3 | Crohn's Disease | COMPLETED | NCT03234907 |
| Vedolizumab IV | Other | Phase PHASE3 | Crohn's Disease | COMPLETED | NCT03234907 |
| No Intervention | Other | Preclinical | Leukemia | COMPLETED | NCT05743465 |
| No Intervention | Other | Preclinical | Leukemia | COMPLETED | NCT05743465 |
| No Intervention | Other | Preclinical | Leukemia | COMPLETED | NCT05743465 |
| No Intervention | Other | Preclinical | Celiac Disease | COMPLETED | NCT05309330 |
| TAK-951 Placebo | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT04486950 |
| TAK-951 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT04486950 |
| TAK-951 Placebo | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT04486950 |
| TAK-951 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT04486950 |
| Placebo | Other | Phase PHASE3 | Relapsed Multiple Myeloma | COMPLETED | NCT01564537 |
| Dexamethasone | Other | Phase PHASE3 | Relapsed Multiple Myeloma | COMPLETED | NCT01564537 |
| Lenalidomide | Other | Phase PHASE3 | Relapsed Multiple Myeloma | COMPLETED | NCT01564537 |
| Ixazomib | Other | Phase PHASE3 | Relapsed Multiple Myeloma | COMPLETED | NCT01564537 |
| Placebo | Other | Phase PHASE3 | Relapsed Multiple Myeloma | COMPLETED | NCT01564537 |
| Dexamethasone | Other | Phase PHASE3 | Relapsed Multiple Myeloma | COMPLETED | NCT01564537 |
| Lenalidomide | Other | Phase PHASE3 | Relapsed Multiple Myeloma | COMPLETED | NCT01564537 |
| Ixazomib | Other | Phase PHASE3 | Relapsed Multiple Myeloma | COMPLETED | NCT01564537 |
| Vial Adapter for Device | Device | Phase PHASE3 | Short Bowel Syndrome | COMPLETED | NCT03596164 |
| Needle | Other | Phase PHASE3 | Short Bowel Syndrome | COMPLETED | NCT03596164 |
| Syringe | Other | Phase PHASE3 | Short Bowel Syndrome | COMPLETED | NCT03596164 |
| Teduglutide | Other | Phase PHASE3 | Short Bowel Syndrome | COMPLETED | NCT03596164 |
| Vial Adapter for Device | Device | Phase PHASE3 | Short Bowel Syndrome | COMPLETED | NCT03596164 |
| Needle | Other | Phase PHASE3 | Short Bowel Syndrome | COMPLETED | NCT03596164 |
| Syringe | Other | Phase PHASE3 | Short Bowel Syndrome | COMPLETED | NCT03596164 |
| Teduglutide | Other | Phase PHASE3 | Short Bowel Syndrome | COMPLETED | NCT03596164 |
| Vial Adapter for Device | Device | Phase PHASE3 | Short Bowel Syndrome | COMPLETED | NCT03596164 |
| Needle | Other | Phase PHASE3 | Short Bowel Syndrome | COMPLETED | NCT03596164 |
| Syringe | Other | Phase PHASE3 | Short Bowel Syndrome | COMPLETED | NCT03596164 |
| Teduglutide | Other | Phase PHASE3 | Short Bowel Syndrome | COMPLETED | NCT03596164 |
| Pravastatin | Other | Phase PHASE1 | Leukemia | TERMINATED | NCT02484261 |
| Bortezomib | Other | Phase PHASE1 | Leukemia | TERMINATED | NCT02484261 |
| Pravastatin | Other | Phase PHASE1 | Leukemia | TERMINATED | NCT02484261 |
| Bortezomib | Other | Phase PHASE1 | Leukemia | TERMINATED | NCT02484261 |
| Paclitaxel | Other | Phase PHASE1 | Advanced Solid Neoplasm | COMPLETED | NCT03330106 |
| Carboplatin | Other | Phase PHASE1 | Advanced Solid Neoplasm | COMPLETED | NCT03330106 |
| Docetaxel | Other | Phase PHASE1 | Advanced Solid Neoplasm | COMPLETED | NCT03330106 |
| Pevonedistat | Other | Phase PHASE1 | Advanced Solid Neoplasm | COMPLETED | NCT03330106 |
| Paclitaxel | Other | Phase PHASE1 | Advanced Solid Neoplasm | COMPLETED | NCT03330106 |
| Carboplatin | Other | Phase PHASE1 | Advanced Solid Neoplasm | COMPLETED | NCT03330106 |
| Docetaxel | Other | Phase PHASE1 | Advanced Solid Neoplasm | COMPLETED | NCT03330106 |
| Pevonedistat | Other | Phase PHASE1 | Advanced Solid Neoplasm | COMPLETED | NCT03330106 |
| PvP003 150 mg | Other | Phase PHASE1 | Digestive System Disease | COMPLETED | NCT03701555 |
| PvP003 | Other | Phase PHASE1 | Digestive System Disease | COMPLETED | NCT03701555 |
| PvP003 placebo | Other | Phase PHASE1 | Digestive System Disease | COMPLETED | NCT03701555 |
| PvP001 600 mg | Other | Phase PHASE1 | Digestive System Disease | COMPLETED | NCT03701555 |
| PvP002 placebo | Other | Phase PHASE1 | Digestive System Disease | COMPLETED | NCT03701555 |
| MTD of PvP001 following 7 days of PPI treatment | Drug | Phase PHASE1 | Digestive System Disease | COMPLETED | NCT03701555 |
| Maximum Tolerated Dose (MTD) of PvP001 | Other | Phase PHASE1 | Digestive System Disease | COMPLETED | NCT03701555 |
| Maximum Feasible Dose (MFD) of PvP002 | Other | Phase PHASE1 | Digestive System Disease | COMPLETED | NCT03701555 |
| PvP001 900 mg | Other | Phase PHASE1 | Digestive System Disease | COMPLETED | NCT03701555 |
| PvP001 300 mg | Other | Phase PHASE1 | Digestive System Disease | COMPLETED | NCT03701555 |
| PvP001 100 mg | Other | Phase PHASE1 | Digestive System Disease | COMPLETED | NCT03701555 |
| PvP001 placebo | Other | Phase PHASE1 | Digestive System Disease | COMPLETED | NCT03701555 |
| Placebo | Other | Phase PHASE2 | Healthy | COMPLETED | NCT01511250 |
| TDV | Other | Phase PHASE2 | Healthy | COMPLETED | NCT01511250 |
| Placebo | Other | Phase PHASE2 | Healthy | COMPLETED | NCT01511250 |
| TDV | Other | Phase PHASE2 | Healthy | COMPLETED | NCT01511250 |
| No Intervention | Other | Preclinical | Carcinoma, Non-Small-Cell Lung | COMPLETED | NCT04887519 |
| Cabozantinib | Other | Phase PHASE2 | Advanced Hepatocellular Carcinoma | COMPLETED | NCT03586973 |
| Cabozantinib | Other | Phase PHASE2 | Advanced Hepatocellular Carcinoma | COMPLETED | NCT03586973 |
| Cabozantinib | Other | Phase PHASE2 | Advanced Hepatocellular Carcinoma | COMPLETED | NCT03586973 |
| Erlotinib | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT02942095 |
| Ixazomib | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT02942095 |
| Erlotinib | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT02942095 |
| Ixazomib | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT02942095 |
| Erlotinib | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT02942095 |
| Ixazomib | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT02942095 |
| TAK-951 Placebo | Other | Phase PHASE2 | Postoperative Nausea and Vomiting (PONV) | COMPLETED | NCT04557189 |
| Ondansetron Placebo | Other | Phase PHASE2 | Postoperative Nausea and Vomiting (PONV) | COMPLETED | NCT04557189 |
| Ondansetron | Other | Phase PHASE2 | Postoperative Nausea and Vomiting (PONV) | COMPLETED | NCT04557189 |
| TAK-951 | Other | Phase PHASE2 | Postoperative Nausea and Vomiting (PONV) | COMPLETED | NCT04557189 |
| TAK-951 Placebo | Other | Phase PHASE2 | Postoperative Nausea and Vomiting (PONV) | COMPLETED | NCT04557189 |
| Ondansetron Placebo | Other | Phase PHASE2 | Postoperative Nausea and Vomiting (PONV) | COMPLETED | NCT04557189 |
| Ondansetron | Other | Phase PHASE2 | Postoperative Nausea and Vomiting (PONV) | COMPLETED | NCT04557189 |
| TAK-951 | Other | Phase PHASE2 | Postoperative Nausea and Vomiting (PONV) | COMPLETED | NCT04557189 |
| Placebo | Other | Phase PHASE1 | Coronavirus Disease (COVID-19) | COMPLETED | NCT04677660 |
| TAK-919 | Other | Phase PHASE1 | Coronavirus Disease (COVID-19) | COMPLETED | NCT04677660 |
| Placebo | Other | Phase PHASE1 | Coronavirus Disease (COVID-19) | COMPLETED | NCT04677660 |
| TAK-919 | Other | Phase PHASE1 | Coronavirus Disease (COVID-19) | COMPLETED | NCT04677660 |
| Another Available A1PI | Other | Phase PHASE4 | Chronic Obstructive Pulmonary Disease (COPD) | WITHDRAWN | NCT05466747 |
| RYMPHYSIA | Other | Phase PHASE4 | Chronic Obstructive Pulmonary Disease (COPD) | WITHDRAWN | NCT05466747 |
| Rituximab | Other | Phase PHASE1 | Mantle Cell Lymphoma | UNKNOWN | NCT02632396 |
| Ixazomib | Other | Phase PHASE1 | Mantle Cell Lymphoma | UNKNOWN | NCT02632396 |
| Rituximab | Other | Phase PHASE1 | Mantle Cell Lymphoma | UNKNOWN | NCT02632396 |
| Ixazomib | Other | Phase PHASE1 | Mantle Cell Lymphoma | UNKNOWN | NCT02632396 |
| IGIV GAMUNEX®-C | Other | Phase PHASE3 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy | COMPLETED | NCT02549170 |
| IGIV GAMMAGARD LIQUID/KIOVIG | Other | Phase PHASE3 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy | COMPLETED | NCT02549170 |
| 0.25% albumin placebo solution with rHuPH20 | Other | Phase PHASE3 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy | COMPLETED | NCT02549170 |
| HYQVIA | Other | Phase PHASE3 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy | COMPLETED | NCT02549170 |
| IGIV GAMUNEX®-C | Other | Phase PHASE3 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy | COMPLETED | NCT02549170 |
| IGIV GAMMAGARD LIQUID/KIOVIG | Other | Phase PHASE3 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy | COMPLETED | NCT02549170 |
| 0.25% albumin placebo solution with rHuPH20 | Other | Phase PHASE3 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy | COMPLETED | NCT02549170 |
| HYQVIA | Other | Phase PHASE3 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy | COMPLETED | NCT02549170 |
| Placebo | Other | Phase PHASE3 | Insomnia | COMPLETED | NCT01048242 |
| rozerem | Other | Phase PHASE3 | Insomnia | COMPLETED | NCT01048242 |
| Placebo | Other | Phase PHASE4 | Colonoscopy | COMPLETED | NCT00645801 |
| lubiprostone (Amitiza) | Other | Phase PHASE4 | Colonoscopy | COMPLETED | NCT00645801 |
| Placebo | Other | Phase PHASE4 | Colonoscopy | COMPLETED | NCT00645801 |
| lubiprostone (Amitiza) | Other | Phase PHASE4 | Colonoscopy | COMPLETED | NCT00645801 |
| TAK-079 Placebo | Other | Phase PHASE2 | Myasthenia Gravis | COMPLETED | NCT04159805 |
| TAK-079 | Other | Phase PHASE2 | Myasthenia Gravis | COMPLETED | NCT04159805 |
| TAK-079 Placebo | Other | Phase PHASE2 | Myasthenia Gravis | COMPLETED | NCT04159805 |
| TAK-079 | Other | Phase PHASE2 | Myasthenia Gravis | COMPLETED | NCT04159805 |
| Cohort 3-Bortezomib (Velcade ®) | Other | Phase PHASE1 | Hematological Malignancy | COMPLETED | NCT01860170 |
| Cohort 2-Bortezomib (Velcade ®) | Other | Phase PHASE1 | Hematological Malignancy | COMPLETED | NCT01860170 |
| Cohort 1-Bortezomib (Velcade ®) | Other | Phase PHASE1 | Hematological Malignancy | COMPLETED | NCT01860170 |
| Cohort 3-Bortezomib (Velcade ®) | Other | Phase PHASE1 | Hematological Malignancy | COMPLETED | NCT01860170 |
| Cohort 2-Bortezomib (Velcade ®) | Other | Phase PHASE1 | Hematological Malignancy | COMPLETED | NCT01860170 |
| Cohort 1-Bortezomib (Velcade ®) | Other | Phase PHASE1 | Hematological Malignancy | COMPLETED | NCT01860170 |
| Placebo | Other | Phase PHASE1 | Prevention of Infection Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) | COMPLETED | NCT04712110 |
| TAK-019 | Other | Phase PHASE1 | Prevention of Infection Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) | COMPLETED | NCT04712110 |
| Placebo | Other | Phase PHASE1 | Prevention of Infection Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) | COMPLETED | NCT04712110 |
| TAK-019 | Other | Phase PHASE1 | Prevention of Infection Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) | COMPLETED | NCT04712110 |
| Vedolizumab | Other | Phase PHASE3 | Hematopoietic Stem Cells | COMPLETED | NCT03657160 |
| Vedolizumab Placebo | Other | Phase PHASE3 | Hematopoietic Stem Cells | COMPLETED | NCT03657160 |
| Vedolizumab | Other | Phase PHASE3 | Hematopoietic Stem Cells | COMPLETED | NCT03657160 |
| Vedolizumab Placebo | Other | Phase PHASE3 | Hematopoietic Stem Cells | COMPLETED | NCT03657160 |
| Vonoprazan | Other | Preclinical | A History of Gastric or Duodenal Ulcers | COMPLETED | NCT03214198 |
| Vonoprazan | Other | Preclinical | A History of Gastric or Duodenal Ulcers | COMPLETED | NCT03214198 |
| Vonoprazan | Other | Preclinical | A History of Gastric or Duodenal Ulcers | COMPLETED | NCT03214198 |
| rurioctocog alfa pegol | Other | Preclinical | Hemophilia A | COMPLETED | NCT03006965 |
| octocog alfa | Other | Preclinical | Hemophilia A | COMPLETED | NCT03006965 |
| rurioctocog alfa pegol | Other | Preclinical | Hemophilia A | COMPLETED | NCT03006965 |
| octocog alfa | Other | Preclinical | Hemophilia A | COMPLETED | NCT03006965 |
| Placebo | Other | Phase PHASE4 | Hypoparathyroidism | COMPLETED | NCT03324880 |
| rhPTH (1-84) | Other | Phase PHASE4 | Hypoparathyroidism | COMPLETED | NCT03324880 |
| Standard Medical Therapy | Drug | Phase PHASE2 | COPD Exacerbation Acute | RECRUITING | NCT05764993 |
| CUVITRU - Ig subcutaneous human 20% | Other | Phase PHASE2 | COPD Exacerbation Acute | RECRUITING | NCT05764993 |
| Standard Medical Therapy | Drug | Phase PHASE2 | COPD Exacerbation Acute | UNKNOWN | NCT05764993 |
| CUVITRU - Ig subcutaneous human 20% | Other | Phase PHASE2 | COPD Exacerbation Acute | UNKNOWN | NCT05764993 |
| Vedolizumab | Other | Phase PHASE4 | Crohn Disease | TERMINATED | NCT02768532 |
| TAK-954 | Other | Phase PHASE2 | Postoperative Gastrointestinal Dysfunction | COMPLETED | NCT03827655 |
| TAK-954 Placebo | Other | Phase PHASE2 | Postoperative Gastrointestinal Dysfunction | COMPLETED | NCT03827655 |
| TAK-954 | Other | Phase PHASE2 | Postoperative Gastrointestinal Dysfunction | COMPLETED | NCT03827655 |
| TAK-954 Placebo | Other | Phase PHASE2 | Postoperative Gastrointestinal Dysfunction | COMPLETED | NCT03827655 |
| TAK-954 | Other | Phase PHASE2 | Postoperative Gastrointestinal Dysfunction | COMPLETED | NCT03827655 |
| TAK-954 Placebo | Other | Phase PHASE2 | Postoperative Gastrointestinal Dysfunction | COMPLETED | NCT03827655 |
| vedolizumab | Other | Phase PHASE4 | Crohn Disease | COMPLETED | NCT02646683 |
| TAK-743 300 mg | Other | Phase PHASE3 | Hereditary Angioedema | COMPLETED | NCT04687137 |
| TAK-743 300 mg | Other | Phase PHASE3 | Hereditary Angioedema | COMPLETED | NCT04687137 |
| TAK-743 300 mg | Other | Phase PHASE3 | Hereditary Angioedema | COMPLETED | NCT04687137 |
| Methotrexate | Other | Phase PHASE4 | Crohn Disease | COMPLETED | NCT02764762 |
| Adalimumab | Other | Phase PHASE4 | Crohn Disease | COMPLETED | NCT02764762 |
| Vedolizumab | Other | Phase PHASE4 | Crohn Disease | COMPLETED | NCT02764762 |
| THEORY BASED INTEGRATED DENGUE EDUCATION AND LEARNING MODULE (iDEAL) | Other | Approved | Knowledge, Attitudes, Practice | UNKNOWN | NCT05863026 |
| THEORY BASED INTEGRATED DENGUE EDUCATION AND LEARNING MODULE (iDEAL) | Other | Approved | Knowledge, Attitudes, Practice | UNKNOWN | NCT05863026 |
| Lenalidomide | Other | Phase PHASE3 | Multiple Myeloma | COMPLETED | NCT01850524 |
| Dexamethasone | Other | Phase PHASE3 | Multiple Myeloma | COMPLETED | NCT01850524 |
| Placebo | Other | Phase PHASE3 | Multiple Myeloma | COMPLETED | NCT01850524 |
| Ixazomib | Other | Phase PHASE3 | Multiple Myeloma | COMPLETED | NCT01850524 |
| Lenalidomide | Other | Phase PHASE3 | Multiple Myeloma | COMPLETED | NCT01850524 |
| Dexamethasone | Other | Phase PHASE3 | Multiple Myeloma | COMPLETED | NCT01850524 |
| Placebo | Other | Phase PHASE3 | Multiple Myeloma | COMPLETED | NCT01850524 |
| Ixazomib | Other | Phase PHASE3 | Multiple Myeloma | COMPLETED | NCT01850524 |
| Non-Interventional | Other | Preclinical | Hemophilia A | COMPLETED | NCT04876365 |
| Lanadelumab 300 mg | Other | Preclinical | Hereditary Angioedema (HAE) | NO_LONGER_AVAILABLE | NCT04583007 |
| Lanadelumab 150 mg | Other | Preclinical | Hereditary Angioedema (HAE) | NO_LONGER_AVAILABLE | NCT04583007 |
| Vedolizumab IV | Other | Phase PHASE4 | Colitis, Ulcerative | COMPLETED | NCT03029143 |
| Vedolizumab IV | Other | Phase PHASE4 | Colitis, Ulcerative | COMPLETED | NCT03029143 |
| Cisplatin & Nab Paclitaxel | Other | Phase PHASE2 | Triple Negative Breast Cancer | COMPLETED | NCT03193853 |
| Tak-228 & Tak-117 | Other | Phase PHASE2 | Triple Negative Breast Cancer | COMPLETED | NCT03193853 |
| Cisplatin & Nab Paclitaxel | Other | Phase PHASE2 | Triple Negative Breast Cancer | COMPLETED | NCT03193853 |
| Tak-228 & Tak-117 | Other | Phase PHASE2 | Triple Negative Breast Cancer | COMPLETED | NCT03193853 |
| Azacitidine | Other | Phase PHASE2 | Acute Myeloid Leukemia in Remission | COMPLETED | NCT04712942 |
| Pevonedistat | Other | Phase PHASE2 | Acute Myeloid Leukemia in Remission | COMPLETED | NCT04712942 |
| Azacitidine | Other | Phase PHASE2 | Acute Myeloid Leukemia in Remission | COMPLETED | NCT04712942 |
| Pevonedistat | Other | Phase PHASE2 | Acute Myeloid Leukemia in Remission | COMPLETED | NCT04712942 |
| No Intervention | Other | Preclinical | Attention Deficit Hyperactivity Disorder (ADHD) | COMPLETED | NCT05870605 |
| Vonoprazan | Other | Phase PHASE1 | Helicobacter Pylori | COMPLETED | NCT04753437 |
| Esomeprazole | Other | Phase PHASE1 | Helicobacter Pylori | COMPLETED | NCT04753437 |
| Bismuth potassium citrate | Other | Phase PHASE1 | Helicobacter Pylori | COMPLETED | NCT04753437 |
| Amoxicillin | Other | Phase PHASE1 | Helicobacter Pylori | COMPLETED | NCT04753437 |
| Clarithromycin | Other | Phase PHASE1 | Helicobacter Pylori | COMPLETED | NCT04753437 |
| Vonoprazan | Other | Phase PHASE1 | Helicobacter Pylori | COMPLETED | NCT04753437 |
| Esomeprazole | Other | Phase PHASE1 | Helicobacter Pylori | COMPLETED | NCT04753437 |
| Bismuth potassium citrate | Other | Phase PHASE1 | Helicobacter Pylori | COMPLETED | NCT04753437 |
| Amoxicillin | Other | Phase PHASE1 | Helicobacter Pylori | COMPLETED | NCT04753437 |
| Clarithromycin | Other | Phase PHASE1 | Helicobacter Pylori | COMPLETED | NCT04753437 |
| Placebo | Other | Phase PHASE4 | Diabetes Mellitus | COMPLETED | NCT01686711 |
| AD-4833 30 mg | Other | Phase PHASE4 | Diabetes Mellitus | COMPLETED | NCT01686711 |
| AD-4833 15 mg | Other | Phase PHASE4 | Diabetes Mellitus | COMPLETED | NCT01686711 |
| Esomeprazole | Other | Phase PHASE3 | Helicobacter Pylori | COMPLETED | NCT04198363 |
| Bismuth Potassium citrate | Other | Phase PHASE3 | Helicobacter Pylori | COMPLETED | NCT04198363 |
| Clarithromycin | Other | Phase PHASE3 | Helicobacter Pylori | COMPLETED | NCT04198363 |
| Amoxicillin | Other | Phase PHASE3 | Helicobacter Pylori | COMPLETED | NCT04198363 |
| Vonoprazan | Other | Phase PHASE3 | Helicobacter Pylori | COMPLETED | NCT04198363 |
| Esomeprazole | Other | Phase PHASE3 | Helicobacter Pylori | COMPLETED | NCT04198363 |
| Bismuth Potassium citrate | Other | Phase PHASE3 | Helicobacter Pylori | COMPLETED | NCT04198363 |
| Clarithromycin | Other | Phase PHASE3 | Helicobacter Pylori | COMPLETED | NCT04198363 |
| Amoxicillin | Other | Phase PHASE3 | Helicobacter Pylori | COMPLETED | NCT04198363 |
| Vonoprazan | Other | Phase PHASE3 | Helicobacter Pylori | COMPLETED | NCT04198363 |
| TAK-018 Placebo | Other | Phase PHASE2 | Crohn Disease | TERMINATED | NCT03943446 |
| TAK-018 | Other | Phase PHASE2 | Crohn Disease | TERMINATED | NCT03943446 |
| TAK-018 Placebo | Other | Phase PHASE2 | Crohn Disease | TERMINATED | NCT03943446 |
| TAK-018 | Other | Phase PHASE2 | Crohn Disease | TERMINATED | NCT03943446 |
| TAK-018 Placebo | Other | Phase PHASE2 | Crohn Disease | TERMINATED | NCT03943446 |
| TAK-018 | Other | Phase PHASE2 | Crohn Disease | TERMINATED | NCT03943446 |
| Ixazomib | Other | Phase PHASE1 | AML | TERMINATED | NCT04079738 |
| TAK-659 | Other | Phase PHASE1 | AML | TERMINATED | NCT04079738 |
| Ixazomib | Other | Phase PHASE1 | AML | TERMINATED | NCT04079738 |
| TAK-659 | Other | Phase PHASE1 | AML | TERMINATED | NCT04079738 |
| Ixazomib | Other | Phase PHASE1 | AML | TERMINATED | NCT04079738 |
| TAK-659 | Other | Phase PHASE1 | AML | TERMINATED | NCT04079738 |
| Alogliptin and Metformin hydrochloride | Other | Preclinical | Type 2 Diabetes Mellitus | COMPLETED | NCT03555565 |
| Alogliptin and Metformin hydrochloride | Other | Preclinical | Type 2 Diabetes Mellitus | COMPLETED | NCT03555565 |
| TAK-951 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05567393 |
| TAK-951 Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05567393 |
| TAK-951 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05567393 |
| TAK-951 Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05567393 |
| Blood sampling | Other | Phase PHASE1 | Lung Diseases, Obstructive | COMPLETED | NCT00159341 |
| Nasal filter paper | Other | Phase PHASE1 | Lung Diseases, Obstructive | COMPLETED | NCT00159341 |
| Nasal lavage | Other | Phase PHASE1 | Lung Diseases, Obstructive | COMPLETED | NCT00159341 |
| Alogliptin/Pioglitazone | Other | Preclinical | Type 2 Diabetes Mellitus | COMPLETED | NCT01990300 |
| placebo | Other | Approved | Metabolic Bone Disease | COMPLETED | NCT01002872 |
| Lanthanum Carbonate (Fosrenol) | Other | Approved | Metabolic Bone Disease | COMPLETED | NCT01002872 |
| No intervention | Other | Preclinical | Exposure During Pregnancy | COMPLETED | NCT05803200 |
| No intervention | Other | Preclinical | Exposure During Pregnancy | COMPLETED | NCT05803200 |
| TAK-925 Placebo | Other | Phase PHASE1 | Idiopathic Hypersomnia | COMPLETED | NCT04091438 |
| TAK-925 | Other | Phase PHASE1 | Idiopathic Hypersomnia | COMPLETED | NCT04091438 |
| TAK-925 Placebo | Other | Phase PHASE1 | Idiopathic Hypersomnia | COMPLETED | NCT04091438 |
| TAK-925 | Other | Phase PHASE1 | Idiopathic Hypersomnia | COMPLETED | NCT04091438 |
| Placebo | Other | Phase PHASE2 | Moderate to Severe Plaque Psoriasis | COMPLETED | NCT04999839 |
| NDI-034858 study drug | Drug | Phase PHASE2 | Moderate to Severe Plaque Psoriasis | COMPLETED | NCT04999839 |
| Placebo | Other | Phase PHASE2 | Moderate to Severe Plaque Psoriasis | COMPLETED | NCT04999839 |
| NDI-034858 study drug | Drug | Phase PHASE2 | Moderate to Severe Plaque Psoriasis | COMPLETED | NCT04999839 |
| Metformin hydrochloride Placebo | Other | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT02068443 |
| Metformin hydrochloride | Other | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT02068443 |
| Alogliptin | Other | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT02068443 |
| Metformin hydrochloride Placebo | Other | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT02068443 |
| Metformin hydrochloride | Other | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT02068443 |
| Alogliptin | Other | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT02068443 |
| BEAM (carmustine (BCNU), etoposide, cytarabine, melphalan) | Other | Phase PHASE1 | Non-hodgkin's Lymphoma | COMPLETED | NCT00571493 |
| Bortezomib | Other | Phase PHASE1 | Non-hodgkin's Lymphoma | COMPLETED | NCT00571493 |
| BEAM (carmustine (BCNU), etoposide, cytarabine, melphalan) | Other | Phase PHASE1 | Non-hodgkin's Lymphoma | COMPLETED | NCT00571493 |
| Bortezomib | Other | Phase PHASE1 | Non-hodgkin's Lymphoma | COMPLETED | NCT00571493 |
| Mefenamic acid | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05064449 |
| Itraconazole | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05064449 |
| Soticlestat | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05064449 |
| TAK-676 + Carboplatin + Paclitaxel | Other | Phase EARLY_PHASE1 | Head and Neck Squamous Cell Carcinoma | COMPLETED | NCT06062602 |
| TAK-676 + Carboplatin + 5-FU | Other | Phase EARLY_PHASE1 | Head and Neck Squamous Cell Carcinoma | COMPLETED | NCT06062602 |
| Carboplatin + 5-FU | Other | Phase EARLY_PHASE1 | Head and Neck Squamous Cell Carcinoma | COMPLETED | NCT06062602 |
| Carboplatin + Paclitaxel | Other | Phase EARLY_PHASE1 | Head and Neck Squamous Cell Carcinoma | COMPLETED | NCT06062602 |
| TAK-676 + Carboplatin | Other | Phase EARLY_PHASE1 | Head and Neck Squamous Cell Carcinoma | COMPLETED | NCT06062602 |
| Paclitaxel | Other | Phase EARLY_PHASE1 | Head and Neck Squamous Cell Carcinoma | COMPLETED | NCT06062602 |
| 5-FU | Other | Phase EARLY_PHASE1 | Head and Neck Squamous Cell Carcinoma | COMPLETED | NCT06062602 |
| Carboplatin | Other | Phase EARLY_PHASE1 | Head and Neck Squamous Cell Carcinoma | COMPLETED | NCT06062602 |
| TAK-676 | Other | Phase EARLY_PHASE1 | Head and Neck Squamous Cell Carcinoma | COMPLETED | NCT06062602 |
| TAK-676 + Carboplatin + Paclitaxel | Other | Phase EARLY_PHASE1 | Head and Neck Squamous Cell Carcinoma | COMPLETED | NCT06062602 |
| TAK-676 + Carboplatin + 5-FU | Other | Phase EARLY_PHASE1 | Head and Neck Squamous Cell Carcinoma | COMPLETED | NCT06062602 |
| Carboplatin + 5-FU | Other | Phase EARLY_PHASE1 | Head and Neck Squamous Cell Carcinoma | COMPLETED | NCT06062602 |
| Carboplatin + Paclitaxel | Other | Phase EARLY_PHASE1 | Head and Neck Squamous Cell Carcinoma | COMPLETED | NCT06062602 |
| TAK-676 + Carboplatin | Other | Phase EARLY_PHASE1 | Head and Neck Squamous Cell Carcinoma | COMPLETED | NCT06062602 |
| Paclitaxel | Other | Phase EARLY_PHASE1 | Head and Neck Squamous Cell Carcinoma | COMPLETED | NCT06062602 |
| 5-FU | Other | Phase EARLY_PHASE1 | Head and Neck Squamous Cell Carcinoma | COMPLETED | NCT06062602 |
| Carboplatin | Other | Phase EARLY_PHASE1 | Head and Neck Squamous Cell Carcinoma | COMPLETED | NCT06062602 |
| TAK-676 | Other | Phase EARLY_PHASE1 | Head and Neck Squamous Cell Carcinoma | COMPLETED | NCT06062602 |
| Ixazomib | Other | Phase PHASE2 | Mantle Cell Lymphoma | RECRUITING | NCT03616782 |
| No Intervention | Other | Preclinical | Non-small Cell Lung Cancer (NSCLC) | WITHDRAWN | NCT05863819 |
| No Intervention | Other | Preclinical | Non-small Cell Lung Cancer (NSCLC) | WITHDRAWN | NCT05863819 |
| No Intervention | Other | Preclinical | Non-small Cell Lung Cancer (NSCLC) | WITHDRAWN | NCT05737849 |
| No Intervention | Other | Preclinical | Non-small Cell Lung Cancer (NSCLC) | WITHDRAWN | NCT05737849 |
| oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, bevacizumab | Other | Phase PHASE3 | Colorectal Cancer | COMPLETED | NCT02394795 |
| oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab | Other | Phase PHASE3 | Colorectal Cancer | COMPLETED | NCT02394795 |
| oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, bevacizumab | Other | Phase PHASE3 | Colorectal Cancer | COMPLETED | NCT02394795 |
| oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab | Other | Phase PHASE3 | Colorectal Cancer | COMPLETED | NCT02394795 |
| Mobocertinib | Other | Phase PHASE1 | Hepatic Impairment | COMPLETED | NCT04056468 |
| Mobocertinib | Other | Phase PHASE1 | Hepatic Impairment | COMPLETED | NCT04056468 |
| Azacitidine 75 mg/m^2 | Other | Phase PHASE1 | Leukemia, Myeloid, Acute | COMPLETED | NCT02782468 |
| Pevonedistat 20 mg/m^2 | Other | Phase PHASE1 | Leukemia, Myeloid, Acute | COMPLETED | NCT02782468 |
| Pevonedistat 10 mg/m^2 | Other | Phase PHASE1 | Leukemia, Myeloid, Acute | COMPLETED | NCT02782468 |
| Pevonedistat 44 mg/m^2 | Other | Phase PHASE1 | Leukemia, Myeloid, Acute | COMPLETED | NCT02782468 |
| Pevonedistat 25 mg/m^2 | Other | Phase PHASE1 | Leukemia, Myeloid, Acute | COMPLETED | NCT02782468 |
| Rifampin | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05098041 |
| Soticlestat | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05098041 |
| Rifampin | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05098041 |
| Soticlestat | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05098041 |
| Dexamethasone | Other | Preclinical | Relapsed and/or Refractory Multiple Myeloma | COMPLETED | NCT03433001 |
| Lenalidomide | Other | Preclinical | Relapsed and/or Refractory Multiple Myeloma | COMPLETED | NCT03433001 |
| Ixazomib | Other | Preclinical | Relapsed and/or Refractory Multiple Myeloma | COMPLETED | NCT03433001 |
| Dexamethasone | Other | Preclinical | Relapsed and/or Refractory Multiple Myeloma | COMPLETED | NCT03433001 |
| Lenalidomide | Other | Preclinical | Relapsed and/or Refractory Multiple Myeloma | COMPLETED | NCT03433001 |
| Ixazomib | Other | Preclinical | Relapsed and/or Refractory Multiple Myeloma | COMPLETED | NCT03433001 |
| Ixazomib | Other | Preclinical | Relapsed/Refractory Multiple Myeloma | COMPLETED | NCT03169361 |
| Ixazomib | Other | Preclinical | Relapsed/Refractory Multiple Myeloma | COMPLETED | NCT03169361 |
| Ixazomib | Other | Preclinical | Relapsed/Refractory Multiple Myeloma | COMPLETED | NCT03169361 |
| SYR-472 | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT01751360 |
| SYR-472 | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT01751360 |
| SYR-472 | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT01751360 |
| Placebo | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT01632007 |
| Alogliptin 25 mg | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT01632007 |
| SYR-472 | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT01632007 |
| Trelagliptin | Other | Preclinical | Type 2 Diabetes Mellitus | COMPLETED | NCT03555591 |
| Trelagliptin | Other | Preclinical | Type 2 Diabetes Mellitus | COMPLETED | NCT03555591 |
| Alogliptin | Other | Phase PHASE4 | Type 2 Diabetes Mellitus | COMPLETED | NCT02771093 |
| Trelagliptin | Other | Phase PHASE4 | Type 2 Diabetes Mellitus | COMPLETED | NCT02771093 |
| Alogliptin | Other | Phase PHASE4 | Type 2 Diabetes Mellitus | COMPLETED | NCT02771093 |
| Trelagliptin | Other | Phase PHASE4 | Type 2 Diabetes Mellitus | COMPLETED | NCT02771093 |
| Alogliptin | Other | Phase PHASE4 | Type 2 Diabetes Mellitus | COMPLETED | NCT02771093 |
| Trelagliptin | Other | Phase PHASE4 | Type 2 Diabetes Mellitus | COMPLETED | NCT02771093 |
| Placebo | Other | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT02512068 |
| Trelagliptin 25 mg | Other | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT02512068 |
| Placebo | Other | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT02324569 |
| SYR-472 | Other | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT02324569 |
| Lansoprazole | Other | Phase PHASE4 | Erosive Esophagitis | COMPLETED | NCT02679508 |
| Vonoprazan | Other | Phase PHASE4 | Erosive Esophagitis | COMPLETED | NCT02679508 |
| SYR-472 | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT01431807 |
| SYR-472 | Other | Phase PHASE3 | Diabetes Mellitus | COMPLETED | NCT01431807 |
| rhPTH(1-84) | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05137730 |
| No Intervention | Other | Preclinical | Von Willebrand Disease (VWD) | COMPLETED | NCT05695560 |
| No Intervention | Other | Preclinical | Von Willebrand Disease (VWD) | COMPLETED | NCT05695560 |
| No Intervention | Other | Preclinical | Von Willebrand Disease (VWD) | COMPLETED | NCT05695560 |
| No Intervention | Other | Phase PHASE4 | Gaucher Disease | COMPLETED | NCT04718779 |
| Digital Engagement Application (GD App) | Other | Phase PHASE4 | Gaucher Disease | COMPLETED | NCT04718779 |
| No Intervention | Other | Phase PHASE4 | Gaucher Disease | COMPLETED | NCT04718779 |
| Digital Engagement Application (GD App) | Other | Phase PHASE4 | Gaucher Disease | COMPLETED | NCT04718779 |
| Alogliptin | Other | Phase PHASE4 | Type 2 Diabetes Mellitus | COMPLETED | NCT03231709 |
| Trelagliptin | Other | Phase PHASE4 | Type 2 Diabetes Mellitus | COMPLETED | NCT03231709 |
| Alogliptin | Other | Phase PHASE4 | Type 2 Diabetes Mellitus | COMPLETED | NCT03231709 |
| Trelagliptin | Other | Phase PHASE4 | Type 2 Diabetes Mellitus | COMPLETED | NCT03231709 |
| Daily DPP-4 inhibitor | Other | Phase PHASE4 | Type 2 Diabetes | COMPLETED | NCT03014479 |
| Trelagliptin | Other | Phase PHASE4 | Type 2 Diabetes | COMPLETED | NCT03014479 |
| Daily DPP-4 inhibitor | Other | Phase PHASE4 | Type 2 Diabetes | COMPLETED | NCT03014479 |
| Trelagliptin | Other | Phase PHASE4 | Type 2 Diabetes | COMPLETED | NCT03014479 |
| SYR-472 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02372097 |
| SYR-472 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02372097 |
| Placebo | Other | Phase PHASE2 | Narcolepsy Type 1 (NT 1) | TERMINATED | NCT04820842 |
| TAK-994 | Other | Phase PHASE2 | Narcolepsy Type 1 (NT 1) | TERMINATED | NCT04820842 |
| Placebo | Other | Phase PHASE2 | Narcolepsy Type 1 (NT 1) | TERMINATED | NCT04820842 |
| TAK-994 | Other | Phase PHASE2 | Narcolepsy Type 1 (NT 1) | TERMINATED | NCT04820842 |
| Lanadelumab | Other | Phase PHASE3 | Angioedema | COMPLETED | NCT04206605 |
| Placebo | Other | Phase PHASE3 | Angioedema | COMPLETED | NCT04206605 |
| Lanadelumab | Other | Phase PHASE3 | Angioedema | COMPLETED | NCT04206605 |
| Placebo | Other | Phase PHASE3 | Angioedema | COMPLETED | NCT04206605 |
| Lanadelumab | Other | Phase PHASE3 | Angioedema | COMPLETED | NCT04206605 |
| Placebo | Other | Phase PHASE3 | Angioedema | COMPLETED | NCT04206605 |
| Brentuximab vedotin | Other | Phase PHASE3 | Diffuse Large B-cell-lymphoma | NOT_YET_RECRUITING | NCT06186986 |
| Brentuximab vedotin | Other | Phase PHASE3 | Diffuse Large B-cell-lymphoma | UNKNOWN | NCT06186986 |
| Lanadelumab | Other | Phase PHASE2 | Hereditary Autoinflammatory Disease | UNKNOWN | NCT04278885 |
| Lanadelumab | Other | Phase PHASE2 | Hereditary Autoinflammatory Disease | UNKNOWN | NCT04278885 |
| Mobocertinib | Other | Phase PHASE1 | Renal Impairment | COMPLETED | NCT04056455 |
| Mobocertinib | Other | Phase PHASE1 | Renal Impairment | COMPLETED | NCT04056455 |
| Evaluation of therapeutical approach after ASCT | Other | Preclinical | Hodgkin Lymphoma, Adult | RECRUITING | NCT04776265 |
| No Intervention | Other | Preclinical | Metachromatic Leukodystrophy (MLD) | WITHDRAWN | NCT05755568 |
| No Intervention | Other | Preclinical | Metachromatic Leukodystrophy (MLD) | WITHDRAWN | NCT05755568 |
| MLN0128 | Other | Phase PHASE1 | Anaplastic Thyroid Cancer | COMPLETED | NCT02244463 |
| MLN0128 | Other | Phase PHASE1 | Anaplastic Thyroid Cancer | COMPLETED | NCT02244463 |
| Ibrutinib | Other | Phase PHASE1 | Mantle-Cell Lymphoma | COMPLETED | NCT03323151 |
| Ixazomib | Other | Phase PHASE1 | Mantle-Cell Lymphoma | COMPLETED | NCT03323151 |
| Niraparib | Other | Phase PHASE2 | Efficacy | NOT_YET_RECRUITING | NCT06237205 |
| Niraparib | Other | Phase PHASE2 | Efficacy | NOT_YET_RECRUITING | NCT06237205 |
| Niraparib | Other | Phase PHASE2 | Efficacy | NOT_YET_RECRUITING | NCT06237205 |
| Soticlestat | Other | Phase PHASE1 | Hepatic Impairment | COMPLETED | NCT05098054 |
| Soticlestat | Other | Phase PHASE1 | Hepatic Impairment | COMPLETED | NCT05098054 |
| Efavirenz | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05995249 |
| Phenytoin | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05995249 |
| Erythromycin | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05995249 |
| TAK-279 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05995249 |
| Efavirenz | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05995249 |
| Phenytoin | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05995249 |
| Erythromycin | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05995249 |
| TAK-279 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05995249 |
| Dengue Tetravalent Vaccine (TDV) | Other | Phase PHASE3 | Dengue Fever | COMPLETED | NCT04313244 |
| 9vHPV Vaccine | Other | Phase PHASE3 | Dengue Fever | COMPLETED | NCT04313244 |
| Dengue Tetravalent Vaccine (TDV) | Other | Phase PHASE3 | Dengue Fever | COMPLETED | NCT04313244 |
| 9vHPV Vaccine | Other | Phase PHASE3 | Dengue Fever | COMPLETED | NCT04313244 |
| Placebo | Other | Phase PHASE4 | Schizophrenia | UNKNOWN | NCT02357797 |
| Vortioxetine | Other | Phase PHASE4 | Schizophrenia | UNKNOWN | NCT02357797 |
| Placebo | Other | Phase PHASE4 | Schizophrenia | ACTIVE_NOT_RECRUITING | NCT02357797 |
| Vortioxetine | Other | Phase PHASE4 | Schizophrenia | ACTIVE_NOT_RECRUITING | NCT02357797 |
| Mobocertinib | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03811834 |
| Mobocertinib | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03811834 |
| Lisdexamfetamine Dimesylate | Other | Phase PHASE4 | Attention Deficit Hyperactivity Disorder | COMPLETED | NCT03337646 |
| Maribavir | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05382104 |
| Methotrexate and Cytarabine | Other | Phase PHASE2 | Acute Lymphoblastic Leukemia | WITHDRAWN | NCT04845035 |
| Berlin-Frankfurt-Münster Chemotherapy | Drug | Phase PHASE2 | Acute Lymphoblastic Leukemia | WITHDRAWN | NCT04845035 |
| Ponatinib | Other | Phase PHASE2 | Acute Lymphoblastic Leukemia | WITHDRAWN | NCT04845035 |
| Dasatinib | Other | Phase PHASE2 | Acute Lymphoblastic Leukemia | WITHDRAWN | NCT04845035 |
| Methotrexate and Cytarabine | Other | Phase PHASE2 | Acute Lymphoblastic Leukemia | WITHDRAWN | NCT04845035 |
| Berlin-Frankfurt-Münster Chemotherapy | Drug | Phase PHASE2 | Acute Lymphoblastic Leukemia | WITHDRAWN | NCT04845035 |
| Ponatinib | Other | Phase PHASE2 | Acute Lymphoblastic Leukemia | WITHDRAWN | NCT04845035 |
| Dasatinib | Other | Phase PHASE2 | Acute Lymphoblastic Leukemia | WITHDRAWN | NCT04845035 |
| ADYNOVATE | Other | Preclinical | Hemophilia A | COMPLETED | NCT03824522 |
| ADYNOVATE | Other | Preclinical | Hemophilia A | COMPLETED | NCT03824522 |
| BrentuximabVedotin (BV) | Other | Phase PHASE1 | Hodgkin Lymphoma | ACTIVE_NOT_RECRUITING | NCT03576378 |
| Soticlestat | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05284760 |
| Soticlestat | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05284760 |
| TAK-510 Placebo | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT04731922 |
| TAK-510 | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT04731922 |
| TAK-510 Placebo | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT04731922 |
| TAK-510 | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT04731922 |
| Fomepizole | Other | Preclinical | Ethylene Glycol Poisoning, Methanol Poisoning | COMPLETED | NCT02415712 |
| Fomepizole | Other | Preclinical | Ethylene Glycol Poisoning, Methanol Poisoning | COMPLETED | NCT02415712 |
| ipilimumab | Other | Phase PHASE1 | Melanoma | TERMINATED | NCT02723006 |
| nivolumab | Other | Phase PHASE1 | Melanoma | TERMINATED | NCT02723006 |
| vedolizumab | Other | Phase PHASE1 | Melanoma | TERMINATED | NCT02723006 |
| TAK-202 | Other | Phase PHASE1 | Melanoma | TERMINATED | NCT02723006 |
| TAK-580 | Other | Phase PHASE1 | Melanoma | TERMINATED | NCT02723006 |
| ipilimumab | Other | Phase PHASE1 | Melanoma | TERMINATED | NCT02723006 |
| nivolumab | Other | Phase PHASE1 | Melanoma | TERMINATED | NCT02723006 |
| vedolizumab | Other | Phase PHASE1 | Melanoma | TERMINATED | NCT02723006 |
| TAK-202 | Other | Phase PHASE1 | Melanoma | TERMINATED | NCT02723006 |
| TAK-580 | Other | Phase PHASE1 | Melanoma | TERMINATED | NCT02723006 |
| ipilimumab | Other | Phase PHASE1 | Melanoma | TERMINATED | NCT02723006 |
| nivolumab | Other | Phase PHASE1 | Melanoma | TERMINATED | NCT02723006 |
| vedolizumab | Other | Phase PHASE1 | Melanoma | TERMINATED | NCT02723006 |
| TAK-202 | Other | Phase PHASE1 | Melanoma | TERMINATED | NCT02723006 |
| TAK-580 | Other | Phase PHASE1 | Melanoma | TERMINATED | NCT02723006 |
| No Intervention | Other | Preclinical | Hodgkin Lymphoma | WITHDRAWN | NCT06104878 |
| ADVATE | Other | Phase PHASE4 | Hemophilia A | COMPLETED | NCT04985682 |
| ADVATE | Other | Phase PHASE4 | Hemophilia A | COMPLETED | NCT04985682 |
| Rasagiline | Other | Preclinical | Parkinson's Disease | COMPLETED | NCT03727139 |
| Rasagiline | Other | Preclinical | Parkinson's Disease | COMPLETED | NCT03727139 |
| Placebo | Other | Phase PHASE2 | Healthy Volunteers | WITHDRAWN | NCT05469802 |
| Purified Inactivated Zika Virus Vaccine (PIZV) | Other | Phase PHASE2 | Healthy Volunteers | WITHDRAWN | NCT05469802 |
| Placebo | Other | Phase PHASE2 | Healthy Volunteers | WITHDRAWN | NCT05469802 |
| Purified Inactivated Zika Virus Vaccine (PIZV) | Other | Phase PHASE2 | Healthy Volunteers | WITHDRAWN | NCT05469802 |
| No Intervention | Other | Preclinical | Inflammatory Bowel Diseases | COMPLETED | NCT04567628 |
| No Intervention | Other | Preclinical | Inflammatory Bowel Diseases | COMPLETED | NCT04567628 |
| No Intervention | Other | Preclinical | Inflammatory Bowel Diseases | COMPLETED | NCT04567628 |
| TDV | Other | Phase PHASE2 | Healthy Volunteers | COMPLETED | NCT02948829 |
| TDV | Other | Phase PHASE2 | Healthy Volunteers | COMPLETED | NCT02948829 |
| Placebo | Other | Phase PHASE1 | Homeostasis | COMPLETED | NCT01216293 |
| Esomeprazole | Other | Phase PHASE1 | Homeostasis | COMPLETED | NCT01216293 |
| Dexlansoprazole | Other | Phase PHASE1 | Homeostasis | COMPLETED | NCT01216293 |
| Placebo | Other | Phase PHASE1 | Homeostasis | COMPLETED | NCT01216293 |
| Esomeprazole | Other | Phase PHASE1 | Homeostasis | COMPLETED | NCT01216293 |
| Dexlansoprazole | Other | Phase PHASE1 | Homeostasis | COMPLETED | NCT01216293 |
| Placebo | Other | Phase PHASE1 | Homeostasis | COMPLETED | NCT01216293 |
| Esomeprazole | Other | Phase PHASE1 | Homeostasis | COMPLETED | NCT01216293 |
| Dexlansoprazole | Other | Phase PHASE1 | Homeostasis | COMPLETED | NCT01216293 |
| Standard of Care | Other | Preclinical | Gaucher Disease | COMPLETED | NCT04721366 |
| Standard of Care | Other | Preclinical | Gaucher Disease | COMPLETED | NCT04721366 |
| TAK-079 Placebo | Other | Phase PHASE1 | Systemic Lupus Erythematosus | COMPLETED | NCT03724916 |
| TAK-079 | Other | Phase PHASE1 | Systemic Lupus Erythematosus | COMPLETED | NCT03724916 |
| TAK-079 Placebo | Other | Phase PHASE1 | Systemic Lupus Erythematosus | COMPLETED | NCT03724916 |
| TAK-079 | Other | Phase PHASE1 | Systemic Lupus Erythematosus | COMPLETED | NCT03724916 |
| B-MAD chemotherapy | Drug | Phase PHASE1 | Extranodal NK/T-cell Lymphoma | COMPLETED | NCT03246750 |
| B-MAD chemotherapy | Drug | Phase PHASE1 | Extranodal NK/T-cell Lymphoma | COMPLETED | NCT03246750 |
| Placebo | Other | Phase PHASE1 | Sickle Cell Disease | COMPLETED | NCT03997760 |
| TAK-755 | Other | Phase PHASE1 | Sickle Cell Disease | COMPLETED | NCT03997760 |
| Placebo | Other | Phase PHASE1 | Sickle Cell Disease | COMPLETED | NCT03997760 |
| TAK-755 | Other | Phase PHASE1 | Sickle Cell Disease | COMPLETED | NCT03997760 |
| Dexamethasone | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT02697383 |
| Ixazomib (MLN9708) | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT02697383 |
| Dexamethasone | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT02697383 |
| Ixazomib (MLN9708) | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT02697383 |
| Dexamethasone | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT02697383 |
| Ixazomib (MLN9708) | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT02697383 |
| Placebo | Other | Phase PHASE2 | Parkinson Disease | COMPLETED | NCT04334317 |
| TAK-071 | Other | Phase PHASE2 | Parkinson Disease | COMPLETED | NCT04334317 |
| Teduglutide | Other | Phase PHASE3 | Short Bowel Syndrome | COMPLETED | NCT05027308 |
| Teduglutide | Other | Phase PHASE3 | Short Bowel Syndrome | COMPLETED | NCT05027308 |
| TAK-279 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06290050 |
| Repaglinide | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06290050 |
| Midazolam | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06290050 |
| TAK-279 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06290050 |
| Repaglinide | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06290050 |
| Midazolam | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06290050 |
| Brentuximab vedotin | Other | Phase PHASE1 | Relapsed or Refractory Hodgkin Lymphoma | COMPLETED | NCT01492088 |
| Brentuximab vedotin | Other | Phase PHASE1 | Relapsed or Refractory Hodgkin Lymphoma | COMPLETED | NCT01492088 |
| Placebo | Other | Phase PHASE2 | Psoriatic Arthritis | COMPLETED | NCT05153148 |
| NDI-034858 | Other | Phase PHASE2 | Psoriatic Arthritis | COMPLETED | NCT05153148 |
| Placebo | Other | Phase PHASE2 | Psoriatic Arthritis | COMPLETED | NCT05153148 |
| NDI-034858 | Other | Phase PHASE2 | Psoriatic Arthritis | COMPLETED | NCT05153148 |
| Niraparib | Other | Phase PHASE2 | Ovarian Cancer | COMPLETED | NCT03759587 |
| Darvadstrocel | Other | Phase PHASE3 | Complex Perianal Fistulas in Adult Participants With Crohn's Disease | COMPLETED | NCT03706456 |
| Darvadstrocel | Other | Phase PHASE3 | Complex Perianal Fistulas in Adult Participants With Crohn's Disease | COMPLETED | NCT03706456 |
| blood sampling (alpha-Galactosidase & LysoGb3) | Other | Approved | Fabry Disease | ACTIVE_NOT_RECRUITING | NCT04943991 |
| blood sampling (alpha-Galactosidase & LysoGb3) | Other | Approved | Fabry Disease | ACTIVE_NOT_RECRUITING | NCT04943991 |
| Glatiramer acetate | Other | Preclinical | Multiple Sclerosis | COMPLETED | NCT03209479 |
| Glatiramer acetate | Other | Preclinical | Multiple Sclerosis | COMPLETED | NCT03209479 |
| No Intervention | Other | Preclinical | Multiple Myeloma | COMPLETED | NCT05882279 |
| No Intervention | Other | Preclinical | Multiple Myeloma | COMPLETED | NCT05882279 |
| Rituximab | Other | Phase PHASE1 | Lymphoma, Non-Hodgkin | TERMINATED | NCT04074330 |
| TAK-981 | Other | Phase PHASE1 | Lymphoma, Non-Hodgkin | TERMINATED | NCT04074330 |
| REPLAGAL | Other | Phase PHASE3 | Fabry Disease | TERMINATED | NCT04840667 |
| Lanadelumab | Other | Phase PHASE3 | Angioedema | COMPLETED | NCT04444895 |
| Brentuximab Vedotin | Other | Phase PHASE2 | Enteropathy Associated T-cell Lymphoma | COMPLETED | NCT03217643 |
| Brentuximab Vedotin | Other | Phase PHASE2 | Enteropathy Associated T-cell Lymphoma | COMPLETED | NCT03217643 |
| Ixazomib | Other | Phase PHASE2 | Plasma Cell Myeloma | ACTIVE_NOT_RECRUITING | NCT03942224 |
| Dexamethasone | Other | Phase PHASE2 | Plasma Cell Myeloma | ACTIVE_NOT_RECRUITING | NCT03942224 |
| Daratumumab | Other | Phase PHASE2 | Plasma Cell Myeloma | ACTIVE_NOT_RECRUITING | NCT03942224 |
| Bortezomib | Other | Phase PHASE2 | Plasma Cell Myeloma | ACTIVE_NOT_RECRUITING | NCT03942224 |
| Ixazomib | Other | Phase PHASE2 | Plasma Cell Myeloma | ACTIVE_NOT_RECRUITING | NCT03942224 |
| Dexamethasone | Other | Phase PHASE2 | Plasma Cell Myeloma | ACTIVE_NOT_RECRUITING | NCT03942224 |
| Daratumumab | Other | Phase PHASE2 | Plasma Cell Myeloma | ACTIVE_NOT_RECRUITING | NCT03942224 |
| Bortezomib | Other | Phase PHASE2 | Plasma Cell Myeloma | ACTIVE_NOT_RECRUITING | NCT03942224 |
| Dexamethasone | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT03439293 |
| Daratumumab | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT03439293 |
| Ixazomib | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT03439293 |
| Dexamethasone | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT03439293 |
| Daratumumab | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT03439293 |
| Ixazomib | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT03439293 |
| Maribavir | Other | Phase PHASE3 | Cytomegalovirus (CMV) | COMPLETED | NCT05137717 |
| Maribavir | Other | Phase PHASE3 | Cytomegalovirus (CMV) | COMPLETED | NCT05137717 |
| Maribavir | Other | Phase PHASE3 | Cytomegalovirus (CMV) | COMPLETED | NCT05137717 |
| Moxifloxacin Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06258265 |
| Moxifloxacin | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06258265 |
| TAK-279 Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06258265 |
| TAK-279 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06258265 |
| Any FDA Approved ALK Inhibitors | Other | Preclinical | Anaplastic Lymphoma Kinase-positive | COMPLETED | NCT03546894 |
| Lorlatinib | Other | Preclinical | Anaplastic Lymphoma Kinase-positive | COMPLETED | NCT03546894 |
| Ceritinib | Other | Preclinical | Anaplastic Lymphoma Kinase-positive | COMPLETED | NCT03546894 |
| Alectinib | Other | Preclinical | Anaplastic Lymphoma Kinase-positive | COMPLETED | NCT03546894 |
| Brigatinib | Other | Preclinical | Anaplastic Lymphoma Kinase-positive | COMPLETED | NCT03546894 |
| Any FDA Approved ALK Inhibitors | Other | Preclinical | Anaplastic Lymphoma Kinase-positive | COMPLETED | NCT03546894 |
| Lorlatinib | Other | Preclinical | Anaplastic Lymphoma Kinase-positive | COMPLETED | NCT03546894 |
| Ceritinib | Other | Preclinical | Anaplastic Lymphoma Kinase-positive | COMPLETED | NCT03546894 |
| Alectinib | Other | Preclinical | Anaplastic Lymphoma Kinase-positive | COMPLETED | NCT03546894 |
| Brigatinib | Other | Preclinical | Anaplastic Lymphoma Kinase-positive | COMPLETED | NCT03546894 |
| Niraparib | Other | Phase PHASE2 | Ovarian Cancer | COMPLETED | NCT03759600 |
| Niraparib | Other | Phase PHASE2 | Ovarian Cancer | COMPLETED | NCT03759600 |
| Niraparib | Other | Phase PHASE2 | Ovarian Cancer | COMPLETED | NCT03759600 |
| gemcitabine | Other | Phase PHASE3 | Adenocarcinoma of the Pancreas | COMPLETED | NCT01231347 |
| Placebo | Other | Phase PHASE3 | Adenocarcinoma of the Pancreas | COMPLETED | NCT01231347 |
| AMG 479 | Other | Phase PHASE3 | Adenocarcinoma of the Pancreas | COMPLETED | NCT01231347 |
| gemcitabine | Other | Phase PHASE3 | Adenocarcinoma of the Pancreas | COMPLETED | NCT01231347 |
| Placebo | Other | Phase PHASE3 | Adenocarcinoma of the Pancreas | COMPLETED | NCT01231347 |
| AMG 479 | Other | Phase PHASE3 | Adenocarcinoma of the Pancreas | COMPLETED | NCT01231347 |
| Subcutaneous vedolizumab | Other | Preclinical | Inflammatory Bowel Diseases | ACTIVE_NOT_RECRUITING | NCT05158517 |
| Subcutaneous vedolizumab | Other | Preclinical | Inflammatory Bowel Diseases | ACTIVE_NOT_RECRUITING | NCT05158517 |
| RIXUBIS | Other | Preclinical | Hemophilia B | COMPLETED | NCT02937831 |
| RIXUBIS | Other | Preclinical | Hemophilia B | COMPLETED | NCT02937831 |
| RIXUBIS | Other | Preclinical | Hemophilia B | COMPLETED | NCT02937831 |
| No Intervention | Other | Preclinical | Multiple Myeloma | COMPLETED | NCT04840680 |
| No Intervention | Other | Preclinical | Multiple Myeloma | COMPLETED | NCT04840680 |
| No Intervention | Other | Preclinical | Hereditary Angioedema (HAE) | COMPLETED | NCT05578417 |
| No Intervention | Other | Preclinical | Hereditary Angioedema (HAE) | COMPLETED | NCT05578417 |
| TAK-105-a Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04964258 |
| TAK-105-a | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04964258 |
| TAK-105-a Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04964258 |
| TAK-105-a | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04964258 |
| No Intervention | Other | Preclinical | Hereditary Angioedema (HAE) | COMPLETED | NCT05489640 |
| No Intervention | Other | Preclinical | Hereditary Angioedema (HAE) | COMPLETED | NCT05489640 |
| No Intervention | Other | Preclinical | Hereditary Angioedema (HAE) | COMPLETED | NCT05489640 |
| TAK-227 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05818956 |
| TAK-227 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05818956 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06111547 |
| TAK-279 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06111547 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06111547 |
| TAK-279 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06111547 |
| pioglitazone | Other | Preclinical | Type II Diabetes Mellitus | COMPLETED | NCT01165190 |
| pioglitazone | Other | Preclinical | Type II Diabetes Mellitus | COMPLETED | NCT01165190 |
| pioglitazone | Other | Preclinical | Type II Diabetes Mellitus | COMPLETED | NCT01165190 |
| Soticlestat | Other | Phase PHASE3 | Lennox Gastaut Syndrome (LGS) | COMPLETED | NCT04938427 |
| Placebo | Other | Phase PHASE3 | Lennox Gastaut Syndrome (LGS) | COMPLETED | NCT04938427 |
| Soticlestat | Other | Phase PHASE3 | Lennox Gastaut Syndrome (LGS) | COMPLETED | NCT04938427 |
| Placebo | Other | Phase PHASE3 | Lennox Gastaut Syndrome (LGS) | COMPLETED | NCT04938427 |
| Brentuximab vedotin (Genetical Recombination) | Other | Preclinical | Untreated CD30-Positive Hodgkin's Lymphoma | COMPLETED | NCT03729609 |
| Brentuximab vedotin (Genetical Recombination) | Other | Preclinical | Untreated CD30-Positive Hodgkin's Lymphoma | COMPLETED | NCT03729609 |
| Brentuximab vedotin (Genetical Recombination) | Other | Preclinical | Untreated CD30-Positive Hodgkin's Lymphoma | COMPLETED | NCT03729609 |
| Trelagliptin | Other | Preclinical | Type 2 Diabetes Mellitus | COMPLETED | NCT04285983 |
| Trelagliptin | Other | Preclinical | Type 2 Diabetes Mellitus | COMPLETED | NCT04285983 |
| TAK228 | Other | Phase PHASE2 | Ovarian Cancer | COMPLETED | NCT03648489 |
| Paclitaxel | Other | Phase PHASE2 | Ovarian Cancer | COMPLETED | NCT03648489 |
| No Intervention | Other | Preclinical | Chronic Idiopathic Constipation (CIC) | RECRUITING | NCT04838522 |
| No Intervention | Other | Preclinical | Chronic Idiopathic Constipation (CIC) | RECRUITING | NCT04838522 |
| No Intervention | Other | Preclinical | Cytomegalovirus (CMV) | COMPLETED | NCT06615921 |
| Ontamalimab | Other | Phase PHASE1 | Steatohepatitis | TERMINATED | NCT07052682 |
| Placebo | Other | Phase PHASE2 | Multiple System Atrophy | COMPLETED | NCT05526391 |
| TAK-341 | Other | Phase PHASE2 | Multiple System Atrophy | COMPLETED | NCT05526391 |
| Placebo | Other | Phase PHASE2 | Multiple System Atrophy | COMPLETED | NCT05526391 |
| TAK-341 | Other | Phase PHASE2 | Multiple System Atrophy | COMPLETED | NCT05526391 |
| Placebo | Other | Phase PHASE2 | Multiple System Atrophy | COMPLETED | NCT05526391 |
| TAK-341 | Other | Phase PHASE2 | Multiple System Atrophy | COMPLETED | NCT05526391 |
| Image-guided radiation therapy | Drug | Phase PHASE1 | Carcinoma, Non-Small-Cell Lung | COMPLETED | NCT04879849 |
| TAK-676 | Other | Phase PHASE1 | Carcinoma, Non-Small-Cell Lung | COMPLETED | NCT04879849 |
| Pembrolizumab | Other | Phase PHASE1 | Carcinoma, Non-Small-Cell Lung | COMPLETED | NCT04879849 |
| No Intervention | Other | Preclinical | Hodgkin Lymphoma | RECRUITING | NCT05100056 |
| No Intervention | Other | Preclinical | Hodgkin Lymphoma | RECRUITING | NCT05100056 |
| ADVATE | Other | Phase PHASE3 | Von Willebrand Disease (VWD) | RECRUITING | NCT05582993 |
| Vonicog Alfa | Other | Phase PHASE3 | Von Willebrand Disease (VWD) | RECRUITING | NCT05582993 |
| Vedolizumab | Other | Phase PHASE4 | Crohn's Disease | RECRUITING | NCT06180382 |
| Adalimumab | Other | Phase PHASE4 | Crohn's Disease | RECRUITING | NCT06180382 |
| Intravenous Immunoglobulin (IVIG) | Other | Phase PHASE4 | Mucopolysaccharidosis (MPS) | WITHDRAWN | NCT05494593 |
| Methotrexate | Other | Phase PHASE4 | Mucopolysaccharidosis (MPS) | WITHDRAWN | NCT05494593 |
| Rituximab | Other | Phase PHASE4 | Mucopolysaccharidosis (MPS) | WITHDRAWN | NCT05494593 |
| ELAPRASE | Other | Phase PHASE4 | Mucopolysaccharidosis (MPS) | WITHDRAWN | NCT05494593 |
| Intravenous Immunoglobulin (IVIG) | Other | Phase PHASE4 | Mucopolysaccharidosis (MPS) | WITHDRAWN | NCT05494593 |
| Methotrexate | Other | Phase PHASE4 | Mucopolysaccharidosis (MPS) | WITHDRAWN | NCT05494593 |
| Rituximab | Other | Phase PHASE4 | Mucopolysaccharidosis (MPS) | WITHDRAWN | NCT05494593 |
| ELAPRASE | Other | Phase PHASE4 | Mucopolysaccharidosis (MPS) | WITHDRAWN | NCT05494593 |
| Intravenous Immunoglobulin (IVIG) | Other | Phase PHASE4 | Mucopolysaccharidosis (MPS) | WITHDRAWN | NCT05494593 |
| Methotrexate | Other | Phase PHASE4 | Mucopolysaccharidosis (MPS) | WITHDRAWN | NCT05494593 |
| Rituximab | Other | Phase PHASE4 | Mucopolysaccharidosis (MPS) | WITHDRAWN | NCT05494593 |
| ELAPRASE | Other | Phase PHASE4 | Mucopolysaccharidosis (MPS) | WITHDRAWN | NCT05494593 |
| Pembrolizumab | Other | Phase PHASE1 | Advanced or Metastatic Solid Tumors | COMPLETED | NCT04381650 |
| TAK-981 | Other | Phase PHASE1 | Advanced or Metastatic Solid Tumors | COMPLETED | NCT04381650 |
| TAK-279 | Other | Phase PHASE3 | Plaque Psoriasis | ACTIVE_NOT_RECRUITING | NCT06550076 |
| TAK-279 | Other | Phase PHASE3 | Plaque Psoriasis | ACTIVE_NOT_RECRUITING | NCT06550076 |
| No Intervention | Other | Preclinical | Short Bowel Syndrome (SBS) | RECRUITING | NCT05561647 |
| Ixazomib | Other | Phase PHASE1 | Newly Diagnosed Primary Amyloidosis | ACTIVE_NOT_RECRUITING | NCT03283917 |
| Dexamethasone | Other | Phase PHASE1 | Newly Diagnosed Primary Amyloidosis | ACTIVE_NOT_RECRUITING | NCT03283917 |
| Daratumumab | Other | Phase PHASE1 | Newly Diagnosed Primary Amyloidosis | ACTIVE_NOT_RECRUITING | NCT03283917 |
| Ixazomib | Other | Phase PHASE1 | Newly Diagnosed Primary Amyloidosis | ACTIVE_NOT_RECRUITING | NCT03283917 |
| Dexamethasone | Other | Phase PHASE1 | Newly Diagnosed Primary Amyloidosis | ACTIVE_NOT_RECRUITING | NCT03283917 |
| Daratumumab | Other | Phase PHASE1 | Newly Diagnosed Primary Amyloidosis | ACTIVE_NOT_RECRUITING | NCT03283917 |
| Tyrosine kinase inhibitor | Other | Phase PHASE2 | NSCLC | ACTIVE_NOT_RECRUITING | NCT04318938 |
| Brigatinib | Other | Phase PHASE2 | NSCLC | ACTIVE_NOT_RECRUITING | NCT04318938 |
| Conditioning chemotherapy | Drug | Phase PHASE1 | Acute Myeloid Leukemia | RECRUITING | NCT05748197 |
| ADCLEC.syn1 CAR T cells | Other | Phase PHASE1 | Acute Myeloid Leukemia | RECRUITING | NCT05748197 |
| Conditioning chemotherapy | Drug | Phase PHASE1 | Acute Myeloid Leukemia | RECRUITING | NCT05748197 |
| ADCLEC.syn1 CAR T cells | Other | Phase PHASE1 | Acute Myeloid Leukemia | RECRUITING | NCT05748197 |
| No intervention | Other | Preclinical | Hereditary Angioedema (HAE) | NOT_YET_RECRUITING | NCT07218393 |
| No intervention | Other | Preclinical | Hereditary Angioedema (HAE) | NOT_YET_RECRUITING | NCT07218393 |
| Vedolizumab | Other | Phase PHASE2 | Ulcerative Colitis | COMPLETED | NCT03196427 |
| Vedolizumab | Other | Phase PHASE2 | Ulcerative Colitis | COMPLETED | NCT03196427 |
| 5-fluorouracil | Other | Phase PHASE1 | Solid Neoplasms | COMPLETED | NCT04420884 |
| Platinum | Other | Phase PHASE1 | Solid Neoplasms | COMPLETED | NCT04420884 |
| Pembrolizumab | Other | Phase PHASE1 | Solid Neoplasms | COMPLETED | NCT04420884 |
| Dazostinag | Other | Phase PHASE1 | Solid Neoplasms | COMPLETED | NCT04420884 |
| 5-fluorouracil | Other | Phase PHASE1 | Solid Neoplasms | COMPLETED | NCT04420884 |
| Platinum | Other | Phase PHASE1 | Solid Neoplasms | COMPLETED | NCT04420884 |
| Pembrolizumab | Other | Phase PHASE1 | Solid Neoplasms | COMPLETED | NCT04420884 |
| Dazostinag | Other | Phase PHASE1 | Solid Neoplasms | COMPLETED | NCT04420884 |
| Lanadelumab | Other | Preclinical | Hereditary Angioedema (HAE) | ACTIVE_NOT_RECRUITING | NCT05397431 |
| Lanadelumab | Other | Preclinical | Hereditary Angioedema (HAE) | ACTIVE_NOT_RECRUITING | NCT05397431 |
| Psychotherapy as Usual (TAU) | Drug | Approved | Major Depression | RECRUITING | NCT07380451 |
| Modular Intervention for Depression Therapy (MIND Therapy) | Drug | Approved | Major Depression | RECRUITING | NCT07380451 |
| TAK-279 | Other | Phase PHASE1 | Hepatic Impairment | COMPLETED | NCT05976321 |
| Pevonedistat | Other | Phase PHASE1 | Myelodysplastic Syndromes | COMPLETED | NCT03814005 |
| Azacitidine | Other | Phase PHASE1 | Myelodysplastic Syndromes | COMPLETED | NCT03814005 |
| Pevonedistat | Other | Phase PHASE1 | Myelodysplastic Syndromes | COMPLETED | NCT03814005 |
| Azacitidine | Other | Phase PHASE1 | Myelodysplastic Syndromes | COMPLETED | NCT03814005 |
| Pevonedistat | Other | Phase PHASE1 | Myelodysplastic Syndromes | COMPLETED | NCT03814005 |
| Azacitidine | Other | Phase PHASE1 | Myelodysplastic Syndromes | COMPLETED | NCT03814005 |
| Tenofovir Disoproxil Fumarate | Other | Preclinical | Hepatitis B | RECRUITING | NCT06586983 |
| Tenofovir Disoproxil Fumarate | Other | Preclinical | Hepatitis B | RECRUITING | NCT06586983 |
| No Intervention | Other | Preclinical | Hodgkin Disease | COMPLETED | NCT04998331 |
| No Intervention | Other | Preclinical | Hodgkin Disease | COMPLETED | NCT04998331 |
| Pomalidomide | Other | Phase PHASE1 | Myeloma | ACTIVE_NOT_RECRUITING | NCT02542657 |
| Ixazomib Citrate | Other | Phase PHASE1 | Myeloma | ACTIVE_NOT_RECRUITING | NCT02542657 |
| Dexamethasone | Other | Phase PHASE1 | Myeloma | ACTIVE_NOT_RECRUITING | NCT02542657 |
| Clarithromycin | Other | Phase PHASE1 | Myeloma | ACTIVE_NOT_RECRUITING | NCT02542657 |
| Pomalidomide | Other | Phase PHASE1 | Myeloma | ACTIVE_NOT_RECRUITING | NCT02542657 |
| Ixazomib Citrate | Other | Phase PHASE1 | Myeloma | ACTIVE_NOT_RECRUITING | NCT02542657 |
| Dexamethasone | Other | Phase PHASE1 | Myeloma | ACTIVE_NOT_RECRUITING | NCT02542657 |
| Clarithromycin | Other | Phase PHASE1 | Myeloma | ACTIVE_NOT_RECRUITING | NCT02542657 |
| Pomalidomide | Other | Phase PHASE1 | Myeloma | ACTIVE_NOT_RECRUITING | NCT02542657 |
| Ixazomib Citrate | Other | Phase PHASE1 | Myeloma | ACTIVE_NOT_RECRUITING | NCT02542657 |
| Dexamethasone | Other | Phase PHASE1 | Myeloma | ACTIVE_NOT_RECRUITING | NCT02542657 |
| Clarithromycin | Other | Phase PHASE1 | Myeloma | ACTIVE_NOT_RECRUITING | NCT02542657 |
| TAK228 | Other | Phase PHASE2 | Ovarian Cancer | COMPLETED | NCT03648489 |
| Paclitaxel | Other | Phase PHASE2 | Ovarian Cancer | COMPLETED | NCT03648489 |
| Rabeprazole | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05918822 |
| Maribavir Pediatric Powder-for-oral Suspension Formulation | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05918822 |
| Maribavir Commercial Tablet Formulation | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05918822 |
| Rabeprazole | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05918822 |
| Maribavir Pediatric Powder-for-oral Suspension Formulation | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05918822 |
| Maribavir Commercial Tablet Formulation | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05918822 |
| Brentuximab Vedotin (Genetical Recombination) | Other | Preclinical | Peripheral T Cell Lymphoma | COMPLETED | NCT04213209 |
| Daratumumab and Hyaluronidase-fihj | Other | Phase PHASE1 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | TERMINATED | NCT04776018 |
| Mezagitamab | Other | Phase PHASE1 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | TERMINATED | NCT04776018 |
| TAK-981 | Other | Phase PHASE1 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | TERMINATED | NCT04776018 |
| Daratumumab and Hyaluronidase-fihj | Other | Phase PHASE1 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | TERMINATED | NCT04776018 |
| Mezagitamab | Other | Phase PHASE1 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | TERMINATED | NCT04776018 |
| TAK-981 | Other | Phase PHASE1 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | TERMINATED | NCT04776018 |
| No Intervention | Other | Preclinical | Dravet Syndrome (DS) | WITHDRAWN | NCT06395792 |
| No Intervention | Other | Preclinical | Dravet Syndrome (DS) | WITHDRAWN | NCT06395792 |
| Reminder messages and counseling | Other | Approved | Suicidal Ideation | COMPLETED | NCT05770388 |
| App Take Care of Your Mood | Other | Approved | Suicidal Ideation | COMPLETED | NCT05770388 |
| Reminder messages and counseling | Other | Approved | Suicidal Ideation | COMPLETED | NCT05770388 |
| App Take Care of Your Mood | Other | Approved | Suicidal Ideation | COMPLETED | NCT05770388 |
| Mobile App | Other | Approved | Major Depressive Disorder | COMPLETED | NCT03242213 |
| Mobile App | Other | Approved | Major Depressive Disorder | COMPLETED | NCT03242213 |
| Durvalumab | Other | Phase PHASE2 | NSCLC, Stage III | WITHDRAWN | NCT05718297 |
| Brigatinib | Other | Phase PHASE2 | NSCLC, Stage III | WITHDRAWN | NCT05718297 |
| Durvalumab | Other | Phase PHASE2 | NSCLC, Stage III | WITHDRAWN | NCT05718297 |
| Brigatinib | Other | Phase PHASE2 | NSCLC, Stage III | WITHDRAWN | NCT05718297 |
| REPLAGAL | Other | Phase PHASE3 | Fabry Disease | COMPLETED | NCT04974749 |
| REPLAGAL | Other | Phase PHASE3 | Fabry Disease | COMPLETED | NCT04974749 |
| Other Biological Agent | Other | Preclinical | Colitis, Ulcerative | COMPLETED | NCT02678052 |
| Vedolizumab | Other | Preclinical | Colitis, Ulcerative | COMPLETED | NCT02678052 |
| Other Biological Agent | Other | Preclinical | Colitis, Ulcerative | COMPLETED | NCT02678052 |
| Vedolizumab | Other | Preclinical | Colitis, Ulcerative | COMPLETED | NCT02678052 |
| Other Biological Agent | Other | Preclinical | Colitis, Ulcerative | COMPLETED | NCT02678052 |
| Vedolizumab | Other | Preclinical | Colitis, Ulcerative | COMPLETED | NCT02678052 |
| Alisertib | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT02187991 |
| Paclitaxel | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT02187991 |
| TAK-019 | Other | Phase PHASE3 | Coronavirus Disease (COVID-19) | COMPLETED | NCT05299359 |
| TAK-019 | Other | Phase PHASE3 | Coronavirus Disease (COVID-19) | COMPLETED | NCT05299359 |
| Web Conciencia Saludable | Other | Approved | Depressive Symptoms | ENROLLING_BY_INVITATION | NCT06628830 |
| VamosJuntxs App | Other | Approved | Depressive Symptoms | ENROLLING_BY_INVITATION | NCT06628830 |
| Web Conciencia Saludable | Other | Approved | Depressive Symptoms | ENROLLING_BY_INVITATION | NCT06628830 |
| VamosJuntxs App | Other | Approved | Depressive Symptoms | ENROLLING_BY_INVITATION | NCT06628830 |
| Web Conciencia Saludable | Other | Approved | Depressive Symptoms | ENROLLING_BY_INVITATION | NCT06628830 |
| VamosJuntxs App | Other | Approved | Depressive Symptoms | ENROLLING_BY_INVITATION | NCT06628830 |
| Placebo | Other | Phase PHASE2 | Narcolepsy Type 1 (NT1) | TERMINATED | NCT04096560 |
| TAK-994 | Other | Phase PHASE2 | Narcolepsy Type 1 (NT1) | TERMINATED | NCT04096560 |
| Placebo | Other | Phase PHASE2 | Narcolepsy Type 1 (NT1) | TERMINATED | NCT04096560 |
| TAK-994 | Other | Phase PHASE2 | Narcolepsy Type 1 (NT1) | TERMINATED | NCT04096560 |
| Other Biologic Agents | Other | Preclinical | Ulcerative Colitis and Crohn's Disease | COMPLETED | NCT02674308 |
| Vedolizumab | Other | Preclinical | Ulcerative Colitis and Crohn's Disease | COMPLETED | NCT02674308 |
| 90Second IBD | Other | Approved | IBD | WITHDRAWN | NCT05686135 |
| PEGylated Recombinant Factor VIII | Other | Preclinical | Hemophilia A | COMPLETED | NCT04941898 |
| PEGylated Recombinant Factor VIII | Other | Preclinical | Hemophilia A | COMPLETED | NCT04941898 |
| Tenofovir disoproxil | Other | Preclinical | Hepatitis B | ACTIVE_NOT_RECRUITING | NCT02344498 |
| Tenofovir disoproxil | Other | Preclinical | Hepatitis B | ACTIVE_NOT_RECRUITING | NCT02344498 |
| TAK-981 | Other | Phase PHASE1 | Neoplasms | TERMINATED | NCT03648372 |
| TAK-981 | Other | Phase PHASE1 | Neoplasms | TERMINATED | NCT03648372 |
| TAK-981 | Other | Phase PHASE1 | Neoplasms | TERMINATED | NCT03648372 |
| Placebo | Other | Phase PHASE3 | Multiple Myeloma | COMPLETED | NCT02181413 |
| Ixazomib Citrate | Other | Phase PHASE3 | Multiple Myeloma | COMPLETED | NCT02181413 |
| Placebo | Other | Phase PHASE3 | Multiple Myeloma | COMPLETED | NCT02181413 |
| Ixazomib Citrate | Other | Phase PHASE3 | Multiple Myeloma | COMPLETED | NCT02181413 |
| Placebo | Other | Phase PHASE3 | Multiple Myeloma | COMPLETED | NCT02181413 |
| Ixazomib Citrate | Other | Phase PHASE3 | Multiple Myeloma | COMPLETED | NCT02181413 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | TERMINATED | NCT06610279 |
| TAK-951 | Other | Phase PHASE1 | Healthy Volunteers | TERMINATED | NCT06610279 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | TERMINATED | NCT06610279 |
| TAK-951 | Other | Phase PHASE1 | Healthy Volunteers | TERMINATED | NCT06610279 |
| TAK-771 | Other | Phase PHASE3 | Primary Immunodeficiency Diseases (PID) | COMPLETED | NCT05150340 |
| TAK-771 | Other | Phase PHASE3 | Primary Immunodeficiency Diseases (PID) | COMPLETED | NCT05150340 |
| Budesonide | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06268301 |
| TAK-672 | Other | Phase PHASE2 | Acquired Hemophilia A | COMPLETED | NCT04580407 |
| TAK-672 | Other | Phase PHASE2 | Acquired Hemophilia A | COMPLETED | NCT04580407 |
| No intervention | Other | Preclinical | T-Cell Lymphoma | COMPLETED | NCT05886478 |
| No intervention | Other | Preclinical | T-Cell Lymphoma | COMPLETED | NCT05886478 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05602818 |
| Alprazolam | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05602818 |
| Soticlestat 900 mg | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05602818 |
| Soticlestat 600 mg | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05602818 |
| Soticlestat 300 mg | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05602818 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05602818 |
| Alprazolam | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05602818 |
| Soticlestat 900 mg | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05602818 |
| Soticlestat 600 mg | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05602818 |
| Soticlestat 300 mg | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05602818 |
| TAK-536 | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT04668157 |
| TAK-536 | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT04668157 |
| Birth companions | Other | Approved | Maternal Care Patterns | COMPLETED | NCT05565196 |
| Birth companions | Other | Approved | Maternal Care Patterns | COMPLETED | NCT05565196 |
| No Intervention | Other | Preclinical | Gaucher Disease | COMPLETED | NCT05702814 |
| No Intervention | Other | Preclinical | Gaucher Disease | COMPLETED | NCT05702814 |
| No Intervention | Other | Preclinical | Gaucher Disease | COMPLETED | NCT05702814 |
| Placebo | Other | Approved | Uric Acid Kidney Stone Disease | COMPLETED | NCT00904046 |
| Pioglitazone | Other | Approved | Uric Acid Kidney Stone Disease | COMPLETED | NCT00904046 |
| Placebo | Other | Approved | Uric Acid Kidney Stone Disease | COMPLETED | NCT00904046 |
| Pioglitazone | Other | Approved | Uric Acid Kidney Stone Disease | COMPLETED | NCT00904046 |
| Placebo | Other | Approved | Uric Acid Kidney Stone Disease | COMPLETED | NCT00904046 |
| Pioglitazone | Other | Approved | Uric Acid Kidney Stone Disease | COMPLETED | NCT00904046 |
| Lanadelumab | Other | Phase PHASE3 | Hereditary Angioedema (HAE) | COMPLETED | NCT05460325 |
| Lanadelumab | Other | Phase PHASE3 | Hereditary Angioedema (HAE) | COMPLETED | NCT05460325 |
| Lanadelumab | Other | Phase PHASE3 | Hereditary Angioedema (HAE) | COMPLETED | NCT05460325 |
| Placebo | Other | Phase PHASE2 | Subarachnoid Hemorrhage, Aneurysmal | RECRUITING | NCT06359782 |
| C1 Esterase Inhibitor Injection [Cinryze] | Other | Phase PHASE2 | Subarachnoid Hemorrhage, Aneurysmal | RECRUITING | NCT06359782 |
| Placebo | Other | Phase PHASE2 | Subarachnoid Hemorrhage, Aneurysmal | RECRUITING | NCT06359782 |
| C1 Esterase Inhibitor Injection [Cinryze] | Other | Phase PHASE2 | Subarachnoid Hemorrhage, Aneurysmal | RECRUITING | NCT06359782 |
| Placebo | Other | Phase PHASE2 | Subarachnoid Hemorrhage, Aneurysmal | RECRUITING | NCT06359782 |
| C1 Esterase Inhibitor Injection [Cinryze] | Other | Phase PHASE2 | Subarachnoid Hemorrhage, Aneurysmal | RECRUITING | NCT06359782 |
| Placebo | Other | Phase PHASE3 | Dravet Syndrome (DS) | COMPLETED | NCT04940624 |
| Soticlestat | Other | Phase PHASE3 | Dravet Syndrome (DS) | COMPLETED | NCT04940624 |
| Static retinal vessel analysis (SVA) | Other | Preclinical | Fabry Disease | RECRUITING | NCT06758648 |
| Ophthalmological consultation | Other | Preclinical | Fabry Disease | RECRUITING | NCT06758648 |
| 1 hour ECG | Other | Preclinical | Fabry Disease | RECRUITING | NCT06758648 |
| 24-hour blood pressure measurement | Other | Preclinical | Fabry Disease | RECRUITING | NCT06758648 |
| 24 hour pulse wave analysis | Other | Preclinical | Fabry Disease | RECRUITING | NCT06758648 |
| Echocardiography | Other | Preclinical | Fabry Disease | RECRUITING | NCT06758648 |
| Optical coherence tomography (OCT) | Other | Preclinical | Fabry Disease | RECRUITING | NCT06758648 |
| Cardio MRI | Other | Preclinical | Fabry Disease | RECRUITING | NCT06758648 |
| Questionnaires (Patient reported outcomes) | Other | Preclinical | Fabry Disease | RECRUITING | NCT06758648 |
| Biochemistry and immune phenotyping | Other | Preclinical | Fabry Disease | RECRUITING | NCT06758648 |
| Dynamic retinal vessel analysis (DVA) | Other | Preclinical | Fabry Disease | RECRUITING | NCT06758648 |
| Static retinal vessel analysis (SVA) | Other | Preclinical | Fabry Disease | RECRUITING | NCT06758648 |
| Ophthalmological consultation | Other | Preclinical | Fabry Disease | RECRUITING | NCT06758648 |
| 1 hour ECG | Other | Preclinical | Fabry Disease | RECRUITING | NCT06758648 |
| 24-hour blood pressure measurement | Other | Preclinical | Fabry Disease | RECRUITING | NCT06758648 |
| 24 hour pulse wave analysis | Other | Preclinical | Fabry Disease | RECRUITING | NCT06758648 |
| Echocardiography | Other | Preclinical | Fabry Disease | RECRUITING | NCT06758648 |
| Optical coherence tomography (OCT) | Other | Preclinical | Fabry Disease | RECRUITING | NCT06758648 |
| Cardio MRI | Other | Preclinical | Fabry Disease | RECRUITING | NCT06758648 |
| Questionnaires (Patient reported outcomes) | Other | Preclinical | Fabry Disease | RECRUITING | NCT06758648 |
| Biochemistry and immune phenotyping | Other | Preclinical | Fabry Disease | RECRUITING | NCT06758648 |
| Dynamic retinal vessel analysis (DVA) | Other | Preclinical | Fabry Disease | RECRUITING | NCT06758648 |
| Static retinal vessel analysis (SVA) | Other | Preclinical | Fabry Disease | RECRUITING | NCT06758648 |
| Ophthalmological consultation | Other | Preclinical | Fabry Disease | RECRUITING | NCT06758648 |
| 1 hour ECG | Other | Preclinical | Fabry Disease | RECRUITING | NCT06758648 |
| 24-hour blood pressure measurement | Other | Preclinical | Fabry Disease | RECRUITING | NCT06758648 |
| 24 hour pulse wave analysis | Other | Preclinical | Fabry Disease | RECRUITING | NCT06758648 |
| Echocardiography | Other | Preclinical | Fabry Disease | RECRUITING | NCT06758648 |
| Optical coherence tomography (OCT) | Other | Preclinical | Fabry Disease | RECRUITING | NCT06758648 |
| Cardio MRI | Other | Preclinical | Fabry Disease | RECRUITING | NCT06758648 |
| Questionnaires (Patient reported outcomes) | Other | Preclinical | Fabry Disease | RECRUITING | NCT06758648 |
| Biochemistry and immune phenotyping | Other | Preclinical | Fabry Disease | RECRUITING | NCT06758648 |
| Dynamic retinal vessel analysis (DVA) | Other | Preclinical | Fabry Disease | RECRUITING | NCT06758648 |
| Paclitaxel | Other | Phase PHASE2 | Squamous Cell Carcinoma | COMPLETED | NCT03719924 |
| Onivyde | Other | Phase PHASE2 | Squamous Cell Carcinoma | COMPLETED | NCT03719924 |
| TAK-861 2 mg and 5 mg | Other | Phase PHASE2 | Narcolepsy Type 2 | COMPLETED | NCT05687916 |
| TAK-861 2 mg | Other | Phase PHASE2 | Narcolepsy Type 2 | COMPLETED | NCT05687916 |
| Placebo | Other | Phase PHASE2 | Narcolepsy Type 2 | COMPLETED | NCT05687916 |
| TAK-861 2 mg and 5 mg | Other | Phase PHASE2 | Narcolepsy Type 2 | COMPLETED | NCT05687916 |
| TAK-861 2 mg | Other | Phase PHASE2 | Narcolepsy Type 2 | COMPLETED | NCT05687916 |
| Placebo | Other | Phase PHASE2 | Narcolepsy Type 2 | COMPLETED | NCT05687916 |
| Placebo | Other | Phase PHASE2 | Narcolepsy Type 1 | COMPLETED | NCT05687903 |
| TAK-861 | Other | Phase PHASE2 | Narcolepsy Type 1 | COMPLETED | NCT05687903 |
| Placebo | Other | Phase PHASE2 | Narcolepsy Type 1 | COMPLETED | NCT05687903 |
| TAK-861 | Other | Phase PHASE2 | Narcolepsy Type 1 | COMPLETED | NCT05687903 |
| An individual family planning counseling | Other | Approved | Postpartum Contraception | NOT_YET_RECRUITING | NCT06766409 |
| A community group-based demonstration counseling method | Other | Approved | Postpartum Contraception | NOT_YET_RECRUITING | NCT06766409 |
| An individual family planning counseling | Other | Approved | Postpartum Contraception | NOT_YET_RECRUITING | NCT06766409 |
| A community group-based demonstration counseling method | Other | Approved | Postpartum Contraception | NOT_YET_RECRUITING | NCT06766409 |
| IGSC 20% infusion | Other | Phase PHASE3 | Primary Immunodeficiency Disease | COMPLETED | NCT04842643 |
| IGSC 20% infusion | Other | Phase PHASE3 | Primary Immunodeficiency Disease | COMPLETED | NCT04842643 |
| Brigatinib | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06132867 |
| Brigatinib | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06132867 |
| Elaprase | Other | Phase PHASE4 | Hunter Syndrome | COMPLETED | NCT05058391 |
| Elaprase | Other | Phase PHASE4 | Hunter Syndrome | COMPLETED | NCT05058391 |
| Elaprase | Other | Phase PHASE4 | Hunter Syndrome | COMPLETED | NCT05058391 |
| ADYNOVATE | Other | Preclinical | Hemophilia A | COMPLETED | NCT03169972 |
| ADYNOVATE | Other | Preclinical | Hemophilia A | COMPLETED | NCT03169972 |
| No Intervention | Other | Preclinical | Hereditary Angioedema (HAE) | COMPLETED | NCT06587464 |
| Vedolizumab IV | Other | Phase PHASE4 | Ulcerative Colitis | COMPLETED | NCT04804540 |
| Vedolizumab IV | Other | Phase PHASE4 | Ulcerative Colitis | COMPLETED | NCT04804540 |
| Budesonide oral suspension | Other | Phase PHASE3 | Eosinophilic Esophagitis (EoE) | TERMINATED | NCT03245840 |
| Budesonide oral suspension | Other | Phase PHASE3 | Eosinophilic Esophagitis (EoE) | TERMINATED | NCT03245840 |
| Placebo | Other | Phase PHASE3 | Eosinophilic Esophagitis (EoE) | COMPLETED | NCT02736409 |
| Oral Budesonide Suspension (OBS) | Other | Phase PHASE3 | Eosinophilic Esophagitis (EoE) | COMPLETED | NCT02736409 |
| Firazyr | Other | Preclinical | Hereditary Angioedema (HAE) | COMPLETED | NCT04057131 |
| TAK-755 | Other | Preclinical | Thrombotic Thrombocytopenic Purpura (TTP) | APPROVED_FOR_MARKETING | NCT05770219 |
| TAK-755 | Other | Preclinical | Thrombotic Thrombocytopenic Purpura (TTP) | APPROVED_FOR_MARKETING | NCT05770219 |
| TAK-755 | Other | Preclinical | Thrombotic Thrombocytopenic Purpura (TTP) | APPROVED_FOR_MARKETING | NCT05770219 |
| No Intervention | Other | Preclinical | Multiple Myeloma | TERMINATED | NCT02761187 |
| No Intervention | Other | Preclinical | Multiple Myeloma | TERMINATED | NCT02761187 |
| SSRI | Other | Preclinical | Major Depressive Disorder | COMPLETED | NCT05932407 |
| Vortioxetine Tablet | Other | Preclinical | Major Depressive Disorder | COMPLETED | NCT05932407 |
| SSRI | Other | Preclinical | Major Depressive Disorder | COMPLETED | NCT05932407 |
| Vortioxetine Tablet | Other | Preclinical | Major Depressive Disorder | COMPLETED | NCT05932407 |
| Pancreatic Clamp Study | Other | Phase PHASE4 | Type 2 Diabetes Mellitus | COMPLETED | NCT00179400 |
| Placebo | Other | Phase PHASE4 | Type 2 Diabetes Mellitus | COMPLETED | NCT00179400 |
| Pioglitazone | Other | Phase PHASE4 | Type 2 Diabetes Mellitus | COMPLETED | NCT00179400 |
| Pancreatic Clamp Study | Other | Phase PHASE4 | Type 2 Diabetes Mellitus | COMPLETED | NCT00179400 |
| Placebo | Other | Phase PHASE4 | Type 2 Diabetes Mellitus | COMPLETED | NCT00179400 |
| Pioglitazone | Other | Phase PHASE4 | Type 2 Diabetes Mellitus | COMPLETED | NCT00179400 |
| Ixazomib | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT02924272 |
| Ixazomib | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT02924272 |
| Azacitidine | Other | Phase PHASE3 | Leukemia, Myeloid, Acute | ACTIVE_NOT_RECRUITING | NCT04090736 |
| Pevonedistat | Other | Phase PHASE3 | Leukemia, Myeloid, Acute | ACTIVE_NOT_RECRUITING | NCT04090736 |
| Azacitidine | Other | Phase PHASE3 | Leukemia, Myeloid, Acute | ACTIVE_NOT_RECRUITING | NCT04090736 |
| Pevonedistat | Other | Phase PHASE3 | Leukemia, Myeloid, Acute | ACTIVE_NOT_RECRUITING | NCT04090736 |
| Azacitidine | Other | Phase PHASE3 | Leukemia, Myeloid, Acute | ACTIVE_NOT_RECRUITING | NCT04090736 |
| Pevonedistat | Other | Phase PHASE3 | Leukemia, Myeloid, Acute | ACTIVE_NOT_RECRUITING | NCT04090736 |
| SOC | Other | Phase PHASE3 | Short Bowel Syndrome | COMPLETED | NCT02949362 |
| Teduglutide | Other | Phase PHASE3 | Short Bowel Syndrome | COMPLETED | NCT02949362 |
| Ixazomib | Other | Phase PHASE3 | Multiple Myeloma | COMPLETED | NCT03748953 |
| Ixazomib | Other | Phase PHASE3 | Multiple Myeloma | COMPLETED | NCT03748953 |
| Ixazomib | Other | Phase PHASE3 | Multiple Myeloma | COMPLETED | NCT03748953 |
| Pathway Platform mobile app | Other | Approved | Major Depressive Disorder | COMPLETED | NCT04891224 |
| Pathway Platform mobile app | Other | Approved | Major Depressive Disorder | COMPLETED | NCT04891224 |
| Vedolizumab SC | Other | Phase PHASE3 | Colitis, Ulcerative | COMPLETED | NCT02620046 |
| Vedolizumab SC | Other | Phase PHASE3 | Colitis, Ulcerative | COMPLETED | NCT02620046 |
| Esomeprazole | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06793943 |
| Digoxin | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06793943 |
| Metformin | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06793943 |
| COC | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06793943 |
| Zasocitinib | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06793943 |
| Esomeprazole | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06793943 |
| Digoxin | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06793943 |
| Metformin | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06793943 |
| COC | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06793943 |
| Zasocitinib | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06793943 |
| Chemotherapy Agents | Drug | Phase PHASE1 | Refractory Lupus Nephritis | WITHDRAWN | NCT06377228 |
| TAK-007 | Other | Phase PHASE1 | Refractory Lupus Nephritis | WITHDRAWN | NCT06377228 |
| Chemotherapy Agents | Drug | Phase PHASE1 | Refractory Lupus Nephritis | WITHDRAWN | NCT06377228 |
| TAK-007 | Other | Phase PHASE1 | Refractory Lupus Nephritis | WITHDRAWN | NCT06377228 |
| Non-interventional Study | Other | Preclinical | Short Bowel Syndrome (SBS) | COMPLETED | NCT05371028 |
| Non-interventional Study | Other | Preclinical | Short Bowel Syndrome (SBS) | COMPLETED | NCT05371028 |
| No Intervention | Other | Phase PHASE3 | Ulcerative Colitis | RECRUITING | NCT05442567 |
| Vedolizumab IV | Other | Phase PHASE3 | Ulcerative Colitis | RECRUITING | NCT05442567 |
| Cabozantinib | Other | Preclinical | Renal Cell Carcinoma | COMPLETED | NCT04804813 |
| Cabozantinib | Other | Preclinical | Renal Cell Carcinoma | COMPLETED | NCT04804813 |
| No intervention | Other | Preclinical | Dravet Syndrome (DS) | COMPLETED | NCT05982717 |
| No intervention | Other | Preclinical | Dravet Syndrome (DS) | COMPLETED | NCT05982717 |
| Brentuximab Vedotin | Other | Preclinical | Hodgkin Lymphoma | RECRUITING | NCT05481437 |
| Idursulfase-IT | Other | Preclinical | Hunter Syndrome | AVAILABLE | NCT05795361 |
| 19(T2)28z1xx TRAC T cell | Other | Phase PHASE1 | B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT05757700 |
| Darvadstrocel | Other | Phase PHASE3 | Crohn's Disease | COMPLETED | NCT04075825 |
| Placebo | Other | Phase PHASE3 | Crohn's Disease | COMPLETED | NCT04075825 |
| Darvadstrocel | Other | Phase PHASE3 | Crohn's Disease | COMPLETED | NCT04075825 |
| Placebo | Other | Phase PHASE3 | Crohn's Disease | COMPLETED | NCT04075825 |
| Darvadstrocel | Other | Phase PHASE3 | Crohn's Disease | COMPLETED | NCT04075825 |
| Placebo | Other | Phase PHASE3 | Crohn's Disease | COMPLETED | NCT04075825 |
| Ponatinib | Other | Preclinical | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | COMPLETED | NCT06945146 |
| Ponatinib | Other | Preclinical | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | COMPLETED | NCT06945146 |
| Antihemophilic Factor (Recombinant) | Other | Phase PHASE3 | Von Willebrand Disease | RECRUITING | NCT02932618 |
| Vonicog alfa | Other | Phase PHASE3 | Von Willebrand Disease | RECRUITING | NCT02932618 |
| Antihemophilic Factor (Recombinant) | Other | Phase PHASE3 | Von Willebrand Disease | RECRUITING | NCT02932618 |
| Vonicog alfa | Other | Phase PHASE3 | Von Willebrand Disease | RECRUITING | NCT02932618 |
| Quality-of-life assessment | Other | Phase PHASE1 | Adult Anaplastic Astrocytoma | COMPLETED | NCT02186509 |
| Alisertib | Other | Phase PHASE1 | Adult Anaplastic Astrocytoma | COMPLETED | NCT02186509 |
| Stereotactic radiosurgery | Procedure | Phase PHASE1 | Adult Anaplastic Astrocytoma | COMPLETED | NCT02186509 |
| Hyperfractionated radiation therapy | Drug | Phase PHASE1 | Adult Anaplastic Astrocytoma | COMPLETED | NCT02186509 |
| Quality-of-life assessment | Other | Phase PHASE1 | Adult Anaplastic Astrocytoma | COMPLETED | NCT02186509 |
| Alisertib | Other | Phase PHASE1 | Adult Anaplastic Astrocytoma | COMPLETED | NCT02186509 |
| Stereotactic radiosurgery | Procedure | Phase PHASE1 | Adult Anaplastic Astrocytoma | COMPLETED | NCT02186509 |
| Hyperfractionated radiation therapy | Drug | Phase PHASE1 | Adult Anaplastic Astrocytoma | COMPLETED | NCT02186509 |
| Bortezomib 1.3mg/m^2 | Other | Phase PHASE1 | Relapsed Acute Leukemia | COMPLETED | NCT00410423 |
| Bortezomib 1.0mg/m^2 | Other | Phase PHASE1 | Relapsed Acute Leukemia | COMPLETED | NCT00410423 |
| Bortezomib with mitoxantrone, etoposide and cytarabine | Other | Phase PHASE1 | Relapsed Acute Leukemia | COMPLETED | NCT00410423 |
| Bortezomib 1.3mg/m^2 | Other | Phase PHASE1 | Relapsed Acute Leukemia | COMPLETED | NCT00410423 |
| Bortezomib 1.0mg/m^2 | Other | Phase PHASE1 | Relapsed Acute Leukemia | COMPLETED | NCT00410423 |
| Bortezomib with mitoxantrone, etoposide and cytarabine | Other | Phase PHASE1 | Relapsed Acute Leukemia | COMPLETED | NCT00410423 |
| Adynovate | Other | Phase PHASE3 | Hemophilia A | COMPLETED | NCT05707351 |
| Adynovate | Other | Phase PHASE3 | Hemophilia A | COMPLETED | NCT05707351 |
| Adynovate | Other | Phase PHASE3 | Hemophilia A | COMPLETED | NCT05707351 |
| SC Investigational Needle Sets | Other | Preclinical | Primary Immunodeficiency Diseases (PIDD) | AVAILABLE | NCT06955793 |
| TAK-881 | Other | Preclinical | Primary Immunodeficiency Diseases (PIDD) | AVAILABLE | NCT06955793 |
| SC Investigational Needle Sets | Other | Preclinical | Primary Immunodeficiency Diseases (PIDD) | AVAILABLE | NCT06955793 |
| TAK-881 | Other | Preclinical | Primary Immunodeficiency Diseases (PIDD) | AVAILABLE | NCT06955793 |
| Velcade (bortezomib) | Other | Phase PHASE1 | Brain Cancer | COMPLETED | NCT00329589 |
| Velcade (bortezomib) | Other | Phase PHASE1 | Brain Cancer | COMPLETED | NCT00329589 |
| Prednisone | Other | Phase PHASE1 | Adenocarcinoma of the Prostate | COMPLETED | NCT01848067 |
| Abiraterone acetate | Other | Phase PHASE1 | Adenocarcinoma of the Prostate | COMPLETED | NCT01848067 |
| Alisertib | Other | Phase PHASE1 | Adenocarcinoma of the Prostate | COMPLETED | NCT01848067 |
| Prednisone | Other | Phase PHASE1 | Adenocarcinoma of the Prostate | COMPLETED | NCT01848067 |
| Abiraterone acetate | Other | Phase PHASE1 | Adenocarcinoma of the Prostate | COMPLETED | NCT01848067 |
| Alisertib | Other | Phase PHASE1 | Adenocarcinoma of the Prostate | COMPLETED | NCT01848067 |
| Prednisone | Other | Phase PHASE1 | Adenocarcinoma of the Prostate | COMPLETED | NCT01848067 |
| Abiraterone acetate | Other | Phase PHASE1 | Adenocarcinoma of the Prostate | COMPLETED | NCT01848067 |
| Alisertib | Other | Phase PHASE1 | Adenocarcinoma of the Prostate | COMPLETED | NCT01848067 |
| TAK-662 | Other | Phase PHASE1 | Congenital Protein C Deficiency | COMPLETED | NCT04984889 |
| TAK-662 | Other | Phase PHASE1 | Congenital Protein C Deficiency | COMPLETED | NCT04984889 |
| Tappt | Other | Preclinical | Inflammatory Bowel Disease (IBD) | RECRUITING | NCT06750731 |
| Tappt | Other | Preclinical | Inflammatory Bowel Disease (IBD) | RECRUITING | NCT06750731 |
| oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, bevacizumab | Other | Preclinical | Colorectal Cancer | ACTIVE_NOT_RECRUITING | NCT02394834 |
| oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab | Other | Preclinical | Colorectal Cancer | ACTIVE_NOT_RECRUITING | NCT02394834 |
| Teduglutide | Other | Preclinical | Short Bowel Syndrome | RECRUITING | NCT05023382 |
| Mobocertinib | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT03807778 |
| TAK-103 | Other | Phase PHASE1 | Solid Tumors | TERMINATED | NCT05164666 |
| TAK-103 | Other | Phase PHASE1 | Solid Tumors | TERMINATED | NCT05164666 |
| TAK-102 | Other | Phase PHASE1 | Solid Tumors | TERMINATED | NCT04405778 |
| TAK-102 | Other | Phase PHASE1 | Solid Tumors | TERMINATED | NCT04405778 |
| TAK-102 | Other | Phase PHASE1 | Solid Tumors | TERMINATED | NCT04405778 |
| Placebo | Other | Phase PHASE3 | Crohn's Disease | RECRUITING | NCT06227910 |
| Upadacitinib | Other | Phase PHASE3 | Crohn's Disease | RECRUITING | NCT06227910 |
| Vedolizumab | Other | Phase PHASE3 | Crohn's Disease | RECRUITING | NCT06227910 |
| Placebo | Other | Phase PHASE3 | Crohn's Disease | RECRUITING | NCT06227910 |
| Upadacitinib | Other | Phase PHASE3 | Crohn's Disease | RECRUITING | NCT06227910 |
| Vedolizumab | Other | Phase PHASE3 | Crohn's Disease | RECRUITING | NCT06227910 |
| Susoctocog Alfa (Genetical Recombination) | Other | Preclinical | Acquired Hemophilia A | RECRUITING | NCT06461533 |
| Susoctocog Alfa (Genetical Recombination) | Other | Preclinical | Acquired Hemophilia A | RECRUITING | NCT06461533 |
| Virtual-reality (VR) Based Solution | Other | Approved | Hemophilia | COMPLETED | NCT05437211 |
| Vonoprazan | Other | Preclinical | Reflux Esophagitis | COMPLETED | NCT03214081 |
| Vonoprazan | Other | Preclinical | Reflux Esophagitis | COMPLETED | NCT03214081 |
| No Intervention | Other | Preclinical | Dengue Fever | RECRUITING | NCT06388785 |
| Placebo | Other | Phase PHASE3 | Dengue Fever | COMPLETED | NCT03999996 |
| Takeda's Dengue Tetravalent Vaccine (Live, Attenuated) (TDV) | Other | Phase PHASE3 | Dengue Fever | COMPLETED | NCT03999996 |
| Placebo | Other | Phase PHASE3 | Dengue Fever | COMPLETED | NCT03999996 |
| Takeda's Dengue Tetravalent Vaccine (Live, Attenuated) (TDV) | Other | Phase PHASE3 | Dengue Fever | COMPLETED | NCT03999996 |
| No Intervention | Other | Preclinical | Primary Immunodeficiency Diseases (PID) | COMPLETED | NCT06150534 |
| No Intervention | Other | Preclinical | Primary Immunodeficiency Diseases (PID) | COMPLETED | NCT06150534 |
| No Intervention | Other | Preclinical | Primary Immunodeficiency Diseases (PID) | COMPLETED | NCT06150534 |
| TAK-853 | Other | Phase PHASE1 | Ovarian Cancer | ACTIVE_NOT_RECRUITING | NCT06390995 |
| TAK-853 | Other | Phase PHASE1 | Ovarian Cancer | ACTIVE_NOT_RECRUITING | NCT06390995 |
| TAK-079 | Other | Phase PHASE2 | Primary Immune Thrombocytopenia | COMPLETED | NCT04278924 |
| Placebo | Other | Phase PHASE2 | Primary Immune Thrombocytopenia | COMPLETED | NCT04278924 |
| Elaprase | Other | Phase PHASE2 | Hunter Syndrome | COMPLETED | NCT02412787 |
| Idursulfase-IT | Other | Phase PHASE2 | Hunter Syndrome | COMPLETED | NCT02412787 |
| Velaglucerase Alfa | Other | Phase PHASE3 | Gaucher Disease | COMPLETED | NCT05529992 |
| Velaglucerase Alfa | Other | Phase PHASE3 | Gaucher Disease | COMPLETED | NCT05529992 |
| Lenalidomide | Other | Phase PHASE2 | Recurrent Plasma Cell Myeloma | COMPLETED | NCT02765854 |
| Ixazomib | Other | Phase PHASE2 | Recurrent Plasma Cell Myeloma | COMPLETED | NCT02765854 |
| Dexamethasone | Other | Phase PHASE2 | Recurrent Plasma Cell Myeloma | COMPLETED | NCT02765854 |
| Lenalidomide | Other | Phase PHASE2 | Recurrent Plasma Cell Myeloma | COMPLETED | NCT02765854 |
| Ixazomib | Other | Phase PHASE2 | Recurrent Plasma Cell Myeloma | COMPLETED | NCT02765854 |
| Dexamethasone | Other | Phase PHASE2 | Recurrent Plasma Cell Myeloma | COMPLETED | NCT02765854 |
| TT3-LITE Regimen (L-TT3) | Other | Phase PHASE3 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT00734877 |
| M-VTD-PACE | Other | Phase PHASE3 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT00734877 |
| TT3-LITE Regimen (L-TT3) | Other | Phase PHASE3 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT00734877 |
| M-VTD-PACE | Other | Phase PHASE3 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT00734877 |
| Placebo | Other | Phase PHASE3 | Narcolepsy Type 1 | COMPLETED | NCT06470828 |
| TAK-861 | Other | Phase PHASE3 | Narcolepsy Type 1 | COMPLETED | NCT06470828 |
| Placebo | Other | Phase PHASE3 | Narcolepsy Type 1 | COMPLETED | NCT06470828 |
| TAK-861 | Other | Phase PHASE3 | Narcolepsy Type 1 | COMPLETED | NCT06470828 |
| TAK-951 Placebo | Other | Phase PHASE1 | Nausea and Vomitting | TERMINATED | NCT06768658 |
| TAK-951 | Other | Phase PHASE1 | Nausea and Vomitting | TERMINATED | NCT06768658 |
| TAK-951 Placebo | Other | Phase PHASE1 | Nausea and Vomitting | TERMINATED | NCT06768658 |
| TAK-951 | Other | Phase PHASE1 | Nausea and Vomitting | TERMINATED | NCT06768658 |
| TAK-951 Placebo | Other | Phase PHASE1 | Nausea and Vomitting | TERMINATED | NCT06768658 |
| TAK-951 | Other | Phase PHASE1 | Nausea and Vomitting | TERMINATED | NCT06768658 |
| Teduglutide | Other | Phase PHASE3 | Short Bowel Syndrome | RECRUITING | NCT06973304 |
| No Intervention | Other | Preclinical | Cytomegalovirus (CMV) | RECRUITING | NCT06213974 |
| No Intervention | Other | Preclinical | Cytomegalovirus (CMV) | RECRUITING | NCT06213974 |
| Prednisone | Other | Phase PHASE2 | Lymphoma | ACTIVE_NOT_RECRUITING | NCT05673785 |
| Doxorubicin | Other | Phase PHASE2 | Lymphoma | ACTIVE_NOT_RECRUITING | NCT05673785 |
| Cyclophosphamide | Other | Phase PHASE2 | Lymphoma | ACTIVE_NOT_RECRUITING | NCT05673785 |
| Brentuximab Vedotin | Other | Phase PHASE2 | Lymphoma | ACTIVE_NOT_RECRUITING | NCT05673785 |
| Prednisone | Other | Phase PHASE2 | Lymphoma | ACTIVE_NOT_RECRUITING | NCT05673785 |
| Doxorubicin | Other | Phase PHASE2 | Lymphoma | ACTIVE_NOT_RECRUITING | NCT05673785 |
| Cyclophosphamide | Other | Phase PHASE2 | Lymphoma | ACTIVE_NOT_RECRUITING | NCT05673785 |
| Brentuximab Vedotin | Other | Phase PHASE2 | Lymphoma | ACTIVE_NOT_RECRUITING | NCT05673785 |
| Prednisone | Other | Phase PHASE2 | Lymphoma | ACTIVE_NOT_RECRUITING | NCT05673785 |
| Doxorubicin | Other | Phase PHASE2 | Lymphoma | ACTIVE_NOT_RECRUITING | NCT05673785 |
| Cyclophosphamide | Other | Phase PHASE2 | Lymphoma | ACTIVE_NOT_RECRUITING | NCT05673785 |
| Brentuximab Vedotin | Other | Phase PHASE2 | Lymphoma | ACTIVE_NOT_RECRUITING | NCT05673785 |
| Placebo | Other | Phase PHASE3 | Dengue Fever | RECRUITING | NCT06665035 |
| TDV | Other | Phase PHASE3 | Dengue Fever | RECRUITING | NCT06665035 |
| Placebo | Other | Phase PHASE3 | Dengue Fever | RECRUITING | NCT06665035 |
| TDV | Other | Phase PHASE3 | Dengue Fever | RECRUITING | NCT06665035 |
| Maribavir | Other | Phase PHASE3 | Cytomegalovirus (CMV) | RECRUITING | NCT05319353 |
| Maribavir | Other | Phase PHASE3 | Cytomegalovirus (CMV) | RECRUITING | NCT05319353 |
| Vedolizumab | Other | Phase PHASE3 | Ulcerative Colitis | ACTIVE_NOT_RECRUITING | NCT04738942 |
| Vedolizumab | Other | Phase PHASE3 | Ulcerative Colitis | ACTIVE_NOT_RECRUITING | NCT04738942 |
| Vedolizumab | Other | Phase PHASE3 | Ulcerative Colitis | ACTIVE_NOT_RECRUITING | NCT04738942 |
| TAK-788 | Other | Phase PHASE1 | Carcinoma, Non-Small-Cell Lung | COMPLETED | NCT04051827 |
| Midazolam | Other | Phase PHASE1 | Carcinoma, Non-Small-Cell Lung | COMPLETED | NCT04051827 |
| ITI | Other | Phase PHASE3 | Hemophilia A | COMPLETED | NCT02615691 |
| PEGylated Recombinant Factor VIII | Other | Phase PHASE3 | Hemophilia A | COMPLETED | NCT02615691 |
| ITI | Other | Phase PHASE3 | Hemophilia A | COMPLETED | NCT02615691 |
| PEGylated Recombinant Factor VIII | Other | Phase PHASE3 | Hemophilia A | COMPLETED | NCT02615691 |
| ITI | Other | Phase PHASE3 | Hemophilia A | COMPLETED | NCT02615691 |
| PEGylated Recombinant Factor VIII | Other | Phase PHASE3 | Hemophilia A | COMPLETED | NCT02615691 |
| Soticlestat | Other | Phase PHASE3 | Dravet Syndrome (DS) | TERMINATED | NCT06422377 |
| Soticlestat | Other | Phase PHASE3 | Dravet Syndrome (DS) | TERMINATED | NCT06422377 |
| Brigatinib | Other | Phase PHASE2 | ALK-positive Advanced NSCLC | COMPLETED | NCT03535740 |
| Brigatinib | Other | Phase PHASE2 | ALK-positive Advanced NSCLC | COMPLETED | NCT03535740 |
| RNAseq | Other | Approved | Non-small Cell Lung Cancer | RECRUITING | NCT05122806 |
| RNAseq | Other | Approved | Non-small Cell Lung Cancer | RECRUITING | NCT05122806 |
| RNAseq | Other | Approved | Non-small Cell Lung Cancer | RECRUITING | NCT05122806 |
| Elaprase | Other | Phase PHASE1 | Hunter Syndrome | COMPLETED | NCT01506141 |
| Idursulfase-IT | Other | Phase PHASE1 | Hunter Syndrome | COMPLETED | NCT01506141 |
| Elaprase | Other | Phase PHASE1 | Hunter Syndrome | COMPLETED | NCT01506141 |
| Idursulfase-IT | Other | Phase PHASE1 | Hunter Syndrome | COMPLETED | NCT01506141 |
| No Intervention | Other | Preclinical | Cytomegalovirus (CMV) | COMPLETED | NCT06615921 |
| OBIZUR | Other | Preclinical | Acquired Hemophilia A | RECRUITING | NCT06550882 |
| OBIZUR | Other | Preclinical | Acquired Hemophilia A | RECRUITING | NCT06550882 |
| Placebo | Other | Phase PHASE4 | Adult Attention-Deficit Hyperactivity Disorder | COMPLETED | NCT02141113 |
| Guanfacine Hydrochloride | Other | Phase PHASE4 | Adult Attention-Deficit Hyperactivity Disorder | COMPLETED | NCT02141113 |
| No Intervention | Other | Preclinical | Chronic Idiopathic Constipation (CIC) | ACTIVE_NOT_RECRUITING | NCT04869280 |
| No Intervention | Other | Preclinical | Chronic Idiopathic Constipation (CIC) | ACTIVE_NOT_RECRUITING | NCT04869280 |
| Ontamalimab | Other | Phase PHASE1 | Steatohepatitis | TERMINATED | NCT07052682 |
| SC Investigational Needle Sets | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06895967 |
| HyQvia | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06895967 |
| TAK-881 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06895967 |
| Simulated Inadvertent Gluten Exposure (SIGE) Gluten-free Bar | Other | Phase PHASE2 | Celiac Disease | COMPLETED | NCT05353985 |
| TAK-062 Placebo | Other | Phase PHASE2 | Celiac Disease | COMPLETED | NCT05353985 |
| Simulated Inadvertent Gluten Exposure (SIGE) Gluten-Bar | Other | Phase PHASE2 | Celiac Disease | COMPLETED | NCT05353985 |
| TAK-062 | Other | Phase PHASE2 | Celiac Disease | COMPLETED | NCT05353985 |
| Simulated Inadvertent Gluten Exposure (SIGE) Gluten-free Bar | Other | Phase PHASE2 | Celiac Disease | COMPLETED | NCT05353985 |
| TAK-062 Placebo | Other | Phase PHASE2 | Celiac Disease | COMPLETED | NCT05353985 |
| Simulated Inadvertent Gluten Exposure (SIGE) Gluten-Bar | Other | Phase PHASE2 | Celiac Disease | COMPLETED | NCT05353985 |
| TAK-062 | Other | Phase PHASE2 | Celiac Disease | COMPLETED | NCT05353985 |
| 19(T2)28z1xx CAR T cells | Other | Phase PHASE1 | Diffuse Large B Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04464200 |
| Freeze-dried Human Protein C Concentrate | Other | Preclinical | Protein C Deficiency | RECRUITING | NCT06590974 |
| Freeze-dried Human Protein C Concentrate | Other | Preclinical | Protein C Deficiency | RECRUITING | NCT06590974 |
| No intervention | Other | Preclinical | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT05735327 |
| TAK-280 | Other | Phase PHASE1 | Unresectable Locally Advanced or Metastatic Cancer | TERMINATED | NCT05220098 |
| TAK-280 | Other | Phase PHASE1 | Unresectable Locally Advanced or Metastatic Cancer | TERMINATED | NCT05220098 |
| TAK-280 | Other | Phase PHASE1 | Unresectable Locally Advanced or Metastatic Cancer | TERMINATED | NCT05220098 |
| Lenalidomide | Other | Phase PHASE3 | Relapsed or Refractory Systemic Light Chain Amyloidosis | TERMINATED | NCT01659658 |
| Thalidomide | Other | Phase PHASE3 | Relapsed or Refractory Systemic Light Chain Amyloidosis | TERMINATED | NCT01659658 |
| Cyclophosphamide | Other | Phase PHASE3 | Relapsed or Refractory Systemic Light Chain Amyloidosis | TERMINATED | NCT01659658 |
| Melphalan | Other | Phase PHASE3 | Relapsed or Refractory Systemic Light Chain Amyloidosis | TERMINATED | NCT01659658 |
| Dexamethasone | Other | Phase PHASE3 | Relapsed or Refractory Systemic Light Chain Amyloidosis | TERMINATED | NCT01659658 |
| IXAZOMIB | Other | Phase PHASE3 | Relapsed or Refractory Systemic Light Chain Amyloidosis | TERMINATED | NCT01659658 |
| Lenalidomide | Other | Phase PHASE3 | Relapsed or Refractory Systemic Light Chain Amyloidosis | TERMINATED | NCT01659658 |
| Thalidomide | Other | Phase PHASE3 | Relapsed or Refractory Systemic Light Chain Amyloidosis | TERMINATED | NCT01659658 |
| Cyclophosphamide | Other | Phase PHASE3 | Relapsed or Refractory Systemic Light Chain Amyloidosis | TERMINATED | NCT01659658 |
| Melphalan | Other | Phase PHASE3 | Relapsed or Refractory Systemic Light Chain Amyloidosis | TERMINATED | NCT01659658 |
| Dexamethasone | Other | Phase PHASE3 | Relapsed or Refractory Systemic Light Chain Amyloidosis | TERMINATED | NCT01659658 |
| IXAZOMIB | Other | Phase PHASE3 | Relapsed or Refractory Systemic Light Chain Amyloidosis | TERMINATED | NCT01659658 |
| No Intervention | Other | Preclinical | Dengue Fever | RECRUITING | NCT06843226 |
| TAK-577 | Other | Preclinical | Von Willebrand Disease (VWD) | AVAILABLE | NCT06173024 |
| TAK-577 | Other | Preclinical | Von Willebrand Disease (VWD) | AVAILABLE | NCT06173024 |
| rFVIII | Other | Phase PHASE3 | Von Willebrand Disease (VWD) | COMPLETED | NCT03879135 |
| rVWF | Other | Phase PHASE3 | Von Willebrand Disease (VWD) | COMPLETED | NCT03879135 |
| rFVIII | Other | Phase PHASE3 | Von Willebrand Disease (VWD) | COMPLETED | NCT03879135 |
| rVWF | Other | Phase PHASE3 | Von Willebrand Disease (VWD) | COMPLETED | NCT03879135 |
| Image-guided radiation therapy | Drug | Phase PHASE1 | Carcinoma, Non-Small-Cell Lung | COMPLETED | NCT04879849 |
| TAK-676 | Other | Phase PHASE1 | Carcinoma, Non-Small-Cell Lung | COMPLETED | NCT04879849 |
| Pembrolizumab | Other | Phase PHASE1 | Carcinoma, Non-Small-Cell Lung | COMPLETED | NCT04879849 |
| Ixazomib (NINLARO®) capsules / Matching placebo capsules | Other | Phase PHASE1 | Relapsing Remitting Multiple Sclerosis | RECRUITING | NCT03783416 |
| Ixazomib (NINLARO®) capsules / Matching placebo capsules | Other | Phase PHASE1 | Relapsing Remitting Multiple Sclerosis | RECRUITING | NCT03783416 |
| Ixazomib (NINLARO®) capsules / Matching placebo capsules | Other | Phase PHASE1 | Relapsing Remitting Multiple Sclerosis | RECRUITING | NCT03783416 |
| TDV | Other | Phase PHASE2 | Dengue Fever | COMPLETED | NCT03746015 |
| TDV | Other | Phase PHASE2 | Dengue Fever | COMPLETED | NCT03746015 |
| No Intervention | Other | Preclinical | Cytomegalovirus (CMV) | RECRUITING | NCT06677892 |
| No Intervention | Other | Preclinical | Cytomegalovirus (CMV) | RECRUITING | NCT06677892 |
| Azilsartan (TAK-536) | Other | Preclinical | Hypertension | COMPLETED | NCT05107960 |
| Azilsartan (TAK-536) | Other | Preclinical | Hypertension | COMPLETED | NCT05107960 |
| Azilsartan (TAK-536) | Other | Preclinical | Hypertension | COMPLETED | NCT05107960 |
| Midazolam | Other | Preclinical | Epilepsy | RECRUITING | NCT05313308 |
| Maribavir (800 mg) | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04497883 |
| Maribavir (200 mg) | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04497883 |
| Maribavir (400 mg) | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04497883 |
| Vedolizumab | Other | Preclinical | Ulcerative Colitis | COMPLETED | NCT03824561 |
| Vedolizumab | Other | Preclinical | Ulcerative Colitis | COMPLETED | NCT03824561 |
| Alectinib | Other | Phase PHASE3 | ALK+ Advanced NSCLC | COMPLETED | NCT03596866 |
| Brigatinib | Other | Phase PHASE3 | ALK+ Advanced NSCLC | COMPLETED | NCT03596866 |
| Alectinib | Other | Phase PHASE3 | ALK+ Advanced NSCLC | COMPLETED | NCT03596866 |
| Brigatinib | Other | Phase PHASE3 | ALK+ Advanced NSCLC | COMPLETED | NCT03596866 |
| Placebo | Other | Phase PHASE3 | Narcolepsy Type 1 | COMPLETED | NCT06505031 |
| TAK-861 | Other | Phase PHASE3 | Narcolepsy Type 1 | COMPLETED | NCT06505031 |
| Placebo | Other | Phase PHASE3 | Narcolepsy Type 1 | COMPLETED | NCT06505031 |
| TAK-861 | Other | Phase PHASE3 | Narcolepsy Type 1 | COMPLETED | NCT06505031 |
| Placebo | Other | Phase PHASE2 | Sleep Apnea | TERMINATED | NCT05814016 |
| Danavorexton | Other | Phase PHASE2 | Sleep Apnea | TERMINATED | NCT05814016 |
| Placebo | Other | Phase PHASE2 | Sleep Apnea | TERMINATED | NCT05814016 |
| Danavorexton | Other | Phase PHASE2 | Sleep Apnea | TERMINATED | NCT05814016 |
| pegaspargase 2500 IU/m2 x 1 | Other | Phase PHASE3 | Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | NCT02716233 |
| pegaspargase 1250 IU/m2 x 2 | Other | Phase PHASE3 | Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | NCT02716233 |
| pegaspargase 2500 IU/m2 x 1 | Other | Phase PHASE3 | Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | NCT02716233 |
| pegaspargase 1250 IU/m2 x 2 | Other | Phase PHASE3 | Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | NCT02716233 |
| CT/PET scans | Other | Phase PHASE2 | Leukemia | ACTIVE_NOT_RECRUITING | NCT01920737 |
| Blood draw | Other | Phase PHASE2 | Leukemia | ACTIVE_NOT_RECRUITING | NCT01920737 |
| Dexamethasone | Other | Phase PHASE2 | Leukemia | ACTIVE_NOT_RECRUITING | NCT01920737 |
| Leucovorin | Other | Phase PHASE2 | Leukemia | ACTIVE_NOT_RECRUITING | NCT01920737 |
| Cytarabine | Other | Phase PHASE2 | Leukemia | ACTIVE_NOT_RECRUITING | NCT01920737 |
| Cyclophosphamide | Other | Phase PHASE2 | Leukemia | ACTIVE_NOT_RECRUITING | NCT01920737 |
| 6-MP (6-Mercaptopurine) | Other | Phase PHASE2 | Leukemia | ACTIVE_NOT_RECRUITING | NCT01920737 |
| Methotrexate | Other | Phase PHASE2 | Leukemia | ACTIVE_NOT_RECRUITING | NCT01920737 |
| PEG-Asparaginase | Other | Phase PHASE2 | Leukemia | ACTIVE_NOT_RECRUITING | NCT01920737 |
| Prednisone | Other | Phase PHASE2 | Leukemia | ACTIVE_NOT_RECRUITING | NCT01920737 |
| Vincristine | Other | Phase PHASE2 | Leukemia | ACTIVE_NOT_RECRUITING | NCT01920737 |
| Daunorubicin | Other | Phase PHASE2 | Leukemia | ACTIVE_NOT_RECRUITING | NCT01920737 |
| CT/PET scans | Other | Phase PHASE2 | Leukemia | ACTIVE_NOT_RECRUITING | NCT01920737 |
| Blood draw | Other | Phase PHASE2 | Leukemia | ACTIVE_NOT_RECRUITING | NCT01920737 |
| Dexamethasone | Other | Phase PHASE2 | Leukemia | ACTIVE_NOT_RECRUITING | NCT01920737 |
| Leucovorin | Other | Phase PHASE2 | Leukemia | ACTIVE_NOT_RECRUITING | NCT01920737 |
| Cytarabine | Other | Phase PHASE2 | Leukemia | ACTIVE_NOT_RECRUITING | NCT01920737 |
| Cyclophosphamide | Other | Phase PHASE2 | Leukemia | ACTIVE_NOT_RECRUITING | NCT01920737 |
| 6-MP (6-Mercaptopurine) | Other | Phase PHASE2 | Leukemia | ACTIVE_NOT_RECRUITING | NCT01920737 |
| Methotrexate | Other | Phase PHASE2 | Leukemia | ACTIVE_NOT_RECRUITING | NCT01920737 |
| PEG-Asparaginase | Other | Phase PHASE2 | Leukemia | ACTIVE_NOT_RECRUITING | NCT01920737 |
| Prednisone | Other | Phase PHASE2 | Leukemia | ACTIVE_NOT_RECRUITING | NCT01920737 |
| Vincristine | Other | Phase PHASE2 | Leukemia | ACTIVE_NOT_RECRUITING | NCT01920737 |
| Daunorubicin | Other | Phase PHASE2 | Leukemia | ACTIVE_NOT_RECRUITING | NCT01920737 |
| Brentuximab vedotin | Other | Phase PHASE4 | T-Cell Lymphoma | COMPLETED | NCT05442554 |
| Brentuximab vedotin | Other | Phase PHASE4 | T-Cell Lymphoma | COMPLETED | NCT05442554 |
| Concomitant Antibiotic Therapy | Drug | Phase PHASE3 | Pouchitis | RECRUITING | NCT06443502 |
| Vedolizumab | Other | Phase PHASE3 | Pouchitis | RECRUITING | NCT06443502 |
| Concomitant Antibiotic Therapy | Drug | Phase PHASE3 | Pouchitis | RECRUITING | NCT06443502 |
| Vedolizumab | Other | Phase PHASE3 | Pouchitis | RECRUITING | NCT06443502 |
| Vedolizumab SC | Other | Phase PHASE3 | Ulcerative Colitis | RECRUITING | NCT06100289 |
| Vedolizumab IV | Other | Phase PHASE3 | Ulcerative Colitis | RECRUITING | NCT06100289 |
| Vedolizumab SC | Other | Phase PHASE3 | Ulcerative Colitis | RECRUITING | NCT06100289 |
| Vedolizumab IV | Other | Phase PHASE3 | Ulcerative Colitis | RECRUITING | NCT06100289 |
| Replagal | Other | Phase PHASE4 | Fabry Disease | RECRUITING | NCT05067868 |
| Replagal | Other | Phase PHASE4 | Fabry Disease | RECRUITING | NCT05067868 |
| Brentuximab vedotin | Other | Phase PHASE4 | Lymphoma | COMPLETED | NCT01909934 |
| Ampicillin | Other | Phase PHASE4 | Surgical Site Infection | COMPLETED | NCT06368102 |
| Ampicillin | Other | Phase PHASE4 | Surgical Site Infection | COMPLETED | NCT06368102 |
| Screening | Other | Preclinical | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT05844033 |
| No intervention | Other | Preclinical | Hypoparathyroidism | ACTIVE_NOT_RECRUITING | NCT01922440 |
| Vedolizumab | Other | Phase PHASE3 | Colitis, Ulcerative | COMPLETED | NCT04779307 |
| Vedolizumab | Other | Phase PHASE3 | Colitis, Ulcerative | COMPLETED | NCT04779307 |
| Chemotherapy Agents | Drug | Phase PHASE1 | Pediatric Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL) | TERMINATED | NCT04501614 |
| Ponatinib | Other | Phase PHASE1 | Pediatric Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL) | TERMINATED | NCT04501614 |
| Chemotherapy Agents | Drug | Phase PHASE1 | Pediatric Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL) | TERMINATED | NCT04501614 |
| Ponatinib | Other | Phase PHASE1 | Pediatric Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL) | TERMINATED | NCT04501614 |
| Subasumstat | Other | Phase PHASE1 | Solid Tumors | TERMINATED | NCT05976334 |
| [14C] Subasumstat | Other | Phase PHASE1 | Solid Tumors | TERMINATED | NCT05976334 |
| Maribavir | Other | Preclinical | Cytomegalovirus (CMV) | RECRUITING | NCT06577363 |
| Maribavir | Other | Preclinical | Cytomegalovirus (CMV) | RECRUITING | NCT06577363 |
| Recombinant ADAMTS13 | Other | Preclinical | Thrombotic Thrombocytopenic Purpura (TTP) | RECRUITING | NCT06441578 |
| Recombinant ADAMTS13 | Other | Preclinical | Thrombotic Thrombocytopenic Purpura (TTP) | RECRUITING | NCT06441578 |
| Valganciclovir | Other | Phase PHASE4 | Transplant Complication | COMPLETED | NCT06034925 |
| Maribavir | Other | Phase PHASE4 | Transplant Complication | COMPLETED | NCT06034925 |
| Leuprorelin Acetate | Other | Preclinical | Spinal and Bulbar Muscular Atrophy | RECRUITING | NCT03555578 |
| Leuprorelin Acetate | Other | Preclinical | Spinal and Bulbar Muscular Atrophy | RECRUITING | NCT03555578 |
| Soticlestat | Other | Phase PHASE3 | Dravet Syndrome (DS) | TERMINATED | NCT05163314 |
| Fazirsiran Injection | Other | Phase PHASE3 | Alpha1-Antitrypsin Deficiency | ACTIVE_NOT_RECRUITING | NCT05899673 |
| Fazirsiran Injection | Other | Phase PHASE3 | Alpha1-Antitrypsin Deficiency | ACTIVE_NOT_RECRUITING | NCT05899673 |
| Vedolizumab IV | Other | Phase PHASE3 | Crohn's Disease (CD) | RECRUITING | NCT04779320 |
| Vedolizumab IV | Other | Phase PHASE3 | Crohn's Disease (CD) | RECRUITING | NCT04779320 |
| Azacitidine | Other | Phase PHASE2 | Acute Myeloid Leukemia (AML) | COMPLETED | NCT04266795 |
| Venetoclax | Other | Phase PHASE2 | Acute Myeloid Leukemia (AML) | COMPLETED | NCT04266795 |
| Pevonedistat | Other | Phase PHASE2 | Acute Myeloid Leukemia (AML) | COMPLETED | NCT04266795 |
| No Intervention | Other | Preclinical | Alpha1-Antitrypsin Deficiency | RECRUITING | NCT06512454 |
| No Intervention | Other | Preclinical | Alpha1-Antitrypsin Deficiency | RECRUITING | NCT06512454 |
| No Intervention | Other | Preclinical | Alpha1-Antitrypsin Deficiency | RECRUITING | NCT06512454 |
| Apremilast | Other | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT06088043 |
| Placebo | Other | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT06088043 |
| TAK-279 | Other | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT06088043 |
| Apremilast | Other | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT06088043 |
| Placebo | Other | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT06088043 |
| TAK-279 | Other | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT06088043 |
| Quality-of-Life Assessment | Other | Phase PHASE2 | Recurrent Plasma Cell Myeloma | ACTIVE_NOT_RECRUITING | NCT03763162 |
| Ixazomib | Other | Phase PHASE2 | Recurrent Plasma Cell Myeloma | ACTIVE_NOT_RECRUITING | NCT03763162 |
| Dexamethasone | Other | Phase PHASE2 | Recurrent Plasma Cell Myeloma | ACTIVE_NOT_RECRUITING | NCT03763162 |
| Daratumumab | Other | Phase PHASE2 | Recurrent Plasma Cell Myeloma | ACTIVE_NOT_RECRUITING | NCT03763162 |
| Bortezomib | Other | Phase PHASE2 | Recurrent Plasma Cell Myeloma | ACTIVE_NOT_RECRUITING | NCT03763162 |
| bortezomib | Other | Phase PHASE2 | Mantle Cell Lymphoma | COMPLETED | NCT00310037 |
| Pevonedistat | Other | Phase PHASE3 | Myelodysplastic Syndrome | COMPLETED | NCT03268954 |
| Azacitidine | Other | Phase PHASE3 | Myelodysplastic Syndrome | COMPLETED | NCT03268954 |
| Pevonedistat | Other | Phase PHASE3 | Myelodysplastic Syndrome | COMPLETED | NCT03268954 |
| Azacitidine | Other | Phase PHASE3 | Myelodysplastic Syndrome | COMPLETED | NCT03268954 |
| Pevonedistat | Other | Phase PHASE3 | Myelodysplastic Syndrome | COMPLETED | NCT03268954 |
| Azacitidine | Other | Phase PHASE3 | Myelodysplastic Syndrome | COMPLETED | NCT03268954 |
| SC Investigational Needle Sets | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06935266 |
| TAK-881 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06935266 |
| SC Investigational Needle Sets | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06935266 |
| TAK-881 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06935266 |
| Placebo for Sulfamethoxazole-Trimethoprim | Other | Phase PHASE2 | Immune Checkpoint Inhibitor-Related Colitis | RECRUITING | NCT06841705 |
| Sulfamethoxazole-Trimethoprim | Other | Phase PHASE2 | Immune Checkpoint Inhibitor-Related Colitis | RECRUITING | NCT06841705 |
| Placebo Vedolizumab | Other | Phase PHASE2 | Immune Checkpoint Inhibitor-Related Colitis | RECRUITING | NCT06841705 |
| Placebo Prednisone Capsules | Other | Phase PHASE2 | Immune Checkpoint Inhibitor-Related Colitis | RECRUITING | NCT06841705 |
| Prednisone Taper | Other | Phase PHASE2 | Immune Checkpoint Inhibitor-Related Colitis | RECRUITING | NCT06841705 |
| Prednisone (and methylprednisolone) | Other | Phase PHASE2 | Immune Checkpoint Inhibitor-Related Colitis | RECRUITING | NCT06841705 |
| Vedolizumab 300 MG Injection [Entyvio] | Other | Phase PHASE2 | Immune Checkpoint Inhibitor-Related Colitis | RECRUITING | NCT06841705 |
| Placebo | Other | Phase PHASE3 | Crohn's Disease | RECRUITING | NCT05837897 |
| Vedolizumab IV | Other | Phase PHASE3 | Crohn's Disease | RECRUITING | NCT05837897 |
| Placebo | Other | Phase PHASE3 | Crohn's Disease | RECRUITING | NCT05837897 |
| Vedolizumab IV | Other | Phase PHASE3 | Crohn's Disease | RECRUITING | NCT05837897 |
| Blood Draw | Other | Phase PHASE4 | Crohn's Disease | ACTIVE_NOT_RECRUITING | NCT04809363 |
| CDPATH™ | Other | Phase PHASE4 | Crohn's Disease | ACTIVE_NOT_RECRUITING | NCT04809363 |
| Blood Draw | Other | Phase PHASE4 | Crohn's Disease | ACTIVE_NOT_RECRUITING | NCT04809363 |
| CDPATH™ | Other | Phase PHASE4 | Crohn's Disease | ACTIVE_NOT_RECRUITING | NCT04809363 |
| Blood Draw | Other | Phase PHASE4 | Crohn's Disease | ACTIVE_NOT_RECRUITING | NCT04809363 |
| CDPATH™ | Other | Phase PHASE4 | Crohn's Disease | ACTIVE_NOT_RECRUITING | NCT04809363 |
| Elaprase | Other | Phase PHASE2 | Hunter Syndrome | ACTIVE_NOT_RECRUITING | NCT06031259 |
| Idursulfase-IT | Other | Phase PHASE2 | Hunter Syndrome | ACTIVE_NOT_RECRUITING | NCT06031259 |
| Elaprase | Other | Phase PHASE2 | Hunter Syndrome | ACTIVE_NOT_RECRUITING | NCT06031259 |
| Idursulfase-IT | Other | Phase PHASE2 | Hunter Syndrome | ACTIVE_NOT_RECRUITING | NCT06031259 |
| Dexamethasone | Other | Phase PHASE2 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02253316 |
| Lenalidomide | Other | Phase PHASE2 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02253316 |
| Ixazomib | Other | Phase PHASE2 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02253316 |
| Dacarbazine | Other | Phase PHASE1 | Hodgkin Disease | ACTIVE_NOT_RECRUITING | NCT02979522 |
| Vinblastine | Other | Phase PHASE1 | Hodgkin Disease | ACTIVE_NOT_RECRUITING | NCT02979522 |
| Doxorubicin | Other | Phase PHASE1 | Hodgkin Disease | ACTIVE_NOT_RECRUITING | NCT02979522 |
| Brentuximab vedotin | Other | Phase PHASE1 | Hodgkin Disease | ACTIVE_NOT_RECRUITING | NCT02979522 |
| Dacarbazine | Other | Phase PHASE1 | Hodgkin Disease | ACTIVE_NOT_RECRUITING | NCT02979522 |
| Vinblastine | Other | Phase PHASE1 | Hodgkin Disease | ACTIVE_NOT_RECRUITING | NCT02979522 |
| Doxorubicin | Other | Phase PHASE1 | Hodgkin Disease | ACTIVE_NOT_RECRUITING | NCT02979522 |
| Brentuximab vedotin | Other | Phase PHASE1 | Hodgkin Disease | ACTIVE_NOT_RECRUITING | NCT02979522 |
| No Intervention | Other | Preclinical | Crohn's Disease | COMPLETED | NCT05192863 |
| No Intervention | Other | Preclinical | Crohn's Disease | COMPLETED | NCT05192863 |
| Darvadstrocel | Other | Phase PHASE3 | Crohn's Disease | TERMINATED | NCT04701411 |
| Darvadstrocel | Other | Phase PHASE3 | Crohn's Disease | TERMINATED | NCT04701411 |
| TAK-279 | Other | Phase PHASE3 | Generalized Pustular Psoriasis | ACTIVE_NOT_RECRUITING | NCT06323356 |
| TAK-279 | Other | Phase PHASE3 | Generalized Pustular Psoriasis | ACTIVE_NOT_RECRUITING | NCT06323356 |
| TAK-771 | Other | Phase PHASE3 | Primary Immunodeficiency Diseases (PID) | COMPLETED | NCT05513586 |
| TAK-771 | Other | Phase PHASE3 | Primary Immunodeficiency Diseases (PID) | COMPLETED | NCT05513586 |
| Icatibant | Other | Preclinical | Hereditary Angioedema (HAE) | COMPLETED | NCT05509569 |
| Icatibant | Other | Preclinical | Hereditary Angioedema (HAE) | COMPLETED | NCT05509569 |
| Icatibant | Other | Preclinical | Hereditary Angioedema (HAE) | COMPLETED | NCT05509569 |
| Darvadstrocel | Other | Preclinical | Crohn's Disease | RECRUITING | NCT05113095 |
| Darvadstrocel | Other | Preclinical | Crohn's Disease | RECRUITING | NCT05113095 |
| Darvadstrocel | Other | Preclinical | Crohn's Disease | RECRUITING | NCT05113095 |
| LIVTENCITY | Other | Preclinical | Cytomegalovirus (CMV) | RECRUITING | NCT06555432 |
| LIVTENCITY | Other | Preclinical | Cytomegalovirus (CMV) | RECRUITING | NCT06555432 |
| Tetravalent Dengue Vaccine (TDV) | Other | Phase PHASE3 | Healthy Volunteers | COMPLETED | NCT02747927 |
| Placebo | Other | Phase PHASE3 | Healthy Volunteers | COMPLETED | NCT02747927 |
| Tetravalent Dengue Vaccine (TDV) | Other | Phase PHASE3 | Healthy Volunteers | COMPLETED | NCT02747927 |
| Placebo | Other | Phase PHASE3 | Healthy Volunteers | COMPLETED | NCT02747927 |
| CurQD (Curcumin + QingDai combination) | Other | Preclinical | Ulcerative Colitis (UC) | ACTIVE_NOT_RECRUITING | NCT07240168 |
| CurQD (Curcumin + QingDai combination) | Other | Preclinical | Ulcerative Colitis (UC) | ACTIVE_NOT_RECRUITING | NCT07240168 |
| CurQD (Curcumin + QingDai combination) | Other | Preclinical | Ulcerative Colitis (UC) | ACTIVE_NOT_RECRUITING | NCT07240168 |
| Apremilast | Other | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT06108544 |
| Placebo | Other | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT06108544 |
| TAK-279 | Other | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT06108544 |
| Apremilast | Other | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT06108544 |
| Placebo | Other | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT06108544 |
| TAK-279 | Other | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT06108544 |
| No Intervention | Other | Preclinical | Hereditary Angioedema (HAE) | ACTIVE_NOT_RECRUITING | NCT05469789 |
| No Intervention | Other | Preclinical | Hereditary Angioedema (HAE) | ACTIVE_NOT_RECRUITING | NCT05469789 |
| No Intervention | Other | Preclinical | Hereditary Angioedema (HAE) | ACTIVE_NOT_RECRUITING | NCT05469789 |
| TAK-123 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04155567 |
| TAK-123 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04155567 |
| No Intervention | Other | Preclinical | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | RECRUITING | NCT06538064 |
| No Intervention | Other | Preclinical | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | RECRUITING | NCT06538064 |
| Vedolizumab | Other | Phase PHASE4 | Crohn's Disease | RECRUITING | NCT06180382 |
| Adalimumab | Other | Phase PHASE4 | Crohn's Disease | RECRUITING | NCT06180382 |
| Placebo | Other | Phase PHASE3 | Healthy Volunteers | COMPLETED | NCT06060067 |
| TDV | Other | Phase PHASE3 | Healthy Volunteers | COMPLETED | NCT06060067 |
| Placebo | Other | Phase PHASE3 | Healthy Volunteers | COMPLETED | NCT06060067 |
| TDV | Other | Phase PHASE3 | Healthy Volunteers | COMPLETED | NCT06060067 |
| TAK-771 | Other | Phase PHASE3 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | ACTIVE_NOT_RECRUITING | NCT05084053 |
| Prednisone | Other | Phase PHASE3 | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) | ACTIVE_NOT_RECRUITING | NCT03589326 |
| Methotrexate | Other | Phase PHASE3 | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) | ACTIVE_NOT_RECRUITING | NCT03589326 |
| Cytarabine | Other | Phase PHASE3 | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) | ACTIVE_NOT_RECRUITING | NCT03589326 |
| Dexamethasone | Other | Phase PHASE3 | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) | ACTIVE_NOT_RECRUITING | NCT03589326 |
| Vincristine | Other | Phase PHASE3 | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) | ACTIVE_NOT_RECRUITING | NCT03589326 |
| Imatinib | Other | Phase PHASE3 | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) | ACTIVE_NOT_RECRUITING | NCT03589326 |
| Ponatinib | Other | Phase PHASE3 | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) | ACTIVE_NOT_RECRUITING | NCT03589326 |
| Prednisone | Other | Phase PHASE3 | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) | ACTIVE_NOT_RECRUITING | NCT03589326 |
| Methotrexate | Other | Phase PHASE3 | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) | ACTIVE_NOT_RECRUITING | NCT03589326 |
| Cytarabine | Other | Phase PHASE3 | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) | ACTIVE_NOT_RECRUITING | NCT03589326 |
| Dexamethasone | Other | Phase PHASE3 | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) | ACTIVE_NOT_RECRUITING | NCT03589326 |
| Vincristine | Other | Phase PHASE3 | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) | ACTIVE_NOT_RECRUITING | NCT03589326 |
| Imatinib | Other | Phase PHASE3 | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) | ACTIVE_NOT_RECRUITING | NCT03589326 |
| Ponatinib | Other | Phase PHASE3 | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) | ACTIVE_NOT_RECRUITING | NCT03589326 |
| No Intervention | Other | Phase PHASE3 | Ulcerative Colitis | RECRUITING | NCT06405087 |
| Vedolizumab SC | Other | Phase PHASE3 | Ulcerative Colitis | RECRUITING | NCT06405087 |
| No Intervention | Other | Preclinical | Constipation | ACTIVE_NOT_RECRUITING | NCT04961840 |
| No Intervention | Other | Preclinical | Constipation | ACTIVE_NOT_RECRUITING | NCT04961840 |
| TAK-186 | Other | Phase PHASE1 | Squamous Cell Cancer of Head and Neck (SCCHN) | TERMINATED | NCT04844073 |
| TAK-186 | Other | Phase PHASE1 | Squamous Cell Cancer of Head and Neck (SCCHN) | TERMINATED | NCT04844073 |
| TAK-186 | Other | Phase PHASE1 | Squamous Cell Cancer of Head and Neck (SCCHN) | TERMINATED | NCT04844073 |
| Brigatinib | Other | Phase PHASE1 | Anaplastic Large Cell Lymphoma, ALK-Positive | RECRUITING | NCT04925609 |
| Brigatinib | Other | Phase PHASE1 | Anaplastic Large Cell Lymphoma, ALK-Positive | RECRUITING | NCT04925609 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06236009 |
| TAK-004 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06236009 |
| No Intervention | Other | Preclinical | Cytomegalovirus (CMV) | RECRUITING | NCT06243731 |
| No Intervention | Other | Preclinical | Cytomegalovirus (CMV) | RECRUITING | NCT06243731 |
| Placebo to match deucravacitinib | Other | Phase PHASE3 | Plaque Psoriasis | ACTIVE_NOT_RECRUITING | NCT06973291 |
| Placebo to match zasocitinib | Other | Phase PHASE3 | Plaque Psoriasis | ACTIVE_NOT_RECRUITING | NCT06973291 |
| Deucravacitinib | Other | Phase PHASE3 | Plaque Psoriasis | ACTIVE_NOT_RECRUITING | NCT06973291 |
| Zasocitinib | Other | Phase PHASE3 | Plaque Psoriasis | ACTIVE_NOT_RECRUITING | NCT06973291 |
| Placebo to match deucravacitinib | Other | Phase PHASE3 | Plaque Psoriasis | ACTIVE_NOT_RECRUITING | NCT06973291 |
| Placebo to match zasocitinib | Other | Phase PHASE3 | Plaque Psoriasis | ACTIVE_NOT_RECRUITING | NCT06973291 |
| Deucravacitinib | Other | Phase PHASE3 | Plaque Psoriasis | ACTIVE_NOT_RECRUITING | NCT06973291 |
| Zasocitinib | Other | Phase PHASE3 | Plaque Psoriasis | ACTIVE_NOT_RECRUITING | NCT06973291 |
| Placebo to match deucravacitinib | Other | Phase PHASE3 | Plaque Psoriasis | ACTIVE_NOT_RECRUITING | NCT06973291 |
| Placebo to match zasocitinib | Other | Phase PHASE3 | Plaque Psoriasis | ACTIVE_NOT_RECRUITING | NCT06973291 |
| Deucravacitinib | Other | Phase PHASE3 | Plaque Psoriasis | ACTIVE_NOT_RECRUITING | NCT06973291 |
| Zasocitinib | Other | Phase PHASE3 | Plaque Psoriasis | ACTIVE_NOT_RECRUITING | NCT06973291 |
| Vedolizumab | Other | Phase PHASE2 | Collagenous Gastritis | ACTIVE_NOT_RECRUITING | NCT06317220 |
| Vedolizumab | Other | Phase PHASE2 | Collagenous Gastritis | ACTIVE_NOT_RECRUITING | NCT06317220 |
| Dexamethasone | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT02461888 |
| Cyclophosphamide | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT02461888 |
| Ixazomib | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT02461888 |
| Placebo | Other | Phase PHASE3 | Moderately to Severely Active Ulcerative Colitis | RECRUITING | NCT03221036 |
| Vedolizumab IV | Other | Phase PHASE3 | Moderately to Severely Active Ulcerative Colitis | RECRUITING | NCT03221036 |
| Placebo | Other | Phase PHASE3 | Moderately to Severely Active Ulcerative Colitis | RECRUITING | NCT03221036 |
| Vedolizumab IV | Other | Phase PHASE3 | Moderately to Severely Active Ulcerative Colitis | RECRUITING | NCT03221036 |
| No Intervention | Other | Preclinical | Lymphoma | ACTIVE_NOT_RECRUITING | NCT04837222 |
| No Intervention | Other | Preclinical | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT04592523 |
| No Intervention | Other | Preclinical | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT04592523 |
| No Intervention | Other | Preclinical | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT04592523 |
| Zasocitinib | Other | Phase PHASE2 | Crohn's Disease | RECRUITING | NCT06764615 |
| Placebo | Other | Phase PHASE2 | Dengue Fever | COMPLETED | NCT06741683 |
| TDV | Other | Phase PHASE2 | Dengue Fever | COMPLETED | NCT06741683 |
| Placebo | Other | Phase PHASE2 | Dengue Fever | COMPLETED | NCT06741683 |
| TDV | Other | Phase PHASE2 | Dengue Fever | COMPLETED | NCT06741683 |
| Cabozantinib | Other | Preclinical | Hepatocellular Cancer | COMPLETED | NCT05100082 |
| Cabozantinib | Other | Preclinical | Hepatocellular Cancer | COMPLETED | NCT05100082 |
| mFOLFOX6 + bevacizumab combination therapy | Drug | Preclinical | Colorectal Cancer | ACTIVE_NOT_RECRUITING | NCT05030493 |
| mFOLFOX6 + panitumumab combination therapy | Drug | Preclinical | Colorectal Cancer | ACTIVE_NOT_RECRUITING | NCT05030493 |
| mFOLFOX6 + bevacizumab combination therapy | Drug | Preclinical | Colorectal Cancer | ACTIVE_NOT_RECRUITING | NCT05030493 |
| mFOLFOX6 + panitumumab combination therapy | Drug | Preclinical | Colorectal Cancer | ACTIVE_NOT_RECRUITING | NCT05030493 |
| Niraparib | Other | Preclinical | Ovarian Cancer | ACTIVE_NOT_RECRUITING | NCT05021562 |
| Bicalutamide | Other | Phase PHASE3 | Prostate Cancer | COMPLETED | NCT01809691 |
| TAK-700 | Other | Phase PHASE3 | Prostate Cancer | COMPLETED | NCT01809691 |
| Bicalutamide | Other | Phase PHASE3 | Prostate Cancer | COMPLETED | NCT01809691 |
| TAK-700 | Other | Phase PHASE3 | Prostate Cancer | COMPLETED | NCT01809691 |
| No intervention | Other | Preclinical | Fabry Disease | RECRUITING | NCT07187440 |
| No intervention | Other | Preclinical | Fabry Disease | RECRUITING | NCT07187440 |
| TAK-226 | Other | Phase PHASE2 | Myelodysplastic Syndromes | NOT_YET_RECRUITING | NCT07319845 |
| TAK-226 | Other | Phase PHASE2 | Myelodysplastic Syndromes | NOT_YET_RECRUITING | NCT07319845 |
| Vedolizumab (Genetical Recombination) | Other | Preclinical | Crohn's Disease | ACTIVE_NOT_RECRUITING | NCT04002180 |
| ADVATE | Other | Phase PHASE3 | Von Willebrand Disease (VWD) | RECRUITING | NCT07129343 |
| VONVENDI | Other | Phase PHASE3 | Von Willebrand Disease (VWD) | RECRUITING | NCT07129343 |
| ADVATE | Other | Phase PHASE3 | Von Willebrand Disease (VWD) | RECRUITING | NCT07129343 |
| VONVENDI | Other | Phase PHASE3 | Von Willebrand Disease (VWD) | RECRUITING | NCT07129343 |
| ADVATE | Other | Phase PHASE3 | Von Willebrand Disease (VWD) | RECRUITING | NCT07129343 |
| VONVENDI | Other | Phase PHASE3 | Von Willebrand Disease (VWD) | RECRUITING | NCT07129343 |
| No intervention | Other | Preclinical | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT05013190 |
| Neratinib | Other | Phase PHASE2 | Neurofibromatosis Type 2 | ACTIVE_NOT_RECRUITING | NCT04374305 |
| Brigatinib | Other | Phase PHASE2 | Neurofibromatosis Type 2 | ACTIVE_NOT_RECRUITING | NCT04374305 |
| Neratinib | Other | Phase PHASE2 | Neurofibromatosis Type 2 | ACTIVE_NOT_RECRUITING | NCT04374305 |
| Brigatinib | Other | Phase PHASE2 | Neurofibromatosis Type 2 | ACTIVE_NOT_RECRUITING | NCT04374305 |
| Neratinib | Other | Phase PHASE2 | Neurofibromatosis Type 2 | ACTIVE_NOT_RECRUITING | NCT04374305 |
| Brigatinib | Other | Phase PHASE2 | Neurofibromatosis Type 2 | ACTIVE_NOT_RECRUITING | NCT04374305 |
| Leuprorelin Acetate Depot 3M | Other | Phase PHASE4 | Central Precocious Puberty | COMPLETED | NCT05341115 |
| Leuprorelin Acetate Depot 3M | Other | Phase PHASE4 | Central Precocious Puberty | COMPLETED | NCT05341115 |
| Leuprorelin Acetate Depot 3M | Other | Phase PHASE4 | Central Precocious Puberty | COMPLETED | NCT05341115 |
| Autologous Stem Cell Transplant | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT02441686 |
| Stem Cell Mobilization | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT02441686 |
| Dexamethasone | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT02441686 |
| Lenalidomide | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT02441686 |
| Bortezomib | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT02441686 |
| Dexlansoprazole | Other | Phase PHASE2 | Gastroesophageal Reflux Disease (GERD) | RECRUITING | NCT02616302 |
| Dexlansoprazole | Other | Phase PHASE2 | Gastroesophageal Reflux Disease (GERD) | RECRUITING | NCT02616302 |
| Vedolizumab | Other | Phase PHASE4 | Moderately to Severely Active Crohn's Disease | RECRUITING | NCT06257706 |
| Vedolizumab | Other | Phase PHASE4 | Moderately to Severely Active Crohn's Disease | RECRUITING | NCT06257706 |
| SC Investigational Needle Sets | Other | Phase PHASE3 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | RECRUITING | NCT06747351 |
| HYQVIA | Other | Phase PHASE3 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | RECRUITING | NCT06747351 |
| TAK-881 | Other | Phase PHASE3 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | RECRUITING | NCT06747351 |
| SC Investigational Needle Sets | Other | Phase PHASE3 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | RECRUITING | NCT06747351 |
| HYQVIA | Other | Phase PHASE3 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | RECRUITING | NCT06747351 |
| TAK-881 | Other | Phase PHASE3 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | RECRUITING | NCT06747351 |
| No intervention | Other | Preclinical | Hereditary Angioedema (HAE) | COMPLETED | NCT06346899 |
| No Intervention | Other | Preclinical | Hypoparathyroidism | COMPLETED | NCT05556629 |
| No Intervention | Other | Preclinical | Hypoparathyroidism | COMPLETED | NCT05556629 |
| Dexamethasone | Other | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT05070247 |
| Tocilizumab | Other | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT05070247 |
| Pembrolizumab | Other | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT05070247 |
| TAK-500 | Other | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT05070247 |
| Dexamethasone | Other | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT05070247 |
| Tocilizumab | Other | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT05070247 |
| Pembrolizumab | Other | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT05070247 |
| TAK-500 | Other | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT05070247 |
| Darvadstrocel | Other | Phase PHASE4 | Crohn's Disease | TERMINATED | NCT04118088 |
| Darvadstrocel | Other | Phase PHASE4 | Crohn's Disease | TERMINATED | NCT04118088 |
| Darvadstrocel | Other | Phase PHASE4 | Crohn's Disease | TERMINATED | NCT04118088 |
| Mezagitamab | Other | Phase PHASE1 | Kidney Disease | COMPLETED | NCT05174221 |
| Mezagitamab | Other | Phase PHASE1 | Kidney Disease | COMPLETED | NCT05174221 |
| Treatment Algorithm C | Drug | Phase PHASE4 | Colitis, Ulcerative | ACTIVE_NOT_RECRUITING | NCT04259138 |
| Treatment Algorithm B | Drug | Phase PHASE4 | Colitis, Ulcerative | ACTIVE_NOT_RECRUITING | NCT04259138 |
| Treatment Algorithm A | Drug | Phase PHASE4 | Colitis, Ulcerative | ACTIVE_NOT_RECRUITING | NCT04259138 |
| Treatment Algorithm C | Drug | Phase PHASE4 | Colitis, Ulcerative | ACTIVE_NOT_RECRUITING | NCT04259138 |
| Treatment Algorithm B | Drug | Phase PHASE4 | Colitis, Ulcerative | ACTIVE_NOT_RECRUITING | NCT04259138 |
| Treatment Algorithm A | Drug | Phase PHASE4 | Colitis, Ulcerative | ACTIVE_NOT_RECRUITING | NCT04259138 |
| TAK-625 | Other | Phase PHASE3 | Progressive Familial Intrahepatic Cholestasis (PFIC) | COMPLETED | NCT05543187 |
| SOC 4F-PCC | Other | Phase PHASE3 | Coagulation Disorder | RECRUITING | NCT05156983 |
| TAK-330 | Other | Phase PHASE3 | Coagulation Disorder | RECRUITING | NCT05156983 |
| SOC 4F-PCC | Other | Phase PHASE3 | Coagulation Disorder | RECRUITING | NCT05156983 |
| TAK-330 | Other | Phase PHASE3 | Coagulation Disorder | RECRUITING | NCT05156983 |
| No Intervention | Other | Preclinical | Cytomegalovirus (CMV) | COMPLETED | NCT06568055 |
| TAK-625 | Other | Phase PHASE3 | Alagille Syndrome (ALGS) | COMPLETED | NCT05543174 |
| TAK-625 | Other | Phase PHASE3 | Alagille Syndrome (ALGS) | COMPLETED | NCT05543174 |
| TAK-113 | Other | Preclinical | Colorectal Cancer | NO_LONGER_AVAILABLE | NCT06195514 |
| TAK-113 | Other | Preclinical | Colorectal Cancer | NO_LONGER_AVAILABLE | NCT06195514 |
| Psychotherapy as Usual (TAU) | Drug | Approved | Major Depression | NOT_YET_RECRUITING | NCT07380451 |
| Modular Intervention for Depression Therapy (MIND Therapy) | Drug | Approved | Major Depression | NOT_YET_RECRUITING | NCT07380451 |
| Psychotherapy as Usual (TAU) | Drug | Approved | Major Depression | NOT_YET_RECRUITING | NCT07380451 |
| Modular Intervention for Depression Therapy (MIND Therapy) | Drug | Approved | Major Depression | NOT_YET_RECRUITING | NCT07380451 |
| DAPT | Other | Phase PHASE4 | Lacunar Stroke | RECRUITING | NCT07111559 |
| rt-PA | Other | Phase PHASE4 | Lacunar Stroke | RECRUITING | NCT07111559 |
| DAPT | Other | Phase PHASE4 | Lacunar Stroke | RECRUITING | NCT07111559 |
| rt-PA | Other | Phase PHASE4 | Lacunar Stroke | RECRUITING | NCT07111559 |
| DAPT | Other | Phase PHASE4 | Lacunar Stroke | RECRUITING | NCT07111559 |
| rt-PA | Other | Phase PHASE4 | Lacunar Stroke | RECRUITING | NCT07111559 |
| HYQVIA | Other | Phase PHASE2 | Primary Immunodeficiency Diseases (PID) | COMPLETED | NCT05755035 |
| TAK-881 | Other | Phase PHASE2 | Primary Immunodeficiency Diseases (PID) | COMPLETED | NCT05755035 |
| HYQVIA | Other | Phase PHASE2 | Primary Immunodeficiency Diseases (PID) | COMPLETED | NCT05755035 |
| TAK-881 | Other | Phase PHASE2 | Primary Immunodeficiency Diseases (PID) | COMPLETED | NCT05755035 |
| Lanadelumab | Other | Preclinical | Hereditary Angioedema (HAE) | COMPLETED | NCT05397431 |
| Ruxolitinib | Other | Phase PHASE2 | Myelofibrosis | RECRUITING | NCT05037760 |
| Elritercept | Other | Phase PHASE2 | Myelofibrosis | RECRUITING | NCT05037760 |
| Ruxolitinib | Other | Phase PHASE2 | Myelofibrosis | RECRUITING | NCT05037760 |
| Elritercept | Other | Phase PHASE2 | Myelofibrosis | RECRUITING | NCT05037760 |
| Oncaspar | Other | Phase PHASE2 | Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | NCT01574274 |
| SC-PEG | Other | Phase PHASE2 | Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | NCT01574274 |
| Elritercept | Other | Phase PHASE2 | Myelodysplastic Syndromes | RECRUITING | NCT04419649 |
| Elritercept | Other | Phase PHASE2 | Myelodysplastic Syndromes | RECRUITING | NCT04419649 |
| Elritercept | Other | Phase PHASE2 | Myelodysplastic Syndromes | RECRUITING | NCT04419649 |
| Placebo | Other | Phase PHASE3 | Dengue Fever | RECRUITING | NCT06579755 |
| TDV | Other | Phase PHASE3 | Dengue Fever | RECRUITING | NCT06579755 |
| Standard of care | Other | Phase PHASE3 | Thrombotic Thrombocytopenic Purpura (TTP) | COMPLETED | NCT03393975 |
| TAK-755 | Other | Phase PHASE3 | Thrombotic Thrombocytopenic Purpura (TTP) | COMPLETED | NCT03393975 |
| Standard of care | Other | Phase PHASE3 | Thrombotic Thrombocytopenic Purpura (TTP) | COMPLETED | NCT03393975 |
| TAK-755 | Other | Phase PHASE3 | Thrombotic Thrombocytopenic Purpura (TTP) | COMPLETED | NCT03393975 |
| Placebo | Other | Phase PHASE2 | Crohn's Disease | RECRUITING | NCT06233461 |
| TAK-279 | Other | Phase PHASE2 | Crohn's Disease | RECRUITING | NCT06233461 |
| Tetravalent Dengue Vaccine (TDV) | Other | Phase PHASE3 | Dengue Fever | ACTIVE_NOT_RECRUITING | NCT07047521 |
| Placebo | Other | Phase PHASE2 | Narcolepsy Type 2 | RECRUITING | NCT06952699 |
| TAK-360 | Other | Phase PHASE2 | Narcolepsy Type 2 | RECRUITING | NCT06952699 |
| Placebo | Other | Phase PHASE2 | Narcolepsy Type 2 | RECRUITING | NCT06952699 |
| TAK-360 | Other | Phase PHASE2 | Narcolepsy Type 2 | RECRUITING | NCT06952699 |
| TAK-411 | Other | Phase PHASE2 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | RECRUITING | NCT06798012 |
| Mirikizumab (MIR) | Other | Preclinical | Crohn's Disease | RECRUITING | NCT06249555 |
| Guselkumab (GUS) | Other | Preclinical | Crohn's Disease | RECRUITING | NCT06249555 |
| Risankizumab (RISA) | Other | Preclinical | Crohn's Disease | RECRUITING | NCT06249555 |
| Ustekinumab (UST) | Other | Preclinical | Crohn's Disease | RECRUITING | NCT06249555 |
| Vedolizumab (VDZ) | Other | Preclinical | Crohn's Disease | RECRUITING | NCT06249555 |
| Mirikizumab (MIR) | Other | Preclinical | Crohn's Disease | RECRUITING | NCT06249555 |
| Guselkumab (GUS) | Other | Preclinical | Crohn's Disease | RECRUITING | NCT06249555 |
| Risankizumab (RISA) | Other | Preclinical | Crohn's Disease | RECRUITING | NCT06249555 |
| Ustekinumab (UST) | Other | Preclinical | Crohn's Disease | RECRUITING | NCT06249555 |
| Vedolizumab (VDZ) | Other | Preclinical | Crohn's Disease | RECRUITING | NCT06249555 |
| Mirikizumab (MIR) | Other | Preclinical | Crohn's Disease | RECRUITING | NCT06249555 |
| Guselkumab (GUS) | Other | Preclinical | Crohn's Disease | RECRUITING | NCT06249555 |
| Risankizumab (RISA) | Other | Preclinical | Crohn's Disease | RECRUITING | NCT06249555 |
| Ustekinumab (UST) | Other | Preclinical | Crohn's Disease | RECRUITING | NCT06249555 |
| Vedolizumab (VDZ) | Other | Preclinical | Crohn's Disease | RECRUITING | NCT06249555 |
| Patient switched from IV vedolizumab to subcutaneous vedolizumab as part of normal patient care | Other | Preclinical | Inflammatory Bowel Disease (IBD) | ACTIVE_NOT_RECRUITING | NCT07123350 |
| Patient switched from IV vedolizumab to subcutaneous vedolizumab as part of normal patient care | Other | Preclinical | Inflammatory Bowel Disease (IBD) | ACTIVE_NOT_RECRUITING | NCT07123350 |
| Placebo | Other | Phase PHASE2 | Acute Ischemic Stroke | NOT_YET_RECRUITING | NCT07392450 |
| TAK-755 | Other | Phase PHASE2 | Acute Ischemic Stroke | NOT_YET_RECRUITING | NCT07392450 |
| No Intervention | Other | Preclinical | Multiple Myeloma | RECRUITING | NCT05879757 |
| No Intervention | Other | Preclinical | Multiple Myeloma | RECRUITING | NCT05879757 |
| Brigatinib | Other | Preclinical | Non-small Cell Lung Cancer (NSCLC) | ACTIVE_NOT_RECRUITING | NCT05721950 |
| Brigatinib | Other | Preclinical | Non-small Cell Lung Cancer (NSCLC) | ACTIVE_NOT_RECRUITING | NCT05721950 |
| rFVIIa | Other | Phase PHASE3 | Hemophilia A | RECRUITING | NCT04563520 |
| FEIBA | Other | Phase PHASE3 | Hemophilia A | RECRUITING | NCT04563520 |
| Emicizumab | Other | Phase PHASE3 | Hemophilia A | RECRUITING | NCT04563520 |
| rFVIIa | Other | Phase PHASE3 | Hemophilia A | RECRUITING | NCT04563520 |
| FEIBA | Other | Phase PHASE3 | Hemophilia A | RECRUITING | NCT04563520 |
| Emicizumab | Other | Phase PHASE3 | Hemophilia A | RECRUITING | NCT04563520 |
| Maralixibat | Other | Preclinical | Alagille Syndrome (ALGS) | RECRUITING | NCT07293897 |
| Maralixibat | Other | Preclinical | Alagille Syndrome (ALGS) | RECRUITING | NCT07293897 |
| Immune Globulin Subcutaneous (Human), 20% Solution | Other | Preclinical | Primary Immunodeficiency Diseases (PID) | RECRUITING | NCT06565078 |
| Immune Globulin Subcutaneous (Human), 20% Solution | Other | Preclinical | Primary Immunodeficiency Diseases (PID) | RECRUITING | NCT06565078 |
| vonicog alfa (rVWF) | Other | Preclinical | Von Willebrand Disease (vWD) | RECRUITING | NCT07404644 |
| vonicog alfa (rVWF) | Other | Preclinical | Von Willebrand Disease (vWD) | RECRUITING | NCT07404644 |
| Dacarbazine | Other | Phase PHASE4 | Hodgkin Lymphoma | RECRUITING | NCT06831370 |
| Vinblastine | Other | Phase PHASE4 | Hodgkin Lymphoma | RECRUITING | NCT06831370 |
| Doxorubicin | Other | Phase PHASE4 | Hodgkin Lymphoma | RECRUITING | NCT06831370 |
| Brentuximab Vedotin | Other | Phase PHASE4 | Hodgkin Lymphoma | RECRUITING | NCT06831370 |
| Dacarbazine | Other | Phase PHASE4 | Hodgkin Lymphoma | RECRUITING | NCT06831370 |
| Vinblastine | Other | Phase PHASE4 | Hodgkin Lymphoma | RECRUITING | NCT06831370 |
| Doxorubicin | Other | Phase PHASE4 | Hodgkin Lymphoma | RECRUITING | NCT06831370 |
| Brentuximab Vedotin | Other | Phase PHASE4 | Hodgkin Lymphoma | RECRUITING | NCT06831370 |
| Zasocitinib | Other | Phase PHASE2 | Crohn's Disease | NOT_YET_RECRUITING | NCT07403968 |
| Zasocitinib | Other | Phase PHASE2 | Crohn's Disease | NOT_YET_RECRUITING | NCT07403968 |
| No intervention | Other | Preclinical | Hereditary Angioedema (HAE) | RECRUITING | NCT07251933 |
| No Intervention | Other | Preclinical | Ulcerative Colitis | ACTIVE_NOT_RECRUITING | NCT05626088 |
| TAK-788 | Other | Phase PHASE1 | Carcinoma, Non-Small-Cell Lung | ACTIVE_NOT_RECRUITING | NCT02716116 |
| TAK-788 | Other | Phase PHASE1 | Carcinoma, Non-Small-Cell Lung | ACTIVE_NOT_RECRUITING | NCT02716116 |
| No intervention | Other | Preclinical | Colorectal Cancer | RECRUITING | NCT07035886 |
| Vedolizumab IV | Other | Preclinical | Crohn's Disease | AVAILABLE | NCT06856135 |
| Vedolizumab IV | Other | Preclinical | Crohn's Disease | AVAILABLE | NCT06856135 |
| Fruquintinib | Other | Phase PHASE4 | Colorectal Cancer | RECRUITING | NCT06562543 |
| dacarbazine | Other | Phase PHASE3 | Hodgkin Lymphoma | COMPLETED | NCT01712490 |
| vinblastine | Other | Phase PHASE3 | Hodgkin Lymphoma | COMPLETED | NCT01712490 |
| bleomycin | Other | Phase PHASE3 | Hodgkin Lymphoma | COMPLETED | NCT01712490 |
| doxorubicin | Other | Phase PHASE3 | Hodgkin Lymphoma | COMPLETED | NCT01712490 |
| brentuximab vedotin | Other | Phase PHASE3 | Hodgkin Lymphoma | COMPLETED | NCT01712490 |
| dacarbazine | Other | Phase PHASE3 | Hodgkin Lymphoma | COMPLETED | NCT01712490 |
| vinblastine | Other | Phase PHASE3 | Hodgkin Lymphoma | COMPLETED | NCT01712490 |
| bleomycin | Other | Phase PHASE3 | Hodgkin Lymphoma | COMPLETED | NCT01712490 |
| doxorubicin | Other | Phase PHASE3 | Hodgkin Lymphoma | COMPLETED | NCT01712490 |
| brentuximab vedotin | Other | Phase PHASE3 | Hodgkin Lymphoma | COMPLETED | NCT01712490 |
| No Intervention | Other | Preclinical | Thrombotic Thrombocytopenic Purpura (TTP) | NOT_YET_RECRUITING | NCT07353099 |
| No Intervention | Other | Preclinical | Thrombotic Thrombocytopenic Purpura (TTP) | NOT_YET_RECRUITING | NCT07353099 |
| Maribavir | Other | Phase PHASE3 | Cytomegalovirus (CMV) | RECRUITING | NCT06439342 |
| Maribavir | Other | Phase PHASE3 | Cytomegalovirus (CMV) | RECRUITING | NCT06439342 |
| Lenalidomide | Other | Phase PHASE2 | Multiple Myeloma (MM) | COMPLETED | NCT01919086 |
| Dexamethasone | Other | Phase PHASE2 | Multiple Myeloma (MM) | COMPLETED | NCT01919086 |
| Bortezomib | Other | Phase PHASE2 | Multiple Myeloma (MM) | COMPLETED | NCT01919086 |
| Lenalidomide | Other | Phase PHASE2 | Multiple Myeloma (MM) | COMPLETED | NCT01919086 |
| Dexamethasone | Other | Phase PHASE2 | Multiple Myeloma (MM) | COMPLETED | NCT01919086 |
| Bortezomib | Other | Phase PHASE2 | Multiple Myeloma (MM) | COMPLETED | NCT01919086 |
| Lenalidomide | Other | Phase PHASE2 | Multiple Myeloma (MM) | COMPLETED | NCT01919086 |
| Dexamethasone | Other | Phase PHASE2 | Multiple Myeloma (MM) | COMPLETED | NCT01919086 |
| Bortezomib | Other | Phase PHASE2 | Multiple Myeloma (MM) | COMPLETED | NCT01919086 |
| Quality of Life questionnaire | Other | Approved | Quality of Life | COMPLETED | NCT04002531 |
| Brief Pain Inventory questionnaire | Other | Approved | Quality of Life | COMPLETED | NCT04002531 |
| 2-hour Holter Monitor | Other | Approved | Quality of Life | COMPLETED | NCT04002531 |
| Urine collection | Other | Approved | Quality of Life | COMPLETED | NCT04002531 |
| Blood draw | Other | Approved | Quality of Life | COMPLETED | NCT04002531 |
| Echocardiogram | Other | Approved | Quality of Life | COMPLETED | NCT04002531 |
| 12 lead electrocardiogram | Other | Approved | Quality of Life | COMPLETED | NCT04002531 |
| Vital signs | Other | Approved | Quality of Life | COMPLETED | NCT04002531 |
| General and Neurological examination | Other | Approved | Quality of Life | COMPLETED | NCT04002531 |
| No intervention | Other | Preclinical | Narcolepsy Type 1 | RECRUITING | NCT07299097 |
| No intervention | Other | Preclinical | Narcolepsy Type 1 | RECRUITING | NCT07299097 |
| No intervention | Other | Preclinical | Narcolepsy Type 1 | RECRUITING | NCT07299097 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07229911 |
| TAK-781 | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07229911 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07229911 |
| TAK-781 | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07229911 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07229911 |
| TAK-781 | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07229911 |
| Placebo | Other | Phase PHASE3 | Alpha1-Antitrypsin Deficiency | RECRUITING | NCT06165341 |
| Fazirsiran Injection | Other | Phase PHASE3 | Alpha1-Antitrypsin Deficiency | RECRUITING | NCT06165341 |
| Placebo | Other | Phase PHASE3 | Alpha1-Antitrypsin Deficiency | RECRUITING | NCT06165341 |
| Fazirsiran Injection | Other | Phase PHASE3 | Alpha1-Antitrypsin Deficiency | RECRUITING | NCT06165341 |
| TAK-861 | Other | Phase PHASE2 | Narcolepsy Type 1 | RECRUITING | NCT05816382 |
| TAK-861 | Other | Phase PHASE2 | Narcolepsy Type 1 | RECRUITING | NCT05816382 |
| Placebo | Other | Phase PHASE3 | Alpha1-Antitrypsin Deficiency | RECRUITING | NCT05677971 |
| Fazirsiran Injection | Other | Phase PHASE3 | Alpha1-Antitrypsin Deficiency | RECRUITING | NCT05677971 |
| Placebo | Other | Phase PHASE3 | Alpha1-Antitrypsin Deficiency | RECRUITING | NCT05677971 |
| Fazirsiran Injection | Other | Phase PHASE3 | Alpha1-Antitrypsin Deficiency | RECRUITING | NCT05677971 |
| Dexamethasone | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04094961 |
| Pomalidomide | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04094961 |
| Ixazomib | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04094961 |
| Dexamethasone | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04094961 |
| Pomalidomide | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04094961 |
| Ixazomib | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04094961 |
| Dexamethasone | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04094961 |
| Pomalidomide | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04094961 |
| Ixazomib | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04094961 |
| Rituximab | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | ACTIVE_NOT_RECRUITING | NCT02339922 |
| Laboratory Biomarker Analysis | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | ACTIVE_NOT_RECRUITING | NCT02339922 |
| Ixazomib Citrate | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | ACTIVE_NOT_RECRUITING | NCT02339922 |
| Rituximab | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | ACTIVE_NOT_RECRUITING | NCT02339922 |
| Laboratory Biomarker Analysis | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | ACTIVE_NOT_RECRUITING | NCT02339922 |
| Ixazomib Citrate | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | ACTIVE_NOT_RECRUITING | NCT02339922 |
| Placebo | Other | Phase PHASE2 | Hidradenitis Suppurativa | RECRUITING | NCT07244263 |
| Zasocitinib (Dose A) | Other | Phase PHASE2 | Hidradenitis Suppurativa | RECRUITING | NCT07244263 |
| Placebo | Other | Phase PHASE2 | Hidradenitis Suppurativa | RECRUITING | NCT07244263 |
| Zasocitinib (Dose A) | Other | Phase PHASE2 | Hidradenitis Suppurativa | RECRUITING | NCT07244263 |
| Epoetin Alfa | Other | Phase PHASE3 | Myelodysplastic Syndrome | RECRUITING | NCT07422480 |
| Elritercept | Other | Phase PHASE3 | Myelodysplastic Syndrome | RECRUITING | NCT07422480 |
| TAK-755 | Other | Phase PHASE2 | Thrombotic Thrombocytopenic Purpura (TTP) | ACTIVE_NOT_RECRUITING | NCT05714969 |
| TAK-755 | Other | Phase PHASE2 | Thrombotic Thrombocytopenic Purpura (TTP) | ACTIVE_NOT_RECRUITING | NCT05714969 |
| Pomalidomide | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT03984097 |
| Bortezomib | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT03984097 |
| Dexamethasone | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT03984097 |
| Lenalidomide | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT03984097 |
| TAK-079 | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT03984097 |
| Placebo tablets | Other | Phase PHASE3 | Major Depressive Disorder | RECRUITING | NCT07204314 |
| Vortioxetine tablets | Other | Phase PHASE3 | Major Depressive Disorder | RECRUITING | NCT07204314 |
| Placebo tablets | Other | Phase PHASE3 | Major Depressive Disorder | RECRUITING | NCT07204314 |
| Vortioxetine tablets | Other | Phase PHASE3 | Major Depressive Disorder | RECRUITING | NCT07204314 |
| Placebo | Other | Phase PHASE3 | Myelodysplastic Syndromes | RECRUITING | NCT06499285 |
| Elritercept | Other | Phase PHASE3 | Myelodysplastic Syndromes | RECRUITING | NCT06499285 |
| No Intervention | Other | Preclinical | Von Willebrand Disease (VWD) | COMPLETED | NCT06433778 |
| Valacyclovir | Other | Phase PHASE2 | Waldenstrom's Macroglobulinemia | ACTIVE_NOT_RECRUITING | NCT00492050 |
| Rituximab | Other | Phase PHASE2 | Waldenstrom's Macroglobulinemia | ACTIVE_NOT_RECRUITING | NCT00492050 |
| Bortezomib | Other | Phase PHASE2 | Waldenstrom's Macroglobulinemia | ACTIVE_NOT_RECRUITING | NCT00492050 |
| No intervention | Other | Preclinical | Hereditary Angioedema (HAE) | NOT_YET_RECRUITING | NCT07445087 |
| No intervention | Other | Preclinical | Hereditary Angioedema (HAE) | NOT_YET_RECRUITING | NCT07445087 |
| No intervention | Other | Preclinical | Hereditary Angioedema (HAE) | NOT_YET_RECRUITING | NCT07445087 |
| No Intervention | Other | Preclinical | Thrombotic Thrombocytopenic Purpura (TTP) | NOT_YET_RECRUITING | NCT07429942 |
| No Intervention | Other | Preclinical | Thrombotic Thrombocytopenic Purpura (TTP) | NOT_YET_RECRUITING | NCT07429942 |
| No Intervention | Other | Preclinical | Short Bowel Syndrome (SBS) | RECRUITING | NCT07319832 |
| No Intervention | Other | Preclinical | Short Bowel Syndrome (SBS) | RECRUITING | NCT07319832 |
| No intervention | Other | Preclinical | Hereditary Angioedema (HAE) | NOT_YET_RECRUITING | NCT07263685 |
| No intervention | Other | Preclinical | Hereditary Angioedema (HAE) | NOT_YET_RECRUITING | NCT07263685 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT06254950 |
| TAK-279 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT06254950 |
| No intervention | Other | Preclinical | Fabry Disease | COMPLETED | NCT05106764 |
| No intervention | Other | Preclinical | Fabry Disease | COMPLETED | NCT05106764 |
| No intervention | Other | Preclinical | Fabry Disease | COMPLETED | NCT05106764 |
| Brigatinib | Other | Preclinical | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT05100069 |
| Brigatinib | Other | Preclinical | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT05100069 |
| Ponatinib | Other | Phase PHASE2 | Myeloid Leukemia, Chronic, Chronic Phase | COMPLETED | NCT02467270 |
| Radiation therapy | Drug | Phase PHASE2 | Malignant Rhabdoid Tumor | ACTIVE_NOT_RECRUITING | NCT02114229 |
| Surgical resection | Other | Phase PHASE2 | Malignant Rhabdoid Tumor | ACTIVE_NOT_RECRUITING | NCT02114229 |
| vincristine | Other | Phase PHASE2 | Malignant Rhabdoid Tumor | ACTIVE_NOT_RECRUITING | NCT02114229 |
| topotecan | Other | Phase PHASE2 | Malignant Rhabdoid Tumor | ACTIVE_NOT_RECRUITING | NCT02114229 |
| etoposide | Other | Phase PHASE2 | Malignant Rhabdoid Tumor | ACTIVE_NOT_RECRUITING | NCT02114229 |
| cyclophosphamide | Other | Phase PHASE2 | Malignant Rhabdoid Tumor | ACTIVE_NOT_RECRUITING | NCT02114229 |
| carboplatin | Other | Phase PHASE2 | Malignant Rhabdoid Tumor | ACTIVE_NOT_RECRUITING | NCT02114229 |
| cisplatin | Other | Phase PHASE2 | Malignant Rhabdoid Tumor | ACTIVE_NOT_RECRUITING | NCT02114229 |
| methotrexate | Other | Phase PHASE2 | Malignant Rhabdoid Tumor | ACTIVE_NOT_RECRUITING | NCT02114229 |
| alisertib | Other | Phase PHASE2 | Malignant Rhabdoid Tumor | ACTIVE_NOT_RECRUITING | NCT02114229 |
| Radiation therapy | Drug | Phase PHASE2 | Malignant Rhabdoid Tumor | ACTIVE_NOT_RECRUITING | NCT02114229 |
| Surgical resection | Other | Phase PHASE2 | Malignant Rhabdoid Tumor | ACTIVE_NOT_RECRUITING | NCT02114229 |
| vincristine | Other | Phase PHASE2 | Malignant Rhabdoid Tumor | ACTIVE_NOT_RECRUITING | NCT02114229 |
| topotecan | Other | Phase PHASE2 | Malignant Rhabdoid Tumor | ACTIVE_NOT_RECRUITING | NCT02114229 |
| etoposide | Other | Phase PHASE2 | Malignant Rhabdoid Tumor | ACTIVE_NOT_RECRUITING | NCT02114229 |
| cyclophosphamide | Other | Phase PHASE2 | Malignant Rhabdoid Tumor | ACTIVE_NOT_RECRUITING | NCT02114229 |
| carboplatin | Other | Phase PHASE2 | Malignant Rhabdoid Tumor | ACTIVE_NOT_RECRUITING | NCT02114229 |
| cisplatin | Other | Phase PHASE2 | Malignant Rhabdoid Tumor | ACTIVE_NOT_RECRUITING | NCT02114229 |
| methotrexate | Other | Phase PHASE2 | Malignant Rhabdoid Tumor | ACTIVE_NOT_RECRUITING | NCT02114229 |
| alisertib | Other | Phase PHASE2 | Malignant Rhabdoid Tumor | ACTIVE_NOT_RECRUITING | NCT02114229 |
| Tofacitinib | Other | Phase PHASE4 | Ulcerative Colitis | RECRUITING | NCT06095128 |
| Vedolizumab | Other | Phase PHASE4 | Ulcerative Colitis | RECRUITING | NCT06095128 |
| Tofacitinib | Other | Phase PHASE4 | Ulcerative Colitis | RECRUITING | NCT06095128 |
| Vedolizumab | Other | Phase PHASE4 | Ulcerative Colitis | RECRUITING | NCT06095128 |
| Ustekinumab | Other | Phase PHASE4 | Crohn's Disease | RECRUITING | NCT06045754 |
| Adalimumab | Other | Phase PHASE4 | Crohn's Disease | RECRUITING | NCT06045754 |
| Vedolizumab | Other | Phase PHASE4 | Crohn's Disease | RECRUITING | NCT06045754 |
| Ustekinumab | Other | Phase PHASE4 | Crohn's Disease | RECRUITING | NCT06045754 |
| Adalimumab | Other | Phase PHASE4 | Crohn's Disease | RECRUITING | NCT06045754 |
| Vedolizumab | Other | Phase PHASE4 | Crohn's Disease | RECRUITING | NCT06045754 |
| Dexamethasone | Other | Phase PHASE4 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT03173092 |
| Lenalidomide | Other | Phase PHASE4 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT03173092 |
| Ixazomib | Other | Phase PHASE4 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT03173092 |
| Dexamethasone | Other | Phase PHASE4 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT03173092 |
| Lenalidomide | Other | Phase PHASE4 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT03173092 |
| Ixazomib | Other | Phase PHASE4 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT03173092 |
| Zasocitinib | Other | Phase PHASE3 | Psoriatic Arthritis | RECRUITING | NCT07286058 |
| Zasocitinib | Other | Phase PHASE3 | Psoriatic Arthritis | RECRUITING | NCT07286058 |
| Zasocitinib | Other | Phase PHASE3 | Psoriatic Arthritis | RECRUITING | NCT07286058 |
| Fazirsiran | Other | Phase PHASE1 | Hepatic Impairment | COMPLETED | NCT05891158 |
| Fazirsiran | Other | Phase PHASE1 | Hepatic Impairment | COMPLETED | NCT05891158 |
| Soticlestat | Other | Phase PHASE2 | Epilepsy | TERMINATED | NCT03635073 |
| Soticlestat | Other | Phase PHASE2 | Epilepsy | TERMINATED | NCT03635073 |
| Placebo | Other | Phase PHASE3 | Narcolepsy Type 1 (NT1) | RECRUITING | NCT07363720 |
| TAK-861 | Other | Phase PHASE3 | Narcolepsy Type 1 (NT1) | RECRUITING | NCT07363720 |
| Placebo | Other | Phase PHASE3 | Narcolepsy Type 1 (NT1) | RECRUITING | NCT07363720 |
| TAK-861 | Other | Phase PHASE3 | Narcolepsy Type 1 (NT1) | RECRUITING | NCT07363720 |
| Placebo | Other | Phase PHASE2 | Idiopathic Hypersomnia | RECRUITING | NCT06812078 |
| TAK-360 | Other | Phase PHASE2 | Idiopathic Hypersomnia | RECRUITING | NCT06812078 |
| Placebo | Other | Phase PHASE2 | Idiopathic Hypersomnia | RECRUITING | NCT06812078 |
| TAK-360 | Other | Phase PHASE2 | Idiopathic Hypersomnia | RECRUITING | NCT06812078 |
| TAK-188 | Other | Phase PHASE1 | Advanced or Metastatic Solid Tumors | RECRUITING | NCT07205718 |
| Dexlansoprazole | Other | Phase PHASE2 | Erosive Esophagitis | ACTIVE_NOT_RECRUITING | NCT02615184 |
| Dexlansoprazole | Other | Phase PHASE2 | Erosive Esophagitis | ACTIVE_NOT_RECRUITING | NCT02615184 |
| No intervention | Other | Preclinical | Lysosomal Disease | ACTIVE_NOT_RECRUITING | NCT07494058 |
| No intervention | Other | Preclinical | Lysosomal Disease | ACTIVE_NOT_RECRUITING | NCT07494058 |
| TAK-505 | Other | Phase PHASE1 | Malignant Solid Tumors | NOT_YET_RECRUITING | NCT07436728 |
| rhARSA | Other | Phase PHASE2 | Metachromatic Leukodystrophy | COMPLETED | NCT01303146 |
| rhARSA | Other | Phase PHASE2 | Metachromatic Leukodystrophy | COMPLETED | NCT01303146 |
| Haematopoietic growth factor | Other | Phase PHASE3 | Hodgkin Lymphoma | RECRUITING | NCT04685616 |
| Dacarbazine | Other | Phase PHASE3 | Hodgkin Lymphoma | RECRUITING | NCT04685616 |
| Vinblastine | Other | Phase PHASE3 | Hodgkin Lymphoma | RECRUITING | NCT04685616 |
| Brentuximab vedotin | Other | Phase PHASE3 | Hodgkin Lymphoma | RECRUITING | NCT04685616 |
| Bleomycin | Other | Phase PHASE3 | Hodgkin Lymphoma | RECRUITING | NCT04685616 |
| Doxorubicin | Other | Phase PHASE3 | Hodgkin Lymphoma | RECRUITING | NCT04685616 |
| Involved site radiotherapy | Drug | Phase PHASE3 | Hodgkin Lymphoma | RECRUITING | NCT04685616 |
| Haematopoietic growth factor | Other | Phase PHASE3 | Hodgkin Lymphoma | RECRUITING | NCT04685616 |
| Dacarbazine | Other | Phase PHASE3 | Hodgkin Lymphoma | RECRUITING | NCT04685616 |
| Vinblastine | Other | Phase PHASE3 | Hodgkin Lymphoma | RECRUITING | NCT04685616 |
| Brentuximab vedotin | Other | Phase PHASE3 | Hodgkin Lymphoma | RECRUITING | NCT04685616 |
| Bleomycin | Other | Phase PHASE3 | Hodgkin Lymphoma | RECRUITING | NCT04685616 |
| Doxorubicin | Other | Phase PHASE3 | Hodgkin Lymphoma | RECRUITING | NCT04685616 |
| Involved site radiotherapy | Drug | Phase PHASE3 | Hodgkin Lymphoma | RECRUITING | NCT04685616 |
| Carboplatin | Other | Phase PHASE3 | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | ACTIVE_NOT_RECRUITING | NCT04129502 |
| Cisplatin | Other | Phase PHASE3 | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | ACTIVE_NOT_RECRUITING | NCT04129502 |
| Pemetrexed | Other | Phase PHASE3 | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | ACTIVE_NOT_RECRUITING | NCT04129502 |
| TAK-788 | Other | Phase PHASE3 | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | ACTIVE_NOT_RECRUITING | NCT04129502 |
| Carboplatin | Other | Phase PHASE3 | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | ACTIVE_NOT_RECRUITING | NCT04129502 |
| Cisplatin | Other | Phase PHASE3 | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | ACTIVE_NOT_RECRUITING | NCT04129502 |
| Pemetrexed | Other | Phase PHASE3 | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | ACTIVE_NOT_RECRUITING | NCT04129502 |
| TAK-788 | Other | Phase PHASE3 | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | ACTIVE_NOT_RECRUITING | NCT04129502 |
| Carboplatin | Other | Phase PHASE3 | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | ACTIVE_NOT_RECRUITING | NCT04129502 |
| Cisplatin | Other | Phase PHASE3 | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | ACTIVE_NOT_RECRUITING | NCT04129502 |
| Pemetrexed | Other | Phase PHASE3 | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | ACTIVE_NOT_RECRUITING | NCT04129502 |
| TAK-788 | Other | Phase PHASE3 | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | ACTIVE_NOT_RECRUITING | NCT04129502 |
| Carboplatin | Other | Phase PHASE3 | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | ACTIVE_NOT_RECRUITING | NCT04129502 |
| Cisplatin | Other | Phase PHASE3 | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | ACTIVE_NOT_RECRUITING | NCT04129502 |
| Pemetrexed | Other | Phase PHASE3 | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | ACTIVE_NOT_RECRUITING | NCT04129502 |
| TAK-788 | Other | Phase PHASE3 | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | ACTIVE_NOT_RECRUITING | NCT04129502 |
| Exercise | Other | Approved | Obesity | ACTIVE_NOT_RECRUITING | NCT01911091 |
| Exercise | Other | Approved | Obesity | ACTIVE_NOT_RECRUITING | NCT01911091 |
| Chemotherapy Agents | Drug | Phase PHASE2 | Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) | ACTIVE_NOT_RECRUITING | NCT05020015 |
| TAK-007 | Other | Phase PHASE2 | Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) | ACTIVE_NOT_RECRUITING | NCT05020015 |
| Technochrom C1-INH Kit | Other | Approved | Hereditary Angioedema (HAE) | NOT_YET_RECRUITING | NCT07293364 |
| Technochrom C1-INH Kit | Other | Approved | Hereditary Angioedema (HAE) | NOT_YET_RECRUITING | NCT07293364 |
| Technochrom C1-INH Kit | Other | Approved | Hereditary Angioedema (HAE) | NOT_YET_RECRUITING | NCT07293364 |
| Placebo | Other | Phase PHASE3 | Kidney Disease | RECRUITING | NCT06963827 |
| Mezagitamab | Other | Phase PHASE3 | Kidney Disease | RECRUITING | NCT06963827 |
| Vedolizumab SC | Other | Phase PHASE4 | Ulcerative Colitis | RECRUITING | NCT06581328 |
| Vedolizumab IV | Other | Phase PHASE4 | Ulcerative Colitis | RECRUITING | NCT06581328 |
| Chemotherapy Agents | Drug | Phase PHASE1 | Leukemia | TERMINATED | NCT05886491 |
| GDX012 | Other | Phase PHASE1 | Leukemia | TERMINATED | NCT05886491 |
| Chemotherapy Agents | Drug | Phase PHASE1 | Leukemia | TERMINATED | NCT05886491 |
| GDX012 | Other | Phase PHASE1 | Leukemia | TERMINATED | NCT05886491 |
| Gluten | Other | Phase PHASE2 | Celiac Disease | COMPLETED | NCT04530123 |
| TAK-101 | Other | Phase PHASE2 | Celiac Disease | COMPLETED | NCT04530123 |
| Placebo | Other | Phase PHASE2 | Celiac Disease | COMPLETED | NCT04530123 |
| Gluten | Other | Phase PHASE2 | Celiac Disease | COMPLETED | NCT04530123 |
| TAK-101 | Other | Phase PHASE2 | Celiac Disease | COMPLETED | NCT04530123 |
| Placebo | Other | Phase PHASE2 | Celiac Disease | COMPLETED | NCT04530123 |
| Placebo | Other | Phase PHASE2 | Celiac Disease | RECRUITING | NCT07298343 |
| ZED1227 + SIGE | Other | Phase PHASE2 | Celiac Disease | RECRUITING | NCT07298343 |
| Placebo | Other | Phase PHASE2 | Celiac Disease | RECRUITING | NCT07298343 |
| ZED1227 + SIGE | Other | Phase PHASE2 | Celiac Disease | RECRUITING | NCT07298343 |
| No intervention | Other | Preclinical | Ulcerative Colitis | COMPLETED | NCT07250815 |
| No intervention | Other | Preclinical | Ulcerative Colitis | COMPLETED | NCT07250815 |
| Electronic Health Record Review | Other | Phase PHASE2 | Hematologic Malignancies | RECRUITING | NCT05952804 |
| Survey Administration | Other | Phase PHASE2 | Hematologic Malignancies | RECRUITING | NCT05952804 |
| Biospecimen Collection | Other | Phase PHASE2 | Hematologic Malignancies | RECRUITING | NCT05952804 |
| Saline | Other | Phase PHASE2 | Hematologic Malignancies | RECRUITING | NCT05952804 |
| Anti-CD19 CAR T Cells Preparation | Other | Phase PHASE2 | Hematologic Malignancies | RECRUITING | NCT05952804 |
| Immune Globulin Infusion (Human), 10% Solution | Other | Phase PHASE2 | Hematologic Malignancies | RECRUITING | NCT05952804 |
| TAK-755 | Other | Phase PHASE3 | Thrombotic Thrombocytopenic Purpura (TTP) | ACTIVE_NOT_RECRUITING | NCT04683003 |
| TAK-755 | Other | Phase PHASE3 | Thrombotic Thrombocytopenic Purpura (TTP) | ACTIVE_NOT_RECRUITING | NCT04683003 |
| Elaprase for intravenous (IV) infusion | Other | Phase PHASE4 | Hunter Syndrome | COMPLETED | NCT02455622 |
| Elaprase for intravenous (IV) infusion | Other | Phase PHASE4 | Hunter Syndrome | COMPLETED | NCT02455622 |
| Thalidomide+Melphalan +Bortezomib+stem cell transplant | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT01242267 |
| Positron Emission Tomography | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | RECRUITING | NCT07224100 |
| Computed Tomography | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | RECRUITING | NCT07224100 |
| Bone Marrow Biopsy | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | RECRUITING | NCT07224100 |
| Bone Marrow Aspiration | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | RECRUITING | NCT07224100 |
| Biospecimen Collection | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | RECRUITING | NCT07224100 |
| Vincristine | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | RECRUITING | NCT07224100 |
| Rituximab | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | RECRUITING | NCT07224100 |
| Prednisone | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | RECRUITING | NCT07224100 |
| Ponatinib | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | RECRUITING | NCT07224100 |
| Pegfilgrastim | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | RECRUITING | NCT07224100 |
| Filgrastim | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | RECRUITING | NCT07224100 |
| Etoposide | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | RECRUITING | NCT07224100 |
| Doxorubicin | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | RECRUITING | NCT07224100 |
| Cyclophosphamide | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | RECRUITING | NCT07224100 |
| Placebo | Other | Phase PHASE3 | Plaque Psoriasis | RECRUITING | NCT07250802 |
| Zasocitinib | Other | Phase PHASE3 | Plaque Psoriasis | RECRUITING | NCT07250802 |
| Placebo | Other | Phase PHASE3 | Plaque Psoriasis | RECRUITING | NCT07250802 |
| Zasocitinib | Other | Phase PHASE3 | Plaque Psoriasis | RECRUITING | NCT07250802 |
| Placebo | Other | Phase PHASE3 | Psoriatic Arthritis | RECRUITING | NCT06671496 |
| Zasocitinib | Other | Phase PHASE3 | Psoriatic Arthritis | RECRUITING | NCT06671496 |
| Placebo | Other | Phase PHASE3 | Psoriatic Arthritis | RECRUITING | NCT06671483 |
| Active Comparator | Other | Phase PHASE3 | Psoriatic Arthritis | RECRUITING | NCT06671483 |
| Zasocitinib | Other | Phase PHASE3 | Psoriatic Arthritis | RECRUITING | NCT06671483 |
| Placebo | Other | Phase PHASE3 | Psoriatic Arthritis | RECRUITING | NCT06671483 |
| Active Comparator | Other | Phase PHASE3 | Psoriatic Arthritis | RECRUITING | NCT06671483 |
| Zasocitinib | Other | Phase PHASE3 | Psoriatic Arthritis | RECRUITING | NCT06671483 |
| Mezagitamab | Other | Phase PHASE3 | Immune Thrombocytopenic Purpura (ITP) | RECRUITING | NCT06948318 |
| Mezagitamab | Other | Phase PHASE3 | Immune Thrombocytopenic Purpura (ITP) | RECRUITING | NCT06948318 |
| Placebo | Other | Phase PHASE2 | Nonsegmental Vitiligo | RECRUITING | NCT07108283 |
| Zasocitinib | Other | Phase PHASE2 | Nonsegmental Vitiligo | RECRUITING | NCT07108283 |
| Placebo | Other | Phase PHASE2 | Nonsegmental Vitiligo | RECRUITING | NCT07108283 |
| Zasocitinib | Other | Phase PHASE2 | Nonsegmental Vitiligo | RECRUITING | NCT07108283 |
| Placebo | Other | Phase PHASE3 | Immune Thrombocytopenic Purpura (ITP) | RECRUITING | NCT06722235 |
| Mezagitamab | Other | Phase PHASE3 | Immune Thrombocytopenic Purpura (ITP) | RECRUITING | NCT06722235 |
| Placebo | Other | Phase PHASE3 | Immune Thrombocytopenic Purpura (ITP) | RECRUITING | NCT06722235 |
| Mezagitamab | Other | Phase PHASE3 | Immune Thrombocytopenic Purpura (ITP) | RECRUITING | NCT06722235 |
| Placebo | Other | Phase PHASE3 | Immune Thrombocytopenic Purpura (ITP) | RECRUITING | NCT06722235 |
| Mezagitamab | Other | Phase PHASE3 | Immune Thrombocytopenic Purpura (ITP) | RECRUITING | NCT06722235 |
| Pomalidomide | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT03984097 |
| Bortezomib | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT03984097 |
| Dexamethasone | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT03984097 |
| Lenalidomide | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT03984097 |
| TAK-079 | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT03984097 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT06254950 |
| TAK-279 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT06254950 |
| Placebo | Other | Phase PHASE2 | Crohn's Disease | RECRUITING | NCT06233461 |
| TAK-279 | Other | Phase PHASE2 | Crohn's Disease | RECRUITING | NCT06233461 |
| Idursulfase-IT | Other | Preclinical | Hunter Syndrome | AVAILABLE | NCT05795361 |
| Idursulfase-IT | Other | Preclinical | Hunter Syndrome | AVAILABLE | NCT05795361 |
| No intervention | Other | Preclinical | Non-small Cell Lung Cancer (NSCLC) | ACTIVE_NOT_RECRUITING | NCT05735327 |
| Brentuximab Vedotin | Other | Preclinical | Hodgkin Lymphoma | RECRUITING | NCT05481437 |
| Brentuximab Vedotin | Other | Preclinical | Hodgkin Lymphoma | RECRUITING | NCT05481437 |
| Teduglutide | Other | Preclinical | Short Bowel Syndrome | ACTIVE_NOT_RECRUITING | NCT05023382 |
| Placebo | Other | Phase PHASE4 | Attention Deficit Hyperactivity Disorder | COMPLETED | NCT04085172 |
| Atomoxetine hydrochloride | Other | Phase PHASE4 | Attention Deficit Hyperactivity Disorder | COMPLETED | NCT04085172 |
| Guanfacine hydrochloride (TAK-503) | Other | Phase PHASE4 | Attention Deficit Hyperactivity Disorder | COMPLETED | NCT04085172 |
| Quality-of-Life Assessment | Other | Phase PHASE2 | Recurrent Plasma Cell Myeloma | ACTIVE_NOT_RECRUITING | NCT03763162 |
| Ixazomib | Other | Phase PHASE2 | Recurrent Plasma Cell Myeloma | ACTIVE_NOT_RECRUITING | NCT03763162 |
| Dexamethasone | Other | Phase PHASE2 | Recurrent Plasma Cell Myeloma | ACTIVE_NOT_RECRUITING | NCT03763162 |
| Daratumumab | Other | Phase PHASE2 | Recurrent Plasma Cell Myeloma | ACTIVE_NOT_RECRUITING | NCT03763162 |
| Bortezomib | Other | Phase PHASE2 | Recurrent Plasma Cell Myeloma | ACTIVE_NOT_RECRUITING | NCT03763162 |
| Quality-of-Life Assessment | Other | Phase PHASE2 | Recurrent Plasma Cell Myeloma | ACTIVE_NOT_RECRUITING | NCT03763162 |
| Ixazomib | Other | Phase PHASE2 | Recurrent Plasma Cell Myeloma | ACTIVE_NOT_RECRUITING | NCT03763162 |
| Dexamethasone | Other | Phase PHASE2 | Recurrent Plasma Cell Myeloma | ACTIVE_NOT_RECRUITING | NCT03763162 |
| Daratumumab | Other | Phase PHASE2 | Recurrent Plasma Cell Myeloma | ACTIVE_NOT_RECRUITING | NCT03763162 |
| Bortezomib | Other | Phase PHASE2 | Recurrent Plasma Cell Myeloma | ACTIVE_NOT_RECRUITING | NCT03763162 |
| No Intervention | Other | Phase PHASE3 | Ulcerative Colitis | RECRUITING | NCT05442567 |
| Vedolizumab IV | Other | Phase PHASE3 | Ulcerative Colitis | RECRUITING | NCT05442567 |
| No Intervention | Other | Phase PHASE3 | Ulcerative Colitis | RECRUITING | NCT05442567 |
| Vedolizumab IV | Other | Phase PHASE3 | Ulcerative Colitis | RECRUITING | NCT05442567 |
| Placebo | Other | Phase PHASE2 | Acute Ischemic Stroke | RECRUITING | NCT07392450 |
| TAK-755 | Other | Phase PHASE2 | Acute Ischemic Stroke | RECRUITING | NCT07392450 |
| Electronic Health Record Review | Other | Phase PHASE2 | Hematologic Malignancies | RECRUITING | NCT05952804 |
| Survey Administration | Other | Phase PHASE2 | Hematologic Malignancies | RECRUITING | NCT05952804 |
| Biospecimen Collection | Other | Phase PHASE2 | Hematologic Malignancies | RECRUITING | NCT05952804 |
| Saline | Other | Phase PHASE2 | Hematologic Malignancies | RECRUITING | NCT05952804 |
| Anti-CD19 CAR T Cells Preparation | Other | Phase PHASE2 | Hematologic Malignancies | RECRUITING | NCT05952804 |
| Immune Globulin Infusion (Human), 10% Solution | Other | Phase PHASE2 | Hematologic Malignancies | RECRUITING | NCT05952804 |
| HGT-1110 | Other | Phase PHASE1 | Metachromatic Leukodystrophy (MLD) | COMPLETED | NCT01887938 |
| Placebo | Other | Phase PHASE3 | Kidney Disease | RECRUITING | NCT06963827 |
| Mezagitamab | Other | Phase PHASE3 | Kidney Disease | RECRUITING | NCT06963827 |
| Placebo | Other | Phase PHASE3 | Kidney Disease | RECRUITING | NCT06963827 |
| Mezagitamab | Other | Phase PHASE3 | Kidney Disease | RECRUITING | NCT06963827 |
| Vedolizumab SC | Other | Phase PHASE4 | Ulcerative Colitis | RECRUITING | NCT06581328 |
| Vedolizumab IV | Other | Phase PHASE4 | Ulcerative Colitis | RECRUITING | NCT06581328 |
| Placebo | Other | Phase PHASE3 | Dengue Fever | RECRUITING | NCT06579755 |
| TDV | Other | Phase PHASE3 | Dengue Fever | RECRUITING | NCT06579755 |
| 19(T2)28z1xx TRAC T cell | Other | Phase PHASE1 | B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT05757700 |
| TAK-505 | Other | Phase PHASE1 | Malignant Solid Tumors | RECRUITING | NCT07436728 |
| TAK-411 | Other | Phase PHASE2 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | RECRUITING | NCT06798012 |
| No intervention | Other | Preclinical | Hereditary Angioedema (HAE) | NOT_YET_RECRUITING | NCT07263685 |
| TAK-188 | Other | Phase PHASE1 | Advanced or Metastatic Solid Tumors | RECRUITING | NCT07205718 |
| rFVIIa | Other | Phase PHASE3 | Hemophilia A | RECRUITING | NCT04563520 |
| FEIBA | Other | Phase PHASE3 | Hemophilia A | RECRUITING | NCT04563520 |
| Emicizumab | Other | Phase PHASE3 | Hemophilia A | RECRUITING | NCT04563520 |
| Psychotherapy as Usual (TAU) | Drug | Approved | Major Depression | RECRUITING | NCT07380451 |
| Modular Intervention for Depression Therapy (MIND Therapy) | Drug | Approved | Major Depression | RECRUITING | NCT07380451 |
Total products: 7433